glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
lymphocytes	I-cell_type	O
and	O	O
their	O	O
sensitivity	O	O
to	O	O
hormone	O	O
action	O	O
.	O	O

The	O	O
study	O	O
demonstrated	O	O
a	O	O
decreased	O	O
level	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
(	O	O
GR	O	O
)	O	O
in	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
lymphocytes	I-cell_type	O
from	O	O
hypercholesterolemic	O	O
subjects	O	O
,	O	O
and	O	O
an	O	O
elevated	O	O
level	O	O
in	O	O
patients	O	O
with	O	O
acute	O	O
myocardial	O	O
infarction	O	O
.	O	O

In	O	O
the	O	O
lymphocytes	O	O
with	O	O
a	O	O
high	O	O
GR	O	O
number	O	O
,	O	O
dexamethasone	O	O
inhibited	O	O
[	O	O
3H	O	O
]	O	O
-thymidine	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
-acetate	O	O
incorporation	O	O
into	O	O
DNA	O	O
and	O	O
cholesterol	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
same	O	O
manner	O	O
as	O	O
in	O	O
the	O	O
control	B-cell_type	O
cells	I-cell_type	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
a	O	O
decreased	O	O
GR	O	O
number	O	O
resulted	O	O
in	O	O
a	O	O
less	O	O
efficient	O	O
dexamethasone	O	O
inhibition	O	O
of	O	O
the	O	O
incorporation	O	O
of	O	O
labeled	O	O
compounds	O	O
.	O	O

These	O	O
data	O	O
showed	O	O
that	O	O
the	O	O
sensitivity	O	O
of	O	O
lymphocytes	O	O
to	O	O
glucocorticoids	O	O
changed	O	O
only	O	O
with	O	O
a	O	O
decrease	O	O
of	O	O
GR	B-protein	O
level	O	O
.	O	O

[	O	O
1	O	O
,	O	O
25-Dihydroxyvitamin	O	O
D3	O	O
receptors	O	O
in	O	O
lymphocytes	I-cell_type	O
and	O	O
T-	O	O
and	O	O
B-lymphocyte	O	O
count	O	O
in	O	O
patients	O	O
with	O	O
glomerulonephritis	O	O
]	O	O

Content	O	O
of	O	O
receptors	O	O
to	O	O
hormonal	O	O
form	O	O
of	O	O
vitamin	O	O
D3	O	O
,	O	O
1.25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
,	O	O
constituted	O	O
27.3	O	O
fmole/mg	O	O
of	O	O
protein	O	O
in	O	O
lymphocytes	O	O
of	O	O
peripheric	O	O
blood	O	O
of	O	O
children	O	O
with	O	O
glomerulonephritis	O	O
.	O	O

In	O	O
the	O	O
patients	O	O
concentration	O	O
of	O	O
total	O	O
and	O	O
ionized	O	O
form	O	O
of	O	O
Ca2+	O	O
was	O	O
decreased	O	O
down	O	O
to	O	O
2.04	O	O
mmole/L	O	O
and	O	O
1.09	O	O
mmole/L	O	O
,	O	O
respectively	O	O
,	O	O
while	O	O
an	O	O
increase	O	O
in	O	O
parathormone	O	O
(	O	O
PTH	O	O
)	O	O
by	O	O
36	O	O
%	O	O
and	O	O
a	O	O
distinct	O	O
decrease	O	O
in	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
D	O	O
concentration	O	O
(	O	O
lower	O	O
than	O	O
1.25	O	O
ng/ml	O	O
)	O	O
was	O	O
found	O	O
in	O	O
blood	O	O
;	O	O
content	O	O
of	O	O
cAMP	O	O
was	O	O
also	O	O
decreased	O	O
in	O	O
lymphocytes	O	O
by	O	O
33	O	O
%	O	O
.	O	O

At	O	O
the	O	O
same	O	O
time	O	O
,	O	O
total	O	O
content	O	O
of	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
was	O	O
decreased	O	O
1.5-fold	O	O
in	O	O
peripheric	O	O
blood	O	O
.	O	O

Treatment	O	O
with	O	O
I-hydroxyvitamin	O	O
D3	O	O
(	O	O
1-1.5	O	O
mg	O	O
daily	O	O
,	O	O
within	O	O
4	O	O
weeks	O	O
)	O	O
led	O	O
to	O	O
normalization	O	O
of	O	O
total	O	O
and	O	O
ionized	O	O
form	O	O
of	O	O
Ca2+	O	O
and	O	O
of	O	O
25	B-protein	O
(	O	O
OH	B-protein	O
)	O	O
D	O	O
,	O	O
but	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
PTH	O	O
content	O	O
in	O	O
blood	O	O
.	O	O

Concentration	O	O
of	O	O
the	O	O
receptors	O	O
to	O	O
1.25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
was	O	O
elevated	O	O
up	O	O
to	O	O
39.7	O	O
fmole/mg	O	O
after	O	O
I	O	O
week	O	O
of	O	O
the	O	O
treatment	O	O
,	O	O
whereas	O	O
it	O	O
was	O	O
decreased	O	O
to	O	O
the	O	O
initial	O	O
level	O	O
24.8	O	O
fmole/mg	O	O
within	O	O
4	O	O
weeks	O	O
;	O	O
simultaneous	O	O
alteration	O	O
in	O	O
the	O	O
cAMP	O	O
content	O	O
was	O	O
observed	O	O
in	O	O
lymphocytes	I-cell_type	O
.	O	O

Treatment	O	O
with	O	O
1-	B-protein	O
(	O	O
OH	B-protein	O
)	O	O
D3	O	O
normalized	O	O
also	O	O
the	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
content	O	O
in	O	O
peripheric	O	O
blood	O	O
.	O	O

The	O	O
data	O	O
obtained	O	O
suggest	O	O
that	O	O
under	O	O
conditions	O	O
of	O	O
glomerulonephritis	O	O
only	O	O
high	O	O
content	O	O
of	O	O
receptors	O	O
to	O	O
1.25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
in	O	O
lymphocytes	O	O
enabled	O	O
to	O	O
perform	O	O
the	O	O
cell	O	O
response	O	O
to	O	O
the	O	O
hormone	O	O
effect	O	O
.	O	O

Tumor	O	O
and	O	O
serum	O	O
beta-2-microglobulin	O	O
expression	O	O
in	O	O
women	O	O
with	O	O
breast	O	O
cancer	O	O
.	O	O

To	O	O
investigate	O	O
whether	O	O
the	O	O
tumor	O	O
expression	O	O
of	O	O
beta-2-microglobulin	B-protein	O
(	I-protein	O
beta	I-protein	O
2-M	I-protein	O
)	O	O
could	O	O
serve	O	O
as	O	O
a	O	O
marker	O	O
of	O	O
tumor	B-protein	O
biologic	O	O
behavior	O	O
,	O	O
the	O	O
authors	O	O
studied	O	O
specimens	O	O
of	O	O
breast	O	O
carcinomas	O	O
from	O	O
60	O	O
consecutive	O	O
female	O	O
patients	O	O
.	O	O

Presence	O	O
of	O	O
beta	O	O
2-M	O	O
was	O	O
analyzed	O	O
by	O	O
immunohistochemistry	O	O
.	O	O

No	O	O
significant	O	O
correlations	O	O
were	O	O
found	O	O
between	O	O
tumor	B-protein	O
beta	O	O
2-M	O	O
expression	O	O
and	O	O
several	O	O
histologic	O	O
attributes	O	O
such	O	O
as	O	O
type	O	O
,	O	O
histologic	O	O
and	O	O
nuclear	O	O
grades	O	O
,	O	O
mitotic	O	O
index	O	O
,	O	O
necrosis	O	O
,	O	O
vascular	O	O
invasion	O	O
,	O	O
and	O	O
lymphocytic	B-protein	O
infiltration	O	O
.	O	O

Likewise	O	O
,	O	O
beta	O	O
2-M	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
markers	O	O
of	O	O
disease	O	O
extension	O	O
such	O	O
as	O	O
TNM	O	O
,	O	O
(	O	O
UICC	O	O
,	O	O
classification	O	O
of	O	O
malignant	B-protein	O
tumors	I-protein	O
)	O	O
staging	O	O
and	O	O
axillary	O	O
lymph	O	O
node	O	O
involvement	O	O
or	O	O
with	O	O
estrogen	O	O
,	O	O
progesterone	O	O
,	O	O
and	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
levels	O	O
.	O	O

However	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significantly	O	O
positive	O	O
association	O	O
between	O	O
tumor	B-protein	O
beta	I-protein	O
2-M	O	O
expression	O	O
and	O	O
the	O	O
degree	O	O
of	O	O
lymphocytic	B-protein	O
infiltration	O	O
in	O	O
the	O	O
tumor	B-cell_type	O
tissue	I-cell_type	O
.	O	O

Beta	O	O
2-M	O	O
serum	O	O
levels	O	O
were	O	O
determined	O	O
by	O	O
an	O	O
enzyme-linked	O	O
immunosorbent	O	O
assay	O	O
in	O	O
samples	O	O
from	O	O
22	O	O
of	O	O
the	O	O
above	O	O
women	I-DNA	O
.	O	O

Although	O	O
some	O	O
of	O	O
the	O	O
highest	O	O
values	O	O
had	O	O
been	O	O
obtained	O	O
in	O	O
women	O	O
with	O	O
larger	O	O
(	O	O
T4	B-protein	O
)	O	O
primary	O	O
tumors	O	O
,	O	O
the	O	O
authors	O	O
failed	O	O
to	O	O
detect	O	O
any	O	O
statistical	O	O
relationship	O	O
between	O	O
beta	O	O
2-M	O	O
expression	O	O
in	O	O
the	O	O
tumor	O	O
with	O	O
serum	O	O
levels	O	O
or	O	O
between	O	O
serum	O	O
beta	O	O
2-M	O	O
and	O	O
the	O	O
above	O	O
histologic	O	O
,	O	O
laboratory	O	O
,	O	O
and	O	O
clinical	O	O
factors	I-protein	O
.	O	O

[	O	O
Preliminary	O	O
observation	O	O
of	O	O
level	O	O
free-form	O	O
E	O	O
receptor	O	O
levels	O	O
in	O	O
serum	O	O
of	O	O
normal	O	O
childbearing-aged	O	O
and	O	O
pregnant	O	O
women	O	O
]	O	O

In	O	O
137	O	O
cases	O	O
of	O	O
childbearing-aged	O	O
and	O	O
pregnant	O	O
women	O	O
,	O	O
free	O	O
form	O	O
E	B-protein	O
receptor	I-protein	O
levels	O	O
(	O	O
sE	B-protein	O
)	O	O
in	O	O
serum	O	O
were	O	O
measured	O	O
by	O	O
ELISA	O	O
.	O	O

The	O	O
level	O	O
of	O	O
sE	O	O
was	O	O
significantly	O	O
decreased	O	O
during	O	O
the	O	O
first	O	O
trimester	O	O
,	O	O
slightly	O	O
higher	O	O
in	O	O
the	O	O
second	O	O
trimester	O	O
,	O	O
and	O	O
recovered	O	O
to	O	O
normal	O	O
in	O	O
the	O	O
third	O	O
trimester	O	O
.	O	O

The	O	O
level	O	O
remained	O	O
lower	O	O
in	O	O
29	O	O
PIH	O	O
women	O	O
but	O	O
appeared	O	O
higher	O	O
in	O	O
overdue	O	O
pregnancies	O	O
as	O	O
compared	O	O
with	O	O
the	O	O
normal	O	O
3rd	O	O
trimester	O	O
range	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
there	O	O
is	O	O
a	O	O
relationship	O	O
between	O	O
a	O	O
change	O	O
in	O	O
T	B-cell_type	O
cell	I-cell_type	O
function	O	O
and	O	O
pregnancy	O	O
.	O	O

Kappa	O	O
B-specific	O	O
DNA	B-protein	O
binding	I-protein	O
proteins	I-protein	O
:	O	O
role	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
human	B-DNA	O
interleukin-2	I-DNA	O
gene	I-DNA	O
expression	O	O
.	O	O

Transcriptional	O	O
activation	O	O
of	O	O
the	O	O
human	B-DNA	O
interleukin-2	I-DNA	O
(	I-DNA	O
IL-2	B-DNA	O
)	I-DNA	O
gene	I-DNA	O
,	O	O
like	O	O
induction	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
receptor	I-DNA	O
alpha	I-DNA	O
(	I-DNA	O
IL-2R	I-DNA	O
alpha	I-DNA	O
)	I-DNA	O
gene	I-DNA	O
and	O	O
the	O	O
type	B-protein	O
1	I-protein	O
human	I-protein	O
immunodeficiency	I-protein	O
virus	O	O
(	O	O
HIV-1	B-DNA	O
)	O	O
,	O	O
is	O	O
shown	O	O
to	O	O
be	O	O
modulated	O	O
by	O	O
a	O	O
kappa	B-DNA	O
B-like	I-DNA	O
enhancer	I-DNA	O
element	I-DNA	O
.	O	O

Mutation	O	O
of	O	O
a	O	O
kappa	B-DNA	O
B	I-DNA	O
core	I-DNA	O
sequence	I-DNA	O
identified	O	O
in	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
(	O	O
-206	O	O
to	O	O
-195	O	O
)	O	O
partially	O	O
inhibits	O	O
both	O	O
mitogen-	O	O
and	O	O
HTLV-I	O	O
Tax-mediated	O	O
activation	O	O
of	O	O
this	O	O
transcription	O	O
unit	O	O
and	O	O
blocks	O	O
the	O	O
specific	O	O
binding	O	O
of	O	O
two	O	O
inducible	B-protein	O
cellular	I-protein	O
factors	I-protein	O
.	O	O

These	O	O
kappa	O	O
B-specific	B-protein	O
proteins	I-protein	O
(	O	O
80	O	O
to	O	O
90	B-protein	O
and	O	O
50	O	O
to	O	O
55	O	O
kilodaltons	O	O
)	O	O
similarly	O	O
interact	O	O
with	O	O
the	O	O
functional	B-DNA	O
kappa	I-DNA	O
B	I-DNA	O
enhancer	I-DNA	O
present	O	O
in	O	O
the	O	O
IL-2R	B-DNA	O
alpha	I-DNA	O
promoter	I-DNA	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
these	O	O
kappa	O	O
B-specific	B-protein	O
proteins	I-protein	O
have	O	O
a	O	O
role	O	O
in	O	O
the	O	O
coordinate	O	O
regulation	O	O
of	O	O
this	O	O
growth	O	O
factor-growth	B-protein	O
factor	I-protein	O
receptor	I-protein	O
gene	O	O
system	O	O
that	O	O
controls	O	O
T	B-cell_type	O
cell	I-cell_type	O
proliferation	O	O
.	O	O

Novel	O	O
region	O	O
within	O	O
the	O	O
V	B-DNA	O
kappa	B-DNA	O
gene	I-DNA	O
promoter	I-DNA	O
is	O	O
responsible	O	O
for	O	O
tissue	O	O
and	O	O
stage-specific	O	O
expression	O	O
of	O	O
immunoglobulin	O	O
genes	O	O
in	O	O
human	B-cell_type	O
lymphoid	I-cell_type	O
neoplasms	O	O
.	O	O

Immunoglobulin	O	O
gene-specific	O	O
transacting	B-protein	O
factors	I-protein	O
have	O	O
been	O	O
shown	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
lymphoid	O	O
tissue-specific	O	O
expression	O	O
of	O	O
immunoglobulin	O	O
genes	B-DNA	O
.	O	O

The	O	O
role	O	O
of	O	O
these	O	O
factors	B-protein	O
in	O	O
B-cell	O	O
differentiation	O	O
and	O	O
stage-specific	O	O
expression	O	O
of	O	O
these	O	O
genes	O	O
is	O	O
,	O	O
however	O	O
,	O	O
not	O	O
fully	O	O
understood	O	O
.	O	O

We	O	O
have	O	O
used	O	O
a	O	O
model	O	O
of	O	O
human	O	O
lymphoid	O	O
neoplasia	O	O
to	O	O
address	O	O
this	O	O
question	O	O
.	O	O

Different	O	O
fragments	O	O
of	O	O
unrearranged	O	O
human	B-DNA	O
variable	I-DNA	O
region	I-DNA	O
of	O	O
immunoglobulin	O	O
kappa	B-DNA	O
gene	I-DNA	O
(	O	O
V	B-protein	O
kappa	I-protein	O
)	O	O
were	O	O
used	O	O
for	O	O
cell-free	O	O
in	O	O
vitro	O	O
transcription	O	O
and	O	O
DNA	O	O
mobility	O	O
shift	O	O
assays	O	O
.	O	O

Previously	O	O
described	O	O
enhancement	O	O
of	O	O
in	O	O
vitro	O	O
transcription	O	O
that	O	O
was	O	O
only	O	O
seen	O	O
with	O	O
nuclear	O	O
extracts	O	O
derived	O	O
from	O	O
B-cell	O	O
neoplasms	O	O
corresponding	O	O
to	O	O
the	O	O
late	O	O
stages	O	O
of	O	O
B-cell	O	O
differentiation	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
dependent	O	O
on	O	O
the	O	O
actions	O	O
of	O	O
these	O	O
factor	O	O
(	O	O
s	O	O
)	O	O
on	O	O
the	O	O
DNA	B-DNA	O
region	I-DNA	O
within	O	O
the	O	O
V	B-DNA	O
kappa	I-DNA	O
gene	I-DNA	O
promoter	I-DNA	O
.	O	O

This	O	O
region	O	O
is	O	O
located	O	O
within	O	O
the	O	O
920	O	O
bp	O	O
fragment	O	O
located	O	O
210	O	O
bp	O	O
upstream	O	O
from	O	O
the	O	O
coding	B-DNA	O
region	I-DNA	O
and	O	O
this	O	O
fragment	O	O
represents	O	O
a	O	O
possible	O	O
novel	O	O
DNA	B-DNA	O
region	I-DNA	O
,	O	O
which	O	O
plays	O	O
a	O	O
role	O	O
in	O	O
the	O	O
stage-	O	O
and	O	O
tissue-specific	O	O
expression	O	O
of	O	O
immunoglobulin	O	O
genes	B-DNA	O
.	O	O

[	O	O
Determination	O	O
of	O	O
the	O	O
sensitivity	O	O
to	O	O
glucocorticoids	O	O
in	O	O
vitro	O	O
]	O	O

A	O	O
modified	O	O
method	O	O
for	O	O
the	O	O
determination	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
is	O	O
suggested	O	O
.	O	O

The	O	O
principal	O	O
distinction	O	O
of	O	O
the	O	O
method	O	O
is	O	O
standardization	O	O
by	O	O
the	O	O
lymphocyte	O	O
count	O	O
in	O	O
a	O	O
sample	O	O
(	O	O
1	O	O
mln	I-protein	O
)	O	O
and	O	O
the	O	O
labeled	B-protein	O
hormone	I-protein	O
concentration	O	O
.	O	O

The	O	O
modification	O	O
saves	O	O
time	O	O
and	O	O
money	O	O
,	O	O
limits	O	O
the	O	O
range	O	O
of	O	O
the	O	O
data	B-DNA	O
variations	I-DNA	O
,	O	O
and	O	O
makes	O	O
use	O	O
of	O	O
a	O	O
lesser	O	O
volume	O	O
of	O	O
blood	B-protein	O
.	O	O

Examinations	O	O
of	O	O
70	O	O
children	O	O
aged	O	O
4	O	O
to	O	O
15	O	O
suffering	O	O
from	O	O
the	O	O
nephrotic	O	O
form	O	O
of	O	O
glomerulonephritis	O	O
have	O	O
made	O	O
it	O	O
possible	O	O
to	O	O
distinguish	O	O
two	O	O
groups	O	O
of	O	O
patients	O	O
:	O	O
with	O	O
relatively	O	O
high	O	O
values	O	O
of	O	O
specific	O	O
binding	O	O
X	B-protein	O
=	I-protein	O
6820.1	I-protein	O
+/-	I-protein	O
530.0	I-protein	O
(	O	O
n	O	O
=	O	O
30	O	O
,	O	O
p	O	O
=	O	O
0.95	O	O
,	O	O
t	O	O
=	O	O
2.04	O	O
)	O	O
,	O	O
this	O	O
corresponding	O	O
to	O	O
a	O	O
clinical	O	O
form	O	O
of	O	O
hormone	O	O
-sensitive	O	O
glomerulonephritis	O	O
,	O	O
and	O	O
with	O	O
relatively	O	O
low	O	O
values	O	O
of	O	O
specific	O	O
binding	O	O
X	B-protein	O
=	I-protein	O
1815.2	I-protein	O
+/-	I-protein	O
302.8	O	O
(	O	O
n	O	O
=	O	O
40	O	O
,	O	O
p	O	O
=	O	O
0.95	O	O
,	O	O
t	O	O
=	O	O
1.96	O	O
)	O	O
,	O	O
that	O	O
corresponds	O	O
to	O	O
hormone	O	O
-resistant	O	O
glomerulonephritis	O	O
.	O	O

Dynamic	O	O
studies	O	O
have	O	O
not	O	O
shown	O	O
any	O	O
statistically	O	O
significant	O	O
changes	O	O
in	O	O
the	O	O
specific	O	O
binding	O	O
values	O	O
.	O	O

These	O	O
results	O	O
permit	O	O
regarding	O	O
the	O	O
specific	O	O
binding	O	O
value	O	O
as	O	O
a	O	O
prognostic	O	O
criterion	O	O
in	O	O
the	O	O
assessment	O	O
of	O	O
corticosteroid	O	O
therapy	O	O
;	O	O
this	O	O
allows	O	O
a	O	O
wide	O	O
employment	O	O
of	O	O
the	O	O
described	O	O
method	O	O
in	O	O
practical	O	O
nephrology	O	O
.	O	O

Octamer-binding	B-protein	O
proteins	I-protein	O
from	O	O
B	B-cell_type	O
or	O	O
HeLa	B-cell_type	O
cells	I-cell_type	O
stimulate	O	O
transcription	O	O
of	O	O
the	O	O
immunoglobulin	O	O
heavy-chain	B-DNA	O
promoter	I-DNA	O
in	O	O
vitro	O	O
.	O	O

The	O	O
B-cell	O	O
-type	O	O
specificity	O	O
of	O	O
the	O	O
immunoglobulin	O	O
(	O	O
Ig	B-protein	O
)	O	O
heavy-chain	O	O
and	O	O
light-chain	O	O
promoters	O	O
is	O	O
mediated	O	O
by	O	O
an	O	O
octanucleotide	O	O
(	O	O
OCTA	B-protein	O
)	O	O
element	O	O
,	O	O
ATGCAAAT	O	O
,	O	O
that	O	O
is	O	O
also	O	O
a	O	O
functional	O	O
component	O	O
of	O	O
other	O	O
RNA	O	O
polymerase	I-protein	O
II	I-protein	O
promoters	I-protein	O
,	O	O
such	O	O
as	O	O
snRNA	O	O
and	O	O
histone	O	O
H2B	O	O
promoters	O	O
.	O	O

Two	O	O
nuclear	B-protein	O
proteins	I-protein	O
that	O	O
bind	O	O
specifically	O	O
and	O	O
with	O	O
high	O	O
affinity	O	O
to	O	O
the	O	O
OCTA	O	O
element	O	O
have	O	O
been	O	O
identified	O	O
.	O	O

NF-A1	O	O
is	O	O
present	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
cell	O	O
types	O	O
,	O	O
whereas	O	O
the	O	O
presence	O	O
of	O	O
NF-A2	O	O
is	O	O
essentially	O	O
confined	O	O
to	O	O
B	B-cell_type	O
cells	I-cell_type	O
,	O	O
leading	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
NF-A2	O	O
activates	O	O
cell-type-specific	O	O
transcription	O	O
of	O	O
the	O	O
Ig	B-DNA	O
promoter	I-DNA	O
and	O	O
NF-A1	O	O
mediates	O	O
the	O	O
other	O	O
responses	O	O
of	O	O
the	O	O
OCTA	B-DNA	O
element	I-DNA	O
.	O	O

Extracts	O	O
of	O	O
the	O	O
B-cell	O	O
line	O	O
,	O	O
BJA-B	O	O
,	O	O
contain	O	O
high	O	O
levels	O	O
of	O	O
NF-A2	O	O
and	O	O
specifically	O	O
transcribe	O	O
Ig	O	O
promoters	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
extracts	O	O
from	O	O
HeLa	B-cell_type	O
cells	I-cell_type	O
transcribed	O	O
the	O	O
Ig	B-DNA	O
promoter	I-DNA	O
poorly	O	O
.	O	O

Surprisingly	O	O
,	O	O
addition	O	O
of	O	O
either	O	O
affinity-enriched	O	O
NF-A2	O	O
or	O	O
NF-A1	O	O
to	O	O
either	O	O
a	O	O
HeLa	O	O
extract	O	O
or	O	O
a	O	O
partially	O	O
purified	O	O
reaction	O	O
system	O	O
specifically	O	O
stimulates	O	O
the	O	O
Ig	B-DNA	O
promoter	I-DNA	O
.	O	O

This	O	O
suggests	O	O
that	O	O
the	O	O
constitutive	O	O
OCTA-binding	B-protein	O
factor	I-protein	O
NF-A1	O	O
can	O	O
activate	O	O
transcription	O	O
of	O	O
the	O	O
Ig	B-DNA	O
promoter	I-DNA	O
and	O	O
that	O	O
B-cell	O	O
-specific	O	O
transcription	O	O
of	O	O
this	O	O
promoter	O	O
,	O	O
at	O	O
least	O	O
in	O	O
vitro	O	O
,	O	O
is	O	O
partially	O	O
due	O	O
to	O	O
a	O	O
quantitative	O	O
difference	O	O
in	O	O
the	O	O
amount	O	O
of	O	O
OCTA-binding	B-protein	O
protein	I-protein	O
.	O	O

Because	O	O
NF-A1	O	O
can	O	O
stimulate	O	O
Ig	O	O
transcription	O	O
,	O	O
the	O	O
inability	O	O
of	O	O
this	O	O
factor	O	O
to	O	O
activate	O	O
in	O	O
vivo	O	O
the	O	O
Ig	B-DNA	O
promoter	I-DNA	O
to	O	O
the	O	O
same	O	O
degree	O	O
as	O	O
the	O	O
snRNA	B-DNA	O
promoters	I-DNA	O
probably	O	O
reflects	O	O
a	O	O
difference	O	O
in	O	O
the	O	O
context	O	O
of	O	O
the	O	O
OCTA	B-DNA	O
element	I-DNA	O
in	O	O
these	O	O
two	O	O
types	O	O
of	O	O
promoters	B-DNA	O
.	O	O

Identification	O	O
of	O	O
a	O	O
putative	O	O
regulator	O	O
of	O	O
early	I-DNA	O
T	I-DNA	O
cell	I-DNA	O
activation	I-DNA	O
genes	I-DNA	O
.	O	O

Molecules	O	O
involved	O	O
in	O	O
the	O	O
antigen	O	O
receptor-dependent	O	O
regulation	O	O
of	O	O
early	O	O
T	O	O
cell	O	O
activation	O	O
genes	O	O
were	O	O
investigated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
functional	O	O
sequences	O	O
of	O	O
the	O	O
T	O	O
cell	O	O
activation-specific	O	O
enhancer	O	O
of	O	O
interleukin-2	B-protein	O
(	O	O
IL-2	B-protein	O
)	O	O
.	O	O

One	O	O
of	O	O
these	O	O
sequences	O	O
forms	O	O
a	O	O
protein	B-protein	O
complex	I-protein	O
,	O	O
NFAT-1	O	O
,	O	O
specifically	O	O
with	O	O
nuclear	O	O
extracts	O	O
of	O	O
activated	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

This	O	O
complex	O	O
appeared	O	O
10	O	O
to	O	O
25	O	O
minutes	O	O
before	O	O
the	O	O
activation	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
gene	I-DNA	O
.	O	O

Studies	O	O
with	O	O
inhibitors	O	O
of	O	O
protein	O	O
synthesis	O	O
indicated	O	O
that	O	O
the	O	O
time	O	O
of	O	O
synthesis	O	O
of	O	O
the	O	O
activator	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
gene	I-DNA	O
in	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
corresponds	O	O
to	O	O
the	O	O
time	O	O
of	O	O
appearance	O	O
of	O	O
NFAT-1	B-protein	O
.	O	O

NFAT-1	O	O
,	O	O
or	O	O
a	O	O
very	O	O
similar	B-protein	O
protein	I-protein	O
,	O	O
bound	O	O
functional	O	O
sequences	O	O
of	O	O
the	O	O
long	B-DNA	O
terminal	I-DNA	O
repeat	I-DNA	O
(	O	O
LTR	B-DNA	O
)	O	O
of	O	O
the	O	O
human	B-DNA	O
immunodeficiency	I-DNA	O
virus	I-DNA	O
type	I-DNA	O
1	O	O
;	O	O
the	O	O
LTR	O	O
of	O	O
this	O	O
virus	O	O
is	O	O
known	O	O
to	O	O
be	O	O
stimulated	O	O
during	O	O
early	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

The	O	O
binding	B-DNA	O
site	I-DNA	O
for	O	O
this	O	O
complex	O	O
activated	O	O
a	O	O
linked	O	O
promoter	I-DNA	O
after	O	O
transfection	O	O
into	O	O
antigen	O	O
receptor-activated	O	O
T	B-cell_type	O
cells	I-cell_type	O
but	O	O
not	O	O
other	O	O
cell	O	O
types	O	O
.	O	O

These	O	O
characteristics	O	O
suggest	O	O
that	O	O
NFAT-1	O	O
transmits	O	O
signals	O	O
initiated	O	O
at	O	O
the	O	O
T	O	O
cell	O	O
antigen	O	O
receptor	O	O
.	O	O

Characterization	O	O
of	O	O
thyroid	B-protein	O
hormone	I-protein	O
receptors	I-protein	O
in	O	O
human	B-cell_type	O
IM-9	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Although	O	O
putatively	O	O
identified	O	O
more	O	O
than	O	O
10	O	O
years	O	O
ago	O	O
,	O	O
thyroid	O	O
hormone	O	O
receptors	O	O
in	O	O
human	O	O
tissues	O	O
remain	O	O
poorly	O	O
characterized	O	O
.	O	O

As	O	O
a	O	O
first	O	O
step	O	O
towards	O	O
understanding	O	O
the	O	O
mechanism	O	O
of	O	O
thyroid	O	O
hormone	O	O
action	O	O
in	O	O
man	O	O
we	O	O
have	O	O
characterized	O	O
T3	O	O
binding	O	O
sites	O	O
in	O	O
nuclei	O	O
of	O	O
the	O	O
human	B-cell_line	O
lymphoblastoid	I-cell_line	O
line	I-cell_line	O
,	I-cell_line	O
IM-9	I-cell_line	O
cells	I-cell_line	O
.	O	O

In	O	O
whole	O	O
cell	O	O
experiments	O	O
at	O	O
37	O	O
degrees	O	O
C	O	O
,	O	O
nuclear	O	O
binding	O	O
of	O	O
[	O	O
125I	O	O
]	O	O
T3	O	O
was	O	O
saturable	O	O
(	O	O
Kd	O	O
34	O	O
+/-	O	O
6	O	O
pmol/l	O	O
)	O	O
and	O	O
of	O	O
finite	O	O
capacity	O	O
(	O	O
approximately	O	O
equal	O	O
to	O	O
350	O	O
sites/cell	O	O
)	O	O
.	O	O

The	O	O
binding	B-DNA	O
sites	I-DNA	O
were	O	O
extracted	O	O
from	O	O
a	O	O
nuclear	O	O
pellet	O	O
by	O	O
treatment	O	O
with	O	O
0.4	O	O
mol/l	O	O
KCl	O	O
and	O	O
sonication	O	O
.	O	O

Separation	O	O
of	O	O
bound	O	O
from	O	O
free	O	O
[	O	O
125I	O	O
]	O	O
T3	O	O
in	O	O
the	O	O
extracts	O	O
was	O	O
achieved	O	O
using	O	O
the	O	O
calcium	O	O
phosphate	O	O
matrix	O	O
,	O	O
hydroxyapatite	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
0.3	O	O
ml	O	O
of	O	O
a	O	O
150	O	O
g/l	O	O
slurry	O	O
.	O	O

Rectilinear	O	O
Scatchard	O	O
plots	O	O
were	O	O
obtained	O	O
only	O	O
when	O	O
the	O	O
hydroxyapatite	O	O
was	O	O
washed	O	O
with	O	O
a	O	O
buffer	O	O
containing	O	O
0.5	O	O
%	O	O
Triton	O	O
X-100	O	O
.	O	O

Under	O	O
these	O	O
conditions	O	O
T3	O	O
binding	O	O
sites	O	O
in	O	O
the	O	O
nuclear	O	O
extracts	O	O
were	O	O
present	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
22.4	O	O
+/-	O	O
8.6	O	O
fmol/mg	O	O
protein	O	O
and	O	O
showed	O	O
an	O	O
affinity	O	O
of	O	O
(	O	O
Kd	O	O
,	O	O
room	O	O
temperature	O	O
)	O	O
140	O	O
+/-	O	O
10	O	O
pmol/l	O	O
.	O	O

The	O	O
same	O	O
assay	O	O
system	O	O
was	O	O
used	O	O
to	O	O
determine	O	O
the	O	O
hierarchy	O	O
of	O	O
affinities	O	O
for	O	O
a	O	O
range	O	O
of	O	O
natural	O	O
and	O	O
synthetic	B-protein	O
analogues	I-protein	O
.	O	O

Calling	O	O
T3	O	O
100	O	O
,	O	O
the	O	O
order	O	O
of	O	O
potencies	O	O
observed	O	O
was	O	O
:	O	O
Triac	O	O
,	O	O
500	O	O
;	O	O
3	O	O
,	O	O
5-diiodo-3'-isopropylthyronine	O	O
,	O	O
89	O	O
;	O	O
T4	O	O
,	O	O
32	O	O
;	O	O
3	O	O
,	O	O
5-dimethyl-3'isopropylthyronine	O	O
2	O	O
;	O	O
3	O	O
,	O	O
5-T2	O	O
,	O	O
0.7	O	O
,	O	O
rT3	O	O
,	O	O
0.4	O	O
;	O	O
3'5'-T2	O	O
,	O	O
less	O	O
than	O	O
0.01	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
T3	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
present	O	O
in	O	O
human	O	O
IM-9	O	O
lymphocyte	O	O
nuclei	O	O
and	O	O
extracts	O	O
thereof	O	O
are	O	O
thyroid	O	O
hormone	B-protein	O
receptors	I-protein	O
.	O	O

These	O	O
cells	I-cell_type	O
may	O	O
be	O	O
a	O	O
useful	O	O
tool	O	O
to	O	O
increase	O	O
our	O	O
understanding	O	O
of	O	O
human	O	O
T3	B-protein	O
receptors	I-protein	O

Definition	O	O
of	O	O
T-cell	O	O
specific	O	O
DNA-binding	B-protein	O
factors	I-protein	O
that	O	O
interact	O	O
with	O	O
a	O	O
3'-silencer	O	O
in	O	O
the	O	O
CD4+	B-DNA	O
T-cell	I-DNA	O
gene	I-DNA	O
Rpt-1	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
region	O	O
3	O	O
'	O	O
to	O	O
the	O	O
CD4+	B-DNA	O
T-cell	I-DNA	O
gene	I-DNA	O
Rpt-1	O	O
(	O	O
encoding	O	O
regulatory	B-protein	O
protein	I-protein	O
T-lymphocyte	O	O
1	O	O
)	O	O
led	O	O
to	O	O
the	O	O
definition	O	O
of	O	O
a	O	O
silencer	B-DNA	O
element	I-DNA	O
that	O	O
inhibits	O	O
heterologous	O	O
gene	O	O
expression	O	O
in	O	O
certain	O	O
CD4+	I-cell_line	O
T-cell	I-cell_line	O
lines	I-cell_line	O
but	O	O
not	O	O
in	O	O
B-cell	O	O
or	O	O
non-lymphoid	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

Functional	O	O
silencer	O	O
activity	O	O
in	O	O
vivo	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
specific	O	O
silencer-DNA-protein	B-protein	O
complex	I-protein	O
in	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
with	O	O
T-cell	O	O
extracts	O	O
.	O	O

Formation	O	O
of	O	O
this	O	O
complex	O	O
was	O	O
selectively	O	O
inhibited	O	O
by	O	O
the	O	O
region	O	O
in	O	O
HIV-1	O	O
containing	O	O
a	O	O
silencer	B-DNA	O
element	I-DNA	O
.	O	O

We	O	O
discuss	O	O
the	O	O
possibility	O	O
that	O	O
DNA-binding	B-protein	O
factors	I-protein	O
may	O	O
coregulate	O	O
HIV-1	O	O
and	O	O
Rpt-1	O	O
gene	O	O
expression	O	O
through	O	O
a	O	O
common	O	O
transcriptional	O	O
silencer	B-DNA	O
element	I-DNA	O
.	O	O

Congenital	O	O
immunodeficiencies	O	O
associated	O	O
with	O	O
absence	O	O
of	O	O
HLA	O	O
class	B-protein	O
II	I-protein	O
antigens	O	O
on	O	O
lymphocytes	I-cell_type	O
result	O	O
from	O	O
distinct	O	O
mutations	O	O
in	O	O
trans-acting	B-protein	O
factors	I-protein	O
.	O	O

Coordinate	O	O
regulation	O	O
of	O	O
HLA	B-DNA	O
class	I-DNA	O
II	I-DNA	O
gene	I-DNA	O
expression	O	O
during	O	O
development	O	O
and	O	O
coinduction	O	O
of	O	O
class	B-protein	O
II	I-protein	O
genes	O	O
by	O	O
soluble	B-protein	O
factors	I-protein	O
suggests	O	O
that	O	O
common	O	O
trans-acting	B-protein	O
factor	I-protein	O
(	O	O
s	O	O
)	O	O
control	O	O
expression	O	O
of	O	O
these	O	O
genes	O	O
.	O	O

In	O	O
B-lymphoblastoid	O	O
cell	O	O
lines	O	O
derived	O	O
from	O	O
two	O	O
independent	O	O
class	O	O
II-deficient	O	O
bare	O	O
lymphocyte	O	O
syndrome	O	O
patients	O	O
,	O	O
we	O	O
observed	O	O
a	O	O
drastic	O	O
decrease	O	O
in	O	O
transcription	O	O
rates	O	O
of	O	O
the	O	O
class	B-DNA	O
II	I-DNA	O
genes	I-DNA	O
.	O	O

When	O	O
these	O	O
cell	O	O
lines	O	O
are	O	O
fused	O	O
,	O	O
class	O	O
II	O	O
genes	O	O
are	O	O
reexpressed	O	O
,	O	O
indicating	O	O
that	O	O
immunodeficiencies	O	O
in	O	O
bare	O	O
lymphocyte	O	O
syndrome	O	O
patients	O	O
are	O	O
the	O	O
result	O	O
of	O	O
two	O	O
distinct	O	O
mutations	O	O
.	O	O

Further	O	O
studies	O	O
show	O	O
that	O	O
genes	O	O
governing	O	O
the	O	O
expression	O	O
of	O	O
class	B-protein	O
II	I-protein	O
antigens	O	O
fall	O	O
into	O	O
at	O	O
least	O	O
three	O	O
complementation	O	O
groups	O	O
;	O	O
two	O	O
of	O	O
these	O	O
were	O	O
previously	O	O
unidentified	O	O
in	O	O
mutant	O	O
cell	O	O
lines	O	O
generated	O	O
in	O	O
vitro	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
report	O	O
the	O	O
identification	O	O
of	O	O
two	O	O
discrete	B-protein	O
complexes	I-protein	O
,	O	O
NFX1.1	O	O
and	O	O
NFX1.2	O	O
,	O	O
that	O	O
bind	O	O
to	O	O
the	O	O
DRA	B-DNA	O
X	I-DNA	O
consensus	I-DNA	O
element	I-DNA	O
.	O	O

Though	O	O
the	O	O
mutation	O	O
in	O	O
at	O	O
least	O	O
one	O	O
mutant	O	O
line	O	O
generated	O	O
in	O	O
vitro	O	O
(	O	O
RJ2.2.5	O	O
)	O	O
affects	O	O
products	O	O
functioning	O	O
via	O	O
interaction	O	O
with	O	O
the	O	O
X	B-protein	O
box	I-protein	O
,	O	O
clear	O	O
alterations	O	O
in	O	O
either	O	O
NFX1.1	O	O
or	O	O
NFX1.2	O	O
are	O	O
not	O	O
found	O	O
in	O	O
any	O	O
of	O	O
the	O	O
mutant	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

In	O	O
vivo	O	O
responsiveness	O	O
to	O	O
glucocorticoid	O	O
correlated	O	O
with	O	O
glucocorticoid	B-protein	O
receptor	O	O
content	O	O
in	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
in	O	O
normal	O	O
humans	O	O
.	O	O

Dexamethasone	O	O
loading	O	O
tests	O	O
(	O	O
0.1	O	O
mg	O	O
dexamethasone/kg	O	O
,	O	O
iv	O	O
)	O	O
were	O	O
performed	O	O
in	O	O
18	O	O
normal	O	O
males	O	O
to	O	O
evaluate	O	O
the	O	O
individual	O	O
responsiveness	O	O
to	O	O
glucocorticoid	O	O
.	O	O

There	O	O
were	O	O
inter-individual	O	O
differences	O	O
in	O	O
increase	O	O
in	O	O
peripheral	O	O
blood	O	O
polymorphonuclear	O	O
leukocyte	O	O
count	O	O
,	O	O
decrease	O	O
in	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
lymphocyte	O	O
count	O	O
,	O	O
and	O	O
increase	O	O
in	O	O
plasma	O	O
free	O	O
fatty	O	O
acids	O	O
levels	O	O
after	O	O
dexamethasone	O	O
injection	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
correlation	O	O
between	O	O
the	O	O
maximum	O	O
increase	O	O
in	O	O
polymorphonuclear	O	O
leukocytes	O	O
and	O	O
the	O	O
maximum	O	O
decrease	O	O
in	O	O
lymphocytes	I-cell_type	O
(	O	O
r	O	O
=	O	O
0.7514	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.0003	O	O
)	O	O
.	O	O

Simultaneous	O	O
measurements	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
content	O	O
by	O	O
whole-cell	O	O
assay	O	O
revealed	O	O
that	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
content	O	O
in	O	O
polymorphonuclear	O	O
leukocytes	O	O
linearly	O	O
correlated	O	O
with	O	O
that	O	O
in	O	O
the	O	O
corresponding	O	O
lymphocytes	I-cell_type	O
(	O	O
r	O	O
=	O	O
0.9482	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.0001	O	O
)	O	O
.	O	O

There	O	O
were	O	O
also	O	O
significant	O	O
correlations	O	O
between	O	O
the	O	O
maximum	O	O
increase	O	O
in	O	O
polymorphonuclear	O	O
leukocytes	O	O
and	O	O
glucocorticoid	O	O
receptor	O	O
content	O	O
in	O	O
polymorphonuclear	O	O
leukocytes	O	O
(	O	O
r	O	O
=	O	O
0.7239	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.0007	O	O
)	O	O
,	O	O
and	O	O
between	O	O
the	O	O
maximum	O	O
decrease	O	O
in	O	O
lymphocytes	I-cell_type	O
and	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
content	O	O
in	O	O
lymphocytes	B-cell_type	O
(	O	O
r	O	O
=	O	O
0.7703	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0.0002	O	O
)	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
individual	O	O
differences	O	O
are	O	O
preserved	O	O
both	O	O
in	O	O
glucocorticoid	O	O
responsiveness	O	O
and	O	O
in	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
content	O	O
in	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
in	O	O
normal	O	O
humans	O	O
.	O	O

Estradiol	O	O
receptors	O	O
in	O	O
the	O	O
cytosol	O	O
of	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
in	O	O
hepatitis	O	O
B	O	O
virus	O	O
carriers	O	O
treated	O	O
with	O	O
interferon-alpha	O	O
.	O	O

Estradiol	O	O
receptors	O	O
in	O	O
the	O	O
cytosol	O	O
of	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
and	O	O
the	O	O
effects	O	O
of	O	O
interferon-alpha	O	O
(	O	O
IFN-alpha	B-protein	O
)	O	O
on	O	O
estradiol	O	O
receptors	O	O
were	O	O
studied	O	O
in	O	O
asymptomatic	O	O
hepatitis	O	O
B	O	O
virus	O	O
(	O	O
HBV	O	O
)	O	O
carriers	O	O
,	O	O
patients	O	O
with	O	O
chronic	O	O
hepatitis	O	O
B	O	O
and	O	O
normal	O	O
controls	O	O
.	O	O

The	O	O
level	O	O
of	O	O
estradiol	O	O
receptors	O	O
in	O	O
the	O	O
cytosol	O	O
of	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
asymptomatic	O	O
HBV	O	O
carriers	O	O
and	O	O
patients	O	O
with	O	O
chronic	O	O
hepatitis	O	O
B	O	O
,	O	O
compared	O	O
to	O	O
normal	O	O
controls	O	O
.	O	O

This	O	O
low	O	O
level	O	O
of	O	O
cytosol	O	O
estradiol	O	O
receptors	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
hepatitis	O	O
B	O	O
was	O	O
increased	O	O
by	O	O
the	O	O
administration	O	O
of	O	O
IFN-alpha	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
when	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
from	O	O
patients	O	O
with	O	O
chronic	O	O
hepatitis	O	O
B	O	O
were	O	O
incubated	O	O
with	O	O
IFN-alpha	O	O
in	O	O
vitro	O	O
,	O	O
the	O	O
level	O	O
of	O	O
cytosol	O	O
estradiol	O	O
receptors	O	O
also	O	O
increased	O	O
by	O	O
increasing	O	O
the	O	O
concentration	O	O
of	O	O
IFN-alpha	O	O
.	O	O

We	O	O
previously	O	O
reported	O	O
that	O	O
the	O	O
response	O	O
of	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
to	O	O
estrogen	O	O
is	O	O
impaired	O	O
in	O	O
HBV	O	O
carriers	O	O
,	O	O
and	O	O
our	O	O
present	O	O
results	O	O
suggested	O	O
that	O	O
this	O	O
may	O	O
be	O	O
due	O	O
to	O	O
the	O	O
low	O	O
level	O	O
of	O	O
estradiol	O	O
receptors	O	O
in	O	O
the	O	O
cytosol	O	O
of	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
.	O	O

Association	O	O
of	O	O
increased	O	O
lytic	O	O
effector	O	O
cell	O	O
function	O	O
with	O	O
high	O	O
estrogen	O	O
receptor	O	O
levels	O	O
in	O	O
tumor-bearing	O	O
patients	O	O
with	O	O
breast	O	O
cancer	O	O
.	O	O

Tumor-bearing	O	O
patients	O	O
with	O	O
breast	O	O
cancer	O	O
were	O	O
assayed	O	O
for	O	O
their	O	O
natural	O	O
killer	O	O
(	O	O
NK	O	O
)	O	O
cell	O	O
activity	O	O
and	O	O
for	O	O
the	O	O
function	O	O
of	O	O
activated	O	O
cytotoxic	O	O
T-cells	O	O
,	O	O
as	O	O
assessed	O	O
by	O	O
lectin-dependent	O	O
cellular	O	O
cytotoxicity	O	O
(	O	O
LDCC	O	O
)	O	O
.	O	O

Tumor-bearing	O	O
patients	O	O
with	O	O
breast	O	O
cancer	O	O
had	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
NK	O	O
activity	O	O
and	O	O
in	O	O
LDCC	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
healthy	O	O
control	O	O
individuals	O	O
.	O	O

Although	O	O
the	O	O
enhanced	O	O
NK	O	O
cell	O	O
activity	O	O
and	O	O
LDCC	O	O
were	O	O
closely	O	O
associated	O	O
with	O	O
high	O	O
levels	O	O
(	O	O
greater	O	O
than	O	O
31	O	O
fmol/mg	O	O
)	O	O
of	O	O
estrogen	B-protein	O
receptor	I-protein	O
(	O	O
ER	B-protein	O
)	O	O
content	O	O
in	O	O
the	O	O
primary	O	O
tumor	O	O
,	O	O
no	O	O
other	O	O
clinical	O	O
or	O	O
histologic	O	O
correlation	O	O
between	O	O
the	O	O
increase	O	O
in	O	O
either	O	O
parameter	O	O
of	O	O
cytotoxic	O	O
effector	O	O
cell	O	O
function	O	O
could	O	O
be	O	O
found	O	O
.	O	O

Thus	O	O
,	O	O
ER	O	O
levels	O	O
greater	O	O
than	O	O
31	O	O
fmol/mg	O	O
might	O	O
be	O	O
associated	O	O
with	O	O
increased	O	O
cytotoxic	O	O
effector	O	O
cell	O	O
function	O	O
in	O	O
tumor-bearing	O	O
patients	O	O
with	O	O
breast	O	O
cancer	O	O
.	O	O

Properties	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
Epstein-Barr	O	O
virus-transformed	O	O
lymphocytes	O	O
from	O	O
patients	O	O
with	O	O
familial	O	O
cortisol	O	O
resistance	O	O
.	O	O

In	O	O
a	O	O
previous	O	O
report	O	O
of	O	O
two	O	O
patients	O	O
with	O	O
familial	O	O
glucocorticoid	O	O
resistance	O	O
due	O	O
to	O	O
reduced	O	O
numbers	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
,	O	O
we	O	O
have	O	O
shown	O	O
decreased	O	O
numbers	O	O
of	O	O
GR	O	O
in	O	O
peripheral	B-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
and	O	O
cultured	O	O
fibroblasts	O	O
but	O	O
normal	O	O
affinity	O	O
of	O	O
GR	O	O
in	O	O
both	O	O
patients	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
peripheral	O	O
lymphocytes	I-cell_type	O
from	O	O
these	O	O
patients	O	O
,	O	O
one	O	O
patient	O	O
's	O	O
son	O	O
and	O	O
daughter	O	O
,	O	O
and	O	O
normal	O	O
subjects	O	O
were	O	O
transformed	O	O
with	O	O
Epstein-Barr	O	O
virus	O	O
.	O	O

Reduced	O	O
numbers	O	O
and	O	O
normal	O	O
affinity	O	O
of	O	O
GR	O	O
were	O	O
found	O	O
in	O	O
the	O	O
Epstein-Barr	O	O
virus-transformed	O	O
lymphocytes	O	O
from	O	O
both	O	O
patients	O	O
while	O	O
the	O	O
son	O	O
and	O	O
daughter	O	O
had	O	O
normal	O	O
numbers	O	O
and	O	O
affinity	O	O
of	O	O
GR	B-protein	O
.	O	O

The	O	O
thermal	O	O
stability	O	O
of	O	O
GR	B-protein	O
and	O	O
thermal	O	O
activation	O	O
of	O	O
cytosolic	O	O
receptors	O	O
in	O	O
both	O	O
patients	O	O
were	O	O
found	O	O
to	O	O
be	O	O
normal	O	O
.	O	O

Although	O	O
the	O	O
percentages	O	O
of	O	O
nuclear	O	O
bound	O	O
GR	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
patients	O	O
and	O	O
normal	O	O
controls	O	O
,	O	O
the	O	O
absolute	O	O
amounts	O	O
of	O	O
nuclear	O	O
bound	O	O
GR	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
about	O	O
one-half	O	O
that	O	O
of	O	O
normal	O	O
controls	O	O
.	O	O

These	O	O
abnormal	O	O
properties	O	O
of	O	O
GR	B-protein	O
(	O	O
reduced	O	O
numbers	O	O
of	O	O
GR	B-protein	O
)	O	O
were	O	O
preserved	O	O
in	O	O
the	O	O
transformed	B-cell_type	O
cells	I-cell_type	O
from	O	O
the	O	O
patients	O	O
.	O	O

Octamer	O	O
transcription	B-protein	O
factors	I-protein	O
1	O	O
and	O	O
2	O	O
each	O	O
bind	O	O
to	O	O
two	O	O
different	O	O
functional	B-DNA	O
elements	I-DNA	O
in	O	O
the	O	O
immunoglobulin	O	O
heavy-chain	B-DNA	O
promoter	I-DNA	O
.	O	O

Immunoglobulin	O	O
heavy-chain	O	O
genes	O	O
contain	O	O
two	O	O
conserved	B-DNA	O
sequence	I-DNA	O
elements	I-DNA	O
5	O	O
'	O	O
to	O	O
the	O	O
site	O	O
of	O	O
transcription	O	O
initiation	O	O
:	O	O
the	O	O
octamer	O	O
ATGCAAAT	O	O
and	O	O
the	O	O
heptamer	O	O
CTCATGA	O	O
.	O	O

Both	O	O
of	O	O
these	O	O
elements	O	O
are	O	O
required	O	O
for	O	O
normal	B-DNA	O
cell-specific	I-DNA	O
promoter	I-DNA	O
function	O	O
.	O	O

The	O	O
present	O	O
study	O	O
demonstrates	O	O
that	O	O
both	O	O
the	O	O
ubiquitous	B-protein	O
and	O	O
lymphoid-cell-specific	O	O
octamer	O	O
transcription	B-protein	O
factors	I-protein	O
(	O	O
OTF-1	O	O
and	O	O
OTF-2	O	O
,	O	O
respectively	O	O
)	O	O
interact	O	O
specifically	O	O
with	O	O
each	O	O
of	O	O
the	O	O
two	O	O
conserved	B-DNA	O
sequence	I-DNA	O
elements	I-DNA	O
,	O	O
forming	O	O
either	O	O
homo-	O	O
or	O	O
heterodimeric	O	O
complexes	O	O
.	O	O

This	O	O
was	O	O
surprising	O	O
,	O	O
since	O	O
the	O	O
heptamer	O	O
and	O	O
octamer	O	O
sequence	B-protein	O
motifs	I-protein	O
bear	O	O
no	O	O
obvious	O	O
similarity	O	O
to	O	O
each	O	O
other	O	O
.	O	O

Binding	O	O
of	O	O
either	O	O
factor	O	O
to	O	O
the	O	O
octamer	B-DNA	O
element	I-DNA	O
occurred	O	O
independently	O	O
.	O	O

However	O	O
,	O	O
OTF	O	O
interaction	O	O
with	O	O
the	O	O
heptamer	B-DNA	O
sequence	I-DNA	O
appeared	O	O
to	O	O
require	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
intact	O	O
octamer	B-protein	O
motif	I-protein	O
and	O	O
occurred	O	O
with	O	O
a	O	O
spacing	O	O
of	O	O
either	O	O
2	O	O
or	O	O
14	O	O
base	O	O
pairs	O	O
between	O	O
the	O	O
two	O	O
elements	O	O
,	O	O
suggesting	O	O
coordinate	O	O
binding	O	O
resulting	O	O
from	O	O
protein-protein	O	O
interactions	O	O
.	O	O

The	O	O
degeneracy	O	O
in	O	O
sequences	O	O
recognized	O	O
by	O	O
the	O	O
OTFs	O	O
may	O	O
be	O	O
important	O	O
in	O	O
widening	O	O
the	O	O
range	O	O
over	O	O
which	O	O
gene	O	O
expression	O	O
can	O	O
be	O	O
modulated	O	O
and	O	O
in	O	O
establishing	O	O
cell	O	O
type	O	O
specificity	O	O
.	O	O

Identification	O	O
of	O	O
a	O	O
novel	O	O
lymphoid	B-protein	O
specific	I-protein	O
octamer	I-protein	O
binding	I-protein	O
protein	I-protein	O
(	O	O
OTF-2B	B-protein	O
)	O	O
by	O	O
proteolytic	O	O
clipping	O	O
bandshift	O	O
assay	O	O
(	O	O
PCBA	O	O
)	O	O
.	O	O

The	O	O
octamer	B-DNA	O
sequence	I-DNA	O
ATGCAAAT	O	O
is	O	O
found	O	O
in	O	O
the	O	O
promoters	O	O
of	O	O
immunoglobulin	O	O
(	O	O
Ig	B-protein	O
)	O	O
heavy	O	O
and	O	O
light	O	O
chain	O	O
genes	O	O
and	O	O
in	O	O
the	O	O
heavy	B-DNA	O
chain	I-DNA	O
enhancer	I-DNA	O
and	O	O
is	O	O
a	O	O
major	O	O
determinant	O	O
of	O	O
the	O	O
cell	O	O
type	O	O
specific	O	O
expression	O	O
of	O	O
Ig	B-DNA	O
genes	I-DNA	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

An	O	O
apparent	O	O
paradox	O	O
is	O	O
that	O	O
the	O	O
same	O	O
sequence	O	O
serves	O	O
as	O	O
an	O	O
upstream	B-DNA	O
promoter	I-DNA	O
or	O	O
enhancer	B-DNA	O
element	I-DNA	O
in	O	O
a	O	O
variety	O	O
of	O	O
housekeeping	O	O
genes	O	O
such	O	O
as	O	O
the	O	O
histone	O	O
H2B	O	O
and	O	O
U	B-DNA	O
snRNA	I-DNA	O
genes	I-DNA	O
.	O	O

The	O	O
differential	O	O
usage	O	O
of	O	O
this	O	O
regulatory	B-DNA	O
sequence	I-DNA	O
motif	I-DNA	O
is	O	O
thought	O	O
to	O	O
be	O	O
mediated	O	O
by	O	O
different	O	O
species	O	O
of	O	O
octamer	B-protein	O
binding	I-protein	O
proteins	I-protein	O
.	O	O

One	O	O
species	O	O
of	O	O
100	O	O
kd	O	O
,	O	O
designated	O	O
OTF-1	O	O
,	O	O
is	O	O
present	O	O
in	O	O
all	O	O
cell	O	O
types	O	O
and	O	O
may	O	O
exert	O	O
its	O	O
activating	O	O
function	O	O
only	O	O
when	O	O
it	O	O
can	O	O
interact	O	O
with	O	O
additional	O	O
adjacent	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

The	O	O
lymphoid	O	O
cell	O	O
specific	O	O
octamer	O	O
binding	O	O
protein	O	O
of	O	O
60	O	O
kd	O	O
(	O	O
OTF-2A	O	O
)	O	O
specifically	O	O
stimulates	O	O
Ig	O	O
promoters	O	O
which	O	O
consist	O	O
essentially	O	O
of	O	O
a	O	O
TATA-box	O	O
and	O	O
an	O	O
octamer	B-DNA	O
sequence	I-DNA	O
upstream	O	O
of	O	O
it	O	O
.	O	O

Here	O	O
we	O	O
present	O	O
evidence	O	O
for	O	O
yet	O	O
another	O	O
B	O	O
cell	O	O
specific	O	O
octamer	O	O
binding	O	O
protein	O	O
of	O	O
75	O	O
kd	O	O
(	O	O
OTF-2B	B-protein	O
)	O	O
.	O	O

From	O	O
several	O	O
findings	O	O
,	O	O
including	O	O
the	O	O
absence	O	O
of	O	O
OTF-2B	B-protein	O
(	O	O
but	O	O
not	O	O
OTF-2A	O	O
)	O	O
from	O	O
a	O	O
lymphocyte	O	O
line	O	O
that	O	O
can	O	O
not	O	O
respond	O	O
to	O	O
the	O	O
IgH	B-DNA	O
enhancer	I-DNA	O
,	O	O
we	O	O
propose	O	O
a	O	O
role	O	O
of	O	O
the	O	O
novel	B-protein	O
octamer	I-protein	O
factor	I-protein	O
in	O	O
the	O	O
long	O	O
range	O	O
activation	O	O
by	O	O
the	O	O
IgH	B-DNA	O
enhancer	I-DNA	O
.	O	O

We	O	O
have	O	O
used	O	O
the	O	O
proteolytic	O	O
clipping	O	O
bandshift	O	O
assay	O	O
(	O	O
PCBA	O	O
)	O	O
technique	O	O
to	O	O
distinguish	O	O
the	O	O
three	O	O
different	O	O
forms	O	O
found	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

This	O	O
analysis	O	O
indicates	O	O
that	O	O
the	O	O
75	O	O
kd-species	O	O
OTF-2B	O	O
is	O	O
closely	O	O
related	O	O
to	O	O
the	O	O
60	O	O
kd	O	O
species	O	O
OTF-2A	O	O
.	O	O

Inhibition	O	O
of	O	O
interleukin	B-protein	O
2	I-protein	O
-induced	O	O
proliferation	O	O
of	O	O
cloned	B-cell_line	O
murine	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
by	O	O
glucocorticoids	O	O
.	O	O

Possible	O	O
involvement	O	O
of	O	O
an	O	O
inhibitory	B-protein	O
protein	I-protein	O
.	O	O

The	O	O
ability	O	O
of	O	O
glucocorticoids	O	O
to	O	O
inhibit	O	O
interleukin	B-protein	O
2	I-protein	O
(	O	O
IL	I-protein	O
2	I-protein	O
)	O	O
-induced	O	O
T	O	O
cell	O	O
proliferation	O	O
in	O	O
two	O	O
cytotoxic	O	O
T	O	O
cell	O	O
(	O	O
CTL	O	O
)	O	O
clones	O	O
has	O	O
been	O	O
studied	O	O
.	O	O

A	O	O
complete	O	O
inhibition	O	O
of	O	O
DNA	O	O
synthesis	O	O
by	O	O
dexamethasone	O	O
(	O	O
Dx	B-protein	O
)	O	O
could	O	O
be	O	O
observed	O	O
when	O	O
IL	O	O
2-depleted	O	O
cultures	O	O
of	O	O
CTL	O	O
were	O	O
either	O	O
incubated	O	O
for	O	O
6	O	O
h	O	O
with	O	O
the	O	O
hormone	O	O
prior	O	O
to	O	O
the	O	O
addition	O	O
of	O	O
IL	O	O
2	O	O
or	O	O
treated	O	O
simultaneously	O	O
with	O	O
Dx	O	O
and	O	O
a	O	O
low	O	O
concentration	O	O
of	O	O
IL	O	O
2	O	O
.	O	O

No	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
and	O	O
affinity	O	O
of	O	O
IL	O	O
2	O	O
receptors	O	O
was	O	O
seen	O	O
after	O	O
6	O	O
h	O	O
incubation	O	O
with	O	O
Dx	O	O
.	O	O

The	O	O
order	O	O
of	O	O
potency	O	O
observed	O	O
with	O	O
the	O	O
different	O	O
steroids	O	O
indicated	O	O
that	O	O
this	O	O
inhibitory	O	O
effect	O	O
was	O	O
mediated	O	O
through	O	O
binding	O	O
to	O	O
a	O	O
specific	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
.	O	O

The	O	O
action	O	O
of	O	O
these	O	O
hormones	O	O
possibly	O	O
involves	O	O
the	O	O
synthesis	O	O
of	O	O
an	O	O
inhibitory	B-protein	O
protein	I-protein	O
(	O	O
s	O	O
)	O	O
,	O	O
since	O	O
the	O	O
presence	O	O
of	O	O
cycloheximide	O	O
during	O	O
the	O	O
incubation	O	O
with	O	O
Dx	O	O
prevented	O	O
the	O	O
inhibition	O	O
of	O	O
DNA	O	O
synthesis	O	O
.	O	O

Furthermore	O	O
,	O	O
supernatant	O	O
from	O	O
Dx-treated	O	O
CTL	O	O
contained	O	O
a	O	O
nondialyzable	B-protein	O
factor	I-protein	O
which	O	O
inhibited	O	O
DNA	O	O
synthesis	O	O
and	O	O
cell	O	O
growth	O	O
of	O	O
CTL	O	O
clones	O	O
induced	O	O
by	O	O
IL	O	O
2	O	O
.	O	O

Blocking	O	O
of	O	O
IL	O	O
2	O	O
synthesis	O	O
and	O	O
IL	B-protein	O
2	I-protein	O
receptor	I-protein	O
formation	O	O
have	O	O
been	O	O
proposed	O	O
as	O	O
one	O	O
of	O	O
the	O	O
major	O	O
mechanisms	O	O
of	O	O
glucocorticoid-induced	O	O
immunosuppression	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
these	O	O
hormones	O	O
may	O	O
also	O	O
affect	O	O
T	O	O
cell	O	O
proliferation	O	O
by	O	O
inhibiting	O	O
IL	O	O
2	O	O
activity	O	O
.	O	O

Identification	O	O
and	O	O
purification	O	O
of	O	O
a	O	O
human	B-protein	O
immunoglobulin-enhancer-binding	I-protein	O
protein	I-protein	O
(	O	O
NF-kappa	B-protein	O
B	I-protein	O
)	O	O
that	O	O
activates	O	O
transcription	O	O
from	O	O
a	O	O
human	B-DNA	O
immunodeficiency	I-DNA	O
virus	I-DNA	O
type	I-DNA	O
1	I-DNA	O
promoter	I-DNA	O
in	O	O
vitro	O	O
.	O	O

The	O	O
enhancer-binding	B-protein	O
factor	I-protein	O
NF-kappa	B-protein	O
B	I-protein	O
,	O	O
which	O	O
is	O	O
found	O	O
only	O	O
in	O	O
cells	O	O
that	O	O
transcribe	O	O
immunoglobulin	O	O
light	O	O
chain	O	O
genes	O	O
,	O	O
has	O	O
been	O	O
purified	O	O
from	O	O
nuclear	O	O
extracts	O	O
of	O	O
Namalwa	B-cell_type	O
cells	I-cell_type	O
(	O	O
human	B-cell_type	O
Burkitt	I-cell_type	O
lymphoma	I-cell_type	O
cells	I-cell_type	O
)	O	O
by	O	O
sequence-specific	O	O
DNA	O	O
affinity	O	O
chromatography	O	O
.	O	O

The	O	O
purified	O	O
NF-kappa	B-protein	O
B	I-protein	O
has	O	O
been	O	O
identified	O	O
as	O	O
a	O	O
51-kDa	O	O
polypeptide	O	O
by	O	O
UV-crosslinking	O	O
analysis	O	O
.	O	O

``	O	O
Footprint	O	O
''	O	O
and	O	O
methylation-interference	O	O
analyses	O	O
have	O	O
shown	O	O
that	O	O
purified	O	O
NF-kappa	B-protein	O
B	I-protein	O
has	O	O
a	O	O
binding	O	O
activity	O	O
specific	O	O
for	O	O
the	O	O
kappa	B-DNA	O
light	I-DNA	O
chain	I-DNA	O
enhancer	I-DNA	O
sequence	I-DNA	O
.	O	O

The	O	O
purified	B-protein	O
factor	I-protein	O
activated	O	O
in	O	O
vitro	O	O
transcription	O	O
of	O	O
the	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	I-protein	O
I	I-protein	O
promoter	I-DNA	O
by	O	O
binding	O	O
to	O	O
an	O	O
upstream	B-DNA	O
NF-kappa	I-DNA	O
B-binding	I-DNA	O
site	I-DNA	O

Lymphocyte	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
binding	O	O
in	O	O
depression	O	O
:	O	O
normal	O	O
values	O	O
following	O	O
recovery	O	O
.	O	O

The	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
sites	O	O
in	O	O
lymphocytes	I-cell_type	O
and	O	O
plasma	O	O
cortisol	O	O
concentrations	O	O
were	O	O
measured	O	O
in	O	O
20	O	O
patients	O	O
who	O	O
had	O	O
recovered	O	O
from	O	O
major	O	O
depressive	O	O
disorder	O	O
and	O	O
20	O	O
healthy	O	O
control	O	O
subjects	O	O
.	O	O

The	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
sites	O	O
in	O	O
lymphocytes	O	O
from	O	O
the	O	O
recovered	O	O
depressed	O	O
group	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
from	O	O
that	O	O
of	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Although	O	O
the	O	O
mean	O	O
plasma	O	O
cortisol	O	O
concentration	O	O
in	O	O
recovered	O	O
depressives	O	O
was	O	O
higher	O	O
than	O	O
in	O	O
control	O	O
subjects	O	O
,	O	O
the	O	O
difference	O	O
only	O	O
just	O	O
reached	O	O
significance	O	O
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
the	O	O
reduction	O	O
in	O	O
glucocorticoid	O	O
receptor	O	O
numbers	O	O
which	O	O
occurs	O	O
during	O	O
acute	O	O
depressive	O	O
illness	O	O
does	O	O
not	O	O
persist	O	O
on	O	O
recovery	O	O
and	O	O
is	O	O
,	O	O
therefore	O	O
,	O	O
state-dependent	O	O
.	O	O

Identification	O	O
and	O	O
purification	O	O
of	O	O
a	O	O
human	B-protein	O
lymphoid-specific	I-protein	O
octamer-binding	I-protein	O
protein	I-protein	O
(	O	O
OTF-2	B-protein	O
)	O	O
that	O	O
activates	O	O
transcription	O	O
of	O	O
an	O	O
immunoglobulin	O	O
promoter	O	O
in	O	O
vitro	O	O
.	O	O

The	O	O
octamer	O	O
sequence	O	O
5'-ATGCAAAT	O	O
,	O	O
in	O	O
either	O	O
orientation	O	O
,	O	O
serves	O	O
as	O	O
an	O	O
upstream	O	O
element	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
promoters	O	O
and	O	O
also	O	O
occurs	O	O
as	O	O
a	O	O
modular	B-DNA	O
enhancer	I-DNA	O
element	I-DNA	O
.	O	O

It	O	O
is	O	O
of	O	O
particular	O	O
interest	O	O
in	O	O
immunoglobulin	O	O
genes	O	O
since	O	O
it	O	O
is	O	O
found	O	O
in	O	O
the	O	O
upstream	B-DNA	O
regions	I-DNA	O
of	O	O
all	O	O
heavy	O	O
and	O	O
light	O	O
chain	O	O
promoters	O	O
and	O	O
in	O	O
the	O	O
heavy	B-DNA	O
chain	I-DNA	O
enhancer	I-DNA	O
,	O	O
both	O	O
of	O	O
which	O	O
are	O	O
known	O	O
to	O	O
be	O	O
necessary	O	O
for	O	O
cell-specific	O	O
expression	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
chromatographic	O	O
separation	O	O
of	O	O
ubiquitous	B-protein	O
and	O	O
B	B-protein	O
cell-specific	I-protein	O
octamer-binding	I-protein	O
proteins	I-protein	O
.	O	O

The	O	O
B	B-protein	O
cell	I-protein	O
factor	I-protein	O
was	O	O
purified	O	O
to	O	O
homogeneity	O	O
using	O	O
affinity	O	O
chromatography	O	O
and	O	O
consists	O	O
of	O	O
three	O	O
peptides	O	O
of	O	O
62	B-protein	O
,	O	O
61	O	O
,	O	O
and	O	O
58.5	O	O
+/-	O	O
1.5	O	O
kd	O	O
.	O	O

Each	O	O
of	O	O
the	O	O
polypeptides	O	O
was	O	O
renatured	O	O
after	O	O
SDS-PAGE	O	O
and	O	O
shown	O	O
to	O	O
bind	O	O
to	O	O
the	O	O
octamer	B-DNA	O
sequence	I-DNA	O
.	O	O

The	O	O
specific	O	O
DNA	O	O
binding	O	O
activity	O	O
of	O	O
the	O	O
pure	B-protein	O
B	I-protein	O
cell-specific	I-protein	O
factor	I-protein	O
was	O	O
indistinguishable	O	O
from	O	O
that	O	O
of	O	O
the	O	O
affinity-purified	B-protein	O
ubiquitous	I-protein	O
factor	I-protein	O
.	O	O

This	O	O
B	B-protein	O
cell-specific	I-protein	O
octamer-binding	I-protein	O
factor	I-protein	O
,	O	O
in	O	O
pure	O	O
form	O	O
,	O	O
activated	O	O
transcription	O	O
from	O	O
a	O	O
kappa	B-DNA	O
light	I-DNA	O
chain	I-DNA	O
promoter	I-DNA	O
in	O	O
vitro	O	O
,	O	O
thus	O	O
demonstrating	O	O
that	O	O
it	O	O
is	O	O
indeed	O	O
a	O	O
B	B-protein	O
cell-specific	I-protein	O
transcription	I-protein	O
factor	I-protein	O
for	O	O
this	O	O
gene	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
ubiquitous	B-protein	O
and	I-protein	O
B	I-protein	O
cell-specific	I-protein	O
octamer-binding	B-protein	O
factors	I-protein	O
,	O	O
we	O	O
identified	O	O
several	O	O
additional	O	O
proteins	O	O
,	O	O
one	O	O
of	O	O
which	O	O
is	O	O
B	O	O
cell	O	O
-specific	O	O
,	O	O
that	O	O
interact	O	O
with	O	O
the	O	O
kappa	B-DNA	O
promoter	I-DNA	O
.	O	O

Decreased	O	O
deoxyribonucleic	O	O
acid	O	O
binding	O	O
of	O	O
glucocorticoid-receptor	B-protein	O
complex	I-protein	O
in	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
the	O	O
glucocorticoid	O	O
resistance	O	O
syndrome	O	O
.	O	O

A	O	O
patient	O	O
with	O	O
the	O	O
syndrome	O	O
of	O	O
glucocorticoid	O	O
resistance	O	O
was	O	O
studied	O	O
.	O	O

A	O	O
27-yr-old	O	O
woman	O	O
initially	O	O
was	O	O
diagnosed	O	O
as	O	O
having	O	O
Cushing	O	O
's	O	O
disease	O	O
,	O	O
based	O	O
on	O	O
the	O	O
findings	O	O
of	O	O
high	O	O
plasma	O	O
ACTH	O	O
and	O	O
serum	O	O
cortisol	O	O
levels	O	O
,	O	O
increased	O	O
urinary	O	O
cortisol	O	O
secretion	O	O
,	O	O
resistance	O	O
to	O	O
adrenal	O	O
suppression	O	O
with	O	O
dexamethasone	O	O
,	O	O
and	O	O
bilateral	O	O
adrenal	O	O
hyperplasia	O	O
by	O	O
computed	O	O
tomography	O	O
and	O	O
scintigraphy	O	O
of	O	O
the	O	O
adrenal	O	O
glands	I-protein	O
.	O	O

However	O	O
,	O	O
she	O	O
had	O	O
no	O	O
signs	O	O
or	O	O
symptoms	O	O
of	O	O
Cushing	O	O
's	O	O
syndrome	O	O
.	O	O

During	O	O
a	O	O
5-yr	O	O
follow-up	O	O
,	O	O
no	O	O
clinical	O	O
abnormalities	O	O
developed	O	O
,	O	O
although	O	O
hypercortisolism	O	O
persisted	O	O
.	O	O

End-organ	O	O
resistance	O	O
to	O	O
cortisol	O	O
was	O	O
suspected	O	O
.	O	O

To	O	O
explain	O	O
the	O	O
end-organ	O	O
resistance	O	O
to	O	O
cortisol	O	O
,	O	O
the	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
in	O	O
peripheral	O	O
mononuclear	O	O
leukocytes	O	O
and	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
from	O	O
a	O	O
forearm	O	O
skin	O	O
biopsy	O	O
were	O	O
characterized	O	O
and	O	O
compared	O	O
with	O	O
the	O	O
results	O	O
of	O	O
similar	O	O
studies	O	O
in	O	O
normal	O	O
subjects	O	O
.	O	O

The	O	O
patient	O	O
's	O	O
GR	O	O
in	O	O
whole	O	O
cell	O	O
assays	O	O
had	O	O
an	O	O
increased	O	O
dissociation	O	O
constant	O	O
(	O	O
Kd	O	O
)	O	O
.	O	O

In	O	O
the	O	O
cytosol	O	O
of	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
from	O	O
the	O	O
patient	O	O
,	O	O
there	O	O
was	O	O
also	O	O
decreased	O	O
binding	O	O
capacity	O	O
.	O	O

The	O	O
thermal	O	O
stability	O	O
and	O	O
the	O	O
sedimentation	O	O
coefficient	O	O
in	O	O
a	O	O
sucrose	O	O
density	O	O
gradient	O	O
of	O	O
the	O	O
receptors	O	O
in	O	O
the	O	O
cytosol	O	O
of	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
from	O	O
the	O	O
patient	O	O
and	O	O
normal	O	O
subjects	O	O
were	O	O
similar	O	O
.	O	O

GR	B-protein	O
complex	I-protein	O
activation	O	O
,	O	O
analyzed	O	O
by	O	O
DEAE-cellulose	O	O
chromatography	O	O
,	O	O
was	O	O
decreased	O	O
in	O	O
the	O	O
patient	O	O
.	O	O

DNA	O	O
binding	O	O
of	O	O
the	O	O
GR	B-protein	O
complex	I-protein	O
after	I-protein	O
temperature-induced	O	O
activation	O	O
was	O	O
lower	O	O
in	O	O
the	O	O
patient	O	O
than	O	O
in	O	O
normal	O	O
subjects	O	O
.	O	O

Nuclear	O	O
translocation	O	O
of	O	O
GR	B-protein	O
complexes	O	O
from	O	O
the	O	O
patient	O	O
was	O	O
also	O	O
slightly	O	O
decreased	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
patient	O	O
's	O	O
glucocorticoid	O	O
resistance	O	O
was	O	O
due	O	O
to	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
affinity	O	O
of	O	O
the	O	O
receptor	O	O
for	O	O
glucocorticoids	O	O
and	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
binding	O	O
of	O	O
the	O	O
GR	B-protein	O
complex	I-protein	O
to	O	O
DNA	O	O
.	O	O

Granulocyte-macrophage	B-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
.	O	O

Sensitive	O	O
and	O	O
receptor-mediated	O	O
regulation	O	O
by	O	O
1	O	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
in	O	O
normal	B-cell_type	O
human	I-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

We	O	O
show	O	O
that	O	O
1	O	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
(	O	O
1	O	O
,	O	O
25	O	O
[	O	O
OH	O	O
]	O	O
2D3	O	O
)	O	O
,	O	O
the	O	O
most	O	O
hormonally	O	O
active	O	O
metabolite	O	O
of	O	O
vitamin	O	O
D3	O	O
,	O	O
modulates	O	O
sensitively	O	O
and	O	O
specifically	O	O
both	O	O
the	O	O
protein	O	O
and	O	O
messenger	O	O
RNA	O	O
accumulation	O	O
of	O	O
the	O	O
multilineage	B-protein	O
growth	I-protein	O
factor	I-protein	O
granulocyte-macrophage	I-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
(	O	O
GM-CSF	B-protein	O
)	O	O
.	O	O

The	O	O
regulation	O	O
of	O	O
GM-CSF	B-protein	O
expression	O	O
is	O	O
seen	O	O
in	O	O
both	O	O
normal	O	O
human	B-cell_type	O
mitogen-activated	I-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
from	O	O
a	O	O
line	O	O
(	O	O
S-LB1	O	O
)	O	O
transformed	O	O
with	O	O
human	O	O
T	O	O
cell	O	O
lymphotropic	O	O
virus	O	O
1	O	O
(	O	O
HTLV-1	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
cells	O	O
from	O	O
a	O	O
HTLV-1	O	O
transformed	B-cell_line	O
T	I-cell_line	O
lymphocyte	I-cell_line	O
line	I-cell_line	O
(	O	O
Ab-VDR	O	O
)	O	O
established	O	O
from	O	O
a	O	O
patient	O	O
with	O	O
vitamin	O	O
D-resistant	O	O
rickets	O	O
type	O	O
II	O	O
with	O	O
undetectable	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
cellular	O	O
receptors	O	O
are	O	O
resistant	O	O
to	O	O
the	O	O
action	O	O
of	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
.	O	O

Inhibition	O	O
of	O	O
GM-CSF	B-protein	O
expression	O	O
by	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
can	O	O
occur	O	O
independently	O	O
of	O	O
interleukin	B-protein	O
2	O	O
regulation	O	O
and	O	O
is	O	O
probably	O	O
mediated	O	O
through	O	O
cellular	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
receptors	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
may	O	O
be	O	O
important	O	O
in	O	O
the	O	O
physiology	O	O
of	O	O
hematopoiesis	O	O
.	O	O

Altered	O	O
interaction	O	O
between	O	O
triiodothyronine	O	O
and	O	O
its	O	O
nuclear	B-protein	O
receptors	O	O
in	O	O
absence	O	O
of	O	O
cortisol	O	O
:	O	O
a	O	O
proposed	O	O
mechanism	O	O
for	O	O
increased	O	O
thyrotropin	O	O
secretion	O	O
in	O	O
corticosteroid	O	O
deficiency	O	O
states	O	O
.	O	O

Thyroid	O	O
hormones	O	O
occasionally	O	O
appear	O	O
less	O	O
effective	O	O
when	O	O
administered	O	O
alone	O	O
to	O	O
patients	O	O
with	O	O
panhypopituitarism	O	O
,	O	O
and	O	O
manifestations	O	O
suggestive	O	O
of	O	O
hypothyroidism	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
patients	O	O
suffering	O	O
from	O	O
untreated	O	O
Addison	O	O
's	O	O
disease	O	O
.	O	O

In	O	O
the	O	O
latter	O	O
condition	O	O
,	O	O
thyrotropin	O	O
secretion	O	O
is	O	O
increased	O	O
:	O	O
this	O	O
occurs	O	O
already	O	O
after	O	O
as	O	O
little	O	O
as	O	O
2	O	O
days	O	O
of	O	O
temporary	O	O
withdrawal	O	O
of	O	O
therapy	B-protein	O
with	O	O
substitution	O	O
doses	O	O
of	O	O
corticosteroids	O	O
while	O	O
circulating	O	O
levels	O	O
of	O	O
thyroid	O	O
hormones	O	O
remain	O	O
within	O	O
normal	O	O
limits	O	O
.	O	O

Therefore	O	O
,	O	O
a	O	O
possible	O	O
role	O	O
of	O	O
cortisol	O	O
in	O	O
interaction	O	O
between	O	O
triiodothyronine	O	O
and	O	O
its	O	O
nuclear	O	O
receptors	O	O
was	O	O
examined	O	O
at	O	O
the	O	O
level	O	O
of	O	O
circulating	O	O
lymphocytes	I-cell_type	O
obtained	O	O
from	O	O
patients	O	O
with	O	O
primary	O	O
or	O	O
secondary	O	O
adrenocortical	O	O
failure	O	O
.	O	O

The	O	O
affinity	O	O
of	O	O
these	O	O
receptors	O	O
was	O	O
found	O	O
to	O	O
be	O	O
decreased	O	O
,	O	O
by	O	O
more	O	O
than	O	O
50	O	O
%	O	O
on	O	O
average	O	O
,	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
cortisol	O	O
treatments	O	O
.	O	O

This	O	O
change	O	O
was	O	O
promptly	O	O
corrected	O	O
upon	O	O
resumption	O	O
of	O	O
therapy	B-protein	O
.	O	O

The	O	O
number	O	O
of	O	O
binding	B-DNA	O
sites	I-DNA	O
was	O	O
not	O	O
significantly	O	O
modified	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
cortisol	O	O
on	O	O
thyroid	B-protein	O
hormone	I-protein	O
receptors	I-protein	O
discussed	O	O
here	O	O
might	O	O
account	O	O
for	O	O
the	O	O
clinical	O	O
observations	O	O
mentioned	O	O
above	O	O
.	O	O

Inhibition	O	O
by	O	O
cortisol	O	O
of	O	O
human	B-cell_line	O
natural	I-cell_line	O
killer	I-cell_line	O
(	O	O
NK	B-protein	O
)	O	O
cell	O	O
activity	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
cortisol	O	O
on	O	O
the	O	O
natural	B-cell_line	O
killer	I-protein	O
(	O	O
NK	O	O
)	O	O
activity	O	O
of	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_line	O
(	I-cell_line	O
PBM	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
were	O	O
studied	O	O
in	O	O
vitro	O	O
using	O	O
a	O	O
direct	O	O
4-h	O	O
51Cr-release	O	O
assay	O	O
and	O	O
K	O	O
562	O	O
cell	O	O
line	O	O
as	O	O
a	O	O
target	O	O
.	O	O

Preincubation	O	O
for	O	O
20	O	O
h	O	O
of	O	O
PBM	B-cell_type	O
cells	I-cell_type	O
drawn	O	O
from	O	O
healthy	O	O
donors	O	O
with	O	O
1	O	O
X	O	O
10	O	O
(	O	O
-8	O	O
)	O	O
to	O	O
1	O	O
X	O	O
10	O	O
(	O	O
-5	O	O
)	O	O
M	O	O
cortisol	O	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
decrease	O	O
of	O	O
NK	O	O
cell	O	O
activity	O	O
.	O	O

The	O	O
magnitude	O	O
of	O	O
the	O	O
suppression	B-protein	O
was	O	O
directly	O	O
related	O	O
to	O	O
the	O	O
steroid	O	O
concentration	O	O
and	O	O
inversely	O	O
related	O	O
to	O	O
the	O	O
number	O	O
of	O	O
effector	B-cell_type	O
cells	I-cell_type	O
.	O	O

Cortisol	O	O
was	O	O
able	O	O
to	O	O
minimize	O	O
the	O	O
enhancement	O	O
of	O	O
NK	O	O
cytotoxicity	O	O
obtainable	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
immune	O	O
interferon	O	O
(	O	O
IFN-gamma	B-protein	O
)	O	O
.	O	O

A	O	O
significantly	O	O
higher	O	O
suppression	O	O
was	O	O
achieved	O	O
after	O	O
sequential	O	O
exposure	O	O
of	O	O
PBM	B-cell_type	O
cells	I-cell_type	O
to	O	O
cortisol	O	O
and	O	O
equimolar	O	O
levels	O	O
of	O	O
prostaglandin	O	O
E2	O	O
(	O	O
PgE2	O	O
)	O	O
.	O	O

The	O	O
concomitant	O	O
incubation	O	O
with	O	O
theophylline	O	O
and	O	O
isobutyl-methylxanthine	O	O
failed	O	O
to	O	O
enhance	O	O
the	O	O
cortisol-induced	O	O
suppression	O	O
,	O	O
whereas	O	O
PgE2-dependent	O	O
inhibition	O	O
significantly	O	O
increased	O	O
after	O	O
exposure	O	O
of	O	O
PBM	B-cell_type	O
cells	I-cell_type	O
to	O	O
methyl-xanthines	O	O
.	O	O

The	O	O
inhibitory	O	O
effect	O	O
of	O	O
cortisol	O	O
was	O	O
partially	O	O
or	O	O
totally	O	O
prevented	O	O
by	O	O
the	O	O
concomitant	O	O
incubation	O	O
with	O	O
equimolar	O	O
amounts	O	O
of	O	O
11-deoxycortisol	O	O
and	O	O
RU	O	O
486	O	O
but	O	O
not	O	O
of	O	O
progesterone	O	O
.	O	O

Treatment	O	O
of	O	O
NK	O	O
effectors	O	O
with	O	O
a	O	O
monoclonal	O	O
anti-human	O	O
corticosteroid-binding	O	O
globulin	O	O
(	O	O
CBG	O	O
)	O	O
antibody	O	O
produced	O	O
an	O	O
enhancement	O	O
of	O	O
the	O	O
spontaneous	O	O
NK	O	O
activity	O	O
and	O	O
a	O	O
partial	O	O
suppression	O	O
of	O	O
cortisol-mediated	O	O
effects	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
endogenous	O	O
glucocorticoids	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
NK	O	O
cell-mediated	O	O
cytotoxicity	O	O
.	O	O

Since	O	O
the	O	O
effect	O	O
of	O	O
cortisol	O	O
was	O	O
additive	O	O
to	O	O
that	O	O
of	O	O
PgE2	O	O
and	O	O
was	O	O
not	O	O
changed	O	O
by	O	O
phosphodiesterase	O	O
inhibitors	O	O
,	O	O
it	O	O
is	O	O
conceivable	O	O
that	O	O
the	O	O
hormone	O	O
acts	O	O
at	O	O
a	O	O
level	O	O
different	O	O
from	O	O
the	O	O
adenylate	O	O
cyclase	O	O
-	O	O
phosphodiesterase	O	O
system	O	O
.	O	O

Data	O	O
obtained	O	O
with	O	O
the	O	O
use	O	O
of	O	O
antiglucocorticoids	O	O
and	O	O
the	O	O
anti-CBG	O	O
antibody	O	O
are	O	O
compatible	O	O
with	O	O
a	O	O
role	O	O
both	O	O
of	O	O
high-affinity	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
and	O	O
of	O	O
CBG	O	O
in	O	O
mediating	O	O
cortisol	O	O
action	O	O
on	O	O
the	O	O
human	O	O
NK	O	O
cell	O	O
activity	O	O
.	O	O

Interaction	O	O
of	O	O
cell-type-specific	O	O
nuclear	B-protein	O
proteins	I-protein	O
with	O	O
immunoglobulin	O	O
VH	B-DNA	O
promoter	I-DNA	O
region	O	O
sequences	O	O
.	O	O

All	B-protein	O
human	I-protein	O
and	O	O
murine	O	O
immunoglobulin	O	O
heavy	O	O
chain	O	O
variable	I-DNA	O
region	I-DNA	O
(	O	O
VH	B-DNA	O
)	O	O
genes	O	O
contain	O	O
the	O	O
sequence	O	O
ATGCAAAT	O	O
approximately	O	O
70	O	O
nucleotides	O	O
5	O	O
'	O	O
from	O	O
the	O	O
site	O	O
of	O	O
transcription	O	O
initiation	O	O
.	O	O

This	O	O
octanucleotide	O	O
,	O	O
in	O	O
reverse	O	O
orientation	O	O
,	O	O
is	O	O
also	O	O
found	O	O
in	O	O
all	O	O
light	O	O
chain	O	O
variable	O	O
region	O	O
(	O	O
VL	O	O
)	O	O
genes	O	O
,	O	O
and	O	O
in	O	O
the	O	O
immunoglobulin	O	O
heavy	O	O
chain	O	O
transcriptional	O	O
enhancer	O	O
.	O	O

Transfection	O	O
studies	O	O
have	O	O
established	O	O
that	O	O
this	O	O
octamer	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
lymphoid-specific	O	O
transcription	O	O
of	O	O
immunoglobulin	O	O
genes	O	O
.	O	O

Octamer-containing	O	O
fragments	O	O
have	O	O
been	O	O
reported	O	O
to	O	O
bind	O	O
a	O	O
factor	O	O
present	O	O
in	O	O
nuclear	O	O
extracts	O	O
of	O	O
human	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
;	O	O
however	O	O
,	O	O
identical	O	O
binding	O	O
activity	O	O
was	O	O
detected	O	O
in	O	O
both	O	O
B	B-cell_type	O
lymphoid	I-cell_type	O
and	O	O
non-lymphoid	B-cell_type	O
cells	I-cell_type	O
.	O	O

Here	O	O
we	O	O
establish	O	O
that	O	O
nuclear	O	O
extracts	O	O
from	O	O
distinct	O	O
cell	O	O
types	O	O
differ	O	O
in	O	O
their	O	O
ability	O	O
to	O	O
interact	O	O
with	O	O
octamer-containing	O	O
fragments	O	O
.	O	O

We	O	O
have	O	O
also	O	O
detected	O	O
a	O	O
DNA-protein	O	O
interaction	O	O
that	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
cell-type	O	O
specificity	O	O
of	O	O
immunoglobulin	O	O
expression	O	O
,	O	O
and	O	O
we	O	O
have	O	O
determined	O	O
that	O	O
a	O	O
sequence	O	O
upstream	O	O
of	O	O
the	O	O
octamer	O	O
participates	O	O
in	O	O
an	O	O
interaction	O	O
with	O	O
a	O	O
nuclear	B-protein	O
protein	I-protein	O
(	O	O
s	O	O
)	O	O
.	O	O

Preferential	O	O
transcription	O	O
of	O	O
HTLV-I	B-DNA	O
LTR	I-DNA	O
in	O	O
cell-free	O	O
extracts	O	O
of	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
producing	O	O
HTLV-I	O	O
viral	B-protein	O
proteins	I-protein	O
.	O	O

The	O	O
promoters	O	O
of	O	O
the	O	O
adenovirus	B-DNA	O
2	I-DNA	O
major	I-DNA	O
late	I-DNA	O
gene	I-DNA	O
,	O	O
the	O	O
mouse	B-DNA	O
beta-globin	I-DNA	O
gene	I-DNA	O
,	O	O
the	O	O
mouse	B-DNA	O
immunoglobulin	I-DNA	O
VH	I-DNA	O
gene	I-DNA	O
and	O	O
the	O	O
LTR	O	O
of	O	O
the	O	O
human	B-protein	O
T-lymphotropic	I-protein	O
retrovirus	I-protein	O
type	I-protein	O
I	I-protein	O
were	O	O
tested	O	O
for	O	O
their	O	O
transcription	O	O
activities	O	O
in	O	O
cell-free	O	O
extracts	O	O
of	O	O
four	O	O
cell	I-cell_line	O
lines	I-cell_line	O
;	O	O
HeLa	O	O
,	O	O
CESS	O	O
(	O	O
Epstein-Barr	O	O
virus-transformed	O	O
human	B-cell_line	O
B	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
)	O	O
,	O	O
MT-1	O	O
(	O	O
HTLV-I-infected	O	O
human	I-cell_line	O
T	I-cell_line	O
cell	I-cell_line	O
line	O	O
without	O	O
viral	O	O
protein	O	O
synthesis	O	O
)	O	O
,	O	O
and	O	O
MT-2	O	O
(	O	O
HTLV-I-infected	O	O
human	I-cell_line	O
T	I-cell_line	O
cell	I-cell_line	O
line	O	O
producing	O	O
viral	O	O
proteins	O	O
)	O	O
.	O	O

LTR	O	O
was	O	O
preferentially	O	O
transcribed	O	O
in	O	O
the	O	O
extracts	O	O
of	O	O
MT-2	O	O
although	O	O
the	O	O
other	O	O
three	O	O
genes	O	O
were	O	O
transcribed	O	O
with	O	O
relatively	O	O
constant	O	O
efficiencies	O	O
in	O	O
different	O	O
extracts	O	O
.	O	O

The	O	O
results	O	O
agree	O	O
well	O	O
with	O	O
the	O	O
previous	O	O
in	O	O
vivo	O	O
studies	O	O
on	O	O
the	O	O
promoter	O	O
activity	O	O
of	O	O
HTLV-I	B-DNA	O
LTR	I-DNA	O
.	O	O

Mixing	O	O
of	O	O
HeLa	O	O
and	O	O
MT-2	O	O
extracts	O	O
revealed	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
LTR-specific	O	O
stimulating	O	O
activity	O	O
in	O	O
MT-2	O	O
extracts	O	O
.	O	O

A	O	O
nuclear	B-protein	O
factor	I-protein	O
that	O	O
binds	O	O
to	O	O
a	O	O
conserved	B-DNA	O
sequence	I-DNA	O
motif	I-DNA	O
in	O	O
transcriptional	O	O
control	O	O
elements	O	O
of	O	O
immunoglobulin	O	O
genes	B-DNA	O
.	O	O

Trans-acting	B-protein	O
factors	I-protein	O
that	O	O
mediate	O	O
B-cell	O	O
specific	O	O
transcription	O	O
of	O	O
immunoglobulin	O	O
genes	O	O
have	O	O
been	O	O
postulated	O	O
based	O	O
on	O	O
an	O	O
analysis	O	O
of	O	O
the	O	O
expression	O	O
of	O	O
exogenously	O	O
introduced	O	O
immunoglobulin	O	O
gene	O	O
recombinants	O	O
in	O	O
lymphoid	B-cell_type	O
and	I-cell_type	O
non-lymphoid	I-cell_type	O
cells	I-cell_type	O
.	O	O

Two	O	O
B-cell-specific	O	O
,	O	O
cis-acting	O	O
transcriptional	O	O
regulatory	O	O
elements	O	O
have	O	O
been	O	O
identified	O	O
.	O	O

One	O	O
element	O	O
is	O	O
located	O	O
in	O	O
the	O	O
intron	O	O
between	O	O
the	O	O
variable	O	O
(	O	O
V	I-DNA	O
)	O	O
and	O	O
constant	B-protein	O
(	O	O
C	I-protein	O
)	O	O
regions	O	O
of	O	O
both	O	O
heavy	O	O
and	O	O
kappa	B-DNA	O
light-chain	I-DNA	O
genes	I-DNA	O
and	O	O
acts	O	O
as	O	O
a	O	O
transcriptional	O	O
enhancer	O	O
.	O	O

The	O	O
second	B-DNA	O
element	I-DNA	O
is	O	O
found	O	O
upstream	O	O
of	O	O
both	O	O
heavy	B-DNA	O
and	I-DNA	O
kappa	B-DNA	O
light-chain	I-DNA	O
gene	I-DNA	O
promoters	I-DNA	O
.	O	O

This	O	O
element	O	O
directs	O	O
lymphoid-specific	O	O
transcription	O	O
even	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
viral	O	O
enhancers	O	O
.	O	O

We	O	O
have	O	O
sought	O	O
nuclear	B-protein	O
factors	I-protein	O
that	O	O
might	O	O
bind	O	O
specifically	O	O
to	O	O
these	O	O
two	O	O
regulatory	O	O
elements	O	O
by	O	O
application	O	O
of	O	O
a	O	O
modified	O	O
gel	O	O
electrophoresis	O	O
DNA	O	O
binding	O	O
assay	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
human	B-protein	O
B-cell	I-protein	O
nuclear	I-protein	O
factor	I-protein	O
(	O	O
IgNF-A	B-protein	O
)	O	O
that	O	O
binds	O	O
to	O	O
DNA	O	O
sequences	O	O
in	O	O
the	O	O
upstream	B-DNA	O
regions	I-DNA	O
of	O	O
both	O	O
the	O	O
mouse	B-DNA	O
heavy	I-DNA	O
and	I-DNA	O
kappa	I-DNA	O
light-chain	I-DNA	O
gene	I-DNA	O
promoters	I-DNA	O
and	O	O
also	O	O
to	O	O
the	O	O
mouse	B-DNA	O
heavy-chain	I-DNA	O
gene	I-DNA	O
enhancer	I-DNA	O
.	O	O

This	O	O
sequence-specific	O	O
binding	O	O
is	O	O
probably	O	O
mediated	O	O
by	O	O
a	O	O
highly	O	O
conserved	B-DNA	O
sequence	I-DNA	O
motif	I-DNA	O
,	O	O
ATTTGCAT	O	O
,	O	O
present	O	O
in	O	O
all	O	O
three	O	O
transcriptional	O	O
elements	O	O
.	O	O

Interestingly	O	O
,	O	O
a	O	O
factor	O	O
showing	O	O
similar	O	O
binding	O	O
specificity	O	O
to	O	O
IgNF-A	O	O
is	O	O
also	O	O
present	O	O
in	O	O
human	B-cell_type	O
HeLa	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
new	O	O
world	O	O
primates	O	O
as	O	O
animal	O	O
models	O	O
of	O	O
glucocorticoid	O	O
resistance	O	O
.	O	O

Many	O	O
New	O	O
World	O	O
primate	O	O
species	O	O
have	O	O
greatly	O	O
increased	O	O
plasma	O	O
cortisol	O	O
concentrations	O	O
,	O	O
decreased	O	O
plasma	O	O
cortisol	O	O
binding	O	O
globulin	O	O
capacity	O	O
and	O	O
affinity	O	O
,	O	O
marked	O	O
resistance	O	O
of	O	O
the	O	O
hypothalamic-pituitary-adrenal	O	O
axis	O	O
to	O	O
suppression	O	O
by	O	O
dexamethasone	O	O
,	O	O
and	O	O
no	O	O
biological	O	O
evidence	O	O
of	O	O
glucocorticoid	O	O
excess	O	O
.	O	O

These	O	O
primates	O	O
also	O	O
have	O	O
high	O	O
levels	O	O
of	O	O
circulating	O	O
progesterone	O	O
,	O	O
estrogen	O	O
,	O	O
mineralocorticoid	O	O
,	O	O
androgen	O	O
and	O	O
vitamin	O	O
D	O	O
.	O	O

The	O	O
glucocorticoid	O	O
target	O	O
tissues	O	O
that	O	O
have	O	O
been	O	O
examined	O	O
(	O	O
circulating	O	O
mononuclear	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
cultured	O	O
skin	O	O
fibroblasts	O	O
)	O	O
have	O	O
normal	O	O
concentrations	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	O	O
with	O	O
decreased	O	O
affinity	O	O
for	O	O
dexamethasone	O	O
.	O	O

Transformation	O	O
of	O	O
B-lymphocytes	O	O
with	O	O
the	O	O
Epstein-Barr	O	O
virus	O	O
leads	O	O
to	O	O
glucocorticoid	O	O
receptor	O	O
induction	O	O
that	O	O
is	O	O
less	O	O
than	O	O
that	O	O
observed	O	O
with	O	O
cells	O	O
from	O	O
Old	O	O
World	O	O
primates	O	O
.	O	O

The	O	O
receptor	O	O
in	O	O
these	O	O
cells	O	O
has	O	O
a	O	O
low	O	O
affinity	O	O
for	O	O
dexamethasone	O	O
.	O	O

The	O	O
low	O	O
affinity	O	O
leads	O	O
to	O	O
an	O	O
increased	O	O
loss	O	O
of	O	O
specific	O	O
bound	O	O
ligand	O	O
during	O	O
thermal	O	O
activation	O	O
.	O	O

Meroreceptor	O	O
generation	O	O
is	O	O
normal	O	O
.	O	O

The	O	O
molecular	O	O
weight	O	O
of	O	O
the	O	O
receptor	B-protein	O
,	O	O
determined	O	O
by	O	O
SDS-PAGE	O	O
,	O	O
is	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
Old	O	O
World	O	O
primates	O	O
(	O	O
approximately	B-protein	O
92	I-protein	O
,	O	O
000	O	O
)	O	O
and	O	O
the	O	O
activation	O	O
pattern	O	O
per	O	O
se	O	O
,	O	O
examined	O	O
in	O	O
vitro	O	O
by	O	O
heating	O	O
cytosol	O	O
and	O	O
performing	O	O
phosphocellulose	O	O
chromatography	O	O
,	O	O
appears	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
human	O	O
controls	O	O
.	O	O

The	O	O
ratios	O	O
of	O	O
nuclear	O	O
to	O	O
cytosolic	O	O
hormone-receptor-complexes	O	O
and	O	O
of	O	O
cytosolic	O	O
activated	O	O
to	O	O
unactivated	B-protein	O
receptor	I-protein	O
complexes	O	O
in	O	O
intact	B-cell_type	O
cells	I-cell_type	O
are	O	O
similar	O	O
to	O	O
Old	O	O
World	O	O
primates	O	O
.	O	O

Results	O	O
from	O	O
mixing	O	O
studies	O	O
do	O	O
not	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
a	O	O
binding	O	O
inhibitor	O	O
(	O	O
s	O	O
)	O	O
or	O	O
a	O	O
deficient	O	O
cytosolic	O	O
positive	O	O
modifier	O	O
(	O	O
s	O	O
)	O	O
of	O	O
binding	O	O
underlies	O	O
the	O	O
findings	O	O
in	O	O
these	O	O
primates	O	O
.	O	O

The	O	O
New	O	O
World	O	O
primates	O	O
,	O	O
unlike	O	O
men	O	O
with	O	O
the	O	O
syndrome	O	O
of	O	O
primary	B-protein	O
cortisol	I-protein	O
resistance	O	O
,	O	O
have	O	O
compensated	O	O
for	O	O
their	O	O
condition	O	O
with	O	O
intra-adrenal	O	O
and	O	O
mineralocorticoid	B-protein	O
receptor	I-protein	O
adaptations	O	O
.	O	O

Thus	O	O
,	O	O
unlike	O	O
Old	O	O
World	O	O
primates	O	O
,	O	O
cortisol	O	O
in	O	O
New	O	O
World	O	O
primates	O	O
has	O	O
only	O	O
weak	O	O
sodium-retaining	O	O
potency	O	O
because	O	O
the	O	O
aldosterone	O	O
receptor	O	O
has	O	O
a	O	O
low	O	O
affinity	O	O
for	O	O
cortisol	O	O
.	O	O

The	O	O
common	O	O
element	O	O
that	O	O
would	O	O
explain	O	O
the	O	O
apparent	O	O
resistance	O	O
to	O	O
six	O	O
steroid	O	O
hormones	O	O
in	O	O
New	O	O
World	O	O
primates	O	O

Acetylation	O	O
and	O	O
modulation	O	O
of	O	O
erythroid	B-protein	O
Kruppel-like	I-protein	O
factor	I-protein	O
(	O	O
EKLF	B-protein	O
)	O	O
activity	O	O
by	O	O
interaction	O	O
with	O	O
histone	O	O
acetyltransferases	O	O
.	O	O

Erythroid	B-protein	O
Kruppel-like	I-protein	O
factor	I-protein	O
(	O	O
EKLF	B-protein	O
)	O	O
is	O	O
a	O	O
red	O	O
cell-specific	O	O
transcriptional	O	O
activator	O	O
that	O	O
is	O	O
crucial	O	O
for	O	O
consolidating	O	O
the	O	O
switch	O	O
to	O	O
high	O	O
levels	O	O
of	O	O
adult	O	O
beta-globin	O	O
expression	O	O
during	O	O
erythroid	O	O
ontogeny	O	O
.	O	O

EKLF	O	O
is	O	O
required	O	O
for	O	O
integrity	O	O
of	O	O
the	O	O
chromatin	B-DNA	O
structure	I-DNA	O
at	O	O
the	O	O
beta-like	O	O
globin	O	O
locus	O	O
,	O	O
and	O	O
it	O	O
interacts	O	O
with	O	O
a	O	O
positive-acting	B-protein	O
factor	I-protein	O
in	O	O
vivo	O	O
.	O	O

We	O	O
find	O	O
that	O	O
EKLF	O	O
is	O	O
an	O	O
acetylated	O	O
transcription	B-protein	O
factor	I-protein	O
,	O	O
and	O	O
that	O	O
it	O	O
interacts	O	O
in	O	O
vivo	O	O
with	O	O
CBP	O	O
,	O	O
p300	O	O
,	O	O
and	O	O
P/CAF	O	O
.	O	O

However	O	O
,	O	O
its	O	O
interactions	O	O
with	O	O
these	O	O
histone	O	O
acetyltransferases	O	O
are	O	O
not	O	O
equivalent	O	O
,	O	O
as	O	O
CBP	O	O
and	O	O
p300	O	O
,	O	O
but	O	O
not	O	O
P/CAF	O	O
,	O	O
utilize	O	O
EKLF	O	O
as	O	O
a	O	O
substrate	O	O
for	O	O
in	O	O
vitro	O	O
acetylation	O	O
within	O	O
its	O	O
trans-activation	O	O
region	O	O
.	O	O

The	O	O
functional	O	O
effects	O	O
of	O	O
these	O	O
interactions	O	O
are	O	O
that	O	O
CBP	O	O
and	O	O
p300	O	O
,	O	O
but	O	O
not	O	O
P/CAF	O	O
,	O	O
enhance	O	O
EKLF	O	O
's	O	O
transcriptional	O	O
activation	O	O
of	O	O
the	O	O
beta-globin	B-DNA	O
promoter	I-DNA	O
in	O	O
erythroid	B-cell_type	O
cells	I-cell_type	O
.	O	O

These	O	O
results	O	O
establish	O	O
EKLF	O	O
as	O	O
a	O	O
tissue-specific	O	O
transcription	B-protein	O
factor	I-protein	O
that	O	O
undergoes	O	O
post-translational	O	O
acetylation	O	O
and	O	O
suggest	O	O
a	O	O
mechanism	O	O
by	O	O
which	O	O
EKLF	O	O
is	O	O
able	O	O
to	O	O
alter	O	O
chromatin	O	O
structure	O	O
and	O	O
induce	O	O
beta-globin	O	O
expression	O	O
within	O	O
the	O	O
beta-like	O	O
globin	O	O
cluster	O	O
.	O	O

Recognition	O	O
of	O	O
herpes	O	O
simplex	O	O
virus	O	O
type	O	O
2	O	O
tegument	O	O
proteins	O	O
by	O	O
CD4	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
infiltrating	O	O
human	O	O
genital	O	O
herpes	O	O
lesions	O	O
.	O	O

The	O	O
local	O	O
cellular	O	O
immune	O	O
response	O	O
to	O	O
herpes	O	O
simplex	O	O
virus	O	O
(	O	O
HSV	O	O
)	O	O
is	O	O
important	O	O
in	O	O
the	O	O
control	O	O
of	O	O
recurrent	O	O
HSV	O	O
infection	O	O
.	O	O

The	O	O
antiviral	O	O
functions	O	O
of	O	O
infiltrating	O	O
CD4-bearing	O	O
T	B-cell_type	O
cells	I-cell_type	O
may	O	O
include	O	O
cytotoxicity	O	O
,	O	O
inhibition	O	O
of	O	O
viral	O	O
growth	O	O
,	O	O
lymphokine	O	O
secretion	O	O
,	O	O
and	O	O
support	O	O
of	O	O
humoral	O	O
and	O	O
CD8	O	O
responses	O	O
.	O	O

The	O	O
antigens	O	O
recognized	O	O
by	O	O
many	O	O
HSV-specific	O	O
CD4	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
localizing	O	O
to	O	O
genital	O	O
HSV-2	O	O
lesions	O	O
are	O	O
unknown	O	O
.	O	O

T	B-cell_type	O
cells	I-cell_type	O
recognizing	O	O
antigens	O	O
encoded	O	O
within	O	O
map	O	O
units	O	O
0.67	O	O
to	O	O
0.73	O	O
of	O	O
HSV	O	O
DNA	O	O
are	O	O
frequently	O	O
recovered	O	O
from	O	O
herpetic	O	O
lesions	O	O
.	O	O

Expression	O	O
cloning	O	O
with	O	O
this	O	O
region	O	O
of	O	O
DNA	O	O
now	O	O
shows	O	O
that	O	O
tegument	O	O
protein	O	O
VP22	O	O
and	O	O
the	O	O
viral	O	O
dUTPase	O	O
,	O	O
encoded	O	O
by	O	O
genes	O	O
UL49	O	O
and	O	O
UL50	O	O
,	O	O
respectively	O	O
,	O	O
are	O	O
T-cell	O	O
antigens	O	O
.	O	O

Separate	O	O
epitopes	O	O
in	O	O
VP22	O	O
were	O	O
defined	O	O
for	O	O
T-cell	O	O
clones	O	O
from	O	O
each	O	O
of	O	O
three	O	O
patients	O	O
.	O	O

Reactivity	O	O
with	O	O
the	O	O
tegument	B-protein	O
protein	I-protein	O
encoded	O	O
by	O	O
UL21	O	O
was	O	O
identified	O	O
for	O	O
an	O	O
additional	O	O
patient	O	O
.	O	O

Three	O	O
new	O	O
epitopes	O	O
were	O	O
identified	O	O
in	O	O
VP16	O	O
,	O	O
a	O	O
tegument	O	O
protein	O	O
associated	O	O
with	O	O
VP22	O	O
.	O	O

Some	O	O
tegument-specific	O	O
CD4	O	O
T-cell	O	O
clones	O	O
exhibited	O	O
cytotoxic	O	O
activity	O	O
against	O	O
HSV-infected	B-cell_type	O
cells	I-cell_type	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
herpes	O	O
simplex	O	O
tegument	O	O
proteins	O	O
are	O	O
processed	O	O
for	O	O
antigen	O	O
presentation	O	O
in	O	O
vivo	O	O
and	O	O
are	O	O
possible	O	O
candidate	O	O
compounds	O	O
for	O	O
herpes	O	O
simplex	O	O
vaccines	O	O
.	O	O

Fibrinogen	O	O
activates	O	O
NF-kappa	B-protein	O
B	I-protein	O
transcription	B-protein	O
factors	I-protein	O
in	O	O
mononuclear	O	O
phagocytes	O	O
.	O	O

Adhesion	O	O
to	O	O
extracellular	O	O
matrices	O	O
is	O	O
known	O	O
to	O	O
modulate	O	O
leukocyte	O	O
activation	O	O
,	O	O
although	O	O
the	O	O
mechanisms	O	O
are	O	O
not	O	O
fully	O	O
understood	O	O
.	O	O

Mononuclear	O	O
phagocytes	O	O
are	O	O
exposed	O	O
to	O	O
fibrinous	O	O
provisional	O	O
matrix	O	O
throughout	O	O
migration	O	O
into	O	O
inflammatory	O	O
foci	O	O
,	O	O
so	O	O
this	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
whether	O	O
fibrinogen	O	O
triggers	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
transcription	I-protein	O
factors	I-protein	O
.	O	O

U937	I-cell_line	O
cells	I-cell_line	O
differentiated	O	O
with	O	O
PMA	O	O
in	O	O
nonadherent	O	O
culture	O	O
were	O	O
shown	O	O
to	O	O
express	O	O
two	O	O
fibrinogen-binding	O	O
integrins	O	O
,	O	O
predominately	O	O
CD11b/CD18	O	O
,	O	O
and	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
,	O	O
CD11c/CD18	O	O
.	O	O

Cells	O	O
stimulated	O	O
with	O	O
fibrinogen	O	O
(	O	O
10-100	B-protein	O
microg/ml	I-protein	O
)	O	O
/Mn2+	O	O
(	O	O
50	O	O
microM	O	O
)	O	O
for	O	O
2	O	O
h	O	O
were	O	O
examined	O	O
by	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
.	O	O

NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
,	O	O
minimal	O	O
in	O	O
unstimulated	B-cell_line	O
cells	I-cell_line	O
,	O	O
was	O	O
substantially	O	O
up-regulated	O	O
by	O	O
fibrinogen	O	O
.	O	O

Fibrinogen	O	O
also	O	O
caused	O	O
activation	O	O
of	O	O
AP-1	B-protein	O
,	O	O
but	O	O
not	O	O
SP1	B-protein	O
or	O	O
cAMP	O	O
response	O	O
element-binding	O	O
protein	O	O
(	O	O
CREB	B-protein	O
)	O	O
factors	I-protein	O
.	O	O

Blocking	O	O
mAbs	O	O
against	O	O
CD18	O	O
and	O	O
CD11b	O	O
abrogated	O	O
fibrinogen	O	O
-induced	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
effects	O	O
on	O	O
transcriptional	O	O
regulation	O	O
,	O	O
U937	B-cell_line	O
cells	I-cell_line	O
were	O	O
transfected	O	O
with	O	O
a	O	O
plasmid	O	O
containing	O	O
the	O	O
HIV-1	B-DNA	O
enhancer	I-DNA	O
(	O	O
bearing	O	O
two	O	O
NF-kappa	B-DNA	O
B	I-DNA	O
sites	I-DNA	O
)	O	O
coupled	O	O
to	O	O
a	O	O
chloramphenicol	B-DNA	O
acetyltransferase	I-DNA	O
(	I-DNA	O
CAT	I-DNA	O
)	I-DNA	O
reporter	I-DNA	O
.	O	O

Cells	O	O
were	O	O
subsequently	O	O
stimulated	O	O
with	O	O
1	O	O
)	O	O
PMA	O	O
for	O	O
24	O	O
h	O	O
,	O	O
inducing	O	O
CAT	O	O
activity	O	O
by	O	O
2.6-fold	O	O
,	O	O
2	O	O
)	O	O
fibrinogen	O	O
/Mn2+	O	O
for	O	O
2	O	O
h	O	O
,	O	O
inducing	O	O
CAT	O	O
activity	O	O
by	O	O
3.2-fold	B-protein	O
,	O	O
or	O	O
3	O	O
)	O	O
costimulation	O	O
with	O	O
fibrinogen	O	O
and	O	O
PMA	O	O
,	O	O
inducing	O	O
5.7-fold	O	O
the	O	O
CAT	B-protein	O
activity	O	O
induced	O	O
by	O	O
PMA	O	O
alone	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
contact	O	O
with	O	O
fibrinogen-derived	B-protein	O
proteins	I-protein	O
may	O	O
contribute	O	O
to	O	O
mononuclear	O	O
phagocyte	O	O
activation	O	O
by	O	O
signaling	O	O
through	O	O
CD11b/CD18	O	O
,	O	O
resulting	O	O
in	O	O
selective	O	O
activation	O	O
of	O	O
transcriptional	O	O
regulatory	B-protein	O
factors	I-protein	O
,	O	O
including	O	O
NF-kappa	B-protein	O
B	I-protein	O
.	O	O

Peripheral	I-cell_line	O
blood	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
and	O	O
monocytes	B-cell_type	O
and	O	O
B	O	O
cell	I-cell_line	O
lines	I-cell_line	O
derived	O	O
from	O	O
patients	O	O
with	O	O
lupus	O	O
express	O	O
estrogen	O	O
receptor	O	O
transcripts	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
normal	B-cell_type	O
cells	I-cell_type	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
identify	O	O
and	O	O
characterize	O	O
estrogen	B-protein	O
receptor	I-protein	O
(	O	O
ER	B-protein	O
)	O	O
transcripts	O	O
expressed	O	O
in	O	O
immune	O	O
cells	O	O
of	O	O
patients	O	O
with	O	O
systemic	O	O
lupus	O	O
erythematosus	O	O
(	O	O
SLE	O	O
)	O	O
and	O	O
healthy	O	O
donors	O	O
.	O	O

METHODS	O	O
:	O	O
Peripheral	B-cell_line	O
blood	I-cell_line	O
monocytes	I-cell_line	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
prepared	O	O
from	O	O
patients	O	O
with	O	O
SLE	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
and	O	O
healthy	O	O
donors	O	O
(	O	O
n	O	O
=	O	O
8	O	O
)	O	O
.	O	O

T	B-cell_type	O
cells	I-cell_type	O
were	O	O
separated	O	O
into	O	O
CD4	B-protein	O
and	O	O
CD8	O	O
.	O	O

Some	O	O
monocytes	B-cell_type	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
stimulated	O	O
with	O	O
estradiol	O	O
,	O	O
PMA	O	O
,	O	O
and	O	O
ionomycin	O	O
.	O	O

Epstein-Barr	O	O
virus-transformed	O	O
B	O	O
cell	I-cell_line	O
lines	I-cell_line	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
and	O	O
B	O	O
cell	O	O
hybridomas	O	O
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
established	O	O
from	O	O
patients	O	O
with	O	O
SLE	O	O
and	O	O
a	O	O
healthy	O	O
individual	O	O
were	O	O
used	O	O
as	O	O
a	O	O
B	O	O
cell	O	O
source	O	O
.	O	O

These	O	O
cells	I-cell_type	O
were	O	O
examined	O	O
for	O	O
ER	B-RNA	O
mRNA	I-RNA	O
by	O	O
reverse	O	O
transcription	O	O
nested	O	O
polymerase	O	O
chain	O	O
reaction	O	O
.	O	O

Amplified	O	O
cDNA	B-protein	O
were	O	O
sequenced	O	O
by	O	O
standard	O	O
methods	O	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
all	O	O
cells	O	O
tested	O	O
,	O	O
ER	B-RNA	O
mRNA	I-RNA	O
was	O	O
expressed	O	O
without	O	O
prior	O	O
in	O	O
vitro	O	O
stimulation	O	O
.	O	O

Partial	O	O
sequences	O	O
from	O	O
exons	O	O
1-8	O	O
were	O	O
nearly	O	O
identical	O	O
to	O	O
the	O	O
published	O	O
sequence	O	O
of	O	O
the	O	O
human	B-RNA	O
ER	B-RNA	O
mRNA	I-RNA	O
.	O	O

There	O	O
were	O	O
no	O	O
notable	O	O
differences	O	O
in	O	O
the	O	O
ER	O	O
transcripts	O	O
between	O	O
patients	O	O
and	O	O
healthy	O	O
controls	O	O
.	O	O

Variant	B-protein	O
receptor	I-protein	O
transcripts	O	O
lacking	O	O
exon	O	O
5	O	O
or	O	O
exon	O	O
7	O	O
,	O	O
which	O	O
encodes	O	O
the	O	O
hormone	B-DNA	O
binding	I-DNA	O
domain	I-DNA	O
,	O	O
were	O	O
identified	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
the	O	O
cells	I-cell_type	O
.	O	O

Precise	O	O
deletion	O	O
of	O	O
the	O	O
exons	O	O
suggests	O	O
that	O	O
they	O	O
are	O	O
alternatively	O	O
spliced	O	O
transcripts	O	O
.	O	O

Whether	O	O
the	O	O
detected	O	O
transcripts	O	O
are	O	O
translated	O	O
into	O	O
functional	B-protein	O
receptor	I-protein	O
proteins	I-protein	O
remains	O	O
to	O	O
be	O	O
determined	O	O
.	O	O

In	O	O
vitro	O	O
stimulation	O	O
did	O	O
not	O	O
affect	O	O
ER	B-RNA	O
mRNA	I-RNA	O
expression	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
variants	O	O
did	O	O
not	O	O
correlate	O	O
with	O	O
disease	O	O
activity	O	O
or	O	O
medication	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Monocytes	O	O
,	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
and	O	O
B	I-cell_type	O
cells	I-cell_type	O
in	O	O
patients	O	O
express	O	O
transcripts	O	O
of	O	O
the	O	O
normal	B-protein	O
wild	I-protein	O
type	I-protein	O
ER	I-protein	O
and	O	O
the	O	O
hormone	B-DNA	O
binding	I-DNA	O
domain	I-DNA	O
variants	O	O
in	O	O
vivo	O	O
.	O	O

DNA	O	O
damaging	O	O
agents	O	O
induce	O	O
expression	O	O
of	O	O
Fas	O	O
ligand	O	O
and	O	O
subsequent	O	O
apoptosis	O	O
in	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
via	O	O
the	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
and	O	O
AP-1	B-protein	O
.	O	O

Apoptosis	O	O
induced	O	O
by	O	O
DNA	O	O
damage	O	O
and	O	O
other	O	O
stresses	O	O
can	O	O
proceed	O	O
via	O	O
expression	O	O
of	O	O
Fas	B-protein	O
ligand	I-protein	O
(	O	O
FasL	B-protein	O
)	O	O
and	O	O
ligation	O	O
of	O	O
its	O	O
receptor	O	O
,	O	O
Fas	O	O
(	O	O
CD95	O	O
)	O	O
.	O	O

We	O	O
report	O	O
that	O	O
activation	O	O
of	O	O
the	O	O
two	O	O
transcription	B-protein	O
factors	I-protein	O
NF-kappa	B-protein	O
B	I-protein	O
and	O	O
AP-1	B-protein	O
is	O	O
crucially	O	O
involved	O	O
in	O	O
FasL	O	O
expression	O	O
induced	O	O
by	O	O
etoposide	O	O
,	O	O
teniposide	O	O
,	O	O
and	O	O
UV	O	O
irradiation	O	O
.	O	O

A	O	O
nondegradable	O	O
mutant	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
blocked	O	O
both	O	O
FasL	O	O
expression	O	O
and	O	O
apoptosis	O	O
induced	O	O
by	O	O
DNA	O	O
damage	O	O
but	O	O
not	O	O
Fas	O	O
ligation	O	O
.	O	O

These	O	O
stimuli	O	O
also	O	O
induced	O	O
the	O	O
stress-activated	B-protein	O
kinase	I-protein	O
pathway	O	O
(	O	O
SAPK/JNK	O	O
)	O	O
,	O	O
which	O	O
was	O	O
required	O	O
for	O	O
the	O	O
maximal	O	O
induction	O	O
of	O	O
apoptosis	O	O
.	O	O

A	O	O
1.2	O	O
kb	O	O
FasL	B-DNA	O
promoter	I-DNA	O
responded	O	O
to	O	O
DNA	O	O
damage	O	O
,	O	O
as	O	O
well	O	O
as	O	O
coexpression	O	O
with	O	O
p65	B-protein	O
Rel	I-protein	O
or	O	O
Fos/Jun	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
relevant	O	O
NF-kappa	B-protein	O
B	I-protein	O
and	O	O
AP-1	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
eliminated	O	O
these	O	O
responses	O	O
.	O	O

Thus	O	O
,	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
and	O	O
AP-1	B-protein	O
contributes	O	O
to	O	O
stress-induced	O	O
apoptosis	O	O
via	O	O
the	O	O
expression	O	O
of	O	O
FasL	O	O
.	O	O

A	O	O
small	O	O
,	O	O
nonpeptidyl	O	O
mimic	O	O
of	O	O
granulocyte-colony-stimulating	B-protein	O
factor	I-protein	O
[	O	O
see	O	O
commetns	O	O
]	O	O

A	O	O
nonpeptidyl	O	O
small	O	O
molecule	O	O
SB	O	O
247464	O	O
,	O	O
capable	O	O
of	O	O
activating	O	O
granulocyte-colony-stimulating	B-protein	O
factor	I-protein	O
(	O	O
G-CSF	O	O
)	O	O
signal	O	O
transduction	O	O
pathways	O	O
,	O	O
was	O	O
identified	O	O
in	O	O
a	O	O
high-throughput	O	O
assay	O	O
in	O	O
cultured	B-cell_type	O
cells	I-cell_type	O
.	O	O

Like	O	O
G-CSF	O	O
,	O	O
SB	O	O
247464	O	O
induced	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
multiple	O	O
signaling	O	O
proteins	I-protein	O
and	O	O
stimulated	B-cell_line	O
primary	B-cell_line	O
murine	I-cell_line	O
bone	I-cell_line	O
marrow	I-cell_line	O
cells	I-cell_line	O
to	O	O
form	O	O
granulocytic	O	O
colonies	O	O
in	O	O
vitro	O	O
.	O	O

It	O	O
also	O	O
elevated	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
neutrophil	O	O
counts	O	O
in	O	O
mice	O	O
.	O	O

The	O	O
extracellular	O	O
domain	O	O
of	O	O
the	O	O
murine	B-protein	O
G-CSF	I-protein	O
receptor	I-protein	O
was	O	O
required	O	O
for	O	O
the	O	O
activity	O	O
of	O	O
SB	O	O
247464	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
compound	O	O
acts	O	O
by	O	O
oligomerizing	B-protein	O
receptor	I-protein	O
chains	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
a	O	O
small	B-protein	O
molecule	I-protein	O
can	O	O
activate	O	O
a	O	O
receptor	O	O
that	O	O
normally	O	O
binds	O	O
a	O	O
relatively	O	O
large	O	O
protein	O	O
ligand	O	O
.	O	O

Minimal	O	O
residual	O	O
disease	O	O
in	O	O
acute	O	O
myelogenous	O	O
leukemia	O	O
with	O	O
PML/RAR	O	O
alpha	I-protein	O
or	O	O
AML1/ETO	O	O
mRNA	I-RNA	O
and	O	O
phenotypic	O	O
analysis	O	O
of	O	O
possible	O	O
T	B-cell_type	O
and	I-cell_type	O
natural	I-cell_type	O
killer	I-cell_type	O
cells	I-cell_type	O
in	O	O
bone	O	O
marrow	O	O
.	O	O

Here	O	O
we	O	O
studied	O	O
minimal	O	O
residual	O	O
disease	O	O
(	O	O
MRD	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
acute	O	O
myeloid	O	O
leukemia	O	O
(	O	O
AML	O	O
)	O	O
who	O	O
have	O	O
PML/RAR	O	O
alpha	O	O
or	O	O
AML1/ETO	O	O
as	O	O
well	O	O
as	O	O
the	O	O
phenotypic	O	O
analysis	O	O
of	O	O
lymphocyte	O	O
subsets	O	O
involved	O	O
in	O	O
antitumor	O	O
immunity	O	O
.	O	O

Eight	O	O
patients	O	O
in	O	O
long-term	O	O
(	O	O
LT	O	O
;	O	O
3	O	O
to	O	O
15	O	O
years	O	O
)	O	O
and	O	O
15	O	O
patients	O	O
in	O	O
short-term	O	O
(	O	O
ST	O	O
;	O	O
up	O	O
to	O	O
3	O	O
years	O	O
)	O	O
remission	O	O
were	O	O
studied	O	O
.	O	O

Using	O	O
the	O	O
reverse	O	O
transcription-polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
RT	O	O
)	O	O
assay	O	O
,	O	O
the	O	O
limit	O	O
of	O	O
detection	O	O
was	O	O
10	O	O
(	O	O
-5	O	O
)	O	O
to	O	O
10	O	O
(	O	O
-6	O	O
)	O	O
for	O	O
PML/RAR	O	O
alpha	B-protein	O
transcript	I-protein	O
and	O	O
10	O	O
(	O	O
-4	O	O
)	O	O
to	O	O
10	O	O
(	O	O
-5	O	O
)	O	O
for	O	O
the	O	O
AML1/ETO	O	O
transcript	I-protein	O
.	O	O

Simultaneously	O	O
,	O	O
T	I-cell_line	O
lymphocyte	I-cell_line	O
subsets	I-cell_line	O
and	O	O
NK	I-cell_type	O
cells	I-cell_type	O
from	O	O
the	O	O
peripheral	B-cell_line	O
blood	I-cell_line	O
(	O	O
PB	O	O
)	O	O
and	O	O
bone	O	O
marrow	O	O
(	O	O
BM	O	O
)	O	O
were	O	O
investigated	O	O
by	O	O
flow	O	O
cytometric	O	O
analysis	O	O
.	O	O

Four	O	O
of	O	O
the	O	O
eight	O	O
patients	O	O
in	O	O
LT	O	O
and	O	O
7	O	O
of	O	O
the	O	O
15	O	O
patients	O	O
in	O	O
ST	O	O
remission	O	O
were	O	O
MRD-positive	O	O
.	O	O

Although	O	O
all	O	O
MRD-positive	O	O
patients	O	O
in	O	O
LT	O	O
remission	O	O
are	O	O
still	O	O
until	O	O
now	O	O
event-free	O	O
,	O	O
3	O	O
of	O	O
the	O	O
7	O	O
MRD-positive	O	O
(	O	O
MRD+	B-protein	O
)	O	O
patients	O	O
in	O	O
ST	O	O
remission	O	O
soon	O	O
relapsed	O	O
.	O	O

The	O	O
total	O	O
populations	O	O
of	O	O
CD4	B-DNA	O
+	I-DNA	O
,	O	O
CD8	B-DNA	O
+	I-DNA	O
and	O	O
CD56	O	O
+	O	O
[	O	O
possible	O	O
T-cell	O	O
and	O	O
natural	O	O
killer	O	O
(	O	O
T/NK	B-protein	O
)	O	O
populations	O	O
]	O	O
in	O	O
the	O	O
BM	O	O
of	O	O
ST	O	O
patients	O	O
and	O	O
MRD+/LT	O	O
patients	O	O
were	O	O
significantly	O	O
(	O	O
p	O	O
<	O	O
.01	O	O
)	O	O
low	O	O
.	O	O

The	O	O
CD8+	O	O
CD28+	O	O
population	O	O
showed	O	O
the	O	O
same	O	O
tendency	O	O
(	O	O
p	O	O
<	I-protein	O
.01-.02	I-protein	O
)	O	O
.	O	O

The	O	O
T/NK	O	O
subsets	O	O
in	O	O
the	O	O
BM	O	O
of	O	O
MRD-negative	O	O
(	O	O
MRD-	O	O
)	O	O
LT	O	O
(	O	O
MRD-/LT	O	O
)	O	O
patients	O	O
showed	O	O
similar	O	O
numbers	O	O
of	O	O
cells	O	O
as	O	O
normal	O	O
volunteers	O	O
.	O	O

Basically	O	O
,	O	O
the	O	O
total	O	O
percentage	O	O
of	O	O
the	O	O
CD4+	B-protein	O
,	O	O
CD8+	O	O
and	O	O
CD56+	O	O
cell	O	O
populations	O	O
in	O	O
the	O	O
BM	O	O
was	O	O
increased	O	O
and	O	O
in	O	O
the	O	O
following	O	O
order	O	O
:	O	O
MRD-/LT	O	O
patients	O	O
,	O	O
normal	O	O
volunteers	O	O
,	O	O
MRD+/LT	O	O
patients	O	O
and	O	O
MRD+	O	O
or	O	O
-/ST	O	O
patients	O	O
.	O	O

The	O	O
percentages	O	O
of	O	O
the	O	O
T/NK-cell	O	O
subsets	O	O
in	O	O
the	O	O
PB	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
among	O	O
these	O	O
groups	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
difference	O	O
of	O	O
the	O	O
possible	O	O
T/NK-cell	O	O
phenotype	O	O
in	O	O
the	O	O
BM	O	O
may	O	O
strongly	O	O
influence	O	O
clinical	O	O
and	O	O
molecular	O	O
remission	O	O
.	O	O

These	O	O
results	O	O
still	O	O
remain	O	O
to	O	O
be	O	O
confirmed	O	O
by	O	O
further	O	O
studies	O	O
of	O	O
the	O	O
functional	O	O
anti-tumor	O	O
immunity	O	O
of	O	O
T/NK	B-cell_type	O
cells	I-cell_type	O
of	O	O
AML	O	O
in	O	O
remission	O	O
.	O	O

Mycobacterium	O	O
tuberculosis	O	O
mannose-capped	O	O
lipoarabinomannan	O	O
can	O	O
induce	O	O
NF-kappaB	O	O
-dependent	O	O
activation	O	O
of	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
long	O	O
terminal	O	O
repeat	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Tuberculosis	O	O
has	O	O
emerged	O	O
as	O	O
an	O	O
epidemic	O	O
,	O	O
extended	O	O
by	O	O
the	O	O
large	O	O
number	O	O
of	O	O
individuals	O	O
infected	O	O
with	O	O
human	B-protein	O
immunodeficiency	I-protein	O
virus	I-protein	O
type	I-protein	O
1	O	O
(	O	O
HIV-1	O	O
)	O	O
.	O	O

The	O	O
major	O	O
goal	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
mycobacterial	O	O
cell	O	O
wall	O	O
component	O	O
mannose-capped	O	O
lipoarabinomannan	O	O
(	O	O
ManLAM	O	O
)	O	O
of	O	O
Mycobacterium	O	O
tuberculosis	O	O
(	O	O
M.	B-protein	O
tuberculosis	I-protein	O
)	O	O
could	O	O
activate	O	O
transcription	O	O
of	O	O
HIV-1	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
with	O	O
the	O	O
use	O	O
of	O	O
an	O	O
in	O	O
vitro	O	O
cell	O	O
culture	O	O
system	O	O
.	O	O

These	O	O
experiments	O	O
are	O	O
of	O	O
prime	O	O
importance	O	O
considering	O	O
that	O	O
CD4	B-protein	O
-expressing	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
represent	O	O
the	O	O
major	O	O
virus	O	O
reservoir	O	O
in	O	O
the	O	O
peripheral	O	O
blood	O	O
of	O	O
infected	O	O
individuals	O	O
.	O	O

Using	O	O
the	O	O
1G5	O	O
cell	O	O
line	O	O
harbouring	O	O
the	O	O
luciferase	B-DNA	O
reporter	I-DNA	O
gene	I-DNA	O
under	O	O
the	O	O
control	O	O
of	O	O
the	O	O
HIV-1	B-DNA	O
LTR	I-DNA	O
,	O	O
it	O	O
was	O	O
first	O	O
found	O	O
that	O	O
culture	B-protein	O
protein	I-protein	O
filtrates	I-protein	O
(	O	O
CFP	B-protein	O
)	O	O
from	O	O
M.	O	O
tuberculosis	O	O
or	O	O
purified	O	O
ManLAM	O	O
could	O	O
activate	O	O
HIV-1	O	O
LTR-dependent	O	O
gene	O	O
expression	O	O
unlike	O	O
similarly	O	O
prepared	O	O
CFP	O	O
extracts	O	O
devoid	O	O
of	O	O
ManLAM	O	O
.	O	O

The	O	O
implication	O	O
of	O	O
protein	B-protein	O
tyrosine	I-protein	O
kinase	I-protein	O
(	O	O
s	O	O
)	O	O
,	O	O
protein	B-protein	O
kinase	I-protein	O
A	O	O
and/or	O	O
protein	B-protein	O
kinase	I-protein	O
C	O	O
was	O	O
highlighted	O	O
by	O	O
the	O	O
abrogation	O	O
of	O	O
the	O	O
ManLAM-mediated	O	O
activation	O	O
of	O	O
HIV-1	B-DNA	O
LTR-driven	I-DNA	O
gene	I-DNA	O
expression	O	O
using	O	O
herbimycin	O	O
A	O	O
and	O	O
H7	O	O
.	O	O

It	O	O
was	O	O
also	O	O
determined	O	O
,	O	O
using	O	O
electrophoresis	O	O
mobility	O	O
shift	O	O
assays	O	O
,	O	O
that	O	O
M.	O	O
tuberculosis	O	O
ManLAM	O	O
led	O	O
to	O	O
the	O	O
nuclear	O	O
translocation	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappaB	O	O
.	O	O

M.	O	O
tuberculosis	O	O
ManLAM	O	O
resulted	O	O
in	O	O
clear	O	O
induction	O	O
of	O	O
the	O	O
luciferase	B-DNA	O
gene	I-DNA	O
placed	O	O
under	O	O
the	O	O
control	O	O
of	O	O
the	O	O
wild-type	B-DNA	O
,	O	O
but	O	O
not	O	O
the	O	O
kappaB-mutated	O	O
,	O	O
HIV-1	B-DNA	O
LTR	I-DNA	O
region	I-DNA	O
.	O	O

Finally	O	O
,	O	O
the	O	O
ManLAM-mediated	O	O
activation	O	O
of	O	O
HIV-1	O	O
LTR	O	O
transcription	O	O
was	O	O
found	O	O
to	O	O
be	O	O
independent	O	O
of	O	O
the	O	O
autocrine	B-protein	O
or	O	O
paracrine	O	O
action	O	O
of	O	O
endogenous	O	O
TNF-alpha	O	O
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
M.	O	O
tuberculosis	O	O
can	O	O
upregulate	O	O
HIV-1	O	O
expression	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
could	O	O
thus	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
influence	O	O
the	O	O
pathogenesis	O	O
of	O	O
HIV-1	O	O
infection	O	O
.	O	O

Human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
long	O	O
terminal	O	O
repeat	O	O
quasispecies	O	O
differ	O	O
in	O	O
basal	O	O
transcription	O	O
and	O	O
nuclear	O	O
factor	O	O
recruitment	O	O
in	O	O
human	B-cell_type	O
glial	I-cell_type	O
cells	I-cell_type	O
and	O	O
lymphocytes	I-cell_type	O
.	O	O

The	O	O
generation	O	O
of	O	O
genomic	O	O
diversity	O	O
during	O	O
the	O	O
course	O	O
of	O	O
infection	O	O
has	O	O
the	O	O
potential	O	O
to	O	O
affect	O	O
all	O	O
aspects	O	O
of	O	O
HIV-1	O	O
replication	O	O
,	O	O
including	O	O
expression	O	O
of	O	O
the	O	O
proviral	B-protein	O
genome	I-protein	O
.	O	O

To	O	O
gain	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
the	O	O
impact	O	O
of	O	O
long	O	O
terminal	B-DNA	O
repeat	I-DNA	O
(	O	O
LTR	B-DNA	O
)	O	O
sequence	O	O
diversity	O	O
on	O	O
LTR-directed	O	O
gene	O	O
expression	O	O
in	O	O
cells	O	O
of	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
and	O	O
immune	O	O
system	O	O
,	O	O
we	O	O
amplified	O	O
and	O	O
cloned	O	O
LTRs	O	O
from	O	O
proviral	O	O
DNA	O	O
in	O	O
HIV-1-infected	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
.	O	O

Sequence	O	O
analysis	O	O
of	O	O
nineteen	O	O
LTRs	O	O
cloned	O	O
from	O	O
2	O	O
adult	O	O
and	O	O
3	O	O
pediatric	O	O
patients	O	O
revealed	O	O
an	O	O
average	O	O
of	O	O
33	O	O
nucleotide	O	O
changes	O	O
(	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
sequence	O	O
of	O	O
the	O	O
LAI	B-DNA	O
LTR	I-DNA	O
)	O	O
within	O	O
the	O	O
455-bp	O	O
U3	O	O
region	O	O
.	O	O

Transient	O	O
expression	O	O
analyses	O	O
in	O	O
cells	O	O
of	O	O
neuroglial	O	O
and	O	O
lymphocytic	B-protein	O
origin	O	O
demonstrated	O	O
that	O	O
some	O	O
of	O	O
these	O	O
LTRs	O	O
had	O	O
activities	O	O
which	O	O
varied	O	O
significantly	O	O
from	O	O
the	O	O
LAI	O	O
LTR	O	O
in	O	O
U-373	B-cell_line	O
MG	I-cell_line	O
cells	I-cell_line	O
(	O	O
an	O	O
astrocytoma	B-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
)	O	O
as	O	O
well	O	O
as	O	O
in	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
(	O	O
a	O	O
CD4-positive	B-cell_line	O
lymphocyte	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
)	O	O
.	O	O

While	O	O
LTRs	O	O
which	O	O
demonstrated	O	O
the	O	O
highest	O	O
activities	O	O
in	O	O
U-373	B-cell_line	O
MG	I-cell_line	O
cells	I-cell_line	O
also	O	O
yielded	O	O
high	O	O
activities	O	O
in	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
,	O	O
the	O	O
LTRs	O	O
were	O	O
generally	O	O
more	O	O
active	O	O
in	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
when	O	O
compared	O	O
to	O	O
the	O	O
LAI	O	O
LTR	O	O
.	O	O

Differences	O	O
in	O	O
LTR	O	O
sequence	O	O
also	O	O
resulted	O	O
in	O	O
differences	O	O
in	O	O
transcription	O	O
factor	O	O
recruitment	O	O
to	O	O
cis-acting	O	O
sites	O	O
within	O	O
the	O	O
U3	O	O
region	O	O
of	O	O
the	O	O
LTR	B-DNA	O
,	O	O
as	O	O
demonstrated	O	O
by	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
naturally	O	O
occurring	O	O
sequence	O	O
variation	O	O
impacted	O	O
transcription	O	O
factor	O	O
binding	O	O
to	O	O
an	O	O
activating	O	O
transcription	O	O
factor	O	O
/	O	O
cAMP	O	O
response	O	O
element	O	O
binding	O	O
(	O	O
ATF	B-DNA	O
/	I-DNA	O
CREB	I-DNA	O
)	O	O
binding	B-DNA	O
site	I-DNA	O
(	O	O
located	O	O
between	O	O
the	O	O
LEF-1	B-protein	O
and	I-protein	O
distal	I-protein	O
NF-kappaB	I-protein	O
transcription	I-protein	O
factor	I-protein	O
binding	I-DNA	O
sites	I-DNA	O
)	O	O
that	O	O
we	O	O
identified	O	O
in	O	O
previous	O	O
studies	O	O
of	O	O
the	O	O
HIV-1	B-DNA	O
LTR	I-DNA	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
LTR	B-DNA	O
sequence	I-DNA	O
changes	O	O
can	O	O
significantly	O	O
affect	O	O
basal	O	O
LTR	O	O
function	O	O
and	O	O
transcription	B-protein	O
factor	I-protein	O
recruitment	O	O
,	O	O
which	O	O
may	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
alter	O	O
the	O	O
course	O	O
of	O	O
viral	O	O
replication	O	O
in	O	O
cells	O	O
of	O	O
CNS	O	O
and	O	O
immune	O	O
system	O	O
origin	O	O
.	O	O

HMG	O	O
box	O	O
containing	O	O
transcription	B-protein	O
factors	I-protein	O
in	O	O
lymphocyte	O	O
differentiation	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
the	O	O
mammalian	B-DNA	O
sex-determining	I-DNA	O
gene	I-DNA	O
Sry	O	O
has	O	O
led	O	O
to	O	O
the	O	O
discovery	O	O
of	O	O
a	O	O
large	O	O
family	O	O
of	O	O
related	O	O
(	O	O
'	O	O
HMG	O	O
box	O	O
'	B-protein	O
)	O	O
transcription	B-protein	O
factors	I-protein	O
that	O	O
control	O	O
developmental	O	O
events	O	O
in	O	O
yeast	O	O
,	O	O
C.	O	O
elegans	O	O
,	O	O
Drosophila	O	O
and	O	O
vertebrates	O	O
.	O	O

In	O	O
lymphocyte	O	O
differentiation	O	O
,	O	O
several	O	O
HMG	O	O
box	O	O
proteins	O	O
play	O	O
a	O	O
decisive	O	O
role	O	O
.	O	O

Sox-4	O	O
is	O	O
important	O	O
for	O	O
very	O	O
early	O	O
B-cell	O	O
differentiation	O	O
,	O	O
while	O	O
TCF-1	O	O
/	O	O
LEF-1	O	O
play	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
early	O	O
thymocyte	O	O
development	O	O
.	O	O

TCF/LEF	O	O
proteins	O	O
have	O	O
recently	O	O
been	O	O
found	O	O
to	O	O
constitute	O	O
a	O	O
downstream	O	O
component	O	O
of	O	O
the	O	O
Wingless/Wnt	B-protein	O
signal	I-protein	O
transduction	O	O
pathway	O	O
.	O	O

In	O	O
flies	O	O
,	O	O
this	O	O
pathway	O	O
controls	O	O
segment	O	O
polarity	O	O
;	O	O
in	O	O
Xenopus	O	O
it	O	O
controls	O	O
the	O	O
definition	O	O
of	O	O
the	O	O
body	O	O
axis	O	O
.	O	O

Deregulation	O	O
of	O	O
the	O	O
pathway	O	O
occurs	O	O
in	O	O
several	O	O
human	O	O
tumors	O	O
.	O	O

These	O	O
insights	O	O
in	O	O
the	O	O
molecular	O	O
events	O	O
that	O	O
are	O	O
involved	O	O
in	O	O
TCF/LEF	O	O
function	O	O
in	O	O
these	O	O
organisms	O	O
may	O	O
eventually	O	O
lead	O	O
to	O	O
the	O	O
understanding	O	O
of	O	O
the	O	O
function	O	O
of	O	O
these	O	O
HMG	O	O
box	O	O
proteins	O	O
in	O	O
lymphoid	O	O
development	O	O

Transcriptional	O	O
regulation	O	O
by	O	O
C/EBP	B-protein	O
alpha	I-protein	O
and	O	O
-beta	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
gene	O	O
for	O	O
the	O	O
MRP14	B-protein	O
myeloid	I-protein	O
calcium	I-protein	O
binding	I-protein	O
protein	I-protein	O
.	O	O

Transcriptional	O	O
regulation	O	O
of	O	O
the	O	O
gene	O	O
for	O	O
the	O	O
myeloid	O	O
calcium	O	O
binding	I-protein	O
protein	I-protein	O
,	O	O
MRP14	O	O
,	O	O
was	O	O
investigated	O	O
in	O	O
human	B-cell_line	O
monocytic	I-cell_line	O
leukemia	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

The	O	O
MRP14	B-DNA	O
gene	I-DNA	O
was	O	O
not	O	O
expressed	O	O
in	O	O
monoblastic	B-cell_line	O
ML-1	I-cell_line	O
cells	I-cell_line	O
,	O	O
promonocytic	O	O
U-937	I-cell_line	O
cells	I-cell_line	O
,	O	O
or	O	O
promyelocytic	O	O
HL-60	O	O
cells	I-cell_type	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
gene	O	O
was	O	O
expressed	O	O
in	O	O
monocytic	B-cell_line	O
THP-1	I-cell_line	O
cells	I-cell_line	O
and	O	O
in	O	O
the	O	O
HL-60	B-cell_line	O
cells	I-cell_line	O
treated	O	O
with	O	O
1	O	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
(	O	O
VD3	O	O
)	O	O
.	O	O

The	O	O
level	O	O
of	O	O
MRP14	O	O
in	O	O
VD3-treated	O	O
HL-60	B-cell_line	O
cells	I-cell_line	O
was	O	O
two-fold	O	O
higher	O	O
than	O	O
that	O	O
in	O	O
THP-1	B-cell_line	O
cells	I-cell_line	O
.	O	O

Among	O	O
several	O	O
known	O	O
transcription	B-protein	O
factor	I-protein	O
binding	I-protein	O
motifs	I-protein	O
,	O	O
nuclear	B-protein	O
protein	I-protein	O
(	O	O
s	O	O
)	O	O
of	O	O
VD3-treated	B-cell_type	O
HL-60	I-cell_type	O
cells	I-cell_type	O
and	O	O
THP-1	B-cell_line	O
cells	I-cell_type	O
bound	O	O
to	O	O
the	O	O
CCAAT/enhancer	B-protein	O
binding	I-protein	O
protein	I-protein	O
(	O	O
C/EBP	B-protein	O
)	O	O
-binding	O	O
motif	O	O
that	O	O
was	O	O
located	O	O
in	O	O
the	O	O
upstream	B-DNA	O
region	I-DNA	O
of	O	O
the	O	O
MRP14	B-DNA	O
gene	I-DNA	O
(	O	O
-81	B-protein	O
)	O	O
,	O	O
as	O	O
evidenced	O	O
by	O	O
the	O	O
competitive	O	O
gel	O	O
mobility-shift	O	O
assay	O	O
.	O	O

An	O	O
antibody	O	O
for	O	O
C/EBP	O	O
alpha	O	O
super-shifted	O	O
the	O	O
nucleoprotein	B-protein	O
complex	I-protein	O
in	O	O
THP-1	B-cell_line	O
cells	I-cell_line	O
but	O	O
not	O	O
in	O	O
the	O	O
VD3-treated	O	O
HL-60	B-cell_line	O
cells	I-cell_line	O
,	O	O
whereas	O	O
an	O	O
antibody	O	O
for	O	O
C/EBP	O	O
beta	O	O
blocked	O	O
the	O	O
formation	O	O
of	O	O
the	O	O
complex	O	O
with	O	O
the	O	O
nuclear	B-protein	O
factor	I-protein	O
of	O	O
the	O	O
HL-60	B-cell_type	O
cells	I-cell_type	O
but	O	O
not	O	O
with	O	O
that	O	O
of	O	O
THP-1	B-cell_type	O
cells	I-cell_type	O
.	O	O

An	O	O
anti-C/EBP	O	O
delta	O	O
antibody	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
complex	B-protein	O
in	O	O
either	O	O
cell	O	O
.	O	O

Thus	O	O
,	O	O
it	O	O
was	O	O
concluded	O	O
that	O	O
C/EBP	O	O
alpha	B-protein	O
and	O	O
-beta	O	O
were	O	O
able	O	O
to	O	O
bind	O	O
to	O	O
the	O	O
C/EBP	B-protein	O
motif	I-protein	O
,	O	O
and	O	O
that	O	O
C/EBP	O	O
alpha	O	O
bound	O	O
to	O	O
the	O	O
motif	O	O
in	O	O
THP-1	B-cell_line	O
cells	I-cell_type	O
and	O	O
C/EBP	O	O
beta	O	O
bound	O	O
to	O	O
that	O	O
in	O	O
the	O	O
VD3-treated	B-cell_line	O
HL-60	I-cell_line	O
cells	I-cell_line	O
.	O	O

Furthermore	O	O
,	O	O
to	O	O
examine	O	O
the	O	O
transcriptional	O	O
activity	O	O
of	O	O
the	O	O
C/EBP	B-DNA	O
motif	I-DNA	O
,	O	O
we	O	O
transfected	O	O
several	O	O
constructed	O	O
luciferase	O	O
reporter	I-DNA	O
DNAs	O	O
into	O	O
HL-60	B-cell_type	O
cells	I-cell_type	O
and	O	O
THP-1	B-cell_line	O
cells	I-cell_line	O
.	O	O

The	O	O
luciferase	O	O
activity	O	O
of	O	O
the	O	O
C/EBP	B-DNA	O
motif	I-DNA	O
in	O	O
HL-60	B-cell_line	O
cells	I-cell_line	O
was	O	O
increased	O	O
by	O	O
VD3	O	O
treatment	O	O
.	O	O

The	O	O
C/EBP	B-DNA	O
motif	I-DNA	O
in	O	O
the	O	O
MRP14	B-DNA	O
gene	I-DNA	O
was	O	O
confirmed	O	O
to	O	O
function	O	O
as	O	O
a	O	O
regulatory	O	O
region	O	O
in	O	O
VD3-treated	O	O
HL-60	B-cell_line	O
cells	I-cell_line	O
and	O	O
THP-1	B-cell_line	O
cells	I-cell_line	O
by	O	O
the	O	O
assay	O	O
.	O	O

Since	O	O
C/EBP	O	O
beta	O	O
was	O	O
also	O	O
detected	O	O
in	O	O
VD3-untreated	O	O
HL-60	O	O
cells	O	O
by	O	O
immunoblotting	O	O
,	O	O
VD3	O	O
activated	O	O
C/EBP	O	O
beta	O	O
to	O	O
bind	O	O
to	O	O
the	O	O
motif	B-protein	O
,	O	O
probably	O	O
through	O	O
post-translational	B-protein	O
modification	I-protein	O
.	O	O

Patients	O	O
with	O	O
high-risk	O	O
myelodysplastic	O	O
syndrome	O	O
can	O	O
have	O	O
polyclonal	O	O
or	O	O
clonal	O	O
haemopoiesis	O	O
in	O	O
complete	O	O
haematological	O	O
remission	O	O
.	O	O

The	O	O
clonality	O	O
of	O	O
mature	B-cell_type	O
peripheral	I-cell_type	O
blood-derived	I-cell_type	O
myeloid	I-cell_type	O
and	I-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
and	O	O
bone	O	O
marrow	O	O
haemopoietic	O	O
progenitors	O	O
from	O	O
18	O	O
females	O	O
with	O	O
myelodysplasia	O	O
(	O	O
MDS	O	O
)	O	O
(	O	O
five	O	O
refractory	O	O
anaemia	O	O
,	O	O
RA	O	O
;	O	O
one	O	O
RA	O	O
with	O	O
ringed	O	O
sideroblasts	O	O
,	O	O
RARS	O	O
;	O	O
three	O	O
chronic	O	O
myelomonocytic	O	O
leukaemia	O	O
,	O	O
CMML	O	O
;	O	O
four	O	O
RA	O	O
with	O	O
excess	O	O
of	O	O
blasts	O	O
,	O	O
RAEB	O	O
;	O	O
five	O	O
RAEB	O	O
in	O	O
transformation	O	O
,	O	O
RAEB-t	O	O
)	O	O
was	O	O
studied	O	O
by	O	O
X-chromosome	O	O
inactivation	O	O
analysis	O	O
.	O	O

Using	O	O
the	O	O
human	O	O
androgen-receptor	I-protein	O
(	O	O
HUMARA	B-protein	O
)	O	O
assay	O	O
,	O	O
we	O	O
analysed	O	O
the	O	O
clonal	O	O
patterns	O	O
of	O	O
highly	O	O
purified	O	O
immature	O	O
CD34+	O	O
38-	O	O
and	O	O
committed	O	O
CD34+	O	O
38+	O	O
marrow-derived	O	O
progenitors	O	O
,	O	O
and	O	O
CD16+	O	O
14-	O	O
granulocytes	O	O
,	O	O
CD14+	O	O
monocytes	B-cell_type	O
,	O	O
CD3+	O	O
T	O	O
and	O	O
CD19+	O	O
B	I-cell_type	O
lymphocytes	I-cell_type	O
from	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
.	O	O

In	O	O
high-risk	O	O
patients	O	O
(	O	O
RAEB	O	O
,	O	O
RAEB-t	O	O
)	O	O
,	O	O
clonality	O	O
analysis	O	O
was	O	O
performed	O	O
before	O	O
and	O	O
after	O	O
intensive	O	O
remission-induction	O	O
treatment	O	O
.	O	O

All	O	O
patients	O	O
,	O	O
except	O	O
one	O	O
with	O	O
RA	O	O
,	O	O
had	O	O
predominance	O	O
of	O	O
a	O	O
single	O	O
clone	O	O
in	O	O
their	O	O
granulocytes	O	O
and	O	O
monocytes	B-cell_type	O
.	O	O

The	O	O
same	O	O
clonal	O	O
pattern	O	O
was	O	O
found	O	O
in	O	O
CD34+	B-cell_line	O
progenitor	I-cell_line	O
cells	I-cell_line	O
.	O	O

In	O	O
contrast	O	O
,	O	O
CD3+	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
were	O	O
polyclonal	O	O
or	O	O
oligoclonal	O	O
in	O	O
14/18	O	O
patients	O	O
.	O	O

X-chromosome	O	O
inactivation	O	O
patterns	O	O
of	O	O
CD19+	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
were	O	O
highly	O	O
concordant	O	O
with	O	O
CD3+	O	O
T	B-cell_type	O
cells	I-cell_type	O
except	O	O
for	O	O
two	O	O
patients	O	O
(	O	O
one	O	O
RA	O	O
,	O	O
one	O	O
CMML	O	O
)	O	O
with	O	O
monoclonal	O	O
B	O	O
and	O	O
polyclonal	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
therefore	O	O
suggesting	O	O
a	O	O
clonal	O	O
mutation	O	O
in	O	O
a	O	O
progenitor	O	O
common	O	O
to	O	O
the	O	O
myeloid	B-DNA	O
and	I-DNA	O
B-lymphoid	I-DNA	O
lineages	I-DNA	O
or	O	O
the	O	O
coexistence	O	O
of	O	O
MDS	O	O
and	O	O
a	O	O
B-cell	O	O
disorder	O	O
in	O	O
these	O	O
particular	O	O
patients	O	O
.	O	O

After	O	O
high-dose	O	O
non-myeloablative	O	O
chemotherapy	O	O
,	O	O
polyclonal	O	O
haemopoiesis	O	O
was	O	O
reinstalled	O	O
in	O	O
the	O	O
mature	B-cell_type	O
myeloid	I-cell_type	O
cells	I-cell_type	O
and	O	O
immature	O	O
and	O	O
committed	O	O
marrow	O	O
progenitors	O	O
in	O	O
three	O	O
of	O	O
four	O	O
patients	O	O
achieving	O	O
complete	O	O
haematological	O	O
remission	O	O
.	O	O

Therefore	O	O
we	O	O
conclude	O	O
that	O	O
most	O	O
haematological	O	O
remissions	O	O
in	O	O
MDS	O	O
are	O	O
associated	O	O
with	O	O
restoration	O	O
of	O	O
polyclonal	O	O
haemopoiesis	O	O
.	O	O

Prominent	O	O
sex	O	O
steroid	O	O
metabolism	O	O
in	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Steroid	O	O
metabolism	O	O
was	O	O
investigated	O	O
in	O	O
cultured	B-cell_line	O
human	I-cell_line	O
B-lymphoblastoid	I-cell_line	O
cells	I-cell_line	O
(	I-cell_line	O
B-LCL	I-cell_line	O
)	I-cell_line	O
,	O	O
and	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
T	I-cell_type	O
and	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

Gene	O	O
expression	O	O
was	O	O
examined	O	O
by	O	O
reverse-transcription	O	O
polymerase	O	O
chain	O	O
reaction	O	O
amplification	O	O
(	O	O
RT-PCR	O	O
)	O	O
.	O	O

Appropriate	O	O
sized	O	O
transcripts	O	O
were	O	O
detected	O	O
in	O	O
both	O	O
cultured	O	O
and	O	O
fresh	O	O
peripheral	O	O
lymphocytes	O	O
for	O	O
CYP11A	O	O
,	O	O
CYP17	O	O
,	O	O
HSD11L	O	O
(	O	O
11beta-hydroxysteroid	O	O
dehydrogenase	O	O
I	B-protein	O
)	O	O
,	O	O
HSD17B1	O	O
(	O	O
17beta-hydroxysteroid	O	O
dehydrogenase	O	O
type	O	O
I	O	O
)	O	O
and	O	O
SRD5A1	O	O
(	O	O
5alpha-reductase	O	O
I	O	O
)	O	O
.	O	O

B-LCL	O	O
,	O	O
but	O	O
not	O	O
T	B-cell_type	O
and	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
,	O	O
expressed	O	O
CYP11B	O	O
.	O	O

There	O	O
was	O	O
minimal	O	O
expression	O	O
of	O	O
HSD3B1	O	O
and	O	O
HSD3B2	O	O
(	O	O
3beta-hydroxysteroid	O	O
dehydrogenase	O	O
I	I-protein	O
and	O	O
II	O	O
)	O	O
in	O	O
B-LCL	O	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Transcripts	O	O
for	O	O
CYP19	O	O
and	O	O
HSD11K	O	O
were	O	O
not	O	O
detected	O	O
.	O	O

Corresponding	O	O
enzymatic	O	O
activity	O	O
was	O	O
detectable	O	O
only	O	O
for	O	O
17-hydroxysteroid	O	O
dehydrogenase	O	O
and	O	O
5alpha-reductase	O	O
,	O	O
respectively	O	O
producing	O	O
testosterone	O	O
and	O	O
5alpha-dihydrotestosterone	O	O
.	O	O

Steroid	O	O
identities	O	O
were	O	O
confirmed	O	O
by	O	O
gas	O	O
chromatography/mass	O	O
spectrometry	O	O
(	O	O
GC/MS	O	O
)	O	O
.	O	O

One	O	O
metabolite	O	O
thought	O	O
to	O	O
be	O	O
deoxycorticosterone	O	O
was	O	O
identified	O	O
by	O	O
GC/MS	O	O
as	O	O
6alpha-hydroxypregnanolone	O	O
.	O	O

It	O	O
was	O	O
concluded	O	O
that	O	O
sex	O	O
hormone	O	O
metabolism	O	O
,	O	O
including	O	O
androgen	O	O
synthesis	O	O
,	O	O
occurs	O	O
in	O	O
lymphocytes	I-cell_type	O
,	O	O
and	O	O
may	O	O
modulate	O	O
immune	O	O
response	O	O
.	O	O

Human	I-cell_line	O
white	I-cell_line	O
blood	I-cell_line	O
cells	I-cell_line	O
and	O	O
hair	O	O
follicles	O	O
are	O	O
good	O	O
sources	O	O
of	O	O
mRNA	B-RNA	O
for	O	O
the	O	O
pterin	O	O
carbinolamine	O	O
dehydratase/dimerization	O	O
cofactor	O	O
of	O	O
HNF1	O	O
for	O	O
mutation	O	O
detection	O	O
.	O	O

Pterin	O	O
carbinolamine	O	O
dehydratase/dimerization	O	O
cofactor	O	O
of	O	O
HNF1	O	O
(	O	O
PCD/DCoH	B-protein	O
)	O	O
is	O	O
a	O	O
protein	O	O
that	O	O
has	O	O
a	O	O
dual	O	O
function	O	O
.	O	O

It	O	O
is	O	O
a	O	O
pterin	O	O
4alpha-carbinolamine	O	O
dehydratase	O	O
that	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
regeneration	O	O
of	O	O
the	O	O
cofactor	O	O
tetrahydrobiopterin	O	O
during	O	O
the	O	O
phenylalanine	O	O
hydroxylase-	O	O
catalyzed	O	O
hydroxylation	O	O
of	O	O
phenylalanine	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
it	O	O
is	O	O
the	O	O
dimerization	O	O
cofactor	O	O
of	O	O
HNF1	O	O
that	O	O
is	O	O
able	O	O
to	O	O
activate	O	O
the	O	O
transcriptional	O	O
activity	O	O
of	O	O
HNF1	O	O
.	O	O

Deficiencies	O	O
in	O	O
the	O	O
gene	O	O
for	O	O
this	O	O
dual	O	O
functional	O	O
protein	O	O
result	O	O
in	O	O
hyperphenylalaninemia	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
the	O	O
PCD/DCoH	B-RNA	O
mRNA	I-RNA	O
is	O	O
present	O	O
in	O	O
human	B-cell_type	O
white	I-cell_type	O
blood	I-cell_type	O
cells	I-cell_type	O
and	O	O
hair	O	O
follicles	O	O
.	O	O

Taking	O	O
advantage	O	O
of	O	O
this	O	O
finding	O	O
,	O	O
a	O	O
sensitive	O	O
,	O	O
rapid	O	O
and	O	O
convenient	O	O
method	O	O
for	O	O
screening	O	O
mutations	O	O
occurring	O	O
in	O	O
the	O	O
coding	O	O
region	O	O
of	O	O
this	O	O
gene	O	O
has	O	O
been	O	O
described	O	O
.	O	O

Copyright	O	O
1998	O	O
Academic	O	O
Press	O	O
.	O	O

Biochemical	O	O
characterization	O	O
of	O	O
the	O	O
NF-Y	B-protein	O
transcription	I-protein	O
factor	I-protein	O
complex	I-protein	O
during	O	O
B	O	O
lymphocyte	O	O
development	O	O
.	O	O

The	O	O
transcription	B-protein	O
factor	I-protein	O
,	O	O
NF-Y	O	O
,	O	O
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
tissue-specific	O	O
major	O	O
histocompatibility	O	O
complex	I-protein	O
class	I-protein	O
II	I-protein	O
gene	I-DNA	O
transcription	O	O
.	O	O

In	O	O
this	O	O
report	O	O
the	O	O
biochemical	O	O
properties	O	O
of	O	O
the	O	O
heterotrimeric	O	O
NF-Y	I-protein	O
complex	I-protein	O
have	O	O
been	O	O
characterized	O	O
during	O	O
stage-specific	O	O
B-cell	O	O
development	O	O
,	O	O
and	O	O
in	O	O
several	O	O
class	O	O
II-	O	O
mutant	O	O
B-cell	O	O
lines	O	O
,	O	O
which	O	O
represent	O	O
distinct	O	O
bare	O	O
lymphocyte	O	O
syndrome	O	O
class	O	O
II	O	O
genetic	O	O
complementation	O	O
groups	O	O
.	O	O

The	O	O
NF-Y	B-protein	O
complex	I-protein	O
derived	O	O
from	O	O
class	O	O
II+	O	O
mature	O	O
B-cells	O	O
bound	O	O
with	O	O
high	O	O
affinity	O	O
to	O	O
anion	O	O
exchangers	O	O
,	O	O
and	O	O
eluted	O	O
as	O	O
an	O	O
intact	O	O
trimeric	B-protein	O
complex	I-protein	O
,	O	O
whereas	O	O
,	O	O
NF-Y	O	O
derived	O	O
from	O	O
class	O	O
II-	O	O
plasma	O	O
B-cells	O	O
,	O	O
and	O	O
from	O	O
bare	O	O
lymphocyte	O	O
syndrome	O	O
group	O	O
II	O	O
cell	O	O
lines	O	O
,	O	O
RJ2.2.5	O	O
and	O	O
RM3	O	O
,	O	O
dissociated	O	O
into	O	O
discrete	O	O
NF-YA	O	O
and	O	O
NF-YB	O	O
:	O	O
C	O	O
subunit	O	O
fractions	O	O
.	O	O

Recombination	O	O
of	O	O
the	O	O
MPC11	O	O
plasma	O	O
B-cell	O	O
derived	O	O
NF-Y	O	O
A	O	O
:	O	O
B	O	O
:	O	O
C	O	O
complex	O	O
with	O	O
the	O	O
low	O	O
molecular	O	O
mass	O	O
protein	O	O
fraction	O	O
,	O	O
NF-Y-associated	O	O
factors	I-protein	O
(	O	O
YAFs	O	O
)	O	O
,	O	O
derived	O	O
from	O	O
mature	O	O
A20	O	O
B-cell	O	O
nuclei	O	O
,	O	O
conferred	O	O
high	O	O
affinity	O	O
anion	O	O
exchange	O	O
binding	O	O
to	O	O
NF-Y	O	O
as	O	O
an	O	O
intact	O	O
trimeric	B-protein	O
complex	I-protein	O
.	O	O

Recombination	O	O
of	O	O
the	O	O
native	O	O
NF-YA	O	O
:	O	O
B	O	O
:	O	O
C	O	O
complex	O	O
with	O	O
the	O	O
transcriptional	O	O
cofactor	O	O
,	O	O
PC4	O	O
,	O	O
likewise	O	O
conferred	O	O
high	O	O
affinity	O	O
NF-Y	O	O
binding	O	O
to	O	O
anion	O	O
exchangers	O	O
,	O	O
and	O	O
stabilized	O	O
NF-Y	O	O
interaction	O	O
with	O	O
CCAAT-box	O	O
DNA	B-protein	O
motifs	I-protein	O
in	O	O
vitro	O	O
.	O	O

Interaction	O	O
between	O	O
PC4	O	O
and	O	O
NF-Y	O	O
was	O	O
mapped	O	O
to	O	O
the	O	O
C-terminal	O	O
region	O	O
of	O	O
PC4	O	O
,	O	O
and	O	O
the	O	O
subunit	O	O
interaction	O	O
subdomain	O	O
of	O	O
the	O	O
highly	O	O
conserved	O	O
DNA	I-protein	O
binding-subunit	I-protein	O
interaction	I-protein	O
domain	I-protein	O
(	O	O
DBD	B-protein	O
)	O	O
of	O	O
NF-YA	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
in	O	O
class	O	O
II+	O	O
mature	O	O
B-cells	O	O
NF-Y	O	O
is	O	O
associated	O	O
with	O	O
the	O	O
protein	O	O
cofactor	O	O
,	O	O
PC4	O	O
,	O	O
which	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
NF-Y-mediated	O	O
transcriptional	O	O
control	O	O
of	O	O
class	B-DNA	O
II	I-DNA	O
genes	I-DNA	O
.	O	O

Arrest	O	O
of	O	O
B	O	O
lymphocyte	O	O
terminal	O	O
differentiation	O	O
by	O	O
CD40	O	O
signaling	O	O
:	O	O
mechanism	O	O
for	O	O
lack	O	O
of	O	O
antibody-secreting	B-cell_type	O
cells	I-cell_type	O
in	O	O
germinal	O	O
centers	O	O
.	O	O

Despite	O	O
extensive	O	O
research	O	O
,	O	O
the	O	O
role	O	O
of	O	O
CD40	O	O
signaling	O	O
in	O	O
B	O	O
cell	O	O
terminal	O	O
differentiation	O	O
remains	O	O
controversial	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
CD40	O	O
engagement	O	O
arrests	O	O
B	O	O
cell	O	O
differentiation	O	O
prior	O	O
to	O	O
plasma	O	O
cell	O	O
formation	O	O
.	O	O

This	O	O
arrest	O	O
is	O	O
manifested	O	O
at	O	O
a	O	O
molecular	O	O
level	O	O
as	O	O
a	O	O
reduction	O	O
in	O	O
mRNA	O	O
levels	O	O
of	O	O
secretory	O	O
immunoglobulin	O	O
gene	O	O
products	O	O
such	O	O
as	O	O
mu	O	O
(	O	O
s	O	O
)	O	O
and	O	O
J	O	O
chain	O	O
as	O	O
well	O	O
as	O	O
the	O	O
loss	O	O
of	O	O
the	O	O
transcriptional	B-protein	O
regulator	I-protein	O
BLIMP-1	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
inhibition	O	O
of	O	O
B	B-protein	O
cell	O	O
differentiation	O	O
by	O	O
CD40	O	O
engagement	O	O
could	O	O
not	O	O
be	O	O
overcome	O	O
by	O	O
either	O	O
mitogens	O	O
or	O	O
cytokines	B-protein	O
,	O	O
but	O	O
could	O	O
be	O	O
reversed	O	O
by	O	O
antibodies	O	O
that	O	O
interfere	O	O
with	O	O
the	O	O
CD40	O	O
/	O	O
gp39	O	O
interaction	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
secretory	O	O
immunoglobulin	O	O
is	O	O
not	O	O
produced	O	O
by	O	O
B	B-cell_type	O
cells	I-cell_type	O
that	O	O
are	O	O
actively	O	O
engaged	O	O
by	O	O
gp39-expressing	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

A	O	O
positively	O	O
charged	O	O
alpha-lipoic	O	O
acid	O	O
analogue	O	O
with	O	O
increased	O	O
cellular	O	O
uptake	O	O
and	O	O
more	O	O
potent	O	O
immunomodulatory	O	O
activity	O	O
.	O	O

alpha-Lipoic	O	O
acid	O	O
(	O	O
LA	O	O
)	O	O
is	O	O
taken	O	O
up	O	O
by	O	O
cells	O	O
and	O	O
reduced	O	O
to	O	O
its	O	O
potent	O	O
dithiol	O	O
form	O	O
,	O	O
dihydrolipoate	O	O
(	O	O
DHLA	B-protein	O
)	O	O
,	O	O
much	O	O
of	O	O
which	O	O
is	O	O
rapidly	O	O
effluxed	O	O
out	O	O
from	O	O
cells	I-cell_type	O
.	O	O

To	O	O
improve	O	O
retention	O	O
in	O	O
cells	O	O
,	O	O
the	O	O
LA	O	O
molecule	O	O
was	O	O
modified	O	O
to	O	O
confer	O	O
a	O	O
positive	O	O
charge	O	O
at	O	O
physiological	O	O
pH	O	O
.	O	O

N	O	O
,	O	O
N-dimethyl	O	O
,	O	O
N'-2-amidoethyl-lipoate	O	O
was	O	O
synthesized	O	O
.	O	O

The	O	O
protonated	O	O
form	O	O
of	O	O
the	O	O
new	O	O
molecule	O	O
is	O	O
referred	O	O
to	O	O
as	O	O
LA-Plus	O	O
.	O	O

The	O	O
uptake	O	O
of	O	O
LA-Plus	O	O
by	O	O
human	B-cell_line	O
Wurzburg	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
was	O	O
higher	O	O
compared	O	O
to	O	O
that	O	O
of	O	O
LA	O	O
.	O	O

Several-fold	O	O
higher	O	O
amounts	O	O
of	O	O
DHLA-Plus	O	O
,	O	O
the	O	O
corresponding	O	O
reduced	O	O
form	O	O
of	O	O
LA-Plus	O	O
,	O	O
were	O	O
detected	O	O
in	O	O
LA-Plus	O	O
treated	O	O
cells	O	O
compared	O	O
to	O	O
the	O	O
amount	O	O
of	O	O
DHLA	O	O
found	O	O
in	O	O
cells	O	O
treated	O	O
with	O	O
LA	O	O
.	O	O

At	O	O
100	O	O
microM	O	O
,	O	O
LA	O	O
did	O	O
not	O	O
but	O	O
LA-Plus	O	O
inhibited	O	O
H2O2	O	O
induced	O	O
NF-kappaB	O	O
activation	O	O
and	O	O
NF-kappaB	O	O
directed	O	O
IL-2	O	O
receptor	O	O
expression	O	O
.	O	O

Both	O	O
LA	O	O
and	O	O
LA-Plus	O	O
synergised	O	O
with	O	O
selenium	O	O
in	O	O
inhibiting	O	O
H2O2	O	O
induced	O	O
NF-kappaB	O	O
activation	O	O
.	O	O

At	O	O
150	O	O
microM	O	O
LA-Plus	O	O
,	O	O
but	O	O
not	O	O
LA	O	O
,	O	O
inhibited	O	O
TNFalpha	O	O
induced	O	O
NF-kappaB	O	O
activation	O	O
.	O	O

At	O	O
5	O	O
microM	O	O
LA-Plus	O	O
,	O	O
but	O	O
not	O	O
LA	O	O
,	O	O
protected	O	O
against	O	O
both	O	O
spontaneous	O	O
and	O	O
etoposide	O	O
induced	O	O
apoptosis	O	O
in	O	O
rat	O	O
thymocytes	B-cell_type	O
.	O	O

LA-Plus	O	O
is	O	O
thus	O	O
an	O	O
improved	O	O
form	O	O
of	O	O
LA	O	O
with	O	O
increased	O	O
therapeutic	O	O
potential	O	O
.	O	O

Copyright	O	O
1998	O	O
Academic	O	O
Press	O	O
.	O	O

Carrier	O	O
identification	O	O
in	O	O
X-linked	O	O
immunodeficiency	O	O
diseases	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
Carrier	O	O
identification	O	O
in	O	O
X-linked	O	O
immunodeficiency	O	O
disorders	O	O
can	O	O
be	O	O
based	O	O
on	O	O
the	O	O
demonstration	O	O
of	O	O
non-random	B-protein	O
X	I-protein	O
inactivation	I-protein	O
(	O	O
NRXI	B-protein	O
)	O	O
in	O	O
affected	O	O
blood	I-cell_type	O
cell	O	O
lineages	O	O
when	O	O
growth	O	O
is	O	O
impaired	O	O
in	O	O
cells	O	O
expressing	O	O
the	O	O
abnormal	O	O
gene	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
utility	O	O
of	O	O
seeking	O	O
evidence	O	O
of	O	O
NRXI	O	O
to	O	O
test	O	O
the	O	O
carrier	O	O
status	O	O
of	O	O
women	O	O
in	O	O
families	O	O
affected	O	O
by	O	O
X-linked	O	O
severe	O	O
combined	O	O
immunodeficiency	O	O
(	O	O
XSCID	O	O
)	O	O
and	O	O
X-linked	O	O
hypogammaglobulinaemia	O	O
(	O	O
XLH	O	O
)	O	O
,	O	O
to	O	O
identify	O	O
as	O	O
carriers	O	O
the	O	O
mothers	O	O
of	O	O
boys	O	O
with	O	O
SCID	O	O
or	O	O
hypogammaglobulinaemia	O	O
whose	O	O
phenotype	O	O
suggested	O	O
X-linkage	O	O
and	O	O
to	O	O
infer	O	O
X-linkage	O	O
in	O	O
boys	O	O
with	O	O
SCID	O	O
or	O	O
hypogammaglobulinaemia	O	O
whose	O	O
disease	O	O
was	O	O
not	O	O
clearly	O	O
X-linked	O	O
on	O	O
the	O	O
basis	O	O
either	O	O
of	O	O
family	O	O
history	O	O
or	O	O
clinical	O	O
and	O	O
immunological	O	O
characteristics	O	O
.	O	O

METHODOLOGY	O	O
:	O	O
A	O	O
polymerase	O	O
chain	O	O
reaction-based	O	O
method	O	O
was	O	O
used	O	O
to	O	O
amplify	O	O
a	O	O
polymorphic	O	O
CAG	O	O
repeat	O	O
in	O	O
the	O	O
first	O	O
exon	O	O
of	O	O
the	O	O
androgen	B-DNA	O
receptor	I-DNA	O
gene	I-DNA	O
after	O	O
selective	O	O
digestion	O	O
of	O	O
the	O	O
active	O	O
X	B-protein	O
chromosome	I-protein	O
with	O	O
a	O	O
methylation-sensitive	B-protein	O
enzyme	O	O
,	O	O
HpaII	O	O
to	O	O
distinguish	O	O
between	O	O
the	O	O
paternal	O	O
and	O	O
maternal	O	O
alleles	O	O
and	O	O
to	O	O
identify	O	O
their	O	O
methylation	O	O
status	O	O
.	O	O

RESULTS	O	O
:	O	O
Heterozygosity	O	O
was	O	O
found	O	O
in	O	O
24	O	O
of	O	O
31	O	O
female	O	O
subjects	O	O
(	O	O
77	O	O
%	O	O
)	O	O
.	O	O

As	O	O
anticipated	O	O
,	O	O
NRXI	O	O
could	O	O
be	O	O
demonstrated	O	O
in	O	O
all	O	O
lymphoid	B-cell_type	O
cells	I-cell_type	O
studied	O	O
from	O	O
obligate	O	O
carriers	O	O
of	O	O
XSCID	O	O
and	O	O
an	O	O
obligate	O	O
carrier	O	O
of	O	O
XLH	O	O
but	O	O
not	O	O
on	O	O
a	O	O
carrier	O	O
of	O	O
X-linked	O	O
immunodeficiency	O	O
with	O	O
hyper-IgM	O	O
.	O	O

The	O	O
finding	O	O
of	O	O
NRXI	O	O
in	O	O
the	O	O
mother	O	O
of	O	O
a	O	O
boy	O	O
with	O	O
a	O	O
SCID	O	O
variant	O	O
showed	O	O
her	O	O
to	O	O
be	O	O
a	O	O
carrier	O	O
of	O	O
XSCID	O	O
and	O	O
establishes	O	O
that	O	O
her	O	O
son	O	O
has	O	O
XSCID	O	O
,	O	O
not	O	O
otherwise	O	O
evident	O	O
from	O	O
available	O	O
data	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
PCR	O	O
assay	O	O
provides	O	O
a	O	O
rapid	O	O
method	O	O
for	O	O
carrier	O	O
detection	O	O
of	O	O
X-linked	O	O
immunodeficiencies	O	O
,	O	O
and	O	O
has	O	O
allowed	O	O
us	O	O
to	O	O
expand	O	O
the	O	O
phenotype	O	O
of	O	O
XSCID	O	O

Leukocyte-endothelial	O	O
interaction	O	O
is	O	O
augmented	O	O
by	O	O
high	O	O
glucose	O	O
concentrations	O	O
and	O	O
hyperglycemia	O	O
in	O	O
a	O	O
NF-kB-dependent	O	O
fashion	O	O
.	O	O

We	O	O
addressed	O	O
the	O	O
role	O	O
of	O	O
hyperglycemia	O	O
in	O	O
leukocyte-endothelium	O	O
interaction	O	O
under	O	O
flow	O	O
conditions	O	O
by	O	O
exposing	O	O
human	B-cell_line	O
umbilical	I-cell_line	O
vein	I-cell_line	O
endothelial	I-cell_line	O
cells	I-cell_line	O
for	O	O
24	O	O
h	O	O
to	O	O
normal	O	O
(	O	O
5	O	O
mM	O	O
)	O	O
,	O	O
high	O	O
concentration	O	O
of	O	O
glucose	O	O
(	O	O
30	O	O
mM	O	O
)	O	O
,	O	O
advanced	O	O
glycosylation	O	O
end	O	O
product-albumin	O	O
(	O	O
100	O	O
microg/ml	O	O
)	O	O
,	O	O
or	O	O
hyperglycemic	O	O
(	O	O
174-316	O	O
mg/dl	O	O
)	O	O
sera	O	O
from	O	O
patients	O	O
with	O	O
diabetes	O	O
and	O	O
abnormal	O	O
hemoglobin	O	O
A1c	O	O
(	O	O
8.1+/-1.4	O	O
%	O	O
)	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
incubation	O	O
endothelial	O	O
cells	O	O
were	O	O
perfused	O	O
with	O	O
total	O	O
leukocyte	O	O
suspension	O	O
in	O	O
a	O	O
parallel	O	O
plate	O	O
flow	O	O
chamber	O	O
under	O	O
laminar	O	O
flow	O	O
(	O	O
1.5	O	O
dyn/cm2	O	O
)	O	O
.	O	O

Rolling	O	O
and	O	O
adherent	B-cell_type	O
cells	I-cell_type	O
were	O	O
evaluated	O	O
by	O	O
digital	O	O
image	O	O
processing	O	O
.	O	O

Results	O	O
showed	O	O
that	O	O
30	O	O
mM	O	O
glucose	O	O
significantly	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
increased	O	O
the	O	O
number	O	O
of	O	O
adherent	O	O
leukocytes	O	O
to	O	O
endothelial	B-cell_type	O
cells	I-cell_type	O
in	O	O
respect	O	O
to	O	O
control	O	O
(	O	O
5	O	O
mM	O	O
glucose	O	O
;	O	O
151+/-19	O	O
versus	O	O
33+/-8	O	O
cells/mm2	O	O
)	O	O
.	O	O

A	O	O
similar	O	O
response	O	O
was	O	O
induced	O	O
by	O	O
endothelial	O	O
stimulation	O	O
with	O	O
IL-1beta	O	O
,	O	O
here	O	O
used	O	O
as	O	O
positive	O	O
control	O	O
(	O	O
195+/-20	O	O
cells/mm2	O	O
)	O	O
.	O	O

The	O	O
number	O	O
of	O	O
rolling	B-cell_type	O
cells	I-cell_type	O
on	O	O
endothelial	B-protein	O
surface	O	O
was	O	O
not	O	O
affected	O	O
by	O	O
high	O	O
glucose	O	O
level	O	O
.	O	O

Stable	O	O
adhesion	O	O
of	O	O
leukocytes	O	O
to	O	O
glucose-treated	O	O
as	O	O
well	O	O
as	O	O
to	O	O
IL-1beta-stimulated	B-cell_line	O
endothelial	I-cell_line	O
cells	I-cell_line	O
was	O	O
preceded	O	O
by	O	O
short	O	O
interaction	O	O
of	O	O
leukocytes	O	O
with	O	O
the	O	O
endothelial	B-protein	O
surface	I-protein	O
.	O	O

The	O	O
distance	O	O
travelled	O	O
by	O	O
leukocytes	O	O
before	O	O
arrest	O	O
on	O	O
30	O	O
mM	O	O
glucose	O	O
,	O	O
or	O	O
on	O	O
IL-1beta-treated	B-cell_line	O
endothelial	I-cell_line	O
cells	I-cell_line	O
,	O	O
was	O	O
significantly	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
higher	O	O
than	O	O
that	O	O
observed	O	O
for	O	O
leukocytes	O	O
adhering	O	O
on	O	O
control	O	O
endothelium	O	O
(	O	O
30	O	O
mM	O	O
glucose	O	O
:	O	O
76.7+/-3.5	O	O
;	O	O
IL1beta	O	O
:	O	O
69.7+/-4	O	O
versus	O	O
5	O	O
mM	O	O
glucose	O	O
:	O	O
21.5+/-5	O	O
microm	O	O
)	O	O
.	O	O

Functional	O	O
blocking	O	O
of	O	O
E-selectin	B-protein	O
,	O	O
intercellular	B-protein	O
cell	I-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
,	O	O
and	O	O
vascular	B-protein	O
cell	O	O
adhesion	O	O
molecule-1	O	O
on	O	O
endothelial	O	O
cells	O	O
with	O	O
the	O	O
corresponding	B-protein	O
mouse	I-protein	O
mAb	I-protein	O
significantly	O	O
inhibited	O	O
glucose-induced	O	O
increase	O	O
in	O	O
leukocyte	O	O
adhesion	O	O
(	O	O
67+/-16	O	O
,	O	O
83+/-12	O	O
,	O	O
62+/-8	O	O
versus	O	O
144+/-21	O	O
cells/	O	O
mm2	O	O
)	O	O
.	O	O

Confocal	O	O
fluorescence	O	O
microscopy	O	O
studies	O	O
showed	O	O
that	O	O
30	O	O
mM	O	O
glucose	O	O
induced	O	O
an	O	O
increase	O	O
in	O	O
endothelial	O	O
surface	O	O
expression	O	O
of	O	O
E-selectin	B-protein	O
,	O	O
intercellular	B-protein	O
cell	I-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
,	O	O
and	O	O
vascular	B-protein	O
cell	I-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
.	O	O

Electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
of	O	O
nuclear	O	O
extracts	O	O
of	O	O
human	B-cell_line	O
umbilical	I-cell_line	O
vein	I-cell_line	O
endothelial	I-cell_line	O
cells	I-cell_line	O
(	O	O
HUVEC	O	O
)	O	O
exposed	O	O
for	O	O
1	O	O
h	O	O
to	O	O
30	O	O
mM	O	O
glucose	O	O
revealed	O	O
an	O	O
intense	O	O
NF-kB	O	O
activation	O	O
.	O	O

Treatment	O	O
of	O	O
HUVEC	O	O
exposed	O	O
to	O	O
high	O	O
glucose	O	O
with	O	O
the	O	O
NF-kB	O	O
inhibitors	O	O
pyrrolidinedithiocarbamate	O	O
(	O	O
100	O	O
microM	O	O
)	O	O
and	O	O
tosyl-phe-chloromethylketone	O	O
(	O	O
25	O	O
microM	O	O
)	O	O
significantly	O	O
reduced	O	O
(	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
leukocyte	O	O
adhesion	O	O
in	O	O
respect	O	O
to	O	O
HUVEC	O	O
treated	O	O
with	O	O
glucose	O	O
alone	O	O
.	O	O

A	O	O
significant	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
inhibitory	O	O
effect	O	O
on	O	O
glucose-induced	O	O
leukocyte	O	O
adhesion	O	O
was	O	O
observed	O	O
after	O	O
blocking	B-protein	O
protein	I-protein	O
kinase	I-protein	O
C	I-protein	O
activity	O	O
with	O	O
staurosporine	O	O
(	O	O
5	O	O
nM	O	O
)	O	O
.	O	O

When	O	O
HUVEC	O	O
were	O	O
treated	O	O
with	O	O
specific	O	O
antisense	O	O
oligodesoxynucleotides	O	O
against	O	O
PKCalpha	O	O
and	O	O
PKCepsilon	O	O
isoforms	O	O
before	O	O
the	O	O
addition	O	O
of	O	O
30	O	O
mM	O	O
glucose	O	O
,	O	O
a	O	O
significant	O	O
(	O	O
P	O	O
<	O	O
0.05	I-protein	O
)	O	O
reduction	O	O
in	O	O
the	O	O
adhesion	O	O
was	O	O
also	O	O
seen	O	O
.	O	O

Advanced	O	O
glycosylation	O	O
end	O	O
product-albumin	O	O
significantly	O	O
increased	O	O
the	O	O
number	O	O
of	O	O
adhering	O	O
leukocytes	O	O
in	O	O
respect	O	O
to	O	O
native	O	O
albumin	O	O
used	O	O
as	O	O
control	O	O
(	O	O
110+/-16	O	O
versus	O	O
66+/-7	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

Sera	O	O
from	O	O
diabetic	O	O
patients	O	O
significantly	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
enhanced	O	O
leukocyte	O	O
adhesion	O	O
as	O	O
compared	O	O
with	O	O
controls	O	O
,	O	O
despite	O	O
normal	O	O
levels	O	O
of	O	O
IL-1beta	O	O
and	O	O
TNFalpha	O	O
in	O	O
these	O	O
sera	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
high	O	O
glucose	O	O
concentration	O	O
and	O	O
hyperglycemia	O	O
promote	O	O
leukocyte	O	O
adhesion	O	O
to	O	O
the	O	O
endothelium	O	O
through	O	O
upregulation	O	O
of	O	O
cell	O	O
surface	O	O
expression	O	O
of	O	O
adhesive	B-protein	O
proteins	I-protein	O
,	O	O
possibly	O	O
depending	O	O
on	O	O
NF-kB	O	O
activation	O	O
.	O	O

Ikaros	O	O
in	O	O
hemopoietic	O	O
lineage	O	O
determination	O	O
and	O	O
homeostasis	O	O
.	O	O

Studies	O	O
on	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
control	O	O
hemopoietic	O	O
differentiation	O	O
have	O	O
focused	O	O
on	O	O
signaling	O	O
cascades	O	O
and	O	O
nuclear	O	O
effectors	O	O
that	O	O
drive	O	O
this	O	O
complex	O	O
developmental	O	O
system	O	O
in	O	O
a	O	O
regulated	O	O
fashion	O	O
.	O	O

Here	O	O
we	O	O
review	O	O
the	O	O
role	O	O
of	O	O
Ikaros	O	O
,	O	O
the	O	O
founding	O	O
member	O	O
of	O	O
a	O	O
unique	B-protein	O
family	I-protein	O
of	O	O
zinc	B-protein	O
finger	I-protein	O
transcription	B-protein	O
factors	I-protein	O
in	O	O
this	O	O
developmental	O	O
process	O	O
.	O	O

Studies	O	O
on	O	O
an	O	O
Ikaros	O	O
null	O	O
mutation	O	O
have	O	O
revealed	O	O
an	O	O
essential	O	O
role	O	O
for	O	O
this	O	O
factor	O	O
in	O	O
lymphoid	O	O
cell	O	O
fate	O	O
determination	O	O
and	O	O
at	O	O
subsequent	O	O
branch	O	O
points	O	O
of	O	O
the	O	O
T	B-cell_type	O
cell	I-cell_type	O
differentiation	O	O
pathway	O	O
.	O	O

Differences	O	O
in	O	O
the	O	O
phenotypes	O	O
of	O	O
a	O	O
null	O	O
and	O	O
a	O	O
dominant	B-DNA	O
negative	I-DNA	O
(	O	O
DN	B-DNA	O
)	O	O
Ikaros	O	O
mutation	O	O
provide	O	O
insight	O	O
into	O	O
a	O	O
regulatory	O	O
network	O	O
through	O	O
which	O	O
Ikaros	O	O
proteins	O	O
exert	O	O
their	O	O
effects	O	O
in	O	O
development	O	O
.	O	O

In	O	O
addition	O	O
a	O	O
comparative	O	O
analysis	O	O
of	O	O
the	O	O
hemopoietic	B-DNA	O
stem	I-DNA	O
cell	O	O
and	O	O
precursor	O	O
compartment	O	O
resulting	O	O
from	O	O
the	O	O
two	O	O
Ikaros	O	O
mutations	O	O
reveals	O	O
a	O	O
profound	O	O
yet	O	O
not	O	O
absolute	O	O
requirement	O	O
for	O	O
Ikaros	O	O

Induction	O	O
of	O	O
early	B-protein	O
B	I-protein	O
cell	I-protein	O
factor	I-protein	O
(	O	O
EBF	B-protein	O
)	O	O
and	O	O
multiple	B-DNA	O
B	I-DNA	O
lineage	I-DNA	O
genes	I-DNA	O
by	O	O
the	O	O
basic	B-protein	O
helix-loop-helix	I-protein	O
transcription	I-protein	O
factor	I-protein	O
E12	O	O
.	O	O

The	O	O
transcription	B-protein	O
factors	I-protein	O
encoded	O	O
by	O	O
the	O	O
E2A	B-DNA	O
and	I-DNA	O
early	I-DNA	O
B	I-DNA	O
cell	I-protein	O
factor	I-protein	O
(	O	O
EBF	B-DNA	O
)	I-DNA	O
genes	I-DNA	O
are	O	O
required	O	O
for	O	O
the	O	O
proper	O	O
development	O	O
of	O	O
B	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

However	O	O
,	O	O
the	O	O
absence	O	O
of	O	O
B	B-cell_type	O
lineage	I-cell_type	O
cells	I-cell_type	O
in	O	O
E2A-	O	O
and	O	O
EBF-deficient	O	O
mice	O	O
has	O	O
made	O	O
it	O	O
difficult	O	O
to	O	O
determine	O	O
the	O	O
function	O	O
or	O	O
relationship	O	O
between	O	O
these	O	O
proteins	O	O
.	O	O

We	O	O
report	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
novel	O	O
model	O	O
system	O	O
in	O	O
which	O	O
the	O	O
role	O	O
of	O	O
E2A	O	O
and	O	O
EBF	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
multiple	O	O
B	B-protein	O
lineage	I-protein	O
traits	O	O
can	O	O
be	O	O
studied	O	O
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
conversion	O	O
of	O	O
70Z/3	O	O
pre-B	I-cell_type	O
lymphocytes	I-cell_type	O
to	O	O
cells	I-cell_type	O
with	O	O
a	O	O
macrophage-like	O	O
phenotype	O	O
is	O	O
associated	O	O
with	O	O
the	O	O
loss	O	O
of	O	O
E2A	O	O
and	O	O
EBF	O	O
.	O	O

Moreover	O	O
,	O	O
we	O	O
show	O	O
that	O	O
ectopic	O	O
expression	O	O
of	O	O
the	O	O
E2A	B-protein	O
protein	I-protein	O
E12	O	O
in	O	O
this	O	O
macrophage	O	O
line	O	O
results	O	O
in	O	O
the	O	O
induction	O	O
of	O	O
many	O	O
B	B-DNA	O
lineage	I-DNA	O
genes	I-DNA	O
,	O	O
including	O	O
EBF	O	O
,	O	O
IL7Ralpha	O	O
,	O	O
lambda5	O	O
,	O	O
and	O	O
Rag-1	O	O
,	O	O
and	O	O
the	O	O
ability	O	O
to	O	O
induce	O	O
kappa	O	O
light	O	O
chain	O	O
in	O	O
response	O	O
to	O	O
mitogen	O	O
.	O	O

Activation	O	O
of	O	O
EBF	O	O
may	O	O
be	O	O
one	O	O
of	O	O
the	O	O
critical	O	O
functions	O	O
of	O	O
E12	O	O
in	O	O
regulating	O	O
the	O	O
B	B-protein	O
lineage	O	O
phenotype	O	O
since	O	O
expression	O	O
of	O	O
EBF	O	O
alone	O	O
leads	O	O
to	O	O
the	O	O
activation	O	O
of	O	O
a	O	O
subset	O	O
of	O	O
E12	B-protein	O
-inducible	O	O
traits	O	O
.	O	O

Our	O	O
data	O	O
demonstrate	O	O
that	O	O
,	O	O
in	O	O
the	O	O
context	O	O
of	O	O
this	O	O
macrophage	O	O
line	O	O
,	O	O
E12	O	O
induces	O	O
expression	O	O
of	O	O
EBF	O	O
and	O	O
together	O	O
these	O	O
transcription	B-protein	O
factors	I-protein	O
coordinately	O	O
regulate	O	O
numerous	O	O
B	O	O
lineage-associated	O	O
genes	O	O
.	O	O

Activation-induced	O	O
down-regulation	O	O
of	O	O
retinoid	B-protein	O
receptor	I-protein	O
RXRalpha	O	O
expression	O	O
in	O	O
human	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Role	O	O
of	O	O
cell	O	O
cycle	O	O
regulation	O	O
.	O	O

A	O	O
5.4-kilobase	O	O
mRNA	I-RNA	O
,	O	O
the	O	O
expression	O	O
of	O	O
which	O	O
is	O	O
down-regulated	O	O
after	O	O
treatment	O	O
of	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
(	O	O
PBMCs	O	O
)	O	O
with	O	O
various	O	O
T	O	O
cell-activating	O	O
agents	O	O
,	O	O
was	O	O
isolated	O	O
using	O	O
an	O	O
mRNA	B-RNA	O
differential	O	O
display	O	O
method	O	O
.	O	O

Nucleotide	O	O
sequence	O	O
analysis	O	O
identified	O	O
the	O	O
5	O	O
'	O	O
end	O	O
of	O	O
this	O	O
RNA	O	O
as	O	O
human	B-cell_type	O
retinoid	I-protein	O
receptor	I-protein	O
RXRalpha	O	O
mRNA	I-RNA	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
the	O	O
nucleotide	O	O
sequence	O	O
of	O	O
3.6	O	O
kilobases	O	O
of	O	O
this	O	O
RNA	O	O
,	O	O
which	O	O
represents	O	O
the	O	O
3	O	O
'	O	O
end	O	O
of	O	O
RXRalpha	B-RNA	O
mRNA	I-RNA	O
,	O	O
the	O	O
sequence	O	O
of	O	O
which	O	O
has	O	O
not	O	O
been	O	O
previously	O	O
described	O	O
.	O	O

Activated	O	O
PBMCs	O	O
also	O	O
expressed	O	O
lower	O	O
levels	O	O
of	O	O
RXRalpha	B-protein	O
protein	I-protein	O
,	O	O
and	O	O
a	O	O
DNA	O	O
binding	O	O
assay	O	O
showed	O	O
that	O	O
the	O	O
activation-induced	O	O
loss	O	O
of	O	O
RXRalpha	O	O
mRNA	I-RNA	O
and	O	O
protein	O	O
expression	O	O
correlated	O	O
with	O	O
the	O	O
loss	O	O
of	O	O
DNA	O	O
binding	O	O
activity	O	O
of	O	O
this	O	O
protein	O	O
.	O	O

We	O	O
present	O	O
evidence	O	O
that	O	O
the	O	O
transition	O	O
from	O	O
G0/G1	O	O
to	O	O
S	O	O
phase	O	O
of	O	O
the	O	O
cell	O	O
cycle	O	O
results	O	O
in	O	O
the	O	O
down-regulation	O	O
of	O	O
RXRalpha	O	O
expression	O	O
and	O	O
that	O	O
cell	O	O
cycle	O	O
inhibitors	O	O
,	O	O
which	O	O
block	O	O
the	O	O
cells	O	O
in	O	O
G1	O	O
phase	O	O
,	O	O
prevent	O	O
this	O	O
down-regulation	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
RXRalpha	O	O
mRNA	I-RNA	O
was	O	O
found	O	O
to	O	O
be	O	O
regulated	O	O
at	O	O
the	O	O
post-transcriptional	O	O
level	O	O
and	O	O
involved	O	O
new	O	O
protein	O	O
synthesis	O	O
.	O	O

These	O	O
observations	O	O
indicate	O	O
that	O	O
the	O	O
levels	O	O
of	O	O
RXRalpha	O	O
expression	O	O
in	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
are	O	O
coupled	O	O
to	O	O
cell	O	O
cycle	O	O
progression	O	O
,	O	O
and	O	O
there	O	O
is	O	O
tight	O	O
regulatory	O	O
control	O	O
of	O	O
RXRalpha	O	O
expression	O	O
during	O	O
the	O	O
transition	O	O
from	O	O
G0/G1	O	O
to	O	O
S	O	O
phase	O	O
of	O	O
the	O	O
cell	O	O
cycle	O	O
.	O	O

Epidemiology	O	O
and	O	O
pathogenesis	O	O
of	O	O
AIDS-related	O	O
lymphomas	O	O
.	O	O

Among	O	O
patients	O	O
with	O	O
congenital	O	O
and	O	O
acquired	O	O
immunodeficiencies	O	O
,	O	O
non-Hodgkin	O	O
's	O	O
lymphoma	O	O
(	O	O
NHLs	O	O
)	O	O
are	O	O
the	O	O
most	O	O
common	O	O
tumors	O	O
of	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

In	O	O
the	O	O
setting	O	O
of	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
(	O	O
HIV	B-protein	O
)	O	O
infection	O	O
,	O	O
as	O	O
many	O	O
as	O	O
10	O	O
%	O	O
to	O	O
20	O	O
%	O	O
of	O	O
people	O	O
ultimately	O	O
developed	O	O
NHLs	O	O
.	O	O

These	O	O
tumors	O	O
are	O	O
clinically	O	O
aggressive	O	O
,	O	O
frequently	O	O
involve	O	O
extranodal	O	O
sites	O	O
,	O	O
and	O	O
often	O	O
exhibit	O	O
unique	O	O
features	O	O
that	O	O
distinguish	O	O
them	O	O
from	O	O
NHL	O	O
arising	O	O
in	O	O
individuals	O	O
with	O	O
other	O	O
forms	O	O
of	O	O
immunosuppression	O	O
.	O	O

Important	O	O
in	O	O
the	O	O
development	O	O
of	O	O
HIV-associated	O	O
NHL	O	O
are	O	O
cytokines	B-protein	O
and	O	O
other	O	O
factors	B-protein	O
that	O	O
induce	O	O
B-cell	O	O
proliferation	O	O
and	O	O
increase	O	O
the	O	O
likelihood	O	O
of	O	O
mutations	O	O
of	O	O
c-myc	B-protein	O
,	O	O
bcl-6	O	O
,	O	O
and	O	O
other	O	O
tumor-suppressor	O	O
genes	O	O
with	O	O
carcinogenic	O	O
potential	O	O
.	O	O

Specific	O	O
forms	O	O
of	O	O
HIV-associated	O	O
NHL	O	O
are	O	O
linked	O	O
to	O	O
expression	O	O
of	O	O
Epstein-Barr	B-protein	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
-latent	O	O
proteins	O	O
;	O	O
the	O	O
newly	O	O
described	O	O
DNA	O	O
virus	O	O
,	O	O
Karposi	O	O
's	O	O
sarcoma-associated	O	O
herpesvirus/human	O	O
herpesvirus-8	O	O
(	O	O
KSHV/HHV-8	O	O
)	O	O
;	O	O
and	O	O
perhaps	O	O
HIV	O	O
.	O	O

Elucidation	O	O
of	O	O
the	O	O
factors	B-protein	O
that	O	O
contribute	O	O
to	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
NHL	O	O
among	O	O
patients	O	O
infected	O	O
with	O	O
HIV	O	O
provides	O	O
insights	O	O
into	O	O
important	O	O
elements	O	O
of	O	O
lymphomagenesis	O	O
.	O	O

Matrix	O	O
metalloproteinase	O	O
expression	O	O
in	O	O
human	O	O
breast	O	O
cancer	O	O
:	O	O
an	O	O
immunohistochemical	O	O
study	O	O
including	O	O
correlation	O	O
with	O	O
cathepsin	O	O
D	O	O
,	O	O
type	O	O
IV	O	O
collagen	O	O
,	O	O
laminin	O	O
,	O	O
fibronectin	O	O
,	O	O
EGFR	O	O
,	O	O
c-erbB-2	O	O
oncoprotein	O	O
,	O	O
p53	O	O
,	O	O
steroid	O	O
receptors	O	O
status	O	O
and	O	O
proliferative	O	O
indices	O	O
.	O	O

Matrix	O	O
metalloproteinase	O	O
s	O	O
(	O	O
MMPs	O	O
)	O	O
are	O	O
a	O	O
group	O	O
of	O	O
enzymes	O	O
thought	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
both	O	O
normal	O	O
connective	O	O
tissue	O	O
matrix	O	O
remodelling	O	O
and	O	O
accelerated	O	O
breakdown	O	O
associated	O	O
with	O	O
tumour	O	O
development	O	O
.	O	O

The	O	O
current	O	O
study	O	O
aimed	O	O
to	O	O
investigate	O	O
the	O	O
immunohistochemical	O	O
expression	O	O
of	O	O
matrix	B-protein	O
metalloproteinase	I-protein	O
3	O	O
(	O	O
MMP-3	O	O
,	O	O
stromelysin-1	O	O
)	O	O
in	O	O
correlation	O	O
with	O	O
the	O	O
expression	O	O
of	O	O
Basement	B-protein	O
Membrane	I-protein	O
(	O	O
BM	B-protein	O
)	I-protein	O
antigen	I-protein	O
(	I-protein	O
type	I-protein	O
IV	I-protein	O
collagen	I-protein	O
,	O	O
laminin	B-protein	O
)	O	O
,	O	O
fibronectin	O	O
,	O	O
cathepsin	O	O
D	O	O
,	O	O
p53	O	O
,	O	O
c-erbB-2	O	O
,	O	O
proliferative	O	O
activity	O	O
(	O	O
Ki-67	O	O
,	O	O
PCNA	O	O
)	O	O
,	O	O
steroid	O	O
receptor	O	O
content	O	O
as	O	O
well	O	O
as	O	O
to	O	O
the	O	O
other	O	O
conventional	O	O
clinicopathological	O	O
parameters	O	O
in	O	O
breast	O	O
cancer	O	O
.	O	O

This	O	O
study	O	O
was	O	O
performed	O	O
on	O	O
a	O	O
series	O	O
of	O	O
frozen	O	O
and	O	O
paraffin	O	O
sections	O	O
from	O	O
84	O	O
breast	O	O
cancer	O	O
specimens	O	O
by	O	O
immunohistochemistry	O	O
using	O	O
the	O	O
monoclonal	B-protein	O
antibody	I-protein	O
MMP-3	O	O
(	O	O
Ab-1	O	O
)	O	O
.	O	O

Stromelysin-1	O	O
(	O	O
ST1	O	O
)	O	O
was	O	O
observed	O	O
in	O	O
about	O	O
10	O	O
%	O	O
of	O	O
epithelial	B-cell_type	O
cells	I-cell_type	O
in	O	O
the	O	O
control	O	O
groups	O	O
(	O	O
cases	O	O
of	O	O
fibrocystic	O	O
and	O	O
benign	O	O
proliferative	O	O
breast	O	O
disease	O	O
)	O	O
,	O	O
while	O	O
expression	O	O
(	O	O
>	O	O
10	O	O
%	O	O
of	O	O
expression	O	O
)	O	O
was	O	O
detected	O	O
in	O	O
89.7	O	O
%	O	O
of	O	O
tumours	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
ST1	O	O
in	O	O
carcinoma	B-cell_type	O
cells	I-cell_type	O
was	O	O
strongly	O	O
associated	O	O
with	O	O
its	O	O
presence	O	O
in	O	O
the	O	O
stroma	O	O
(	O	O
p	O	O
<	I-protein	O
0.001	I-protein	O
)	O	O
.	O	O

A	O	O
significantly	O	O
positive	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
ST1	O	O
expression	O	O
,	O	O
and	O	O
p53	B-protein	O
tumour	O	O
suppressor	O	O
gene	B-protein	O
product	I-protein	O
(	O	O
p	O	O
=	O	O
0.004	O	O
)	O	O
,	O	O
and	O	O
a	O	O
relationship	O	O
with	O	O
c-erbB-2	B-protein	O
protein	I-protein	O
and	O	O
progesterone	B-protein	O
receptor	I-protein	O
status	O	O
was	O	O
also	O	O
indicated	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
ST1	O	O
expression	O	O
in	O	O
breast	O	O
cancer	O	O
tissue	O	O
is	O	O
irrespective	O	O
of	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
extracellular	O	O
matrix	O	O
component	O	O
,	O	O
the	O	O
proteolytic	O	O
enzyme	O	O
cathepsin	O	O
D	O	O
and	O	O
the	O	O
growth	O	O
fraction	O	O
of	O	O
the	O	O
tumour	O	O
,	O	O
and	O	O
that	O	O
it	O	O
could	O	O
be	O	O
a	O	O
potential	O	O
new	O	O
prognostic	O	O
marker	O	O
in	O	O
breast	O	O
cancer	O	O
.	O	O

Use	O	O
of	O	O
transfected	B-cell_line	O
liver	I-cell_type	O
cells	I-cell_type	O
to	O	O
evaluate	O	O
potential	O	O
mechanisms	O	O
of	O	O
alcohol-induced	O	O
liver	O	O
injury	O	O
[	O	O
see	O	O
comments	O	O
]	O	O

There	O	O
is	O	O
increased	O	O
activity	O	O
of	O	O
the	O	O
proinflammatory	B-protein	O
cytokine	I-protein	O
,	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
(	O	O
TNF	B-protein	O
)	O	O
in	O	O
alcoholic	O	O
liver	O	O
disease	O	O
(	O	O
ALD	O	O
)	O	O
.	O	O

Hepatic	O	O
neutrophil	O	O
infiltration	O	O
is	O	O
a	O	O
principal	O	O
injurious	O	O
manifestation	O	O
of	O	O
ALD	O	O
.	O	O

TNF	B-protein	O
can	O	O
induce	O	O
cellular	O	O
oxidative	O	O
injury	O	O
directly	O	O
,	O	O
and	O	O
indirectly	O	O
by	O	O
inducing	O	O
neutrophil	O	O
chemotactic	B-protein	O
factor	I-protein	O
(	O	O
IL-8	B-protein	O
)	O	O
production	O	O
by	O	O
hepatocytes	O	O
.	O	O

IL-8	O	O
activates	O	O
and	O	O
chemotactically	O	O
attracts	O	O
neutrophils	O	O
to	O	O
the	O	O
liver	O	O
where	O	O
they	O	O
release	O	O
oxidizing	O	O
substances	O	O
.	O	O

Patients	O	O
with	O	O
ALD	O	O
also	O	O
have	O	O
decreased	O	O
protective	O	O
factors	O	O
for	O	O
cellular	O	O
oxidative	O	O
injury	O	O
.	O	O

Manganous	O	O
superoxide	O	O
dismutase	O	O
(	O	O
MnSOD	O	O
)	O	O
is	O	O
an	O	O
antioxidant	O	O
protective	O	O
factor	O	O
.	O	O

The	O	O
objectives	O	O
of	O	O
these	O	O
studies	O	O
were	O	O
to	O	O
investigate	O	O
mechanisms	O	O
for	O	O
induction	O	O
of	O	O
an	O	O
injurious	B-protein	O
factor	I-protein	O
(	O	O
IL-8	B-protein	O
)	O	O
and	O	O
a	O	O
protective	B-protein	O
factor	I-protein	O
(	O	O
MnSOD	O	O
)	O	O
in	O	O
the	O	O
HepG2	B-cell_line	O
human	I-cell_line	O
hepatoma	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
.	O	O

In	O	O
the	O	O
first	O	O
set	O	O
of	O	O
experiments	O	O
,	O	O
IL-8	O	O
gene	O	O
reporter	O	O
constructs	O	O
were	O	O
used	O	O
to	O	O
transiently	O	O
transfect	O	O
a	O	O
derivative	O	O
(	O	O
MVh2E1-9	O	O
)	O	O
of	O	O
the	O	O
HepG2	B-cell_line	O
cell	I-cell_line	O
line	O	O
which	O	O
expresses	O	O
P-4502E1	O	O
and	O	O
metabolizes	O	O
ethanol	O	O
.	O	O

Inactivation	O	O
of	O	O
the	O	O
NF-kappaB	B-DNA	O
and	I-DNA	O
3'NF-IL-6	I-DNA	O
DNA	I-DNA	O
binding	I-DNA	O
sites	I-DNA	O
decreased	O	O
IL-8	O	O
gene	O	O
transcriptional	O	O
activation	O	O
in	O	O
response	O	O
to	O	O
TNF	B-protein	O
while	O	O
inactivation	O	O
of	O	O
the	O	O
5'NF-IL-6	B-DNA	O
binding	I-DNA	O
site	I-DNA	O
increased	O	O
IL-8	O	O
gene	O	O
transcriptional	O	O
activity	O	O
in	O	O
response	O	O
to	O	O
TNF	B-protein	O
.	O	O

This	O	O
system	O	O
may	O	O
be	O	O
useful	O	O
to	O	O
assess	O	O
the	O	O
effects	O	O
of	O	O
ethanol	O	O
on	O	O
TNF	B-protein	O
-induced	O	O
hepatocyte	O	O
IL-8	O	O
production	O	O
.	O	O

In	O	O
the	O	O
second	O	O
set	O	O
of	O	O
experiments	O	O
,	O	O
HepG2	B-cell_type	O
cells	I-cell_type	O
were	O	O
cultured	O	O
in	O	O
25	O	O
to	O	O
100	O	O
mmol	O	O
concentrations	O	O
of	O	O
ethanol	O	O
.	O	O

Both	O	O
TNF	B-protein	O
and	O	O
ethanol	O	O
increased	O	O
HepG2	O	O
cell	O	O
MnSOD	O	O
activity	O	O
in	O	O
short-term	O	O
(	O	O
72	O	O
hr	O	O
)	O	O
cultures	O	O
with	O	O
ethanol	O	O
.	O	O

However	O	O
,	O	O
after	O	O
long-term	O	O
(	O	O
10	O	O
weeks	O	O
)	O	O
culture	O	O
with	O	O
ethanol	O	O
,	O	O
there	O	O
was	O	O
no	O	O
induction	O	O
of	O	O
MnSOD	O	O
by	O	O
ethanol	O	O
and	O	O
there	O	O
was	O	O
a	O	O
diminished	O	O
induction	O	O
of	O	O
MnSOD	O	O
in	O	O
response	O	O
to	O	O
TNF	B-protein	O
.	O	O

Further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
assess	O	O
the	O	O
effect	O	O
of	O	O
this	O	O
diminished	O	O
induction	O	O
of	O	O
MnSOD	O	O
with	O	O
chronic	O	O
ethanol	O	O
culture	O	O
on	O	O
HepG2	O	O
cell	O	O
susceptibility	O	O
to	O	O
TNF	B-protein	O
cytotoxicity	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
transfected	O	O
liver	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
can	O	O
be	O	O
used	O	O
to	O	O
evaluate	O	O
mechanisms	O	O
for	O	O
increased	O	O
injurious	O	O
factors	B-protein	O
and	O	O
decreased	O	O
protective	O	O
factors	B-protein	O
in	O	O
alcoholic	O	O
liver	O	O
injury	O	O
.	O	O

Tissue	B-protein	O
factor	I-protein	O
transcription	O	O
driven	O	O
by	O	O
Egr-1	O	O
is	O	O
a	O	O
critical	O	O
mechanism	O	O
of	O	O
murine	O	O
pulmonary	O	O
fibrin	O	O
deposition	O	O
in	O	O
hypoxia	O	O
.	O	O

Local	O	O
hypoxemia	O	O
and	O	O
stasis	O	O
trigger	O	O
thrombosis	O	O
.	O	O

We	O	O
have	O	O
demonstrated	O	O
previously	O	O
that	O	O
in	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
normobaric	O	O
hypoxia	O	O
pulmonary	O	O
fibrin	O	O
deposition	O	O
is	O	O
a	O	O
result	O	O
of	O	O
expression	O	O
of	O	O
tissue	B-protein	O
factor	I-protein	O
,	O	O
especially	O	O
in	O	O
oxygen-deprived	O	O
mononuclear	O	O
phagocytes	O	O
(	O	O
MPs	O	O
)	O	O
.	O	O

We	O	O
now	O	O
show	O	O
that	O	O
transcription	B-protein	O
factor	I-protein	O
early-growth-response	I-protein	O
gene	I-protein	O
product	I-protein	O
(	O	O
Egr-1	O	O
)	O	O
is	O	O
rapidly	O	O
activated	O	O
in	O	O
hypoxia	O	O
,	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
,	O	O
and	O	O
is	O	O
responsible	O	O
for	O	O
transcription	O	O
and	O	O
expression	O	O
of	O	O
tissue	B-protein	O
factor	I-protein	O
in	O	O
hypoxic	O	O
lung	O	O
.	O	O

MPs	O	O
and	O	O
HeLa	B-cell_type	O
cells	I-cell_type	O
subjected	O	O
to	O	O
hypoxia	O	O
(	O	O
pO2	O	O
approximately	O	O
13	O	O
torr	O	O
)	O	O
had	O	O
increased	O	O
levels	O	O
of	O	O
tissue	B-protein	O
factor	I-protein	O
transcripts	O	O
(	O	O
approximately	O	O
18-fold	B-protein	O
)	O	O
and	O	O
an	O	O
increased	O	O
rate	O	O
of	O	O
transcription	O	O
(	O	O
approximately	B-protein	O
15-fold	I-protein	O
)	O	O
,	O	O
based	O	O
on	O	O
nuclear	O	O
run-on	O	O
analysis	O	O
.	O	O

Gel-shift	O	O
analysis	O	O
of	O	O
nuclear	O	O
extracts	O	O
from	O	O
hypoxic	O	O
MPs	O	O
and	O	O
HeLa	B-cell_type	O
cells	I-cell_type	O
demonstrated	O	O
increased	O	O
DNA-binding	O	O
activity	O	O
at	O	O
the	O	O
serum	O	O
response	O	O
region	O	O
(	O	O
SRR	O	O
;	O	O
-111/+14	O	O
bp	O	O
)	O	O
of	O	O
the	O	O
tissue	B-protein	O
factor	I-protein	O
promoter	I-DNA	O
at	O	O
Egr-1	O	O
motifs	O	O
.	O	O

Using	O	O
32P-labeled	O	O
Egr	O	O
consensus	O	O
oligonucleotide	O	O
,	O	O
we	O	O
observed	O	O
induction	O	O
of	O	O
DNA-binding	O	O
activity	O	O
in	O	O
nuclear	O	O
extracts	O	O
from	O	O
hypoxic	O	O
lung	O	O
and	O	O
HeLa	O	O
cells	O	O
because	O	O
of	O	O
activation	O	O
of	O	O
Egr-1	O	O
,	O	O
by	O	O
means	O	O
of	O	O
supershift	O	O
analysis	O	O
.	O	O

Transient	O	O
transfection	O	O
of	O	O
HeLa	B-cell_type	O
cells	I-cell_type	O
with	O	O
chimeric	O	O
plasmids	O	O
containing	O	O
wild-type	O	O
or	O	O
mutant	O	O
SRR	O	O
from	O	O
the	O	O
tissue	B-DNA	O
factor	I-DNA	O
promoter	I-DNA	O
showed	O	O
that	O	O
intact	O	O
Sp1	B-DNA	O
sites	I-DNA	O
are	O	O
necessary	O	O
for	O	O
basal	O	O
promoter	O	O
activity	O	O
,	O	O
whereas	O	O
the	O	O
integrity	O	O
of	O	O
Egr-1	O	O
sites	O	O
was	O	O
required	O	O
for	O	O
hypoxia-enhanced	O	O
expression	O	O
.	O	O

A	O	O
central	O	O
role	O	O
for	O	O
Egr-1	O	O
in	O	O
hypoxia-mediated	O	O
tissue	B-protein	O
factor	I-protein	O
expression	O	O
was	O	O
confirmed	O	O
by	O	O
experiments	O	O
with	O	O
homozygous	O	O
Egr-1	O	O
null	O	O
mice	O	O
;	O	O
wild-type	O	O
mice	O	O
subjected	O	O
to	O	O
oxygen	O	O
deprivation	O	O
expressed	O	O
tissue	O	O
factor	O	O
and	O	O
showed	O	O
fibrin	O	O
deposition	O	O
,	O	O
but	O	O
hypoxic	O	O
homozygous	O	O
Egr-1	O	O
null	O	O
mice	O	O
displayed	O	O
neither	O	O
tissue	O	O
factor	O	O
nor	O	O
fibrin	O	O
.	O	O

These	O	O
data	O	O
delineate	O	O
a	O	O
novel	O	O
biology	O	O
for	O	O
hypoxia-induced	O	O
fibrin	O	O
deposition	O	O
,	O	O
in	O	O
which	O	O
oxygen	O	O
deprivation-induced	O	O
activation	O	O
of	O	O
Egr-1	O	O
,	O	O
resulting	O	O
in	O	O
expression	O	O
of	O	O
tissue	B-protein	O
factor	I-protein	O
,	O	O
has	O	O
an	O	O
unexpected	O	O
and	O	O
central	O	O
role	O	O
.	O	O

Kinetics	O	O
of	O	O
cytokine	B-protein	O
and	O	O
NFAT	B-protein	O
gene	O	O
expression	O	O
in	O	O
human	O	O
interleukin-2-dependent	O	O
T	O	O
lymphoblasts	O	O
stimulated	O	O
via	O	O
T-cell	B-protein	O
receptor	I-protein	O
.	O	O

T	B-cell_type	O
cells	I-cell_type	O
respond	O	O
to	O	O
mitogenic	O	O
or	O	O
antigenic	O	O
stimulation	O	O
by	O	O
proliferation	O	O
and	O	O
by	O	O
turning	O	O
on	O	O
cytokine	B-protein	O
gene	O	O
expression	O	O
.	O	O

Here	O	O
we	O	O
have	O	O
analysed	O	O
the	O	O
kinetics	O	O
and	O	O
nature	O	O
of	O	O
cytokine	B-protein	O
production	O	O
in	O	O
human	O	O
peripheral	O	O
blood-derived	O	O
T	O	O
lymphoblasts	O	O
stimulated	O	O
with	O	O
anti-CD3	O	O
antibodies	O	O
or	O	O
Lens	O	O
culinaris	O	O
lectin	O	O
(	O	O
LCL	O	O
)	O	O
.	O	O

T	B-cell_type	O
cells	I-cell_type	O
were	O	O
purified	O	O
from	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
(	O	O
PBMC	O	O
)	O	O
and	O	O
primarily	O	O
activated	O	O
with	O	O
anti-CD3	O	O
antibodies	O	O
and	O	O
cultured	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
interleukin-2	B-protein	O
(	O	O
IL-2	B-protein	O
)	O	O
.	O	O

Anti-CD3-restimulated	O	O
T	B-cell_type	O
cells	I-cell_type	O
(	O	O
mainly	O	O
CD8+	O	O
)	O	O
produced	O	O
IL-2	B-protein	O
,	O	O
interferon-gamma	B-protein	O
(	O	O
IFN-gamma	B-protein	O
)	O	O
and	O	O
tumour	O	O
necrosis	B-protein	O
factor-alpha	I-protein	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
and	O	O
low	O	O
levels	O	O
of	O	O
IL-4	B-protein	O
and	O	O
IL-10	B-protein	O
transcripts	I-protein	O
and	O	O
proteins	O	O
.	O	O

No	O	O
IL-6	O	O
gene	O	O
expression	O	O
was	O	O
observed	O	O
.	O	O

In	O	O
LCL-stimulated	O	O
cells	O	O
the	O	O
cytokine	B-protein	O
production	O	O
pattern	O	O
was	O	O
very	O	O
similar	O	O
.	O	O

Steady-state	O	O
mRNA	B-RNA	O
levels	O	O
of	O	O
IL-2	B-protein	O
,	O	O
IL-10	B-protein	O
and	O	O
IFN-gamma	B-protein	O
peaked	O	O
at	O	O
3	O	O
hr	O	O
after	O	O
anti-CD3	O	O
stimulation	O	O
and	O	O
declined	O	O
rapidly	O	O
thereafter	O	O
.	O	O

The	O	O
kinetics	O	O
of	O	O
TNF-alpha	O	O
mRNA	I-RNA	O
expression	O	O
was	O	O
faster	O	O
,	O	O
being	O	O
at	O	O
its	O	O
peak	O	O
level	O	O
1	O	O
hr	O	O
after	O	O
stimulation	O	O
.	O	O

Anti-CD3-stimulated	O	O
IL-2	B-DNA	O
gene	I-DNA	O
expression	O	O
was	O	O
down-regulated	O	O
by	O	O
protein	O	O
synthesis	O	O
inhibitor	O	O
,	O	O
whereas	O	O
IL-10	B-protein	O
,	O	O
IFN-gamma	B-protein	O
and	O	O
TNF-alpha	O	O
genes	O	O
were	O	O
readily	O	O
induced	O	O
independent	O	O
of	O	O
ongoing	O	O
protein	O	O
synthesis	O	O
.	O	O

T-cell	B-protein	O
receptor	I-protein	O
stimulation	O	O
also	O	O
induced	O	O
a	O	O
very	O	O
rapid	O	O
expression	O	O
of	O	O
c-jun	O	O
,	O	O
c-fos	B-DNA	O
and	I-DNA	O
NFATc1	I-DNA	O
(	O	O
NFATc	B-protein	O
)	O	O
genes	I-DNA	O
,	O	O
the	O	O
gene	O	O
products	O	O
of	O	O
which	O	O
are	O	O
involved	O	O
in	O	O
cytokine	B-protein	O
gene	O	O
expression	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
cytokines	B-protein	O
synthesized	O	O
by	O	O
IL-2-dependent	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
predominantly	O	O
IL-2	B-protein	O
,	O	O
IFN-gamma	B-protein	O
and	O	O
TNF-alpha	O	O
.	O	O

An	O	O
animal	O	O
model	O	O
to	O	O
study	O	O
local	O	O
oxidation	O	O
of	O	O
LDL	O	O
and	O	O
its	O	O
biological	O	O
effects	O	O
in	O	O
the	O	O
arterial	O	O
wall	O	O
.	O	O

Oxidized	O	O
LDL	O	O
(	O	O
oxLDL	O	O
)	O	O
is	O	O
present	O	O
in	O	O
atherosclerotic	O	O
lesions	O	O
and	O	O
is	O	O
believed	O	O
to	O	O
play	O	O
a	O	O
key	O	O
role	O	O
in	O	O
atherogenesis	O	O
.	O	O

Mainly	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
cell	O	O
culture	O	O
studies	O	O
,	O	O
oxLDL	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
produce	O	O
many	O	O
biological	O	O
effects	O	O
that	O	O
influence	O	O
the	O	O
atherosclerotic	O	O
process	O	O
.	O	O

To	O	O
study	O	O
LDL	O	O
oxidation	O	O
in	O	O
vivo	O	O
,	O	O
we	O	O
have	O	O
established	O	O
a	O	O
model	O	O
in	O	O
which	O	O
Sprague-Dawley	O	O
rats	O	O
are	O	O
given	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
unmodified	B-protein	O
human	I-protein	O
LDL	I-protein	O
(	O	O
>	O	O
or	O	O
=	B-protein	O
4	I-protein	O
mg/kg	I-protein	O
body	I-protein	O
weight	I-protein	O
)	O	O
.	O	O

Within	O	O
6	O	O
hours	O	O
,	O	O
an	O	O
accumulation	O	O
of	O	O
apolipoprotein	B-protein	O
B	I-protein	O
and	O	O
epitopes	B-protein	O
present	O	O
on	O	O
oxLDL	O	O
are	O	O
detected	O	O
in	O	O
the	O	O
arterial	O	O
endothelium	O	O
and	O	O
media	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
oxLDL	O	O
is	O	O
associated	O	O
with	O	O
activation	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
nuclear	O	O
factor-kappaB	O	O
in	O	O
the	O	O
endothelium	O	O
as	O	O
well	O	O
as	O	O
endothelial	O	O
expression	O	O
of	O	O
intercellular	B-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
.	O	O

Injection	O	O
of	O	O
LDL	O	O
enriched	O	O
with	O	O
the	O	O
antioxidant	O	O
probucol	O	O
resulted	O	O
in	O	O
arterial	O	O
accumulation	O	O
of	O	O
apolipoprotein	O	O
B	O	O
,	O	O
but	O	O
the	O	O
expression	O	O
of	O	O
oxLDL-specific	O	O
epitopes	I-protein	O
was	O	O
reduced	O	O
at	O	O
24	O	O
hours	O	O
.	O	O

Thus	O	O
,	O	O
this	O	O
simple	O	O
model	O	O
has	O	O
the	O	O
potential	O	O
to	O	O
analyze	O	O
the	O	O
mechanisms	O	O
behind	O	O
and	O	O
biological	O	O
effects	O	O
of	O	O
LDL	O	O
oxidation	O	O
in	O	O
vivo	O	O
.	O	O

Molecular	O	O
mechanisms	O	O
of	O	O
promoter	O	O
regulation	O	O
of	O	O
the	O	O
gp34	B-DNA	O
gene	I-DNA	O
that	O	O
is	O	O
trans-activated	O	O
by	O	O
an	O	O
oncoprotein	O	O
Tax	O	O
of	O	O
human	O	O
T	O	O
cell	O	O
leukemia	O	O
virus	O	O
type	O	O
I	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
molecular	O	O
mechanism	O	O
of	O	O
transcriptional	O	O
activation	O	O
of	O	O
the	O	O
gp34	B-DNA	O
gene	I-DNA	O
by	O	O
the	O	O
Tax	O	O
oncoprotein	O	O
of	O	O
human	O	O
T	O	O
cell	O	O
leukemia	O	O
virus	O	O
type	I-protein	O
I	I-protein	O
(	O	O
HTLV-I	O	O
)	O	O
.	O	O

gp34	O	O
is	O	O
a	O	O
type	O	O
II	O	O
transmembrane	O	O
molecule	O	O
belonging	O	O
to	O	O
the	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
family	I-protein	O
and	O	O
is	O	O
constitutively	O	O
expressed	O	O
on	O	O
HTLV-I-producing	B-cell_type	O
cells	I-cell_type	O
but	O	O
not	O	O
normal	O	O
resting	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
transcriptional	B-DNA	O
regulatory	I-DNA	O
region	I-DNA	O
of	O	O
the	O	O
gp34	B-DNA	O
gene	I-DNA	O
was	O	O
activated	O	O
by	O	O
HTLV-I	O	O
Tax	O	O
in	O	O
the	O	O
human	B-cell_line	O
T	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
Jurkat	O	O
,	O	O
in	O	O
which	O	O
endogenous	O	O
gp34	O	O
is	O	O
induced	O	O
by	O	O
Tax	O	O
.	O	O

Sequence	O	O
analysis	O	O
demonstrated	O	O
that	O	O
two	O	O
NF-kappaB-like	O	O
elements	O	O
(	O	O
1	O	O
and	O	O
2	O	O
)	O	O
were	O	O
present	O	O
in	O	O
the	O	O
regulatory	O	O
region	O	O
.	O	O

Both	O	O
NF-kappaB-like	O	O
elements	O	O
were	O	O
able	O	O
to	O	O
bind	O	O
to	O	O
NF-kappaB	O	O
or	O	O
its	O	O
related	B-protein	O
factor	I-protein	O
(	O	O
s	O	O
)	O	O
in	O	O
a	O	O
Tax	O	O
-dependent	O	O
manner	O	O
.	O	O

Chloramphenicol	O	O
acetyltransferase	O	O
assays	O	O
indicated	O	O
that	O	O
NF-kappaB-like	O	O
element	O	O
1	O	O
was	O	O
Tax	O	O
-responsive	O	O
,	O	O
although	O	O
the	O	O
activity	O	O
was	O	O
lower	O	O
than	O	O
that	O	O
the	O	O
native	B-DNA	O
promoter	I-DNA	O
.	O	O

NF-kappaB	O	O
-like	O	O
element	O	O
2	O	O
elevated	O	O
promoter	O	O
activity	O	O
when	O	O
combined	O	O
with	O	O
NF-kappaB-like	O	O
element	O	O
1	O	O
,	O	O
indicating	O	O
cooperative	O	O
function	O	O
of	O	O
the	O	O
elements	B-DNA	O
for	O	O
maximum	O	O
promoter	I-DNA	O
function	O	O
.	O	O

Unlike	O	O
typical	O	O
NF-kappaB	O	O
elements	O	O
,	O	O
the	O	O
NF-kappaB-like	B-DNA	O
elements	I-DNA	O
in	O	O
gp34	O	O
were	O	O
not	O	O
activated	O	O
by	O	O
treatment	O	O
of	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
with	O	O
phorbol	O	O
ester	O	O
despite	O	O
induction	O	O
of	O	O
the	O	O
NF-kappaB	B-protein	O
-like	I-protein	O
binding	O	O
activity	O	O
.	O	O

Chloramphenicol	O	O
acetyltransferase	B-DNA	O
reporter	I-DNA	O
assays	I-DNA	O
using	O	O
the	O	O
region	B-DNA	O
upstream	O	O
of	O	O
the	O	O
NF-kappaB-like	B-DNA	O
elements	I-DNA	O
identified	O	O
an	O	O
upstream	B-DNA	O
region	I-DNA	O
that	O	O
reduced	O	O
transcription	O	O
from	O	O
cognate	B-protein	O
and	O	O
noncognate	I-DNA	O
core	I-DNA	O
promoters	I-DNA	O
in	O	O
a	O	O
Tax-independent	O	O
manner	O	O
.	O	O

Our	O	O
results	O	O
imply	O	O
complex	O	O
regulation	O	O
of	O	O
expression	O	O
of	O	O
the	O	O
gp34	B-DNA	O
gene	I-DNA	O
and	O	O
suggest	O	O
implication	O	O
of	O	O
gp34	O	O
in	O	O
proliferation	O	O
of	O	O
HTLV-I	B-cell_line	O
infected	I-cell_line	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

beta-Amyloid	O	O
fibrils	O	O
activate	O	O
parallel	O	O
mitogen-activated	O	O
protein	O	O
kinase	O	O
pathways	O	O
in	O	O
microglia	O	O
and	O	O
THP1	O	O
monocytes	B-cell_type	O
.	O	O

The	O	O
senile	O	O
plaques	O	O
of	O	O
Alzheimer	O	O
's	O	O
disease	O	O
are	O	O
foci	O	O
of	O	O
local	O	O
inflammatory	O	O
responses	O	O
,	O	O
as	O	O
evidenced	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
acute	O	O
phase	B-protein	O
proteins	I-protein	O
and	O	O
oxidative	O	O
damage	O	O
.	O	O

Fibrillar	O	O
forms	O	O
of	O	O
beta-amyloid	O	O
(	O	O
Abeta	B-protein	O
)	O	O
,	O	O
which	O	O
are	O	O
the	O	O
primary	O	O
constituents	O	O
of	O	O
senile	O	O
plaques	O	O
,	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
activate	O	O
tyrosine	O	O
kinase-dependent	O	O
signal	O	O
transduction	O	O
cascades	O	O
,	O	O
resulting	O	O
in	O	O
inflammatory	O	O
responses	O	O
in	O	O
microglia	O	O
.	O	O

However	O	O
,	O	O
the	O	O
downstream	O	O
signaling	O	O
pathways	O	O
mediating	O	O
Abeta	O	O
-induced	O	O
inflammatory	O	O
events	O	O
are	O	O
not	O	O
well	O	O
characterized	O	O
.	O	O

We	O	O
report	O	O
that	O	O
exposure	O	O
of	O	O
primary	O	O
rat	O	O
microglia	O	O
and	O	O
human	B-cell_type	O
THP1	I-cell_type	O
monocytes	I-cell_type	O
to	O	O
fibrillar	O	O
Abeta	O	O
results	O	O
in	O	O
the	O	O
tyrosine	O	O
kinase	O	O
-dependent	O	O
activation	O	O
of	O	O
two	O	O
parallel	O	O
signal	O	O
transduction	O	O
cascades	O	O
involving	O	O
members	O	O
of	O	O
the	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
(	O	O
MAPK	B-protein	O
)	O	O
superfamily	O	O
.	O	O

Abeta	O	O
stimulated	O	O
the	O	O
rapid	O	O
,	O	O
transient	O	O
activation	O	O
of	O	O
extracellular	B-protein	O
signal-regulated	B-protein	O
kinase	I-protein	O
1	I-protein	O
(	O	O
ERK1	O	O
)	O	O
and	O	O
ERK2	O	O
in	O	O
microglia	O	O
and	O	O
ERK2	O	O
in	O	O
THP1	O	O
monocytes	B-cell_type	O
.	O	O

A	O	O
second	O	O
superfamily	O	O
member	O	O
,	O	O
p38	O	O
MAPK	O	O
,	O	O
was	O	O
also	O	O
activated	O	O
with	O	O
similar	O	O
kinetics	O	O
.	O	O

Scavenger	B-protein	O
receptor	I-protein	O
and	O	O
receptor	O	O
for	O	O
advanced	O	O
glycated	O	O
end	O	O
products	B-protein	O
(	O	O
RAGE	O	O
)	O	O
ligands	O	O
failed	O	O
to	O	O
activate	O	O
ERK	O	O
and	O	O
p38	O	O
MAPK	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
significant	O	O
increases	O	O
in	O	O
protein	O	O
tyrosine	O	O
phosphorylation	O	O
,	O	O
demonstrating	O	O
that	O	O
scavenger	O	O
receptors	O	O
and	O	O
RAGE	O	O
are	O	O
not	O	O
linked	O	O
to	O	O
these	O	O
pathways	O	O
.	O	O

Importantly	O	O
,	O	O
the	O	O
stress-activated	B-protein	O
protein	I-protein	O
kinases	I-protein	O
(	O	O
SAPKs	O	O
)	O	O
were	O	O
not	O	O
significantly	O	O
activated	O	O
in	O	O
response	O	O
to	O	O
Abeta	O	O
.	O	O

Downstream	O	O
effectors	O	O
of	O	O
the	O	O
MAPK	O	O
signal	O	O
transduction	O	O
cascades	O	O
include	O	O
MAPKAP	O	O
kinases	O	O
,	O	O
such	O	O
as	O	O
RSK1	O	O
and	O	O
RSK2	O	O
,	O	O
as	O	O
well	O	O
as	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

Exposure	O	O
of	O	O
microglia	O	O
and	O	O
THP1	O	O
monocytes	B-cell_type	O
to	O	O
Abeta	O	O
resulted	O	O
in	O	O
the	O	O
activation	O	O
of	O	O
RSK1	O	O
and	O	O
RSK2	O	O
and	O	O
phosphorylation	O	O
of	O	O
cAMP	O	O
response	O	O
element-binding	O	O
protein	O	O
at	O	O
Ser133	O	O
,	O	O
providing	O	O
a	O	O
mechanism	O	O
for	O	O
Abeta	O	O
-induced	O	O
changes	O	O
in	O	O
gene	O	O
expression	O	O

Regulation	O	O
of	O	O
cellular	O	O
retinoic	O	O
acid	O	O
binding	I-protein	O
protein	I-protein	O
(	O	O
CRABP	B-protein	O
II	I-protein	O
)	O	O
during	O	O
human	O	O
monocyte	O	O
differentiation	O	O
in	O	O
vitro	O	O
.	O	O

Cellular	O	O
retinoic	O	O
acid	O	O
binding	B-protein	O
proteins	I-protein	O
(	O	O
CRABP	B-protein	O
)	O	O
are	O	O
low	O	O
molecular	O	O
weight	O	O
proteins	O	O
whose	O	O
precise	O	O
function	O	O
remains	O	O
unknown	O	O
.	O	O

They	O	O
bind	O	O
retinoids	O	O
and	O	O
may	O	O
thereby	O	O
modulate	O	O
the	O	O
intracellular	O	O
steady-state	O	O
concentration	O	O
of	O	O
retinoids	O	O
.	O	O

Whereas	O	O
CRABP	O	O
I	O	O
is	O	O
ubiquitously	O	O
expressed	O	O
,	O	O
CRABP	O	O
II	O	O
is	O	O
mainly	O	O
detected	O	O
in	O	O
various	O	O
cell	O	O
types	O	O
of	O	O
the	O	O
skin	O	O
.	O	O

By	O	O
representative	O	O
difference	O	O
analysis	O	O
we	O	O
found	O	O
that	O	O
CRABP	O	O
II	O	O
is	O	O
also	O	O
strongly	O	O
expressed	O	O
in	O	O
human	O	O
monocyte-derived	O	O
macrophages	O	O
(	O	O
MAC	O	O
)	O	O
but	O	O
not	O	O
in	O	O
freshly	O	O
isolated	O	O
monocytes	B-cell_type	O
(	O	O
MO	O	O
)	O	O
.	O	O

The	O	O
CRABP	B-RNA	O
II	I-protein	O
mRNA	I-RNA	O
was	O	O
gradually	O	O
upregulated	O	O
during	O	O
differentiation	O	O
from	O	O
MO	O	O
to	O	O
MAC	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
2	O	O
%	O	O
serum	O	O
.	O	O

Adherence	O	O
,	O	O
which	O	O
is	O	O
important	O	O
for	O	O
MO	O	O
differentiation	O	O
,	O	O
induced	O	O
CRABP	O	O
II	I-protein	O
expression	O	O
,	O	O
but	O	O
the	O	O
addition	O	O
of	O	O
10	O	O
(	O	O
-7	B-protein	O
)	O	O
M	O	O
retinoic	O	O
acid	O	O
inhibited	O	O
the	O	O
upregulation	O	O
of	O	O
CRABP	O	O
II	O	O
expression	O	O
during	O	O
MO/MAC	O	O
differentiation	O	O
.	O	O

As	O	O
MO	O	O
can	O	O
differentiate	O	O
along	O	O
the	O	O
classical	O	O
pathway	O	O
not	O	O
only	O	O
to	O	O
MAC	O	O
but	O	O
also	O	O
to	O	O
dendritic	O	O
cells	O	O
we	O	O
analyzed	O	O
the	O	O
expression	O	O
of	O	O
CRABP	O	O
II	O	O
in	O	O
MO-derived	B-cell_type	O
dendritic	I-cell_type	O
cells	I-cell_type	O
cultured	O	O
with	O	O
10	O	O
%	O	O
FCS	O	O
,	O	O
IL-4	O	O
,	O	O
and	O	O
GM-CSF	B-protein	O
.	O	O

In	O	O
contrast	O	O
to	O	O
MAC	O	O
,	O	O
MO-derived	O	O
dendritic	O	O
cells	O	O
showed	O	O
an	O	O
extremely	O	O
low	O	O
expression	O	O
of	O	O
CRABP	B-protein	O
II	I-protein	O
.	O	O

From	O	O
these	O	O
results	O	O
we	O	O
conclude	O	O
(	O	O
1	O	O
)	O	O
that	O	O
the	O	O
availability	O	O
and	O	O
the	O	O
metabolism	O	O
of	O	O
retinoids	O	O
may	O	O
be	O	O
different	O	O
in	O	O
MAC	O	O
compared	O	O
to	O	O
MO	O	O
and	O	O
dendritic	B-cell_type	O
cells	I-cell_type	O
and	O	O
(	O	O
2	O	O
)	O	O
that	O	O
this	O	O
may	O	O
influence	O	O
differentiation	O	O
and	O	O
activation	O	O
of	O	O
those	B-cell_type	O
cells	I-cell_type	O
.	O	O

Transcription	B-protein	O
factor	I-protein	O
B-cell-specific	I-protein	O
activator	I-protein	O
protein	I-protein	O
(	O	O
BSAP	B-protein	O
)	O	O
is	O	O
differentially	O	O
expressed	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
and	O	O
in	O	O
subsets	O	O
of	O	O
B-cell	O	O
lymphomas	O	O
.	O	O

The	O	O
paired	B-DNA	O
box	I-DNA	O
containing	I-DNA	O
gene	I-DNA	O
PAX-5	O	O
encodes	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
BSAP	B-protein	O
(	O	O
B-cell-specific	B-protein	O
activator	I-protein	O
protein	I-protein	O
)	O	O
,	O	O
which	O	O
plays	O	O
a	O	O
key	O	O
role	O	O
in	O	O
B-lymphocyte	O	O
development	O	O
.	O	O

Despite	O	O
its	O	O
known	O	O
involvement	O	O
in	O	O
a	O	O
rare	O	O
subtype	O	O
of	O	O
non-Hodgkin	O	O
's	O	O
lymphoma	O	O
(	O	O
NHL	B-protein	O
)	O	O
,	O	O
a	O	O
detailed	O	O
examination	O	O
of	O	O
BSAP	B-protein	O
expression	O	O
in	O	O
NHL	O	O
has	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
analyzed	O	O
normal	O	O
and	O	O
malignant	O	O
lymphoid	O	O
tissues	O	O
and	O	O
cell	O	O
lines	O	O
,	O	O
including	O	O
102	O	O
cases	O	O
of	O	O
B-cell	O	O
NHL	O	O
,	O	O
23	O	O
cases	O	O
of	O	O
T-	O	O
and	O	O
null-cell	O	O
NHL	O	O
,	O	O
and	O	O
18	O	O
cases	O	O
of	O	O
Hodgkin	O	O
's	O	O
disease	O	O
.	O	O

Normal	O	O
lymphoid	O	O
tissues	O	O
showed	O	O
strong	O	O
nuclear	O	O
BSAP	B-protein	O
expression	O	O
in	O	O
mantle	O	O
zone	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
,	O	O
less	O	O
intense	O	O
reactivity	O	O
in	O	O
follicular	O	O
center	O	O
B	I-cell_type	O
cells	I-cell_type	O
,	O	O
and	O	O
no	O	O
expression	O	O
in	O	O
cells	O	O
of	O	O
the	O	O
T-cell-rich	O	O
zones	O	O
.	O	O

Monocytoid	O	O
B	I-cell_type	O
cells	I-cell_type	O
showed	O	O
weak	O	O
expression	O	O
,	O	O
whereas	O	O
plasma	O	O
cells	O	O
and	O	O
extrafollicular	O	O
large	O	O
transformed	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
were	O	O
negative	O	O
.	O	O

Of	O	O
the	O	O
102	O	O
B-cell	O	O
NHLs	O	O
,	O	O
83	O	O
(	O	O
81	O	O
%	O	O
)	O	O
demonstrated	O	O
BSAP	O	O
expression	O	O
.	O	O

All	O	O
of	O	O
the	O	O
13	O	O
(	O	O
100	O	O
%	O	O
)	O	O
B-cell	O	O
chronic	O	O
lymphocytic	B-protein	O
leukemias	O	O
(	O	O
B-CLLs	B-protein	O
)	O	O
,	O	O
21	O	O
of	O	O
(	O	O
100	O	O
%	O	O
)	O	O
mantle	O	O
cells	O	O
(	O	O
MCLs	O	O
)	O	O
,	O	O
and	O	O
20	O	O
of	O	O
21	O	O
(	O	O
95	O	O
%	O	O
)	O	O
follicular	O	O
lymphomas	O	O
(	O	O
FLs	O	O
)	O	O
were	O	O
positive	O	O
.	O	O

Moderate	O	O
staining	O	O
intensities	O	O
were	O	O
found	O	O
in	O	O
most	O	O
B-CLL	O	O
and	O	O
FL	O	O
cases	O	O
,	O	O
whereas	O	O
most	O	O
MCLs	O	O
showed	O	O
strong	O	O
reactions	O	O
,	O	O
paralleling	O	O
the	O	O
strong	O	O
reactivity	O	O
of	O	O
nonmalignant	B-cell_type	O
mantle	I-cell_type	O
cells	I-cell_type	O
.	O	O

Eight	O	O
of	O	O
12	B-protein	O
(	O	O
67	O	O
%	O	O
)	O	O
marginal	O	O
zone	O	O
lymphoma	O	O
cases	O	O
showed	O	O
negative	O	O
or	O	O
low	O	O
BSAP	O	O
levels	O	O
,	O	O
and	O	O
17	O	O
of	O	O
24	O	O
(	O	O
71	O	O
%	O	O
)	O	O
large	O	O
B-cell	O	O
lymphomas	O	O
displayed	O	O
moderate	O	O
to	O	O
strong	O	O
expression	O	O
.	O	O

None	O	O
of	O	O
the	O	O
23	B-protein	O
T-	I-protein	O
and	O	O
null-cell	O	O
lymphomas	O	O
reacted	O	O
with	O	O
the	O	O
BSAP	B-protein	O
antisera	I-protein	O
,	O	O
whereas	O	O
in	O	O
Hodgkin	O	O
's	O	O
disease	O	O
,	O	O
2	O	O
of	O	O
4	O	O
(	O	O
50	O	O
%	O	O
)	O	O
nodular	O	O
lymphocytic	O	O
predominance	O	O
and	O	O
5	O	O
of	O	O
14	O	O
(	O	O
36	O	O
%	O	O
)	O	O
classical	O	O
cases	O	O
showed	O	O
weak	O	O
nuclear	O	O
or	O	O
nucleolar	O	O
BSAP	O	O
reactions	O	O
in	O	O
a	O	O
fraction	O	O
of	O	O
the	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
.	O	O

Western	O	O
blot	O	O
analysis	O	O
showed	O	O
a	O	O
52-kD	O	O
BSAP	O	O
band	O	O
in	O	O
B-cell	O	O
lines	O	O
,	O	O
but	O	O
not	O	O
in	O	O
non-B-cell	O	O
or	O	O
plasma	O	O
cell	O	O
lines	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
BSAP	B-protein	O
expression	O	O
is	O	O
largely	O	O
restricted	O	O
to	O	O
lymphomas	O	O
of	O	O
B-cell	O	O
lineage	O	O
and	O	O
that	O	O
BSAP	B-protein	O
expression	O	O
varies	O	O
in	O	O
B-cell	O	O
subsets	O	O
and	O	O
subtypes	O	O
of	O	O
B-cell	O	O
NHL	O	O
.	O	O

The	O	O
high	O	O
levels	O	O
of	O	O
BSAP	B-protein	O
,	O	O
especially	O	O
those	O	O
found	O	O
in	O	O
large-cell	O	O
lymphomas	O	O
and	O	O
in	O	O
some	O	O
follicular	O	O
lymphomas	O	O
,	O	O
may	O	O
be	O	O
a	O	O
consequence	O	O
of	O	O
deregulated	B-DNA	O
gene	I-DNA	O
expression	O	O
and	O	O
suggest	O	O
a	O	O
possible	O	O
involvement	O	O
of	O	O
PAX-5	O	O
in	O	O
certain	O	O
B-cell	O	O
malignancies	O	O
.	O	O

This	O	O
is	O	O
a	O	O
US	O	O
government	O	O
work	O	O
.	O	O

There	O	O
are	O	O
no	O	O
restrictions	O	O
on	O	O
its	O	O
use	O	O
.	O	O

Mitogen	O	O
and	O	O
growth	O	O
factor-induced	O	O
activation	O	O
of	O	O
a	O	O
STAT-like	O	O
molecule	O	O
in	O	O
channel	B-cell_line	O
catfish	I-cell_line	O
lymphoid	I-cell_line	O
cells	I-cell_line	O
.	O	O

This	O	O
article	O	O
describes	O	O
the	O	O
identification	O	O
of	O	O
a	O	O
putative	B-protein	O
STAT	I-protein	O
molecule	I-protein	O
in	O	O
the	O	O
channel	O	O
catfish	I-protein	O
(	O	O
Ictalurus	B-protein	O
punctatus	I-protein	O
)	O	O
,	O	O
the	O	O
first	O	O
report	O	O
of	O	O
such	O	O
a	O	O
molecule	O	O
in	O	O
a	O	O
'lower	B-DNA	O
'	I-DNA	O
vertebrate	O	O
.	O	O

A	O	O
monoclonal	O	O
antibody	O	O
against	O	O
human	O	O
STAT6	O	O
recognizes	O	O
an	O	O
approximately	O	O
100	O	O
kDa	I-protein	O
molecule	O	O
that	O	O
becomes	O	O
activated	O	O
and	O	O
translocates	O	O
to	O	O
the	O	O
nucleus	O	O
upon	O	O
both	O	O
growth	B-protein	O
factor	I-protein	O
and	O	O
mitogen	O	O
stimulation	O	O
of	O	O
catfish	O	O
leukocytes	O	O
.	O	O

This	O	O
presumed	O	O
catfish	O	O
STAT	O	O
binds	O	O
the	O	O
mammalian	O	O
interferon-gamma	O	O
activation	O	O
site	O	O
,	O	O
a	O	O
known	O	O
motif	O	O
of	O	O
mammalian	B-protein	O
STAT	I-protein	O
binding	I-protein	O
,	O	O
as	O	O
shown	O	O
by	O	O
electromobility	O	O
shift	O	O
assays	O	O
.	O	O

Purification	O	O
of	O	O
the	O	O
proteins	O	O
present	O	O
in	O	O
these	O	O
DNA	O	O
complexes	O	O
confirms	O	O
that	O	O
the	O	O
catfish	O	O
reactive	O	O
molecule	O	O
binds	O	O
to	O	O
the	O	O
interferon-gamma	B-DNA	O
activation	I-DNA	O
site	I-DNA	O
sequence	I-DNA	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
STAT	B-protein	O
molecules	I-protein	O
have	O	O
been	O	O
highly	O	O
conserved	O	O
in	O	O
vertebrate	O	O
evolution	O	O
.	O	O

Isolation	O	O
and	O	O
analysis	O	O
of	O	O
a	O	O
T	O	O
cell	O	O
clone	O	O
variant	O	O
exhibiting	O	O
constitutively	O	O
phosphorylated	O	O
Ser133	O	O
cAMP	O	O
response	O	O
element-binding	O	O
protein	O	O
.	O	O

In	O	O
driving	O	O
T	O	O
cell	O	O
proliferation	O	O
,	O	O
IL-2	B-protein	O
stimulates	O	O
a	O	O
new	O	O
program	O	O
of	O	O
gene	O	O
expression	O	O
that	O	O
includes	O	O
proliferating	O	O
cell	O	O
nuclear	O	O
antigen	O	O
(	O	O
PCNA	B-protein	O
)	O	O
,	O	O
a	O	O
requisite	O	O
processivity	O	O
factor	O	O
for	O	O
DNA	O	O
polymerase	O	O
delta	O	O
.	O	O

PCNA	O	O
transcription	O	O
is	O	O
regulated	O	O
in	O	O
part	O	O
through	O	O
tandem	O	O
CRE	O	O
sequences	O	O
in	O	O
the	O	O
promoter	O	O
and	O	O
CRE	O	O
binding	O	O
proteins	O	O
;	O	O
IL-2	O	O
stimulates	O	O
CREB	O	O
phosphorylation	O	O
in	O	O
the	O	O
resting	O	O
cloned	O	O
T	O	O
lymphocyte	O	O
,	O	O
L2	O	O
.	O	O

After	O	O
culturing	B-cell_type	O
L2	I-cell_type	O
cells	I-cell_type	O
for	O	O
greater	O	O
than	O	O
91	O	O
days	O	O
,	O	O
we	O	O
consistently	O	O
isolate	O	O
a	O	O
stable	O	O
variant	O	O
that	O	O
exhibits	O	O
constitutive	O	O
CREB	O	O
phosphorylation	O	O
.	O	O

L2	O	O
and	O	O
L2	O	O
variant	B-cell_type	O
cells	I-cell_type	O
were	O	O
tested	O	O
for	O	O
IL-2	O	O
responsiveness	O	O
and	O	O
rapamycin	O	O
sensitivity	O	O
with	O	O
respect	O	O
to	O	O
specific	O	O
kinase	O	O
activity	O	O
,	O	O
PCNA	O	O
expression	O	O
and	O	O
proliferation	O	O
.	O	O

In	O	O
L2	B-cell_type	O
cells	I-cell_type	O
,	O	O
IL-2	B-protein	O
stimulated	O	O
and	O	O
rapamycin	O	O
inhibited	O	O
the	O	O
following	O	O
:	O	O
cAMP-independent	O	O
CREB	O	O
kinase	O	O
activity	O	O
,	O	O
PCNA	O	O
expression	O	O
and	O	O
proliferation	O	O
.	O	O

In	O	O
L2	O	O
variant	B-cell_type	O
cells	I-cell_type	O
,	O	O
CREB	O	O
kinase	O	O
activity	O	O
was	O	O
constitutively	O	O
high	O	O
;	O	O
IL-2	O	O
stimulated	O	O
and	O	O
rapamycin	O	O
blocked	O	O
PCNA	O	O
expression	O	O
and	O	O
proliferation	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
IL-2	B-protein	O
induces	O	O
a	O	O
rapamycin-sensitive	O	O
,	O	O
cAMP-independent	O	O
CREB	O	O
kinase	O	O
activity	O	O
in	O	O
L2	B-cell_type	O
cells	I-cell_type	O
.	O	O

However	O	O
,	O	O
phosphorylation	O	O
of	O	O
CREB	O	O
alone	O	O
is	O	O
not	O	O
sufficient	O	O
to	O	O
drive	O	O
PCNA	O	O
expression	O	O
and	O	O
L2	O	O
cell	O	O
proliferation	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
IL-2	B-protein	O
.	O	O

Serotonin	O	O
derivative	O	O
,	O	O
N-	O	O
(	O	O
p-coumaroyl	O	O
)	O	O
serotonin	O	O
,	O	O
inhibits	O	O
the	O	O
production	O	O
of	O	O
TNF-alpha	B-protein	O
,	O	O
IL-1alpha	O	O
,	O	O
IL-1beta	O	O
,	O	O
and	O	O
IL-6	O	O
by	O	O
endotoxin-stimulated	O	O
human	B-cell_type	O
blood	I-cell_type	O
monocytes	I-cell_type	O
.	O	O

We	O	O
have	O	O
reported	O	O
that	O	O
N-	O	O
(	O	O
p-coumaroyl	O	O
)	O	O
serotonin	O	O
(	O	O
CS	O	O
)	O	O
and	O	O
its	O	O
derivatives	O	O
with	O	O
antioxidative	O	O
activity	O	O
are	O	O
present	O	O
in	O	O
safflower	O	O
seeds	O	O
.	O	O

As	O	O
reactive	O	O
oxygen	O	O
species	O	O
(	O	O
ROS	O	O
)	O	O
are	O	O
implicated	O	O
in	O	O
the	O	O
signaling	O	O
of	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
,	O	O
we	O	O
examined	O	O
whether	O	O
CS	O	O
has	O	O
a	O	O
suppressive	O	O
effect	O	O
on	O	O
inflammatory	O	O
cytokine	O	O
generation	O	O
from	O	O
human	O	O
monocyte	O	O
s	O	O
in	O	O
vitro	O	O
.	O	O

CS	O	O
at	O	O
50-200	O	O
microM	O	O
reduced	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
(	O	O
TNF	B-protein	O
)	O	O
,	O	O
interleukin-1	O	O
(	O	O
IL-1	B-protein	O
)	O	O
,	O	O
and	O	O
IL-6	O	O
activities	O	O
in	O	O
the	O	O
culture	O	O
supernatants	O	O
from	O	O
LPS-stimulated	O	O
human	B-cell_type	O
blood	I-cell_type	O
monocytes	I-cell_type	O
without	O	O
cytotoxicity	O	O
.	O	O

ELISA	O	O
assay	O	O
revealed	O	O
that	O	O
the	O	O
production	O	O
of	O	O
TNF-alpha	B-protein	O
,	O	O
IL-1alpha	O	O
,	O	O
IL-1beta	O	O
,	O	O
and	O	O
IL-6	O	O
was	O	O
inhibited	O	O
by	O	O
CS	O	O
.	O	O

Northern	O	O
blot	O	O
analysis	O	O
showed	O	O
that	O	O
LPS-induced	O	O
expression	O	O
of	O	O
these	O	O
cytokine	B-RNA	O
mRNA	I-RNA	O
in	O	O
monocytes	B-cell_type	O
was	O	O
suppressed	O	O
by	O	O
CS	O	O
.	O	O

NF-kappaB	O	O
activation	O	O
was	O	O
also	O	O
inhibited	O	O
by	O	O
CS	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
CS	O	O
has	O	O
a	O	O
suppressive	O	O
effect	O	O
on	O	O
proinflammatory	O	O
cytokine	O	O
production	O	O
from	O	O
monocytes	B-cell_type	O
,	O	O
and	O	O
this	O	O
effect	O	O
is	O	O
based	O	O
in	O	O
part	O	O
on	O	O
the	O	O
suppression	O	O
of	O	O
cytokine	B-protein	O
mRNA	I-RNA	O
expression	O	O
through	O	O
inhibition	O	O
of	O	O
NF-kappaB	O	O
activation	O	O
.	O	O

Elevated	O	O
expression	O	O
of	O	O
differentiation	B-protein	O
inhibitory	I-protein	O
factor	I-protein	O
nm23	B-RNA	O
mRNA	I-RNA	O
in	O	O
monoblastic	O	O
crisis	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
chronic	O	O
myelogenous	O	O
leukemia	O	O
.	O	O

Differentiation	O	O
inhibitory	I-protein	O
factor	I-protein	O
nm23	B-DNA	O
gene	I-DNA	O
has	O	O
been	O	O
found	O	O
to	O	O
be	O	O
expressed	O	O
in	O	O
high	O	O
quantities	O	O
in	O	O
acute	O	O
myelogenous	O	O
leukemia	O	O
(	O	O
AML	O	O
)	O	O
,	O	O
especially	O	O
in	O	O
acute	O	O
monocytic	O	O
leukemia	O	O
(	O	O
AML-M5	O	O
)	O	O
and	O	O
is	O	O
suggested	O	O
as	O	O
a	O	O
new	O	O
prognostic	O	O
factor	O	O
in	O	O
AML-M5	O	O
.	O	O

We	O	O
report	O	O
an	O	O
example	O	O
of	O	O
elevated	O	O
expression	O	O
of	O	O
nm23	B-RNA	O
mRNA	I-RNA	O
in	O	O
a	O	O
patient	O	O
with	O	O
chronic	O	O
myelogenous	O	O
leukemia	O	O
(	O	O
CML	O	O
)	O	O
who	O	O
developed	O	O
monoblastic	O	O
crisis	O	O
.	O	O

Relative	O	O
levels	O	O
of	O	O
nm23-H1	B-RNA	O
and	O	O
-H2	B-RNA	O
mRNA	I-RNA	O
extracted	O	O
from	O	O
the	O	O
patient	B-cell_type	O
's	I-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
and	O	O
bone	O	O
marrow	O	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
were	O	O
measured	O	O
by	O	O
quantitative	O	O
reverse	O	O
transcriptase	O	O
polymerase	O	O
chain	O	O
reaction	O	O
.	O	O

The	O	O
level	O	O
of	O	O
nm23-H1	B-RNA	O
mRNA	I-RNA	O
in	O	O
CML	B-cell_type	O
cells	I-cell_type	O
at	O	O
the	O	O
chronic	O	O
phase	O	O
was	O	O
as	O	O
high	O	O
as	O	O
that	O	O
in	O	O
bone	B-cell_line	O
marrow	I-cell_line	O
cells	I-cell_line	O
from	O	O
healthy	O	O
volunteers	O	O
.	O	O

The	O	O
mRNA	B-RNA	O
level	O	O
of	O	O
nm23-H2	O	O
was	O	O
slightly	O	O
below	O	O
the	O	O
normal	O	O
level	O	O
.	O	O

At	O	O
blastic	O	O
crisis	O	O
,	O	O
however	O	O
,	O	O
expression	O	O
of	O	O
both	O	O
nm23-H1	O	O
and	O	O
-H2	B-RNA	O
mRNA	I-RNA	O
was	O	O
elevated	O	O
to	O	O
about	O	O
three	O	O
to	O	O
nine	O	O
times	O	O
of	O	O
that	O	O
at	O	O
the	O	O
chronic	O	O
phase	O	O
.	O	O

Proliferated	O	O
blastic	I-cell_line	O
cells	I-cell_line	O
were	O	O
positive	O	O
for	O	O
non-specific	O	O
esterase	O	O
,	O	O
and	O	O
the	O	O
serum	O	O
lysozyme	O	O
level	O	O
was	O	O
elevated	O	O
and	O	O
diagnosed	O	O
as	O	O
monoblastic	O	O
crisis	O	O
.	O	O

The	O	O
patient	O	O
received	O	O
combined	O	O
chemotherapy	O	O
but	O	O
response	O	O
was	O	O
partial	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
compatible	O	O
with	O	O
our	O	O
previous	O	O
report	O	O
that	O	O
nm23	B-DNA	O
gene	I-DNA	O
is	O	O
overexpressed	O	O
in	O	O
monocytic	O	O
leukemia	O	O
.	O	O

Increased	O	O
transcription	O	O
decreases	O	O
the	O	O
spontaneous	O	O
mutation	O	O
rate	O	O
at	O	O
the	O	O
thymidine	O	O
kinase	O	O
locus	O	O
in	O	O
human	B-cell_type	O
cells	I-cell_type	O
.	O	O

Transcription	O	O
increases	O	O
DNA	O	O
repair	O	O
efficiency	O	O
and	O	O
modulates	O	O
the	O	O
distribution	O	O
of	O	O
certain	O	O
types	O	O
of	O	O
DNA	O	O
damage	O	O
.	O	O

Furthermore	O	O
,	O	O
increased	O	O
transcription	O	O
level	O	O
stimulates	O	O
spontaneous	O	O
mutation	O	O
rate	O	O
in	O	O
yeast	O	O
.	O	O

We	O	O
explored	O	O
whether	O	O
transcription	O	O
level	O	O
affects	O	O
spontaneous	O	O
mutation	O	O
rate	O	O
in	O	O
human	B-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
first	O	O
developed	O	O
two	O	O
thymidine	B-protein	O
kinase	I-protein	O
(	O	O
tk	O	O
)	O	O
inducible	O	O
human	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
using	O	O
the	O	O
Gal4-Estrogen	O	O
receptor	I-protein	O
system	O	O
.	O	O

In	O	O
our	O	O
TK6i-G3	O	O
and	O	O
G9	O	O
tk	O	O
heterozygous	O	O
cell	O	O
lines	O	O
,	O	O
the	O	O
active	O	O
tk	O	O
allele	O	O
is	O	O
linked	O	O
to	O	O
an	O	O
inducible	O	O
promoter	O	O
element	O	O
.	O	O

Tk	O	O
mRNA	I-RNA	O
is	O	O
induced	O	O
following	O	O
treatment	O	O
with	O	O
estrogen	O	O
.	O	O

Spontaneous	O	O
mutation	O	O
rate	O	O
was	O	O
significantly	O	O
decreased	O	O
in	O	O
human	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
after	O	O
induction	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
report	O	O
in	O	O
yeast	O	O
.	O	O

Thus	O	O
,	O	O
humans	O	O
may	O	O
have	O	O
evolved	O	O
different	O	O
or	O	O
additional	O	O
mechanisms	O	O
to	O	O
deal	O	O
with	O	O
transcription	O	O
related	O	O
spontaneous	O	O
mutagenesis	O	O
.	O	O

Copyright	O	O
1998	O	O
Elsevier	O	O
Science	O	O
B.V	O	O
.	O	O

All	O	O
rights	O	O
reserved	O	O
.	O	O

Mutation	O	O
of	O	O
BCL-6	B-DNA	O
gene	I-DNA	O
in	O	O
normal	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
by	O	O
the	O	O
process	O	O
of	O	O
somatic	O	O
hypermutation	O	O
of	O	O
Ig	B-DNA	O
genes	I-DNA	O
.	O	O

Immunoglobulin	O	O
(	O	O
Ig	B-DNA	O
)	O	O
genes	O	O
are	O	O
hypermutated	O	O
in	O	O
B	B-cell_type	O
lymphocytes	I-cell_type	O
that	O	O
are	O	O
the	O	O
precursors	O	O
to	O	O
memory	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
mutations	O	O
are	O	O
linked	O	O
to	O	O
transcription	O	O
initiation	O	O
,	O	O
but	O	O
non-Ig	O	O
promoters	O	O
are	O	O
permissible	O	O
for	O	O
the	O	O
mutation	O	O
process	O	O
;	O	O
thus	O	O
,	O	O
other	O	O
genes	O	O
expressed	O	O
in	O	O
mutating	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
may	O	O
also	O	O
be	O	O
subject	O	O
to	O	O
somatic	O	O
hypermutation	O	O
.	O	O

Significant	O	O
mutations	O	O
were	O	O
not	O	O
observed	O	O
in	O	O
c-MYC	O	O
,	O	O
S14	O	O
,	O	O
or	O	O
alpha-fetoprotein	O	O
(	O	O
AFP	O	O
)	O	O
genes	O	O
,	O	O
but	O	O
BCL-6	O	O
was	O	O
highly	O	O
mutated	O	O
in	O	O
a	O	O
large	O	O
proportion	O	O
of	O	O
memory	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
of	O	O
normal	O	O
individuals	O	O
.	O	O

The	O	O
mutation	O	O
pattern	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
Ig	B-DNA	O
genes	I-DNA	O
.	O	O

CD28-mediated	O	O
activation	O	O
in	O	O
CD45RA+	O	O
and	O	O
CD45RO+	O	O
T	B-cell_type	O
cells	I-cell_type	O
:	O	O
enhanced	O	O
levels	O	O
of	O	O
reactive	O	O
oxygen	O	O
intermediates	O	O
and	O	O
c-Rel	O	O
nuclear	O	O
translocation	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
have	O	O
analyzed	O	O
the	O	O
effect	O	O
of	O	O
complete	O	O
T	O	O
cell	O	O
activation	O	O
(	O	O
anti-CD3	O	O
plus	O	O
anti-CD28	O	O
)	O	O
on	O	O
the	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
in	O	O
CD45RA+	O	O
(	O	O
naive	O	O
)	O	O
and	O	O
CD45RO+	O	O
(	O	O
memory/effector	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Long	O	O
exposure	O	O
(	O	O
24	O	O
h	O	O
)	O	O
induced	O	O
stronger	O	O
NF-kappaB	O	O
DNA	O	O
binding	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
than	O	O
in	O	O
CD45RO+	B-cell_type	O
cells	I-cell_type	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
nuclear	B-protein	O
c-Rel	I-protein	O
protein	I-protein	O
indicated	O	O
that	O	O
after	O	O
anti-CD3+anti-CD28	O	O
stimulation	O	O
the	O	O
level	O	O
of	O	O
c-Rel	O	O
was	O	O
higher	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
cytoplasmic	O	O
inhibitor	O	O
IkappaBalpha	O	O
indicated	O	O
that	O	O
anti-CD3+anti-CD28	O	O
stimulation	O	O
induced	O	O
a	O	O
long-lasting	O	O
degradation	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
but	O	O
in	O	O
CD45RO+	O	O
cells	O	O
the	O	O
degradation	O	O
process	O	O
was	O	O
more	O	O
rapid	O	O
.	O	O

Because	O	O
the	O	O
CD28	O	O
costimulus	O	O
is	O	O
known	O	O
to	O	O
induce	O	O
the	O	O
production	O	O
of	O	O
reactive	O	O
oxygen	O	O
intermediates	O	O
(	O	O
ROIs	O	O
)	O	O
,	O	O
the	O	O
intracellular	O	O
ROI	O	O
levels	O	O
in	O	O
CD45RA+	O	O
and	O	O
CD45RO+	B-cell_type	O
cells	I-cell_type	O
were	O	O
compared	O	O
by	O	O
flow	O	O
cytometry	O	O
.	O	O

ROIs	O	O
were	O	O
produced	O	O
in	O	O
both	O	O
cell	O	O
types	O	O
,	O	O
but	O	O
more	O	O
strongly	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
data	O	O
presented	O	O
in	O	O
this	O	O
study	O	O
further	O	O
emphasize	O	O
the	O	O
differences	O	O
between	O	O
CD45RA+	O	O
and	O	O
CD45RO+	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
in	O	O
ROI-dependent	O	O
signaling	O	O
pathways	O	O
.	O	O

Non-Hodgkin	O	O
's	O	O
lymphoma	O	O
involving	O	O
bilateral	O	O
breasts	O	O
[	O	O
see	O	O
comments	O	O
]	O	O

We	O	O
describe	O	O
here	O	O
two	O	O
cases	O	O
of	O	O
diffuse	O	O
large	O	O
cell	O	O
type	O	O
non-Hodgkin	O	O
's	O	O
lymphoma	O	O
affecting	O	O
the	O	O
bilateral	O	O
breasts	O	O
.	O	O

The	O	O
contralateral	O	O
tumor	O	O
in	O	O
one	O	O
case	O	O
appeared	O	O
17	O	O
months	O	O
after	O	O
the	O	O
first	O	O
mastectomy	O	O
,	O	O
whereas	O	O
the	O	O
bilateral	O	O
tumors	O	O
occurred	O	O
concurrently	O	O
in	O	O
the	O	O
other	O	O
patient	O	O
who	O	O
was	O	O
pregnant	O	O
and	O	O
showed	O	O
widespread	O	O
dissemination	O	O
at	O	O
initial	O	O
presentation	O	O
.	O	O

Lymphoma	B-cell_type	O
cells	I-cell_type	O
from	O	O
both	O	O
cases	O	O
showed	O	O
the	O	O
mature	O	O
B-cell	O	O
immunophenotype	O	O
and	O	O
had	O	O
rearrangements	O	O
of	O	O
the	O	O
BCL6	B-DNA	O
gene	I-DNA	O
.	O	O

Both	O	O
patients	O	O
developed	O	O
progressive	O	O
disease	O	O
despite	O	O
chemo-radiotherapy	O	O
and	O	O
died	O	O
of	O	O
leukemic	B-protein	O
manifestations	O	O
.	O	O

There	O	O
were	O	O
no	O	O
apparent	O	O
pathological	O	O
features	O	O
of	O	O
lymphomas	O	O
of	O	O
mucosa-associated	O	O
lymphoid	O	O
tissue	O	O
origin	O	O

Biochemical	O	O
characterization	O	O
of	O	O
MIP-1	B-protein	O
alpha	I-protein	O
nuclear	I-protein	O
protein	I-protein	O
.	O	O

A	O	O
family	O	O
of	O	O
hematopoietic	O	O
specific	O	O
transcription	B-protein	O
factors	I-protein	O
,	O	O
MIP-1	B-protein	O
alpha	I-protein	O
nuclear	I-protein	O
protein	I-protein	O
(	O	O
MNP	B-protein	O
)	O	O
family	O	O
,	O	O
has	O	O
recently	O	O
been	O	O
identified	O	O
.	O	O

They	O	O
are	O	O
intimately	O	O
involved	O	O
in	O	O
regulating	O	O
the	O	O
transcription	O	O
of	O	O
the	O	O
huMIP-1	B-DNA	O
alpha	I-DNA	O
gene	I-DNA	O
in	O	O
monocytes	B-cell_type	O
,	O	O
T-cells	O	O
,	O	O
and	O	O
transformed	O	O
B-cells	O	O
.	O	O

One	O	O
member	O	O
of	O	O
the	O	O
family	B-protein	O
(	I-protein	O
MNP-1	I-protein	O
)	O	O
is	O	O
essential	O	O
for	O	O
promoter	O	O
activity	O	O
in	O	O
monocytes	B-cell_type	O
and	O	O
B-cells	O	O
,	O	O
while	O	O
another	O	O
(	O	O
MNP-2	O	O
)	O	O
is	O	O
required	O	O
for	O	O
full	O	O
promotor	O	O
activity	O	O
in	O	O
T-cells	O	O
.	O	O

A	O	O
third	O	O
member	O	O
of	O	O
the	O	O
family	O	O
(	O	O
MNP-3	I-protein	O
)	O	O
is	O	O
expressed	O	O
in	O	O
PMA	O	O
induced	O	O
HL60	B-cell_type	O
cells	I-cell_type	O
and	O	O
probably	O	O
has	O	O
a	O	O
role	O	O
in	O	O
monocyte	O	O
differentiation	O	O
.	O	O

In	O	O
this	O	O
communication	O	O
we	O	O
demonstrate	O	O
by	O	O
two	O	O
techniques	O	O
that	O	O
MNP-1	O	O
and	O	O
MNP-2	O	O
are	O	O
distinct	O	O
but	O	O
related	O	O
factors	I-protein	O
,	O	O
and	O	O
we	O	O
present	O	O
further	O	O
evidence	O	O
to	O	O
show	O	O
that	O	O
MNP-1	O	O
acts	O	O
as	O	O
a	O	O
heterodimer	O	O
.	O	O

Bcl-3	O	O
expression	O	O
and	O	O
nuclear	O	O
translocation	O	O
are	O	O
induced	O	O
by	O	O
granulocyte-macrophage	B-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
and	O	O
erythropoietin	O	O
in	O	O
proliferating	O	O
human	O	O
erythroid	I-cell_line	O
precursors	I-cell_line	O
.	O	O

Bcl-3	O	O
is	O	O
a	O	O
proto-oncogene	O	O
involved	O	O
in	O	O
the	O	O
chromosomal	O	O
translocation	O	O
t	O	O
(	O	O
14	O	O
;	O	O
19	O	O
)	O	O
found	O	O
in	O	O
some	O	O
patients	O	O
with	O	O
chronic	O	O
lymphocytic	O	O
leukemia	O	O
.	O	O

It	O	O
shares	O	O
structural	O	O
similarities	O	O
with	O	O
and	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
IkappaB	B-protein	O
family	I-protein	O
of	I-protein	O
proteins	I-protein	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
involvement	O	O
of	O	O
Bcl-3	O	O
in	O	O
hematopoietic	O	O
growth	O	O
factor-stimulated	O	O
erythroid	O	O
proliferation	O	O
and	O	O
differentiation	O	O
was	O	O
examined	O	O
.	O	O

In	O	O
TF-1	B-cell_type	O
cells	I-cell_type	O
,	O	O
an	O	O
erythroleukemia	O	O
cell	O	O
line	O	O
,	O	O
granulocyte-macrophage	B-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
(	O	O
GM-CSF	B-protein	O
)	O	O
and	O	O
erythropoietin	O	O
(	O	O
Epo	B-protein	O
)	O	O
greatly	O	O
enhanced	O	O
Bcl-3	O	O
expression	O	O
at	O	O
both	O	O
the	O	O
protein	O	O
and	O	O
mRNA	I-RNA	O
levels	O	O
in	O	O
association	O	O
with	O	O
stimulation	O	O
of	O	O
proliferation	O	O
.	O	O

Bcl-3	O	O
protein	O	O
was	O	O
also	O	O
highly	O	O
expressed	O	O
in	O	O
early	O	O
burst-forming	O	O
unit-erythroid	O	O
(	O	O
BFU-E	O	O
)	O	O
-derived	O	O
erythroid	O	O
precursors	O	O
(	O	O
day	O	O
7	O	O
)	O	O
and	O	O
decreased	O	O
during	O	O
maturation	O	O
(	O	O
days	O	O
10	O	O
and	O	O
14	O	O
)	O	O
,	O	O
suggesting	O	O
that	O	O
Bcl-3	O	O
is	O	O
involved	O	O
in	O	O
normal	O	O
erythroid	O	O
proliferation	O	O
.	O	O

In	O	O
these	O	O
hematopoietic	B-cell_type	O
cells	I-cell_type	O
,	O	O
Bcl-3	O	O
was	O	O
hyperphosphorylated	O	O
.	O	O

GM-CSF	B-protein	O
and	O	O
Epo	B-protein	O
modulated	O	O
the	O	O
subcellular	O	O
localization	O	O
of	O	O
Bcl-3	O	O
.	O	O

Upon	O	O
stimulation	O	O
of	O	O
TF-1	B-cell_type	O
cells	I-cell_type	O
with	O	O
GM-CSF	B-protein	O
or	O	O
Epo	B-protein	O
,	O	O
the	O	O
nuclear	O	O
translocation	O	O
of	O	O
Bcl-3	O	O
was	O	O
dramatically	O	O
enhanced	O	O
.	O	O

Overexpression	O	O
of	O	O
Bcl-3	O	O
in	O	O
TF-1	B-cell_type	O
cells	I-cell_type	O
by	O	O
transient	O	O
transfection	O	O
along	O	O
with	O	O
the	O	O
NF-kappaB	B-protein	O
factors	I-protein	O
p50	I-protein	O
or	O	O
p52	O	O
resulted	O	O
in	O	O
significant	O	O
induction	O	O
of	O	O
an	O	O
human	O	O
immunodeficiency	B-protein	O
virus-type	I-protein	O
1	O	O
(	O	O
HIV-1	B-DNA	O
)	O	O
kappaB-TATA-luceriferase	O	O
reporter	I-DNA	O
plasmid	O	O
,	O	O
demonstrating	O	O
that	O	O
Bcl-3	O	O
has	O	O
a	O	O
positive	O	O
role	O	O
in	O	O
transactivation	O	O
of	O	O
kappaB-containing	O	O
genes	I-DNA	O
in	O	O
erythroid	B-cell_type	O
cells	I-cell_type	O
.	O	O

Stimulation	O	O
with	O	O
GM-CSF	B-protein	O
enhanced	O	O
c-myb	O	O
mRNA	B-RNA	O
expression	O	O
in	O	O
these	O	O
cells	O	O
.	O	O

Bcl-3	O	O
in	O	O
nuclear	O	O
extracts	O	O
of	O	O
TF-1	B-cell_type	O
cells	I-cell_type	O
bound	O	O
to	O	O
a	O	O
kappaB	B-DNA	O
enhancer	I-DNA	O
in	O	O
the	O	O
c-myb	B-DNA	O
promoter	I-DNA	O
together	O	O
with	O	O
NF-kappaB2/p52	O	O
and	O	O
this	O	O
binding	O	O
activity	O	O
was	O	O
enhanced	O	O
by	O	O
GM-CSF	B-protein	O
stimulation	O	O
.	O	O

Furthermore	O	O
,	O	O
cotransfection	O	O
of	O	O
Bcl-3	O	O
with	O	O
p52	O	O
or	O	O
p50	O	O
in	O	O
TF-1	B-cell_type	O
cells	I-cell_type	O
resulted	O	O
in	O	O
significant	O	O
activation	O	O
of	O	O
a	O	O
c-myb	O	O
kappaB-TATA-luceriferase	O	O
reporter	I-DNA	O
plasmid	I-DNA	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
Bcl-3	O	O
may	O	O
participate	O	O
in	O	O
the	O	O
transcriptional	O	O
regulation	O	O
of	O	O
certain	O	O
kappaB-containing	O	O
genes	O	O
involved	O	O
in	O	O
hematopoiesis	O	O
,	O	O
including	O	O
c-myb	O	O
.	O	O

Copyright	O	O
1998	O	O
by	O	O
The	O	O
American	O	O
Society	O	O
of	O	O
Hematology	O	O
.	O	O

5-Lipoxygenase	O	O
compartmentalization	O	O
in	O	O
granulocytic	B-cell_line	O
cells	I-cell_line	O
is	O	O
modulated	O	O
by	O	O
an	O	O
internal	O	O
bipartite	O	O
nuclear	O	O
localizing	O	O
sequence	O	O
and	O	O
nuclear	B-protein	O
factor	I-protein	O
kappa	I-protein	O
B	I-protein	O
complex	I-protein	O
formation	O	O
.	O	O

A	O	O
region	O	O
of	O	O
basic	O	O
amino	O	O
acids	O	O
spanning	O	O
residues	O	O
639-656	O	O
in	O	O
the	O	O
human	O	O
5-lipoxygenase	O	O
sequence	O	O
resembles	O	O
a	O	O
consensus	O	O
bipartite	O	O
nuclear	O	O
localizing	O	O
sequence	O	O
.	O	O

A	O	O
synthetic	O	O
peptide	O	O
consisting	O	O
of	O	O
the	O	O
Kaposi	B-protein	O
fibroblast	I-protein	O
growth	I-protein	O
factor	I-protein	O
signal	O	O
sequence	O	O
fused	O	O
to	O	O
the	O	O
5-lipoxygenase639-656	O	O
bipartite	O	O
nuclear	O	O
localizing	O	O
sequence	O	O
has	O	O
a	O	O
prominent	O	O
inhibitory	O	O
effect	O	O
on	O	O
5-lipoxygenase	O	O
catalysis	O	O
in	O	O
granulocytic	O	O
HL-60	O	O
cells	O	O
activated	O	O
by	O	O
calcium	O	O
ionophor	O	O
A23187	O	O
.	O	O

Recombinant	O	O
5-lipoxygenase	O	O
was	O	O
not	O	O
affected	O	O
by	O	O
the	O	O
peptide	O	O
.	O	O

The	O	O
peptide	O	O
also	O	O
inhibited	O	O
redistribution	O	O
of	O	O
5-lipoxygenase	O	O
from	O	O
the	O	O
cytosol	O	O
to	O	O
the	O	O
nuclear	O	O
membrane	O	O
of	O	O
HL-60	B-cell_type	O
cells	I-cell_type	O
stimulated	O	O
by	O	O
A23187	O	O
.	O	O

5-Lipoxygenase	O	O
protein	O	O
was	O	O
detected	O	O
in	O	O
nuclear	B-protein	O
factor	I-protein	O
kappaB	O	O
(	O	O
NF-kappaB	O	O
)	O	O
p65	O	O
subunit	O	O
immunoprecipitate	O	O
fractions	O	O
prepared	O	O
from	O	O
HL-60	O	O
cell	O	O
lysates	O	O
.	O	O

The	O	O
amount	O	O
of	O	O
5-lipoxygenase	B-protein	O
protein	I-protein	O
coimmunoprecipitated	O	O
by	O	O
NF-kappaB	O	O
antiserum	O	O
was	O	O
increased	O	O
following	O	O
A23187	O	O
stimulation	O	O
.	O	O

In	O	O
cells	O	O
treated	O	O
with	O	O
agents	O	O
that	O	O
block	O	O
5-lipoxygenase	O	O
translocation	O	O
to	O	O
the	O	O
nucleus	O	O
,	O	O
5-lipoxygenase	O	O
protein	O	O
appearing	O	O
in	O	O
the	O	O
NF-kappaB	O	O
immunoprecipitate	O	O
was	O	O
diminished	O	O
.	O	O

Our	O	O
results	O	O
implicate	O	O
an	O	O
internal	O	O
bipartite	O	O
nuclear	O	O
localizing	O	O
sequence	O	O
as	O	O
a	O	O
regulatory	O	O
domain	O	O
that	O	O
modulates	O	O
5-lipoxygenase	O	O
redistribution	O	O
and	O	O
catalysis	O	O
in	O	O
granulocytic	B-cell_line	O
cells	I-cell_line	O
.	O	O

Additionally	O	O
,	O	O
our	O	O
results	O	O
suggest	O	O
that	O	O
molecular	O	O
determinants	O	O
which	O	O
govern	O	O
5-lipoxygenase	O	O
and	O	O
NF-kappaB	O	O
redistribution	O	O
to	O	O
the	O	O
nucleus	O	O
may	O	O
be	O	O
coordinately	O	O
controlled	O	O
in	O	O
granulocytic	B-cell_line	O
cells	I-cell_line	O
.	O	O

Copyright	O	O
1998	O	O
Academic	O	O
Press	O	O
.	O	O

Inhibition	O	O
of	O	O
CD28/CD3-mediated	O	O
costimulation	O	O
of	O	O
naive	O	O
and	O	O
memory	O	O
human	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
by	O	O
intracellular	O	O
incorporation	O	O
of	O	O
polyclonal	B-protein	O
antibodies	I-protein	O
specific	O	O
for	O	O
the	O	O
activator	B-protein	O
protein-1	I-protein	O
transcriptional	I-protein	O
complex	I-protein	O
.	O	O

A	O	O
number	O	O
of	O	O
indirect	O	O
methods	O	O
have	O	O
been	O	O
utilized	O	O
in	O	O
demonstrating	O	O
activator	I-protein	O
protein-1	I-protein	O
transcription	I-protein	O
factor	I-protein	O
function	O	O
in	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
activity	O	O
.	O	O

However	O	O
,	O	O
there	O	O
has	O	O
been	O	O
no	O	O
direct	O	O
demonstration	O	O
that	O	O
activator	O	O
protein-1	O	O
is	O	O
involved	O	O
in	O	O
CD28-dependent	O	O
costimulation	O	O
of	O	O
IL-2	B-protein	O
gene	O	O
transcription	O	O
in	O	O
freshly	O	O
isolated	O	O
naive	O	O
and	O	O
memory	O	O
human	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

To	O	O
address	O	O
this	O	O
issue	O	O
,	O	O
the	O	O
method	O	O
of	O	O
scrape	O	O
loading	O	O
was	O	O
applied	O	O
to	O	O
purified	B-cell_line	O
peripheral	B-cell_type	O
blood	I-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Since	O	O
scrape	O	O
loading	O	O
relies	O	O
on	O	O
adherent	B-cell_line	O
cells	I-cell_line	O
,	O	O
peripheral	B-cell_line	O
blood	I-cell_line	O
human	I-cell_line	O
T	I-cell_line	O
(	I-cell_line	O
PB-T	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
were	O	O
immobilized	O	O
on	O	O
the	O	O
nonspecific	O	O
cell	I-protein	O
attachment	I-protein	O
factor	I-protein	O
poly-L-lysine	O	O
.	O	O

Cells	O	O
scraped	O	O
off	O	O
poly-L-lysine	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
Ig	O	O
FITC	O	O
efficiently	O	O
incorporated	O	O
Ig	O	O
,	O	O
with	O	O
relatively	O	O
uniform	O	O
fluorescence	O	O
.	O	O

T	B-cell_type	O
cells	I-cell_type	O
retained	O	O
their	O	O
physical	O	O
parameters	O	O
as	O	O
measured	O	O
by	O	O
forward	O	O
and	O	O
side	O	O
light	O	O
scatter	O	O
,	O	O
and	O	O
functional	O	O
activity	O	O
as	O	O
measured	O	O
by	O	O
costimulation	O	O
of	O	O
proliferation	O	O
and	O	O
IL-2	B-protein	O
production	O	O
after	O	O
being	O	O
scraped	O	O
off	O	O
this	O	O
substrate	O	O
.	O	O

CD28/CD3-costimulated	O	O
T	B-cell_type	O
cells	I-cell_type	O
produced	O	O
intracellular	O	O
IL-2	B-protein	O
from	O	O
all	O	O
subsets	O	O
measured	O	O
(	O	O
CD4+	B-protein	O
,	O	O
CD4-	O	O
,	O	O
CD45RO+	O	O
,	O	O
and	O	O
CD45RO-	O	O
)	O	O
.	O	O

IL-2	B-protein	O
production	O	O
and	O	O
intracellular	O	O
accumulation	O	O
in	O	O
nonscraped	O	O
PB-T	B-cell_type	O
cells	I-cell_type	O
activated	O	O
with	O	O
CD28/CD3	O	O
coligation	O	O
were	O	O
skewed	O	O
favoring	O	O
CD45RO+	O	O
and	O	O
CD4+	O	O
subsets	O	O
,	O	O
as	O	O
was	O	O
IL-2	O	O
production	O	O
in	O	O
scraped	O	O
PB-T	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
intracellular	O	O
incorporation	O	O
of	O	O
Abs	O	O
specific	O	O
for	O	O
c-Fos	B-protein	O
and	O	O
c-Jun	B-protein	O
family	I-protein	O
members	O	O
by	O	O
scrape	O	O
loading	O	O
inhibited	O	O
the	O	O
production	O	O
and	O	O
intracellular	O	O
accumulation	O	O
of	O	O
IL-2	B-protein	O
within	O	O
6	O	O
h	O	O
of	O	O
costimulation	O	O
with	O	O
PMA/ionomycin	B-protein	O
,	O	O
or	O	O
costimulation	O	O
by	O	O
CD28	B-protein	O
and	O	O
CD3	B-protein	O
ligation	O	O
.	O	O

Scrape	O	O
loading	O	O
thus	O	O
provides	O	O
an	O	O
efficient	O	O
mechanism	O	O
for	O	O
intracellular	O	O
incorporation	O	O
of	O	O
macromolecules	O	O
,	O	O
and	O	O
the	O	O
first	O	O
direct	O	O
evidence	O	O
that	O	O
c-Fos	B-protein	O
and	O	O
c-Jun	O	O
are	O	O
involved	O	O
in	O	O
transcription	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
gene	I-DNA	O
within	O	O
its	O	O
correct	O	O
chromosomal	O	O
context	O	O
,	O	O
in	O	O
resting	B-cell_line	O
human	I-cell_line	O
T	I-cell_line	O
lymphocyte	O	O
subpopulations	O	O
.	O	O

Differential	O	O
expression	O	O
of	O	O
Nur77	O	O
family	O	O
members	O	O
in	O	O
human	O	O
T-lymphotropic	O	O
virus	O	O
type	I-cell_type	O
1-infected	I-cell_type	O
cells	I-cell_type	O
:	O	O
transactivation	O	O
of	O	O
the	O	O
TR3/nur77	B-DNA	O
gene	I-DNA	O
by	O	O
Tax	O	O
protein	O	O
.	O	O

We	O	O
analyzed	O	O
the	O	O
differential	O	O
expression	O	O
and	O	O
regulation	O	O
of	O	O
three	O	O
members	O	O
of	O	O
the	O	O
Nur77	B-protein	O
transcription	I-protein	O
factor	I-protein	O
family	I-protein	O
by	O	O
the	O	O
human	B-protein	O
T-lymphotropic	I-protein	O
virus	I-protein	O
type	I-protein	O
1	I-protein	O
(	O	O
HTLV-1	B-protein	O
)	I-protein	O
Tax	I-protein	O
protein	I-protein	O
.	O	O

We	O	O
have	O	O
demonstrated	O	O
that	O	O
in	O	O
both	O	O
HTLV-1-infected	B-cell_type	O
cells	I-cell_type	O
and	O	O
Tax-expressing	O	O
JPX-9	B-cell_type	O
cells	I-cell_type	O
,	O	O
TR3/nur77	O	O
is	O	O
highly	O	O
expressed	O	O
,	O	O
whereas	O	O
neither	O	O
NOR-1	O	O
nor	O	O
NOT	O	O
expression	O	O
is	O	O
detectable	O	O
.	O	O

Transient	O	O
transfection	O	O
analysis	O	O
further	O	O
confirmed	O	O
the	O	O
Tax	O	O
transactivation	O	O
of	O	O
the	O	O
TR3/nur77	B-DNA	O
promoter	I-DNA	O
but	O	O
not	O	O
the	O	O
NOR-1	B-DNA	O
promoter	I-DNA	O
in	O	O
different	O	O
cell	I-cell_type	O
types	I-cell_type	O
.	O	O

Furthermore	O	O
,	O	O
expression	O	O
of	O	O
a	O	O
luciferase	B-DNA	O
reporter	I-DNA	O
gene	I-DNA	O
driven	O	O
by	O	O
the	O	O
NGFI-B	O	O
(	O	O
rat	O	O
homolog	O	O
of	O	O
TR3/Nur77	B-DNA	O
)	O	O
response	O	O
element	O	O
(	O	O
NBRE	O	O
)	O	O
provided	O	O
evidence	O	O
that	O	O
Tax	O	O
-mediated	O	O
transactivation	O	O
resulted	O	O
in	O	O
the	O	O
induction	O	O
of	O	O
a	O	O
functional	O	O
protein	O	O
.	O	O

Cotransfection	O	O
assays	O	O
with	O	O
the	O	O
TR3/nur77	B-DNA	O
promoter	I-DNA	O
sequence	I-DNA	O
or	O	O
the	O	O
NBRE	O	O
binding	O	O
motif	O	O
together	O	O
with	O	O
a	O	O
series	O	O
of	O	O
Tax	O	O
mutants	O	O
have	O	O
shown	O	O
that	O	O
Tax	O	O
-induced	O	O
TR3/nur77	O	O
expression	O	O
is	O	O
mediated	O	O
by	O	O
CREB/ATF-related	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

Negative	O	O
regulation	O	O
of	O	O
the	O	O
heat	B-DNA	O
shock	O	O
transcriptional	O	O
response	O	O
by	O	O
HSBP1	O	O
.	O	O

In	O	O
response	O	O
to	O	O
stress	O	O
,	O	O
heat	O	O
shock	B-protein	O
factor	I-protein	O
1	O	O
(	O	O
HSF1	O	O
)	O	O
acquires	O	O
rapid	O	O
DNA	O	O
binding	O	O
and	O	O
transient	O	O
transcriptional	O	O
activity	O	O
while	O	O
undergoing	O	O
conformational	O	O
transition	O	O
from	O	O
an	O	O
inert	O	O
non-DNA-binding	O	O
monomer	O	O
to	O	O
active	O	O
functional	O	O
trimers	O	O
.	O	O

Attenuation	O	O
of	O	O
the	O	O
inducible	O	O
transcriptional	O	O
response	O	O
occurs	O	O
during	O	O
heat	O	O
shock	O	O
or	O	O
upon	O	O
recovery	O	O
at	O	O
non-stress	O	O
conditions	O	O
and	O	O
involves	O	O
dissociation	O	O
of	O	O
the	O	O
HSF1	O	O
trimer	O	O
and	O	O
loss	O	O
of	O	O
activity	O	O
.	O	O

We	O	O
have	O	O
used	O	O
the	O	O
hydrophobic	O	O
repeats	O	O
of	O	O
the	O	O
HSF1	B-DNA	O
trimerization	I-DNA	O
domain	I-DNA	O
in	O	O
the	O	O
yeast	O	O
two-hybrid	O	O
protein	O	O
interaction	O	O
assay	O	O
to	O	O
identify	O	O
heat	O	O
shock	B-protein	O
factor	I-protein	O
binding	I-protein	O
protein	I-protein	O
1	I-protein	O
(	O	O
HSBP1	B-protein	O
)	O	O
,	O	O
a	O	O
novel	O	O
,	O	O
conserved	O	O
,	O	O
76-amino-acid	O	O
protein	O	O
that	O	O
contains	O	O
two	O	O
extended	O	O
arrays	O	O
of	O	O
hydrophobic	O	O
repeats	O	O
that	O	O
interact	O	O
with	O	O
the	O	O
HSF1	O	O
heptad	O	O
repeats	O	O
.	O	O

HSBP1	O	O
is	O	O
nuclear-localized	O	O
and	O	O
interacts	O	O
in	O	O
vivo	O	O
with	O	O
the	O	O
active	O	O
trimeric	O	O
state	O	O
of	O	O
HSF1	O	O
that	O	O
appears	O	O
during	O	O
heat	O	O
shock	O	O
.	O	O

During	O	O
attenuation	O	O
of	O	O
HSF1	O	O
to	O	O
the	O	O
inert	O	O
monomer	O	O
,	O	O
HSBP1	O	O
associates	O	O
with	O	O
Hsp70	O	O
.	O	O

HSBP1	O	O
negatively	O	O
affects	O	O
HSF1	O	O
DNA-binding	O	O
activity	O	O
,	O	O
and	O	O
overexpression	O	O
of	O	O
HSBP1	O	O
in	O	O
mammalian	B-cell_type	O
cells	I-cell_type	O
represses	O	O
the	O	O
transactivation	O	O
activity	O	O
of	O	O
HSF1	O	O
.	O	O

To	O	O
establish	O	O
a	O	O
biological	O	O
role	O	O
for	O	O
HSBP1	O	O
,	O	O
the	O	O
homologous	O	O
Caenorhabditis	O	O
elegans	O	O
protein	O	O
was	O	O
overexpressed	O	O
in	O	O
body	O	O
wall	O	O
muscle	B-cell_type	O
cells	I-cell_type	O
and	O	O
was	O	O
shown	O	O
to	O	O
block	O	O
activation	O	O
of	O	O
the	O	O
heat	O	O
shock	O	O
response	O	O
from	O	O
a	O	O
heat	O	O
shock	O	O
promoter-reporter	O	O
construct	O	O
.	O	O

Alteration	O	O
in	O	O
the	O	O
level	O	O
of	O	O
HSBP1	O	O
expression	O	O
in	O	O
C.	O	O
elegans	O	O
has	O	O
severe	O	O
effects	O	O
on	O	O
survival	O	O
of	O	O
the	O	O
animals	O	O
after	O	O
thermal	O	O
and	O	O
chemical	B-protein	O
stress	I-protein	O
,	O	O
consistent	O	O
with	O	O
a	O	O
role	O	O
for	O	O
HSBP1	O	O
as	O	O
a	O	O
negative	O	O
regulator	O	O
of	O	O
the	O	O
heat	O	O
shock	O	O
response	O	O
.	O	O

Long-range	O	O
transcriptional	O	O
regulation	O	O
of	O	O
cytokine	B-protein	O
gene	O	O
expression	O	O
.	O	O

Most	O	O
studies	O	O
on	O	O
the	O	O
control	O	O
of	O	O
cytokine	B-protein	O
gene	I-DNA	O
expression	O	O
have	O	O
involved	O	O
the	O	O
functional	O	O
analysis	O	O
of	O	O
proximal	B-DNA	O
promoters	I-DNA	O
.	O	O

Recent	O	O
work	O	O
has	O	O
identified	O	O
distal	O	O
elements	O	O
that	O	O
mediate	O	O
long-range	O	O
cytokine	B-protein	O
gene	O	O
regulation	O	O
and	O	O
has	O	O
implicated	O	O
chromatin	O	O
reorganization	O	O
in	O	O
regulation	O	O
of	O	O
cytokine	B-protein	O
gene	O	O
loci	O	O
.	O	O

These	O	O
studies	O	O
have	O	O
begun	O	O
to	O	O
elucidate	O	O
the	O	O
basis	O	O
for	O	O
cell-specificity	O	O
and	O	O
high-level	O	O
expression	O	O
of	O	O
cytokine	B-protein	O
genes	I-DNA	O
.	O	O

A	O	O
signaling	O	O
complex	O	O
of	O	O
Ca2+-calmodulin-dependent	B-protein	O
protein	I-protein	O
kinase	I-protein	O
IV	I-protein	O
and	O	O
protein	O	O
phosphatase	O	O
2A	O	O
[	O	O
see	O	O
comments	O	O
]	O	O

Stimulation	O	O
of	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
results	O	O
in	O	O
a	O	O
rapid	O	O
increase	O	O
in	O	O
intracellular	O	O
calcium	O	O
concentration	O	O
(	O	O
[	O	O
Ca2+	O	O
]	O	O
i	O	O
)	O	O
that	O	O
parallels	O	O
the	O	O
activation	O	O
of	O	O
Ca2+-calmodulin-dependent	B-protein	O
protein	I-protein	O
kinase	I-protein	O
IV	I-protein	O
(	O	O
CaMKIV	B-protein	O
)	O	O
,	O	O
a	O	O
nuclear	O	O
enzyme	O	O
that	O	O
can	O	O
phosphorylate	O	O
and	O	O
activate	O	O
the	O	O
cyclic	O	O
adenosine	O	O
monophosphate	O	O
(	O	O
cAMP	O	O
)	O	O
response	O	O
element-binding	O	O
protein	O	O
(	O	O
CREB	O	O
)	O	O
.	O	O

However	O	O
,	O	O
inactivation	O	O
of	O	O
CaMKIV	O	O
occurs	O	O
despite	O	O
the	O	O
sustained	O	O
increase	O	O
in	O	O
[	O	O
Ca2+	O	O
]	O	O
i	O	O
that	O	O
is	O	O
required	O	O
for	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

A	O	O
stable	O	O
and	O	O
stoichiometric	B-protein	O
complex	I-protein	O
of	O	O
CaMKIV	O	O
with	O	O
protein	B-protein	O
serine-threonine	I-protein	O
phosphatase	I-protein	O
2A	O	O
(	O	O
PP2A	O	O
)	O	O
was	O	O
identified	O	O
in	O	O
which	O	O
PP2A	O	O
dephosphorylates	O	O
CaMKIV	O	O
and	O	O
functions	O	O
as	O	O
a	O	O
negative	O	O
regulator	O	O
of	O	O
CaMKIV	O	O
signaling	O	O
.	O	O

In	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
,	O	O
inhibition	O	O
of	O	O
PP2A	O	O
activity	O	O
by	O	O
small	O	O
t	O	O
antigen	O	O
enhanced	O	O
activation	O	O
of	O	O
CREB	B-protein	O
-mediated	O	O
transcription	O	O
by	O	O
CaMKIV	O	O
.	O	O

These	O	O
findings	O	O
reveal	O	O
an	O	O
intracellular	O	O
signaling	O	O
mechanism	O	O
whereby	O	O
a	O	O
protein	B-protein	O
serine-threonine	I-protein	O
kinase	I-protein	O
(	O	O
CaMKIV	O	O
)	O	O
is	O	O
regulated	O	O
by	O	O
a	O	O
tightly	O	O
associated	O	O
protein	O	O
serine-threonine	O	O
phosphatase	O	O
(	O	O
PP2A	B-protein	O
)	O	O
.	O	O

Hypoxia	O	O
down-regulates	O	O
MCP-1	O	O
expression	O	O
:	O	O
implications	O	O
for	O	O
macrophage	O	O
distribution	O	O
in	O	O
tumors	O	O
.	O	O

Monocyte	B-protein	O
chemoattractant	I-protein	O
protein	I-protein	O
1	O	O
(	O	O
MCP-1	O	O
)	O	O
is	O	O
likely	O	O
to	O	O
contribute	O	O
to	O	O
the	O	O
macrophage	O	O
infiltrate	O	O
in	O	O
human	O	O
ovarian	O	O
carcinomas	O	O
.	O	O

Although	O	O
MCP-1	O	O
is	O	O
predominantly	O	O
expressed	O	O
by	O	O
the	O	O
tumor	B-DNA	O
parenchyma	I-DNA	O
,	O	O
macrophages	O	O
accumulate	O	O
at	O	O
highest	O	O
density	O	O
in	O	O
necrotic	O	O
regions	O	O
,	O	O
which	O	O
are	O	O
associated	O	O
with	O	O
low	O	O
oxygen	O	O
tensions	O	O
.	O	O

Tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
alpha	I-protein	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
can	O	O
stimulate	O	O
MCP-1	O	O
production	O	O
and	O	O
is	O	O
also	O	O
present	O	O
within	O	O
ovarian	O	O
carcinomas	O	O
.	O	O

We	O	O
have	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
hypoxia	O	O
both	O	O
on	O	O
MCP-1	O	O
expression	O	O
in	O	O
ovarian	O	O
cancer	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
and	O	O
monocyte	O	O
migration	O	O
.	O	O

Hypoxia	O	O
down-regulated	O	O
TNF-alpha-induced	O	O
MCP-1	O	O
mRNA	B-RNA	O
and	O	O
protein	O	O
production	O	O
by	O	O
ovarian	B-cell_type	O
cancer	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
effect	O	O
was	O	O
mimicked	O	O
by	O	O
cobalt	O	O
chloride	O	O
and	O	O
desferrioxamine	O	O
,	O	O
consistent	O	O
with	O	O
a	O	O
specific	O	O
oxygen-sensing	O	O
mechanism	O	O
.	O	O

Unlike	O	O
antioxidants	O	O
,	O	O
hypoxia	O	O
did	O	O
not	O	O
inhibit	O	O
nuclear	B-protein	O
factor	I-protein	O
KB	O	O
mobilization	O	O
.	O	O

Monocyte	O	O
migration	O	O
in	O	O
response	O	O
to	O	O
MCP-1	O	O
was	O	O
also	O	O
diminished	O	O
under	O	O
hypoxic	O	O
conditions	O	O
.	O	O

Down-regulation	O	O
of	O	O
MCP-1	O	O
expression	O	O
and	O	O
the	O	O
inhibition	O	O
of	O	O
monocyte	O	O
migration	O	O
are	O	O
independent	O	O
effects	O	O
of	O	O
hypoxia	O	O
that	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
distribution	O	O
of	O	O
macrophages	O	O
within	O	O
ovarian	O	O
tumors	O	O
.	O	O

Activation	O	O
of	O	O
nuclear	B-protein	O
factor	I-protein	O
kappa	I-protein	O
B	I-protein	O
inflammatory	I-protein	O
bowel	O	O
disease	O	O
[	O	O
see	O	O
comments	O	O
]	O	O

BACKGROUND	O	O
:	O	O
Expression	O	O
of	O	O
pro-inflammatory	B-protein	O
cytokines	I-protein	O
is	O	O
increased	O	O
in	O	O
the	O	O
intestinal	O	O
lamina	O	O
propria	O	O
of	O	O
patients	O	O
with	O	O
inflammatory	O	O
bowel	O	O
disease	O	O
(	O	O
IBD	B-protein	O
)	O	O
.	O	O

Nuclear	B-protein	O
factor	I-protein	O
kappa	I-protein	O
B	I-protein	O
(	O	O
NF	B-protein	O
kappa	I-protein	O
B	I-protein	O
)	O	O
controls	O	O
transcription	O	O
of	O	O
inflammation	B-cell_type	O
genes	I-cell_type	O
.	O	O

On	O	O
activation	O	O
,	O	O
NF	O	O
kappa	O	O
B	I-protein	O
is	O	O
rapidly	O	O
released	O	O
from	O	O
its	O	O
cytoplasmic	O	O
inhibitor	O	O
(	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
)	O	O
,	O	O
transmigrates	O	O
into	O	O
the	O	O
nucleus	O	O
,	O	O
and	O	O
binds	O	O
to	O	O
DNA	O	O
response	O	O
elements	O	O
in	O	O
gene	B-DNA	O
promoter	I-DNA	O
regions	I-DNA	O
.	O	O

AIMS	O	O
:	O	O
To	O	O
investigate	O	O
whether	O	O
increased	O	O
activation	O	O
of	O	O
NF	B-protein	O
kappa	I-protein	O
B	I-protein	O
is	O	O
important	O	O
in	O	O
IBD	O	O
and	O	O
may	O	O
be	O	O
down-regulated	O	O
by	O	O
anti-inflammatory	O	O
treatment	O	O
.	O	O

METHODS	O	O
:	O	O
Activation	O	O
of	O	O
NF	O	O
kappa	B-DNA	O
B	I-protein	O
was	O	O
determined	O	O
by	O	O
western	O	O
blot	O	O
assessment	O	O
and	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
in	O	O
nuclear	O	O
extracts	O	O
of	O	O
colonic	O	O
biopsy	O	O
samples	O	O
as	O	O
well	O	O
as	O	O
lamina	O	O
propria	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
.	O	O

RESULTS	O	O
:	O	O
Nuclear	O	O
levels	O	O
of	O	O
NF	O	O
kappa	B-DNA	O
B	I-protein	O
p65	I-protein	O
are	O	O
increased	O	O
in	O	O
lamina	O	O
propria	O	O
biopsy	O	O
specimens	O	O
from	O	O
patients	O	O
with	O	O
Crohn	O	O
's	O	O
disease	O	O
in	O	O
comparison	O	O
with	O	O
patients	O	O
with	O	O
ulcerative	O	O
colitis	O	O
and	O	O
controls	O	O
.	O	O

Increased	O	O
activation	O	O
of	O	O
NF	O	O
kappa	B-DNA	O
B	I-DNA	O
was	O	O
detected	O	O
in	O	O
lamina	O	O
propria	O	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
from	O	O
patients	O	O
with	O	O
active	O	O
IBD	O	O
.	O	O

Corticosteroids	O	O
strongly	O	O
inhibit	O	O
intestinal	O	O
NF	O	O
kappa	O	O
B	O	O
activation	O	O
in	O	O
IBD	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
by	O	O
stabilising	O	O
the	O	O
cytosolic	O	O
inhibitor	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
against	O	O
activation	O	O
induced	O	O
degradation	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
both	O	O
IBDs	O	O
,	O	O
but	O	O
particularly	O	O
Crohn	O	O
's	O	O
disease	O	O
,	O	O
increased	O	O
activation	O	O
of	O	O
NF	B-protein	O
kappa	I-protein	O
B	I-protein	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
the	O	O
inflammatory	O	O
response	O	O
.	O	O

Inhibition	O	O
of	O	O
NF	B-protein	O
kappa	I-protein	O
B	I-protein	O
activation	O	O
may	O	O
represent	O	O
a	O	O
mechanism	O	O
by	O	O
which	O	O
steroids	O	O
exert	O	O
an	O	O
anti-inflammatory	O	O
effect	O	O
in	O	O
IBD	O	O

Insufficient	O	O
glycemic	O	O
control	O	O
increases	O	O
nuclear	B-protein	O
factor-kappa	I-protein	O
B	I-protein	O
binding	O	O
activity	O	O
in	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
isolated	O	O
from	O	O
patients	O	O
with	O	O
type	O	O
1	O	O
diabetes	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
redox-sensitive	O	O
transcription	B-protein	O
factor	I-protein	O
nuclear	B-protein	O
factor-kappa	I-protein	O
B	I-protein	O
(	O	O
NF-kappa	B-protein	O
B	I-protein	O
)	O	O
is	O	O
believed	O	O
to	O	O
contribute	O	O
to	O	O
late	O	O
diabetic	O	O
complications	O	O
.	O	O

It	O	O
is	O	O
unknown	O	O
whether	O	O
NF-kappa	B-protein	O
B	I-protein	O
is	O	O
influenced	O	O
by	O	O
glycemic	O	O
control	O	O
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
:	O	O
To	O	O
determine	O	O
whether	O	O
NF-kappa	B-protein	O
B	I-protein	O
is	O	O
activated	O	O
in	O	O
patients	O	O
with	O	O
insufficient	O	O
glycemic	O	O
control	O	O
(	O	O
HbA1c	O	O
>	O	O
10	O	O
%	O	O
)	O	O
,	O	O
we	O	O
developed	O	O
a	O	O
tissue	O	O
culture-independent	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
(	O	O
EMSA	O	O
)	O	O
-based	O	O
semiquantitative	O	O
detection	O	O
system	O	O
that	O	O
allowed	O	O
us	O	O
to	O	O
determine	O	O
NF-kappa	O	O
B	O	O
activation	O	O
in	O	O
ex	O	O
vivo-isolated	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
(	O	O
PBMCs	O	O
)	O	O
.	O	O

We	O	O
included	O	O
43	O	O
patients	O	O
with	O	O
type	O	O
1	O	O
diabetes	O	O
in	O	O
this	O	O
cross-sectional	O	O
study	O	O
.	O	O

10	O	O
of	O	O
those	O	O
received	O	O
the	O	O
antioxidant	O	O
thioctic	O	O
acid	O	O
(	O	O
600	O	O
mg/day	O	O
p.o.	O	O
)	O	O
for	O	O
2	O	O
weeks	O	O
.	O	O

RESULTS	O	O
:	O	O
Monocytes	O	O
of	O	O
patients	O	O
with	O	O
HbA1c	O	O
levels	O	O
>	O	O
10	O	O
%	O	O
demonstrated	O	O
significantly	O	O
higher	O	O
NF-kappa	B-protein	O
B	I-protein	O
binding	O	O
activity	O	O
in	O	O
an	O	O
EMSA	O	O
and	O	O
a	O	O
stronger	O	O
NF-kappa	B-protein	O
B	I-protein	O
staining	O	O
in	O	O
immunohistochemistry	O	O
than	O	O
monocytes	B-cell_type	O
of	O	O
patients	O	O
with	O	O
HbA1c	O	O
levels	O	O
of	O	O
6-8	O	O
%	O	O
.	O	O

The	O	O
increase	O	O
in	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
correlated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
plasmatic	O	O
markers	O	O
of	O	O
lipid	O	O
peroxidation	O	O
.	O	O

Treatment	O	O
with	O	O
the	O	O
antioxidant	O	O
thioctic	O	O
acid	O	O
decreased	O	O
NF-kappa	B-protein	O
B	I-protein	O
binding	O	O
activity	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Hyperglycemia	O	O
induces	O	O
activation	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappa	B-protein	O
B	I-protein	O
in	O	O
ex	O	O
vivo-isolated	O	O
PBMCs	O	O
of	O	O
patients	O	O
with	O	O
type	O	O
1	O	O
diabetes	O	O
.	O	O

NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
is	O	O
at	O	O
least	O	O
partially	O	O
dependent	O	O
on	O	O
oxidative	O	O
stress	O	O
,	O	O
since	O	O
the	O	O
antioxidant	O	O
thioctic	O	O
acid	O	O
significantly	O	O
lowered	O	O
the	O	O
extent	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
binding	O	O
activity	O	O
.	O	O

Synergistic	O	O
activation	O	O
of	O	O
MAP	B-protein	O
kinase	I-protein	O
(	O	O
ERK1/2	O	O
)	O	O
by	O	O
erythropoietin	O	O
and	O	O
stem	B-protein	O
cell	I-protein	O
factor	I-protein	O
is	O	O
essential	O	O
for	O	O
expanded	O	O
erythropoiesis	O	O
.	O	O

Stem	B-protein	O
cell	I-protein	O
factor	I-protein	O
(	O	O
SCF	B-protein	O
)	O	O
and	O	O
erythropoietin	O	O
(	O	O
EPO	O	O
)	O	O
work	O	O
synergistically	O	O
to	O	O
support	O	O
erythropoiesis	O	O
,	O	O
but	O	O
the	O	O
mechanism	O	O
for	O	O
this	O	O
synergism	O	O
is	O	O
unknown	O	O
.	O	O

By	O	O
using	O	O
purified	O	O
human	B-cell_line	O
erythroid	I-cell_line	O
colony-forming	I-cell_line	O
cells	I-cell_line	O
(	O	O
ECFC	O	O
)	O	O
,	O	O
we	O	O
have	O	O
found	O	O
that	O	O
SCF	O	O
and	O	O
EPO	O	O
synergistically	O	O
activate	O	O
MAP	B-protein	O
kinase	I-protein	O
(	O	O
MAPK	O	O
,	O	O
ERK1/2	O	O
)	O	O
,	O	O
which	O	O
correlates	O	O
with	O	O
the	O	O
cell	O	O
growth	O	O
and	O	O
thus	O	O
may	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
synergistic	O	O
effects	O	O
.	O	O

Treatment	O	O
of	O	O
the	O	O
cells	O	O
with	O	O
PD98059	B-protein	O
and	O	O
wortmannin	O	O
,	O	O
inhibitors	O	O
of	O	O
MEK	B-protein	O
and	I-protein	O
PI-3	I-protein	O
kinase	I-protein	O
,	O	O
respectively	O	O
,	O	O
inhibited	O	O
the	O	O
synergistic	O	O
activation	O	O
of	O	O
MAPK	O	O
and	O	O
also	O	O
the	O	O
cell	O	O
growth	I-protein	O
,	O	O
further	O	O
supporting	O	O
this	O	O
conclusion	O	O
.	O	O

Wortmannin	O	O
only	O	O
inhibits	O	O
MAPK	O	O
activation	O	O
induced	O	O
by	O	O
EPO	O	O
but	O	O
not	O	O
that	O	O
by	O	O
SCF	O	O
,	O	O
suggesting	O	O
that	O	O
SCF	O	O
and	O	O
EPO	O	O
may	O	O
activate	O	O
MAPK	O	O
through	O	O
different	O	O
pathways	O	O
,	O	O
which	O	O
would	O	O
facilitate	O	O
synergy	O	O
.	O	O

Furthermore	O	O
,	O	O
EPO	O	O
,	O	O
but	O	O
not	O	O
SCF	O	O
,	O	O
led	O	O
to	O	O
activation	O	O
of	O	O
STAT5	O	O
,	O	O
whereas	O	O
SCF	O	O
and	O	O
wortmannin	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
EPO	O	O
-induced	O	O
STAT5	O	O
activation	O	O
,	O	O
suggesting	O	O
that	O	O
STAT5	O	O
is	O	O
not	O	O
involved	O	O
in	O	O
the	O	O
synergistic	O	O
action	O	O
of	O	O
SCF	O	O
and	O	O
EPO	O	O
.	O	O

Together	O	O
,	O	O
the	O	O
data	O	O
suggest	O	O
that	O	O
synergistic	O	O
activation	O	O
of	O	O
MAPK	O	O
by	O	O
SCF	O	O
and	O	O
EPO	O	O
is	O	O
essential	O	O
for	O	O
expanded	O	O
erythropoiesis	O	O
.	O	O

Copyright	O	O
1998	O	O
by	O	O
The	O	O
American	O	O
Society	O	O
of	O	O
Hematology	O	O
.	O	O

The	O	O
molecular	O	O
and	O	O
phenotypic	O	O
profile	O	O
of	O	O
primary	O	O
central	O	O
nervous	O	O
system	O	O
lymphoma	O	O
identifies	O	O
distinct	O	O
categories	O	O
of	O	O
the	O	O
disease	B-DNA	O
and	O	O
is	O	O
consistent	O	O
with	O	O
histogenetic	O	O
derivation	O	O
from	O	O
germinal	O	O
center-related	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

Primary	O	O
central	O	O
nervous	O	O
system	O	O
lymphoma	O	O
(	O	O
PCNSL	O	O
)	O	O
is	O	O
a	O	O
major	O	O
cause	O	O
of	O	O
morbidity	O	O
and	O	O
mortality	O	O
among	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
(	O	O
HIV	O	O
)	O	O
-infected	O	O
individuals	O	O
.	O	O

The	O	O
precise	O	O
histogenetic	O	O
derivation	O	O
and	O	O
the	O	O
molecular	O	O
pathogenesis	O	O
of	O	O
PCNSL	O	O
is	O	O
poorly	O	O
understood	O	O
.	O	O

In	O	O
an	O	O
attempt	O	O
to	O	O
clarify	O	O
the	O	O
histogenesis	O	O
and	O	O
pathogenesis	O	O
of	O	O
these	O	O
lymphomas	O	O
,	O	O
49	O	O
PCNSL	O	O
(	O	O
26	O	O
acquired	O	O
immunodeficiency	O	O
syndrome	O	O
[	O	O
AIDS	O	O
]	O	O
-related	O	O
and	O	O
23	O	O
AIDS-unrelated	O	O
)	O	O
were	O	O
analyzed	O	O
for	O	O
multiple	O	O
biologic	O	O
markers	O	O
,	O	O
which	O	O
are	O	O
known	O	O
to	O	O
bear	O	O
histogenetic	O	O
and	O	O
pathogenetic	O	O
significance	O	O
for	O	O
mature	O	O
B-cell	O	O
neoplasms	O	O
.	O	O

PCNSL	O	O
associated	O	O
frequently	O	O
(	O	O
50.0	O	O
%	O	O
)	O	O
with	O	O
mutations	O	O
of	O	O
BCL-6	O	O
5	O	O
'	O	O
noncoding	O	O
regions	O	O
,	O	O
which	O	O
are	O	O
regarded	O	O
as	O	O
a	O	O
marker	O	O
of	O	O
B-cell	O	O
transition	O	O
through	O	O
the	O	O
germinal	B-protein	O
center	I-protein	O
(	O	O
GC	B-protein	O
)	O	O
.	O	O

Expression	O	O
of	O	O
BCL-6	B-protein	O
protein	I-protein	O
,	O	O
which	O	O
is	O	O
restricted	O	O
to	O	O
GC	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
throughout	O	O
physiologic	O	O
B-cell	O	O
maturation	O	O
,	O	O
was	O	O
detected	O	O
in	O	O
100	O	O
%	O	O
AIDS-unrelated	O	O
PCNSL	O	O
and	O	O
in	O	O
56.2	O	O
%	O	O
AIDS-related	O	O
cases	O	O
.	O	O

Notably	O	O
,	O	O
among	O	O
AIDS-related	O	O
PCNSL	O	O
,	O	O
expression	O	O
of	O	O
BCL-6	O	O
was	O	O
mutually	O	O
exclusive	O	O
with	O	O
expression	O	O
of	O	O
Epstein-Barr	B-protein	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
-encoded	O	O
latent	O	O
membrane	O	O
protein	O	O
(	O	O
LMP	O	O
)	O	O
-1	O	O
and	O	O
,	O	O
with	O	O
few	O	O
exceptions	O	O
,	O	O
also	O	O
of	O	O
BCL-2	O	O
.	O	O

All	O	O
but	O	O
one	O	O
PCNSL	O	O
expressed	O	O
hMSH2	O	O
,	O	O
which	O	O
among	O	O
mature	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
selectively	O	O
stains	O	O
GC	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
PCNSL	O	O
may	O	O
be	O	O
frequently	O	O
related	O	O
to	O	O
GC	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
and	O	O
may	O	O
be	O	O
segregated	O	O
into	O	O
two	O	O
major	O	O
biologic	O	O
categories	O	O
based	O	O
on	O	O
the	O	O
expression	O	O
pattern	O	O
of	O	O
BCL-6	O	O
,	O	O
LMP-1	O	O
,	O	O
and	O	O
BCL-2	O	O
.	O	O

BCL-6	O	O
(	O	O
+	O	O
)	O	O
/	O	O
LMP-1	O	O
(	O	O
-	O	O
)	O	O
/	O	O
BCL-2	O	O
(	O	O
-	O	O
)	O	O
PCNSL	O	O
occur	O	O
both	O	O
in	O	O
the	O	O
presence	O	O
and	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
HIV	B-protein	O
infection	O	O
and	O	O
consistently	O	O
display	O	O
a	O	O
large	O	O
noncleaved	O	O
cell	O	O
morphology	O	O
.	O	O

Conversely	O	O
,	O	O
BCL-6	O	O
(	O	O
-	O	O
)	O	O
/	O	O
LMP-1	O	O
(	O	O
+	O	O
)	O	O
/	O	O
BCL-2	O	O
(	O	O
+	O	O
)	O	O
PCNSL	O	O
are	O	O
restricted	O	O
to	O	O
HIV-infected	O	O
hosts	O	O
and	O	O
are	O	O
represented	O	O
by	O	O
lymphomas	O	O
with	O	O
immunoblastic	O	O
features	O	O
.	O	O

These	O	O
data	O	O
are	O	O
relevant	O	O
for	O	O
the	O	O
pathogenesis	O	O
and	O	O
histogenesis	O	O
of	O	O
PCNSL	O	O
and	O	O
may	O	O
be	O	O
helpful	O	O
to	O	O
segregate	O	O
distinct	O	O
biologic	O	O
and	O	O
prognostic	O	O
categories	O	O
of	O	O
these	O	O
lymphomas	O	O
.	O	O

Copyright	O	O
1998	O	O
by	O	O
The	O	O
American	O	O
Society	O	O
of	O	O
Hematology	O	O
.	O	O

Antioxidant	O	O
regulation	O	O
of	O	O
phorbol	O	O
ester-induced	O	O
adhesion	O	O
of	O	O
human	B-cell_line	O
Jurkat	I-cell_line	O
T-cells	I-cell_line	O
to	I-cell_line	O
endothelial	I-cell_line	O
cells	I-cell_line	O
.	O	O

Regulation	O	O
of	O	O
adhesion	B-protein	O
molecule	I-protein	O
expression	O	O
and	O	O
function	O	O
by	O	O
reactive	O	O
oxygen	O	O
species	O	O
via	O	O
specific	O	O
redox	O	O
sensitive	O	O
mechanisms	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
clinically	O	O
safe	O	O
antioxidants	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
adhesion	O	O
molecule	O	O
expression	O	O
in	O	O
human	B-cell_line	O
endothelial	I-cell_line	O
cells	I-cell_line	O
(	O	O
ECV	O	O
)	O	O
,	O	O
and	O	O
adherence	O	O
of	O	O
human	B-cell_line	O
Jurkat	I-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
to	O	O
ECV	B-cell_type	O
cells	I-cell_type	O
were	O	O
investigated	O	O
.	O	O

The	O	O
thiol	O	O
antioxidant	O	O
,	O	O
alpha-lipoate	O	O
,	O	O
at	O	O
clinically	O	O
relevant	O	O
doses	O	O
down-regulated	O	O
phorbol	O	O
12-myristate	O	O
13-acetate	O	O
(	O	O
PMA	O	O
)	O	O
-induced	O	O
adhesion	O	O
molecule	O	O
expression	O	O
and	O	O
cell-cell	O	O
adhesion	O	O
.	O	O

Inhibition	O	O
of	O	O
PMA-induced	O	O
ICAM-1	B-protein	O
and	O	O
VCAM-1	B-protein	O
expression	O	O
as	O	O
well	O	O
as	O	O
PMA-induced	O	O
adhesion	O	O
of	O	O
Jurkat	O	O
T-cells	O	O
to	O	O
ECV	B-cell_type	O
cells	I-cell_type	O
by	O	O
alpha-lipoate	O	O
was	O	O
dose	O	O
dependent	O	O
(	O	O
50-250	O	O
microM	O	O
)	O	O
.	O	O

The	O	O
effect	O	O
was	O	O
significant	O	O
for	O	O
ICAM-1	O	O
(	O	O
p	O	O
<	I-protein	O
.01	I-protein	O
)	O	O
and	O	O
VCAM-1	B-protein	O
(	O	O
p	O	O
<	O	O
.01	O	O
)	O	O
expression	O	O
in	O	O
cells	O	O
pretreated	O	O
with	O	O
100	O	O
microM	O	O
alpha-lipoate	O	O
compared	O	O
to	O	O
PMA-activated	O	O
untreated	O	O
cells	O	O
.	O	O

Inhibition	O	O
of	O	O
PMA-induced	O	O
adhesion	B-protein	O
molecule	I-protein	O
expression	O	O
and	O	O
cell-cell	O	O
adhesion	O	O
was	O	O
more	O	O
pronounced	O	O
when	O	O
a	O	O
combination	O	O
of	O	O
antioxidants	O	O
,	O	O
alpha-lipoate	O	O
and	O	O
alpha-tocopherol	O	O
,	O	O
were	O	O
used	O	O
compared	O	O
to	O	O
the	O	O
use	O	O
of	O	O
either	O	O
of	O	O
these	O	O
antioxidant	O	O
alone	O	O
.	O	O

The	O	O
regulation	O	O
of	O	O
adhesion	B-protein	O
molecule	I-protein	O
expression	O	O
and	O	O
function	O	O
by	O	O
low	O	O
concentration	O	O
of	O	O
antioxidants	O	O
investigated	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
NF-kappaB	O	O
regulated	O	O
or	O	O
transcription	O	O
dependent	O	O
because	O	O
no	O	O
change	O	O
in	O	O
the	O	O
mRNA	B-RNA	O
response	O	O
was	O	O
observed	O	O
.	O	O

Protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
(	O	O
PKC	O	O
)	O	O
has	O	O
been	O	O
suggested	O	O
to	O	O
regulate	O	O
PMA-induced	O	O
adhesion	O	O
molecule	O	O
expression	O	O
by	O	O
post-transcriptional	O	O
stabilization	O	O
of	O	O
adhesion	B-protein	O
molecule	I-protein	O
mRNA	I-RNA	O
.	O	O

Alpha-lipoate	O	O
pretreatment	O	O
did	O	O
not	O	O
influence	O	O
the	O	O
response	O	O
of	O	O
PKC	O	O
activity	O	O
to	O	O
PMA	O	O
.	O	O

Oxidants	O	O
are	O	O
known	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
cell	O	O
adhesion	O	O
processes	O	O
.	O	O

Treatment	O	O
of	O	O
ECV	B-cell_type	O
cells	I-cell_type	O
with	O	O
PMA	O	O
induced	O	O
generation	O	O
of	O	O
intracellular	O	O
oxidants	O	O
.	O	O

Alpha-lipoate	O	O
(	O	O
100	O	O
or	O	O
250	O	O
microM	O	O
)	O	O
treatment	O	O
decreased	O	O
PMA-induced	O	O
generation	O	O
of	O	O
intracellular	O	O
oxidants	O	O
.	O	O

The	O	O
inhibitory	O	O
effect	O	O
of	O	O
low	O	O
concentration	O	O
of	O	O
alpha-lipaote	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
alpha-tocopherol	O	O
on	O	O
agonist-induced	O	O
adhesion	O	O
processes	O	O
observed	O	O
in	O	O
this	O	O
study	O	O
may	O	O
be	O	O
of	O	O
potential	O	O
therapeutic	O	O
value	O	O
.	O	O

Binding	O	O
of	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
to	O	O
CD4	B-protein	O
and	O	O
CXCR4	B-protein	O
receptors	I-protein	O
differentially	O	O
regulates	O	O
expression	O	O
of	O	O
inflammatory	B-DNA	O
genes	I-DNA	O
and	O	O
activates	O	O
the	O	O
MEK	O	O
/ERK	O	O
signaling	O	O
pathway	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
shown	O	O
that	O	O
binding	O	O
of	O	O
human	B-protein	O
immunodeficiency	I-protein	O
virus	I-protein	O
type	I-protein	O
1	I-protein	O
(	O	O
HIV-1	B-protein	O
)	O	O
virions	O	O
to	O	O
CD4	B-protein	O
receptors	I-protein	O
stimulates	O	O
association	O	O
of	O	O
Lck	O	O
with	O	O
Raf-1	B-protein	O
and	O	O
results	O	O
in	O	O
the	O	O
activation	O	O
of	O	O
Raf-1	B-protein	O
kinase	I-protein	O
in	O	O
a	O	O
Ras-independent	O	O
manner	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
HIV-1	O	O
envelope	O	O
glycoproteins	O	O
of	O	O
both	O	O
T-cell-tropic	O	O
and	O	O
macrophagetropic	O	O
strains	O	O
rapidly	O	O
activate	O	O
the	O	O
ERK/mitogen-activated	B-protein	O
protein	I-protein	O
(	O	O
MAP	B-protein	O
)	O	O
kinase	I-protein	O
pathway	O	O
and	O	O
the	O	O
binding	O	O
of	O	O
nuclear	B-protein	O
transcription	B-protein	O
factors	I-protein	O
(	O	O
AP-1	B-protein	O
,	O	O
NF-kappaB	O	O
,	O	O
and	O	O
C/EBP	O	O
)	O	O
and	O	O
stimulate	O	O
expression	O	O
of	O	O
cytokine	B-protein	O
and	O	O
chemokine	O	O
genes	O	O
.	O	O

The	O	O
activation	O	O
of	O	O
this	O	O
signaling	O	O
pathway	O	O
requires	O	O
functional	O	O
CD4	B-protein	O
receptors	I-protein	O
and	O	O
is	O	O
independent	O	O
of	O	O
binding	O	O
to	O	O
CXCR4	O	O
.	O	O

Binding	O	O
of	O	O
the	O	O
natural	O	O
ligand	I-protein	O
stromal	I-protein	O
cell-derived	I-protein	O
factor	I-protein	O
1	O	O
(	O	O
SDF-1	O	O
)	O	O
to	O	O
CXCR4	O	O
,	O	O
which	O	O
inhibits	O	O
entry	O	O
of	O	O
T-cell-tropic	O	O
HIV-1	O	O
,	O	O
activates	O	O
also	O	O
the	O	O
ERK/	B-protein	O
MAP	I-protein	O
kinase	I-protein	O
pathway	O	O
.	O	O

However	O	O
,	O	O
SDF-1	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
CD4-mediated	O	O
expression	O	O
of	O	O
cytokine	B-protein	O
and	O	O
chemokine	O	O
genes	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
firm	O	O
molecular	O	O
evidence	O	O
that	O	O
binding	O	O
of	O	O
HIV-1	O	O
envelope	O	O
glycoproteins	O	O
to	O	O
CD4	B-protein	O
receptor	I-protein	O
initiates	O	O
a	O	O
signaling	O	O
pathway	O	O
(	O	O
s	O	O
)	O	O
independent	O	O
of	O	O
the	O	O
binding	O	O
to	O	O
the	O	O
chemokine	B-protein	O
receptor	I-protein	O
that	O	O
leads	O	O
to	O	O
the	O	O
aberrant	O	O
expression	O	O
of	O	O
inflammatory	B-DNA	O
genes	I-DNA	O
and	O	O
may	O	O
contribute	O	O
significantly	O	O
to	O	O
HIV-1	O	O
replication	O	O
as	O	O
well	O	O
as	O	O
to	O	O
deregulation	O	O
of	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

Antigen	O	O
receptor	O	O
signaling	O	O
induces	O	O
MAP	O	O
kinase-mediated	O	O
phosphorylation	O	O
and	O	O
degradation	O	O
of	O	O
the	O	O
BCL-6	B-protein	O
transcription	I-protein	O
factor	I-protein	O
.	O	O

The	O	O
bcl-6	O	O
proto-oncogene	O	O
encodes	O	O
a	O	O
POZ/zinc	O	O
finger	O	O
transcriptional	O	O
repressor	O	O
expressed	O	O
in	O	O
germinal	O	O
center	O	O
(	O	O
GC	O	O
)	O	O
B	I-cell_type	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
required	O	O
for	O	O
GC	O	O
formation	O	O
and	O	O
antibody	O	O
affinity	O	O
maturation	O	O
.	O	O

Deregulation	O	O
of	O	O
bcl-6	O	O
expression	O	O
by	O	O
chromosomal	O	O
rearrangements	O	O
and	O	O
point	O	O
mutations	O	O
of	O	O
the	O	O
bcl-6	B-DNA	O
promoter	I-DNA	O
region	I-DNA	O
are	O	O
implicated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
B-cell	O	O
lymphoma	O	O
.	O	O

The	O	O
signals	O	O
regulating	O	O
bcl-6	O	O
expression	O	O
are	O	O
not	O	O
known	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
antigen	B-protein	O
receptor	I-protein	O
activation	O	O
leads	O	O
to	O	O
BCL-6	O	O
phosphorylation	O	O
by	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
(	O	O
MAPK	O	O
)	O	O
.	O	O

Phosphorylation	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
targets	O	O
BCL-6	O	O
for	O	O
rapid	O	O
degradation	O	O
by	O	O
the	O	O
ubiquitin	O	O
/	O	O
proteasome	O	O
pathway	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
BCL-6	O	O
expression	O	O
is	O	O
directly	O	O
controlled	O	O
by	O	O
the	O	O
antigen	B-protein	O
receptor	I-protein	O
via	O	O
MAPK	O	O
activation	O	O
.	O	O

This	O	O
signaling	O	O
pathway	O	O
may	O	O
be	O	O
crucial	O	O
for	O	O
the	O	O
control	O	O
of	O	O
B-cell	O	O
differentiation	O	O
and	O	O
antibody	O	O
response	O	O
and	O	O
has	O	O
implications	O	O
for	O	O
the	O	O
regulation	O	O
of	O	O
other	O	O
POZ/zinc	O	O
finger	O	O
transcription	B-protein	O
factors	I-protein	O
in	O	O
other	O	O
tissues	O	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
are	O	O
differentially	O	O
expressed	O	O
in	O	O
the	O	O
cells	O	O
and	O	O
tissues	O	O
of	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

Cytosolic	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
binding	O	O
studies	O	O
on	O	O
immune	O	O
tissues	O	O
demonstrate	O	O
that	O	O
the	O	O
thymus	O	O
exhibits	O	O
three	O	O
to	O	O
four	O	O
times	O	O
higher	O	O
levels	O	O
of	O	O
GR	B-protein	O
protein	I-protein	O
than	O	O
the	O	O
spleen	O	O
.	O	O

High	O	O
levels	O	O
of	O	O
GR	B-protein	O
are	O	O
consistent	O	O
with	O	O
the	O	O
exquisite	O	O
sensitivity	O	O
of	O	O
the	O	O
thymus	O	O
to	O	O
glucocorticoid	O	O
exposure	O	O
.	O	O

Nevertheless	O	O
,	O	O
whole	O	O
cell	O	O
binding	O	O
studies	O	O
reveal	O	O
similar	O	O
levels	O	O
of	O	O
GR	B-protein	O
in	O	O
immature	B-cell_line	O
thymic	I-cell_line	O
T	I-cell_line	O
lymphocytes	I-cell_type	O
and	O	O
more	O	O
mature	B-cell_type	O
,	O	O
splenic	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Moreover	O	O
,	O	O
whole	O	O
cell	O	O
binding	O	O
techniques	O	O
indicate	O	O
that	O	O
neutrophils	O	O
(	O	O
which	O	O
represent	O	O
roughly	O	O
30	O	O
%	O	O
of	O	O
splenic	O	O
leukocytes	O	O
)	O	O
exhibit	O	O
higher	O	O
GR	O	O
than	O	O
both	O	O
T	B-cell_type	O
and	I-cell_type	O
B	I-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
further	O	O
contradicting	O	O
results	O	O
from	O	O
cytosolic	O	O
binding	O	O
studies	O	O
.	O	O

To	O	O
address	O	O
these	O	O
inconsistencies	O	O
,	O	O
GR	B-protein	O
protein	O	O
was	O	O
assessed	O	O
in	O	O
immune	B-cell_type	O
cells	I-cell_type	O
and	O	O
tissues	O	O
using	O	O
cytosolic	O	O
radioligand	O	O
binding	O	O
.	O	O

Western	O	O
blot	O	O
analysis	O	O
,	O	O
and	O	O
immunocytochemistry	O	O
.	O	O

Consistent	O	O
with	O	O
previous	O	O
cytosolic	B-protein	O
receptor	I-protein	O
binding	O	O
studies	O	O
on	O	O
immune	O	O
tissue	O	O
homogenates	O	O
,	O	O
thymic	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
found	O	O
to	O	O
have	O	O
higher	O	O
levels	O	O
of	O	O
GR	B-cell_line	O
than	O	O
T	B-cell_type	O
cells	I-cell_type	O
isolated	O	O
from	O	O
the	O	O
spleen	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
neutrophils	O	O
were	O	O
found	O	O
to	O	O
have	O	O
fewer	O	O
GR	O	O
than	O	O
lymphocytes	I-cell_type	O
and	O	O
monocytes	B-cell_type	O
.	O	O

These	O	O
results	O	O
indicate	O	O
a	O	O
meaningful	O	O
relationship	O	O
between	O	O
receptor	O	O
expression	O	O
and	O	O
known	O	O
sensitivity	O	O
to	O	O
glucocorticoids	O	O
.	O	O

Functional	O	O
replacement	O	O
of	O	O
the	O	O
mouse	B-DNA	O
E2A	I-DNA	O
gene	I-DNA	O
with	O	O
a	O	O
human	B-protein	O
HEB	I-protein	O
cDNA	I-protein	O
.	O	O

The	O	O
mammalian	O	O
E2A	O	O
,	O	O
HEB	O	O
,	O	O
and	O	O
E2-2	O	O
genes	O	O
encode	O	O
a	O	O
unique	O	O
class	O	O
of	O	O
basic	B-protein	O
helix-loop-helix	I-protein	O
(	O	O
bHLH	B-protein	O
)	O	O
transcription	B-protein	O
factors	I-protein	O
that	O	O
are	O	O
evolutionarily	O	O
conserved	O	O
and	O	O
essential	O	O
for	O	O
embryonic	O	O
and	O	O
postnatal	O	O
development	O	O
.	O	O

While	O	O
the	O	O
structural	B-DNA	O
and	I-DNA	O
functional	I-DNA	O
similarities	I-DNA	O
among	O	O
the	O	O
gene	B-DNA	O
products	I-DNA	O
are	O	O
well	O	O
demonstrated	O	O
,	O	O
it	O	O
is	O	O
not	O	O
clear	O	O
why	O	O
deletion	O	O
of	O	O
E2A	B-protein	O
,	O	O
but	O	O
not	O	O
HEB	O	O
or	O	O
E2-2	O	O
,	O	O
leads	O	O
to	O	O
a	O	O
complete	O	O
arrest	O	O
in	O	O
B-lymphocyte	O	O
development	O	O
.	O	O

To	O	O
understand	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
the	O	O
functional	O	O
specificity	O	O
between	O	O
E2A	O	O
and	O	O
HEB	O	O
/	O	O
E2-2	O	O
in	O	O
mammalian	O	O
development	O	O
,	O	O
we	O	O
generated	O	O
and	O	O
tested	O	O
a	O	O
panel	O	O
of	O	O
E2A	O	O
knockin	O	O
mutations	O	O
including	O	O
subtle	O	O
mutations	O	O
in	O	O
the	O	O
E12	O	O
and	O	O
E47	O	O
exons	O	O
and	O	O
substitution	O	O
of	O	O
both	O	O
E12	O	O
and	O	O
E47	O	O
exons	O	O
with	O	O
a	O	O
human	O	O
HEB	I-protein	O
cDNA	I-protein	O
.	O	O

We	O	O
find	O	O
that	O	O
the	O	O
alternatively	O	O
spliced	O	O
E12	O	O
and	O	O
E47	O	O
bHLH	O	O
proteins	O	O
of	O	O
the	O	O
E2A	B-DNA	O
gene	I-DNA	O
play	O	O
similar	O	O
and	O	O
additive	O	O
roles	O	O
in	O	O
supporting	O	O
B	O	O
lymphopoiesis	O	O
.	O	O

Further	O	O
,	O	O
we	O	O
find	O	O
that	O	O
HEB	O	O
driven	O	O
by	O	O
the	O	O
endogenous	O	O
E2A	O	O
promoter	I-DNA	O
can	O	O
functionally	O	O
replace	O	O
E2A	O	O
in	O	O
supporting	O	O
B-cell	O	O
commitment	O	O
and	O	O
differentiation	O	O
toward	O	O
completion	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
postnatal	O	O
lethality	O	O
associated	O	O
with	O	O
E2A	O	O
disruption	O	O
is	O	O
fully	O	O
rescued	O	O
by	O	O
the	O	O
addition	O	O
of	O	O
HEB	O	O
.	O	O

This	O	O
study	O	O
suggests	O	O
that	O	O
the	O	O
functional	O	O
divergence	O	O
among	O	O
E12	O	O
,	O	O
E47	O	O
,	O	O
and	O	O
HEB	O	O
in	O	O
different	O	O
cell	O	O
types	O	O
is	O	O
partially	O	O
defined	O	O
by	O	O
the	O	O
context	O	O
of	O	O
gene	O	O
expression	O	O
.	O	O

Biased	O	O
dependency	O	O
of	O	O
CD80	O	O
versus	O	O
CD86	O	O
in	O	O
the	O	O
induction	O	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
regulating	O	O
the	O	O
human	B-DNA	O
IL-2	I-DNA	O
promoter	I-DNA	O
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
signals	O	O
obtained	O	O
by	O	O
ligation	O	O
of	O	O
the	O	O
TCR	B-protein	O
,	O	O
T	B-cell_type	O
cells	I-cell_type	O
need	O	O
additional	O	O
,	O	O
co-stimulatory	O	O
signals	O	O
to	O	O
be	O	O
activated	O	O
.	O	O

One	O	O
such	O	O
co-stimulatory	O	O
signal	O	O
is	O	O
delivered	O	O
when	O	O
CD28	O	O
on	O	O
T	B-cell_type	O
cells	I-cell_type	O
binds	O	O
to	O	O
CD80	O	O
or	O	O
CD86	O	O
on	O	O
antigen-presenting	O	O
cells	O	O
(	O	O
APC	O	O
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
analyzed	O	O
the	O	O
ability	O	O
of	O	O
CD80	O	O
and	O	O
CD86	O	O
to	O	O
co-stimulate	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
activated	O	O
by	O	O
superantigen	O	O
.	O	O

Using	O	O
the	O	O
Raji	B-DNA	O
B	I-DNA	O
cell	O	O
lymphoma	O	O
,	O	O
which	O	O
express	O	O
similar	O	O
levels	O	O
of	O	O
CD80	O	O
and	O	O
CD86	O	O
,	O	O
it	O	O
was	O	O
found	O	O
that	O	O
T	O	O
cell	O	O
proliferation	O	O
was	O	O
mainly	O	O
co-stimulated	O	O
by	O	O
CD80	O	O
.	O	O

To	O	O
further	O	O
characterize	O	O
the	O	O
consequences	O	O
of	O	O
this	O	O
biased	O	O
co-stimulatory	O	O
dependency	O	O
,	O	O
we	O	O
employed	O	O
a	O	O
well-defined	O	O
system	O	O
of	O	O
transfected	B-cell_line	O
CHO	B-cell_type	O
cells	I-cell_type	O
expressing	O	O
human	O	O
MHC	I-protein	O
class	O	O
II	O	O
together	O	O
with	O	O
CD80	O	O
,	O	O
CD86	O	O
or	O	O
CD80	O	O
and	O	O
CD86	O	O
.	O	O

Proliferation	O	O
of	O	O
freshly	O	O
prepared	B-cell_line	O
CD4+	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
required	O	O
the	O	O
presence	O	O
of	O	O
either	O	O
CD80	O	O
or	O	O
CD86	O	O
.	O	O

However	O	O
,	O	O
IL-2	B-protein	O
production	O	O
reached	O	O
only	O	O
suboptimal	O	O
levels	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
CD86	O	O
but	O	O
optimal	O	O
levels	O	O
with	O	O
CD80	O	O
.	O	O

To	O	O
analyze	O	O
IL-2	B-protein	O
transcriptional	O	O
activity	O	O
in	O	O
CD80	O	O
and	O	O
CD86	O	O
co-stimulated	O	O
T	B-cell_type	O
cells	I-cell_type	O
we	O	O
used	O	O
Jurkat	O	O
T	B-cell_type	O
cells	I-cell_type	O
transfected	O	O
with	O	O
luciferase	B-DNA	O
reporter	I-DNA	O
gene	I-DNA	O
constructs	I-DNA	O
.	O	O

CD80	O	O
induced	O	O
higher	O	O
levels	O	O
of	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
-enhancer	O	O
activity	O	O
compared	O	O
to	O	O
CD86	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
activity	O	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
regulating	O	O
the	O	O
IL-2	B-DNA	O
promoter-enhancer	I-DNA	O
region	I-DNA	O
including	O	O
activation	O	O
protein-1	B-protein	O
,	O	O
CD28	O	O
response	O	O
element	O	O
and	O	O
nuclear	B-protein	O
factor	I-protein	O
kappaB	O	O
were	O	O
4-8	O	O
times	O	O
higher	O	O
after	O	O
CD80	O	O
compared	O	O
to	O	O
CD86	O	O
ligation	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
eventual	O	O
appearance	O	O
of	O	O
CD80	O	O
on	O	O
recently	O	O
activated	O	O
CD86+	O	O
APC	O	O
is	O	O
important	O	O
for	O	O
the	O	O
superinduction	O	O
of	O	O
IL-2	B-protein	O
production	O	O
and	O	O
to	O	O
support	O	O
vigorous	O	O
T	O	O
cell	O	O
proliferation	O	O
.	O	O

Duplication	O	O
of	O	O
the	O	O
DR3	B-DNA	O
gene	I-DNA	O
on	O	O
human	O	O
chromosome	O	O
1p36	O	O
and	O	O
its	O	O
deletion	O	O
in	O	O
human	O	O
neuroblastoma	O	O
.	O	O

The	O	O
human	B-DNA	O
DR3	I-DNA	O
gene	I-DNA	O
,	O	O
whose	O	O
product	I-protein	O
is	O	O
also	O	O
known	O	O
as	O	O
Wsl-1/APO-3/TRAMP/LARD	O	O
,	O	O
encodes	O	O
a	O	O
tumor	O	O
necrosis	O	O
factor-related	O	O
receptor	I-protein	O
that	O	O
is	O	O
expressed	O	O
primarily	O	O
on	O	O
the	O	O
surface	O	O
of	O	O
thymocytes	B-cell_type	O
and	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

DR3	O	O
is	O	O
capable	O	O
of	O	O
inducing	O	O
both	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
and	O	O
apoptosis	O	O
when	O	O
overexpressed	O	O
in	O	O
mammalian	B-cell_type	O
cells	I-cell_type	O
,	O	O
although	O	O
its	O	O
ligand	O	O
has	O	O
not	O	O
yet	O	O
been	O	O
identified	O	O
.	O	O

We	O	O
report	O	O
here	O	O
that	O	O
the	O	O
DR3	B-DNA	O
gene	I-DNA	O
locus	O	O
is	O	O
tandemly	O	O
duplicated	O	O
on	O	O
human	O	O
chromosome	O	O
band	O	O
1p36.2-p36.3	O	O
and	O	O
that	O	O
these	O	O
genes	O	O
are	O	O
hemizygously	O	O
deleted	O	O
and/or	O	O
translocated	O	O
to	O	O
another	O	O
chromosome	O	O
in	O	O
neuroblastoma	O	O
(	O	O
NB	O	O
)	O	O
cell	O	O
lines	O	O
with	O	O
amplified	O	O
MYCN	O	O
.	O	O

Duplication	O	O
of	O	O
at	O	O
least	O	O
a	O	O
portion	O	O
of	O	O
the	O	O
DR3	B-DNA	O
gene	I-DNA	O
,	O	O
including	O	O
the	O	O
extracellular	B-DNA	O
and	I-DNA	O
transmembrane	I-DNA	O
regions	I-DNA	O
but	O	O
not	O	O
the	O	O
cytoplasmic	B-protein	O
domain	I-protein	O
,	O	O
was	O	O
demonstrated	O	O
by	O	O
both	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybridization	O	O
and	O	O
genomic	O	O
Southern	O	O
blotting	O	O
.	O	O

In	O	O
most	O	O
NB	O	O
cell	O	O
lines	O	O
,	O	O
both	O	O
the	O	O
DR3	O	O
and	O	O
the	O	O
DR3L	O	O
sequences	O	O
are	O	O
simultaneously	O	O
deleted	O	O
and/or	O	O
translocated	O	O
to	O	O
another	O	O
chromosome	O	O
.	O	O

Finally	O	O
,	O	O
DR3/	O	O
Wsl-1	O	O
protein	O	O
expression	O	O
is	O	O
quite	O	O
variable	O	O
among	O	O
these	O	O
NB	O	O
cell	O	O
lines	O	O
,	O	O
with	O	O
very	O	O
low	O	O
or	O	O
undetectable	O	O
levels	O	O
in	O	O
7	O	O
of	O	O
17	O	O
NB	O	O
cell	O	O
lines	O	O

Differential	O	O
protection	O	O
of	O	O
normal	O	O
and	O	O
malignant	B-protein	O
human	I-protein	O
myeloid	I-protein	O
progenitors	I-protein	O
(	O	O
CFU-GM	O	O
)	O	O
from	O	O
Ara-C	O	O
toxicity	O	O
using	O	O
cycloheximide	O	O
.	O	O

Cycloheximide	O	O
,	O	O
a	O	O
reversible	O	O
protein	O	O
synthesis	O	O
inhibitor	O	O
,	O	O
is	O	O
thought	O	O
to	O	O
block	O	O
DNA	O	O
replication	O	O
in	O	O
normal	B-cell_type	O
cells	I-cell_type	O
by	O	O
preventing	O	O
synthesis	O	O
of	O	O
a	O	O
labile	B-protein	O
protein	I-protein	O
.	O	O

In	O	O
animal	O	O
systems	O	O
,	O	O
cycloheximide	O	O
protects	O	O
normal	B-cell_type	O
cells	I-cell_type	O
from	O	O
cytotoxic	O	O
S-phase	O	O
specific	O	O
agents	O	O
,	O	O
such	O	O
as	O	O
cytosine	O	O
arabinoside	O	O
(	O	O
Ara-C	O	O
)	O	O
.	O	O

Malignant	B-cell_type	O
cells	I-cell_type	O
appear	O	O
not	O	O
to	O	O
be	O	O
susceptible	O	O
to	O	O
cycloheximide-induced	O	O
cycle	O	O
arrest	O	O
and	O	O
,	O	O
subsequently	O	O
,	O	O
may	O	O
not	O	O
be	O	O
protected	O	O
from	O	O
Ara-C	O	O
cytotoxicity	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
cycloheximide	O	O
on	O	O
granulocyte/macrophage	B-protein	O
progenitors	I-protein	O
(	O	O
CFU-GM	B-protein	O
)	O	O
after	O	O
in	O	O
vitro	O	O
Ara-C	O	O
exposure	O	O
was	O	O
examined	O	O
using	O	O
normal	O	O
human	O	O
bone	O	O
marrow	O	O
,	O	O
malignant	O	O
progenitors	O	O
from	O	O
patients	O	O
with	O	O
chronic	O	O
myelogenous	O	O
leukemia	O	O
(	O	O
CML	O	O
)	O	O
,	O	O
and	O	O
clonogenic	O	O
cells	O	O
from	O	O
the	O	O
human	O	O
acute	O	O
nonlymphocytic	O	O
leukemia	O	O
cell	O	O
lines	O	O
HL-60	O	O
and	O	O
KG-1	O	O
.	O	O

Mononuclear	O	O
or	O	O
clonogenic	B-cell_type	O
cells	I-cell_type	O
were	O	O
incubated	O	O
for	O	O
one	O	O
hour	O	O
with	O	O
cycloheximide	O	O
,	O	O
followed	O	O
by	O	O
the	O	O
addition	O	O
,	O	O
for	O	O
three	O	O
or	O	O
17	O	O
hours	O	O
,	O	O
of	O	O
Ara-C	O	O
before	O	O
being	O	O
plated	O	O
in	O	O
a	O	O
methylcellulose	O	O
culture	O	O
system	O	O
.	O	O

CFU-GM	O	O
survival	O	O
was	O	O
significantly	O	O
increase	O	O
if	O	O
normal	B-cell_type	O
cells	I-cell_type	O
were	O	O
treated	O	O
with	O	O
cycloheximide	O	O
before	O	O
Ara-C	O	O
exposure	O	O
.	O	O

Similar	O	O
cycloheximide	O	O
pretreatment	O	O
of	O	O
CML	O	O
progenitors	B-protein	O
and	O	O
clonogenic	O	O
HL-60	O	O
and	O	O
KG-1	B-cell_type	O
cells	I-cell_type	O
failed	O	O
to	O	O
protect	O	O
CFU-GM	O	O
from	O	O
Ara-C-induced	O	O
cytotoxicity	O	O
.	O	O

Primary	O	O
cortisol	O	O
resistance	O	O
accompanied	O	O
by	O	O
a	O	O
reduction	O	O
in	O	O
glucocorticoid	O	O
receptors	O	O
in	O	O
two	O	O
members	O	O
of	O	O
the	O	O
same	O	O
family	O	O
.	O	O

This	O	O
report	O	O
describes	O	O
studies	O	O
of	O	O
a	O	O
man	O	O
suspected	O	O
of	O	O
having	O	O
primary	I-DNA	O
cortisol	O	O
resistance	O	O
.	O	O

This	O	O
conclusion	O	O
is	O	O
based	O	O
on	O	O
his	O	O
high	O	O
plasma	O	O
cortisol	O	O
levels	O	O
and	O	O
high	O	O
24-h	O	O
urinary	O	O
17-hydroxycorticosteroid	O	O
and	O	O
cortisol	O	O
excretion	O	O
,	O	O
plus	O	O
the	O	O
fact	O	O
that	O	O
he	O	O
had	O	O
no	O	O
manifestations	O	O
of	O	O
Cushing	O	O
's	O	O
syndrome	O	O
.	O	O

Among	O	O
family	O	O
members	O	O
tested	O	O
,	O	O
his	O	O
mother	O	O
also	O	O
had	O	O
hypercortisolemia	O	O
.	O	O

Both	O	O
mother	O	O
and	O	O
son	O	O
had	O	O
high	O	O
levels	O	O
of	O	O
unbound	O	O
plasma	O	O
cortisol	O	O
,	O	O
but	O	O
their	O	O
plasma	O	O
ACTH	O	O
concentrations	O	O
were	O	O
within	O	O
the	O	O
normal	O	O
range	O	O
.	O	O

Both	O	O
were	O	O
partially	O	O
resistant	O	O
to	O	O
dexamethasone	O	O
adrenal	O	O
suppression	O	O
,	O	O
and	O	O
both	O	O
had	O	O
mild	O	O
hypertension	O	O
without	O	O
hypokalemia	O	O
.	O	O

To	O	O
study	O	O
this	O	O
apparent	O	O
end-organ	O	O
resistance	O	O
to	O	O
cortisol	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
glucocorticoid	O	O
receptors	O	O
in	O	O
peripheral	B-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
.	O	O

Using	O	O
whole	O	O
cell	O	O
assays	O	O
,	O	O
glucocorticoid	B-protein	O
receptors	O	O
in	O	O
both	O	O
patients	O	O
were	O	O
found	O	O
to	O	O
have	O	O
reduced	O	O
total	O	O
binding	O	O
capacity	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
these	O	O
two	O	O
patients	O	O
,	O	O
members	O	O
of	O	O
the	O	O
same	O	O
family	O	O
,	O	O
have	O	O
primary	B-protein	O
cortisol	O	O
resistance	O	O
accompanied	O	O
by	O	O
a	O	O
reduced	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
.	O	O

[	O	O
Glucocorticoid	B-protein	O
receptors	I-protein	O
and	O	O
response	O	O
to	O	O
polychemotherapy	O	O
in	O	O
acute	O	O
lymphatic	O	O
leukemia	O	O
]	O	O

Glucocorticoid	B-protein	O
receptor	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
levels	O	O
were	O	O
quantified	O	O
in	O	O
leukemic	O	O
blasts	O	O
from	O	O
peripheral	O	O
blood	O	O
of	O	O
86	O	O
patients	O	O
with	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
.	O	O

The	O	O
subsequent	O	O
achievement	O	O
of	O	O
complete	O	O
remission	O	O
after	O	O
combination	O	O
chemotherapy	O	O
was	O	O
correlated	O	O
with	O	O
high	O	O
receptor	O	O
levels	O	O
.	O	O

Forty-seven	O	O
of	O	O
50	O	O
patients	O	O
with	O	O
leukemic	I-cell_type	O
cells	I-cell_type	O
containing	O	O
more	O	O
than	O	O
6	O	O
,	O	O
000	B-protein	O
receptor	I-protein	O
sites	O	O
and	O	O
22	O	O
of	O	O
36	O	O
patients	O	O
with	O	O
cells	I-cell_type	O
containing	O	O
less	O	O
than	O	O
6	O	O
,	O	O
000	B-protein	O
receptor	I-protein	O
sites	O	O
achieved	O	O
remission	O	O
.	O	O

The	O	O
study	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
leukemic	B-cell_type	O
cells	I-cell_type	O
may	O	O
predict	O	O
response	O	O
to	O	O
combination	O	O
chemotherapy	O	O
in	O	O
patients	O	O
with	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
.	O	O

Specific	O	O
uptake	O	O
of	O	O
1	O	O
,	O	O
25-dihydroxycholecalciferol	O	O
by	O	O
human	O	O
chronic	O	O
myeloid	I-cell_type	O
leukemia	I-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
have	O	O
examined	O	O
mononuclear	O	O
cell	O	O
preparations	O	O
from	O	O
patients	O	O
with	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
[	O	O
CML	O	O
]	O	O
for	O	O
binding	O	O
of	O	O
and	O	O
response	O	O
to	O	O
1	O	O
,	O	O
25-dihydroxycholecalciferol	O	O
[	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
]	O	O
.	O	O

Whole	B-cell_type	O
cells	I-cell_type	O
specifically	O	O
took	O	O
up	O	O
[	O	O
3H	O	O
]	O	O
-1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
with	O	O
high	O	O
affinity	O	O
(	O	O
Kd	O	O
3.6	O	O
X	O	O
10	O	O
(	O	O
-11	O	O
)	O	O
M	O	O
)	O	O
and	O	O
low	O	O
capacity	O	O
.	O	O

Subcellular	O	O
fractionation	O	O
of	O	O
labeled	B-cell_type	O
cells	I-cell_type	O
showed	O	O
that	O	O
binding	O	O
was	O	O
restricted	O	O
to	O	O
cytosols	O	O
and	O	O
nuclei	O	O
.	O	O

Sucrose	O	O
gradient	O	O
centrifugation	O	O
of	O	O
cells	O	O
preincubated	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
-1	I-protein	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
revealed	O	O
a	O	O
single	O	O
3.6S	O	O
peak	O	O
which	O	O
was	O	O
totally	O	O
displaced	O	O
with	O	O
100-fold	O	O
excess	O	O
nonradioactive	O	O
hormone	O	O
.	O	O

However	O	O
,	O	O
we	O	O
were	O	O
unable	O	O
to	O	O
demonstrate	O	O
specific	O	O
binding	O	O
of	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
by	O	O
postlabeling	O	O
standard	O	O
cytosol	O	O
preparations	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
cytosols	O	O
prepared	O	O
from	O	O
a	O	O
mixture	O	O
of	O	O
CML	B-cell_type	O
cells	I-cell_type	O
and	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
receptor-positive	O	O
T47D	O	O
(	O	O
human	O	O
breast	O	O
cancer	O	O
)	O	O
cells	O	O
had	O	O
less	O	O
than	O	O
10	O	O
%	O	O
of	O	O
the	O	O
binding	O	O
measured	O	O
in	O	O
T47D	O	O
cytosol	O	O
alone	O	O
.	O	O

However	O	O
,	O	O
the	O	O
levels	O	O
of	O	O
binding	O	O
in	O	O
T47D	O	O
cytosols	O	O
were	O	O
not	O	O
reduced	O	O
if	O	O
the	O	O
receptors	O	O
were	O	O
occupied	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
-1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
prior	O	O
to	O	O
the	O	O
addition	O	O
of	O	O
the	O	O
CML	O	O
cytosols	O	O
.	O	O

Thus	B-cell_type	O
,	O	O
CML	B-cell_type	O
cells	I-cell_type	O
appear	O	O
to	O	O
contain	O	O
both	O	O
the	O	O
receptor	O	O
for	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
and	O	O
an	O	O
unknown	O	O
substance	O	O
which	O	O
prevents	O	O
its	O	O
detection	O	O
following	O	O
the	O	O
preparation	O	O
of	O	O
cytosol	O	O
.	O	O

Cells	O	O
from	O	O
patients	O	O
with	O	O
CML	O	O
in	O	O
the	O	O
chronic	O	O
phase	O	O
specifically	O	O
bound	O	O
more	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
[	O	O
18.0	O	O
+/-	O	O
3.2	O	O
(	O	O
S.E.	O	O
)	O	O
fmol/10	O	O
(	O	O
7	O	O
)	O	O
cells	O	O
]	O	O
than	O	O
did	O	O
those	O	O
in	O	O
acute	O	O
myeloid	O	O
transformation	O	O
[	O	O
7.2	O	O
+/-	O	O
1.5	O	O
]	O	O
or	O	O
than	O	O
did	O	O
cells	O	O
from	O	O
patients	O	O
with	O	O
acute	O	O
myeloid	O	O
leukemia	O	O
[	O	O
2.6	O	O
+/-	O	O
0.8	O	O
]	O	O
.	O	O

Only	I-cell_type	O
cells	I-cell_type	O
from	O	O
the	O	O
first	O	O
group	O	O
of	O	O
patients	O	O
responded	O	O
to	O	O
the	O	O
addition	O	O
of	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
by	O	O
differentiating	O	O
along	O	O
the	O	O
monocyte-macrophage	B-protein	O
pathway	I-protein	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
differentiation-induction	O	O
effect	O	O
of	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
is	O	O
likely	O	O
to	O	O
depend	O	O
on	O	O
adequate	O	O
levels	O	O
of	O	O
receptor	O	O
and	O	O
that	O	O
intact	B-cell_type	O
cells	I-cell_type	O
rather	O	O
than	O	O
cytosol	O	O
preparations	O	O
should	O	O
be	O	O
studied	O	O
before	O	O
cells	O	O
of	O	O
a	O	O
particular	O	O
tissue	O	O
are	O	O
designated	O	O
as	O	O
receptor	O	O
negative	O	O
.	O	O

Effect	O	O
of	O	O
cell	O	O
cycle	O	O
position	O	O
on	O	O
dexamethasone	O	O
binding	O	O
by	O	O
mouse	B-cell_line	O
and	I-cell_line	O
human	I-cell_line	O
lymphoid	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
:	O	O
correlation	O	O
between	O	O
an	O	O
increase	O	O
in	O	O
dexamethasone	O	O
binding	O	O
during	O	O
S	O	O
phase	O	O
and	O	O
dexamethasone	O	O
sensitivity	O	O
.	O	O

We	O	O
determined	O	O
the	O	O
effect	O	O
of	O	O
cell	O	O
cycle	O	O
position	O	O
on	O	O
the	O	O
amount	O	O
of	O	O
dexamethasone	O	O
that	O	O
was	O	O
specifically	O	O
bound	O	O
by	O	O
mouse	B-cell_line	O
and	O	O
human	B-cell_line	O
lymphoid	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

Cell	O	O
lines	O	O
that	O	O
were	O	O
either	O	O
sensitive	O	O
or	O	O
resistant	O	O
to	O	O
growth	O	O
inhibition	O	O
by	O	O
dexamethasone	O	O
were	O	O
compared	O	O
.	O	O

Exponentially	O	O
growing	B-cell_type	O
cells	I-cell_type	O
were	O	O
separated	O	O
by	O	O
centrifugal	O	O
elutriation	O	O
into	O	O
fractions	O	O
that	O	O
corresponded	O	O
to	O	O
different	O	O
positions	O	O
in	O	O
the	O	O
cell	O	O
cycle	O	O
.	O	O

The	O	O
cell	O	O
cycle	O	O
phase	O	O
distribution	O	O
of	O	O
each	O	O
fraction	O	O
was	O	O
estimated	O	O
by	O	O
flow	O	O
cytometry	O	O
and	O	O
autoradiography	O	O
.	O	O

The	O	O
amount	O	O
of	O	O
dexamethasone	O	O
bound	O	O
per	O	O
cell	O	O
in	O	O
each	O	O
fraction	O	O
was	O	O
measured	O	O
by	O	O
a	O	O
whole	O	O
cell	O	O
binding	O	O
assay	O	O
.	O	O

In	O	O
three	O	O
dexamethasone-sensitive	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
(	O	O
two	O	O
mouse	O	O
and	O	O
one	O	O
human	O	O
)	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
amount	O	O
of	O	O
dexamethasone	O	O
bound	O	O
per	O	O
cell	O	O
increased	O	O
2-4-fold	O	O
between	O	O
G1	O	O
phase	O	O
and	O	O
S	O	O
phase	O	O
,	O	O
and	O	O
then	O	O
decreased	O	O
during	O	O
G2/M	O	O
phase	O	O
.	O	O

Results	O	O
were	O	O
the	O	O
same	O	O
when	O	O
the	O	O
amount	O	O
of	O	O
dexamethasone	O	O
bound	O	O
per	O	O
milligram	O	O
of	O	O
cell	B-protein	O
protein	I-protein	O
was	O	O
measured	O	O
.	O	O

Binding	O	O
affinity	O	O
was	O	O
the	O	O
same	O	O
during	O	O
G1	O	O
phase	O	O
and	O	O
S	O	O
phase	O	O
,	O	O
but	O	O
the	O	O
proportion	O	O
of	O	O
bound	O	O
dexamethasone	O	O
that	O	O
translocated	O	O
to	O	O
the	O	O
nucleus	O	O
was	O	O
greater	O	O
during	O	O
S	O	O
phase	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
amount	O	O
of	O	O
dexamethasone	O	O
bound	O	O
per	O	O
cell	O	O
by	O	O
three	O	O
dexamethasone-resistant	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
(	O	O
two	O	O
mouse	O	O
and	O	O
one	O	O
human	O	O
)	O	O
did	O	O
not	O	O
increase	O	O
during	O	O
S	O	O
phase	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
cell	O	O
cycle	O	O
changes	O	O
in	O	O
dexamethasone	O	O
binding	O	O
are	O	O
not	O	O
simply	O	O
related	O	O
to	O	O
changes	O	O
in	O	O
cell	O	O
protein	O	O
or	O	O
cell	O	O
volume	O	O
during	O	O
the	O	O
cell	O	O
cycle	O	O
.	O	O

An	O	O
increase	O	O
in	O	O
dexamethasone	O	O
binding	O	O
during	O	O
S	O	O
phase	O	O
may	O	O
be	O	O
required	O	O
for	O	O
dexamethasone	O	O
to	O	O
inhibit	O	O
cell	O	O
growth	O	O
,	O	O
and	O	O
a	O	O
failure	O	O
of	O	O
dexamethasone	O	O
binding	O	O
to	O	O
increase	O	O
during	O	O
S	O	O
phase	O	O
might	O	O
represent	O	O
a	O	O
new	O	O
mechanism	O	O
of	O	O
dexamethasone	O	O
resistance	O	O
in	O	O
lymphoid	B-cell_type	O
cells	I-cell_type	O
.	O	O

Presence	O	O
and	O	O
steroid	O	O
inducibility	O	O
of	O	O
glutamine	O	O
synthetase	O	O
in	O	O
human	B-cell_type	O
leukemic	I-cell_type	O
cells	I-cell_type	O
.	O	O

Glutamine	O	O
synthetase	O	O
(	O	O
EC	O	O
6.3.1.2	O	O
;	O	O
GS	O	O
)	O	O
is	O	O
present	O	O
in	O	O
lymphoblasts	O	O
from	O	O
patients	O	O
with	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
(	O	O
ALL	O	O
)	O	O
as	O	O
well	O	O
as	O	O
in	O	O
normal	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

In	O	O
16	O	O
out	O	O
of	O	O
20	O	O
ALL	O	O
patients	O	O
studied	O	O
exposure	O	O
of	O	O
the	O	O
cells	O	O
to	O	O
physiological	O	O
concentrations	O	O
of	O	O
dexamethasone	O	O
in	O	O
vitro	O	O
increased	O	O
enzyme	O	O
activity	O	O
above	O	O
the	O	O
control	O	O
levels	O	O
.	O	O

The	O	O
increase	O	O
was	O	O
specific	O	O
for	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
ligands	O	O
.	O	O

A	O	O
direct	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
the	O	O
magnitude	O	O
of	O	O
glucocorticoid-mediated	O	O
increase	O	O
of	O	O
GS	O	O
activity	O	O
and	O	O
the	O	O
cellular	O	O
levels	O	O
of	O	O
specific	O	O
glucocorticoid	B-protein	O
receptors	O	O
assayed	O	O
in	O	O
the	O	O
same	O	O
cell	O	O
specimen	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
basal	O	O
levels	O	O
of	O	O
the	O	O
enzyme	O	O
measured	O	O
in	O	O
cells	O	O
prior	O	O
to	O	O
exposure	O	O
to	O	O
dexamethasone	O	O
correlated	O	O
negatively	O	O
with	O	O
receptor	O	O
density	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
presence	O	O
of	O	O
steroid-inducible	O	O
GS	O	O
in	O	O
ALL	B-cell_type	O
cells	I-cell_type	O
may	O	O
prove	O	O
to	O	O
be	O	O
a	O	O
marker	O	O
for	O	O
functional	O	O
receptor	O	O
sites	O	O
.	O	O

Binding	O	O
of	O	O
progestins	O	O
to	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
.	O	O

Correlation	O	O
to	O	O
their	O	O
glucocorticoid-like	O	O
effects	O	O
on	O	O
in	O	O
vitro	O	O
functions	O	O
of	O	O
human	B-cell_type	O
mononuclear	I-cell_type	O
leukocytes	O	O
.	O	O

A	O	O
number	O	O
of	O	O
physiological	O	O
and	O	O
synthetic	O	O
progestins	O	O
were	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
compete	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone	O	O
for	O	O
the	O	O
binding	O	O
to	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
of	O	O
human	B-cell_type	O
mononuclear	I-cell_type	O
leukocytes	O	O
and	O	O
their	O	O
ability	O	O
to	O	O
elicit	O	O
glucocorticoid-like	O	O
effects	O	O
on	O	O
the	O	O
same	O	O
cells	I-cell_type	O
.	O	O

As	O	O
compared	O	O
to	O	O
the	O	O
reference	O	O
compound	O	O
dexamethasone	O	O
(	O	O
relative	O	O
receptor	I-protein	O
binding	O	O
affinity	O	O
defined	O	O
as	O	O
100	O	O
%	O	O
)	O	O
,	O	O
two	O	O
potent	O	O
synthetic	O	O
progestins	O	O
with	O	O
a	O	O
pregnane-type	O	O
structure	O	O
,	O	O
megestrol	O	O
acetate	O	O
and	O	O
medroxyprogesterone	O	O
acetate	O	O
,	O	O
were	O	O
found	O	O
to	O	O
display	O	O
a	O	O
considerable	O	O
binding	O	O
affinity	O	O
towards	O	O
the	O	O
receptor	O	O
(	O	O
46	O	O
and	O	O
42	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
relative	O	O
binding	O	O
affinity	O	O
of	O	O
the	O	O
naturally	O	O
occurring	O	O
ligand	O	O
,	O	O
cortisol	O	O
,	O	O
to	O	O
the	O	O
receptor	O	O
was	O	O
clearly	B-protein	O
lower	I-protein	O
(	O	O
25	O	O
%	O	O
)	O	O
.	O	O

The	O	O
effective	O	O
binding	O	O
of	O	O
medroxyprogesterone	O	O
acetate	O	O
to	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
was	O	O
confirmed	O	O
by	O	O
direct	O	O
binding	O	O
studies	O	O
utilizing	O	O
a	O	O
tritiated	O	O
derivative	O	O
of	O	O
this	O	O
steroid	O	O
.	O	O

No	O	O
evidence	O	O
for	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
specific	O	O
progesterone	B-protein	O
receptor	I-protein	O
in	O	O
human	O	O
mononuclear	O	O
leukocytes	O	O
was	O	O
obtained	O	O
as	O	O
judged	O	O
by	O	O
the	O	O
results	O	O
of	O	O
competition	O	O
experiments	O	O
where	O	O
a	O	O
progesterone	O	O
receptor-specific	O	O
ligand	O	O
[	O	O
3H	O	O
]	O	O
Org	O	O
2058	O	O
was	O	O
used	O	O
.	O	O

Medroxyprogesterone	O	O
acetate	O	O
and	O	O
megestrol	O	O
acetate	O	O
also	O	O
induced	O	O
glucocorticoid-like	O	O
effects	O	O
on	O	O
the	O	O
lymphocyte	O	O
functions	O	O
.	O	O

These	O	O
included	O	O
inhibition	O	O
of	O	O
the	O	O
proliferative	O	O
responses	O	O
to	O	O
the	O	O
T-cell	O	O
mitogens	O	O
concanavalin	O	O
A	O	O
and	O	O
phytohaemagglutinin	O	O
and	O	O
an	O	O
enhanced	O	O
accumulation	O	O
of	O	O
immunoglobulin	O	O
secreting	B-cell_type	O
cells	I-cell_type	O
in	O	O
pokeweed	O	O
mitogen-stimulated	O	O
cultures	O	O
.	O	O

The	O	O
progestin	O	O
effect	O	O
appears	O	O
to	O	O
be	O	O
mediated	O	O
through	O	O
a	O	O
radiosensitive	O	O
(	O	O
suppressor	O	O
)	O	O
subpopulation	O	O
of	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
synthetic	O	O
progestins	O	O
related	O	O
structurally	O	O
to	O	O
19-nortestosterone	O	O
,	O	O
norethisterone	O	O
and	O	O
d-norgestrel	O	O
,	O	O
were	O	O
virtually	O	O
devoid	O	O
of	O	O
binding	O	O
affinity	O	O
towards	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
nor	O	O
did	O	O
they	O	O
measurably	O	O
influence	O	O
the	O	O
in	O	O
vitro	O	O
lymphocyte	O	O
functions	O	O
.	O	O

These	O	O
studies	O	O
demonstrate	O	O
that	O	O
certain	O	O
progestins	O	O
in	O	O
common	O	O
clinical	O	O
use	O	O
probably	O	O
possess	O	O
inherent	O	O
glucocorticoid	O	O
activity	O	O
and	O	O
suggest	O	O
that	O	O
side	O	O
effects	O	O
attributable	O	O
to	O	O
this	O	O
character	O	O
(	O	O
e.g.	O	O
suppression	O	O
of	O	O
the	O	O
pituitary-adrenal	O	O
axis	O	O
)	O	O
might	O	O
be	O	O
expected	O	O
when	O	O
these	O	O
compounds	O	O
are	O	O
used	O	O
in	O	O
pharmacological	O	O
doses	O	O
.	O	O

Metabolic	O	O
and	O	O
ultrastructural	O	O
aspects	O	O
of	O	O
the	O	O
in	O	O
vitro	O	O
lysis	O	O
of	O	O
chronic	O	O
lymphocytic	B-cell_type	O
leukemia	I-cell_type	O
cells	I-cell_type	O
by	O	O
glucocorticoids	O	O
.	O	O

Human	O	O
chronic	O	O
lymphocytic	O	O
leukemia	O	O
(	O	O
CLL	O	O
)	O	O
cells	O	O
like	O	O
prothymocytes	O	O
and	O	O
immunoactivated	O	O
T-lymphocytes	O	O
are	O	O
readily	O	O
lysed	O	O
in	O	O
vitro	O	O
by	O	O
pharmacological	O	O
concentrations	O	O
of	O	O
glucocorticoids	O	O
such	O	O
as	O	O
cortisol	O	O
,	O	O
whereas	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
thymocytes	B-cell_type	O
are	O	O
unaffected	O	O
by	O	O
the	O	O
hormone	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
metabolic	O	O
and	O	O
ultrastructural	O	O
aspects	O	O
of	O	O
the	O	O
cortisol-induced	O	O
killing	O	O
process	O	O
of	O	O
CLL	B-cell_type	O
cells	I-cell_type	O
are	O	O
recorded	O	O
.	O	O

In	O	O
vitro	O	O
lysis	O	O
was	O	O
found	O	O
to	O	O
be	O	O
temperature	O	O
dependent	O	O
and	O	O
was	O	O
detected	O	O
only	O	O
after	O	O
6	O	O
to	O	O
8	O	O
hr	O	O
incubation	O	O
with	O	O
cortisol	O	O
by	O	O
means	O	O
of	O	O
the	O	O
trypan	O	O
blue	I-protein	O
exclusion	I-protein	O
test	O	O
.	O	O

However	O	O
,	O	O
30	O	O
min	O	O
of	O	O
incubation	O	O
with	O	O
cortisol	O	O
at	O	O
either	O	O
37	O	O
degrees	O	O
or	O	O
4	O	O
degrees	O	O
followed	O	O
by	O	O
the	O	O
removal	O	O
of	O	O
the	O	O
hormone	O	O
was	O	O
still	O	O
sufficient	O	O
to	O	O
induce	O	O
the	O	O
lytic	O	O
process	O	O
.	O	O

Ultrastructural	O	O
studies	O	O
demonstrated	O	O
sequential	O	O
changes	O	O
in	O	O
the	O	O
cytoplasm	O	O
,	O	O
including	O	O
swelling	O	O
of	O	O
mitochondria	O	O
and	O	O
cytoplasmic	B-protein	O
decompartmentalization	O	O
,	O	O
followed	O	O
by	O	O
loss	O	O
of	O	O
surface	O	O
microvilli	O	O
with	O	O
the	O	O
appearance	O	O
of	O	O
``	O	O
holes	O	O
''	O	O
in	O	O
the	O	O
cell	O	O
membrane	O	O
,	O	O
and	O	O
subsequent	O	O
condensation	O	O
of	O	O
nuclear	B-protein	O
chromatin	O	O
.	O	O

The	O	O
large	O	O
holes	O	O
in	O	O
the	O	O
membrane	O	O
appearing	O	O
after	O	O
6	O	O
hr	O	O
of	O	O
incubation	O	O
with	O	O
the	O	O
hormone	O	O
may	O	O
be	O	O
the	O	O
cause	O	O
for	O	O
the	O	O
penetration	O	O
of	O	O
the	O	O
viable	O	O
stain	O	O
into	O	O
the	O	O
dead	B-cell_type	O
cells	I-cell_type	O
,	O	O
as	O	O
seen	O	O
by	O	O
light	O	O
microscopy	O	O
.	O	O

Addition	O	O
of	O	O
metabolic	O	O
inhibitors	O	O
including	O	O
actinomycin	O	O
D	O	O
,	O	O
puromycin	O	O
,	O	O
and	O	O
cycloheximide	O	O
following	O	O
administration	O	O
of	O	O
cortisol	O	O
resulted	O	O
in	O	O
inhibition	O	O
of	O	O
the	O	O
cell	O	O
lysis	O	O
.	O	O

An	O	O
excess	O	O
of	O	O
an	O	O
antagonist	O	O
such	O	O
as	O	O
cortexolone	O	O
was	O	O
found	O	O
to	O	O
inhibit	O	O
the	O	O
cortisol-induced	O	O
cytolysis	O	O
of	O	O
the	O	O
CLL	B-cell_type	O
cells	I-cell_type	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
glucocorticoid-induced	O	O
lysis	O	O
of	O	O
human	B-cell_type	O
CLL	I-cell_type	O
cells	I-cell_type	O
is	O	O
similar	O	O
to	O	O
the	O	O
phenomenon	O	O
observed	O	O
in	O	O
rat	O	O
or	O	O
murine	B-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
is	O	O
mediated	O	O
by	O	O
interaction	O	O
of	O	O
the	O	O
steroid	B-protein	O
molecule	I-protein	O
with	O	O
the	O	O
cytoplasmic	B-protein	O
receptor	I-protein	O
.	O	O

The	O	O
resulting	O	O
complex	O	O
appears	O	O
to	O	O
activate	O	O
specific	O	O
gene	O	O
(	O	O
s	O	O
)	O	O
the	O	O
products	O	O
of	O	O
which	O	O
eventually	O	O
cause	O	O
cytolysis	O	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
in	O	O
lymphoid	O	O
tumors	O	O
.	O	O

There	O	O
is	O	O
a	O	O
range	O	O
of	O	O
levels	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
numbers	O	O
seen	O	O
in	O	O
the	O	O
various	O	O
subclasses	O	O
of	O	O
acute	O	O
lymphatic	O	O
leukemia	O	O
(	O	O
ALL	O	O
)	O	O
.	O	O

This	O	O
variability	O	O
can	O	O
not	O	O
be	O	O
explained	O	O
by	O	O
the	O	O
known	O	O
correlation	O	O
between	O	O
active	O	O
cell	O	O
proliferation	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
receptors	B-protein	O
,	O	O
since	O	O
the	O	O
tumors	O	O
with	O	O
the	O	O
highest	B-protein	O
growth	I-protein	O
fraction	I-protein	O
(	O	O
i.e.	O	O
,	O	O
Burkitt	O	O
's	O	O
lymphoma	O	O
and	O	O
T-cell	O	O
leukemia	O	O
)	O	O
tend	O	O
to	O	O
have	O	O
lower	O	O
average	O	O
receptor	O	O
numbers	O	O
than	O	O
do	O	O
tumors	O	O
with	O	O
lower	O	O
growth	O	O
fractions	O	O
such	O	O
as	O	O
common	O	O
ALL	O	O
.	O	O

All	O	O
clinical	O	O
specimens	O	O
from	O	O
patients	O	O
with	O	O
lymphatic	O	O
leukemia	O	O
have	O	O
some	O	O
measurable	O	O
level	O	O
of	O	O
glucocorticoid	O	O
receptors	O	O
;	O	O
therefore	O	O
,	O	O
the	O	O
resistance	O	O
seen	O	O
in	O	O
vivo	O	O
can	O	O
not	O	O
be	O	O
explained	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
receptors	B-protein	O
.	O	O

However	O	O
,	O	O
there	O	O
has	O	O
been	O	O
a	O	O
positive	O	O
correlation	O	O
,	O	O
in	O	O
our	O	O
hands	O	O
,	O	O
with	O	O
receptor	O	O
level	O	O
and	O	O
prognosis	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
in	O	O
vitro	O	O
models	O	O
,	O	O
it	O	O
is	O	O
proposed	O	O
that	O	O
perhaps	O	O
the	O	O
high	O	O
receptor	O	O
cell	O	O
lines	O	O
(	O	O
i.e.	O	O
,	O	O
common	O	O
ALL	O	O
of	O	O
childhood	B-protein	O
)	O	O
have	O	O
relative	O	O
stability	O	O
of	O	O
their	O	O
genetic	O	O
material	O	O
making	O	O
glucocorticoid-resistant	O	O
mutations	O	O
less	O	O
likely	O	O
to	O	O
occur	O	O
in	O	O
patients	O	O
with	O	O
these	O	O
cells	O	O
than	O	O
in	O	O
low-receptor	O	O
cell	O	O
lines	O	O
(	O	O
i.e.	O	O
,	O	O
T-cell	O	O
leukemia	O	O
)	O	O
.	O	O

This	O	O
greater	O	O
genetic	O	O
variability	O	O
in	O	O
the	O	O
low-receptor	O	O
lines	O	O
could	O	O
account	O	O
for	O	O
the	O	O
earlier	O	O
emergence	O	O
of	O	O
clinical	O	O
glucocorticoid	O	O
resistance	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

[	O	O
Tumor	O	O
histology	O	O
and	O	O
steroid	O	O
receptors	O	O
in	O	O
breast	O	O
carcinoma	O	O
]	O	O

In	O	O
Specimens	O	O
of	O	O
115	O	O
patients	O	O
with	O	O
breast	O	O
cancer	O	O
4	O	O
tumorparameters	O	O
(	O	O
tumorsize	O	O
,	O	O
tumorboder	O	O
,	O	O
nucleargrade	O	O
,	O	O
lymphocytic	B-protein	O
stromal	O	O
reaction	O	O
)	O	O
3	O	O
features	O	O
of	O	O
regional	O	O
lymphnodes	O	O
(	O	O
sinushistiocytosis	B-protein	O
,	O	O
T-cellreaction	O	O
,	O	O
lymphnode	O	O
metastases	O	O
)	O	O
and	O	O
estrogen	O	O
and	O	O
progesteron	O	O
receptors	O	O
were	O	O
determined	O	O
.	O	O

A	O	O
strong	O	O
sinushistiocytosis	O	O
and	O	O
T-cellreaction	O	O
could	O	O
be	O	O
verified	O	O
mainly	O	O
in	O	O
metastases	O	O
in	O	O
free	O	O
lymphnodes	O	O
.	O	O

The	O	O
steroid	B-protein	O
receptor	I-protein	O
content	O	O
does	O	O
not	O	O
correlate	O	O
with	O	O
histological	O	O
parameters	O	O

Aldosterone-receptor	O	O
deficiency	O	O
in	O	O
pseudohypoaldosteronism	O	O
.	O	O

Pseudohypoaldosteronism	O	O
,	O	O
a	O	O
syndrome	O	O
characterized	O	O
by	O	O
salt	O	O
wasting	O	O
and	O	O
failure	O	O
to	O	O
thrive	O	O
,	O	O
usually	O	O
presents	O	O
in	O	O
infancy	O	O
as	O	O
high	O	O
urinary	O	O
levels	O	O
of	O	O
sodium	O	O
despite	O	O
hyponatremia	O	O
,	O	O
hyperkalemia	O	O
,	O	O
hyperreninemia	O	O
,	O	O
and	O	O
elevated	O	O
aldosterone	O	O
levels	O	O
.	O	O

We	O	O
have	O	O
investigated	O	O
this	O	O
syndrome	O	O
for	O	O
the	O	O
possibility	O	O
of	O	O
abnormal	B-protein	O
Type	I-protein	O
I	I-protein	O
or	O	O
``	O	O
mineralocorticoid-like	O	O
''	O	O
receptors	O	O
,	O	O
which	O	O
have	O	O
intrinsic	O	O
steroid	O	O
specificity	O	O
indistinguishable	O	O
from	O	O
that	O	O
of	O	O
renal	O	O
mineralocorticoid	O	O
receptors	O	O
and	O	O
are	O	O
found	O	O
in	O	O
many	B-cell_type	O
tissues	I-cell_type	O
and	I-cell_type	O
cells	I-cell_type	O
,	O	O
including	O	O
mononuclear	O	O
leukocytes	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
three	O	O
patients	O	O
with	O	O
pseudohypoaldosteronism	O	O
:	O	O
the	O	O
28-year-old	O	O
index	O	O
case	O	O
in	O	O
Melbourne	O	O
(	O	O
Patient	O	O
1	O	O
)	O	O
and	O	O
two	O	O
siblings	O	O
in	O	O
Munich	O	O
,	O	O
eight	O	O
and	O	O
two	O	O
years	O	O
of	O	O
age	O	O
(	O	O
Patients	O	O
2	O	O
and	O	O
3	O	O
)	O	O
;	O	O
clinically	O	O
,	O	O
Patient	O	O
3	O	O
had	O	O
a	O	O
less	O	O
severe	O	O
case	O	O
than	O	O
his	O	O
sister	O	O
.	O	O

Percoll-separated	O	O
control	O	O
monocytes	B-cell_type	O
bound	O	O
[	O	O
3H	O	O
]	O	O
aldosterone	O	O
with	O	O
high	O	O
affinity	O	O
(	O	O
Kd	O	O
approximately	O	O
3	O	O
nM	O	O
)	O	O
and	O	O
limited	O	O
capacity	O	O
(	O	O
150	O	O
to	O	O
600	O	O
sites	O	O
per	O	O
cell	O	O
)	O	O
.	O	O

On	O	O
repeated	O	O
examination	O	O
,	O	O
no	O	O
[	O	O
3H	O	O
]	O	O
aldosterone	O	O
binding	O	O
was	O	O
found	O	O
in	O	O
monocytes	B-cell_type	O
from	O	O
Patients	O	O
1	O	O
and	O	O
2	O	O
;	O	O
in	O	O
Patient	O	O
3	O	O
,	O	O
the	O	O
levels	O	O
were	O	O
62	O	O
sites	O	O
per	O	O
cell	O	O
,	O	O
more	O	O
than	O	O
2	O	O
S.D.	O	O
below	O	O
those	O	O
of	O	O
the	O	O
control	O	O
.	O	O

Levels	O	O
in	O	O
the	O	O
parents	O	O
of	O	O
the	O	O
Munich	O	O
patients	O	O
(	O	O
first	O	O
cousins	O	O
)	O	O
were	O	O
normal	O	O
.	O	O

It	O	O
appears	O	O
that	O	O
pseudohypoaldosteronism	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
Type	O	O
I	B-protein	O
receptor	I-protein	O
defect	O	O
,	O	O
that	O	O
the	O	O
defect	O	O
may	O	O
be	O	O
complete	O	O
or	O	O
partial	O	O
,	O	O
that	O	O
transmission	O	O
may	O	O
be	O	O
autosomal	O	O
recessive	O	O
,	O	O
and	O	O
that	O	O
the	O	O
study	O	O
of	O	O
patients	O	O
with	O	O
pseudohypoaldosteronism	O	O
may	O	O
indicate	O	O
physiologic	O	O
roles	O	O
for	O	O
Type	O	O
I	B-protein	O
receptors	I-protein	O
in	O	O
nonepithelial	O	O
tissues	O	O
.	O	O

Glucocorticoid	O	O
inhibition	O	O
of	O	O
urokinase-like	O	O
plasminogen	O	O
activators	B-protein	O
in	O	O
cultured	O	O
human	O	O
lymphoblasts	O	O
.	O	O

Two	O	O
human	B-cell_line	O
lymphoblast	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
,	I-cell_line	O
LICR-LON-HMy2	I-cell_line	O
(	I-cell_line	O
HMy2	I-cell_line	O
cells	I-cell_line	O
)	O	O
and	O	O
GM4672A	B-cell_type	O
cells	I-cell_type	O
,	O	O
are	O	O
moderately	O	O
growth	O	O
inhibited	O	O
by	O	O
dexamethasone	O	O
(	O	O
1	O	O
,	O	O
4-pregnadien-9-fluoro-16	O	O
alpha-methyl-11	O	O
beta	O	O
,	O	O
17	O	O
alpha	I-protein	O
,	O	O
21-triol-3	O	O
,	O	O
20-dione	O	O
)	O	O
(	O	O
Dex	O	O
)	O	O
.	O	O

Both	O	O
cell	O	O
types	O	O
secrete	O	O
a	O	O
urokinase	O	O
(	O	O
UK	O	O
)	O	O
-like	O	O
plasminogen	O	O
activator	I-protein	O
(	O	O
PA	B-protein	O
)	O	O
.	O	O

Treatment	O	O
of	O	O
both	O	O
HMy2	B-cell_type	O
and	I-cell_type	O
GM4672A	I-cell_type	O
cells	I-cell_type	O
with	O	O
Dex	O	O
for	O	O
1-4	O	O
days	O	O
inhibits	O	O
extracellular	O	O
PA	O	O
activity	O	O
in	O	O
a	O	O
concentration-dependent	O	O
manner	O	O
,	O	O
being	O	O
half-maximal	O	O
at	O	O
approximately	O	O
1	O	O
X	O	O
10	O	O
(	O	O
-9	O	O
)	O	O
M	O	O
.	O	O

Inhibition	O	O
of	O	O
PA	O	O
in	O	O
both	O	O
cell	I-cell_type	O
types	I-cell_type	O
is	O	O
specific	O	O
for	O	O
active	O	O
glucocorticoids	O	O
,	O	O
and	O	O
this	O	O
specificity	O	O
parallels	O	O
the	O	O
ability	O	O
of	O	O
various	O	O
steroids	O	O
to	O	O
bind	O	O
to	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
.	O	O

HMy2	O	O
cell	O	O
PA	O	O
is	O	O
fully	O	O
suppressible	O	O
by	O	O
Dex	O	O
,	O	O
whereas	O	O
up	O	O
to	O	O
one	O	O
third	O	O
of	O	O
the	O	O
activator	O	O
expressed	O	O
by	O	O
GM4672A	B-cell_type	O
cells	I-cell_type	O
is	O	O
resistant	O	O
to	O	O
glucocorticoid	O	O
inhibition	O	O
.	O	O

Mixing	O	O
experiments	O	O
using	O	O
a	O	O
UK	O	O
standard	O	O
and	O	O
conditioned	O	O
media	O	O
from	O	O
Dex-treated	O	O
cells	O	O
suggest	O	O
an	O	O
absence	O	O
of	O	O
glucocorticoid-inducible	O	O
inhibitors	O	O
to	O	O
UK	O	O
or	O	O
plasmin	O	O
in	O	O
both	O	O
cell	I-cell_type	O
types	I-cell_type	O
.	O	O

However	O	O
,	O	O
conditioned	O	O
media	O	O
from	O	O
Dex-treated	O	O
GM4672A	O	O
cells	O	O
inhibits	O	O
a	O	O
portion	O	O
of	O	O
the	O	O
homologous	O	O
cellular	O	O
activator	I-protein	O
in	O	O
conditioned	O	O
media	O	O
from	O	O
control	I-cell_line	O
GM4672A	I-cell_line	O
cells	I-cell_line	O
.	O	O

Thus	O	O
,	O	O
low	O	O
levels	O	O
of	O	O
glucocorticoid-inducible	O	O
inhibitors	O	O
may	O	O
contribute	O	O
to	O	O
,	O	O
but	O	O
can	O	O
not	O	O
fully	O	O
account	O	O
for	O	O
,	O	O
Dex	O	O
inhibition	O	O
of	O	O
GM4672A	O	O
PA	O	O
activity	O	O
.	O	O

Glucocorticoid-inducible	O	O
inhibitors	O	O
in	O	O
HMy2	B-cell_type	O
cells	I-cell_type	O
are	O	O
either	O	O
totally	O	O
absent	O	O
or	O	O
are	O	O
present	O	O
at	O	O
undetectable	O	O
levels	O	O
.	O	O

Thus	O	O
,	O	O
regulation	O	O
of	O	O
UK-like	O	O
PAs	O	O
in	O	O
HMy2	O	O
and	O	O
GM4672A	B-cell_type	O
cells	I-cell_type	O
differs	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
extent	O	O
to	O	O
which	O	O
glucocorticoids	O	O
inhibit	O	O
constitutively	O	O
expressed	O	O
activator	O	O
levels	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
possible	O	O
contribution	O	O
of	O	O
glucocorticoid-inducible	O	O
inhibitors	O	O
to	O	O
the	O	O
regulatory	O	O
process	O	O
in	O	O
GM4672A	B-cell_type	O
cells	I-cell_type	O
.	O	O

Characterization	O	O
of	O	O
aldosterone	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
in	O	O
circulating	O	O
human	B-cell_type	O
mononuclear	I-cell_type	O
leukocytes	O	O
.	O	O

Aldosterone	O	O
binding	O	O
sites	O	O
in	O	O
human	O	O
mononuclear	O	O
leukocytes	O	O
were	O	O
characterized	O	O
after	O	O
separation	O	O
of	O	O
cells	I-cell_type	O
from	O	O
blood	O	O
by	O	O
a	O	O
Percoll	O	O
gradient	O	O
.	O	O

After	O	O
washing	O	O
and	O	O
resuspension	O	O
in	O	O
RPMI-1640	B-cell_line	O
medium	I-cell_line	O
,	I-cell_line	O
cells	I-cell_line	O
were	O	O
incubated	O	O
at	O	O
37	O	O
degrees	O	O
C	O	O
for	O	O
1	O	O
h	O	O
with	O	O
different	O	O
concentrations	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
aldosterone	O	O
plus	O	O
a	O	O
100-fold	O	O
concentration	O	O
of	O	O
RU-26988	O	O
(	O	O
11	B-protein	O
alpha	I-protein	O
,	O	O
17	O	O
alpha-dihydroxy-17	O	O
beta-propynylandrost-1	O	O
,	O	O
4	O	O
,	O	O
6-trien-3-one	O	O
)	O	O
,	O	O
with	O	O
or	O	O
without	O	O
an	O	O
excess	O	O
of	O	O
unlabeled	O	O
aldosterone	O	O
.	O	O

Aldosterone	O	O
binds	O	O
to	O	O
a	O	O
single	O	O
class	O	O
of	O	O
receptors	O	O
with	O	O
an	O	O
affinity	O	O
of	O	O
2.7	O	O
+/-	O	O
0.5	O	O
nM	O	O
(	O	O
means	O	O
+/-	O	O
SD	O	O
,	O	O
n	O	O
=	O	O
14	O	O
)	O	O
and	O	O
a	O	O
capacity	O	O
of	O	O
290	O	O
+/-	O	O
108	O	O
sites/cell	O	O
(	O	O
n	O	O
=	O	O
14	O	O
)	O	O
.	O	O

The	O	O
specificity	O	O
data	O	O
show	O	O
a	O	O
hierarchy	O	O
of	O	O
affinity	O	O
of	O	O
desoxycorticosterone	O	O
=	O	O
corticosterone	O	O
=	O	O
aldosterone	O	O
greater	O	O
than	O	O
hydrocortisone	O	O
greater	O	O
than	O	O
dexamethasone	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
mononuclear	O	O
leukocytes	O	O
could	O	O
be	O	O
useful	O	O
for	O	O
studying	O	O
the	O	O
physiological	O	O
significance	O	O
of	O	O
these	O	O
mineralocorticoid	O	O
receptors	O	O
and	O	O
their	O	O
regulation	O	O
in	O	O
humans	O	O
.	O	O

Mineralocorticoid	O	O
and	O	O
glucocorticoid	B-protein	O
receptors	O	O
in	O	O
circulating	O	O
mononuclear	O	O
leukocytes	O	O
of	O	O
patients	O	O
with	O	O
primary	O	O
hyperaldosteronism	O	O
.	O	O

Mineralocorticoid	O	O
and	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
were	O	O
measured	O	O
in	O	O
circulating	O	O
mononuclear	O	O
leukocytes	O	O
in	O	O
5	O	O
patients	O	O
affected	O	O
by	O	O
Conn	O	O
's	O	O
syndrome	O	O
(	O	O
3	O	O
cases	O	O
of	O	O
bilateral	O	O
adrenal	O	O
hyperplasia	O	O
and	O	O
2	O	O
cases	O	O
of	O	O
adenoma	O	O
plus	O	O
unilateral	O	O
hyperplasia	O	O
)	O	O
.	O	O

The	O	O
number	O	O
of	O	O
the	O	O
binding	B-DNA	O
sites	I-DNA	O
per	I-DNA	O
cell	I-DNA	O
resulted	O	O
significantly	O	O
lower	O	O
(	O	O
189	O	O
+/-	O	O
114	O	O
,	O	O
mean	O	O
+/-	O	O
SD	O	O
)	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
the	O	O
normal	O	O
controls	O	O
(	O	O
298	O	O
+/-	I-protein	O
105	I-protein	O
)	O	O
.	O	O

The	O	O
affinity	O	O
of	O	O
aldosterone	O	O
for	O	O
the	O	O
receptor	O	O
was	O	O
found	O	O
to	O	O
be	O	O
not	O	O
different	O	O
than	O	O
that	O	O
of	O	O
healthy	O	O
control	O	O
subjects	O	O
.	O	O

The	O	O
capacity	O	O
and	O	O
the	O	O
affinity	O	O
of	O	O
dexamethasone	O	O
for	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
ranged	O	O
in	O	O
the	O	O
normal	O	O
values	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
a	O	O
possible	O	O
down-regulation	O	O
of	O	O
mineralocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
humans	O	O
.	O	O

Short-term	O	O
and	O	O
long-term	O	O
effects	O	O
of	O	O
estrogen	O	O
on	O	O
lymphoid	B-cell_type	O
tissues	I-cell_type	O
and	I-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
with	O	O
some	O	O
remarks	O	O
on	O	O
the	O	O
significance	O	O
for	O	O
carcinogenesis	O	O
.	O	O

Estrogens	O	O
have	O	O
long	O	O
been	O	O
thought	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
regulating	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

The	O	O
difference	O	O
in	O	O
some	O	O
types	O	O
of	O	O
immune	O	O
responses	O	O
between	O	O
males	O	O
and	O	O
females	O	O
is	O	O
well-known	O	O
,	O	O
as	O	O
is	O	O
the	O	O
pronounced	O	O
thymic	O	O
involution	O	O
induced	O	O
by	O	O
exogenous	O	O
estrogens	O	O
.	O	O

Estrogens	O	O
stimulate	O	O
some	O	O
aspects	O	O
of	O	O
macrophage	O	O
activity	O	O
and	O	O
,	O	O
depending	O	O
on	O	O
dose	O	O
and	O	O
mitogen	B-protein	O
,	O	O
inhibit	O	O
or	O	O
stimulate	O	O
lymphocyte	O	O
proliferative	O	O
response	O	O
in	O	O
vitro	O	O
.	O	O

Another	O	O
example	O	O
is	O	O
the	O	O
estrogen	O	O
effect	O	O
on	O	O
the	O	O
delayed	B-DNA	O
type	I-DNA	O
hypersensitivity	O	O
response	O	O
.	O	O

A	O	O
broad	O	O
review	O	O
is	O	O
given	O	O
of	O	O
such	O	O
estrogen	O	O
effects	O	O
on	O	O
lymphoid	B-cell_type	O
tissue	O	O
and	O	O
immune	O	O
response	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
studies	O	O
published	O	O
so	O	O
far	O	O
are	O	O
phenomenological	O	O
.	O	O

However	O	O
,	O	O
the	O	O
recent	O	O
description	O	O
of	O	O
estrogen	B-protein	O
receptors	I-protein	O
in	O	O
the	O	O
thymus	O	O
and	O	O
in	O	O
some	O	O
lymphocyte	O	O
subpopulations	O	O
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
deeper	O	O
understanding	O	O
of	O	O
regulating	B-protein	O
factors	I-protein	O
in	O	O
the	O	O
immune	O	O
system	O	O
,	O	O
open	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
more	O	O
detailed	O	O
understanding	O	O
of	O	O
the	O	O
estrogen	O	O
mechanism	O	O
of	O	O
interference	O	O
.	O	O

Estrogen	O	O
effects	O	O
in	O	O
adults	O	O
are	O	O
reversible	O	O
.	O	O

After	O	O
treating	O	O
neonatal	O	O
mice	O	O
with	O	O
the	O	O
synthetic	O	O
estrogen	I-protein	O
diethylstilbestrol	O	O
(	O	O
DES	B-protein	O
)	O	O
,	O	O
disturbances	O	O
are	O	O
induced	O	O
in	O	O
lymphocyte	O	O
populations	O	O
and	O	O
lymphocyte	O	O
functions	O	O
which	O	O
are	O	O
permanent	O	O
and	O	O
irreversible	O	O
.	O	O

Lymphocytes	O	O
from	O	O
adult	O	O
,	O	O
neonatally	O	O
DES-treated	O	O
female	O	O
mice	O	O
have	O	O
a	O	O
reduced	O	O
mitogen	O	O
response	O	O
to	O	O
ConA	O	O
and	O	O
LPS	O	O
(	O	O
T	O	O
and	O	O
B	B-protein	O
cell	I-protein	O
mitogen	I-protein	O
)	O	O
and	O	O
the	O	O
delayed	O	O
type	O	O
hypersensitivity	O	O
response	O	O
is	O	O
depressed	O	O
.	O	O

A	O	O
detailed	O	O
analysis	O	O
demonstrated	O	O
a	O	O
decreased	O	O
T	O	O
helper	O	O
cell	O	O
population	O	O
.	O	O

The	O	O
activity	O	O
of	O	O
Natural	B-cell_type	O
Killer	I-cell_type	O
cells	I-cell_type	O
is	O	O
permanently	O	O
reduced	O	O
and	O	O
this	O	O
functional	O	O
impairment	O	O
is	O	O
related	O	O
to	O	O
a	O	O
decreased	O	O
number	O	O
of	O	O
these	O	O
cells	O	O
,	O	O
in	O	O
turn	O	O
determined	O	O
at	O	O
the	O	O
bone	O	O
marrow	O	O
level	O	O
.	O	O

The	O	O
same	O	O
animals	O	O
have	O	O
an	O	O
increased	O	O
sensitivity	O	O
to	O	O
chemical	O	O
carcinogens	O	O
(	O	O
methylcholanthrene	O	O
)	O	O
and	O	O
they	O	O
spontaneously	O	O
develop	O	O
epithelial	O	O
changes	O	O
in	O	O
the	O	O
uterine	O	O
cervix	O	O
which	O	O
morphologically	O	O
are	O	O
similar	O	O
to	O	O
adenocarcinoma	O	O
.	O	O

The	O	O
association	O	O
between	O	O
estrogen-associated	O	O
malignancy	O	O
and	O	O
estrogen	O	O
effects	O	O
in	O	O
lymphocyte	O	O
functions	O	O
deserves	O	O
further	O	O
study	O	O
.	O	O

Drugs	O	O
affecting	O	O
the	O	O
hormonal	O	O
receptors	O	O
of	O	O
normal	O	O
and	O	O
leukaemic	O	O
peripheral	O	O
leucocytes	O	O
.	O	O

The	O	O
authors	O	O
investigated	O	O
the	O	O
behaviour	O	O
of	O	O
steroid	O	O
hormone	O	O
uptake	O	O
in	O	O
leukaemic	B-cell_type	O
cells	I-cell_type	O
(	O	O
CML	O	O
,	O	O
CLL	O	O
,	O	O
AML	O	O
,	O	O
ALL	O	O
)	O	O
,	O	O
in	O	O
basal	O	O
conditions	O	O
and	O	O
after	O	O
incubation	O	O
with	O	O
drugs	O	O
which	O	O
modify	O	O
the	O	O
cellular	O	O
concentration	O	O
of	O	O
cAMP	O	O
,	O	O
PGE	O	O
and	O	O
PGF	O	O
.	O	O

The	O	O
results	O	O
demonstrated	O	O
the	O	O
presence	O	O
in	O	O
leukaemic	O	O
cells	O	O
of	O	O
an	O	O
alteration	O	O
in	O	O
the	O	O
incorporation	O	O
of	O	O
steroid	O	O
hormones	O	O
.	O	O

This	O	O
alteration	O	O
was	O	O
scarcely	O	O
modified	O	O
by	O	O
incubation	O	O
with	O	O
theophylline	O	O
,	O	O
which	O	O
increases	O	O
cellular	O	O
concentration	O	O
of	O	O
cAMP	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
it	O	O
was	O	O
moderately	O	O
counteracted	O	O
by	O	O
thioproline	O	O
and	O	O
was	O	O
evidently	O	O
inhibited	O	O
by	O	O
flurbiprofen	O	O
,	O	O
which	O	O
also	O	O
reduced	O	O
cellular	O	O
concentrations	O	O
of	O	O
prostaglandins	O	O
,	O	O
particularly	O	O
PGE2	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
PGF2	O	O
which	O	O
showed	O	O
a	O	O
poor	O	O
response	O	O
.	O	O

Differences	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
behavior	O	O
of	O	O
hormonal	O	O
uptake	O	O
of	O	O
CML	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
that	O	O
of	O	O
AML	O	O
,	O	O
CLL	O	O
and	O	O
ALL	O	O
peripheral	O	O
leucocytes	O	O
.	O	O

Human	O	O
breast	O	O
cancer	O	O
and	O	O
impaired	O	O
NK	O	O
cell	O	O
function	O	O
.	O	O

Recent	O	O
advances	O	O
in	O	O
tumor	O	O
immunology	O	O
have	O	O
led	O	O
to	O	O
the	O	O
discovery	O	O
of	O	O
a	O	O
new	O	O
lymphoid	O	O
cell	O	O
with	O	O
unique	O	O
antitumor	O	O
activity	O	O
.	O	O

Natural	I-cell_line	O
killer	I-cell_line	O
(	I-cell_line	O
NK	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
form	O	O
an	O	O
antitumor	O	O
surveillance	O	O
system	O	O
and	O	O
appear	O	O
to	O	O
be	O	O
vital	O	O
in	O	O
preventing	O	O
tumor	O	O
growth	O	O
and	O	O
metastasis	O	O
in	O	O
animal	O	O
models	O	O
.	O	O

We	O	O
studied	O	O
NK	O	O
activity	O	O
in	O	O
patients	O	O
with	O	O
benign	O	O
and	O	O
malignant	O	O
breast	O	O
disease	O	O
,	O	O
using	O	O
a	O	O
chromium-51	O	O
release	O	O
microtiter	O	O
cytotoxicity	O	O
assay	O	O
with	O	O
K562	B-cell_type	O
cells	I-cell_type	O
as	O	O
targets	O	O
.	O	O

Compared	O	O
with	O	O
benign	O	O
controls	O	O
,	O	O
patients	O	O
with	O	O
malignancies	O	O
had	O	O
significantly	O	O
depressed	O	O
NK	O	O
-mediated	O	O
lysis	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
lysis	O	O
in	O	O
those	O	O
with	O	O
advanced	O	O
disease	O	O
(	O	O
stages	B-protein	O
II	I-protein	O
,	O	O
III	O	O
,	O	O
and	O	O
IV	B-protein	O
)	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
in	O	O
those	O	O
with	O	O
limited	O	O
disease	O	O
(	O	O
stage	B-protein	O
I	I-protein	O
)	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

NK	O	O
activity	O	O
was	O	O
not	O	O
correlated	O	O
to	O	O
estrogen	O	O
or	O	O
progesterone	O	O
receptor	O	O
states	O	O
.	O	O

Positive	O	O
correlation	O	O
of	O	O
a	O	O
depressed	O	O
natural	O	O
killer	O	O
activity	O	O
with	O	O
the	O	O
extent	O	O
of	O	O
tumor	O	O
spread	O	O
supports	O	O
the	O	O
concept	O	O
of	O	O
an	O	O
NK	O	O
cell	O	O
immune	O	O
surveillance	O	O
system	O	O
in	O	O
breast	O	O
cancer	O	O
and	O	O
emphasizes	O	O
its	O	O
importance	O	O
in	O	O
this	O	O
malignancy	O	O
.	O	O

Immunosuppressive	O	O
effect	O	O
of	O	O
serum	O	O
progesterone	O	O
during	O	O
pregnancy	O	O
depends	O	O
on	O	O
the	O	O
progesterone	O	O
binding	O	O
capacity	O	O
of	O	O
the	O	O
lymphocytes	I-cell_type	O
.	O	O

Cytotoxic	O	O
activity	O	O
and	O	O
progesterone	O	O
binding	O	O
capacity	O	O
of	O	O
the	O	O
lymphocytes	I-cell_type	O
,	O	O
together	O	O
with	O	O
serum	O	O
progesterone	O	O
concentrations	O	O
,	O	O
were	O	O
determined	O	O
in	O	O
women	O	O
with	O	O
normal	O	O
pregnancy	O	O
or	O	O
with	O	O
a	O	O
clinical	O	O
diagnosis	O	O
of	O	O
threatened	O	O
abortion	O	O
or	O	O
threatened	O	O
premature	O	O
labour	O	O
.	O	O

The	O	O
lymphocytes	O	O
of	O	O
women	O	O
with	O	O
threatened	O	O
abortion	O	O
or	O	O
threatened	O	O
premature	O	O
labour	O	O
showed	O	O
significantly	O	O
higher	O	O
cytotoxic	O	O
activity	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
and	O	O
significantly	O	O
lower	O	O
progesterone	O	O
binding	O	O
capacity	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
than	O	O
did	O	O
lymphocytes	O	O
obtained	O	O
from	O	O
the	O	O
healthy	O	O
pregnant	O	O
women	O	O
.	O	O

Significant	O	O
inverse	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
progesterone	O	O
binding	O	O
capacity	O	O
and	O	O
cytotoxic	O	O
activity	O	O
of	O	O
the	O	O
lymphocytes	B-protein	O
(	I-protein	O
P	I-protein	O
less	I-protein	O
than	O	O
0.001	B-protein	O
)	O	O
,	O	O
but	O	O
the	O	O
progesterone	O	O
concentration	O	O
of	O	O
the	O	O
pregnancy	O	O
serum	O	O
appeared	O	O
to	O	O
have	O	O
no	O	O
influence	O	O
on	O	O
the	O	O
other	O	O
two	O	O
parameters	O	O
.	O	O

The	O	O
findings	O	O
indicate	O	O
that	O	O
intact	O	O
progesterone	O	O
binding	O	O
capacity	O	O
of	O	O
the	O	O
lymphocytes	B-protein	O
is	O	O
an	O	O
essential	O	O
factor	O	O
for	O	O
the	O	O
manifestation	O	O
of	O	O
the	O	O
blocking	O	O
effect	O	O
exerted	O	O
by	O	O
pregnancy	O	O
serum	O	O
on	O	O
lymphocyte	O	O
cytotoxicity	O	O
in	O	O
vitro	O	O
.	O	O

Serum	O	O
sex	O	O
steroid	O	O
and	O	O
peptide	O	O
hormone	O	O
concentrations	O	O
,	O	O
and	O	O
endometrial	O	O
estrogen	O	O
and	O	O
progestin	O	O
receptor	O	O
levels	O	O
during	O	O
administration	O	O
of	O	O
human	O	O
leukocyte	O	O
interferon	O	O
.	O	O

Five	O	O
normally	O	O
cycling	O	O
healthy	O	O
women	O	O
were	O	O
given	O	O
daily	O	O
subcutaneous	O	O
injections	O	O
of	O	O
human	O	O
leukocyte	O	O
interferon	O	O
(	O	O
3	O	O
X	O	O
10	O	O
(	O	O
6	O	O
)	O	O
units/day	O	O
)	O	O
from	O	O
the	O	O
3rd	O	O
through	O	O
23rd	O	O
day	O	O
of	O	O
the	O	O
menstrual	O	O
cycle	O	O
,	O	O
and	O	O
serum	O	O
steroid	O	O
and	O	O
peptide	O	O
hormone	O	O
concentrations	O	O
monitored	O	O
at	O	O
3-day	O	O
intervals	O	O
during	O	O
the	O	O
treatment	O	O
and	O	O
the	O	O
preceding	O	O
control	O	O
cycle	O	O
.	O	O

Concentrations	O	O
of	O	O
cytosol	O	O
and	O	O
nuclear	O	O
estrogen	B-protein	O
receptors	I-protein	O
(	O	O
ERC	O	O
and	O	O
ERN	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
progestin	O	O
receptors	O	O
(	O	O
PRC	O	O
and	O	O
PRN	O	O
)	O	O
were	O	O
also	O	O
measured	O	O
from	O	O
endometrial	O	O
biopsies	O	O
taken	O	O
on	O	O
the	O	O
24th	O	O
day	O	O
of	O	O
the	O	O
control	O	O
and	O	O
treatment	O	O
cycle	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
an	O	O
extensive	O	O
monitoring	O	O
of	O	O
clinical	O	O
chemical	O	O
and	O	O
hematological	O	O
tests	O	O
from	O	O
the	O	O
blood	O	O
samples	O	O
were	O	O
performed	O	O
.	O	O

Serum	O	O
estradiol	O	O
and	O	O
progesterone	O	O
concentrations	O	O
were	O	O
significantly	O	O
decreased	O	O
during	O	O
the	O	O
treatment	O	O
cycle	O	O
,	O	O
suggesting	O	O
that	O	O
interferon	O	O
interacts	O	O
in	O	O
vivo	O	O
with	O	O
the	O	O
function	O	O
of	O	O
both	O	O
FSH	O	O
and	O	O
LH	O	O
.	O	O

No	O	O
significant	O	O
changes	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
serum	O	O
peptide	O	O
hormone	O	O
concentrations	O	O
measured	O	O
(	O	O
FSH	O	O
,	O	O
LH	O	O
,	O	O
prolactin	O	O
,	O	O
insulin	O	O
,	O	O
growth	O	O
hormone	O	O
and	O	O
TSH	O	O
)	O	O
;	O	O
neither	O	O
were	O	O
the	O	O
levels	O	O
of	O	O
endometrial	O	O
ERC	O	O
,	O	O
ERN	O	O
,	O	O
PRC	O	O
and	O	O
PRN	O	O
affected	O	O
by	O	O
interferon	O	O
administration	O	O
.	O	O

As	O	O
expected	O	O
,	O	O
interferon	O	O
administration	O	O
resulted	O	O
in	O	O
decreased	O	O
leukocyte	O	O
counts	O	O
.	O	O

Moreover	O	O
,	O	O
an	O	O
increasing	O	O
tendency	O	O
in	O	O
the	O	O
activities	O	O
of	O	O
serum	O	O
alkaline	O	O
phosphatase	O	O
and	O	O
gamma-glutamyltransferase	O	O
during	O	O
the	O	O
interferon	O	O
therapy	O	O
shows	O	O
that	O	O
interferon	O	O
may	O	O
slightly	O	O
interfere	O	O
with	O	O
the	O	O
liver	O	O
function	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
one	O	O
of	O	O
the	O	O
mechanisms	O	O
by	O	O
which	O	O
interferon	O	O
treatment	O	O
may	O	O
affect	O	O
the	O	O
growth	O	O
of	O	O
hormone-dependent	O	O
neoplasms	O	O
could	O	O
be	O	O
the	O	O
interaction	O	O
with	O	O
production	O	O
and/or	O	O
function	O	O
of	O	O
circulating	O	O
hormonal	O	O
compounds	O	O
.	O	O

[	O	O
Glucocorticoid	B-DNA	O
receptor	I-DNA	O
level	O	O
in	O	O
the	O	O
blood	O	O
leukocytes	O	O
in	O	O
different	O	O
acute	O	O
diseases	O	O
]	O	O

Content	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
cytosol	O	O
of	O	O
blood	O	O
leukocytes	O	O
,	O	O
concentration	O	O
of	O	O
cortisol	O	O
and	O	O
amount	O	O
of	O	O
leukocytes	O	O
in	O	O
blood	O	O
were	O	O
studied	O	O
in	O	O
20	O	O
patients	O	O
with	O	O
acute	O	O
impairments	O	O
within	O	O
the	O	O
second	O	O
day	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

Content	O	O
of	O	O
receptors	O	O
in	O	O
cytosol	O	O
of	O	O
blood	O	O
leukocytes	O	O
was	O	O
studied	O	O
using	O	O
3H-triamcinolone	O	O
acetonide	O	O
.	O	O

Distinct	O	O
increase	O	O
in	O	O
amount	O	O
of	O	O
the	O	O
leukocyte	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
was	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
poisoning	O	O
by	O	O
dichlorethane	O	O
and	O	O
hypnotic	O	O
drugs	O	O
under	O	O
conditions	O	O
of	O	O
acute	O	O
myocardial	O	O
infarction	O	O
.	O	O

In	O	O
acute	O	O
pancreatitis	O	O
content	O	O
of	O	O
the	O	O
leukocyte	B-protein	O
receptors	I-protein	O
was	O	O
not	O	O
altered	O	O
as	O	O
compared	O	O
with	O	O
controls	O	O
.	O	O

Concentration	O	O
of	O	O
endogenous	O	O
cortisol	O	O
was	O	O
increased	O	O
in	O	O
blood	O	O
of	O	O
all	O	O
the	O	O
patients	O	O
,	O	O
except	O	O
of	O	O
the	O	O
cases	O	O
of	O	O
acetate	O	O
intoxication	O	O
.	O	O

Reverse	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
concentration	O	O
of	O	O
cortisol	O	O
in	O	O
blood	O	O
and	O	O
content	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
leukocytes	O	O
.	O	O

But	O	O
in	O	O
the	O	O
patients	O	O
with	O	O
acute	O	O
pancreatitis	O	O
the	O	O
decrease	O	O
in	O	O
content	O	O
of	O	O
leukocyte	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
was	O	O
not	O	O
observed	O	O
although	O	O
there	O	O
was	O	O
an	O	O
increase	O	O
in	O	O
cortisol	O	O
concentration	O	O
in	O	O
blood	O	O
.	O	O

The	O	O
role	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
immunological	O	O
processes	O	O
under	O	O
conditions	O	O
of	O	O
purulent	O	O
complications	O	O
and	O	O
possibility	O	O
to	O	O
regulate	O	O
the	O	O
metabolism	O	O
in	O	O
leukocytes	O	O

Therapeutic	O	O
concentrations	O	O
of	O	O
glucocorticoids	O	O
suppress	O	O
the	O	O
antimicrobial	O	O
activity	O	O
of	O	O
human	B-DNA	O
macrophages	I-DNA	O
without	O	O
impairing	O	O
their	O	O
responsiveness	O	O
to	O	O
gamma	O	O
interferon	O	O
.	O	O

By	O	O
exposing	O	O
human	O	O
blood-derived	O	O
macrophages	O	O
and	O	O
alveolar	O	O
macrophages	O	O
in	O	O
vitro	O	O
to	O	O
dexamethasone	O	O
,	O	O
we	O	O
showed	O	O
in	O	O
these	O	O
studies	O	O
that	O	O
glucocorticoids	O	O
markedly	O	O
suppress	O	O
the	O	O
antimicrobial	O	O
activity	O	O
of	O	O
macrophages	B-protein	O
but	O	O
not	O	O
macrophage	O	O
activation	O	O
by	O	O
lymphokines	O	O
.	O	O

As	O	O
little	O	O
as	O	O
2.5	O	O
X	O	O
10	O	O
(	O	O
-8	B-protein	O
)	O	O
mol/liter	O	O
of	O	O
dexamethasone	O	O
prevented	O	O
macrophages	O	O
from	O	O
inhibiting	O	O
germination	O	O
of	O	O
Aspergillus	O	O
spores	O	O
or	O	O
from	O	O
eliminating	O	O
ingested	O	O
bacteria	O	O
such	O	O
as	O	O
Listeria	O	O
,	O	O
Nocardia	O	O
,	O	O
or	O	O
Salmonella	O	O
.	O	O

Damage	O	O
to	O	O
macrophage	O	O
function	O	O
was	O	O
inhibited	O	O
by	O	O
progesterone	O	O
and	O	O
appeared	O	O
to	O	O
be	O	O
receptor-mediated	O	O
.	O	O

In	O	O
accordance	O	O
with	O	O
in	O	O
vivo	O	O
observations	O	O
,	O	O
dexamethasone	O	O
required	O	O
24-36	O	O
h	O	O
to	O	O
suppress	O	O
antimicrobial	O	O
activity	O	O
.	O	O

While	O	O
glucocorticoids	O	O
interfered	O	O
with	O	O
base-line	O	O
activity	O	O
of	O	O
macrophages	O	O
,	O	O
dexamethasone	O	O
concentrations	O	O
comparable	O	O
to	O	O
drug	O	O
levels	O	O
in	O	O
patients	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
macrophage	O	O
activation	O	O
.	O	O

Proliferating	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
gamma-interferon	O	O
thus	O	O
increased	O	O
the	O	O
antimicrobial	O	O
activity	O	O
of	O	O
phagocytes	O	O
exposed	O	O
to	O	O
glucocorticoids	O	O
over	O	O
that	O	O
of	O	O
control	B-cell_type	O
cells	I-cell_type	O
.	O	O

Macrophage	O	O
activation	O	O
and	O	O
correction	O	O
of	O	O
the	O	O
dexamethasone	O	O
effect	O	O
by	O	O
gamma-interferon	O	O
,	O	O
however	O	O
,	O	O
was	O	O
dependent	O	O
on	O	O
the	O	O
pathogen	O	O
.	O	O

The	O	O
lymphokine	O	O
enhanced	O	O
the	O	O
antimicrobial	O	O
activity	O	O
of	O	O
dexamethasone-treated	O	O
macrophages	O	O
against	O	O
Listeria	O	O
and	O	O
Salmonella	O	O
but	O	O
not	O	O
against	O	O
Aspergillus	O	O
or	O	O
Nocardia	O	O
.	O	O

Dexamethasone-induced	O	O
damage	O	O
to	O	O
the	O	O
antimicrobial	O	O
activity	O	O
of	O	O
human	O	O
macrophages	O	O
in	O	O
vitro	O	O
parallels	O	O
observations	O	O
that	O	O
glucocorticoids	O	O
render	O	O
laboratory	O	O
animals	O	O
susceptible	O	O
to	O	O
listeriosis	O	O
and	O	O
aspergillosis	O	O
by	O	O
damaging	O	O
resident	O	O
macrophages	O	O
.	O	O

Suppression	O	O
of	O	O
macrophage	O	O
antimicrobial	O	O
activity	O	O
should	O	O
thus	O	O
be	O	O
considered	O	O
when	O	O
treating	O	O
patients	O	O
with	O	O
glucocorticoids	O	O
;	O	O
its	O	O
prevention	O	O
by	O	O
gamma-interferon	O	O
might	O	O
be	O	O
beneficial	O	O
for	O	O
some	O	O
but	O	O
not	O	O
all	O	O
pathogens	O	O
.	O	O

Interleukin	B-protein	O
2	I-protein	O
receptor	I-protein	O
(	O	O
Tac	B-protein	O
antigen	I-protein	O
)	O	O
expression	O	O
in	O	O
HTLV-I-associated	O	O
adult	O	O
T-cell	O	O
leukemia	O	O
.	O	O

Interleukin-2	B-protein	O
(	O	O
IL-2	B-protein	O
)	O	O
is	O	O
a	O	O
lymphokine	O	O
synthesized	O	O
by	O	O
some	O	O
T-cells	O	O
following	O	O
activation	O	O
.	O	O

Resting	O	O
T-cells	O	O
do	O	O
not	O	O
express	O	O
IL-2	B-protein	O
receptors	I-protein	O
,	O	O
but	O	O
receptors	O	O
are	O	O
rapidly	O	O
expressed	O	O
on	O	O
T-cells	O	O
following	O	O
interaction	O	O
of	O	O
antigens	B-protein	O
,	O	O
mitogens	O	O
,	O	O
or	O	O
monoclonal	B-protein	O
antibodies	O	O
with	O	O
the	O	O
antigen-specific	O	O
T-cell	B-protein	O
receptor	I-protein	O
complex	I-protein	O
.	O	O

Using	O	O
anti-Tac	O	O
,	O	O
a	O	O
monoclonal	O	O
antibody	O	O
that	O	O
recognizes	O	O
the	O	O
IL-2	B-protein	O
receptor	I-protein	O
,	O	O
the	O	O
receptor	O	O
has	O	O
been	O	O
purified	O	O
and	O	O
shown	O	O
to	O	O
be	O	O
a	O	O
Mr	O	O
33	O	O
,	O	O
000	O	O
peptide	O	O
that	O	O
is	O	O
posttranslationally	O	O
glycosylated	O	O
to	O	O
a	O	O
Mr	O	O
55	O	O
,	O	O
000	O	O
mature	O	O
form	O	O
.	O	O

Normal	O	O
resting	O	O
T-cells	O	O
and	O	O
most	O	O
leukemic	O	O
T-cell	O	O
populations	O	O
do	O	O
not	O	O
express	O	O
IL-2	B-protein	O
receptors	O	O
;	O	O
however	O	O
,	O	O
the	O	O
leukemic	O	O
cells	O	O
of	O	O
the	O	O
11	O	O
patients	O	O
examined	O	O
who	O	O
had	O	O
human	O	O
T-cell	O	O
lymphotropic	O	O
virus-associated	O	O
adult	O	O
T-cell	O	O
leukemia	O	O
expressed	O	O
the	O	O
Tac	O	O
antigen	O	O
.	O	O

In	O	O
human	O	O
T-cell	O	O
lymphotropic	O	O
virus-I	O	O
infected	B-cell_type	O
cells	I-cell_type	O
,	O	O
the	O	O
Mr	O	O
42	O	O
,	O	O
000	O	O
long	O	O
open	O	O
reading	O	O
frame	O	O
protein	O	O
encoded	O	O
in	O	O
part	O	O
by	O	O
the	O	O
pX	O	O
region	O	O
of	O	O
this	O	O
virus	O	O
may	O	O
act	O	O
as	O	O
a	O	O
transacting	O	O
transcriptional	O	O
activator	O	O
that	O	O
induces	O	O
IL-2	B-protein	O
receptor	I-protein	O
gene	O	O
transcription	O	O
,	O	O
thus	O	O
providing	O	O
an	O	O
explanation	O	O
for	O	O
the	O	O
constant	O	O
association	O	O
of	O	O
IL-2	B-protein	O
receptor	I-protein	O
expression	O	O
with	O	O
adult	O	O
T-cell	O	O
lymphotropic	O	O
virus-I	O	O
infection	O	O
of	O	O
lymphoid	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
constant	O	O
expression	O	O
of	O	O
large	O	O
numbers	O	O
of	O	O
IL-2	B-protein	O
receptors	O	O
which	O	O
may	O	O
be	O	O
aberrant	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
uncontrolled	O	O
growth	O	O
of	O	O
adult	O	O
T-cell	O	O
leukemia	O	O
cells	O	O
.	O	O

Two	O	O
patients	O	O
with	O	O
Tac-positive	O	O
adult	O	O
T-cell	O	O
leukemia	O	O
have	O	O
been	O	O
treated	O	O
with	O	O
the	O	O
anti-Tac	O	O
.	O	O

One	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
6-	O	O
and	O	O
3-mo	O	O
remissions	O	O
of	O	O
his	O	O
leukemia	O	O
following	O	O
two	O	O
courses	O	O
of	O	O
therapy	B-protein	O
with	O	O
this	O	O
monoclonal	O	O
antibody	O	O
directed	O	O
toward	O	O
this	O	O
growth	O	O
factor	O	O
receptor	O	O
.	O	O

Lymphocyte	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
binding	O	O
in	O	O
depressed	O	O
patients	O	O
with	O	O
hypercortisolemia	O	O
.	O	O

Despite	O	O
elevated	O	O
levels	O	O
of	O	O
serum	O	O
and	O	O
urinary	O	O
cortisol	O	O
,	O	O
patients	O	O
with	O	O
depressive	O	O
illness	O	O
manifest	O	O
none	O	O
of	O	O
the	O	O
clinical	O	O
stigmata	O	O
of	O	O
glucocorticoid	O	O
excess	O	O
.	O	O

This	O	O
hypercortisolemia	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
clinical	O	O
effects	O	O
suggests	O	O
a	O	O
state	O	O
of	O	O
hormone	O	O
resistance	O	O
and	O	O
could	O	O
be	O	O
mediated	O	O
by	O	O
alterations	O	O
in	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
.	O	O

Earlier	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
small	O	O
doses	O	O
of	O	O
glucocorticoids	O	O
cause	O	O
a	O	O
decrease	O	O
in	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
binding	O	O
in	O	O
normal	B-cell_type	O
human	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

White	B-cell_type	O
cells	I-cell_type	O
from	O	O
depressed	O	O
patients	O	O
with	O	O
significant	O	O
hypercortisolemia	O	O
would	O	O
be	O	O
expected	O	O
to	O	O
show	O	O
a	O	O
similar	O	O
change	O	O
in	O	O
receptor	O	O
concentration	O	O
if	O	O
peripheral	O	O
tissues	O	O
are	O	O
adequately	O	O
exposed	O	O
to	O	O
and	O	O
sensitive	O	O
to	O	O
the	O	O
hormone	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
compared	O	O
the	O	O
binding	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone	O	O
to	O	O
lymphocytes	I-cell_type	O
from	O	O
normal	O	O
subjects	O	O
and	O	O
depressed	O	O
patients	O	O
with	O	O
hypercortisolemia	O	O
.	O	O

Lymphocytes	O	O
from	O	O
normal	O	O
subjects	O	O
had	O	O
a	O	O
mean	O	O
receptor	O	O
concentration	O	O
of	O	O
10.2	O	O
+/-	O	O
0.66	O	O
fm/10	O	O
(	O	O
6	B-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
(	O	O
S.E.M.	B-protein	O
)	O	O
and	O	O
a	O	O
dissociation	O	O
constant	O	O
of	O	O
4.8	O	O
+/-	O	O
0.47	O	O
nM	O	O
.	O	O

Lymphocytes	O	O
from	O	O
depressed	O	O
patients	O	O
with	O	O
abnormal	O	O
0800	O	O
h	O	O
serum	O	O
cortisol	O	O
after	O	O
dexamethasone	O	O
had	O	O
a	O	O
mean	O	O
receptor	O	O
concentration	O	O
of	O	O
8.8	O	O
+/-	O	O
0.75	O	O
fm/10	O	O
(	O	O
6	O	O
)	O	O
cells	O	O
,	O	O
which	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
from	O	O
that	O	O
in	O	O
lymphocytes	I-cell_type	O
from	O	O
normal	O	O
subjects	O	O
or	O	O
from	O	O
depressed	O	O
subjects	O	O
with	O	O
normal	O	O
post-dexamethasone	O	O
cortisol	O	O
levels	O	O
(	O	O
9.4	O	O
+/-	O	O
0.95	O	O
fm/10	O	O
(	O	O
6	O	O
)	O	O
cells	O	O
)	O	O
.	O	O

Lymphocytes	O	O
from	O	O
depressed	O	O
patients	O	O
with	O	O
elevated	O	O
urinary	O	O
free	O	O
cortisol	O	O
excretion	O	O
(	O	O
UFC	O	O
)	O	O
also	O	O
had	O	O
normal	O	O
receptor	O	O
concentration	O	O
and	O	O
binding	O	O
affinity	O	O
for	O	O
dexamethasone	O	O
.	O	O

The	O	O
lack	O	O
of	O	O
a	O	O
change	O	O
in	O	O
lymphocyte	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
concentration	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
cortisol	O	O
excess	O	O
suggests	O	O
the	O	O
possibility	O	O
that	O	O
hypercortisolemia	O	O
in	O	O
depressive	O	O
illness	O	O
represents	O	O
a	O	O
state	O	O
of	O	O
peripheral	O	O
glucocorticoid	O	O
resistance	O	O
.	O	O

Structure	O	O
and	O	O
regulation	O	O
of	O	O
the	O	O
glucocorticoid	B-protein	O
hormone	I-protein	O
receptor	I-protein	O
.	O	O

The	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
is	O	O
an	O	O
intracellular	O	O
protein	O	O
which	O	O
possesses	O	O
three	O	O
distinct	O	O
domains	O	O
,	O	O
one	O	O
that	O	O
binds	O	O
agonist	O	O
and	O	O
antagonist	O	O
steroids	O	O
,	O	O
one	O	O
that	O	O
binds	O	O
DNA	O	O
,	O	O
and	O	O
one	O	O
that	O	O
binds	O	O
anti-receptor	O	O
antibodies	O	O
and	O	O
is	O	O
required	O	O
for	O	O
glucocorticoid	O	O
modulation	O	O
of	O	O
gene	O	O
expression	O	O
.	O	O

In	O	O
intact	B-cell_type	O
cells	I-cell_type	O
,	O	O
receptor	O	O
number	O	O
,	O	O
affinity	O	O
and	O	O
activity	O	O
can	O	O
change	O	O
in	O	O
response	O	O
to	O	O
factors	B-protein	O
that	O	O
bind	O	O
to	O	O
the	O	O
receptor	O	O
,	O	O
or	O	O
that	O	O
act	O	O
indirectly	O	O
through	O	O
ill-defined	O	O
mechanisms	O	O
which	O	O
may	O	O
include	O	O
resumption	O	O
or	O	O
arrest	O	O
of	O	O
cell	O	O
cycling	O	O
and	O	O
variations	O	O
in	O	O
intracellular	O	O
calcium	O	O
ion	O	O
concentrations	O	O
.	O	O

Some	O	O
of	O	O
these	O	O
factors	I-protein	O
appear	O	O
to	O	O
exert	O	O
their	O	O
effect	O	O
by	O	O
controlling	O	O
critical	O	O
receptor	O	O
properties	O	O
such	O	O
as	O	O
ATP-dependent	O	O
phosphorylation	O	O
,	O	O
integrity	O	O
of	O	O
thiol	O	O
groups	O	O
,	O	O
and	O	O
exposure	O	O
of	O	O
key	O	O
amino	O	O
acid	O	O
residues	O	O
.	O	O

Glucocorticoid	O	O
agonists	O	O
promote	O	O
the	O	O
'transformation	O	O
'	O	O
of	O	O
the	O	O
receptor	O	O
into	O	O
the	O	O
DNA-binding	O	O
state	O	O
,	O	O
which	O	O
is	O	O
competent	O	O
for	O	O
modulating	O	O
gene	O	O
expression	O	O
.	O	O

Glucocorticoid	O	O
antagonists	O	O
are	O	O
steroids	O	O
that	O	O
interact	O	O
with	O	O
the	O	O
receptor	B-protein	O
but	O	O
either	O	O
fail	O	O
to	O	O
produce	O	O
a	O	O
stable	O	O
complex	O	O
or	O	O
produce	O	O
a	O	O
stable	O	O
but	O	O
inefficient	O	O
complex	I-protein	O
.	O	O

Although	O	O
substituent	O	O
groups	O	O
that	O	O
confer	O	O
agonist	O	O
or	O	O
antagonist	O	O
activity	O	O
to	O	O
the	O	O
steroid	O	O
have	O	O
been	O	O
identified	O	O
,	O	O
the	O	O
molecular	O	O
determinants	O	O
of	O	O
this	O	O
difference	O	O
at	O	O
the	O	O
receptor	O	O
level	O	O
remain	O	O
unknown	O	O
.	O	O

Most	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
data	O	O
on	O	O
receptor	O	O
regulation	O	O
can	O	O
be	O	O
accommodated	O	O
by	O	O
postulating	O	O
the	O	O
existence	O	O
of	O	O
an	O	O
intracellular	O	O
cycle	O	O
that	O	O
involves	O	O
five	O	O
states	O	O
of	O	O
the	O	O
receptor	B-protein	O
.	O	O

The	O	O
active	O	O
free	B-protein	O
receptor	I-protein	O
is	O	O
phosphorylated	O	O
,	O	O
reduced	O	O
,	O	O
and	O	O
presumably	O	O
oligomeric	O	O
(	O	O
state	O	O
A	O	O
)	O	O
.	O	O

Following	O	O
binding	O	O
of	O	O
an	O	O
agonist	B-DNA	O
(	I-DNA	O
state	I-DNA	O
B	I-DNA	O
)	O	O
,	O	O
it	O	O
can	O	O
become	O	O
transformed	O	O
by	O	O
dissociation	O	O
into	O	O
its	O	O
subunits	B-protein	O
and	O	O
dephosphorylation	O	O
(	O	O
state	O	O
C	B-protein	O
)	O	O
.	O	O

The	O	O
transformed	B-protein	O
receptor	I-protein	O
then	O	O
interacts	O	O
with	O	O
chromatin	B-DNA	O
(	O	O
state	O	O
D	O	O
)	O	O
.	O	O

Dissociation	O	O
of	O	O
the	O	O
steroid	O	O
and	O	O
oxidation	O	O
of	O	O
receptor	I-protein	O
thiol	O	O
group	O	O
(	O	O
s	O	O
)	O	O
lead	O	O
to	O	O
the	O	O
inactive	B-protein	O
receptor	I-protein	O
form	O	O
(	O	O
state	O	O
E	O	O
)	O	O
.	O	O

Reduction	O	O
and	O	O
rephosphorylation	O	O
of	O	O
the	O	O
receptor	O	O
enable	O	O
it	O	O
to	O	O
bind	O	O
steroids	O	O
again	O	O
so	O	O
that	O	O
the	O	O
cycle	O	O
is	O	O
closed	O	O
.	O	O

Thermodynamics	O	O
of	O	O
steroid	O	O
binding	O	O
to	O	O
the	O	O
human	B-protein	O
glucocorticoid	I-protein	O
receptor	I-protein	O
.	O	O

The	O	O
thermodynamics	O	O
of	O	O
the	O	O
interaction	O	O
of	O	O
glucocorticoids	O	O
with	O	O
their	B-protein	O
receptor	I-protein	O
were	O	O
studied	O	O
in	O	O
cytosol	O	O
from	O	O
human	B-cell_type	O
lymphoblastoid	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
rate	O	O
and	O	O
affinity	O	O
constants	O	O
of	O	O
dexamethasone	O	O
and	O	O
cortisol	O	O
between	O	O
0	O	O
degree	O	O
and	O	O
25	O	O
degrees	O	O
C	O	O
were	O	O
calculated	O	O
by	O	O
curve-fitting	O	O
from	O	O
time-course	O	O
and	O	O
equilibrium	O	O
kinetics	O	O
.	O	O

The	O	O
data	O	O
were	O	O
consistent	O	O
with	O	O
a	O	O
simple	B-DNA	O
reversible	I-DNA	O
bimolecular	O	O
interaction	O	O
.	O	O

Arrhenius	O	O
and	O	O
Va	O	O
n't	O	O
Hoff	O	O
plots	O	O
were	O	O
curvilinear	O	O
for	O	O
both	O	O
steroids	O	O
.	O	O

At	O	O
equilibrium	O	O
,	O	O
the	O	O
solution	O	O
for	O	O
the	O	O
equation	O	O
delta	O	O
G	O	O
=	O	O
delta	O	O
H	O	O
-	O	O
T	O	O
X	O	O
delta	O	O
S	O	O
(	O	O
eqn.	O	O
1	O	O
)	O	O
was	O	O
(	O	O
in	O	O
kJ	O	O
X	O	O
mol-1	O	O
)	O	O
-47	O	O
=	O	O
36	O	O
-	O	O
83	O	O
(	O	O
dexamethasone	O	O
)	O	O
and	O	O
-42	O	O
=	O	O
-9	O	O
-	O	O
33	O	O
(	O	O
cortisol	O	O
)	O	O
at	O	O
0	O	O
degree	O	O
C	O	O
.	O	O

Enthalpy	O	O
and	O	O
entropy	O	O
changes	O	O
decreased	O	O
quasi-linearly	O	O
with	O	O
temperature	O	O
such	O	O
that	O	O
,	O	O
at	O	O
25	O	O
degrees	O	O
C	O	O
,	O	O
the	O	O
respective	O	O
values	O	O
were	O	O
-50	O	O
=	O	O
-75	O	O
+	O	O
25	O	O
and	O	O
-43	O	O
=	O	O
-48	O	O
+	O	O
5	O	O
.	O	O

Thus	O	O
,	O	O
for	O	O
both	O	O
steroids	O	O
,	O	O
the	O	O
interaction	O	O
was	O	O
entropy-driven	O	O
at	O	O
low	O	O
temperature	O	O
and	O	O
became	O	O
entirely	O	O
enthalpy-driven	O	O
at	O	O
20	O	O
degrees	O	O
C	O	O
.	O	O

Thermodynamic	O	O
values	O	O
for	O	O
the	O	O
transition	O	O
state	O	O
were	O	O
calculated	O	O
from	O	O
the	O	O
rate	O	O
constants	O	O
.	O	O

For	O	O
the	O	O
forward	O	O
reaction	O	O
,	O	O
eqn.	O	O
(	O	O
1	O	O
)	O	O
gave	O	O
45	O	O
=	O	O
84	O	O
-	O	O
39	O	O
(	O	O
dexamethasone	O	O
)	O	O
and	O	O
46	O	O
=	O	O
60	O	O
-	O	O
14	O	O
(	O	O
cortisol	O	O
)	O	O
at	O	O
0	O	O
degree	O	O
C	O	O
,	O	O
and	O	O
44	O	O
=	O	O
24	O	O
+	O	O
20	O	O
(	O	O
dexamethasone	O	O
)	O	O
and	O	O
46	O	O
=	O	O
28	O	O
+	O	O
18	O	O
(	O	O
cortisol	O	O
)	O	O
at	O	O
25	O	O
degrees	O	O
C	O	O
.	O	O

These	O	O
data	O	O
fit	O	O
quite	O	O
well	O	O
with	O	O
a	O	O
two-step	O	O
model	O	O
[	O	O
Ross	O	O
&	O	O
Subramanian	O	O
(	O	O
1981	B-protein	O
)	O	O
Biochemistry	O	O
20	O	O
,	O	O
3096-3102	O	O
]	O	O
proposed	O	O
for	O	O
ligand-protein	O	O
interactions	O	O
,	O	O
which	O	O
involves	O	O
a	O	O
partial	O	O
immobilization	O	O
of	O	O
the	O	O
reacting	O	O
species	O	O
governed	O	O
by	O	O
hydrophobic	O	O
forces	O	O
,	O	O
followed	O	O
by	O	O
stabilization	O	O
of	O	O
the	O	O
complex	B-protein	O
by	O	O
short-range	O	O
interactions	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
this	O	O
model	O	O
,	O	O
an	O	O
analysis	O	O
of	O	O
the	O	O
transition-state	O	O
thermodynamics	I-DNA	O
led	O	O
to	O	O
the	O	O
conclusion	O	O
that	O	O
no	O	O
more	O	O
than	O	O
half	O	O
of	O	O
the	O	O
steroid	O	O
molecular	O	O
area	O	O
is	O	O
engaged	O	O
in	O	O
the	O	O
binding	O	O
process	O	O
.	O	O

Cell	O	O
cycle-related	O	O
changes	O	O
in	O	O
number	O	O
of	O	O
T-lymphocyte	O	O
receptors	O	O
for	O	O
glucocorticoids	O	O
and	O	O
insulin	O	O
.	O	O

Enriched	O	O
human	O	O
peripheral	O	O
T-lymphocytes	O	O
were	O	O
stimulated	O	O
with	O	O
PHA	O	O
and	O	O
examined	O	O
for	O	O
variations	O	O
in	O	O
insulin	O	O
and	O	O
glucocorticoid	O	O
(	O	O
dexamethasone	O	O
)	O	O
receptor	O	O
numbers	O	O
during	O	O
the	O	O
early	O	O
phases	O	O
of	O	O
the	O	O
cell	O	O
cycle	O	O
.	O	O

Cells	O	O
in	O	O
G0	O	O
,	O	O
G1a	O	O
and	O	O
G1b	O	O
phases	O	O
,	O	O
where	O	O
the	O	O
G1a	O	O
-	O	O
G1b	O	O
transition	O	O
is	O	O
an	O	O
Interleukin	O	O
2	O	O
dependent	O	O
event	O	O
,	O	O
were	O	O
quantitated	O	O
by	O	O
flow	O	O
cytometry	O	O
.	O	O

Few	O	O
but	O	O
significant	O	O
numbers	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
(	O	O
2700/cell	O	O
)	O	O
and	O	O
no	O	O
insulin	O	O
receptors	O	O
(	O	O
-1/cell	O	O
)	O	O
were	O	O
found	O	O
in	O	O
the	O	O
resting	O	O
(	O	O
G0	O	O
)	O	O
phase	O	O
.	O	O

As	B-cell_type	O
cells	I-cell_type	O
entered	O	O
the	O	O
G1a	O	O
phase	O	O
the	O	O
specific	O	O
binding	O	O
of	O	O
dexamethasone	O	O
increased	O	O
and	O	O
of	O	O
insulin	B-protein	O
took	I-protein	O
place	O	O
.	O	O

Although	O	O
the	O	O
specific	O	O
binding	O	O
further	O	O
increased	O	O
as	O	O
T-cells	O	O
entered	O	O
the	O	O
G1b	O	O
phase	O	O
(	O	O
as	O	O
measured	O	O
at	O	O
44	O	O
h	O	O
of	O	O
incubation	O	O
and	O	O
using	O	O
hydroxyurea-treated	B-cell_type	O
cells	I-cell_type	O
)	O	O
,	O	O
the	O	O
major	O	O
changes	O	O
in	O	O
the	O	O
specific	O	O
binding	O	O
of	O	O
dexamethasone	O	O
took	O	O
place	O	O
during	O	O
the	O	O
period	O	O
16	O	O
-	O	O
20	O	O
h	O	O
after	O	O
stimulation	O	O
.	O	O

Based	O	O
on	O	O
these	O	O
findings	O	O
,	O	O
it	O	O
is	O	O
concluded	O	O
that	O	O
both	O	O
receptor	O	O
types	O	O
(	O	O
cell	O	O
membrane	O	O
and	O	O
cytoplasmic	B-protein	O
receptors	I-protein	O
)	O	O
are	O	O
being	O	O
formed	O	O
and	O	O
increased	O	O
at	O	O
G1	O	O
phase	O	O
prior	O	O
to	O	O
cell	O	O
proliferation	O	O
,	O	O
indicating	O	O
the	O	O
importance	O	O
of	O	O
G1	O	O
phase	O	O
in	O	O
immunoregulation	O	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
and	O	O
cortico-sensitivity	O	O
in	O	O
a	O	O
human	B-cell_line	O
clonal	I-cell_line	O
monocytic	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
,	O	O
CM-SM	O	O
.	O	O

CM-SM	O	O
is	O	O
a	O	O
clonal	O	O
line	O	O
of	O	O
human	B-cell_type	O
precursor	I-cell_type	O
mononuclear	O	O
phagocytes	O	O
inducible	O	O
to	O	O
macrophage	O	O
differentiation	O	O
in	O	O
response	O	O
to	O	O
the	O	O
tumor	O	O
promoter	O	O
phorbol	O	O
ester	O	O
12-O-tetradecanoyl-phorbol-13-acetate	O	O
(	O	O
TPA	O	O
)	O	O
.	O	O

Untreated	O	O
CM-SM	B-cell_type	O
cells	I-cell_type	O
contain	O	O
single	O	O
class	O	O
,	O	O
high-affinity	O	O
(	O	O
KD	O	O
=	I-protein	O
4.0	I-protein	O
X	I-protein	O
10	I-protein	O
(	O	O
-9	B-protein	O
)	I-protein	O
M	O	O
)	O	O
glucocorticoid-specific	O	O
receptor	O	O
sites	O	O
(	O	O
approximately	O	O
60	O	O
,	O	O
000	O	O
per	O	O
cell	O	O
)	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
a	O	O
whole	O	O
cell	O	O
assay	O	O
,	O	O
at	O	O
37	O	O
degrees	O	O
C	O	O
,	O	O
using	O	O
[	O	O
3H	O	O
]	O	O
triamcinolone	O	O
acetonide	O	O
(	O	O
TA	O	O
)	O	O
.	O	O

Exposure	O	O
of	O	O
CM-SM	O	O
to	O	O
dexamethasone	O	O
(	O	O
DEX	B-protein	O
)	O	O
produced	O	O
a	O	O
progressive	O	O
,	O	O
dose-	O	O
and	O	O
time-related	O	O
series	O	O
of	O	O
changes	O	O
in	O	O
CM-SM	O	O
cell	O	O
growth	O	O
,	O	O
saturation	O	O
density	O	O
,	O	O
morphology	O	O
,	O	O
and	O	O
functional	O	O
properties	O	O
,	O	O
with	O	O
half-maximal	O	O
effects	O	O
at	O	O
about	O	O
10	O	O
(	O	O
-9	O	O
)	O	O
M	O	O
for	O	O
DEX	O	O
.	O	O

TA-receptor	O	O
sites	O	O
rapidly	O	O
decreased	O	O
(	O	O
about	O	O
70	O	O
%	O	O
)	O	O
after	O	O
DEX	O	O
treatment	O	O
,	O	O
without	O	O
any	O	O
apparent	O	O
change	O	O
in	O	O
steroid	O	O
specificity	O	O
and	O	O
affinity	O	O
.	O	O

After	O	O
5	O	O
days	O	O
in	O	O
culture	O	O
with	O	O
a	O	O
saturating	O	O
concentration	I-protein	O
(	O	O
3.6	B-protein	O
X	I-protein	O
10	I-protein	O
(	O	O
-8	B-protein	O
)	I-protein	O
M	O	O
)	O	O
of	O	O
hormone	O	O
,	O	O
the	O	O
cells	O	O
reached	O	O
a	O	O
saturation	O	O
density	O	O
of	O	O
about	O	O
9.0	B-protein	O
X	I-protein	O
10	O	O
(	O	O
6	O	O
)	O	O
viable	O	O
cells/ml	O	O
(	O	O
about	O	O
4.0	O	O
X	O	O
10	O	O
(	O	O
6	O	O
)	O	O
viable	O	O
cells/ml	O	O
in	O	O
the	O	O
controls	O	O
)	O	O
,	O	O
while	O	O
the	O	O
modal	O	O
volume	O	O
of	O	O
the	O	O
resulting	O	O
cell	O	O
population	O	O
was	O	O
approximately	O	O
60	O	O
%	O	O
,	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
volume	O	O
of	O	O
untreated	B-cell_type	O
cells	I-cell_type	O
.	O	O

DEX-treated	B-cell_type	O
cells	I-cell_type	O
appeared	O	O
less	O	O
differentiated	O	O
than	O	O
controls	O	O
,	O	O
as	O	O
assessed	O	O
by	O	O
combined	O	O
morphologic	O	O
,	O	O
antigenic	O	O
,	O	O
and	O	O
cytoenzymatic	O	O
analyses	O	O
.	O	O

DEX	O	O
almost	O	O
completely	O	O
inhibited	O	O
TPA	O	O
activation	O	O
of	O	O
the	O	O
following	O	O
macrophage	O	O
functions	O	O
:	O	O
adherency	O	O
to	O	O
the	O	O
culture	O	O
plate	O	O
,	O	O
expression	O	O
of	O	O
lysosomal	O	O
enzymes	O	O
,	O	O
Fc	O	O
and	O	O
C3	B-protein	O
receptors	I-protein	O
,	O	O
and	O	O
stimulation	O	O
of	O	O
phagocytosis	O	O
.	O	O

After	O	O
removal	O	O
of	O	O
DEX	O	O
,	O	O
the	O	O
cells	O	O
,	O	O
within	O	O
a	O	O
few	O	O
passages	O	O
,	O	O
returned	O	O
to	O	O
a	O	O
state	O	O
apparently	O	O
identical	O	O
to	O	O
the	O	O
untreated	O	O
controls	O	O
and	O	O
could	O	O
be	O	O
induced	O	O
to	O	O
macrophage	O	O
differentiation	O	O
in	O	O
response	O	O
to	O	O
TPA	O	O
.	O	O

Acute	O	O
lymphoblastic	O	O
leukemia	O	O
in	O	O
children	O	O
:	O	O
current	O	O
status	O	O
,	O	O
controversies	O	O
,	O	O
and	O	O
future	O	O
perspective	O	O
.	O	O

Disease-free	O	O
survival	O	O
(	O	O
DFS	O	O
)	O	O
in	O	O
childhood	O	O
ALL	O	O
is	O	O
60	O	O
%	O	O
,	O	O
and	O	O
survival	O	O
in	O	O
good	O	O
,	O	O
average	O	O
,	O	O
and	O	O
poor	O	O
prognostic	O	O
groups	O	O
defined	O	O
by	O	O
initial	O	O
WBC	O	O
and	O	O
age	O	O
is	O	O
90	O	O
,	O	O
60	O	O
,	O	O
and	O	O
45	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Additional	O	O
immunological	O	O
,	O	O
morphological	O	O
,	O	O
biochemical	O	O
,	O	O
cytokinetic	O	O
,	O	O
and	O	O
cytogenetic	B-protein	O
factors	I-protein	O
have	O	O
been	O	O
identified	O	O
,	O	O
illustrating	O	O
the	O	O
heterogeneity	O	O
of	O	O
ALL	O	O
and	O	O
its	O	O
derivation	O	O
from	O	O
malignant	O	O
clones	O	O
at	O	O
various	O	O
stages	O	O
of	O	O
differentiation	O	O
and	O	O
with	O	O
varying	O	O
rates	O	O
of	O	O
proliferation	O	O
.	O	O

Of	O	O
biologic	O	O
importance	O	O
,	O	O
these	O	O
factors	I-protein	O
may	O	O
refine	O	O
further	O	O
the	O	O
characteristic	O	O
features	O	O
of	O	O
clinically-determined	O	O
prognostic	O	O
groups	O	O
.	O	O

Multivariate	O	O
analysis	O	O
of	O	O
large	O	O
prospective	O	O
trials	O	O
with	O	O
homogeneous	O	O
therapy	O	O
will	O	O
be	O	O
required	O	O
to	O	O
determine	O	O
the	O	O
independent	O	O
prognostic	O	O
importance	O	O
of	O	O
these	O	O
factors	B-protein	O
.	O	O

Current	O	O
treatment	O	O
strategies	O	O
in	O	O
ALL	O	O
include	O	O
(	O	O
1	O	O
)	O	O
tailoring	O	O
therapy	O	O
and	O	O
its	O	O
intensity	O	O
to	O	O
prognostic	O	O
groups	O	O
;	O	O
(	O	O
2	O	O
)	O	O
multiple-drug	O	O
combinations	O	O
in	O	O
induction	O	O
;	O	O
(	O	O
3	O	O
)	O	O
early	O	O
use	O	O
of	O	O
intrathecal	O	O
(	O	O
IT	O	O
)	O	O
methotrexate	O	O
(	O	O
MTX	O	O
)	O	O
;	O	O
(	O	O
4	O	O
)	O	O
CNS	O	O
prophylaxis	O	O
with	O	O
IT	O	O
MTX	O	O
alone	O	O
in	O	O
good	O	O
prognosis	O	O
patients	O	O
and	O	O
combined	O	O
cranial	O	O
radiation	O	O
(	O	O
CXRT	O	O
)	O	O
,	O	O
1800	O	O
rads	O	O
plus	O	O
IT	O	O
MTX	O	O
,	O	O
in	O	O
average	O	O
and	O	O
poor	O	O
prognosis	O	O
patients	O	O
.	O	O

Current	O	O
studies	O	O
show	O	O
a	O	O
CNS	O	O
relapse	O	O
rate	O	O
of	O	O
5	O	O
%	O	O
in	O	O
all	O	O
prognostic	O	O
groups	O	O
.	O	O

Late	O	O
neuropsychological	O	O
defects	O	O
caused	O	O
by	O	O
cranial	O	O
XRT	O	O
and	O	O
IT	O	O
MTX	O	O
have	O	O
prompted	O	O
programs	O	O
designed	O	O
to	O	O
reduce	O	O
the	O	O
potential	O	O
late	O	O
toxicity	O	O
of	O	O
CNS	O	O
prophylaxis	O	O
.	O	O

More	O	O
pronounced	O	O
in	O	O
younger	O	O
children	O	O
,	O	O
these	O	O
abnormalities	O	O
include	O	O
decreased	O	O
IQ	O	O
,	O	O
visual-motor	O	O
incoordination	O	O
,	O	O
poor	O	O
performance	O	O
in	O	O
mathematics	O	O
,	O	O
and	O	O
memory	O	O
dysfunction	O	O
.	O	O

Until	O	O
1980	O	O
,	O	O
more	O	O
intensive	O	O
induction	O	O
,	O	O
consolidation	O	O
,	O	O
and	O	O
maintenance	O	O
therapy	O	O
had	O	O
failed	O	O
to	O	O
prolong	O	O
DFS	O	O
in	O	O
children	O	O
with	O	O
a	O	O
poor	O	O
prognosis	O	O
.	O	O

In	O	O
West	O	O
Germany	O	O
(	O	O
Berlin-Frankfurt-Muenster	O	O
protocol	O	O
)	O	O
a	O	O
70	O	O
to	O	O
75	O	O
%	O	O
DFS	O	O
is	O	O
seen	O	O
in	O	O
all	O	O
patients	O	O
regardless	O	O
of	O	O
initial	O	O
WBC	O	O
,	O	O
suggesting	O	O
that	O	O
effective	O	O
therapy	O	O
will	O	O
override	O	O
prognostic	O	O
factors	I-protein	O
.	O	O

Ultra-high-dose	O	O
MTX	O	O
,	O	O
without	O	O
cranial	O	O
radiation	O	O
,	O	O
is	O	O
also	O	O
showing	O	O
promise	O	O
in	O	O
poor	O	O
prognosis	O	O
patients	O	O
.	O	O

Other	O	O
issues	O	O
include	O	O
the	O	O
optimal	O	O
duration	O	O
of	O	O
therapy	O	O
,	O	O
the	O	O
role	O	O
of	O	O
testicular	O	O
biopsies	O	O
,	O	O
and	O	O
prophylactic	O	O
testicular	O	O
radiation	O	O
.	O	O

Recent	O	O
studies	O	O
suggest	O	O
that	O	O
prognostic	B-protein	O
factors	I-protein	O
lose	O	O
their	O	O
significance	O	O
after	O	O
2	O	O
years	O	O
of	O	O
continuous	O	O
complete	O	O
remission	O	O
and	O	O
that	O	O
2	O	O
years	O	O
of	O	O
maintenance	O	O
therapy	O	O
is	O	O
adequate	O	O
.	O	O

Bilateral	O	O
open-wedge	O	O
testicular	O	O
biopsies	O	O
have	O	O
identified	O	O
occult	O	O
testicular	O	O
disease	O	O
in	O	O
8	O	O
to	O	O
10	O	O
%	O	O
of	O	O
males	O	O
.	O	O

A	O	O
unified	O	O
approach	O	O
to	O	O
children	O	O
with	O	O
leukemia/lymphoma	O	O
,	O	O
a	O	O
group	O	O
with	O	O
a	O	O
particularly	O	O
poor	O	O
prognosis	O	O
,	O	O
utilizing	O	O
NHL-type	O	O
therapy	O	O
may	O	O
be	O	O
more	O	O
effective	O	O
than	O	O
conventional	O	O
ALL	O	O
therapy	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O

Glucocorticoid	B-protein	O
receptor	I-protein	O
and	O	O
in	O	O
vitro	O	O
sensitivity	O	O
to	O	O
steroid	O	O
hormones	O	O
in	O	O
human	O	O
lymphoproliferative	O	O
diseases	O	O
and	O	O
myeloid	O	O
leukemia	O	O
.	O	O

The	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
quantitation	O	O
by	O	O
a	O	O
whole-cell	O	O
assay	O	O
and/or	O	O
cytosol	O	O
technique	O	O
and	O	O
the	O	O
in	O	O
vitro	O	O
sensitivity	O	O
to	O	O
steroids	O	O
have	O	O
been	O	O
assessed	O	O
in	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
cells	I-cell_type	O
from	O	O
normal	O	O
donors	O	O
and	O	O
patients	O	O
with	O	O
chronic	O	O
lymphatic	O	O
leukemia	O	O
(	O	O
CLL	O	O
)	O	O
,	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
(	O	O
ALL	O	O
)	O	O
,	O	O
lymphosarcoma	O	O
cell	O	O
leukemia	O	O
(	O	O
LSCL	O	O
)	O	O
,	O	O
acute	O	O
nonlymphatic	O	O
leukemia	O	O
(	O	O
ANLL	O	O
)	O	O
,	O	O
and	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
(	O	O
CML	O	O
)	O	O
.	O	O

Within	O	O
the	O	O
lymphoproliferative	O	O
diseases	O	O
,	O	O
ALL	O	O
cells	O	O
exhibited	O	O
the	O	O
highest	O	O
GR	O	O
concentration	O	O
(	O	O
regardless	O	O
of	O	O
the	O	O
method	B-protein	O
used	I-protein	O
)	O	O
and	O	O
the	O	O
highest	O	O
in	O	O
vitro	O	O
inhibition	O	O
of	O	O
spontaneous	O	O
[	O	O
3H	O	O
]	O	O
thymidine	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
TdR	O	O
)	O	O
uptake	O	O
by	O	O
glucocorticoids	O	O
.	O	O

A	O	O
significant	O	O
relationship	O	O
between	O	O
GR	B-protein	O
concentration	O	O
(	O	O
whole-cell	O	O
assay	O	O
)	O	O
and	O	O
in	O	O
vitro	O	O
sensitivity	O	O
to	O	O
dexamethasone	O	O
was	O	O
also	O	O
found	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
CLL	B-cell_type	O
cells	I-cell_type	O
presented	O	O
the	O	O
highest	O	O
sensitivity	O	O
to	O	O
glucocorticoids	O	O
in	O	O
PHA-stimulated	B-cell_line	O
cell	I-cell_line	O
cultures	O	O
.	O	O

Cells	O	O
from	O	O
the	O	O
only	O	O
two	O	O
ALL	O	O
patients	O	O
who	O	O
did	O	O
not	O	O
undergo	O	O
a	O	O
remission	O	O
after	O	O
glucocorticoid-inclusive	O	O
chemotherapy	O	O
had	O	O
both	O	O
the	O	O
lowest	O	O
in	O	O
vitro	O	O
sensitivity	O	O
to	O	O
dexamethasone	O	O
and	O	O
the	O	O
lowest	O	O
GR	O	O
concentration	O	O
with	O	O
whole-cell	O	O
assay	O	O
.	O	O

Concerning	O	O
myeloid	O	O
leukemia	O	O
,	O	O
ANLL	O	O
patients	O	O
had	O	O
GR	O	O
concentrations	O	O
slightly	O	O
higher	O	O
than	O	O
those	O	O
found	O	O
in	O	O
the	O	O
ALL	O	O
group	O	O
but	O	O
exhibited	O	O
the	O	O
lowest	O	O
degree	O	O
of	O	O
inhibition	O	O
of	O	O
spontaneous	O	O
[	O	O
3H	O	O
]	O	O
TdR	O	O
uptake	O	O
by	O	O
dexamethasone	O	O
(	O	O
stimulatory	O	O
effects	O	O
occurred	O	O
in	O	O
some	O	O
cases	O	O
)	O	O
.	O	O

CML	B-cell_type	O
cells	I-cell_type	O
exhibited	O	O
an	O	O
inhibition	O	O
degree	O	O
by	O	O
in	O	O
vitro	O	O
glucocorticoids	O	O
significantly	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
ANLL	B-cell_type	O
cells	I-cell_type	O
but	O	O
not	O	O
different	O	O
from	O	O
that	O	O
of	O	O
lymphoproliferative	O	O
diseases	O	O
.	O	O

No	O	O
clear	O	O
relationship	O	O
among	O	O
GR	O	O
pattern	O	O
,	O	O
in	O	O
vitro	O	O
cell	O	O
sensitivity	O	O
to	O	O
glucocorticoids	O	O
,	O	O
and	O	O
clinicohematologic	O	O
parameters	O	O
was	O	O
observed	O	O
in	O	O
myeloid	O	O
leukemia-bearing	O	O
patients	O	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
and	O	O
in	O	O
vitro	O	O
corticosensitivity	O	O
of	O	O
peanut-positive	O	O
and	O	O
peanut-negative	O	O
human	O	O
thymocyte	O	O
subpopulations	O	O
.	O	O

In	O	O
6	O	O
human	O	O
thymus	O	O
glands	O	O
,	O	O
the	O	O
immature	O	O
subset	O	O
of	O	O
thymocytes	B-cell_type	O
was	O	O
separated	O	O
from	O	O
the	O	O
more	O	O
mature	O	O
one	O	O
,	O	O
by	O	O
differential	O	O
peanut	O	O
lectin	O	O
agglutination	O	O
.	O	O

These	O	O
2	O	O
cell	O	O
subpopulations	O	O
were	O	O
analyzed	O	O
for	O	O
glucocorticoid	O	O
receptor	O	O
content	O	O
by	O	O
using	O	O
a	O	O
whole	O	O
cell	O	O
assay	O	O
,	O	O
with	O	O
(	O	O
3H	O	O
)	O	O
-triamcinolone	O	O
acetonide	O	O
as	O	O
tracer	O	O
.	O	O

The	O	O
unagglutinated	O	O
thymocytes	B-cell_type	O
(	O	O
peanut	B-DNA	O
negative	I-DNA	O
)	O	O
contained	O	O
about	O	O
2	O	O
times	O	O
more	O	O
receptor	O	O
sites	O	O
per	O	O
cell	O	O
than	O	O
agglutinated	O	O
(	O	O
peanut	O	O
positive	O	O
)	O	O
ones	O	O
(	O	O
7650	O	O
+/-	O	O
1550	O	O
S.D.	O	O
verus	O	O
3195	O	O
+/-	O	O
896	O	O
S.D.	O	O
)	O	O
.	O	O

The	O	O
affinity	O	O
for	O	O
steroid	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
cell	O	O
subsets	O	O
,	O	O
as	O	O
was	O	O
the	O	O
stereospecificity	O	O
for	O	O
glucocorticoids	O	O
,	O	O
the	O	O
time-course	O	O
of	O	O
steroid-receptor	O	O
association	O	O
,	O	O
and	O	O
cytoplasmic	O	O
to	O	O
nuclear	O	O
translocation	O	O
.	O	O

Despite	O	O
the	O	O
greater	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
sites	O	O
,	O	O
the	O	O
peanut-negative	O	O
thymocyte	O	O
subpopulation	O	O
did	O	O
not	O	O
differ	O	O
from	O	O
the	O	O
peanut-positive	O	O
one	O	O
in	O	O
its	O	O
sensitivity	O	O
to	O	O
the	O	O
inhibitory	O	O
effects	O	O
of	O	O
triamcinolone	O	O
acetonide	O	O
,	O	O
as	O	O
determined	O	O
by	O	O
measurements	O	O
of	O	O
the	O	O
incorporation	O	O
of	O	O
radiolabeled	B-protein	O
precursors	I-protein	O
of	O	O
protein	B-protein	O
and	I-protein	O
DNA	I-protein	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
peanut-negative	O	O
subset	O	O
appeared	O	O
more	O	O
resistant	O	O
in	O	O
vitro	O	O
to	O	O
the	O	O
steroid-induced	O	O
cell	O	O
lysis	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
peanut-positive	O	O
one	O	O
.	O	O

Thus	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
density	O	O
and	O	O
corticosensitivity	O	O
are	O	O
not	O	O
directly	O	O
correlated	O	O
and	O	O
that	O	O
the	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
sites	O	O
may	O	O
be	O	O
dependent	O	O
on	O	O
the	O	O
degree	O	O
of	O	O
immunologic	O	O
maturation	O	O

Defective	O	O
binding	O	O
and	O	O
function	O	O
of	O	O
1	O	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
receptors	O	O
in	O	O
peripheral	B-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
of	O	O
patients	O	O
with	O	O
end-organ	O	O
resistance	O	O
to	O	O
1	O	O
,	O	O
25-dihydroxyvitamin	O	O
D	O	O
.	O	O

Lectin-induced	O	O
DNA	O	O
synthesis	O	O
by	O	O
peripheral	B-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
from	O	O
17	O	O
normal	O	O
donors	O	O
was	O	O
inhibited	O	O
(	O	O
40-60	O	O
%	O	O
)	O	O
by	O	O
1	O	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
(	O	O
1	O	O
,	O	O
25	O	O
[	O	O
OH	O	O
]	O	O
2D3	O	O
)	O	O
at	O	O
physiological	O	O
concentrations	O	O
(	O	O
10	O	O
(	O	O
-10	O	O
)	O	O
-10	O	O
(	O	O
-9	O	O
)	O	O
M	O	O
)	O	O
.	O	O

The	O	O
lymphocytes	I-cell_type	O
acquire	O	O
specific	O	O
receptors	O	O
for	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
upon	O	O
activation	O	O
by	O	O
the	O	O
lectins	O	O
.	O	O

This	O	O
process	O	O
precedes	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
.	O	O

We	O	O
studied	O	O
lymphocytes	I-cell_type	O
from	O	O
six	O	O
patients	O	O
from	O	O
four	O	O
different	O	O
kindreds	O	O
with	O	O
the	O	O
syndrome	O	O
of	O	O
hereditary	O	O
end-organ	O	O
resistance	O	O
to	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	B-protein	O
)	O	O
2D	O	O
(	O	O
the	O	O
so-called	O	O
vitamin	O	O
D-dependent	O	O
rickets	O	O
type	O	O
II	O	O
)	O	O
.	O	O

In	O	O
five	O	O
patients	O	O
(	O	O
three	O	O
kindreds	O	O
)	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
did	O	O
not	O	O
acquire	O	O
receptors	O	O
for	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
upon	O	O
phytohemagglutinin-induced	O	O
activation	O	O
.	O	O

Moreover	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
normal	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
the	O	O
mitogenic	O	O
stimulation	O	O
of	O	O
these	O	O
patients	O	O
'	B-cell_type	O
lymphocytes	I-cell_type	O
by	O	O
phytohemagglutinin	O	O
and	O	O
concanavalin	O	O
A	O	O
was	O	O
not	O	O
inhibited	O	O
by	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
.	O	O

Activated	O	O
lymphocytes	O	O
of	O	O
the	O	O
sixth	O	O
patient	O	O
from	O	O
a	O	O
fourth	O	O
kindred	O	O
exhibited	O	O
normal	O	O
binding	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
but	O	O
the	O	O
hormone	O	O
failed	O	O
to	O	O
inhibit	O	O
the	O	O
mitogenic	O	O
stimulation	O	O
.	O	O

A	O	O
similar	O	O
pattern	O	O
of	O	O
the	O	O
vitamin	O	O
D	O	O
effector	O	O
system	O	O
was	O	O
previously	O	O
observed	O	O
in	O	O
fibroblasts	O	O
cultured	O	O
from	O	O
skin	O	O
biopsies	O	O
of	O	O
the	O	O
same	O	O
group	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
conclusions	O	O
from	O	O
these	O	O
findings	O	O
are	O	O
:	O	O
(	O	O
a	O	O
)	O	O
the	O	O
inhibition	O	O
of	O	O
mitogenic	O	O
stimulation	O	O
by	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
is	O	O
mediated	O	O
by	O	O
specific	O	O
functional	O	O
receptors	O	O
to	O	O
the	O	O
hormone	B-DNA	O
;	O	O
and	O	O
(	O	O
b	O	O
)	O	O
the	O	O
receptors	O	O
for	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
in	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
are	O	O
probably	O	O
controlled	O	O
genetically	O	O
by	O	O
the	O	O
same	O	O
mechanisms	O	O
as	O	O
the	O	O
effector	O	O
system	O	O
in	O	O
well-characterized	O	O
target	O	O
organs	O	O
of	O	O
the	O	O
hormone	O	O
,	O	O
such	O	O
as	O	O
intestine	O	O
and	O	O
kidney	O	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
of	O	O
mononuclear	O	O
leukocytes	O	O
from	O	O
myasthenia	O	O
gravis	O	O
patients	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
performed	O	O
to	O	O
analyse	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
binding	O	O
in	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
leukocytes	O	O
(	O	O
MNL	O	O
)	O	O
from	O	O
39	O	O
myasthenia	O	O
gravis	O	O
(	O	O
MG	O	O
)	O	O
patients	O	O
(	O	O
unoperated	O	O
patients	O	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
,	O	O
thymectomized	O	O
patients	O	O
(	O	O
n	O	O
=	O	O
14	O	O
)	O	O
and	O	O
patients	O	O
receiving	O	O
glucocorticoids	O	O
:	O	O
thymectomized	O	O
(	O	O
n	O	O
=	O	O
11	O	O
)	O	O
and	O	O
unoperated	O	O
(	O	O
n	O	O
=	O	O
6	O	O
]	O	O
.	O	O

A	O	O
whole	O	O
cell	O	O
binding	O	O
assay	O	O
with	O	O
3	O	O
(	O	O
H	B-protein	O
)	O	O
dexamethasone	O	O
was	O	O
used	O	O
.	O	O

GR	O	O
mean	O	O
values	O	O
were	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
MNL	O	O
of	O	O
MG	O	O
patients	O	O
(	O	O
thymectomized	O	O
or	O	O
not	O	O
)	O	O
not	O	O
receiving	O	O
glucocorticoid	O	O
than	O	O
in	O	O
the	O	O
MNL	O	O
of	O	O
healthy	O	O
donors	O	O
.	O	O

Affinity	O	O
was	O	O
within	O	O
the	O	O
normal	O	O
range	O	O
.	O	O

Sex	O	O
,	O	O
age	O	O
or	O	O
clinical	O	O
forms	O	O
of	O	O
illness	O	O
did	O	O
not	O	O
influence	O	O
the	O	O
results	O	O
.	O	O

In	O	O
patients	O	O
receiving	O	O
prednisone	O	O
(	O	O
Pd	O	O
)	O	O
the	O	O
GR	O	O
values	O	O
were	O	O
significantly	O	O
lower	O	O
than	O	O
in	O	O
MG	O	O
patients	O	O
without	O	O
Pd	O	O
therapy	O	O
,	O	O
independent	O	O
of	O	O
Pd	O	O
dose	O	O
or	O	O
time	O	O
of	O	O
administration	O	O
.	O	O

No	O	O
differences	O	O
in	O	O
receptor	O	O
binding	O	O
between	O	O
normal	O	O
subjects	O	O
and	O	O
MG	O	O
patients	O	O
receiving	O	O
Pd	O	O
have	O	O
been	O	O
found	O	O
.	O	O

Immunological	O	O
interference	O	O
of	O	O
high	O	O
dose	O	O
corticosteroids	O	O
.	O	O

High-dose	O	O
corticosteroids	O	O
(	O	O
HDC	O	O
)	O	O
will	O	O
influence	O	O
cellular	O	O
as	O	O
well	O	O
as	O	O
humoral	O	O
participants	O	O
of	O	O
the	O	O
immune	O	O
response	O	O
.	O	O

The	O	O
lymphoid	O	O
tissue	O	O
will	O	O
decrease	O	O
in	O	O
size	O	O
and	O	O
weight	O	O
after	O	O
prolonged	O	O
treatment	O	O
with	O	O
HDC	O	O
.	O	O

Lymphocyte	O	O
functions	O	O
will	O	O
be	O	O
impaired	O	O
.	O	O

Reduced	O	O
synthesis	O	O
of	O	O
B-	O	O
as	O	O
well	O	O
as	O	O
T-lymphocytes	O	O
will	O	O
be	O	O
seen	O	O
.	O	O

The	O	O
inhibitory	O	O
effect	O	O
on	O	O
B-cell	O	O
function	O	O
can	O	O
be	O	O
observed	O	O
both	O	O
as	O	O
decreased	O	O
serum	O	O
levels	O	O
of	O	O
immunoglobulins	O	O
and	O	O
as	O	O
impaired	O	O
binding	O	O
of	O	O
antibodies	B-protein	O
and	O	O
complement	O	O
to	O	O
the	O	O
cellular	O	O
surface	O	O
.	O	O

Reduced	O	O
T-cell	O	O
function	O	O
indicated	O	O
by	O	O
impaired	O	O
stimulation	O	O
by	O	O
PHA	O	O
and	O	O
porkweed	O	O
as	O	O
well	O	O
as	O	O
by	O	O
impaired	O	O
lymphokinin	O	O
effects	O	O
on	O	O
leukocyte	O	O
migration	O	O
inhibition	O	O
has	O	O
been	O	O
reported	O	O
.	O	O

Reduced	O	O
lymphocyte	O	O
adherence	O	O
to	O	O
antigen	O	O
and	O	O
suppressed	O	O
lymphocyte	O	O
reaction	O	O
have	O	O
also	O	O
been	O	O
observed	O	O
.	O	O

Humoral	B-protein	O
factors	I-protein	O
involved	O	O
in	O	O
chemotaxis	O	O
,	O	O
opsonisation	O	O
,	O	O
phagocytosis	O	O
,	O	O
vascular	O	O
permeability	O	O
leading	O	O
to	O	O
leakage	O	O
of	O	O
fluid	B-cell_type	O
and	I-cell_type	O
cells	I-cell_type	O
and	O	O
factors	B-protein	O
involved	O	O
in	O	O
lysis	O	O
of	O	O
antigens	O	O
are	O	O
impaired	O	O
.	O	O

This	O	O
can	O	O
be	O	O
explained	O	O
partly	O	O
by	O	O
the	O	O
observed	O	O
reduced	O	O
complement	O	O
activation	O	O
via	O	O
the	O	O
alternative	O	O
as	O	O
well	O	O
as	O	O
the	O	O
classical	O	O
pathway	O	O
in	O	O
association	O	O
with	O	O
HDC	O	O
therapy	O	O
.	O	O

Acute	O	O
processes	O	O
with	O	O
increased	O	O
vascular	B-protein	O
permeability	O	O
and	O	O
accumulation	O	O
of	O	O
leukocytes	O	O
as	O	O
impairing	B-protein	O
factors	I-protein	O
could	O	O
be	O	O
influenced	O	O
beneficially	O	O
by	O	O
HDC	O	O
therapy	O	O
.	O	O

This	O	O
positive	O	O
effect	O	O
can	O	O
be	O	O
seen	O	O
in	O	O
treatment	O	O
of	O	O
septic	O	O
shock	O	O
or	O	O
rejection	O	O
of	O	O
a	O	O
transplant	O	O
.	O	O

However	O	O
,	O	O
if	O	O
sepsis	O	O
or	O	O
rejection	O	O
is	O	O
not	O	O
rapidly	O	O
reversed	O	O
,	O	O
complications	O	O
such	O	O
as	O	O
multisystem	O	O
organ	O	O
failure	O	O
and	O	O
bacteremia	O	O
are	O	O
prone	O	O
to	O	O
appear	O	O
.	O	O

Identification	O	O
of	O	O
human	O	O
leukemic	B-protein	O
glucocorticoid	I-protein	O
receptors	I-protein	O
using	O	O
affinity	O	O
labeling	O	O
and	O	O
anti-human	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
antibodies	O	O
.	O	O

Antisera	O	O
raised	O	O
against	O	O
human	O	O
lymphoid	O	O
glucocorticoid	O	O
receptors	O	O
were	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
affinity	O	O
label	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone	O	O
21-mesylate	O	O
[	O	O
(	O	O
3H	O	O
]	O	O
DM	O	O
)	O	O
to	O	O
identify	O	O
the	O	O
glucocorticoid	O	O
receptors	O	O
of	O	O
the	O	O
human	O	O
B-lymphoblastoid	O	O
cell	O	O
line	O	O
IM-9	O	O
and	O	O
the	O	O
human	O	O
T-cell	O	O
leukemic	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
CEM-C7	O	O
.	O	O

Antisera	O	O
were	O	O
obtained	O	O
following	O	O
immunization	O	O
of	O	O
New	O	O
Zealand	O	O
White	O	O
rabbits	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
triamcinolone	O	O
acetonide	O	O
[	O	O
(	O	O
3H	O	O
]	O	O
TA	O	O
)	O	O
-glucocorticoid	O	O
receptor	O	O
complexes	O	O
partially	O	O
purified	O	O
by	O	O
two-stage	O	O
DNA-cellulose	O	O
chromatography	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
anti-human	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
antibodies	I-protein	O
was	O	O
verified	O	O
by	O	O
:	O	O
(	O	O
a	O	O
)	O	O
adsorption	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
TA-receptor-antibody	O	O
complexes	O	O
to	O	O
Protein	O	O
A	O	O
;	O	O
(	O	O
b	O	O
)	O	O
a	O	O
shift	O	O
to	O	O
higher	O	O
apparent	O	O
molecular	O	O
weight	O	O
in	O	O
the	O	O
elution	O	O
position	O	O
from	O	O
Sephacryl	O	O
S300	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
TA-receptor	O	O
complexes	O	O
incubated	O	O
with	O	O
immune	O	O
serum	O	O
;	O	O
and	O	O
(	O	O
c	O	O
)	O	O
the	O	O
ability	O	O
of	O	O
immune	O	O
serum	O	O
to	O	O
displace	O	O
[	O	O
3H	O	O
]	O	O
TA-receptor	O	O
complexes	O	O
on	O	O
sucrose	O	O
gradients	O	O
.	O	O

These	O	O
antibodies	O	O
also	O	O
recognized	O	O
rat	O	O
liver	O	O
and	O	O
murine	O	O
S49	O	O
cell	O	O
glucocorticoid	O	O
receptors	O	O
.	O	O

Sodium	O	O
dodecyl	O	O
sulfate-polyacrylamide	O	O
gel	O	O
electrophoresis	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
DM-labeled	O	O
IM-9	O	O
cytosol	O	O
identified	O	O
a	O	O
major	O	O
competable	O	O
band	O	O
with	O	O
a	O	O
molecular	O	O
weight	O	O
of	O	O
approximately	O	O
90	B-protein	O
,	O	O
000	O	O
,	O	O
three	O	O
minor	O	O
competable	O	O
components	O	O
with	O	O
molecular	O	O
weights	O	O
of	O	O
approximately	O	O
78	O	O
,	O	O
000	O	O
,	O	O
approximately	O	O
51	O	O
,	O	O
000	O	O
,	O	O
and	O	O
approximately	O	O
38	O	O
,	O	O
500	O	O
,	O	O
and	O	O
at	O	O
least	O	O
21	O	O
other	O	O
noncompetable	O	O
components	O	O
.	O	O

Following	O	O
immunoprecipitation	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
DM-labeled	O	O
cytosol	O	O
with	O	O
immune	O	O
serum	O	O
,	O	O
only	O	O
the	O	O
Mr	O	O
90	O	O
,	O	O
000	O	O
and	O	O
78	O	O
,	O	O
000	O	O
components	O	O
were	O	O
seen	O	O
.	O	O

Sodium	O	O
dodecyl	O	O
sulfate-polyacrylamide	O	O
gel	O	O
electrophoresis	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
DM-labeled	O	O
CEM-C7	O	O
cytosol	O	O
revealed	O	O
a	O	O
larger	O	O
number	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
DM-labeled	O	O
components	O	O
.	O	O

However	O	O
,	O	O
after	O	O
immunoprecipitation	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
DM-labeled	O	O
CEM-C7	O	O
cytosol	O	O
,	O	O
a	O	O
predominant	O	O
competable	O	O
component	O	O
with	O	O
a	O	O
molecular	O	O
weight	O	O
of	O	O
90	O	O
,	O	O
000	O	O
was	O	O
easily	O	O
identified	O	O
.	O	O

This	O	O
component	O	O
was	O	O
markedly	O	O
diminished	O	O
when	O	O
cytosols	O	O
from	O	O
the	O	O
glucocorticoid	O	O
receptor-deficient	O	O
cell	O	O
line	O	O
ICR-27	O	O
were	O	O
used	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
combination	O	O
of	O	O
affinity	O	O
labeling	O	O
and	O	O
anti-human	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
antibodies	O	O
is	O	O
capable	O	O
of	O	O
providing	O	O
direct	O	O
physical	O	O
identification	O	O
of	O	O
human	O	O
lymphoid	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
.	O	O

Effect	O	O
of	O	O
thymosin	O	O
on	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
activity	O	O
and	O	O
glucocorticoid	O	O
sensitivity	O	O
of	O	O
human	B-cell_type	O
thymocytes	I-cell_type	O
.	O	O

Incubation	O	O
with	O	O
thymosin	O	O
fraction	O	O
5	O	O
,	O	O
(	O	O
TMS	O	O
F5	O	O
at	O	O
300	O	O
micrograms/ml	O	O
)	O	O
a	O	O
partially	O	O
purified	O	O
thymic	O	O
factor	O	O
,	O	O
reduced	O	O
the	O	O
steroid	O	O
binding	O	O
activity	O	O
of	O	O
human	B-cell_type	O
infant	I-protein	O
thymocytes	I-protein	O
from	O	O
9.6	O	O
+/-	O	O
2.1	O	O
fmole/ml	O	O
to	O	O
5.0	O	O
+/-	O	O
2.0	O	O
fmole/ml	O	O
.	O	O

The	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
activity	O	O
in	O	O
normal	O	O
infant	O	O
thymocytes	O	O
was	O	O
found	O	O
to	O	O
be	O	O
2	O	O
,	O	O
146	O	O
+/-	O	O
726	O	O
(	O	O
s.d.	O	O
)	O	O
sites	O	O
per	O	O
cell	O	O
with	O	O
dissociation	O	O
constant	O	O
of	O	O
1.4	O	O
+/-	O	O
0.6	O	O
X	O	O
10	O	O
(	O	O
-8	O	O
)	O	O
M	O	O
.	O	O

TMS	O	O
F5	O	O
also	O	O
increased	O	O
the	O	O
resistance	O	O
of	O	O
human	B-cell_type	O
thymocytes	I-cell_type	O
to	O	O
the	O	O
cytolytic	O	O
effect	O	O
of	O	O
dexamethasone	O	O
(	O	O
2.5	B-protein	O
X	I-protein	O
10	I-protein	O
(	O	O
-8	B-protein	O
)	I-protein	O
M	O	O
)	O	O
to	O	O
168.6	O	O
+/-	O	O
30.2	O	O
%	O	O
of	O	O
control	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.01	O	O
)	O	O
.	O	O

In	O	O
animals	O	O
,	O	O
medullary	O	O
and	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
are	O	O
more	O	O
resistant	O	O
to	O	O
glucocorticoids	O	O
than	O	O
immature	O	O
thymic	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
results	O	O
show	O	O
that	O	O
thymosin	O	O
can	O	O
induce	O	O
changes	O	O
consistent	O	O
with	O	O
differentiation	O	O
in	O	O
human	B-cell_type	O
thymocytes	I-cell_type	O
.	O	O

These	O	O
in	O	O
vitro	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
physiological	O	O
role	O	O
of	O	O
thymosin	O	O
in	O	O
intrathymic	O	O
T	O	O
cell	O	O
maturation	O	O
in	O	O
man	O	O
.	O	O

Incubation	O	O
of	O	O
a	O	O
human	O	O
malignant	O	O
thymus	O	O
derived	I-cell_line	O
T	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
(	O	O
MOLT	O	O
3	O	O
)	O	O
with	O	O
TMS	O	O
F5	O	O
also	O	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
the	O	O
number	O	O
of	O	O
steroid	O	O
binding	O	O
sites	O	O
to	O	O
44.2	O	O
+/-	O	O
15.3	O	O
%	O	O
of	O	O
control	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.05	O	O
)	O	O
,	O	O
but	O	O
TMS	O	O
F5	O	O
did	O	O
not	O	O
significantly	O	O
reduce	O	O
the	O	O
glucocorticoid	O	O
sensitivity	O	O
of	O	O
MOLT	B-cell_type	O
3	I-cell_type	O
cells	I-cell_type	O
.	O	O

Specific	O	O
high-affinity	O	O
receptors	O	O
for	O	O
1	O	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
in	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
:	O	O
presence	O	O
in	O	O
monocytes	B-cell_type	O
and	O	O
induction	O	O
in	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
following	O	O
activation	O	O
.	O	O

Human	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
monocytes	I-cell_type	O
have	O	O
high	O	O
affinity	O	O
binding	O	O
sites	O	O
for	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
(	O	O
Kd	O	O
0.14	O	O
nM	O	O
,	O	O
sedimentation	O	O
coefficient	O	O
3.7S	O	O
)	O	O
.	O	O

Resting	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
however	O	O
,	O	O
do	O	O
not	O	O
have	O	O
a	O	O
demonstrable	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
receptor	I-protein	O
.	O	O

After	O	O
activation	O	O
with	O	O
phytohemagglutinin	O	O
the	O	O
T	B-cell_type	O
cells	I-cell_type	O
exhibit	O	O
the	O	O
receptor	O	O
within	O	O
24	O	O
h	O	O
,	O	O
and	O	O
this	O	O
expression	O	O
is	O	O
blocked	O	O
by	O	O
cycloheximide	O	O
.	O	O

The	O	O
receptor	O	O
in	O	O
activated	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
has	O	O
a	O	O
sedimentation	O	O
coefficient	O	O
of	O	O
3.7S	O	O
and	O	O
a	O	O
high	O	O
affinity	O	O
(	O	O
Kd	O	O
0.10	O	O
nM	O	O
)	O	O
for	O	O
the	O	O
ligand	O	O
.	O	O

Effects	O	O
of	O	O
chronic	O	O
glucocorticoid	O	O
excess	O	O
in	O	O
man	O	O
on	O	O
insulin	O	O
binding	O	O
to	O	O
circulating	B-cell_type	O
cells	I-cell_type	O
:	O	O
differences	O	O
between	O	O
endogenous	O	O
and	O	O
exogenous	O	O
hypercorticism	O	O
.	O	O

We	O	O
measured	O	O
[	O	O
125I	O	O
]	O	O
insulin	O	O
binding	O	O
to	O	O
circulating	O	O
monocytes	B-cell_type	O
or	O	O
erythrocytes	O	O
from	O	O
16	O	O
patients	O	O
with	O	O
chronic	O	O
glucocorticoid	O	O
excess	O	O
,	O	O
9	O	O
chronically	O	O
treated	O	O
with	O	O
prednisone	O	O
and	O	O
7	O	O
with	O	O
adrenocortical	O	O
hyperfunction	O	O
.	O	O

With	O	O
monocytes	B-cell_type	O
,	O	O
[	O	O
125I	O	O
]	O	O
insulin	O	O
binding	O	O
was	O	O
iincreased	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

Analysis	O	O
of	O	O
binding	O	O
data	O	O
indicated	O	O
that	O	O
increased	O	O
binding	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
prednisone	O	O
was	O	O
due	O	O
to	O	O
an	O	O
ncrease	O	O
in	O	O
receptor	O	O
concentration	O	O
,	O	O
whereas	O	O
in	O	O
patients	O	O
with	O	O
adrenocortical	O	O
hyperfunction	O	O
,	O	O
it	O	O
was	O	O
due	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
receptor	O	O
affinity	O	O
.	O	O

With	O	O
erythrocytes	O	O
from	O	O
patients	O	O
with	O	O
adrenocortical	O	O
hyperfunction	O	O
there	O	O
was	O	O
an	O	O
increase	O	O
in	O	O
receptor	O	O
affinity	O	O
and	O	O
a	O	O
decrease	O	O
in	O	O
receptor	O	O
concentration	O	O
,	O	O
so	O	O
that	O	O
the	O	O
binding	O	O
of	O	O
[	O	O
125I	O	O
]	O	O
insulin	O	O
was	O	O
normal	O	O
.	O	O

The	O	O
disparity	O	O
of	O	O
results	O	O
between	O	O
endogenous	O	O
and	O	O
exogenous	O	O
hypercorticism	O	O
,	O	O
between	O	O
the	O	O
two	O	O
cell	O	O
types	O	O
,	O	O
and	O	O
between	O	O
the	O	O
present	O	O
studies	O	O
and	O	O
previous	O	O
studies	O	O
suggest	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
glucocorticoid	O	O
excess	O	O
on	O	O
the	O	O
insulin	B-protein	O
receptor	I-protein	O
are	O	O
extremely	B-protein	O
complex	I-protein	O
and	O	O
wide-ranging	O	O
and	O	O
that	O	O
in	O	O
this	O	O
condition	O	O
,	O	O
extrapolations	O	O
in	O	O
humans	O	O
from	O	O
data	O	O
with	O	O
circulating	O	O
cells	O	O
to	O	O
liver	O	O
and	O	O
muscle	O	O
may	O	O
not	O	O
be	O	O
appropriate	O	O
.	O	O

Reduced	O	O
level	O	O
of	O	O
cellular	O	O
glucocorticoid	B-protein	O
receptors	O	O
in	O	O
patients	O	O
with	O	O
anorexia	O	O
nervosa	O	O
.	O	O

Specific	O	O
glucocorticoid	B-protein	O
receptors	O	O
were	O	O
measured	O	O
in	O	O
circulating	O	O
mononuclear	O	O
leukocytes	O	O
from	O	O
12	O	O
patients	O	O
with	O	O
anorexia	O	O
nervosa	O	O
and	O	O
21	O	O
healthy	O	O
control	O	O
subjects	O	O
.	O	O

Cells	O	O
from	O	O
patients	O	O
were	O	O
found	O	O
to	O	O
contain	O	O
a	O	O
significantly	O	O
(	O	O
p	I-DNA	O
less	I-DNA	O
than	O	O
0.01	O	O
)	O	O
lower	O	O
level	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
(	O	O
3830	O	O
+/-	O	O
210	O	O
sites/cell	O	O
,	O	O
mean	O	O
+/-	O	O
SE	O	O
)	O	O
than	O	O
those	O	O
from	O	O
controls	O	O
(	O	O
4930	O	O
+/-	O	O
250	O	O
sites/cell	O	O
)	O	O
.	O	O

A	O	O
partial	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
defect	O	O
may	O	O
well	O	O
explain	O	O
the	O	O
abnormal	O	O
cortisol	O	O
metabolism	O	O
and	O	O
glucocorticoid	O	O
resistance	O	O
commonly	O	O
found	O	O
in	O	O
patients	O	O
with	O	O
anorexia	O	O
nervosa	O	O
.	O	O

Regulation	O	O
of	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
in	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

The	O	O
presence	O	O
of	O	O
a	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
in	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
is	O	O
well	O	O
established	O	O
,	O	O
but	O	O
factors	I-protein	O
affecting	O	O
its	O	O
regulation	O	O
have	O	O
not	O	O
been	O	O
described	O	O
.	O	O

Using	O	O
a	O	O
competitive	O	O
binding	O	O
whole	O	O
cell	O	O
assay	O	O
,	O	O
we	O	O
have	O	O
examined	O	O
the	O	O
binding	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
-dexamethasone	O	O
at	O	O
24	O	O
and	O	O
37	O	O
degrees	O	O
C	O	O
in	O	O
untreated	O	O
normal	O	O
subjects	O	O
and	O	O
in	O	O
healthy	O	O
subjects	O	O
taking	O	O
various	O	O
glucocorticoid	O	O
preparations	O	O
.	O	O

At	O	O
24	O	O
degrees	O	O
C	O	O
normal	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
had	O	O
6000	O	O
binding	O	O
sites/cell	O	O
and	O	O
a	O	O
dissociation	O	O
constant	O	O
of	O	O
4	B-protein	O
x	I-protein	O
10	I-protein	O
(	O	O
-9	B-protein	O
)	O	O
M	O	O
.	O	O

The	O	O
administration	O	O
of	O	O
1	O	O
mg	O	O
of	O	O
dexamethasone	O	O
,	O	O
5	O	O
mg	O	O
of	O	O
prednisone	B-protein	O
,	O	O
and	O	O
37.5	O	O
mg	O	O
of	O	O
cortisone	O	O
acetate	O	O
resulted	O	O
in	O	O
a	O	O
30	O	O
%	O	O
decrease	O	O
in	O	O
binding	O	O
sites	O	O
after	O	O
1	O	O
week	O	O
with	O	O
no	O	O
change	O	O
in	O	O
binding	O	O
affinity	O	O
.	O	O

No	O	O
changes	O	O
in	O	O
the	O	O
number	O	O
of	O	O
binding	O	O
sites	O	O
was	O	O
noted	O	O
before	O	O
1	O	O
week	O	O
and	O	O
the	O	O
diminished	O	O
number	O	O
persisted	O	O
for	O	O
1	O	O
week	O	O
after	O	O
discontinuation	O	O
of	O	O
glucocorticoid	O	O
treatment	O	O
.	O	O

Lymphocytes	O	O
from	O	O
hospitalized	O	O
patients	O	O
taking	O	O
40-60	O	O
mg	O	O
of	O	O
dexamethasone	O	O
daily	O	O
demonstrated	O	O
the	O	O
same	O	O
change	O	O
in	O	O
number	O	O
of	O	O
binding	O	O
sites	O	O
that	O	O
was	O	O
seen	O	O
in	O	O
normal	O	O
subjects	O	O
taking	O	O
1	O	O
mg	O	O
of	O	O
dexamethasone	O	O
.	O	O

When	O	O
binding	O	O
assays	O	O
were	O	O
carried	O	O
out	O	O
at	O	O
physiologic	O	O
temperature	O	O
there	O	O
was	O	O
the	O	O
same	O	O
decrease	O	O
in	O	O
number	O	O
of	O	O
binding	O	O
sites	O	O
after	O	O
dexamethasone	O	O
administration	O	O
,	O	O
and	O	O
in	O	O
addition	O	O
,	O	O
there	O	O
was	O	O
a	O	O
two-fold	O	O
increase	O	O
in	O	O
binding	O	O
affinity	O	O
.	O	O

Glucocorticoid	O	O
administration	O	O
results	O	O
in	O	O
a	O	O
time-dependent	O	O
decrease	O	O
in	O	O
the	O	O
number	O	O
of	O	O
lymphocyte	O	O
glucocorticoid	O	O
binding	O	O
sites	O	O
that	O	O
is	O	O
independent	O	O
of	O	O
the	O	O
type	O	O
of	O	O
glucocorticoid	O	O
administered	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
in	O	O
vivo	O	O
demonstration	O	O
that	O	O
glucocorticoids	O	O
modulate	O	O
their	O	O
own	O	O
receptors	O	O
in	O	O
man	O	O
.	O	O

Immunoglobulin	O	O
localization	O	O
in	O	O
benign	O	O
and	O	O
malignant	O	O
lesions	O	O
of	O	O
the	O	O
human	B-cell_line	O
mammary	I-cell_line	O
gland	I-cell_type	O
.	O	O

Using	O	O
direct	O	O
imunofluorescence	O	O
,	O	O
lesions	O	O
from	O	O
266	O	O
human	O	O
breast	O	O
specimens	O	O
were	O	O
studied	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
IgA	O	O
,	O	O
IgM	O	O
,	O	O
or	O	O
IgG	O	O
localization	O	O
.	O	O

The	O	O
lesions	O	O
included	O	O
benign	I-DNA	O
elements	I-DNA	O
from	O	O
66	O	O
subcutaneous	O	O
mastectomy	O	O
specimens	O	O
in	O	O
which	O	O
the	O	O
absence	O	O
of	O	O
simultaneous	O	O
breast	O	O
malignancy	O	O
was	O	O
documented	O	O
,	O	O
primary	O	O
breast	O	O
carcinomas	O	O
from	O	O
153	O	O
mastectomy	O	O
specimens	O	O
,	O	O
and	O	O
47	O	O
biopsies	O	O
containing	O	O
metastatic	O	O
breast	O	O
cancer	O	O
.	O	O

A	O	O
statistically	O	O
significant	O	O
association	O	O
of	O	O
IgA	O	O
and	O	O
IgM	O	O
with	O	O
benign	O	O
lesions	O	O
was	O	O
contrasted	O	O
to	O	O
the	O	O
association	O	O
of	O	O
IgG	O	O
with	O	O
malignant	O	O
lesions	O	O
.	O	O

In	O	O
both	O	O
primary	O	O
and	O	O
metastatic	O	O
lesions	O	O
,	O	O
IgG	O	O
localization	O	O
was	O	O
associated	O	O
with	O	O
estrogen-receptor-poor	O	O
primary	O	O
cancers	O	O
as	O	O
compared	O	O
with	O	O
estrogen-receptor-rich	O	O
primary	O	O
cancers	O	O
.	O	O

Among	O	O
primary	O	O
breast	O	O
cancer	O	O
patients	O	O
,	O	O
IgG	O	O
localization	O	O
in	O	O
the	O	O
tumor	O	O
correlated	O	O
with	O	O
relative	O	O
lymphopenia	O	O
.	O	O

A	O	O
shorter	O	O
disease-free	O	O
interval	O	O
was	O	O
noted	O	O
in	O	O
association	O	O
with	O	O
IgG	O	O
localization	O	O
among	O	O
the	O	O
metastatic	O	O
breast	O	O
lesions	O	O
.	O	O

No	O	O
statistically	O	O
significant	O	O
association	O	O
between	O	O
stage	O	O
of	O	O
disease	O	O
and	O	O
immunoglobulin	O	O
presence	O	O
was	O	O
demonstrable	O	O
.	O	O

Moderate-to-severe	O	O
intraductal	O	O
epithelial	O	O
hyperplasias	O	O
were	O	O
more	O	O
often	O	O
associated	O	O
with	O	O
immunoglobulin	O	O
G	O	O
localization	O	O
that	O	O
were	O	O
other	O	O
benign	O	O
lesions	O	O

Correlation	O	O
of	O	O
steroid	O	O
receptors	O	O
with	O	O
histologic	O	O
differentiation	O	O
in	O	O
mammary	O	O
carcinoma	O	O
.	O	O

A	O	O
Singapore	O	O
experience	O	O
.	O	O

Cancer	O	O
of	O	O
the	O	O
breast	O	O
is	O	O
the	O	O
most	O	O
common	O	O
tumor	O	O
in	O	O
females	O	O
in	O	O
Singapore	O	O
,	O	O
with	O	O
the	O	O
rate	O	O
of	O	O
20.7	O	O
per	O	O
100	O	O
,	O	O
000	O	O
per	O	O
year	O	O
(	O	O
1977	O	O
estimate	O	O
)	O	O
,	O	O
which	O	O
is	O	O
predicted	O	O
to	O	O
increase	O	O
to	O	O
29.8	O	O
per	O	O
100	O	O
,	O	O
000	O	O
women	O	O
per	O	O
year	O	O
by	O	O
1995	O	O
.	O	O

A	O	O
detailed	O	O
histopathologic	O	O
review	O	O
of	O	O
50	O	O
primary	O	O
breast	O	O
cancer	O	O
tumors	O	O
analyzed	O	O
for	O	O
estrogen	B-protein	O
receptor	I-protein	O
(	O	O
ER	B-protein	O
)	O	O
level	O	O
was	O	O
carried	O	O
out	O	O
and	O	O
a	O	O
variety	O	O
of	O	O
morphologic	O	O
features	O	O
correlated	O	O
with	O	O
ER	O	O
results	O	O
to	O	O
identify	O	O
any	O	O
factors	I-protein	O
that	O	O
will	O	O
improve	O	O
the	O	O
management	O	O
and	O	O
prognosis	O	O
for	O	O
breast	O	O
cancer	O	O
.	O	O

Cytosol	O	O
was	O	O
incubated	O	O
with	O	O
3H-estradiol	O	O
in	O	O
the	O	O
presence	O	O
and	O	O
absence	O	O
of	O	O
cold	O	O
diethylstilbestrol	O	O
,	O	O
and	O	O
bound	O	O
and	O	O
free	B-protein	O
hormone	I-protein	O
were	O	O
separated	O	O
by	O	O
Dextran-coated	O	O
charcoal	O	O
method	O	O
.	O	O

Tumors	O	O
binding	O	O
more	O	O
than	O	O
5	O	O
fmol/mg	O	O
cytosol	O	O
protein	O	O
were	O	O
classified	O	O
as	O	O
ER	O	O
-positive	O	O
.	O	O

Progesterone	B-protein	O
receptor	I-protein	O
(	O	O
PR	O	O
)	O	O
level	O	O
was	O	O
analyzed	O	O
in	O	O
some	O	O
specimens	O	O
with	O	O
the	O	O
use	O	O
of	O	O
a	O	O
similar	O	O
method	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
Chinese	O	O
(	O	O
90	O	O
%	O	O
)	O	O
.	O	O

Three	O	O
patients	O	O
were	O	O
Malays	O	O
,	O	O
one	O	O
was	O	O
Indian	O	O
,	O	O
and	O	O
one	O	O
was	O	O
European	O	O
in	O	O
this	O	O
series	O	O
.	O	O

Results	O	O
indicated	O	O
that	O	O
there	O	O
was	O	O
strong	O	O
correlation	O	O
between	O	O
ER	O	O
level	O	O
,	O	O
age	O	O
,	O	O
and	O	O
histologic	O	O
grade	O	O
of	O	O
the	O	O
tumors	O	O
.	O	O

No	O	O
correlation	O	O
existed	O	O
between	O	O
absence	O	O
or	O	O
presence	O	O
of	O	O
lymph	O	O
node	O	O
metastases	O	O
and	O	O
ER	B-protein	O
.	O	O

Although	O	O
there	O	O
was	O	O
a	O	O
trend	O	O
for	O	O
ER	B-protein	O
-positive	O	O
tumors	O	O
to	O	O
have	O	O
a	O	O
low-grade	B-protein	O
lymphocytic	I-protein	O
infiltration	I-protein	O
,	O	O
the	O	O
difference	O	O
was	O	O
not	O	O
statistically	O	O
significant	O	O
.	O	O

Mononuclear	I-cell_line	O
cells	I-cell_line	O
infiltrating	O	O
human	O	O
mammary	O	O
carcinomas	O	O
:	O	O
immunohistochemical	O	O
analysis	O	O
with	O	O
monoclonal	O	O
antibodies	O	O
.	O	O

Breast	O	O
carcinomas	O	O
were	O	O
examined	O	O
by	O	O
the	O	O
immunoperoxidase	O	O
technique	O	O
using	O	O
antisera	O	O
specific	O	O
for	O	O
lymphocyte	O	O
subsets	O	O
,	O	O
monocytes	B-cell_type	O
,	O	O
NK	B-cell_type	O
cells	I-cell_type	O
and	O	O
major	O	O
histocompatibility	O	O
antigens	O	O
(	O	O
HLA-A	O	O
,	O	O
-B	O	O
,	O	O
-C	O	O
;	O	O
Ia-like	O	O
)	O	O
.	O	O

Sixty-four	O	O
per	O	O
cent	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
a	O	O
moderate	O	O
or	O	O
strong	O	O
mononuclear	O	O
cell	O	O
infiltration	O	O
,	O	O
77	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
without	O	O
mononuclear	O	O
cell	O	O
infiltration	O	O
had	O	O
receptors	O	O
for	O	O
estrogens	O	O
as	O	O
compared	O	O
to	O	O
51	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
infiltration	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
the	O	O
infiltrating	B-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
were	O	O
T	B-cell_type	O
cells	I-cell_type	O
;	O	O
generally	O	O
the	O	O
OKT8	O	O
cells	O	O
were	O	O
predominant	O	O
.	O	O

The	O	O
Leu	O	O
3A/OKT8	O	O
cell	O	O
ratio	O	O
was	O	O
not	O	O
related	O	O
to	O	O
histological	O	O
type	O	O
,	O	O
tumor	O	O
size	O	O
,	O	O
age	O	O
of	O	O
the	O	O
patient	O	O
or	O	O
presence	O	O
of	O	O
metastases	O	O
.	O	O

Some	O	O
of	O	O
the	O	O
T	B-cell_type	O
cells	I-cell_type	O
had	O	O
the	O	O
Ia	O	O
antigen	O	O
and	O	O
were	O	O
thus	O	O
probably	O	O
activated	O	O
.	O	O

The	O	O
B	B-cell_type	O
cells	I-cell_type	O
were	O	O
either	O	O
absent	O	O
or	O	O
less	O	O
numerous	O	O
than	O	O
the	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

There	O	O
was	O	O
no	O	O
relation	O	O
between	O	O
their	O	O
distribution	O	O
and	O	O
the	O	O
various	O	O
parameters	O	O
studied	O	O
.	O	O

A	O	O
few	O	O
monocytes	B-cell_type	O
were	O	O
heterogeneous	O	O
according	O	O
to	O	O
their	O	O
markers	O	O
(	O	O
OKM	B-protein	O
I	I-protein	O
and	O	O
acid	O	O
phosphatase	O	O
)	O	O
.	O	O

In	O	O
6	O	O
cases	O	O
only	O	O
there	O	O
was	O	O
a	O	O
strong	O	O
infiltration	O	O
of	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
positive	O	O
for	O	O
acid	O	O
phosphatase	O	O
.	O	O

The	O	O
number	O	O
of	O	O
the	O	O
natural	B-cell_type	O
killer	I-cell_type	O
cells	I-cell_type	O
was	O	O
also	O	O
low	O	O
.	O	O

Only	O	O
a	O	O
few	O	O
mononuclear	O	O
infiltrating	B-cell_type	O
cells	I-cell_type	O
had	O	O
receptors	O	O
for	O	O
transferrin	O	O
.	O	O

There	O	O
was	O	O
a	O	O
positive	O	O
correlation	O	O
between	O	O
the	O	O
inflammatory	O	O
infiltration	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
HLA	O	O
class-I	O	O
antigens	O	O
on	O	O
tumor	O	O
cell	O	O
s	O	O
.	O	O

Some	O	O
of	O	O
the	O	O
antisera	O	O
specific	O	O
for	O	O
lymphocyte	O	O
subsets	O	O
also	O	O
stained	O	O
the	O	O
breast	O	O
carcinoma	O	O
cells	O	O
.	O	O

The	O	O
great	O	O
variations	O	O
in	O	O
the	O	O
subsets	O	O
of	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
in	O	O
breast	O	O
carcinomas	O	O
may	O	O
correspond	O	O
to	O	O
various	O	O
systems	O	O
of	O	O
defense	O	O
against	O	O
neoplasm	O	O
.	O	O

A	O	O
case	O	O
of	O	O
male	O	O
pseudohermaphroditism	O	O
with	O	O
normal	O	O
androgen	B-protein	O
receptor	I-protein	O
binding	O	O
and	O	O
47	O	O
,	O	O
XYY	O	O
karyotype	O	O
.	O	O

A	O	O
case	O	O
of	O	O
male	O	O
pseudohermaphroditism	O	O
with	O	O
47	O	O
,	O	O
XYY	O	O
karyotype	O	O
in	O	O
blood	O	O
and	O	O
cutaneous	O	O
fibroblasts	O	O
is	O	O
described	O	O
.	O	O

The	O	O
plasma	O	O
testosterone	O	O
response	O	O
to	O	O
HCG	O	O
stimulation	O	O
was	O	O
slightly	O	O
below	O	O
the	O	O
normal	O	O
range	O	O
on	O	O
two	O	O
occasions	O	O
suggesting	O	O
a	O	O
deficit	O	O
of	O	O
gonadal	O	O
function	O	O
.	O	O

A	O	O
study	O	O
of	O	O
the	O	O
receptors	O	O
for	O	O
dihydrotestosterone	O	O
in	O	O
fibroblasts	O	O
of	O	O
genital	O	O
and	O	O
nongenital	O	O
skin	O	O
showed	O	O
a	O	O
normal	O	O
concentration	O	O
of	O	O
receptors	O	O
in	O	O
genital	O	O
skin	O	O
;	O	O
5-alpha-reductase	O	O
activity	O	O
in	O	O
fibroblasts	O	O
of	O	O
the	O	O
genital	O	O
skin	O	O
was	O	O
low	O	O
,	O	O
but	O	O
the	O	O
plasma	O	O
relationship	O	O
testosterone/dihydrotestosterone	O	O
under	O	O
HCG	O	O
stimulation	O	O
was	O	O
normal	O	O
.	O	O

The	O	O
diagnostic	O	O
possibility	O	O
of	O	O
a	O	O
complete	O	O
testicular	O	O
feminization	O	O
syndrome	O	O
with	O	O
normal	B-protein	O
receptors	I-protein	O
for	O	O
dihydrotestosterone	O	O
is	O	O
commented	O	O
on	O	O
.	O	O

1	O	O
,	O	O
25-Dihydroxyvitamin	O	O
D3	O	O
inhibits	O	O
antigen-induced	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

The	O	O
proliferative	O	O
response	O	O
of	O	O
murine	B-cell_line	O
spleen	I-cell_line	O
and	O	O
thymus	B-cell_type	O
cells	I-cell_type	O
to	O	O
antigen	O	O
but	O	O
not	O	O
to	O	O
lectin	O	O
was	O	O
inhibited	O	O
by	O	O
the	O	O
active	O	O
metabolite	O	O
of	O	O
vitamin	B-protein	O
D3	I-protein	O
,	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
.	O	O

To	O	O
directly	O	O
examine	O	O
the	O	O
effect	O	O
of	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
on	O	O
T	O	O
cell	O	O
activation	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
other	O	O
complicating	O	O
interactions	O	O
,	O	O
we	O	O
utilized	O	O
a	O	O
panel	O	O
of	O	O
cloned	O	O
Ia-restricted	O	O
T	O	O
cell	O	O
hybridomas	O	O
that	O	O
secrete	O	O
IL	O	O
2	O	O
on	O	O
activation	O	O
by	O	O
cloned	O	O
Ia-bearing	O	O
stimulator	O	O
cells	O	O
(	O	O
TA3	O	O
)	O	O
or	O	O
when	O	O
stimulated	O	O
by	O	O
mitogen	B-protein	O
.	O	O

Physiologic	O	O
concentrations	O	O
of	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
(	O	O
0.01	O	O
to	O	O
0.1	O	O
nm	O	O
)	O	O
inhibited	O	O
the	O	O
antigen-induced	O	O
secretion	O	O
of	O	O
IL	O	O
2	O	O
by	O	O
several	O	O
of	O	O
these	O	O
T	O	O
cell	O	O
hybridomas	O	O
.	O	O

This	O	O
inhibition	O	O
was	O	O
dependent	O	O
on	O	O
the	O	O
concentration	O	O
of	O	O
the	O	O
free	B-protein	O
hormone	I-protein	O
and	O	O
could	O	O
be	O	O
overcome	O	O
by	O	O
increasing	O	O
the	O	O
number	O	O
of	O	O
Ia-bearing	B-cell_type	O
stimulator	I-cell_type	O
cells	I-cell_type	O
used	O	O
.	O	O

Pretreatment	O	O
of	O	O
the	O	O
T	B-DNA	O
hybridoma	I-DNA	O
but	O	O
not	O	O
the	O	O
TA3	O	O
stimulator	O	O
cell	O	O
with	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
resulted	O	O
in	O	O
inhibition	O	O
of	O	O
activation	O	O
.	O	O

These	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
finding	O	O
that	O	O
specific	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	B-protein	O
)	O	O
2D3	O	O
receptors	O	O
are	O	O
present	O	O
on	O	O
the	O	O
T	O	O
cell	O	O
hybridomas	O	O
but	O	O
are	O	O
lacking	O	O
in	O	O
TA3	B-cell_type	O
cells	I-cell_type	O
.	O	O

1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
failed	O	O
,	O	O
however	O	O
,	O	O
to	O	O
inhibit	O	O
the	O	O
activation	O	O
of	O	O
the	O	O
T	B-protein	O
cell	I-protein	O
hybridomas	O	O
by	O	O
lectin	O	O
or	O	O
by	O	O
an	O	O
anti-Thy-1	O	O
antibody	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
may	O	O
be	O	O
interfering	O	O
with	O	O
early	O	O
events	O	O
of	O	O
antigen-induced	O	O
T	O	O
cell	O	O
activation	O	O
,	O	O
perhaps	O	O
by	O	O
hindering	O	O
T	O	O
cell	O	O
recognition	O	O
of	O	O
the	O	O
relevant	O	O
antigen	O	O
on	O	O
stimulator	O	O
cell	O	O
surfaces	O	O
.	O	O

This	O	O
system	O	O
should	O	O
prove	O	O
useful	O	O
in	O	O
studying	O	O
the	O	O
molecular	O	O
mechanisms	O	O
by	O	O
which	O	O
1	O	O
,	O	O
25-	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
acts	O	O
to	O	O
inhibit	O	O
T	O	O
cell	O	O
activation	O	O
and	O	O
subsequent	O	O
IL	O	O
2	O	O
production	O	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
and	O	O
steroid	O	O
sensitivity	O	O
in	O	O
normal	O	O
and	O	O
neoplastic	B-cell_line	O
human	I-cell_line	O
lymphoid	I-cell_line	O
tissues	O	O
:	O	O
a	O	O
review	O	O
.	O	O

The	O	O
determination	O	O
of	O	O
estrogen	B-protein	O
and	O	O
progesterone	B-protein	O
receptors	I-protein	O
in	O	O
breast	O	O
cancer	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
useful	O	O
in	O	O
predicting	O	O
the	O	O
response	O	O
to	O	O
endocrine	O	O
therapy	O	O
.	O	O

Given	O	O
their	O	O
well-known	O	O
inhibitory	O	O
effects	O	O
on	O	O
lymphoid	O	O
tissue	O	O
,	O	O
glucocorticoids	O	O
have	O	O
been	O	O
used	O	O
widely	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
leukemia	O	O
.	O	O

Given	O	O
these	O	O
facts	O	O
,	O	O
over	O	O
the	O	O
last	O	O
10	O	O
years	O	O
,	O	O
several	O	O
investigators	O	O
have	O	O
measured	O	O
the	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
normal	O	O
and	O	O
neoplastic	O	O
lymphoid	O	O
tissue	O	O
to	O	O
see	O	O
whether	O	O
their	O	O
number	O	O
correlated	O	O
with	O	O
glucocorticoid	O	O
responsiveness	O	O
in	O	O
vitro	O	O
or	O	O
in	O	O
vivo	O	O
.	O	O

No	O	O
clear	O	O
correlation	O	O
could	O	O
be	O	O
established	O	O
between	O	O
the	O	O
level	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
and	O	O
the	O	O
in	O	O
vitro	O	O
action	O	O
of	O	O
steroids	O	O
in	O	O
normal	B-cell_type	O
and	O	O
neoplastic	B-cell_line	O
lymphoid	I-cell_line	O
tissue	I-cell_line	O
.	O	O

In	O	O
contrast	O	O
,	O	O
attempts	O	O
to	O	O
correlate	O	O
glucocorticoid	O	O
receptor	O	O
levels	O	O
in	O	O
acute	O	O
lymphocytic	O	O
leukemia	O	O
to	O	O
in	O	O
vivo	O	O
steroid	O	O
responsiveness	O	O
and	O	O
immunological	O	O
type	O	O
using	O	O
the	O	O
whole-cell-binding	O	O
assay	O	O
for	O	O
receptor	O	O
determination	O	O
and	O	O
selecting	O	O
the	O	O
patients	O	O
according	O	O
to	O	O
age	O	O
and	O	O
immunological	O	O
criteria	O	O
have	O	O
been	O	O
more	O	O
successful	O	O
.	O	O

[	O	O
Glucocorticoid	O	O
receptors	O	O
in	O	O
normal	B-cell_type	O
human	I-cell_type	O
lymphocytes	I-cell_type	O
]	O	O

Glucocorticoid	O	O
(	O	O
GC	B-protein	O
)	O	O
receptors	O	O
were	O	O
studied	O	O
in	O	O
intact	O	O
lymphocytes	I-cell_type	O
from	O	O
11	O	O
donors	O	O
.	O	O

GC	O	O
binding	O	O
parameters	O	O
were	O	O
found	O	O
to	O	O
be	O	O
highly	O	O
reproducible	O	O
in	O	O
repeated	O	O
experiments	O	O
with	O	O
lymphocytes	I-cell_type	O
.	O	O

It	O	O
was	O	O
shown	O	O
that	O	O
GC	O	O
receptors	O	O
in	O	O
donors	O	O
'	B-cell_type	O
lymphocytes	I-cell_type	O
could	O	O
be	O	O
distributed	O	O
into	O	O
two	O	O
different	O	O
classes	O	O
similarly	O	O
to	O	O
the	O	O
pattern	O	O
seen	O	O
in	O	O
skin	O	O
fibroblasts	O	O
.	O	O

Human	O	O
lymphocytes	O	O
are	O	O
an	O	O
adequate	O	O
object	O	O
for	O	O
studying	O	O
genetically	O	O
determined	O	O
variability	O	O
of	O	O
GC	O	O
receptors	O	O
and	O	O
its	O	O
clinical	O	O
importance	O	O
.	O	O

Specific	O	O
estrogen	O	O
binding	O	O
sites	O	O
in	O	O
human	B-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
and	I-cell_line	O
thymic	I-cell_line	O
cells	I-cell_line	O
.	O	O

The	O	O
binding	O	O
of	O	O
estrogen	O	O
in	O	O
preparations	O	O
of	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
,	O	O
as	O	O
well	O	O
as	O	O
by	O	O
splenic	B-cell_type	O
and	I-cell_line	O
thymic	I-cell_line	O
cells	I-cell_line	O
is	O	O
demonstrated	O	O
by	O	O
three	O	O
different	O	O
approaches	O	O
(	O	O
Dextran-coated	O	O
charcoal	O	O
method	O	O
,	O	O
whole	O	O
cell	O	O
assay	O	O
,	O	O
and	O	O
gel	O	O
filtration	O	O
on	O	O
a	O	O
sepharose	O	O
4B	O	O
column	O	O
)	O	O
.	O	O

Scatchard	O	O
's	O	O
analysis	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
-moxestrol	O	O
(	O	O
R2858	B-protein	O
)	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
-estradiol	O	O
binding	O	O
proves	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
single	O	O
class	B-DNA	O
of	O	O
receptor	I-DNA	O
sites	I-DNA	O
having	O	O
a	O	O
dissociation	O	O
constant	O	O
of	O	O
0.18-2.4	B-protein	O
X	I-protein	O
10	I-protein	O
(	O	O
-9	B-protein	O
)	O	O
M	O	O
.	O	O

Physicochemical	O	O
properties	O	O
of	O	O
the	O	O
binder	O	O
,	O	O
including	O	O
binding	O	O
capacity	O	O
and	O	O
steroid	O	O
specificity	O	O
,	O	O
are	O	O
quite	O	O
similar	O	O
to	O	O
those	O	O
reported	O	O
for	O	O
the	O	O
thymus	O	O
of	O	O
small	O	O
mammalian	O	O
species	O	O
or	O	O
human	O	O
thymoma	O	O
.	O	O

Administration	O	O
of	O	O
fibroblast	O	O
interferon	O	O
to	O	O
patients	O	O
with	O	O
advanced	O	O
breast	O	O
cancer	O	O
:	O	O
possible	O	O
effects	O	O
on	O	O
skin	O	O
metastasis	O	O
and	O	O
on	O	O
hormone	B-protein	O
receptors	I-protein	O
.	O	O

Eleven	O	O
patients	O	O
with	O	O
metastasized	O	O
breast	O	O
cancer	O	O
received	O	O
8	O	O
intramuscular	O	O
injections	O	O
of	O	O
6	O	O
x	O	O
10	O	O
(	O	O
6	O	O
)	O	O
units	O	O
of	O	O
human	O	O
fibroblast	O	O
interferon	O	O
over	O	O
a	O	O
period	O	O
of	O	O
40	O	O
days	O	O
.	O	O

The	O	O
injections	O	O
did	O	O
not	O	O
cause	O	O
local	O	O
irritation	O	O
or	O	O
inflammation	O	O
.	O	O

Fever	O	O
occurred	O	O
in	O	O
only	O	O
1	O	O
of	O	O
the	O	O
11	O	O
patients	O	O
.	O	O

Although	O	O
several	O	O
types	O	O
of	O	O
metastases	O	O
were	O	O
monitored	O	O
,	O	O
only	O	O
skin	O	O
nodules	O	O
consistently	O	O
(	O	O
10	O	O
out	O	O
of	O	O
11	O	O
patients	O	O
)	O	O
exhibited	O	O
changes	O	O
that	O	O
were	O	O
suggestive	O	O
of	O	O
a	O	O
therapeutic	O	O
effect	O	O
of	O	O
the	O	O
treatment	O	O
regimen	O	O
:	O	O
either	O	O
a	O	O
simple	O	O
decrease	O	O
in	O	O
size	O	O
of	O	O
some	O	O
nodules	O	O
or	O	O
central	O	O
necrosis	O	O
accompanied	O	O
by	O	O
an	O	O
inflammatory	O	O
reaction	O	O
.	O	O

NK-activity	O	O
of	O	O
peripheral	O	O
blood	O	O
leukocytes	O	O
was	O	O
significantly	O	O
increased	O	O
after	O	O
administration	O	O
of	O	O
the	O	O
first	B-DNA	O
dose	I-DNA	O
;	I-DNA	O
the	O	O
effect	O	O
of	O	O
subsequent	O	O
injections	O	O
was	O	O
less	O	O
clear	O	O
.	O	O

Receptors	O	O
for	O	O
estrogens	O	O
and	O	O
progestogens	O	O
were	O	O
increased	O	O
in	O	O
the	O	O
tumor	O	O
biopsies	O	O
of	O	O
2	O	O
out	O	O
of	O	O
2	O	O
and	O	O
5	O	O
out	O	O
of	O	O
6	O	O
patients	O	O
tested	O	O
respectively	O	O
.	O	O

Decreased	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
binding	O	O
in	O	O
adrenal	O	O
insufficiency	O	O
.	O	O

To	O	O
examine	O	O
the	O	O
effect	O	O
of	O	O
glucocorticoid	O	O
deficiency	O	O
on	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
,	O	O
we	O	O
examine	O	O
the	O	O
binding	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone	O	O
to	O	O
lymphocytes	I-cell_type	O
in	O	O
normal	O	O
subjects	O	O
and	O	O
patients	O	O
with	O	O
adrenal	O	O
insufficiency	O	O
before	O	O
and	O	O
after	O	O
glucocorticoid	O	O
replacement	O	O
therapy	O	O
.	O	O

Using	O	O
a	O	O
whole	O	O
cell	O	O
competitive	O	O
binding	O	O
assay	O	O
,	O	O
normal	B-cell_type	O
human	I-cell_type	O
lymphocytes	I-cell_type	O
had	O	O
5977	O	O
+/-	O	O
1487	O	O
(	O	O
mean	O	O
+/-	O	O
SD	O	O
)	O	O
binding	O	O
sites/cell	O	O
and	O	O
a	O	O
dissociation	O	O
constant	O	O
of	O	O
10	O	O
+/-	O	O
2	O	O
nM	O	O
.	O	O

Lymphocytes	O	O
from	O	O
patients	O	O
with	O	O
untreated	O	O
adrenal	O	O
insufficiency	O	O
had	O	O
fewer	O	O
binding	O	O
sites	O	O
(	O	O
3364	O	O
+/-322	O	O
)	O	O
and	O	O
a	O	O
2-fold	O	O
increase	O	O
in	O	O
binding	O	O
affinity	O	O
(	O	O
5.4	O	O
+/-	O	O
0.9	O	O
mM	O	O
)	O	O
.	O	O

The	O	O
administration	O	O
of	O	O
conventional	O	O
replacement	O	O
doses	O	O
of	O	O
cortisone	O	O
acetate	O	O
for	O	O
6	O	O
months	O	O
caused	O	O
no	O	O
change	O	O
in	O	O
receptor	O	O
number	O	O
,	O	O
but	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
decrease	O	O
in	O	O
binding	O	O
affinity	O	O
toward	O	O
normal	O	O
.	O	O

After	O	O
long	O	O
term	O	O
glucocorticoid	O	O
replacement	O	O
therapy	O	O
,	O	O
binding	O	O
parameters	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
in	O	O
patients	O	O
before	O	O
treatment	O	O
.	O	O

The	O	O
physiological	O	O
implications	O	O
of	O	O
the	O	O
decreased	B-protein	O
receptor	I-protein	O
number	O	O
and	O	O
increased	O	O
binding	O	O
affinity	O	O
in	O	O
adrenal	O	O
insufficiency	O	O
remain	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O

Glucocorticoid	B-protein	O
receptor	I-protein	O
concentrations	O	O
and	O	O
terminal	O	O
transferase	O	O
activity	O	O
as	O	O
indicators	O	O
of	O	O
prognosis	O	O
in	O	O
acute	O	O
non-lymphocytic	O	O
leukaemia	O	O
.	O	O

Activity	O	O
of	O	O
terminal	O	O
deoxynucleotidyl	B-protein	O
transferase	I-protein	O
(	O	O
TdT	B-protein	O
)	O	O
,	O	O
adenosine	O	O
deaminase	O	O
,	O	O
and	O	O
5'nucleotidase	O	O
and	O	O
the	O	O
cellular	O	O
concentration	O	O
of	O	O
glucocorticoid	O	O
(	O	O
dexamethasone	O	O
)	O	O
receptor	O	O
were	O	O
determined	O	O
in	O	O
25	O	O
patients	O	O
with	O	O
acute	O	O
non-lymphocytic	O	O
leukaemia	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
treated	O	O
according	O	O
to	O	O
a	O	O
common	O	O
protocol	O	O
.	O	O

Increased	O	O
activity	O	O
of	O	O
TdT	O	O
(	O	O
greater	O	O
than	O	O
0.1	O	O
unit/microgram	O	O
DNA	O	O
)	O	O
was	O	O
found	O	O
in	O	O
11	O	O
patients	O	O
.	O	O

This	O	O
group	O	O
of	O	O
patients	O	O
was	O	O
shown	O	O
to	O	O
have	O	O
higher	O	O
remission	O	O
and	O	O
survival	O	O
rates	O	O
(	O	O
p	O	O
=	O	O
0.06	O	O
)	O	O
compared	O	O
with	O	O
patients	O	O
with	O	O
low	O	O
activity	O	O
of	O	O
TdT	O	O
.	O	O

The	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
concentration	O	O
of	O	O
the	O	O
leukaemic	B-cell_type	O
blast	I-cell_type	O
cells	I-cell_type	O
ranged	O	O
from	O	O
0	O	O
to	O	O
0.94	O	O
fmol/microgram	O	O
DNA	O	O
.	O	O

Thirteen	O	O
patients	O	O
had	O	O
blast	B-cell_type	O
cells	I-cell_type	O
with	O	O
a	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
concentration	O	O
over	O	O
0.22	O	O
fmol/microgram	O	O
DNA	O	O
.	O	O

These	O	O
patients	O	O
had	O	O
significantly	O	O
increased	O	O
remission	O	O
and	O	O
survival	O	O
rates	O	O
(	O	O
p	O	O
=	O	O
0.006	O	O
)	O	O
compared	O	O
with	O	O
those	O	O
with	O	O
a	O	O
low	O	O
receptor	O	O
concentration	O	O
.	O	O

This	O	O
finding	O	O
can	O	O
not	O	O
be	O	O
explained	O	O
by	O	O
a	O	O
difference	O	O
in	O	O
sensitivity	O	O
to	O	O
glucocorticoids	O	O
since	O	O
these	O	O
were	O	O
not	O	O
used	O	O
as	O	O
therapeutic	O	O
agents	O	O
.	O	O

Adenosine	O	O
deaminase	O	O
and	O	O
5'nucleotidase	O	O
activities	O	O
both	O	O
varied	O	O
within	O	O
two	O	O
orders	O	O
of	O	O
magnitude	O	O
.	O	O

No	O	O
correlation	O	O
could	O	O
be	O	O
found	O	O
between	O	O
activities	O	O
of	O	O
these	O	O
enzymes	O	O
and	O	O
remission	O	O
or	O	O
survival	O	O
rate	O	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
measurements	O	O
of	O	O
TdT	O	O
activity	O	O
and	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
concentration	O	O
yield	O	O
valuable	O	O
prognostic	O	O
information	O	O
in	O	O
acute	O	O
non-lymphocytic	O	O
leukaemia	O	O

[	O	O
3H	O	O
]	O	O
cortivazol	O	O
:	O	O
a	O	O
unique	O	O
high	O	O
affinity	O	O
ligand	O	O
for	O	O
the	O	O
glucocorticoid	O	O
receptor	O	O
.	O	O

Cortivazol	O	O
(	O	O
CVZ	B-protein	O
)	O	O
and	O	O
deacylcortivazol	O	O
(	O	O
DAC	O	O
)	O	O
are	O	O
pyrazolosteroids	O	O
with	O	O
potent	O	O
glucocorticoid	O	O
activity	O	O
.	O	O

In	O	O
previous	O	O
work	O	O
we	O	O
showed	O	O
that	O	O
DAC	O	O
is	O	O
40-fold	O	O
more	O	O
potent	O	O
than	O	O
dexamethasone	O	O
(	O	O
DEX	O	O
)	O	O
in	O	O
lysing	O	O
leukemic	O	O
lymphoblasts	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
interaction	O	O
between	O	O
these	O	O
atypical	O	O
steroids	O	O
and	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
,	O	O
we	O	O
examined	O	O
the	O	O
binding	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
CVZ	O	O
to	O	O
cytosol	O	O
from	O	O
glucocorticoid-sensitive	O	O
and	O	O
-resistant	O	O
variants	O	O
of	O	O
the	O	O
human	B-cell_line	O
leukemic	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
CEM	O	O
C7	O	O
.	O	O

In	O	O
glucocorticoid-sensitive	B-cell_type	O
cells	I-cell_type	O
[	O	O
3H	O	O
]	O	O
CVZ	O	O
causes	O	O
a	O	O
2-fold	O	O
induction	O	O
of	O	O
glutamine	O	O
synthetase	O	O
and	O	O
binds	O	O
to	O	O
a	O	O
protein	O	O
in	O	O
the	O	O
4.6	O	O
S	O	O
region	O	O
of	O	O
high	O	O
salt	O	O
sucrose	O	O
gradients	O	O
.	O	O

On	O	O
DEAE-cellulose	O	O
chromatography	O	O
,	O	O
[	O	O
3H	O	O
]	O	O
CVZ-receptor	O	O
complexes	O	O
show	O	O
a	O	O
shift	O	O
from	O	O
high	O	O
(	O	O
0.25	O	O
M	O	O
KP	O	O
)	O	O
to	O	O
low	O	O
salt	O	O
(	O	O
0.09	O	O
M	O	O
KP	O	O
)	O	O
eluting	O	O
forms	O	O
upon	O	O
activation	O	O
.	O	O

CVZ	O	O
competes	O	O
for	O	O
a	O	O
97	O	O
,	O	O
000-dalton	O	O
protein	O	O
labeled	O	O
by	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone	O	O
mesylate	O	O
.	O	O

Scatchard	O	O
analysis	O	O
of	O	O
the	O	O
binding	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
CVZ	O	O
in	O	O
glucocorticoid-sensitive	B-cell_type	O
cells	I-cell_type	O
revealed	O	O
a	O	O
curvilinear	O	O
plot	O	O
which	O	O
resolved	O	O
into	O	O
high	O	O
(	O	O
0.4	O	O
nM	O	O
)	O	O
and	O	O
low	O	O
(	O	O
11	O	O
nM	O	O
)	O	O
affinity	O	O
components	O	O
.	O	O

The	O	O
receptor	O	O
concentration	O	O
of	O	O
the	O	O
low	B-DNA	O
affinity	I-DNA	O
site	I-DNA	O
(	O	O
0.30	B-protein	O
pmol/mg	I-protein	O
protein	I-protein	O
)	O	O
was	O	O
approximately	O	O
twice	O	O
that	O	O
of	O	O
the	O	O
high	O	O
affinity	O	O
site	B-protein	O
(	O	O
0.14	B-protein	O
pmol/mg	I-protein	O
protein	I-protein	O
)	O	O
.	O	O

Dissociation	O	O
experiments	O	O
with	O	O
dilution	O	O
and/or	O	O
excess	O	O
unlabeled	O	O
CVZ	O	O
supported	O	O
the	O	O
presence	O	O
of	O	O
independent	O	O
sites	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
binding	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
DEX	O	O
to	O	O
C7	O	O
cytosol	O	O
revealed	O	O
a	O	O
single	O	O
class	O	O
of	O	O
binding	B-DNA	O
sites	I-DNA	O
(	O	O
Kd	I-DNA	O
=	I-DNA	O
1.9	I-DNA	O
nM	O	O
;	O	O
receptor	O	O
concentration	O	O
,	O	O
0.46	O	O
pmol/mg	O	O
protein	O	O
)	O	O
.	O	O

Examination	O	O
of	O	O
the	O	O
binding	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
CVZ	I-protein	O
using	I-protein	O
10	O	O
(	O	O
-5	O	O
)	O	O
M	O	O
DEX	O	O
as	O	O
the	O	O
competing	O	O
ligand	O	O
showed	O	O
that	O	O
DEX	O	O
binds	O	O
only	O	O
to	O	O
the	O	O
low	O	O
affinity	O	O
site	O	O
detected	O	O
by	O	O
[	O	O
3H	O	O
]	O	O
CVZ	O	O
.	O	O

In	O	O
cytosol	O	O
from	O	O
a	O	O
glucocorticoid-resistant	O	O
cell	O	O
line	O	O
with	O	O
virtually	O	O
no	O	O
[	O	O
3H	O	O
]	O	O
DEX	O	O
binding	O	O
,	O	O
[	O	O
3H	O	O
]	O	O
CVZ	O	O
detected	O	O
a	O	O
single	O	O
high	O	O
affinity	O	O
binding	O	O
site	O	O
that	O	O
was	O	O
similar	O	O
in	O	O
dissociation	O	O
constant	O	O
(	O	O
0.8	O	O
nM	O	O
)	O	O
and	O	O
receptor	O	O
concentration	O	O
(	O	O
0.13	O	O
pmol/mg	O	O
protein	O	O
)	O	O
to	O	O
the	O	O
high	O	O
affinity	O	O
site	O	O
detected	O	O
in	O	O
the	O	O
glucocorticoid-sensitive	O	O
cell	O	O
line	O	O
C7	O	O
.	O	O

A	O	O
controlled	O	O
pore	O	O
glass	O	O
bead	O	O
assay	O	O
for	O	O
the	O	O
measurement	O	O
of	O	O
cytoplasmic	B-protein	O
and	O	O
nuclear	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
.	O	O

An	O	O
assay	O	O
for	O	O
the	O	O
quantitation	O	O
of	O	O
cytoplasmic	B-protein	O
and	O	O
nuclear	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
lymphoid	O	O
tissue	O	O
has	O	O
been	O	O
developed	O	O
using	O	O
controlled	O	O
pore	O	O
glass	O	O
(	O	O
CPG	O	O
)	O	O
beads	O	O
.	O	O

Soluble	B-protein	O
receptor	I-protein	O
--	O	O
3H-steroid	O	O
complex	O	O
(	O	O
cytosol	O	O
or	O	O
nuclear	O	O
extract	O	O
)	O	O
is	O	O
adsorbed	O	O
quantitatively	O	O
within	O	O
the	O	O
crevasses	O	O
of	O	O
porous	O	O
glass	O	O
beads	O	O
.	O	O

Excess	O	O
labeled	O	O
steroid	O	O
as	O	O
well	O	O
as	O	O
most	O	O
non-specifically	O	O
bound	O	O
steroid	O	O
is	O	O
easily	O	O
washed	O	O
away	O	O
,	O	O
leaving	O	O
the	O	O
hormone-receptor	B-protein	O
complex	I-protein	O
retained	O	O
by	O	O
the	O	O
beads	O	O
.	O	O

Bound	O	O
3H-steroid	O	O
is	O	O
eluted	O	O
with	O	O
ethanol	O	O
and	O	O
measured	O	O
for	O	O
radioactivity	O	O
.	O	O

This	O	O
procedure	O	O
which	O	O
is	O	O
simple	O	O
,	O	O
rapid	O	O
,	O	O
and	O	O
highly	O	O
reproducible	O	O
is	O	O
carried	O	O
out	O	O
using	O	O
frozen	O	O
samples	O	O
(	O	O
stable	O	O
for	O	O
many	O	O
months	O	O
)	O	O
containing	O	O
as	O	O
few	O	O
as	O	O
1	O	O
X	B-cell_line	O
10	I-cell_line	O
(	I-cell_line	O
7	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
.	O	O

A	O	O
comparison	O	O
of	O	O
the	O	O
CPG	O	O
assay	O	O
to	O	O
dextran	O	O
coated	O	O
charcoal	O	O
and	O	O
a	O	O
whole	O	O
cell	O	O
assay	O	O
demonstrates	O	O
that	O	O
CPG	O	O
and	O	O
dextran	O	O
coated	O	O
charcoal	O	O
give	O	O
equivalent	O	O
measurements	O	O
of	O	O
cytosolic	O	O
receptor	O	O
concentration	O	O
,	O	O
while	O	O
the	O	O
CPG	O	O
and	O	O
whole	O	O
cell	O	O
assays	O	O
provide	O	O
equivalent	O	O
values	O	O
for	O	O
total	O	O
receptor	O	O
content	O	O
.	O	O

Plasmacytoid	O	O
blast	O	O
crisis	O	O
in	O	O
B-cell	O	O
chronic	O	O
lymphocytic	O	O
leukemia	O	O
:	O	O
effect	O	O
of	O	O
estradiol	O	O
on	O	O
growth	O	O
and	O	O
differentiation	O	O
in	O	O
vitro	O	O
.	O	O

Evolution	O	O
of	O	O
a	O	O
case	O	O
of	O	O
chronic	O	O
lymphocytic	B-protein	O
leukemia	O	O
(	O	O
CLL	O	O
)	O	O
into	O	O
blast	O	O
crisis	O	O
was	O	O
found	O	O
to	O	O
be	O	O
characterized	O	O
by	O	O
three	O	O
unusual	O	O
features	O	O
(	O	O
1	O	O
)	O	O
the	O	O
phenotype	O	O
of	O	O
the	O	O
emerging	B-cell_type	O
blast	I-cell_type	O
cells	I-cell_type	O
was	O	O
that	O	O
of	O	O
pre-plasmacytoid	B-cell_type	O
cells	I-cell_type	O
as	O	O
shown	O	O
by	O	O
plasma	O	O
cell	O	O
morphology	O	O
and	O	O
an	O	O
immunological	O	O
phenotype	O	O
corresponding	O	O
partially	O	O
with	O	O
CLL-	O	O
or	O	O
intermediate	O	O
B-cells	O	O
,	O	O
partially	O	O
with	O	O
plasma	O	O
cells	O	O
(	O	O
terminal	O	O
transferase	O	O
-	O	O
,	O	O
common	O	O
acute	O	O
lymphocytic	O	O
leukemia	O	O
antigen	O	O
-	O	O
,	O	O
Ia+	O	O
,	O	O
surface	O	O
immunoglobulin	O	O
heavy	O	O
chains	O	O
-	O	O
,	O	O
surface	O	O
kappa	O	O
light	O	O
chains	O	O
+	O	O
,	O	O
intracytoplasmic	O	O
immunoglobulin	O	O
A+	O	O
and	O	O
G+	O	O
,	O	O
BA-1+	O	O
,	O	O
polyclonal	O	O
gammaglobulin	O	O
production	O	O
)	O	O
;	O	O
(	O	O
2	O	O
)	O	O
cytogenetic	O	O
analysis	O	O
of	O	O
spontaneous	O	O
metaphases	O	O
revealed	O	O
that	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
typical	O	O
CLL	O	O
abnormality	O	O
,	O	O
trisomy	O	O
12	O	O
,	O	O
in	O	O
all	O	O
of	O	O
the	O	O
cells	O	O
,	O	O
an	O	O
additional	O	O
translocation	O	O
between	O	O
chromosomes	O	O
14	O	O
and	O	O
17	O	O
was	O	O
present	O	O
in	O	O
40	O	O
%	O	O
with	O	O
a	O	O
presumptive	O	O
breakpoint	O	O
on	O	O
chromosome	O	O
14	O	O
(	O	O
q12-3	O	O
)	O	O
never	O	O
described	O	O
before	O	O
(	O	O
commonly	O	O
q32	O	O
)	O	O
and	O	O
(	O	O
3	O	O
)	O	O
the	O	O
progression	O	O
of	O	O
the	O	O
disease	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
striking	O	O
increase	O	O
in	O	O
the	O	O
expression	O	O
by	O	O
the	O	O
transformed	B-cell_type	O
cells	I-cell_type	O
of	O	O
specific	O	O
binding	B-DNA	O
sites	I-DNA	O
for	O	O
estradiol	O	O
(	O	O
E2	B-protein	O
)	O	O
due	O	O
to	O	O
an	O	O
actual	O	O
increase	O	O
in	O	O
total	O	O
cellular	O	O
receptor	I-protein	O
proteins	I-protein	O
and	O	O
not	O	O
to	O	O
a	O	O
change	O	O
in	O	O
receptor	O	O
affinity	O	O
for	O	O
E2	O	O
.	O	O

The	O	O
functional	O	O
status	O	O
of	O	O
the	O	O
steroid	B-protein	O
receptors	I-protein	O
was	O	O
confirmed	O	O
by	O	O
nuclear	O	O
transfer	O	O
of	O	O
the	O	O
cytoplasmic	B-protein	O
hormone-receptor	I-protein	O
complex	I-protein	O
upon	O	O
temperature	O	O
activation	O	O
.	O	O

Since	O	O
the	O	O
rise	O	O
in	O	O
E2-receptor	O	O
display	O	O
paralleled	O	O
a	O	O
large	O	O
increase	O	O
in	O	O
the	O	O
proliferative	O	O
activity	O	O
of	O	O
the	O	O
cells	I-cell_type	O
as	O	O
well	O	O
as	O	O
a	O	O
change	O	O
in	O	O
their	O	O
maturation	O	O
status	O	O
the	O	O
question	O	O
was	O	O
raised	O	O
as	O	O
to	O	O
whether	O	O
the	O	O
E2-receptor	O	O
should	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
physiological	O	O
marker	O	O
of	O	O
growth	O	O
rate	O	O
or	O	O
of	O	O
cellular	O	O
differentiation	O	O
.	O	O

Exposure	O	O
of	O	O
the	O	O
patient	B-cell_type	O
's	I-cell_type	O
blast	I-cell_type	O
cells	I-cell_type	O
to	O	O
E2	O	O
in	O	O
vitro	O	O
resulted	O	O
in	O	O
cessation	O	O
of	O	O
cell	O	O
growth	O	O
following	O	O
at	O	O
least	O	O
one	O	O
mitosis	O	O
after	O	O
addition	O	O
of	O	O
the	O	O
inducer	O	O
as	O	O
seen	O	O
from	O	O
the	O	O
replacement	O	O
of	O	O
the	O	O
large	O	O
blasts	O	O
by	O	O
small	B-cell_type	O
CLL-like	I-cell_type	O
cells	I-cell_type	O
without	O	O
definite	O	O
signs	O	O
of	O	O
alteration	O	O
of	O	O
the	O	O
differentiation	O	O
status	O	O
.	O	O

This	O	O
suggests	O	O
the	O	O
association	O	O
of	O	O
E2-receptor	O	O
expression	O	O
with	O	O
control	O	O
of	O	O
growth	O	O
rather	O	O
than	O	O
cell	O	O
maturation	O	O
.	O	O

Multiple	O	O
forms	O	O
and	O	O
fragments	O	O
of	O	O
cytosolic	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
from	O	O
human	B-cell_type	O
leukemic	I-cell_type	O
cells	I-cell_type	O
and	I-cell_type	O
normal	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Therapy	O	O
with	O	O
glucocorticoids	O	O
is	O	O
generally	O	O
more	O	O
effective	O	O
in	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
than	O	O
in	O	O
other	O	O
types	O	O
of	O	O
human	O	O
leukemia	O	O
.	O	O

Previous	O	O
studies	O	O
,	O	O
however	O	O
,	O	O
have	O	O
not	O	O
revealed	O	O
any	O	O
consistent	O	O
relationship	O	O
between	O	O
clinical	O	O
responsiveness	O	O
and	O	O
the	O	O
cellular	O	O
or	O	O
cytosolic	O	O
concentration	O	O
of	O	O
glucocorticoid-binding	O	O
sites	O	O
.	O	O

The	O	O
objectives	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
determine	O	O
whether	O	O
there	O	O
are	O	O
intrinsic	O	O
structural	O	O
differences	O	O
among	O	O
the	O	O
glucocorticoid	O	O
receptors	O	O
in	O	O
various	O	O
types	O	O
of	O	O
leukemic	B-cell_type	O
cells	I-cell_type	O
and	I-cell_type	O
normal	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
endogenous	O	O
peptidases	O	O
in	O	O
receptor	O	O
degradation	O	O
.	O	O

Cytosols	O	O
were	O	O
prepared	O	O
from	O	O
fresh	O	O
or	O	O
rapidly	O	O
frozen	O	O
leukocytes	O	O
from	O	O
6	O	O
healthy	O	O
adults	O	O
and	O	O
35	O	O
high-risk	O	O
leukemia	O	O
patients	O	O
(	O	O
median	O	O
white	O	O
blood	O	O
cell	O	O
count	O	O
,	O	O
150	O	O
,	O	O
000	O	O
cells/microliter	O	O
;	O	O
median	O	O
age	O	O
,	O	O
13	O	O
years	O	O
)	O	O
.	O	O

Receptors	O	O
were	O	O
labeled	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
triamcinolone	O	O
acetonide	O	O
and	O	O
quantitated	O	O
by	O	O
charcoal-dextran	O	O
treatment	O	O
or	O	O
Sephadex	O	O
LH-20	O	O
chromatography	O	O
.	O	O

Mean	O	O
and	O	O
median	O	O
cytosolic	O	O
receptor	O	O
concentrations	O	O
in	O	O
12	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
specimens	O	O
lacking	O	O
the	O	O
standard	O	O
B-cell	O	O
or	O	O
T-cell	O	O
markers	O	O
(	O	O
``	O	O
null	O	O
cells	O	O
''	O	O
)	O	O
were	O	O
approximately	O	O
4-fold	O	O
higher	O	O
than	O	O
in	O	O
23	O	O
other	O	O
leukemic	O	O
cell	O	O
specimens	O	O
.	O	O

No	O	O
other	O	O
consistent	O	O
differences	O	O
in	O	O
receptor	O	O
content	O	O
were	O	O
observed	O	O
.	O	O

Agarose	O	O
filtration	O	O
and	O	O
ultracentrifugation	O	O
in	O	O
hypotonic	O	O
buffers	O	O
containing	O	O
20	O	O
mM	O	O
Na2MoO4	O	O
revealed	O	O
complexes	O	O
of	O	O
similar	O	O
size	O	O
and	O	O
shape	O	O
in	O	O
all	O	O
clinical	O	O
specimens	O	O
tested	O	O
and	O	O
two	O	O
established	B-cell_line	O
leukemic	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

They	O	O
had	O	O
Stokes	O	O
radii	O	O
(	O	O
Rs	O	O
)	O	O
of	O	O
8.1	O	O
+/-	O	O
0.5	O	O
(	O	O
S.D.	O	O
)	O	O
nm	O	O
(	O	O
n	O	O
=	O	O
50	O	O
)	O	O
,	O	O
sedimentation	O	O
coefficients	O	O
of	O	O
9.5	O	O
+/-	O	O
0.3S	O	O
(	O	O
n	O	O
=	O	O
40	O	O
)	O	O
,	O	O
molecular	O	O
weights	O	O
of	O	O
approximately	O	O
330	O	O
,	O	O
000	O	O
,	O	O
and	O	O
axial	O	O
ratios	O	O
(	O	O
a/b	O	O
)	O	O
of	O	O
approximately	B-protein	O
12	I-protein	O
.	O	O

In	O	O
hypertonic	O	O
,	O	O
molybdate-free	O	O
buffer	O	O
,	O	O
these	O	O
oligomeric	O	O
complexes	O	O
were	O	O
dissociated	O	O
into	O	O
subunits	O	O
with	O	O
Rs	O	O
of	O	O
5.9	O	O
+/-	O	O
0.3	O	O
nm	O	O
(	O	O
n	O	O
=	B-protein	O
12	I-protein	O
)	O	O
and	O	O
a/b	O	O
of	O	O
11	O	O
to	O	O
12	B-protein	O
,	O	O
as	O	O
observed	O	O
previously	O	O
for	O	O
other	O	O
receptors	B-protein	O
.	O	O

Fragmentation	O	O
of	O	O
the	O	O
oligomer	O	O
and	O	O
the	O	O
subunit	O	O
was	O	O
evident	O	O
in	O	O
some	O	O
cytosols	O	O
.	O	O

High	O	O
activities	O	O
of	O	O
peptidases	O	O
of	O	O
various	O	O
specificities	O	O
were	O	O
detected	O	O
in	O	O
leukemic	O	O
cell	O	O
cytosols	O	O
,	O	O
as	O	O
in	O	O
other	O	O
cytosols	O	O
,	O	O
by	O	O
fluorometric	O	O
assays	O	O
with	O	O
derivatives	O	O
of	O	O
7-amino-4-methylcoumarin	O	O
.	O	O

Receptor	O	O
cleavage	O	O
by	O	O
these	O	O
and	O	O
other	O	O
endogenous	O	O
enzymes	O	O
may	O	O
account	O	O
for	O	O
previous	O	O
observations	O	O
of	O	O
``	O	O
abnormal	O	O
''	O	O
receptors	O	O
in	O	O
cytosols	O	O
from	O	O
some	O	O
leukemic	O	O
specimens	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
intrinsic	O	O
structural	O	O
defects	O	O
in	O	O
the	O	O
receptors	O	O
are	O	O
unlikely	O	O
explanations	O	O
for	O	O
the	O	O
unresponsiveness	O	O
of	O	O
some	O	O
types	O	O
of	O	O
leukemia	O	O
to	O	O
steroid	O	O
therapy	B-protein	O
.	O	O

Glucocorticoid	B-protein	O
receptor	I-protein	O
number	O	O
and	O	O
intracellular	O	O
water	O	O
space	O	O
.	O	O

In	O	O
order	O	O
to	O	O
elucidate	O	O
the	O	O
relationship	O	O
between	O	O
cell	O	O
water	O	O
content	O	O
and	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
,	O	O
eleven	O	O
normal	O	O
and	O	O
malignant	O	O
lymphoid	O	O
or	O	O
myelomonocytic	O	O
cell	O	O
types	O	O
originating	O	O
from	O	O
mouse	O	O
,	O	O
rat	O	O
and	O	O
man	O	O
were	O	O
investigated	O	O
.	O	O

The	O	O
cellular	O	O
water	O	O
space	O	O
was	O	O
measured	O	O
with	O	O
3H2O	B-protein	O
,	O	O
and	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
number	O	O
was	O	O
measured	O	O
in	O	O
a	O	O
whole-cell	O	O
binding	O	O
assay	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone	O	O
at	O	O
30	O	O
and	O	O
37	O	O
degrees	O	O
C	O	O
.	O	O

The	O	O
intracellular	O	O
water	O	O
phase	O	O
concentration	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
(	O	O
around	O	O
40	O	O
nmol/l	O	O
cell	O	O
water	O	O
)	O	O
,	O	O
and	O	O
the	O	O
dependence	O	O
of	O	O
receptor	O	O
affinity	O	O
on	O	O
temperature	O	O
were	O	O
similar	O	O
in	O	O
normal	O	O
and	O	O
malignant	O	O
rodent	O	O
and	O	O
human	B-cell_type	O
cells	I-cell_type	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
comparisons	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
levels	O	O
are	O	O
best	O	O
made	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
intracellular	B-protein	O
receptor	I-protein	O
concentrations	O	O
.	O	O

Covalent	O	O
labeling	O	O
of	O	O
rat	O	O
thymocyte	O	O
and	O	O
human	B-protein	O
lymphoid	I-protein	O
glucocorticoid	I-protein	O
receptor	I-protein	O
.	O	O

Lymphoid	B-cell_type	O
cells	I-cell_type	O
contain	O	O
specific	O	O
receptors	O	O
for	O	O
glucocorticoids	O	O
.	O	O

We	O	O
have	O	O
used	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone-21-mesylate	O	O
to	O	O
label	O	O
covalently	O	O
glucocorticoid	O	O
receptors	O	O
in	O	O
rat	O	O
thymic	O	O
lymphocytes	I-cell_type	O
and	O	O
in	O	O
neoplastic	B-cell_type	O
cells	I-cell_type	O
obtained	O	O
from	O	O
patients	O	O
with	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
and	O	O
malignant	O	O
lymphoma	O	O
.	O	O

The	O	O
covalently	O	O
labeled	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
were	O	O
identified	O	O
by	O	O
polyacrylamide	O	O
gel	O	O
electrophoresis	O	O
(	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
0.1	O	O
%	O	O
sodium	O	O
dodecyl	O	O
sulfate	O	O
)	O	O
.	O	O

In	O	O
cytosolic	O	O
fractions	O	O
prepared	O	O
from	O	O
rat	O	O
thymic	O	O
lymphocytes	I-cell_type	O
,	O	O
[	O	O
3H	O	O
]	O	O
-dexamethasone-21-mesylate	O	O
labels	O	O
a	O	O
protein	O	O
(	O	O
Mr	O	O
approximately	O	O
equal	O	O
to	O	O
95	O	O
,	O	O
000	O	O
)	O	O
which	O	O
was	O	O
identified	O	O
as	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
by	O	O
the	O	O
following	O	O
criteria	O	O
:	O	O
(	O	O
a	O	O
)	O	O
labeling	O	O
of	O	O
this	O	O
moiety	O	O
is	O	O
inhibited	O	O
by	O	O
treatment	O	O
with	O	O
a	O	O
100-fold	O	O
molar	O	O
excess	O	O
of	O	O
glucocorticoids	O	O
,	O	O
such	O	O
as	O	O
dexamethasone	O	O
and	O	O
triamcinolone	O	O
acetonide	O	O
;	O	O
and	O	O
(	O	O
b	O	O
)	O	O
the	O	O
covalently	O	O
labeled	O	O
Mr	O	O
approximately	O	O
equal	O	O
to	O	O
95	O	O
,	O	O
000	O	O
protein	O	O
is	O	O
activated	O	O
(	O	O
by	O	O
heating	O	O
at	O	O
20	O	O
degrees	O	O
for	O	O
30	O	O
min	O	O
)	O	O
to	O	O
a	O	O
form	O	O
that	O	O
binds	O	O
to	O	O
DNA-cellulose	O	O
.	O	O

When	O	O
intact	O	O
thymocytes	B-cell_type	O
are	O	O
treated	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone-21-mesylate	O	O
,	O	O
an	O	O
Mr	O	O
approximately	O	O
equal	O	O
to	O	O
95	O	O
,	O	O
000	O	O
moiety	O	O
is	O	O
also	O	O
labeled	O	O
covalently	O	O
.	O	O

Approximately	O	O
35	O	O
%	O	O
of	O	O
the	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
can	O	O
be	O	O
labeled	O	O
covalently	O	O
when	O	O
intact	O	O
thymocytes	O	O
are	O	O
treated	O	O
with	O	O
100	O	O
nM	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone-21-mesylate	O	O
for	O	O
30	O	O
min	O	O
at	O	O
4	O	O
degrees	O	O
.	O	O

Neoplastic	B-cell_type	O
cells	I-cell_type	O
from	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
and	O	O
malignant	O	O
lymphoma	O	O
were	O	O
treated	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone-21-mesylate	O	O
.	O	O

In	O	O
all	O	O
samples	O	O
,	O	O
an	O	O
Mr	O	O
approximately	O	O
equal	O	O
to	O	O
95	O	O
,	O	O
000	O	O
moiety	O	O
was	O	O
labeled	O	O
covalently	O	O
;	O	O
labeling	O	O
was	O	O
inhibited	O	O
by	O	O
excess	O	O
glucocorticoid	O	O
.	O	O

Smaller	O	O
moieties	O	O
were	O	O
also	O	O
identified	O	O
by	O	O
competition	O	O
experiments	O	O
;	O	O
these	O	O
may	O	O
represent	O	O
proteolytic	O	O
fragments	O	O
of	O	O
the	O	O
Mr	O	O
approximately	O	O
equal	O	O
to	O	O
95	O	O
,	O	O
000	O	O
receptor	O	O
.	O	O

Thus	O	O
,	O	O
in	O	O
rat	O	O
and	O	O
human	B-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
,	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone-21-mesylate	O	O
can	O	O
be	O	O
used	O	O
to	O	O
label	O	O
covalently	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
.	O	O

The	O	O
association	O	O
of	O	O
cytosol	O	O
oestrogen	O	O
and	O	O
progesterone	O	O
receptors	O	O
with	O	O
histological	O	O
features	O	O
of	O	O
breast	O	O
cancer	O	O
and	O	O
early	O	O
recurrence	O	O
of	O	O
disease	O	O
.	O	O

Two	O	O
hundred	O	O
and	O	O
eighty-eight	O	O
primary	O	O
breast	O	O
tumours	O	O
were	O	O
examined	O	O
for	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
oestrogen	B-protein	O
(	O	O
REc	B-protein	O
)	O	O
and	O	O
progesterone	O	O
(	O	O
RPc	B-protein	O
)	O	O
receptors	O	O
.	O	O

Analysis	O	O
has	O	O
shown	O	O
a	O	O
relative	O	O
interdependence	O	O
between	O	O
the	O	O
steroid	B-protein	O
receptor	I-protein	O
status	O	O
of	O	O
primary	B-protein	O
breast	I-protein	O
cancer	O	O
and	O	O
other	O	O
prognostic	O	O
variables	O	O
such	O	O
as	O	O
histological	O	O
grade	O	O
,	O	O
lymphocytic	O	O
infiltration	O	O
and	O	O
tumour	O	O
elastosis	O	O
.	O	O

There	O	O
were	O	O
significant	O	O
associations	O	O
between	O	O
epithelial	O	O
cellularity	O	O
,	O	O
stromal	O	O
fibrosis	O	O
and	O	O
the	O	O
value	O	O
of	O	O
REc	O	O
in	O	O
those	O	O
tumours	O	O
in	O	O
which	O	O
the	O	O
receptor	O	O
was	O	O
present	O	O
.	O	O

Cellularity	O	O
and	O	O
fibrosis	O	O
were	O	O
unrelated	O	O
to	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
oestrogen	B-protein	O
receptor	I-protein	O
.	O	O

By	O	O
contrast	O	O
,	O	O
neither	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
nor	O	O
the	O	O
value	O	O
of	O	O
RPc	O	O
could	O	O
be	O	O
related	O	O
to	O	O
cellularity	O	O
or	O	O
fibrosis	O	O
.	O	O

The	O	O
value	O	O
of	O	O
REc	O	O
and	O	O
RPc	O	O
analysis	O	O
as	O	O
an	O	O
indicator	O	O
of	O	O
prognosis	O	O
was	O	O
examined	O	O
in	O	O
a	O	O
sub-group	O	O
of	O	O
175	O	O
patients	O	O
receiving	O	O
no	O	O
additional	O	O
treatment	O	O
following	O	O
mastectomy	O	O
.	O	O

Overall	O	O
relapse-free	O	O
survival	O	O
(	O	O
RFS	O	O
)	O	O
was	O	O
no	O	O
different	O	O
for	O	O
those	O	O
patients	O	O
with	O	O
receptors	O	O
compared	O	O
to	O	O
those	O	O
without	O	O
them	O	O
(	O	O
REc	O	O
P	O	O
=	O	O
0.11	O	O
,	O	O
RPc	O	O
P	O	O
=	O	O
0.7	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
RFS	O	O
of	O	O
receptor	O	O
positive	O	O
and	O	O
negative	O	O
tumours	O	O
when	O	O
the	O	O
axillary	O	O
node	O	O
status	O	O
was	O	O
taken	O	O
into	O	O
account	O	O
.	O	O

Clinical	O	O
implications	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
human	O	O
leukemia	O	O
.	O	O

Normal	B-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
contain	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
.	O	O

A	O	O
variety	O	O
of	O	O
stimuli	O	O
that	O	O
activate	O	O
these	O	O
cells	O	O
also	O	O
induce	O	O
increases	O	O
in	O	O
receptor	O	O
concentration	O	O
.	O	O

Similar	O	O
glucocorticoid	B-protein	O
receptors	O	O
can	O	O
be	O	O
detected	O	O
in	O	O
lymphoid	B-cell_type	O
cells	I-cell_type	O
from	O	O
patients	O	O
with	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
(	O	O
ALL	O	O
)	O	O
.	O	O

Absence	O	O
of	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
(	O	O
usually	O	O
found	O	O
in	O	O
treated	O	O
patients	O	O
)	O	O
predicts	O	O
lack	O	O
of	O	O
glucocorticoid	O	O
responsiveness	O	O
.	O	O

Furthermore	O	O
,	O	O
in	O	O
our	O	O
hands	O	O
,	O	O
glucocorticoid	O	O
receptor	O	O
levels	O	O
correlate	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
complete	O	O
remission	O	O
in	O	O
ALL	O	O
(	O	O
though	O	O
not	O	O
in	O	O
other	O	O
forms	O	O
of	O	O
leukemia	O	O
)	O	O
.	O	O

This	O	O
association	O	O
is	O	O
independent	O	O
of	O	O
cell	B-protein	O
type	O	O
,	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
or	O	O
initial	O	O
leukocyte	O	O
count	O	O
.	O	O

The	O	O
level	O	O
of	O	O
receptor	O	O
shows	O	O
a	O	O
negative	O	O
correlation	O	O
with	O	O
increasing	O	O
aggressiveness	O	O
of	O	O
the	O	O
tumor	O	O
(	O	O
null-cell	O	O
leukemia	O	O
greater	O	O
than	O	O
T-cell	O	O
leukemia	O	O
greater	O	O
than	O	O
Burkitt	O	O
's	O	O
lymphoma	O	O
)	O	O
.	O	O

Corticosteroid-mediated	O	O
immunoregulation	O	O
in	O	O
man	O	O
.	O	O

Glucocorticoids	O	O
have	O	O
profound	O	O
and	O	O
complex	O	O
effects	O	O
on	O	O
the	O	O
human	O	O
immune	O	O
response	O	O
.	O	O

However	O	O
,	O	O
the	O	O
precise	O	O
mechanisms	O	O
of	O	O
the	O	O
corticosteroid-induced	O	O
immunoregulation	O	O
in	O	O
man	O	O
have	O	O
not	O	O
been	O	O
precisely	O	O
defined	O	O
.	O	O

Intracytoplasmic	O	O
corticosteroid-specific	O	O
receptors	O	O
appear	O	O
to	O	O
be	O	O
an	O	O
important	O	O
common	O	O
pathway	O	O
for	O	O
steroid-induced	O	O
changes	O	O
,	O	O
but	O	O
variations	O	O
of	O	O
receptor	O	O
parameters	O	O
do	O	O
not	O	O
account	O	O
for	O	O
the	O	O
multifaceted	O	O
effects	O	O
on	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

Human	O	O
circulating	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
redistribute	O	O
out	O	O
of	O	O
the	O	O
intravascular	O	O
compartment	O	O
following	O	O
treatment	O	O
with	O	O
corticosteroids	O	O
.	O	O

Although	O	O
certain	O	O
components	O	O
at	O	O
this	O	O
redistribution	O	O
phenomenon	O	O
have	O	O
been	O	O
well-characterized	O	O
,	O	O
the	O	O
importance	O	O
of	O	O
this	O	O
compartmental	O	O
cellular	O	O
shift	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
mechanisms	O	O
of	O	O
corticosteroid-induced	O	O
immunoregulation	O	O
are	O	O
less	O	O
well-defined	O	O
.	O	O

Recent	O	O
observations	O	O
that	O	O
activated	B-cell_type	O
lymphocytes	I-cell_type	O
may	O	O
be	O	O
sensitive	O	O
to	O	O
the	O	O
lytic	O	O
effects	O	O
of	O	O
glucocorticoids	O	O
suggest	O	O
that	O	O
under	O	O
certain	O	O
situations	O	O
the	O	O
elimination	O	O
of	O	O
selected	O	O
subsets	O	O
of	O	O
cells	I-cell_type	O
may	O	O
be	O	O
a	O	O
relevant	O	O
mechanism	O	O
of	O	O
corticosteroid-mediated	O	O
immunoregulation	O	O
in	O	O
man	O	O
.	O	O

Corticosteroid-mediated	O	O
effects	O	O
on	O	O
monocyte	O	O
function	O	O
may	O	O
be	O	O
an	O	O
important	O	O
mechanism	O	O
of	O	O
drug-induced	O	O
immunoregulation	O	O
in	O	O
monocyte-dependent	O	O
responses	O	O
.	O	O

In	O	O
some	O	O
experimental	O	O
conditions	O	O
,	O	O
corticosteroids	O	O
inhibit	O	O
Interleukin	O	O
1	O	O
production	O	O
by	O	O
monocytes	B-cell_type	O
.	O	O

The	O	O
immunoregulatory	O	O
effects	O	O
of	O	O
corticosteroids	O	O
on	O	O
lymphocyte	O	O
immune	O	O
responses	O	O
are	O	O
complex	B-protein	O
.	O	O

In	O	O
vitro	O	O
corticosteroids	O	O
appear	O	O
to	O	O
selectively	O	O
affect	O	O
early	O	O
immunoregulatory	O	O
events	O	O
as	O	O
opposed	O	O
to	O	O
altering	O	O
an	O	O
established	O	O
response	O	O
.	O	O

Multiple	O	O
sites	O	O
of	O	O
steroid-induced	O	O
modulations	O	O
of	O	O
human	B-protein	O
B	I-protein	O
cell	O	O
responses	O	O
have	O	O
been	O	O
defined	O	O
.	O	O

Human	I-cell_line	O
lymphoid	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
and	O	O
glucocorticoids	O	O
:	O	O
II	O	O
.	O	O

Whole	O	O
cell	O	O
and	O	O
cytoplasmic	O	O
binding	O	O
properties	O	O
of	O	O
lymphoblastoid	O	O
,	O	O
leukaemia	O	O
and	O	O
lymphoma	O	O
lines	O	O
.	O	O

The	O	O
glucocorticoid	O	O
binding	O	O
properties	O	O
of	O	O
18	B-cell_line	O
human	I-cell_line	O
lymphoid	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
(	O	O
HLCL	O	O
)	O	O
have	O	O
been	O	O
investigated	O	O
.	O	O

The	O	O
specificity	O	O
of	O	O
steroid	O	O
binding	O	O
was	O	O
confirmed	O	O
with	O	O
various	O	O
glucocorticoid	O	O
agonists	O	O
and	O	O
antagonists	O	O
.	O	O

A	O	O
gradation	O	O
in	O	O
whole	O	O
cell	O	O
and	O	O
cytoplasmic	O	O
glucocorticoid	O	O
binding	O	O
capacity	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
different	O	O
cell	I-cell_line	O
line	I-cell_line	O
types	O	O
:	O	O
lymphoblastoid	O	O
greater	O	O
than	O	O
lymphoma	O	O
greater	O	O
than	O	O
leukaemia	O	O
.	O	O

The	O	O
cytoplasmic	B-protein	O
receptors	I-protein	O
of	O	O
leukaemia	O	O
and	O	O
lymphoblastoid	O	O
lines	O	O
appeared	O	O
to	O	O
contain	O	O
both	O	O
proteinaceous	O	O
and	O	O
phospholipid	O	O
components	O	O
.	O	O

Cytoplasmic	O	O
steroid-receptor	O	O
complexes	O	O
exhibited	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
sedimentation	O	O
coefficients	O	O
(	O	O
8.5-11.3S	B-protein	O
)	O	O
in	O	O
low	O	O
ionic	O	O
strength	O	O
buffer	O	O
but	O	O
there	O	O
was	O	O
no	O	O
correlation	O	O
with	O	O
cell	O	O
line	O	O
type	O	O
or	O	O
glucocorticoid	O	O
sensitivity	O	O
.	O	O

Activation	O	O
of	O	O
these	O	O
complexes	O	O
by	O	O
heat	O	O
(	O	O
37	B-protein	O
degrees	I-protein	O
C	I-protein	O
)	O	O
or	O	O
exposure	O	O
to	O	O
high	O	O
ionic	O	O
strength	O	O
buffer	O	O
(	O	O
0.3	O	O
M	O	O
NaCl	O	O
)	O	O
induced	O	O
nuclear	O	O
binding	O	O
of	O	O
steroid	O	O
but	O	O
only	O	O
complexes	O	O
in	O	O
high	O	O
ionic	O	O
strength	O	O
buffer	O	O
manifested	O	O
changes	O	O
in	O	O
sedimentation	O	O
coefficient	O	O
.	O	O

No	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
level	O	O
or	O	O
nature	O	O
of	O	O
glucocorticoid	B-protein	O
binding	O	O
and	O	O
the	O	O
cytolethal	B-protein	O
or	O	O
cytostatic	O	O
responsiveness	O	O
of	O	O
HLCL	O	O
to	O	O
glucocorticoid	O	O
treatment	O	O
in	O	O
vitro	O	O
.	O	O

The	O	O
resistance	O	O
to	O	O
cytolethal	O	O
effects	O	O
can	O	O
not	O	O
be	O	O
ascribed	O	O
to	O	O
a	O	O
failure	O	O
of	O	O
cells	O	O
to	O	O
take	O	O
up	O	O
and	O	O
bind	O	O
steroid	O	O
or	O	O
to	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
molecular	O	O
species	O	O
of	O	O
cytoplasmic	B-protein	O
receptors	I-protein	O
present	O	O
.	O	O

The	O	O
molecular	O	O
mechanisms	O	O
by	O	O
which	O	O
glucocorticoids	O	O
achieve	O	O
cytolethal	O	O
responses	O	O
in	O	O
human	B-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O

CD28	O	O
-mediated	O	O
activation	O	O
in	O	O
CD45RA+	O	O
and	O	O
CD45RO+	O	O
T	B-cell_type	O
cells	I-cell_type	O
:	O	O
enhanced	O	O
levels	O	O
of	O	O
reactive	O	O
oxygen	O	O
intermediates	O	O
and	O	O
c-Rel	O	O
nuclear	O	O
translocation	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
have	O	O
analyzed	O	O
the	O	O
effect	O	O
of	O	O
complete	O	O
T	O	O
cell	O	O
activation	O	O
(	O	O
anti-CD3	O	O
plus	O	O
anti-CD28	O	O
)	O	O
on	O	O
the	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
in	O	O
CD45RA+	O	O
(	O	O
naive	O	O
)	O	O
and	O	O
CD45RO+	O	O
(	O	O
memory/effector	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Long	O	O
exposure	O	O
(	O	O
24	O	O
h	O	O
)	O	O
induced	O	O
stronger	O	O
NF-kappaB	O	O
DNA	O	O
binding	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
than	O	O
in	O	O
CD45RO+	B-cell_type	O
cells	I-cell_type	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
nuclear	B-protein	O
c-Rel	I-protein	O
protein	I-protein	O
indicated	O	O
that	O	O
after	O	O
anti-CD3+anti-CD28	O	O
stimulation	O	O
the	O	O
level	O	O
of	O	O
c-Rel	O	O
was	O	O
higher	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
cytoplasmic	O	O
inhibitor	O	O
IkappaBalpha	O	O
indicated	O	O
that	O	O
anti-CD3+anti-CD28	O	O
stimulation	O	O
induced	O	O
a	O	O
long-lasting	O	O
degradation	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
but	O	O
in	O	O
CD45RO+	O	O
cells	O	O
the	O	O
degradation	O	O
process	O	O
was	O	O
more	O	O
rapid	O	O
.	O	O

Because	O	O
the	O	O
CD28	O	O
costimulus	O	O
is	O	O
known	O	O
to	O	O
induce	O	O
the	O	O
production	O	O
of	O	O
reactive	O	O
oxygen	O	O
intermediates	O	O
(	O	O
ROIs	O	O
)	O	O
,	O	O
the	O	O
intracellular	O	O
ROI	O	O
levels	O	O
in	O	O
CD45RA+	O	O
and	O	O
CD45RO+	B-cell_type	O
cells	I-cell_type	O
were	O	O
compared	O	O
by	O	O
flow	O	O
cytometry	O	O
.	O	O

ROIs	O	O
were	O	O
produced	O	O
in	O	O
both	O	O
cell	O	O
types	O	O
,	O	O
but	O	O
more	O	O
strongly	O	O
in	O	O
CD45RA+	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
data	O	O
presented	O	O
in	O	O
this	O	O
study	O	O
further	O	O
emphasize	O	O
the	O	O
differences	O	O
between	O	O
CD45RA+	O	O
and	O	O
CD45RO+	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
in	O	O
ROI-dependent	O	O
signaling	O	O
pathways	O	O
.	O	O

Ikaros	O	O
in	O	O
hemopoietic	O	O
lineage	O	O
determination	O	O
and	O	O
homeostasis	O	O
.	O	O

Studies	O	O
on	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
control	O	O
hemopoietic	O	O
differentiation	O	O
have	O	O
focused	O	O
on	O	O
signaling	O	O
cascades	O	O
and	O	O
nuclear	O	O
effectors	O	O
that	O	O
drive	O	O
this	O	O
complex	O	O
developmental	O	O
system	O	O
in	O	O
a	O	O
regulated	O	O
fashion	O	O
.	O	O

Here	O	O
we	O	O
review	O	O
the	O	O
role	O	O
of	O	O
Ikaros	O	O
,	O	O
the	O	O
founding	O	O
member	O	O
of	O	O
a	O	O
unique	B-protein	O
family	I-protein	O
of	O	O
zinc	B-protein	O
finger	I-protein	O
transcription	B-protein	O
factors	I-protein	O
in	O	O
this	O	O
developmental	O	O
process	O	O
.	O	O

Studies	O	O
on	O	O
an	O	O
Ikaros	O	O
null	O	O
mutation	O	O
have	O	O
revealed	O	O
an	O	O
essential	O	O
role	O	O
for	O	O
this	O	O
factor	O	O
in	O	O
lymphoid	O	O
cell	O	O
fate	O	O
determination	O	O
and	O	O
at	O	O
subsequent	O	O
branch	O	O
points	O	O
of	O	O
the	O	O
T	B-cell_type	O
cell	I-cell_type	O
differentiation	O	O
pathway	O	O
.	O	O

Differences	O	O
in	O	O
the	O	O
phenotypes	O	O
of	O	O
a	O	O
null	O	O
and	O	O
a	O	O
dominant	B-DNA	O
negative	I-DNA	O
(	O	O
DN	B-DNA	O
)	O	O
Ikaros	O	O
mutation	O	O
provide	O	O
insight	O	O
into	O	O
a	O	O
regulatory	O	O
network	O	O
through	O	O
which	O	O
Ikaros	O	O
proteins	O	O
exert	O	O
their	O	O
effects	O	O
in	O	O
development	O	O
.	O	O

In	O	O
addition	O	O
a	O	O
comparative	O	O
analysis	O	O
of	O	O
the	O	O
hemopoietic	B-DNA	O
stem	I-DNA	O
cell	O	O
and	O	O
precursor	O	O
compartment	O	O
resulting	O	O
from	O	O
the	O	O
two	O	O
Ikaros	O	O
mutations	O	O
reveals	O	O
a	O	O
profound	O	O
yet	O	O
not	O	O
absolute	O	O
requirement	O	O
for	O	O
Ikaros	O	O
in	O	O
the	O	O
production	O	O
and	O	O
differentiation	O	O
of	O	O
these	O	O
populations	O	O
.	O	O

Overexpression	O	O
of	O	O
p65	B-protein	O
and	O	O
c-Jun	B-protein	O
substitutes	O	O
for	O	O
B7-1	O	O
costimulation	O	O
by	O	O
targeting	O	O
the	O	O
CD28RE	O	O
within	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
.	O	O

The	O	O
role	O	O
of	O	O
Rel	B-protein	O
and	I-protein	O
activation	I-protein	O
protein-1	I-protein	O
(	O	O
AP-1	B-protein	O
)	O	O
in	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
activity	O	O
in	O	O
B7-1-	O	O
and	O	O
leukocyte	O	O
function-associated	O	O
Ag-3	O	O
(	O	O
LFA.	O	O
3	O	O
)	O	O
-costimulated	O	O
T	B-cell_type	O
cells	I-cell_type	O
has	O	O
been	O	O
evaluated	O	O
.	O	O

We	O	O
demonstrate	O	O
that	O	O
overexpression	O	O
of	O	O
c-Jun	B-protein	O
but	O	O
not	O	O
c-Fos	O	O
increases	O	O
IL-2	B-protein	O
promoter	O	O
activity	O	O
in	O	O
both	O	O
B7-1-	O	O
and	O	O
LFA-3-costimulated	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
.	O	O

Cotransfection	O	O
of	O	O
both	O	O
c-Jun	B-protein	O
and	O	O
c-Fos	O	O
substitutes	O	O
for	O	O
B7-1	O	O
costimulation	O	O
in	O	O
driving	O	O
an	O	O
activation	O	O
protein-1	O	O
response	O	O
element	O	O
but	O	O
not	O	O
for	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
.	O	O

Overexpression	O	O
of	O	O
Rel	B-protein	O
proteins	I-protein	O
demonstrated	O	O
that	O	O
p65-expressing	B-cell_line	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
transcribed	O	O
equally	O	O
well	O	O
a	O	O
nuclear	B-protein	O
factor	I-protein	O
kappabeta	O	O
reporter	O	O
construct	O	O
when	O	O
costimulated	O	O
with	O	O
B7-1	O	O
or	O	O
LFA-3	B-protein	O
,	O	O
but	O	O
transcription	O	O
of	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
or	O	O
CD28	O	O
response	O	O
element	O	O
(	O	O
CD28RE	O	O
)	O	O
-driven	O	O
reporters	O	O
was	O	O
superior	O	O
in	O	O
B7-1-costimulated	B-cell_type	O
cells	I-cell_type	O
.	O	O

Combined	O	O
expression	O	O
of	O	O
c-Jun	B-protein	O
and	O	O
p65	B-protein	O
induced	O	O
vigorous	O	O
transcription	O	O
of	O	O
IL-2	B-protein	O
promoter-	O	O
and	O	O
CD28RE-driven	O	O
reporter	I-DNA	O
constructs	I-DNA	O
in	O	O
both	O	O
LFA-3-	B-cell_line	O
and	O	O
B7-1-costimulated	B-cell_line	O
Jurkat	I-cell_line	O
cells	I-cell_line	O
.	O	O

Mutating	O	O
the	O	O
CD28RE	O	O
but	O	O
not	O	O
the	O	O
upstream	B-protein	O
nuclear	I-protein	O
factor	I-protein	O
kappabeta-binding	O	O
site	O	O
in	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
reduced	O	O
B7-1	O	O
-driven	O	O
transcription	O	O
>	O	O
90	O	O
%	O	O
.	O	O

The	O	O
results	O	O
implicates	O	O
a	O	O
major	O	O
role	O	O
of	O	O
the	O	O
CD28RE	O	O
in	O	O
the	O	O
integration	O	O
of	O	O
p65	O	O
/	O	O
c-Jun	B-protein	O
-mediated	O	O
transcription	O	O
within	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
.	O	O

We	O	O
suggest	O	O
that	O	O
the	O	O
transition	O	O
from	O	O
an	O	O
autocrine	O	O
LFA-3	B-protein	O
-driven	O	O
immune	O	O
response	O	O
to	O	O
a	O	O
B7	B-protein	O
--	O	O
induced	O	O
paracrine	O	O
immune	O	O
response	O	O
involves	O	O
the	O	O
activation	O	O
of	O	O
c-Jun	B-protein	O
and	O	O
p65	B-protein	O
,	O	O
which	O	O
target	O	O
the	O	O
CD28RE	O	O
region	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
.	O	O

Defects	O	O
in	O	O
actin-cap	O	O
formation	O	O
in	O	O
Vav-deficient	O	O
mice	O	O
implicate	O	O
an	O	O
actin	O	O
requirement	O	O
for	O	O
lymphocyte	O	O
signal	O	O
transduction	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Antigen-receptor	O	O
interactions	O	O
on	O	O
lymphocytes	O	O
result	O	O
in	O	O
local	O	O
clustering	O	O
of	O	O
actin	O	O
,	O	O
receptors	O	O
and	O	O
signaling	O	O
molecules	O	O
into	O	O
an	O	O
asymmetric	O	O
membrane	O	O
structure	O	O
termed	O	O
a	O	O
cap	B-DNA	O
.	O	O

Although	O	O
actin	O	O
polymerization	O	O
is	O	O
known	O	O
to	O	O
be	O	O
required	O	O
,	O	O
the	O	O
mechanisms	O	O
underlying	O	O
cap	O	O
formation	O	O
are	O	O
unclear	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
events	O	O
underlying	O	O
cap	O	O
formation	O	O
using	O	O
mice	O	O
bearing	O	O
a	O	O
null	O	O
mutation	O	O
in	O	O
vav	O	O
(	O	O
vav	O	O
-/-	O	O
)	O	O
,	O	O
a	O	O
gene	O	O
that	O	O
encodes	O	O
a	O	O
guanine-nucleotide	O	O
exchange	I-protein	O
factor	I-protein	O
for	O	O
the	O	O
GTPase	O	O
Rac	O	O
.	O	O

RESULTS	O	O
:	O	O
Lymphocytes	O	O
from	O	O
vav	O	O
-/-	O	O
mice	O	O
failed	O	O
to	O	O
form	O	O
T-cell	O	O
receptor	O	O
caps	O	O
following	O	O
activation	O	O
and	O	O
had	O	O
a	O	O
defective	O	O
actin	O	O
cytoskeleton	O	O
.	O	O

The	O	O
vav-/-	B-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
were	O	O
deficient	O	O
in	O	O
interleukin-2	O	O
(	O	O
IL-2	B-protein	O
)	O	O
production	O	O
and	O	O
proliferation	O	O
,	O	O
and	O	O
the	O	O
peak	O	O
of	O	O
Ca2+	O	O
mobilization	O	O
was	O	O
reduced	O	O
although	O	O
of	O	O
normal	O	O
duration	O	O
.	O	O

Activation	O	O
of	O	O
Jun	B-protein	O
N-terminal	I-protein	O
kinase	I-protein	O
or	O	O
stress-activated	B-protein	O
kinase	I-protein	O
(	O	O
JNK	O	O
or	O	O
SAPK	O	O
)	O	O
and	O	O
mitogen-activated	O	O
protein	O	O
kinase	O	O
(	O	O
MAPK	O	O
)	O	O
and	O	O
the	O	O
induction	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
NF-ATc1	O	O
and	O	O
egr-1	O	O
genes	O	O
was	O	O
normal	O	O
.	O	O

Despite	O	O
the	O	O
reduced	O	O
Ca2+	O	O
mobilization	O	O
,	O	O
translocation	O	O
of	O	O
cytoplasmic	O	O
NF-ATc	O	O
to	O	O
the	O	O
nucleus	O	O
was	O	O
normal	O	O
,	O	O
reflecting	O	O
that	O	O
the	O	O
lower	O	O
levels	O	O
of	O	O
Ca2+	O	O
in	O	O
vav-/-	B-cell_type	O
cells	I-cell_type	O
were	O	O
still	O	O
sufficient	O	O
to	O	O
activate	O	O
calcineurin	O	O
.	O	O

Treatment	O	O
of	O	O
lymphocytes	I-cell_type	O
with	O	O
cytochalasin	O	O
D	O	O
,	O	O
which	O	O
blocks	O	O
actin	O	O
polymerization	O	O
,	O	O
inhibited	O	O
cap	O	O
formation	O	O
and	O	O
produced	O	O
defects	O	O
in	O	O
signaling	O	O
and	O	O
IL-2	B-protein	O
transcriptional	O	O
induction	O	O
in	O	O
response	O	O
to	O	O
antigen-receptor	O	O
signaling	O	O
that	O	O
were	O	O
nearly	O	O
identical	O	O
to	O	O
those	O	O
seen	O	O
in	O	O
vav-/-	B-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
transfection	O	O
studies	O	O
,	O	O
either	O	O
constitutively	O	O
active	O	O
Vav	O	O
or	O	O
Rac	O	O
could	O	O
complement	O	O
constitutively	O	O
active	O	O
calcineurin	O	O
to	O	O
activate	O	O
NF-AT-dependent	O	O
transcription	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
results	O	O
indicate	O	O
that	O	O
Vav	O	O
is	O	O
required	O	O
for	O	O
cap	O	O
formation	O	O
in	O	O
lymphocytes	I-cell_type	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
correlation	O	O
between	O	O
cap	B-protein	O
formation	I-protein	O
,	O	O
IL-2	B-protein	O
production	O	O
and	O	O
proliferation	O	O
supports	O	O
the	O	O
hypothesis	O	O
that	O	O
an	O	O
actin-dependent	O	O
pathway	O	O
is	O	O
a	O	O
source	O	O
of	O	O
specialized	O	O
growth	O	O
regulatory	O	O
signals	O	O
.	O	O

CD14	O	O
-dependent	O	O
activation	O	O
of	O	O
human	B-cell_type	O
endothelial	I-cell_type	O
cells	I-cell_type	O
by	O	O
Bacteroides	O	O
fragilis	O	O
outer	O	O
membrane	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
capacity	O	O
of	O	O
isolated	O	O
Bacteriodes	O	O
fragilis	O	O
outer	O	O
membrane	O	O
,	O	O
B.	O	O
fragilis	O	O
NCTC9343	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
;	O	O
endotoxin	O	O
)	O	O
,	O	O
and	O	O
B.	O	O
fragilis	O	O
NCTC9343	O	O
capsular	O	O
polysaccharides	O	O
to	O	O
activate	O	O
human	O	O
umbilical	O	O
vein	O	O
endothelial	O	O
cell	O	O
(	O	O
HUVEC	O	O
)	O	O
monolayers	O	O
.	O	O

To	O	O
assess	O	O
HUVEC	O	O
activation	O	O
,	O	O
E-selectin	B-protein	O
expression	O	O
was	O	O
measured	O	O
by	O	O
enzyme-linked	O	O
immunosorbent	O	O
assay	O	O
(	O	O
ELISA	B-protein	O
)	O	O
,	O	O
Northern	O	O
blot	O	O
analysis	O	O
for	O	O
E-selectin-specific	O	O
mRNA	O	O
,	O	O
and	O	O
electrophoretic	O	O
gel	O	O
mobility	O	O
shift	O	O
assay	O	O
(	O	O
EMSA	O	O
)	O	O
for	O	O
NF-kappa	B-protein	O
B	I-protein	O
,	O	O
a	O	O
transcription	B-protein	O
factor	I-protein	O
necessary	O	O
for	O	O
E-selectin	B-protein	O
gene	O	O
activation	O	O
.	O	O

Exposure	O	O
of	O	O
HUVECs	O	O
to	O	O
B.	O	O
fragilis	O	O
outer	O	O
membrane	O	O
fractions	O	O
,	O	O
separated	O	O
from	O	O
other	O	O
components	O	O
of	O	O
the	O	O
B.	O	O
fragilis	O	O
cell	O	O
wall	O	O
by	O	O
isopycnic	O	O
,	O	O
sucrose	O	O
gradient	O	O
centrifugation	O	O
,	O	O
significantly	O	O
increased	O	O
surface	O	O
expression	O	O
of	O	O
E-selectin	B-protein	O
and	O	O
induced	O	O
functional	O	O
endothelial	O	O
cell	O	O
-dependent	O	O
leukocyte	O	O
adhesion	O	O
.	O	O

B.	O	O
fragilis	O	O
outer	O	O
membranes	O	O
induced	O	O
translocation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
to	O	O
HUVEC	O	O
nuclei	O	O
and	O	O
accumulation	O	O
of	O	O
E-selectin	B-RNA	O
mRNA	I-RNA	O
in	O	O
HUVEC	O	O
cytoplasm	O	O
.	O	O

E-selectin	B-protein	O
expression	O	O
induced	O	O
by	O	O
B.	O	O
fragilis	O	O
outer	O	O
membranes	O	O
was	O	O
not	O	O
blocked	O	O
by	O	O
polymixin	O	O
B	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
E-selectin	B-protein	O
expression	O	O
induced	O	O
by	O	O
outer	O	O
membrane	O	O
fractions	O	O
purified	O	O
from	O	O
E.	O	O
coli	O	O
was	O	O
competitively	O	O
inhibited	O	O
by	O	O
polymixin	O	O
B	O	O
.	O	O

Neither	O	O
purified	O	O
B.	O	O
fragilis	O	O
LPS	O	O
,	O	O
a	O	O
prominent	O	O
constituent	O	O
of	O	O
the	O	O
outer	O	O
membrane	I-protein	O
,	O	O
nor	O	O
purified	O	O
B.	O	O
fragilis	O	O
capsular	O	O
polysaccharides	O	O
induced	O	O
HUVEC	O	O
activation	O	O
.	O	O

Two	O	O
different	O	O
monoclonal	B-protein	O
antibodies	O	O
directed	O	O
against	O	O
human	O	O
CD14	O	O
completely	O	O
inhibited	O	O
B.	O	O
fragilis	O	O
outer	O	O
membrane-induced	O	O
NF-kappa	O	O
B	O	O
activation	O	O
,	O	O
E-selectin	O	O
transcription	O	O
,	O	O
and	O	O
E-selectin	B-protein	O
surface	O	O
expression	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
outer	O	O
membrane	O	O
component	O	O
of	O	O
the	O	O
B.	O	O
fragilis	I-protein	O
cell	I-protein	O
wall	O	O
contains	O	O
a	O	O
proinflammatory	B-protein	O
factor	I-protein	O
(	O	O
s	O	O
)	O	O
,	O	O
that	O	O
is	O	O
not	O	O
LPS	O	O
,	O	O
which	O	O
induces	O	O
human	O	O
endothelial	O	O
cell	O	O
activation	O	O
by	O	O
a	O	O
soluble	O	O
CD14	O	O
-dependent	O	O
mechanism	O	O
.	O	O

NF-kappaB	O	O
protects	O	O
HIV-1-infected	B-cell_type	O
myeloid	I-cell_type	O
cells	I-cell_type	O
from	O	O
apoptosis	O	O
.	O	O

HIV-1	O	O
infection	O	O
of	O	O
primary	B-cell_type	O
monocytic	I-cell_type	O
cells	I-cell_type	O
and	O	O
myeloid	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
results	O	O
in	O	O
sustained	O	O
NF-kappaB	O	O
activation	O	O
.	O	O

Recently	O	O
,	O	O
NF-kappaB	O	O
induction	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
protecting	B-cell_type	O
cells	I-cell_type	O
from	O	O
programmed	O	O
cell	O	O
death	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
sought	O	O
to	O	O
investigate	O	O
whether	O	O
constitutive	O	O
NF-kappaB	O	O
activity	O	O
in	O	O
chronically	O	O
HIV-1-infected	O	O
promonocytic	O	O
U937	O	O
(	O	O
U9-IIIB	O	O
)	O	O
and	O	O
myeloblastic	O	O
PLB-985	O	O
(	O	O
PLB-IIIB	O	O
)	O	O
cells	O	O
affects	O	O
apoptotic	O	O
signaling	O	O
.	O	O

TNFalpha	O	O
and	O	O
cycloheximide	O	O
caused	O	O
infected	O	O
cells	O	O
to	O	O
undergo	O	O
apoptosis	O	O
more	O	O
rapidly	O	O
than	O	O
parental	B-cell_line	O
U937	I-cell_line	O
and	I-cell_line	O
PLB-985	I-cell_line	O
cells	I-cell_line	O
.	O	O

Inhibition	O	O
of	O	O
TNFalpha	O	O
-induced	O	O
NF-kappaB	O	O
activation	O	O
using	O	O
the	O	O
antioxidant	O	O
N-acetylcysteine	O	O
(	O	O
NAC	B-protein	O
)	O	O
resulted	O	O
in	O	O
increased	O	O
apoptosis	O	O
in	O	O
both	O	O
U937	B-cell_line	O
and	I-cell_line	O
U9-IIIB	I-cell_line	O
cells	I-cell_line	O
,	O	O
while	O	O
preactivation	O	O
of	O	O
NF-kappaB	O	O
with	O	O
the	O	O
non-apoptotic	O	O
inducer	O	O
IL-1beta	O	O
caused	O	O
a	O	O
relative	O	O
decrease	O	O
in	O	O
apoptosis	O	O
.	O	O

Inhibition	O	O
of	O	O
constitutive	O	O
NF-kappaB	O	O
activity	O	O
in	O	O
U9-IIIB	O	O
and	O	O
PLB-IIIB	B-cell_type	O
cells	I-cell_type	O
also	O	O
induced	O	O
apoptosis	O	O
,	O	O
suggesting	O	O
that	O	O
NF-kappaB	O	O
protects	O	O
cells	O	O
from	O	O
a	O	O
persistent	O	O
apoptotic	O	O
signal	O	O
.	O	O

TNFalpha	O	O
plus	O	O
NAC	O	O
treatment	O	O
resulted	O	O
in	O	O
a	O	O
marked	O	O
decrease	O	O
in	O	O
Bcl-2	O	O
protein	O	O
levels	O	O
in	O	O
HIV-1-infected	B-cell_type	O
cells	I-cell_type	O
,	O	O
coupled	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
Bax	O	O
protein	O	O
compared	O	O
to	O	O
uninfected	O	O
cells	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
difference	O	O
in	O	O
susceptibility	O	O
to	O	O
TNFalpha	O	O
-induced	O	O
apoptosis	O	O
may	O	O
relate	O	O
to	O	O
the	O	O
differences	O	O
in	O	O
relative	O	O
levels	O	O
of	O	O
Bcl-2	O	O
and	O	O
Bax	O	O
.	O	O

The	O	O
protective	O	O
role	O	O
of	O	O
NF-kappaB	O	O
in	O	O
blocking	O	O
TNFalpha-	O	O
and	O	O
HIV-1-induced	O	O
apoptosis	O	O
was	O	O
supported	O	O
by	O	O
studies	O	O
in	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
engineered	O	O
to	O	O
express	O	O
IkappaB	B-protein	O
alpha	I-protein	O
repressor	I-protein	O
mutants	I-protein	O
(	O	O
TD-IkappaB	B-protein	O
)	O	O
under	O	O
the	O	O
control	O	O
of	O	O
a	O	O
tetracycline-responsive	B-DNA	O
promoter	I-DNA	O
.	O	O

Cells	O	O
underwent	O	O
apoptosis	O	O
in	O	O
response	O	O
to	O	O
TNFalpha	O	O
only	O	O
when	O	O
NF-kappaB	O	O
activation	O	O
was	O	O
inhibited	O	O
by	O	O
TD-IkappaB	O	O
expression	O	O
.	O	O

As	O	O
was	O	O
observed	O	O
for	O	O
the	O	O
U9-IIIB	B-cell_type	O
cells	I-cell_type	O
,	O	O
TNFalpha	O	O
treatment	O	O
also	O	O
induced	O	O
a	O	O
marked	O	O
decrease	O	O
in	O	O
Bcl-2	O	O
protein	O	O
levels	O	O
in	O	O
TD-IkappaB	B-cell_line	O
expressing	I-cell_line	O
cells	I-cell_line	O
.	O	O

These	O	O
experiments	O	O
demonstrate	O	O
that	O	O
apoptotic	O	O
signaling	O	O
is	O	O
perturbed	O	O
in	O	O
HIV-1-infected	O	O
U9-IIIB	O	O
cells	O	O
and	O	O
indicate	O	O
that	O	O
NF-kappaB	O	O
activation	O	O
may	O	O
play	O	O
an	O	O
additional	O	O
protective	O	O
role	O	O
against	O	O
HIV-1-induced	O	O
apoptosis	O	O
in	O	O
myeloid	B-cell_type	O
cells	I-cell_type	O
.	O	O

Human	O	O
normal	O	O
peripheral	O	O
blood	O	O
B-lymphocytes	O	O
are	O	O
deficient	O	O
in	O	O
DNA-dependent	O	O
protein	O	O
kinase	O	O
activity	O	O
due	O	O
to	O	O
the	O	O
expression	O	O
of	O	O
a	O	O
variant	O	O
form	O	O
of	O	O
the	O	O
Ku86	B-protein	O
protein	I-protein	O
.	O	O

The	O	O
heterodimeric	B-protein	O
Ku	I-protein	O
protein	I-protein	O
,	O	O
which	O	O
comprises	O	O
a	O	O
86	B-protein	O
kDa	I-protein	O
(	O	O
Ku86	B-protein	O
)	O	O
amd	O	O
a	O	O
70	B-protein	O
kDa	I-protein	O
(	O	O
Ku70	B-protein	O
)	O	O
subunits	O	O
,	O	O
is	O	O
an	O	O
abundant	O	O
nuclear	O	O
DNA-binding	O	O
protein	O	O
which	O	O
binds	O	O
in	O	O
vitro	O	O
to	O	O
DNA	O	O
termini	O	O
without	O	O
sequence	O	O
specificity	O	O
.	O	O

Ku	O	O
is	O	O
the	O	O
DNA-targeting	O	O
component	O	O
of	O	O
the	O	O
large	O	O
catalytic	O	O
sub-unit	O	O
of	O	O
the	O	O
DNA-dependent	B-protein	O
protein	I-protein	O
kinase	I-protein	O
complex	I-protein	O
(	O	O
DNA-PK	O	O
[	O	O
CS	O	O
]	O	O
)	O	O
,	O	O
that	O	O
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
mammalian	O	O
double-strand	O	O
break	O	O
repair	O	O
and	O	O
lymphoid	O	O
V	O	O
(	O	O
D	O	O
)	O	O
J	O	O
recombination	O	O
.	O	O

By	O	O
using	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
,	O	O
we	O	O
demonstrated	O	O
that	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
major	O	O
Ku	O	O
x	O	O
DNA	O	O
complex	I-protein	O
usually	O	O
detected	O	O
in	O	O
cell	O	O
line	O	O
extracts	O	O
,	O	O
a	O	O
second	O	O
complex	O	O
with	O	O
faster	O	O
electrophoretic	O	O
mobility	O	O
was	O	O
observed	O	O
in	O	O
normal	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
lymphocytes	I-cell_type	O
(	O	O
PBL	O	O
)	O	O
extracts	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
this	O	O
faster	O	O
migrating	O	O
complex	O	O
was	O	O
restricted	O	O
to	O	O
B	B-cell_type	O
cells	I-cell_type	O
among	O	O
the	O	O
circulating	O	O
lymphocyte	O	O
population	O	O
.	O	O

Western	O	O
blot	O	O
analysis	O	O
revealed	O	O
that	O	O
B	B-cell_type	O
cells	I-cell_type	O
express	O	O
a	O	O
variant	O	O
form	O	O
of	O	O
the	O	O
Ku86	B-protein	O
protein	I-protein	O
with	O	O
an	O	O
apparent	O	O
molecular	O	O
weight	O	O
of	O	O
69	B-protein	O
kDa	I-protein	O
,	O	O
and	O	O
not	O	O
the	O	O
86	B-protein	O
kDa-	I-protein	O
full-length	I-protein	O
protein	I-protein	O
.	O	O

Although	O	O
the	O	O
heterodimer	O	O
Ku70/variant-Ku86	O	O
binds	O	O
to	O	O
DNA-ends	O	O
,	O	O
this	O	O
altered	O	O
form	O	O
of	O	O
the	O	O
Ku	B-protein	O
heterodimer	I-protein	O
has	O	O
a	O	O
decreased	O	O
ability	O	O
to	O	O
recruit	O	O
the	O	O
catalytic	O	O
component	O	O
of	O	O
the	O	O
complex	B-protein	O
,	O	O
DNA-PK	O	O
(	O	O
CS	B-protein	O
)	O	O
,	O	O
which	O	O
contributes	O	O
to	O	O
an	O	O
absence	O	O
of	O	O
detectable	O	O
DNA-PK	O	O
activity	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

These	O	O
data	O	O
provide	O	O
a	O	O
molecular	O	O
basis	O	O
for	O	O
the	O	O
increased	O	O
sensitivity	O	O
of	O	O
B	B-cell_type	O
cells	I-cell_type	O
to	O	O
ionizing	O	O
radiation	O	O
and	O	O
identify	O	O
a	O	O
new	O	O
mechanism	O	O
of	O	O
regulation	O	O
of	O	O
DNA-PK	O	O
activity	O	O
that	O	O
operates	O	O
in	O	O
vivo	O	O
.	O	O

Co-stimulation	O	O
of	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
with	O	O
IL-2	B-protein	O
and	O	O
anti-CD3	O	O
monoclonal	B-protein	O
antibodies	I-protein	O
induces	O	O
phosphorylation	O	O
of	O	O
CREB	O	O
.	O	O

Phosphorylation	O	O
of	O	O
the	O	O
cAMP-response	B-DNA	O
element	I-DNA	O
binding	I-DNA	O
protein	O	O
CREB	O	O
within	O	O
1	O	O
h	O	O
of	O	O
CD2	O	O
but	O	O
not	O	O
CD3	O	O
cross-linking	O	O
of	O	O
human	B-protein	O
PBMC	I-protein	O
was	O	O
recently	O	O
demonstrated	O	O
.	O	O

The	O	O
absence	O	O
of	O	O
P-CREB	O	O
following	O	O
CD3	B-protein	O
cross-linking	I-protein	O
was	O	O
unexpected	O	O
,	O	O
as	O	O
other	O	O
laboratories	O	O
reported	O	O
increased	O	O
phosphorylation	O	O
of	O	O
CREB	O	O
following	O	O
CD3	O	O
cross-linking	O	O
of	O	O
the	O	O
Jurkat	B-cell_line	O
lymphocyte	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
.	O	O

Due	O	O
to	O	O
Jurkat	O	O
T-cells	O	O
being	O	O
IL-2-independent	O	O
,	O	O
it	O	O
was	O	O
postulated	O	O
that	O	O
IL-2	B-protein	O
might	O	O
provide	O	O
a	O	O
necessary	O	O
co-stimulus	O	O
for	O	O
phosphorylation	O	O
of	O	O
CREB	O	O
in	O	O
primary	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Therefore	O	O
,	O	O
P-CREB	O	O
was	O	O
evaluated	O	O
following	O	O
co-stimulation	O	O
of	O	O
human	O	O
PBMC	O	O
through	O	O
the	O	O
IL-2	B-protein	O
and	O	O
CD2	O	O
or	O	O
CD3	B-protein	O
receptors	I-protein	O
.	O	O

IL-2	B-protein	O
did	O	O
not	O	O
further	O	O
augment	O	O
phosphorylation	O	O
of	O	O
CREB	O	O
following	O	O
CD2	O	O
cross-linking	O	O
.	O	O

However	O	O
,	O	O
while	O	O
neither	O	O
IL-2	B-protein	O
nor	O	O
CD3	O	O
cross-linking	O	O
alone	O	O
induced	O	O
P-CREB	O	O
,	O	O
a	O	O
4.5-fold	O	O
increase	O	O
in	O	O
phosphorylation	O	O
of	O	O
CREB	O	O
within	O	O
1	O	O
h	O	O
of	O	O
IL-2/CD3	O	O
co-stimulation	O	O
was	O	O
observed	O	O
.	O	O

Phosphorylation	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
the	O	O
induction	O	O
of	O	O
cAMP	O	O
,	O	O
and	O	O
inhibition	O	O
of	O	O
PKA	O	O
signaling	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
P-CREB	O	O
.	O	O

Consistent	O	O
with	O	O
signal	O	O
transduction	O	O
through	O	O
p56lck	O	O
or	O	O
p59fyn	O	O
,	O	O
inhibition	O	O
of	O	O
PTK	O	O
signaling	O	O
reduced	O	O
phosphorylation	O	O
50	O	O
%	O	O
.	O	O

Interestingly	O	O
,	O	O
inhibiting	O	O
PKC	O	O
signaling	O	O
with	O	O
calphostin	O	O
C	O	O
further	O	O
increased	O	O
P-CREB	O	O
levels	O	O
3-fold	O	O
over	O	O
that	O	O
observed	O	O
in	O	O
IL-2/CD3	B-cell_type	O
co-stimulated	I-cell_type	O
cells	I-cell_type	O
not	O	O
pretreated	O	O
with	O	O
a	O	O
PKC	O	O
inhibitor	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
previous	O	O
studies	O	O
performed	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
exogenous	O	O
IL-2	B-protein	O
,	O	O
no	O	O
increase	O	O
in	O	O
binding	O	O
of	O	O
CREB	O	O
to	O	O
a	O	O
32P-labeled	O	O
oligonucleotide	O	O
probe	O	O
was	O	O
observed	O	O
by	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
IL-2	B-protein	O
and	O	O
CD3	B-protein	O
signaling	O	O
pathways	O	O
provide	O	O
a	O	O
necessary	O	O
and	O	O
co-operative	O	O
stimulus	O	O
promoting	O	O
phosphorylation	O	O
of	O	O
CREB	O	O
following	B-protein	O
receptor	I-protein	O
cross-linking	O	O
.	O	O

HIV-1	O	O
infection	O	O
induces	O	O
a	O	O
selective	O	O
reduction	O	O
in	O	O
STAT5	O	O
protein	O	O
expression	O	O
.	O	O

HIV-1	O	O
infection	O	O
is	O	O
accompanied	O	O
by	O	O
qualitative	O	O
and	O	O
quantitative	O	O
defects	O	O
in	O	O
CD4+	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Loss	O	O
of	O	O
immune	O	O
function	O	O
in	O	O
HIV	O	O
patients	O	O
is	O	O
usually	O	O
associated	O	O
with	O	O
a	O	O
profound	O	O
dysregulation	O	O
of	O	O
cytokine	B-protein	O
production	O	O
.	O	O

To	O	O
investigate	O	O
whether	O	O
cytokine	O	O
signaling	O	O
defects	O	O
occur	O	O
during	O	O
HIV	O	O
infection	O	O
,	O	O
PHA	O	O
blasts	O	O
from	O	O
healthy	O	O
human	O	O
donors	O	O
were	O	O
infected	O	O
with	O	O
two	O	O
strains	O	O
of	O	O
HIV-1	O	O
and	O	O
screened	O	O
for	O	O
the	O	O
expression	O	O
of	O	O
STAT	B-protein	O
proteins	I-protein	O
used	O	O
in	O	O
cytokine	B-protein	O
signaling	O	O
.	O	O

A	O	O
selective	O	O
decrease	O	O
in	O	O
STAT5B	O	O
was	O	O
seen	O	O
8	O	O
days	O	O
after	O	O
infection	O	O
with	O	O
the	O	O
BZ167	O	O
dual-tropic	O	O
HIV	O	O
isolate	O	O
,	O	O
but	O	O
not	O	O
with	O	O
the	O	O
Ba-L	B-protein	O
,	O	O
M-tropic	O	O
strain	O	O
.	O	O

Based	O	O
on	O	O
these	O	O
findings	O	O
,	O	O
purified	O	O
T	B-cell_type	O
cells	I-cell_type	O
from	O	O
HIV-infected	O	O
patients	O	O
in	O	O
different	O	O
stages	O	O
of	O	O
disease	O	O
were	O	O
also	O	O
tested	O	O
for	O	O
STAT	O	O
expression	O	O
;	O	O
decreases	O	O
in	O	O
STAT5A	O	O
,	O	O
STAT5B	O	O
,	O	O
and	O	O
STAT1alpha	O	O
were	O	O
observed	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
STATs	O	O
seen	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
after	O	O
HIV	O	O
infection	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
loss	O	O
of	O	O
T	O	O
cell	O	O
function	O	O
in	O	O
HIV	O	O
disease	O	O
.	O	O

Transcription	B-protein	O
factors	I-protein	O
that	O	O
regulate	O	O
monocyte	O	O
/	O	O
macrophage	O	O
differentiation	O	O
.	O	O

Although	O	O
all	O	O
the	O	O
cells	O	O
in	O	O
an	O	O
organism	O	O
contain	O	O
the	O	O
same	O	O
genetic	O	O
information	O	O
,	O	O
differences	O	O
in	O	O
the	O	O
cell	O	O
phenotype	O	O
arise	O	O
from	O	O
the	O	O
expression	O	O
of	O	O
lineage-specific	B-protein	O
genes	I-cell_type	O
.	O	O

During	O	O
myelopoiesis	O	O
,	O	O
external	O	O
differentiating	O	O
signals	O	O
regulate	O	O
the	O	O
expression	O	O
of	O	O
a	O	O
set	O	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

The	O	O
combined	O	O
action	O	O
of	O	O
these	O	O
transcription	B-protein	O
factors	I-protein	O
subsequently	O	O
determines	O	O
the	O	O
expression	O	O
of	O	O
myeloid-specific	B-DNA	O
genes	I-DNA	O
and	O	O
the	O	O
generation	O	O
of	O	O
monocytes	B-cell_type	O
and	O	O
macrophages	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
PU.1	O	O
has	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
this	O	O
process	O	O
.	O	O

We	O	O
review	O	O
the	O	O
contribution	O	O
of	O	O
several	O	O
transcription	B-protein	O
factors	I-protein	O
to	O	O
the	O	O
control	O	O
of	O	O
macrophage	O	O
development	O	O

Transcription	B-protein	O
factor	I-protein	O
LKLF	O	O
is	O	O
sufficient	O	O
to	O	O
program	O	O
T	O	O
cell	O	O
quiescence	O	O
via	O	O
a	O	O
c-Myc	O	O
--	O	O
dependent	O	O
pathway	O	O
.	O	O

T	B-cell_type	O
lymphocytes	I-cell_type	O
circulate	O	O
in	O	O
a	O	O
quiescent	O	O
state	O	O
until	O	O
they	O	O
encounter	O	O
cognate	O	O
antigen	O	O
bound	O	O
to	O	O
the	O	O
surface	O	O
of	O	O
an	O	O
antigen-presenting	O	O
cell	I-cell_type	O
.	O	O

The	O	O
molecular	O	O
pathways	O	O
that	O	O
regulate	O	O
T	O	O
cell	O	O
quiescence	O	O
remain	O	O
largely	O	O
unknown	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
forced	O	O
expression	O	O
of	O	O
the	O	O
lung	B-protein	O
Kruppel-like	I-protein	O
transcription	I-protein	O
factor	I-protein	O
(	O	O
LKLF	B-protein	O
)	O	O
in	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
is	O	O
sufficient	O	O
to	O	O
program	O	O
a	O	O
quiescent	O	O
phenotype	O	O
characterized	O	O
by	O	O
decreased	O	O
proliferation	O	O
,	O	O
reduced	O	O
cell	O	O
size	O	O
and	O	O
protein	O	O
synthesis	O	O
and	O	O
decreased	O	O
surface	O	O
expression	O	O
of	O	O
activation	O	O
markers	O	O
.	O	O

Conversely	O	O
,	O	O
LKLF-deficient	B-cell_type	O
peripheral	I-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
produced	O	O
by	O	O
gene	O	O
targeting	O	O
showed	O	O
increased	O	O
proliferation	O	O
,	O	O
increased	O	O
cell	O	O
size	O	O
and	O	O
enhanced	O	O
expression	O	O
of	O	O
surface	O	O
activation	O	O
markers	O	O
in	O	O
vivo	O	O
.	O	O

LKLF	O	O
appeared	O	O
to	O	O
function	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
by	O	O
decreasing	O	O
expression	O	O
of	O	O
the	O	O
proto-oncogene	O	O
encoding	O	O
c-Myc	O	O
.	O	O

Forced	O	O
expression	O	O
of	O	O
LKLF	O	O
was	O	O
associated	O	O
with	O	O
markedly	O	O
decreased	O	O
c-Myc	O	O
expression	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
many	O	O
effects	O	O
of	O	O
LKLF	O	O
expression	O	O
were	O	O
mimicked	O	O
by	O	O
expression	O	O
of	O	O
the	O	O
dominant-negative	B-protein	O
MadMyc	I-protein	O
protein	I-protein	O
and	O	O
rescued	O	O
by	O	O
overexpression	O	O
of	O	O
c-Myc	O	O
.	O	O

Thus	O	O
,	O	O
LKLF	O	O
is	O	O
both	O	O
necessary	O	O
and	O	O
sufficient	O	O
to	O	O
program	O	O
quiescence	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
functions	O	O
,	O	O
in	O	O
part	O	O
,	O	O
by	O	O
negatively	O	O
regulating	O	O
a	O	O
c-Myc	O	O
--	O	O
dependent	O	O
pathway	O	O
.	O	O

HTLV-1	O	O
p12	B-protein	O
(	O	O
I	B-protein	O
)	I-protein	O
protein	I-protein	O
enhances	O	O
STAT5	O	O
activation	O	O
and	O	O
decreases	O	O
the	O	O
interleukin-2	O	O
requirement	O	O
for	O	O
proliferation	O	O
of	O	O
primary	B-cell_type	O
human	I-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
p12	B-protein	O
(	I-protein	O
I	I-protein	O
)	I-protein	O
protein	I-protein	O
,	O	O
encoded	O	O
by	O	O
the	O	O
pX	O	O
open	O	O
reading	O	O
frame	O	O
I	O	O
of	O	O
the	O	O
human	B-protein	O
T-lymphotropic	I-protein	O
virus	I-protein	O
type	I-protein	O
1	I-protein	O
(	O	O
HTLV-1	O	O
)	O	O
,	O	O
is	O	O
a	O	O
hydrophobic	O	O
protein	O	O
that	O	O
localizes	O	O
to	O	O
the	O	O
endoplasmic	O	O
reticulum	O	O
and	O	O
the	O	O
Golgi	O	O
.	O	O

Although	O	O
p12	O	O
(	O	O
I	B-protein	O
)	O	O
contains	O	O
4	O	O
minimal	O	O
proline-rich	O	O
,	O	O
src	O	O
homology	B-protein	O
3-binding	I-protein	O
motifs	I-protein	O
(	O	O
PXXP	B-protein	O
)	O	O
,	O	O
a	O	O
characteristic	O	O
commonly	O	O
found	O	O
in	O	O
proteins	O	O
involved	O	O
in	O	O
signaling	O	O
pathways	O	O
,	O	O
it	O	O
has	O	O
not	O	O
been	O	O
known	O	O
whether	O	O
p12	O	O
(	O	O
I	B-protein	O
)	O	O
has	O	O
a	O	O
role	O	O
in	O	O
modulating	O	O
intracellular	O	O
signaling	O	O
pathways	O	O
.	O	O

This	O	O
study	O	O
demonstrated	O	O
that	O	O
p12	O	O
(	O	O
I	B-protein	O
)	O	O
binds	O	O
to	O	O
the	O	O
cytoplasmic	B-protein	O
domain	I-protein	O
of	O	O
the	O	O
interleukin-2	B-protein	O
receptor	I-protein	O
(	O	O
IL-2R	B-protein	O
)	I-protein	O
beta	I-protein	O
chain	O	O
that	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
recruitment	O	O
of	O	O
the	O	O
Jak1	B-protein	O
and	I-protein	O
Jak3	I-protein	O
kinases	I-protein	O
.	O	O

As	O	O
a	O	O
result	O	O
of	O	O
this	O	O
interaction	O	O
,	O	O
p12	O	O
(	O	O
I	B-protein	O
)	O	O
increases	O	O
signal	O	O
transducers	O	O
and	O	O
activators	O	O
of	O	O
transcription	O	O
5	O	O
(	O	O
STAT5	B-protein	O
)	O	O
DNA	O	O
binding	O	O
and	O	O
transcriptional	B-protein	O
activity	O	O
and	O	O
this	O	O
effect	O	O
depends	O	O
on	O	O
the	O	O
presence	O	O
of	O	O
both	O	O
IL-2R	B-protein	O
beta	I-protein	O
and	O	O
gamma	I-protein	O
(	O	O
c	B-protein	O
)	O	O
chains	O	O
and	O	O
Jak3	B-protein	O
.	O	O

Transduction	O	O
of	O	O
primary	B-cell_type	O
human	I-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
(	O	O
PBMCs	O	O
)	O	O
with	O	O
a	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1-based	O	O
retroviral	O	O
vector	O	O
expressing	I-protein	O
p12	I-protein	O
(	O	O
I	B-protein	O
)	O	O
also	O	O
resulted	O	O
in	O	O
increased	O	O
STAT5	O	O
phosphorylation	O	O
and	O	O
DNA	O	O
binding	O	O
.	O	O

However	O	O
,	O	O
p12	O	O
(	O	O
I	B-protein	O
)	O	O
could	O	O
increase	O	O
proliferation	O	O
of	O	O
human	O	O
PBMCs	O	O
only	O	O
after	O	O
stimulation	O	O
of	O	O
T-cell	B-protein	O
receptors	I-protein	O
by	O	O
treatment	O	O
of	O	O
cells	O	O
with	O	O
low	O	O
concentrations	O	O
of	O	O
alphaCD3	O	O
and	O	O
alphaCD28	B-protein	O
antibodies	I-protein	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
proliferative	O	O
advantage	O	O
of	O	O
p12	B-protein	O
(	O	O
I	B-protein	O
)	O	O
-transduced	O	O
PBMCs	O	O
was	O	O
evident	O	O
mainly	O	O
at	O	O
low	O	O
concentrations	O	O
of	O	O
IL-2	B-protein	O
.	O	O

Together	O	O
,	O	O
these	O	O
data	O	O
indicate	O	O
that	O	O
p12	O	O
(	O	O
I	B-protein	O
)	O	O
may	O	O
confer	O	O
a	O	O
proliferative	O	O
advantage	O	O
on	O	O
HTLV-1-infected	O	O
cells	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
suboptimal	O	O
antigen	O	O
stimulation	O	O
and	O	O
that	O	O
this	O	O
event	O	O
may	O	O
account	O	O
for	O	O
the	O	O
clonal	O	O
proliferation	O	O
of	O	O
infected	O	O
T	B-cell_type	O
cells	I-cell_type	O
in	O	O
vivo	O	O
.	O	O

(	O	O
Blood.	O	O
2001	O	O
;	O	O
98	O	O
:	O	O
823-829	O	O
)	O	O

Single	O	O
dose	O	O
intranasal	O	O
administration	O	O
of	O	O
retinal	O	O
autoantigen	O	O
generates	O	O
a	O	O
rapid	O	O
accumulation	O	O
and	O	O
cell	O	O
activation	O	O
in	O	O
draining	O	O
lymph	O	O
node	O	O
and	O	O
spleen	O	O
:	O	O
implications	O	O
for	O	O
tolerance	O	O
therapy	O	O
.	O	O

BACKGROUND/AIMS	O	O
:	O	O
A	O	O
single	O	O
intranasal	O	O
delivery	O	O
of	O	O
retinal	O	O
autoantigen	O	O
suppresses	O	O
effectively	O	O
experimental	O	O
autoimmune	O	O
uveoretinitis	O	O
(	O	O
EAU	O	O
)	O	O
.	O	O

To	O	O
further	O	O
unravel	O	O
underlying	O	O
mechanisms	O	O
the	O	O
authors	O	O
wished	O	O
to	O	O
determine	O	O
,	O	O
firstly	O	O
,	O	O
the	O	O
kinetics	O	O
of	O	O
antigen	O	O
delivery	O	O
and	O	O
,	O	O
secondly	O	O
,	O	O
the	O	O
early	B-protein	O
cellular	O	O
responses	O	O
involved	O	O
in	O	O
the	O	O
initial	O	O
stages	O	O
of	O	O
nasal	O	O
mucosal	O	O
tolerance	O	O
induction	O	O
.	O	O

METHODS	O	O
:	O	O
Flow	O	O
cytometry	O	O
,	O	O
cell	O	O
proliferation	O	O
assays	O	O
,	O	O
and	O	O
microscopy	O	O
were	O	O
used	O	O
to	O	O
track	O	O
antigen	O	O
following	O	O
a	O	O
single	O	O
,	O	O
intranasal	O	O
dose	O	O
of	O	O
Alexa-488	O	O
labelled	O	O
retinal	O	O
antigen	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
rapid	O	O
accumulation	O	O
of	O	O
antigen	O	O
within	O	O
both	O	O
superficial	O	O
cervical	O	O
lymph	O	O
nodes	O	O
(	O	O
SCLN	O	O
)	O	O
and	O	O
spleen	O	O
was	O	O
observed	O	O
after	O	O
30	O	O
minutes	O	O
.	O	O

Significant	O	O
proliferative	O	O
responses	O	O
to	O	O
IRBP	O	O
were	O	O
elicited	O	O
by	O	O
48	O	O
hours	O	O
indicating	O	O
that	O	O
systemic	O	O
priming	O	O
of	O	O
naive	O	O
T	B-cell_type	O
cells	I-cell_type	O
to	O	O
retinal	O	O
antigen	O	O
had	O	O
occurred	O	O
.	O	O

Cell	O	O
activation	O	O
was	O	O
further	O	O
confirmed	O	O
by	O	O
immunoprecipitation	O	O
studies	O	O
,	O	O
which	O	O
demonstrated	O	O
phosphorylation	O	O
of	O	O
STAT4	B-protein	O
but	O	O
not	O	O
STAT6	O	O
in	O	O
both	O	O
lymph	O	O
nodes	O	O
and	O	O
spleen	O	O
.	O	O

However	O	O
,	O	O
at	O	O
24	O	O
hours	O	O
,	O	O
STAT4	O	O
heterodimerisation	O	O
with	O	O
STAT	B-protein	O
3	O	O
was	O	O
only	O	O
observed	O	O
in	O	O
spleen	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
results	O	O
provide	O	O
novel	O	O
evidence	O	O
that	O	O
following	O	O
a	O	O
single	O	O
intranasal	O	O
application	O	O
rapid	O	O
transfer	O	O
of	O	O
antigen	O	O
occurs	O	O
.	O	O

Resulting	O	O
T	O	O
cell	O	O
proliferation	O	O
develops	O	O
consequent	O	O
to	O	O
differential	O	O
cell	O	O
signalling	O	O
in	O	O
SCLN	O	O
and	O	O
spleen	O	O
.	O	O

Further	O	O
understanding	O	O
of	O	O
these	O	O
underlying	O	O
cellular	O	O
mechanisms	O	O
,	O	O
in	O	O
particular	O	O
as	O	O
is	O	O
inferred	O	O
by	O	O
the	O	O
results	O	O
the	O	O
contribution	O	O
of	O	O
local	B-protein	O
versus	I-protein	O
systemic	O	O
tolerance	O	O
induction	O	O
,	O	O
may	O	O
assist	O	O
in	O	O
strategies	O	O
to	O	O
clinically	O	O
apply	O	O
mucosal	O	O
tolerance	O	O
therapy	O	O
successfully	O	O
.	O	O

Regulation	O	O
of	O	O
interleukin	B-protein	O
(	I-protein	O
IL	I-protein	O
)	I-protein	O
-18	I-protein	O
receptor	I-protein	O
alpha	I-protein	O
chain	I-protein	O
expression	O	O
on	O	O
CD4	B-protein	O
(	I-cell_line	O
+	I-cell_line	O
)	I-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
during	O	O
T	O	O
helper	O	O
(	O	O
Th	O	O
)	O	O
1/Th2	O	O
differentiation	O	O
.	O	O

Critical	O	O
downregulatory	O	O
role	O	O
of	O	O
IL-4	B-protein	O
.	O	O

Interleukin	B-protein	O
(	O	O
IL	I-protein	O
)	O	O
-18	O	O
has	O	O
been	O	O
well	O	O
characterized	O	O
as	O	O
a	O	O
costimulatory	O	O
factor	O	O
for	O	O
the	O	O
induction	O	O
of	O	O
IL-12-mediated	O	O
interferon	O	O
(	O	O
IFN	O	O
)	O	O
-gamma	O	O
production	O	O
by	O	O
T	O	O
helper	O	O
(	O	O
Th	I-cell_line	O
)	I-cell_line	O
1	I-cell_line	O
cells	I-cell_line	O
,	O	O
but	O	O
also	O	O
can	O	O
induce	O	O
IL-4	O	O
production	O	O
and	O	O
thus	O	O
facilitate	O	O
the	O	O
differentiation	O	O
of	O	O
Th2	B-cell_type	O
cells	I-cell_type	O
.	O	O

To	O	O
determine	O	O
the	O	O
mechanisms	O	O
by	O	O
which	O	O
IL-18	O	O
might	O	O
regulate	O	O
these	O	O
diametrically	O	O
distinct	O	O
immune	O	O
responses	O	O
,	O	O
we	O	O
have	O	O
analyzed	O	O
the	O	O
role	O	O
of	O	O
cytokines	B-protein	O
in	O	O
the	O	O
regulation	O	O
of	O	O
IL-18	B-protein	O
receptor	I-protein	O
alpha	I-protein	O
chain	I-protein	O
(	O	O
IL-18Ralpha	B-protein	O
)	O	O
expression	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
peripheral	B-protein	O
CD4	I-protein	O
(	I-cell_line	O
+	I-cell_line	O
)	I-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
constitutively	O	O
expressed	O	O
the	O	O
IL-18Ralpha	O	O
.	O	O

Upon	O	O
antigen	O	O
stimulation	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
IL-12	B-protein	O
,	O	O
marked	O	O
enhancement	O	O
of	O	O
IL-18Ralpha	O	O
expression	O	O
was	O	O
observed	O	O
.	O	O

IL-12	B-protein	O
-mediated	O	O
upregulation	O	O
of	O	O
IL-18Ralpha	O	O
required	O	O
IFN-gamma	B-protein	O
.	O	O

Activated	O	O
CD4	B-protein	O
(	O	O
+	I-cell_line	O
)	I-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
that	O	O
expressed	O	O
low	O	O
levels	O	O
of	O	O
IL-18Ralpha	O	O
could	O	O
produce	O	O
IFN-gamma	B-protein	O
when	O	O
stimulated	O	O
with	O	O
the	O	O
combination	O	O
of	O	O
IL-12	B-protein	O
and	O	O
IL-18	O	O
,	O	O
while	O	O
CD4	B-protein	O
(	O	O
+	I-cell_line	O
)	I-cell_line	O
cells	I-cell_type	O
which	O	O
expressed	O	O
high	O	O
levels	O	O
of	O	O
IL-18Ralpha	O	O
could	O	O
respond	O	O
to	O	O
IL-18	O	O
alone	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
T	O	O
cell	O	O
stimulation	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
IL-4	O	O
resulted	O	O
in	O	O
a	O	O
downregulation	O	O
of	O	O
IL-18Ralpha	O	O
expression	O	O
.	O	O

Both	O	O
IL-4	B-protein	O
(	O	O
-/	O	O
)	O	O
-	O	O
and	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
(	O	O
Stat	I-protein	O
)	O	O
6	O	O
(	O	O
-/	O	O
)	O	O
-	O	O
T	B-cell_type	O
cells	I-cell_type	O
expressed	O	O
higher	O	O
levels	O	O
of	O	O
IL-18Ralpha	O	O
after	O	O
TCR	B-protein	O
stimulation	O	O
.	O	O

Furthermore	O	O
,	O	O
activated	O	O
T	B-cell_type	O
cells	I-cell_type	O
from	O	O
Stat6	O	O
(	O	O
-/	O	O
)	O	O
-	O	O
mice	O	O
produced	O	O
more	O	O
IFN-gamma	O	O
in	O	O
response	O	O
to	O	O
IL-18	O	O
than	O	O
wild-type	O	O
controls	O	O
.	O	O

Thus	O	O
,	O	O
positive/negative	O	O
regulation	O	O
of	O	O
the	O	O
IL-18Ralpha	O	O
by	O	O
the	O	O
major	B-protein	O
inductive	I-protein	O
cytokines	I-protein	O
(	O	O
IL-12	B-protein	O
and	I-protein	O
IL-4	B-protein	O
)	O	O
determines	O	O
the	O	O
capacity	O	O
of	O	O
IL-18	O	O
to	O	O
polarize	O	O
an	O	O
immune	O	O
response	O	O
.	O	O

Glucocorticoid-regulated	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

Glucocorticoids	O	O
are	O	O
the	O	O
most	O	O
effective	O	O
antiinflammatory	O	O
drugs	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
asthma	O	O
.	O	O

They	O	O
act	O	O
by	O	O
binding	O	O
to	O	O
a	O	O
specific	B-protein	O
receptor	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
that	O	O
,	O	O
upon	O	O
activation	O	O
,	O	O
translocates	O	O
to	O	O
the	O	O
nucleus	O	O
and	O	O
either	O	O
increases	O	O
(	O	O
transactivates	B-protein	O
)	O	O
or	O	O
decreases	O	O
(	O	O
transrepresses	O	O
)	O	O
gene	O	O
expression	O	O
.	O	O

Inhibition	O	O
of	O	O
pro-inflammatory	B-protein	O
transcription	B-protein	O
factors	I-protein	O
such	O	O
as	B-protein	O
activator	I-protein	O
protein	I-protein	O
(	O	O
AP	B-protein	O
)	I-protein	O
-1	I-protein	O
,	O	O
signal	B-protein	O
transducers	I-protein	O
and	I-protein	O
activators	I-protein	O
of	I-protein	O
transcription	I-protein	O
(	O	O
STATs	B-protein	O
)	I-protein	O
,	O	O
nuclear	B-protein	O
factor	I-protein	O
of	I-protein	O
activated	I-protein	O
T	I-protein	O
cells	I-protein	O
(	O	O
NFAT	B-protein	O
)	O	O
and	O	O
nuclear	B-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
-kappa	O	O
B	O	O
is	O	O
thought	O	O
to	O	O
be	O	O
a	O	O
major	O	O
action	O	O
of	O	O
glucocorticoids	O	O
.	O	O

Acetylation	O	O
of	O	O
histones	O	O
allows	O	O
unwinding	O	O
of	O	O
the	O	O
local	B-DNA	O
DNA	I-DNA	O
structure	I-DNA	O
and	O	O
enables	O	O
RNA	O	O
polymerase	O	O
II	O	O
to	O	O
enhance	O	O
gene	O	O
transcription	O	O
.	O	O

Histone	O	O
acetylation	O	O
is	O	O
regulated	O	O
by	O	O
a	O	O
balance	O	O
between	O	O
the	O	O
activity	O	O
of	O	O
histone	B-protein	O
acetyltransferases	I-protein	O
(	O	O
HATs	B-protein	O
)	O	O
and	O	O
histone	O	O
deacetylases	O	O
(	O	O
HDACs	O	O
)	O	O
.	O	O

GR	O	O
acts	O	O
as	O	O
a	O	O
direct	O	O
inhibitor	O	O
of	O	O
NF-kappa	B-protein	O
B-induced	I-protein	O
HAT	O	O
activity	O	O
and	O	O
also	O	O
by	O	O
recruiting	O	O
HDAC2	O	O
to	O	O
the	O	O
NF-kappa	B-protein	O
B/HAT	I-protein	O
complex	I-protein	O
.	O	O

A	O	O
sub-group	O	O
of	O	O
patients	O	O
with	O	O
glucocorticoid-insensitive	O	O
asthma	O	O
have	O	O
an	O	O
inability	O	O
to	O	O
induce	O	O
histone	O	O
acetylation	O	O
in	O	O
response	O	O
to	O	O
dexamethasone	O	O
suggesting	O	O
reduced	O	O
expression	O	O
of	O	O
a	O	O
GR-specific	O	O
HAT	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
pharmacological	O	O
manipulation	O	O
of	O	O
specific	O	O
histone	O	O
acetylation	O	O
status	O	O
is	O	O
a	O	O
potentially	O	O
useful	O	O
approach	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
inflammatory	O	O
diseases	O	O
.	O	O

Identification	O	O
of	O	O
the	O	O
precise	O	O
mechanism	O	O
by	O	O
which	O	O
activated	O	O
GR	O	O
recruits	O	O
HDAC2	O	O
may	O	O
reveal	O	O
new	O	O
targets	O	O
for	O	O
the	O	O
development	O	O
of	O	O
drugs	O	O
that	O	O
may	O	O
dissociate	O	O
the	O	O
antiinflammatory	O	O
actions	O	O
of	O	O
glucocorticoids	O	O
from	O	O
their	O	O
side	O	O
effects	O	O
that	O	O
are	O	O
largely	O	O
due	O	O
to	O	O
gene	O	O
induction	O	O
.	O	O

Copyright	O	O
Academic	O	O
Press	O	O
.	O	O

Differential	O	O
ultraviolet-B-induced	O	O
immunomodulation	O	O
in	O	O
XPA	O	O
,	O	O
XPC	O	O
,	O	O
and	O	O
CSB	O	O
DNA	O	O
repair-deficient	O	O
mice	O	O
.	O	O

Ultraviolet	O	O
B	O	O
irradiation	O	O
has	O	O
serious	O	O
consequences	O	O
for	O	O
cellular	O	O
immunity	O	O
and	O	O
can	O	O
suppress	O	O
the	O	O
rejection	O	O
of	O	O
skin	O	O
tumors	O	O
and	O	O
the	O	O
resistance	O	O
to	O	O
infectious	O	O
diseases	O	O
.	O	O

DNA	O	O
damage	O	O
plays	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
these	O	O
immunomodulatory	O	O
effects	O	O
of	O	O
ultraviolet	O	O
B	O	O
,	O	O
as	O	O
impaired	O	O
repair	O	O
of	O	O
ultraviolet-B-induced	O	O
DNA	O	O
damage	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
cause	O	O
suppression	O	O
of	O	O
cellular	O	O
immunity	O	O
.	O	O

Ultraviolet-B-induced	O	O
DNA	O	O
damage	O	O
is	O	O
repaired	O	O
by	O	O
the	O	O
nucleotide	O	O
excision	O	O
repair	O	O
mechanism	O	O
very	O	O
efficiently	O	O
.	O	O

Nucleotide	O	O
excision	O	O
repair	O	O
comprises	O	O
two	O	O
subpathways	O	O
:	O	O
transcription-coupled	O	O
and	O	O
global	O	O
genome	O	O
repair	O	O
.	O	O

In	O	O
this	O	O
study	O	O
the	O	O
immunologic	O	O
consequences	O	O
of	O	O
specific	O	O
nucleotide	O	O
excision	O	O
repair	O	O
defects	O	O
in	O	O
three	O	O
mouse	O	O
models	O	O
,	O	O
XPA	O	O
,	O	O
XPC	O	O
,	O	O
and	O	O
CSB	O	O
mutant	O	O
mice	O	O
,	O	O
were	O	O
investigated	O	O
.	O	O

XPA	O	O
mice	O	O
carry	O	O
a	O	O
total	O	O
nucleotide	O	O
excision	O	O
repair	O	O
defect	O	O
,	O	O
whereas	O	O
XPC	O	O
and	O	O
CSB	O	O
mice	O	O
only	O	O
lack	O	O
global	O	O
genome	O	O
and	O	O
transcription-coupled	O	O
nucleotide	O	O
excision	O	O
repair	O	O
,	O	O
respectively	O	O
.	O	O

Our	O	O
data	O	O
demonstrate	O	O
that	O	O
cellular	O	O
immune	O	O
parameters	O	O
in	O	O
XPA	O	O
,	O	O
XPC	O	O
,	O	O
and	O	O
CSB	O	O
mice	O	O
are	O	O
normal	O	O
compared	O	O
with	O	O
their	O	O
wild-type	O	O
(	O	O
control	O	O
)	O	O
littermates	O	O
.	O	O

This	O	O
may	O	O
indicate	O	O
that	O	O
the	O	O
reported	O	O
altered	O	O
cellular	O	O
responses	O	O
in	O	O
xeroderma	O	O
pigmentosum	O	O
patients	O	O
are	O	O
not	O	O
constitutive	O	O
but	O	O
could	O	O
be	O	O
due	O	O
to	O	O
external	B-protein	O
factors	I-protein	O
,	O	O
such	O	O
as	O	O
ultraviolet	O	O
B	O	O
.	O	O

Upon	O	O
exposure	O	O
to	O	O
ultraviolet	O	O
B	O	O
,	O	O
only	O	O
XPA	O	O
mice	O	O
are	O	O
very	O	O
sensitive	O	O
to	O	O
ultraviolet-B-induced	O	O
inhibition	O	O
of	O	O
Th1-mediated	O	O
contact	O	O
hypersensitivity	O	O
responses	O	O
and	O	O
interferon-gamma	O	O
production	O	O
in	O	O
skin	O	O
draining	O	O
lymph	O	O
nodes	O	O
.	O	O

Lipopolysaccharide-stimulated	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
alpha	I-protein	O
and	O	O
interleukin-10	O	O
production	O	O
are	O	O
significantly	O	O
augmented	O	O
in	O	O
both	O	O
XPA	O	O
and	O	O
CSB	O	O
mice	O	O
after	O	O
ultraviolet	O	O
B	O	O
exposure	O	O
.	O	O

Lymph	O	O
node	O	O
cell	O	O
numbers	O	O
were	O	O
increased	O	O
very	O	O
significantly	O	O
in	O	O
XPA	O	O
,	O	O
mildly	O	O
increased	O	O
in	O	O
CSB	O	O
,	O	O
and	O	O
not	O	O
in	O	O
XPC	O	O
mice	O	O
.	O	O

In	O	O
general	O	O
XPC	O	O
mice	O	O
do	O	O
not	O	O
exhibit	O	O
any	O	O
indication	O	O
of	O	O
enhanced	O	O
ultraviolet	O	O
B	O	O
susceptibility	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
immune	O	O
parameters	O	O
analyzed	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
both	O	O
global	O	O
genome	O	O
repair	O	O
and	O	O
transcription-coupled	O	O
repair	O	O
are	O	O
needed	O	O
to	O	O
prevent	O	O
immunomodulation	O	O
by	O	O
ultraviolet	B-protein	O
B	I-protein	O
,	O	O
whereas	O	O
transcription-coupled	O	O
repair	O	O
is	O	O
the	O	O
major	O	O
DNA	O	O
repair	O	O
subpathway	O	O
of	O	O
nucleotide	O	O
excision	O	O
repair	O	O
that	O	O
prevents	O	O
the	O	O
acute	O	O
ultraviolet-B-induced	O	O
effects	O	O
such	O	O
as	O	O
erythema	O	O
.	O	O

Biomechanical	O	O
strain	O	O
induces	O	O
class	O	O
a	O	O
scavenger	O	O
receptor	I-protein	O
expression	O	O
in	O	O
human	B-cell_line	O
monocyte/macrophages	I-cell_line	O
and	I-cell_line	O
THP-1	I-cell_line	O
cells	I-cell_line	O
:	O	O
a	O	O
potential	O	O
mechanism	O	O
of	O	O
increased	O	O
atherosclerosis	O	O
in	O	O
hypertension	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Although	O	O
hypertension	O	O
is	O	O
an	O	O
important	O	O
risk	O	O
factor	O	O
for	O	O
the	O	O
development	O	O
of	O	O
atherosclerosis	O	O
,	O	O
the	O	O
mechanisms	O	O
for	O	O
this	O	O
interaction	O	O
are	O	O
incompletely	O	O
described	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
suggested	O	O
that	O	O
biomechanical	O	O
strain	O	O
regulates	O	O
macrophage	O	O
phenotype	O	O
.	O	O

We	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
biomechanical	O	O
strain	O	O
can	O	O
induce	O	O
expression	O	O
of	O	O
the	O	O
class	B-protein	O
A	I-protein	O
scavenger	I-protein	O
receptor	I-protein	O
(	O	O
SRA	B-protein	O
)	O	O
,	O	O
an	O	O
important	O	O
lipoprotein	B-protein	O
receptor	I-protein	O
in	O	O
atherogenesis	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
Human	O	O
monocyte/macrophages	O	O
or	O	O
THP-1	O	O
cells	O	O
were	O	O
cultured	O	O
in	O	O
a	O	O
device	O	O
that	O	O
imposes	O	O
uniform	O	O
biaxial	O	O
cyclic	O	O
1-Hz	O	O
strains	O	O
of	O	O
0	O	O
%	O	O
,	O	O
1	O	O
%	O	O
,	O	O
2	O	O
%	O	O
,	O	O
or	O	O
3	O	O
%	O	O
,	O	O
and	O	O
SRA	O	O
expression	O	O
was	O	O
analyzed	O	O
.	O	O

Mechanical	O	O
strains	O	O
induced	O	O
SRA	O	O
mRNA	I-RNA	O
(	O	O
3.5+/-0.6-fold	O	O
at	O	O
3	O	O
%	O	O
strain	O	O
for	O	O
48	O	O
hours	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
SRA	O	O
protein	O	O
in	O	O
THP-1	B-cell_line	O
cells	I-cell_line	O
in	O	O
an	O	O
amplitude-dependent	O	O
manner	O	O
.	O	O

This	O	O
induction	O	O
was	O	O
accompanied	O	O
by	O	O
augmented	O	O
expression	O	O
of	O	O
the	O	O
class	B-protein	O
B	I-protein	O
scavenger	I-protein	O
receptor	I-protein	O
CD36	I-protein	O
(	O	O
2.8+/-0.3-fold	B-protein	O
,	O	O
P	O	O
<	O	O
0.001	B-protein	O
)	O	O
but	O	O
not	O	O
by	O	O
increased	O	O
peroxisome	O	O
proliferator-activated	O	O
receptor-gamma	O	O
expression	O	O
.	O	O

To	O	O
evaluate	O	O
this	O	O
effect	O	O
in	O	O
vivo	O	O
,	O	O
apolipoprotein	O	O
E	O	O
(	O	O
-/-	O	O
)	O	O
mice	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
standard	O	O
chow	O	O
,	O	O
a	O	O
high-cholesterol	O	O
diet	O	O
,	O	O
or	O	O
a	O	O
high-cholesterol	O	O
diet	O	O
with	O	O
hypertension	O	O
induced	O	O
by	O	O
angiotensin	O	O
II	O	O
infusion	O	O
for	O	O
8	O	O
weeks	O	O
.	O	O

Immunohistochemistry	O	O
revealed	O	O
that	O	O
among	O	O
macrophages	O	O
in	O	O
atherosclerotic	O	O
lesions	O	O
of	O	O
the	O	O
aorta	O	O
,	O	O
the	O	O
proportion	O	O
of	O	O
macrophages	O	O
with	O	O
SRA	O	O
expression	O	O
was	O	O
highest	O	O
in	O	O
hypertensive	O	O
animals	O	O
on	O	O
a	O	O
high-cholesterol	O	O
diet	O	O
(	O	O
43.9+/-0.7	O	O
%	O	O
,	O	O
versus	O	O
12.0+/-2.0	O	O
%	O	O
for	O	O
normotensive	O	O
animals	O	O
on	O	O
a	O	O
high-cholesterol	O	O
diet	O	O
and	O	O
4.7+/-4.7	O	O
%	O	O
for	O	O
animals	O	O
on	O	O
standard	O	O
chow	O	O
;	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Biomechanical	O	O
strain	O	O
induces	O	O
SRA	O	O
expression	O	O
by	O	O
monocyte/macrophages	O	O
,	O	O
suggesting	O	O
a	O	O
novel	O	O
mechanism	O	O
for	O	O
promotion	O	O
of	O	O
atherosclerosis	O	O
in	O	O
hypertensive	O	O
patients	O	O
.	O	O

High	O	O
glucose	O	O
induces	O	O
MCP-1	O	O
expression	O	O
partly	O	O
via	O	O
tyrosine	O	O
kinase-AP-1	O	O
pathway	O	O
in	O	O
peritoneal	B-cell_type	O
mesothelial	I-cell_type	O
cells	I-cell_type	O
.	O	O

BACKGROUND	O	O
:	O	O
High	O	O
glucose	O	O
in	O	O
peritoneal	O	O
dialysis	O	O
solutions	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
peritoneal	O	O
fibrosis	O	O
in	O	O
chronic	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
(	O	O
CAPD	O	O
)	O	O
patients	O	O
.	O	O

However	O	O
,	O	O
the	O	O
mechanisms	O	O
are	O	O
not	O	O
very	O	O
clear	O	O
.	O	O

Peritoneal	O	O
macrophages	O	O
seem	O	O
to	O	O
participate	O	O
in	O	O
the	O	O
process	O	O
of	O	O
peritoneal	O	O
fibrosis	O	O
and	O	O
monocyte	O	O
chemoattractant	B-protein	O
protein-1	I-protein	O
(	O	O
MCP-1	B-protein	O
)	O	O
plays	O	O
a	O	O
key	O	O
role	O	O
in	O	O
the	O	O
recruitment	O	O
of	O	O
monocytes	B-cell_type	O
toward	O	O
the	O	O
peritoneal	O	O
cavity	O	O
.	O	O

However	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
effect	O	O
of	O	O
high	O	O
glucose	O	O
on	O	O
MCP-1	O	O
expression	O	O
and	O	O
its	O	O
signal	O	O
transduction	O	O
pathway	O	O
in	O	O
human	B-cell_line	O
peritoneal	I-cell_line	O
mesothelial	I-cell_line	O
cells	I-cell_line	O
.	O	O

METHODS	O	O
:	O	O
Mesothelial	O	O
cells	O	O
were	O	O
cultured	O	O
with	O	O
glucose	O	O
(	O	O
5	O	O
to	O	O
100	O	O
mmol/L	O	O
)	O	O
or	O	O
mannitol	O	O
chronically	O	O
for	O	O
up	O	O
to	O	O
seven	O	O
days	O	O
.	O	O

MCP-1	O	O
expression	O	O
of	O	O
mRNA	B-RNA	O
and	O	O
protein	O	O
was	O	O
measured	O	O
by	O	O
Northern	O	O
blot	O	O
analysis	O	O
and	O	O
enzyme-linked	O	O
immunosorbent	O	O
assay	O	O
(	O	O
ELISA	O	O
)	O	O
.	O	O

Chemotactic	O	O
activity	O	O
of	O	O
high-glucose-conditioned	O	O
culture	O	O
supernatant	O	O
was	O	O
measured	O	O
by	O	O
chemotactic	O	O
assay	O	O
.	O	O

To	O	O
examine	O	O
the	O	O
roles	O	O
of	O	O
the	O	O
transcription	B-protein	O
factors	I-protein	O
activator	I-protein	O
protein-1	I-protein	O
(	O	O
AP-1	B-protein	O
)	I-protein	O
and	O	O
nuclear	B-protein	O
factor-kappaB	I-protein	O
(	O	O
NF-kappaB	B-protein	O
)	O	O
,	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
(	O	O
EMSA	O	O
)	O	O
was	O	O
performed	O	O
.	O	O

RESULTS	O	O
:	O	O
Glucose	O	O
induced	O	O
MCP-1	O	O
mRNA	O	O
expression	O	O
in	O	O
a	O	O
time-	O	O
and	O	O
dose-dependent	O	O
manner	O	O
.	O	O

MCP-1	O	O
protein	O	O
in	O	O
cell	O	O
culture	O	O
supernant	O	O
was	O	O
also	O	O
increased	O	O
.	O	O

Equivalent	O	O
concentrations	O	O
of	O	O
mannitol	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
.	O	O

High-glucose-conditioned	O	O
supernatant	O	O
possessed	O	O
an	O	O
increased	O	O
chemotactic	O	O
activity	O	O
for	O	O
monocytes	B-cell_type	O
,	O	O
which	O	O
was	O	O
neutralized	O	O
by	O	O
anti-MCP-1	O	O
antibody	O	O
.	O	O

EMSA	O	O
revealed	O	O
that	O	O
glucose	O	O
increased	O	O
the	O	O
AP-1	B-protein	O
binding	O	O
activity	O	O
in	O	O
a	O	O
time-	O	O
and	O	O
dose-dependent	O	O
manner	O	O
,	O	O
but	O	O
not	O	O
NF-kappaB	O	O
.	O	O

Curcumin	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
AP-1	B-protein	O
,	O	O
dose-dependently	O	O
suppressed	O	O
the	O	O
induction	O	O
of	O	O
MCP-1	B-RNA	O
mRNA	I-RNA	O
by	O	O
high	O	O
glucose	O	O
.	O	O

Tyrosine	O	O
kinase	O	O
inhibitors	O	O
such	O	O
as	O	O
genistein	O	O
(	O	O
12.5	O	O
to	O	O
50	O	O
micromol/L	O	O
)	O	O
and	O	O
herbimycin	O	O
A	O	O
(	O	O
0.1	O	O
to	O	O
1	O	O
micromol/L	O	O
)	O	O
inhibited	O	O
the	O	O
high-glucose-induced	O	O
MCP-1	O	O
mRNA	O	O
expression	O	O
in	O	O
a	O	O
dose-dependent	O	O
manner	O	O
,	O	O
and	O	O
also	O	O
suppressed	O	O
the	O	O
high-glucose-induced	O	O
AP-1	B-protein	O
binding	O	O
activity	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
:	O	O
High	O	O
glucose	O	O
induced	O	O
mesothelial	O	O
MCP-1	O	O
expression	O	O
partly	O	O
via	O	O
the	O	O
tyrosine	O	O
kinase-	O	O
AP-1	O	O
pathway	O	O
.	O	O

Signal	O	O
thresholds	O	O
and	O	O
modular	O	O
synergy	O	O
during	O	O
expression	O	O
of	O	O
costimulatory	O	O
molecules	O	O
in	O	O
B	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

We	O	O
analyzed	O	O
intracellular	O	O
pathways	O	O
modulating	O	O
surface	O	O
densities	O	O
of	O	O
CD80	O	O
and	O	O
CD86	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
activated	O	O
through	O	O
ligation	O	O
of	O	O
the	O	O
Ag	B-protein	O
receptor	I-protein	O
,	O	O
and	O	O
the	O	O
adhesion	B-protein	O
molecule	I-protein	O
CD54	O	O
.	O	O

Whereas	O	O
B	B-protein	O
cell	I-protein	O
Ag	I-protein	O
receptor	I-protein	O
(	O	O
BCR	B-protein	O
)	O	O
cross-linking	O	O
alone	O	O
stimulated	O	O
increased	O	O
expression	O	O
of	O	O
CD86	O	O
,	O	O
up-regulation	O	O
of	O	O
CD80	O	O
required	O	O
dual	O	O
stimulation	O	O
with	O	O
anti-IgM	O	O
and	O	O
anti-CD54	O	O
.	O	O

The	O	O
principal	O	O
downstream	O	O
component	O	O
contributed	O	O
by	O	O
BCR	O	O
signaling	O	O
,	O	O
toward	O	O
both	O	O
CD80	O	O
and	O	O
CD86	O	O
induction	O	O
,	O	O
was	O	O
the	O	O
elevated	O	O
concentration	O	O
of	O	O
free	B-protein	O
cytoplasmic	I-protein	O
Ca	I-protein	O
(	O	O
2+	B-protein	O
)	O	O
,	O	O
recruited	O	O
by	O	O
way	O	O
of	O	O
capacitative	O	O
influx	O	O
.	O	O

This	O	O
alone	O	O
was	O	O
sufficient	O	O
to	O	O
generate	O	O
an	O	O
increase	O	O
in	O	O
CD86	O	O
levels	O	O
.	O	O

However	O	O
,	O	O
CD80	O	O
enhancement	O	O
required	O	O
the	O	O
concerted	O	O
action	O	O
of	O	O
both	O	O
intracellular	B-protein	O
Ca	I-protein	O
(	O	O
2+	B-protein	O
)	O	O
concentration	O	O
and	O	O
CD54-initiated	O	O
pathways	O	O
.	O	O

The	O	O
nexus	O	O
between	O	O
anti-IgM	O	O
and	O	O
anti-CD54	O	O
stimulation	O	O
,	O	O
in	O	O
the	O	O
context	O	O
of	O	O
CD80	O	O
regulation	O	O
,	O	O
was	O	O
identified	O	O
to	O	O
involve	O	O
a	O	O
self-propagating	O	O
process	O	O
of	O	O
sequential	O	O
synergy	O	O
.	O	O

The	O	O
first	O	O
step	O	O
involved	O	O
amplified	O	O
accumulation	O	O
of	O	O
intracellular	O	O
cAMP	O	O
,	O	O
as	O	O
a	O	O
result	O	O
of	O	O
cross-talk	O	O
between	O	O
BCR	O	O
-mobilized	O	O
Ca	O	O
(	O	O
2+	O	O
)	O	O
and	O	O
CD54-derived	O	O
signals	O	O
.	O	O

This	O	O
then	O	O
facilitated	O	O
a	O	O
second	O	O
synergistic	O	O
interaction	O	O
between	O	O
Ca	O	O
(	O	O
2+	B-protein	O
)	O	O
and	O	O
cAMP	O	O
,	O	O
culminating	O	O
in	O	O
CD80	O	O
expression	O	O
.	O	O

Our	O	O
findings	O	O
of	O	O
distinct	O	O
signal	O	O
transducer	O	O
requirements	O	O
,	O	O
with	O	O
the	O	O
added	O	O
consequences	O	O
of	O	O
cross-talk	O	O
,	O	O
offers	O	O
an	O	O
explanation	O	O
for	O	O
variable	O	O
modulation	O	O
of	O	O
costimulatory	O	O
molecule	O	O
expression	O	O
in	O	O
response	O	O
to	O	O
diverse	O	O
physiological	O	O
stimuli	O	O
.	O	O

Importantly	O	O
,	O	O
these	O	O
results	O	O
also	O	O
reveal	O	O
how	O	O
concentration	O	O
threshold	O	O
barriers	O	O
for	O	O
recruitment	O	O
of	O	O
individual	O	O
second	O	O
messengers	O	O
can	O	O
be	O	O
overcome	O	O
by	O	O
constructive	O	O
convergence	O	O
of	O	O
signaling	O	O
modules	O	O
.	O	O

The	O	O
role	O	O
of	O	O
Epstein-Barr	O	O
virus	O	O
in	O	O
neoplastic	O	O
transformation	O	O
.	O	O

In	O	O
this	O	O
review	O	O
,	O	O
we	O	O
focus	O	O
on	O	O
new	O	O
data	O	O
from	O	O
basic	O	O
,	O	O
translational	O	O
and	O	O
clinical	O	O
research	O	O
relating	O	O
to	O	O
the	O	O
Epstein-Barr	O	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
.	O	O

Beside	O	O
its	O	O
well-known	O	O
tropism	O	O
for	O	O
B	B-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
epithelial	B-cell_type	O
cells	I-cell_type	O
,	O	O
EBV	O	O
also	O	O
infects	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
monocytes	B-cell_type	O
and	O	O
granulocytes	O	O
.	O	O

After	O	O
primary	B-protein	O
infection	O	O
,	O	O
EBV	O	O
persists	O	O
throughout	O	O
the	O	O
life	O	O
span	O	O
in	O	O
resting	O	O
memory	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
,	O	O
from	O	O
where	O	O
it	O	O
is	O	O
reactivated	O	O
upon	O	O
breakdown	O	O
of	O	O
cellular	O	O
immunity	O	O
.	O	O

In	O	O
the	O	O
process	O	O
of	O	O
neoplastic	O	O
transformation	O	O
,	O	O
the	O	O
EBV-encoded	B-protein	O
latent	I-protein	O
membrane	I-protein	O
protein	I-protein	O
1	O	O
(	O	O
LMP1	B-protein	O
)	O	O
oncogene	O	O
represents	O	O
the	O	O
major	O	O
driving	O	O
force	O	O
.	O	O

LMP1	O	O
acts	O	O
like	O	O
a	O	O
constitutively	O	O
activated	O	O
receptor	O	O
of	O	O
the	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
receptor	I-protein	O
family	I-protein	O
and	O	O
allows	O	O
the	O	O
amplification	O	O
or	O	O
bypassing	O	O
of	O	O
physiological	O	O
regulatory	O	O
signals	O	O
through	O	O
direct	O	O
and	O	O
indirect	O	O
interactions	O	O
with	O	O
proteins	O	O
of	O	O
the	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
receptor-associated	I-protein	O
factor	I-protein	O
(	O	O
TRAF	B-protein	O
)	O	O
family	O	O
.	O	O

TRAF2	O	O
-mediated	O	O
NF-kappaB	O	O
activation	O	O
,	O	O
AP-1	B-protein	O
induction	O	O
and	O	O
JAK3	O	O
/	O	O
STAT	O	O
activation	O	O
may	O	O
result	O	O
in	O	O
sustained	O	O
proliferation	O	O
leading	O	O
to	O	O
lymphoma	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
LMP1	O	O
to	O	O
suppress	O	O
germinal	O	O
center	O	O
formation	O	O
and	O	O
its	O	O
capacity	O	O
to	O	O
mediate	O	O
its	O	O
own	O	O
transcriptional	O	O
activation	O	O
shed	O	O
new	O	O
light	O	O
on	O	O
the	O	O
pathogenesis	O	O
of	O	O
EBV-associated	B-protein	O
latency	I-protein	O
type	I-protein	O
II	I-protein	O
lymphoproliferations	O	O
like	O	O
Hodgkin	O	O
's	O	O
disease	O	O
and	O	O
angioimmunoblastic	O	O
lymphadenopathy	O	O
.	O	O

The	O	O
carboxy	O	O
terminus	O	O
of	O	O
LMP1	O	O
is	O	O
also	O	O
a	O	O
reliable	O	O
marker	O	O
for	O	O
individual	O	O
EBV	O	O
strain	O	O
identification	O	O
and	O	O
thus	O	O
offers	O	O
new	O	O
possibilities	O	O
in	O	O
tracing	O	O
the	O	O
molecular	O	O
events	O	O
leading	O	O
to	O	O
posttransplant	O	O
lymphoproliferative	O	O
disorders	O	O
(	O	O
PTLDs	O	O
)	O	O
.	O	O

Cytotoxic	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
directed	O	O
against	O	O
well-characterized	O	O
epitopes	O	O
of	O	O
EBV	O	O
latency	O	O
genes	O	O
represent	O	O
an	O	O
already	O	O
successful	O	O
and	O	O
promising	O	O
therapeutic	O	O
approach	O	O
to	O	O
EBV-associated	O	O
lymphomas	O	O
,	O	O
in	O	O
particular	O	O
PTLDs	O	O

Interferon-alpha	O	O
drives	O	O
T	O	O
cell-mediated	O	O
immunopathology	O	O
in	O	O
the	O	O
intestine	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
interferon	B-protein	O
(	O	O
IFN	B-protein	O
)	O	O
-alpha	O	O
to	O	O
induce	O	O
autoimmunity	O	O
and	O	O
exacerbate	O	O
Th1	O	O
diseases	O	O
is	O	O
well	O	O
known	O	O
.	O	O

We	O	O
have	O	O
recently	O	O
described	O	O
enhanced	O	O
expression	O	O
of	O	O
IFN-alpha	O	O
in	O	O
the	O	O
mucosa	O	O
of	O	O
patients	O	O
with	O	O
celiac	O	O
disease	O	O
(	O	O
CD	B-protein	O
)	O	O
,	O	O
a	O	O
gluten-sensitive	O	O
Th1-mediated	O	O
enteropathy	O	O
,	O	O
characterized	O	O
by	O	O
villous	O	O
atrophy	O	O
and	O	O
crypt	O	O
cell	O	O
hyperplasia	O	O
.	O	O

Previous	O	O
studies	O	O
from	O	O
this	O	O
laboratory	O	O
have	O	O
shown	O	O
that	O	O
T	O	O
cell	O	O
activation	O	O
in	O	O
explant	O	O
cultures	O	O
of	O	O
human	O	O
fetal	O	O
gut	O	O
can	O	O
also	O	O
result	O	O
in	O	O
villous	O	O
atrophy	O	O
and	O	O
crypt	O	O
cell	O	O
hyperplasia	O	O
.	O	O

We	O	O
have	O	O
,	O	O
therefore	O	O
,	O	O
examined	O	O
changes	O	O
that	O	O
take	O	O
place	O	O
in	O	O
explant	O	O
cultures	O	O
of	O	O
human	O	O
fetal	O	O
gut	O	O
after	O	O
activation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
with	O	O
anti-CD3	O	O
and/or	O	O
IFN-alpha	O	O
.	O	O

We	O	O
show	O	O
that	O	O
activation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
with	O	O
anti-CD3	O	O
alone	O	O
elicits	O	O
a	O	O
small	O	O
IFN-gamma	B-protein	O
and	O	O
TNF-alpha	O	O
response	O	O
with	O	O
no	O	O
tissue	O	O
injury	O	O
.	O	O

Similarly	O	O
,	O	O
no	O	O
changes	O	O
are	O	O
seen	O	O
in	O	O
explants	O	O
cultured	O	O
with	O	O
IFN-alpha	O	O
alone	O	O
.	O	O

However	O	O
,	O	O
addition	O	O
of	O	O
IFN-alpha	O	O
with	O	O
anti-CD3	O	O
results	O	O
in	O	O
enhanced	O	O
Th1	O	O
response	O	O
and	O	O
crypt	O	O
cell	O	O
hyperplasia	O	O
.	O	O

This	O	O
is	O	O
associated	O	O
with	O	O
enhanced	O	O
phosphorylation	O	O
of	O	O
STAT1	B-protein	O
,	O	O
STAT3	B-protein	O
,	O	O
and	O	O
Fyn	B-protein	O
,	O	O
a	O	O
Src	B-protein	O
homology	I-protein	O
tyrosine	I-protein	O
kinase	I-protein	O
,	O	O
which	O	O
interacts	O	O
with	O	O
both	O	O
TCR	B-protein	O
and	O	O
IFN-alpha	O	O
signal	O	O
components	O	O
.	O	O

Together	O	O
these	O	O
data	O	O
indicate	O	O
that	O	O
IFN-alpha	O	O
can	O	O
facilitate	O	O
activation	O	O
of	O	O
Th1-reactive	B-cell_type	O
cells	I-cell_type	O
in	O	O
the	O	O
gut	O	O
and	O	O
drive	O	O
immunopathology	O	O
.	O	O

Suppression	O	O
of	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
alpha	I-protein	O
production	O	O
by	O	O
cAMP	O	O
in	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
:	O	O
dissociation	O	O
with	O	O
mRNA	B-RNA	O
level	O	O
and	O	O
independent	O	O
of	O	O
interleukin-10	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Elevation	O	O
of	O	O
cellular	O	O
cAMP	O	O
inhibits	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
-stimulated	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
alpha	I-protein	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
production	O	O
and	O	O
increases	O	O
the	O	O
expression	O	O
of	O	O
interleukin	B-protein	O
(	I-protein	O
IL	I-protein	O
)	O	O
-10	O	O
in	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
.	O	O

TNF-alpha	O	O
gene	O	O
expression	O	O
obligates	O	O
activation	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
nuclear	I-protein	O
factor	I-protein	O
kappaB	I-protein	O
(	O	O
NF-kappaB	B-protein	O
)	O	O
.	O	O

Exogenous	O	O
IL-10	O	O
inhibits	O	O
NF-kappaB	O	O
in	O	O
monocytes	B-cell_type	O
and	O	O
thus	O	O
attenuates	O	O
TNF-alpha	O	O
production	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
role	O	O
of	O	O
endogenous	O	O
IL-10	B-protein	O
in	O	O
the	O	O
regulation	O	O
of	O	O
NF-kappaB	O	O
activation	O	O
and	O	O
TNF-alpha	O	O
production	O	O
in	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
by	O	O
cAMP	O	O
.	O	O

METHODS	O	O
:	O	O
Human	O	O
monocytes	O	O
were	O	O
stimulated	O	O
with	O	O
Escherichia	O	O
coli	O	O
LPS	O	O
(	O	O
100	O	O
ng/ml	O	O
)	O	O
with	O	O
and	O	O
without	O	O
forskolin	O	O
(	O	O
FSK	O	O
,	O	O
50	O	O
microM	O	O
)	O	O
or	O	O
dibutyryl	O	O
cyclic	O	O
AMP	O	O
(	O	O
dbcAMP	O	O
,	O	O
100	O	O
microM	O	O
)	O	O
.	O	O

Cytokine	O	O
(	O	O
TNF-alpha	B-protein	O
and	O	O
IL-10	B-protein	O
)	O	O
release	O	O
was	O	O
measured	O	O
by	O	O
immunoassay	O	O
.	O	O

TNF-alpha	O	O
mRNA	I-RNA	O
was	O	O
measured	O	O
by	O	O
reverse	O	O
transcription	O	O
polymerase	O	O
chain	O	O
reaction	O	O
,	O	O
and	O	O
NF-kappaB	O	O
DNA	O	O
binding	O	O
activity	O	O
was	O	O
assessed	O	O
by	O	O
gel	O	O
mobility	O	O
shift	O	O
assay	O	O
.	O	O

RESULTS	O	O
:	O	O
cAMP-elevating	O	O
agents	O	O
inhibited	O	O
LPS-stimulated	O	O
TNF-alpha	O	O
release	O	O
(	O	O
0.77	O	O
+/-	O	O
0.13	O	O
ng/10	O	O
(	O	O
6	O	O
)	O	O
cells	O	O
in	O	O
LPS	O	O
+	O	O
dbcAMP	O	O
and	O	O
0.68	O	O
+/-	O	O
0.19	O	O
ng/10	O	O
(	O	O
6	O	O
)	O	O
cells	O	O
in	O	O
LPS	O	O
+	O	O
FSK	O	O
,	O	O
both	O	O
P	O	O
<	O	O
0.05	O	O
vs	O	O
1.61	O	O
+/-	O	O
0.34	O	O
ng/10	O	O
(	O	O
6	O	O
)	O	O
cells	O	O
in	O	O
LPS	O	O
alone	O	O
)	O	O
.	O	O

Conversely	O	O
,	O	O
cAMP	O	O
enhanced	O	O
LPS-stimulated	O	O
IL-10	B-protein	O
release	O	O
(	O	O
100	O	O
+/-	O	O
21.5	O	O
pg/10	O	O
(	O	O
6	O	O
)	O	O
cells	O	O
in	O	O
LPS	O	O
+	O	O
dbcAMP	O	O
and	O	O
110	O	O
+/-	O	O
25.2	O	O
pg/10	O	O
(	O	O
6	O	O
)	O	O
cells	O	O
in	O	O
LPS	O	O
+	O	O
FSK	O	O
,	O	O
both	O	O
P	O	O
<	O	O
0.05	O	O
vs	O	O
53.3	O	O
+/-	O	O
12.8	O	O
pg/10	O	O
(	O	O
6	O	O
)	O	O
cells	O	O
in	O	O
LPS	O	O
alone	O	O
)	O	O
.	O	O

Neither	O	O
TNF-alpha	O	O
mRNA	B-RNA	O
expression	O	O
nor	O	O
NF-kappaB	O	O
activation	O	O
stimulated	O	O
by	O	O
LPS	O	O
was	O	O
inhibited	O	O
by	O	O
the	O	O
cAMP-elevating	O	O
agents	O	O
.	O	O

Neutralization	O	O
of	O	O
IL-10	B-protein	O
with	O	O
a	O	O
specific	O	O
antibody	O	O
did	O	O
not	O	O
attenuate	O	O
the	O	O
effect	O	O
of	O	O
cAMP-elevating	O	O
agents	O	O
on	O	O
TNF-alpha	O	O
production	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
results	O	O
indicate	O	O
that	O	O
cAMP	O	O
inhibits	O	O
LPS-stimulated	O	O
TNF-alpha	O	O
production	O	O
through	O	O
a	O	O
posttranscriptional	O	O
mechanism	O	O
that	O	O
is	O	O
independent	O	O
of	O	O
endogenous	O	O
IL-10	B-protein	O
.	O	O

Copyright	O	O
2001	O	O
Academic	O	O
Press	O	O
.	O	O

Activation	O	O
of	O	O
the	O	O
p21	B-DNA	O
(	I-DNA	O
CIP1/WAF1	I-DNA	O
)	I-DNA	O
promoter	I-DNA	O
by	O	O
bone	O	O
morphogenetic	O	O
protein-2	O	O
in	O	O
mouse	B-cell_type	O
B	I-cell_type	O
lineage	I-cell_type	O
cells	I-cell_type	O
.	O	O

BMPs	O	O
exert	O	O
a	O	O
negative	O	O
growth	O	O
effect	O	O
on	O	O
various	O	O
types	O	O
of	O	O
cells	I-cell_type	O
.	O	O

We	O	O
have	O	O
previously	O	O
reported	O	O
that	O	O
BMP-2	O	O
inhibited	O	O
the	O	O
growth	O	O
of	O	O
HS-72	B-cell_line	O
mouse	I-cell_line	O
hybridoma	I-cell_line	O
cells	I-cell_line	O
by	O	O
inducing	O	O
p21	O	O
(	O	O
CIP1/WAF1	B-protein	O
)	O	O
expression	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
demonstrated	O	O
that	O	O
BMP-2	O	O
activated	O	O
the	O	O
mouse	B-DNA	O
p21	I-DNA	O
(	O	O
CIP1/WAF1	B-DNA	O
)	I-DNA	O
promoter	I-DNA	O
in	O	O
HS-72	B-cell_type	O
cells	I-cell_type	O
,	O	O
and	O	O
that	O	O
a	O	O
29-base	O	O
pair	O	O
(	O	O
b	B-DNA	O
)	O	O
region	O	O
of	O	O
the	O	O
promoter	B-DNA	O
(	I-DNA	O
-1928/-1900	I-DNA	O
relative	O	O
to	O	O
the	O	O
TATA	B-DNA	O
box	I-DNA	O
)	O	O
,	O	O
conserved	O	O
between	O	O
mice	O	O
and	O	O
humans	O	O
,	O	O
was	O	O
responsive	O	O
to	O	O
BMP-2	O	O
as	O	O
well	O	O
as	O	O
expression	O	O
of	O	O
Smad1	B-protein	O
,	O	O
Smad4	O	O
,	O	O
and	O	O
constitutively	O	O
active	O	O
mutants	O	O
of	O	O
BMP	B-protein	O
type	I-protein	O
I	I-protein	O
receptors	I-protein	O
.	O	O

Furthermore	O	O
,	O	O
an	O	O
oligonucleotide	O	O
containing	O	O
the	O	O
29-b	B-DNA	O
region	I-DNA	O
was	O	O
found	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
Smad4	O	O
and	O	O
phosphorylated	O	O
Smad1	O	O
in	O	O
the	O	O
nuclear	O	O
extract	O	O
of	O	O
BMP-2	O	O
-stimulated	O	O
HS-72	B-cell_type	O
cells	I-cell_type	O
.	O	O

These	O	O
results	O	O
suggested	O	O
that	O	O
BMP-2	O	O
might	O	O
activate	B-protein	O
p21	I-protein	O
(	O	O
CIP1/WAF1	B-protein	O
)	O	O
transcription	O	O
by	O	O
inducing	O	O
a	O	O
binding	O	O
of	O	O
Smad4	B-protein	O
and	O	O
Smad1	O	O
to	O	O
the	O	O
29-b	B-DNA	O
region	I-DNA	O
in	O	O
HS-72	B-cell_type	O
cells	I-cell_type	O
.	O	O

Dendritic	O	O
cell	O	O
development	O	O
from	O	O
common	O	O
myeloid	B-cell_type	O
progenitors	I-cell_type	O
.	O	O

Dendritic	I-cell_line	O
cells	I-cell_line	O
(	O	O
DCs	O	O
)	O	O
are	O	O
professional	O	O
antigen-presenting	O	O
cells	O	O
which	O	O
both	O	O
initiate	O	O
adaptive	O	O
immune	O	O
responses	O	O
and	O	O
control	O	O
tolerance	O	O
to	O	O
self-antigens	O	O
.	O	O

It	O	O
has	O	O
been	O	O
suggested	O	O
that	O	O
these	O	O
different	O	O
effects	O	O
on	O	O
responder	B-cell_type	O
cells	I-cell_type	O
depend	O	O
on	O	O
subsets	O	O
of	O	O
DCs	O	O
arising	O	O
from	O	O
either	O	O
myeloid	O	O
or	O	O
lymphoid	O	O
hematopoietic	O	O
origins	O	O
.	O	O

In	O	O
this	O	O
model	O	O
,	O	O
CD8	O	O
alpha+	O	O
Mac-1-	O	O
DCs	O	O
are	O	O
supposed	O	O
to	O	O
be	O	O
of	O	O
lymphoid	O	O
while	O	O
CD8	O	O
alpha-	O	O
Mac-1+	O	O
DCs	O	O
are	O	O
supposed	O	O
to	O	O
be	O	O
of	O	O
myeloid	O	O
origin	O	O
.	O	O

Here	O	O
we	O	O
summarize	O	O
our	O	O
findings	O	O
that	O	O
both	O	O
CD8	O	O
alpha+	O	O
and	O	O
CD8	O	O
alpha-	O	O
DCs	O	O
can	O	O
arise	O	O
from	O	O
clonogenic	O	O
common	O	O
myeloid	O	O
progenitors	O	O
(	O	O
CMPs	O	O
)	O	O
in	O	O
both	O	O
thymus	O	O
and	O	O
spleen	O	O
.	O	O

Therefore	O	O
CD8	O	O
alpha	B-protein	O
expression	O	O
DCs	O	O
does	O	O
not	O	O
indicate	O	O
a	O	O
lymphoid	O	O
origin	O	O
and	O	O
differences	O	O
among	O	O
CD8	O	O
alpha+	O	O
and	O	O
CD8	O	O
alpha-	O	O
DCs	O	O
might	O	O
rather	O	O
reflect	O	O
maturation	O	O
status	O	O
than	O	O
ontogeny	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
transplantation	O	O
studies	O	O
,	O	O
it	O	O
seems	O	O
likely	O	O
that	O	O
most	O	O
of	O	O
the	O	O
DCs	O	O
in	O	O
secondary	O	O
lymphoid	O	O
organs	O	O
and	O	O
a	O	O
substantial	O	O
fraction	O	O
of	O	O
thymic	O	O
DCs	O	O
are	O	O
myeloid-derived	O	O
.	O	O

Macrophage	O	O
stimulation	O	O
with	O	O
Murabutide	O	O
,	O	O
an	O	O
HIV-suppressive	O	O
muramyl	O	O
peptide	O	O
derivative	O	O
,	O	O
selectively	O	O
activates	O	O
extracellular	O	O
signal-regulated	O	O
kinases	O	O
1	O	O
and	O	O
2	O	O
,	O	O
C/EBPbeta	O	O
and	O	O
STAT1	O	O
:	O	O
role	O	O
of	O	O
CD14	O	O
and	O	O
Toll-like	B-protein	O
receptors	I-protein	O
2	O	O
and	O	O
4	O	O
.	O	O

The	O	O
smallest	O	O
unit	O	O
of	O	O
bacterial	O	O
peptidoglycans	O	O
known	O	O
to	O	O
be	O	O
endowed	O	O
with	O	O
biological	O	O
activities	O	O
is	O	O
muramyl	O	O
dipeptide	O	O
(	O	O
MDP	O	O
)	O	O
.	O	O

A	O	O
clinically	O	O
acceptable	O	O
synthetic	O	O
derivative	O	O
of	O	O
MDP	O	O
,	O	O
namely	O	O
murabutide	O	O
(	O	O
MB	O	O
)	O	O
,	O	O
has	O	O
been	O	O
found	O	O
to	O	O
present	O	O
interesting	O	O
pharmacological	O	O
properties	O	O
and	O	O
to	O	O
suppress	O	O
HIV-1	O	O
replication	O	O
in	O	O
monocyte-derived	O	O
macrophages	O	O
(	O	O
MDM	O	O
)	O	O
.	O	O

We	O	O
have	O	O
addressed	O	O
the	O	O
signaling	O	O
events	O	O
activated	O	O
in	O	O
MDM	O	O
following	O	O
stimulation	O	O
with	O	O
either	O	O
MB	O	O
or	O	O
the	O	O
potent	O	O
immunostimulant	O	O
LPS	O	O
.	O	O

We	O	O
also	O	O
examined	O	O
whether	O	O
signaling	O	O
by	O	O
muramyl	O	O
peptides	O	O
involves	O	O
the	O	O
use	O	O
of	O	O
cell	O	O
surface	B-protein	O
receptors	I-protein	O
,	O	O
including	O	O
CD14	O	O
and	O	O
Toll-like	B-protein	O
receptor	I-protein	O
2	O	O
(	O	O
TLR2	O	O
)	O	O
or	O	O
TLR4	O	O
that	O	O
are	O	O
known	O	O
to	O	O
be	O	O
signal-transducing	O	O
receptors	O	O
for	O	O
other	O	O
bacterial	O	O
cell	O	O
wall	O	O
components	O	O
.	O	O

We	O	O
demonstrate	O	O
that	O	O
,	O	O
unlike	O	O
LPS	O	O
,	O	O
the	O	O
safe	O	O
immunomodulator	O	O
MB	O	O
selectively	O	O
activates	O	O
extracellular	O	O
signal-regulated	O	O
kinases	O	O
(	O	O
Erk	O	O
)	O	O
1/2	O	O
,	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
detectable	O	O
Jun	O	O
N-terminal	B-protein	O
kinase	I-protein	O
(	O	O
JNK	O	O
)	O	O
or	O	O
p38	O	O
mitogen-activated	O	O
kinase	O	O
activation	O	O
.	O	O

Furthermore	O	O
,	O	O
STAT1	B-protein	O
activation	O	O
but	O	O
weak	O	O
or	O	O
no	O	O
activation	O	O
of	O	O
STAT3	B-protein	O
or	O	O
STAT5	O	O
respectively	O	O
,	O	O
could	O	O
be	O	O
detected	O	O
in	O	O
MB-stimulated	O	O
MDM	O	O
.	O	O

Using	I-cell_line	O
MonoMac6	I-cell_line	O
cells	I-cell_line	O
,	O	O
we	O	O
observed	O	O
high	O	O
C/EBPbeta	O	O
and	O	O
AP-1	B-protein	O
but	O	O
weaker	O	O
and	O	O
transient	O	O
NF-kappaB	O	O
activation	O	O
by	O	O
MB	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
truncated	O	O
form	O	O
of	O	O
C/EBPbeta	O	O
,	O	O
known	O	O
to	O	O
repress	O	O
HIV-1	O	O
transcription	O	O
,	O	O
was	O	O
detected	O	O
in	O	O
extracts	O	O
from	O	O
MB-treated	B-cell_line	O
THP-1	I-cell_line	O
cells	I-cell_line	O
.	O	O

Surprisingly	O	O
,	O	O
neither	O	O
MB	O	O
nor	O	O
MDP	O	O
were	O	O
able	O	O
to	O	O
transduce	O	O
signals	O	O
via	O	O
CD14	O	O
and	O	O
TLR2	O	O
or	O	O
4	O	O
.	O	O

These	O	O
findings	O	O
present	O	O
major	O	O
differences	O	O
in	O	O
the	O	O
early	B-DNA	O
cell	O	O
activation	O	O
process	O	O
between	O	O
LPS	O	O
and	O	O
muramyl	O	O
peptides	O	O
,	O	O
and	O	O
strongly	O	O
argue	O	O
for	O	O
the	O	O
implication	O	O
of	O	O
co-receptors	O	O
other	O	O
than	O	O
TLR2	O	O
and	O	O
TLR4	O	O
in	O	O
mediating	O	O
the	O	O
signaling	O	O
events	O	O
induced	O	O
by	O	O
defined	O	O
subunits	O	O
of	O	O
bacterial	O	O
peptidoglycans	O	O
.	O	O

Nuclear	O	O
peroxisome	O	O
proliferator-activated	O	O
receptors	B-protein	O
alpha	I-protein	O
and	O	O
gamma	O	O
have	O	O
opposing	O	O
effects	O	O
on	O	O
monocyte	O	O
chemotaxis	O	O
in	O	O
endometriosis	O	O
.	O	O

The	O	O
peroxisome	B-protein	O
proliferator-activated	I-protein	O
receptors	I-protein	O
(	O	O
PPARs	B-protein	O
)	O	O
alpha	B-protein	O
and	O	O
gamma	O	O
are	O	O
nuclear	O	O
receptors	O	O
that	O	O
play	O	O
important	O	O
roles	O	O
in	O	O
inflammatory	O	O
diseases	O	O
like	O	O
ulcerative	O	O
colitis	O	O
and	O	O
arthritis	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
possible	O	O
role	O	O
of	O	O
PPARs	O	O
in	O	O
macrophage	O	O
attraction	O	O
into	O	O
the	O	O
peritoneal	O	O
cavity	O	O
of	O	O
patients	O	O
with	O	O
endometriosis	O	O
.	O	O

We	O	O
identified	O	O
PPAR-alpha	O	O
and	O	O
-gamma	O	O
messenger	O	O
RNA	O	O
by	O	O
RT-PCR	B-protein	O
and	O	O
protein	O	O
by	O	O
immunoblotting	O	O
of	O	O
lysates	O	O
of	O	O
peritoneal	B-cell_type	O
macrophages	I-cell_type	O
and	O	O
monocytic	B-cell_line	O
U937	I-cell_line	O
cells	I-cell_line	O
.	O	O

Using	O	O
immunocytochemistry	O	O
,	O	O
we	O	O
localized	O	O
PPAR-alpha	O	O
and	O	O
-gamma	O	O
within	O	O
the	O	O
nuclei	O	O
of	O	O
both	O	O
cell	I-cell_type	O
types	I-cell_type	O
.	O	O

Monocyte	O	O
chemotactic	O	O
activity	O	O
of	O	O
peritoneal	O	O
fluid	O	O
from	O	O
patients	O	O
with	O	O
endometriosis	O	O
was	O	O
quantified	O	O
in	O	O
Boyden	O	O
chambers	O	O
.	O	O

Migration	O	O
of	O	O
U937	B-cell_line	O
cells	I-cell_line	O
was	O	O
increased	O	O
by	O	O
WY	O	O
14643	O	O
and	O	O
reduced	O	O
by	O	O
rosiglitazone	O	O
.	O	O

Peritoneal	O	O
fluid	O	O
from	O	O
patients	O	O
with	O	O
endometriosis	O	O
activated	O	O
U937	B-cell_line	O
cells	I-cell_line	O
transiently	O	O
transfected	O	O
with	O	O
a	O	O
PPAR-alpha/GAL4	B-DNA	O
luciferase	I-DNA	O
reporter	I-DNA	O
.	O	O

By	O	O
contrast	O	O
,	O	O
peritoneal	O	O
fluid	O	O
did	O	O
not	O	O
cause	O	O
significant	O	O
activation	O	O
of	O	O
PPAR-gamma/GAL4	O	O
constructs	O	O
.	O	O

The	O	O
U937	B-cell_line	O
cells	I-cell_line	O
transiently	O	O
transfected	O	O
with	O	O
a	O	O
PPAR	B-DNA	O
response	I-DNA	O
element	I-DNA	O
luciferase	I-DNA	O
reporter	I-DNA	O
showed	O	O
disease	O	O
stage-dependent	O	O
up-regulation	O	O
when	O	O
treated	O	O
with	O	O
peritoneal	O	O
fluid	O	O
from	O	O
patients	O	O
with	O	O
endometriosis	O	O
.	O	O

Treatment	O	O
with	O	O
peritoneal	O	O
fluid	O	O
from	O	O
healthy	O	O
controls	O	O
down-regulated	O	O
PPAR	O	O
response	O	O
element	O	O
transactivation	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
peritoneal	O	O
fluid	O	O
of	O	O
endometriosis	O	O
patients	O	O
contains	O	O
activators	O	O
of	O	O
PPAR-alpha	O	O
that	O	O
stimulate	O	O
macrophage	O	O
chemotaxis	O	O
.	O	O

Inhibitors	O	O
of	O	O
PPAR-alpha	O	O
or	O	O
activators	B-protein	O
of	O	O
PPAR-gamma	O	O
could	O	O
be	O	O
developed	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
inflammation	O	O
associated	O	O
with	O	O
endometriosis	O	O
.	O	O

Long-term-impaired	O	O
expression	O	O
of	O	O
nuclear	B-protein	O
factor-kappa	I-protein	O
B	I-protein	O
and	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
in	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
of	O	O
trauma	O	O
patients	O	O
.	O	O

Nuclear	B-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
-kappa	O	O
B	O	O
expression	O	O
and	O	O
dimer	O	O
characteristics	O	O
were	O	O
studied	O	O
in	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
(	O	O
PBMCs	O	O
)	O	O
of	O	O
major-trauma	O	O
patients	O	O
and	O	O
healthy	O	O
controls	O	O
.	O	O

Analysis	O	O
of	O	O
PBMCs	O	O
on	O	O
days	O	O
1	O	O
,	O	O
3	O	O
,	O	O
5	O	O
,	O	O
and	O	O
10	O	O
after	O	O
trauma	O	O
revealed	O	O
that	O	O
expression	O	O
of	O	O
both	O	O
p65p50	B-protein	O
heterodimers	I-protein	O
and	O	O
p50p50	O	O
homodimers	O	O
was	O	O
significantly	O	O
reduced	O	O
compared	O	O
with	O	O
that	O	O
in	O	O
controls	O	O
.	O	O

In	O	O
vitro	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
stimulation	O	O
of	O	O
PBMCs	O	O
induced	O	O
NF-kappa	B-protein	O
B	I-protein	O
translocation	O	O
.	O	O

However	O	O
,	O	O
throughout	O	O
the	O	O
survey	O	O
,	O	O
p65p50	O	O
activation	O	O
remained	O	O
significantly	O	O
lower	O	O
in	O	O
trauma	O	O
patients	O	O
than	O	O
in	O	O
controls	O	O
.	O	O

After	O	O
LPS	O	O
stimulation	O	O
in	O	O
vitro	O	O
,	O	O
the	O	O
p65p50/p50p50	O	O
ratio	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
PBMCs	O	O
from	O	O
trauma	O	O
patients	O	O
than	O	O
from	O	O
healthy	O	O
controls	O	O
.	O	O

The	O	O
ex	O	O
vivo	O	O
expression	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
was	O	O
higher	O	O
in	O	O
PBMCs	O	O
of	O	O
controls	O	O
than	O	O
of	O	O
trauma	O	O
patients	O	O
.	O	O

LPS	O	O
did	O	O
not	O	O
induce	O	O
I	O	O
kappa	O	O
B	O	O
expression	O	O
in	O	O
PBMCs	O	O
from	O	O
trauma	O	O
patients	O	O
,	O	O
but	O	O
strong	O	O
induction	O	O
was	O	O
obtained	O	O
with	O	O
staphylococci	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
defect	O	O
is	O	O
not	O	O
universal	O	O
and	O	O
depends	O	O
on	O	O
the	O	O
nature	O	O
of	O	O
the	O	O
activating	B-protein	O
signal	I-protein	O
.	O	O

Although	O	O
no	O	O
direct	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
levels	O	O
of	O	O
interleukin-10	B-protein	O
or	O	O
transforming	B-protein	O
growth	I-protein	O
factor-beta	I-protein	O
and	O	O
NF-kappa	B-protein	O
B	I-protein	O
,	O	O
these	O	O
immunosuppressive	O	O
cytokines	B-protein	O
were	O	O
significantly	O	O
elevated	O	O
in	O	O
trauma	O	O
patients	O	O
by	O	O
10	O	O
days	O	O
after	O	O
admission	O	O
.	O	O

The	O	O
long-term	O	O
low-basal	O	O
and	O	O
LPS-induced	O	O
nuclear	O	O
translocation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
recalled	O	O
long-term	O	O
immunoparalysis	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
severe	O	O
inflammatory	O	O
stress	O	O
such	O	O
as	O	O
trauma	O	O
.	O	O

Hepatic	O	O
ischemia-reperfusion	O	O
injury	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
morbidity	O	O
associated	O	O
with	O	O
liver	O	O
transplantation	O	O
and	O	O
major	O	O
hepatic	O	O
resections	O	O
is	O	O
partly	O	O
a	O	O
result	O	O
of	O	O
ischemia-reperfusion	O	O
injury	O	O
.	O	O

DATA	O	O
SOURCES	O	O
:	O	O
The	O	O
entire	O	O
world	O	O
literature	O	O
on	O	O
the	O	O
subject	O	O
was	O	O
searched	O	O
via	O	O
Medline	O	O
.	O	O

Keywords	O	O
included	O	O
reperfusion	O	O
injury	O	O
,	O	O
transplantation	O	O
,	O	O
liver	O	O
resection	O	O
,	O	O
nitric	O	O
oxide	O	O
,	O	O
endothelin	O	O
,	O	O
cytokines	O	O
,	O	O
Kupffer	O	O
cells	O	O
,	O	O
ischemic/ischaemic	O	O
preconditioning	O	O
,	O	O
and	O	O
nuclear	B-protein	O
factor-kappa	I-protein	O
B	I-protein	O
.	O	O

CONCLUSIONS	O	O
:	O	O
An	O	O
imbalance	O	O
between	O	O
endothelin	O	O
and	O	O
nitric	O	O
oxide	O	O
levels	O	O
results	O	O
in	O	O
failure	O	O
of	O	O
the	O	O
hepatic	O	O
microcirculation	O	O
at	O	O
the	O	O
onset	O	O
of	O	O
reperfusion	O	O
.	O	O

Activation	O	O
of	O	O
nuclear	B-protein	O
factor-kappa	I-protein	O
B	I-protein	O
in	O	O
the	O	O
liver	O	O
promotes	O	O
proinflammatory	O	O
cytokine	B-protein	O
and	O	O
adhesion	O	O
molecule	O	O
synthesis	O	O
.	O	O

These	O	O
result	O	O
in	O	O
oxygen-derived	O	O
free	O	O
radical	O	O
production	O	O
and	O	O
neutrophil	O	O
recruitment	O	O
,	O	O
further	O	O
contributing	O	O
to	O	O
cellular	O	O
injury	O	O
.	O	O

Various	O	O
therapeutic	O	O
modalities	O	O
acting	O	O
on	O	O
the	O	O
above	O	O
mediators	O	O
have	O	O
been	O	O
successfully	O	O
used	O	O
to	O	O
attenuate	O	O
reperfusion	O	O
injury	O	O
in	O	O
animal	O	O
models	O	O
of	O	O
hepatic	O	O
transplantation	O	O
and	O	O
resection	O	O
.	O	O

Application	O	O
of	O	O
the	O	O
knowledge	O	O
gained	O	O
from	O	O
animal	O	O
models	O	O
of	O	O
hepatic	O	O
ischemia-reperfusion	O	O
to	O	O
the	O	O
clinical	O	O
setting	O	O
will	O	O
improve	O	O
the	O	O
outcome	O	O
of	O	O
hepatic	O	O
surgery	O	O
.	O	O

Down-regulation	O	O
of	O	O
IL-12	B-DNA	O
p40	I-DNA	O
gene	I-DNA	O
in	O	O
Plasmodium	O	O
berghei-infected	O	O
mice	O	O
.	O	O

We	O	O
analyzed	O	O
the	O	O
mechanism	O	O
that	O	O
causes	O	O
suppression	O	O
of	O	O
IL-12	B-protein	O
p40	O	O
gene	O	O
induction	O	O
during	O	O
Plasmodium	O	O
berghei	O	O
infection	O	O
.	O	O

Although	O	O
IL-12	B-protein	O
together	O	O
with	O	O
IFN-gamma	B-protein	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
protection	O	O
against	O	O
pathogenic	O	O
infection	O	O
,	O	O
the	O	O
IL-12	B-protein	O
p70	I-protein	O
protein	I-protein	O
production	O	O
of	O	O
infected	O	O
macrophages	O	O
is	O	O
lower	O	O
than	O	O
that	O	O
by	O	O
the	O	O
uninfected	O	O
macrophages	O	O
.	O	O

We	O	O
showed	O	O
in	O	O
the	O	O
present	O	O
study	O	O
that	O	O
the	O	O
induction	O	O
of	O	O
IL-12	B-DNA	O
p40	I-DNA	O
gene	I-DNA	O
but	O	O
not	O	O
IL-12	B-protein	O
p35	O	O
gene	O	O
in	O	O
macrophages	O	O
of	O	O
P.	O	O
berghei-infected	O	O
mice	O	O
was	O	O
profoundly	O	O
inhibited	O	O
.	O	O

The	O	O
inhibition	O	O
was	O	O
induced	O	O
by	O	O
interaction	O	O
with	O	O
macrophages	O	O
that	O	O
had	O	O
contacted	O	O
with	O	O
P.	O	O
berghei-infected	O	O
erythrocytes	O	O
and	O	O
was	O	O
mediated	O	O
by	O	O
a	O	O
soluble	B-protein	O
factor	I-protein	O
,	O	O
IL-10	B-protein	O
.	O	O

There	O	O
was	O	O
comparable	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
in	O	O
uninfected	B-cell_type	O
and	I-cell_type	O
infected	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
induction	O	O
of	O	O
IFN-regulatory	B-DNA	O
factor-1	I-DNA	O
gene	I-DNA	O
was	O	O
comparable	O	O
in	O	O
transcription	O	O
level	O	O
in	O	O
uninfected	O	O
and	O	O
infected	B-cell_type	O
cells	I-cell_type	O
,	O	O
while	O	O
the	O	O
unidentified	O	O
complex	O	O
formation	O	O
of	O	O
IFN-regulatory	O	O
factor-1	O	O
was	O	O
observed	O	O
in	O	O
infected	B-cell_type	O
cells	I-cell_type	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
inhibition	O	O
of	O	O
the	O	O
IL-12	B-DNA	O
p40	I-DNA	O
gene	I-DNA	O
induction	O	O
appeared	O	O
to	O	O
be	O	O
regulated	O	O
at	O	O
transcriptional	O	O
regulation	O	O
level	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

The	O	O
Friend	O	O
of	O	O
GATA	B-protein	O
proteins	I-protein	O
U-shaped	O	O
,	O	O
FOG-1	O	O
,	O	O
and	O	O
FOG-2	O	O
function	O	O
as	O	O
negative	O	O
regulators	O	O
of	O	O
blood	B-protein	O
,	O	O
heart	O	O
,	O	O
and	O	O
eye	O	O
development	O	O
in	O	O
Drosophila	O	O
.	O	O

Friend	O	O
of	O	O
GATA	B-protein	O
(	O	O
FOG	B-protein	O
)	I-protein	O
proteins	I-protein	O
regulate	O	O
GATA	O	O
factor-activated	O	O
gene	O	O
transcription	O	O
.	O	O

During	O	O
vertebrate	O	O
hematopoiesis	O	O
,	O	O
FOG	O	O
and	O	O
GATA	B-protein	O
proteins	O	O
cooperate	O	O
to	O	O
promote	O	O
erythrocyte	O	O
and	O	O
megakaryocyte	O	O
differentiation	O	O
.	O	O

The	O	O
Drosophila	O	O
FOG	I-protein	O
homologue	I-protein	O
U-shaped	I-protein	O
(	O	O
Ush	B-protein	O
)	O	O
is	O	O
expressed	O	O
similarly	O	O
in	O	O
the	O	O
blood	O	O
cell	O	O
anlage	O	O
during	O	O
embryogenesis	O	O
.	O	O

During	O	O
hematopoiesis	O	O
,	O	O
the	O	O
acute	O	O
myeloid	O	O
leukemia	O	O
1	O	O
homologue	O	O
Lozenge	O	O
and	O	O
Glial	B-cell_type	O
cells	I-cell_type	O
missing	O	O
are	O	O
required	O	O
for	O	O
the	O	O
production	O	O
of	O	O
crystal	B-cell_type	O
cells	I-cell_type	O
and	O	O
plasmatocytes	O	O
,	O	O
respectively	O	O
.	O	O

However	O	O
,	O	O
additional	O	O
factors	I-protein	O
have	O	O
been	O	O
predicted	O	O
to	O	O
control	O	O
crystal	O	O
cell	O	O
proliferation	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
show	O	O
that	O	O
Ush	O	O
is	O	O
expressed	O	O
in	O	O
hemocyte	O	O
precursors	O	O
and	O	O
plasmatocytes	O	O
throughout	O	O
embryogenesis	O	O
and	O	O
larval	O	O
development	O	O
,	O	O
and	O	O
the	O	O
GATA	B-protein	O
factor	I-protein	O
Serpent	O	O
is	O	O
essential	O	O
for	O	O
Ush	O	O
embryonic	O	O
expression	O	O
.	O	O

Furthermore	O	O
,	O	O
loss	O	O
of	O	O
ush	O	O
function	O	O
results	O	O
in	O	O
an	O	O
overproduction	O	O
of	O	O
crystal	B-cell_type	O
cells	I-cell_type	O
,	O	O
whereas	O	O
forced	O	O
expression	O	O
of	O	O
Ush	O	O
reduces	O	O
this	O	O
cell	O	O
population	O	O
.	O	O

Murine	O	O
FOG-1	O	O
and	O	O
FOG-2	O	O
also	O	O
can	O	O
repress	O	O
crystal	O	O
cell	O	O
production	O	O
,	O	O
but	O	O
a	O	O
mutant	O	O
version	O	O
of	O	O
FOG-2	O	O
lacking	O	O
a	O	O
conserved	O	O
motif	I-protein	O
that	O	O
binds	O	O
the	O	O
corepressor	B-protein	O
C-terminal	I-protein	O
binding	I-protein	O
protein	I-protein	O
fails	O	O
to	O	O
affect	O	O
the	O	O
cell	B-protein	O
lineage	I-protein	O
.	O	O

The	O	O
GATA	B-protein	O
factor	I-protein	O
Pannier	I-protein	O
(	O	O
Pnr	B-protein	O
)	O	O
is	O	O
required	O	O
for	O	O
eye	O	O
and	O	O
heart	O	O
development	O	O
in	O	O
Drosophila	O	O
.	O	O

When	O	O
Ush	O	O
,	O	O
FOG-1	O	O
,	O	O
FOG-2	O	O
,	O	O
or	O	O
mutant	O	O
FOG-2	O	O
is	O	O
coexpressed	O	O
with	O	O
Pnr	O	O
during	O	O
these	O	O
developmental	O	O
processes	O	O
,	O	O
severe	O	O
eye	O	O
and	O	O
heart	O	O
phenotypes	O	O
result	O	O
,	O	O
consistent	O	O
with	O	O
a	O	O
conserved	O	O
negative	O	O
regulation	O	O
of	O	O
Pnr	O	O
function	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
fly	B-protein	O
and	I-protein	O
mouse	I-protein	O
FOG	I-protein	O
proteins	I-protein	O
function	O	O
similarly	O	O
in	O	O
three	O	O
distinct	O	O
cellular	O	O
contexts	O	O
in	O	O
Drosophila	O	O
,	O	O
but	O	O
may	O	O
use	O	O
different	O	O
mechanisms	O	O
to	O	O
regulate	O	O
genetic	O	O
events	O	O
in	O	O
blood	O	O
vs	O	O
.	O	O
cardial	O	O
or	O	O
eye	O	O
cell	O	O
lineages	O	O

The	O	O
RING	B-protein	O
finger	I-protein	O
protein	I-protein	O
Siah-1	O	O
regulates	O	O
the	O	O
level	O	O
of	O	O
the	O	O
transcriptional	O	O
coactivator	O	O
OBF-1	O	O
.	O	O

The	O	O
transcriptional	O	O
coactivator	O	O
OBF-1	O	O
,	O	O
which	O	O
interacts	O	O
with	O	O
Oct-1	B-protein	O
and	O	O
Oct-2	O	O
and	O	O
the	O	O
octamer	B-DNA	O
site	I-DNA	O
DNA	O	O
,	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
critical	O	O
for	O	O
development	O	O
of	O	O
a	O	O
normal	O	O
immune	O	O
response	O	O
and	O	O
the	O	O
formation	O	O
of	O	O
germinal	O	O
centers	O	O
in	O	O
secondary	O	O
lymphoid	O	O
organs	O	O
.	O	O

Here	O	O
we	O	O
have	O	O
identified	O	O
the	O	O
RING	B-protein	O
finger	I-protein	O
protein	I-protein	O
Siah-1	O	O
as	O	O
a	O	O
protein	O	O
interacting	O	O
specifically	O	O
with	O	O
OBF-1	O	O
.	O	O

This	O	O
interaction	O	O
is	O	O
mediated	O	O
by	O	O
the	O	O
C-terminal	O	O
part	O	O
of	O	O
Siah-1	O	O
and	O	O
by	O	O
residues	O	O
in	O	O
the	O	O
N-terminus	O	O
of	O	O
OBF-1	O	O
,	O	O
partly	O	O
distinct	O	O
from	O	O
the	O	O
residues	O	O
required	O	O
for	O	O
formation	O	O
of	O	O
a	O	O
complex	O	O
with	O	O
the	O	O
Oct	B-protein	O
POU	I-protein	O
domains	I-protein	O
and	O	O
the	O	O
DNA	O	O
.	O	O

Interaction	O	O
between	O	O
Siah-1	O	O
and	O	O
OBF-1	O	O
leads	O	O
to	O	O
downregulation	O	O
of	O	O
OBF-1	B-protein	O
protein	I-protein	O
level	O	O
but	O	O
not	O	O
mRNA	O	O
,	O	O
and	O	O
to	O	O
a	O	O
corresponding	O	O
reduction	O	O
in	O	O
octamer	O	O
site-dependent	O	O
transcription	O	O
activation	O	O
.	O	O

Inhibition	O	O
of	O	O
the	O	O
ubiquitin-proteasome	O	O
pathway	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
leads	O	O
to	O	O
elevated	O	O
levels	O	O
of	O	O
OBF-1	B-protein	O
protein	I-protein	O
.	O	O

Furthermore	O	O
,	O	O
in	O	O
immunized	O	O
mice	O	O
,	O	O
OBF-1	O	O
protein	O	O
amounts	O	O
are	O	O
dramatically	O	O
increased	O	O
in	O	O
primary	B-cell_type	O
activated	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
,	O	O
without	O	O
concomitant	O	O
increase	O	O
in	O	O
OBF-1	O	O
mRNA	I-RNA	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
Siah-1	O	O
is	O	O
part	O	O
of	O	O
a	O	O
novel	O	O
regulatory	O	O
loop	O	O
controlling	O	O
the	O	O
level	O	O
of	O	O
OBF-1	O	O
protein	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
beta-catenin	O	O
--	O	O
TCF-1	O	O
pathway	O	O
ensures	O	O
CD4	B-protein	O
(	O	O
+	B-DNA	O
)	I-DNA	O
CD8	I-DNA	O
(	I-DNA	O
+	I-DNA	O
)	O	O
thymocyte	O	O
survival	O	O
.	O	O

The	O	O
association	O	O
of	O	O
trans-acting	B-protein	O
T	I-protein	O
cell	I-protein	O
factors	I-protein	O
(	O	O
TCFs	B-protein	O
)	I-protein	O
or	O	O
lymphoid	B-protein	O
enhancer	I-protein	O
factor	I-protein	O
1	O	O
(	O	O
LEF-1	O	O
)	O	O
with	O	O
their	O	O
coactivator	O	O
beta-catenin	O	O
mediates	O	O
transient	O	O
transcriptional	O	O
responses	O	O
to	O	O
extracellular	O	O
Wnt	O	O
signals	O	O
.	O	O

We	O	O
show	O	O
here	O	O
that	O	O
T	O	O
cell	O	O
maturation	O	O
depends	O	O
on	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
beta-catenin	B-DNA	O
--	I-DNA	O
binding	I-DNA	O
domain	I-DNA	O
in	O	O
TCF-1	O	O
.	O	O

This	O	O
domain	O	O
is	O	O
necessary	O	O
to	O	O
mediate	O	O
the	O	O
survival	O	O
of	O	O
immature	O	O
CD4	B-protein	O
(	I-protein	O
+	I-protein	O
)	I-protein	O
CD8	I-protein	O
(	O	O
+	O	O
)	O	O
double-positive	O	O
(	O	O
DP	B-protein	O
)	O	O
thymocytes	B-cell_type	O
.	O	O

Accelerated	O	O
spontaneous	O	O
thymocyte	O	O
death	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
TCF-1	O	O
correlates	O	O
with	O	O
aberrantly	O	O
low	O	O
expression	O	O
of	O	O
the	O	O
anti-apoptotic	B-protein	O
protein	I-protein	O
Bcl-x	I-protein	O
(	O	O
L	B-protein	O
)	O	O
.	O	O

Increasing	O	O
anti-apoptotic	O	O
effectors	O	O
in	O	O
thymocytes	O	O
by	O	O
the	O	O
use	O	O
of	O	O
a	O	O
Bcl-2	O	O
transgene	O	O
rescued	O	O
TCF-1-deficient	O	O
DP	O	O
thymocytes	B-cell_type	O
from	O	O
apoptosis	O	O
.	O	O

Thus	O	O
,	O	O
TCF-1	O	O
,	O	O
upon	O	O
association	O	O
with	O	O
beta-catenin	O	O
,	O	O
transiently	O	O
ensures	O	O
the	O	O
survival	O	O
of	O	O
immature	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
which	O	O
enables	O	O
them	O	O
to	O	O
generate	O	O
and	O	O
edit	B-protein	O
T	I-protein	O
cell	I-protein	O
receptor	I-protein	O
(	O	O
TCR	B-protein	O
)	O	O
alpha	O	O
chains	O	O
and	O	O
attempt	O	O
TCR	B-protein	O
-mediated	O	O
positive	O	O
selection	O	O
.	O	O

TRAIL/Apo2L	O	O
ligand	O	O
selectively	O	O
induces	O	O
apoptosis	O	O
and	O	O
overcomes	O	O
drug	O	O
resistance	O	O
in	O	O
multiple	O	O
myeloma	O	O
:	O	O
therapeutic	O	O
applications	O	O
.	O	O

Multiple	O	O
myeloma	O	O
(	O	O
MM	O	O
)	O	O
remains	O	O
incurable	O	O
and	O	O
novel	O	O
treatments	O	O
are	O	O
urgently	O	O
needed	O	O
.	O	O

Preclinical	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
evaluations	O	O
were	O	O
performed	O	O
to	O	O
assess	O	O
the	O	O
potential	O	O
therapeutic	O	O
applications	O	O
of	O	O
human	B-protein	O
recombinant	I-protein	O
tumor	I-protein	O
necrosis	I-protein	O
factor	I-protein	O
(	O	O
TNF	B-protein	O
)	O	O
-related	O	O
apoptosis-inducing	O	O
ligand/Apo2	O	O
ligand	O	O
(	O	O
TRAIL/Apo2L	O	O
)	O	O
in	O	O
MM	O	O
.	O	O

TRAIL/Apo2L	O	O
potently	O	O
induced	O	O
apoptosis	O	O
of	O	O
MM	B-cell_type	O
cells	I-cell_type	O
from	O	O
patients	O	O
and	O	O
the	O	O
majority	O	O
of	O	O
MM	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
,	O	O
including	O	O
cells	I-cell_type	O
sensitive	O	O
or	O	O
resistant	O	O
to	O	O
dexamethasone	O	O
(	O	O
Dex	B-protein	O
)	O	O
,	O	O
doxorubicin	O	O
(	O	O
Dox	O	O
)	O	O
,	O	O
melphalan	O	O
,	O	O
and	O	O
mitoxantrone	O	O
.	O	O

TRAIL/Apo2L	O	O
also	O	O
overcame	O	O
the	O	O
survival	O	O
effect	O	O
of	O	O
interleukin	O	O
6	O	O
on	O	O
MM	B-cell_type	O
cells	I-cell_type	O
and	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
survival	O	O
of	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
and	I-cell_type	O
bone	I-cell_type	O
marrow	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
and	O	O
purified	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
from	O	O
healthy	O	O
donors	O	O
.	O	O

The	O	O
status	O	O
of	O	O
the	O	O
TRAIL	B-protein	O
receptors	I-protein	O
(	O	O
assessed	O	O
by	O	O
immunoblotting	O	O
and	O	O
flow	O	O
cytometry	O	O
)	O	O
could	O	O
not	O	O
predict	O	O
TRAIL	O	O
sensitivity	O	O
of	O	O
MM	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
anti-MM	O	O
activity	O	O
of	O	O
TRAIL/Apo2L	O	O
was	O	O
confirmed	O	O
in	O	O
nu/xid/bg	O	O
mice	O	O
xenografted	O	O
with	O	O
human	B-cell_type	O
MM	I-cell_type	O
cells	I-cell_type	O
;	O	O
TRAIL	O	O
(	O	O
500	O	O
microg	O	O
intraperitoneally	O	O
daily	O	O
for	O	O
14	O	O
days	O	O
)	O	O
was	O	O
well	O	O
tolerated	O	O
and	O	O
significantly	O	O
suppressed	O	O
the	O	O
growth	O	O
of	O	O
plasmacytomas	O	O
.	O	O

Dox	O	O
up-regulated	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
TRAIL	B-DNA	O
receptor	I-DNA	O
death	I-DNA	O
receptor	I-DNA	O
5	I-DNA	O
(	O	O
DR5	B-protein	O
)	O	O
and	O	O
synergistically	O	O
enhanced	O	O
the	O	O
effect	O	O
of	O	O
TRAIL	O	O
not	O	O
only	O	O
against	O	O
MM	O	O
cells	O	O
sensitive	O	O
to	O	O
,	O	O
but	O	O
also	O	O
against	O	O
those	O	O
resistant	O	O
to	O	O
,	O	O
Dex-	O	O
or	O	O
Dox-induced	O	O
apoptosis	O	O
.	O	O

Nuclear	B-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
-kappaB	O	O
inhibitors	O	O
,	O	O
such	O	O
as	O	O
SN50	O	O
(	O	O
a	O	O
cell-permeable	O	O
inhibitor	O	O
of	O	O
the	O	O
nuclear	B-protein	O
translocation	O	O
and	O	O
transcriptional	O	O
activity	O	O
of	O	O
NF-kappaB	B-protein	O
)	O	O
or	O	O
the	O	O
proteasome	O	O
inhibitor	O	O
PS-341	O	O
,	O	O
enhanced	O	O
the	O	O
proapoptotic	O	O
activity	O	O
of	O	O
TRAIL/Apo2L	O	O
against	O	O
TRAIL-sensitive	O	O
MM	O	O
cells	O	O
,	O	O
whereas	O	O
SN50	O	O
reversed	O	O
the	O	O
TRAIL	O	O
resistance	O	O
of	O	O
ARH-77	O	O
and	O	O
IM-9	O	O
MM	B-cell_type	O
cells	I-cell_type	O
.	O	O

Importantly	O	O
,	O	O
normal	B-cell_type	O
B	I-cell_type	O
lymphocytes	I-cell_type	O
were	O	O
not	O	O
sensitized	O	O
to	O	O
TRAIL	O	O
by	O	O
either	O	O
Dox	O	O
,	O	O
SN50	O	O
,	O	O
or	O	O
PS-341	O	O
.	O	O

These	O	O
preclinical	O	O
studies	O	O
suggest	O	O
that	O	O
TRAIL/Apo2L	O	O
can	O	O
overcome	O	O
conventional	O	O
drug	O	O
resistance	O	O
and	O	O
provide	O	O
the	O	O
basis	O	O
for	O	O
clinical	O	O
trials	O	O
of	O	O
TRAIL	O	O
-based	O	O
treatment	O	O
regimens	O	O
to	O	O
improve	O	O
outcome	O	O
in	O	O
patients	O	O
with	O	O
MM	O	O
.	O	O

(	O	O
Blood.	O	O
2001	O	O
;	O	O
98	O	O
:	O	O
795-804	O	O
)	O	O

CD28	O	O
costimulation	O	O
is	O	O
required	O	O
not	O	O
only	O	O
to	O	O
induce	O	O
IL-12	B-protein	O
receptor	O	O
but	O	O
also	O	O
to	O	O
render	O	O
janus	O	O
kinases/STAT4	O	O
responsive	O	O
to	O	O
IL-12	O	O
stimulation	O	O
in	O	O
TCR-triggered	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
activation	O	O
of	O	O
resting	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
for	O	O
the	O	O
acquisition	O	O
of	O	O
various	O	O
functions	O	O
depends	O	O
on	O	O
whether	O	O
CD28	O	O
costimulatory	O	O
signals	O	O
are	O	O
provided	O	O
upon	O	O
T	O	O
cell	O	O
receptor	O	O
stimulation	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O	O
how	O	O
CD28	O	O
costimulation	O	O
functions	O	O
to	O	O
allow	O	O
TCR	B-protein	O
-triggered	O	O
resting	O	O
T	O	O
cells	O	O
to	O	O
acquire	O	O
IL-12	O	O
responsiveness	O	O
.	O	O

When	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
are	O	O
stimulated	O	O
with	O	O
low	O	O
doses	O	O
of	O	O
anti-CD3	B-protein	O
mAb	B-protein	O
,	O	O
CD28	B-protein	O
costimulation	O	O
was	O	O
required	O	O
for	O	O
the	O	O
optimal	O	O
levels	O	O
of	O	O
IL-12	B-protein	O
receptor	I-protein	O
(	O	O
IL-12R	B-protein	O
)	O	O
expression	O	O
.	O	O

However	O	O
,	O	O
stimulation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
with	O	O
high	O	O
doses	O	O
of	O	O
anti-CD3	O	O
alone	O	O
induced	O	O
comparable	O	O
levels	O	O
of	O	O
IL-12R	O	O
expression	O	O
to	O	O
those	O	O
induced	O	O
upon	O	O
CD28	O	O
costimulation	O	O
.	O	O

Nevertheless	O	O
,	O	O
there	O	O
was	O	O
a	O	O
substantial	O	O
difference	O	O
in	O	O
IL-12	O	O
responsiveness	O	O
between	O	O
these	O	O
two	O	O
groups	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
:	O	O
compared	O	O
to	O	O
anti-CD28-costimulated	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
T	B-cell_type	O
cells	I-cell_type	O
that	O	O
were	O	O
not	O	O
costimulated	O	O
with	O	O
anti-CD28	O	O
exhibited	O	O
decreased	O	O
levels	O	O
of	O	O
Janus	B-protein	O
kinases	I-protein	O
(	O	O
JAK	B-protein	O
)	O	O
JAK2/TYK2	O	O
and	O	O
STAT4	B-protein	O
phosphorylation	O	O
and	O	O
IFN-y	O	O
production	O	O
following	O	O
IL-12	O	O
stimulation	O	O
.	O	O

Importantly	O	O
,	O	O
STAT6	O	O
phosphorylation	O	O
following	O	O
IL-4	O	O
stimulation	O	O
was	O	O
not	O	O
decreased	O	O
in	O	O
anti-CD28-uncostimulated	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

These	O	O
resutls	O	O
indicate	O	O
that	O	O
CD28	O	O
costimulation	O	O
not	O	O
only	O	O
contributes	O	O
to	O	O
up-regulating	O	O
IL-12R	O	O
expression	O	O
but	O	O
is	O	O
also	O	O
required	O	O
to	O	O
render	O	O
JAKs/STAT4	O	O
responsive	O	O
to	O	O
IL-12	O	O
stimulation	O	O
.	O	O

Constitutively	O	O
activated	O	O
Akt-1	O	O
is	O	O
vital	O	O
for	O	O
the	O	O
survival	O	O
of	O	O
human	O	O
monocyte-differentiated	O	O
macrophages	O	O
.	O	O

Role	O	O
of	O	O
Mcl-1	O	O
,	O	O
independent	O	O
of	O	O
nuclear	B-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
-kappaB	O	O
,	O	O
Bad	O	O
,	O	O
or	O	O
caspase	O	O
activation	O	O
.	O	O

Recent	O	O
data	O	O
from	O	O
mice	O	O
deficient	O	O
for	O	O
phosphatase	O	O
and	O	O
tensin	O	O
homologue	O	O
deleted	O	O
from	O	O
chromosome	O	O
10	O	O
or	O	O
src	O	O
homology	O	O
2	O	O
domain-containing	O	O
5	O	O
'	O	O
inositol	O	O
phosphatase	O	O
,	O	O
phosphatases	O	O
that	O	O
negatively	O	O
regulate	O	O
the	O	O
phosphatidylinositol	O	O
3-kinase	O	O
(	O	O
PI3K	O	O
)	O	O
pathway	O	O
,	O	O
revealed	O	O
an	O	O
increased	O	O
number	O	O
of	O	O
macrophages	O	O
in	O	O
these	O	O
animals	O	O
,	O	O
suggesting	O	O
an	O	O
essential	O	O
role	O	O
for	O	O
the	O	O
PI3K	O	O
pathway	O	O
for	O	O
macro-phage	O	O
survival	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
focused	O	O
on	O	O
the	O	O
role	O	O
of	O	O
the	O	O
PI3K-regulated	B-protein	O
serine/threonine	I-protein	O
kinase	I-protein	O
Akt-1	O	O
in	O	O
modulating	O	O
macrophage	O	O
survival	O	O
.	O	O

Akt-1	O	O
was	O	O
constitutively	O	O
activated	O	O
in	O	O
human	O	O
macrophages	O	O
and	O	O
addition	O	O
of	O	O
the	O	O
PI3K	O	O
inhibitor	O	O
,	O	O
LY294002	O	O
,	O	O
suppressed	O	O
the	O	O
activation	O	O
of	O	O
Akt-1	B-protein	O
and	O	O
induced	O	O
cell	O	O
death	O	O
.	O	O

Furthermore	O	O
,	O	O
suppression	O	O
of	O	O
Akt-1	O	O
by	O	O
inhibition	O	O
of	O	O
PI3K	O	O
or	O	O
a	O	O
dominant	B-protein	O
negative	I-protein	O
(	O	O
DN	B-protein	O
)	O	O
Akt-1	O	O
resulted	O	O
in	O	O
loss	O	O
of	O	O
mitochondrial	O	O
transmembrane	O	O
potential	O	O
,	O	O
activation	O	O
of	O	O
caspases-9	O	O
and	O	O
-3	O	O
,	O	O
and	O	O
DNA	O	O
fragmentation	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
PI3K	O	O
inhibition	O	O
were	O	O
reversed	O	O
by	O	O
the	O	O
ectopic	O	O
expression	O	O
of	O	O
constitutively	O	O
activated	O	O
Akt-1	I-protein	O
or	O	O
Bcl-x	O	O
(	O	O
L	B-protein	O
)	O	O
.	O	O

Inhibition	O	O
of	O	O
PI3K	O	O
/Akt-1	O	O
pathway	O	O
either	O	O
by	O	O
LY294002	O	O
or	O	O
DN	O	O
Akt-1	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
constitutive	O	O
or	O	O
inducible	O	O
activation	O	O
of	O	O
nuclear	B-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
-kappaB	O	O
in	O	O
human	O	O
macrophages	O	O
.	O	O

However	O	O
,	O	O
after	O	O
inhibition	O	O
of	O	O
the	O	O
PI3K	O	O
/	I-protein	O
Akt-1	I-protein	O
pathway	O	O
,	O	O
a	O	O
marked	O	O
decrease	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
antiapoptotic	B-protein	O
molecule	I-protein	O
Mcl-1	O	O
,	O	O
but	O	O
not	O	O
other	O	O
Bcl-2	O	O
family	O	O
members	O	O
was	O	O
observed	O	O
,	O	O
and	O	O
Mcl-1	O	O
rescued	O	O
macrophages	O	O
from	O	O
LY294002-induced	O	O
cell	O	O
death	O	O
.	O	O

Further	O	O
,	O	O
inhibition	O	O
of	O	O
Mcl-1	O	O
by	O	O
antisense	O	O
oligonucleotides	O	O
,	O	O
also	O	O
resulted	O	O
in	O	O
macrophage	O	O
apoptosis	O	O
.	O	O

Thus	O	O
,	O	O
our	O	O
findings	O	O
demonstrate	O	O
that	O	O
the	O	O
constitutive	O	O
activation	O	O
of	O	O
Akt-1	O	O
regulates	O	O
macrophage	O	O
survival	O	O
through	O	O
Mcl-1	O	O
,	O	O
which	O	O
is	O	O
independent	O	O
of	O	O
caspases	O	O
,	O	O
NF-kappaB	O	O
,	O	O
or	O	O
Bad	O	O
.	O	O

GRbeta	O	O
expression	O	O
in	O	O
nasal	O	O
polyp	B-cell_type	O
inflammatory	I-cell_type	O
cells	I-cell_type	O
and	O	O
its	O	O
relationship	O	O
to	O	O
the	O	O
anti-inflammatory	O	O
effects	O	O
of	O	O
intranasal	O	O
fluticasone	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Nasal	O	O
polyposis	O	O
disease	O	O
is	O	O
an	O	O
inflammatory	O	O
disorder	O	O
with	O	O
intense	O	O
eosinophilic	O	O
infiltration	O	O
of	O	O
respiratory	O	O
mucosa	O	O
that	O	O
is	O	O
often	O	O
difficult	O	O
to	O	O
control	O	O
with	O	O
topical	O	O
steroids	O	O
.	O	O

Recent	O	O
evidence	O	O
suggests	O	O
that	O	O
overexpression	O	O
of	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
splice	O	O
variant	O	O
GRbeta	O	O
in	O	O
inflammatory	B-cell_type	O
cells	I-cell_type	O
might	O	O
contribute	O	O
to	O	O
steroid	O	O
insensitivity	O	O
in	O	O
diseases	O	O
such	O	O
as	O	O
asthma	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
purposes	O	O
of	O	O
this	O	O
investigation	O	O
were	O	O
to	O	O
determine	O	O
whether	O	O
nasal	O	O
polyp	O	O
(	O	O
NP	O	O
)	O	O
inflammatory	O	O
cells	O	O
overexpress	O	O
GRbeta	O	O
and	O	O
to	O	O
examine	O	O
whether	O	O
GRbeta	O	O
overexpression	O	O
is	O	O
associated	O	O
with	O	O
insensitivity	O	O
to	O	O
the	O	O
potent	O	O
topical	O	O
steroid	O	O
fluticasone	O	O
propionate	O	O
(	O	O
FP	O	O
)	O	O
.	O	O

METHODS	O	O
:	O	O
Biopsies	O	O
were	O	O
obtained	O	O
from	O	O
10	O	O
subjects	O	O
with	O	O
NPs	O	O
before	O	O
and	O	O
4	O	O
weeks	O	O
after	O	O
treatment	O	O
with	O	O
intranasal	O	O
FP	O	O
.	O	O

Middle	O	O
turbinates	O	O
biopsies	O	O
from	O	O
6	O	O
healthy	O	O
,	O	O
nonallergic	O	O
subjects	O	O
served	O	O
as	O	O
normal	O	O
controls	O	O
.	O	O

Biopsies	O	O
were	O	O
immunostained	O	O
for	O	O
inflammatory	O	O
cell	O	O
markers	O	O
as	O	O
well	O	O
as	O	O
GRbeta	O	O
and	O	O
probed	O	O
for	O	O
various	O	O
cytokine	B-RNA	O
mRNA	I-RNA	O
.	O	O

The	O	O
anti-inflammatory	O	O
response	O	O
to	O	O
FP	O	O
was	O	O
examined	O	O
in	O	O
relation	O	O
to	O	O
pretreatment	O	O
levels	O	O
of	O	O
GRbeta	O	O
expression	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
total	O	O
numbers	O	O
of	O	O
inflammatory	B-cell_type	O
cells	I-cell_type	O
were	O	O
increased	O	O
in	O	O
NPs	O	O
.	O	O

The	O	O
percentage	O	O
of	O	O
inflammatory	B-cell_type	O
cells	I-cell_type	O
expressing	O	O
GRbeta	O	O
was	O	O
also	O	O
increased	O	O
(	O	O
40.5	O	O
%	O	O
+/-	O	O
19.2	O	O
%	O	O
vs	O	O
16.1	O	O
%	O	O
+/-	O	O
4.0	O	O
%	O	O
,	O	O
P	O	O
=.009	O	O
)	O	O
.	O	O

GRbeta	O	O
expression	O	O
in	O	O
NPs	O	O
was	O	O
almost	O	O
exclusive	O	O
to	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
eosinophils	B-cell_type	O
,	O	O
and	O	O
macrophages	O	O
.	O	O

An	O	O
inverse	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
baseline	O	O
inflammatory	O	O
cell	O	O
GRbeta	O	O
expression	O	O
and	O	O
the	O	O
reduction	O	O
after	O	O
FP	O	O
treatment	O	O
in	O	O
EG2-positive	O	O
eosinophils	B-cell_type	O
,	O	O
CD4-positive	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
endothelial	O	O
VCAM-1	O	O
expression	O	O
,	O	O
and	O	O
IL-4	B-cell_line	O
mRNA-positive	I-cell_line	O
cells	I-cell_line	O
.	O	O

NPs	O	O
that	O	O
were	O	O
``	O	O
FP-insensitive	O	O
''	O	O
in	O	O
terms	O	O
of	O	O
suppression	O	O
of	O	O
eosinophil	O	O
numbers	O	O
(	O	O
major	B-protein	O
basic	I-protein	O
protein	I-protein	O
-positive	O	O
)	O	O
had	O	O
a	O	O
significantly	O	O
greater	O	O
percentage	O	O
of	O	O
GRbeta-positive	B-cell_type	O
inflammatory	I-cell_type	O
cells	I-cell_type	O
,	O	O
a	O	O
higher	O	O
ratio	O	O
of	O	O
GRbeta-positive/GRalpha-positive	B-cell_type	O
cells	I-cell_type	O
,	O	O
and	O	O
increased	O	O
numbers	O	O
of	O	O
GRbeta-positive	B-protein	O
eosinophils	I-protein	O
and	O	O
macrophages	O	O
in	O	O
comparison	O	O
with	O	O
those	O	O
that	O	O
were	O	O
``	O	O
FP-sensitive.	O	O
''	O	O

``	O	O
FP-insensitive	O	O
''	O	O
NPs	O	O
also	O	O
demonstrated	O	O
a	O	O
higher	O	O
percentage	O	O
of	O	O
IL-5-positive	B-cell_type	O
inflammatory	I-cell_type	O
cells	I-cell_type	O
expressing	O	O
GRbeta	O	O
before	O	O
and	O	O
after	O	O
FP	O	O
treatment	O	O
.	O	O

CONCLUSION	O	O
:	O	O
GRbeta	O	O
expression	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
marker	O	O
of	O	O
steroid	O	O
insensitivity	O	O
in	O	O
NPs	O	O
.	O	O

Expression	O	O
of	O	O
GRbeta	O	O
by	O	O
NP	B-cell_line	O
inflammatory	I-cell_line	O
cells	I-cell_line	O
,	O	O
particularly	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
eosinophils	B-protein	O
,	O	O
might	O	O
render	O	O
them	I-DNA	O
resistant	O	O
to	O	O
suppression	O	O
by	O	O
topical	O	O
steroids	O	O
and	O	O
thereby	O	O
contribute	O	O
to	O	O
persistent	O	O
NP	O	O
inflammation	O	O
.	O	O

Transcriptional	O	O
regulation	O	O
of	O	O
galectin-10	B-protein	O
(	O	O
eosinophil	B-protein	O
Charcot-Leyden	I-protein	O
crystal	I-protein	O
protein	I-protein	O
)	O	O
:	O	O
a	O	O
GC	O	O
box	O	O
(	O	O
-44	O	O
to	O	O
-50	O	O
)	O	O
controls	O	O
butyric	O	O
acid	O	O
induction	O	O
of	O	O
gene	O	O
expression	O	O
.	O	O

Galectin-10	O	O
(	O	O
gal-10	B-protein	O
,	O	O
also	O	O
known	O	O
as	O	O
Charcot-Leyden	O	O
crystal	O	O
protein	O	O
)	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
galectin	B-protein	O
family	I-protein	O
of	O	O
beta-galactoside	B-protein	O
binding	I-protein	O
proteins	I-protein	O
that	O	O
is	O	O
expressed	O	O
uniquely	O	O
in	O	O
eosinophilic	O	O
and	O	O
basophilic	O	O
leukocytes	O	O
.	O	O

To	O	O
gain	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
galectin	B-DNA	O
gene	I-DNA	O
expression	O	O
,	O	O
we	O	O
present	O	O
an	O	O
analysis	O	O
of	O	O
the	O	O
transcriptional	O	O
regulation	O	O
of	O	O
the	O	O
gene	O	O
encoding	O	O
gal-10	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
minimal	B-DNA	O
promoter	I-DNA	O
revealed	O	O
nine	O	O
consensus-binding	O	O
sites	O	O
for	O	O
transcription	B-protein	O
factors	I-protein	O
,	O	O
including	O	O
several	O	O
that	O	O
are	O	O
also	O	O
found	O	O
in	O	O
the	O	O
minimal	O	O
promoters	O	O
of	O	O
galectins	B-protein	O
-1	I-protein	O
,	O	O
-2	O	O
,	O	O
and	O	O
-3	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
gal-10	O	O
promoter	O	O
activity	O	O
after	O	O
disruption	O	O
of	O	O
either	O	O
the	O	O
GC	O	O
box	O	O
(	O	O
-44	O	O
to	O	O
-50	O	O
)	O	O
or	O	O
the	O	O
Oct	B-DNA	O
site	I-DNA	O
(	O	O
-255	O	O
to	O	O
-261	O	O
)	O	O
suggests	O	O
that	O	O
these	O	O
sites	O	O
,	O	O
along	O	O
with	O	O
the	O	O
previously	O	O
characterized	O	O
GATA	O	O
and	O	O
EoTF	O	O
sites	O	O
,	O	O
are	O	O
necessary	O	O
for	O	O
full	O	O
promoter	O	O
activity	O	O
.	O	O

By	O	O
supershift	O	O
analysis	O	O
,	O	O
we	O	O
demonstrate	O	O
binding	O	O
of	O	O
the	O	O
transcription	B-protein	O
factors	I-protein	O
Sp1	B-protein	O
and	O	O
Oct1	O	O
to	O	O
the	O	O
consensus	B-DNA	O
GC	I-DNA	O
box	I-DNA	O
and	O	O
the	O	O
Oct	B-DNA	O
site	I-DNA	O
,	O	O
respectively	O	O
.	O	O

Similar	O	O
to	O	O
gal-1	O	O
,	O	O
gal-10	O	O
expression	O	O
is	O	O
induced	O	O
by	O	O
butyric	O	O
acid	O	O
,	O	O
an	O	O
effect	O	O
that	O	O
is	O	O
lost	O	O
upon	O	O
ablation	O	O
of	O	O
the	O	O
GC	O	O
box	O	O
.	O	O

Additionally	O	O
,	O	O
we	O	O
demonstrate	O	O
AML3	O	O
binding	O	O
to	O	O
the	O	O
consensus	B-DNA	O
AML	I-DNA	O
site	I-DNA	O
and	O	O
YY1	O	O
binding	O	O
to	O	O
the	O	O
Inr	B-DNA	O
sequence	I-DNA	O
,	O	O
both	O	O
elements	B-DNA	O
functioning	O	O
as	O	O
silencers	O	O
in	O	O
the	O	O
gal-10	B-DNA	O
promoter	I-DNA	O
.	O	O

Tumour-stromal	O	O
interactions	O	O
.	O	O

Role	O	O
of	O	O
the	O	O
stroma	O	O
in	O	O
mammary	O	O
development	O	O
.	O	O

Mammary	O	O
development	O	O
depends	O	O
on	O	O
branching	O	O
morphogenesis	O	O
,	O	O
namely	O	O
the	O	O
bifurcation	O	O
and	O	O
extension	O	O
of	O	O
ductal	B-protein	O
growth	I-protein	O
points	I-protein	O
(	O	O
end	B-protein	O
buds	I-protein	O
)	O	O
and	O	O
secretory	O	O
lobules	O	O
into	O	O
a	O	O
more	O	O
or	O	O
less	O	O
fatty	O	O
stroma	O	O
.	O	O

Because	O	O
breast	O	O
carcinomas	O	O
are	O	O
overwhelmingly	O	O
ductal	O	O
in	O	O
origin	O	O
,	O	O
this	O	O
review	O	O
focuses	O	O
on	O	O
stromal	O	O
influences	O	O
guiding	O	O
postnatal	O	O
ductal	O	O
development	O	O
and	O	O
there	O	O
is	O	O
only	O	O
the	O	O
briefest	O	O
account	O	O
of	O	O
the	O	O
role	O	O
of	O	O
embryonic	B-protein	O
stroma	I-protein	O
(	O	O
mesenchyme	B-protein	O
)	O	O
.	O	O

The	O	O
stroma	O	O
as	O	O
the	O	O
necessary	O	O
target	O	O
for	O	O
endocrine	O	O
mammogens	O	O
and	O	O
the	O	O
source	O	O
of	O	O
stimulatory	B-protein	O
growth	I-protein	O
factors	I-protein	O
is	O	O
described	O	O
and	O	O
the	O	O
importance	O	O
of	O	O
mammary	O	O
epithelium-induced	O	O
modifications	O	O
of	O	O
the	O	O
periductal	B-protein	O
stroma	I-protein	O
is	O	O
emphasized	O	O
.	O	O

Evidence	O	O
is	O	O
presented	O	O
that	O	O
if	O	O
they	O	O
are	O	O
to	O	O
grow	O	O
,	O	O
end	O	O
buds	O	O
must	O	O
condition	O	O
proximal	O	O
fatty	O	O
stroma	O	O
by	O	O
recruiting	O	O
white	B-cell_type	O
blood	I-cell_type	O
cells	I-cell_type	O
as	O	O
well	O	O
as	O	O
inducing	O	O
stromal	O	O
cell	O	O
division	O	O
and	O	O
,	O	O
possibly	O	O
,	O	O
estrogen	O	O
receptors	O	O
.	O	O

The	O	O
induction	O	O
of	O	O
a	O	O
fibrous	O	O
stromal	O	O
tunic	O	O
around	O	O
the	O	O
end	O	O
bud	O	O
is	O	O
described	O	O
and	O	O
its	O	O
likely	O	O
role	O	O
as	O	O
a	O	O
complex	O	O
ductal	O	O
morphogen	O	O
is	O	O
discussed	O	O
;	O	O
a	O	O
possible	O	O
role	O	O
in	O	O
growth	O	O
inhibition	O	O
is	O	O
also	O	O
considered	O	O
.	O	O

Although	O	O
the	O	O
signals	O	O
governing	O	O
fibrotic	O	O
induction	O	O
,	O	O
ductal	O	O
morphogenesis	O	O
,	O	O
and	O	O
growth	O	O
inhibition	O	O
are	O	O
unknown	O	O
,	O	O
a	O	O
role	O	O
for	O	O
transforming	B-protein	O
growth	I-protein	O
factor-beta	I-protein	O
is	O	O
highly	O	O
likely	O	O
and	O	O
is	O	O
discussed	O	O
.	O	O

Finally	O	O
,	O	O
a	O	O
need	O	O
for	O	O
new	O	O
conceptual	O	O
and	O	O
experimental	O	O
approaches	O	O
to	O	O
understanding	O	O
stromal-epithelial	O	O
signaling	O	O
is	O	O
discussed	O	O
.	O	O

Adipophilin	O	O
is	O	O
a	O	O
sensitive	O	O
marker	O	O
for	O	O
lipid	O	O
loading	O	O
in	O	O
human	B-cell_type	O
blood	I-cell_type	O
monocytes	I-cell_type	O
.	O	O

Adipophilin	O	O
,	O	O
a	O	O
marker	O	O
of	O	O
lipid	O	O
accumulation	O	O
initially	O	O
described	O	O
in	O	O
adipocytes	O	O
,	O	O
was	O	O
recently	O	O
shown	O	O
to	O	O
be	O	O
induced	O	O
in	O	O
macrophage	O	O
foam	B-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
found	O	O
that	O	O
even	O	O
freshly	O	O
isolated	B-protein	O
blood	I-protein	O
monocytes	I-protein	O
express	O	O
adipophilin	O	O
and	O	O
that	O	O
the	O	O
amount	O	O
of	O	O
adipophilin	B-protein	O
protein	I-protein	O
is	O	O
variable	O	O
in	O	O
monocytes	B-cell_type	O
from	O	O
different	O	O
healthy	O	O
individuals	O	O
.	O	O

However	O	O
,	O	O
the	O	O
physiological	O	O
expression	O	O
of	O	O
adipophilin	O	O
does	O	O
not	O	O
correlate	O	O
with	O	O
the	O	O
levels	O	O
of	O	O
free	B-protein	O
fatty	I-protein	O
acids	I-protein	O
,	O	O
cholesterylesters	O	O
or	O	O
free	B-protein	O
cholesterol	O	O
.	O	O

Enzymatically	O	O
modified	O	O
low-density	O	O
lipoprotein	O	O
(	O	O
E-LDL	O	O
)	O	O
induces	O	O
rapid	O	O
foam	O	O
cell	O	O
formation	O	O
in	O	O
monocytes	B-cell_type	O
and	O	O
upregulates	O	O
adipophilin	O	O
mRNA	O	O
and	O	O
protein	O	O
within	O	O
2	O	O
h	O	O
of	O	O
incubation	O	O
.	O	O

This	O	O
rapid	O	O
induction	O	O
of	O	O
adipophilin	O	O
is	O	O
accompanied	O	O
by	O	O
a	O	O
significant	O	O
increase	O	O
of	O	O
free	B-protein	O
fatty	I-protein	O
acids	I-protein	O
in	O	O
monocytes	B-cell_type	O
incubated	O	O
with	O	O
E-LDL	O	O
.	O	O

Adipophilin	O	O
facilitates	O	O
the	O	O
uptake	O	O
of	O	O
free	B-protein	O
fatty	I-protein	O
acids	I-protein	O
,	O	O
and	O	O
here	O	O
we	O	O
demonstrate	O	O
that	O	O
free	O	O
fatty	O	O
acids	O	O
increase	O	O
is	O	O
related	O	O
to	O	O
the	O	O
early	O	O
upregulation	O	O
of	O	O
adipophilin	O	O
expression	O	O
in	O	O
blood	B-cell_type	O
monocytes	I-cell_type	O
.	O	O

Fatty	O	O
acids	B-protein	O
are	O	O
ligands	O	O
for	O	O
peroxisome	O	O
proliferator-activated	O	O
receptor-gamma	O	O
(	O	O
PPARgamma	O	O
)	O	O
,	O	O
and	O	O
the	O	O
upregulation	O	O
of	O	O
adipophilin	O	O
mRNA	I-RNA	O
by	O	O
PPARgamma	O	O
agonists	O	O
like	O	O
15d-PGJ	O	O
(	O	O
2	O	O
)	O	O
and	O	O
ciglitazone	O	O
indicates	O	O
that	O	O
PPARgamma	O	O
may	O	O
mediate	O	O
the	O	O
induction	O	O
of	O	O
adipophilin	O	O
expression	O	O
in	O	O
human	B-cell_type	O
blood	I-cell_type	O
monocytes	I-cell_type	O
.	O	O

Constitutive	O	O
expression	O	O
of	O	O
MHC	B-DNA	O
class	I-DNA	O
II	I-DNA	O
genes	I-DNA	O
in	O	O
melanoma	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
results	O	O
from	O	O
the	O	O
transcription	O	O
of	O	O
class	B-protein	O
II	I-protein	O
transactivator	O	O
abnormally	O	O
initiated	O	O
from	O	O
its	O	O
B	B-DNA	O
cell-specific	I-DNA	O
promoter	I-DNA	O
.	O	O

In	O	O
melanoma	O	O
cell	O	O
lines	O	O
,	O	O
two	O	O
different	O	O
patterns	O	O
of	O	O
MHC	B-protein	O
class	O	O
II	O	O
expression	O	O
have	O	O
been	O	O
described	O	O
,	O	O
either	O	O
an	O	O
IFN	O	O
gamma-inducible	O	O
expression	O	O
of	O	O
HLA-DR	O	O
and	O	O
HLA-DP	O	O
,	O	O
with	O	O
a	O	O
faint	O	O
or	O	O
null	O	O
expression	O	O
of	O	O
HLA-DQ	B-protein	O
,	O	O
resembling	O	O
that	O	O
described	O	O
for	O	O
melanocytes	O	O
,	O	O
or	O	O
a	O	O
constitutive	O	O
expression	O	O
,	O	O
i.e.	O	O
,	O	O
IFN-gamma	B-protein	O
independent	O	O
,	O	O
of	O	O
all	O	O
three	O	O
HLA-D	O	O
isotypes	O	O
.	O	O

As	O	O
this	O	O
latter	O	O
phenotype	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
a	O	O
more	O	O
rapid	O	O
progression	O	O
of	O	O
melanoma	O	O
tumors	O	O
,	O	O
we	O	O
have	O	O
analyzed	O	O
in	O	O
different	O	O
melanoma	O	O
cell	O	O
lines	O	O
the	O	O
molecular	O	O
mechanisms	O	O
leading	O	O
to	O	O
this	O	O
abnormal	O	O
pattern	O	O
of	O	O
MHC	O	O
class	O	O
II	O	O
expression	O	O
.	O	O

In	O	O
agreement	O	O
with	O	O
the	O	O
evidence	O	O
of	O	O
a	O	O
coordinate	O	O
transcription	O	O
of	O	O
the	O	O
HLA-D	B-DNA	O
genes	I-DNA	O
in	O	O
these	O	O
cell	I-cell_line	O
lines	I-cell_line	O
,	O	O
we	O	O
have	O	O
shown	O	O
the	O	O
constitutive	O	O
expression	O	O
of	O	O
CIITA	B-DNA	O
(	I-DNA	O
class	I-DNA	O
II	I-DNA	O
transactivator	I-DNA	O
)	O	O
transcripts	O	O
,	O	O
CIITA	B-DNA	O
being	O	O
known	O	O
as	O	O
the	O	O
master	O	O
switch	O	O
of	O	O
MHC	B-protein	O
class	I-protein	O
II	I-protein	O
expression	O	O
.	O	O

Unexpectedly	O	O
,	O	O
these	O	O
transcripts	O	O
initiate	O	O
from	O	O
promoter	O	O
III	O	O
of	O	O
the	O	O
CIITA	B-DNA	O
gene	I-DNA	O
,	O	O
a	O	O
promoter	O	O
that	O	O
is	O	O
mainly	O	O
used	O	O
constitutively	O	O
in	O	O
B	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

This	O	O
expression	O	O
was	O	O
further	O	O
shown	O	O
to	O	O
occur	O	O
through	O	O
factor	I-protein	O
(	O	O
s	O	O
)	O	O
acting	O	O
on	O	O
the	O	O
enhancer	B-DNA	O
located	O	O
upstream	O	O
of	O	O
CIITA	B-DNA	O
promoter	I-DNA	O
III	O	O
,	O	O
which	O	O
was	O	O
previously	O	O
described	O	O
in	O	O
epithelioid	B-cell_type	O
cells	I-cell_type	O
as	O	O
an	O	O
IFN-gamma-response	O	O
sequence	O	O
.	O	O

The	O	O
hypothesis	O	O
of	O	O
a	O	O
general	O	O
abnormality	O	O
of	O	O
the	O	O
IFN-gamma	B-protein	O
transduction	O	O
pathway	O	O
was	O	O
dismissed	O	O
.	O	O

Constitutive	O	O
transcription	O	O
of	O	O
CIITA	B-DNA	O
from	O	O
promoter	I-DNA	O
III	O	O
having	O	O
been	O	O
observed	O	O
in	O	O
unrelated	O	O
melanoma	O	O
cell	I-cell_line	O
lines	I-cell_line	O
,	O	O
we	O	O
propose	O	O
the	O	O
hypothesis	O	O
that	O	O
this	O	O
phenomenon	O	O
might	O	O
not	O	O
be	O	O
a	O	O
random	O	O
event	O	O
,	O	O
but	O	O
could	O	O
be	O	O
linked	O	O
to	O	O
the	O	O
neoplasic	O	O
state	O	O
of	O	O
the	O	O
melanoma	B-cell_type	O
cells	I-cell_type	O

Caspase	O	O
-mediated	O	O
calcineurin	O	O
activation	O	O
contributes	O	O
to	O	O
IL-2	O	O
release	O	O
during	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

Calcineurin	O	O
,	O	O
a	O	O
Ca	O	O
(	O	O
2+	B-protein	O
)	I-protein	O
/calmodulin-dependent	I-protein	O
Ser/Thr	I-protein	O
phosphatase	I-protein	O
(	I-protein	O
protein	I-protein	O
phosphatase	I-protein	O
2B	I-protein	O
)	O	O
,	O	O
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
IL-2	O	O
production	O	O
during	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

It	O	O
has	O	O
been	O	O
previously	O	O
reported	O	O
that	O	O
IL-2	O	O
release	O	O
in	O	O
activated	O	O
Jurkat	O	O
T	O	O
requires	O	O
caspase-like	O	O
activity	O	O
(	O	O
Posmantur	O	O
et	O	O
al.	O	O
(	O	O
1998	O	O
)	O	O
Exp.	O	O
Cell.	O	O
Res.	O	O
244	O	O
,	O	O
302-309	O	O
)	O	O
.	O	O

We	O	O
report	O	O
here	O	O
that	O	O
the	O	O
60-kDa	O	O
catalytic	O	O
subunit	O	O
of	O	O
calcineurin	B-protein	O
A	O	O
(	O	O
Cn	O	O
A	O	O
)	O	O
was	O	O
partially	O	O
cleaved	O	O
to	O	O
a	O	O
45-kDa	O	O
form	O	O
in	O	O
phytohemagglutinin	O	O
A	O	O
(	O	O
PHA	O	O
)	O	O
or	O	O
phorbol	O	O
ester	O	O
+	O	O
ionomycin	O	O
(	O	O
P	O	O
+	O	O
I	I-cell_line	O
)	O	O
-activated	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
.	O	O

In	O	O
parallel	O	O
,	O	O
proteolytic	O	O
activation	O	O
of	O	O
upstream	B-protein	O
caspases	I-protein	O
(	O	O
caspase-8	B-protein	O
and	I-protein	O
-9	I-protein	O
)	O	O
as	O	O
well	O	O
as	O	O
effector	O	O
caspase-3	O	O
was	O	O
also	O	O
observed	O	O
.	O	O

Cn	O	O
A	O	O
cleavage	O	O
was	O	O
caspase	O	O
mediated	O	O
,	O	O
since	O	O
it	O	O
was	O	O
inhibitable	O	O
by	O	O
pan-caspase	O	O
inhibitor	O	O
Cbz-Asp-CH	O	O
(	O	O
2	O	O
)	O	O
OC	O	O
(	O	O
O	O	O
)	O	O
-2	O	O
,	O	O
6-dichlorobenzene	O	O
(	O	O
Z-D-DCB	O	O
)	O	O
.	O	O

Cn	O	O
A	O	O
cleavage	O	O
was	O	O
also	O	O
observed	O	O
when	O	O
purified	O	O
calcineurin	O	O
was	O	O
digested	O	O
in	O	O
vitro	O	O
with	O	O
caspase-3	O	O
.	O	O

Truncated	O	O
Cn	O	O
A	O	O
was	O	O
associated	O	O
with	O	O
enhanced	O	O
phosphatase	O	O
activity	O	O
and	O	O
reduced	O	O
calmodulin	O	O
sensitivity	O	O
.	O	O

Furthermore	O	O
,	O	O
in	O	O
PHA	O	O
or	O	O
P	O	O
+	O	O
I-activated	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
,	O	O
dephosphorylation	O	O
of	O	O
calcineurin	O	O
substrate	O	O
NFATc	O	O
(	O	O
a	O	O
transcription	B-protein	O
factor	I-protein	O
known	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
transactivation	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
gene	I-DNA	O
)	O	O
,	O	O
was	O	O
also	O	O
suppressed	O	O
by	O	O
Z-D-DCB	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
results	O	O
suggest	O	O
that	O	O
caspase-mediated	O	O
cleavage	O	O
of	O	O
Cn	O	O
A	O	O
contributes	O	O
to	O	O
IL-2	B-protein	O
production	O	O
during	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

Copyright	O	O
2001	O	O
Academic	O	O
Press	O	O
.	O	O

Maturation	O	O
of	O	O
human	B-cell_type	O
dendritic	I-cell_type	O
cells	I-cell_type	O
as	O	O
sulfasalazine	O	O
target	O	O
.	O	O

AIM	O	O
:	O	O
Sulfasalazine	O	O
,	O	O
a	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
drug	O	O
,	O	O
is	O	O
effective	O	O
in	O	O
treating	O	O
some	O	O
autoimmune	O	O
diseases	O	O
,	O	O
but	O	O
its	O	O
mechanism	O	O
of	O	O
action	O	O
is	O	O
unclear	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
dendritic	B-cell_type	O
cells	I-cell_type	O
could	O	O
be	O	O
a	O	O
possible	O	O
target	O	O
of	O	O
the	O	O
drug	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
sulfasalazine	O	O
and	O	O
its	O	O
metabolites	B-protein	O
,	O	O
aminosalicylate	O	O
and	O	O
sulfapyridine	O	O
,	O	O
on	O	O
in	O	O
vitro	O	O
maturation	O	O
(	O	O
terminal	O	O
differentiation	O	O
)	O	O
of	O	O
human	B-cell_type	O
myeloid	I-cell_type	O
dendritic	I-cell_type	O
cells	I-cell_type	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
prepared	O	O
immature	O	O
dendritic	O	O
cells	O	O
by	O	O
incubating	O	O
CD14-positive	B-cell_type	O
cells	I-cell_type	O
in	O	O
the	O	O
presence	O	O
of	O	O
granulocyte-	O	O
macrophage	O	O
colony-stimulating	I-protein	O
factor	I-protein	O
and	O	O
interleukin	B-protein	O
(	I-protein	O
IL	I-protein	O
)	O	O
-4	O	O
.	O	O

The	O	O
cells	O	O
were	O	O
matured	O	O
by	O	O
addition	O	O
of	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
(	O	O
TNF	B-protein	O
)	O	O
-a	O	O
,	O	O
IL-1	B-protein	O
beta	I-protein	O
,	O	O
and	O	O
prostaglandin	O	O
E2	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
sulfasalazine	O	O
or	O	O
its	O	O
metabolites	O	O
--	O	O
aminosalicylate	O	O
and	O	O
sulfapyridine	O	O
,	O	O
or	O	O
their	O	O
combinations	O	O
.	O	O

We	O	O
quantified	O	O
the	O	O
effect	O	O
of	O	O
drugs	O	O
on	O	O
the	O	O
dendritic	O	O
cell	O	O
characteristics	O	O
,	O	O
such	O	O
as	O	O
stimulation	O	O
of	O	O
autologous	O	O
and	O	O
allogeneic	O	O
pan-T	O	O
cell	O	O
proliferation	O	O
,	O	O
surface	O	O
marker	O	O
phenotype	O	O
,	O	O
IL-12	B-protein	O
p40	O	O
subunit	O	O
secretion	O	O
,	O	O
and	O	O
activation	O	O
of	O	O
nuclear	B-protein	O
transcription	I-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
-kappa	O	O
B	O	O
.	O	O

RESULTS	O	O
:	O	O
Dendritic	O	O
cells	O	O
treated	O	O
with	O	O
sulfasalazine	O	O
(	O	O
1.25	O	O
micromol/L	O	O
or	O	O
2.5	O	O
micromol/L	O	O
)	O	O
could	O	O
not	O	O
stimulate	O	O
T	O	O
cells	O	O
(	O	O
p	O	O
<	O	O
0.028	O	O
,	O	O
two-sided	O	O
paired	O	O
t-test	O	O
)	O	O
.	O	O

In	O	O
distinction	O	O
to	O	O
drug-free	O	O
maturing	O	O
dendritic	B-cell_type	O
cells	I-cell_type	O
,	O	O
2.5	O	O
micromol/L	O	O
sulfasalazine	O	O
upregulated	O	O
the	O	O
levels	O	O
of	O	O
CD14	O	O
and	O	O
CD68	O	O
and	O	O
downregulated	O	O
the	O	O
levels	O	O
of	O	O
CD40	B-protein	O
,	O	O
CD80	O	O
,	O	O
and	O	O
CD83	O	O
(	O	O
for	O	O
all	O	O
CD	O	O
markers	O	O
,	O	O
p	O	O
<	O	O
0.03	O	O
for	O	O
difference	O	O
between	O	O
measurements	O	O
in	O	O
the	O	O
absence	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
sulfasalazine	O	O
)	O	O
.	O	O

From	O	O
concentration-dependent	O	O
changes	O	O
in	O	O
CD83	O	O
expression	O	O
,	O	O
we	O	O
found	O	O
an	O	O
apparent	O	O
ID50	O	O
>	O	O
>	O	O
1.5	O	O
micromol/L	O	O
sulfasalazine	O	O
.	O	O

The	O	O
apparent	O	O
ID50	O	O
value	O	O
for	O	O
aminosalicylate-inhibited	O	O
maturation	O	O
was	O	O
4	O	O
micromol/L	O	O
.	O	O

Sulfapyridine	O	O
had	O	O
no	O	O
effect	O	O
.	O	O

At	O	O
1.25	O	O
micromol/L	O	O
,	O	O
sulfasalazine	O	O
largely	O	O
inhibited	O	O
NF-kB	O	O
activation	O	O
in	O	O
dendritic	B-cell_type	O
cells	I-cell_type	O
.	O	O

CONCLUSION	O	O
:	O	O
Maturing	O	O
human	B-cell_type	O
dendritic	I-cell_type	O
cells	I-cell_type	O
are	O	O
hundred-fold	O	O
more	O	O
sensitive	O	O
to	O	O
sulfasalazine	O	O
than	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
NK	B-cell_type	O
cells	I-cell_type	O
and	O	O
the	O	O
most	O	O
sensitive	O	O
human	B-cell_type	O
cells	I-cell_type	O
described	O	O
so	O	O
far	O	O
.	O	O

Thus	O	O
,	O	O
dendritic	O	O
cell	O	O
maturation	O	O
is	O	O
an	O	O
important	O	O
target	O	O
of	O	O
sulfasalazine	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
role	O	O
of	O	O
dendritic	B-cell_type	O
cells	I-cell_type	O
in	O	O
(	O	O
auto	O	O
)	O	O
immunity	O	O
,	O	O
inhibition	O	O
of	O	O
their	O	O
maturation	O	O
might	O	O
provide	O	O
a	O	O
target	O	O
for	O	O
further	O	O
optimization	O	O
of	O	O
sulfasalazine	B-protein	O
therapy	I-protein	O
.	O	O

Defective	O	O
function	O	O
of	O	O
the	O	O
proteasome	B-DNA	O
in	O	O
autoimmunity	O	O
:	O	O
involvement	O	O
of	O	O
impaired	O	O
NF-kappaB	O	O
activation	O	O
.	O	O

Type	O	O
1	O	O
diabetes	O	O
(	O	O
also	O	O
known	O	O
as	O	O
insulin-dependent	O	O
diabetes	O	O
mellitus	O	O
or	O	O
juvenile-onset	O	O
diabetes	O	O
)	O	O
is	O	O
usually	O	O
caused	O	O
by	O	O
T	O	O
cell-mediated	O	O
autoimmunity	O	O
,	O	O
with	O	O
a	O	O
prediabetic	O	O
state	O	O
characterized	O	O
by	O	O
the	O	O
production	O	O
of	O	O
autoantibodies	O	O
specific	O	O
for	O	O
proteins	I-protein	O
expressed	O	O
by	O	O
pancreatic	B-cell_type	O
beta	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
nonobese	O	O
patient	O	O
with	O	O
diabetes	O	O
(	O	O
NOD	B-protein	O
)	O	O
mouse	O	O
is	O	O
a	O	O
spontaneous	O	O
model	O	O
of	O	O
type	O	O
1	O	O
diabetes	O	O
with	O	O
a	O	O
strong	O	O
genetic	O	O
component	O	O
that	O	O
maps	O	O
to	O	O
the	O	O
major	B-DNA	O
histocompatibility	I-protein	O
complex	I-protein	O
(	I-DNA	O
MHC	I-DNA	O
)	O	O
region	O	O
of	O	O
the	O	O
genome	B-protein	O
.	O	O

A	O	O
specific	O	O
proteasome	O	O
defect	O	O
has	O	O
been	O	O
identified	O	O
in	O	O
NOD	O	O
mouse	O	O
in	O	O
select	O	O
lymphocytic	O	O
and	O	O
monocytic	O	O
lineages	O	O
that	O	O
results	O	O
from	O	O
down-regulation	O	O
of	O	O
expression	O	O
of	O	O
the	O	O
proteasome	B-DNA	O
subunit	I-DNA	O
LMP2	I-DNA	O
,	O	O
which	O	O
is	O	O
encoded	O	O
by	O	O
a	O	O
gene	O	O
in	O	O
the	O	O
MHC	B-DNA	O
genomic	I-DNA	O
region	I-DNA	O
.	O	O

This	O	O
defect	O	O
prevents	O	O
the	O	O
proteolytic	O	O
processing	O	O
required	O	O
for	O	O
the	O	O
production	O	O
and	O	O
activation	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
nuclear	I-protein	O
factor-kappaB	I-protein	O
(	O	O
NF-kappaB	B-protein	O
)	O	O
,	O	O
which	O	O
plays	O	O
important	O	O
roles	O	O
in	O	O
immune	O	O
and	O	O
inflammatory	O	O
responses	O	O
,	O	O
as	O	O
well	O	O
as	O	O
increases	O	O
the	O	O
susceptibility	O	O
of	O	O
the	O	O
affected	B-cell_type	O
cells	I-cell_type	O
to	O	O
apoptosis	O	O
induced	O	O
by	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor-alpha	I-protein	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
.	O	O

The	O	O
novel	O	O
role	O	O
of	O	O
the	O	O
proteasome	B-DNA	O
in	O	O
dysfunction	O	O
in	O	O
autoimmunity	O	O
is	O	O
presented	O	O
and	O	O
documented	O	O
to	O	O
be	O	O
both	O	O
tissue	O	O
and	O	O
developmental	O	O
stage	O	O
specific	O	O
.	O	O

We	O	O
propose	O	O
a	O	O
role	O	O
of	O	O
the	O	O
proteasome	B-DNA	O
as	O	O
a	O	O
step	O	O
in	O	O
disease	B-cell_line	O
pathogenesis	I-cell_line	O
and	O	O
tissue	O	O
targeting	O	O
.	O	O

Down-regulation	O	O
of	O	O
TDT	O	O
transcription	O	O
in	O	O
CD4	B-protein	O
(	O	O
+	O	O
)	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
thymocytes	O	O
by	O	O
Ikaros	B-protein	O
proteins	I-protein	O
in	O	O
direct	O	O
competition	O	O
with	O	O
an	O	O
Ets	O	O
activator	I-protein	O
.	O	O

Ikaros	O	O
is	O	O
a	O	O
unique	O	O
regulator	O	O
of	O	O
lymphopoiesis	O	O
that	O	O
associates	O	O
with	O	O
pericentromeric	O	O
heterochromatin	O	O
and	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
heritable	O	O
gene	O	O
inactivation	O	O
.	O	O

Binding	O	O
and	O	O
competition	O	O
experiments	O	O
demonstrate	O	O
that	O	O
Ikaros	O	O
dimers	O	O
compete	O	O
with	O	O
an	O	O
Ets	O	O
activator	O	O
for	O	O
occupancy	O	O
of	O	O
the	O	O
lymphocyte-specific	B-DNA	O
TdT	I-DNA	O
promoter	I-DNA	O
.	O	O

Mutations	O	O
that	O	O
selectively	O	O
disrupt	O	O
Ikaros	O	O
binding	O	O
to	O	O
an	O	O
integrated	O	O
TdT	O	O
promoter	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
promoter	O	O
function	O	O
in	O	O
a	O	O
CD4	B-DNA	O
(	O	O
+	I-DNA	O
)	O	O
CD8	O	O
(	O	O
+	I-DNA	O
)	O	O
thymocyte	O	O
line	I-cell_line	O
.	O	O

However	O	O
,	O	O
these	O	O
mutations	O	O
abolished	O	O
down-regulation	O	O
on	O	O
differentiation	O	O
,	O	O
providing	O	O
evidence	O	O
that	O	O
Ikaros	O	O
plays	O	O
a	O	O
direct	O	O
role	O	O
in	O	O
repression	O	O
.	O	O

Reduced	O	O
access	O	O
to	O	O
restriction	O	O
enzyme	O	O
cleavage	O	O
suggested	O	O
that	O	O
chromatin	O	O
alterations	O	O
accompany	O	O
down-regulation	O	O
.	O	O

The	O	O
Ikaros-dependent	O	O
down-regulation	O	O
event	O	O
and	O	O
the	O	O
observed	O	O
chromatin	O	O
alterations	O	O
appear	O	O
to	O	O
precede	O	O
pericentromeric	O	O
repositioning	O	O
.	O	O

Current	O	O
models	O	O
propose	O	O
that	O	O
the	O	O
functions	O	O
of	O	O
Ikaros	O	O
should	O	O
be	O	O
disrupted	O	O
by	O	O
a	O	O
small	O	O
isoform	O	O
that	O	O
retains	O	O
the	O	O
dimerization	B-protein	O
domain	I-protein	O
and	O	O
lacks	O	O
the	O	O
DNA-binding	B-protein	O
domain	I-protein	O
.	O	O

Surprisingly	O	O
,	O	O
in	O	O
the	O	O
CD4	B-DNA	O
(	I-DNA	O
+	I-DNA	O
)	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
thymocyte	O	O
line	O	O
,	O	O
overexpression	O	O
of	O	O
a	O	O
small	B-protein	O
Ikaros	I-protein	O
isoform	I-protein	O
had	O	O
no	O	O
effect	O	O
on	O	O
differentiation	O	O
or	O	O
on	O	O
the	O	O
pericentromeric	O	O
targeting	O	O
and	O	O
DNA-binding	O	O
properties	O	O
of	O	O
Ikaros	O	O
.	O	O

Rather	O	O
,	O	O
the	O	O
small	B-protein	O
isoform	I-protein	O
assembled	O	O
into	O	O
multimeric	O	O
complexes	O	O
with	O	O
DNA-bound	O	O
Ikaros	O	O
at	O	O
the	O	O
pericentromeric	O	O
foci	O	O
.	O	O

The	O	O
capacity	O	O
for	O	O
in	O	O
vivo	O	O
multimer	O	O
formation	O	O
suggests	O	O
that	O	O
interactions	O	O
between	O	O
Ikaros	O	O
dimers	O	O
bound	O	O
to	O	O
the	O	O
TdT	B-DNA	O
promoter	I-DNA	O
and	O	O
those	O	O
bound	O	O
to	O	O
pericentromeric	O	O
repeat	O	O
sequences	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
pericentromeric	O	O
repositioning	O	O
of	O	O
the	O	O
inactive	B-DNA	O
gene	I-DNA	O
.	O	O

Type	O	O
I	B-protein	O
interferons	O	O
and	O	O
IL-12	B-protein	O
:	O	O
convergence	O	O
and	O	O
cross-regulation	O	O
among	O	O
mediators	O	O
of	O	O
cellular	O	O
immunity	O	O
.	O	O

Therapeutic	O	O
use	O	O
of	O	O
type	B-protein	O
I	I-protein	O
IFN	I-protein	O
(	O	O
IFN-alpha/beta	B-protein	O
)	O	O
has	O	O
become	O	O
common	O	O
.	O	O

Many	O	O
of	O	O
the	O	O
diverse	O	O
diseases	O	O
targeted	O	O
are	O	O
marked	O	O
by	O	O
pathogenetic	O	O
abnormalities	O	O
in	O	O
cell-mediated	O	O
immunity	O	O
(	O	O
CMI	O	O
)	O	O
,	O	O
these	O	O
cellular	O	O
immune	O	O
responses	O	O
either	O	O
causing	O	O
injury	O	O
to	O	O
the	O	O
host	O	O
,	O	O
lacking	O	O
sufficient	O	O
vigor	O	O
for	O	O
virus	O	O
or	O	O
tumor	O	O
clearance	O	O
,	O	O
or	O	O
both	O	O
.	O	O

In	O	O
general	O	O
,	O	O
therapeutic	O	O
efficacy	O	O
is	O	O
limited	O	O
.	O	O

It	O	O
is	O	O
thus	O	O
notable	O	O
that	O	O
the	O	O
pleiotropic	O	O
effects	O	O
of	O	O
type	O	O
I	B-protein	O
IFN	O	O
on	O	O
CMI	O	O
remain	O	O
poorly	O	O
understood	O	O
.	O	O

We	O	O
characterized	O	O
the	O	O
effects	O	O
of	O	O
type	O	O
I	B-protein	O
IFN	O	O
on	O	O
the	O	O
production	O	O
of	O	O
IL-12	B-protein	O
,	O	O
the	O	O
central	O	O
immunoregulatory	B-protein	O
cytokine	I-protein	O
of	O	O
the	O	O
CD4	B-DNA	O
(	I-DNA	O
+	I-DNA	O
)	O	O
T	O	O
cell	O	O
arm	O	O
of	O	O
CMI	O	O
.	O	O

We	O	O
show	O	O
that	O	O
type	O	O
I	B-protein	O
IFN	O	O
are	O	O
potent	O	O
inhibitors	O	O
of	O	O
IL-12	B-protein	O
production	O	O
by	O	O
human	B-protein	O
monocytes/macrophages	I-protein	O
.	O	O

The	O	O
underlying	O	O
mechanism	O	O
involves	O	O
transcriptional	O	O
inhibition	O	O
of	O	O
the	O	O
IL-12p40	B-DNA	O
gene	I-DNA	O
,	O	O
marked	O	O
by	O	O
down-regulation	O	O
of	O	O
PU.1	O	O
binding	O	O
activity	O	O
at	O	O
the	O	O
upstream	O	O
Ets	O	O
site	I-DNA	O
of	O	O
the	O	O
IL-12p40	B-DNA	O
promoter	I-DNA	O
.	O	O

Type	O	O
I	O	O
IFN	O	O
have	O	O
previously	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
able	O	O
to	O	O
substitute	O	O
for	O	O
IL-12	O	O
in	O	O
driving	O	O
IFN-gamma	O	O
production	O	O
from	O	O
T	B-cell_type	O
and	I-cell_type	O
NK	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
ability	O	O
of	O	O
IFN-alpha/beta	O	O
to	O	O
suppress	O	O
IL-12	B-protein	O
production	O	O
while	O	O
up-regulating	O	O
IFN-gamma	B-protein	O
production	O	O
suggests	O	O
a	O	O
possible	O	O
mechanistic	O	O
basis	O	O
for	O	O
the	O	O
difficulties	O	O
of	O	O
employing	O	O
these	O	O
cytokines	B-protein	O
in	O	O
diseases	O	O
involving	O	O
abnormalities	O	O
of	O	O
CMI	O	O
.	O	O

Nuclear	O	O
factor-kappaB	O	O
suppressive	O	O
and	O	O
inhibitor-kappaB	O	O
stimulatory	O	O
effects	O	O
of	O	O
troglitazone	O	O
in	O	O
obese	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
:	O	O
evidence	O	O
of	O	O
an	O	O
antiinflammatory	O	O
action	O	O
?	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
recently	O	O
that	O	O
troglitazone	O	O
exerts	O	O
an	O	O
anti-inflammatory	O	O
effect	O	O
,	O	O
in	O	O
vitro	O	O
,	O	O
and	O	O
in	O	O
experimental	O	O
animals	O	O
.	O	O

To	O	O
test	O	O
these	O	O
properties	O	O
in	O	O
humans	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
troglitazone	O	O
on	O	O
the	O	O
proinflammatory	B-protein	O
transcription	I-protein	O
factor	I-protein	O
nuclear	O	O
factor-kappaB	O	O
and	O	O
its	O	O
inhibitory	O	O
protein	O	O
IkappaB	O	O
in	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
(	O	O
MNC	O	O
)	O	O
and	O	O
plasma	O	O
soluble	O	O
intracellular	O	O
adhesion	O	O
molecule-1	O	O
,	O	O
monocyte	O	O
chemoattractant	O	O
protein-1	B-protein	O
,	O	O
plasminogen	O	O
activator	I-protein	O
inhibitor-1	I-protein	O
,	O	O
and	O	O
C-reactive	B-protein	O
protein	I-protein	O
.	O	O

We	O	O
also	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
troglitazone	O	O
on	O	O
reactive	O	O
oxygen	O	O
species	O	O
generation	O	O
,	O	O
p47	O	O
(	O	O
phox	O	O
)	O	O
subunit	O	O
expression	O	O
,	O	O
9-hydroxyoctadecadienoic	O	O
acid	O	O
(	O	O
9-HODE	O	O
)	O	O
,	O	O
13-HODE	O	O
,	O	O
o-tyrosine	O	O
,	O	O
and	O	O
m-tyrosine	O	O
in	O	O
obese	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
.	O	O

Seven	O	O
obese	O	O
patients	O	O
with	O	O
type	O	O
2	O	O
diabetes	O	O
were	O	O
treated	O	O
with	O	O
troglitazone	O	O
(	O	O
400	O	O
mg/day	O	O
)	O	O
for	O	O
4	O	O
weeks	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
obtained	O	O
at	O	O
weekly	O	O
intervals	O	O
.	O	O

Nuclear	O	O
factor-kappaB	O	O
binding	O	O
activity	O	O
in	O	O
MNC	O	O
nuclear	O	O
extracts	O	O
was	O	O
significantly	O	O
inhibited	O	O
after	O	O
troglitazone	O	O
treatment	O	O
at	O	O
week	O	O
1	O	O
and	O	O
continued	O	O
to	O	O
be	O	O
inhibited	O	O
up	O	O
to	O	O
week	O	O
4	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
IkappaB	O	O
protein	O	O
levels	O	O
increased	O	O
significantly	O	O
after	O	O
troglitazone	O	O
treatment	O	O
at	O	O
week	O	O
1	O	O
,	O	O
and	O	O
this	O	O
increase	O	O
persisted	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Plasma	O	O
monocyte	O	O
chemoattractant	O	O
protein-1	B-protein	O
and	O	O
soluble	B-protein	O
intracellular	I-protein	O
adhesion	I-protein	O
molecule-1	O	O
concentrations	O	O
did	O	O
not	O	O
decrease	O	O
significantly	O	O
after	O	O
troglitazone	O	O
treatment	O	O
,	O	O
although	O	O
there	O	O
was	O	O
a	O	O
trend	O	O
toward	O	O
inhibition	O	O
.	O	O

Reactive	O	O
oxygen	O	O
species	O	O
generation	O	O
by	O	O
polymorphonuclear	B-cell_type	O
cells	I-cell_type	O
and	O	O
MNC	O	O
,	O	O
p47	O	O
(	O	O
phox	B-protein	O
)	O	O
subunit	O	O
protein	O	O
quantities	O	O
,	O	O
plasminogen	O	O
activator	O	O
inhibitor-1	O	O
,	O	O
and	O	O
C-reactive	O	O
protein	O	O
levels	O	O
decreased	O	O
significantly	O	O
after	O	O
troglitazone	O	O
intake	O	O
.	O	O

13-HODE/linoleic	O	O
acid	O	O
and	O	O
9-HODE/linoleic	O	O
acid	O	O
ratios	O	O
also	O	O
decreased	O	O
after	O	O
troglitazone	O	O
intake	O	O
.	O	O

However	O	O
,	O	O
o-tyrosine/phenylalanine	O	O
and	O	O
m-tyrosine/phenylalanine	O	O
ratios	O	O
did	O	O
not	O	O
change	O	O
significantly	O	O
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
troglitazone	O	O
has	O	O
profound	O	O
antiinflammatory	O	O
effects	O	O
in	O	O
addition	O	O
to	O	O
antioxidant	O	O
effects	O	O
in	O	O
obese	O	O
type	O	O
2	O	O
diabetics	O	O
;	O	O
these	O	O
effects	O	O
may	O	O
be	O	O
relevant	O	O
to	O	O
the	O	O
recently	O	O
described	O	O
beneficial	O	O
antiatherosclerotic	O	O
effects	O	O
of	O	O
troglitazone	O	O
at	O	O
the	O	O
vascular	O	O
level	O	O
.	O	O

OX40	O	O
stimulation	O	O
by	O	O
gp34/OX40	O	O
ligand	O	O
enhances	O	O
productive	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
infection	O	O
.	O	O

OX40	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
(	O	O
TNF	B-protein	O
)	I-protein	O
receptor	I-protein	O
superfamily	I-protein	O
and	O	O
known	O	O
to	O	O
be	O	O
an	O	O
important	O	O
costimulatory	O	O
molecule	O	O
expressed	O	O
on	O	O
activated	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

To	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
costimulation	O	O
of	O	O
OX40	O	O
in	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HIV-1	O	O
)	O	O
infection	O	O
by	O	O
its	O	O
natural	O	O
ligand	O	O
,	O	O
gp34	O	O
,	O	O
the	O	O
OX40-transfected	O	O
ACH-2	O	O
cell	O	O
line	O	O
,	O	O
ACH-2/OX40	O	O
,	O	O
chronically	O	O
infected	O	O
with	O	O
HIV-1	O	O
,	O	O
was	O	O
cocultured	O	O
with	O	O
paraformaldehyde	O	O
(	O	O
PFA	O	O
)	O	O
-fixed	O	O
gp34-transfected	O	O
mouse	O	O
cell	O	O
line	O	O
,	O	O
SV-T2/gp34	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
HIV-1	O	O
production	O	O
was	O	O
strongly	O	O
induced	O	O
.	O	O

This	O	O
was	O	O
followed	O	O
by	O	O
apparent	O	O
apoptosis	O	O
,	O	O
and	O	O
both	O	O
processes	O	O
were	O	O
specifically	O	O
inhibited	O	O
by	O	O
the	O	O
gp34	O	O
-specific	O	O
neutralizing	O	O
monoclonal	O	O
antibody	O	O
5A8	O	O
.	O	O

Endogenous	O	O
TNF	B-protein	O
alpha	I-protein	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
and	O	O
TNF-beta	O	O
production	O	O
were	O	O
not	O	O
involved	O	O
in	O	O
the	O	O
enhanced	O	O
HIV-1	O	O
production	O	O
.	O	O

Furthermore	O	O
,	O	O
enhanced	O	O
HIV-1	O	O
transcription	O	O
in	O	O
gp34	O	O
-stimulated	O	O
ACH-2/OX40	B-cell_type	O
cells	I-cell_type	O
was	O	O
dependent	O	O
on	O	O
the	O	O
kappa	B-DNA	O
B	I-DNA	O
site	I-DNA	O
of	O	O
the	O	O
HIV-1	B-DNA	O
long	I-DNA	O
terminal	I-DNA	O
repeat	I-DNA	O
,	O	O
and	O	O
the	O	O
OX40-gp34	O	O
interaction	O	O
activated	O	O
NF-kappa	B-protein	O
B	I-protein	O
consisting	O	O
of	O	O
p50	B-protein	O
and	O	O
p65	B-protein	O
subunits	I-protein	O
.	O	O

When	B-protein	O
primary	I-protein	O
activated	I-protein	O
CD4	I-protein	O
(	O	O
+	I-DNA	O
)	I-cell_line	O
T	B-cell_type	O
cells	I-cell_type	O
acutely	O	O
infected	O	O
with	O	O
HIV-1	O	O
(	O	O
NL4-3	B-protein	O
)	O	O
(	O	O
CXCR4-using	O	O
T-cell-line-tropic	O	O
)	O	O
were	O	O
cocultured	O	O
with	O	O
PFA-fixed	O	O
gp34	O	O
(	O	O
+	O	O
)	O	O
human	O	O
T-cell	O	O
leukemia	O	O
virus	O	O
type	O	O
1-bearing	O	O
MT-2	O	O
cells	O	O
or	O	O
SV-T2/gp34	O	O
cells	O	O
,	O	O
HIV-1	O	O
production	O	O
was	O	O
also	O	O
markedly	O	O
enhanced	O	O
.	O	O

The	O	O
enhancement	O	O
was	O	O
again	O	O
significantly	O	O
inhibited	O	O
by	O	O
5A8	O	O
.	O	O

The	O	O
present	O	O
study	O	O
first	O	O
shows	O	O
that	O	O
OX40-gp34	O	O
interaction	O	O
stimulates	O	O
HIV-1	O	O
expression	O	O
and	O	O
suggests	O	O
that	O	O
OX40	O	O
triggering	O	O
by	O	O
gp34	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
enhancing	O	O
HIV-1	O	O
production	O	O
in	O	O
both	O	O
acutely	O	O
and	O	O
latently	O	O
infected	O	O
CD4	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
in	O	O
vivo	O	O
.	O	O

Troglitazone	O	O
,	O	O
a	O	O
PPARgamma	O	O
ligand	O	O
,	O	O
inhibits	O	O
osteopontin	O	O
gene	O	O
expression	O	O
in	O	O
human	B-cell_line	O
monocytes/macrophage	I-cell_line	O
THP-1	I-cell_line	O
cells	I-cell_line	O
.	O	O

Peroxizome	O	O
proliferator-activated	O	O
receptor-gamma	O	O
(	O	O
PPARgamma	O	O
)	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
nuclear	B-protein	O
receptor	I-protein	O
family	I-protein	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
that	O	O
regulate	O	O
adipocyte	O	O
differentiation	O	O
.	O	O

Recent	O	O
studies	O	O
indicate	O	O
that	O	O
liganded	O	O
PPARgamma	O	O
not	O	O
only	O	O
promotes	O	O
differentiation	O	O
but	O	O
also	O	O
inhibits	O	O
the	O	O
activation	O	O
of	O	O
macrophages	O	O
.	O	O

Osteopontin	O	O
,	O	O
a	O	O
component	O	O
of	O	O
extracellular	O	O
matrix	O	O
,	O	O
is	O	O
synthesized	O	O
by	O	O
macrophages	O	O
in	O	O
atherosclerotic	O	O
plaques	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
examined	O	O
whether	O	O
PPARgamma	O	O
ligand	O	O
regulates	O	O
osteopontin	O	O
gene	O	O
expression	O	O
in	O	O
THP-1	B-cell_line	O
cells	I-cell_line	O
,	O	O
a	O	O
cell	O	O
line	O	O
derived	O	O
from	O	O
human	B-cell_type	O
monocytic	I-cell_type	O
leukemia	I-cell_type	O
cells	I-cell_type	O
which	O	O
can	O	O
differentiate	O	O
to	O	O
macrophage	O	O
upon	O	O
stimulation	O	O
with	O	O
phorbol	O	O
ester	O	O
PMA	O	O
.	O	O

Northern	O	O
blot	O	O
analysis	O	O
showed	O	O
that	O	O
osteopontin	O	O
expression	O	O
is	O	O
markedly	O	O
induced	O	O
in	O	O
response	O	O
to	O	O
PMA	O	O
.	O	O

Troglitazone	O	O
,	O	O
a	O	O
PPARgamma	O	O
ligand	O	O
,	O	O
dramatically	O	O
attenuated	O	O
the	O	O
PMA-induced	O	O
osteopontin	O	O
expression	O	O
.	O	O

Transient	O	O
transfection	O	O
assays	O	O
of	O	O
the	O	O
human	O	O
osteopontin	I-DNA	O
promoter/luciferase	I-DNA	O
construct	O	O
which	O	O
contains	O	O
a	O	O
5'-flanking	B-DNA	O
region	I-DNA	O
between	O	O
-1500	O	O
and	O	O
+87	O	O
relative	O	O
to	O	O
the	O	O
transcription	O	O
start	O	O
site	O	O
demonstrate	O	O
that	O	O
either	O	O
treatment	O	O
with	O	O
troglitazone	O	O
or	O	O
cotransfection	O	O
of	O	O
PPARgamma	O	O
expression	O	O
vector	O	O
inhibits	O	O
osteopontin	O	O
promoter	O	O
activity	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
troglitazone	O	O
reduces	O	O
osteopontin	O	O
gene	O	O
expression	O	O
at	O	O
transcriptional	O	O
level	O	O
through	O	O
PPARgamma	O	O
activation	O	O
,	O	O
and	O	O
suggest	O	O
the	O	O
role	O	O
of	O	O
troglitazone	O	O
in	O	O
inhibiting	O	O
the	O	O
ability	O	O
of	O	O
macrophages	O	O
to	O	O
produce	O	O
extracellular	O	O
matrix	O	O
,	O	O
which	O	O
is	O	O
particularly	O	O
relevant	O	O
to	O	O
atherosclerotic	O	O
plaque	O	O
formation	O	O
.	O	O

Transcription	O	O
factor	O	O
NF-kappa	B-protein	O
B	I-protein	O
regulates	O	O
Ig	O	O
lambda	O	O
light	O	O
chain	O	O
gene	O	O
rearrangement	O	O
.	O	O

The	O	O
tissue-	O	O
and	O	O
stage-specific	O	O
assembly	O	O
of	O	O
Ig	B-protein	O
and	O	O
TCR	B-protein	O
genes	O	O
is	O	O
mediated	O	O
by	O	O
a	O	O
common	O	O
V	O	O
(	O	O
D	O	O
)	O	O
J	O	O
recombinase	O	O
complex	O	O
in	O	O
precursor	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Directed	O	O
alterations	O	O
in	O	O
the	O	O
accessibility	O	O
of	O	O
V	O	O
,	O	O
D	O	O
,	O	O
and	O	O
J	O	O
gene	O	O
segments	O	O
target	O	O
the	O	O
recombinase	O	O
to	O	O
specific	O	O
Ag	B-protein	O
receptor	I-protein	O
loci	O	O
.	O	O

Accessibility	O	O
within	O	O
a	O	O
given	O	O
locus	O	O
is	O	O
regulated	O	O
by	O	O
the	O	O
functional	O	O
interaction	O	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
with	O	O
cognate	B-DNA	O
enhancer	I-DNA	O
elements	I-DNA	O
and	O	O
correlates	O	O
with	O	O
the	O	O
transcriptional	O	O
activity	O	O
of	O	O
unrearranged	B-DNA	O
gene	I-DNA	O
segments	O	O
.	O	O

As	O	O
demonstrated	O	O
in	O	O
our	O	O
prior	O	O
studies	O	O
,	O	O
rearrangement	O	O
of	O	O
the	O	O
Igkappa	B-DNA	O
locus	I-DNA	O
is	O	O
regulated	O	O
by	O	O
the	O	O
inducible	B-protein	O
transcription	I-protein	O
factor	I-protein	O
NF-kappaB	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
the	O	O
Igkappa	B-DNA	O
locus	I-DNA	O
,	O	O
known	O	O
transcriptional	O	O
control	O	O
elements	O	O
in	O	O
the	O	O
Iglambda	B-DNA	O
locus	I-DNA	O
lack	I-DNA	O
functional	I-DNA	O
NF-kappaB	I-DNA	O
binding	I-DNA	O
sites	I-DNA	O
.	O	O

Consistent	O	O
with	O	O
this	O	O
observation	O	O
,	O	O
the	O	O
expression	O	O
of	O	O
assembled	O	O
Iglambda	O	O
genes	I-DNA	O
in	O	O
mature	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
NF-kappaB	O	O
independent	O	O
.	O	O

Nonetheless	O	O
,	O	O
we	O	O
now	O	O
show	O	O
that	O	O
specific	O	O
repression	O	O
of	O	O
NF-kappaB	O	O
inhibits	O	O
germline	O	O
transcription	O	O
and	O	O
recombination	O	O
of	O	O
Iglambda	O	O
gene	O	O
segments	O	O
in	O	O
precursor	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

Molecular	O	O
analyses	O	O
indicate	O	O
that	O	O
the	O	O
block	O	O
in	O	O
NF-kappaB	O	O
impairs	O	O
Iglambda	O	O
rearrangement	O	O
at	O	O
the	O	O
level	O	O
of	O	O
recombinase	O	O
accessibility	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
activities	O	O
of	O	O
known	O	O
Iglambda	B-DNA	O
promoter	I-DNA	O
and	O	O
enhancer	B-DNA	O
elements	I-DNA	O
are	O	O
unaffected	O	O
in	O	O
the	O	O
same	O	O
cellular	O	O
background	O	O
.	O	O

These	O	O
findings	O	O
expand	O	O
the	O	O
range	O	O
of	O	O
NF-kappaB	O	O
action	O	O
in	O	O
precursor	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
beyond	O	O
Igkappa	O	O
to	O	O
include	O	O
the	O	O
control	O	O
of	O	O
recombinational	O	O
accessibility	O	O
at	O	O
both	O	O
L	O	O
chain	O	O
loci	O	O
.	O	O

Moreover	O	O
,	O	O
our	O	O
results	O	O
strongly	O	O
suggest	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
novel	O	O
Iglambda	B-DNA	O
regulatory	I-DNA	O
element	I-DNA	O
that	O	O
is	O	O
either	O	O
directly	O	O
or	O	O
indirectly	O	O
activated	O	O
by	O	O
NF-kappaB	O	O
during	O	O
the	O	O
early	B-DNA	O
stages	I-DNA	O
of	O	O
B	O	O
cell	O	O
development	O	O
.	O	O

Transcription	B-protein	O
factor	I-protein	O
STAT5A	O	O
is	O	O
a	O	O
substrate	O	O
of	O	O
Bruton	O	O
's	O	O
tyrosine	O	O
kinase	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

STAT5A	O	O
is	O	O
a	O	O
molecular	O	O
regulator	O	O
of	O	O
proliferation	O	O
,	O	O
differentiation	O	O
,	O	O
and	O	O
apoptosis	O	O
in	O	O
lymphohematopoietic	B-cell_type	O
cells	I-cell_type	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
STAT5A	O	O
can	O	O
serve	O	O
as	O	O
a	O	O
functional	O	O
substrate	O	O
of	O	O
Bruton	B-protein	O
's	I-protein	O
tyrosine	I-protein	O
kinase	I-protein	O
(	O	O
BTK	O	O
)	O	O
.	O	O

Purified	O	O
recombinant	O	O
BTK	O	O
was	O	O
capable	O	O
of	O	O
directly	O	O
binding	O	O
purified	O	O
recombinant	O	O
STAT5A	O	O
with	O	O
high	O	O
affinity	O	O
(	O	O
K	B-protein	O
(	O	O
d	B-protein	O
)	O	O
=	O	O
44	O	O
nm	O	O
)	O	O
,	O	O
as	O	O
determined	O	O
by	O	O
surface	O	O
plasmon	O	O
resonance	O	O
using	O	O
a	O	O
BIAcore	O	O
biosensor	O	O
system	O	O
.	O	O

BTK	O	O
was	O	O
also	O	O
capable	O	O
of	O	O
tyrosine-phosphorylating	O	O
ectopically	O	O
expressed	O	O
recombinant	O	O
STAT5A	O	O
on	O	O
Tyr	O	O
(	O	O
694	O	O
)	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
in	O	O
a	O	O
Janus	B-protein	O
kinase	I-protein	O
3	O	O
-independent	O	O
fashion	O	O
.	O	O

BTK	O	O
phosphorylated	O	O
the	O	O
Y665F	O	O
,	O	O
Y668F	O	O
,	O	O
and	O	O
Y682F	O	O
,	O	O
Y683F	O	O
mutants	O	O
but	O	O
not	O	O
the	O	O
Y694F	O	O
mutant	O	O
of	O	O
STAT5A	O	O
.	O	O

STAT5A	O	O
mutations	O	O
in	O	O
the	O	O
Src	B-protein	O
homology	I-protein	O
2	I-protein	O
(	O	O
SH2	I-DNA	O
)	O	O
and	O	O
SH3	O	O
domains	O	O
did	O	O
not	O	O
alter	O	O
the	O	O
BTK	O	O
-mediated	O	O
tyrosine	O	O
phosphorylation	O	O
.	O	O

Recombinant	O	O
BTK	O	O
proteins	O	O
with	O	O
mutant	O	O
pleckstrin	O	O
homology	B-protein	O
,	O	O
SH2	B-protein	O
,	O	O
or	O	O
SH3	O	O
domains	O	O
were	O	O
capable	O	O
of	O	O
phosphorylating	O	O
STAT5A	O	O
,	O	O
whereas	O	O
recombinant	O	O
BTK	O	O
proteins	O	O
with	O	O
SH1/kinase	O	O
domain	O	O
mutations	O	O
were	O	O
not	O	O
.	O	O

In	O	O
pull-down	O	O
experiments	O	O
,	O	O
only	O	O
full-length	O	O
BTK	O	O
and	O	O
its	O	O
SH1/kinase	O	O
domain	O	O
(	O	O
but	O	O
not	O	O
the	O	O
pleckstrin	B-protein	O
homology	I-protein	O
,	I-protein	O
SH2	I-protein	O
,	O	O
or	O	O
SH3	O	O
domains	I-protein	O
)	O	O
were	O	O
capable	O	O
of	O	O
binding	O	O
STAT5A	O	O
.	O	O

Ectopically	O	O
expressed	O	O
BTK	B-protein	O
kinase	I-protein	O
domain	O	O
was	O	O
capable	O	O
of	O	O
tyrosine-phosphorylating	O	O
STAT5A	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

BTK	O	O
-mediated	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
ectopically	O	O
expressed	O	O
wild	O	O
type	O	O
(	O	O
but	O	O
not	O	O
Tyr	B-protein	O
(	O	O
694	B-protein	O
)	O	O
mutant	O	O
)	O	O
STAT5A	O	O
enhanced	O	O
its	O	O
DNA	O	O
binding	O	O
activity	O	O
.	O	O

In	O	O
BTK	O	O
-competent	O	O
chicken	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
,	O	O
anti-IgM-stimulated	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
STAT5	B-protein	O
protein	I-protein	O
was	O	O
prevented	O	O
by	O	O
pretreatment	O	O
with	O	O
the	O	O
BTK	O	O
inhibitor	O	O
LFM-A13	O	O
but	O	O
not	O	O
by	O	O
pretreatment	O	O
with	O	O
the	O	O
JAK3	O	O
inhibitor	O	O
HI-P131	O	O
.	O	O

B	B-protein	O
cell	I-protein	O
antigen	I-protein	O
receptor	I-protein	O
ligation	O	O
resulted	O	O
in	O	O
enhanced	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
STAT5	O	O
in	O	O
BTK	O	O
-deficient	O	O
chicken	O	O
B	I-cell_type	O
cells	I-cell_type	O
reconstituted	O	O
with	O	O
wild	O	O
type	O	O
human	O	O
BTK	O	O
but	O	O
not	O	O
in	O	O
BTK	O	O
-deficient	O	O
chicken	O	O
B	O	O
cells	O	O
reconstituted	O	O
with	O	O
kinase-inactive	O	O
mutant	O	O
BTK	O	O
.	O	O

Similarly	O	O
,	O	O
anti-IgM	O	O
stimulation	O	O
resulted	O	O
in	O	O
enhanced	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
STAT5A	O	O
in	O	O
BTK	B-cell_type	O
-competent	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
from	O	O
wild	O	O
type	O	O
mice	O	O
but	O	O
not	O	O
in	O	O
BTK	B-cell_type	O
-deficient	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
from	O	O
XID	O	O
mice	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
B	B-cell_type	O
cells	I-cell_type	O
from	O	O
XID	O	O
mice	O	O
,	O	O
B	I-cell_type	O
cells	I-cell_type	O
from	O	O
JAK3	O	O
knockout	O	O
mice	O	O
showed	O	O
a	O	O
normal	O	O
STAT5A	O	O
phosphorylation	O	O
response	O	O
to	O	O
anti-IgM	O	O
stimulation	O	O
.	O	O

These	O	O
findings	O	O
provide	O	O
unprecedented	O	O
experimental	O	O
evidence	O	O
that	O	O
BTK	O	O
plays	O	O
a	O	O
nonredundant	O	O
and	O	O
pivotal	O	O
role	O	O
in	O	O
B	O	O
cell	O	O
antigen	O	O
receptor-mediated	O	O
STAT5A	O	O
activation	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O

Role	O	O
of	O	O
T-bet	O	O
in	O	O
commitment	O	O
of	O	O
TH1	B-cell_type	O
cells	I-cell_type	O
before	O	O
IL-12	O	O
-dependent	O	O
selection	O	O
.	O	O

How	O	O
cytokines	O	O
control	O	O
differentiation	O	O
of	O	O
helper	B-cell_line	O
T	I-cell_line	O
(	I-cell_line	O
TH	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
is	O	O
controversial	O	O
.	O	O

We	O	O
show	O	O
that	O	O
T-bet	O	O
,	O	O
without	O	O
apparent	O	O
assistance	O	O
from	O	O
interleukin	B-protein	O
12	I-protein	O
(	O	O
IL-12	B-protein	O
)	O	O
/	O	O
STAT4	B-protein	O
,	O	O
specifies	O	O
TH1	O	O
effector	O	O
fate	O	O
by	O	O
targeting	O	O
chromatin	O	O
remodeling	O	O
to	O	O
individual	O	O
interferon-gamma	O	O
(	O	O
IFN-gamma	B-protein	O
)	O	O
alleles	O	O
and	O	O
by	O	O
inducing	O	O
IL-12	B-protein	O
receptor	I-protein	O
beta2	O	O
expression	O	O
.	O	O

Subsequently	O	O
,	O	O
it	O	O
appears	O	O
that	O	O
IL-12	B-protein	O
/	O	O
STAT4	O	O
serves	O	O
two	O	O
essential	O	O
functions	O	O
in	O	O
the	O	O
development	O	O
of	O	O
TH1	B-cell_type	O
cells	I-cell_type	O
:	O	O
as	O	O
growth	O	O
signal	O	O
,	O	O
inducing	O	O
survival	O	O
and	O	O
cell	O	O
division	O	O
;	O	O
and	O	O
as	O	O
trans-activator	O	O
,	O	O
prolonging	O	O
IFN-gamma	O	O
synthesis	O	O
through	O	O
a	O	O
genetic	O	O
interaction	O	O
with	O	O
the	O	O
coactivator	B-protein	O
,	O	O
CREB-binding	B-protein	O
protein	I-protein	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
a	O	O
cytokine	B-protein	O
does	O	O
not	O	O
simply	O	O
induce	O	O
TH	O	O
fate	O	O
choice	O	O
but	O	O
instead	O	O
may	O	O
act	O	O
as	O	O
an	O	O
essential	O	O
secondary	O	O
stimulus	O	O
that	O	O
mediates	O	O
selective	O	O
survival	O	O
of	O	O
a	O	O
lineage	O	O
.	O	O

Stat6	O	O
is	O	O
necessary	O	O
and	O	O
sufficient	O	O
for	O	O
IL-4	O	O
's	O	O
role	O	O
in	O	O
Th2	O	O
differentiation	O	O
and	O	O
cell	O	O
expansion	O	O
.	O	O

IL-4	O	O
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
the	O	O
differentiation	O	O
of	O	O
T	O	O
CR-stimulated	O	O
naive	O	O
CD4	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
to	O	O
the	O	O
Th2	O	O
phenotype	O	O
.	O	O

In	O	O
response	O	O
to	O	O
IL-4	O	O
,	O	O
the	O	O
IL-4R	O	O
activates	O	O
a	O	O
set	O	O
of	O	O
phosphotyrosine	B-protein	O
binding	I-protein	O
domain-containing	I-protein	O
proteins	I-protein	O
,	O	O
including	O	O
insulin	B-protein	O
receptor	I-protein	O
substrate	O	O
1/2	O	O
,	O	O
Shc	O	O
,	O	O
and	O	O
IL-4R	O	O
interacting	B-protein	O
protein	I-protein	O
,	O	O
as	O	O
well	O	O
as	O	O
Stat6	O	O
.	O	O

Stat6	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
required	O	O
for	O	O
Th2	O	O
differentiation	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
roles	O	O
of	O	O
the	O	O
phosphotyrosine	O	O
binding	O	O
adaptors	O	O
in	O	O
Th2	O	O
differentiation	O	O
,	O	O
we	O	O
prepared	O	O
a	O	O
retrovirus	O	O
containing	O	O
a	O	O
mutant	O	O
of	O	O
the	O	O
human	B-DNA	O
(	I-DNA	O
h	I-DNA	O
)	O	O
IL-4R	O	O
alpha-chain	O	O
,	O	O
Y497F	O	O
,	O	O
which	O	O
is	O	O
unable	O	O
to	O	O
recruit	O	O
these	O	O
adaptors	O	O
.	O	O

The	O	O
mutant	O	O
hIL-4Ralpha	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
wild-type	O	O
(	O	O
WT	O	O
)	O	O
hIL-4Ralpha	O	O
,	O	O
was	O	O
introduced	O	O
into	O	O
naive	O	O
CD4	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

Upon	O	O
hIL-4	O	O
stimulation	O	O
,	O	O
Y497F	O	O
worked	O	O
as	O	O
well	O	O
as	O	O
the	O	O
WT	O	O
hIL-4Ralpha	O	O
in	O	O
driving	O	O
Th2	O	O
differentiation	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
Gata3	O	O
up-regulation	O	O
and	O	O
IL-4	O	O
production	O	O
.	O	O

Furthermore	O	O
,	O	O
IL-4-driven	O	O
cell	O	O
expansion	O	O
was	O	O
also	O	O
normal	O	O
in	O	O
the	O	O
cells	O	O
infected	O	O
with	O	O
Y497F	O	O
,	O	O
although	O	O
cells	O	O
infected	O	O
with	O	O
Y497F	O	O
were	O	O
not	O	O
capable	O	O
of	O	O
phosphorylating	O	O
insulin	B-protein	O
receptor	I-protein	O
substrate	O	O
2	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
signal	O	O
pathway	O	O
mediated	O	O
by	O	O
Y497	O	O
is	O	O
dispensable	O	O
for	O	O
both	O	O
IL-4	O	O
-driven	O	O
Th2	O	O
differentiation	O	O
and	O	O
cell	O	O
expansion	O	O
.	O	O

Both	O	O
WT	O	O
and	O	O
Y497F	O	O
hIL-4Ralpha	O	O
lose	O	O
the	O	O
ability	O	O
to	O	O
drive	O	O
Th2	O	O
differentiation	O	O
and	O	O
cell	O	O
expansion	O	O
in	O	O
Stat6-knockout	O	O
CD4	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

A	O	O
constitutively	O	O
activated	O	O
form	O	O
of	O	O
Stat6	O	O
introduced	O	O
into	O	O
CD4	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
resulted	O	O
in	O	O
both	O	O
Th2	O	O
differentiation	O	O
and	O	O
enhanced	O	O
cell	O	O
expansion	O	O
.	O	O

Thus	O	O
,	O	O
activated	O	O
Stat6	O	O
is	O	O
necessary	O	O
and	O	O
sufficient	O	O
to	O	O
mediate	O	O
both	O	O
IL-4	O	O
-driven	O	O
Th2	O	O
differentiation	O	O
and	O	O
cell	O	O
expansion	O	O
in	O	O
CD4	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
effect	O	O
of	O	O
HIV-1	B-protein	O
regulatory	I-protein	O
proteins	I-protein	O
on	O	O
cellular	O	O
genes	O	O
:	O	O
derepression	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
by	O	O
Tat	O	O
.	O	O

In	O	O
HIV-infected	O	O
individuals	O	O
dysregulation	O	O
of	O	O
the	O	O
immune	O	O
system	O	O
is	O	O
characterized	O	O
by	O	O
severe	O	O
disorders	O	O
of	O	O
the	O	O
cytokine	B-protein	O
network	I-protein	O
.	O	O

Increase	O	O
secretion	O	O
of	O	O
IL-2	B-protein	O
,	O	O
the	O	O
major	B-DNA	O
T	I-DNA	O
cell	I-protein	O
growth	I-protein	O
and	O	O
differentiation	O	O
cytokine	B-protein	O
,	O	O
may	O	O
play	O	O
a	O	O
decisive	O	O
role	O	O
in	O	O
sensitization	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
for	O	O
activation	O	O
induced	O	O
apoptosis	O	O
and	O	O
indirect	O	O
death	O	O
of	O	O
activated	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
through	O	O
augmented	O	O
virus	O	O
replication	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
cause	O	O
of	O	O
enhanced	O	O
IL-2	B-protein	O
secretion	O	O
and	O	O
found	O	O
that	O	O
the	O	O
HIV	B-protein	O
Tat	I-protein	O
induces	O	O
this	O	O
effect	O	O
.	O	O

We	O	O
demonstrate	O	O
that	O	O
increased	O	O
IL-2	B-protein	O
secretion	O	O
is	O	O
due	O	O
to	O	O
Tat	O	O
-enhanced	O	O
IL-2	B-protein	O
promoter	O	O
activation	O	O
.	O	O

Tat	O	O
derepresses	O	O
and	O	O
activates	O	O
the	O	O
distal	B-DNA	O
AP-1	I-DNA	O
site	I-DNA	O
(	O	O
position	O	O
-185	O	O
to	O	O
-177	O	O
)	O	O
in	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
.	O	O

In	O	O
nonstimulated	O	O
T	B-cell_type	O
cells	I-cell_type	O
a	O	O
repressor	O	O
complex	O	O
containing	O	O
NF-IL6	O	O
,	O	O
JunB	O	O
,	O	O
c-Fos	O	O
and	O	O
Fra-1	B-protein	O
is	O	O
formed	O	O
on	O	O
the	O	O
AP-1	B-DNA	O
(	I-DNA	O
IL-2/d	I-DNA	O
)	O	O
site	O	O
and	O	O
represses	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
activity	O	O
.	O	O

After	O	O
T	O	O
cell	O	O
activation	O	O
,	O	O
a	O	O
heterodimeric	O	O
activator	O	O
containing	O	O
p65	B-protein	O
and	I-protein	O
c-Jun	I-protein	O
binds	O	O
to	O	O
the	O	O
AP-1	B-DNA	O
(	I-DNA	O
IL-2/d	I-DNA	O
)	I-DNA	O
site	I-DNA	O
.	O	O

HIV	O	O
Tat	O	O
enhances	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
and	O	O
consequently	O	O
,	O	O
activates	O	O
the	O	O
AP-1	B-DNA	O
(	I-DNA	O
IL-2/d	I-DNA	O
)	O	O
site	O	O
.	O	O

Our	O	O
data	O	O
provide	O	O
evidence	O	O
for	O	O
a	O	O
novel	O	O
mechanism	O	O
by	O	O
which	O	O
HIV	O	O
Tat	O	O
dysregulates	O	O
IL-2	B-protein	O
production	O	O
and	O	O
therefore	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
HIV-1	O	O
infection	O	O
in	O	O
a	O	O
way	O	O
yet	O	O
to	O	O
be	O	O
clarified	O	O
.	O	O

Transforming	O	O
growth	O	O
factor-beta1	O	O
interferes	O	O
with	O	O
thrombopoietin-induced	O	O
signal	O	O
transduction	O	O
in	O	O
megakaryoblastic	O	O
and	O	O
erythroleukemic	B-cell_type	O
cells	I-cell_type	O
.	O	O

OBJECTIVE	O	O
:	O	O
Thrombopoietin	O	O
(	O	O
TPO	O	O
)	O	O
and	O	O
transforming	B-protein	O
growth	I-protein	O
factor-beta	I-protein	O
(	O	O
1	O	O
)	O	O
(	O	O
TGF-beta	O	O
(	O	O
1	O	O
)	O	O
)	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
exert	O	O
opposite	O	O
effects	O	O
on	O	O
proliferation	O	O
and	O	O
megakaryocytic	O	O
differentiation	O	O
of	O	O
hematopoietic	B-cell_type	O
cells	I-cell_type	O
.	O	O

To	O	O
determine	O	O
whether	O	O
TGF-beta	O	O
(	O	O
1	O	O
)	O	O
interferes	O	O
directly	O	O
with	O	O
TPO	O	O
-induced	O	O
signal	O	O
transduction	O	O
in	O	O
hematopoietic	B-cell_type	O
cells	I-cell_type	O
,	O	O
we	O	O
compared	O	O
the	O	O
regulatory	O	O
effects	O	O
in	O	O
the	O	O
TPO	O	O
-responsive	O	O
cell	O	O
lines	O	O
Mo-7e	O	O
and	O	O
HEL	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
The	O	O
cells	O	O
were	O	O
stimulated	O	O
by	O	O
100	O	O
ng/mL	O	O
TPO	O	O
and/or	O	O
100	O	O
ng/mL	O	O
TGF-beta1	O	O
and	O	O
analyzed	O	O
for	O	O
proliferation	O	O
(	O	O
3H	O	O
thymidine	O	O
incorporation	O	O
)	O	O
,	O	O
viability	O	O
(	O	O
trypan	O	O
blue	O	O
exclusion	O	O
)	O	O
,	O	O
and	O	O
protein	O	O
expression	O	O
and	O	O
phosphorylation	O	O
(	O	O
Western	O	O
blot	B-protein	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
TPO	O	O
enhanced	O	O
the	O	O
proliferation	O	O
of	O	O
Mo-7e	B-cell_type	O
cells	I-cell_type	O
as	O	O
determined	O	O
by	O	O
3H-thymidine	O	O
incorporation	O	O
,	O	O
whereas	O	O
TGF-beta1	O	O
suppressed	O	O
baseline	O	O
cell	O	O
growth	O	O
and	O	O
antagonized	O	O
the	O	O
proliferative	O	O
effect	O	O
of	O	O
TPO	O	O
.	O	O

TPO	O	O
-induced	O	O
proliferation	O	O
also	O	O
was	O	O
reduced	O	O
by	O	O
a	O	O
specific	O	O
inhibitor	O	O
of	O	O
the	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
(	O	O
MAPK	B-protein	O
)	O	O
pathway	O	O
(	O	O
PD098059	O	O
)	O	O
,	O	O
which	O	O
inhibits	O	O
activation	O	O
of	O	O
the	O	O
MAPK	O	O
extracellular	B-protein	O
signal-regulated	I-protein	O
kinases	I-protein	O
(	O	O
ERK	O	O
)	O	O
ERK1	O	O
and	O	O
ERK2	O	O
,	O	O
and	O	O
AG490	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
Janus	O	O
kinase-2	O	O
,	O	O
which	O	O
completely	O	O
blocked	O	O
TPO	O	O
-induced	O	O
proliferation	O	O
.	O	O

As	O	O
demonstrated	O	O
by	O	O
Western	O	O
blotting	O	O
,	O	O
TGF-beta1	O	O
reduced	O	O
the	O	O
TPO	O	O
-stimulated	O	O
ERK1	O	O
/	O	O
ERK2	O	O
and	O	O
STAT5	O	O
phosphorylation	O	O
in	O	O
Mo-7e	O	O
and	O	O
HEL	B-cell_line	O
cells	I-cell_line	O
.	O	O

This	O	O
effect	O	O
was	O	O
completely	O	O
reversed	O	O
by	O	O
preincubation	O	O
with	O	O
a	O	O
tyrosine	O	O
phosphatase	O	O
inhibitor	O	O
(	O	O
Na3VO4	B-protein	O
)	O	O
,	O	O
which	O	O
suggests	O	O
that	O	O
TGF-beta1	O	O
activated	O	O
a	O	O
phosphatase	O	O
.	O	O

Although	O	O
STAT3	B-protein	O
also	O	O
was	O	O
activated	O	O
by	O	O
TPO	O	O
,	O	O
STAT3	B-protein	O
activation	O	O
remained	O	O
unaltered	O	O
by	O	O
TGF-beta1	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Taken	O	O
together	O	O
,	O	O
these	O	O
data	O	O
suggest	O	O
that	O	O
TGF-beta1	O	O
modulates	O	O
TPO	O	O
-mediated	O	O
effects	O	O
on	O	O
megakaryocytic	O	O
proliferation	O	O
by	O	O
interfering	O	O
with	O	O
TPO	O	O
-induced	O	O
signal	O	O
transduction	O	O
,	O	O
particularly	O	O
by	O	O
reducing	O	O
the	O	O
activities	O	O
of	O	O
MAPK	O	O
ERK1/ERK2	O	O
and	O	O
STAT5	O	O
.	O	O

Invariant	O	O
chain	O	O
induces	O	O
B	O	O
cell	O	O
maturation	O	O
by	O	O
activating	O	O
a	O	O
TAF	O	O
(	O	O
II	I-protein	O
)	O	O
105-NF-kappaB	O	O
-dependent	O	O
transcription	O	O
program	O	O
.	O	O

Early	O	O
stages	O	O
of	O	O
B	O	O
cell	O	O
development	O	O
occur	O	O
in	O	O
the	O	O
bone	O	O
marrow	O	O
,	O	O
resulting	O	O
in	O	O
formation	O	O
of	O	O
immature	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

From	O	O
there	O	O
these	O	O
immature	O	O
cells	O	O
migrate	O	O
to	O	O
the	O	O
spleen	O	O
where	O	O
they	O	O
differentiate	O	O
to	O	O
mature	B-cell_type	O
cells	I-cell_type	O
.	O	O

This	O	O
final	O	O
maturation	O	O
step	O	O
is	O	O
crucial	O	O
for	O	O
the	O	O
B	B-cell_type	O
cells	I-cell_type	O
to	O	O
become	O	O
responsive	O	O
to	O	O
antigens	O	O
and	O	O
to	O	O
participate	O	O
in	O	O
the	O	O
immune	O	O
response	O	O
.	O	O

Recently	O	O
,	O	O
invariant	O	O
chain	O	O
(	O	O
Ii	O	O
)	O	O
,	O	O
a	O	O
major	B-protein	O
histocompatibility	I-protein	O
complex	I-protein	O
class	I-protein	O
II	I-protein	O
chaperone	I-protein	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
transcription	B-protein	O
factors	I-protein	O
c-Rel	I-protein	O
and	O	O
p65/RelA	O	O
,	O	O
were	O	O
found	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
final	O	O
antigen-independent	O	O
differentiation	O	O
stage	O	O
of	O	O
B	B-cell_type	O
cells	I-cell_type	O
in	O	O
the	O	O
spleen	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
a	O	O
possible	O	O
link	O	O
between	O	O
Ii	O	O
-dependent	O	O
B	O	O
cell	O	O
maturation	O	O
and	O	O
the	O	O
NF-kappaB	O	O
pathway	O	O
.	O	O

Our	O	O
studies	O	O
indicate	O	O
that	O	O
Ii	O	O
-induced	O	O
B	B-protein	O
cell	O	O
maturation	O	O
involves	O	O
activation	O	O
of	O	O
transcription	O	O
mediated	O	O
by	O	O
the	O	O
NF-kappaB	O	O
p65/RelA	O	O
homodimer	O	O
and	O	O
requires	O	O
the	O	O
B	B-protein	O
cell-enriched	I-protein	O
coactivator	I-protein	O
TBP-associated	I-protein	O
factor	I-protein	O
(	O	O
II	B-protein	O
)	O	O
105	O	O
.	O	O

Androgens	O	O
indirectly	O	O
accelerate	O	O
thymocyte	O	O
apoptosis	O	O
.	O	O

Apoptotic	O	O
processes	O	O
,	O	O
or	O	O
the	O	O
disturbance	O	O
of	O	O
the	O	O
natural	O	O
regulation	O	O
of	O	O
these	O	O
processes	O	O
,	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
autoimmune	O	O
diseases	O	O
(	O	O
AID	B-protein	O
)	O	O
.	O	O

Women	O	O
are	O	O
,	O	O
in	O	O
general	O	O
,	O	O
more	O	O
susceptible	O	O
than	O	O
men	O	O
to	O	O
develop	O	O
AID	O	O
like	O	O
rheumatoid	O	O
arthritis	O	O
.	O	O

Androgens	O	O
and	O	O
glucocorticoids	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
oestrogens	O	O
,	O	O
have	O	O
favourable	O	O
effects	O	O
in	O	O
AID	O	O
models	O	O
as	O	O
well	O	O
as	O	O
in	O	O
human	O	O
AID	O	O
.	O	O

It	O	O
is	O	O
known	O	O
that	O	O
glucocorticoids	O	O
(	O	O
GC	O	O
)	O	O
,	O	O
used	O	O
for	O	O
treatment	O	O
of	O	O
AID	O	O
,	O	O
increase	O	O
apoptosis	O	O
in	O	O
the	O	O
thymus	O	O
resulting	O	O
in	O	O
decreased	O	O
numbers	O	O
of	O	O
CD4+	O	O
CD8+	O	O
thymocytes	B-cell_type	O
.	O	O

It	O	O
was	O	O
asked	O	O
whether	O	O
androgens	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
oestrogens	O	O
,	O	O
exert	O	O
their	O	O
favourable	O	O
effects	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
AID	O	O
by	O	O
a	O	O
mechanism	O	O
comparable	O	O
to	O	O
that	O	O
described	O	O
for	O	O
GC	O	O
by	O	O
eliminating	O	O
the	O	O
apoptosis	O	O
prone	I-protein	O
CD4+	I-protein	O
CD8+	O	O
population	O	O
in	O	O
the	O	O
thymus	O	O
.	O	O

Although	O	O
both	O	O
androgens	O	O
and	O	O
oestrogens	O	O
proved	O	O
thymolytic	O	O
,	O	O
a	O	O
significantly	O	O
decreased	O	O
percentage	O	O
of	O	O
CD4+	O	O
CD8+	O	O
thymocytes	O	O
was	O	O
observed	O	O
by	O	O
flow	O	O
cytometry	O	O
after	O	O
treatment	O	O
of	O	O
mice	O	O
with	O	O
the	O	O
androgen	B-protein	O
methyltestosterone	I-protein	O
,	O	O
but	O	O
not	O	O
with	O	O
the	O	O
oestrogen	O	O
ethinylestradiol	I-protein	O
.	O	O

To	O	O
investigate	O	O
whether	O	O
the	O	O
observed	O	O
thymolytic	O	O
effects	O	O
were	O	O
due	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
hormone	B-protein	O
receptors	I-protein	O
on	O	O
thymocytes	B-cell_type	O
,	O	O
cells	I-cell_type	O
were	O	O
isolated	O	O
from	O	O
the	O	O
thymus	O	O
and	O	O
incubated	O	O
with	O	O
androgens	O	O
or	O	O
oestrogens	O	O
to	O	O
measure	O	O
apoptosis	O	O
.	O	O

Several	O	O
techniques	O	O
were	O	O
used	O	O
to	O	O
determine	O	O
thymocyte	O	O
apoptosis	O	O
in	O	O
vitro	O	O
,	O	O
but	O	O
no	O	O
enhanced	O	O
apoptotic	O	O
signal	O	O
was	O	O
observed	O	O
.	O	O

Using	O	O
the	O	O
very	O	O
sensitive	O	O
TUNEL	O	O
assay	O	O
,	O	O
no	O	O
direct	O	O
effect	O	O
of	O	O
androgens	O	O
on	O	O
thymocytes	B-cell_type	O
in	O	O
vitro	O	O
could	O	O
be	O	O
observed	O	O
.	O	O

This	O	O
is	O	O
in	O	O
sharp	O	O
contrast	O	O
to	O	O
the	O	O
high	O	O
signal	O	O
observed	O	O
with	O	O
GC	O	O
.	O	O

Therefore	O	O
,	O	O
upon	O	O
in	O	O
vivo	O	O
androgen	O	O
treatment	O	O
,	O	O
other	O	O
cells	O	O
containing	O	O
androgen	B-protein	O
receptors	I-protein	O
than	O	O
thymocytes	O	O
are	O	O
probably	O	O
involved	O	O
in	O	O
inducing	O	O
the	O	O
increase	O	O
in	O	O
thymic	O	O
apoptosis	O	O
.	O	O

To	O	O
study	O	O
the	O	O
role	O	O
of	O	O
the	O	O
androgen	B-protein	O
receptor	I-protein	O
on	O	O
thymocyte	O	O
apoptosis	O	O
,	O	O
androgen	B-protein	O
receptor	I-protein	O
mutant	O	O
(	O	O
Tfm/Y	O	O
)	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
androgens	O	O
.	O	O

No	O	O
alterations	O	O
of	O	O
thymocyte	O	O
subpopulations	O	O
were	O	O
seen	O	O
,	O	O
suggesting	O	O
that	O	O
changes	O	O
in	O	O
the	O	O
percentage	O	O
of	O	O
CD4+	B-protein	O
CD8+	O	O
thymocytes	O	O
after	O	O
administration	O	O
of	O	O
androgens	O	O
depend	O	O
on	O	O
the	O	O
presence	O	O
of	O	O
functional	O	O
androgen	B-protein	O
receptors	I-protein	O
.	O	O

Thus	O	O
,	O	O
it	O	O
is	O	O
concluded	O	O
that	O	O
androgens	O	O
indirectly	O	O
accelerate	O	O
thymocyte	O	O
apoptosis	O	O
in	O	O
vivo	O	O
.	O	O

Inhibition	O	O
of	O	O
the	O	O
transcription	B-protein	O
factors	I-protein	O
AP-1	I-protein	O
and	O	O
NF-kappaB	O	O
in	O	O
CD4	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
by	O	O
peroxisome	O	O
proliferator-activated	B-protein	O
receptor	I-protein	O
gamma	O	O
ligands	O	O
.	O	O

The	O	O
peroxisome	B-protein	O
proliferator-activated	I-protein	O
receptor	I-protein	O
gamma	I-protein	O
(	O	O
PPARgamma	B-protein	O
)	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
nuclear	B-protein	O
hormone	I-protein	O
receptor	I-protein	O
superfamily	I-protein	O
,	O	O
is	O	O
essential	O	O
for	O	O
adipocyte	O	O
differentiation	O	O
and	O	O
glucose	O	O
homeostasis	O	O
.	O	O

PPARgamma	O	O
has	O	O
been	O	O
found	O	O
recently	O	O
to	O	O
regulate	O	O
macrophage	O	O
activation	O	O
in	O	O
response	O	O
to	O	O
mitogens	O	O
and	O	O
inflammation	O	O
.	O	O

Our	O	O
study	O	O
shows	O	O
PPARgamma	O	O
to	O	O
be	O	O
preferentially	O	O
expressed	O	O
in	O	O
the	O	O
nuclei	O	O
of	O	O
resting	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
to	O	O
increase	O	O
upon	O	O
activation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
by	O	O
either	O	O
anti-CD3	O	O
and	O	O
anti-CD28	O	O
or	O	O
phorbol	O	O
myristyl	O	O
acetate	O	O
(	O	O
PMA	O	O
)	O	O
.	O	O

We	O	O
also	O	O
found	O	O
the	O	O
PPARgamma	O	O
ligand	O	O
ciglitizone	O	O
to	O	O
attenuate	O	O
the	O	O
activation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
by	O	O
inhibiting	O	O
cytokine	B-protein	O
gene	I-DNA	O
expression	O	O
and	O	O
anti-CD3	B-protein	O
and	O	O
anti-CD28	O	O
or	O	O
PMA-induced	O	O
proliferative	O	O
responses	O	O
.	O	O

Inhibition	O	O
of	O	O
both	O	O
the	O	O
proliferative	O	O
response	O	O
and	O	O
inflammatory	O	O
cytokine	B-protein	O
expression	O	O
in	O	O
CD4	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
was	O	O
correlated	O	O
with	O	O
suppression	O	O
of	O	O
the	O	O
activated	B-protein	O
transcription	I-protein	O
factors	I-protein	O
AP1	I-protein	O
and	O	O
NF-kappaB	O	O
.	O	O

PPARgamma	O	O
ligands	O	O
also	O	O
strongly	O	O
inhibited	O	O
SEA-induced	O	O
Vbeta3	O	O
T	O	O
cell	O	O
activation	O	O
in	O	O
vivo	O	O
.	O	O

These	O	O
results	O	O
,	O	O
together	O	O
with	O	O
previous	O	O
findings	O	O
of	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
PPARgamma	O	O
ligands	O	O
on	O	O
activated	O	O
macrophages	B-protein	O
,	O	O
provide	O	O
clear	O	O
evidence	O	O
for	O	O
PPARgamma	O	O
as	O	O
a	O	O
negative	O	O
regulator	O	O
of	O	O
the	O	O
inflammatory	O	O
activation	O	O
of	O	O
both	O	O
macrophage	O	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

PPARgamma	O	O
may	O	O
thus	O	O
be	O	O
a	O	O
potential	O	O
therapeutic	O	O
target	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
autoimmunity	O	O
.	O	O

A	O	O
prominent	O	O
role	O	O
for	O	O
activator	O	O
protein-1	O	O
in	O	O
the	O	O
transcription	O	O
of	O	O
the	O	O
human	B-DNA	O
2B4	I-DNA	O
(	I-DNA	O
CD244	I-DNA	O
)	I-DNA	O
gene	I-DNA	O
in	O	O
NK	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
cell	O	O
surface	O	O
glycoprotein	B-protein	O
2B4	I-protein	O
(	O	O
CD244	B-protein	O
)	O	O
of	O	O
the	O	O
Ig	B-protein	O
superfamily	I-protein	O
is	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
NK	O	O
and	O	O
T	O	O
lymphocyte	O	O
functions	O	O
.	O	O

We	O	O
have	O	O
recently	O	O
identified	O	O
CD48	O	O
as	O	O
the	O	O
high	O	O
affinity	O	O
counterreceptor	O	O
for	O	O
2B4	O	O
in	O	O
both	O	O
mice	O	O
and	O	O
humans	O	O
.	O	O

The	O	O
cytoplasmic	B-protein	O
domain	I-protein	O
of	O	O
2B4	O	O
associates	O	O
with	O	O
src	B-protein	O
homology	I-protein	O
2	I-protein	O
domain-containing	I-protein	O
protein	I-protein	O
or	O	O
signaling	O	O
lymphocyte	O	O
activation	O	O
molecule-associated	O	O
protein	O	O
,	O	O
whose	O	O
mutation	O	O
is	O	O
the	O	O
underlying	O	O
genetic	O	O
defect	O	O
in	O	O
the	O	O
X-linked	O	O
lymphoproliferative	O	O
syndrome	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
report	O	O
the	O	O
molecular	O	O
cloning	O	O
and	O	O
characterization	O	O
of	O	O
the	O	O
human	B-DNA	O
2B4	I-DNA	O
(	I-DNA	O
h2B4	I-DNA	O
)	I-DNA	O
promoter	I-DNA	O
.	O	O

Through	O	O
primer	O	O
extension	O	O
analysis	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
transcription	O	O
of	O	O
the	O	O
h2B4	B-DNA	O
gene	I-DNA	O
initiates	O	O
at	O	O
multiple	O	O
start	O	O
sites	O	O
.	O	O

We	O	O
isolated	O	O
h2B4	O	O
genomic	O	O
clones	O	O
and	O	O
PCR	O	O
amplified	O	O
the	O	O
5	O	O
'	O	O
untranslated	O	O
region	O	O
containing	O	O
the	O	O
promoter	B-DNA	O
elements	I-DNA	O
.	O	O

We	O	O
have	O	O
identified	O	O
a	O	O
functional	B-DNA	O
AP-1	I-DNA	O
site	I-DNA	O
that	O	O
lies	O	O
between	O	O
(	O	O
-106	O	O
to	O	O
-100	O	O
)	O	O
through	O	O
transient	O	O
transfection	O	O
analysis	O	O
in	O	O
YT	B-cell_line	O
cells	I-cell_line	O
,	O	O
a	O	O
human	B-cell_line	O
NK	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
.	O	O

EMSAs	O	O
with	O	O
Abs	O	O
specific	O	O
for	O	O
various	O	O
protein	B-protein	O
factors	I-protein	O
of	O	O
the	O	O
AP-1	B-protein	O
family	I-protein	O
revealed	O	O
that	O	O
multiple	O	O
members	O	O
of	O	O
the	O	O
Jun	B-protein	O
family	I-protein	O
are	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
the	O	O
h2B4	B-DNA	O
gene	I-DNA	O
.	O	O

Mutation	O	O
of	O	O
the	O	O
AP-1	B-DNA	O
site	I-DNA	O
not	O	O
only	O	O
abolishes	O	O
protein/DNA	O	O
interactions	O	O
but	O	O
also	O	O
promoter	O	O
activity	O	O
.	O	O

These	O	O
results	O	O
demonstrate	O	O
a	O	O
significant	O	O
role	O	O
for	O	O
AP-1	O	O
in	O	O
the	O	O
transcriptional	O	O
regulation	O	O
of	O	O
the	O	O
h2B4	B-DNA	O
gene	I-DNA	O
.	O	O

Functional	O	O
correction	O	O
of	O	O
FA-C	B-cell_type	O
cells	I-cell_type	O
with	O	O
FANCC	O	O
suppresses	O	O
the	O	O
expression	O	O
of	O	O
interferon	B-DNA	O
gamma-inducible	I-DNA	O
genes	I-DNA	O
.	O	O

Because	O	O
hematopoietic	B-cell_type	O
cells	I-cell_type	O
derived	O	O
from	O	O
Fanconi	O	O
anemia	O	O
(	O	O
FA	O	O
)	O	O
patients	O	O
of	O	O
the	O	O
C-complementation	O	O
group	O	O
(	O	O
FA-C	B-protein	O
)	O	O
are	O	O
hypersensitive	O	O
to	O	O
the	O	O
inhibitory	O	O
effects	O	O
of	O	O
interferon	B-protein	O
gamma	I-protein	O
(	O	O
IFNgamma	O	O
)	O	O
,	O	O
the	O	O
products	O	O
of	O	O
certain	O	O
IFNgamma-inducible	O	O
genes	I-DNA	O
known	O	O
to	O	O
influence	O	O
hematopoietic	O	O
cell	O	O
survival	O	O
were	O	O
quantified	O	O
.	O	O

High	O	O
constitutive	O	O
expression	O	O
of	O	O
the	O	O
IFNgamma-inducible	B-DNA	O
genes	I-DNA	O
,	O	O
IFN-stimulated	B-protein	O
gene	I-protein	O
factor	I-protein	O
3	I-protein	O
gamma	I-protein	O
subunit	I-protein	O
(	O	O
ISGF3gamma	B-protein	O
)	I-protein	O
,	O	O
IFN	B-protein	O
regulatory	I-protein	O
factor-1	I-protein	O
(	O	O
IRF-1	B-protein	O
)	O	O
,	O	O
and	O	O
the	O	O
cyclin-dependent	B-protein	O
kinase	I-protein	O
inhibitor	O	O
p21	O	O
(	O	O
WAF1	O	O
)	O	O
was	O	O
found	O	O
in	O	O
FANCC	O	O
mutant	O	O
B	O	O
lymphoblasts	O	O
,	O	O
low-density	O	O
bone	O	O
marrow	O	O
cells	I-cell_line	O
,	O	O
and	O	O
murine	O	O
embryonic	O	O
fibroblasts	O	O
.	O	O

Paradoxically	O	O
,	O	O
these	O	O
cells	O	O
do	O	O
not	O	O
activate	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
(	O	O
STAT	B-protein	O
)	O	O
1	O	O
properly	O	O
.	O	O

In	O	O
an	O	O
attempt	O	O
to	O	O
clarify	O	O
mechanisms	O	O
by	O	O
which	O	O
FA-C	B-cell_type	O
cells	I-cell_type	O
overexpress	O	O
IFNgamma-inducible	O	O
genes	O	O
in	O	O
the	O	O
face	O	O
of	O	O
defective	O	O
STAT1	B-protein	O
phosphorylation	O	O
,	O	O
it	O	O
was	O	O
reasoned	O	O
that	O	O
decreased	O	O
levels	O	O
of	O	O
activated	O	O
STAT1	B-protein	O
might	O	O
result	O	O
in	O	O
reduced	O	O
expression	O	O
of	O	O
a	O	O
hematopoietic	B-protein	O
IFNgamma-responsive	I-protein	O
protein	I-protein	O
that	O	O
normally	O	O
modulates	O	O
expression	O	O
of	O	O
other	O	O
IFNgamma-responsive	B-DNA	O
genes	I-DNA	O
.	O	O

Levels	O	O
of	O	O
the	O	O
IFNgamma	B-protein	O
-inducible	I-protein	O
factor	I-protein	O
IFN	I-protein	O
consensus	I-protein	O
sequence	I-protein	O
binding	I-protein	O
protein	I-protein	O
(	O	O
ICSBP	B-protein	O
)	O	O
,	O	O
a	O	O
negative	O	O
trans-acting	O	O
regulator	O	O
of	O	O
some	O	O
IFNgamma-inducible	O	O
genes	O	O
,	O	O
were	O	O
quantified	O	O
.	O	O

ICSBP	O	O
levels	O	O
were	O	O
reduced	O	O
in	O	O
FA-C	O	O
B	O	O
lymphoblasts	O	O
and	O	O
MEFs	O	O
.	O	O

However	O	O
,	O	O
enforced	O	O
expression	O	O
of	O	O
ICSBP	O	O
failed	O	O
to	O	O
down-regulate	O	O
IRF-1	O	O
,	O	O
ISGF3gamma	O	O
,	O	O
and	O	O
p21	O	O
(	O	O
WAF1	O	O
)	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
FANCC	B-protein	O
protein	I-protein	O
functions	O	O
to	O	O
modulate	O	O
expression	O	O
of	O	O
a	O	O
family	O	O
of	O	O
genes	O	O
that	O	O
in	O	O
normal	B-cell_type	O
cells	I-cell_type	O
are	O	O
inducible	O	O
only	O	O
by	O	O
specific	O	O
environmental	O	O
cues	O	O
for	O	O
apoptosis	O	O
or	O	O
mitogenic	O	O
inhibition	O	O
,	O	O
but	O	O
it	O	O
does	O	O
so	O	O
independently	O	O
of	O	O
the	O	O
classic	B-protein	O
IFN-STAT1	I-protein	O
pathway	I-protein	O
and	O	O
is	O	O
not	O	O
the	O	O
direct	O	O
result	O	O
of	O	O
reduced	B-protein	O
ICSBP	I-protein	O
expression	O	O
.	O	O

A	O	O
genetic	O	O
investigation	O	O
of	O	O
E2A	O	O
function	O	O
in	O	O
lymphocyte	O	O
development	O	O
.	O	O

Lymphocytes	O	O
are	O	O
derived	O	O
from	O	O
hematopoietic	B-cell_type	O
stem	I-cell_type	O
cells	I-cell_type	O
(	O	O
HSC	O	O
)	O	O
following	O	O
a	O	O
series	O	O
of	O	O
regulated	O	O
differentiation	O	O
events	O	O
.	O	O

Multipotent	O	O
HSCs	O	O
become	O	O
committed	O	O
to	O	O
the	O	O
B	B-protein	O
cell	O	O
lineage	O	O
in	O	O
bone	O	O
marrow	O	O
and	O	O
the	O	O
T	O	O
cell	O	O
lineage	O	O
in	O	O
the	O	O
thymus	O	O
after	O	O
receiving	O	O
appropriate	O	O
signals	O	O
from	O	O
the	O	O
corresponding	O	O
microenvironment	O	O
.	O	O

These	O	O
committed	B-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
must	O	O
then	O	O
undergo	O	O
V	O	O
(	O	O
D	O	O
)	O	O
J	O	O
recombination	O	O
at	O	O
the	O	O
immunoglobulin	O	O
gene	O	O
or	O	O
T	O	O
cell	B-DNA	O
receptor	I-DNA	O
gene	I-DNA	O
locus	O	O
resulting	O	O
in	O	O
clonal	O	O
production	O	O
of	O	O
functional	O	O
B	I-cell_type	O
or	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
respectively	O	O
.	O	O

Lymphocyte	O	O
commitment	O	O
and	O	O
differentiation	O	O
are	O	O
accompanied	O	O
by	O	O
programmed	O	O
gene	O	O
expression	O	O
or	O	O
repression	O	O
events	O	O
which	O	O
are	O	O
driven	O	O
by	O	O
lineage	O	O
and	O	O
stage	O	O
specific	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

The	O	O
basic-helix-loop-helix	B-protein	O
(	O	O
bHLH	B-protein	O
)	I-protein	O
transcription	I-protein	O
factors	I-protein	O
encoded	O	O
by	O	O
the	O	O
E2A	B-DNA	O
gene	I-DNA	O
are	O	O
involved	O	O
in	O	O
several	O	O
differentiation	O	O
events	O	O
during	O	O
B	O	O
and	O	O
T	O	O
cell	O	O
development	O	O
,	O	O
including	O	O
lineage	O	O
commitment	O	O
,	O	O
initiation	O	O
of	O	O
V	O	O
(	O	O
D	O	O
)	O	O
J	O	O
recombination	O	O
,	O	O
and	O	O
antigen	O	O
receptor	O	O
mediated	O	O
proliferation	O	O
and	O	O
differentiation	O	O
.	O	O

Several	O	O
recent	O	O
reviews	O	O
have	O	O
provided	O	O
a	O	O
comprehensive	O	O
discussion	O	O
of	O	O
biochemical	O	O
,	O	O
cellular	O	O
,	O	O
and	O	O
genetic	O	O
research	O	O
on	O	O
E2A	O	O
function	O	O
in	O	O
lymphocyte	O	O
development	O	O
(	O	O
1	O	O
,	O	O
2	O	O
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
only	O	O
discuss	O	O
some	O	O
of	O	O
the	O	O
genetic	O	O
approaches	O	O
our	O	O
laboratory	O	O
(	O	O
except	O	O
where	O	O
it	O	O
is	O	O
noted	O	O
)	O	O
has	O	O
undertaken	O	O
to	O	O
investigate	O	O
the	O	O
molecular	O	O
pathways	O	O
mediated	O	O
by	O	O
E2A	O	O
transcription	B-protein	O
factors	I-protein	O
in	O	O
lymphocyte	O	O
development	O	O

D609	O	O
inhibits	O	O
ionizing	O	O
radiation-induced	O	O
oxidative	O	O
damage	O	O
by	O	O
acting	O	O
as	O	O
a	O	O
potent	O	O
antioxidant	O	O
.	O	O

Tricyclodecan-9-yl-xanthogenate	O	O
(	O	O
D609	B-protein	O
)	O	O
has	O	O
been	O	O
extensively	O	O
studied	O	O
in	O	O
biological	O	O
systems	O	O
and	O	O
exhibits	O	O
a	O	O
variety	O	O
of	O	O
biological	O	O
functions	O	O
,	O	O
including	O	O
antiviral	O	O
,	O	O
antitumor	O	O
,	O	O
and	O	O
anti-inflammatory	O	O
activities	O	O
.	O	O

Most	O	O
of	O	O
these	O	O
activities	O	O
have	O	O
been	O	O
largely	O	O
attributed	O	O
to	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
D609	O	O
on	O	O
phosphatidylcholine-specific	B-protein	O
phospholipase	I-protein	O
C	I-protein	O
.	O	O

However	O	O
,	O	O
as	O	O
a	O	O
xanthate	O	O
derivative	O	O
,	O	O
D609	O	O
is	O	O
a	O	O
strong	O	O
electrolyte	O	O
and	O	O
readily	O	O
dissociates	O	O
to	O	O
xanthate	O	O
anions	O	O
and	O	O
cations	O	O
of	O	O
alkali	O	O
metals	O	O
in	O	O
solution	O	O
.	O	O

Xanthate	O	O
anions	O	O
and	O	O
protonated	O	O
xanthic	O	O
acid	O	O
contain	O	O
a	O	O
free	O	O
thiol	O	O
moiety	O	O
and	O	O
are	O	O
highly	O	O
reductive	O	O
.	O	O

This	O	O
implies	O	O
that	O	O
D609	O	O
and	O	O
other	O	O
xanthate	O	O
derivatives	O	O
may	O	O
function	O	O
as	O	O
potent	O	O
antioxidants	O	O
.	O	O

Indeed	O	O
,	O	O
we	O	O
found	O	O
that	O	O
D609	O	O
inhibited	O	O
the	O	O
Fenton	O	O
reaction-induced	O	O
oxidation	O	O
of	O	O
dihydrorhodamine	O	O
123	O	O
in	O	O
a	O	O
dose-dependent	O	O
manner	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
pyrrolidinedithiocarbamate	O	O
,	O	O
a	O	O
well	O	O
known	O	O
antioxidant	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
D609	O	O
inhibited	O	O
the	O	O
formation	O	O
of	O	O
the	O	O
alpha-phenyl-tert-butylnitrone-free	O	O
radical	O	O
spin	O	O
adducts	O	O
and	O	O
lipid	O	O
peroxidation	O	O
of	O	O
synaptosomal	O	O
membranes	O	O
by	O	O
the	O	O
Fenton	O	O
reagents	O	O
.	O	O

Furthermore	O	O
,	O	O
preincubation	O	O
of	O	O
lymphocytes	O	O
with	O	O
D609	O	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
diminution	O	O
of	O	O
ionizing	O	O
radiation	O	O
(	O	O
IR	B-protein	O
)	O	O
-induced	O	O
1	O	O
)	O	O
production	O	O
of	O	O
reactive	O	O
oxygen	O	O
species	O	O
;	O	O
2	O	O
)	O	O
decrease	O	O
in	O	O
intracellular	O	O
reduced	O	O
glutathione	O	O
;	O	O
3	O	O
)	O	O
oxidative	O	O
damage	O	O
to	O	O
proteins	O	O
and	O	O
lipids	O	O
;	O	O
and	O	O
4	O	O
)	O	O
activation	O	O
of	O	O
nuclear	O	O
factor-kappaB	O	O
.	O	O

Moreover	O	O
,	O	O
when	O	O
D609	O	O
(	O	O
50	O	O
mg/kg	O	O
i.v.	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
mice	O	O
10	O	O
min	O	O
prior	O	O
to	O	O
total	O	O
body	O	O
IR	O	O
(	O	O
6.5	O	O
and	O	O
8.5	O	O
Gy	O	O
)	O	O
,	O	O
it	O	O
protected	O	O
the	O	O
mice	O	O
from	O	O
IR-induced	O	O
lethality	O	O
.	O	O

Thus	O	O
,	O	O
these	O	O
results	O	O
indicate	O	O
that	O	O
D609	O	O
is	O	O
a	O	O
potent	O	O
antioxidant	O	O
and	O	O
has	O	O
the	O	O
ability	O	O
to	O	O
inhibit	O	O
IR-induced	O	O
cellular	O	O
oxidative	O	O
stress	O	O
.	O	O

Inhibition	O	O
of	O	O
AP-1	B-protein	O
by	O	O
the	O	O
glucocorticoid-inducible	B-protein	O
protein	I-protein	O
GILZ	O	O
.	O	O

The	O	O
immunosuppressive	O	O
effects	O	O
of	O	O
glucocorticoids	O	O
arise	O	O
largely	O	O
by	O	O
inhibition	O	O
of	O	O
cytokine	B-protein	O
gene	O	O
expression	O	O
,	O	O
which	O	O
has	O	O
been	O	O
ascribed	O	O
to	O	O
interference	O	O
between	O	O
the	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
and	O	O
transcription	B-protein	O
factors	I-protein	O
such	O	O
as	O	O
AP-1	B-protein	O
and	O	O
NF-kappa	B-protein	O
B	I-protein	O
as	O	O
well	O	O
as	O	O
by	O	O
competition	O	O
for	O	O
common	O	O
coactivators	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
glucocorticoid-induced	O	O
inhibition	O	O
of	O	O
interleukin-2	B-RNA	O
mRNA	I-RNA	O
expression	O	O
in	O	O
activated	B-cell_type	O
normal	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
required	O	O
new	O	O
protein	O	O
synthesis	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
phenomenon	O	O
is	O	O
secondary	O	O
to	O	O
expression	O	O
of	O	O
glucocorticoid-regulated	O	O
genes	B-DNA	O
.	O	O

One	O	O
of	O	O
the	O	O
most	O	O
prominent	O	O
glucocorticoid-induced	O	O
genes	I-DNA	O
is	O	O
glucocorticoid-induced	O	O
leucine	O	O
zipper	O	O
(	O	O
GILZ	O	O
)	O	O
,	O	O
which	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
inhibit	O	O
activation-induced	O	O
up-regulation	O	O
of	O	O
Fas	O	O
ligand	O	O
(	O	O
FasL	O	O
)	O	O
mRNA	I-RNA	O
.	O	O

Indeed	O	O
,	O	O
transient	O	O
expression	O	O
of	O	O
GILZ	O	O
in	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
blocked	O	O
induction	O	O
of	O	O
a	O	O
reporter	B-DNA	O
construct	I-DNA	O
driven	O	O
by	O	O
the	O	O
FasL	B-DNA	O
promoter	I-DNA	O
.	O	O

This	O	O
could	O	O
be	O	O
accounted	O	O
for	O	O
by	O	O
GILZ	O	O
-mediated	O	O
inhibition	O	O
of	O	O
Egr-2	O	O
and	O	O
Egr-3	B-protein	O
,	O	O
NFAT/AP-1	O	O
-inducible	O	O
transcription	B-protein	O
factors	I-protein	O
that	O	O
bind	O	O
a	O	O
regulatory	B-DNA	O
element	I-DNA	O
in	O	O
the	O	O
FasL	B-DNA	O
promoter	I-DNA	O
and	O	O
up-regulate	O	O
FasL	O	O
expression	O	O
.	O	O

GILZ	O	O
also	O	O
potently	O	O
inhibited	O	O
AP-1-driven	O	O
and	O	O
IL-2	O	O
promoter-driven	O	O
reporter	B-DNA	O
constructs	I-DNA	O
,	O	O
and	O	O
recombinant	O	O
GILZ	O	O
specifically	O	O
interacted	O	O
with	O	O
c-Fos	O	O
and	O	O
c-Jun	O	O
in	O	O
vitro	O	O
and	O	O
inhibited	O	O
the	O	O
binding	O	O
of	O	O
active	O	O
AP-1	O	O
to	O	O
its	O	O
target	O	O
DNA	O	O
.	O	O

Whereas	O	O
homodimerization	O	O
of	O	O
GILZ	O	O
required	O	O
the	O	O
presence	O	O
of	O	O
its	O	O
leucine	B-protein	O
zipper	O	O
,	O	O
the	O	O
interaction	O	O
with	O	O
c-Fos	B-protein	O
and	I-protein	O
c-Jun	I-protein	O
occurred	O	O
through	O	O
the	O	O
N-terminal	O	O
60-amino	O	O
acid	O	O
region	O	O
of	O	O
GILZ	O	O
.	O	O

Thus	O	O
,	O	O
GILZ	O	O
represents	O	O
a	O	O
glucocorticoid-induced	O	O
gene	O	O
product	O	O
that	O	O
can	O	O
inhibit	O	O
a	O	O
variety	O	O
of	O	O
activation-induced	O	O
events	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
by	O	O
direct	O	O
interference	O	O
with	O	O
AP-1	B-protein	O
,	O	O
and	O	O
is	O	O
therefore	O	O
a	O	O
candidate	O	O
for	O	O
a	O	O
mediator	O	O
of	O	O
glucocorticoid-induced	O	O
immunosuppression	O	O
.	O	O

Pharmacokinetic	O	O
differences	O	O
between	O	O
a	O	O
T	O	O
cell-tolerizing	O	O
and	O	O
a	O	O
T	O	O
cell-activating	O	O
peptide	O	O
.	O	O

Vaccination	O	O
with	O	O
a	O	O
peptide	O	O
representing	O	O
a	O	O
CTL	O	O
epitope	O	O
from	O	O
the	O	O
human	B-protein	O
papillomavirus	I-protein	O
(	O	O
HPV	B-protein	O
)	I-protein	O
16	I-protein	O
E7	I-protein	O
protein	I-protein	O
induces	O	O
a	O	O
specific	O	O
CTL	O	O
response	O	O
that	O	O
prevents	O	O
the	O	O
outgrowth	O	O
of	O	O
HPV16	O	O
E7-expressing	O	O
tumors	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
vaccination	O	O
with	O	O
a	O	O
peptide	O	O
encoding	O	O
an	O	O
adenovirus	B-DNA	O
type	I-DNA	O
5	I-DNA	O
(	O	O
Ad5	B-protein	O
)	O	O
E1A	O	O
CTL	O	O
epitope	O	O
results	O	O
in	O	O
CTL	O	O
tolerance	O	O
and	O	O
enhanced	O	O
growth	O	O
of	O	O
an	O	O
Ad5	O	O
E1A-expressing	O	O
tumor	O	O
.	O	O

It	O	O
is	O	O
unclear	O	O
why	O	O
these	O	O
peptides	O	O
induce	O	O
such	O	O
opposite	O	O
effects	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
a	O	O
difference	O	O
in	O	O
pharmacokinetics	O	O
can	O	O
explain	O	O
the	O	O
functional	O	O
contrasts	O	O
,	O	O
tritiated	O	O
Ad5	O	O
E1A	O	O
and	O	O
HPV16	O	O
E7	O	O
peptides	O	O
were	O	O
injected	O	O
into	O	O
mice	O	O
.	O	O

Results	O	O
show	O	O
that	O	O
the	O	O
tolerizing	O	O
peptide	O	O
spread	O	O
through	O	O
the	O	O
body	O	O
16	O	O
times	O	O
faster	O	O
than	O	O
the	O	O
activating	O	O
peptide	O	O
and	O	O
was	O	O
cleared	O	O
at	O	O
least	O	O
2	O	O
times	O	O
faster	O	O
.	O	O

The	O	O
HPV16	O	O
E7	O	O
peptide	O	O
kinetics	O	O
correlated	O	O
with	O	O
the	O	O
kinetics	O	O
of	O	O
HPV16	O	O
E7	O	O
-specific	O	O
CTL	O	O
induction	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
Ad5	O	O
E1A	O	O
peptide	O	O
injection	O	O
resulted	O	O
in	O	O
physical	O	O
deletion	O	O
of	O	O
preexisting	O	O
Ad5	O	O
E1A	O	O
-specific	O	O
CTLs	O	O
within	O	O
24	O	O
h	O	O
after	O	O
injection	O	O
.	O	O

This	O	O
tolerization	O	O
occurred	O	O
at	O	O
the	O	O
time	O	O
when	O	O
the	O	O
peptide	O	O
reached	O	O
its	O	O
maximum	O	O
peptide	O	O
concentration	O	O
in	O	O
the	O	O
organs	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
ubiquitous	O	O
expression	O	O
of	O	O
the	O	O
tolerizing	B-protein	O
Ad5	I-protein	O
E1A	I-protein	O
peptide	O	O
within	O	O
a	O	O
short	O	O
period	O	O
of	O	O
time	O	O
causes	O	O
activation-induced	O	O
cell	O	O
death	O	O
of	O	O
Ad5	O	O
E1A	O	O
-specific	O	O
CTLs	O	O
.	O	O

Therefore	O	O
,	O	O
information	O	O
on	O	O
the	O	O
pharmacokinetics	O	O
of	O	O
peptides	O	O
is	O	O
vital	O	O
for	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
peptide-based	O	O
vaccines	O	O
.	O	O

Smad3	O	O
and	O	O
Smad4	O	O
mediate	O	O
transforming	O	O
growth	O	O
factor-beta1	O	O
-induced	O	O
IgA	O	O
expression	O	O
in	O	O
murine	B-cell_type	O
B	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Transforming	B-protein	O
growth	I-protein	O
factor	I-protein	O
(	O	O
TGF	B-protein	O
)	O	O
-beta1	O	O
is	O	O
well	O	O
established	O	O
as	O	O
a	O	O
critical	O	O
IgA	O	O
isotype	O	O
switching	O	O
factor	O	O
and	O	O
Smad	O	O
molecules	O	O
have	O	O
been	O	O
reported	O	O
to	O	O
act	O	O
as	O	O
transducers	O	O
and	O	O
transcriptional	O	O
factors	B-protein	O
in	O	O
the	O	O
expression	O	O
of	O	O
TGF-beta1	O	O
-targeted	O	O
genes	I-DNA	O
.	O	O

We	O	O
examined	O	O
the	O	O
involvement	O	O
of	O	O
Smad	B-protein	O
proteins	I-protein	O
in	O	O
TGF-beta1	O	O
-induced	O	O
IgA	O	O
expression	O	O
.	O	O

First	O	O
,	O	O
we	O	O
found	O	O
that	O	O
TGF-beta1	O	O
significantly	O	O
increases	O	O
endogenous	O	O
germ-line	O	O
(	O	O
GL	O	O
)	O	O
alpha	O	O
transcripts	O	O
by	O	O
LPS-stimulated	O	O
CH12.LX.4933	O	O
(	O	O
mu	O	O
(	O	O
+	I-cell_line	O
)	I-cell_line	O
)	O	O
B	B-cell_type	O
lymphoma	I-cell_type	O
cells	I-cell_type	O
.	O	O

To	O	O
investigate	O	O
its	O	O
signaling	O	O
mechanisms	O	O
,	O	O
the	O	O
lymphoma	O	O
cell	O	O
line	O	O
was	O	O
transfected	O	O
with	O	O
pFL3	O	O
that	O	O
contains	O	O
the	O	O
TGF-beta-responsive	O	O
element	O	O
of	O	O
the	O	O
GLalpha	B-DNA	O
promoter	I-DNA	O
,	O	O
and	O	O
stimulated	O	O
with	O	O
TGF-beta1	O	O
.	O	O

Similar	O	O
to	O	O
endogenous	O	O
GLalpha	O	O
transcripts	O	O
,	O	O
TGF-beta1	O	O
induces	O	O
GLalpha	O	O
promoter	O	O
activity	O	O
and	O	O
overexpression	O	O
of	O	O
Smad3	O	O
markedly	O	O
enhances	O	O
the	O	O
promoter	O	O
activity	O	O
.	O	O

This	O	O
activity	O	O
is	O	O
further	O	O
augmented	O	O
by	O	O
cotransfected	O	O
Smad4	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
Smad7	O	O
substantially	O	O
abrogates	O	O
the	O	O
synergistic	O	O
effect	O	O
of	O	O
Smad3/4	O	O
on	O	O
GLalpha	B-DNA	O
promoter	I-DNA	O
activity	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
overexpression	O	O
of	O	O
Smad3/4	O	O
enhances	O	O
TGF-beta1	O	O
-induced	O	O
endogenous	O	O
GLalpha	O	O
transcripts	O	O
in	O	O
normal	O	O
spleen	O	O
B	O	O
cell	O	O
s	O	O
.	O	O

Finally	O	O
,	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
TGF-beta1	O	O
,	O	O
overexpression	O	O
of	O	O
Smad3/4	O	O
selectively	O	O
increases	O	O
both	O	O
surface	O	O
IgA	O	O
expression	O	O
and	O	O
IgA	O	O
production	O	O
.	O	O

The	O	O
results	O	O
from	O	O
the	O	O
present	O	O
study	O	O
indicate	O	O
that	O	O
Smad3	O	O
,	O	O
Smad4	O	O
,	O	O
and	O	O
Smad7	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
serve	O	O
as	O	O
mediators	O	O
linking	O	O
TGF-beta1	O	O
to	O	O
transcriptional	O	O
regulation	O	O
of	O	O
IgA	O	O
switching	O	O
related	O	O
gene	O	O
and	O	O
regulation	O	O
of	O	O
IgA	O	O
class	O	O
switching	O	O
.	O	O

The	O	O
translesion	O	O
DNA	B-protein	O
polymerase	I-protein	O
zeta	O	O
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
Ig	O	O
and	O	O
bcl-6	O	O
somatic	O	O
hypermutation	O	O
.	O	O

Ig	O	O
somatic	O	O
mutations	O	O
would	O	O
be	O	O
introduced	O	O
by	O	O
a	O	O
polymerase	O	O
(	O	O
pol	O	O
)	O	O
while	O	O
repairing	O	O
DNA	O	O
outside	O	O
main	O	O
DNA	O	O
replication	O	O
.	O	O

We	O	O
show	O	O
that	O	O
human	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
constitutively	O	O
express	O	O
the	O	O
translesion	O	O
pol	O	O
zeta	O	O
,	O	O
which	O	O
effectively	O	O
extends	O	O
DNA	O	O
past	O	O
mismatched	O	O
bases	O	O
(	O	O
mispair	O	O
extender	O	O
)	O	O
,	O	O
and	O	O
pol	O	O
eta	O	O
,	O	O
which	O	O
bypasses	O	O
DNA	O	O
lesions	O	O
in	O	O
an	O	O
error-free	O	O
fashion	O	O
.	O	O

Upon	O	O
B	B-protein	O
cell	I-protein	O
receptor	I-protein	O
(	O	O
BCR	O	O
)	O	O
engagement	O	O
and	O	O
coculture	O	O
with	O	O
activated	O	O
CD4+	I-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
,	O	O
these	O	O
lymphocytes	O	O
upregulated	O	O
pol	O	O
zeta	O	O
,	O	O
downregulated	O	O
pol	O	O
eta	O	O
,	O	O
and	O	O
mutated	O	O
the	O	O
Ig	O	O
and	O	O
bcl-6	O	O
genes	O	O
.	O	O

Inhibition	O	O
of	O	O
the	O	O
pol	B-DNA	O
zeta	O	O
REV3	O	O
catalytic	O	O
subunit	O	O
by	O	O
specific	O	O
phosphorothioate-modified	O	O
oligonucleotides	O	O
impaired	O	O
Ig	O	O
and	O	O
bcl-6	O	O
hypermutation	O	O
and	O	O
UV	O	O
damage-induced	O	O
DNA	O	O
mutagenesis	O	O
,	O	O
without	O	O
affecting	O	O
cell	O	O
cycle	O	O
or	O	O
viability	O	O
.	O	O

Thus	O	O
,	O	O
pol	O	O
zeta	O	O
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
Ig	O	O
and	O	O
bcl-6	O	O
hypermutation	O	O
,	O	O
perhaps	O	O
facilitated	O	O
by	O	O
the	O	O
downregulation	O	O
of	O	O
pol	O	O
eta	O	O
.	O	O

Molecular	O	O
mechanism	O	O
of	O	O
cell	O	O
cycle	O	O
progression	O	O
induced	O	O
by	O	O
the	O	O
oncogene	B-protein	O
product	I-protein	O
Tax	O	O
of	O	O
human	O	O
T-cell	O	O
leukemia	O	O
virus	O	O
type	O	O
I	O	O
.	O	O

The	O	O
trans-activator	B-protein	O
protein	I-protein	O
Tax	O	O
of	O	O
human	O	O
T-cell	O	O
leukemia	O	O
virus	O	O
type	I-protein	O
I	I-protein	O
(	O	O
HTLV-I	O	O
)	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
adult	O	O
T-cell	O	O
leukemia	O	O
through	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
its	O	O
ability	O	O
to	O	O
stimulate	O	O
cell	O	O
growth	O	O
.	O	O

We	O	O
previously	O	O
reported	O	O
that	O	O
Tax	O	O
induced	O	O
cell	O	O
cycle	O	O
progression	O	O
from	O	O
G0/G1	O	O
phase	O	O
to	O	O
S	O	O
and	O	O
G2/M	O	O
phases	O	O
in	O	O
human	B-cell_line	O
T-cell	I-cell_line	O
line	I-cell_line	O
Kit	I-cell_line	O
225	I-cell_line	O
cells	I-cell_line	O
.	O	O

To	O	O
elucidate	O	O
molecular	O	O
mechanism	O	O
of	O	O
Tax	O	O
-induced	O	O
cell	O	O
cycle	O	O
progression	O	O
,	O	O
we	O	O
systematically	O	O
examined	O	O
the	O	O
effects	O	O
of	O	O
Tax	O	O
on	O	O
biochemical	O	O
events	O	O
associated	O	O
with	O	O
cell	O	O
cycle	O	O
progression	O	O
.	O	O

Introduction	O	O
of	O	O
Tax	O	O
into	O	O
resting	B-cell_line	O
Kit	I-cell_line	O
225	I-cell_line	O
cells	I-cell_line	O
induced	O	O
activation	O	O
of	O	O
the	O	O
G1/S	O	O
transition	O	O
regulation	O	O
cascade	O	O
consisting	O	O
of	O	O
activation	O	O
of	O	O
cyclin	B-protein	O
dependent	B-protein	O
kinase	I-protein	O
2	I-protein	O
(	O	O
CDK2	B-protein	O
)	O	O
and	O	O
CDK4	O	O
,	O	O
phosphorylation	O	O
of	O	O
the	O	O
Rb	B-protein	O
family	I-protein	O
proteins	I-protein	O
and	O	O
an	O	O
increase	O	O
in	O	O
free	O	O
E2F	B-protein	O
.	O	O

The	O	O
kinase	O	O
activation	O	O
was	O	O
found	O	O
to	O	O
result	O	O
from	O	O
Tax	O	O
-induced	O	O
expression	O	O
of	O	O
genes	O	O
for	O	O
cell	O	O
cycle	O	O
regulatory	O	O
molecules	O	O
including	O	O
cyclin	O	O
D2	O	O
,	O	O
cyclin	O	O
E	O	O
,	O	O
E2F1	O	O
,	O	O
CDK2	O	O
,	O	O
CDK4	O	O
and	O	O
CDK6	O	O
,	O	O
and	O	O
Tax	O	O
-induced	O	O
reduction	O	O
of	O	O
CDK	O	O
inhibitors	O	O
p19	O	O
(	O	O
INK4d	B-protein	O
)	O	O
and	O	O
p27	O	O
(	O	O
Kip1	O	O
)	O	O
.	O	O

These	O	O
modulations	O	O
by	O	O
Tax	O	O
always	O	O
paralleled	O	O
the	O	O
ability	O	O
of	O	O
Tax	O	O
to	O	O
activate	O	O
the	O	O
NF-kappaB	B-protein	O
transcription	I-protein	O
pathway	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
the	O	O
important	O	O
role	O	O
of	O	O
Tax	O	O
-mediated	O	O
trans-activation	O	O
of	O	O
the	O	O
genes	B-DNA	O
for	O	O
cell	O	O
cycle	O	O
regulatory	O	O
molecules	O	O
in	O	O
Tax	O	O
-induced	O	O
cell	O	O
cycle	O	O
progression	O	O
.	O	O

Cot	O	O
kinase	O	O
induces	O	O
cyclooxygenase-2	O	O
expression	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
through	O	O
activation	O	O
of	O	O
the	O	O
nuclear	B-protein	O
factor	I-protein	O
of	O	O
activated	B-cell_type	O
T	I-protein	O
cells	I-cell_type	O
.	O	O

Cyclooxygenase-2	O	O
(	O	O
COX-2	O	O
)	O	O
is	O	O
induced	O	O
in	O	O
human	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
upon	O	O
T	O	O
cell	O	O
receptor	O	O
triggering	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
Cot	B-protein	O
kinase	I-protein	O
,	O	O
a	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
kinase	I-protein	O
kinase	I-protein	O
involved	O	O
in	O	O
T	O	O
cell	O	O
activation	O	O
,	O	O
up-regulates	O	O
COX-2	O	O
gene	O	O
expression	O	O
in	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
.	O	O

Induction	O	O
of	O	O
COX-2	O	O
promoter	O	O
activity	O	O
by	O	O
Cot	B-protein	O
kinase	I-protein	O
occurred	O	O
mainly	O	O
through	O	O
activation	O	O
of	O	O
the	O	O
nuclear	B-protein	O
factor	I-protein	O
of	I-protein	O
activated	I-protein	O
T	I-protein	O
cells	I-protein	O
(	O	O
NFAT	B-protein	O
)	O	O
.	O	O

Mutation	O	O
of	O	O
the	O	O
distal	B-DNA	O
(	I-DNA	O
-105/-97	I-DNA	O
)	I-DNA	O
and	I-DNA	O
proximal	I-DNA	O
(	O	O
-76/-61	B-protein	O
)	O	O
NFAT	O	O
response	O	O
elements	O	O
in	O	O
the	O	O
COX-2	B-DNA	O
promoter	I-DNA	O
abolished	O	O
the	O	O
activation	O	O
induced	O	O
by	O	O
Cot	O	O
kinase	O	O
.	O	O

Even	O	O
more	O	O
,	O	O
coexpression	O	O
of	O	O
a	O	O
dominant	O	O
negative	O	O
version	O	O
of	O	O
NFAT	B-protein	O
inhibited	O	O
Cot	O	O
kinase	O	O
-mediated	O	O
COX-2	O	O
promoter	O	O
activation	O	O
,	O	O
whereas	O	O
cotransfection	O	O
of	O	O
a	O	O
constitutively	O	O
active	O	O
version	O	O
of	O	O
the	O	O
calcium-dependent	O	O
phosphatase	I-protein	O
calcineurin	I-protein	O
synergizes	O	O
with	O	O
Cot	B-protein	O
kinase	I-protein	O
in	O	O
the	O	O
up-regulation	O	O
of	O	O
COX-2	O	O
promoter	O	O
-driven	O	O
transcription	O	O
.	O	O

Strikingly	O	O
,	O	O
Cot	B-protein	O
kinase	I-protein	O
increased	O	O
transactivation	O	O
mediated	O	O
by	O	O
a	O	O
GAL4-NFAT	O	O
fusion	O	O
protein	O	O
containing	O	O
the	O	O
N-terminal	B-DNA	O
transactivation	I-DNA	O
domain	I-DNA	O
of	O	O
NFATp	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
phorbol	O	O
ester	O	O
plus	O	O
calcium	O	O
ionophore	O	O
A23187	O	O
,	O	O
Cot	O	O
kinase	O	O
increases	O	O
both	O	O
COX-2	O	O
promoter	O	O
activity	O	O
and	O	O
NFAT	O	O
-mediated	O	O
transactivation	O	O
in	O	O
a	O	O
cyclosporin	O	O
A-independent	O	O
manner	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
Cot	O	O
kinase	O	O
up-regulates	O	O
COX-2	O	O
promoter	O	O
-driven	O	O
transcription	O	O
through	O	O
the	O	O
NFAT	O	O
response	O	O
elements	O	O
,	O	O
being	O	O
the	O	O
Cot	B-protein	O
kinase	I-protein	O
-induced	O	O
NFAT	O	O
-dependent	O	O
transactivation	O	O
presumably	O	O
implicated	O	O
in	O	O
this	O	O
up-regulation	O	O
.	O	O

Positive	O	O
and	O	O
negative	O	O
roles	O	O
of	O	O
the	O	O
trans-acting	B-protein	O
T	I-protein	O
cell	O	O
factor-1	O	O
for	O	O
the	O	O
acquisition	O	O
of	O	O
distinct	O	O
Ly-49	B-protein	O
MHC	I-protein	O
class	I-protein	O
I	I-protein	O
receptors	I-protein	O
by	O	O
NK	B-cell_type	O
cells	I-cell_type	O
.	O	O

Members	O	O
of	O	O
the	O	O
Ly-49	B-DNA	O
gene	I-DNA	O
family	O	O
code	O	O
for	O	O
class	O	O
I	B-protein	O
MHC-specific	I-protein	O
receptors	I-protein	O
that	O	O
regulate	O	O
NK	O	O
cell	O	O
function	O	O
.	O	O

Due	O	O
to	O	O
a	O	O
combinatorial	O	O
distribution	O	O
of	O	O
Ly-49	B-cell_line	O
receptors	I-cell_line	O
,	O	O
NK	B-cell_type	O
cells	I-cell_type	O
display	O	O
considerable	O	O
clonal	O	O
heterogeneity	O	O
.	O	O

The	O	O
acquisition	O	O
of	O	O
one	O	O
Ly-49	B-protein	O
receptor	I-protein	O
,	O	O
Ly-49A	O	O
is	O	O
strictly	O	O
dependent	O	O
on	O	O
the	O	O
transcriptional	B-protein	O
trans-acting	I-protein	O
factor	I-protein	O
T	I-protein	O
cell-specific	I-protein	O
factor-1	I-protein	O
(	O	O
TCF-1	B-protein	O
)	O	O
.	O	O

Indeed	O	O
,	O	O
TCF-1	O	O
binds	O	O
to	O	O
two	O	O
sites	O	O
in	O	O
the	O	O
Ly-49a	B-DNA	O
promoter	I-DNA	O
and	O	O
regulates	O	O
its	O	O
activity	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
Ly-49a	B-DNA	O
gene	I-DNA	O
is	O	O
a	O	O
direct	O	O
TCF-1	O	O
target	O	O
.	O	O

TCF-1	O	O
deficiency	O	O
resulted	O	O
in	O	O
the	O	O
altered	O	O
usage	O	O
of	O	O
additional	O	O
Ly-49	B-protein	O
receptors	I-protein	O
.	O	O

We	O	O
show	O	O
in	O	O
this	O	O
study	O	O
,	O	O
using	O	O
TCF-1	I-protein	O
beta	I-protein	O
(	O	O
2	O	O
)	O	O
-microglobulin	O	O
double-deficient	O	O
mice	O	O
,	O	O
that	O	O
these	O	O
repertoire	O	O
alterations	O	O
are	O	O
not	O	O
due	O	O
to	O	O
Ly-49/MHC	O	O
class	B-protein	O
I	I-protein	O
interactions	O	O
.	O	O

Our	O	O
findings	O	O
rather	O	O
suggest	O	O
a	O	O
TCF-1	O	O
-dependent	O	O
,	O	O
cell	O	O
autonomous	O	O
effect	O	O
on	O	O
the	O	O
acquisition	O	O
of	O	O
multiple	O	O
Ly-49	B-protein	O
receptors	I-protein	O
.	O	O

Besides	O	O
reduced	B-protein	O
receptor	I-protein	O
usage	O	O
(	O	O
Ly-49A	O	O
and	O	O
D	O	O
)	O	O
,	O	O
we	O	O
also	O	O
observed	O	O
no	O	O
effect	O	O
(	O	O
Ly-49C	O	O
)	O	O
and	O	O
significantly	O	O
expanded	O	O
(	O	O
Ly-49G	O	O
and	O	O
I	B-protein	O
)	O	O
receptor	O	O
usage	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
TCF-1	O	O
.	O	O

These	O	O
effects	O	O
did	O	O
not	O	O
in	O	O
all	O	O
cases	O	O
correlate	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
TCF	O	O
binding	O	O
sites	O	O
in	O	O
the	O	O
respective	B-DNA	O
proximal	I-DNA	O
promoter	I-DNA	O
.	O	O

Therefore	O	O
,	O	O
besides	O	O
TCF-1	O	O
binding	O	O
to	O	O
the	O	O
proximal	B-DNA	O
promoter	I-DNA	O
,	O	O
Ly-49	O	O
acquisition	O	O
may	O	O
also	O	O
be	O	O
regulated	O	O
by	O	O
TCF-1	O	O
binding	O	O
to	O	O
more	O	O
distant	O	O
cis-acting	O	O
elements	O	O
and/or	O	O
by	O	O
regulating	O	O
the	O	O
expression	O	O
of	O	O
additional	O	O
trans-acting	B-protein	O
factors	I-protein	O
.	O	O

Consistent	O	O
with	O	O
the	O	O
observed	O	O
differential	O	O
,	O	O
positive	O	O
or	O	O
negative	O	O
role	O	O
of	O	O
TCF-1	O	O
for	O	O
Ly-49	O	O
receptor	O	O
acquisition	O	O
,	O	O
reporter	B-DNA	O
gene	I-DNA	O
assays	O	O
revealed	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
inducing	O	O
as	O	O
well	O	O
as	O	O
a	O	O
repressing	O	O
TCF	I-DNA	O
site	I-DNA	O
in	O	O
certain	O	O
proximal	B-DNA	O
Ly-49	I-DNA	O
promoters	I-DNA	O
.	O	O

These	O	O
findings	O	O
reveal	O	O
an	O	O
important	O	O
role	O	O
of	O	O
TCF-1	O	O
for	O	O
the	O	O
formation	O	O
of	O	O
the	O	O
NK	B-protein	O
cell	I-protein	O
receptor	I-protein	O
repertoire	O	O
.	O	O

Ligation	O	O
of	O	O
CD11b	B-protein	O
and	O	O
CD11c	B-protein	O
beta	I-protein	O
(	O	O
2	O	O
)	O	O
integrins	O	O
by	O	O
antibodies	B-protein	O
or	O	O
soluble	O	O
CD23	O	O
induces	O	O
macrophage	O	O
inflammatory	B-protein	O
protein	I-protein	O
1alpha	O	O
(	O	O
MIP-1alpha	O	O
)	O	O
and	O	O
MIP-1beta	O	O
production	O	O
in	O	O
primary	B-cell_line	O
human	B-cell_type	O
monocytes	I-cell_type	O
through	O	O
a	O	O
pathway	O	O
dependent	O	O
on	O	O
nuclear	O	O
factor-kappaB	O	O
.	O	O

Chemokines	O	O
and	O	O
adhesion	O	O
molecules	O	O
such	O	O
as	O	O
integrins	O	O
play	O	O
a	O	O
major	B-DNA	O
part	I-DNA	O
in	O	O
the	O	O
trafficking	O	O
,	O	O
extravasation	O	O
,	O	O
and	O	O
recruitment	O	O
of	O	O
leukocytes	O	O
to	O	O
inflammatory	O	O
sites	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
beta	B-protein	O
(	O	O
2	I-protein	O
)	O	O
integrin	O	O
engagement	O	O
on	O	O
chemokine	O	O
production	O	O
by	O	O
freshly	O	O
isolated	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
.	O	O

We	O	O
found	O	O
that	O	O
ligation	O	O
of	O	O
CD11b	O	O
or	O	O
CD11c	O	O
but	O	O
not	O	O
CD11a	O	O
alpha	O	O
chains	O	O
of	O	O
beta	B-protein	O
(	O	O
2	I-protein	O
)	O	O
integrins	O	O
by	O	O
antibodies	B-protein	O
or	O	O
soluble	O	O
CD23	O	O
(	O	O
sCD23	B-protein	O
)	O	O
fusion	O	O
proteins	O	O
rapidly	O	O
induced	O	O
transcription	O	O
and	O	O
secretion	O	O
of	O	O
interleukin	B-protein	O
8	I-protein	O
,	O	O
macrophage	B-protein	O
inflammatory	I-protein	O
protein	I-protein	O
(	O	O
MIP	B-protein	O
)	O	O
1alpha	O	O
,	O	O
and	O	O
MIP-1beta	O	O
.	O	O

Because	O	O
the	O	O
promoters	O	O
of	O	O
these	O	O
chemokine	O	O
genes	O	O
contain	O	O
kappaB	O	O
binding	O	O
sites	O	O
,	O	O
we	O	O
assessed	O	O
the	O	O
possible	O	O
role	O	O
of	O	O
nuclear	B-protein	O
factor-kappaB	I-protein	O
(	O	O
NF-kappaB	B-protein	O
)	O	O
in	O	O
controlling	O	O
induction	O	O
of	O	O
the	O	O
genes	B-DNA	O
through	O	O
beta	I-protein	O
(	O	O
2	O	O
)	O	O
integrin	O	O
engagement	O	O
.	O	O

Electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
showed	O	O
that	O	O
sCD23	O	O
or	O	O
antibodies	O	O
to	O	O
CD11b	O	O
or	O	O
to	O	O
CD11c	O	O
up-regulated	O	O
DNA-binding	O	O
activity	O	O
of	O	O
NF-kappaB	O	O
.	O	O

Activation	O	O
of	O	O
NF-kappaB	O	O
was	O	O
accompanied	O	O
by	O	O
degradation	O	O
of	O	O
its	O	O
cytosolic	O	O
inhibitor	O	O
IkappaB-alpha	O	O
.	O	O

Blockade	O	O
of	O	O
depletion	O	O
of	O	O
IkappaB-alpha	O	O
by	O	O
proteasome	B-protein	O
inhibitors	O	O
(	O	O
proteasome	B-protein	O
inhibitor	I-protein	O
I	I-protein	O
or	O	O
acetyl-leucinyl-leucinyl-norleucinal	O	O
)	O	O
led	O	O
to	O	O
concomitant	O	O
inhibition	O	O
of	O	O
NF-kappaB	O	O
DNA-binding	O	O
activity	O	O
and	O	O
expression	O	O
of	O	O
MIP-1alpha	O	O
and	O	O
MIP-1beta	O	O
messenger	O	O
RNA	O	O
induced	O	O
by	O	O
beta	O	O
(	O	O
2	O	O
)	O	O
integrin	O	O
ligation	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
triggering	O	O
of	O	O
CD11b	B-protein	O
or	O	O
CD11c	B-protein	O
beta	I-protein	O
(	O	O
2	O	O
)	O	O
integrin	O	O
on	O	O
primary	B-protein	O
human	I-protein	O
monocytes	I-protein	O
provides	O	O
activation	O	O
signals	O	O
leading	O	O
to	O	O
nuclear	O	O
translocation	O	O
of	O	O
NF-kappaB	O	O
and	O	O
subsequent	O	O
secretion	O	O
of	O	O
MIP-1alpha	O	O
and	O	O
MIP-1beta	O	O
that	O	O
may	O	O
have	O	O
an	O	O
important	O	O
role	O	O
in	O	O
recruitment	O	O
of	O	O
other	O	O
inflammatory	B-cell_type	O
cells	I-cell_type	O
during	O	O
initiation	O	O
of	O	O
an	O	O
inflammatory	O	O
response	O	O

Synergistic	O	O
transcriptional	O	O
activation	O	O
of	O	O
human	O	O
Acyl-coenzyme	O	O
A	O	O
:	O	O
cholesterol	O	O
acyltransterase-1	O	O
gene	O	O
by	O	O
interferon-gamma	O	O
and	O	O
all-trans-retinoic	B-cell_line	O
acid	I-cell_line	O
THP-1	I-cell_line	O
cells	I-cell_line	O
.	O	O

Acyl-coenzyme	O	O
A	O	O
:	O	O
cholesterol	O	O
acyltransferase	O	O
(	O	O
ACAT	O	O
)	O	O
is	O	O
an	O	O
intracellular	O	O
enzyme	O	O
involved	O	O
in	O	O
cellular	O	O
cholesterol	O	O
homeostasis	O	O
and	O	O
in	O	O
atherosclerotic	O	O
foam	O	O
cell	O	O
formation	O	O
.	O	O

Human	O	O
ACAT-1	O	O
gene	O	O
contains	O	O
two	O	O
promoters	O	O
(	O	O
P1	O	O
and	O	O
P7	O	O
)	O	O
,	O	O
each	O	O
located	O	O
in	O	O
a	O	O
different	O	O
chromosome	O	O
(	O	O
1	O	O
and	O	O
7	O	O
)	O	O
(	O	O
Li	O	O
,	O	O
B.	O	O
L.	O	O
,	O	O
Li	O	O
,	O	O
X.	O	O
L.	O	O
,	O	O
Duan	O	O
,	O	O
Z.	O	O
J.	O	O
,	O	O
Lee	O	O
,	O	O
O.	O	O
,	O	O
Lin	O	O
,	O	O
S.	O	O
,	O	O
Ma	O	O
,	O	O
Z.	O	O
M.	O	O
,	O	O
Chang	O	O
,	O	O
C.	O	O
C.	O	O
,	O	O
Yang	O	O
,	O	O
X.	O	O
Y.	O	O
,	O	O
Park	O	O
,	O	O
J.	O	O
P.	O	O
,	O	O
Mohandas	O	O
,	O	O
T.	O	O
K.	O	O
,	O	O
Noll	O	O
,	O	O
W.	O	O
,	O	O
Chan	O	O
,	O	O
L.	O	O
,	O	O
and	O	O
Chang	O	O
,	O	O
T.	O	O
Y.	O	O
(	O	O
1999	O	O
)	O	O
J.	O	O
Biol	O	O
Chem.	O	O
274	O	O
,	O	O
11060-11071	O	O
)	O	O
.	O	O

Interferon-gamma	O	O
(	O	O
IFN-gamma	B-protein	O
)	O	O
,	O	O
a	O	O
cytokine	O	O
that	O	O
exerts	O	O
many	O	O
pro-atherosclerotic	O	O
effects	O	O
in	O	O
vivo	O	O
,	O	O
causes	O	O
up-regulation	O	O
of	O	O
ACAT-1	O	O
mRNA	B-RNA	O
in	O	O
human	B-cell_type	O
blood	I-cell_type	O
monocyte-derived	I-cell_type	O
macrophages	I-cell_type	O
and	O	O
macrophage-like	B-cell_type	O
cells	I-cell_type	O
but	O	O
not	O	O
in	O	O
other	O	O
cell	O	O
types	O	O
.	O	O

To	O	O
examine	O	O
the	O	O
molecular	O	O
nature	O	O
of	O	O
this	O	O
observation	O	O
,	O	O
we	O	O
identified	O	O
within	O	O
the	O	O
ACAT-1	O	O
P1	O	O
promoter	O	O
a	O	O
159-base	O	O
pair	O	O
core	O	O
region	O	O
.	O	O

This	O	O
region	O	O
contains	O	O
4	O	O
Sp1	B-DNA	O
elements	I-DNA	O
and	O	O
an	O	O
IFN-gamma	B-protein	O
activated	I-protein	O
sequence	I-DNA	O
(	O	O
GAS	B-protein	O
)	O	O
that	O	O
overlaps	O	O
with	O	O
the	O	O
second	B-DNA	O
Sp1	I-DNA	O
element	I-DNA	O
.	O	O

In	O	O
the	O	O
monocytic	B-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
THP-1	I-cell_line	O
cell	O	O
,	O	O
the	O	O
combination	O	O
of	O	O
IFN-gamma	B-protein	O
and	O	O
all-trans-retinoic	O	O
acid	O	O
(	O	O
a	O	O
known	O	O
differentiation	O	O
agent	O	O
)	O	O
enhances	O	O
the	O	O
ACAT-1	O	O
P1	O	O
promoter	I-DNA	O
but	O	O
not	O	O
the	O	O
P7	B-DNA	O
promoter	I-DNA	O
.	O	O

Additional	O	O
experiments	O	O
showed	O	O
that	O	O
all-trans-retinoic	O	O
acid	O	O
causes	O	O
large	O	O
induction	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
STAT1	B-protein	O
,	O	O
while	O	O
IFN-gamma	B-protein	O
causes	O	O
activation	O	O
of	O	O
STAT1	O	O
such	O	O
that	O	O
it	O	O
binds	O	O
to	O	O
the	O	O
GAS/Sp1	B-DNA	O
site	I-DNA	O
in	O	O
the	O	O
ACAT-1	B-DNA	O
P1	I-DNA	O
promoter	I-DNA	O
.	O	O

Our	O	O
work	O	O
provides	O	O
a	O	O
molecular	O	O
mechanism	O	O
to	O	O
account	O	O
for	O	O
the	O	O
effect	O	O
of	O	O
IFN-gamma	B-protein	O
in	O	O
causing	O	O
transcriptional	O	O
activation	O	O
of	O	O
ACAT-1	O	O
in	O	O
macrophage-like	B-cell_type	O
cells	I-cell_type	O
.	O	O

Inhaled	O	O
nitric	O	O
oxide	O	O
down-regulates	O	O
intrapulmonary	O	O
nitric	O	O
oxide	O	O
production	O	O
in	O	O
lipopolysaccharide-induced	O	O
acute	O	O
lung	O	O
injury	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
examine	O	O
whether	O	O
inhaled	O	O
nitric	O	O
oxide	O	O
(	O	O
NO	O	O
)	O	O
affected	O	O
the	O	O
intrapulmonary	O	O
production	O	O
of	O	O
NO	O	O
,	O	O
reactive	O	O
oxygen	O	O
species	O	O
,	O	O
and	O	O
nuclear	O	O
factor-kappaB	O	O
in	O	O
a	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
-induced	O	O
model	O	O
of	O	O
acute	O	O
lung	O	O
injury	O	O
.	O	O

DESIGN	O	O
:	O	O
Prospective	O	O
,	O	O
randomized	O	O
,	O	O
laboratory	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
Experimental	O	O
laboratory	O	O
at	O	O
a	O	O
biomedical	O	O
institute	O	O
.	O	O

SUBJECTS	O	O
:	O	O
Twenty	O	O
male	O	O
rabbits	O	O
weighing	O	O
2.5-3.5	O	O
kg	O	O
.	O	O

INTERVENTIONS	O	O
:	O	O
Saline	O	O
or	O	O
LPS	O	O
(	O	O
5	O	O
mg/kg	O	O
of	O	O
body	O	O
weight	O	O
)	O	O
was	O	O
administered	O	O
intravenously	O	O
with	O	O
or	O	O
without	O	O
NO	O	O
inhalation	O	O
(	O	O
10	O	O
ppm	O	O
)	O	O
in	O	O
each	O	O
group	O	O
of	O	O
five	O	O
rabbits	O	O
.	O	O

MEASUREMENTS	O	O
AND	O	O
MAIN	O	O
RESULTS	O	O
:	O	O
LPS	O	O
increased	O	O
the	O	O
lung	O	O
leak	O	O
index	O	O
,	O	O
the	O	O
neutrophils	O	O
and	O	O
NO	O	O
levels	O	O
in	O	O
bronchoalveolar	O	O
lavage	O	O
fluid	O	O
,	O	O
and	O	O
NO	O	O
levels	O	O
produced	O	O
by	O	O
resting	O	O
and	O	O
stimulated	O	O
alveolar	O	O
macrophages	O	O
.	O	O

Inhaled	O	O
NO	O	O
decreased	O	O
the	O	O
lung	O	O
leak	O	O
index	O	O
,	O	O
the	O	O
neutrophils	O	O
and	O	O
NO	O	O
levels	O	O
as	O	O
measured	O	O
by	O	O
nitrite	O	O
levels	O	O
in	O	O
the	O	O
lavage	O	O
fluid	O	O
,	O	O
and	O	O
NO	O	O
produced	O	O
by	O	O
the	O	O
resting	O	O
and	O	O
stimulated	O	O
alveolar	O	O
macrophages	O	O
.	O	O

Inhaled	O	O
NO	O	O
also	O	O
blocked	O	O
the	O	O
activities	O	O
of	O	O
reactive	O	O
oxygen	O	O
species	O	O
and	O	O
nuclear	O	O
factor-kappaB	O	O
binding	O	O
to	O	O
DNA	O	O
in	O	O
lavage	B-cell_type	O
cells	I-cell_type	O
and	O	O
in	O	O
alveolar	O	O
macrophages	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Inhaled	O	O
NO	O	O
attenuates	O	O
LPS-induced	O	O
acute	O	O
lung	O	O
injury	O	O
,	O	O
possibly	O	O
by	O	O
decreasing	O	O
NO	O	O
production	O	O
in	O	O
the	O	O
lungs	O	O
.	O	O

The	O	O
mechanism	O	O
of	O	O
reducing	O	O
NO	O	O
production	O	O
resulting	O	O
from	O	O
inhaled	O	O
NO	O	O
may	O	O
involve	O	O
,	O	O
in	O	O
part	O	O
,	O	O
the	O	O
activities	O	O
of	O	O
reactive	O	O
oxygen	O	O
species	O	O
and/or	O	O
nuclear	O	O
factor-kappaB	O	O
.	O	O

Treatment	O	O
of	O	O
allergic	O	O
airway	O	O
inflammation	O	O
and	O	O
hyperresponsiveness	O	O
by	O	O
antisense-induced	O	O
local	O	O
blockade	O	O
of	O	O
GATA-3	O	O
expression	O	O
.	O	O

Recent	O	O
studies	O	O
in	O	O
transgenic	O	O
mice	O	O
have	O	O
revealed	O	O
that	O	O
expression	O	O
of	O	O
a	O	O
dominant	O	O
negative	O	O
form	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
GATA-3	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
can	O	O
prevent	O	O
T	O	O
helper	O	O
cell	O	O
type	O	O
2	O	O
(	O	O
Th2	O	O
)	O	O
-mediated	O	O
allergic	O	O
airway	O	O
inflammation	O	O
in	O	O
mice	O	O
.	O	O

However	O	O
,	O	O
it	O	O
remains	O	O
unclear	O	O
whether	O	O
GATA-3	O	O
plays	O	O
a	O	O
role	O	O
in	O	O
the	O	O
effector	O	O
phase	O	O
of	O	O
allergic	O	O
airway	O	O
inflammation	O	O
and	O	O
whether	O	O
antagonizing	O	O
the	O	O
expression	O	O
and/or	O	O
function	O	O
of	O	O
GATA-3	O	O
can	O	O
be	O	O
used	O	O
for	O	O
the	O	O
therapy	O	O
of	O	O
allergic	O	O
airway	O	O
inflammation	O	O
and	O	O
hyperresponsiveness	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
analyzed	O	O
the	O	O
effects	O	O
of	O	O
locally	O	O
antagonizing	O	O
GATA-3	O	O
function	O	O
in	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
asthma	O	O
.	O	O

We	O	O
could	O	O
suppress	O	O
GATA-3	O	O
expression	O	O
in	O	O
interleukin	B-protein	O
(	O	O
IL	I-protein	O
)	I-cell_line	O
-4	I-cell_line	O
-producing	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
by	O	O
an	O	O
antisense	O	O
phosphorothioate	O	O
oligonucleotide	O	O
overlapping	O	O
the	O	O
translation	O	O
start	O	O
site	O	O
of	O	O
GATA-3	O	O
,	O	O
whereas	O	O
nonsense	O	O
control	O	O
oligonucleotides	O	O
were	O	O
virtually	O	O
inactive	O	O
.	O	O

In	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
asthma	O	O
associated	O	O
with	O	O
allergic	O	O
pulmonary	O	O
inflammation	O	O
and	O	O
hyperresponsiveness	O	O
in	O	O
ovalbumin	O	O
(	O	O
OVA	O	O
)	O	O
-sensitized	O	O
mice	O	O
,	O	O
local	O	O
intranasal	O	O
administration	O	O
of	O	O
fluorescein	O	O
isothiocyanate-labeled	O	O
GATA-3	O	O
antisense	O	O
oligonucleotides	O	O
led	O	O
to	O	O
DNA	O	O
uptake	O	O
in	O	O
lung	O	O
cells	O	O
associated	O	O
with	O	O
a	O	O
reduction	O	O
of	O	O
intracellular	O	O
GATA-3	O	O
expression	O	O
.	O	O

Such	O	O
intrapulmonary	O	O
blockade	O	O
of	O	O
GATA-3	O	O
expression	O	O
caused	O	O
an	O	O
abrogation	O	O
of	O	O
signs	O	O
of	O	O
lung	O	O
inflammation	O	O
including	O	O
infiltration	O	O
of	O	O
eosinophils	B-protein	O
and	O	O
Th2	O	O
cytokine	B-protein	O
production	O	O
.	O	O

Furthermore	O	O
,	O	O
treatment	O	O
with	O	O
antisense	O	O
but	O	O
not	O	O
nonsense	O	O
oligonucleotides	O	O
induced	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
airway	O	O
hyperresponsiveness	O	O
in	O	O
OVA-sensitized	O	O
mice	O	O
to	O	O
levels	O	O
comparable	O	O
to	O	O
saline-treated	O	O
control	O	O
mice	O	O
,	O	O
as	O	O
assessed	O	O
by	O	O
both	O	O
enhanced	O	O
pause	O	O
(	O	O
PenH	O	O
)	O	O
responses	O	O
and	O	O
pulmonary	O	O
resistance	O	O
determined	O	O
by	O	O
body	O	O
plethysmography	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
a	O	O
critical	O	O
role	O	O
for	O	O
GATA-3	O	O
in	O	O
the	O	O
effector	O	O
phase	O	O
of	O	O
a	O	O
murine	O	O
asthma	O	O
model	O	O
and	O	O
suggest	O	O
that	O	O
local	O	O
delivery	O	O
of	O	O
GATA-3	O	O
antisense	O	O
oligonucleotides	O	O
may	O	O
be	O	O
a	O	O
novel	O	O
approach	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
airway	O	O
hyperresponsiveness	O	O
such	O	O
as	O	O
in	O	O
asthma	O	O
.	O	O

This	O	O
approach	O	O
has	O	O
the	O	O
potential	O	O
advantage	O	O
of	O	O
suppressing	O	O
the	O	O
expression	O	O
of	O	O
various	O	O
proinflammatory	O	O
Th2	O	O
cytokines	B-protein	O
simultaneously	O	O
rather	O	O
than	O	O
suppressing	O	O
the	O	O
activity	O	O
of	O	O
a	O	O
single	O	O
cytokine	B-protein	O
.	O	O

T	O	O
helper-cell	O	O
phenotype	O	O
regulates	O	O
atherosclerosis	O	O
in	O	O
mice	O	O
under	O	O
conditions	O	O
of	O	O
mild	O	O
hypercholesterolemia	O	O
.	O	O

BACKGROUND	O	O
:	O	O
T	B-cell_type	O
cells	I-cell_type	O
are	O	O
implicated	O	O
in	O	O
atherosclerosis	O	O
,	O	O
but	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
genetic	O	O
control	O	O
or	O	O
molecular	O	O
pathways	O	O
,	O	O
especially	O	O
under	O	O
conditions	O	O
of	O	O
mild	O	O
hypercholesterolemia	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
BALB/c	O	O
mice	O	O
,	O	O
making	O	O
a	O	O
CD4+	O	O
Th2	O	O
(	O	O
IL-4+	O	O
)	O	O
cell	O	O
response	O	O
,	O	O
express	O	O
both	O	O
MHC	O	O
class	O	O
II	O	O
antigens	O	O
(	O	O
IA	O	O
(	O	O
d	O	O
)	O	O
,	O	O
IE	O	O
(	O	O
d	O	O
)	O	O
)	O	O
and	O	O
are	O	O
atherosclerosis-resistant	O	O
.	O	O

C57Bl/6	O	O
mice	O	O
produce	O	O
a	O	O
CD4+	O	O
Th1	O	O
(	O	O
interferon	O	O
[	O	O
IFN	O	O
]	O	O
gamma+	O	O
)	O	O
response	O	O
,	O	O
express	O	O
IA	O	O
(	O	O
b	O	O
)	O	O
but	O	O
no	O	O
IE	O	O
,	O	O
and	O	O
are	O	O
atherosclerosis-prone	O	O
.	O	O

To	O	O
evaluate	O	O
T	O	O
helper-cell	O	O
phenotype	O	O
in	O	O
fatty	O	O
streak	O	O
formation	O	O
,	O	O
wild-type	O	O
C57Bl/6	O	O
mice	O	O
(	O	O
IA	O	O
(	O	O
b	O	O
)	O	O
+IE-	O	O
)	O	O
and	O	O
transgenic	O	O
mice	O	O
,	O	O
either	O	O
AB	O	O
(	O	O
o	O	O
)	O	O
,	O	O
IA	O	O
(	O	O
b	O	O
)	O	O
-IE-	O	O
;	O	O
ABEalpha	O	O
,	O	O
IA-IE	O	O
(	O	O
k	O	O
)	O	O
+	O	O
;	O	O
or	O	O
BL	O	O
:	O	O
TG	O	O
:	O	O
Ealpha	O	O
,	O	O
IA	O	O
(	O	O
b	O	O
)	O	O
+IE	O	O
(	O	O
k	O	O
)	O	O
+	O	O
,	O	O
were	O	O
fed	O	O
a	O	O
high-cholesterol	O	O
diet	O	O
for	O	O
16	O	O
weeks	O	O
and	O	O
evaluated	O	O
histomorphometrically	O	O
for	O	O
aortic	O	O
lesions	O	O
.	O	O

Lesion	O	O
size	O	O
in	O	O
AB	O	O
(	O	O
o	O	O
)	O	O
,	O	O
ABEalpha	O	O
,	O	O
and	O	O
BL	O	O
:	O	O
TG	O	O
:	O	O
Ealpha	O	O
strains	O	O
was	O	O
decreased	O	O
by	O	O
54	O	O
%	O	O
,	O	O
79	O	O
%	O	O
,	O	O
and	O	O
82	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
compared	O	O
with	O	O
wild-type	O	O
,	O	O
correlating	O	O
with	O	O
decreased	O	O
Th1	O	O
and	O	O
increased	O	O
Th2	O	O
expression	O	O
and	O	O
suggesting	O	O
that	O	O
T	O	O
helper-cell	O	O
phenotype	O	O
is	O	O
important	O	O
in	O	O
fatty	O	O
lesion	O	O
development	O	O
.	O	O

Decreasing	O	O
Th1	B-cell_type	O
cells	I-cell_type	O
by	O	O
antibodies	B-protein	O
(	O	O
alpha-CD4	B-protein	O
)	O	O
or	O	O
cytokines	B-protein	O
(	O	O
IL-4	B-protein	O
)	O	O
also	O	O
caused	O	O
>	O	O
/=80	O	O
%	O	O
reductions	O	O
in	O	O
lesion	O	O
size	O	O
.	O	O

Immunohistology	O	O
revealed	O	O
IFN-gamma	B-protein	O
,	O	O
but	O	O
not	O	O
IL-4	O	O
,	O	O
colocalized	O	O
with	O	O
activated	O	O
macrophages	O	O
.	O	O

Confirming	O	O
these	O	O
findings	O	O
in	O	O
a	O	O
different	O	O
mouse	B-DNA	O
strain	I-DNA	O
,	O	O
BALB/c	O	O
Stat	I-protein	O
6	O	O
knockout	O	O
mice	O	O
(	O	O
Th2	O	O
cell-deficient	B-protein	O
)	O	O
developed	O	O
aortic	O	O
lesions	O	O
comparable	O	O
to	O	O
C57Bl/6	O	O
mice	O	O
on	O	O
the	O	O
same	O	O
diet	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
mildly	O	O
hypercholesterolemic	O	O
C57Bl/6	O	O
mice	O	O
,	O	O
presence	O	O
of	O	O
IA	O	O
(	O	O
b	B-protein	O
)	O	O
and	O	O
absence	O	O
of	O	O
IE	O	O
regulated	O	O
CD4+	O	O
T	O	O
helper-cell	O	O
phenotype	O	O
;	O	O
fatty	O	O
lesions	O	O
were	O	O
proportional	O	O
to	O	O
IFNgamma+	O	O
Th1	O	O
cells	O	O
in	O	O
both	O	O
C57Bl/6	O	O
and	O	O
BALB/c	O	O
strains	O	O
.	O	O

IFN-gamma	B-protein	O
may	O	O
participate	O	O
through	O	O
macrophage	O	O
activation	O	O
,	O	O
whereas	O	O
IL-4	O	O
may	O	O
act	O	O
to	O	O
limit	O	O
Th1-cell	O	O
response	O	O
.	O	O

Requirement	O	O
for	O	O
p38	O	O
and	O	O
p44/p42	O	O
mitogen-activated	O	O
protein	O	O
kinases	O	O
in	O	O
RAGE	O	O
-mediated	O	O
nuclear	O	O
factor-kappaB	O	O
transcriptional	O	O
activation	O	O
and	O	O
cytokine	O	O
secretion	O	O
.	O	O

Advanced	O	O
glycation	B-protein	O
end	I-protein	O
product	I-protein	O
(	O	O
AGE	O	O
)	O	O
activation	O	O
of	O	O
the	O	O
signal-transducing	B-protein	O
receptor	I-protein	O
for	O	O
AGE	O	O
(	O	O
RAGE	B-protein	O
)	O	O
has	O	O
been	O	O
linked	O	O
to	O	O
a	O	O
proinflammatory	O	O
phenotypic	O	O
change	O	O
within	O	O
cells	O	O
.	O	O

However	O	O
,	O	O
the	O	O
precise	O	O
intracellular	O	O
signaling	O	O
pathways	O	O
involved	O	O
have	O	O
not	O	O
been	O	O
elucidated	O	O
.	O	O

We	O	O
demonstrate	O	O
here	O	O
that	O	O
human	O	O
serum	O	O
albumin	O	O
modified	O	O
with	O	O
N	O	O
(	O	O
varepsilon	O	O
)	O	O
-	O	O
(	O	O
carboxymethyl	O	O
)	O	O
lysine	O	O
(	O	O
CML	O	O
)	O	O
,	O	O
a	O	O
major	O	O
AGE	O	O
adduct	O	O
that	O	O
progressively	O	O
accumulates	O	O
with	O	O
aging	O	O
,	O	O
diabetes	O	O
,	O	O
and	O	O
renal	O	O
failure	O	O
,	O	O
induced	O	O
nuclear	B-protein	O
factor	I-protein	O
(	O	O
NF	O	O
)	O	O
-kappaB	O	O
-driven	O	O
reporter	O	O
gene	O	O
expression	O	O
in	O	O
human	B-cell_type	O
monocytic	I-cell_type	O
THP-1	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
NF-kappaB	O	O
response	O	O
was	O	O
blocked	O	O
with	O	O
a	O	O
synthetic	O	O
peptide	O	O
corresponding	O	O
to	O	O
the	O	O
putative	O	O
ligand-binding	I-DNA	O
domain	I-DNA	O
of	O	O
RAGE	O	O
,	O	O
with	O	O
anti-	O	O
RAGE	O	O
antiserum	O	O
,	O	O
and	O	O
by	O	O
coexpression	O	O
of	O	O
truncated	B-protein	O
receptors	I-protein	O
lacking	O	O
the	O	O
intracellular	B-protein	O
domain	I-protein	O
.	O	O

Signal	O	O
transduction	O	O
from	O	O
RAGE	O	O
to	O	O
NF-kappaB	O	O
involved	O	O
the	O	O
generation	O	O
of	O	O
reactive	O	O
oxygen	O	O
species	O	O
,	O	O
since	O	O
reporter	B-DNA	O
gene	I-DNA	O
expression	O	O
was	O	O
blocked	O	O
with	O	O
the	O	O
antioxidant	O	O
N-acetyl-L-cysteine	O	O
.	O	O

CML-modified	O	O
albumin	O	O
produced	O	O
rapid	O	O
transient	O	O
activation	O	O
of	O	O
tyrosine	O	O
phosphorylation	O	O
,	O	O
extracellular	O	O
signal-regulated	B-protein	O
kinase	I-protein	O
1	O	O
and	O	O
2	O	O
,	O	O
and	O	O
p38	B-protein	O
mitogen-activated	I-protein	O
protein	I-protein	O
kinase	I-protein	O
(	O	O
MAPK	O	O
)	O	O
,	O	O
but	O	O
not	O	O
c-Jun	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
-terminal	O	O
kinase	O	O
.	O	O

RAGE	O	O
-mediated	O	O
NF-kappaB	O	O
activation	O	O
was	O	O
suppressed	O	O
by	O	O
the	O	O
selective	B-protein	O
p38	O	O
MAPK	O	O
inhibitor	O	O
SB203580	O	O
and	O	O
by	O	O
coexpression	O	O
of	O	O
a	O	O
kinase-dead	O	O
p38	O	O
dominant-negative	O	O
mutant	O	O
.	O	O

Activation	O	O
of	O	O
NF-kappaB	O	O
by	O	O
CML-modified	O	O
albumin	O	O
increased	O	O
secretion	O	O
of	O	O
proinflammatory	B-protein	O
cytokines	I-protein	O
(	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor-alpha	I-protein	O
,	O	O
interleukin-1beta	O	O
,	O	O
and	O	O
monocyte	O	O
chemoattractant	O	O
protein-1	B-protein	O
)	O	O
severalfold	O	O
,	O	O
and	O	O
inhibition	O	O
of	O	O
p38	O	O
MAPK	O	O
blocked	O	O
these	O	O
increases	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
p38	O	O
MAPK	O	O
activation	O	O
mediates	O	O
RAGE	O	O
-induced	O	O
NF-kappaB	O	O
-dependent	O	O
secretion	O	O
of	O	O
proinflammatory	O	O
cytokines	B-protein	O
and	O	O
suggest	O	O
that	O	O
accelerated	O	O
inflammation	O	O
may	O	O
be	O	O
a	O	O
consequence	O	O
of	O	O
cellular	O	O
activation	O	O
induced	O	O
by	O	O
this	O	O
receptor	O	O
.	O	O

Antigen-receptor	O	O
cross-linking	O	O
and	O	O
lipopolysaccharide	O	O
trigger	O	O
distinct	O	O
phosphoinositide	O	O
3-kinase	O	O
-dependent	O	O
pathways	O	O
to	O	O
NF-kappa	B-protein	O
B	O	O
activation	O	O
in	O	O
primary	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
NF-kappaB/Rel	O	O
transcription	B-protein	O
factors	I-protein	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
genes	O	O
involved	O	O
in	O	O
B	O	O
cell	O	O
development	O	O
,	O	O
differentiation	O	O
and	O	O
function	O	O
.	O	O

Nuclear	O	O
NF-kappaB	O	O
is	O	O
induced	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
by	O	O
engagement	O	O
of	O	O
either	O	O
the	O	O
BCR	B-protein	O
or	O	O
CD40	O	O
or	O	O
by	O	O
stimulation	O	O
with	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
.	O	O

Despite	O	O
the	O	O
importance	O	O
of	O	O
NF-kappaB	O	O
to	O	O
B	B-protein	O
cell	O	O
function	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
signaling	O	O
pathways	O	O
leading	O	O
to	O	O
NF-kappaB	O	O
activation	O	O
.	O	O

In	O	O
this	O	O
report	O	O
we	O	O
address	O	O
the	O	O
role	O	O
of	O	O
phosphoinositide	O	O
3'-kinase	O	O
(	O	O
PI	B-protein	O
3-kinase	I-protein	O
)	O	O
in	O	O
BCR	O	O
-	O	O
and	O	O
LPS-induced	O	O
NF-kappaB	O	O
activation	O	O
using	O	O
populations	O	O
of	O	O
primary	B-cell_type	O
murine	I-cell_type	O
resting	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

Using	O	O
the	O	O
specific	O	O
pharmacological	O	O
inhibitors	O	O
of	O	O
PI	O	O
3-kinase	O	O
,	O	O
Wortmannin	O	O
and	O	O
LY294002	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
PI	O	O
3-kinase	O	O
activity	O	O
is	O	O
vital	O	O
for	O	O
BCR	O	O
-induced	O	O
NF-kappaB	O	O
DNA-binding	O	O
activity	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
show	O	O
that	O	O
this	O	O
is	O	O
achieved	O	O
via	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
-dependent	O	O
degradation	O	O
of	O	O
IkappaBalpha	O	O
.	O	O

Similar	O	O
analyses	O	O
reveal	O	O
that	O	O
PI	O	O
3-kinase	O	O
is	O	O
also	O	O
critical	O	O
in	O	O
triggering	O	O
NF-kappaB	O	O
DNA-binding	O	O
activity	O	O
and	O	O
IkappaBalpha	O	O
degradation	O	O
following	O	O
LPS	O	O
stimulation	O	O
.	O	O

Interestingly	O	O
,	O	O
a	O	O
PKC	O	O
inhibitor	O	O
which	O	O
blocked	O	O
the	O	O
BCR	O	O
-induced	O	O
IkappaBalpha	O	O
degradation	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
degradation	O	O
of	O	O
IkappaBalpha	O	O
after	O	O
LPS	O	O
stimulation	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
results	O	O
indicate	O	O
the	O	O
involvement	O	O
of	O	O
PI	O	O
3-kinase	O	O
in	O	O
at	O	O
least	O	O
two	O	O
distinct	O	O
signaling	O	O
pathways	O	O
leading	O	O
to	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

Tetramer-guided	O	O
epitope	O	O
mapping	O	O
:	O	O
rapid	O	O
identification	O	O
and	O	O
characterization	O	O
of	O	O
immunodominant	O	O
CD4+	B-protein	O
T	O	O
cell	O	O
epitopes	O	O
from	O	O
complex	O	O
antigens	O	O
.	O	O

T	O	O
cell	O	O
responses	O	O
to	O	O
Ags	O	O
involve	O	O
recognition	O	O
of	O	O
selected	O	O
peptide	O	O
epitopes	O	O
contained	O	O
within	O	O
the	O	O
antigenic	B-protein	O
protein	I-protein	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
describe	O	O
a	O	O
new	O	O
approach	O	O
for	O	O
direct	O	O
identification	O	O
of	O	O
CD4+	B-protein	O
T	O	O
cell	O	O
epitopes	O	O
of	O	O
complex	I-protein	O
Ags	O	O
that	O	O
uses	O	O
human	O	O
class	O	O
II	O	O
tetramers	O	O
to	O	O
identify	O	O
reactive	B-cell_type	O
cells	I-cell_type	O
.	O	O

With	O	O
a	O	O
panel	O	O
of	O	O
60	O	O
overlapping	O	O
peptides	O	O
covering	O	O
the	O	O
entire	O	O
sequence	O	O
of	O	O
the	O	O
VP16	B-protein	O
protein	I-protein	O
,	O	O
a	O	O
major	O	O
Ag	O	O
for	O	O
HSV-2	O	O
,	O	O
we	O	O
generated	O	O
a	O	O
panel	O	O
of	O	O
class	B-protein	O
II	I-protein	O
MHC	I-protein	O
tetramers	O	O
loaded	O	O
with	O	O
peptide	O	O
pools	O	O
that	O	O
were	O	O
used	O	O
to	O	O
stain	O	O
peripheral	O	O
lymphocytes	O	O
of	O	O
an	O	O
HSV-2	O	O
infected	O	O
individual	O	O
.	O	O

With	O	O
this	O	O
approach	O	O
,	O	O
we	O	O
identified	O	O
four	O	O
new	O	O
DRA1*0101/DRB1*0401-	O	O
and	O	O
two	O	O
DRA1*0101/DRB1*0404-restricted	O	O
,	O	O
VP16-specific	O	O
epitopes	O	O
.	O	O

By	O	O
using	O	O
tetramers	O	O
to	O	O
sort	O	O
individual	B-cell_type	O
cells	I-cell_type	O
,	O	O
we	O	O
easily	O	O
obtained	O	O
a	O	O
large	O	O
number	O	O
of	O	O
clones	O	O
specific	O	O
to	O	O
these	O	O
epitopes	O	O
.	O	O

Although	O	O
DRA1*0101/DRB1*0401	O	O
and	O	O
DRA1*0101/DRB1*0404	O	O
are	O	O
structurally	O	O
very	O	O
similar	O	O
,	O	O
nonoverlapping	O	O
VP16	O	O
epitopes	O	O
were	O	O
identified	O	O
,	O	O
illustrating	O	O
high	O	O
selectivity	O	O
of	O	O
individual	O	O
allele	O	O
polymorphisms	O	O
within	O	O
common	O	O
MHC	O	O
variants	O	O
.	O	O

This	O	O
rapid	O	O
approach	O	O
to	O	O
detecting	O	O
CD4+	O	O
T	O	O
cell	O	O
epitopes	O	O
from	O	O
complex	O	O
Ags	O	O
can	O	O
be	O	O
applied	O	O
to	O	O
any	O	O
known	O	O
Ag	O	O
that	O	O
gives	O	O
a	O	O
T	O	O
cell	O	O
response	O	O
.	O	O

Localized	O	O
pancreatic	O	O
NF-kappaB	O	O
activation	O	O
and	O	O
inflammatory	O	O
response	O	O
in	O	O
taurocholate-induced	O	O
pancreatitis	O	O
.	O	O

Transcription	B-protein	O
factor	I-protein	O
nuclear	B-protein	O
factor-kappaB	I-protein	O
(	O	O
NF-kappaB	B-protein	O
)	O	O
is	O	O
activated	O	O
in	O	O
cerulein	O	O
pancreatitis	O	O
and	O	O
mediates	O	O
cytokine	B-protein	O
expression	O	O
.	O	O

The	O	O
role	O	O
of	O	O
transcription	B-protein	O
factor	I-protein	O
activation	O	O
in	O	O
other	O	O
models	O	O
of	O	O
pancreatitis	O	O
has	O	O
not	O	O
been	O	O
established	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
upregulation	O	O
of	O	O
NF-kappaB	B-protein	O
and	O	O
inflammatory	B-protein	O
molecules	I-protein	O
,	O	O
and	O	O
their	O	O
correlation	O	O
with	O	O
local	O	O
pancreatic	O	O
injury	O	O
,	O	O
in	O	O
a	O	O
model	O	O
of	O	O
severe	O	O
pancreatitis	O	O
.	O	O

Rats	O	O
received	O	O
intraductal	O	O
infusion	O	O
of	O	O
taurocholate	O	O
or	O	O
saline	O	O
,	O	O
and	O	O
the	O	O
pancreatic	O	O
head	O	O
and	O	O
tail	O	O
were	O	O
analyzed	O	O
separately	O	O
.	O	O

NF-kappaB	O	O
and	O	O
activator	B-protein	O
protein-1	I-protein	O
(	O	O
AP-1	B-protein	O
)	O	O
activation	O	O
were	O	O
assessed	O	O
by	O	O
gel	O	O
shift	O	O
assay	O	O
,	O	O
and	O	O
mRNA	O	O
expression	O	O
of	O	O
interleukin-6	B-protein	O
,	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor-alpha	I-protein	O
,	O	O
KC	O	O
,	O	O
monocyte	O	O
chemoattractant	O	O
protein-1	B-protein	O
,	O	O
and	O	O
inducible	O	O
nitric	O	O
oxide	O	O
synthase	O	O
was	O	O
assessed	O	O
by	O	O
semiquantitative	O	O
RT-PCR	O	O
.	O	O

Morphological	O	O
damage	O	O
and	O	O
trypsin	O	O
activation	O	O
were	O	O
much	O	O
greater	O	O
in	O	O
the	O	O
pancreatic	O	O
head	O	O
than	O	O
tail	O	O
,	O	O
in	O	O
parallel	O	O
with	O	O
a	O	O
stronger	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
and	O	O
cytokine	B-RNA	O
mRNA	I-RNA	O
.	O	O

Saline	O	O
infusion	O	O
mildly	O	O
affected	O	O
these	O	O
parameters	O	O
.	O	O

AP-1	O	O
was	O	O
strongly	O	O
activated	O	O
in	O	O
both	O	O
pancreatic	O	O
segments	O	O
after	O	O
either	O	O
taurocholate	O	O
or	O	O
saline	O	O
infusion	O	O
.	O	O

NF-kappaB	O	O
inhibition	O	O
with	O	O
N-acetylcysteine	O	O
ameliorated	O	O
the	O	O
local	O	O
inflammatory	O	O
response	O	O
.	O	O

Correlation	O	O
between	O	O
localized	O	O
NF-kappaB	O	O
activation	O	O
,	O	O
cytokine	O	O
upregulation	O	O
,	O	O
and	O	O
tissue	O	O
damage	O	O
suggests	O	O
a	O	O
key	O	O
role	O	O
for	O	O
NF-kappaB	O	O
in	O	O
the	O	O
development	O	O
of	O	O
the	O	O
inflammatory	O	O
response	O	O
of	O	O
acute	O	O
pancreatitis	O	O
.	O	O

CD45	O	O
tyrosine	O	O
phosphatase	O	O
controls	O	O
common	O	O
gamma-chain	O	O
cytokine	B-protein	O
-mediated	O	O
STAT	B-protein	O
and	O	O
extracellular	O	O
signal-related	O	O
kinase	O	O
phosphorylation	O	O
in	O	O
activated	O	O
human	O	O
lymphoblasts	O	O
:	O	O
inhibition	O	O
of	O	O
proliferation	O	O
without	O	O
induction	O	O
of	O	O
apoptosis	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
test	O	O
whether	O	O
CD45	O	O
signals	O	O
can	O	O
influence	O	O
signaling	O	O
processes	O	O
in	O	O
activated	O	O
human	O	O
lymphoblasts	O	O
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
we	O	O
generated	O	O
lymphoblasts	O	O
which	O	O
proliferate	O	O
in	O	O
response	O	O
to	O	O
common	O	O
gamma-chain	O	O
cytokines	O	O
,	O	O
but	O	O
readily	O	O
undergo	O	O
apoptosis	O	O
after	O	O
cytokine	B-protein	O
withdrawal	O	O
.	O	O

In	O	O
experiments	O	O
with	O	O
the	O	O
CD45R0	B-protein	O
mAb	I-protein	O
UCHL-1	O	O
,	O	O
but	O	O
not	O	O
control	O	O
CD45	O	O
mAbs	O	O
,	O	O
we	O	O
found	O	O
significant	O	O
inhibition	O	O
of	O	O
proliferation	O	O
.	O	O

Interestingly	O	O
,	O	O
the	O	O
pan-CD45	O	O
mAb	I-protein	O
GAP8.3	O	O
,	O	O
which	O	O
is	O	O
most	O	O
effective	O	O
in	O	O
inhibition	O	O
of	O	O
OKT-3-mediated	O	O
proliferation	O	O
in	O	O
quiescent	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
was	O	O
ineffective	O	O
in	O	O
lymphoblasts	O	O
.	O	O

Addition	O	O
of	O	O
CD3	B-protein	O
mAb	I-protein	O
OKT-3	O	O
had	O	O
no	O	O
influence	O	O
on	O	O
IL-2-mediated	O	O
proliferation	O	O
(	O	O
with	O	O
or	O	O
without	O	O
UCHL-1	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
after	O	O
addition	O	O
of	O	O
OKT-3	O	O
to	O	O
IL-4	O	O
-	O	O
and	O	O
IL-7	O	O
-stimulated	O	O
proliferation	O	O
assays	O	O
,	O	O
UCHL-1	O	O
signals	O	O
could	O	O
not	O	O
significantly	O	O
alter	O	O
cellular	O	O
proliferation	O	O
.	O	O

We	O	O
did	O	O
not	O	O
find	O	O
induction	O	O
of	O	O
apoptosis	O	O
following	O	O
CD45R0	O	O
signaling	O	O
.	O	O

In	O	O
Western	O	O
blots	O	O
using	O	O
mAbs	O	O
detecting	O	O
phosphorylated	O	O
STAT-3	O	O
,	O	O
STAT-5	O	O
,	O	O
STAT-6	O	O
,	O	O
or	O	O
extracellular	O	O
signal-related	O	O
kinase	O	O
1/2	O	O
,	O	O
we	O	O
found	O	O
that	O	O
CD45R0	O	O
signaling	O	O
could	O	O
effectively	O	O
diminish	O	O
phosphorylation	O	O
of	O	O
these	O	O
intracellular	O	O
signaling	O	O
components	O	O
.	O	O

Using	O	O
RT-PCR	O	O
,	O	O
we	O	O
found	O	O
that	O	O
CD45R0	O	O
signaling	O	O
inhibited	O	O
IL-2	O	O
mRNA	O	O
production	O	O
without	O	O
major	O	O
influence	O	O
on	O	O
IL-13	B-protein	O
,	O	O
IL-5	B-protein	O
,	O	O
or	O	O
IFN-gamma	B-RNA	O
mRNA	I-RNA	O
levels	O	O
.	O	O

Costimulation	O	O
with	O	O
OKT-3	O	O
and	O	O
IL-2	B-protein	O
optimally	O	O
induced	O	O
secretion	O	O
of	O	O
IFN-gamma	B-protein	O
,	O	O
TNF-alpha	O	O
,	O	O
and	O	O
IL-5	B-protein	O
,	O	O
which	O	O
was	O	O
not	O	O
decreased	O	O
by	O	O
CD45	O	O
signals	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
we	O	O
illustrate	O	O
that	O	O
CD45R0	O	O
signals	O	O
control	O	O
early	O	O
cytokine	O	O
receptor-associated	O	O
signaling	O	O
processes	O	O
and	O	O
mRNA	O	O
and	O	O
DNA	O	O
synthesis	O	O
in	O	O
activated	O	O
human	O	O
lymphoblasts	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
show	O	O
the	O	O
existence	O	O
of	O	O
CD45	B-protein	O
epitopes	I-protein	O
(	O	O
GAP8.3	B-protein	O
)	O	O
,	O	O
which	O	O
are	O	O
active	O	O
and	O	O
critical	O	O
for	O	O
signaling	O	O
in	O	O
quiescent	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
but	O	O
are	O	O
nonfunctional	O	O
in	O	O
activated	O	O
human	O	O
lymphoblasts	O	O
.	O	O

Pax5	O	O
determines	O	O
the	O	O
identity	O	O
of	O	O
B	B-cell_type	O
cells	I-cell_type	O
from	O	O
the	O	O
beginning	O	O
to	O	O
the	O	O
end	O	O
of	O	O
B-lymphopoiesis	O	O
.	O	O

Despite	O	O
being	O	O
one	O	O
of	O	O
the	O	O
most	O	O
intensively	O	O
studied	O	O
cell	O	O
types	O	O
,	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
B	B-protein	O
cell	O	O
specification	O	O
is	O	O
largely	O	O
unknown	O	O
.	O	O

The	O	O
Pax5	B-DNA	O
gene	I-DNA	O
encoding	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
BSAP	B-protein	O
is	O	O
required	O	O
for	O	O
progression	O	O
of	O	O
B-lymphopoiesis	O	O
beyond	O	O
the	O	O
pro-B	O	O
cell	O	O
stage	O	O
.	O	O

Pax5-deficient	I-cell_line	O
pro-B	I-cell_line	O
cells	I-cell_line	O
are	O	O
,	O	O
however	O	O
,	O	O
not	O	O
yet	O	O
committed	O	O
to	O	O
the	O	O
B-lymphoid	B-protein	O
lineage	I-protein	O
,	O	O
but	O	O
instead	O	O
have	O	O
a	O	O
broad	O	O
lymphomyeloid	O	O
developmental	O	O
potential	O	O
.	O	O

Pax5	O	O
appears	O	O
to	O	O
mediate	O	O
B-lineage	O	O
commitment	O	O
by	O	O
repressing	O	O
the	O	O
transcription	O	O
of	O	O
non-B-lymphoid	B-DNA	O
genes	I-DNA	O
and	O	O
by	O	O
simultaneously	O	O
activating	O	O
the	O	O
expression	O	O
of	O	O
B-lineage-specific	B-DNA	O
genes	I-DNA	O
.	O	O

Pax5	O	O
thus	O	O
functions	O	O
both	O	O
as	O	O
a	O	O
transcriptional	B-protein	O
repressor	I-protein	O
and	O	O
activator	I-protein	O
,	O	O
depending	O	O
on	O	O
its	O	O
interactions	O	O
with	O	O
corepressors	O	O
of	O	O
the	O	O
Groucho	B-protein	O
protein	I-protein	O
family	I-protein	O
or	O	O
with	O	O
positive	O	O
regulators	O	O
such	O	O
as	O	O
the	O	O
TATA-binding	B-protein	O
protein	I-protein	O
.	O	O

Once	O	O
committed	O	O
to	O	O
the	O	O
B-lineage	B-cell_type	O
,	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
require	O	O
Pax5	O	O
function	O	O
to	O	O
maintain	O	O
their	O	O
B-lymphoid	O	O
identity	O	O
throughout	O	O
B	O	O
cell	O	O
development	O	O

Partners	O	O
in	O	O
transcription	O	O
:	O	O
NFAT	O	O
and	O	O
AP-1	B-protein	O
.	O	O

Combinatorial	O	O
regulation	O	O
is	O	O
a	O	O
powerful	O	O
mechanism	O	O
that	O	O
enables	O	O
tight	O	O
control	O	O
of	O	O
gene	O	O
expression	O	O
,	O	O
via	O	O
integration	O	O
of	O	O
multiple	O	O
signaling	O	O
pathways	O	O
that	O	O
induce	O	O
different	O	O
transcription	B-protein	O
factors	I-protein	O
required	O	O
for	O	O
enhanceosome	O	O
assembly	O	O
.	O	O

The	O	O
four	O	O
calcium-regulated	O	O
transcription	B-protein	O
factors	I-protein	O
of	O	O
the	O	O
NFAT	B-protein	O
family	I-protein	O
act	O	O
synergistically	O	O
with	O	O
AP-1	B-protein	O
(	O	O
Fos/Jun	B-protein	O
)	O	O
proteins	O	O
on	O	O
composite	O	O
DNA	B-DNA	O
elements	I-DNA	O
which	O	O
contain	O	O
adjacent	O	O
NFAT	B-protein	O
and	O	O
AP-1	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
,	O	O
where	O	O
they	O	O
form	O	O
highly	O	O
stable	O	O
ternary	O	O
complexes	O	O
to	O	O
regulate	O	O
the	O	O
expression	O	O
of	O	O
diverse	O	O
inducible	O	O
genes	I-DNA	O
.	O	O

Concomitant	O	O
induction	O	O
of	O	O
NFAT	B-protein	O
and	O	O
AP-1	B-protein	O
requires	O	O
concerted	O	O
activation	O	O
of	O	O
two	O	O
different	O	O
signaling	O	O
pathways	O	O
:	O	O
calcium/calcineurin	O	O
,	O	O
which	O	O
promotes	O	O
NFAT	O	O
dephosphorylation	O	O
,	O	O
nuclear	O	O
translocation	O	O
and	O	O
activation	O	O
;	O	O
and	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
(	O	O
PKC	O	O
)	O	O
/Ras	O	O
,	O	O
which	O	O
promotes	O	O
the	O	O
synthesis	O	O
,	O	O
phosphorylation	O	O
and	O	O
activation	O	O
of	O	O
members	O	O
of	O	O
the	O	O
Fos	B-protein	O
and	O	O
Jun	O	O
families	O	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

A	O	O
fifth	O	O
member	O	O
of	O	O
the	O	O
NFAT	B-protein	O
family	I-protein	O
,	O	O
NFAT5	O	O
,	O	O
controls	O	O
the	O	O
cellular	O	O
response	O	O
to	O	O
osmotic	O	O
stress	O	O
,	O	O
by	O	O
a	O	O
mechanism	O	O
that	O	O
requires	O	O
dimer	O	O
formation	O	O
and	O	O
is	O	O
independent	O	O
of	O	O
calcineurin	O	O
or	O	O
of	O	O
interaction	O	O
with	O	O
AP-1	B-protein	O
.	O	O

Pharmacological	O	O
interference	O	O
with	O	O
theNFAT	O	O
:	O	O
AP-1	O	O
interaction	O	O
may	O	O
be	O	O
useful	O	O
in	O	O
selective	O	O
manipulation	O	O
of	O	O
the	O	O
immune	O	O
response	O	O
.	O	O

Balanced	O	O
activation	O	O
of	O	O
NFAT	B-protein	O
and	O	O
AP-1	B-protein	O
is	O	O
known	O	O
to	O	O
be	O	O
required	O	O
for	O	O
productive	O	O
immune	O	O
responses	O	O
,	O	O
but	O	O
the	O	O
role	O	O
of	O	O
NFAT	B-protein	O
:	O	O
AP-1	O	O
interactions	O	O
in	O	O
other	O	O
cell	O	O
types	O	O
and	O	O
biological	O	O
processes	O	O
remains	O	O
to	O	O
be	O	O
understood	O	O
.	O	O

Cytokine	O	O
production	O	O
by	O	O
Vgamma	O	O
(	O	O
+	O	O
)	O	O
-T-cell	O	O
subsets	O	O
is	O	O
an	O	O
important	O	O
factor	I-protein	O
determining	O	O
CD4	B-protein	O
(	O	O
+	O	O
)	O	O
-Th-cell	O	O
phenotype	O	O
and	O	O
susceptibility	O	O
of	O	O
BALB/c	O	O
mice	O	O
to	O	O
coxsackievirus	O	O
B3-induced	O	O
myocarditis	O	O
.	O	O

Two	O	O
coxsackievirus	O	O
B3	O	O
(	O	O
CVB3	B-protein	O
)	O	O
variants	O	O
(	O	O
H3	O	O
and	O	O
H310A1	O	O
)	O	O
differ	O	O
by	O	O
a	O	O
single	O	O
amino	O	O
acid	O	O
mutation	O	O
in	O	O
the	O	O
VP2	O	O
capsid	O	O
protein	O	O
.	O	O

H3	O	O
induces	O	O
severe	O	O
myocarditis	O	O
in	O	O
BALB/c	O	O
mice	O	O
,	O	O
but	O	O
H310A1	O	O
is	O	O
amyocarditic	O	O
.	O	O

Infection	O	O
with	O	O
H3	O	O
,	O	O
but	O	O
not	O	O
H310A1	O	O
,	O	O
preferentially	O	O
activates	O	O
Vgamma4	O	O
Vdelta4	I-cell_line	O
cells	I-cell_line	O
,	O	O
which	O	O
are	O	O
strongly	O	O
positive	O	O
for	O	O
gamma	B-protein	O
interferon	I-protein	O
(	O	O
IFN-gamma	B-protein	O
)	O	O
,	O	O
whereas	O	O
Vgamma1	O	O
Vdelta4	O	O
cells	O	O
are	O	O
increased	O	O
in	O	O
both	O	O
H3	O	O
and	O	O
H310A1	O	O
virus-infected	O	O
animals	O	O
.	O	O

Depletion	O	O
of	O	O
Vgamma1	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
using	O	O
monoclonal	O	O
anti-Vgamma1	O	O
antibody	O	O
enhanced	O	O
myocarditis	O	O
and	O	O
CD4	B-protein	O
(	O	O
+	O	O
)	O	O
-	O	O
,	O	O
IFN-gamma	B-protein	O
(	O	O
+	O	O
)	O	O
-cell	O	O
responses	O	O
in	O	O
both	O	O
H3-	O	O
and	O	O
H310A1-infected	O	O
mice	O	O
yet	O	O
decreased	O	O
the	O	O
CD4	O	O
(	O	O
+	O	O
)	O	O
-	O	O
,	O	O
IL-4	O	O
(	O	O
+	O	O
)	O	O
-cell	O	O
response	O	O
.	O	O

Depleting	O	O
Vgamma4	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
suppressed	O	O
myocarditis	O	O
and	O	O
reduced	B-protein	O
CD4	I-protein	O
(	O	O
+	I-DNA	O
)	O	O
IFN-gamma	B-protein	O
(	O	O
+	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
but	O	O
increased	O	O
CD4	B-protein	O
(	O	O
+	B-protein	O
)	I-protein	O
IL-4	I-cell_line	O
(	I-cell_line	O
+	I-cell_line	O
)	I-cell_line	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
role	O	O
of	O	O
cytokine	B-protein	O
production	O	O
by	O	O
Vgamma1	O	O
(	O	O
+	O	O
)	O	O
and	O	O
Vgamma4	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
was	O	O
investigated	O	O
by	O	O
adoptively	O	O
transferring	O	O
these	O	O
cells	O	O
isolated	O	O
from	O	O
H3-infected	O	O
BALB/c	O	O
Stat4	O	O
knockout	O	O
(	O	O
Stat4ko	O	O
)	O	O
(	O	O
defective	O	O
in	O	O
IFN-gamma	B-protein	O
expression	O	O
)	O	O
or	O	O
BALB/c	O	O
Stat6ko	O	O
(	O	O
defective	O	O
in	O	O
IL-4	O	O
expression	O	O
)	O	O
mice	O	O
into	O	O
H3	O	O
virus-infected	O	O
wild-type	O	O
BALB/c	O	O
recipients	O	O
.	O	O

Vgamma4	O	O
and	O	O
Vgamma1	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
from	O	O
Stat4ko	O	O
mice	O	O
expressed	O	O
IL-4	O	O
but	O	O
no	O	O
or	O	O
minimal	O	O
IFN-gamma	B-protein	O
,	O	O
whereas	O	O
these	O	O
cell	O	O
populations	O	O
derived	O	O
from	O	O
Stat6ko	O	O
mice	O	O
expressed	O	O
IFN-gamma	B-protein	O
but	O	O
no	O	O
IL-4	O	O
.	O	O

Stat4ko	O	O
Vgamma1	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
(	O	O
IL-4	B-protein	O
(	O	O
+	O	O
)	O	O
)	O	O
suppress	O	O
myocarditis	O	O
.	O	O

Stat6ko	O	O
Vgamma1	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
(	O	O
IFN-gamma	B-protein	O
(	O	O
+	O	O
)	O	O
)	O	O
were	O	O
not	O	O
inhibitory	O	O
.	O	O

Stat6ko	O	O
Vgamma4	O	O
(	O	O
+	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
(	O	O
IFN-gamma	B-protein	O
(	O	O
+	I-DNA	O
)	O	O
)	O	O
significantly	O	O
enhanced	O	O
myocarditis	O	O
.	O	O

Stat4ko	O	O
Vgamma4	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
(	O	O
IL-4	B-protein	O
(	O	O
+	O	O
)	O	O
)	O	O
neither	O	O
inhibited	O	O
nor	O	O
enhanced	O	O
disease	O	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
distinct	O	O
gammadelta-T-cell	O	O
subsets	O	O
control	O	O
myocarditis	O	O
susceptibility	O	O
and	O	O
bias	O	O
the	O	O
CD4	B-protein	O
(	O	O
+	I-DNA	O
)	O	O
-Th-cell	O	O
response	O	O
.	O	O

The	O	O
cytokines	B-protein	O
produced	O	O
by	O	O
the	O	O
Vgamma	O	O
subpopulation	O	O
have	O	O
a	O	O
significant	O	O
influence	O	O
on	O	O
the	O	O
CD4	B-DNA	O
(	I-DNA	O
+	I-DNA	O
)	O	O
-Th-cell	O	O
phenotype	O	O
.	O	O

Plasmin	O	O
-induced	O	O
expression	O	O
of	O	O
cytokines	B-protein	O
and	O	O
tissue	B-protein	O
factor	I-protein	O
in	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
involves	O	O
AP-1	O	O
and	O	O
IKKbeta	O	O
-mediated	O	O
NF-kappaB	O	O
activation	O	O
.	O	O

It	O	O
was	O	O
previously	O	O
shown	O	O
that	O	O
plasmin	O	O
activates	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
monocytes	I-cell_type	O
in	O	O
terms	O	O
of	O	O
lipid	O	O
mediator	O	O
release	O	O
and	O	O
chemotactic	O	O
migration	O	O
.	O	O

Here	O	O
it	O	O
is	O	O
demonstrated	O	O
that	O	O
plasmin	O	O
induces	O	O
proinflammatory	O	O
cytokine	O	O
release	O	O
and	O	O
tissue	B-protein	O
factor	I-protein	O
(	O	O
TF	O	O
)	O	O
expression	O	O
by	O	O
monocytes	B-cell_type	O
.	O	O

Plasmin	O	O
0.043	O	O
to	O	O
1.43	O	O
CTA	O	O
U/mL	O	O
,	O	O
but	O	O
not	O	O
active	O	O
site-blocked	O	O
plasmin	O	O
,	O	O
triggered	O	O
concentration-dependent	O	O
expression	O	O
of	O	O
mRNA	B-RNA	O
for	O	O
interleukin-1alpha	O	O
(	O	O
IL-1alpha	B-protein	O
)	O	O
,	O	O
IL-1beta	O	O
,	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor-alpha	I-protein	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
,	O	O
and	O	O
TF	O	O
with	O	O
maximum	O	O
responses	O	O
after	O	O
4	O	O
hours	O	O
.	O	O

Plasmin	O	O
-mediated	O	O
mRNA	I-RNA	O
expression	O	O
was	O	O
inhibited	O	O
in	O	O
a	O	O
concentration-dependent	O	O
manner	O	O
by	O	O
the	O	O
lysine	B-protein	O
analogue	I-protein	O
trans-4-	I-protein	O
(	O	O
aminomethyl	B-protein	O
)	O	O
cyclohexane-1-carboxylic	O	O
acid	O	O
(	O	O
t-AMCA	B-protein	O
)	O	O
.	O	O

Increases	O	O
in	O	O
mRNA	B-RNA	O
levels	O	O
were	O	O
followed	O	O
by	O	O
concentration-	O	O
and	O	O
time-dependent	O	O
release	O	O
of	O	O
IL-1alpha	O	O
,	O	O
IL-1beta	O	O
and	O	O
TNF-alpha	O	O
and	O	O
by	O	O
TF	O	O
expression	O	O
on	O	O
monocyte	O	O
surfaces	O	O
.	O	O

Neither	O	O
cytokines	B-protein	O
nor	O	O
TF	O	O
could	O	O
be	O	O
detected	O	O
when	O	O
monocytes	O	O
were	O	O
preincubated	O	O
with	O	O
actinomycin	O	O
D	O	O
or	O	O
cycloheximide	O	O
.	O	O

Electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
indicated	O	O
plasmin	O	O
-induced	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
;	O	O
DNA-binding	O	O
complexes	O	O
were	O	O
composed	O	O
of	O	O
p50	B-protein	O
,	O	O
p65	B-protein	O
,	O	O
and	O	O
c-Rel	B-protein	O
,	O	O
as	O	O
shown	O	O
by	O	O
supershift	O	O
experiments	O	O
.	O	O

Nuclear	O	O
translocation	O	O
of	O	O
NF-kappaB/Rel	B-protein	O
proteins	I-protein	O
coincided	O	O
with	O	O
IkappaBalpha	O	O
degradation	O	O
.	O	O

At	O	O
variance	O	O
with	O	O
endotoxic	O	O
lipopolysaccharide	O	O
,	O	O
plasmin	O	O
elicited	O	O
the	O	O
rapid	O	O
degradation	O	O
of	O	O
another	O	O
cytoplasmic	O	O
NF-kappaB	O	O
inhibitor	O	O
,	O	O
p105	O	O
.	O	O

Proteolysis	O	O
of	O	O
NF-kappaB	O	O
inhibitors	O	O
was	O	O
apparently	O	O
due	O	O
to	O	O
transient	O	O
activation	O	O
of	O	O
IkappaB	B-protein	O
kinase	I-protein	O
(	O	O
IKK	B-protein	O
)	O	O
beta	O	O
that	O	O
reached	O	O
maximum	O	O
activity	O	O
at	O	O
1	O	O
hour	O	O
after	O	O
plasmin	O	O
stimulation	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
AP-1	B-protein	O
binding	O	O
was	O	O
increased	O	O
in	O	O
plasmin	O	O
-treated	O	O
monocytes	B-cell_type	O
,	O	O
with	O	O
most	O	O
complexes	O	O
composed	O	O
of	O	O
JunD	O	O
,	O	O
c-Fos	O	O
,	O	O
and	O	O
FosB	O	O
.	O	O

These	O	O
findings	O	O
further	O	O
substantiate	O	O
the	O	O
role	O	O
of	O	O
plasmin	O	O
as	O	O
a	O	O
proinflammatory	O	O
activator	O	O
of	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
and	O	O
reveal	O	O
an	O	O
important	O	O
new	O	O
link	O	O
between	O	O
the	O	O
plasminogen-plasmin	O	O
system	O	O
and	O	O
inflammation	O	O
.	O	O

(	O	O
Blood.	O	O
2001	O	O
;	O	O
97	O	O
:	O	O
3941-3950	O	O
)	O	O

STAT3	O	O
is	O	O
constitutively	O	O
active	O	O
in	O	O
some	O	O
patients	O	O
with	O	O
Polycythemia	O	O
rubra	O	O
vera	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
Polycythemia	O	O
vera	O	O
is	O	O
a	O	O
clonal	O	O
stem	O	O
cell	O	O
disorder	O	O
characterized	O	O
by	O	O
hyperproliferation	O	O
of	O	O
the	O	O
erythroid	B-protein	O
,	O	O
myeloid	O	O
,	O	O
and	O	O
megakaryocytic	B-protein	O
lineages	I-protein	O
.	O	O

While	O	O
it	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
progenitor	O	O
cells	O	O
of	O	O
P.	O	O
vera	O	O
patients	O	O
are	O	O
hypersensitive	O	O
to	O	O
several	O	O
growth	O	O
factors	I-protein	O
including	O	O
erythropoietin	O	O
,	O	O
insulin-like	O	O
growth	O	O
factor-1	O	O
,	O	O
thrombopoietin	O	O
,	O	O
interleukin-3	O	O
,	O	O
and	O	O
granulocyte/monocyte	B-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
,	O	O
the	O	O
molecular	O	O
pathogenesis	O	O
of	O	O
this	O	O
disease	O	O
remains	O	O
unknown	O	O
.	O	O

Growth	B-protein	O
factor	I-protein	O
hypersensitivity	O	O
could	O	O
be	O	O
mediated	O	O
by	O	O
changes	O	O
in	O	O
signal	O	O
transduction	O	O
pathways	O	O
.	O	O

We	O	O
therefore	O	O
investigated	O	O
a	O	O
common	O	O
downstream	O	O
effector	O	O
of	O	O
cytokines	B-protein	O
,	O	O
the	O	O
signal	B-protein	O
transducers	I-protein	O
and	I-protein	O
activators	I-protein	O
of	I-protein	O
transcription	I-protein	O
(	O	O
STATs	B-protein	O
)	I-protein	O
.	O	O

A	O	O
constitutive	O	O
activation	O	O
of	O	O
STAT	B-protein	O
factors	I-protein	O
could	O	O
explain	O	O
the	O	O
increased	O	O
proliferation	O	O
of	O	O
P.	B-cell_type	O
vera	I-cell_type	O
cells	I-cell_type	O
even	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
growth	O	O
factor	O	O
stimulation	O	O
.	O	O

METHODS	O	O
:	O	O
Peripheral	O	O
granulocytes	O	O
from	O	O
patients	O	O
with	O	O
P.	O	O
vera	O	O
and	O	O
from	O	O
healthy	O	O
volunteers	O	O
were	O	O
assayed	O	O
for	O	O
STAT1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
5	O	O
DNA	O	O
binding	O	O
by	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
.	O	O

RESULTS	O	O
:	O	O
Four	O	O
of	O	O
14	O	O
P.	O	O
vera	O	O
patients	O	O
analyzed	O	O
showed	O	O
constitutive	O	O
STAT3	O	O
DNA	O	O
binding	O	O
in	O	O
unstimulated	O	O
peripheral	O	O
granulocytes	O	O
,	O	O
while	O	O
none	O	O
of	O	O
the	O	O
17	O	O
healthy	O	O
volunteers	O	O
tested	O	O
did	O	O
.	O	O

None	O	O
of	O	O
the	O	O
subjects	O	O
showed	O	O
constitutive	O	O
STAT1	B-protein	O
or	O	O
STAT5	O	O
activity	O	O
.	O	O

Western	O	O
blotting	O	O
demonstrated	O	O
that	O	O
,	O	O
in	O	O
the	O	O
three	O	O
patients	O	O
,	O	O
STAT3	O	O
is	O	O
constitutively	O	O
phosphorylated	O	O
on	O	O
Tyr	O	O
705	O	O
,	O	O
whereas	O	O
it	O	O
is	O	O
unphosphorylated	O	O
in	O	O
the	O	O
other	O	O
patients	O	O
and	O	O
in	O	O
controls	O	O
.	O	O

Interestingly	O	O
,	O	O
constitutive	O	O
STAT3	O	O
activity	O	O
did	O	O
not	O	O
correlate	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
disease	O	O
or	O	O
the	O	O
treatment	O	O
regimen	O	O
.	O	O

It	O	O
was	O	O
observed	O	O
in	O	O
a	O	O
recently	O	O
diagnosed	O	O
patient	O	O
and	O	O
in	O	O
two	O	O
patients	O	O
treated	O	O
only	O	O
with	O	O
phlebotomy	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
data	O	O
suggest	O	O
that	O	O
constitutive	O	O
phosphorylation	O	O
and	O	O
activation	O	O
of	O	O
STAT3	B-protein	O
is	O	O
not	O	O
a	O	O
secondary	O	O
event	O	O
induced	O	O
by	O	O
mutagenizing	O	O
agents	O	O
or	O	O
by	O	O
prolonged	O	O
hyperproliferation	O	O
of	O	O
hematopoietic	B-cell_type	O
cells	I-cell_type	O
,	O	O
but	O	O
rather	O	O
represents	O	O
a	O	O
primary	O	O
molecular	O	O
aberration	O	O
.	O	O

Constitutively	O	O
active	O	O
STAT3	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
growth	B-protein	O
factor	I-protein	O
hypersensitivity	O	O
of	O	O
P.	B-cell_type	O
vera	I-cell_type	O
cells	I-cell_type	O
.	O	O

Identification	O	O
of	O	O
phosphorylation	O	O
sites	O	O
for	O	O
Bruton	O	O
's	O	O
tyrosine	O	O
kinase	O	O
within	O	O
the	O	O
transcriptional	O	O
regulator	O	O
BAP/TFII-I	O	O
.	O	O

Bruton	O	O
's	O	O
tyrosine	B-protein	O
kinase	I-protein	O
(	O	O
Btk	O	O
)	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
Tec	B-protein	O
family	I-protein	O
of	O	O
cytosolic	B-protein	O
kinases	I-protein	O
,	O	O
is	O	O
essential	O	O
for	O	O
B	O	O
cell	O	O
development	O	O
and	O	O
function	O	O
.	O	O

BAP/TFII-I	O	O
,	O	O
a	O	O
protein	O	O
implicated	O	O
in	O	O
transcriptional	O	O
regulation	O	O
,	O	O
is	O	O
associated	O	O
with	O	O
Btk	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
and	O	O
is	O	O
transiently	O	O
phosphorylated	O	O
on	O	O
tyrosine	O	O
following	O	O
B	O	O
cell	B-protein	O
receptor	I-protein	O
engagement	O	O
.	O	O

BAP/TFII-I	O	O
is	O	O
a	O	O
substrate	O	O
for	O	O
Btk	O	O
in	O	O
vitro	O	O
and	O	O
is	O	O
hyperphosphorylated	O	O
on	O	O
tyrosine	O	O
upon	O	O
coexpression	O	O
with	O	O
Btk	O	O
in	O	O
mammalian	B-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
an	O	O
effort	O	O
to	O	O
understand	O	O
the	O	O
physiologic	O	O
consequences	O	O
of	O	O
BAP/TFII-I	O	O
tyrosine	O	O
phosphorylation	O	O
following	O	O
B	O	O
cell	O	O
receptor	O	O
stimulation	O	O
,	O	O
site-directed	O	O
mutagenesis	O	O
and	O	O
phosphopeptide	O	O
mapping	O	O
were	O	O
used	O	O
to	O	O
locate	O	O
the	O	O
predominant	O	O
sites	O	O
of	O	O
BAP/TFII-I	O	O
phosphorylation	O	O
by	O	O
Btk	O	O
in	O	O
vitro	O	O
.	O	O

These	O	O
residues	O	O
,	O	O
Tyr248	O	O
,	O	O
Tyr357	O	O
,	O	O
and	O	O
Tyr462	O	O
,	O	O
were	O	O
also	O	O
found	O	O
to	O	O
be	O	O
the	O	O
major	O	O
sites	O	O
for	O	O
Btk	O	O
-dependent	O	O
phosphorylation	O	O
of	O	O
BAP/TFII-I	O	O
in	O	O
vivo	O	O
.	O	O

Residues	O	O
Tyr357	O	O
and	O	O
Tyr462	O	O
are	O	O
contained	O	O
within	O	O
the	O	O
loop	B-DNA	O
regions	I-DNA	O
of	O	O
adjacent	O	O
helix-loop-helix-like	O	O
repeats	O	O
within	O	O
BAP/TFII-I	O	O
.	O	O

Mutation	O	O
of	O	O
either	O	O
Tyr248	O	O
,	O	O
Tyr357	O	O
,	O	O
or	O	O
Tyr462	O	O
to	O	O
phenylalanine	O	O
reduced	O	O
transcription	O	O
from	O	O
a	O	O
c-fos	B-DNA	O
promoter	I-DNA	O
relative	O	O
to	O	O
wild-type	O	O
BAP/TFII-I	O	O
in	O	O
transfected	B-cell_line	O
COS-7	I-cell_line	O
cells	I-cell_line	O
,	O	O
consistent	O	O
with	O	O
the	O	O
interpretation	O	O
that	O	O
phosphorylation	O	O
at	O	O
these	O	O
sites	O	O
contributes	O	O
to	O	O
transcriptional	O	O
activation	O	O
.	O	O

Phosphorylation	O	O
of	O	O
BAP/TFII-I	O	O
by	O	O
Btk	O	O
may	O	O
link	O	O
engagement	O	O
of	O	O
receptors	O	O
such	O	O
as	O	O
surface	O	O
immunoglobulin	O	O
to	O	O
modulation	O	O
of	O	O
gene	O	O
expression	O	O
.	O	O

Expression	O	O
of	O	O
interferon	B-protein	O
consensus	I-protein	O
sequence	I-protein	O
binding	I-protein	O
protein	I-protein	O
induces	O	O
potent	O	O
immunity	O	O
against	O	O
BCR/ABL-induced	O	O
leukemia	O	O
.	O	O

Mice	O	O
deficient	O	O
in	O	O
the	O	O
interferon	B-DNA	O
consensus	B-DNA	O
sequence	I-DNA	O
binding	I-protein	O
protein	I-protein	O
(	O	O
ICSBP	B-protein	O
)	O	O
develop	O	O
a	O	O
disease	O	O
resembling	O	O
chronic	O	O
myeloid	O	O
leukemia	O	O
(	O	O
CML	O	O
)	O	O
,	O	O
which	O	O
in	O	O
humans	O	O
is	O	O
caused	O	O
by	O	O
the	O	O
BCR/ABL	O	O
oncoprotein	O	O
.	O	O

Interferon-alpha	O	O
(	O	O
IFN-alpha	B-protein	O
)	O	O
induces	O	O
ICSBP	O	O
expression	O	O
and	O	O
is	O	O
an	O	O
effective	O	O
therapy	O	O
for	O	O
CML	O	O
.	O	O

This	O	O
study	O	O
examined	O	O
whether	O	O
enforced	O	O
expression	O	O
of	O	O
ICSBP	O	O
might	O	O
antagonize	O	O
BCR/ABL-induced	O	O
leukemia	O	O
;	O	O
results	O	O
demonstrated	O	O
that	O	O
ICSBP-modified	O	O
cells	O	O
generated	O	O
a	O	O
protective	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
cytotoxic	O	O
T-cell	O	O
response	O	O
against	O	O
BCR/ABL-transformed	O	O
BaF3	O	O
cells	O	O
in	O	O
a	O	O
murine	O	O
leukemia	O	O
model	O	O
.	O	O

ICSBP	O	O
expression	O	O
represents	O	O
a	O	O
novel	O	O
means	O	O
of	O	O
stimulating	O	O
a	O	O
host	O	O
immune	O	O
response	O	O
to	O	O
BCR/ABL	O	O
(	O	O
+	O	O
)	O	O
leukemia	O	O
cells	O	O
and	O	O
a	O	O
potential	O	O
strategy	O	O
for	O	O
immunotherapy	O	O
of	O	O
CML	O	O
.	O	O

(	O	O
Blood.	O	O
2001	O	O
;	O	O
97	O	O
:	O	O
3491-3497	O	O
)	O	O

A	O	O
transcriptional	O	O
block	O	O
in	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
at	O	O
the	O	O
-150	O	O
AP-1	O	O
site	O	O
in	O	O
effector	B-cell_line	O
CD8+	I-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
.	O	O

Both	O	O
CD4+	I-cell_line	O
and	O	O
CD8+	O	O
T	B-cell_type	O
cells	I-cell_type	O
that	O	O
produce	O	O
IL-2	B-protein	O
in	O	O
response	O	O
to	O	O
Ag	O	O
recognition	O	O
have	O	O
been	O	O
isolated	O	O
.	O	O

However	O	O
,	O	O
most	O	O
effector	O	O
CD8+	O	O
T	B-cell_type	O
cells	I-cell_type	O
recovered	O	O
after	O	O
exposure	O	O
to	O	O
Ag	O	O
do	O	O
not	O	O
produce	O	O
sufficient	O	O
IL-2	O	O
to	O	O
sustain	O	O
growth	O	O
,	O	O
and	O	O
depend	O	O
on	O	O
CD4+	B-cell_line	O
T	I-cell_line	O
helper	I-cell_type	O
cells	I-cell_type	O
for	O	O
this	O	O
obligate	O	O
growth	O	O
factor	I-protein	O
.	O	O

IL-2	B-protein	O
expression	O	O
in	O	O
CD4+	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
is	O	O
primarily	O	O
controlled	O	O
at	O	O
the	O	O
level	O	O
of	O	O
transcription	O	O
,	O	O
but	O	O
mechanisms	O	O
restricting	O	O
IL-2	B-protein	O
production	O	O
in	O	O
CD8+	O	O
T	B-cell_type	O
cells	I-cell_type	O
have	O	O
not	O	O
been	O	O
elucidated	O	O
.	O	O

To	O	O
evaluate	O	O
transcriptional	O	O
regulation	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
gene	I-DNA	O
in	O	O
CD8+	B-cell_type	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
we	O	O
stably	O	O
transfected	O	O
reporter	B-DNA	O
genes	I-DNA	O
into	O	O
Ag	O	O
-specific	O	O
CD8+	O	O
T	O	O
cell	O	O
clones	O	O
.	O	O

CD28+	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
unable	O	O
to	O	O
transcribe	O	O
the	O	O
IL-2	B-DNA	O
gene	I-DNA	O
in	O	O
response	O	O
to	O	O
antigenic	O	O
stimulation	O	O
had	O	O
a	O	O
block	O	O
in	O	O
transactivation	O	O
of	O	O
the	O	O
-150	B-DNA	O
CD28	I-DNA	O
response	I-DNA	O
element	I-DNA	O
(	O	O
CD28RE	B-DNA	O
)	O	O
/AP-1	O	O
site	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
,	O	O
but	O	O
did	O	O
transactivate	O	O
the	O	O
composite	O	O
NFAT/AP-1	O	O
and	O	O
OCT/AP-1	B-DNA	O
sites	I-DNA	O
,	O	O
and	O	O
a	O	O
consensus	B-DNA	O
AP-1	I-DNA	O
motif	I-DNA	O
.	O	O

Mutation	O	O
of	O	O
the	O	O
nonconsensus	O	O
-150	I-DNA	O
AP-1	I-DNA	O
site	I-DNA	O
to	O	O
a	O	O
consensus	B-DNA	O
AP-1	I-DNA	O
site	I-DNA	O
,	O	O
or	O	O
insertion	O	O
of	O	O
a	O	O
CD28RE/AP-1	B-DNA	O
consensus	I-DNA	O
site	I-DNA	O
upstream	O	O
of	O	O
the	O	O
native	B-DNA	O
-150	I-DNA	O
CD28RE/AP-1	I-DNA	O
site	I-DNA	O
restored	O	O
transactivation	O	O
of	O	O
the	O	O
altered	B-DNA	O
promoter	I-DNA	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
defect	O	O
at	O	O
the	O	O
-150	O	O
site	O	O
may	O	O
reflect	O	O
the	O	O
absence	O	O
or	O	O
inactivity	O	O
of	O	O
a	O	O
required	B-protein	O
factor	I-protein	O
rather	O	O
than	O	O
repression	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
.	O	O

Stem	O	O
cell	B-protein	O
factor	I-protein	O
and	O	O
interleukin-3	O	O
induce	O	O
stepwise	O	O
generation	O	O
of	O	O
erythroid	B-cell_type	O
precursor	I-cell_type	O
cells	I-cell_type	O
from	O	O
a	O	O
basic	O	O
fibroblast	O	O
growth	O	O
factor	O	O
-dependent	O	O
hematopoietic	O	O
stem	O	O
cell	O	O
line	O	O
,	O	O
A-6	O	O
.	O	O

A	O	O
m	O	O
ultipotent	O	O
immature	O	O
myeloid	O	O
cell	O	O
population	O	O
was	O	O
produced	O	O
from	O	O
a	O	O
basic	O	O
fibroblast	I-protein	O
growth	I-protein	O
factor	I-protein	O
(	O	O
bFGF	O	O
)	O	O
-dependent	O	O
hematopoietic	O	O
stem	O	O
cell	O	O
line	O	O
,	O	O
A-6	O	O
,	O	O
when	O	O
cultured	O	O
with	O	O
stem	B-protein	O
cell	I-protein	O
factor	I-protein	O
(	O	O
SCF	O	O
)	O	O
replacing	O	O
bFGF	O	O
.	O	O

Those	B-cell_type	O
cells	I-cell_type	O
were	O	O
positive	O	O
for	O	O
stem	O	O
cell	O	O
markers	O	O
,	O	O
c-kit	O	O
and	O	O
CD34	O	O
,	O	O
and	O	O
a	O	O
myeloid	O	O
cell	O	O
marker	I-protein	O
,	O	O
F4/80	O	O
.	O	O

Some	O	O
cell	O	O
fractions	O	O
were	O	O
also	O	O
positive	O	O
for	O	O
Mac-1	O	O
,	O	O
a	O	O
macrophage	O	O
marker	O	O
or	O	O
Gr-1	O	O
,	O	O
a	O	O
granulocytic	O	O
maker	O	O
,	O	O
but	O	O
negative	O	O
for	O	O
an	O	O
erythroid	O	O
marker	O	O
TER119	O	O
.	O	O

They	O	O
also	O	O
showed	O	O
the	O	O
expression	O	O
of	O	O
mRNA	B-RNA	O
for	O	O
the	O	O
myeloid-specific	O	O
PU.1	O	O
but	O	O
did	O	O
not	O	O
that	O	O
for	O	O
the	O	O
erythroid-specific	O	O
GATA-1	B-protein	O
.	O	O

Among	O	O
various	O	O
cytokines	B-protein	O
,	O	O
interleukin-3	O	O
(	O	O
IL-3	O	O
)	O	O
induced	O	O
erythroid	B-cell_type	O
precursor	I-cell_type	O
cells	I-cell_type	O
that	O	O
expressed	O	O
the	O	O
erythroid-specific	O	O
GATA-1	B-protein	O
and	O	O
beta-major	O	O
globin	O	O
.	O	O

The	O	O
quantitative	O	O
analysis	O	O
showed	O	O
that	O	O
erythroid	B-cell_type	O
precursor	B-cell_type	O
cells	I-cell_type	O
were	O	O
newly	O	O
produced	O	O
from	O	O
the	O	O
immature	B-cell_type	O
myeloid	I-cell_type	O
cells	I-cell_type	O
by	O	O
cultivation	O	O
with	O	O
IL-3	O	O
.	O	O

SCF	O	O
and	O	O
IL-3	O	O
induced	O	O
stepwise	O	O
generation	O	O
of	O	O
erythroid	B-cell_type	O
precursor	I-cell_type	O
cells	I-cell_type	O
from	O	O
an	O	O
A-6	O	O
hematopoietic	O	O
stem	O	O
cell	O	O
line	O	O
.	O	O

Copyright	O	O
2001	O	O
Academic	O	O
Press	O	O
.	O	O

Distinct	O	O
BMI-1	O	O
and	O	O
EZH2	O	O
expression	O	O
patterns	O	O
in	O	O
thymocytes	B-cell_type	O
and	O	O
mature	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
suggest	O	O
a	O	O
role	O	O
for	O	O
Polycomb	O	O
genes	O	O
in	O	O
human	B-cell_type	O
T	I-cell_type	O
cell	I-cell_type	O
differentiation	O	O
.	O	O

BMI-1	O	O
and	O	O
EZH2	B-protein	O
Polycomb-group	I-protein	O
(	O	O
PcG	B-protein	O
)	O	O
proteins	O	O
belong	O	O
to	O	O
two	O	O
distinct	O	O
protein	O	O
complexes	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
hematopoiesis	O	O
.	O	O

Using	O	O
unique	O	O
PcG-specific	O	O
antisera	O	O
and	O	O
triple	O	O
immunofluorescence	O	O
,	O	O
we	O	O
found	O	O
that	O	O
mature	O	O
resting	O	O
peripheral	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
expressed	O	O
BMI-1	O	O
,	O	O
whereas	O	O
dividing	O	O
blasts	O	O
were	O	O
EZH2	O	O
(	O	O
+	O	O
)	O	O
.	O	O

By	O	O
contrast	O	O
,	O	O
subcapsular	O	O
immature	O	O
double-negative	O	O
(	O	O
DN	O	O
)	O	O
(	O	O
CD4	O	O
(	O	O
-	O	O
)	O	O
/CD8	O	O
(	O	O
-	O	O
)	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
in	O	O
the	O	O
thymus	O	O
coexpressed	O	O
BMI-1	O	O
and	O	O
EZH2	O	O
or	O	O
were	O	O
BMI-1	O	O
single	O	O
positive	O	O
.	O	O

Their	O	O
descendants	O	O
,	O	O
double-positive	O	O
(	O	O
DP	O	O
;	O	O
CD4	O	O
(	O	O
+	O	O
)	O	O
/CD8	O	O
(	O	O
+	O	O
)	O	O
)	O	O
cortical	O	O
thymocytes	O	O
,	O	O
expressed	O	O
EZH2	O	O
without	O	O
BMI-1	O	O
.	O	O

Most	O	O
EZH2	O	O
(	O	O
+	O	O
)	O	O
DN	O	O
and	O	O
DP	O	O
thymocytes	O	O
were	O	O
dividing	O	O
,	O	O
while	O	O
DN	O	O
BMI-1	O	O
(	O	O
+	O	O
)	O	O
/EZH2	O	O
(	O	O
-	O	O
)	O	O
thymocytes	O	O
were	O	O
resting	O	O
and	O	O
proliferation	O	O
was	O	O
occasionally	O	O
noted	O	O
in	O	O
DN	O	O
BMI-1	O	O
(	O	O
+	O	O
)	O	O
/EZH2	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
.	O	O

Maturation	O	O
of	O	O
DP	O	O
cortical	O	O
thymocytes	O	O
to	O	O
single-positive	O	O
(	O	O
CD4	B-protein	O
(	I-protein	O
+	I-protein	O
)	I-protein	O
/CD8	I-protein	O
(	O	O
-	B-protein	O
)	I-protein	O
or	O	O
CD8	B-protein	O
(	O	O
+	O	O
)	O	O
/CD4	O	O
(	O	O
-	B-protein	O
)	O	O
)	O	O
medullar	O	O
thymocytes	O	O
correlated	O	O
with	O	O
decreased	O	O
detectability	O	O
of	O	O
EZH2	O	O
and	O	O
continued	O	O
relative	O	O
absence	O	O
of	O	O
BMI-1	O	O
.	O	O

Our	O	O
data	O	O
show	O	O
that	O	O
BMI-1	O	O
and	O	O
EZH2	O	O
expression	O	O
in	O	O
mature	B-cell_type	O
peripheral	I-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
is	O	O
mutually	O	O
exclusive	O	O
and	O	O
linked	O	O
to	O	O
proliferation	O	O
status	O	O
,	O	O
and	O	O
that	O	O
this	O	O
pattern	O	O
is	O	O
not	O	O
yet	O	O
established	O	O
in	O	O
thymocytes	O	O
of	O	O
the	O	O
cortex	O	O
and	O	O
medulla	O	O
.	O	O

T	O	O
cell	O	O
stage-specific	O	O
PcG	O	O
expression	O	O
profiles	O	O
suggest	O	O
that	O	O
PcG	O	O
genes	O	O
contribute	O	O
to	O	O
regulation	O	O
of	O	O
T	B-cell_type	O
cell	I-cell_type	O
differentiation	O	O
.	O	O

They	O	O
probably	O	O
reflect	O	O
stabilization	O	O
of	O	O
cell	O	O
type-specific	O	O
gene	O	O
expression	O	O
and	O	O
irreversibility	O	O
of	O	O
lineage	O	O
choice	O	O
.	O	O

The	O	O
difference	O	O
in	O	O
PcG	O	O
expression	O	O
between	O	O
medullar	O	O
thymocytes	B-cell_type	O
and	O	O
mature	O	O
interfollicular	O	O
T	B-cell_type	O
cells	I-cell_type	O
indicates	O	O
that	O	O
additional	O	O
maturation	O	O
processes	O	O
occur	O	O
after	O	O
thymocyte	O	O
transportation	O	O
from	O	O
the	O	O
thymus	O	O
.	O	O

Stepwise	O	O
lineage	O	O
restriction	O	O
of	O	O
progenitors	B-protein	O
in	O	O
lympho-myelopoiesis	O	O
.	O	O

It	O	O
has	O	O
long	O	O
been	O	O
controversial	O	O
whether	O	O
hematopoiesis	O	O
progresses	O	O
through	O	O
ordered	O	O
stages	O	O
of	O	O
determination	O	O
as	O	O
in	O	O
embryonic	O	O
development	O	O
.	O	O

This	O	O
is	O	O
due	O	O
to	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
methodology	O	O
capable	O	O
of	O	O
exactly	O	O
determining	O	O
the	O	O
developmental	O	O
potential	O	O
of	O	O
hematopoietic	B-cell_type	O
stem/progenitor	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
multilineage	O	O
progenitor	O	O
(	O	O
MLP	I-DNA	O
)	O	O
assay	O	O
enabled	O	O
us	O	O
to	O	O
discriminate	O	O
among	O	O
seven	O	O
types	O	O
of	O	O
hematopoietic	O	O
progenitors	B-protein	O
,	O	O
which	O	O
are	O	O
multipotent	O	O
progenitor	O	O
p-MTB	O	O
(	O	O
capable	O	O
of	O	O
generating	B-protein	O
myeloid	I-protein	O
,	O	O
T	B-cell_type	O
and	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
)	O	O
,	O	O
bipotent	O	O
progenitors	O	O
p-MT	O	O
,	O	O
p-MB	O	O
and	O	O
p-TB	O	O
,	O	O
and	O	O
unipotent	O	O
progenitors	O	O
p-M	O	O
,	O	O
p-T	O	O
and	O	O
p-B	O	O
.	O	O

Among	O	O
these	O	O
seven	O	O
types	O	O
,	O	O
the	O	O
p-TB	O	O
type	O	O
progenitor	O	O
was	O	O
found	O	O
to	O	O
be	O	O
absent	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
the	O	O
process	O	O
of	O	O
lineage	O	O
commitment	O	O
proceeds	O	O
through	O	O
an	O	O
ordered	O	O
but	O	O
not	O	O
random	O	O
process	O	O
.	O	O

By	O	O
extending	O	O
the	O	O
area	O	O
of	O	O
investigation	O	O
to	O	O
include	O	O
the	O	O
erythroid	B-protein	O
lineage	I-protein	O
,	O	O
more	O	O
convincing	O	O
evidence	O	O
for	O	O
the	O	O
ordered	O	O
process	O	O
was	O	O
obtained	O	O
.	O	O

Detailed	O	O
and	O	O
exact	O	O
illustration	O	O
of	O	O
the	O	O
process	O	O
of	O	O
hematopoiesis	O	O
will	O	O
provide	O	O
an	O	O
opportunity	O	O
to	O	O
revive	O	O
hematopoiesis	O	O
as	O	O
one	O	O
of	O	O
the	O	O
most	O	O
fascinating	O	O
targets	O	O
of	O	O
research	O	O
in	O	O
developmental	O	O
biology	O	O

Epstein-Barr	O	O
Virus	O	O
and	O	O
its	O	O
glycoprotein-350	O	O
upregulate	O	O
IL-6	O	O
in	O	O
human	O	O
B-lymphocytes	O	O
via	O	O
CD21	O	O
,	O	O
involving	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
and	O	O
different	O	O
signaling	O	O
pathways	O	O
.	O	O

Epstein-Barr	O	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
is	O	O
a	O	O
ubiquitous	O	O
and	O	O
highly	O	O
immunotropic	O	O
gamma	O	O
herpesvirus	O	O
that	O	O
infects	O	O
more	O	O
than	O	O
90	O	O
%	O	O
of	O	O
humans	O	O
worldwide	O	O
.	O	O

Its	O	O
pathogenicity	O	O
leads	O	O
to	O	O
a	O	O
number	O	O
of	O	O
diseases	O	O
including	O	O
tumors	O	O
that	O	O
result	O	O
from	O	O
EBV	O	O
's	O	O
ability	O	O
to	O	O
readily	O	O
transform	O	O
B-lymphocytes	O	O
and	O	O
,	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
,	O	O
epithelial	B-cell_type	O
cells	I-cell_type	O
.	O	O

EBV	O	O
utilizes	O	O
CD21/CR2	O	O
as	O	O
its	O	O
receptor	O	O
on	O	O
B	B-cell_type	O
cells	I-cell_type	O
to	O	O
initiate	O	O
the	O	O
infection	O	O
process	O	O
.	O	O

EBV	O	O
binds	O	O
to	O	O
CR2	O	O
through	O	O
its	O	O
major	O	O
envelope	B-protein	O
glycoprotein-350	I-protein	O
(	O	O
gp350	B-protein	O
)	O	O
and	O	O
is	O	O
also	O	O
a	O	O
remarkable	O	O
immunomodulating	O	O
agent	O	O
.	O	O

We	O	O
had	O	O
previously	O	O
shown	O	O
that	O	O
EBV	O	O
is	O	O
capable	O	O
of	O	O
modulating	O	O
the	O	O
synthesis	O	O
of	O	O
a	O	O
number	O	O
of	O	O
cytokines	B-protein	O
.	O	O

We	O	O
now	O	O
show	O	O
that	O	O
while	O	O
both	O	O
purified	O	O
recombinant	O	O
gp350	O	O
(	O	O
rgp350	B-protein	O
)	O	O
and	O	O
EBV	O	O
upregulate	O	O
IL-6	O	O
mRNA	B-RNA	O
synthesis	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
,	O	O
EBV-induced	O	O
IL-6	O	O
gene	O	O
activation	O	O
occurs	O	O
for	O	O
a	O	O
significantly	O	O
longer	O	O
period	O	O
of	O	O
time	O	O
(	O	O
i.e.	B-protein	O
12	I-protein	O
hours	O	O
for	O	O
EBV	O	O
as	O	O
compared	O	O
to	O	O
6	O	O
hours	O	O
for	O	O
rgp350	O	O
)	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
half-life	O	O
of	O	O
EBV-induced	O	O
IL-6	O	O
mRNA	I-RNA	O
was	O	O
also	O	O
significantly	O	O
longer	O	O
(	O	O
10	O	O
hours	O	O
)	O	O
than	O	O
that	O	O
of	O	O
mRNA	B-RNA	O
induced	O	O
by	O	O
rgp350	O	O
(	O	O
about	O	O
6	O	O
hours	O	O
)	O	O
.	O	O

Both	O	O
EBV	O	O
and	O	O
gp350	O	O
enhance	O	O
the	O	O
binding	O	O
of	O	O
the	O	O
NF-kappaB	B-protein	O
transcription	I-protein	O
factor	I-protein	O
,	O	O
as	O	O
determined	O	O
by	O	O
band-shift	O	O
and	O	O
augment	O	O
NF-kappaB	O	O
-mediated	O	O
activation	O	O
of	O	O
a	O	O
CAT	B-DNA	O
reporter	I-DNA	O
plasmid	I-DNA	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
while	O	O
the	O	O
activation	O	O
of	O	O
IL-6	O	O
gene	O	O
expression	O	O
by	O	O
gp350	O	O
is	O	O
mediated	O	O
primarily	O	O
by	O	O
the	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
pathway	I-protein	O
,	O	O
EBV	O	O
can	O	O
mediate	O	O
its	O	O
effects	O	O
through	O	O
multiple	O	O
signaling	O	O
pathways	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
showing	O	O
that	O	O
the	O	O
binding	O	O
of	O	O
a	O	O
herpesvirus	O	O
envelope	O	O
glycoprotein	O	O
to	O	O
CR2	O	O
on	O	O
human	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
results	O	O
in	O	O
the	O	O
activation	O	O
of	O	O
the	O	O
NF-kappaB	B-protein	O
transcription	I-protein	O
factor	I-protein	O
leading	O	O
to	O	O
the	O	O
upregulation	O	O
of	O	O
IL-6	O	O
gene	O	O
expression	O	O
in	O	O
these	O	O
lymphocytes	I-cell_type	O
.	O	O

Copyright	O	O
2001	O	O
Academic	O	O
Press	O	O
.	O	O

Gene-	O	O
and	O	O
tissue-specificity	O	O
of	O	O
mutation	O	O
in	O	O
Big	O	O
Blue	O	O
rats	O	O
treated	O	O
with	O	O
the	O	O
hepatocarcinogen	O	O
N-hydroxy-2-acetylaminofluorene	O	O
.	O	O

In	O	O
a	O	O
previous	O	O
study	O	O
,	O	O
we	O	O
found	O	O
that	O	O
treating	O	O
transgenic	O	O
Big	O	O
Blue	O	O
rats	O	O
with	O	O
the	O	O
hepatocarcinogen	O	O
N-hydroxy-2-acetylaminofluorene	O	O
(	O	O
N-OH-AAF	O	O
)	O	O
produced	O	O
the	O	O
same	O	O
major	O	O
DNA	O	O
adduct	O	O
in	O	O
the	O	O
target	O	O
liver	O	O
and	O	O
the	O	O
nontarget	O	O
spleen	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
bone	B-cell_line	O
marrow	I-cell_line	O
cells	I-cell_line	O
,	O	O
induced	O	O
lacI	O	O
mutants	O	O
in	O	O
the	O	O
liver	O	O
,	O	O
and	O	O
induced	O	O
much	O	O
lower	O	O
frequencies	O	O
of	O	O
l	O	O
acI	O	O
and	O	O
hprt	O	O
mutants	O	O
in	O	O
spleen	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
sequence	O	O
analysis	O	O
was	O	O
conducted	O	O
on	O	O
lacI	O	O
DNA	O	O
and	O	O
hprt	B-protein	O
cDNA	I-protein	O
from	O	O
the	O	O
mutants	O	O
,	O	O
to	O	O
determine	O	O
the	O	O
mutational	O	O
specificity	O	O
of	O	O
N-OH-AAF	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

All	O	O
the	O	O
mutation	O	O
spectra	O	O
from	O	O
N-OH-AAF-treated	O	O
rats	O	O
differed	O	O
significantly	O	O
from	O	O
corresponding	O	O
mutation	O	O
profiles	O	O
from	O	O
untreated	O	O
animals	O	O
(	O	O
P	O	O
=	O	O
0.02	O	O
to	O	O
P	O	O
<	O	O
0.0001	O	O
)	O	O
.	O	O

Although	O	O
there	O	O
were	O	O
similarities	O	O
among	O	O
the	O	O
mutational	O	O
patterns	O	O
derived	O	O
from	O	O
N-OH-AAF-treated	O	O
rats	O	O
(	O	O
e.g.	O	O
,	O	O
G	O	O
:	O	O
C	O	O
--	O	O
>	O	O
T	O	O
:	O	O
A	O	O
transversion	O	O
was	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
in	O	O
all	O	O
mutation	O	O
sets	O	O
)	O	O
,	O	O
there	O	O
were	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
patterns	O	O
of	O	O
basepair	O	O
substitution	O	O
and	O	O
frameshift	O	O
mutation	O	O
between	O	O
the	O	O
liver	O	O
and	O	O
spleen	O	O
lymphocyte	O	O
lacI	O	O
mutants	O	O
(	O	O
P	O	O
=	O	O
0.02	O	O
)	O	O
and	O	O
between	O	O
the	O	O
spleen	O	O
lymphocyte	O	O
lacI	O	O
and	O	O
hprt	O	O
mutants	O	O
(	O	O
P	O	O
=	O	O
0.04	O	O
)	O	O
.	O	O

Also	O	O
,	O	O
multiplex	O	O
PCR	O	O
analysis	O	O
of	O	O
genomic	O	O
DNA	O	O
from	O	O
the	O	O
hprt	O	O
mutants	O	O
indicated	O	O
that	O	O
12	O	O
%	O	O
of	O	O
mutants	O	O
from	O	O
treated	O	O
rats	O	O
had	O	O
major	O	O
deletions	O	O
in	O	O
the	O	O
hprt	B-DNA	O
gene	I-DNA	O
;	O	O
no	O	O
corresponding	O	O
incidence	O	O
of	O	O
large	O	O
deletions	O	O
was	O	O
evident	O	O
among	O	O
lacI	O	O
mutations	O	O
.	O	O

All	O	O
the	O	O
mutation	O	O
profiles	O	O
reflect	O	O
the	O	O
general	O	O
mutational	O	O
specificity	O	O
of	O	O
the	O	O
major	B-DNA	O
DNA	I-DNA	O
adduct	I-DNA	O
formed	O	O
by	O	O
N-OH-AAF	O	O
.	O	O

The	O	O
differences	O	O
between	O	O
N-OH-AAF	O	O
mutation	O	O
in	O	O
the	O	O
endogenous	O	O
gene	O	O
and	O	O
transgene	O	O
can	O	O
be	O	O
partially	O	O
explained	O	O
by	O	O
the	O	O
structures	O	O
of	O	O
the	O	O
two	O	O
genes	B-DNA	O
.	O	O

The	O	O
tissue-specificity	O	O
of	O	O
the	O	O
mutation	O	O
spectra	O	O
may	O	O
contribute	O	O
to	O	O
targeting	O	O
tumor	O	O
formation	O	O
to	O	O
the	O	O
liver	O	O
.	O	O

Environ.	O	O
Mol.	O	O
Mutagen.	O	O
37	O	O
:	O	O
203-214	O	O
,	O	O
2001	O	O
.	O	O

Published	O	O
2001	O	O
Wiley-Liss	O	O
,	O	O
Inc	O	O
.	O	O

Caspase	O	O
-dependent	O	O
cleavage	O	O
of	O	O
the	O	O
hematopoietic	B-protein	O
specific	I-protein	O
adaptor	I-protein	O
protein	I-protein	O
Gads	O	O
alters	O	O
signalling	O	O
from	O	O
the	O	O
T	B-cell_type	O
cell	I-cell_type	O
receptor	I-protein	O
.	O	O

Gads	O	O
is	O	O
a	O	O
SH2	O	O
and	O	O
SH3	O	O
domain	O	O
-containing	O	O
,	O	O
hematopoietic-specific	O	O
adaptor	B-protein	O
protein	O	O
that	O	O
functions	O	O
in	O	O
signalling	O	O
from	O	O
the	O	O
T	B-cell_type	O
cell	I-cell_type	O
receptor	I-protein	O
.	O	O

Gads	O	O
acts	O	O
by	O	O
linking	O	O
SLP-76	O	O
,	O	O
bound	O	O
by	O	O
the	O	O
carboxy-terminal	O	O
Gads	O	O
SH3	I-protein	O
domain	I-protein	O
,	O	O
to	O	O
tyrosine	O	O
phosphorylated	O	O
LAT	O	O
which	O	O
contains	O	O
binding	O	O
sites	O	O
for	O	O
the	O	O
Gads	B-protein	O
SH2	I-protein	O
domain	I-protein	O
.	O	O

Gads	O	O
is	O	O
distinguished	O	O
from	O	O
Grb2	O	O
and	O	O
the	O	O
closely	O	O
related	O	O
Grap	O	O
protein	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
120	B-DNA	O
amino	I-DNA	O
acid	O	O
unique	O	O
region	O	O
between	O	O
the	O	O
SH2	B-protein	O
domain	I-protein	O
and	O	O
the	O	O
carboxy	O	O
terminal	I-DNA	O
SH3	I-DNA	O
domain	I-DNA	O
.	O	O

Here	O	O
we	O	O
demonstrate	O	O
that	O	O
the	O	O
unique	O	O
region	O	O
of	O	O
Gads	O	O
contains	O	O
a	O	O
capase	B-DNA	O
cleavage	I-DNA	O
site	I-DNA	O
.	O	O

Induction	O	O
of	O	O
apoptosis	O	O
in	O	O
lymphocytes	I-cell_type	O
results	O	O
in	O	O
detectable	O	O
Gads	O	O
cleavage	O	O
by	O	O
60	O	O
min	O	O
.	O	O

Gads	O	O
cleavage	O	O
is	O	O
blocked	O	O
in	O	O
vivo	O	O
by	O	O
treating	B-cell_type	O
cells	I-cell_type	O
with	O	O
a	O	O
caspase	O	O
3	O	O
inhibitor	O	O
.	O	O

A	O	O
putative	O	O
caspase	B-DNA	O
3	I-DNA	O
cleavage	I-DNA	O
site	I-DNA	O
was	O	O
identified	O	O
within	O	O
the	O	O
unique	B-DNA	O
region	I-DNA	O
and	O	O
mutation	O	O
of	O	O
this	O	O
site	O	O
prevented	O	O
Gads	O	O
cleavage	O	O
in	O	O
vitro	O	O
,	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

The	O	O
Gads	O	O
cleavage	O	O
products	B-protein	O
retained	O	O
the	O	O
predicted	B-protein	O
binding	I-protein	O
specificity	O	O
for	O	O
SLP-76	O	O
and	O	O
LAT	O	O
.	O	O

Expression	O	O
of	O	O
the	O	O
Gads	O	O
cleavage	I-protein	O
products	I-protein	O
in	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
inhibited	O	O
NFAT	O	O
activation	O	O
following	O	O
TCR	B-protein	O
cross	O	O
linking	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
cleavage	O	O
of	O	O
Gads	O	O
in	O	O
vivo	O	O
could	O	O
function	O	O
to	O	O
alter	O	O
signalling	O	O
downstream	O	O
of	O	O
the	O	O
T	B-protein	O
cell	I-protein	O
receptor	I-protein	O
by	O	O
disrupting	O	O
cross	O	O
talk	O	O
between	O	O
SLP-76	O	O
and	O	O
LAT	O	O
.	O	O

Targeting	O	O
of	O	O
p300	O	O
to	O	O
the	O	O
interleukin-2	B-DNA	O
promoter	I-DNA	O
via	O	O
CREB-Rel	O	O
cross-talk	O	O
during	O	O
mitogen	O	O
and	O	O
oncogenic	O	O
molecular	O	O
signaling	O	O
in	O	O
activated	O	O
T-cells	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
explore	O	O
the	O	O
mechanisms	O	O
of	O	O
targeting	O	O
of	O	O
p300	O	O
to	O	O
the	O	O
interleukin-2	B-protein	O
(	O	O
IL-2	B-protein	O
)	O	O
promoter	O	O
in	O	O
response	O	O
to	O	O
mitogenic	O	O
and	O	O
oncogenic	O	O
molecular	O	O
signals	O	O
.	O	O

Recruitment	O	O
of	O	O
p300	O	O
by	O	O
cAMP-responsive	O	O
element-binding	O	O
protein-Rel	O	O
cross-talk	O	O
at	O	O
the	O	O
composite	O	O
CD28	O	O
response	O	O
element	O	O
(	O	O
CD28RE	O	O
)	O	O
-	O	O
TRE	O	O
element	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
is	O	O
essential	O	O
for	O	O
promoter	O	O
inducibility	O	O
during	O	O
T-cell	O	O
activation	O	O
,	O	O
and	O	O
CD28RE-TRE	O	O
is	O	O
the	O	O
exclusive	O	O
target	O	O
of	O	O
the	O	O
human	O	O
T-cell	O	O
lymphotropic	O	O
virus	O	O
type	O	O
I	O	O
oncoprotein	O	O
Tax	O	O
.	O	O

The	O	O
intrinsic	O	O
histone	O	O
acetyltransferase	O	O
activity	O	O
of	O	O
p300	O	O
is	O	O
dispensable	O	O
for	O	O
activation	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
,	O	O
and	O	O
the	O	O
N-terminal	O	O
743	O	O
residues	O	O
contain	O	O
the	O	O
minimal	O	O
structural	I-DNA	O
requirements	I-DNA	O
for	O	O
synergistic	O	O
transactivation	O	O
of	O	O
the	O	O
CD28RE-TRE	O	O
,	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
,	O	O
and	O	O
endogenous	O	O
IL-2	B-DNA	O
gene	I-DNA	O
expression	O	O
.	O	O

Mutational	O	O
analysis	O	O
of	O	O
p300	O	O
reveals	O	O
differential	O	O
structural	O	O
requirements	O	O
for	O	O
the	O	O
N-terminal	O	O
p300	O	O
module	O	O
by	O	O
individual	O	O
cis-elements	O	O
within	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
.	O	O

These	O	O
findings	O	O
provide	O	O
evidence	O	O
that	O	O
p300	O	O
assembles	O	O
at	O	O
the	O	O
IL-2	B-DNA	O
promoter	O	O
to	O	O
form	O	O
an	O	O
enhanceosome-like	O	O
signal	O	O
transduction	O	O
target	O	O
that	O	O
is	O	O
centrally	O	O
integrated	O	O
at	O	O
the	O	O
CD28RE-TRE	O	O
element	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
through	O	O
specific	O	O
protein	O	O
module-targeted	O	O
associations	O	O
in	O	O
activated	O	O
T-cells	O	O
.	O	O

Regulation	O	O
of	O	O
cytokine	B-protein	O
production	O	O
in	O	O
T-cell	O	O
responses	O	O
to	O	O
inhalant	O	O
allergen	O	O
:	O	O
GATA-3	O	O
expression	O	O
distinguishes	O	O
between	O	O
Th1-	O	O
and	O	O
Th2-polarized	O	O
immunity	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
precise	O	O
nature	O	O
of	O	O
allergen-specific	O	O
cytokine	O	O
responses	O	O
in	O	O
atopics	O	O
versus	O	O
non-atopics	O	O
,	O	O
in	O	O
particular	O	O
the	O	O
'Th1	O	O
polarity	O	O
'	O	O
of	O	O
responses	O	O
in	O	O
non-atopics	O	O
,	O	O
remains	O	O
controversial	O	O
.	O	O

This	O	O
is	O	O
due	O	O
in	O	O
part	O	O
to	O	O
the	O	O
relative	O	O
insensitivity	O	O
of	O	O
cytokine	B-protein	O
detection	O	O
systems	O	O
,	O	O
and	O	O
associated	O	O
variations	O	O
in	O	O
kinetics	O	O
of	O	O
cytokine	B-protein	O
production	O	O
and	O	O
catabolism	O	O
in	O	O
in	O	O
vitro	O	O
culture	O	O
systems	O	O
.	O	O

As	O	O
an	O	O
alternative	O	O
to	O	O
cytokine	B-protein	O
measurement	O	O
,	O	O
this	O	O
study	O	O
focuses	O	O
on	O	O
expression	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
GATA-3	O	O
for	O	O
analysis	O	O
of	O	O
allergen-specific	O	O
Th	O	O
cell	O	O
responses	O	O
.	O	O

METHODS	O	O
:	O	O
Cord	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
were	O	O
Th1-	O	O
or	O	O
Th2-polarized	O	O
by	O	O
culture	O	O
in	O	O
IL-12-	O	O
or	O	O
IL-4-employing	O	O
established	O	O
methods	O	O
;	O	O
PBMC	O	O
from	O	O
house	O	O
dust	O	O
mite	O	O
(	O	O
HDM	O	O
)	O	O
-sensitive	O	O
atopics	O	O
and	O	O
controls	O	O
were	O	O
stimulated	O	O
overnight	O	O
with	O	O
HDM	O	O
;	O	O
cytokine	O	O
production	O	O
was	O	O
measured	O	O
by	O	O
ELISA	O	O
and	O	O
GATA-3	O	O
mRNA	O	O
expression	O	O
by	O	O
PCR	O	O
.	O	O

RESULTS	O	O
:	O	O
Cytokine	O	O
-driven	O	O
Th2	O	O
polarization	O	O
of	O	O
naive	O	O
T	B-cell_type	O
cells	I-cell_type	O
is	O	O
associated	O	O
with	O	O
marked	O	O
upregulation	O	O
of	O	O
GATA-3	B-protein	O
expression	O	O
,	O	O
whereas	O	O
a	O	O
reciprocal	O	O
expression	O	O
pattern	O	O
accompanies	O	O
differentiation	O	O
towards	O	O
the	O	O
Th1	O	O
cytokine	O	O
phenotype	O	O
.	O	O

In	O	O
T	B-cell_type	O
cells	I-cell_type	O
from	O	O
HDM	O	O
skin	O	O
prick	O	O
test-positive	O	O
(	O	O
HDM-SPT+/HDM-IgE+	O	O
)	O	O
volunteers	O	O
,	O	O
overnight	O	O
stimulation	O	O
results	O	O
in	O	O
marked	O	O
upregulation	O	O
of	O	O
GATA-3	O	O
expression	O	O
,	O	O
compared	O	O
to	O	O
an	O	O
equally	O	O
marked	O	O
downregulation	O	O
of	O	O
expression	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
from	O	O
SPT-/IgE-	O	O
subjects	O	O
.	O	O

In	O	O
subjects	O	O
who	O	O
are	O	O
HDM-SPT+	O	O
but	O	O
IgE-	O	O
,	O	O
GATA-3	O	O
expression	O	O
levels	O	O
remained	O	O
relatively	O	O
stable	O	O
during	O	O
culture	O	O
with	O	O
HDM	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Upregulation	O	O
of	O	O
GATA-3	O	O
expression	O	O
in	O	O
PBMC	O	O
is	O	O
a	O	O
hallmark	O	O
of	O	O
the	O	O
early	O	O
phase	O	O
of	O	O
Th2	O	O
recall	O	O
responses	O	O
to	O	O
specific	O	O
allergen	O	O
in	O	O
atopics	O	O
.	O	O

The	O	O
reciprocal	O	O
expression	O	O
pattern	O	O
observed	O	O
in	O	O
HDM-specific	O	O
recall	O	O
responses	O	O
of	O	O
non-atopics	O	O
provides	O	O
independent	O	O
confirmation	O	O
of	O	O
the	O	O
presence	O	O
of	O	O
underlying	O	O
Th1-like	O	O
immunity	O	O
in	O	O
these	O	O
subjects	O	O
.	O	O

The	O	O
parallel	O	O
findings	O	O
in	O	O
neonatal	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
suggest	O	O
that	O	O
the	O	O
same	O	O
approach	O	O
may	O	O
be	O	O
utilized	O	O
for	O	O
monitoring	O	O
the	O	O
progress	O	O
of	O	O
allergen-specific	O	O
Th1/Th2	O	O
memory	O	O
development	O	O
during	O	O
early	O	O
childhood	O	O
,	O	O
and	O	O
hence	O	O
in	O	O
assessment	O	O
of	O	O
risk	O	O
for	O	O
future	O	O
allergic	O	O
disease	O	O
.	O	O

Copyright	O	O
2001	O	O
S.	O	O
Karger	O	O
AG	O	O
,	O	O
Basel	O	O

The	O	O
heat	O	O
shock	O	O
response	O	O
reduces	O	O
myelin	O	O
oligodendrocyte	O	O
glycoprotein	O	O
-induced	O	O
experimental	O	O
autoimmune	O	O
encephalomyelitis	O	O
in	O	O
mice	O	O
.	O	O

The	O	O
stress	O	O
response	O	O
(	O	O
SR	B-DNA	O
)	O	O
can	O	O
block	O	O
inflammatory	B-DNA	O
gene	I-DNA	O
expression	O	O
by	O	O
preventing	O	O
activation	O	O
of	O	O
transcription	B-protein	O
factor	I-protein	O
nuclear	B-protein	O
factor-kappa	I-protein	O
B	I-protein	O
(	O	O
NF-kappaB	B-protein	O
)	O	O
.	O	O

As	B-DNA	O
inflammatory	I-DNA	O
gene	I-DNA	O
expression	O	O
contributes	O	O
to	O	O
the	O	O
pathogenesis	O	O
of	O	O
demyelinating	O	O
diseases	O	O
,	O	O
we	O	O
tested	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
SR	O	O
on	O	O
the	O	O
progression	O	O
of	O	O
the	O	O
demyelinating	O	O
disease	O	O
experimental	O	O
autoimmune	O	O
encephalomyelitis	O	O
(	O	O
EAE	B-protein	O
)	O	O
.	O	O

EAE	O	O
was	O	O
actively	O	O
induced	O	O
in	O	O
C57BL/6	O	O
mice	O	O
using	O	O
an	O	O
encephalitogenic	O	O
myelin	O	O
oligodendrocyte	O	O
glycoprotein	O	O
(	O	O
MOG	O	O
(	O	O
35-55	O	O
)	O	O
)	O	O
peptide	O	O
.	O	O

Whole	O	O
body	O	O
hyperthermia	O	O
was	O	O
used	O	O
to	O	O
induce	O	O
a	O	O
heat	O	O
shock	O	O
response	O	O
(	O	O
HSR	O	O
)	O	O
in	O	O
immunized	O	O
mice	O	O
2	O	O
days	O	O
after	O	O
the	O	O
booster	O	O
MOG	O	O
(	O	O
35-55	O	O
)	O	O
peptide	O	O
injection	O	O
.	O	O

The	O	O
HSR	O	O
reduced	O	O
the	O	O
incidence	O	O
of	O	O
EAE	O	O
by	O	O
70	O	O
%	O	O
,	O	O
delayed	O	O
disease	O	O
onset	O	O
by	O	O
6	O	O
days	O	O
,	O	O
and	O	O
attenuated	O	O
disease	O	O
severity	O	O
.	O	O

The	O	O
HSR	O	O
attenuated	O	O
leukocyte	O	O
infiltration	O	O
into	O	O
CNS	O	O
assessed	O	O
by	O	O
quantitation	O	O
of	O	O
perivascular	O	O
infiltrates	O	O
,	O	O
and	O	O
by	O	O
reduced	O	O
staining	O	O
for	O	O
CD4	B-protein	O
and	O	O
CD25	O	O
immunopositive	O	O
T-cells	O	O
.	O	O

T-cell	O	O
activation	O	O
,	O	O
assessed	O	O
by	O	O
the	O	O
production	O	O
of	O	O
interferon	B-protein	O
gamma	I-protein	O
(	O	O
IFNgamma	B-protein	O
)	O	O
in	O	O
response	O	O
to	O	O
MOG	O	O
(	O	O
35-55	O	O
)	O	O
,	O	O
was	O	O
also	O	O
decreased	O	O
by	O	O
the	O	O
HSR	O	O
.	O	O

The	O	O
HSR	B-DNA	O
reduced	I-DNA	O
inflammatory	I-DNA	O
gene	I-DNA	O
expression	O	O
in	O	O
the	O	O
brain	O	O
that	O	O
normally	O	O
occurs	O	O
during	O	O
EAE	O	O
,	O	O
including	O	O
the	O	O
early	O	O
increase	O	O
in	O	O
RANTES	O	O
(	O	O
regulated	O	O
on	O	O
activation	O	O
of	O	O
normal	O	O
T-cell	O	O
expressed	O	O
and	O	O
secreted	O	O
)	O	O
expression	O	O
,	O	O
and	O	O
the	O	O
later	O	O
expression	O	O
of	O	O
the	O	O
inducible	O	O
form	O	O
of	O	O
nitric	O	O
oxide	O	O
synthase	O	O
.	O	O

The	O	O
early	O	O
activation	O	O
of	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappaB	O	O
was	O	O
also	O	O
blocked	O	O
by	O	O
the	O	O
HSR	O	O
.	O	O

The	O	O
finding	O	O
that	O	O
the	O	O
SR	B-protein	O
reduces	I-protein	O
inflammation	O	O
in	O	O
the	O	O
brain	O	O
and	O	O
the	O	O
clinical	O	O
severity	O	O
of	O	O
EAE	O	O
opens	O	O
a	O	O
novel	O	O
therapeutic	O	O
approach	O	O
for	O	O
prevention	O	O
of	O	O
autoimmune	O	O
diseases	O	O
.	O	O

In	O	O
vivo	O	O
detection	O	O
of	O	O
intracellular	O	O
signaling	O	O
pathways	O	O
in	O	O
developing	O	O
thymocytes	B-cell_type	O
.	O	O

Information	O	O
regarding	O	O
the	O	O
intracellular	O	O
signaling	O	O
processes	O	O
that	O	O
occur	O	O
during	O	O
the	O	O
development	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
has	O	O
largely	O	O
been	O	O
obtained	O	O
with	O	O
the	O	O
use	O	O
of	O	O
transgenic	O	O
mouse	O	O
models	O	O
,	O	O
which	O	O
although	O	O
providing	O	O
invaluable	O	O
information	O	O
are	O	O
time	O	O
consuming	O	O
and	O	O
costly	O	O
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
we	O	O
have	O	O
developed	O	O
a	O	O
novel	O	O
system	O	O
that	O	O
facilitates	O	O
the	O	O
in	O	O
vivo	O	O
analysis	O	O
of	O	O
signal	O	O
transduction	O	O
pathways	O	O
during	O	O
T-lymphocyte	O	O
development	O	O
.	O	O

This	O	O
approach	O	O
uses	O	O
reporter-plasmids	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
intracellular	O	O
signals	O	O
mediated	O	O
by	O	O
the	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
or	O	O
cyclic	O	O
AMP-dependent	O	O
protein	O	O
kinase	O	O
.	O	O

Reporter-plasmids	O	O
are	O	O
transfected	O	O
into	O	O
thymocytes	B-cell_type	O
in	O	O
fetal	O	O
thymic	O	O
organ	O	O
culture	O	O
by	O	O
accelerated	O	O
DNA/particle	O	O
bombardment	O	O
(	O	O
gene	O	O
gun	O	O
)	O	O
,	O	O
and	O	O
the	O	O
activation	O	O
of	O	O
a	O	O
signaling	O	O
pathway	O	O
is	O	O
determined	O	O
in	O	O
the	O	O
form	O	O
of	O	O
a	O	O
standard	O	O
luciferase	O	O
assay	O	O
.	O	O

Importantly	O	O
,	O	O
this	O	O
powerful	O	O
technique	O	O
preserves	O	O
the	O	O
structural	O	O
integrity	O	O
of	O	O
the	O	O
thymus	O	O
,	O	O
and	O	O
will	O	O
provide	O	O
an	O	O
invaluable	O	O
tool	O	O
to	O	O
study	O	O
how	O	O
thymocytes	O	O
respond	O	O
to	O	O
normal	O	O
environmental	O	O
stimuli	O	O
encountered	O	O
during	O	O
differentiation	O	O
within	O	O
the	O	O
thymic	O	O
milieu	O	O
.	O	O

Thus	O	O
,	O	O
this	O	O
method	O	O
allows	O	O
for	O	O
the	O	O
monitoring	O	O
of	O	O
signals	O	O
that	O	O
occur	O	O
in	O	O
a	O	O
biological	O	O
time	O	O
frame	O	O
,	O	O
such	O	O
as	O	O
during	O	O
differentiation	O	O
,	O	O
and	O	O
within	O	O
the	O	O
natural	O	O
environment	O	O
of	O	O
differentiating	B-cell_line	O
cells	I-cell_type	O
.	O	O

Core-binding	B-protein	O
factor	I-protein	O
beta	I-protein	O
(	O	O
CBFbeta	B-protein	O
)	O	O
,	O	O
but	O	O
not	O	O
CBFbeta-smooth	O	O
muscle	O	O
myosin	O	O
heavy	O	O
chain	O	O
,	O	O
rescues	O	O
definitive	O	O
hematopoiesis	O	O
in	O	O
CBFbeta	O	O
-deficient	O	O
embryonic	O	O
stem	O	O
cells	O	O
.	O	O

Core-binding	B-protein	O
factor	I-protein	O
beta	I-protein	O
(	O	O
CBFbeta	B-protein	O
)	O	O
is	O	O
the	O	O
non-DNA-binding	O	O
subunit	O	O
of	O	O
the	O	O
heterodimeric	O	O
CBFs	I-protein	O
.	O	O

Genes	O	O
encoding	O	O
CBFbeta	O	O
(	O	O
CBFB	O	O
)	O	O
,	O	O
and	O	O
one	O	O
of	O	O
the	O	O
DNA-binding	B-protein	O
CBFalpha	I-protein	O
subunits	I-protein	O
,	O	O
Runx1	O	O
(	O	O
also	O	O
known	O	O
as	O	O
CBFalpha2	O	O
,	O	O
AML1	O	O
,	O	O
and	O	O
PEBP2alphaB	O	O
)	O	O
,	O	O
are	O	O
required	O	O
for	O	O
normal	O	O
hematopoiesis	O	O
and	O	O
are	O	O
also	O	O
frequent	O	O
targets	O	O
of	O	O
chromosomal	O	O
translocations	O	O
in	O	O
acute	O	O
leukemias	O	O
in	O	O
humans	O	O
.	O	O

Homozygous	O	O
disruption	O	O
of	O	O
either	O	O
the	O	O
Runx1	B-DNA	O
or	O	O
Cbfb	B-DNA	O
gene	I-DNA	O
in	O	O
mice	O	O
results	O	O
in	O	O
embryonic	O	O
lethality	O	O
at	O	O
midgestation	O	O
due	O	O
to	O	O
hemorrhaging	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
and	O	O
severely	O	O
impairs	O	O
fetal	O	O
liver	O	O
hematopoiesis	O	O
.	O	O

Results	O	O
of	O	O
this	O	O
study	O	O
show	O	O
that	O	O
Cbfb-deficient	O	O
mouse	O	O
embryonic	O	O
stem	I-protein	O
(	O	O
ES	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
can	O	O
differentiate	O	O
into	O	O
primitive	O	O
erythroid	O	O
colonies	O	O
in	O	O
vitro	O	O
,	O	O
but	O	O
are	O	O
impaired	O	O
in	O	O
their	O	O
ability	O	O
to	O	O
produce	O	O
definitive	O	O
erythroid	O	O
and	O	O
myeloid	O	O
colonies	O	O
,	O	O
mimicking	O	O
the	O	O
in	O	O
vivo	O	O
defect	O	O
.	O	O

Definitive	O	O
hematopoiesis	O	O
is	O	O
restored	O	O
by	O	O
ectopic	O	O
expression	O	O
of	O	O
full-length	O	O
Cbfb	O	O
transgenes	O	O
,	O	O
as	O	O
well	O	O
as	O	O
by	O	O
a	O	O
transgene	O	O
encoding	O	O
only	O	O
the	O	O
heterodimerization	O	O
domain	O	O
of	O	O
CBFbeta	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
CBFbeta	O	O
-	O	O
smooth	O	O
muscle	O	O
myosin	O	O
heavy	O	O
chain	O	O
(	O	O
SMMHC	O	O
)	O	O
fusion	O	O
protein	O	O
generated	O	O
by	O	O
the	O	O
inv	O	O
(	O	O
16	O	O
)	O	O
associated	O	O
with	O	O
acute	O	O
myeloid	O	O
leukemias	O	O
(	O	O
M4Eo	O	O
)	O	O
can	O	O
not	O	O
rescue	O	O
definitive	O	O
hematopoiesis	O	O
by	O	O
Cbfb-deficient	O	O
ES	O	O
cells	O	O
.	O	O

Sequences	O	O
responsible	O	O
for	O	O
the	O	O
inability	O	O
of	O	O
CBFbeta	O	O
-SMMHC	O	O
to	O	O
rescue	O	O
definitive	O	O
hematopoiesis	O	O
reside	O	O
in	O	O
the	O	O
SMMHC	O	O
portion	O	O
of	O	O
the	O	O
fusion	O	O
protein	O	O
.	O	O

Results	O	O
also	O	O
show	O	O
that	O	O
the	O	O
CBFbeta-SMMHC	O	O
fusion	O	O
protein	O	O
transdominantly	O	O
inhibits	O	O
definitive	O	O
hematopoiesis	O	O
,	O	O
but	O	O
not	O	O
to	O	O
the	O	O
same	O	O
extent	O	O
as	O	O
homozygous	O	O
loss	O	O
of	O	O
Runx1	O	O
or	O	O
Cbfb	O	O
.	O	O

CBFbeta-SMMHC	O	O
preferentially	O	O
inhibits	O	O
the	O	O
differentiation	O	O
of	O	O
myeloid	B-cell_line	O
lineage	I-cell_line	O
cells	I-cell_line	O
,	O	O
while	O	O
increasing	O	O
the	O	O
number	O	O
of	O	O
blastlike	B-cell_type	O
cells	I-cell_type	O
in	O	O
culture	O	O
.	O	O

The	O	O
latency	O	O
pattern	O	O
of	O	O
Epstein-Barr	O	O
virus	O	O
infection	O	O
and	O	O
viral	O	O
IL-10	B-protein	O
expression	O	O
in	O	O
cutaneous	O	O
natural	O	O
killer/T-cell	O	O
lymphomas	O	O
.	O	O

The	O	O
nasal	B-protein	O
type	I-protein	O
,	O	O
extranodal	O	O
natural	I-protein	O
killer	I-protein	O
or	I-protein	O
T	I-protein	O
(	O	O
NK/T	B-protein	O
)	O	O
-cell	O	O
lymphoma	O	O
is	O	O
usually	O	O
associated	O	O
with	O	O
latent	O	O
Epstein-Barr	O	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
infection	O	O
.	O	O

In	O	O
order	O	O
to	O	O
elucidate	O	O
the	O	O
EBV	B-DNA	O
gene	I-DNA	O
expression	O	O
patterns	O	O
in	O	O
vivo	O	O
,	O	O
we	O	O
examined	O	O
eight	O	O
patients	O	O
with	O	O
cutaneous	O	O
EBV-related	O	O
NK/T-cell	O	O
lymphomas	O	O
,	O	O
including	O	O
six	O	O
patients	O	O
with	O	O
a	O	O
NK-cell	O	O
phenotype	O	O
and	O	O
two	O	O
patients	O	O
with	O	O
a	O	O
T-cell	O	O
phenotype	O	O
.	O	O

The	O	O
implication	O	O
of	O	O
EBV	O	O
in	O	O
the	O	O
skin	O	O
lesions	O	O
was	O	O
determined	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
EBV-DNA	B-protein	O
,	O	O
EBV-encoded	O	O
nuclear	B-protein	O
RNA	I-protein	O
(	O	O
EBER	B-protein	O
)	O	O
and	O	O
a	O	O
clonality	O	O
of	O	O
EBV-DNA	O	O
fragments	O	O
containing	O	O
the	O	O
terminal	B-DNA	O
repeats	I-DNA	O
.	O	O

Transcripts	O	O
of	O	O
EBV-encoded	B-DNA	O
genes	I-DNA	O
were	O	O
screened	O	O
by	O	O
reverse	O	O
transcription-	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
RT-PCR	O	O
)	O	O
,	O	O
and	O	O
confirmed	O	O
by	O	O
Southern	O	O
blot	O	O
hybridization	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
EBV-related	O	O
antigens	O	O
was	O	O
examined	O	O
by	O	O
immunostaining	O	O
using	O	O
paraffin-embedded	O	O
tissue	O	O
sections	O	O
and	O	O
cell	O	O
pellets	O	O
of	O	O
EBV-positive	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

Our	O	O
study	O	O
demonstrated	O	O
that	O	O
all	O	O
samples	O	O
from	O	O
the	O	O
patients	O	O
contained	O	O
EBV	O	O
nuclear	I-protein	O
antigen	I-protein	O
(	O	O
EBNA	B-protein	O
)	I-protein	O
-1	I-protein	O
mRNA	I-RNA	O
which	O	O
was	O	O
transcribed	O	O
using	O	O
the	O	O
Q	B-DNA	O
promoter	I-DNA	O
,	O	O
whereas	O	O
both	O	O
the	O	O
Q	B-DNA	O
promoter	I-DNA	O
and	O	O
another	O	O
upstream	B-DNA	O
promoter	I-DNA	O
(	O	O
Cp/Wp	B-protein	O
)	O	O
were	O	O
used	O	O
in	O	O
EBV-positive	O	O
cell	O	O
lines	O	O
,	O	O
B95.8	O	O
,	O	O
Raji	O	O
and	O	O
Jiyoye	O	O
.	O	O

Latent	O	O
membrane	O	O
protein-1	O	O
(	O	O
LMP-1	O	O
)	O	O
mRNA	I-RNA	O
was	O	O
detected	O	O
in	O	O
seven	O	O
of	O	O
eight	O	O
patients	O	O
and	O	O
all	O	O
cell	O	O
lines	O	O
,	O	O
whereas	O	O
EBNA-2	O	O
transcripts	O	O
were	O	O
found	O	O
only	O	O
in	O	O
the	O	O
cell	B-cell_line	O
lines	I-cell_line	O
.	O	O

Immunostaining	O	O
showed	O	O
no	O	O
LMP-1	O	O
,	O	O
EBNA-2	O	O
or	O	O
ZEBRA	O	O
antigens	O	O
in	O	O
the	O	O
paraffin-embedded	O	O
tissue	O	O
sections	O	O
,	O	O
although	O	O
they	O	O
were	O	O
positive	O	O
in	O	O
the	O	O
cell	B-cell_line	O
line	I-cell_line	O
cells	I-cell_line	O
.	O	O

Latent	O	O
BHRF1	O	O
transcripts	O	O
encoding	O	O
bcl-2	O	O
homologue	O	O
and	O	O
BCRF1	O	O
transcripts	O	O
encoding	O	O
viral	O	O
interleukin	B-protein	O
(	O	O
vIL	B-protein	O
)	O	O
-10	O	O
were	O	O
detected	O	O
in	O	O
one	O	O
and	O	O
two	O	O
of	O	O
eight	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

A	O	O
patient	O	O
with	O	O
NK-cell	O	O
lymphoma	O	O
expressing	O	O
both	O	O
transcripts	O	O
died	O	O
of	O	O
rapid	O	O
progression	O	O
of	O	O
the	O	O
illness	B-DNA	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
restricted	O	O
expression	O	O
of	O	O
the	O	O
latency-associated	B-DNA	O
EBV	I-DNA	O
genes	I-DNA	O
and	O	O
the	O	O
production	O	O
of	O	O
vIL-10	O	O
and	O	O
bcl-2	O	O
homologue	O	O
may	O	O
favour	O	O
tumour	O	O
growth	O	O
,	O	O
evading	O	O
the	O	O
host	O	O
immune	O	O
surveillance	O	O
.	O	O

Copyright	O	O
2001	O	O
Cancer	O	O
Research	O	O
Campaign	O	O
.	O	O

Oxidized	O	O
alkyl	O	O
phospholipids	O	O
are	O	O
specific	O	O
,	O	O
high	O	O
affinity	O	O
peroxisome	O	O
proliferator-activated	O	O
receptor	O	O
gamma	O	O
ligands	O	O
and	O	O
agonists	O	O
.	O	O

Synthetic	O	O
high	O	O
affinity	O	O
peroxisome	O	O
proliferator-activated	O	O
receptor	O	O
(	O	O
PPAR	O	O
)	O	O
agonists	O	O
are	O	O
known	O	O
,	O	O
but	O	O
biologic	O	O
ligands	O	O
are	O	O
of	O	O
low	O	O
affinity	O	O
.	O	O

Oxidized	O	O
low	O	O
density	O	O
lipoprotein	O	O
(	O	O
oxLDL	O	O
)	O	O
is	O	O
inflammatory	O	O
and	O	O
signals	O	O
through	O	O
PPARs	O	O
.	O	O

We	O	O
showed	O	O
,	O	O
by	O	O
phospholipase	O	O
A	O	O
(	O	O
1	O	O
)	O	O
digestion	O	O
,	O	O
that	O	O
PPARgamma	O	O
agonists	O	O
in	O	O
oxLDL	O	O
arise	O	O
from	O	O
the	O	O
small	O	O
pool	O	O
of	O	O
alkyl	O	O
phosphatidylcholines	O	O
in	O	O
LDL	O	O
.	O	O

We	O	O
identified	O	O
an	O	O
abundant	O	O
oxidatively	O	O
fragmented	O	O
alkyl	O	O
phospholipid	O	O
in	O	O
oxLDL	O	O
,	O	O
hexadecyl	O	O
azelaoyl	O	O
phosphatidylcholine	O	O
(	O	O
azPC	O	O
)	O	O
,	O	O
as	O	O
a	O	O
high	O	O
affinity	O	O
ligand	O	O
and	O	O
agonist	O	O
for	O	O
PPARgamma	O	O
.	O	O

[	O	O
(	O	O
3	B-protein	O
)	O	O
H	O	O
]	O	O
azPC	O	O
bound	O	O
recombinant	O	O
PPARgamma	O	O
with	O	O
an	O	O
affinity	O	O
(	O	O
K	I-protein	O
(	O	O
d	B-protein	O
)	I-protein	O
(	O	O
(	O	O
app	B-protein	O
)	O	O
)	O	O
approximately	O	O
40	O	O
nm	O	O
)	O	O
that	O	O
was	O	O
equivalent	O	O
to	O	O
rosiglitazone	O	O
(	O	O
BRL49653	O	O
)	O	O
,	O	O
and	O	O
competition	O	O
with	O	O
rosiglitazone	O	O
showed	O	O
that	O	O
binding	O	O
occurred	O	O
in	O	O
the	O	O
ligand-binding	O	O
pocket	O	O
.	O	O

azPC	O	O
induced	O	O
PPRE	O	O
reporter	B-DNA	O
gene	I-DNA	O
expression	O	O
,	O	O
as	O	O
did	O	O
rosiglitazone	O	O
,	O	O
with	O	O
a	O	O
half-maximal	O	O
effect	O	O
at	O	O
100	O	O
nm	O	O
.	O	O

Overexpression	O	O
of	O	O
PPARalpha	O	O
or	O	O
PPARgamma	O	O
revealed	O	O
that	O	O
azPC	O	O
was	O	O
a	O	O
specific	O	O
PPARgamma	O	O
agonist	O	O
.	O	O

The	O	O
scavenger	B-protein	O
receptor	I-protein	O
CD36	O	O
is	O	O
encoded	O	O
by	O	O
a	O	O
PPRE-responsive	B-DNA	O
gene	I-DNA	O
,	O	O
and	O	O
azPC	O	O
enhanced	O	O
expression	O	O
of	O	O
CD36	O	O
in	O	O
primary	B-cell_line	O
human	B-cell_type	O
monocytes	I-cell_type	O
.	O	O

We	O	O
found	O	O
that	O	O
anti-CD36	O	O
inhibited	O	O
azPC	O	O
uptake	O	O
,	O	O
and	O	O
it	O	O
inhibited	O	O
PPRE	O	O
reporter	O	O
induction	O	O
.	O	O

Results	O	O
with	O	O
a	O	O
small	O	O
molecule	O	O
phospholipid	O	O
flippase	O	O
mimetic	O	O
suggest	O	O
azPC	O	O
acts	O	O
intracellularly	O	O
and	O	O
that	O	O
cellular	O	O
azPC	O	O
accumulation	O	O
was	O	O
efficient	O	O
.	O	O

Thus	O	O
,	O	O
certain	O	O
alkyl	O	O
phospholipid	O	O
oxidation	O	O
products	O	O
in	O	O
oxLDL	O	O
are	O	O
specific	O	O
,	O	O
high	O	O
affinity	O	O
extracellular	O	O
ligands	O	O
and	O	O
agonists	O	O
for	O	O
PPARgamma	O	O
that	O	O
induce	O	O
PPAR-responsive	O	O
genes	O	O

Regulation	O	O
of	O	O
the	O	O
human	B-DNA	O
MAT2B	I-DNA	O
gene	I-DNA	O
encoding	O	O
the	O	O
regulatory	B-protein	O
beta	I-protein	O
subunit	O	O
of	O	O
methionine	O	O
adenosyltransferase	I-protein	O
,	O	O
MAT	B-protein	O
II	I-protein	O
.	O	O

Methionine	O	O
adenosyltransferase	O	O
(	O	O
MAT	O	O
)	O	O
catalyzes	O	O
the	O	O
biosynthesis	O	O
of	O	O
S-adenosylmethionine	O	O
(	O	O
AdoMet	B-protein	O
)	O	O
,	O	O
a	O	O
key	O	O
molecule	O	O
in	O	O
transmethylation	O	O
reactions	O	O
and	O	O
polyamine	O	O
biosynthesis	O	O
.	O	O

The	O	O
MAT	B-protein	O
II	I-protein	O
isozyme	O	O
consists	O	O
of	O	O
a	O	O
catalytic	B-protein	O
alpha2	I-protein	O
and	O	O
a	O	O
regulatory	B-DNA	O
beta	I-DNA	O
subunit	I-DNA	O
.	O	O

Down-regulation	O	O
of	O	O
the	O	O
MAT	B-protein	O
II	I-protein	O
beta	I-protein	O
subunit	O	O
expression	O	O
causes	O	O
a	O	O
6-10-fold	O	O
increase	O	O
in	O	O
intracellular	O	O
AdoMet	O	O
levels	O	O
.	O	O

To	O	O
understand	O	O
the	O	O
mechanism	O	O
by	O	O
which	O	O
the	O	O
beta	B-DNA	O
subunit	I-DNA	O
expression	O	O
is	O	O
regulated	O	O
,	O	O
we	O	O
cloned	O	O
the	O	O
MAT2B	B-DNA	O
gene	I-DNA	O
,	O	O
determined	O	O
its	O	O
organization	O	O
,	O	O
characterized	O	O
its	O	O
5'-flanking	O	O
sequences	O	O
,	O	O
and	O	O
elucidated	O	O
the	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
regulation	O	O
of	O	O
its	O	O
promoter	O	O
.	O	O

Transcription	O	O
of	O	O
the	O	O
MAT2B	B-DNA	O
gene	I-DNA	O
initiates	O	O
at	O	O
position	O	O
-203	O	O
relative	O	O
to	O	O
the	O	O
translation	B-DNA	O
start	I-DNA	O
site	I-DNA	O
.	O	O

Promoter	O	O
deletion	O	O
analysis	O	O
defined	O	O
a	O	O
minimal	O	O
promoter	O	O
between	O	O
positions	O	O
+52	O	O
and	O	O
+93	O	O
base	O	O
pairs	O	O
,	O	O
a	O	O
GC-rich	O	O
region	O	O
.	O	O

Inclusion	O	O
of	O	O
the	O	O
sequences	O	O
between	O	O
-4	O	O
and	O	O
+52	O	O
enhanced	O	O
promoter	O	O
activity	O	O
;	O	O
this	O	O
was	O	O
primarily	O	O
because	O	O
of	O	O
an	O	O
Sp1	B-DNA	O
recognition	I-DNA	O
site	I-DNA	O
at	O	O
+9/+15	O	O
.	O	O

The	O	O
inclusion	O	O
of	O	O
sequences	O	O
up	O	O
to	O	O
position	O	O
-115	O	O
provided	O	O
full	O	O
activity	O	O
;	O	O
this	O	O
was	O	O
attributed	O	O
to	O	O
a	O	O
TATA	O	O
at	O	O
-32	O	O
.	O	O

The	O	O
Sp1	B-DNA	O
site	I-DNA	O
at	O	O
position	O	O
+9	O	O
was	O	O
key	O	O
for	O	O
the	O	O
formation	O	O
of	O	O
protein.DNA	B-protein	O
complexes	I-protein	O
.	O	O

Mutation	O	O
of	O	O
both	O	O
the	O	O
Sp1	B-DNA	O
site	I-DNA	O
at	O	O
+9	O	O
and	O	O
the	O	O
TATA	B-DNA	O
at	O	O
-32	O	O
reduced	O	O
promoter	O	O
activity	O	O
to	O	O
its	O	O
minimal	O	O
level	O	O
.	O	O

Supershift	O	O
assays	O	O
showed	O	O
no	O	O
effect	O	O
of	O	O
the	O	O
anti-Sp1	O	O
antibody	O	O
on	O	O
complex	B-protein	O
formation	I-protein	O
,	O	O
whereas	O	O
the	O	O
anti-Sp3	O	O
antibody	O	O
had	O	O
a	O	O
strong	O	O
effect	O	O
on	O	O
protein.DNA	O	O
complex	O	O
formation	O	O
,	O	O
suggesting	O	O
that	O	O
Sp3	O	O
is	O	O
one	O	O
of	O	O
the	O	O
main	B-protein	O
factors	I-protein	O
binding	O	O
to	O	O
this	O	O
Sp1	B-DNA	O
site	I-DNA	O
.	O	O

Chromatin	O	O
immunoprecipitation	O	O
assays	O	O
supported	O	O
the	O	O
involvement	O	O
of	O	O
both	O	O
Sp1	B-protein	O
and	O	O
Sp3	O	O
in	O	O
complexes	O	O
formed	O	O
on	O	O
the	O	O
MAT2B	B-DNA	O
promoter	I-DNA	O
.	O	O

The	O	O
data	O	O
show	O	O
that	O	O
the	O	O
5'-untranslated	O	O
sequences	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
regulating	O	O
the	O	O
MAT2B	B-DNA	O
gene	I-DNA	O
and	O	O
identifies	O	O
the	O	O
Sp1	B-DNA	O
site	I-DNA	O
at	O	O
+9	O	O
as	O	O
a	O	O
potential	O	O
target	O	O
for	O	O
modulating	O	O
MAT2B	O	O
expression	O	O
,	O	O
a	O	O
process	O	O
that	O	O
can	O	O
have	O	O
a	O	O
major	O	O
effect	O	O
on	O	O
intracellular	B-DNA	O
AdoMet	I-DNA	O
levels	I-DNA	O
.	O	O

Molecular	O	O
pathogenesis	O	O
of	O	O
influenza	O	O
A	O	O
virus	O	O
infection	O	O
and	O	O
virus-induced	O	O
regulation	O	O
of	O	O
cytokine	B-protein	O
gene	O	O
expression	O	O
.	O	O

Despite	O	O
vaccines	O	O
and	O	O
antiviral	O	O
substances	O	O
influenza	O	O
still	O	O
causes	O	O
significant	O	O
morbidity	O	O
and	O	O
mortality	O	O
world	O	O
wide	O	O
.	O	O

Better	O	O
understanding	O	O
of	O	O
the	O	O
molecular	O	O
mechanisms	O	O
of	O	O
influenza	O	O
virus	O	O
replication	O	O
,	O	O
pathogenesis	O	O
and	O	O
host	O	O
immune	O	O
responses	O	O
is	O	O
required	O	O
for	O	O
the	O	O
development	O	O
of	O	O
more	O	O
efficient	O	O
means	O	O
of	O	O
prevention	O	O
and	O	O
treatment	O	O
of	O	O
influenza	O	O
.	O	O

Influenza	O	O
A	O	O
virus	O	O
,	O	O
which	O	O
replicates	O	O
in	O	O
epithelial	B-cell_type	O
cells	I-cell_type	O
and	O	O
leukocytes	O	O
,	O	O
regulates	O	O
host	O	O
cell	O	O
transcriptional	O	O
and	O	O
translational	O	O
systems	O	O
and	O	O
activates	O	O
,	O	O
as	O	O
well	O	O
as	O	O
downregulates	O	O
apoptotic	O	O
pathways	O	O
.	O	O

Influenza	O	O
A	O	O
virus	O	O
infection	O	O
results	O	O
in	O	O
the	O	O
production	O	O
of	O	O
chemotactic	O	O
(	O	O
RANTES	B-protein	O
,	O	O
MIP-1	B-protein	O
alpha	I-protein	O
,	O	O
MCP-1	O	O
,	O	O
MCP-3	O	O
,	O	O
and	O	O
IP-10	B-protein	O
)	O	O
,	O	O
pro-inflammatory	O	O
(	O	O
IL-1	B-protein	O
beta	I-protein	O
,	O	O
IL-6	O	O
,	O	O
IL-18	O	O
,	O	O
and	O	O
TNF-alpha	B-protein	O
)	O	O
,	O	O
and	O	O
antiviral	O	O
(	O	O
IFN-alpha/beta	O	O
)	O	O
cytokines	O	O
.	O	O

Cytokine	O	O
gene	O	O
expression	O	O
is	O	O
associated	O	O
with	O	O
the	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
,	O	O
AP-1	B-protein	O
,	O	O
STAT	B-protein	O
and	O	O
IRF	O	O
signal	O	O
transducing	O	O
molecules	O	O
in	O	O
influenza	B-cell_line	O
A	I-cell_line	O
virus-infected	I-cell_line	O
cells	I-cell_line	O
.	O	O

In	O	O
addition	O	O
of	O	O
upregulating	O	O
cytokine	B-protein	O
gene	O	O
expression	O	O
,	O	O
influenza	O	O
A	O	O
virus	O	O
infection	O	O
activates	O	O
caspase-1	O	O
enzyme	O	O
,	O	O
which	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
proteolytic	O	O
processing	O	O
of	O	O
proIL-1	B-protein	O
beta	I-protein	O
and	O	O
proIL-18	O	O
into	O	O
their	O	O
biologically	O	O
active	O	O
forms	O	O
.	O	O

Influenza	O	O
A	O	O
virus-induced	O	O
IFN-alpha/beta	O	O
is	O	O
essential	O	O
in	O	O
host	O	O
's	O	O
antiviral	O	O
defence	O	O
by	O	O
activating	O	O
the	O	O
expression	O	O
of	O	O
antiviral	O	O
Mx	O	O
,	O	O
PKR	O	O
and	O	O
oligoadenylate	O	O
synthetase	O	O
genes	O	O
.	O	O

IFN-alpha/beta	O	O
also	O	O
prolongs	O	O
T	O	O
cell	O	O
survival	O	O
,	O	O
upregulates	O	O
IL-12	B-protein	O
and	O	O
IL-18	O	O
receptor	O	O
gene	O	O
expression	O	O
and	O	O
together	O	O
with	O	O
IL-18	O	O
stimulates	O	O
NK	O	O
and	O	O
T	O	O
cell	O	O
IFN-gamma	B-protein	O
production	O	O
and	O	O
the	O	O
development	O	O
of	O	O
Th1-type	O	O
immune	O	O
response	O	O
.	O	O

Comparison	O	O
of	O	O
hprt	O	O
and	O	O
lacI	O	O
mutant	O	O
frequency	O	O
with	O	O
DNA	O	O
adduct	O	O
formation	O	O
in	O	O
N-hydroxy-2-acetylaminofluorene-treated	O	O
Big	O	O
Blue	O	O
rats	O	O
.	O	O

N-Hydroxy-2-acetylaminofluorene	O	O
(	O	O
N-OH-AAF	B-protein	O
)	O	O
is	O	O
the	O	O
proximate	O	O
carcinogenic	O	O
metabolite	O	O
of	O	O
the	O	O
powerful	O	O
rat	O	O
liver	O	O
carcinogen	O	O
2-acetylaminofluorene	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
transgenic	O	O
Big	O	O
Blue	O	O
(	O	O
R	O	O
)	O	O
rats	O	O
were	O	O
used	O	O
to	O	O
examine	O	O
the	O	O
relationship	O	O
between	O	O
in	O	O
vivo	O	O
mutagenicity	O	O
and	O	O
DNA	O	O
adduct	O	O
formation	O	O
by	O	O
N-OH-AAF	O	O
in	O	O
the	O	O
target	O	O
liver	O	O
compared	O	O
with	O	O
that	O	O
in	O	O
nontarget	O	O
tissues	O	O
.	O	O

Male	O	O
rats	O	O
were	O	O
given	O	O
one	O	O
,	O	O
two	O	O
,	O	O
or	O	O
four	O	O
doses	O	O
of	O	O
25	O	O
mg	O	O
N-OH-AAF/kg	O	O
body	O	O
weight	O	O
by	O	O
i.p.	O	O
injection	O	O
at	O	O
4-day	O	O
intervals	O	O
,	O	O
and	O	O
groups	O	O
of	O	O
treated	O	O
and	O	O
control	O	O
rats	O	O
were	O	O
euthanized	O	O
up	O	O
to	O	O
10	O	O
weeks	O	O
after	O	O
beginning	O	O
the	O	O
dosing	O	O
.	O	O

Mutant	O	O
frequencies	O	O
were	O	O
measured	O	O
in	O	O
the	O	O
spleen	O	O
lymphocyte	O	O
hprt	O	O
gene	O	O
,	O	O
and	O	O
lacI	O	O
mutant	O	O
frequencies	O	O
were	O	O
determined	O	O
in	O	O
the	O	O
liver	O	O
and	O	O
spleen	O	O
lymphocytes	I-cell_type	O
.	O	O

At	O	O
6	O	O
weeks	O	O
after	O	O
beginning	O	O
the	O	O
dosing	O	O
,	O	O
the	O	O
hprt	O	O
mutant	O	O
frequency	O	O
in	O	O
spleen	O	O
lymphocytes	O	O
from	O	O
the	O	O
four-dose	O	O
group	O	O
was	O	O
16.5	O	O
x	O	O
10	O	O
(	O	O
-6	O	O
)	O	O
compared	O	O
with	O	O
3.2	O	O
x	O	O
10	O	O
(	O	O
-6	O	O
)	O	O
in	O	O
control	O	O
animals	O	O
.	O	O

Also	O	O
at	O	O
6	O	O
weeks	O	O
,	O	O
rats	O	O
given	O	O
one	O	O
,	O	O
two	O	O
,	O	O
or	O	O
four	O	O
doses	O	O
of	O	O
N-OH-AAF	O	O
had	O	O
lacI	O	O
mutant	O	O
frequencies	O	O
in	O	O
the	O	O
liver	O	O
of	O	O
97.6	O	O
,	O	O
155.6	O	O
,	O	O
and	O	O
406.8	O	O
x	O	O
10	O	O
(	O	O
-6	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
compared	O	O
with	O	O
a	O	O
control	O	O
frequency	O	O
of	O	O
25.7	O	O
x	O	O
10	O	O
(	O	O
-6	O	O
)	O	O
;	O	O
rats	O	O
given	O	O
four	O	O
doses	O	O
had	O	O
lacI	O	O
mutant	O	O
frequencies	O	O
in	O	O
spleen	O	O
lymphocytes	O	O
of	O	O
55.8	O	O
x	O	O
10	O	O
(	O	O
-6	O	O
)	O	O
compared	O	O
with	O	O
a	O	O
control	O	O
frequency	O	O
of	O	O
20.4	O	O
x	O	O
10	O	O
(	O	O
-6	O	O
)	O	O
.	O	O

Additional	O	O
rats	O	O
were	O	O
evaluated	O	O
for	O	O
DNA	O	O
adduct	O	O
formation	O	O
in	O	O
the	O	O
liver	O	O
,	O	O
spleen	O	O
lymphocytes	I-cell_type	O
,	O	O
and	O	O
bone	O	O
marrow	O	O
by	O	O
(	O	O
32	O	O
)	O	O
P-postlabeling	O	O
.	O	O

Adduct	O	O
analysis	O	O
was	O	O
conducted	O	O
1	O	O
day	O	O
after	O	O
one	O	O
,	O	O
two	O	O
,	O	O
and	O	O
four	O	O
treatments	O	O
with	O	O
N-OH-AAF	O	O
,	O	O
5	O	O
days	O	O
after	O	O
one	O	O
treatment	O	O
,	O	O
and	O	O
9	O	O
days	O	O
after	O	O
two	O	O
treatments	O	O
.	O	O

N-	O	O
(	O	O
Deoxyguanosin-8-yl	O	O
)	O	O
-2-aminofluorene	O	O
was	O	O
the	O	O
major	O	O
DNA	O	O
adduct	O	O
identified	O	O
in	O	O
all	O	O
the	O	O
tissues	O	O
examined	O	O
.	O	O

Adduct	O	O
concentrations	O	O
increased	O	O
with	O	O
total	O	O
dose	O	O
to	O	O
maximum	O	O
values	O	O
in	O	O
samples	O	O
taken	O	O
1	O	O
day	O	O
after	O	O
two	O	O
doses	O	O
,	O	O
and	O	O
remained	O	O
essentially	O	O
the	O	O
same	O	O
after	O	O
four	O	O
doses	O	O
.	O	O

In	O	O
samples	O	O
taken	O	O
after	O	O
four	O	O
doses	O	O
,	O	O
adduct	O	O
levels	O	O
were	O	O
103	O	O
,	O	O
28	O	O
,	O	O
and	O	O
7	O	O
fmol/microg	O	O
of	O	O
DNA	O	O
in	O	O
liver	O	O
,	O	O
spleen	O	O
lymphocytes	I-cell_type	O
,	O	O
and	O	O
bone	O	O
marrow	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
extent	O	O
of	O	O
both	O	O
DNA	O	O
adduct	I-protein	O
formation	I-protein	O
and	O	O
mutant	O	O
induction	O	O
correlates	O	O
with	O	O
the	O	O
organ	O	O
specificity	O	O
for	O	O
N-OH-AAF	O	O
carcinogenesis	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

Environ.	O	O
Mol.	O	O
Mutagen.	O	O
37	O	O
:	O	O
195-202	O	O
,	O	O
2001	O	O
.	O	O

Published	O	O
2001	O	O
Wiley-Liss	O	O
,	O	O
Inc	O	O
.	O	O

Expression	O	O
of	O	O
Mad1	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
leads	O	O
to	O	O
reduced	O	O
thymic	O	O
cellularity	O	O
and	O	O
impaired	O	O
mitogen-induced	O	O
proliferation	O	O
.	O	O

To	O	O
investigate	O	O
Mad1	O	O
function	O	O
in	O	O
vivo	O	O
,	O	O
transgenic	O	O
mice	O	O
were	O	O
generated	O	O
that	O	O
express	O	O
a	O	O
Mad1	O	O
transgene	O	O
in	O	O
T	B-cell_type	O
lineage	I-cell_type	O
cells	I-cell_type	O
under	O	O
the	O	O
control	O	O
of	O	O
the	O	O
proximal	B-DNA	O
lck	I-DNA	O
promoter	I-DNA	O
.	O	O

Thymus	O	O
size	O	O
in	O	O
lck-Mad1	O	O
transgenic	O	O
mice	O	O
is	O	O
drastically	O	O
reduced	O	O
although	O	O
representation	O	O
of	O	O
the	O	O
various	O	O
thymocyte	O	O
sub	O	O
populations	O	O
appears	O	O
normal	O	O
.	O	O

To	O	O
investigate	O	O
more	O	O
closely	O	O
any	O	O
effects	O	O
of	O	O
Mad1	O	O
expression	O	O
on	O	O
thymocytes	B-cell_type	O
,	O	O
we	O	O
examined	O	O
thymic	O	O
selection	O	O
using	O	O
MHC	O	O
class	O	O
I-restricted	O	O
H-Y-TCR	O	O
transgenic	O	O
mice	O	O
.	O	O

Mad1	O	O
expression	O	O
in	O	O
vivo	O	O
reduces	O	O
the	O	O
efficiency	O	O
of	O	O
positive	O	O
selection	O	O
.	O	O

Furthermore	O	O
,	O	O
thymocytes	B-cell_type	O
and	O	O
splenic	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
from	O	O
lck-Mad1	O	O
transgenic	O	O
mice	O	O
display	O	O
a	O	O
profound	O	O
proliferative	O	O
defect	O	O
in	O	O
response	O	O
to	O	O
activation	O	O
with	O	O
either	O	O
PMA/Ionomycin	O	O
or	O	O
immobilized	O	O
anti-CD3/CD28	O	O
antibody	O	O
.	O	O

This	O	O
proliferative	O	O
defect	O	O
is	O	O
not	O	O
reversed	O	O
by	O	O
addition	O	O
of	O	O
exogenous	O	O
IL-2	B-protein	O
and	O	O
is	O	O
p53-independent	O	O
.	O	O

The	O	O
growth	O	O
inhibition	O	O
caused	O	O
by	O	O
Mad1	O	O
is	O	O
overcome	O	O
by	O	O
expression	O	O
of	O	O
active	O	O
c-Myc	O	O
.	O	O

Differential	O	O
requirement	O	O
for	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
PU.1	O	O
in	O	O
the	O	O
generation	O	O
of	O	O
natural	B-cell_type	O
killer	I-cell_type	O
cells	I-cell_type	O
versus	O	O
B	B-cell_type	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

PU.1	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
Ets	B-protein	O
family	I-protein	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
required	O	O
for	O	O
the	O	O
development	O	O
of	O	O
various	O	O
lymphoid	I-cell_type	O
and	O	O
myeloid	B-protein	O
cell	I-protein	O
lineages	I-protein	O
,	O	O
but	O	O
its	O	O
role	O	O
in	O	O
natural	B-cell_line	O
killer	I-cell_line	O
(	O	O
NK	O	O
)	O	O
cell	O	O
development	O	O
is	O	O
not	O	O
known	O	O
.	O	O

The	O	O
study	O	O
shows	O	O
that	O	O
PU.1	O	O
is	O	O
expressed	O	O
in	O	O
NK	B-cell_type	O
cells	I-cell_type	O
and	O	O
that	O	O
,	O	O
on	O	O
cell	O	O
transfer	O	O
into	O	O
alymphoid	O	O
Rag2/gammac	O	O
(	O	O
-/-	O	O
)	O	O
mice	O	O
,	O	O
hematopoietic	O	O
progenitors	O	O
of	O	O
PU.1	O	O
(	O	O
-/-	O	O
)	O	O
fetal	O	O
liver	O	O
cells	O	O
could	O	O
generate	O	O
functional	O	O
NK	O	O
cells	O	O
but	O	O
not	O	O
B	O	O
or	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Nevertheless	O	O
,	O	O
the	O	O
numbers	O	O
of	O	O
bone	B-cell_line	O
marrow	B-cell_line	O
NK	I-cell_line	O
cell	I-cell_line	O
precursors	I-cell_line	O
and	I-cell_line	O
splenic	I-cell_line	O
mature	I-cell_line	O
NK	I-cell_line	O
cells	I-cell_line	O
were	O	O
reduced	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

Moreover	O	O
,	O	O
PU.1	O	O
(	O	O
-/-	I-cell_line	O
)	I-cell_line	O
NK	I-cell_line	O
cells	O	O
displayed	O	O
reduced	O	O
expression	O	O
of	O	O
the	O	O
receptors	O	O
for	O	O
stem	B-protein	O
cell	I-protein	O
factor	I-protein	O
and	O	O
interleukin	B-protein	O
(	I-protein	O
IL	I-protein	O
)	O	O
-7	O	O
,	O	O
suggesting	O	O
a	O	O
nonredundant	O	O
role	O	O
for	O	O
PU.1	O	O
in	O	O
regulating	O	O
the	O	O
expression	O	O
of	O	O
these	O	O
cytokine	B-protein	O
receptor	O	O
genes	O	O
during	O	O
NK	O	O
cell	O	O
development	O	O
.	O	O

PU.1	O	O
(	O	O
-/-	B-cell_line	O
)	I-cell_line	O
NK	I-cell_line	O
cells	I-cell_line	O
also	O	O
showed	O	O
defective	O	O
expression	O	O
of	O	O
inhibitory	O	O
and	O	O
activating	O	O
members	O	O
of	O	O
the	O	O
Ly49	B-protein	O
family	I-protein	O
and	O	O
failed	O	O
to	O	O
proliferate	O	O
in	O	O
response	O	O
to	O	O
IL-2	B-protein	O
and	O	O
IL-12	B-protein	O
.	O	O

Thus	O	O
,	O	O
despite	O	O
the	O	O
less	O	O
stringent	O	O
requirement	O	O
for	O	O
PU.1	O	O
in	O	O
NK	O	O
cell	O	O
development	O	O
compared	O	O
to	O	O
B	O	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
PU.1	O	O
regulates	O	O
NK	O	O
cell	O	O
differentiation	O	O
and	O	O
homeostasis	O	O
.	O	O

Benzene-extracted	O	O
components	O	O
are	O	O
important	O	O
for	O	O
the	O	O
major	O	O
activity	O	O
of	O	O
diesel	O	O
exhaust	O	O
particles	O	O
:	O	O
effect	O	O
on	O	O
interleukin-8	O	O
gene	O	O
expression	O	O
in	O	O
human	B-cell_type	O
bronchial	I-cell_type	O
epithelial	I-cell_type	O
cells	I-cell_type	O
.	O	O

Epidemiologic	O	O
and	O	O
experimental	O	O
studies	O	O
suggest	O	O
that	O	O
diesel	O	O
exhaust	O	O
particles	O	O
(	O	O
DEPs	O	O
)	O	O
may	O	O
be	O	O
related	O	O
to	O	O
increasing	O	O
respiratory	O	O
mortality	O	O
and	O	O
morbidity	O	O
.	O	O

We	O	O
have	O	O
shown	O	O
that	O	O
DEPs	O	O
augmented	O	O
the	O	O
production	O	O
of	O	O
inflammatory	B-protein	O
cytokines	I-protein	O
by	O	O
human	B-cell_line	O
airway	I-cell_line	O
epithelial	I-cell_line	O
cells	I-cell_type	O
in	O	O
vitro	O	O
.	O	O

To	O	O
better	O	O
understand	O	O
the	O	O
mechanisms	O	O
of	O	O
their	O	O
proinflammatory	O	O
activities	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
several	O	O
components	O	O
extracted	O	O
from	O	O
DEPs	O	O
on	O	O
interleukin	B-protein	O
(	I-protein	O
IL	I-protein	O
)	O	O
-8	O	O
expression	O	O
in	O	O
human	O	O
bronchial	O	O
epithelial	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
BEAS-2B	O	O
and	O	O
normal	O	O
human	B-cell_line	O
airway	I-cell_line	O
epithelial	I-cell_line	O
cells	I-cell_type	O
obtained	O	O
from	O	O
very	O	O
peripheral	O	O
airways	O	O
by	O	O
an	O	O
ultrathin	O	O
bronchoscope	O	O
.	O	O

We	O	O
used	O	O
several	O	O
agents	O	O
active	O	O
on	O	O
signal	O	O
transduction	O	O
pathways	O	O
in	O	O
cytokine	B-protein	O
expression	O	O
,	O	O
such	O	O
as	O	O
the	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
inhibitor	O	O
staurosporin	O	O
,	O	O
antioxidant	O	O
agents	O	O
including	O	O
N-acetyl	O	O
cysteine	O	O
(	O	O
NAC	O	O
)	O	O
and	O	O
pyrrolidine	O	O
dithiocarbamate	O	O
(	O	O
PDTC	O	O
)	O	O
,	O	O
and	O	O
p38	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
(	O	O
MAPK	O	O
)	O	O
inhibitor	O	O
SB203580	O	O
.	O	O

Benzene-extracted	O	O
components	O	O
showed	O	O
effects	O	O
mimicking	O	O
DEPs	O	O
on	O	O
IL-8	O	O
gene	O	O
expression	O	O
,	O	O
release	O	O
of	O	O
several	O	O
cytokines	B-protein	O
(	O	O
IL-8	B-protein	O
;	O	O
granulocyte	O	O
macrophage	O	O
colony-stimulating	O	O
factor	O	O
;	O	O
and	O	O
regulated	O	O
on	O	O
activation	O	O
,	O	O
normal	O	O
T	B-cell_type	O
cells	I-cell_type	O
expressed	O	O
and	O	O
secreted	O	O
)	O	O
and	O	O
nuclear	B-protein	O
factor	I-protein	O
(	O	O
NF	O	O
)	O	O
-kappa	O	O
B	O	O
activation	O	O
.	O	O

We	O	O
also	O	O
found	O	O
that	O	O
NAC	O	O
,	O	O
PDTC	O	O
,	O	O
and	O	O
SB203580	O	O
suppressed	O	O
the	O	O
activities	O	O
of	O	O
DEPs	B-protein	O
and	O	O
their	O	O
benzene	O	O
extracts	O	O
,	O	O
suggesting	O	O
the	O	O
roles	O	O
of	O	O
oxidants-mediated	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
and	O	O
p38MAPK	O	O
pathways	O	O
.	O	O

Finally	O	O
,	O	O
benzo	O	O
[	O	O
a	O	O
]	O	O
pyrene	O	O
,	O	O
one	O	O
of	O	O
the	O	O
important	O	O
compounds	O	O
included	O	O
in	O	O
the	O	O
benzene	O	O
component	O	O
,	O	O
replicated	O	O
the	O	O
activities	O	O
shown	O	O
by	O	O
DEPs	O	O
.	O	O

The	O	O
nuclear	B-protein	O
receptor	I-protein	O
PPAR	O	O
gamma	O	O
is	O	O
expressed	O	O
by	O	O
mouse	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
PPAR	O	O
gamma	O	O
agonists	O	O
induce	O	O
apoptosis	O	O
.	O	O

Peroxisome	O	O
proliferator-activated	B-protein	O
receptor	I-protein	O
(	O	O
PPAR	B-protein	O
)	O	O
-gamma	O	O
is	O	O
a	O	O
nuclear	O	O
hormone	B-protein	O
receptor	I-protein	O
that	O	O
serves	O	O
as	O	O
a	O	O
trans	B-protein	O
factor	I-protein	O
to	O	O
regulate	O	O
lipid	O	O
metabolism	O	O
.	O	O

Intense	O	O
interest	O	O
is	O	O
focused	O	O
on	O	O
PPAR-gamma	O	O
and	O	O
its	O	O
ligands	O	O
owing	O	O
to	O	O
its	O	O
putative	O	O
role	O	O
in	O	O
adipocyte	O	O
differentiation	O	O
.	O	O

Little	O	O
is	O	O
known	O	O
,	O	O
however	O	O
,	O	O
about	O	O
the	O	O
functions	O	O
of	O	O
PPAR-gamma	O	O
in	O	O
the	O	O
immune	O	O
system	O	O
,	O	O
especially	O	O
in	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

We	O	O
demonstrate	O	O
that	O	O
both	O	O
naive	O	O
and	O	O
activated	O	O
ovalbumin-specific	O	O
T	B-cell_type	O
cells	I-cell_type	O
from	O	O
DO11.10-transgenic	O	O
mice	O	O
express	O	O
PPAR-gamma	O	O
mRNA	I-RNA	O
and	O	O
protein	O	O
.	O	O

In	O	O
order	O	O
to	O	O
determine	O	O
the	O	O
function	O	O
of	O	O
PPAR-gamma	O	O
,	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
stimulated	O	O
with	O	O
phorbol	O	O
12-myristate	O	O
13-acetate	O	O
and	O	O
ionomycin	O	O
or	O	O
antigen	B-cell_type	O
and	O	O
antigen-presenting	B-cell_type	O
cells	I-cell_type	O
.	O	O

Simultaneous	O	O
exposure	O	O
to	O	O
PPAR-gamma	O	O
ligands	O	O
(	O	O
e.g.	O	O
15-deoxy-Delta	O	O
(	O	O
12	B-protein	O
,	O	O
14	O	O
)	O	O
-prostaglandin	O	O
J	O	O
(	O	O
2	O	O
)	O	O
,	O	O
troglitazone	O	O
)	O	O
showed	O	O
drastic	O	O
inhibition	O	O
of	O	O
proliferation	O	O
and	O	O
significant	O	O
decreases	O	O
in	O	O
cell	O	O
viability	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
cell	O	O
viability	O	O
was	O	O
due	O	O
to	O	O
apoptosis	O	O
of	O	O
the	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
and	O	O
occurred	I-cell_line	O
only	I-cell_line	O
when	O	O
cells	O	O
were	O	O
treated	O	O
with	O	O
PPAR-gamma	O	O
,	O	O
and	O	O
not	O	O
PPAR-alpha	O	O
agonists	O	O
,	O	O
revealing	O	O
specificity	O	O
of	O	O
this	O	O
response	O	O
for	O	O
PPAR-gamma	O	O
.	O	O

These	O	O
observations	O	O
suggest	O	O
that	O	O
PPAR-gamma	O	O
agonists	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
regulating	O	O
T	O	O
cell-mediated	O	O
immune	O	O
responses	O	O
by	O	O
inducing	O	O
apoptosis	O	O
.	O	O

T	O	O
cell	O	O
death	O	O
via	O	O
PPAR-gamma	O	O
ligation	O	O
may	O	O
act	O	O
as	O	O
a	O	O
potent	O	O
anti-inflammatory	O	O
signal	O	O
in	O	O
the	O	O
immune	O	O
system	O	O
,	O	O
and	O	O
ligands	O	O
could	O	O
possibly	O	O
be	O	O
used	O	O
to	O	O
control	O	O
disorders	O	O
in	O	O
which	O	O
excessive	O	O
inflammation	O	O
occurs	O	O
.	O	O

Suppression	O	O
of	O	O
lung	O	O
inflammation	O	O
in	O	O
rats	O	O
by	O	O
prevention	O	O
of	O	O
NF-kappaB	O	O
activation	O	O
in	O	O
the	O	O
liver	O	O
.	O	O

Activation	O	O
of	O	O
NF-kappaB	O	O
and	O	O
production	O	O
of	O	O
NF-kappaB	B-protein	O
-dependent	O	O
chemokines	O	O
are	O	O
thought	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
neutrophilic	O	O
lung	O	O
inflammation	O	O
.	O	O

Calpain-1	O	O
inhibitor	O	O
(	O	O
CI-1	B-protein	O
)	O	O
blocks	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
by	O	O
preventing	O	O
proteolysis	O	O
of	O	O
the	O	O
inhibitory	B-protein	O
protein	I-protein	O
IkappaB-alpha	O	O
by	O	O
the	O	O
ubiquitin/proteasome	B-protein	O
pathway	I-protein	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
inhibition	O	O
of	O	O
proteasome	O	O
function	O	O
with	O	O
CI-1	O	O
would	O	O
block	O	O
NF-kappaB	O	O
activation	O	O
in	O	O
vivo	O	O
after	O	O
intraperitoneal	O	O
(	O	O
i.p.	O	O
)	O	O
treatment	O	O
with	O	O
bacterial	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
,	O	O
and	O	O
that	O	O
NF-kappaB	O	O
inhibition	O	O
would	O	O
be	O	O
associated	O	O
with	O	O
suppression	O	O
of	O	O
chemokine	B-protein	O
gene	O	O
expression	O	O
and	O	O
attenuation	O	O
of	O	O
neutrophilic	O	O
alveolitis	O	O
.	O	O

We	O	O
treated	O	O
rats	O	O
with	O	O
a	O	O
single	O	O
i.p.	O	O
injection	O	O
of	O	O
CI-1	O	O
(	O	O
10	O	O
mg/kg	I-protein	O
)	O	O
two	O	O
hours	O	O
prior	O	O
to	O	O
i.p.	O	O
LPS	O	O
(	O	O
7	O	O
mg/kg	O	O
)	O	O
.	O	O

Treatment	O	O
with	O	O
Cl-1	O	O
prevented	O	O
degradation	O	O
of	O	O
IkappaB-alpha	O	O
and	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
in	O	O
the	O	O
liver	O	O
in	O	O
response	O	O
to	O	O
LPS	O	O
;	O	O
however	O	O
,	O	O
Cl-1	O	O
treatment	O	O
had	O	O
no	O	O
detected	O	O
effect	O	O
on	O	O
NF-kappaB	O	O
activation	O	O
in	O	O
lung	O	O
tissue	O	O
.	O	O

CI-1	O	O
treatment	O	O
prior	O	O
to	O	O
LPS	O	O
resulted	O	O
in	O	O
40	O	O
%	O	O
lower	O	O
MIP-2	O	O
concentration	O	O
in	O	O
lung	O	O
lavage	O	O
fluid	O	O
compared	O	O
to	O	O
rats	O	O
treated	O	O
with	O	O
vehicle	O	O
prior	O	O
to	O	O
LPS	O	O
(	O	O
502	O	O
+/-	O	O
112	O	O
pg/ml	O	O
vs.	O	O
859	O	O
+/-144	O	O
pg/ml	O	O
,	O	O
P	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
CI-1	O	O
treatment	O	O
substantially	O	O
inhibited	O	O
LPS-induced	O	O
neutrophilic	O	O
alveolitis	O	O
(	O	O
2.7+	O	O
/-	O	O
1.2	O	O
x	O	O
10	O	O
(	O	O
5	O	O
)	O	O
vs.	O	O
43.7	O	O
+/-	O	O
12.2	O	O
x	O	O
10	O	O
(	O	O
5	O	O
)	O	O
lung	O	O
lavage	O	O
neutrophils	O	O
,	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
NF-kappaB	O	O
inhibition	O	O
in	O	O
the	O	O
liver	O	O
can	O	O
alter	O	O
lung	O	O
inflammation	O	O
induced	O	O
by	O	O
systemic	O	O
LPS	O	O
treatment	O	O
and	O	O
suggest	O	O
that	O	O
a	O	O
liver-lung	O	O
interaction	O	O
contributes	O	O
to	O	O
the	O	O
inflammatory	O	O
response	O	O
of	O	O
the	O	O
lung	O	O
.	O	O

Notch1	O	O
regulates	O	O
maturation	O	O
of	O	O
CD4+	B-protein	O
and	O	O
CD8+	O	O
thymocytes	O	O
by	O	O
modulating	O	O
TCR	B-protein	O
signal	O	O
strength	O	O
.	O	O

Notch	O	O
signaling	O	O
regulates	O	O
cell	O	O
fate	O	O
decisions	O	O
in	O	O
multiple	O	O
lineages	O	O
.	O	O

We	O	O
demonstrate	O	O
in	O	O
this	O	O
report	O	O
that	O	O
retroviral	O	O
expression	O	O
of	O	O
activated	O	O
Notch1	O	O
in	O	O
mouse	O	O
thymocytes	O	O
abrogates	O	O
differentiation	O	O
of	O	O
immature	O	O
CD4+CD8+	O	O
thymocytes	O	O
into	O	O
both	O	O
CD4	B-protein	O
and	O	O
CD8	O	O
mature	I-protein	O
single-positive	I-protein	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
ability	O	O
of	O	O
Notch1	O	O
to	O	O
inhibit	O	O
T	O	O
cell	O	O
development	O	O
was	O	O
observed	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
with	O	O
both	O	O
normal	O	O
and	O	O
TCR	B-protein	O
transgenic	O	O
thymocytes	O	O
.	O	O

Notch1	O	O
-mediated	O	O
developmental	O	O
arrest	O	O
was	O	O
dose	O	O
dependent	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
impaired	O	O
thymocyte	O	O
responses	O	O
to	O	O
TCR	B-protein	O
stimulation	O	O
.	O	O

Notch1	O	O
also	O	O
inhibited	O	O
TCR-mediated	O	O
signaling	O	O
in	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
constitutively	O	O
active	O	O
Notch1	O	O
abrogates	O	O
CD4+	B-protein	O
and	O	O
CD8+	O	O
maturation	O	O
by	O	O
interfering	O	O
with	O	O
TCR	B-protein	O
signal	O	O
strength	O	O
and	O	O
provide	O	O
an	O	O
explanation	O	O
for	O	O
the	O	O
physiological	O	O
regulation	O	O
of	O	O
Notch	O	O
expression	O	O
during	O	O
thymocyte	O	O
development	O	O
.	O	O

Expression	O	O
of	O	O
SART3	O	O
antigen	O	O
and	O	O
induction	O	O
of	O	O
CTLs	O	O
by	O	O
SART3-derived	O	O
peptides	O	O
in	O	O
breast	O	O
cancer	O	O
patients	O	O
.	O	O

We	O	O
recently	O	O
reported	O	O
the	O	O
SART3	O	O
tumour-rejection	O	O
antigen	O	O
as	O	O
possessing	O	O
tumour	O	O
epitopes	O	O
capable	O	O
of	O	O
inducing	O	O
HLA-class	B-protein	O
I-restricted	I-protein	O
cytotoxic	I-protein	O
T	I-protein	O
lymphocytes	I-cell_type	O
(	O	O
CTLs	B-protein	O
)	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
expression	O	O
of	O	O
the	O	O
SART3	O	O
antigen	O	O
in	O	O
breast	O	O
cancer	O	O
to	O	O
explore	O	O
an	O	O
appropriate	O	O
molecule	O	O
for	O	O
use	O	O
in	O	O
specific	O	O
immunotherapy	O	O
of	O	O
breast	O	O
cancer	O	O
patients	O	O
.	O	O

The	O	O
SART3	O	O
antigen	O	O
was	O	O
detected	O	O
in	O	O
all	O	O
of	O	O
the	O	O
breast	O	O
cancer	O	O
cell	O	O
lines	O	O
tested	O	O
,	O	O
30	O	O
of	O	O
40	O	O
(	O	O
75	O	O
%	O	O
)	O	O
breast	O	O
cancer	O	O
tissue	O	O
samples	O	O
,	O	O
and	O	O
0	O	O
of	O	O
3	O	O
non-tumourous	O	O
breast	O	O
tissue	O	O
samples	O	O
.	O	O

SART3	O	O
derived	O	O
peptides	O	O
at	O	O
positions	O	O
109-118	O	O
and	O	O
315-323	O	O
induced	O	O
HLA-A24	O	O
restricted	O	O
CTLs	O	O
that	O	O
reacted	O	O
to	O	O
breast	O	O
cancer	O	O
cells	O	O
from	O	O
the	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
(	O	O
PBMCs	O	O
)	O	O
of	O	O
breast	O	O
cancer	O	O
patients	O	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
SART3	O	O
antigen	O	O
and	O	O
its	O	O
peptides	O	O
could	O	O
be	O	O
an	O	O
appropriate	O	O
molecule	O	O
for	O	O
use	O	O
in	O	O
specific	O	O
immunotherapy	O	O
of	O	O
the	O	O
majority	O	O
of	O	O
HLA-A24-positive	O	O
breast	O	O
cancer	O	O
patients	O	O

Autostimulation	O	O
of	O	O
the	O	O
Epstein-Barr	B-DNA	O
virus	O	O
BRLF1	O	O
promoter	O	O
is	O	O
mediated	O	O
through	O	O
consensus	O	O
Sp1	O	O
and	O	O
Sp3	O	O
binding	O	O
sites	O	O
.	O	O

As	O	O
an	O	O
essential	O	O
step	O	O
in	O	O
the	O	O
lytic	O	O
cascade	O	O
,	O	O
the	O	O
Rta	O	O
homologues	O	O
of	O	O
gammaherpesviruses	O	O
all	O	O
activate	O	O
their	O	O
own	O	O
expression	O	O
.	O	O

Consistent	O	O
with	O	O
this	O	O
biologic	O	O
function	O	O
,	O	O
the	O	O
Epstein-Barr	O	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
Rta	O	O
protein	O	O
powerfully	O	O
stimulates	O	O
the	O	O
promoter	O	O
of	O	O
its	O	O
own	O	O
gene	O	O
,	O	O
Rp	O	O
,	O	O
in	O	O
EBV-positive	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
in	O	O
transient-transfection	O	O
reporter-based	O	O
assays	O	O
.	O	O

We	O	O
analyzed	O	O
the	O	O
activity	O	O
of	O	O
RpCAT	O	O
in	O	O
response	O	O
to	O	O
Rta	O	O
by	O	O
deletional	O	O
and	O	O
site-directed	O	O
mutagenesis	O	O
.	O	O

Two	O	O
cognate	O	O
Sp1	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
located	O	O
at	O	O
-279	O	O
and	O	O
-45	O	O
relative	O	O
to	O	O
the	O	O
transcriptional	O	O
start	O	O
site	O	O
proved	O	O
crucial	O	O
for	O	O
Rta-mediated	O	O
activation	O	O
.	O	O

Previously	O	O
described	O	O
binding	O	O
sites	O	O
for	O	O
the	O	O
cellular	B-protein	O
transcription	I-protein	O
factor	I-protein	O
Zif268	O	O
and	O	O
the	O	O
viral	B-DNA	O
transactivator	I-DNA	O
ZEBRA	O	O
were	O	O
found	O	O
to	O	O
be	O	O
dispensable	O	O
for	O	O
activation	O	O
of	O	O
RpCAT	O	O
by	O	O
Rta	O	O
.	O	O

Gel	O	O
shift	O	O
analysis	O	O
,	O	O
using	O	O
extracts	O	O
of	O	O
B	B-cell_type	O
cells	I-cell_type	O
in	O	O
latency	O	O
or	O	O
induced	O	O
into	O	O
the	O	O
lytic	O	O
cycle	O	O
,	O	O
identified	O	O
Sp1	O	O
and	O	O
Sp3	O	O
as	O	O
the	O	O
predominant	B-protein	O
cellular	I-protein	O
proteins	I-protein	O
bound	O	O
to	O	O
Rp	O	O
near	O	O
-45	O	O
.	O	O

During	O	O
the	O	O
lytic	O	O
cycle	O	O
,	O	O
ZEBRA	O	O
bound	O	O
Rp	O	O
near	O	O
the	O	O
Sp1/Sp3	B-DNA	O
site	I-DNA	O
.	O	O

The	O	O
binding	O	O
of	O	O
Sp1	B-protein	O
and	O	O
Sp3	O	O
to	O	O
Rp	O	O
correlated	O	O
with	O	O
the	O	O
reporter	B-DNA	O
activities	O	O
in	O	O
the	O	O
mutagenesis	O	O
study	O	O
,	O	O
establishing	O	O
a	O	O
direct	O	O
link	O	O
between	O	O
transcriptional	O	O
activation	O	O
of	O	O
Rp	O	O
by	O	O
Rta	B-protein	O
and	O	O
DNA	B-protein	O
binding	I-protein	O
by	O	O
Sp1	B-protein	O
and/or	O	O
Sp3	O	O
.	O	O

The	O	O
relative	O	O
abundance	O	O
or	O	O
functional	O	O
state	O	O
of	O	O
the	O	O
cellular	B-DNA	O
Sp1	I-DNA	O
and	O	O
Sp3	O	O
transcription	B-protein	O
factors	I-protein	O
may	O	O
be	O	O
altered	O	O
in	O	O
response	O	O
to	O	O
stimuli	O	O
that	O	O
induce	O	O
the	O	O
BRLF1	O	O
promoter	O	O
and	O	O
thereby	O	O
contribute	O	O
to	O	O
the	O	O
activation	O	O
of	O	O
the	O	O
viral	O	O
lytic	O	O
cycle	O	O
.	O	O

Gene	O	O
transfer	O	O
of	O	O
antisense	O	O
hypoxia	O	O
inducible	O	O
factor-1	O	O
alpha	I-protein	O
enhances	O	O
the	O	O
therapeutic	O	O
efficacy	O	O
of	O	O
cancer	O	O
immunotherapy	O	O
.	O	O

Solid	O	O
tumors	O	O
meet	O	O
their	O	O
demands	O	O
for	O	O
nascent	O	O
blood	O	O
vessels	O	O
and	O	O
increased	O	O
glycolysis	O	O
,	O	O
to	O	O
combat	O	O
hypoxia	O	O
,	O	O
by	O	O
activating	O	O
multiple	O	O
genes	O	O
involved	O	O
in	O	O
angiogenesis	O	O
and	O	O
glucose	O	O
metabolism	O	O
.	O	O

Hypoxia	O	O
inducible	O	O
factor-1	O	O
(	O	O
HIF-1	B-protein	O
)	O	O
is	O	O
a	O	O
constitutively	O	O
expressed	O	O
basic	O	O
helix-loop-helix	O	O
transcription	B-protein	O
factor	I-protein	O
,	O	O
formed	O	O
by	O	O
the	O	O
assembly	O	O
of	O	O
HIF-1alpha	B-protein	O
and	I-protein	O
HIF-1beta	I-protein	O
(	O	O
Arnt	B-protein	O
)	O	O
,	O	O
that	O	O
is	O	O
stablized	O	O
in	O	O
response	O	O
to	O	O
hypoxia	O	O
,	O	O
and	O	O
rapidly	O	O
degraded	O	O
under	O	O
normoxic	O	O
conditions	O	O
.	O	O

It	O	O
activates	O	O
the	O	O
transcription	O	O
of	O	O
genes	B-DNA	O
important	O	O
for	O	O
maintaining	O	O
oxygen	O	O
homeostasis	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
engineered	O	O
down-regulation	O	O
of	O	O
HIF-1alpha	O	O
by	O	O
intratumoral	O	O
gene	O	O
transfer	O	O
of	O	O
an	O	O
antisense	O	O
HIF-1alpha	O	O
plasmid	O	O
leads	O	O
to	O	O
the	O	O
down-regulation	O	O
of	O	O
VEGF	O	O
,	O	O
and	O	O
decreased	O	O
tumor	O	O
microvessel	O	O
density	O	O
.	O	O

Antisense	O	O
HIF-1alpha	O	O
monotherapy	O	O
resulted	O	O
in	O	O
the	O	O
complete	O	O
and	O	O
permanent	O	O
rejection	O	O
of	O	O
small	O	O
(	O	O
0.1	O	O
cm	O	O
in	O	O
diameter	O	O
)	O	O
EL-4	O	O
tumors	O	O
,	O	O
which	O	O
is	O	O
unusual	O	O
for	O	O
an	O	O
anti-angiogenic	O	O
agent	O	O
where	O	O
transient	O	O
suppression	O	O
of	O	O
tumor	O	O
growth	O	O
is	O	O
the	O	O
norm	O	O
.	O	O

It	O	O
induced	O	O
NK	O	O
cell	O	O
-dependent	O	O
rejection	O	O
of	O	O
tumors	O	O
,	O	O
but	O	O
failed	O	O
to	O	O
stimulate	O	O
systemic	O	O
T	O	O
cell	O	O
-mediated	O	O
anti-tumor	O	O
immunity	O	O
,	O	O
and	O	O
synergized	O	O
with	O	O
B7-1-mediated	O	O
immunotherapy	O	O
to	O	O
cause	O	O
the	O	O
NK	O	O
cell	O	O
and	O	O
CD8	O	O
T	O	O
cell	O	O
-dependent	O	O
rejection	O	O
of	O	O
larger	O	O
EL-4	O	O
tumors	O	O
(	O	O
0.4	O	O
cm	O	O
in	O	O
diameter	O	O
)	O	O
that	O	O
were	O	O
refractory	O	O
to	O	O
monotherapies	O	O
.	O	O

Mice	O	O
cured	O	O
of	O	O
their	O	O
tumors	O	O
by	O	O
combination	O	O
therapy	O	O
resisted	O	O
a	O	O
rechallenge	O	O
with	O	O
parental	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
,	O	O
indicating	O	O
systemic	O	O
antitumor	O	O
immunity	O	O
had	O	O
been	O	O
achieved	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
whilst	O	O
intensive	O	O
investigations	O	O
are	O	O
in	O	O
progress	O	O
to	O	O
target	O	O
the	O	O
many	O	O
HIF-1	O	O
effectors	O	O
,	O	O
the	O	O
results	O	O
herein	O	O
indicate	O	O
that	O	O
blocking	O	O
hypoxia-inducible	O	O
pathways	O	O
and	O	O
enhancing	O	O
NK-mediated	O	O
antitumor	O	O
immunity	O	O
by	O	O
targeting	O	O
HIF-1	O	O
itself	O	O
may	O	O
be	O	O
advantageous	O	O
,	O	O
especially	O	O
when	O	O
combined	O	O
with	O	O
cancer	O	O
immunotherapy	O	O
.	O	O

Runx2	O	O
:	O	O
a	O	O
novel	O	O
oncogenic	O	O
effector	O	O
revealed	O	O
by	O	O
in	O	O
vivo	O	O
complementation	O	O
and	O	O
retroviral	O	O
tagging	O	O
.	O	O

The	O	O
Runx2	O	O
(	O	O
Cbfa1	O	O
,	O	O
Pebp2alphaA	O	O
,	O	O
Aml3	O	O
)	O	O
gene	O	O
was	O	O
previously	O	O
identified	O	O
as	O	O
a	O	O
frequent	O	O
target	O	O
for	O	O
transcriptional	O	O
activation	O	O
by	O	O
proviral	O	O
insertion	O	O
in	O	O
T-cell	O	O
lymphomas	O	O
of	O	O
CD2-MYC	O	O
transgenic	O	O
mice	O	O
.	O	O

We	O	O
have	O	O
recently	O	O
shown	O	O
that	O	O
over-expression	O	O
of	O	O
the	O	O
full-length	B-protein	O
,	O	O
most	O	O
highly	O	O
expressed	O	O
Runx2	O	O
isoform	O	O
in	O	O
the	O	O
thymus	O	O
perturbs	O	O
T-cell	O	O
development	O	O
,	O	O
leads	O	O
to	O	O
development	O	O
of	O	O
spontaneous	O	O
lymphomas	O	O
at	O	O
low	O	O
frequency	O	O
and	O	O
is	O	O
strongly	O	O
synergistic	O	O
with	O	O
Myc	O	O
.	O	O

To	O	O
gain	O	O
further	O	O
insight	O	O
into	O	O
the	O	O
relationship	O	O
of	O	O
Runx2	O	O
to	O	O
other	O	O
lymphomagenic	O	O
pathways	O	O
,	O	O
we	O	O
tested	O	O
the	O	O
effect	O	O
of	O	O
combining	O	O
the	O	O
CD2-Runx2	O	O
transgene	O	O
either	O	O
with	O	O
a	O	O
Pim1	B-protein	O
transgene	I-protein	O
(	O	O
E	B-protein	O
(	O	O
mu	B-protein	O
)	O	O
-Pim1	O	O
)	O	O
or	O	O
with	O	O
the	O	O
p53	O	O
null	O	O
genotype	O	O
,	O	O
as	O	O
each	O	O
of	O	O
these	O	O
displays	O	O
independent	O	O
synergy	O	O
with	O	O
Myc	O	O
.	O	O

In	O	O
both	O	O
cases	O	O
we	O	O
observed	O	O
synergistic	O	O
tumour	O	O
development	O	O
.	O	O

However	O	O
,	O	O
Runx2	O	O
appeared	O	O
to	O	O
have	O	O
a	O	O
dominant	O	O
effect	O	O
on	O	O
the	O	O
tumour	O	O
phenotype	O	O
in	O	O
each	O	O
case	O	O
,	O	O
with	O	O
most	O	O
tumours	O	O
conforming	O	O
to	O	O
the	O	O
CD3	B-protein	O
(	I-protein	O
+	I-protein	O
)	O	O
,	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
,	O	O
CD4	B-protein	O
(	O	O
+/-	B-protein	O
)	O	O
phenotype	O	O
seen	O	O
in	O	O
CD2-Runx2	O	O
mice	O	O
.	O	O

Neonatal	O	O
infection	O	O
of	O	O
CD2-Runx2	O	O
mice	O	O
with	O	O
Moloney	B-protein	O
murine	I-protein	O
leukaemia	O	O
virus	O	O
(	O	O
Moloney	O	O
MLV	O	O
)	O	O
also	O	O
led	O	O
to	O	O
a	O	O
dramatic	O	O
acceleration	O	O
of	O	O
tumour	O	O
onset	O	O
.	O	O

Analysis	O	O
of	O	O
known	O	O
Moloney	O	O
MLV	O	O
target	O	O
genes	O	O
in	O	O
these	O	O
lymphomas	O	O
showed	O	O
a	O	O
high	O	O
frequency	O	O
of	O	O
rearrangement	O	O
at	O	O
c-Myc	O	O
or	O	O
N-Myc	O	O
(	O	O
82	O	O
%	O	O
)	O	O
,	O	O
and	O	O
a	O	O
significant	O	O
number	O	O
at	O	O
Pim1	O	O
or	O	O
Pim2	O	O
(	O	O
23	O	O
%	O	O
)	O	O
,	O	O
and	O	O
at	O	O
Pal1/Gfi1	O	O
(	O	O
18	O	O
%	O	O
)	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
Runx2	O	O
makes	O	O
a	O	O
distinct	O	O
contribution	O	O
to	O	O
T-cell	O	O
lymphoma	O	O
development	O	O
which	O	O
does	O	O
not	O	O
coincide	O	O
with	O	O
any	O	O
of	O	O
the	O	O
oncogene	O	O
complementation	O	O
groups	O	O
previously	O	O
identified	O	O
by	O	O
retroviral	O	O
tagging	O	O
.	O	O

The	O	O
involvement	O	O
of	O	O
TNF-alpha	O	O
-related	O	O
apoptosis-inducing	O	O
ligand	O	O
in	O	O
the	O	O
enhanced	O	O
cytotoxicity	O	O
of	O	O
IFN-beta	O	O
-stimulated	O	O
human	B-cell_type	O
dendritic	I-cell_type	O
cells	I-cell_type	O
to	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
.	O	O

TNF-alpha	O	O
-related	O	O
apoptosis-inducing	O	O
ligand	O	O
(	O	O
TRAIL	O	O
)	O	O
is	O	O
characterized	O	O
by	O	O
its	O	O
preferential	O	O
induction	O	O
of	O	O
apoptosis	O	O
of	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
but	O	O
not	B-cell_type	O
normal	I-cell_type	O
cells	I-cell_type	O
.	O	O

Dendritic	I-cell_line	O
cells	I-cell_line	O
(	O	O
DCs	O	O
)	O	O
,	O	O
besides	O	O
their	O	O
role	O	O
as	O	O
APCs	O	O
,	O	O
now	O	O
have	O	O
been	O	O
demonstrated	O	O
to	O	O
exert	O	O
cytotoxicity	O	O
or	O	O
cytostasis	O	O
on	O	O
some	O	O
tumor	O	O
cells	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
that	O	O
both	O	O
human	O	O
CD34	O	O
(	O	O
+	O	O
)	O	O
stem	O	O
cell	O	O
-derived	O	O
DCs	O	O
(	O	O
CD34DCs	B-protein	O
)	O	O
and	O	O
human	B-protein	O
CD14	I-protein	O
(	O	O
+	O	O
)	O	O
monocyte	O	O
-derived	O	O
DCs	O	O
(	O	O
MoDCs	B-protein	O
)	O	O
express	O	O
TRAIL	O	O
and	O	O
exhibit	O	O
cytotoxicity	O	O
to	O	O
some	O	O
types	O	O
of	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
partially	O	O
through	O	O
TRAIL	O	O
.	O	O

Moderate	O	O
expression	O	O
of	O	O
TRAIL	O	O
appeared	O	O
on	O	O
CD34DCs	O	O
from	O	O
the	O	O
8th	O	O
day	O	O
of	O	O
culture	O	O
and	O	O
was	O	O
also	O	O
seen	O	O
on	O	O
freshly	O	O
isolated	O	O
monocytes	B-cell_type	O
.	O	O

The	O	O
level	O	O
of	O	O
TRAIL	O	O
expression	O	O
remained	O	O
constant	O	O
until	O	O
DC	O	O
maturation	O	O
.	O	O

TRAIL	O	O
expression	O	O
on	O	O
immature	O	O
CD34DCs	O	O
or	O	O
MoDCs	O	O
was	O	O
greatly	O	O
up-regulated	O	O
after	O	O
IFN-beta	O	O
stimulation	O	O
.	O	O

Moreover	O	O
,	O	O
IFN-beta	O	O
could	O	O
strikingly	O	O
enhance	O	O
the	O	O
ability	O	O
of	O	O
CD34DCs	O	O
or	O	O
MoDCs	O	O
to	O	O
kill	O	O
TRAIL-sensitive	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
,	O	O
but	O	O
LPS	O	O
did	O	O
not	O	O
have	O	O
such	O	O
an	O	O
effect	O	O
.	O	O

The	O	O
up-regulation	O	O
of	O	O
TRAIL	O	O
on	O	O
IFN-beta	O	O
-stimulated	O	O
DCs	O	O
partially	O	O
contributed	O	O
to	O	O
the	O	O
increased	O	O
cytotoxicity	O	O
of	O	O
DCS	O	O
:	O	O
Pretreatment	O	O
of	O	O
TRAIL-sensitive	B-cell_type	O
tumor	I-cell_type	O
cells	I-cell_type	O
with	O	O
caspase-3	O	O
inhibitor	O	O
could	O	O
significantly	O	O
increase	O	O
their	O	O
resistance	O	O
to	O	O
the	O	O
cytotoxicity	O	O
of	O	O
IFN-beta	O	O
-stimulated	O	O
DCS	O	O
:	O	O
In	O	O
contrast	O	O
,	O	O
NF-kappaB	O	O
inhibitor	O	O
could	O	O
significantly	O	O
increase	O	O
the	O	O
sensitivity	O	O
of	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
to	O	O
the	O	O
killing	O	O
by	O	O
nonstimulated	O	O
or	O	O
LPS-stimulated	O	O
DCS	O	O
:	O	O
Our	O	O
studies	O	O
demonstrate	O	O
that	O	O
IFN-beta	O	O
-stimulated	O	O
DCs	O	O
are	O	O
functionally	O	O
cytotoxic	O	O
.	O	O

Thus	O	O
,	O	O
an	O	O
innate	O	O
mechanism	O	O
of	O	O
DC-mediated	O	O
antitumor	O	O
immunity	O	O
might	O	O
exist	O	O
in	O	O
vivo	O	O
in	O	O
which	O	O
DCs	O	O
act	O	O
as	O	O
effectors	O	O
to	O	O
directly	O	O
kill	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
partially	O	O
via	O	O
TRAIL	O	O
.	O	O

Subsequently	O	O
,	O	O
DCs	O	O
act	O	O
as	O	O
APCs	O	O
involved	O	O
in	O	O
the	O	O
uptake	O	O
,	O	O
processing	O	O
,	O	O
and	O	O
presentation	O	O
of	O	O
apoptotic	O	O
tumor	O	O
Ags	O	O
to	O	O
cross-prime	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
CTL	B-cell_type	O
cells	I-cell_type	O
.	O	O

Tumor	B-cell_type	O
cells	I-cell_type	O
regulate	O	O
the	O	O
lytic	O	O
activity	O	O
of	O	O
tumor-specific	O	O
cytotoxic	O	O
t	O	O
lymphocytes	O	O
by	O	O
modulating	O	O
the	O	O
inhibitory	O	O
natural	I-protein	O
killer	I-protein	O
receptor	I-protein	O
function	O	O
.	O	O

Tumor-infiltrating	O	O
p58+	O	O
T	B-cell_type	O
cells	I-cell_type	O
from	O	O
a	O	O
renal	O	O
tumor	O	O
were	O	O
specifically	O	O
expanded	O	O
in	O	O
response	O	O
to	O	O
tumor	O	O
cell	O	O
stimulation	O	O
and	O	O
cloned	O	O
.	O	O

These	O	O
p58+	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
found	O	O
to	O	O
express	O	O
a	O	O
memory	O	O
phenotype	O	O
and	O	O
corresponded	O	O
to	O	O
clonal	O	O
TCRBV3	O	O
T-cell	O	O
expansion	O	O
.	O	O

Functionally	O	O
,	O	O
p58	O	O
(	O	O
+	O	O
)	O	O
CTLs	O	O
displayed	O	O
a	O	O
low	O	O
lytic	O	O
activity	O	O
for	O	O
HLA-A2	O	O
tumor	O	O
and	O	O
normal	B-cell_type	O
cells	I-cell_type	O
.	O	O

However	O	O
,	O	O
this	O	O
lytic	O	O
activity	O	O
was	O	O
significantly	O	O
increased	O	O
after	O	O
blockade	O	O
of	O	O
p58	O	O
with	O	O
specific	O	O
monoclonal	B-protein	O
antibodies	I-protein	O
.	O	O

Interestingly	O	O
,	O	O
we	O	O
demonstrated	O	O
that	O	O
stimulation	O	O
by	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
was	O	O
required	O	O
to	O	O
trigger	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
p58	O	O
on	O	O
the	O	O
lytic	O	O
activity	O	O
of	O	O
antigen-specific	O	O
CTLs	O	O
and	O	O
that	O	O
stimulation	O	O
of	O	O
the	O	O
inhibitory	O	O
function	O	O
of	O	O
p58	O	O
by	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
correlated	O	O
with	O	O
an	O	O
inhibition	O	O
of	O	O
nuclear	O	O
factor-kappaB	O	O
activation	O	O
in	O	O
p58+	O	O
tumor-specific	O	O
CTLS	O	O
.	O	O

T-cell	O	O
factor-1	O	O
expression	O	O
during	O	O
human	O	O
natural	O	O
killer	O	O
cell	O	O
development	O	O
and	O	O
in	O	O
circulating	O	O
CD56	O	O
(	O	O
+	O	O
)	O	O
bright	B-cell_type	O
natural	I-cell_type	O
killer	I-cell_type	O
cells	I-cell_type	O
.	O	O

Transcription	B-protein	O
factors	I-protein	O
are	O	O
essential	O	O
to	O	O
govern	O	O
differentiation	O	O
along	O	O
the	O	O
lymphoid	O	O
lineage	O	O
from	O	O
uncommitted	O	O
hematopoietic	B-cell_type	O
stem	I-cell_type	O
cells	I-cell_type	O
.	O	O

Although	O	O
many	O	O
of	O	O
these	O	O
transcription	B-protein	O
factors	I-protein	O
have	O	O
putative	O	O
roles	O	O
based	O	O
on	O	O
murine	B-DNA	O
knockout	I-DNA	O
experiments	O	O
,	O	O
their	O	O
function	O	O
in	O	O
human	O	O
lymphoid	O	O
development	O	O
is	O	O
less	O	O
known	O	O
and	O	O
was	O	O
studied	O	O
further	O	O
.	O	O

Transcription	B-protein	O
factor	I-protein	O
expression	O	O
in	O	O
fresh	O	O
and	O	O
cultured	O	O
adult	O	O
human	O	O
bone	O	O
marrow	O	O
and	O	O
umbilical	I-cell_line	O
cord	I-cell_line	O
blood	I-cell_line	O
progenitors	I-cell_line	O
was	O	O
evaluated	O	O
.	O	O

We	O	O
found	O	O
that	O	O
fresh	O	O
CD34	O	O
(	O	O
+	O	O
)	O	O
Lin	O	O
(	O	O
-	O	O
)	O	O
cells	O	O
that	O	O
are	O	O
human	B-protein	O
leukocyte	I-protein	O
antigen	I-protein	O
(	O	O
HLA	B-protein	O
)	I-protein	O
-DR	I-protein	O
(	O	O
-	O	O
)	O	O
or	O	O
CD38	O	O
(	O	O
-	O	O
)	O	O
constitutively	O	O
express	O	O
GATA-3	O	O
but	O	O
not	O	O
T-cell	O	O
factor-1	O	O
(	O	O
TCF-1	O	O
)	O	O
or	O	O
Id-3	O	O
.	O	O

Culture	O	O
with	O	O
the	O	O
murine	O	O
fetal	O	O
liver	O	O
cell	O	O
line	O	O
AFT024	O	O
and	O	O
defined	O	O
cytokines	O	O
was	O	O
capable	O	O
of	O	O
inducing	O	O
TCF-1	B-RNA	O
mRNA	I-RNA	O
.	O	O

However	O	O
,	O	O
no	O	O
T-cell	B-DNA	O
receptor	I-DNA	O
gene	O	O
rearrangement	O	O
was	O	O
identified	O	O
in	O	O
cultured	O	O
progeny	O	O
.	O	O

Id-3	O	O
,	O	O
a	O	O
basic	O	O
helix	O	O
loop	O	O
helix	O	O
factor	O	O
with	O	O
dominant	O	O
negative	O	O
function	O	O
for	O	O
T-cell	O	O
differentiation	O	O
transcription	B-protein	O
factors	I-protein	O
,	O	O
also	O	O
was	O	O
upregulated	O	O
and	O	O
may	O	O
explain	O	O
unsuccessful	O	O
T-cell	O	O
maturation	O	O
.	O	O

To	O	O
better	O	O
understand	O	O
the	O	O
developmental	O	O
link	O	O
between	O	O
natural	B-cell_line	O
killer	I-cell_line	O
(	I-cell_line	O
NK	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
derived	O	O
from	O	O
progenitors	O	O
,	O	O
we	O	O
studied	O	O
NK	O	O
cell	O	O
subsets	O	O
circulating	O	O
in	O	O
blood	O	O
.	O	O

CD56	O	O
(	O	O
+bright	O	O
)	O	O
,	O	O
but	O	O
not	O	O
CD56	O	O
(	O	O
+dim	I-cell_line	O
)	I-cell_line	O
,	O	O
NK	O	O
cells	O	O
constitutively	O	O
express	O	O
TCF-1	O	O
by	O	O
reverse	O	O
transcriptase	O	O
polymerase	O	O
chain	O	O
reaction	O	O
and	O	O
Western	O	O
blot	O	O
analysis	O	O
.	O	O

The	O	O
TCF-1	O	O
isoform	O	O
found	O	O
in	O	O
CD56	B-cell_line	O
(	I-cell_line	O
+bright	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
,	O	O
which	O	O
express	O	O
lectin	O	O
but	O	O
not	O	O
immunoglobulin	O	O
class	B-protein	O
I	I-protein	O
recognizing	O	O
inhibitory	O	O
receptors	I-protein	O
,	O	O
was	O	O
identical	O	O
to	O	O
that	O	O
induced	O	O
in	O	O
NK	O	O
cell	O	O
differentiation	O	O
culture	O	O
and	O	O
was	O	O
distinctly	O	O
different	O	O
from	O	O
isoforms	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
TCF-1	O	O
does	O	O
not	O	O
target	O	O
human	O	O
killer	O	O
immunoglobulin	O	O
receptor	O	O
genes	O	O
,	O	O
TCF-1	O	O
is	O	O
uniquely	O	O
expressed	O	O
in	O	O
circulating	O	O
CD56	O	O
(	O	O
+bright	I-cell_line	O
)	I-cell_line	O
NK	I-cell_line	O
cells	I-cell_line	O
,	O	O
and	O	O
specific	O	O
TCF-1	O	O
isoforms	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
regulating	O	O
NK	O	O
differentiation	O	O
from	O	O
a	O	O
common	O	O
NK/T-cell	O	O
progenitor	O	O
.	O	O

Transcriptional	O	O
activation	O	O
by	O	O
a	O	O
matrix	O	O
associating	I-protein	O
region-binding	I-protein	O
protein	I-protein	O
.	O	O

contextual	O	O
requirements	O	O
for	O	O
the	O	O
function	O	O
of	O	O
bright	O	O
.	O	O

Bright	O	O
(	O	O
B	B-protein	O
cell	O	O
regulator	O	O
of	O	O
IgH	B-protein	O
transcription	O	O
)	O	O
is	O	O
a	O	O
B	O	O
cell	O	O
-specific	O	O
,	O	O
matrix	O	O
associating	O	O
region-binding	O	O
protein	O	O
that	O	O
transactivates	O	O
gene	O	O
expression	O	O
from	O	O
the	O	O
IgH	O	O
intronic	I-protein	O
enhancer	I-protein	O
(	O	O
E	O	O
mu	O	O
)	O	O
.	O	O

We	O	O
show	O	O
here	O	O
that	O	O
Bright	O	O
has	O	O
multiple	O	O
contextual	O	O
requirements	O	O
to	O	O
function	O	O
as	O	O
a	O	O
transcriptional	B-protein	O
activator	I-protein	O
.	O	O

Bright	O	O
can	O	O
not	O	O
transactivate	O	O
via	O	O
out	O	O
of	O	O
context	O	O
,	O	O
concatenated	B-protein	O
binding	I-protein	O
sites	I-protein	O
.	O	O

Transactivation	O	O
is	O	O
maximal	O	O
on	O	O
integrated	O	O
substrates	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
three	O	O
previously	O	O
identified	O	O
binding	B-DNA	O
sites	I-DNA	O
in	O	O
E	O	O
mu	O	O
are	O	O
required	O	O
for	O	O
full	O	O
Bright	O	O
transactivation	O	O
.	O	O

The	O	O
Bright	O	O
DNA	B-protein	O
binding	I-protein	O
domain	I-protein	O
defined	O	O
a	O	O
new	O	O
family	O	O
,	O	O
which	O	O
includes	O	O
SWI1	O	O
,	O	O
a	O	O
component	O	O
of	O	O
the	O	O
SWI.SNF	B-protein	O
complex	I-protein	O
shown	O	O
to	O	O
have	O	O
high	O	O
mobility	O	O
group-like	O	O
DNA	O	O
binding	O	O
characteristics	O	O
.	O	O

Similar	O	O
to	O	O
one	O	O
group	O	O
of	O	O
high	O	O
mobility	O	O
group	O	O
box	O	O
proteins	O	O
,	O	O
Bright	O	O
distorts	O	O
E	O	O
mu	O	O
binding	O	O
site	O	O
-containing	O	O
DNA	O	O
on	O	O
binding	O	O
,	O	O
supporting	O	O
the	O	O
concept	O	O
that	O	O
it	O	O
mediates	O	O
E	O	O
mu	O	O
remodeling	O	O
.	O	O

Transfection	O	O
studies	O	O
further	O	O
implicate	O	O
Bright	O	O
in	O	O
facilitating	O	O
spatially	O	O
separated	O	O
promoter-enhancer	O	O
interactions	O	O
in	O	O
both	O	O
transient	O	O
and	O	O
stable	O	O
assays	O	O
.	O	O

Finally	O	O
,	O	O
we	O	O
show	O	O
that	O	O
overexpression	O	O
of	O	O
Bright	O	O
leads	O	O
to	O	O
enhanced	O	O
DNase	B-protein	O
I	I-protein	O
sensitivity	O	O
of	O	O
the	O	O
endogenous	O	O
E	O	O
mu	O	O
matrix	O	O
associating	O	O
regions	O	O
.	O	O

These	O	O
data	O	O
further	O	O
suggest	O	O
that	O	O
Bright	O	O
may	O	O
contribute	O	O
to	O	O
increased	O	O
gene	O	O
expression	O	O
by	O	O
remodeling	O	O
the	O	O
immunoglobulin	O	O
locus	O	O
during	O	O
B	O	O
cell	O	O
development	O	O
.	O	O

Analysis	O	O
of	O	O
BCL-6	O	O
mutations	O	O
in	O	O
classic	O	O
Hodgkin	O	O
disease	O	O
of	O	O
the	O	O
B-	O	O
and	O	O
T-cell	B-protein	O
type	I-protein	O
.	O	O

BCL-6	O	O
is	O	O
essential	O	O
for	O	O
germinal	O	O
center	O	O
formation	O	O
and	O	O
thus	O	O
for	O	O
affinity	O	O
maturation	O	O
of	O	O
immunoglobulin	O	O
(	O	O
Ig	O	O
)	O	O
genes	O	O
by	O	O
somatic	O	O
mutations	O	O
.	O	O

The	O	O
5'-noncoding	B-DNA	O
region	I-DNA	O
of	O	O
the	O	O
BCL-6	B-DNA	O
gene	I-DNA	O
is	O	O
even	O	O
a	O	O
target	O	O
for	O	O
the	O	O
mutation	O	O
machinery	O	O
.	O	O

Translocations	O	O
of	O	O
the	O	O
BCL-6	B-DNA	O
gene	I-DNA	O
to	O	O
heterologous	O	O
promoters	O	O
and	O	O
mutations	O	O
of	O	O
its	O	O
5'-noncoding	O	O
regulatory	O	O
region	O	O
were	O	O
reported	O	O
to	O	O
be	O	O
potential	O	O
mechanisms	O	O
for	O	O
deregulating	O	O
BCL-6	O	O
expression	O	O
and	O	O
for	O	O
playing	O	O
a	O	O
role	O	O
in	O	O
the	O	O
genesis	O	O
of	O	O
non-Hodgkin	O	O
lymphoma	O	O
.	O	O

In	O	O
line	O	O
with	O	O
this	O	O
hypothesis	O	O
is	O	O
the	O	O
observation	O	O
that	O	O
B-cell	O	O
lymphoma	O	O
with	O	O
somatic	O	O
mutations	O	O
,	O	O
such	O	O
as	O	O
diffuse	O	O
large	O	O
B-cell	O	O
lymphoma	O	O
and	O	O
follicular	O	O
lymphoma	O	O
,	O	O
also	O	O
carry	O	O
BCL-6	O	O
mutations	O	O
,	O	O
some	O	O
of	O	O
which	O	O
are	O	O
recurrently	O	O
detectable	O	O
.	O	O

Classic	O	O
Hodgkin	O	O
disease	O	O
(	O	O
cHD	O	O
)	O	O
is	O	O
also	O	O
derived	O	O
from	O	O
B	O	O
cells	O	O
with	O	O
high	O	O
loads	O	O
of	O	O
somatic	O	O
mutations	O	O
and	O	O
thus	O	O
a	O	O
further	O	O
candidate	O	O
for	O	O
BCL-6	O	O
mutations	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
presence	O	O
and	O	O
potential	O	O
role	O	O
of	O	O
BCL-6	O	O
mutations	O	O
in	O	O
cHD	O	O
,	O	O
the	O	O
5'-noncoding	O	O
BCL-6	O	O
proportion	O	O
of	O	O
single	O	O
Hodgkin	O	O
and	O	O
Reed-Sternberg	O	O
(	O	O
HRS	I-cell_line	O
)	O	O
cells	O	O
from	O	O
6	O	O
cases	O	O
of	O	O
cHD	O	O
and	O	O
6	O	O
cases	O	O
of	O	O
HD-derived	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
was	O	O
analyzed	O	O
.	O	O

All	O	O
B-cell-derived	O	O
HD	O	O
cases	O	O
and	O	O
cell	O	O
lines	O	O
harbored	O	O
BCL-6	O	O
mutations	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
both	O	O
T-cell-derived	O	O
HD	O	O
cases	O	O
and	O	O
cell	O	O
lines	O	O
were	O	O
devoid	O	O
of	O	O
BCL-6	O	O
mutations	O	O
.	O	O

With	O	O
only	O	O
one	O	O
exception	O	O
,	O	O
there	O	O
were	O	O
no	O	O
lymphoma-specific	O	O
recurrent	O	O
BCL-6	O	O
mutations	O	O
detected	O	O
,	O	O
and	O	O
BCL-6	O	O
protein	O	O
was	O	O
absent	O	O
from	O	O
the	O	O
HRS	O	O
cells	O	O
of	O	O
most	O	O
cases	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
(	O	O
1	O	O
)	O	O
somatic	O	O
BCL-6	O	O
mutations	O	O
are	O	O
restricted	O	O
to	O	O
cHD	O	O
cases	O	O
of	O	O
B-cell	O	O
origin	O	O
,	O	O
and	O	O
(	O	O
2	O	O
)	O	O
the	O	O
BCL-6	O	O
mutations	O	O
represent	O	O
mostly	O	O
irrelevant	O	O
somatic	O	O
base	O	O
substitutions	O	O
without	O	O
consequences	O	O
for	O	O
BCL-6	O	O
protein	O	O
expression	O	O
and	O	O
the	O	O
pathogenesis	O	O
of	O	O
cHD	O	O
.	O	O

Gadd45gamma	O	O
is	O	O
dispensable	O	O
for	O	O
normal	O	O
mouse	O	O
development	O	O
and	O	O
T-cell	O	O
proliferation	O	O
.	O	O

Gadd45gamma	O	O
,	O	O
a	O	O
family	O	O
member	O	O
of	O	O
the	O	O
growth	O	O
arrest	B-protein	O
and	I-protein	O
DNA	I-protein	O
damage-inducible	I-protein	O
gene	I-protein	O
family	I-protein	O
45	O	O
(	O	O
Gadd45	O	O
)	O	O
,	O	O
is	O	O
strongly	O	O
induced	O	O
by	O	O
interleukin-2	B-protein	O
(	O	O
IL-2	B-protein	O
)	O	O
in	O	O
peripheral	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

While	O	O
in	O	O
most	O	O
tissues	O	O
all	O	O
Gadd45	O	O
family	O	O
members	O	O
are	O	O
expressed	O	O
,	O	O
Gadd45gamma	O	O
is	O	O
the	O	O
only	O	O
member	O	O
that	O	O
is	O	O
induced	O	O
by	O	O
IL-2	B-protein	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
the	O	O
IL-2	B-protein	O
-induced	O	O
expression	O	O
of	O	O
Gadd45gamma	O	O
is	O	O
dependent	O	O
on	O	O
a	O	O
signaling	O	O
pathway	O	O
mediated	O	O
by	O	O
the	O	O
tyrosine	B-protein	O
kinase	I-protein	O
Jak3	I-protein	O
and	O	O
the	O	O
transcription	B-protein	O
factors	I-protein	O
Stat5a	I-protein	O
and	O	O
Stat5b	O	O
(	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
)	O	O
.	O	O

Previous	O	O
studies	O	O
with	O	O
ectopically	O	O
overexpressed	O	O
Gadd45gamma	O	O
in	O	O
various	O	O
cell	I-cell_line	O
lines	I-cell_line	O
implicated	O	O
its	O	O
function	O	O
in	O	O
negative	O	O
growth	O	O
control	O	O
.	O	O

To	O	O
analyze	O	O
the	O	O
physiological	O	O
role	O	O
of	O	O
Gadd45gamma	O	O
we	O	O
used	O	O
homologous	O	O
recombination	O	O
to	O	O
generate	O	O
mice	O	O
lacking	O	O
Gadd45gamma	O	O
.	O	O

Gadd45gamma	O	O
-deficient	O	O
mice	O	O
develop	O	O
normally	O	O
,	O	O
are	O	O
indistinguishable	O	O
from	O	O
their	O	O
littermates	O	O
,	O	O
and	O	O
are	O	O
fertile	O	O
.	O	O

Furthermore	O	O
,	O	O
hematopoiesis	O	O
in	O	O
mice	O	O
lacking	O	O
Gadd45gamma	O	O
is	O	O
not	O	O
impaired	O	O
and	O	O
Gadd45gamma	O	O
-deficient	O	O
T	O	O
lymphocytes	O	O
show	O	O
normal	O	O
responses	O	O
to	O	O
IL-2	B-protein	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
Gadd45gamma	O	O
is	O	O
not	O	O
essential	O	O
for	O	O
normal	O	O
mouse	O	O
development	O	O
and	O	O
hematopoiesis	O	O
,	O	O
possibly	O	O
due	O	O
to	O	O
functional	O	O
redundancy	O	O
among	O	O
the	O	O
Gadd45	O	O
family	O	O
members	O	O
.	O	O

Gadd45gamma	O	O
is	O	O
also	O	O
dispensable	O	O
for	O	O
IL-2	B-protein	O
-induced	O	O
T-cell	O	O
proliferation	O	O
.	O	O

Decreased	O	O
expression	O	O
of	O	O
c-myc	B-protein	O
family	I-protein	O
genes	I-DNA	O
in	O	O
thymuses	O	O
from	O	O
myasthenia	O	O
gravis	O	O
patients	O	O
.	O	O

The	O	O
thymus	O	O
is	O	O
a	O	O
critical	O	O
organ	O	O
for	O	O
the	O	O
elimination	O	O
of	O	O
autoreactive	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
by	O	O
apoptosis	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
expression	O	O
of	O	O
apoptosis-associated	B-DNA	O
genes	I-DNA	O
,	O	O
bcl-xL	O	O
,	O	O
bad	O	O
,	O	O
caspase-3	O	O
,	O	O
and	O	O
c-myc	B-protein	O
family	I-protein	O
genes	O	O
in	O	O
myasthenia	O	O
gravis	O	O
(	O	O
MG	O	O
)	O	O
thymuses	O	O
.	O	O

We	O	O
observed	O	O
that	O	O
the	O	O
mRNA	B-RNA	O
levels	O	O
of	O	O
myc	B-protein	O
family	I-protein	O
genes	I-protein	O
,	O	O
c-myc	B-protein	O
and	O	O
max	O	O
,	O	O
were	O	O
markedly	O	O
reduced	O	O
in	O	O
MG	O	O
thymuses	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
c-myc	B-protein	O
-mediated	O	O
signaling	O	O
is	O	O
abnormal	O	O
in	O	O
MG	O	O
thymuses	O	O
.	O	O

The	O	O
levels	O	O
of	O	O
molecules	O	O
whose	O	O
expressions	O	O
are	O	O
associated	O	O
with	O	O
myc	O	O
,	O	O
such	O	O
as	O	O
STAM	O	O
,	O	O
prothymosin-alpha	O	O
,	O	O
and	O	O
NFkappaB	O	O

Immunohistochemical	O	O
detection	O	O
of	O	O
interferon-gamma-producing	B-cell_type	O
cells	I-cell_type	O
in	O	O
dermatophytosis	O	O
.	O	O

Skin	O	O
lesions	O	O
of	O	O
dermatophytosis	O	O
are	O	O
thought	O	O
to	O	O
be	O	O
a	O	O
result	O	O
of	O	O
a	O	O
T	B-cell_type	O
cell	I-cell_type	O
-dependent	O	O
inflammatory	O	O
response	O	O
that	O	O
is	O	O
mediated	O	O
by	O	O
various	O	O
cytokines	B-protein	O
.	O	O

We	O	O
examined	O	O
whether	O	O
IFN-gamma-positive	B-cell_type	O
cells	I-cell_type	O
(	O	O
as	O	O
expression	O	O
of	O	O
Th1	O	O
response	O	O
)	O	O
were	O	O
present	O	O
in	O	O
the	O	O
skin	O	O
lesions	O	O
of	O	O
dermatophytosis	O	O
in	O	O
situ	O	O
by	O	O
immunohistochemical	O	O
techniques	O	O
.	O	O

Mixtures	O	O
of	O	O
CD4-positive	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
and	O	O
CD8-positive	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
found	O	O
to	O	O
be	O	O
present	O	O
in	O	O
the	O	O
dermal	O	O
infiltrates	O	O
of	O	O
the	O	O
lesions	O	O
.	O	O

Considerable	O	O
numbers	O	O
of	O	O
CD1a-positive	B-cell_type	O
cells	I-cell_type	O
were	O	O
detected	O	O
in	O	O
the	O	O
upper	O	O
dermis	O	O
and	O	O
epidermis	O	O
.	O	O

A	O	O
marked	O	O
accumulation	O	O
of	O	O
CD68-positive	B-cell_type	O
cells	I-cell_type	O
was	O	O
found	O	O
in	O	O
the	O	O
upper	O	O
dermis	O	O
.	O	O

IFN-gamma-positive	B-cell_type	O
cells	I-cell_type	O
were	O	O
present	O	O
in	O	O
the	O	O
upper	O	O
dermis	O	O
of	O	O
the	O	O
lesions	O	O
.	O	O

The	O	O
pattern	O	O
of	O	O
IFN-gamma	B-protein	O
staining	O	O
appeared	O	O
to	O	O
be	O	O
intracellular	O	O
in	O	O
mononuclear	B-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
staining	O	O
was	O	O
considered	O	O
to	O	O
be	O	O
highly	O	O
specific	O	O
because	O	O
it	O	O
could	O	O
be	O	O
completely	O	O
blocked	O	O
by	O	O
preabsorption	O	O
with	O	O
recombinant	O	O
IFN-gamma	B-protein	O
.	O	O

Our	O	O
data	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
skin	O	O
lesions	O	O
of	O	O
dermatophytosis	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
Th1	O	O
response	O	O
.	O	O

Th1	O	O
response	O	O
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
IFN-gamma	B-protein	O
release	O	O
,	O	O
is	O	O
thought	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
host	O	O
defense	O	O
against	O	O
dermatophytes	O	O
and	O	O
to	O	O
reflect	O	O
cutaneous	O	O
reaction	O	O
in	O	O
dermatophytosis	O	O
.	O	O

Regulation	O	O
of	O	O
the	O	O
helix-loop-helix	B-protein	O
proteins	I-protein	O
,	O	O
E2A	O	O
and	O	O
Id3	O	O
,	O	O
by	O	O
the	O	O
Ras	B-protein	O
-	I-protein	O
ERK	O	O
MAPK	O	O
cascade	O	O
.	O	O

Activation	O	O
of	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
(	O	O
MAPK	B-protein	O
)	O	O
pathways	O	O
leads	O	O
to	O	O
cellular	O	O
differentiation	O	O
and/or	O	O
proliferation	O	O
in	O	O
a	O	O
wide	O	O
variety	O	O
of	O	O
cell	O	O
types	O	O
,	O	O
including	O	O
developing	O	O
thymocytes	B-cell_type	O
.	O	O

The	O	O
basic	B-protein	O
helix-loop-helix	I-protein	O
(	O	O
bHLH	B-protein	O
)	I-protein	O
proteins	I-protein	O
E12	O	O
and	O	O
E47	O	O
and	O	O
an	O	O
inhibitor	O	O
HLH	B-protein	O
protein	I-protein	O
,	O	O
Id3	O	O
,	O	O
play	O	O
key	O	O
roles	O	O
in	O	O
thymocyte	O	O
differentiation	O	O
.	O	O

We	O	O
show	O	O
here	O	O
that	O	O
E2A	O	O
DNA	O	O
binding	O	O
is	O	O
lowered	O	O
in	O	O
primary	O	O
immature	O	O
thymocytes	O	O
consequent	O	O
to	O	O
T	O	O
cell	B-protein	O
receptor	I-protein	O
(	O	O
TCR	B-protein	O
)	O	O
-mediated	O	O
ligation	O	O
.	O	O

Whereas	O	O
expression	O	O
of	O	O
E2A	O	O
mRNA	I-RNA	O
and	O	O
protein	O	O
are	O	O
unaltered	O	O
,	O	O
Id3	O	O
transcripts	O	O
are	O	O
rapidly	O	O
induced	O	O
upon	O	O
signaling	O	O
from	O	O
the	O	O
TCR	B-protein	O
.	O	O

Activation	O	O
of	O	O
Id3	B-protein	O
transcription	O	O
is	O	O
regulated	O	O
in	O	O
a	O	O
dose-dependent	O	O
manner	O	O
by	O	O
the	O	O
extracellular	B-protein	O
signal-regulated	I-protein	O
kinase	I-protein	O
(	O	O
ERK	O	O
)	O	O
MAPK	O	O
module	O	O
.	O	O

These	O	O
observations	O	O
directly	O	O
connect	O	O
the	O	O
ERK	O	O
MAPK	O	O
cascade	O	O
and	O	O
HLH	O	O
proteins	O	O
in	O	O
a	O	O
linear	O	O
pathway	O	O
.	O	O

Retinoic	O	O
acid	O	O
up-regulates	O	O
myeloid	O	O
ICAM-3	O	O
expression	O	O
and	O	O
function	O	O
in	O	O
a	O	O
cell-specific	O	O
fashion	O	O
--	O	O
evidence	O	O
for	O	O
retinoid	O	O
signaling	O	O
pathways	O	O
in	O	O
the	O	O
mast	O	O
cell	O	O
lineage	O	O
.	O	O

Investigation	O	O
of	O	O
mast	O	O
cell	O	O
responsiveness	O	O
toward	B-protein	O
retinoic	I-protein	O
acid	O	O
(	O	O
RA	B-protein	O
)	O	O
revealed	O	O
selective	O	O
promotion	O	O
of	O	O
ICAM-3	O	O
expression	O	O
in	O	O
the	O	O
human	B-cell_line	O
mast	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
HMC-1	O	O
.	O	O

This	O	O
process	O	O
was	O	O
dose-	O	O
and	O	O
time-dependent	O	O
and	O	O
detectable	O	O
by	O	O
flow	O	O
cytometry	O	O
,	O	O
Western	O	O
blot	O	O
analysis	O	O
,	O	O
ELISA	O	O
,	O	O
and	O	O
Northern	O	O
blot	O	O
analysis	O	O
.	O	O

ICAM-3	O	O
modulation	O	O
was	O	O
found	O	O
to	O	O
be	O	O
cell-type	O	O
dependent	O	O
,	O	O
detectable	O	O
also	O	O
for	O	O
HL-60	O	O
cells	I-cell_type	O
and	O	O
monocytes	B-cell_type	O
but	O	O
not	O	O
U-937	O	O
and	O	O
only	O	O
weakly	O	O
for	O	O
KU812	O	O
cells	O	O
.	O	O

Terminally	O	O
differentiated	O	O
skin	O	O
mast	B-cell_type	O
cells	I-cell_type	O
also	O	O
failed	O	O
to	O	O
up-modulate	O	O
their	O	O
ICAM-3	O	O
,	O	O
suggesting	O	O
the	O	O
requirement	O	O
for	O	O
some	O	O
degree	O	O
of	O	O
immaturity	O	O
for	O	O
the	O	O
process	O	O
.	O	O

RA-mediated	O	O
effects	O	O
on	O	O
ICAM-1	O	O
expression	O	O
,	O	O
studied	O	O
in	O	O
parallel	O	O
,	O	O
were	O	O
clearly	O	O
distinct	O	O
from	O	O
those	O	O
on	O	O
ICAM-3	O	O
.	O	O

Investigation	O	O
of	O	O
retinoid	B-protein	O
receptor	I-protein	O
expression	O	O
,	O	O
known	O	O
to	O	O
mediate	O	O
intracellular	O	O
RA	O	O
signaling	O	O
,	O	O
revealed	O	O
presence	O	O
of	O	O
RAR	O	O
alpha	B-protein	O
,	O	O
RAR	O	O
gamma	O	O
,	O	O
RXR	O	O
beta	O	O
,	O	O
and	O	O
RXR	O	O
gamma	O	O
transcripts	O	O
in	O	O
all	O	O
cell	B-cell_line	O
lines	I-cell_line	O
studied	O	O
,	O	O
and	O	O
HMC-1	O	O
cells	O	O
were	O	O
the	O	O
only	O	O
line	O	O
lacking	O	O
RXR	O	O
alpha	O	O
.	O	O

RAR	B-protein	O
beta	I-protein	O
,	O	O
not	O	O
expressed	O	O
at	O	O
baseline	O	O
,	O	O
was	O	O
induced	O	O
by	O	O
RA	O	O
in	O	O
a	O	O
fashion	O	O
obviously	O	O
correlating	O	O
with	O	O
ICAM-3	O	O
up-regulation	O	O
.	O	O

Increased	O	O
ICAM-3	O	O
expression	O	O
was	O	O
of	O	O
functional	O	O
significance	O	O
,	O	O
such	O	O
that	O	O
processes	O	O
stimulated	O	O
or	O	O
co-stimulated	O	O
via	O	O
ICAM-3	O	O
(	O	O
homotypic	B-protein	O
aggregation	I-protein	O
,	O	O
IL-8	O	O
secretion	O	O
)	O	O
were	O	O
clearly	O	O
enhanced	O	O
upon	O	O
RA	O	O
pretreatment	O	O
,	O	O
suggesting	O	O
that	O	O
RA	O	O
may	O	O
contribute	O	O
via	O	O
hitherto	O	O
unrecognized	O	O
pathways	O	O
to	O	O
immune	O	O
function	O	O
and	O	O
host	O	O
defense	O	O
.	O	O

CD28	O	O
and	O	O
T	O	O
cell	O	O
co-stimulation	O	O
.	O	O

Over	O	O
the	O	O
last	O	O
decade	O	O
the	O	O
concept	O	O
of	O	O
T	O	O
cell	O	O
co-stimulation	O	O
has	O	O
emerged	O	O
to	O	O
take	O	O
a	O	O
central	O	O
role	O	O
in	O	O
the	O	O
process	O	O
of	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

However	O	O
,	O	O
the	O	O
exact	O	O
definition	O	O
of	O	O
co-stimulation	O	O
is	O	O
still	O	O
unclear	O	O
.	O	O

In	O	O
this	O	O
review	O	O
,	O	O
we	O	O
re-examine	O	O
the	O	O
concept	O	O
of	O	O
co-stimulation	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
while	O	O
co-stimulation	O	O
is	O	O
important	O	O
,	O	O
there	O	O
is	O	O
little	O	O
evidence	O	O
to	O	O
link	O	O
co-stimulation	O	O
with	O	O
T	O	O
cell	O	O
anergy	O	O
.	O	O

We	O	O
then	O	O
suggest	O	O
a	O	O
framework	O	O
for	O	O
studying	O	O
co-stimulation	O	O
.	O	O

Focusing	O	O
on	O	O
recent	O	O
advances	O	O
in	O	O
our	O	O
understanding	O	O
of	O	O
CD28	B-protein	O
,	O	O
we	O	O
discuss	O	O
four	O	O
areas	O	O
of	O	O
T	O	O
cell	O	O
activation	O	O
where	O	O
co-stimulation	O	O
may	O	O
play	O	O
a	O	O
role	O	O
.	O	O

Regulation	O	O
of	O	O
activator	B-protein	O
protein-1	I-protein	O
and	O	O
NF-kappa	B-protein	O
B	I-protein	O
in	O	O
CD8+	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
exposed	O	O
to	O	O
peripheral	O	O
self-antigens	O	O
.	O	O

The	O	O
transcriptional	O	O
events	O	O
that	O	O
control	O	O
T	O	O
cell	O	O
tolerance	O	O
to	O	O
peripheral	O	O
self	O	O
Ags	O	O
are	O	O
still	O	O
unknown	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
analyzed	O	O
the	O	O
regulation	O	O
of	O	O
AP-1	B-protein	O
-	O	O
and	O	O
NF-kappa	B-protein	O
B	I-protein	O
-mediated	O	O
transcription	O	O
during	O	O
in	O	O
vivo	O	O
induction	O	O
of	O	O
tolerance	O	O
to	O	O
a	O	O
self	O	O
Ag	O	O
expressed	O	O
exclusively	O	O
on	O	O
hepatocytes	O	O
.	O	O

Naive	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
Desire	O	O
(	O	O
Des	O	O
)	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
isolated	O	O
from	O	O
the	O	O
Des	O	O
TCR-transgenic	O	O
mice	O	O
that	O	O
are	O	O
specific	O	O
for	O	O
the	O	O
H-2K	B-protein	O
(	O	O
b	B-protein	O
)	I-protein	O
class	I-protein	O
I	I-protein	O
Ag	O	O
were	O	O
transferred	O	O
into	O	O
Alb-K	O	O
(	O	O
b	O	O
)	O	O
-transgenic	O	O
mice	O	O
that	O	O
express	O	O
the	O	O
H-2K	O	O
(	O	O
b	O	O
)	O	O
Ag	O	O
on	O	O
hepatocytes	O	O
only	O	O
.	O	O

Tolerance	O	O
develops	O	O
in	O	O
these	O	O
mice	O	O
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
self-reactive	B-protein	O
CD8	I-protein	O
(	O	O
+	O	O
)	O	O
Des	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
transiently	O	O
activated	O	O
,	O	O
then	O	O
became	O	O
unresponsive	O	O
and	O	O
were	O	O
further	O	O
deleted	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
Des	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
activated	O	O
in	O	O
vivo	O	O
with	O	O
APCs	O	O
,	O	O
which	O	O
express	O	O
high	O	O
AP-1	B-protein	O
and	O	O
high	O	O
NF-kappa	B-protein	O
B	I-protein	O
transcriptional	O	O
activity	O	O
,	O	O
the	O	O
unresponsive	O	O
CD8	I-protein	O
(	O	O
+	O	O
)	O	O
Des	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
expressed	O	O
no	O	O
AP-1	O	O
and	O	O
only	O	O
weak	O	O
NF-kappa	B-protein	O
B	I-protein	O
transcriptional	O	O
activity	O	O
.	O	O

The	O	O
differences	O	O
in	O	O
NF-kappa	B-protein	O
B	I-protein	O
transcriptional	O	O
activity	O	O
correlated	O	O
with	O	O
the	O	O
generation	O	O
of	O	O
distinct	O	O
NF-kappa	B-protein	O
B	I-protein	O
complexes	I-protein	O
.	O	O

Indeed	O	O
,	O	O
in	O	O
vivo	O	O
primed	O	O
T	B-cell_type	O
cells	I-cell_type	O
predominantly	O	O
express	O	O
p50/p50	O	O
and	O	O
p65/p50	O	O
dimers	O	O
,	O	O
whereas	O	O
these	O	O
p50-containing	O	O
complexes	O	O
are	O	O
barely	O	O
detectable	O	O
in	O	O
tolerant	O	O
T	B-cell_type	O
cells	I-cell_type	O
that	O	O
express	O	O
p65-	O	O
and	O	O
c-Rel-containing	O	O
complexes	O	O
.	O	O

These	O	O
observations	O	O
suggest	O	O
that	O	O
fine	O	O
regulation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
complex	I-protein	O
formation	O	O
may	O	O
determine	O	O
T	O	O
cell	O	O
fate	O	O
.	O	O

Transcriptional	O	O
regulation	O	O
in	O	O
lymphocytes	I-cell_type	O
.	O	O

Lymphocytes	O	O
have	O	O
been	O	O
used	O	O
to	O	O
investigate	O	O
many	O	O
cellular	O	O
processes	O	O
,	O	O
including	O	O
lineage	O	O
commitment	O	O
,	O	O
differentiation	O	O
,	O	O
proliferation	O	O
and	O	O
apoptosis	O	O
.	O	O

The	O	O
transcription	B-protein	O
factors	I-protein	O
that	O	O
mediate	O	O
these	O	O
processes	O	O
are	O	O
often	O	O
expressed	O	O
broadly	O	O
in	O	O
many	B-cell_type	O
cell	I-cell_type	O
types	I-cell_type	O
.	O	O

The	O	O
emerging	O	O
theme	O	O
is	O	O
one	O	O
of	O	O
cell-type-specific	O	O
regulation	O	O
,	O	O
affecting	O	O
not	O	O
only	O	O
the	O	O
functional	O	O
activation	O	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
but	O	O
also	O	O
their	O	O
access	O	O
to	O	O
appropriate	O	O
regions	O	O
of	O	O
DNA	O	O
.	O	O

Existence	O	O
of	O	O
retinoic	O	O
acid-receptor	O	O
-independent	O	O
retinoid	O	O
X-receptor	O	O
-dependent	O	O
pathway	O	O
in	O	O
myeloid	O	O
cell	O	O
function	O	O
.	O	O

We	O	O
previously	O	O
reported	O	O
that	O	O
ER-27191	O	O
(	O	O
4-	O	O
[	O	O
4	O	O
,	O	O
5	O	O
,	O	O
7	O	O
,	O	O
8	O	O
,	O	O
9	O	O
,	O	O
10-hexahydro-7	O	O
,	O	O
7	O	O
,	O	O
10	O	O
,	O	O
10-tetramethyl-1-	O	O
(	O	O
3-pyridylmethyl	O	O
)	O	O
anthra	O	O
[	O	O
1	O	O
,	O	O
2-b	O	O
]	O	O
pyrrol-3-yl	O	O
]	O	O
benzoic	O	O
acid	O	O
)	O	O
is	O	O
a	O	O
potent	O	O
antagonist	O	O
of	O	O
retinoic	O	O
acid	O	O
receptor	O	O
(	O	O
RAR	O	O
)	O	O
,	O	O
and	O	O
ER-35795	O	O
(	O	O
(	O	O
2E	O	O
,	O	O
4E	O	O
,	O	O
6E	O	O
)	O	O
-7-	O	O
[	O	O
1-	O	O
(	O	O
1-methylethyl	O	O
)	O	O
-8-chloro-1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
4-tetrahydroquinolin-6-yl	O	O
]	O	O
-6-fluoro-3-methyl-2	O	O
,	O	O
4	O	O
,	O	O
6-nonatrienoic	O	O
acid	O	O
)	O	O
is	O	O
a	O	O
novel	O	O
retinoid	O	O
X	B-protein	O
receptor	I-protein	O
(	O	O
RXR	O	O
)	O	O
-specific	O	O
agonist	O	O
.	O	O

By	O	O
using	O	O
these	O	O
compounds	O	O
,	O	O
we	O	O
investigated	O	O
whether	O	O
distinct	O	O
RAR	O	O
-dependent	O	O
and	O	O
RXR	O	O
-dependent	O	O
pathways	O	O
operate	O	O
to	O	O
mediate	O	O
the	O	O
diverse	O	O
activities	O	O
of	O	O
retinoids	B-protein	O
,	O	O
particularly	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
RXR	O	O
pathway	O	O
on	O	O
cellular	O	O
function	O	O
.	O	O

ER-27191	O	O
completely	O	O
antagonized	O	O
HL60	O	O
cell	O	O
differentiation	O	O
induced	O	O
by	O	O
all-trans-retinoic	O	O
acid	O	O
(	O	O
atRA	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
differentiation	O	O
induced	O	O
by	O	O
the	O	O
ER-35795	O	O
was	O	O
not	O	O
antagonized	O	O
at	O	O
all	O	O
by	O	O
the	O	O
RAR	O	O
antagonist	O	O
,	O	O
but	O	O
was	O	O
inhibited	O	O
by	O	O
an	O	O
RXR	O	O
homodimer	I-protein	O
antagonist	I-protein	O
(	O	O
LGD100754	B-protein	O
,	O	O
(	O	O
2E	B-protein	O
,	O	O
4E	O	O
,	O	O
6Z	O	O
)	O	O
-7-	O	O
(	O	O
3-n-propoxy-5	O	O
,	O	O
6	O	O
,	O	O
7	O	O
,	O	O
8-tetrahydro-5	O	O
,	O	O
5	O	O
,	O	O
8	O	O
,	O	O
8-tetramethylnaphthalen-2-yl	O	O
)	O	O
-3-methylocta-2	O	O
,	O	O
4	O	O
,	O	O
6-trienoic	O	O
acid	O	O
)	O	O
.	O	O

Its	O	O
agonistic	O	O
action	O	O
on	O	O
RXR/RAR	O	O
heterodimer	O	O
,	O	O
on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
was	O	O
neutralized	O	O
by	O	O
the	O	O
RAR	O	O
antagonist	O	O
.	O	O

During	O	O
HL60	O	O
cell	O	O
differentiation	O	O
,	O	O
atRA	O	O
induced	O	O
RARbeta	O	O
mRNA	O	O
,	O	O
while	O	O
the	O	O
RXR	O	O
had	O	O
no	O	O
effect	O	O
.	O	O

Interestingly	O	O
,	O	O
a	O	O
functional	O	O
RXR	O	O
-pathway	O	O
was	O	O
also	O	O
seen	O	O
in	O	O
lipopolysaccharide-induced	O	O
inhibition	O	O
of	O	O
mouse	O	O
splenocyte	O	O
proliferation	O	O
.	O	O

These	O	O
results	O	O
strongly	O	O
suggest	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
pharmacological	O	O
RXR	O	O
-dependent	O	O
pathway	O	O
that	O	O
is	O	O
activated	O	O
by	O	O
a	O	O
ligand	O	O
that	O	O
can	O	O
bind	O	O
to	O	O
RXR	O	O
.	O	O

Targeting	O	O
Src	O	O
homology	B-protein	O
2	I-protein	O
domain-containing	I-protein	O
tyrosine	O	O
phosphatase	O	O
(	O	O
SHP-1	B-protein	O
)	O	O
into	O	O
lipid	O	O
rafts	O	O
inhibits	O	O
CD3	O	O
-induced	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

To	O	O
study	O	O
the	O	O
mechanism	O	O
by	O	O
which	O	O
protein	O	O
tyrosine	O	O
phosphatases	B-protein	O
(	O	O
PTPs	O	O
)	O	O
regulate	O	O
CD3	O	O
-induced	O	O
tyrosine	O	O
phosphorylation	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
distribution	O	O
of	O	O
PTPs	O	O
in	O	O
subdomains	O	O
of	O	O
plasma	O	O
membrane	O	O
.	O	O

We	O	O
report	O	O
here	O	O
that	O	O
the	O	O
bulk	O	O
PTP	O	O
activity	O	O
associated	O	O
with	O	O
T	O	O
cell	O	O
membrane	O	O
is	O	O
present	O	O
outside	O	O
the	O	O
lipid	O	O
rafts	O	O
,	O	O
as	O	O
determined	O	O
by	O	O
sucrose	O	O
density	O	O
gradient	O	O
sedimentation	O	O
.	O	O

In	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
,	O	O
approximately	O	O
5	O	O
--	O	O
10	O	O
%	O	O
of	O	O
Src	O	O
homology	B-protein	O
2	I-protein	O
domain-containing	I-protein	O
tyrosine	I-protein	O
phosphatase	I-protein	O
(	O	O
SHP-1	B-protein	O
)	O	O
is	O	O
constitutively	O	O
associated	O	O
with	O	O
plasma	O	O
membrane	O	O
,	O	O
and	O	O
nearly	O	O
50	O	O
%	O	O
of	O	O
SHP-2	O	O
is	O	O
translocated	O	O
to	O	O
plasma	O	O
membrane	O	O
after	O	O
vanadate	O	O
treatment	O	O
.	O	O

Similar	O	O
to	O	O
transmembrane	O	O
PTP	O	O
,	O	O
CD45	O	O
,	O	O
the	O	O
membrane-associated	O	O
populations	O	O
of	O	O
SHP-1	O	O
and	O	O
SHP-2	O	O
are	O	O
essentially	O	O
excluded	O	O
from	O	O
lipid	O	O
rafts	O	O
,	O	O
where	O	O
other	O	O
signaling	O	O
molecules	O	O
such	O	O
as	O	O
Lck	O	O
,	O	O
linker	O	O
for	O	O
activation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
and	O	O
CD3	B-protein	O
zeta	I-protein	O
are	O	O
enriched	O	O
.	O	O

We	O	O
further	O	O
demonstrated	O	O
that	O	O
CD3	B-protein	O
-induced	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
these	O	O
substrates	O	O
is	O	O
largely	O	O
restricted	O	O
to	O	O
lipid	O	O
rafts	O	O
,	O	O
unless	O	O
PTPs	O	O
are	O	O
inhibited	O	O
.	O	O

It	O	O
suggests	O	O
that	O	O
a	O	O
restricted	O	O
partition	O	O
of	O	O
PTPs	O	O
among	O	O
membrane	O	O
subdomains	O	O
may	O	O
regulate	O	O
protein	O	O
tyrosine	O	O
phosphorylation	O	O
in	O	O
T	O	O
cell	O	O
membrane	O	O
.	O	O

To	O	O
test	O	O
this	O	O
hypothesis	O	O
,	O	O
we	O	O
targeted	O	O
SHP-1	O	O
into	O	O
lipid	O	O
rafts	O	O
by	O	O
using	O	O
the	O	O
N-terminal	B-protein	O
region	O	O
of	O	O
Lck	O	O
(	O	O
residues	O	O
1	O	O
--	O	O
14	O	O
)	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
expression	O	O
of	O	O
Lck/SHP-1	O	O
chimera	O	O
inside	O	O
lipid	O	O
rafts	O	O
profoundly	O	O
inhibits	O	O
CD3	O	O
-induced	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
CD3	B-protein	O
zeta/epsilon	I-protein	O
,	O	O
IL-2	B-protein	O
generation	O	O
,	O	O
and	O	O
nuclear	O	O
mobilization	O	O
of	O	O
NF-AT	B-protein	O
.	O	O

Collectively	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
exclusion	O	O
of	O	O
PTPs	O	O
from	O	O
lipid	O	O
rafts	O	O
may	O	O
be	O	O
a	O	O
mechanism	O	O
that	O	O
potentiates	O	O
TCR	B-protein	O
/	O	O
CD3	O	O
activation	O	O

An	O	O
instructive	O	O
component	O	O
in	O	O
T	O	O
helper	B-protein	O
cell	I-protein	O
type	I-protein	O
2	I-protein	O
(	O	O
Th2	O	O
)	O	O
development	O	O
mediated	O	O
by	O	O
GATA-3	O	O
.	O	O

Although	O	O
interleukin	B-protein	O
(	O	O
IL	B-protein	O
)	O	O
-12	O	O
and	O	O
IL-4	B-protein	O
polarize	I-protein	O
naive	I-protein	O
CD4	I-protein	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
toward	O	O
T	O	O
helper	B-protein	O
cell	I-protein	O
type	I-protein	O
1	I-protein	O
(	O	O
Th1	B-protein	O
)	O	O
or	O	O
Th2	O	O
phenotypes	O	O
,	O	O
it	O	O
is	O	O
not	O	O
known	O	O
whether	O	O
cytokines	O	O
instruct	O	O
the	O	O
developmental	O	O
fate	O	O
in	O	O
uncommitted	O	O
progenitors	O	O
or	O	O
select	O	O
for	O	O
outgrowth	O	O
of	O	O
cells	O	O
that	O	O
have	O	O
stochastically	O	O
committed	O	O
to	O	O
a	O	O
particular	O	O
fate	O	O
.	O	O

To	O	O
distinguish	O	O
these	O	O
instructive	O	O
and	O	O
selective	B-protein	O
models	O	O
,	O	O
we	O	O
used	O	O
surface	O	O
affinity	O	O
matrix	O	O
technology	O	O
to	O	O
isolate	O	O
committed	O	O
progenitors	O	O
based	O	O
on	O	O
cytokine	O	O
secretion	O	O
phenotype	O	O
and	O	O
developed	O	O
retroviral-based	O	O
tagging	O	O
approaches	O	O
to	O	O
directly	O	O
monitor	O	O
individual	O	O
progenitor	O	O
fate	O	O
decisions	O	O
at	O	O
the	O	O
clonal	O	O
and	O	O
population	O	O
levels	O	O
.	O	O

We	O	O
observe	O	O
IL-4	O	O
-dependent	O	O
redirection	O	O
of	O	O
phenotype	O	O
in	O	O
cells	O	O
that	O	O
have	O	O
already	O	O
committed	O	O
to	O	O
a	O	O
non-IL-4-producing	O	O
fate	O	O
,	O	O
inconsistent	O	O
with	O	O
predictions	O	O
of	O	O
the	O	O
selective	B-protein	O
model	O	O
.	O	O

Further	O	O
,	O	O
retroviral	O	O
tagging	O	O
of	O	O
naive	B-protein	O
progenitors	I-protein	O
with	O	O
the	O	O
Th2-specific	B-protein	O
transcription	I-protein	O
factor	I-protein	O
GATA-3	O	O
provided	O	O
direct	O	O
evidence	O	O
for	O	O
instructive	O	O
differentiation	O	O
,	O	O
and	O	O
no	O	O
evidence	O	O
for	O	O
the	O	O
selective	O	O
outgrowth	O	O
of	O	O
cells	I-cell_type	O
committed	O	O
to	O	O
either	O	O
the	O	O
Th1	O	O
or	O	O
Th2	O	O
fate	O	O
.	O	O

These	O	O
data	O	O
would	O	O
seem	O	O
to	O	O
exclude	O	O
selection	O	O
as	O	O
an	O	O
exclusive	O	O
mechanism	O	O
in	O	O
Th1	O	O
/	O	O
Th2	O	O
differentiation	O	O
,	O	O
and	O	O
support	O	O
an	O	O
instructive	O	O
model	O	O
of	O	O
cytokine-driven	O	O
transcriptional	O	O
programming	O	O
of	O	O
cell	O	O
fate	O	O
decisions	O	O
.	O	O

In	O	O
vitro-activated	O	O
human	B-cell_line	O
lupus	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
express	O	O
normal	O	O
estrogen	B-protein	O
receptor	I-protein	O
proteins	I-protein	O
which	O	O
bind	O	O
to	O	O
the	O	O
estrogen	B-DNA	O
response	I-DNA	O
element	I-DNA	O
.	O	O

We	O	O
have	O	O
shown	O	O
that	O	O
estrogen	B-protein	O
receptor	I-protein	O
(	O	O
ERalpha	O	O
,	O	O
ERbeta	O	O
)	O	O
transcripts	O	O
are	O	O
expressed	O	O
in	O	O
SLE	O	O
and	O	O
normal	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
T	O	O
cell	O	O
nuclear	O	O
extracts	O	O
from	O	O
female	O	O
lupus	O	O
patients	O	O
and	O	O
normal	O	O
donors	O	O
were	O	O
tested	O	O
for	O	O
biologically	O	O
active	O	O
ER	B-protein	O
proteins	O	O
capable	O	O
of	O	O
binding	O	O
to	O	O
the	O	O
human	O	O
estrogen	B-DNA	O
response	I-DNA	O
element	I-DNA	O
(	O	O
hERE	O	O
)	O	O
by	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
.	O	O

When	B-cell_line	O
peripheral	I-cell_line	O
blood	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
were	O	O
stimulated	O	O
with	O	O
17beta-estradiol	O	O
(	O	O
E2	B-protein	O
)	O	O
,	O	O
PMA	O	O
and	O	O
ionomycin	O	O
,	O	O
two	O	O
major	O	O
retarded	O	O
bands	O	O
in	O	O
T	O	O
cell	O	O
nuclear	O	O
extracts	O	O
exhibited	O	O
a	O	O
migration	O	O
pattern	O	O
similar	O	O
to	O	O
slow	O	O
migrating	O	O
protein-ERE	O	O
complexes	O	O
in	O	O
human	O	O
breast	O	O
cancer	O	O
cell	O	O
extracts	O	O
.	O	O

T	B-cell_type	O
cells	I-cell_type	O
cultured	O	O
only	O	O
with	O	O
E2	O	O
did	O	O
not	O	O
have	O	O
these	O	O
complexes	O	O
.	O	O

The	O	O
formation	O	O
of	O	O
the	O	O
complexes	O	O
was	O	O
inhibited	O	O
by	O	O
competition	O	O
with	O	O
the	O	O
hERE	O	O
cold	O	O
oligonucleotide	O	O
and	O	O
partially	O	O
with	O	O
anti-ERalpha	B-protein	O
antibodies	I-protein	O
.	O	O

There	O	O
was	O	O
no	O	O
notable	O	O
difference	O	O
in	O	O
the	O	O
migration	O	O
pattern	O	O
of	O	O
ERE-binding	O	O
proteins	O	O
between	O	O
the	O	O
SLE	O	O
and	O	O
normal	O	O
T	O	O
cell	O	O
extracts	O	O
.	O	O

Together	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
activated	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
,	O	O
whether	O	O
lupus-derived	O	O
or	O	O
normal-derived	O	O
,	O	O
contain	O	O
biologically	O	O
active	O	O
ERalpha	O	O
proteins	O	O
.	O	O

Other	B-protein	O
factors	I-protein	O
may	O	O
be	O	O
responsible	O	O
for	O	O
differential	O	O
sensitivity	O	O
of	O	O
lupus	O	O
T	B-cell_type	O
cells	I-cell_type	O
to	O	O
estrogen	O	O
.	O	O

Mechanism	O	O
of	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
protease	O	O
inhibitor	O	O
on	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
alpha	I-protein	O
production	O	O
of	O	O
monocytes	B-cell_type	O
.	O	O

If	O	O
the	O	O
inflammatory	O	O
response	O	O
becomes	O	O
excessive	O	O
or	O	O
uncontrolled	O	O
by	O	O
some	O	O
stimuli	O	O
,	O	O
inappropriate	O	O
inflammatory	O	O
responses	O	O
occur	O	O
.	O	O

Monocytes	O	O
are	O	O
extremely	B-cell_line	O
important	I-cell_line	O
cells	I-cell_line	O
for	O	O
regulating	O	O
the	O	O
cytokine	B-protein	O
network	I-protein	O
and	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
alpha	I-protein	O
(	O	O
TNFalpha	B-protein	O
)	O	O
and	O	O
interleukin-	O	O
(	O	O
IL	O	O
)	O	O
10	O	O
,	O	O
which	O	O
are	O	O
mainly	O	O
synthesized	O	O
by	O	O
monocytes	B-cell_type	O
,	O	O
are	O	O
representative	O	O
cytokines	B-protein	O
that	O	O
play	O	O
a	O	O
central	O	O
role	O	O
in	O	O
the	O	O
cytokine	B-protein	O
network	O	O
.	O	O

Protease	O	O
inhibitors	O	O
such	O	O
as	O	O
gabexate	O	O
mesilate	O	O
(	O	O
GM	B-protein	O
)	O	O
and	O	O
ulinastatin	O	O
(	O	O
UTI	O	O
)	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
have	O	O
various	O	O
beneficial	O	O
effects	O	O
by	O	O
inhibiting	O	O
the	O	O
activation	O	O
of	O	O
leukocytes	O	O
,	O	O
but	O	O
the	O	O
mechanism	O	O
for	O	O
this	O	O
has	O	O
yet	O	O
to	O	O
be	O	O
fully	O	O
elucidated	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
investigated	O	O
the	O	O
mechanism	O	O
of	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
protease	O	O
inhibitors	O	O
on	O	O
the	O	O
proinflammatory	O	O
cytokine	O	O
production	O	O
of	O	O
lipopolysaccharide-	O	O
(	O	O
LPS	O	O
)	O	O
stimulated	O	O
monocytes	B-cell_type	O
.	O	O

LPS-stimulated	O	O
monocytes	B-cell_type	O
were	O	O
treated	O	O
with	O	O
GM	O	O
or	O	O
UTI	O	O
.	O	O

The	O	O
value	O	O
of	O	O
TNFalpha	B-protein	O
and	O	O
IL-10	B-protein	O
in	O	O
the	O	O
culture	O	O
medium	O	O
of	O	O
monocytes	B-cell_type	O
was	O	O
measured	O	O
and	O	O
each	O	O
mRNA	B-RNA	O
expression	O	O
was	O	O
assayed	O	O
.	O	O

The	O	O
inhibitory	O	O
effect	O	O
of	O	O
protease	O	O
inhibitors	O	O
on	O	O
the	O	O
activity	O	O
of	O	O
intracellular	O	O
signal	O	O
transduction	O	O
pathways	O	O
such	O	O
as	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
(	O	O
PKC	B-protein	O
)	O	O
and	O	O
nuclear	B-protein	O
factor	I-protein	O
kappa	I-protein	O
B	I-protein	O
(	O	O
NFkappaB	O	O
)	O	O
were	O	O
also	O	O
evaluated	O	O
.	O	O

GM	O	O
decreased	O	O
the	O	O
TNFalpha	O	O
production	O	O
of	O	O
LPS-stimulated	O	O
monocytes	B-cell_type	O
as	O	O
shown	O	O
by	O	O
the	O	O
inhibition	O	O
of	O	O
mRNA	B-RNA	O
expression	O	O
and	O	O
increased	O	O
the	O	O
IL-10	B-protein	O
production	O	O
of	O	O
LPS-stimulated	B-cell_type	O
monocytes	I-cell_type	O
.	O	O

GM	O	O
also	O	O
suppressed	O	O
the	O	O
NFkappaB	O	O
activity	O	O
of	O	O
LPS-stimulated	B-cell_type	O
monocytes	I-cell_type	O
.	O	O

UTI	O	O
decreased	O	O
the	O	O
TNFalpha	O	O
production	O	O
of	O	O
LPS-stimulated	O	O
monocytes	B-cell_type	O
,	O	O
but	O	O
did	O	O
not	O	O
inhibit	O	O
the	O	O
TNFalpha	O	O
mRNA	I-RNA	O
expression	O	O
.	O	O

The	O	O
present	O	O
study	O	O
shows	O	O
that	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
GM	O	O
on	O	O
the	O	O
TNFalpha	O	O
production	O	O
of	O	O
activated	I-protein	O
human	I-protein	O
monocytes	I-protein	O
is	O	O
mediated	O	O
by	O	O
the	O	O
suppression	O	O
of	O	O
NFkappaB	O	O
activation	O	O
,	O	O
while	O	O
the	O	O
mechanism	O	O
of	O	O
UTI	O	O
inhibiting	O	O
TNFalpha	O	O
production	O	O
of	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
may	O	O
be	O	O
due	O	O
to	O	O
the	O	O
inhibition	O	O
of	O	O
either	O	O
the	O	O
translation	O	O
or	O	O
secretion	O	O
of	O	O
TNFalpha	O	O
.	O	O

Homocysteine	O	O
stimulates	O	O
the	O	O
expression	O	O
of	O	O
monocyte	O	O
chemoattractant	O	O
protein-1	O	O
in	O	O
endothelial	B-cell_type	O
cells	I-cell_type	O
leading	O	O
to	O	O
enhanced	O	O
monocyte	O	O
chemotaxis	O	O
.	O	O

Hyperhomocysteinemia	O	O
has	O	O
been	O	O
identified	O	O
as	O	O
an	O	O
independent	B-protein	O
risk	I-protein	O
factor	I-protein	O
for	O	O
atherosclerosis	O	O
.	O	O

The	O	O
infiltration	O	O
of	O	O
monocytes	B-cell_type	O
into	O	O
the	O	O
arterial	O	O
wall	O	O
is	O	O
one	O	O
of	O	O
the	O	O
key	O	O
events	O	O
during	O	O
atherogenesis	O	O
.	O	O

Monocyte	O	O
chemoattractant	B-protein	O
protein-1	I-protein	O
(	O	O
MCP-1	B-protein	O
)	O	O
is	O	O
a	O	O
potent	O	O
chemokine	O	O
that	O	O
stimulates	O	O
the	O	O
migration	O	O
of	O	O
monocytes	B-cell_type	O
into	O	O
the	O	O
intima	O	O
of	O	O
the	O	O
arterial	O	O
wall	O	O
.	O	O

The	O	O
mechanism	O	O
by	O	O
which	O	O
increased	O	O
monocyte	O	O
infiltration	O	O
occurs	O	O
in	O	O
atherosclerotic	O	O
lesions	O	O
in	O	O
patients	O	O
with	O	O
hyperhomocysteinemia	O	O
has	O	O
not	O	O
been	O	O
delineated	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
homocysteine	O	O
on	O	O
MCP-1	O	O
production	O	O
in	O	O
endothelial	B-cell_type	O
cells	I-cell_type	O
.	O	O

Cells	O	O
were	O	O
incubated	O	O
with	O	O
homocysteine	O	O
.	O	O

The	O	O
secretion	O	O
of	O	O
MCP-1	B-protein	O
protein	I-protein	O
was	O	O
significantly	O	O
increased	O	O
(	O	O
195	O	O
%	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
control	O	O
)	O	O
in	O	O
cells	O	O
treated	O	O
with	O	O
pathological	O	O
concentrations	O	O
of	O	O
homocysteine	O	O
.	O	O

Such	O	O
effect	O	O
was	O	O
accompanied	O	O
by	O	O
an	O	O
increased	O	O
expression	O	O
of	O	O
MCP-1	B-RNA	O
mRNA	I-RNA	O
(	O	O
176	O	O
%	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
control	O	O
)	O	O
in	O	O
endothelial	B-cell_type	O
cells	I-cell_type	O
which	O	O
resulted	O	O
in	O	O
enhanced	O	O
monocyte	O	O
chemotaxis	O	O
.	O	O

The	O	O
p38	O	O
MAP	B-protein	O
kinase	I-protein	O
as	O	O
well	O	O
as	O	O
other	O	O
members	O	O
of	O	O
the	O	O
p38	B-protein	O
MAP	I-protein	O
kinase	I-protein	O
pathway	O	O
,	O	O
including	O	O
MKK3	O	O
,	O	O
MKK6	O	O
,	O	O
ATF-2	O	O
and	O	O
Elk-1	O	O
,	O	O
were	O	O
activated	O	O
in	O	O
homocysteine-treated	B-cell_type	O
cells	I-cell_type	O
.	O	O

Homocysteine-induced	O	O
MCP-1	O	O
expression	O	O
and	O	O
subsequent	O	O
monocyte	O	O
chemotaxis	O	O
were	O	O
blocked	O	O
by	O	O
a	O	O
p38	O	O
MAP	B-protein	O
kinase	I-protein	O
inhibitor	O	O
(	O	O
SB203580	O	O
)	O	O
suggesting	O	O
that	O	O
the	O	O
p38	O	O
MAP	O	O
kinase	O	O
pathway	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
homocysteine-induced	O	O
MCP-1	O	O
expression	O	O
in	O	O
endothelial	B-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
contrast	O	O
,	O	O
staurosporine	O	O
,	O	O
a	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
inhibitor	O	O
,	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
homocysteine-induced	O	O
MCP-1	O	O
expression	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
our	O	O
results	O	O
indicate	O	O
that	O	O
homocysteine	O	O
stimulates	O	O
MCP-1	O	O
expression	O	O
in	O	O
endothelial	B-cell_type	O
cells	I-cell_type	O
leading	O	O
to	O	O
enhanced	O	O
monocyte	O	O
chemotaxis	O	O
.	O	O

Inducible	O	O
resistance	O	O
to	O	O
Fas-mediated	O	O
apoptosis	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

Apoptosis	O	O
produced	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
through	O	O
Fas	O	O
(	O	O
APO-1	O	O
,	O	O
CD95	O	O
)	O	O
triggering	O	O
is	O	O
regulated	O	O
by	O	O
signals	O	O
derived	O	O
from	O	O
other	O	O
surface	O	O
receptors	O	O
:	O	O
CD40	O	O
engagement	O	O
produces	O	O
upregulation	O	O
of	O	O
Fas	O	O
expression	O	O
and	O	O
marked	O	O
susceptibility	O	O
to	O	O
Fas	O	O
-induced	O	O
cell	O	O
death	O	O
,	O	O
whereas	O	O
antigen	O	O
receptor	O	O
engagement	O	O
,	O	O
or	O	O
IL-4R	O	O
engagement	O	O
,	O	O
inhibits	O	O
Fas	O	O
killing	O	O
and	O	O
in	O	O
so	O	O
doing	O	O
induces	O	O
a	O	O
state	O	O
of	O	O
Fas	O	O
-resistance	O	O
,	O	O
even	O	O
in	O	O
otherwise	O	O
sensitive	O	O
,	O	O
CD40	O	O
-stimulated	O	O
targets	O	O
.	O	O

Surface	O	O
immunoglobulin	O	O
and	O	O
IL-4R	O	O
utilize	O	O
at	O	O
least	O	O
partially	O	O
distinct	O	O
pathways	O	O
to	O	O
produce	O	O
Fas	O	O
-resistance	O	O
that	O	O
differentially	O	O
depend	O	O
on	O	O
PKC	O	O
and	O	O
STAT6	O	O
,	O	O
respectively	O	O
.	O	O

Further	O	O
,	O	O
surface	O	O
immunoglobulin	O	O
signaling	O	O
for	O	O
inducible	O	O
Fas	O	O
-resistance	O	O
bypasses	O	O
Btk	O	O
,	O	O
requires	O	O
NF-kappaB	O	O
,	O	O
and	O	O
entails	O	O
new	O	O
macromolecular	O	O
synthesis	O	O
.	O	O

Terminal	O	O
effectors	O	O
of	O	O
B	B-protein	O
cell	O	O
Fas	O	O
-resistance	O	O
include	O	O
the	O	O
known	O	O
anti-apoptotic	O	O
gene	I-DNA	O
products	B-protein	O
,	O	O
Bcl-xL	O	O
and	O	O
FLIP	O	O
,	O	O
and	O	O
a	O	O
novel	O	O
anti-apoptotic	O	O
gene	O	O
that	O	O
encodes	O	O
FAIM	O	O
(	O	O
Fas	O	O
Apoptosis	O	O
Inhibitory	O	O
Molecule	O	O
)	O	O
.	O	O

faim	O	O
was	O	O
identified	O	O
by	O	O
differential	O	O
display	O	O
and	O	O
exists	O	O
in	O	O
two	O	O
alternatively	O	O
spliced	O	O
forms	O	O
;	O	O
faim-S	O	O
is	O	O
broadly	O	O
expressed	O	O
,	O	O
but	O	O
faim-L	O	O
expression	O	O
is	O	O
tissue-specific	O	O
.	O	O

The	O	O
FAIM	B-DNA	O
sequence	I-DNA	O
is	O	O
highly	O	O
evolu-	O	O
tionarily	O	O
conserved	O	O
,	O	O
suggesting	O	O
an	O	O
important	O	O
role	O	O
for	O	O
this	O	O
molecule	O	O
throughout	O	O
phylogeny	O	O
.	O	O

Inducible	O	O
resistance	O	O
to	O	O
Fas	O	O
killing	O	O
is	O	O
hypothesized	O	O
to	O	O
protect	O	O
foreign	O	O
antigen-specific	O	O
B	O	O
cells	O	O
during	O	O
potentially	O	O
hazardous	O	O
interactions	O	O
with	O	O
FasL-bearing	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
whereas	O	O
autoreactive	O	O
B	O	O
cells	O	O
fail	O	O
to	O	O
become	O	O
Fas	O	O
-resistant	O	O
and	O	O
are	O	O
deleted	O	O
via	O	O
Fas	O	O
-dependent	O	O
cytotoxicity	O	O
.	O	O

Inadvertent	O	O
or	O	O
aberrant	O	O
acquisition	O	O
of	O	O
Fas	O	O
-resistance	O	O
may	O	O
permit	O	O
autoreactive	O	O
B	O	O
cells	O	O
to	O	O
escape	O	O
Fas	O	O
deletion	O	O
,	O	O
and	O	O
malignant	O	O
lymphocytes	O	O
to	O	O
impede	O	O
anti-tumor	O	O
immunity	O	O
.	O	O

Stromal	O	O
cell-derived	B-protein	O
factor	I-protein	O
1	O	O
alpha	B-protein	O
-induced	O	O
chemotaxis	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
is	O	O
mediated	O	O
by	O	O
nitric	O	O
oxide	O	O
signaling	O	O
pathways	O	O
.	O	O

Stromal	O	O
cell-derived	B-protein	O
factor	I-protein	O
1	I-protein	O
alpha	I-protein	O
(	O	O
SDF1	B-protein	O
alpha	I-protein	O
)	O	O
and	O	O
its	O	O
cognate	B-protein	O
chemokine	I-protein	O
receptor	I-protein	O
CXCR4	O	O
act	O	O
as	O	O
potent	O	O
chemoattractants	O	O
and	O	O
regulate	O	O
trafficking	O	O
and	O	O
homing	O	O
of	O	O
hematopoietic	B-cell_type	O
progenitor	I-cell_type	O
cells	I-cell_type	O
and	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

However	O	O
,	O	O
the	O	O
molecular	O	O
mechanisms	O	O
regulating	O	O
SDF1	O	O
alpha	O	O
-driven	O	O
cell	O	O
migration	O	O
are	O	O
not	O	O
well	O	O
defined	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
explored	O	O
the	O	O
roles	O	O
of	O	O
the	O	O
second	O	O
messenger	I-protein	O
NO	I-protein	O
and	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappa	B-protein	O
B	I-protein	O
in	O	O
SDF1	O	O
alpha	B-protein	O
-induced	O	O
T	O	O
cell	O	O
migration	O	O
.	O	O

SDF1	O	O
alpha	O	O
treatment	O	O
of	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
increased	O	O
the	O	O
activity	O	O
of	O	O
NO	O	O
synthase	O	O
,	O	O
which	O	O
catalyzes	O	O
the	O	O
generation	O	O
of	O	O
NO	O	O
.	O	O

We	O	O
observed	O	O
that	O	O
pretreatment	O	O
of	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
or	O	O
activated	O	O
PBLs	O	O
with	O	O
several	O	O
NO	O	O
donors	O	O
significantly	O	O
enhanced	O	O
the	O	O
SDF1	B-protein	O
alpha	I-protein	O
-induced	O	O
migration	O	O
,	O	O
whereas	O	O
various	O	O
inhibitors	O	O
of	O	O
NO	O	O
synthase	O	O
markedly	O	O
abrogated	O	O
the	O	O
chemotactic	O	O
response	O	O
in	O	O
a	O	O
concentration-dependent	O	O
manner	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
observed	O	O
that	O	O
inhibitors	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappa	B-protein	O
B	I-protein	O
,	O	O
which	O	O
is	O	O
linked	O	O
to	O	O
NO	O	O
signaling	O	O
pathways	O	O
,	O	O
also	O	O
significantly	O	O
blocked	O	O
the	O	O
SDF1	O	O
alpha	O	O
-induced	O	O
chemotactic	O	O
response	O	O
.	O	O

However	O	O
,	O	O
these	O	O
compounds	O	O
did	O	O
not	O	O
have	O	O
a	O	O
significant	O	O
effect	O	O
on	O	O
SDF1	B-protein	O
alpha	I-protein	O
-induced	I-protein	O
mitogen-activated	I-protein	O
protein	I-protein	O
kinase	I-protein	O
activity	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
MAP/Erk	B-protein	O
kinase	I-protein	O
kinase	I-protein	O
inhibitor	O	O
PD98059	O	O
did	O	O
not	O	O
abrogate	O	O
SDF1	O	O
alpha	O	O
-induced	O	O
chemotaxis	O	O
.	O	O

AKT	O	O
,	O	O
which	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
mediate	O	O
NO	O	O
production	O	O
,	O	O
was	O	O
also	O	O
phosphorylated	O	O
upon	O	O
SDF1	O	O
alpha	O	O
stimulation	O	O
.	O	O

These	O	O
studies	O	O
suggest	O	O
that	O	O
NO-related	O	O
signaling	O	O
pathways	O	O
may	O	O
mediate	O	O
SDF1	O	O
alpha	B-protein	O
-induced	O	O
chemotaxis	O	O
,	O	O
but	O	O
not	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
activation	O	O
.	O	O

The	O	O
lack	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
transactivation	O	O
and	O	O
PKC	O	O
epsilon	O	O
expression	O	O
in	O	O
CD4	B-protein	O
(	O	O
+	O	O
)	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
thymocytes	B-cell_type	O
correlates	O	O
with	O	O
negative	O	O
selection	O	O
.	O	O

Deletion	O	O
of	O	O
autoreactive	O	O
thymocytes	B-cell_type	O
at	O	O
the	O	O
DP	O	O
stage	O	O
is	O	O
the	O	O
basis	O	O
for	O	O
tolerance	O	O
to	O	O
thymus-expressed	O	O
self	O	O
antigens	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
investigated	O	O
whether	O	O
distinct	O	O
signalling	O	O
pathways	O	O
are	O	O
induced	O	O
in	O	O
DP	O	O
thymocytes	O	O
as	O	O
compared	O	O
to	O	O
mature	O	O
T	B-cell_type	O
cells	I-cell_type	O
upon	O	O
stimulation	O	O
with	O	O
antigen	O	O
.	O	O

Using	O	O
triple	O	O
transgenic	O	O
mice	O	O
expressing	O	O
a	O	O
TCR	B-protein	O
transgene	O	O
,	O	O
dominant	O	O
negative	O	O
ras/Mek	B-protein	O
proteins	I-protein	O
and	O	O
a	O	O
reporter	B-DNA	O
gene	I-DNA	O
construct	O	O
with	O	O
AP-1	B-protein	O
or	O	O
NF-kappa	B-protein	O
B	I-protein	O
binding	I-DNA	O
sites	I-DNA	O
,	O	O
we	O	O
showed	O	O
a	O	O
complete	O	O
lack	O	O
of	O	O
transcriptional	O	O
activity	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
but	O	O
not	O	O
AP-1	B-protein	O
in	O	O
DP	O	O
thymocytes	B-cell_type	O
,	O	O
whereas	O	O
both	O	O
were	O	O
transcriptionally	O	O
active	O	O
in	O	O
mature	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
after	O	O
antigenic	O	O
stimulation	O	O
.	O	O

Lack	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
induction	O	O
correlated	O	O
with	O	O
increased	O	O
death	O	O
in	O	O
response	O	O
to	O	O
antigen	O	O
.	O	O

AP-1	B-protein	O
induction	O	O
was	O	O
dependent	O	O
on	O	O
the	O	O
integrity	O	O
of	O	O
the	O	O
ras/Mek	O	O
pathway	O	O
indicating	O	O
that	O	O
this	O	O
pathway	O	O
was	O	O
activated	O	O
in	O	O
the	O	O
DP	O	O
thymocytes	B-cell_type	O
.	O	O

In	O	O
contrast	O	O
,	O	O
we	O	O
found	O	O
a	O	O
complete	O	O
lack	O	O
of	O	O
constitutive	O	O
expression	O	O
of	O	O
the	O	O
epsilon	B-protein	O
isoform	I-protein	O
of	O	O
Protein	B-protein	O
Kinase	I-protein	O
C	I-protein	O
(	O	O
PKC	B-protein	O
)	O	O
in	O	O
DP	O	O
thymocytes	B-cell_type	O
,	O	O
although	O	O
it	O	O
was	O	O
present	O	O
in	O	O
mature	B-cell_type	O
thymocytes	B-cell_type	O
and	O	O
peripheral	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

Taken	O	O
together	O	O
the	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
lack	O	O
of	O	O
PKC	O	O
epsilon	O	O
in	O	O
DP	O	O
thymocytes	B-cell_type	O
could	O	O
lead	O	O
to	O	O
the	O	O
absence	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
activity	O	O
after	O	O
antigenic	O	O
stimulation	O	O
contributing	O	O
to	O	O
negative	O	O
selection	O	O
.	O	O

Cell	O	O
Death	O	O
and	O	O
Differentiation	O	O
(	O	O
2000	O	O
)	O	O
7	O	O
,	O	O
1253	O	O
-	O	O
1262	O	O
.	O	O

CD2	O	O
stimulation	O	O
leads	O	O
to	O	O
the	O	O
delayed	O	O
and	O	O
prolonged	O	O
activation	O	O
of	O	O
STAT1	B-protein	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
but	O	O
not	B-cell_type	O
NK	I-cell_type	O
cells	I-cell_type	O
.	O	O

OBJECTIVE	O	O
:	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
can	O	O
be	O	O
activated	O	O
by	O	O
soluble	B-protein	O
factors	I-protein	O
such	O	O
as	O	O
cytokines	B-protein	O
or	O	O
through	O	O
direct	O	O
cell-cell	O	O
interactions	O	O
.	O	O

Although	O	O
cytokine	B-protein	O
receptors	O	O
are	O	O
known	O	O
to	O	O
signal	O	O
through	O	O
STAT	B-protein	O
family	I-protein	O
transcription	I-protein	O
factors	I-protein	O
,	O	O
the	O	O
mechanisms	O	O
by	O	O
which	O	O
other	O	O
cell-surface	O	O
molecules	O	O
,	O	O
such	O	O
as	O	O
CD2	O	O
,	O	O
transduce	O	O
signals	O	O
is	O	O
unclear	O	O
.	O	O

The	O	O
goal	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
stimulation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
through	O	O
CD2	O	O
recapitulates	O	O
aspects	O	O
of	O	O
cytokine	B-protein	O
-induced	O	O
T-cell	O	O
activation	O	O
by	O	O
use	O	O
of	O	O
STAT	B-protein	O
transcription	I-protein	O
factors	I-protein	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
treated	O	O
with	O	O
anti-CD2	O	O
antibodies	O	O
or	O	O
cells	O	O
bearing	O	O
the	O	O
natural	O	O
CD2	O	O
ligand	O	O
CD58	O	O
,	O	O
after	O	O
which	O	O
signaling	O	O
through	O	O
STAT	O	O
transcription	B-protein	O
factors	I-protein	O
was	O	O
assessed	O	O
.	O	O

RESULTS	O	O
:	O	O
Stimulation	O	O
of	O	O
CD2	O	O
on	O	O
primary	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
leads	O	O
to	O	O
the	O	O
tyrosine	O	O
phosphorylation	O	O
,	O	O
nuclear	O	O
translocation	O	O
,	O	O
and	O	O
DNA	O	O
binding	O	O
of	O	O
STAT1	B-protein	O
.	O	O

In	O	O
contrast	O	O
to	O	O
stimulation	O	O
by	O	O
cytokines	B-protein	O
,	O	O
the	O	O
activation	O	O
of	O	O
STAT1	B-protein	O
in	O	O
response	O	O
to	O	O
CD2	O	O
ligation	O	O
is	O	O
delayed	O	O
and	O	O
does	O	O
not	O	O
involve	O	O
Jak	O	O
kinases	O	O
.	O	O

Furthermore	O	O
,	O	O
while	O	O
STAT	B-protein	O
phosphorylation	O	O
induced	O	O
by	O	O
cytokines	B-protein	O
is	O	O
generally	O	O
transient	O	O
,	O	O
STAT1	B-protein	O
phosphorylation	O	O
following	O	O
CD2	O	O
stimulation	O	O
persists	O	O
for	O	O
a	O	O
period	O	O
of	O	O
days	O	O
.	O	O

Transcription	O	O
of	O	O
key	O	O
target	O	O
genes	B-DNA	O
such	O	O
as	O	O
IRF1	O	O
and	O	O
c-fos	B-DNA	O
proceeds	O	O
with	O	O
delayed	O	O
kinetics	O	O
following	O	O
CD2	O	O
stimulation	O	O
,	O	O
suggesting	O	O
that	O	O
this	O	O
unique	O	O
pattern	O	O
of	O	O
STAT	B-protein	O
activation	O	O
may	O	O
lead	O	O
to	O	O
a	O	O
distinct	O	O
cellular	O	O
response	O	O
following	O	O
CD2	O	O
ligation	O	O
.	O	O

This	O	O
pathway	O	O
appears	O	O
to	O	O
be	O	O
restricted	O	O
to	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
as	O	O
stimulation	O	O
of	O	O
CD2	O	O
on	O	O
NK	I-cell_type	O
cells	I-cell_type	O
does	O	O
not	O	O
lead	O	O
to	O	O
STAT1	B-protein	O
activation	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Stimulation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
through	O	O
cell-surface	O	O
molecules	O	O
such	O	O
as	O	O
CD2	O	O
involves	O	O
activation	O	O
of	O	O
STAT	B-protein	O
transcription	I-protein	O
factors	I-protein	O
,	O	O
thus	O	O
recapitulating	O	O
elements	O	O
of	O	O
cytokine	B-protein	O
signaling	O	O
.	O	O

NFATc1	O	O
and	O	O
NFATc2	O	O
together	O	O
control	O	O
both	O	O
T	O	O
and	O	O
B	O	O
cell	O	O
activation	O	O
and	O	O
differentiation	O	O
.	O	O

NFAT	B-protein	O
transcription	B-protein	O
factors	I-protein	O
play	O	O
critical	O	O
roles	O	O
in	O	O
gene	O	O
transcription	O	O
during	O	O
immune	O	O
responses	O	O
.	O	O

To	O	O
investigate	O	O
further	O	O
the	O	O
two	O	O
most	O	O
prominent	O	O
NFAT	B-protein	O
family	O	O
members	O	O
,	O	O
NFATc1	O	O
and	O	O
NFATc2	O	O
,	O	O
we	O	O
generated	O	O
mice	O	O
bearing	O	O
lymphoid	O	O
systems	O	O
devoid	O	O
of	O	O
both	O	O
.	O	O

Doubly	I-cell_line	O
deficient	I-cell_line	O
T	B-cell_type	O
cells	I-cell_type	O
displayed	O	O
cell	O	O
surface	O	O
markers	O	O
of	O	O
activation	O	O
yet	O	O
were	O	O
significantly	O	O
deficient	O	O
in	O	O
the	O	O
development	O	O
of	O	O
multiple	O	O
effector	O	O
functions	O	O
,	O	O
including	O	O
Th	O	O
cytokine	B-protein	O
production	O	O
,	O	O
surface	O	O
effector	O	O
molecule	O	O
expression	O	O
,	O	O
and	O	O
cytolytic	O	O
activity	O	O
.	O	O

Nevertheless	O	O
,	O	O
doubly	O	O
deficient	O	O
B	B-cell_type	O
cells	I-cell_type	O
were	O	O
hyperactivated	O	O
,	O	O
as	O	O
evidenced	O	O
by	O	O
extremely	O	O
elevated	O	O
serum	O	O
IgG1	O	O
and	O	O
IgE	O	O
,	O	O
as	O	O
well	O	O
as	O	O
plasma	O	O
cell	O	O
expansion	O	O
and	O	O
infiltration	O	O
of	O	O
end	O	O
organs	O	O
.	O	O

Thus	O	O
,	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
NFATc1	O	O
and	O	O
NFATc2	O	O
are	O	O
dispensable	O	O
for	O	O
inflammatory	O	O
reactivity	O	O
but	O	O
are	O	O
required	O	O
for	O	O
effector	O	O
differentiation	O	O
,	O	O
while	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
,	O	O
NFATs	O	O
regulate	O	O
both	O	O
normal	O	O
homeostasis	O	O
and	O	O
differentiation	O	O
.	O	O

Epstein-barr	O	O
virus	O	O
immediate-early	O	O
protein	O	O
BZLF1	O	O
is	O	O
SUMO-1	O	O
modified	O	O
and	O	O
disrupts	O	O
promyelocytic	O	O
leukemia	O	O
bodies	O	O
.	O	O

Although	O	O
the	O	O
immediate-early	O	O
proteins	O	O
of	O	O
both	O	O
herpes	O	O
simplex	O	O
virus	O	O
(	O	O
HSV	O	O
)	O	O
and	O	O
cytomegalovirus	O	O
(	O	O
CMV	O	O
)	O	O
are	O	O
known	O	O
to	O	O
modify	O	O
promyelocytic	O	O
leukemia	O	O
(	O	O
PML	O	O
)	O	O
(	O	O
ND10	O	O
)	O	O
bodies	O	O
in	O	O
the	O	O
nucleus	O	O
of	O	O
the	O	O
host	O	O
cell	O	O
,	O	O
it	O	O
has	O	O
been	O	O
unclear	O	O
whether	O	O
lytic	O	O
infection	O	O
with	O	O
gamma	O	O
herpesviruses	O	O
induces	O	O
a	O	O
similar	O	O
effect	O	O
.	O	O

The	O	O
PML	B-protein	O
protein	I-protein	O
is	O	O
induced	O	O
by	O	O
interferon	O	O
,	O	O
involved	O	O
in	O	O
major	O	O
histocompatibility	O	O
complex	I-protein	O
class	I-protein	O
I	I-protein	O
presentation	O	O
,	O	O
and	O	O
necessary	O	O
for	O	O
certain	O	O
types	O	O
of	O	O
apoptosis	O	O
.	O	O

Therefore	O	O
,	O	O
it	O	O
is	O	O
likely	O	O
that	O	O
PML	O	O
bodies	O	O
function	O	O
in	O	O
an	O	O
antiviral	O	O
capacity	O	O
.	O	O

SUMO-1	O	O
modification	O	O
of	O	O
PML	O	O
is	O	O
known	O	O
to	O	O
be	O	O
required	O	O
for	O	O
the	O	O
formation	O	O
of	O	O
PML	O	O
bodies	O	O
.	O	O

To	O	O
examine	O	O
whether	O	O
Epstein-Barr	O	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
lytic	O	O
replication	O	O
interferes	O	O
with	O	O
PML	O	O
bodies	O	O
,	O	O
we	O	O
expressed	O	O
the	O	O
EBV	O	O
immediate-early	O	O
genes	O	O
BZLF1	O	O
(	O	O
Z	O	O
)	O	O
and	O	O
BRLF1	O	O
(	O	O
R	O	O
)	O	O
in	O	O
EBV-positive	O	O
cell	O	O
lines	O	O
and	O	O
examined	O	O
PML	O	O
localization	O	O
.	O	O

Both	O	O
Z	O	O
and	O	O
R	O	O
expression	O	O
resulted	O	O
in	O	O
PML	O	O
dispersion	O	O
in	O	O
EBV-positive	B-cell_type	O
cells	I-cell_type	O
.	O	O

Z	O	O
but	O	O
not	O	O
R	O	O
expression	O	O
is	O	O
sufficient	O	O
to	O	O
disrupt	O	O
PML	O	O
bodies	O	O
in	O	O
EBV-negative	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

We	O	O
show	O	O
that	O	O
dispersion	O	O
of	O	O
PML	O	O
bodies	O	O
by	O	O
Z	O	O
requires	O	O
a	O	O
portion	O	O
of	O	O
the	O	O
transcriptional	B-protein	O
activation	I-protein	O
domain	I-protein	O
of	O	O
Z	O	O
but	O	O
not	O	O
the	O	O
DNA-binding	O	O
function	O	O
.	O	O

As	O	O
was	O	O
previously	O	O
reported	O	O
for	O	O
the	O	O
HSV-1	O	O
ICP0	O	O
and	O	O
CMV	O	O
IE1	O	O
proteins	O	O
,	O	O
Z	O	O
reduces	O	O
the	O	O
amount	O	O
of	O	O
SUMO-1-modified	O	O
PML	O	O
.	O	O

We	O	O
also	O	O
found	O	O
that	O	O
Z	O	O
itself	O	O
is	O	O
SUMO-1	O	O
modified	O	O
(	O	O
through	O	O
amino	O	O
acid	O	O
12	I-protein	O
)	O	O
and	O	O
that	O	O
Z	O	O
competes	O	O
with	O	O
PML	O	O
for	O	O
limiting	O	O
amounts	O	O
of	O	O
SUMO-1	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
disruption	O	O
of	O	O
PML	O	O
bodies	O	O
is	O	O
important	O	O
for	O	O
efficient	O	O
lytic	O	O
replication	O	O
of	O	O
EBV	O	O
.	O	O

Furthermore	O	O
,	O	O
Z	O	O
may	O	O
potentially	O	O
alter	O	O
the	O	O
function	O	O
of	O	O
a	O	O
variety	O	O
of	O	O
cellular	O	O
proteins	O	O
by	O	O
inhibiting	O	O
SUMO-1	O	O
modification	O	O

Suppression	O	O
of	O	O
nuclear	O	O
factor-kappaB	O	O
and	O	O
stimulation	O	O
of	O	O
inhibitor	O	O
kappaB	O	O
by	O	O
troglitazone	O	O
:	O	O
evidence	O	O
for	O	O
an	O	O
anti-inflammatory	O	O
effect	O	O
and	O	O
a	O	O
potential	O	O
antiatherosclerotic	O	O
effect	O	O
in	O	O
the	O	O
obese	O	O
.	O	O

To	O	O
elucidate	O	O
whether	O	O
troglitazone	O	O
exerts	O	O
an	O	O
antiinflammatory	O	O
effect	O	O
in	O	O
humans	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
suppression	O	O
of	O	O
nuclear	B-protein	O
factor	I-protein	O
kappaB	O	O
(	O	O
NFkappaB	O	O
)	O	O
in	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
(	O	O
MNC	O	O
)	O	O
by	O	O
this	O	O
drug	O	O
.	O	O

We	O	O
measured	O	O
intranuclear	O	O
NFkappaB	O	O
,	O	O
total	O	O
cellular	O	O
NFkappaB	O	O
,	O	O
inhibitor	O	O
kappaB	O	O
(	O	O
IkappaB	O	O
)	O	O
alpha	B-protein	O
,	O	O
reactive	O	O
oxygen	O	O
species	O	O
(	O	O
ROS	O	O
)	O	O
generation	O	O
,	O	O
and	O	O
p47	O	O
(	O	O
phox	O	O
)	O	O
subunit	O	O
(	O	O
a	O	O
key	O	O
component	B-protein	O
protein	I-protein	O
of	O	O
nicotinamide	O	O
adenine	O	O
dinucleotide	O	O
phosphate	O	O
oxidase	O	O
)	O	O
in	O	O
MNC	O	O
.	O	O

Plasma	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
(	O	O
TNF	B-protein	O
)	O	O
-alpha	O	O
,	O	O
soluble	B-protein	O
intercellular	I-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
(	O	O
sICAM-1	B-protein	O
)	O	O
,	O	O
monocyte	O	O
chemoattractant	O	O
protein-1	B-protein	O
(	O	O
MCP-1	B-protein	O
)	O	O
,	O	O
plasminogen	O	O
activator	O	O
inhibitor	O	O
type	I-protein	O
1	I-protein	O
(	O	O
PAI-1	B-protein	O
)	I-protein	O
,	O	O
C-reactive	B-protein	O
protein	I-protein	O
(	O	O
CRP	B-protein	O
)	O	O
,	O	O
and	O	O
interleukin	B-protein	O
(	O	O
IL	O	O
)	O	O
-10	O	O
(	O	O
antiinflammatory	O	O
cytokine	B-protein	O
)	O	O
concentrations	O	O
were	O	O
also	O	O
measured	O	O
as	O	O
mediators	O	O
of	O	O
inflammatory	O	O
activity	O	O
that	O	O
are	O	O
regulated	O	O
by	O	O
the	O	O
proinflammatory	B-protein	O
transcription	I-protein	O
factor	I-protein	O
NFkappaB	O	O
.	O	O

Seven	O	O
nondiabetic	O	O
obese	O	O
patients	O	O
were	O	O
given	O	O
400	O	O
mg	O	O
troglitazone	O	O
daily	O	O
for	O	O
4	O	O
weeks	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
collected	O	O
before	O	O
and	O	O
at	O	O
weekly	O	O
intervals	O	O
thereafter	O	O
.	O	O

MNC	O	O
were	O	O
separated	O	O
;	O	O
and	O	O
the	O	O
levels	O	O
of	O	O
intranuclear	O	O
NFkappaB	O	O
,	O	O
total	O	O
cellular	O	O
NFkappaB	O	O
,	O	O
IkappaBalpha	O	O
,	O	O
and	O	O
p47	O	O
(	O	O
phox	O	O
)	O	O
subunit	O	O
and	O	O
ROS	O	O
generation	O	O
were	O	O
determined	O	O
.	O	O

Plasma	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
insulin	O	O
glucose	O	O
,	O	O
TNFalpha	O	O
,	O	O
sICAM	O	O
,	O	O
MCP-1	O	O
,	O	O
PAI-1	O	O
,	O	O
CRP	O	O
,	O	O
and	O	O
IL-10	B-protein	O
.	O	O

Plasma	O	O
insulin	O	O
concentrations	O	O
fell	O	O
significantly	O	O
at	O	O
week	O	O
1	O	O
,	O	O
from	O	O
31.2	O	O
+/-	O	O
29.1	O	O
to	O	O
14.2	O	O
+/-	O	O
11.4	O	O
mU/L	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
and	O	O
remained	O	O
low	O	O
throughout	O	O
4	O	O
weeks	O	O
.	O	O

Plasma	O	O
glucose	O	O
concentrations	O	O
did	O	O
not	O	O
alter	O	O
significantly	O	O
.	O	O

There	O	O
was	O	O
a	O	O
fall	O	O
in	O	O
intranuclear	O	O
NFkappaB	O	O
,	O	O
total	O	O
cellular	O	O
NFkappaB	O	O
,	O	O
and	O	O
p47	O	O
(	O	O
phox	O	O
)	O	O
subunit	O	O
,	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
cellular	O	O
IkappaBalpha	O	O
at	O	O
week	O	O
2	O	O
,	O	O
which	O	O
persisted	O	O
until	O	O
week	O	O
4	O	O
.	O	O

There	O	O
was	O	O
a	O	O
parallel	O	O
fall	O	O
in	O	O
ROS	O	O
generation	O	O
by	O	O
MNC	O	O
at	O	O
week	O	O
1	O	O
;	O	O
this	O	O
progressed	O	O
and	O	O
persisted	O	O
until	O	O
week	O	O
4	O	O
(	O	O
P	O	O
<	O	O
0.001	O	O
)	O	O
.	O	O

Plasma	O	O
TNF-alpha	O	O
,	O	O
sICAM-1	O	O
,	O	O
MCP-1	O	O
,	O	O
and	O	O
PAI-1	O	O
concentrations	O	O
fell	O	O
significantly	O	O
at	O	O
week	O	O
4	O	O
.	O	O

Plasma	O	O
IL-10	B-protein	O
concentration	O	O
increased	O	O
significantly	O	O
,	O	O
whereas	O	O
plasma	O	O
CRP	O	O
concentrations	O	O
decreased	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
troglitazone	O	O
has	O	O
an	O	O
antiinflammatory	O	O
action	O	O
that	O	O
may	O	O
contribute	O	O
to	O	O
its	O	O
putative	O	O
antiatherosclerotic	O	O
effects	O	O
.	O	O

Tyrosine	O	O
phosphorylation-dependent	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
.	O	O

Requirement	O	O
for	O	O
p56	O	O
LCK	O	O
and	O	O
ZAP-70	B-protein	O
protein	I-protein	O
tyrosine	O	O
kinases	O	O
.	O	O

Phosphorylation	O	O
of	O	O
the	O	O
N-terminal	B-protein	O
domain	I-protein	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
inhibitory	I-protein	O
subunits	I-protein	O
induces	O	O
activation	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappa	B-protein	O
B	I-protein	O
.	O	O

Although	O	O
serine	O	O
phosphorylation	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
induce	O	O
ubiquitination	O	O
and	O	O
subsequent	O	O
proteasome-mediated	O	O
degradation	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B-alpha	I-protein	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
mechanisms	O	O
that	O	O
lead	O	O
to	O	O
release	O	O
of	O	O
active	O	O
NF-kappa	B-protein	O
B	I-protein	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
as	O	O
a	O	O
consequence	O	O
of	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B-alpha	I-protein	O
[	O	O
Imbert	O	O
,	O	O
V.	O	O
,	O	O
Rupec	O	O
,	O	O
R.A.	O	O
,	O	O
Livolsi	O	O
,	O	O
A.	O	O
,	O	O
Pahl	O	O
,	O	O
H.L.	O	O
,	O	O
Traenckner	O	O
,	O	O
B.M.	O	O
,	O	O
Mueller-Dieckmann	O	O
,	O	O
C.	O	O
,	O	O
Farahifar	O	O
,	O	O
D.	O	O
,	O	O
Rossi	O	O
,	O	O
B.	O	O
,	O	O
Auberger	O	O
,	O	O
P.	O	O
,	O	O
Baeuerle	O	O
,	O	O
P.	O	O
&	O	O
Peyron	O	O
,	O	O
J.F.	O	O
(	O	O
1996	O	O
)	O	O
Cell	O	O
86	O	O
,	O	O
787	O	O
--	O	O
798	O	O
]	O	O
.	O	O

The	O	O
involvement	O	O
of	O	O
the	O	O
tyrosine	B-protein	O
kinases	I-protein	O
p56	I-protein	O
(	O	O
lck	B-protein	O
)	O	O
and	O	O
ZAP-70	O	O
in	O	O
this	O	O
reaction	O	O
is	O	O
demonstrated	O	O
here	O	O
using	O	O
specific	O	O
pharmacological	O	O
inhibitors	O	O
and	O	O
Jurkat	O	O
mutants	O	O
unable	O	O
to	O	O
express	O	O
these	O	O
kinases	O	O
.	O	O

Although	O	O
the	O	O
inhibitors	O	O
prevented	O	O
both	O	O
pervanadate-induced	O	O
phosphorylation	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B-alpha	I-protein	O
on	O	O
Tyr42	O	O
and	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
,	O	O
we	O	O
observed	O	O
that	O	O
,	O	O
in	O	O
p56	O	O
(	O	O
lck	O	O
)	O	O
-deficient	O	O
Jurkat	O	O
mutants	O	O
,	O	O
NF-kappa	B-protein	O
B	I-protein	O
could	O	O
still	O	O
associate	O	O
with	O	O
I	O	O
kappa	O	O
B-alpha	O	O
despite	O	O
phosphorylation	O	O
on	O	O
Tyr42	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
SH2	B-protein	O
domain	I-protein	O
of	O	O
p56	O	O
(	O	O
lck	B-protein	O
)	O	O
appeared	O	O
to	O	O
be	O	O
required	O	O
for	O	O
pervanadate-induced	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
but	O	O
not	O	O
for	O	O
Tyr42	O	O
phosphorylation	O	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
p56	O	O
(	O	O
lck	B-protein	O
)	O	O
and	O	O
ZAP-70	O	O
are	O	O
key	O	O
components	O	O
of	O	O
the	O	O
signaling	O	O
pathway	O	O
that	O	O
leads	O	O
to	O	O
phosphotyrosine-dependent	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
confirm	O	O
that	O	O
tyrosine	O	O
kinases	O	O
must	O	O
control	O	O
at	O	O
least	O	O
two	O	O
different	O	O
steps	O	O
to	O	O
induce	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
.	O	O

Finally	O	O
,	O	O
we	O	O
show	O	O
that	O	O
H	B-protein	O
(	O	O
2	O	O
)	O	O
O	O	O
(	O	O
2	O	O
)	O	O
,	O	O
which	O	O
stimulates	O	O
p56	O	O
(	O	O
lck	O	O
)	O	O
and	O	O
ZAP-70	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
is	O	O
an	O	O
activator	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
through	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B-alpha	I-protein	O
.	O	O

Specific	O	O
missense	O	O
mutations	O	O
in	O	O
NEMO	O	O
result	O	O
in	O	O
hyper-IgM	O	O
syndrome	O	O
with	O	O
hypohydrotic	O	O
ectodermal	O	O
dysplasia	O	O
.	O	O

The	O	O
gene	O	O
that	O	O
encodes	O	O
nuclear	B-protein	O
factor	I-protein	O
kappaB	O	O
(	O	O
NF-kappaB	O	O
)	O	O
essential	O	O
modulator	O	O
(	O	O
or	O	O
NEMO	O	O
,	O	O
also	O	O
known	O	O
as	O	O
IKKgamma	O	O
)	O	O
is	O	O
required	O	O
for	O	O
activation	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappaB	I-protein	O
.	O	O

We	O	O
describe	O	O
mutations	O	O
in	O	O
the	O	O
putative	O	O
zinc-finger	I-DNA	O
domain	I-DNA	O
of	O	O
NEMO	O	O
that	O	O
result	O	O
in	O	O
an	O	O
X-linked	O	O
primary	O	O
immunodeficiency	O	O
characterized	O	O
by	O	O
hyper-IgM	O	O
syndrome	O	O
and	O	O
hypohydrotic	O	O
ectodermal	O	O
dysplasia	O	O
(	O	O
XHM-ED	O	O
)	O	O
.	O	O

These	O	O
mutations	O	O
prevent	O	O
CD40	O	O
ligand	O	O
(	O	O
CD40L	O	O
)	O	O
-mediated	O	O
degradation	O	O
of	O	O
inhibitor	O	O
of	O	O
NF-kappaB	B-protein	O
alpha	I-protein	O
(	O	O
IkappaB-alpha	B-protein	O
)	O	O
and	O	O
account	O	O
for	O	O
the	O	O
following	O	O
observations	O	O
:	O	O
B	B-cell_type	O
cells	I-cell_type	O
from	O	O
XHM-ED	O	O
patients	O	O
are	O	O
unable	O	O
to	O	O
undergo	O	O
immunoglobulin	O	O
class-switch	O	O
recombination	O	O
and	O	O
antigen-presenting	O	O
cells	I-cell_type	O
(	O	O
APCs	O	O
)	O	O
are	O	O
unable	O	O
to	O	O
synthesize	O	O
the	O	O
NF-kappaB-regulated	O	O
cytokines	B-protein	O
interleukin	I-protein	O
12	I-protein	O
(	O	O
IL-12	B-protein	O
)	O	O
or	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
alpha	I-protein	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
when	O	O
stimulated	O	O
with	O	O
CD40L	O	O
.	O	O

Nevertheless	O	O
,	O	O
innate	O	O
immunity	O	O
is	O	O
preserved	O	O
in	O	O
XHM-ED	O	O
patients	O	O
because	O	O
APCs	O	O
retain	O	O
the	O	O
capacity	O	O
to	O	O
respond	O	O
to	O	O
stimulation	O	O
by	O	O
lipopolysaccharide	O	O
or	O	O
Staphylococcus	O	O
aureus	O	O
Cowan	O	O
's	O	O
antigen	O	O
(	O	O
SAC	O	O
)	O	O
.	O	O

Overall	O	O
,	O	O
the	O	O
phenotype	O	O
observed	O	O
in	O	O
XHM-ED	O	O
patients	O	O
shows	O	O
that	O	O
the	O	O
putative	O	O
zinc-finger	I-protein	O
domain	I-protein	O
of	O	O
NEMO	O	O
has	O	O
a	O	O
regulatory	O	O
function	O	O
and	O	O
demonstrates	O	O
the	O	O
definite	O	O
requirement	O	O
of	O	O
CD40	O	O
-mediated	O	O
NF-kappaB	O	O
activation	O	O
for	O	O
B	O	O
cell	O	O
immunoglobulin	O	O
class-switching	O	O
.	O	O

Granulocytic	O	O
differentiation	O	O
of	O	O
human	B-cell_line	O
NB4	I-cell_line	O
promyelocytic	I-cell_line	O
leukemia	I-cell_line	O
cells	I-cell_line	O
induced	O	O
by	O	O
all-trans	O	O
retinoic	O	O
acid	O	O
metabolites	O	O
.	O	O

The	O	O
metabolism	O	O
of	O	O
all-trans	O	O
retinoic	O	O
acid	O	O
(	O	O
ATRA	B-protein	O
)	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
partly	O	O
responsible	O	O
for	O	O
the	O	O
in	O	O
vivo	O	O
resistance	O	O
to	O	O
ATRA	O	O
seen	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
human	O	O
acute	O	O
promyelocytic	O	O
leukemia	O	O
(	O	O
APL	O	O
)	O	O
.	O	O

However	O	O
,	O	O
ATRA	O	O
metabolism	O	O
appears	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
growth	O	O
inhibition	O	O
of	O	O
several	O	O
cancer	O	O
cell	O	O
lines	O	O
in	O	O
vitro	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
in	O	O
vitro	O	O
activity	O	O
of	O	O
the	O	O
principal	O	O
metabolites	O	O
of	O	O
ATRA	O	O
[	O	O
4-hydroxy-retinoic	O	O
acid	O	O
(	O	O
4-OH-RA	B-protein	O
)	O	O
,	O	O
18-hydroxy-retinoic	O	O
acid	O	O
(	O	O
18-OH-RA	O	O
)	O	O
,	O	O
4-oxo-retinoic	O	O
acid	O	O
(	O	O
4-oxo-RA	O	O
)	O	O
,	O	O
and	O	O
5	O	O
,	O	O
6-epoxy-retinoic	O	O
acid	O	O
(	O	O
5	O	O
,	O	O
6-epoxy-RA	O	O
)	O	O
]	O	O
in	O	O
NB4	O	O
,	O	O
a	O	O
human	O	O
promyelocytic	O	O
leukemia	O	O
cell	O	O
line	O	O
that	O	O
exhibits	O	O
the	O	O
APL	O	O
diagnostic	O	O
t	O	O
(	O	O
15	O	O
;	O	O
17	O	O
)	O	O
chromosomal	O	O
translocation	O	O
and	O	O
expresses	O	O
the	O	O
PML-RAR	O	O
alpha	O	O
fusion	O	O
protein	O	O
.	O	O

We	O	O
established	O	O
that	O	O
the	O	O
four	O	O
ATRA	O	O
metabolites	O	O
were	O	O
indeed	O	O
formed	O	O
by	O	O
the	O	O
NB4	B-cell_type	O
cells	I-cell_type	O
in	O	O
vitro	O	O
.	O	O

NB4	O	O
cell	O	O
growth	O	O
was	O	O
inhibited	O	O
(	O	O
69-78	O	O
%	O	O
at	O	O
120	O	O
h	O	O
)	O	O
and	O	O
cell	O	O
cycle	O	O
progression	O	O
in	O	O
the	O	O
G1	O	O
phase	O	O
(	O	O
82-85	O	O
%	O	O
at	O	O
120	O	O
h	O	O
)	O	O
was	O	O
blocked	O	O
by	O	O
ATRA	O	O
and	O	O
all	O	O
of	O	O
the	O	O
metabolites	O	O
at	O	O
1	O	O
microM	O	O
concentration	O	O
.	O	O

ATRA	O	O
and	O	O
its	O	O
metabolites	O	O
could	O	O
induce	O	O
NB4	O	O
cells	O	O
differentiation	O	O
with	O	O
similar	O	O
activity	O	O
,	O	O
as	O	O
evaluated	O	O
by	O	O
cell	O	O
morphology	O	O
,	O	O
by	O	O
the	O	O
nitroblue	O	O
tetrazolium	O	O
reduction	O	O
test	O	O
(	O	O
82-88	O	O
%	O	O
at	O	O
120	O	O
h	O	O
)	O	O
or	O	O
by	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
maturation	O	O
specific	O	O
cell	O	O
surface	O	O
marker	O	O
CD11c	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
nuclear	O	O
body	O	O
reorganization	O	O
to	O	O
macropunctated	O	O
structures	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
degradation	O	O
of	O	O
PML-RAR	B-protein	O
alpha	I-protein	O
,	O	O
was	O	O
found	O	O
to	O	O
be	O	O
similar	O	O
for	O	O
ATRA	O	O
and	O	O
all	O	O
of	O	O
its	O	O
metabolites	B-protein	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
relative	O	O
potency	O	O
of	O	O
the	O	O
retinoids	O	O
using	O	O
the	O	O
nitroblue	O	O
tetrazolium	O	O
reduction	O	O
test	O	O
showed	O	O
effective	O	O
concentrations	O	O
required	O	O
to	O	O
differentiate	O	O
50	O	O
%	O	O
of	O	O
cells	O	O
in	O	O
72	O	O
h	O	O
as	O	O
follows	O	O
:	O	O
ATRA	O	O
,	O	O
15.8	O	O
+/-	O	O
1.7	O	O
nM	O	O
;	O	O
4-oxo-RA	O	O
,	O	O
38.3	O	O
+/-	O	O
1.3	O	O
nM	O	O
;	O	O
18-OH-RA	O	O
,	O	O
55.5	O	O
+/-	O	O
1.8	O	O
nM	O	O
;	O	O
4-OH-RA	O	O
,	O	O
79.8	O	O
+/-	O	O
1.8	O	O
nM	O	O
;	O	O
and	O	O
5	O	O
,	O	O
6-epoxy-RA	O	O
,	O	O
99.5	O	O
+/-	O	O
1.5	O	O
nM	O	O
.	O	O

The	O	O
ATRA	O	O
metabolites	O	O
were	O	O
found	O	O
to	O	O
exert	O	O
their	O	O
differentiation	O	O
effects	O	O
via	O	O
the	O	O
RAR	B-protein	O
alpha	I-protein	O
nuclear	I-protein	O
receptors	I-protein	O
,	O	O
because	O	O
the	O	O
RAR	O	O
alpha-specific	O	O
antagonist	O	O
BMS614	O	O
blocked	O	O
metabolite-induced	O	O
CD11c	O	O
expression	O	O
in	O	O
NB4	O	O
cells	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
the	O	O
principal	O	O
ATRA	O	O
Phase	O	O
1	O	O
metabolites	O	O
can	O	O
elicit	O	O
leukemia	O	O
cell	O	O
growth	O	O
inhibition	O	O
and	O	O
differentiation	O	O
in	O	O
vitro	O	O
through	O	O
the	O	O
RAR	O	O
alpha	I-protein	O
signaling	O	O
pathway	O	O
,	O	O
and	O	O
they	O	O
suggest	O	O
that	O	O
these	O	O
metabolites	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
ATRA	O	O
antileukemic	O	O
activity	O	O
in	O	O
vivo	O	O
.	O	O

Expression	O	O
of	O	O
oestrogen	O	O
and	O	O
progesterone	O	O
receptors	O	O
by	O	O
mast	B-cell_type	O
cells	I-cell_type	O
alone	O	O
,	O	O
but	O	O
not	O	O
lymphocytes	I-cell_type	O
,	O	O
macrophages	O	O
or	O	O
other	O	O
immune	O	O
cells	O	O
in	O	O
human	O	O
upper	O	O
airways	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Nasal	O	O
polyposis	O	O
often	O	O
coexists	O	O
with	O	O
asthma	O	O
in	O	O
airway	O	O
inflammatory	O	O
conditions	O	O
characterised	O	O
by	O	O
the	O	O
infiltration	O	O
of	O	O
a	O	O
range	O	O
of	O	O
immune	B-cell_type	O
cells	I-cell_type	O
.	O	O

A	O	O
potentially	O	O
important	O	O
role	O	O
for	O	O
ovarian	O	O
hormones	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
airway	O	O
inflammation	O	O
but	O	O
the	O	O
cellular	O	O
target	O	O
for	O	O
such	O	O
action	O	O
is	O	O
not	O	O
known	O	O
.	O	O

METHODS	O	O
:	O	O
Expression	O	O
of	O	O
oestrogen	B-protein	O
receptors	I-protein	O
(	O	O
ER	B-protein	O
)	O	O
and	O	O
progesterone	O	O
receptors	O	O
(	O	O
PR	O	O
)	O	O
was	O	O
examined	O	O
using	O	O
immunohistochemistry	O	O
in	O	O
formalin	O	O
fixed	O	O
nasal	O	O
polyp	O	O
tissues	O	O
from	O	O
47	O	O
subjects	O	O
.	O	O

The	O	O
cells	I-cell_type	O
positive	O	O
for	O	O
ER	B-protein	O
or	O	O
PR	O	O
were	O	O
confirmed	O	O
by	O	O
spatial	O	O
location	O	O
,	O	O
dual	O	O
immunolabelling	O	O
,	O	O
and	O	O
histochemical	O	O
staining	O	O
.	O	O

RESULTS	O	O
:	O	O
Consistent	O	O
with	O	O
the	O	O
known	O	O
features	O	O
of	O	O
nasal	O	O
polyps	O	O
,	O	O
CD4+	O	O
(	O	O
T	O	O
helper/inducer	O	O
)	O	O
,	O	O
CD8+	O	O
(	O	O
cytotoxic/suppressor	O	O
)	O	O
,	O	O
CD68+	O	O
(	O	O
macrophages	O	O
)	O	O
,	O	O
mast	O	O
cells	O	O
,	O	O
eosinophils	O	O
and	O	O
neutrophils	O	O
were	O	O
all	O	O
clearly	O	O
detected	O	O
by	O	O
their	O	O
relevant	O	O
monoclonal	O	O
antibodies	O	O
or	O	O
appropriate	O	O
histochemical	O	O
staining	O	O
,	O	O
but	O	O
only	O	O
mast	O	O
cells	O	O
tested	O	O
positive	O	O
for	O	O
ER	O	O
/PR	O	O
labelling	O	O
with	O	O
their	O	O
polyclonal	O	O
and	O	O
monoclonal	O	O
antibodies	O	O
.	O	O

The	O	O
frequencies	O	O
for	O	O
expression	O	O
were	O	O
61.7	O	O
%	O	O
for	O	O
ER	O	O
positive	O	O
and	O	O
59.6	O	O
%	O	O
for	O	O
PR	O	O
positive	O	O
cells	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
ER	B-protein	O
/	O	O
PR	O	O
was	O	O
independent	O	O
of	O	O
patient	O	O
sex	O	O
and	O	O
age	O	O
but	O	O
was	O	O
highly	O	O
correlated	O	O
with	O	O
the	O	O
numbers	O	O
of	O	O
mast	B-cell_type	O
cells	I-cell_type	O
(	O	O
r	O	O
=	O	O
0.973	O	O
,	O	O
p	O	O
<	O	O
0.001	O	O
for	O	O
ER	B-protein	O
;	O	O
r	O	O
=	O	O
0.955	O	O
,	O	O
p	O	O
<	O	O
0.001	O	O
for	O	O
PR	O	O
)	O	O
.	O	O

Fewer	O	O
than	O	O
5	O	O
%	O	O
of	O	O
mast	B-cell_type	O
cells	I-cell_type	O
were	O	O
found	O	O
to	O	O
be	O	O
negative	O	O
for	O	O
ER	O	O
/	O	O
PR	O	O
expression	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Mast	O	O
cells	O	O
alone	O	O
,	O	O
but	O	O
not	O	O
lymphocytes	I-cell_type	O
,	O	O
macrophages	O	O
,	O	O
or	O	O
other	O	O
immune	O	O
cells	O	O
,	O	O
express	O	O
ER	O	O
/	O	O
PR	O	O
in	O	O
human	O	O
upper	O	O
airways	O	O
.	O	O

Numerous	O	O
ER/PR	O	O
positive	O	O
mast	B-cell_type	O
cells	I-cell_type	O
exist	O	O
in	O	O
nasal	O	O
polyps	O	O
,	O	O
indicating	O	O
that	O	O
this	O	O
may	O	O
be	O	O
a	O	O
major	O	O
route	O	O
for	O	O
the	O	O
involvement	O	O
of	O	O
sex	O	O
hormones	O	O
in	O	O
airway	O	O
inflammation	O	O
when	O	O
exposed	O	O
to	O	O
the	O	O
higher	O	O
and	O	O
varying	O	O
concentration	O	O
of	O	O
oestrogen	O	O
and	O	O
progesterone	O	O
characteristic	O	O
of	O	O
females	O	O
.	O	O

NF	O	O
kappa	O	O
b	O	O
signaling	O	O
in	O	O
posthypoxic	B-cell_line	O
endothelial	I-cell_line	O
cells	I-cell_line	O
:	O	O
relevance	O	O
to	O	O
E-selectin	O	O
expression	O	O
and	O	O
neutrophil	O	O
adhesion	O	O
.	O	O

Our	O	O
previous	O	O
studies	O	O
have	O	O
implicated	O	O
the	O	O
nuclear	B-protein	O
transcription	I-protein	O
factor	I-protein	O
kappa	I-protein	O
B	I-protein	O
(	O	O
NF	B-protein	O
kappa	I-protein	O
B	I-protein	O
)	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
adhesion	O	O
molecule	O	O
expression	O	O
in	O	O
endothelial	B-cell_type	O
cells	I-cell_type	O
exposed	O	O
to	O	O
anoxia-reoxygenation	O	O
(	O	O
A/R	O	O
)	O	O
or	O	O
a	O	O
redox	O	O
imbalance	O	O
.	O	O

The	O	O
objectives	O	O
of	O	O
this	O	O
study	O	O
were	O	O
(	O	O
1	O	O
)	O	O
to	O	O
define	O	O
the	O	O
kinetics	O	O
of	O	O
NF	B-protein	O
kappa	I-protein	O
B	I-protein	O
activation	O	O
by	O	O
examining	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
degradation	O	O
and	O	O
the	O	O
nuclear	O	O
translocation	O	O
of	O	O
p65	B-protein	O
in	O	O
response	O	O
to	O	O
A/R	O	O
or	O	O
redox	O	O
imbalance	O	O
(	O	O
induced	O	O
by	O	O
treatment	O	O
of	O	O
cells	O	O
with	O	O
diamide	O	O
and	O	O
buthionine	O	O
sulfoximine	O	O
)	O	O
and	O	O
(	O	O
2	O	O
)	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
signal	O	O
for	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
degradation	O	O
,	O	O
nuclear	O	O
translocation	O	O
of	O	O
p65	B-protein	O
,	O	O
and	O	O
E-selectin	B-protein	O
-mediated	O	O
neutrophil	O	O
adhesion	O	O
is	O	O
related	O	O
to	O	O
the	O	O
activity	O	O
of	O	O
protein	B-protein	O
tyrosine	I-protein	O
kinase	I-protein	O
(	O	O
PTK	B-protein	O
)	O	O
,	O	O
protein	O	O
tyrosine	O	O
phosphatase	O	O
(	O	O
PTPase	B-protein	O
)	O	O
and/or	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
(	O	O
PKC	O	O
)	O	O
.	O	O

The	O	O
results	O	O
demonstrate	O	O
that	O	O
both	O	O
A/R	O	O
and	O	O
redox	O	O
imbalance	O	O
led	O	O
to	O	O
I	O	O
kappa	O	O
B	O	O
alpha	O	O
degradation	O	O
within	O	O
30	O	O
min	O	O
and	O	O
the	O	O
concomitant	O	O
appearance	O	O
of	O	O
p65	B-protein	O
in	O	O
the	O	O
nucleus	O	O
,	O	O
consistent	O	O
with	O	O
rapid	O	O
cytosolic	O	O
activation	O	O
of	O	O
NF	B-protein	O
kappa	I-protein	O
B	I-protein	O
and	O	O
subsequent	O	O
nuclear	O	O
translocation	O	O
of	O	O
the	O	O
activated	B-protein	O
p65	I-protein	O
subunit	I-protein	O
.	O	O

Inhibition	O	O
of	O	O
PKC	O	O
blocked	O	O
I	I-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
degradation	O	O
and	O	O
p65	O	O
translocation	O	O
in	O	O
A/R-challenged	O	O
,	O	O
but	O	O
not	O	O
redox-altered	O	O
,	O	O
endothelial	B-cell_type	O
cells	I-cell_type	O
.	O	O

However	O	O
,	O	O
both	O	O
A/R-	O	O
and	O	O
redox-induced	O	O
NF	O	O
kappa	O	O
B	O	O
activation	O	O
was	O	O
blocked	O	O
by	O	O
inhibition	O	O
of	O	O
PTK	O	O
.	O	O

Similarly	O	O
,	O	O
A/R-induced	O	O
E-selectin	B-protein	O
expression	O	O
and	O	O
neutrophil-endothelial	O	O
cell	O	O
adhesion	O	O
were	O	O
blocked	O	O
by	O	O
inhibition	O	O
of	O	O
PKC	O	O
or	O	O
PTK	O	O
,	O	O
while	O	O
only	O	O
PTK	O	O
inhibited	O	O
the	O	O
redox-induced	O	O
adhesion	O	O
response	O	O
.	O	O

Pretreatment	O	O
of	O	O
cells	I-cell_type	O
with	O	O
N-acetyl	O	O
cysteine	O	O
effectively	O	O
blocked	O	O
A/R-	O	O
or	O	O
redox-induced	O	O
I	O	O
kappa	O	O
B	O	O
degradation	O	O
and	O	O
significantly	O	O
attenuated	O	O
the	O	O
respective	O	O
neutrophil	O	O
adhesion	O	O
responses	O	O
.	O	O

Collectively	O	O
,	O	O
these	O	O
findings	O	O
indicate	O	O
that	O	O
A/R-induced	O	O
E-selectin	B-protein	O
expression	O	O
and	O	O
neutrophil-endothelial	O	O
cell	O	O
adhesion	O	O
are	O	O
mediated	O	O
by	O	O
both	O	O
PKC	O	O
and	O	O
PTK	O	O
,	O	O
which	O	O
signal	O	O
rapid	O	O
activation	O	O
of	O	O
NF	O	O
kappa	I-protein	O
B	I-protein	O
.	O	O

This	O	O
A/R-induced	O	O
NF	O	O
kappa	B-DNA	O
B	I-DNA	O
signaling	O	O
response	O	O
appears	O	O
to	O	O
be	O	O
mediated	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
by	O	O
intracellular	O	O
redox	O	O
imbalance	O	O
.	O	O

Copyright	O	O
2001	O	O
S.	O	O
Karger	O	O
AG	O	O
,	O	O
Basel	O	O

Induction	O	O
of	O	O
apoptosis	O	O
in	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
by	O	O
the	O	O
herbicide	B-protein	O
2	I-protein	O
,	O	O
4-dichlorophenoxyacetic	O	O
acid	O	O
.	O	O

Dimethylammonium	O	O
salt	O	O
of	O	O
2	O	O
,	O	O
4-dichlorophenoxyacetic	O	O
acid	O	O
(	O	O
DMA-2	B-protein	O
,	O	O
4-D	O	O
)	O	O
is	O	O
a	O	O
widely	O	O
used	O	O
herbicide	O	O
that	O	O
is	O	O
considered	O	O
moderately	O	O
toxic	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
we	O	O
found	O	O
that	O	O
DMA-2	O	O
,	O	O
4-D	O	O
is	O	O
able	O	O
to	O	O
cause	O	O
apoptosis	O	O
in	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
lymphocytes	I-cell_type	O
of	O	O
healthy	O	O
individuals	O	O
and	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
.	O	O

Apoptosis	O	O
induced	O	O
by	O	O
DMA-2	O	O
,	O	O
4-D	O	O
was	O	O
dose	O	O
and	O	O
time	O	O
dependent	O	O
,	O	O
independent	O	O
of	O	O
Fas	O	O
,	O	O
TNF	B-protein	O
receptor	I-protein	O
1	O	O
or	O	O
the	O	O
aromatic	O	O
hydrocarbon	I-protein	O
receptor	I-protein	O
,	O	O
and	O	O
involved	O	O
disruption	O	O
of	O	O
the	O	O
mitochondrial	O	O
transmembrane	O	O
potential	O	O
and	O	O
activation	O	O
of	O	O
caspase-9	O	O
.	O	O

ZVAD-FMK	O	O
,	O	O
a	O	O
broad-spectrum	O	O
inhibitor	O	O
of	O	O
caspases	O	O
,	O	O
blocked	O	O
DMA-2	O	O
,	O	O
4-D-induced	O	O
apoptosis	O	O
completely	O	O
.	O	O

While	O	O
an	O	O
inhibitor	O	O
of	O	O
caspase-9	B-protein	O
,	O	O
as	O	O
well	O	O
as	O	O
caspase-9	O	O
and	O	O
caspase-3	O	O
inhibitors	O	O
in	O	O
combination	O	O
,	O	O
strongly	O	O
blocked	O	O
DMA-2	O	O
,	O	O
4-D-induced	O	O
apoptosis	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
caspase-3	O	O
had	O	O
a	O	O
moderate	O	O
inhibitory	O	O
effect	O	O
.	O	O

Unlike	O	O
Fas	O	O
-mediated	O	O
apoptosis	O	O
,	O	O
the	O	O
initiator	O	O
caspase	O	O
,	O	O
caspase-8	O	O
,	O	O
was	O	O
not	O	O
involved	O	O
in	O	O
DMA-2	O	O
,	O	O
4-D-induced	O	O
apoptosis	O	O
.	O	O

Transfection	O	O
of	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
with	O	O
Bcl-2	O	O
prevented	O	O
DMA-2	O	O
,	O	O
4-D-induced	O	O
disruption	O	O
of	O	O
the	O	O
mitochondrial	O	O
transmembrane	O	O
potential	O	O
and	O	O
led	O	O
to	O	O
a	O	O
complete	O	O
blockage	O	O
of	O	O
apoptosis	O	O
.	O	O

Our	O	O
data	O	O
indicate	O	O
that	O	O
DMA-2	O	O
,	O	O
4-D	O	O
kills	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
by	O	O
initiating	O	O
apoptosis	O	O
via	O	O
a	O	O
direct	O	O
effect	O	O
on	O	O
mitochondria	O	O
.	O	O

The	O	O
activation	O	O
of	O	O
caspases	O	O
occurs	O	O
downstream	O	O
of	O	O
mitochondrial	O	O
damage	B-protein	O
,	O	O
and	O	O
the	O	O
dysfunction	O	O
of	O	O
mitochondria	O	O
appears	O	O
to	O	O
be	O	O
sufficient	O	O
for	O	O
triggering	O	O
all	O	O
downstream	O	O
events	O	O
leading	O	O
to	O	O
apoptosis	O	O
.	O	O

Inhibition	O	O
of	O	O
Th1	O	O
differentiation	O	O
by	O	O
IL-6	O	O
is	O	O
mediated	O	O
by	O	O
SOCS1	O	O
.	O	O

Interleukin	B-protein	O
6	O	O
(	O	O
IL-6	O	O
)	O	O
is	O	O
a	O	O
cytokine	O	O
produced	O	O
by	O	O
immune	O	O
and	O	O
nonimmune	B-cell_type	O
cells	I-cell_type	O
and	O	O
exhibits	O	O
functional	O	O
pleiotropy	O	O
and	O	O
redundancy	O	O
.	O	O

IL-6	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
differentiation	O	O
of	O	O
several	O	O
cell	I-cell_type	O
types	I-cell_type	O
.	O	O

Here	O	O
,	O	O
we	O	O
describe	O	O
a	O	O
novel	O	O
function	O	O
of	O	O
IL-6	O	O
:	O	O
the	O	O
negative	O	O
regulation	O	O
of	O	O
CD4	B-protein	O
+	I-protein	O
Th1	O	O
cell	O	O
differentiation	O	O
.	O	O

While	O	O
IL-6	O	O
-directed	O	O
CD4	B-protein	O
+	O	O
Th2	O	O
differentiation	O	O
is	O	O
mediated	O	O
by	O	O
IL-4	B-protein	O
,	O	O
inhibition	O	O
of	O	O
Th1	O	O
differentiation	O	O
by	O	O
IL-6	O	O
is	O	O
independent	O	O
of	O	O
IL-4	B-protein	O
.	O	O

IL-6	O	O
upregulates	O	O
suppressor	O	O
of	O	O
cytokine	B-protein	O
signaling	O	O
1	O	O
(	O	O
SOCS1	O	O
)	O	O
expression	O	O
in	O	O
activated	B-cell_type	O
CD4+	I-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
,	O	O
thereby	O	O
interfering	O	O
with	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	B-protein	O
1	I-protein	O
(	O	O
STAT1	B-protein	O
)	O	O
phosphorylation	O	O
induced	O	O
by	O	O
interferon	B-protein	O
gamma	I-protein	O
(	O	O
IFNgamma	O	O
)	O	O
.	O	O

Inhibition	O	O
of	O	O
IFNgamma	O	O
receptor-mediated	O	O
signals	O	O
by	O	O
IL-6	O	O
prevents	O	O
autoregulation	O	O
of	O	O
IFNgamma	B-DNA	O
gene	I-DNA	O
expression	O	O
by	O	O
IFNgamma	O	O
during	O	O
CD4+	O	O
T	O	O
cell	O	O
activation	O	O
,	O	O
thereby	O	O
preventing	O	O
Th1	O	O
differentiation	O	O
.	O	O

Thus	O	O
,	O	O
IL-6	O	O
promotes	O	O
CD4	O	O
+	O	O
Th2	O	O
differentiation	O	O
and	O	O
inhibits	O	O
Th1	O	O
differentiation	O	O
by	O	O
two	O	O
independent	O	O
molecular	O	O
mechanisms	O	O
.	O	O

Interaction	O	O
between	O	O
CCAAT/enhancer	O	O
binding	O	O
protein	O	O
and	O	O
cyclic	O	O
AMP	O	O
response	O	O
element	B-protein	O
binding	O	O
protein	O	O
1	O	O
regulates	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
transcription	O	O
in	O	O
cells	O	O
of	O	O
the	O	O
monocyte/macrophage	B-protein	O
lineage	I-protein	O
.	O	O

Recent	O	O
observations	O	O
have	O	O
shown	O	O
two	O	O
CCAAT/enhancer	B-protein	O
binding	I-protein	O
protein	I-protein	O
(	O	O
C/EBP	B-protein	O
)	O	O
binding	O	O
sites	O	O
to	O	O
be	O	O
critically	O	O
important	O	O
for	O	O
efficient	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HIV-1	O	O
)	O	O
replication	O	O
within	O	O
cells	O	O
of	O	O
the	O	O
monocyte/macrophage	B-protein	O
lineage	I-protein	O
,	O	O
a	O	O
cell	O	O
type	O	O
likely	O	O
involved	O	O
in	O	O
transport	O	O
of	O	O
the	O	O
virus	O	O
to	O	O
the	O	O
brain	O	O
.	O	O

Additionally	O	O
,	O	O
sequence	O	O
variation	O	O
at	O	O
C/EBP	O	O
site	O	O
I	O	O
,	O	O
which	O	O
lies	O	O
immediately	O	O
upstream	O	O
of	O	O
the	O	O
distal	B-protein	O
nuclear	I-protein	O
factor	I-protein	O
kappa	I-protein	O
B	I-protein	O
site	O	O
and	O	O
immediately	O	O
downstream	O	O
of	O	O
a	O	O
binding	B-DNA	O
site	I-DNA	O
for	O	O
activating	B-protein	O
transcription	I-protein	O
factor	I-protein	O
(	O	O
ATF	B-protein	O
)	O	O
/	O	O
cyclic	O	O
AMP	O	O
response	O	O
element	O	O
binding	O	O
protein	O	O
(	O	O
CREB	O	O
)	O	O
,	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
affect	O	O
HIV-1	O	O
long	O	O
terminal	O	O
repeat	O	O
(	O	O
LTR	O	O
)	O	O
activity	O	O
.	O	O

Given	O	O
that	O	O
C/EBP	O	O
proteins	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
interact	O	O
with	O	O
many	O	O
other	O	O
transcription	B-protein	O
factors	I-protein	O
including	O	O
members	O	O
of	O	O
the	O	O
ATF/CREB	B-protein	O
family	I-protein	O
,	O	O
we	O	O
proceeded	O	O
to	O	O
determine	O	O
whether	O	O
an	O	O
adjacent	O	O
ATF/CREB	B-DNA	O
binding	I-DNA	O
site	I-DNA	O
could	O	O
affect	O	O
C/EBP	O	O
protein	O	O
binding	O	O
to	O	O
C/EBP	B-DNA	O
site	I-DNA	O
I	I-protein	O
.	O	O

Electrophoretic	O	O
mobility	O	O
shift	O	O
analyses	O	O
indicated	O	O
that	O	O
selected	O	O
ATF/CREB	O	O
site	O	O
variants	O	O
assisted	O	O
in	O	O
the	O	O
recruitment	O	O
of	O	O
C/EBP	O	O
proteins	O	O
to	O	O
an	O	O
adjacent	O	O
,	O	O
naturally	O	O
occurring	O	O
,	O	O
low-affinity	O	O
C/EBP	O	O
site	O	O
.	O	O

This	O	O
biophysical	O	O
interaction	O	O
appears	O	O
to	O	O
occur	O	O
via	O	O
at	O	O
least	O	O
two	O	O
mechanisms	O	O
.	O	O

First	O	O
,	O	O
low	O	O
amounts	O	O
of	O	O
CREB-1	O	O
and	O	O
C/EBP	O	O
appear	O	O
to	O	O
heterodimerize	O	O
and	O	O
bind	O	O
to	O	O
a	O	O
site	O	O
consisting	O	O
of	O	O
a	O	O
half	B-DNA	O
site	I-DNA	O
from	O	O
both	O	O
the	O	O
ATF/CREB	B-DNA	O
and	I-DNA	O
C/EBP	I-DNA	O
binding	I-DNA	O
sites	I-DNA	O
.	O	O

In	O	O
addition	O	O
,	O	O
CREB-1	O	O
homodimers	O	O
bind	O	O
to	O	O
the	O	O
ATF/CREB	B-DNA	O
site	I-DNA	O
and	O	O
recruit	O	O
C/EBP	O	O
dimers	O	O
to	O	O
their	O	O
cognate	O	O
weak	O	O
binding	O	O
sites	O	O
.	O	O

This	O	O
interaction	O	O
is	O	O
reciprocal	O	O
,	O	O
since	O	O
C/EBP	O	O
dimer	O	O
binding	O	O
to	O	O
a	O	O
strong	O	O
C/EBP	O	O
site	O	O
leads	O	O
to	O	O
enhanced	O	O
CREB-1	O	O
recruitment	O	O
to	O	O
ATF/CREB	O	O
sites	O	O
that	O	O
are	O	O
weakly	O	O
bound	O	O
by	O	O
CREB	O	O
.	O	O

Sequence	O	O
variation	O	O
at	O	O
both	O	O
C/EBP	O	O
and	O	O
ATF/CREB	O	O
sites	O	O
affects	O	O
the	O	O
molecular	O	O
interactions	O	O
involved	O	O
in	O	O
mediating	O	O
both	O	O
of	O	O
these	O	O
mechanisms	O	O
.	O	O

Most	O	O
importantly	O	O
,	O	O
sequence	O	O
variation	O	O
at	O	O
the	O	O
ATF/CREB	O	O
binding	O	O
site	O	O
affected	O	O
basal	O	O
LTR	O	O
activity	O	O
as	O	O
well	O	O
as	O	O
LTR	O	O
function	O	O
following	O	O
interleukin-6	O	O
stimulation	O	O
,	O	O
a	O	O
treatment	O	O
that	O	O
leads	O	O
to	O	O
increases	O	O
in	O	O
C/EBP	O	O
activation	O	O
.	O	O

Thus	O	O
,	O	O
HIV-1	O	O
LTR	B-DNA	O
ATF/CREB	I-DNA	O
binding	I-DNA	O
site	I-DNA	O
sequence	I-DNA	O
variation	O	O
may	O	O
modulate	O	O
cellular	O	O
signaling	O	O
at	O	O
the	O	O
viral	O	O
promoter	O	O
through	O	O
the	O	O
C/EBP	O	O
pathway	O	O

Selective	O	O
inhibition	O	O
of	O	O
interleukin-4	O	O
gene	O	O
expression	O	O
in	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
by	O	O
aspirin	O	O
.	O	O

Previous	O	O
studies	O	O
indicated	O	O
that	O	O
aspirin	O	O
(	O	O
acetylsalicylic	O	O
acid	O	O
[	O	O
ASA	O	O
]	O	O
)	O	O
can	O	O
have	O	O
profound	O	O
immunomodulatory	O	O
effects	O	O
by	O	O
regulating	O	O
cytokine	O	O
gene	O	O
expression	O	O
in	O	O
several	O	O
types	O	O
of	O	O
cells	I-cell_type	O
.	O	O

This	O	O
study	O	O
is	O	O
the	O	O
first	O	O
in	O	O
which	O	O
concentrations	O	O
of	O	O
ASA	O	O
in	O	O
the	O	O
therapeutic	O	O
range	O	O
were	O	O
found	O	O
to	O	O
significantly	O	O
reduce	B-protein	O
interleukin	I-protein	O
(	I-protein	O
IL	I-protein	O
)	O	O
-4	O	O
secretion	O	O
and	O	O
RNA	O	O
expression	O	O
in	O	O
freshly	O	O
isolated	O	O
and	O	O
mitogen-primed	B-cell_line	O
human	I-cell_line	O
CD4+	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
.	O	O

In	O	O
contrast	O	O
,	O	O
ASA	O	O
did	O	O
not	O	O
affect	O	O
IL-13	O	O
,	O	O
interferon-gamma	O	O
,	O	O
and	O	O
IL-2	B-protein	O
expression	O	O
.	O	O

ASA	O	O
inhibited	O	O
IL-4	B-protein	O
,	O	O
but	O	O
not	O	O
IL-2	B-protein	O
,	O	O
promoter-driven	O	O
chloramphenicol	O	O
acetyltransferase	O	O
expression	O	O
in	O	O
transiently	B-cell_line	O
transfected	I-cell_line	O
Jurkat	I-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
.	O	O

The	O	O
structurally	O	O
unrelated	O	O
nonsteroidal	O	O
anti-inflammatory	O	O
drugs	O	O
indomethacin	O	O
and	O	O
flurbiprofen	O	O
did	O	O
not	O	O
affect	O	O
cytokine	O	O
gene	O	O
expression	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
whereas	O	O
the	O	O
weak	O	O
cyclo-oxygenase	O	O
inhibitor	O	O
salicylic	O	O
acid	O	O
was	O	O
at	O	O
least	O	O
as	O	O
effective	O	O
as	O	O
ASA	O	O
in	O	O
inhibiting	O	O
IL-4	O	O
expression	O	O
and	O	O
promoter	O	O
activity	O	O
.	O	O

The	O	O
inhibitory	O	O
effect	O	O
of	O	O
ASA	O	O
on	O	O
IL-4	B-protein	O
transcription	O	O
was	O	O
not	O	O
mediated	O	O
by	O	O
decreased	O	O
nuclear	O	O
expression	O	O
of	O	O
the	O	O
known	O	O
salicylate	I-protein	O
target	I-protein	O
nuclear	I-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
-kappaB	O	O
and	O	O
was	O	O
accompanied	O	O
by	O	O
reduced	O	O
binding	O	O
of	O	O
an	O	O
inducible	B-protein	O
factor	I-protein	O
to	O	O
an	O	O
IL-4	B-DNA	O
promoter	I-DNA	O
region	I-DNA	O
upstream	O	O
of	O	O
,	O	O
but	O	O
not	O	O
overlapping	O	O
,	O	O
the	O	O
NF	O	O
of	O	O
activated	B-protein	O
T	I-protein	O
cells-	I-protein	O
and	O	O
NF-kappaB-binding	O	O
P1	O	O
element	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
anti-inflammatory	O	O
salicylates	O	O
,	O	O
by	O	O
means	O	O
of	O	O
a	O	O
previously	O	O
unrecognized	O	O
mechanism	O	O
of	O	O
action	O	O
,	O	O
can	O	O
influence	O	O
the	O	O
nature	O	O
of	O	O
adaptive	O	O
immune	O	O
responses	O	O
by	O	O
selectively	O	O
inhibiting	O	O
the	O	O
expression	O	O
of	O	O
IL-4	B-protein	O
,	O	O
a	O	O
critical	O	O
effector	O	O
of	O	O
these	O	O
responses	O	O
,	O	O
in	O	O
CD4+	B-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
.	O	O

Molecular	O	O
and	O	O
cellular	O	O
mediators	O	O
of	O	O
interleukin-1	O	O
-dependent	O	O
acute	O	O
inflammatory	O	O
arthritis	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
examine	O	O
the	O	O
molecular	O	O
and	O	O
cellular	O	O
mechanisms	O	O
in	O	O
a	O	O
model	O	O
of	O	O
acute	O	O
inflammatory	O	O
monarticular	O	O
arthritis	O	O
induced	O	O
by	O	O
methylated	O	O
bovine	O	O
serum	O	O
albumin	O	O
(	O	O
mBSA	B-protein	O
)	O	O
and	O	O
interleukin-1	B-protein	O
(	O	O
IL-1	B-protein	O
)	O	O
.	O	O

METHODS	O	O
:	O	O
Mice	O	O
were	O	O
injected	O	O
intraarticularly	O	O
with	O	O
mBSA	O	O
on	O	O
day	O	O
0	O	O
and	O	O
subcutaneously	O	O
with	O	O
recombinant	O	O
human	O	O
IL-1beta	O	O
on	O	O
days	O	O
0-2	O	O
.	O	O

At	O	O
day	O	O
7	O	O
,	O	O
knee	O	O
joints	O	O
were	O	O
removed	O	O
and	O	O
assessed	O	O
histologically	O	O
.	O	O

Flow	O	O
cytometry	O	O
and	O	O
RNase	O	O
protection	O	O
were	O	O
used	O	O
to	O	O
analyze	O	O
IL-1	O	O
-dependent	O	O
events	O	O
.	O	O

RESULTS	O	O
:	O	O
C57BL/6	O	O
(	O	O
B6	O	O
)	O	O
,	O	O
129/Sv	O	O
,	O	O
and	O	O
(	O	O
B6	O	O
x	O	O
129/	O	O
Sv	O	O
)	O	O
F1	O	O
hybrid	O	O
mice	O	O
,	O	O
all	O	O
H-2b	O	O
strains	O	O
,	O	O
were	O	O
susceptible	O	O
to	O	O
mBSA	O	O
/IL-1-induced	O	O
arthritis	O	O
,	O	O
whereas	O	O
C3H/HeJ	O	O
(	O	O
H-2k	O	O
)	O	O
mice	O	O
were	O	O
not	O	O
.	O	O

B6	O	O
mice	O	O
lacking	O	O
T	B-cell_type	O
and	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
(	O	O
RAG1-/-	B-protein	O
)	O	O
or	O	O
major	B-protein	O
histocompatibility	I-protein	O
complex	I-protein	O
(	I-protein	O
MHC	I-protein	O
)	I-protein	O
class	I-protein	O
II	I-protein	O
antigens	I-protein	O
(	O	O
MHCII-/-	B-protein	O
)	O	O
,	O	O
and	O	O
B6	O	O
mice	O	O
treated	O	O
with	O	O
a	O	O
CD4+	B-protein	O
T	O	O
cell-depleting	O	O
monoclonal	O	O
antibody	O	O
,	O	O
were	O	O
resistant	O	O
to	O	O
disease	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
B	B-protein	O
cell-deficient	O	O
(	O	O
muMT/	B-protein	O
muMT	I-protein	O
)	O	O
mice	O	O
developed	O	O
arthritis	O	O
at	O	O
an	O	O
incidence	O	O
and	O	O
severity	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
controls	O	O
.	O	O

RelB-deficient	O	O
(	O	O
RelB-/-	O	O
)	O	O
bone	O	O
marrow	O	O
chimeric	O	O
mice	O	O
had	O	O
arthritis	O	O
that	O	O
was	O	O
significantly	O	O
reduced	O	O
in	O	O
incidence	O	O
and	O	O
severity	O	O
.	O	O

In	O	O
B6	O	O
mice	O	O
,	O	O
flow	O	O
cytometry	O	O
demonstrated	O	O
an	O	O
IL-1-dependent	O	O
leukocyte	O	O
infiltration	O	O
into	O	O
the	O	O
synovial	O	O
compartment	O	O
and	O	O
RNase	O	O
protection	O	O
assays	O	O
revealed	O	O
induction	O	O
of	O	O
messenger	O	O
RNA	O	O
(	O	O
mRNA	I-RNA	O
)	O	O
for	O	O
the	O	O
chemokines	B-protein	O
monocyte	I-protein	O
chemoattractant	I-protein	O
protein	I-protein	O
1	I-protein	O
,	O	O
macrophage	B-protein	O
inhibitory	I-protein	O
protein	I-protein	O
2	I-protein	O
(	O	O
MIP-2	O	O
)	O	O
,	O	O
RANTES	O	O
,	O	O
MIP-1alpha	O	O
,	O	O
and	O	O
MIP-1beta	O	O
,	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Arthritis	O	O
induced	O	O
by	O	O
mBSA	O	O
/	O	O
IL-1	O	O
is	O	O
strain	O	O
specific	O	O
and	O	O
dependent	O	O
on	O	O
CD4+	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
at	O	O
least	O	O
partially	O	O
on	O	O
RelB	O	O
,	O	O
but	O	O
not	O	O
on	O	O
B	B-cell_type	O
lymphocytes	I-cell_type	O
or	O	O
antibody	O	O
.	O	O

IL-1	O	O
contributes	O	O
to	O	O
leukocyte	O	O
recruitment	O	O
to	O	O
the	O	O
synovium	O	O
and	O	O
directly	O	O
induces	O	O
chemokine	I-protein	O
mRNA	I-RNA	O
production	O	O
by	O	O
synovial	B-cell_type	O
cells	I-cell_type	O
.	O	O

This	O	O
model	O	O
of	O	O
acute	O	O
monarticular	O	O
arthritis	O	O
is	O	O
particularly	O	O
suitable	O	O
for	O	O
further	O	O
investigations	O	O
into	O	O
cell-mediated	O	O
immunity	O	O
in	O	O
arthritis	O	O
and	O	O
the	O	O
role	O	O
of	O	O
IL-1	B-protein	O
.	O	O

Positive	O	O
and	O	O
negative	O	O
regulation	O	O
of	O	O
granulopoiesis	O	O
by	O	O
endogenous	O	O
RARalpha	O	O
.	O	O

Acute	O	O
promyelocytic	O	O
leukemia	O	O
(	O	O
APL	O	O
)	O	O
is	O	O
always	O	O
associated	O	O
with	O	O
chromosomal	O	O
translocations	O	O
that	O	O
disrupt	O	O
the	O	O
retinoic	O	O
acid	B-protein	O
receptor	I-protein	O
alpha	I-protein	O
(	O	O
RARalpha	B-DNA	O
)	I-DNA	O
gene	I-DNA	O
.	O	O

Whether	O	O
these	O	O
translocations	O	O
relate	O	O
to	O	O
a	O	O
role	O	O
for	O	O
endogenous	O	O
RARalpha	O	O
in	O	O
normal	O	O
granulopoiesis	O	O
remains	O	O
uncertain	O	O
because	O	O
most	O	O
studies	O	O
addressing	O	O
this	O	O
question	O	O
have	O	O
used	O	O
non-physiological	O	O
overexpression	O	O
systems	O	O
.	O	O

Granulocyte	O	O
differentiation	O	O
in	O	O
cells	O	O
derived	O	O
from	O	O
RARalpha-deficient	O	O
(	O	O
RARalpha	O	O
(	O	O
-/-	B-protein	O
)	O	O
)	O	O
mice	O	O
was	O	O
studied	O	O
and	O	O
evaluated	O	O
in	O	O
the	O	O
context	O	O
of	O	O
agonist-bound	O	O
and	O	O
ligand-free	O	O
RARalpha	O	O
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
that	O	O
RARalpha	O	O
is	O	O
dispensable	O	O
for	O	O
granulopoiesis	O	O
,	O	O
as	O	O
RARalpha	O	O
(	O	O
-/-	O	O
)	O	O
mice	O	O
have	O	O
a	O	O
normal	O	O
granulocyte	O	O
population	O	O
despite	O	O
an	O	O
impaired	O	O
ability	O	O
to	O	O
respond	O	O
to	O	O
retinoids	O	O
.	O	O

However	O	O
,	O	O
although	O	O
it	O	O
is	O	O
not	O	O
absolutely	O	O
required	O	O
,	O	O
RARalpha	O	O
can	O	O
bidirectionally	O	O
modulate	O	O
granulopoiesis	O	O
.	O	O

RARalpha	O	O
stimulates	O	O
differentiation	O	O
in	O	O
response	O	O
to	O	O
exogenous	O	O
retinoic	O	O
acid	O	O
.	O	O

Furthermore	O	O
,	O	O
endogenous	O	O
retinoids	O	O
control	O	O
granulopoiesis	O	O
in	O	O
vivo	O	O
,	O	O
as	O	O
either	O	O
vitamin	O	O
A-deficient	O	O
mice	O	O
or	O	O
animals	O	O
treated	O	O
with	O	O
an	O	O
RAR	O	O
antagonist	O	O
accumulate	O	O
more	O	O
immature	O	O
granulocytes	O	O
in	O	O
their	O	O
bone	O	O
marrow	O	O
.	O	O

Conversely	O	O
,	O	O
RARalpha	O	O
acts	O	O
to	O	O
limit	O	O
differentiation	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
ligand	O	O
because	O	O
granulocyte	O	O
precursors	O	O
from	O	O
RARalpha	O	O
(	O	O
-/-	O	O
)	O	O
mice	O	O
differentiate	O	O
earlier	O	O
in	O	O
culture	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
block	O	O
in	O	O
granulopoiesis	O	O
exerted	O	O
by	O	O
RARalpha	O	O
fusion	O	O
proteins	O	O
expressed	O	O
in	O	O
APL	B-cell_type	O
cells	I-cell_type	O
may	O	O
correspond	O	O
to	O	O
an	O	O
amplification	O	O
of	O	O
a	O	O
normal	O	O
function	O	O
of	O	O
unliganded	O	O
RARalpha	O	O
.	O	O

Expression	O	O
and	O	O
function	O	O
of	O	O
a	O	O
stem	B-DNA	O
cell	I-DNA	O
promoter	I-DNA	O
for	O	O
the	O	O
murine	B-DNA	O
CBFalpha2	I-DNA	O
gene	I-DNA	O
:	O	O
distinct	O	O
roles	O	O
and	O	O
regulation	O	O
in	O	O
natural	O	O
killer	I-cell_type	O
and	O	O
T	O	O
cell	O	O
development	O	O
.	O	O

The	O	O
Runt	B-protein	O
family	I-protein	O
transcription	I-protein	O
factor	I-protein	O
CBFalpha2	I-protein	O
(	O	O
AML1	B-protein	O
,	O	O
PEBP2alphaB	O	O
,	O	O
or	O	O
Runx1	O	O
)	O	O
is	O	O
required	O	O
by	O	O
hematopoietic	B-cell_type	O
stem	I-cell_type	O
cells	I-cell_type	O
and	O	O
expressed	O	O
at	O	O
high	O	O
levels	O	O
in	O	O
T-lineage	B-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
CBFalpha2	O	O
is	O	O
usually	O	O
transcribed	O	O
from	O	O
a	O	O
different	O	O
promoter	B-DNA	O
(	O	O
distal	B-DNA	O
promoter	I-DNA	O
)	O	O
than	O	O
in	O	O
myeloid	B-cell_type	O
cells	I-cell_type	O
(	O	O
proximal	B-DNA	O
promoter	I-DNA	O
)	O	O
,	O	O
but	O	O
the	O	O
developmental	O	O
and	O	O
functional	O	O
significance	O	O
of	O	O
this	O	O
promoter	O	O
switch	O	O
has	O	O
not	O	O
been	O	O
known	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
that	O	O
both	O	O
coding	O	O
and	O	O
noncoding	O	O
sequences	O	O
of	O	O
the	O	O
distal	B-DNA	O
5	I-DNA	O
'	I-DNA	O
end	O	O
are	O	O
highly	O	O
conserved	O	O
between	O	O
the	O	O
human	O	O
and	O	O
the	O	O
murine	B-DNA	O
genes	I-DNA	O
,	O	O
and	O	O
the	O	O
distal	B-DNA	O
promoter	I-DNA	O
is	O	O
responsible	O	O
for	O	O
the	O	O
overwhelming	O	O
majority	O	O
of	O	O
CBFalpha2	O	O
expression	O	O
in	O	O
murine	B-cell_type	O
hematopoietic	I-cell_type	O
stem	I-cell_type	O
cells	I-cell_type	O
as	O	O
well	O	O
as	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Distal	O	O
promoter	O	O
activity	O	O
is	O	O
maintained	O	O
throughout	O	O
T	O	O
cell	O	O
development	O	O
and	O	O
at	O	O
lower	O	O
levels	O	O
in	O	O
B	O	O
cell	O	O
development	O	O
,	O	O
but	O	O
downregulated	O	O
in	O	O
natural	O	O
killer	O	O
cell	O	O
development	O	O
.	O	O

The	O	O
distal	B-protein	O
N-terminal	I-protein	O
isoform	I-protein	O
binds	O	O
to	O	O
functionally	O	O
important	O	O
regulatory	O	O
sites	O	O
from	O	O
known	O	O
target	O	O
genes	O	O
with	O	O
two-	O	O
to	O	O
threefold	O	O
higher	O	O
affinity	O	O
than	O	O
the	O	O
proximal	B-protein	O
N-terminal	I-protein	O
isoform	I-protein	O
.	O	O

Neither	O	O
full-length	O	O
isoform	O	O
alters	O	O
growth	O	O
of	O	O
a	O	O
myeloid	B-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
under	O	O
nondifferentiating	O	O
conditions	O	O
,	O	O
but	O	O
the	O	O
proximal	B-protein	O
isoform	I-protein	O
selectively	O	O
delays	O	O
mitotic	O	O
arrest	O	O
of	O	O
the	O	O
cell	O	O
line	O	O
under	O	O
differentiating	O	O
conditions	O	O
,	O	O
resulting	O	O
in	O	O
the	O	O
generation	O	O
of	O	O
greater	O	O
numbers	O	O
of	O	O
neutrophils	O	O
.	O	O

Constitutive	O	O
PI3-K	O	O
activity	O	O
is	O	O
essential	O	O
for	O	O
proliferation	O	O
,	O	O
but	O	O
not	O	O
survival	O	O
,	O	O
of	O	O
Theileria	B-cell_type	O
parva-transformed	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

Theileria	O	O
is	O	O
an	O	O
intracellular	O	O
parasite	O	O
that	O	O
causes	O	O
lymphoproliferative	O	O
disorders	O	O
in	O	O
cattle	O	O
,	O	O
and	O	O
infection	O	O
of	O	O
leucocytes	O	O
induces	O	O
a	O	O
transformed	O	O
phenotype	O	O
similar	O	O
to	O	O
tumour	B-cell_type	O
cells	I-cell_type	O
,	O	O
but	O	O
the	O	O
mechanisms	O	O
by	O	O
which	O	O
the	O	O
parasite	O	O
induces	O	O
this	O	O
phenotype	O	O
are	O	O
not	O	O
understood	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
infected	O	O
B	O	O
lymphocytes	O	O
display	O	O
constitutive	O	O
phosphoinositide	O	O
3-kinase	O	O
(	O	O
PI3-K	B-protein	O
)	O	O
activity	O	O
,	O	O
which	O	O
appears	O	O
to	O	O
be	O	O
necessary	O	O
for	O	O
proliferation	O	O
,	O	O
but	O	O
not	O	O
survival	O	O
.	O	O

Importantly	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
one	O	O
mechanism	O	O
by	O	O
which	O	O
PI3-K	O	O
mediates	O	O
the	O	O
proliferation	O	O
of	O	O
infected	B-cell_type	O
B	I-cell_type	O
lymphocytes	I-cell_type	O
is	O	O
through	O	O
the	O	O
induction	O	O
of	O	O
a	O	O
granulocyte-monocyte	B-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
(	O	O
GM-CSF	B-protein	O
)	O	O
-dependent	O	O
autocrine	O	O
loop	O	O
.	O	O

PI3-K	O	O
induction	O	O
of	O	O
GM-CSF	B-protein	O
appears	O	O
to	O	O
be	O	O
at	O	O
the	O	O
transcriptional	O	O
level	O	O
and	O	O
,	O	O
consistently	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
PI3-K	O	O
is	O	O
also	O	O
involved	O	O
in	O	O
the	O	O
constitutive	O	O
induction	O	O
of	O	O
AP-1	B-protein	O
and	O	O
NF-kappaB	O	O
,	O	O
which	O	O
characterizes	O	O
Theileria-infected	O	O
leucocytes	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
results	O	O
highlight	O	O
a	O	O
novel	O	O
strategy	O	O
exploited	O	O
by	O	O
the	O	O
intracellular	O	O
parasite	O	O
Theileria	O	O
to	O	O
induce	O	O
continued	O	O
proliferation	O	O
of	O	O
its	O	O
host	O	O
leucocyte	O	O
.	O	O

Lymphokine	O	O
dependence	O	O
of	O	O
STAT3	B-protein	O
activation	O	O
produced	O	O
by	O	O
surface	O	O
immunoglobulin	O	O
cross-linking	O	O
and	O	O
by	O	O
phorbol	O	O
ester	O	O
plus	O	O
calcium	O	O
ionophore	O	O
treatment	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

Stimulation	O	O
of	O	O
B	B-cell_type	O
cells	I-cell_type	O
by	O	O
surface	O	O
immunoglobulin	O	O
(	O	O
sIg	B-protein	O
)	O	O
triggering	O	O
,	O	O
or	O	O
through	O	O
the	O	O
mitogenic	O	O
combination	O	O
of	O	O
phorbol	O	O
ester	O	O
and	O	O
calcium	O	O
ionophore	O	O
,	O	O
is	O	O
accompanied	O	O
by	O	O
activation	O	O
of	O	O
STAT	B-protein	O
transcription	I-protein	O
factors	I-protein	O
.	O	O

The	O	O
mechanism	O	O
responsible	O	O
for	O	O
the	O	O
delayed	O	O
nuclear	O	O
accumulation	O	O
of	O	O
phosphorylated	O	O
STAT3	O	O
was	O	O
examined	O	O
in	O	O
detail	O	O
,	O	O
focusing	O	O
on	O	O
the	O	O
role	O	O
of	O	O
B	B-protein	O
cell-derived	O	O
lymphokines	O	O
.	O	O

sIg	O	O
-induced	O	O
activation	O	O
of	O	O
STAT3	O	O
was	O	O
partially	O	O
inhibited	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
obtained	O	O
from	O	O
IL-6-	O	O
or	O	O
IL-10-deficient	O	O
mice	O	O
,	O	O
and	O	O
was	O	O
partially	O	O
blocked	O	O
by	O	O
neutralizing	O	O
antibodies	O	O
directed	O	O
against	O	O
either	O	O
of	O	O
these	O	O
lymphokines	O	O
.	O	O

sIg	O	O
-induced	O	O
STAT3	O	O
activation	O	O
was	O	O
completely	O	O
inhibited	O	O
by	O	O
combining	O	O
IL-6-	O	O
and	O	O
IL-10-specific	O	O
neutralizing	O	O
antibodies	O	O
,	O	O
or	O	O
by	O	O
adding	O	O
individual	O	O
neutralizing	O	O
antibodies	O	O
to	O	O
B	B-cell_type	O
cells	I-cell_type	O
obtained	O	O
from	O	O
lymphokine-deficient	O	O
animals	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
IL-10	B-protein	O
alone	O	O
appeared	O	O
to	O	O
account	O	O
for	O	O
STAT3	O	O
activation	O	O
resulting	O	O
from	O	O
B	O	O
cell	O	O
stimulation	O	O
with	O	O
phorbol	O	O
ester	O	O
and	O	O
calcium	O	O
ionophore	O	O
.	O	O

In	O	O
keeping	O	O
with	O	O
these	O	O
results	O	O
,	O	O
soluble	O	O
IL-6	O	O
and	O	O
IL-10	B-protein	O
were	O	O
found	O	O
in	O	O
supernatant	O	O
fluid	O	O
obtained	O	O
from	O	O
stimulated	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

This	O	O
work	O	O
indicates	O	O
that	O	O
a	O	O
lymphokine	O	O
pathway	O	O
is	O	O
responsible	O	O
for	O	O
STAT3	O	O
activation	O	O
that	O	O
occurs	O	O
late	O	O
after	O	O
B	O	O
cell	O	O
stimulation	O	O
,	O	O
and	O	O
points	O	O
out	O	O
differences	O	O
in	O	O
B	O	O
cell	O	O
activation	O	O
that	O	O
result	O	O
from	O	O
stimulation	O	O
through	O	O
the	O	O
antigen	B-protein	O
receptor	I-protein	O
and	O	O
through	O	O
pharmacological	O	O
mimicry	O	O
of	O	O
signaling	O	O
mediators	O	O
.	O	O

Transcription	B-protein	O
factor	I-protein	O
AP-4	O	O
is	O	O
a	O	O
ligand	O	O
for	O	O
immunoglobulin-kappa	O	O
promoter	O	O
E-box	O	O
elements	O	O
.	O	O

Immunoglobulin	O	O
(	O	O
Ig	B-protein	O
)	O	O
-kappa	O	O
promoters	O	O
from	O	O
humans	O	O
and	O	O
mice	O	O
share	O	O
conserved	O	O
sequences	O	O
.	O	O

The	O	O
octamer	B-DNA	O
element	I-DNA	O
is	O	O
common	O	O
to	O	O
all	O	O
Ig	O	O
promoters	O	O
and	O	O
pivotal	O	O
for	O	O
their	O	O
function	O	O
.	O	O

However	O	O
,	O	O
other	O	O
conserved	O	O
sequence	B-protein	O
motifs	I-protein	O
,	O	O
that	O	O
differ	O	O
between	O	O
Ig	O	O
variable	O	O
gene	O	O
families	O	O
,	O	O
are	O	O
required	O	O
for	O	O
normal	O	O
promoter	O	O
function	O	O
.	O	O

These	O	O
conserved	B-protein	O
motifs	I-protein	O
do	O	O
not	O	O
stimulate	O	O
transcription	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
an	O	O
octamer	O	O
.	O	O

One	O	O
example	O	O
is	O	O
an	O	O
E-box	O	O
of	O	O
the	O	O
E47/E12	B-protein	O
type	I-protein	O
(	O	O
5'-CAGCTG-3	I-DNA	O
'	I-DNA	O
)	O	O
,	O	O
which	O	O
is	O	O
found	O	O
in	O	O
all	O	O
promoters	O	O
of	O	O
the	O	O
human	B-DNA	O
and	I-DNA	O
murine	I-DNA	O
Ig-kappa	I-DNA	O
gene	I-DNA	O
subgroups/families	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
subgroups	B-protein	O
II	I-protein	O
and	O	O
VI	B-protein	O
and	O	O
their	B-protein	O
related	O	O
murine	O	O
families	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
we	O	O
show	O	O
that	O	O
the	O	O
ubiquitously	O	O
expressed	O	O
transcription	B-protein	O
factor	I-protein	O
AP-4	O	O
,	O	O
and	O	O
not	O	O
E47	O	O
,	O	O
interacts	O	O
specifically	O	O
with	O	O
the	O	O
kappa	B-DNA	O
promoter	I-DNA	O
E-boxes	O	O
when	O	O
tested	O	O
in	O	O
electrophoretic	O	O
mobility-shift	O	O
assays	O	O
using	O	O
nuclear	O	O
extracts	O	O
derived	O	O
from	O	O
human	O	O
and	O	O
murine	I-cell_line	O
B-cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

Furthermore	O	O
,	O	O
AP-4	O	O
,	O	O
unlike	O	O
E47	O	O
,	O	O
did	O	O
not	O	O
act	O	O
as	O	O
a	O	O
transactivator	O	O
,	O	O
which	O	O
is	O	O
in	O	O
agreement	O	O
with	O	O
previous	O	O
studies	O	O
on	O	O
intact	O	O
kappa	B-DNA	O
promoters	I-DNA	O
,	O	O
showing	O	O
that	O	O
transcription	O	O
is	O	O
absent	O	O
when	O	O
the	O	O
octamer	O	O
element	I-DNA	O
has	O	O
been	O	O
mutated	O	O
.	O	O

Based	O	O
on	O	O
these	O	O
data	O	O
,	O	O
and	O	O
the	O	O
conservation	O	O
of	O	O
the	O	O
5'-CAGCTG-3	B-protein	O
'	I-protein	O
motif	I-protein	O
among	I-protein	O
human	B-DNA	O
and	I-DNA	O
murine	I-DNA	O
kappa	I-DNA	O
promoters	I-DNA	O
,	O	O
we	O	O
propose	O	O
that	O	O
AP-4	O	O
is	O	O
the	O	O
major	O	O
ligand	O	O
for	O	O
Ig-kappa	O	O
promoter	O	O
E-boxes	O	O
.	O	O

A	O	O
16-mer	O	O
peptide	O	O
(	O	O
RQIKIWFQNRRMKWKK	O	O
)	O	O
from	O	O
antennapedia	O	O
preferentially	O	O
targets	O	O
the	O	O
Class	O	O
I	O	O
pathway	O	O
.	O	O

Translocation	O	O
of	O	O
antigenic	O	O
peptides	O	O
into	O	O
the	O	O
cytosol	O	O
of	O	O
antigen	B-cell_type	O
presenting	I-cell_type	O
cells	I-cell_type	O
facilitates	O	O
proteosomal	O	O
processing	O	O
and	O	O
loading	O	O
into	O	O
Class	O	O
I	O	O
molecules	O	O
for	O	O
MHC	O	O
presentation	O	O
on	O	O
the	O	O
cell	O	O
surface	O	O
.	O	O

The	O	O
DNA	B-protein	O
binding	I-protein	O
domain	I-protein	O
of	O	O
the	O	O
Drosophila	B-protein	O
transcription	I-protein	O
factor	I-protein	O
(	O	O
Antennapedia	B-protein	O
)	O	O
,	O	O
a	O	O
60	B-protein	O
amino	I-protein	O
acid	O	O
protein	O	O
,	O	O
is	O	O
rapidly	O	O
taken	O	O
up	O	O
by	O	O
cells	O	O
and	O	O
has	O	O
been	O	O
fused	O	O
to	O	O
selected	O	O
antigens	O	O
to	O	O
enhance	O	O
their	O	O
immunogenicity	O	O
.	O	O

We	O	O
now	O	O
demonstrate	O	O
that	O	O
a	O	O
16	O	O
amino	O	O
acid	O	O
peptide	O	O
from	O	O
antennapedia	O	O
can	O	O
facilitate	O	O
the	O	O
cytoplasmic	O	O
uptake	O	O
of	O	O
CTL	O	O
epitope	O	O
9-mer	O	O
peptides	O	O
.	O	O

Synthetic	O	O
peptides	O	O
were	O	O
made	O	O
containing	O	O
the	O	O
16-mer	B-DNA	O
antennapedia	I-DNA	O
peptide	O	O
linked	O	O
in	O	O
tandem	O	O
to	O	O
the	O	O
ovalbumin	O	O
SIINFEKL	O	O
CTL	O	O
peptide	O	O
.	O	O

The	O	O
peptide	O	O
complex	O	O
was	O	O
shown	O	O
to	O	O
rapidly	O	O
internalise	O	O
into	O	O
APCs	O	O
by	O	O
confocal	O	O
microscopy	O	O
.	O	O

This	O	O
peptide	O	O
induced	O	O
CTL	O	O
in	O	O
C57BL/6	O	O
mice	O	O
and	O	O
protected	O	O
them	O	O
against	O	O
growth	O	O
of	O	O
an	O	O
ovalbumin	O	O
expressing	O	O
tumour	O	O
cell	O	O
line	O	O
(	O	O
E.G7-OVA	O	O
)	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
the	O	O
hybrid	B-DNA	O
peptide	I-DNA	O
to	O	O
be	O	O
processed	O	O
and	O	O
presented	O	O
by	O	O
APCs	O	O
was	O	O
similar	O	O
,	O	O
whether	O	O
the	O	O
SIINFEKL	O	O
sequence	O	O
was	O	O
appended	O	O
at	O	O
the	O	O
C-terminus	O	O
or	O	O
N-terminus	O	O
of	O	O
the	O	O
Antennapedia	B-protein	O
peptide	I-protein	O
.	O	O

The	O	O
production	O	O
of	O	O
synthetic	O	O
peptides	O	O
containing	O	O
other	O	O
CTL	O	O
peptide	O	O
epitopes	O	O
may	O	O
be	O	O
useful	O	O
for	O	O
priming	O	O
CTLs	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O

Bone	O	O
marrow	O	O
cells	O	O
promote	O	O
TH2	O	O
polarization	O	O
and	O	O
inhibit	O	O
virus-specific	O	O
CTL	O	O
generation	O	O
.	O	O

This	O	O
laboratory	O	O
recently	O	O
reported	O	O
that	O	O
human	B-cell_line	O
bone	I-cell_line	O
marrow	I-cell_line	O
cells	I-cell_line	O
(	O	O
BMC	O	O
)	O	O
inhibit	O	O
the	O	O
generation	O	O
of	O	O
virus-specific	O	O
CTL	O	O
in	O	O
culture	O	O
.	O	O

The	O	O
culture	O	O
supernatants	O	O
contained	O	O
increased	O	O
levels	O	O
of	O	O
prostaglandin	B-protein	O
E	I-protein	O
(	I-protein	O
2	I-protein	O
)	O	O
(	O	O
PGE	B-protein	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
shown	O	O
to	O	O
favor	O	O
TH2	O	O
cell	O	O
development	O	O
)	O	O
and	O	O
also	O	O
inhibited	O	O
EBV-CTL	O	O
effector	O	O
cell	O	O
development	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
obtained	O	O
PBL	O	O
from	O	O
Epstein-Barr	O	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
IgG	O	O
antibody	O	O
positive	O	O
kidney	O	O
transplant	O	O
recipients	O	O
(	O	O
R	O	O
)	O	O
and	O	O
their	O	O
living-related	O	O
donors	O	O
(	O	O
LRD	O	O
)	O	O
one	O	O
year	O	O
after	O	O
renal	O	O
transplantation	O	O
.	O	O

EBV-specific	O	O
CTL	O	O
were	O	O
then	O	O
generated	O	O
in	O	O
vitro	O	O
by	O	O
stimulating	O	O
PBL	O	O
with	O	O
autologous	B-cell_type	O
EBV-transformed	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
(	O	O
EBV-B	O	O
)	O	O
in	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
autologous	O	O
BMC	O	O
.	O	O

The	O	O
addition	O	O
of	O	O
BMC	O	O
to	O	O
the	O	O
EBV-CTL	O	O
generation	O	O
cultures	O	O
increased	O	O
the	O	O
intracellular	O	O
expression	O	O
in	O	O
CD3+	O	O
cells	O	O
of	O	O
IL-4	B-protein	O
,	O	O
-5	O	O
,	O	O
-6	O	O
,	O	O
-10	O	O
,	O	O
and	O	O
-13	O	O
.	O	O

These	O	O
CD3+	B-cell_type	O
cells	I-cell_type	O
also	O	O
expressed	O	O
increased	O	O
levels	O	O
of	O	O
the	O	O
TH2	O	O
associated	O	O
receptor	I-protein	O
CCR3	O	O
.	O	O

Inhibition	O	O
was	O	O
even	O	O
observed	O	O
by	O	O
preparing	O	O
EBV-CTL	O	O
generating	O	O
cultures	O	O
in	O	O
trans-wells	O	O
that	O	O
separated	O	O
the	O	O
autologous	O	O
BMC	O	O
from	O	O
the	O	O
PBL	O	O
+	O	O
EBV-B	O	O
.	O	O

It	O	O
was	O	O
then	O	O
observed	O	O
that	O	O
CD3+	B-cell_type	O
cells	I-cell_type	O
obtained	O	O
after	O	O
7	O	O
days	O	O
of	O	O
culture	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
autologous	O	O
BMC	O	O
could	O	O
be	O	O
used	O	O
as	O	O
inhibitors	O	O
of	O	O
EBV-CTL	O	O
generation	O	O
.	O	O

Protein	O	O
Kinase	O	O
A	O	O
(	O	O
PKA	B-protein	O
)	O	O
,	O	O
a	O	O
cAMP	O	O
kinase	I-protein	O
that	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
upregulation	O	O
of	O	O
TH2	O	O
cytokine	B-protein	O
activity	O	O
,	O	O
was	O	O
increased	O	O
in	O	O
EBV-CTL	O	O
cultures	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
BMC	O	O
.	O	O

Additionally	O	O
,	O	O
IL-4-mediated	O	O
signal	O	O
transduction	O	O
and	O	O
activation	O	O
of	O	O
transcription	O	O
(	O	O
STAT-6	B-protein	O
)	O	O
phosphorylation	O	O
was	O	O
slightly	O	O
increased	O	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
the	O	O
BMC	O	O
inhibition	O	O
is	O	O
mediated	O	O
by	O	O
soluble	B-protein	O
factors	I-protein	O
(	O	O
cytokines	B-protein	O
)	O	O
and	O	O
that	O	O
cell-cell	O	O
contact	O	O
in	O	O
this	O	O
autologous	O	O
system	O	O
is	O	O
not	O	O
required	O	O
,	O	O
so	O	O
that	O	O
BMC	O	O
(	O	O
at	O	O
least	O	O
partially	O	O
,	O	O
via	O	O
cytokine	B-protein	O
production	O	O
)	O	O
promote	O	O
TH2	O	O
polarization	O	O
in	O	O
culture	O	O
.	O	O

Moreover	O	O
,	O	O
TH2	B-cell_type	O
cells	I-cell_type	O
induced	O	O
by	O	O
culturing	O	O
with	O	O
autologous	O	O
BMC	O	O
directly	O	O
inhibit	O	O
EBV-CTL	O	O
generation	O	O
,	O	O
and	O	O
TH2	O	O
associated	O	O
PKA	O	O
,	O	O
CCR3	O	O
,	O	O
and	O	O
STAT-6	O	O
phosphorylation	O	O
are	O	O
enhanced	O	O
by	O	O
BMC	O	O
.	O	O

Reduction	O	O
in	O	O
DNA	O	O
binding	O	O
activity	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
Pax-5a	O	O
in	O	O
B	B-cell_type	O
lymphocytes	I-cell_type	O
of	O	O
aged	O	O
mice	O	O
.	O	O

Aging	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
intrinsic	O	O
changes	O	O
of	O	O
the	O	O
humoral	O	O
immune	O	O
response	O	O
,	O	O
which	O	O
may	O	O
lead	O	O
to	O	O
an	O	O
increased	O	O
occurrence	O	O
of	O	O
autoimmune	O	O
disorders	O	O
and	O	O
pathogenic	O	O
susceptibility	O	O
.	O	O

The	O	O
transcription	B-protein	O
factor	I-protein	O
Pax-5	O	O
is	O	O
a	O	O
key	O	O
regulator	O	O
of	O	O
B	B-protein	O
cell	O	O
development	O	O
.	O	O

Pax-5a/B	O	O
cell-specific	B-protein	O
activator	I-protein	O
protein	I-protein	O
and	O	O
an	O	O
alternatively	B-protein	O
spliced	I-protein	O
isoform	I-protein	O
,	O	O
Pax-5d	O	O
,	O	O
may	O	O
have	O	O
opposing	O	O
functions	O	O
in	O	O
transcriptional	O	O
regulation	O	O
due	O	O
to	O	O
the	O	O
lack	O	O
of	O	O
a	O	O
transactivation	B-DNA	O
domain	I-DNA	O
in	O	O
Pax-5d	O	O
.	O	O

To	O	O
study	O	O
B	O	O
cell	O	O
-specific	O	O
changes	O	O
that	O	O
occur	O	O
during	O	O
the	O	O
aging	O	O
process	O	O
,	O	O
we	O	O
investigated	O	O
expression	O	O
patterns	O	O
of	O	O
Pax-5a	O	O
and	O	O
5d	O	O
in	O	O
mature	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
of	O	O
young	O	O
and	O	O
aged	O	O
mice	O	O
.	O	O

RNase	O	O
protection	O	O
assays	O	O
showed	O	O
a	O	O
similar	O	O
transcriptional	O	O
pattern	O	O
for	O	O
both	O	O
age	O	O
groups	O	O
that	O	O
indicates	O	O
that	O	O
aging	O	O
has	O	O
no	O	O
affect	O	O
on	O	O
transcription	O	O
initiation	O	O
or	O	O
alternative	O	O
splicing	O	O
for	O	O
either	O	O
isoform	B-protein	O
.	O	O

In	O	O
contrast	O	O
,	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
DNA	O	O
binding	O	O
activity	O	O
of	O	O
Pax-5a	B-protein	O
but	O	O
not	O	O
Pax-5d	B-protein	O
protein	I-protein	O
was	O	O
observed	O	O
in	O	O
aged	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
in	O	O
vitro	O	O
,	O	O
while	O	O
Western	O	O
blot	O	O
analyses	O	O
showed	O	O
that	O	O
similar	O	O
levels	O	O
of	O	O
Pax-5a	B-protein	O
and	O	O
5d	B-protein	O
proteins	I-protein	O
were	O	O
present	O	O
in	O	O
both	O	O
age	O	O
groups	O	O
.	O	O

The	O	O
observed	O	O
decrease	O	O
in	O	O
Pax-5a	O	O
binding	O	O
activity	O	O
correlated	O	O
with	O	O
changes	O	O
in	O	O
expression	O	O
of	O	O
two	O	O
Pax-5	O	O
target	O	O
genes	O	O
in	O	O
aged	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

Expression	O	O
of	O	O
the	O	O
Ig	O	O
J	O	O
chain	O	O
and	O	O
the	O	O
secreted	O	O
form	O	O
of	O	O
Ig	O	O
mu	O	O
,	O	O
which	O	O
are	O	O
both	O	O
known	O	O
to	O	O
be	O	O
suppressed	O	O
by	O	O
Pax-5a	O	O
in	O	O
mature	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
,	O	O
were	O	O
increased	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
of	O	O
aged	O	O
mice	O	O
.	O	O

Together	O	O
,	O	O
our	O	O
studies	O	O
suggest	O	O
that	O	O
changes	O	O
associated	O	O
with	O	O
the	O	O
aging	O	O
phenotype	O	O
cause	O	O
posttranslational	O	O
modification	O	O
(	O	O
s	O	O
)	O	O
of	O	O
Pax-5a	O	O
but	O	O
not	O	O
Pax-5d	O	O
,	O	O
which	O	O
may	O	O
lead	O	O
to	O	O
an	O	O
abnormal	O	O
B	O	O
cell	O	O
phenotype	O	O
in	O	O
aged	O	O
mice	O	O
,	O	O
associated	O	O
with	O	O
elevated	O	O
levels	O	O
of	O	O
J	O	O
chain	O	O
,	O	O
and	O	O
secretion	O	O
of	O	O
IgM	O	O

NF-kappa	B-protein	O
B/Rel	O	O
participation	O	O
in	O	O
the	O	O
lymphokine-dependent	O	O
proliferation	O	O
of	O	O
T	B-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
.	O	O

Proliferative	O	O
responses	O	O
of	O	O
lymphoid	B-cell_type	O
cells	I-cell_type	O
to	O	O
IL-2	B-protein	O
and	O	O
IL-4	O	O
depend	O	O
on	O	O
activation	O	O
of	O	O
the	O	O
cells	I-cell_type	O
,	O	O
but	O	O
the	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
by	O	O
which	O	O
activation	O	O
enhances	O	O
cellular	O	O
competence	O	O
to	O	O
respond	O	O
to	O	O
cytokines	B-protein	O
is	O	O
not	O	O
fully	O	O
understood	O	O
.	O	O

The	O	O
NF-kappaB/Rel	O	O
family	O	O
represents	O	O
one	O	O
signal	O	O
transduction	O	O
pathway	O	O
induced	O	O
during	O	O
such	O	O
activation	O	O
.	O	O

We	O	O
show	O	O
in	O	O
this	O	O
study	O	O
that	O	O
inhibition	O	O
of	O	O
NF-kappaB	O	O
through	O	O
the	O	O
expression	O	O
of	O	O
an	O	O
IkappaBalpha	B-protein	O
(	I-protein	O
inhibitory	I-protein	O
protein	I-protein	O
that	O	O
dissociates	O	O
from	O	O
NF-kappaB	O	O
)	O	O
mutant	O	O
refractory	O	O
to	O	O
signal-induced	O	O
degradation	O	O
(	O	O
IkappaBalpha	O	O
(	O	O
DeltaN	O	O
)	O	O
)	O	O
interfered	O	O
with	O	O
the	O	O
acquisition	O	O
of	O	O
competence	O	O
to	O	O
proliferate	O	O
in	O	O
response	O	O
to	O	O
IL-4	O	O
as	O	O
well	O	O
as	O	O
IL-2	B-protein	O
.	O	O

Thymocytes	O	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
from	O	O
IkappaBalpha	O	O
(	O	O
DeltaN	O	O
)	O	O
transgenic	O	O
mice	O	O
expressed	O	O
normal	O	O
levels	O	O
of	O	O
IL-2R	B-protein	O
subunits	I-protein	O
.	O	O

However	O	O
,	O	O
transgenic	B-cell_type	O
cells	I-cell_type	O
exhibited	O	O
a	O	O
dramatic	O	O
defect	O	O
in	O	O
Stat5A	O	O
activation	O	O
treatment	O	O
with	O	O
IL-2	B-protein	O
,	O	O
and	O	O
a	O	O
similar	O	O
defect	O	O
was	O	O
observed	O	O
for	O	O
IL-4	B-protein	O
-induced	O	O
Stat5	B-protein	O
.	O	O

In	O	O
contrast	O	O
,	O	O
T	B-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
with	O	O
inhibition	O	O
of	O	O
NF-kappaB	O	O
showed	O	O
normal	O	O
insulin	B-protein	O
receptor	I-protein	O
substrate-2	O	O
phosphorylation	O	O
and	O	O
only	O	O
a	O	O
modest	O	O
decrease	O	O
in	O	O
Stat6	O	O
activation	O	O
and	O	O
insulin	O	O
receptor	O	O
substrate-1	O	O
phosphorylation	O	O
after	O	O
IL-4	O	O
stimulation	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
NF-kappaB/Rel/IkappaBalpha	O	O
system	O	O
can	O	O
regulate	O	O
cytokine	O	O
receptor	O	O
capacitation	O	O
through	O	O
effects	O	O
on	O	O
the	O	O
induction	O	O
of	O	O
downstream	O	O
signaling	O	O
by	O	O
the	O	O
Stat	B-protein	O
transcription	I-protein	O
factor	I-protein	O
family	I-protein	O
.	O	O

BMS-189453	O	O
,	O	O
a	O	O
novel	O	O
retinoid	B-protein	O
receptor	I-protein	O
antagonist	O	O
,	O	O
is	O	O
a	O	O
potent	O	O
testicular	O	O
toxin	O	O
.	O	O

BMS-189453	O	O
is	O	O
a	O	O
synthetic	O	O
retinoid	O	O
that	O	O
acts	O	O
as	O	O
an	O	O
antagonist	O	O
at	O	O
retinoic	O	O
acid	O	O
receptors	O	O
alpha	O	O
,	O	O
beta	O	O
,	O	O
and	O	O
gamma	O	O
.	O	O

In	O	O
Sprague	O	O
Dawley	O	O
rats	O	O
at	O	O
daily	O	O
oral	O	O
doses	O	O
of	O	O
15	O	O
,	O	O
60	O	O
,	O	O
or	O	O
240	O	O
mg/kg	O	O
for	O	O
1	O	O
month	O	O
,	O	O
BMS-189453	O	O
produced	O	O
increases	O	O
in	O	O
leukocyte	O	O
counts	O	O
,	O	O
alkaline	O	O
phosphatase	O	O
and	O	O
alanine	O	O
aminotransferase	O	O
levels	O	O
,	O	O
and	O	O
marked	O	O
testicular	O	O
degeneration	O	O
and	O	O
atrophy	O	O
at	O	O
all	O	O
doses	O	O
.	O	O

Significant	O	O
overt	O	O
signs	O	O
of	O	O
toxicity	O	O
and	O	O
deaths	O	O
occurred	O	O
at	O	O
240	O	O
mg/kg	O	O
,	O	O
whereas	O	O
body-weight	O	O
and	O	O
food-consumption	O	O
decreases	O	O
occurred	O	O
at	O	O
60	O	O
and	O	O
240	O	O
mg/kg	O	O
.	O	O

When	O	O
BMS-189453	O	O
was	O	O
administered	O	O
to	O	O
male	O	O
rats	O	O
at	O	O
daily	O	O
doses	O	O
ranging	O	O
from	O	O
12.5	O	O
to	O	O
100	O	O
mg/kg	O	O
for	O	O
1	O	O
week	O	O
,	O	O
only	O	O
minimal	O	O
testicular	O	O
changes	O	O
occurred	O	O
at	O	O
all	O	O
doses	O	O
,	O	O
shortly	O	O
after	O	O
the	O	O
dosing	O	O
period	O	O
.	O	O

However	O	O
,	O	O
after	O	O
a	O	O
1-month	O	O
drug-free	O	O
observation	O	O
period	O	O
,	O	O
marked	O	O
testicular	O	O
atrophy	O	O
was	O	O
evident	O	O
at	O	O
all	O	O
doses	O	O
.	O	O

BMS-189453	O	O
was	O	O
then	O	O
administered	O	O
at	O	O
doses	O	O
of	O	O
2	O	O
,	O	O
10	O	O
,	O	O
or	O	O
50	O	O
mg/kg	O	O
to	O	O
male	O	O
rats	O	O
for	O	O
1	O	O
,	O	O
3	O	O
,	O	O
or	O	O
7	O	O
consecutive	O	O
days	O	O
.	O	O

Dose-	O	O
and	O	O
duration-dependent	O	O
testicular	O	O
toxicity	O	O
that	O	O
occurred	O	O
after	O	O
a	O	O
1-month	O	O
observation	O	O
period	O	O
did	O	O
not	O	O
recover	O	O
,	O	O
and	O	O
,	O	O
in	O	O
some	O	O
cases	O	O
,	O	O
was	O	O
more	O	O
severe	O	O
4	O	O
months	O	O
after	O	O
the	O	O
last	O	O
dose	O	O
.	O	O

In	O	O
rabbits	O	O
administered	O	O
BMS-189453	O	O
at	O	O
oral	O	O
doses	O	O
of	O	O
2	O	O
,	O	O
10	O	O
,	O	O
or	O	O
50	O	O
mg/kg	O	O
for	O	O
1	O	O
week	O	O
,	O	O
testicular	O	O
degeneration	O	O
and	O	O
atrophy	O	O
were	O	O
evident	O	O
in	O	O
the	O	O
high-dose	O	O
group	O	O
at	O	O
1	O	O
month	O	O
following	O	O
treatment	O	O
.	O	O

These	O	O
studies	O	O
indicate	O	O
that	O	O
retinoid	O	O
antagonists	O	O
can	O	O
selectively	O	O
produce	O	O
progressive	O	O
and	O	O
prolonged	O	O
testicular	O	O
toxicity	O	O
after	O	O
single	O	O
or	O	O
repeated	O	O
oral	O	O
doses	O	O
that	O	O
are	O	O
otherwise	O	O
well	O	O
tolerated	O	O
.	O	O

Sequential	O	O
involvement	O	O
of	O	O
NFAT	B-protein	O
and	O	O
Egr	O	O
transcription	B-protein	O
factors	I-protein	O
in	O	O
FasL	O	O
regulation	O	O
.	O	O

The	O	O
critical	O	O
function	O	O
of	O	O
NFAT	B-protein	O
proteins	I-protein	O
in	O	O
maintaining	O	O
lymphoid	O	O
homeostasis	O	O
was	O	O
revealed	O	O
in	O	O
mice	O	O
lacking	O	O
both	O	O
NFATp	O	O
and	O	O
NFAT4	O	O
(	O	O
DKO	O	O
)	O	O
.	O	O

DKO	O	O
mice	O	O
exhibit	O	O
increased	O	O
lymphoproliferation	O	O
,	O	O
decreased	O	O
activation-induced	O	O
cell	O	O
death	O	O
,	O	O
and	O	O
impaired	O	O
induction	O	O
of	O	O
FasL	O	O
.	O	O

The	O	O
transcription	B-protein	O
factors	I-protein	O
Egr2	O	O
and	O	O
Egr3	O	O
are	O	O
potent	O	O
activators	B-protein	O
of	O	O
FasL	B-protein	O
expression	O	O
.	O	O

Here	O	O
we	O	O
find	O	O
that	O	O
Egr2	O	O
and	O	O
Egr3	O	O
are	O	O
NFAT	O	O
target	O	O
genes	O	O
.	O	O

Activation	O	O
of	O	O
FasL	O	O
occurs	O	O
via	O	O
the	O	O
NFAT	B-protein	O
-dependent	O	O
induction	O	O
of	O	O
Egr3	B-protein	O
,	O	O
as	O	O
demonstrated	O	O
by	O	O
the	O	O
ability	O	O
of	O	O
exogenously	O	O
provided	O	O
NFATp	O	O
to	O	O
restore	O	O
Egr	O	O
-dependent	O	O
FasL	O	O
promoter	O	O
activity	O	O
in	O	O
DKO	O	O
lymph	O	O
node	O	O
cells	O	O
.	O	O

Further	O	O
,	O	O
Egr3	O	O
expression	O	O
is	O	O
enriched	O	O
in	O	O
Th1	B-cell_type	O
cells	I-cell_type	O
,	O	O
suggesting	O	O
a	O	O
molecular	O	O
basis	O	O
for	O	O
the	O	O
known	O	O
preferential	O	O
expression	O	O
of	O	O
FasL	O	O
in	O	O
the	O	O
Th1	O	O
versus	I-protein	O
Th2	O	O
subset	O	O
.	O	O

Mechanisms	O	O
and	O	O
clinical	O	O
relevance	O	O
of	O	O
nongenomic	O	O
glucocorticoid	O	O
actions	O	O
.	O	O

Glucocorticoids	O	O
have	O	O
profound	O	O
anti-inflammatory	O	O
and	O	O
immunosuppressive	O	O
actions	O	O
when	O	O
used	O	O
therapeutically	O	O
.	O	O

The	O	O
therapeutic	O	O
dose	O	O
is	O	O
quite	O	O
variable	O	O
and	O	O
depends	O	O
on	O	O
the	O	O
disease	B-DNA	O
,	O	O
but	O	O
ranges	O	O
from	O	O
very	O	O
low	O	O
to	O	O
extremely	O	O
high	O	O
.	O	O

The	O	O
rationale	O	O
for	O	O
the	O	O
use	O	O
of	O	O
various	O	O
dosage	O	O
regimens	O	O
for	O	O
specific	O	O
clinical	O	O
indications	O	O
is	O	O
the	O	O
existence	O	O
of	O	O
three	O	O
distinct	O	O
,	O	O
therapeutically	O	O
relevant	O	O
effects	O	O
:	O	O
genomic	O	O
,	O	O
specific	O	O
nongenomic	O	O
and	O	O
unspecific	O	O
nongenomic	O	O
.	O	O

Genomic	O	O
effects	O	O
are	O	O
mediated	O	O
by	O	O
cytosolic	O	O
receptors	O	O
that	O	O
alter	O	O
expression	O	O
of	O	O
specific	O	O
genes	O	O
.	O	O

Specific	O	O
nongenomic	O	O
effects	O	O
occur	O	O
within	O	O
a	O	O
few	O	O
minutes	O	O
and	O	O
are	O	O
mediated	O	O
by	O	O
steroid-selective	O	O
membrane	O	O
receptors	O	O
.	O	O

Unspecific	O	O
nongenomic	O	O
effects	O	O
occur	O	O
within	O	O
seconds	O	O
,	O	O
but	O	O
only	O	O
at	O	O
high	O	O
glucocorticoid	O	O
dosages	O	O
,	O	O
and	O	O
seem	O	O
to	O	O
result	O	O
from	O	O
direct	O	O
interactions	O	O
with	O	O
biological	O	O
membranes	O	O
.	O	O

For	O	O
unspecific	O	O
nongenomic	O	O
effects	O	O
,	O	O
methylprednisolone	O	O
and	O	O
other	O	O
glucocorticoids	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
inhibit	O	O
cation	O	O
cycling	O	O
across	O	O
the	O	O
plasma	O	O
membrane	O	O
,	O	O
but	O	O
to	O	O
have	O	O
little	O	O
effect	O	O
on	O	O
protein	O	O
synthesis	O	O
.	O	O

Thus	O	O
,	O	O
glucocorticoids	O	O
could	O	O
diminish	O	O
or	O	O
prevent	O	O
the	O	O
acute	O	O
immune	O	O
response	O	O
by	O	O
interfering	O	O
with	O	O
processes	O	O
such	O	O
as	O	O
the	O	O
rise	O	O
in	O	O
intracellular	O	O
Ca2+	O	O
concentration	O	O
.	O	O

It	O	O
is	O	O
proposed	O	O
that	O	O
the	O	O
additional	O	O
therapeutic	O	O
benefit	O	O
of	O	O
higher	O	O
doses	O	O
is	O	O
obtained	O	O
via	O	O
these	O	O
nongenomic	O	O
effects	O	O
.	O	O

High	O	O
glucose-induced	O	O
intercellular	B-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
(	O	O
ICAM-1	B-protein	O
)	O	O
expression	O	O
through	O	O
an	O	O
osmotic	O	O
effect	O	O
in	O	O
rat	O	O
mesangial	B-cell_type	O
cells	I-cell_type	O
is	O	O
PKC-NF-kappa	O	O
B-dependent	O	O
.	O	O

AIMS/HYPOTHESIS	O	O
:	O	O
Infiltration	O	O
of	O	O
mononuclear	B-cell_type	O
cells	I-cell_type	O
and	O	O
glomerular	O	O
enlargement	O	O
accompanied	O	O
by	O	O
glomerular	O	O
cell	O	O
proliferation	O	O
are	O	O
very	O	O
early	O	O
characteristics	O	O
of	O	O
the	O	O
pathophysiology	O	O
of	O	O
diabetes	O	O
.	O	O

To	O	O
clarify	O	O
the	O	O
mechanism	O	O
of	O	O
early	O	O
diabetic	O	O
nephropathy	O	O
,	O	O
we	O	O
measured	O	O
[	O	O
3H	O	O
]	O	O
-thymidine	O	O
incorporation	O	O
and	O	O
cell	O	O
numbers	O	O
to	O	O
show	O	O
the	O	O
influence	O	O
of	O	O
a	O	O
high	O	O
ambient	O	O
glucose	O	O
concentration	O	O
and	O	O
the	O	O
osmotic	O	O
effect	O	O
on	O	O
rat	O	O
mesangial	O	O
cell	O	O
proliferation	O	O
.	O	O

We	O	O
also	O	O
measured	O	O
the	O	O
effect	O	O
of	O	O
high	O	O
glucose	O	O
on	O	O
the	O	O
expression	O	O
of	O	O
intercellular	B-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
and	O	O
vascular	B-protein	O
adhesion	O	O
molecule-1	O	O
by	O	O
flow	O	O
cytometry	O	O
and	O	O
semiquantitative	O	O
RT-PCR	O	O
in	O	O
mesangial	B-cell_type	O
cells	I-cell_type	O
and	O	O
the	O	O
adhesion	O	O
of	O	O
leukocytes	O	O
to	O	O
mesangial	B-cell_type	O
cells	I-cell_type	O
.	O	O

METHODS/RESULTS	O	O
:	O	O
Cells	O	O
exposed	O	O
to	O	O
high	O	O
D-glucose	O	O
(	O	O
30	O	O
mmol/l	O	O
)	O	O
caused	O	O
an	O	O
increase	O	O
in	O	O
[	O	O
3H	O	O
]	O	O
-thymidine	O	O
incorporation	O	O
and	O	O
cell	O	O
numbers	O	O
at	O	O
24	O	O
and	O	O
48	O	O
h	O	O
and	O	O
normalized	O	O
at	O	O
72	O	O
h	O	O
(	O	O
p	O	O
<	O	O
0.05	O	O
)	O	O
,	O	O
whereas	O	O
these	O	O
changes	O	O
were	O	O
not	O	O
found	O	O
in	O	O
high	O	O
mannitol	O	O
(	O	O
30	O	O
mmol/l	O	O
)	O	O
,	O	O
IL-1	B-protein	O
beta	O	O
,	O	O
or	O	O
TNF	B-protein	O
alpha	I-protein	O
-stimulated	I-protein	O
mesangial	I-cell_line	O
cells	I-cell_line	O
.	O	O

Cells	O	O
exposed	O	O
to	O	O
high-glucose	O	O
(	O	O
15	O	O
,	O	O
30	O	O
,	O	O
or	O	O
60	O	O
mmol/l	O	O
)	O	O
or	O	O
osmotic	O	O
agents	O	O
(	O	O
L-glucose	O	O
,	O	O
raffinose	O	O
and	O	O
mannitol	O	O
)	O	O
showed	O	O
that	O	O
intercellular	O	O
adhesion	O	O
molecule-1	O	O
expression	O	O
began	O	O
to	O	O
increase	O	O
after	O	O
24	O	O
h	O	O
,	O	O
reached	O	O
its	O	O
maximum	O	O
at	O	O
24	O	O
and	O	O
48	O	O
h	O	O
and	O	O
gradually	O	O
decreased	O	O
afterwards	O	O
.	O	O

The	O	O
stimulatory	O	O
effects	O	O
of	O	O
high	O	O
glucose	O	O
and	O	O
high	O	O
mannitol	O	O
on	O	O
mRNA	B-RNA	O
expression	O	O
were	O	O
observed	O	O
as	O	O
early	O	O
as	O	O
6	O	O
h	O	O
and	O	O
reached	O	O
its	O	O
maximum	O	O
at	O	O
12	O	O
h	O	O
.	O	O

Up-regulation	O	O
of	O	O
ICAM-1	B-protein	O
protein	I-protein	O
and	O	O
mRNA	I-RNA	O
was	O	O
also	O	O
found	O	O
in	O	O
IL-1-beta	O	O
and	O	O
TNF-alpha	O	O
-stimulated	O	O
mesangial	B-cell_type	O
cells	I-cell_type	O
.	O	O

Neither	O	O
vascular	B-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
protein	I-protein	O
nor	O	O
mRNA	O	O
expression	O	O
was	O	O
,	O	O
however	O	O
,	O	O
affected	O	O
by	O	O
high	O	O
glucose	O	O
and	O	O
high	O	O
mannitol	O	O
.	O	O

Notably	O	O
,	O	O
the	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
inhibitors	O	O
calphostin	B-protein	O
C	I-protein	O
and	O	O
staurosporine	O	O
reduced	O	O
high	O	O
glucose-	O	O
or	O	O
high	O	O
mannitol-induced	O	O
intercellular	O	O
adhesion	O	O
molecule-1	O	O
mRNA	O	O
expression	O	O
and	O	O
high	O	O
glucose-induced	O	O
proliferation	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
NF-kappa	B-protein	O
B	I-protein	O
inhibitor	O	O
N-tosyl-L-phenylalanine	O	O
chloromethyl	O	O
ketone	O	O
reduced	O	O
high	O	O
glucose-	O	O
or	O	O
high	O	O
mannitol-induced	O	O
intercellular	O	O
adhesion	O	O
molecule-1	O	O
mRNA	O	O
expression	O	O
and	O	O
high	O	O
glucose-induced	O	O
proliferation	O	O
.	O	O

Results	O	O
showed	O	O
that	O	O
high	O	O
glucose	O	O
(	O	O
15	O	O
,	O	O
30	O	O
mmol/l	O	O
)	O	O
or	O	O
high	O	O
concentrations	O	O
of	O	O
osmotic	O	O
agents	O	O
remarkably	O	O
increased	O	O
the	O	O
number	O	O
of	O	O
adherent	O	O
leukocytes	O	O
to	O	O
mesangial	B-cell_type	O
cells	I-cell_type	O
(	O	O
p	O	O
<	O	O
0.01	O	O
)	O	O
compared	O	O
with	O	O
control	O	O
cells	O	O
(	O	O
5	O	O
mmol/l	O	O
D-glucose	O	O
)	O	O
.	O	O

Functional	O	O
blocking	O	O
of	O	O
intercellular	B-protein	O
adhesion	O	O
molecule-1	O	O
on	O	O
mesangial	B-cell_type	O
cells	I-cell_type	O
with	O	O
rat	O	O
intercellular	B-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
monoclonal	O	O
antibody	O	O
,	O	O
calphostin	O	O
C	O	O
,	O	O
staurosporine	O	O
,	O	O
or	O	O
N-tosyl-L-phenylalanine	O	O
chloromethyl	O	O
ketone	O	O
significantly	O	O
inhibited	O	O
high	O	O
glucose-	O	O
or	O	O
high	O	O
mannitol-induced	O	O
increase	O	O
in	O	O
leukocyte	O	O
adhesion	O	O
(	O	O
p	O	O
<	O	O
<	O	O
0.05	O	O
)	O	O
.	O	O

CONCLUSION/INTERPRETATION	O	O
:	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
high	O	O
glucose	O	O
can	O	O
upregulate	O	O
intercellular	O	O
adhesion	O	O
molecule-1	B-protein	O
protein	I-protein	O
and	O	O
mRNA	B-RNA	O
expression	O	O
but	O	O
not	O	O
vascular	B-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
expression	O	O
in	O	O
mesangial	B-cell_type	O
cells	I-cell_type	O
and	O	O
promote	O	O
leukocyte	O	O
adhesion	O	O
through	O	O
up-regulation	O	O
of	O	O
intercellular	B-protein	O
adhesion	O	O
molecule-1	O	O
through	O	O
osmotic	O	O
effect	O	O
,	O	O
possibly	O	O
depending	O	O
on	O	O
the	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
nuclear	I-protein	O
factor-kappa	I-protein	O
B	I-protein	O
(	O	O
PKC	O	O
-	I-protein	O
NF-kappa	B-protein	O
B	I-protein	O
)	O	O
pathway	O	O
.	O	O

High	O	O
glucose	O	O
itself	O	O
can	O	O
also	O	O
promote	O	O
mesangial	O	O
cell	O	O
proliferation	O	O
through	O	O
the	O	O
PKC-NF-kappa	O	O
B	O	O
pathways	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
hyperglycaemia	O	O
in	O	O
itself	O	O
seems	O	O
to	O	O
be	O	O
an	O	O
important	O	O
factor	O	O
in	O	O
the	O	O
development	O	O
of	O	O
early	O	O
diabetic	O	O
nephropathy	O	O
.	O	O

Combined	O	O
corticosteroid/	O	O
granulocyte	B-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
(	O	O
G-CSF	B-protein	O
)	O	O
therapy	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
congenital	O	O
neutropenia	O	O
unresponsive	O	O
to	O	O
G-CSF	O	O
:	O	O
Activated	O	O
glucocorticoid	O	O
receptors	O	O
synergize	O	O
with	O	O
G-CSF	O	O
signals	O	O
.	O	O

More	O	O
than	O	O
90	O	O
%	O	O
of	O	O
patients	O	O
with	O	O
severe	O	O
congenital	O	O
neutropenia	O	O
(	O	O
SCN	O	O
)	O	O
respond	O	O
to	O	O
granulocyte	B-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
(	O	O
G-CSF	O	O
)	O	O
therapy	O	O
.	O	O

The	O	O
basis	O	O
for	O	O
the	O	O
refractory	O	O
state	O	O
in	O	O
the	O	O
remaining	O	O
patients	O	O
is	O	O
unknown	O	O
.	O	O

To	O	O
address	O	O
this	O	O
issue	O	O
,	O	O
we	O	O
studied	O	O
a	O	O
child	O	O
with	O	O
SCN	O	O
who	O	O
was	O	O
totally	O	O
unresponsive	O	O
to	O	O
G-CSF	O	O
and	O	O
had	O	O
a	O	O
novel	O	O
point	O	O
mutation	O	O
in	O	O
the	O	O
extracellular	O	O
domain	O	O
of	O	O
the	O	O
G-CSF	B-protein	O
receptor	I-protein	O
(	O	O
GCSF-R	B-protein	O
)	O	O
.	O	O

Marrow	O	O
stromal	O	O
support	O	O
of	O	O
granulopoiesis	O	O
was	O	O
evaluated	O	O
by	O	O
plating	O	O
CD34	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
on	O	O
preformed	O	O
stromal	O	O
layers	O	O
.	O	O

Nonadherent	B-cell_type	O
cells	I-cell_type	O
were	O	O
harvested	O	O
and	O	O
assayed	O	O
in	O	O
clonogenic	O	O
assays	O	O
for	O	O
granulocytic	O	O
colony	O	O
production	O	O
.	O	O

The	O	O
in	O	O
vitro	O	O
effect	O	O
of	O	O
G-CSF	O	O
and	O	O
corticosteroids	O	O
on	O	O
granulopoiesis	O	O
was	O	O
evaluated	O	O
in	O	O
clonogenic	O	O
assays	O	O
of	O	O
marrow	B-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
,	O	O
by	O	O
proliferation	O	O
studies	O	O
of	O	O
the	O	O
murine	B-cell_line	O
myeloid	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
32D	O	O
expressing	O	O
the	O	O
patient	O	O
's	O	O
mutated	O	O
G-CSFR	O	O
,	O	O
and	O	O
by	O	O
measuring	O	O
STAT5	O	O
activation	O	O
in	O	O
nuclear	O	O
extracts	O	O
from	O	O
stimulated	B-cell_type	O
cells	I-cell_type	O
.	O	O

Patient	O	O
's	O	O
stroma	O	O
supported	O	O
granulopoiesis	O	O
derived	O	O
from	O	O
control	O	O
marrow	O	O
CD34	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
in	O	O
a	O	O
normal	O	O
manner	O	O
.	O	O

Normal	O	O
stroma	O	O
,	O	O
however	O	O
,	O	O
failed	O	O
to	O	O
induce	O	O
granulopoiesis	O	O
from	O	O
patient	O	O
's	O	O
CD34	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
.	O	O

Clonogenic	O	O
assays	O	O
of	O	O
the	O	O
patient	O	O
's	O	O
marrow	O	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
incorporating	O	O
either	O	O
G-CSF	O	O
or	O	O
hydrocortisone	O	O
produced	O	O
little	O	O
neutrophil	O	O
growth	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
inclusion	O	O
of	O	O
both	O	O
G-CSF	O	O
and	O	O
hydrocortisone	O	O
in	O	O
the	O	O
cytokine	B-protein	O
``	O	O
cocktail	O	O
''	O	O
markedly	O	O
increased	O	O
the	O	O
neutrophil	O	O
numbers	O	O
.	O	O

Proliferation	O	O
of	O	O
32D	B-cell_type	O
cells	I-cell_type	O
expressing	O	O
the	O	O
mutated	B-protein	O
receptor	I-protein	O
and	O	O
STAT5	O	O
activation	O	O
were	O	O
improved	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
G-CSF	O	O
and	O	O
dexamethasone	O	O
.	O	O

When	O	O
small	O	O
daily	O	O
doses	O	O
of	O	O
oral	O	O
prednisone	O	O
were	O	O
then	O	O
administered	O	O
to	O	O
the	O	O
patient	O	O
with	O	O
conventional	O	O
doses	O	O
of	O	O
subcutaneous	O	O
G-CSF	O	O
,	O	O
the	O	O
patient	O	O
responded	O	O
with	O	O
increased	O	O
neutrophil	O	O
numbers	O	O
and	O	O
with	O	O
a	O	O
complete	O	O
reversal	O	O
of	O	O
the	O	O
infectious	O	O
problems	I-protein	O
.	O	O

These	O	O
data	O	O
provide	O	O
insight	O	O
into	O	O
SCN	O	O
unresponsive	O	O
to	O	O
standard	O	O
G-CSF	O	O
treatment	O	O
and	O	O
to	O	O
the	O	O
potential	O	O
corrective	O	O
action	O	O
of	O	O
combined	O	O
treatment	O	O
with	O	O
G-CSF	O	O
and	O	O
corticosteroids	O	O
through	O	O
synergistic	O	O
activation	O	O
of	O	O
STAT5	O	O
.	O	O

Human	O	O
renal	O	O
mesangial	O	O
cells	O	O
are	O	O
a	O	O
target	O	O
for	O	O
the	O	O
anti-inflammatory	O	O
action	O	O
of	O	O
9-cis	O	O
retinoic	O	O
acid	O	O
.	O	O

Mesangial	B-cell_type	O
cells	I-cell_type	O
play	O	O
an	O	O
active	O	O
role	O	O
in	O	O
the	O	O
inflammatory	O	O
response	O	O
to	O	O
glomerular	O	O
injury	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
in	O	O
cultured	B-cell_line	O
human	I-cell_line	O
mesangial	I-cell_line	O
cells	I-cell_line	O
(	O	O
CHMC	O	O
)	O	O
several	O	O
effects	O	O
of	O	O
9-cis	O	O
retinoic	O	O
acid	O	O
(	O	O
9-cRA	B-protein	O
)	O	O
,	O	O
an	O	O
activator	O	O
of	O	O
both	O	O
retinoic	O	O
acid	B-protein	O
receptors	I-protein	O
(	O	O
RARs	O	O
)	O	O
and	O	O
retinoid	O	O
X	B-protein	O
receptors	I-protein	O
(	O	O
RXRs	O	O
)	O	O
.	O	O

9-cRA	O	O
inhibited	O	O
foetal	O	O
calf	O	O
serum-induced	O	O
CHMC	O	O
proliferation	O	O
.	O	O

It	O	O
also	O	O
prevented	O	O
CHMC	O	O
death	O	O
induced	O	O
by	O	O
the	O	O
inflammatory	O	O
mediator	O	O
H	I-protein	O
(	O	O
2	O	O
)	O	O
O	O	O
(	O	O
2	O	O
)	O	O
.	O	O

This	O	O
preventive	O	O
effect	O	O
was	O	O
not	O	O
due	O	O
to	O	O
any	O	O
increase	O	O
in	O	O
H	O	O
(	O	O
2	O	O
)	O	O
O	O	O
(	O	O
2	O	O
)	O	O
catabolism	O	O
and	O	O
it	O	O
persisted	O	O
even	O	O
when	O	O
both	O	O
catalase	O	O
and	O	O
glutathione	O	O
synthesis	O	O
were	O	O
inhibited	O	O
.	O	O

Finally	O	O
,	O	O
9-cRA	O	O
diminished	O	O
monocyte	O	O
adhesion	O	O
to	O	O
FCS-stimulated	O	O
CHMC	O	O
.	O	O

Interestingly	O	O
,	O	O
the	O	O
retinoid	O	O
also	O	O
inhibited	O	O
in	O	O
FCS-stimulated	O	O
cells	O	O
the	O	O
protein	O	O
expression	O	O
of	O	O
two	O	O
mesangial	B-protein	O
adhesion	I-protein	O
molecules	I-protein	O
,	O	O
fibronectin	B-protein	O
and	O	O
osteopontin	O	O
,	O	O
but	O	O
it	O	O
did	O	O
not	O	O
modify	O	O
the	O	O
protein	O	O
expression	O	O
of	O	O
intercellular	B-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
and	O	O
vascular	B-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
.	O	O

All	O	O
major	O	O
RARs	O	O
and	O	O
RXRs	O	O
isotypes	O	O
were	O	O
expressed	O	O
in	O	O
CHMC	O	O
regardless	O	O
of	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
9-cRA	O	O
.	O	O

Transcripts	O	O
to	O	O
RAR-alpha	O	O
,	O	O
RAR-beta	O	O
and	O	O
RXR-alpha	O	O
increased	O	O
after	O	O
incubation	O	O
with	O	O
9-cRA	O	O
whereas	O	O
RXR-gamma	O	O
was	O	O
inhibited	O	O
,	O	O
suggesting	O	O
a	O	O
major	O	O
role	O	O
for	O	O
RARs	O	O
and	O	O
RXRs	O	O
in	O	O
9-cRA-anti-inflammatory	O	O
effects	O	O
.	O	O

9-cRA	O	O
was	O	O
toxic	O	O
only	O	O
at	O	O
50	O	O
microM	O	O
(	O	O
a	O	O
concentration	O	O
50	O	O
-	O	O
5000	O	O
times	O	O
higher	O	O
than	O	O
required	O	O
for	O	O
the	O	O
effects	O	O
above	O	O
)	O	O
.	O	O

Cell	O	O
death	O	O
occurred	O	O
by	O	O
apoptosis	O	O
,	O	O
whose	O	O
onset	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
pronounced	O	O
increase	O	O
in	O	O
catalase	O	O
activity	O	O
and	O	O
reduced	O	O
glutathione	O	O
content	O	O
,	O	O
being	O	O
more	O	O
effectively	O	O
induced	O	O
by	O	O
all-trans	O	O
retinoic	O	O
acid	O	O
.	O	O

Modulation	O	O
of	O	O
the	O	O
oxidant/antioxidant	O	O
balance	O	O
failed	O	O
to	O	O
inhibit	O	O
apoptosis	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
mesangial	B-cell_type	O
cells	I-cell_type	O
might	O	O
be	O	O
a	O	O
target	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
inflammatory	O	O
glomerulopathies	O	O
with	O	O
9-cRA	O	O
.	O	O

Expression	O	O
of	O	O
mammalian	B-DNA	O
defensin	I-DNA	O
genes	I-DNA	O
.	O	O

Antimicrobial	O	O
peptides	O	O
are	O	O
a	O	O
prevalent	O	O
mechanism	O	O
of	O	O
host	O	O
defense	O	O
found	O	O
throughout	O	O
nature	O	O
.	O	O

In	O	O
mammals	O	O
,	O	O
defensins	O	O
are	O	O
among	O	O
the	O	O
most	O	O
abundant	O	O
of	O	O
these	O	O
broad-spectrum	O	O
antibiotics	O	O
,	O	O
and	O	O
are	O	O
expressed	O	O
in	O	O
epithelial	B-cell_type	O
and	O	O
hematopoietic	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
defensin	O	O
peptides	O	O
are	O	O
especially	O	O
abundant	O	O
in	O	O
neutrophils	O	O
;	O	O
however	O	O
,	O	O
gene	O	O
expression	O	O
is	O	O
limited	O	O
to	O	O
the	O	O
promyelocyte	O	O
stage	O	O
.	O	O

In	O	O
epithelial	B-cell_type	O
cells	I-cell_type	O
,	O	O
defensin	O	O
genes	O	O
are	O	O
found	O	O
as	O	O
both	O	O
constitutively	O	O
expressed	O	O
and	O	O
inducible	O	O
.	O	O

Induction	O	O
has	O	O
been	O	O
observed	O	O
in	O	O
vitro	O	O
by	O	O
stimulation	O	O
with	O	O
bacterial	O	O
lipopolysaccharide	O	O
as	O	O
well	O	O
as	O	O
inflammatory	O	O
mediators	O	O
.	O	O

In	O	O
vivo	O	O
,	O	O
up-regulation	O	O
of	O	O
several	O	O
defensin	O	O
genes	O	O
occurs	O	O
in	O	O
both	O	O
infectious	O	O
and	O	O
inflammatory	O	O
states	O	O
.	O	O

Gene	O	O
regulation	O	O
occurs	O	O
via	O	O
signal	O	O
transduction	O	O
pathways	O	O
common	O	O
to	O	O
other	O	O
innate	O	O
immune	O	O
responses	O	O
,	O	O
utilizing	O	O
transcription	B-protein	O
factors	I-protein	O
such	O	O
as	O	O
nuclear	B-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
-kappaB	O	O
and	O	O
NF	O	O
interleukin-6	O	O
.	O	O

Together	O	O
,	O	O
the	O	O
data	O	O
suggest	O	O
a	O	O
broad-based	O	O
innate	O	O
host	O	O
defense	O	O
whereby	O	O
potent	O	O
antimicrobial	O	O
peptides	O	O
are	O	O
present	O	O
to	O	O
prevent	O	O
initial	O	O
colonization	O	O
by	O	O
pathogenic	O	O
microorganisms	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
recognition	O	O
of	O	O
bacteria	O	O
coupled	O	O
with	O	O
a	O	O
nascent	O	O
inflammatory	O	O
response	O	O
can	O	O
bolster	O	O
this	O	O
defense	O	O
by	O	O
a	O	O
coordinated	O	O
up-regulation	O	O
of	O	O
the	O	O
peptides	O	O
.	O	O

Multiple	O	O
signals	O	O
required	O	O
for	O	O
cyclic	O	O
AMP-responsive	O	O
element	B-protein	O
binding	I-protein	O
protein	I-protein	O
(	O	O
CREB	B-protein	O
)	O	O
binding	O	O
protein	I-protein	O
interaction	O	O
induced	O	O
by	O	O
CD3/CD28	O	O
costimulation	O	O
.	O	O

The	O	O
optimal	O	O
activation	O	O
of	O	O
cAMP-responsive	B-protein	O
element	I-protein	O
binding	I-protein	O
protein	I-protein	O
(	O	O
CREB	B-protein	O
)	O	O
,	O	O
similar	O	O
to	O	O
the	O	O
full	O	O
activation	O	O
of	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
requires	O	O
the	O	O
stimulation	O	O
of	O	O
both	O	O
CD3	B-protein	O
and	O	O
CD28	B-protein	O
.	O	O

Using	O	O
a	O	O
reporter	O	O
system	O	O
to	O	O
detect	O	O
interaction	O	O
of	O	O
CREB	B-protein	O
and	O	O
CREB-binding	B-protein	O
protein	I-protein	O
(	O	O
CBP	B-protein	O
)	O	O
,	O	O
in	O	O
this	O	O
study	O	O
we	O	O
found	O	O
that	O	O
CREB	O	O
binds	O	O
to	O	O
CBP	O	O
only	O	O
by	O	O
engagement	O	O
of	O	O
both	O	O
CD3	B-protein	O
and	O	O
CD28	B-protein	O
.	O	O

CD3/CD28	O	O
-promoted	O	O
CREB	O	O
-	O	O
CBP	O	O
interaction	O	O
was	O	O
dependent	O	O
on	O	O
p38	B-protein	O
mitogen-activated	I-protein	O
protein	I-protein	O
kinase	I-protein	O
(	O	O
MAPK	B-protein	O
)	O	O
and	O	O
calcium/calmodulin-dependent	B-protein	O
protein	I-protein	O
kinase	I-protein	O
(	O	O
CaMK	O	O
)	O	O
IV	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
previously	O	O
identified	O	O
extracellular	O	O
signal-regulated	O	O
kinase	O	O
pathway	O	O
.	O	O

Extracellular	O	O
signal-regulated	B-protein	O
kinase	I-protein	O
,	O	O
CaMKIV	O	O
,	O	O
and	O	O
p38	O	O
MAPK	O	O
were	O	O
also	O	O
the	O	O
kinases	O	O
involved	O	O
in	O	O
CREB	O	O
Ser	O	O
(	O	O
133	O	O
)	O	O
phosphorylation	O	O
induced	O	O
by	O	O
CD3/CD28	O	O
.	O	O

A	O	O
reconstitution	O	O
experiment	O	O
illustrated	O	O
that	O	O
optimum	O	O
CREB	O	O
-	O	O
CBP	O	O
interaction	O	O
and	O	O
CREB	O	O
trans-activation	O	O
were	O	O
attained	O	O
when	O	O
these	O	O
three	O	O
kinase	O	O
pathways	O	O
were	O	O
simultaneously	O	O
activated	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
that	O	O
coordinated	O	O
activation	O	O
of	O	O
different	O	O
kinases	O	O
leads	O	O
to	O	O
full	O	O
activation	O	O
of	O	O
CREB	O	O
.	O	O

Notably	O	O
,	O	O
CD28	O	O
ligation	O	O
activated	O	O
p38	O	O
MAPK	O	O
and	O	O
CaMKIV	O	O
,	O	O
the	O	O
kinases	O	O
stimulated	O	O
by	O	O
CD3	O	O
engagement	O	O
,	O	O
suggesting	O	O
that	O	O
CD28	O	O
acts	O	O
by	O	O
increasing	O	O
the	O	O
activation	O	O
extent	O	O
of	O	O
p38	B-protein	O
MAPK	I-protein	O
and	O	O
CaMKIV	O	O
.	O	O

These	O	O
results	O	O
support	O	O
the	O	O
model	O	O
of	O	O
a	O	O
minimum	O	O
activation	O	O
threshold	O	O
for	O	O
CREB	O	O
-	O	O
CBP	O	O
interaction	O	O
that	O	O
can	O	O
be	O	O
reached	O	O
only	O	O
when	O	O
both	O	O
CD3	B-protein	O
and	O	O
CD28	O	O
are	O	O
stimulated	O	O
.	O	O

The	O	O
murine	B-DNA	O
IL-2	I-DNA	O
promoter	I-DNA	O
contains	O	O
distal	O	O
regulatory	I-DNA	O
elements	I-DNA	O
responsive	O	O
to	O	O
the	O	O
Ah	B-protein	O
receptor	I-protein	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
evolutionarily	B-protein	O
conserved	I-protein	O
bHLH-PAS	I-protein	O
transcription	I-protein	O
factor	I-protein	O
family	I-protein	O
.	O	O

Signaling	O	O
through	O	O
the	O	O
TCR	B-protein	O
and	O	O
costimulatory	O	O
signals	O	O
primarily	O	O
control	O	O
transcription	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
gene	I-DNA	O
in	O	O
naive	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
minimal	B-DNA	O
promoter	I-DNA	O
necessary	O	O
for	O	O
this	O	O
expression	O	O
lies	O	O
proximal	B-protein	O
,	O	O
between	O	O
-300	O	O
and	O	O
the	O	O
transcription	B-DNA	O
start	I-DNA	O
site	O	O
.	O	O

We	O	O
had	O	O
previously	O	O
shown	O	O
that	O	O
activation	O	O
of	O	O
the	O	O
arylhydrocarbon	B-protein	O
receptor	I-protein	O
(	O	O
AHR	B-protein	O
)	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
bHLH-PAS	B-protein	O
family	I-protein	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
,	O	O
leads	O	O
to	O	O
increased	O	O
mRNA	O	O
expression	O	O
of	O	O
IL-2	B-protein	O
in	O	O
murine	O	O
fetal	O	O
thymocytes	B-cell_type	O
.	O	O

The	O	O
AHR	O	O
is	O	O
abundant	O	O
in	O	O
the	O	O
thymus	O	O
and	O	O
may	O	O
play	O	O
a	O	O
role	O	O
for	O	O
the	O	O
development	O	O
of	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

Moreover	O	O
,	O	O
its	O	O
overactivation	O	O
by	O	O
chemicals	O	O
such	O	O
as	O	O
dioxins	O	O
leads	O	O
to	O	O
immunosuppression	O	O
and	O	O
thymic	O	O
involution	O	O
.	O	O

Binding	O	O
motifs	O	O
for	O	O
the	O	O
liganded	O	O
AHR	O	O
can	O	O
be	O	O
identified	O	O
in	O	O
the	O	O
distal	O	O
region	O	O
-1300	O	O
to	O	O
-800	O	O
of	O	O
the	O	O
mouse	B-DNA	O
IL-2	I-DNA	O
promoter	I-DNA	O
.	O	O

We	O	O
show	O	O
here	O	O
that	O	O
these	O	O
DNA	B-protein	O
motifs	I-protein	O
,	O	O
the	O	O
so-called	O	O
dioxin	O	O
response	O	O
elements	O	O
,	O	O
after	O	O
binding	O	O
to	O	O
the	O	O
liganded	O	O
AHR	O	O
are	O	O
sufficient	O	O
to	O	O
transactivate	B-protein	O
luciferase	I-protein	O
expression	O	O
in	O	O
a	O	O
reporter	B-DNA	O
gene	I-DNA	O
system	O	O
.	O	O

The	O	O
IL-2	B-DNA	O
gene	I-DNA	O
can	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
AHR	O	O
also	O	O
in	O	O
thymocytes	B-cell_type	O
in	O	O
vivo	O	O
after	O	O
injection	O	O
of	O	O
2	O	O
,	O	O
3	O	O
,	O	O
7	O	O
,	O	O
8-tetrachlorodibenzo-p-dioxin	O	O
,	O	O
a	O	O
potent	O	O
ligand	O	O
of	O	O
the	O	O
AHR	O	O
.	O	O

The	O	O
AHR	O	O
mediates	O	O
the	O	O
IL-2	B-protein	O
induction	O	O
as	O	O
shown	O	O
with	O	O
AHR	O	O
-deficient	O	O
mice	O	O
.	O	O

However	O	O
,	O	O
in	O	O
spleen	B-cell_type	O
cells	I-cell_type	O
in	O	O
vitro	O	O
costimulation	O	O
via	O	O
the	O	O
TCR	B-protein	O
is	O	O
necessary	O	O
for	O	O
optimal	O	O
IL-2	O	O
gene	O	O
induction	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
region	O	O
contains	O	O
novel	O	O
distal	O	O
regulatory	O	O
elements	O	O
that	O	O
can	O	O
be	O	O
addressed	O	O
by	O	O
the	O	O
AHR	O	O
to	O	O
induce	O	O
IL-2	B-protein	O
and	O	O
can	O	O
cooperate	O	O
with	O	O
the	O	O
proximal	B-DNA	O
promoter	I-DNA	O

Visualization	O	O
of	O	O
Syk-antigen	B-protein	O
receptor	I-protein	O
interactions	O	O
using	O	O
green	B-protein	O
fluorescent	I-protein	O
protein	I-protein	O
:	O	O
differential	O	O
roles	O	O
for	O	O
Syk	O	O
and	O	O
Lyn	B-protein	O
in	O	O
the	O	O
regulation	O	O
of	O	O
receptor	O	O
capping	O	O
and	O	O
internalization	O	O
.	O	O

The	O	O
cross-linking	O	O
of	O	O
the	O	O
B	B-protein	O
cell	I-protein	O
Ag	I-protein	O
receptor	I-protein	O
(	O	O
BCR	B-protein	O
)	O	O
is	O	O
coupled	O	O
to	O	O
the	O	O
stimulation	O	O
of	O	O
multiple	O	O
intracellular	O	O
signal	O	O
transduction	O	O
cascades	O	O
via	O	O
receptor-associated	B-protein	O
,	O	O
protein	I-protein	O
tyrosine	I-protein	O
kinases	I-protein	O
of	O	O
both	O	O
the	O	O
Src	O	O
and	O	O
Syk	I-protein	O
families	O	O
.	O	O

To	O	O
monitor	O	O
changes	O	O
in	O	O
the	O	O
subcellular	O	O
distribution	O	O
of	O	O
Syk	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
responding	O	O
to	O	O
BCR	O	O
cross-linking	O	O
,	O	O
we	O	O
expressed	O	O
in	O	O
Syk	O	O
-deficient	O	O
DT40	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
a	O	O
fusion	O	O
protein	O	O
consisting	O	O
of	O	O
Syk	O	O
coupled	O	O
to	O	O
green	O	O
fluorescent	O	O
protein	O	O
.	O	O

Treatment	O	O
of	O	O
these	O	O
cells	O	O
with	O	O
anti-IgM	O	O
Abs	O	O
leads	O	O
to	O	O
the	O	O
recruitment	O	O
of	O	O
the	O	O
kinase	B-protein	O
from	O	O
cytoplasmic	O	O
and	O	O
nuclear	O	O
compartments	O	O
to	O	O
the	O	O
site	O	O
of	O	O
the	O	O
cross-linked	B-protein	O
receptor	I-protein	O
at	O	O
the	O	O
plasma	O	O
membrane	O	O
.	O	O

The	O	O
Syk-receptor	O	O
complexes	O	O
aggregate	O	O
into	O	O
membrane	O	O
patches	O	O
that	O	O
redistribute	O	O
to	O	O
form	O	O
a	O	O
cap	O	O
at	O	O
one	O	O
pole	O	O
of	O	O
the	O	O
cell	O	O
.	O	O

Syk	O	O
is	O	O
not	O	O
demonstrably	O	O
associated	O	O
with	O	O
the	O	O
internalized	B-protein	O
receptor	I-protein	O
.	O	O

Catalytically	O	O
active	O	O
Syk	O	O
promotes	O	O
and	O	O
stabilizes	O	O
the	O	O
formation	O	O
of	O	O
tightly	O	O
capped	O	O
BCR	O	O
complexes	O	O
at	O	O
the	O	O
plasma	O	O
membrane	O	O
.	O	O

Lyn	B-protein	O
is	O	O
not	O	O
required	O	O
for	O	O
the	O	O
recruitment	O	O
of	O	O
Syk	O	O
to	O	O
the	O	O
cross-linked	B-protein	O
receptor	I-protein	O
,	O	O
but	O	O
is	O	O
required	O	O
for	O	O
the	O	O
internalization	O	O
of	O	O
the	O	O
clustered	B-protein	O
BCR	I-protein	O
complexes	I-protein	O
.	O	O

In	O	O
the	O	O
absence	O	O
of	O	O
Lyn	B-protein	O
,	O	O
receptor-Syk	O	O
complexes	O	O
at	O	O
the	O	O
plasma	O	O
membrane	O	O
are	O	O
long	O	O
lived	O	O
,	O	O
and	O	O
the	O	O
receptor-mediated	O	O
activation	O	O
of	O	O
the	O	O
NF-AT	B-protein	O
transcription	I-protein	O
factor	I-protein	O
is	O	O
enhanced	O	O
.	O	O

Thus	O	O
,	O	O
Lyn	B-protein	O
appears	O	O
to	O	O
function	O	O
to	O	O
negatively	O	O
regulate	O	O
aspects	O	O
of	O	O
BCR	O	O
-dependent	O	O
signaling	O	O
by	O	O
stimulating	B-protein	O
receptor	I-protein	O
internalization	O	O
and	O	O
down-regulation	O	O
.	O	O

Renal	O	O
interstitial	O	O
fibrosis	O	O
is	O	O
reduced	O	O
in	O	O
angiotensin	O	O
II	O	O
type	O	O
1a	O	O
receptor	I-protein	O
-deficient	O	O
mice	O	O
.	O	O

Unilateral	O	O
ureteral	O	O
obstruction	O	O
(	O	O
UUO	O	O
)	O	O
results	O	O
in	O	O
tubulointerstitial	O	O
fibrosis	O	O
of	O	O
the	O	O
affected	O	O
kidney	O	O
by	O	O
stimulating	O	O
the	O	O
renin-angiotensin	O	O
system	O	O
.	O	O

This	O	O
study	O	O
established	O	O
a	O	O
UUO	O	O
model	O	O
in	O	O
angiotensin	O	O
type	O	O
1a	O	O
receptor	I-protein	O
(	O	O
AT1a	O	O
)	O	O
deficient	O	O
(	O	O
mutant	O	O
)	O	O
mice	O	O
to	O	O
elucidate	O	O
the	O	O
role	O	O
of	O	O
angiotensin	O	O
II	O	O
through	O	O
AT1a	O	O
on	O	O
the	O	O
fibrosis	O	O
of	O	O
the	O	O
obstructed	B-protein	O
kidney	I-protein	O
(	O	O
OBK	B-protein	O
)	O	O
.	O	O

The	O	O
relative	O	O
volume	O	O
of	O	O
the	O	O
tubulointerstitium	O	O
was	O	O
measured	O	O
by	O	O
an	O	O
image	O	O
analyzer	O	O
;	O	O
deposition	O	O
of	O	O
collagen	O	O
types	O	O
III	O	O
and	O	O
IV	B-protein	O
and	O	O
monocyte	O	O
/	O	O
macrophage	O	O
infiltration	O	O
were	O	O
histologically	O	O
examined	O	O
using	O	O
specific	O	O
antibodies	O	O
.	O	O

Also	O	O
determined	O	O
were	O	O
the	O	O
mRNA	B-RNA	O
levels	O	O
of	O	O
transforming	B-protein	O
growth	I-protein	O
factor-beta	O	O
by	O	O
Northern	O	O
blot	O	O
analysis	O	O
.	O	O

Nuclear	O	O
factor-kappaB	O	O
activity	O	O
was	O	O
assessed	O	O
by	O	O
gel	O	O
shift	O	O
assay	O	O
.	O	O

UUO	O	O
in	O	O
wild	O	O
mice	O	O
resulted	O	O
in	O	O
a	O	O
marked	O	O
expansion	O	O
of	O	O
relative	O	O
volume	O	O
of	O	O
the	O	O
tubulointerstitium	O	O
,	O	O
together	O	O
with	O	O
increased	O	O
deposition	O	O
of	O	O
collagen	O	O
types	O	O
III	O	O
and	O	O
IV	B-protein	O
and	O	O
number	O	O
of	O	O
infiltrated	O	O
monocytes	B-cell_type	O
/	O	O
macrophages	O	O
in	O	O
the	O	O
interstitium	O	O
,	O	O
relative	O	O
to	O	O
sham-operated	O	O
mice	O	O
.	O	O

In	O	O
comparison	O	O
,	O	O
these	O	O
changes	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
mutant	O	O
mice	O	O
with	O	O
UUO	O	O
.	O	O

The	O	O
mRNA	B-RNA	O
level	O	O
of	O	O
transforming	B-protein	O
growth	I-protein	O
factor-beta	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
OBK	O	O
of	O	O
wild	O	O
mice	O	O
with	O	O
UUO	O	O
compared	O	O
with	O	O
sham-operated	O	O
mice	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
increase	O	O
in	O	O
mRNA	B-RNA	O
level	O	O
in	O	O
the	O	O
OBK	O	O
of	O	O
mutant	O	O
mice	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
in	O	O
wild	O	O
mice	O	O
.	O	O

Finally	O	O
,	O	O
UUO	O	O
resulted	O	O
in	O	O
activation	O	O
of	O	O
nuclear	O	O
factor-kappaB	O	O
in	O	O
wild	O	O
mice	O	O
but	O	O
was	O	O
inhibited	O	O
in	O	O
the	O	O
OBK	O	O
of	O	O
mutant	O	O
mice	O	O
.	O	O

The	O	O
results	O	O
provide	O	O
direct	O	O
evidence	O	O
that	O	O
angiotensin	O	O
II	O	O
acting	O	O
via	O	O
the	O	O
AT1a	O	O
plays	O	O
a	O	O
pivotal	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
tubulointerstitial	O	O
fibrosis	O	O
in	O	O
UUO	O	O
.	O	O

HLA-DQ	O	O
tetramers	O	O
identify	O	O
epitope-specific	O	O
T	B-cell_type	O
cells	I-cell_type	O
in	O	O
peripheral	O	O
blood	O	O
of	O	O
herpes	O	O
simplex	O	O
virus	O	O
type	O	O
2-infected	O	O
individuals	O	O
:	O	O
direct	O	O
detection	O	O
of	O	O
immunodominant	O	O
antigen-responsive	O	O
cells	O	O
.	O	O

Ag-specific	B-cell_line	O
CD4+	I-cell_line	O
T	I-cell_line	O
cells	I-cell_line	O
are	O	O
present	O	O
in	O	O
peripheral	O	O
blood	O	O
in	O	O
low	O	O
frequency	O	O
,	O	O
where	O	O
they	O	O
undergo	O	O
recruitment	O	O
and	O	O
expansion	O	O
during	O	O
immune	O	O
responses	O	O
and	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
numerous	O	O
autoimmune	O	O
diseases	O	O
.	O	O

MHC	O	O
tetramers	O	O
,	O	O
which	O	O
constitute	O	O
a	O	O
labeled	O	O
MHC-peptide	O	O
ligand	O	O
suitable	O	O
for	O	O
binding	O	O
to	O	O
the	O	O
Ag-specific	B-protein	O
receptor	I-protein	O
on	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
provide	O	O
a	O	O
novel	O	O
approach	O	O
for	O	O
the	O	O
detection	O	O
and	O	O
characterization	O	O
of	O	O
such	O	O
rare	B-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
utilized	O	O
this	O	O
technology	O	O
to	O	O
identify	O	O
HLA	O	O
DQ	O	O
-restricted	O	O
Ag-specific	O	O
T	O	O
cells	O	O
in	O	O
the	O	O
peripheral	O	O
blood	O	O
of	O	O
human	O	O
subjects	O	O
and	O	O
to	O	O
identify	O	O
immunodominant	O	O
epitopes	O	O
associated	O	O
with	O	O
viral	O	O
infection	O	O
.	O	O

Peptides	O	O
representing	O	O
potential	O	O
epitope	O	O
regions	O	O
of	O	O
the	O	O
VP16	B-protein	O
protein	I-protein	O
from	O	O
HSV-2	O	O
were	O	O
loaded	O	O
onto	O	O
recombinant	O	O
DQ0602	O	O
molecules	O	O
to	O	O
generate	O	O
a	O	O
panel	O	O
of	O	O
Ag-specific	O	O
DQ0602	O	O
tetramers	O	O
.	O	O

VP16	O	O
Ag	O	O
-specific	O	O
DQ-restricted	O	O
T	B-cell_type	O
cells	I-cell_type	O
were	O	O
identified	O	O
and	O	O
expanded	O	O
from	O	O
the	O	O
peripheral	O	O
blood	O	O
of	O	O
HSV-2-infected	O	O
individuals	O	O
,	O	O
representing	O	O
two	O	O
predominant	O	O
epitope	O	O
specificities	O	O
.	O	O

Although	O	O
the	O	O
VP16	B-protein	O
369-380	I-protein	O
peptide	O	O
has	O	O
a	O	O
lower	O	O
binding	O	O
affinity	O	O
for	O	O
DQ0602	O	O
molecules	O	O
than	O	O
the	O	O
VP16	O	O
33-52	I-protein	O
peptide	O	O
,	O	O
T	B-cell_type	O
cells	I-cell_type	O
that	O	O
recognized	O	O
the	O	O
VP16	O	O
369-380	I-protein	O
peptide	O	O
occurred	O	O
at	O	O
a	O	O
much	O	O
higher	O	O
frequency	O	O
than	O	O
those	O	O
that	O	O
were	O	O
specific	O	O
for	O	O
the	O	O
VP16	O	O
33-52	O	O
peptide	O	O
.	O	O

Down-regulation	O	O
of	O	O
BOB.1/OBF.1	O	O
and	O	O
Oct2	O	O
in	O	O
classical	O	O
Hodgkin	O	O
disease	O	O
but	O	O
not	O	O
in	O	O
lymphocyte	O	O
predominant	O	O
Hodgkin	O	O
disease	O	O
correlates	O	O
with	O	O
immunoglobulin	O	O
transcription	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
the	O	O
tumor	B-cell_type	O
cells	I-cell_type	O
(	O	O
L	I-cell_line	O
&	I-cell_line	O
H	I-cell_line	O
cells	I-cell_line	O
)	O	O
of	O	O
lymphocyte	O	O
predominant	O	O
Hodgkin	O	O
disease	O	O
(	O	O
LPHD	B-protein	O
)	O	O
,	O	O
Hodgkin	O	O
and	O	O
Reed-Sternberg	O	O
(	O	O
HRS	O	O
)	O	O
cells	O	O
of	O	O
classical	O	O
Hodgkin	O	O
disease	O	O
(	O	O
cHD	O	O
)	O	O
are	O	O
unable	O	O
to	O	O
transcribe	O	O
immunoglobulin	O	O
,	O	O
despite	O	O
the	O	O
presence	O	O
of	O	O
rearranged	O	O
immunoglobulin	O	O
genes	O	O
.	O	O

Although	O	O
initial	O	O
studies	O	O
have	O	O
suggested	O	O
crippling	O	O
immunoglobulin	O	O
gene	O	O
mutations	O	O
to	O	O
be	O	O
the	O	O
cause	O	O
of	O	O
absent	O	O
immunoglobulin	O	O
expression	O	O
in	O	O
cHD	O	O
,	O	O
recent	O	O
work	O	O
of	O	O
our	O	O
group	O	O
has	O	O
demonstrated	O	O
an	O	O
impaired	O	O
activation	O	O
of	O	O
the	O	O
immunoglobulin	O	O
promoter	O	O
as	O	O
a	O	O
superior	O	O
mechanism	O	O
.	O	O

As	O	O
immunoglobulin	O	O
transcription	O	O
is	O	O
mainly	O	O
regulated	O	O
by	O	O
the	O	O
B-cell	O	O
transcription	B-protein	O
factors	I-protein	O
Oct2	I-protein	O
and	O	O
BOB.1/OBF.1	B-protein	O
,	O	O
we	O	O
analyzed	O	O
35	O	O
cases	O	O
of	O	O
LPHD	O	O
,	O	O
32	O	O
cases	O	O
of	O	O
cHD	O	O
,	O	O
and	O	O
2	O	O
Hodgkin	O	O
disease	O	O
cell	O	O
lines	O	O
for	O	O
the	O	O
expression	O	O
of	O	O
these	O	O
transcription	B-protein	O
factors	I-protein	O
and	O	O
also	O	O
in	O	O
parallel	O	O
for	O	O
immunoglobulin	O	O
expression	O	O
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
an	O	O
absence	O	O
of	O	O
Oct2	O	O
and/or	O	O
BOB.1/OBF.1	O	O
in	O	O
cHD	O	O
and	O	O
a	O	O
striking	O	O
overexpression	O	O
of	O	O
Oct2	O	O
in	O	O
LPHD	O	O
.	O	O

Immunoglobulin	O	O
expression	O	O
was	O	O
lacking	O	O
in	O	O
cHD	O	O
but	O	O
present	O	O
in	O	O
LPHD	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
reintroduction	O	O
of	O	O
BOB.1/OBF.1	O	O
and	O	O
Oct2	O	O
into	O	O
cultured	O	O
HRS	O	O
cells	O	O
restored	O	O
the	O	O
activity	O	O
of	O	O
cotransduced	O	O
immunoglobulin	O	O
promoter	B-DNA	O
constructs	I-DNA	O
.	O	O

Our	O	O
findings	O	O
dismiss	O	O
the	O	O
concept	O	O
that	O	O
the	O	O
different	O	O
immunoglobulin	O	O
expression	O	O
in	O	O
cHD	O	O
and	O	O
LPHD	O	O
is	O	O
due	O	O
to	O	O
disrupting	O	O
mutations	O	O
of	O	O
immunoglobulin	O	O
V	O	O
genes	B-DNA	O
in	O	O
cHD	O	O
but	O	O
is	O	O
most	O	O
likely	O	O
due	O	O
to	O	O
a	O	O
down-regulation	O	O
of	O	O
Oct2	O	O
and/or	O	O
BOB.1/OBF.1	O	O
.	O	O

This	O	O
study	O	O
further	O	O
revealed	O	O
Oct2	O	O
as	O	O
a	O	O
new	O	O
and	O	O
valuable	O	O
marker	O	O
for	O	O
the	O	O
identification	O	O
of	O	O
L	O	O
&	I-cell_type	O
H	I-cell_type	O
cells	I-cell_type	O
and	O	O
their	O	O
distinction	O	O
from	O	O
HRS	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
impairment	O	O
of	O	O
immunoglobulin	O	O
transcription	O	O
with	O	O
a	O	O
down-regulated	O	O
synthesis	O	O
of	O	O
Oct2	B-protein	O
and	O	O
BOB.1/OBF.1	O	O
is	O	O
the	O	O
first	O	O
established	O	O
general	O	O
recurrent	O	O
defect	O	O
found	O	O
in	O	O
HRS	B-cell_type	O
cells	I-cell_type	O
.	O	O

Constitutive	O	O
expression	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
is	O	O
a	O	O
characteristic	O	O
feature	O	O
of	O	O
mycosis	O	O
fungoides	O	O
:	O	O
implications	O	O
for	O	O
apoptosis	O	O
resistance	O	O
and	O	O
pathogenesis	O	O
.	O	O

The	O	O
NF-kappa	B-protein	O
B	I-protein	O
family	I-protein	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
is	O	O
an	O	O
important	O	O
regulator	O	O
of	O	O
genes	O	O
expressed	O	O
during	O	O
inflammatory	O	O
responses	O	O
,	O	O
immunoglobulin	O	O
(	O	O
Ig	O	O
)	O	O
class	O	O
switching	O	O
,	O	O
cellular	O	O
differentiation	O	O
,	O	O
and	O	O
apoptosis	O	O
.	O	O

Recently	O	O
,	O	O
members	O	O
of	O	O
the	O	O
NF-kappaB	B-protein	O
family	I-protein	O
,	O	O
including	O	O
p65	B-protein	O
(	O	O
Rel	I-protein	O
A	I-protein	O
)	O	O
,	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
promoting	O	O
survival	O	O
of	O	O
various	O	O
hematopoeitic	O	O
neoplasms	O	O
,	O	O
including	O	O
T	O	O
cell	O	O
malignancies	O	O
such	O	O
as	O	O
adult	O	O
T	O	O
cell	O	O
leukemia-lymphoma	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
expression	O	O
of	O	O
active	O	O
NF-kappa	B-protein	O
B	I-protein	O
p65	I-protein	O
(	O	O
Rel	B-protein	O
A	I-protein	O
)	O	O
in	O	O
cases	O	O
of	O	O
mycosis	O	O
fungoides	O	O
(	O	O
MF	B-protein	O
)	O	O
and	O	O
the	O	O
effect	O	O
of	O	O
chemical	O	O
inhibitors	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
on	O	O
apoptosis	O	O
in	O	O
cutaneous	B-cell_line	O
T	I-cell_line	O
cell	I-cell_line	O
lymphoma	I-cell_line	O
(	I-cell_line	O
CTCL	I-cell_line	O
)	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

Paraffin-embedded	O	O
tissues	O	O
from	O	O
23	O	O
cutaneous	O	O
lesions	O	O
and	O	O
a	O	O
single	O	O
lymph	O	O
node	O	O
biopsy	O	O
from	O	O
patients	O	O
diagnosed	O	O
with	O	O
MF	O	O
were	O	O
evaluated	O	O
for	O	O
p65	O	O
(	O	O
Rel	O	O
A	O	O
)	O	O
expression	O	O
by	O	O
using	O	O
a	O	O
monoclonal	B-protein	O
mouse	O	O
antibody	O	O
that	O	O
detects	O	O
the	O	O
activated	O	O
form	O	O
of	O	O
p65	B-protein	O
(	O	O
Rel	I-protein	O
A	I-protein	O
)	O	O
.	O	O

Apoptosis	O	O
after	O	O
treatment	O	O
with	O	O
the	O	O
NF-kappa	B-protein	O
B	I-protein	O
inhibitors	O	O
gliotoxin	O	O
,	O	O
MG132	O	O
,	O	O
BAY	O	O
11-7082	O	O
,	O	O
and	O	O
BAY	O	O
11-7085	O	O
was	O	O
quantitatively	O	O
measured	O	O
in	O	O
the	O	O
CTCL	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
HuT-78	O	O
and	O	O
HH	O	O
by	O	O
propidium	O	O
iodide	O	O
(	O	O
PI	O	O
)	O	O
/cell	O	O
cycle	O	O
analysis	O	O
for	O	O
detection	O	O
of	O	O
a	O	O
hypodiploid	O	O
(	O	O
sub-G	I-protein	O
(	I-protein	O
0	I-protein	O
)	O	O
)	O	O
population	O	O
and	O	O
by	O	O
determination	O	O
of	O	O
increased	O	O
Annexin	O	O
V/7-amino-actinomycin	O	O
D	O	O
(	O	O
7-AAD	O	O
)	O	O
expression	O	O
.	O	O

Nuclear	O	O
extracts	O	O
from	O	O
CTCL	B-cell_type	O
cells	I-cell_type	O
before	O	O
and	O	O
after	O	O
chemical	O	O
inhibition	O	O
were	O	O
analyzed	O	O
for	O	O
NF-kappa	B-protein	O
B	O	O
nuclear	O	O
DNA-binding	O	O
activity	O	O
by	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
(	O	O
EMSA	O	O
)	O	O
with	O	O
quantitative	O	O
densitometry	O	O
.	O	O

Nuclear	O	O
expression	O	O
of	O	O
p65	B-protein	O
(	O	O
Rel	B-protein	O
A	I-protein	O
)	O	O
before	O	O
and	O	O
after	O	O
treatment	O	O
with	O	O
the	O	O
various	O	O
inhibitory	O	O
compounds	O	O
was	O	O
measured	O	O
by	O	O
immunofluorescence	O	O
staining	O	O
in	O	O
each	O	O
CTCL	B-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
.	O	O

Neoplastic	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
from	O	O
22	O	O
of	O	O
24	O	O
cases	O	O
of	O	O
MF	O	O
showed	O	O
strong	O	O
nuclear	O	O
and	O	O
cytoplasmic	O	O
expression	O	O
of	O	O
active	O	O
p65	B-protein	O
(	O	O
Rel	I-protein	O
A	I-protein	O
)	O	O
.	O	O

Compared	O	O
with	O	O
untreated	B-cell_line	O
control	I-cell_line	O
cells	I-cell_line	O
,	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
apoptosis	O	O
,	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
NF-kappa	B-protein	O
B	I-protein	O
DNA-binding	O	O
activity	O	O
,	O	O
and	O	O
a	O	O
marked	O	O
decrease	O	O
in	O	O
nuclear	B-protein	O
p65	I-protein	O
(	O	O
Rel	O	O
A	O	O
)	O	O
expression	O	O
were	O	O
seen	O	O
in	O	O
cells	O	O
from	O	O
both	O	O
CTCL	O	O
cell	O	O
lines	O	O
after	O	O
chemical	O	O
NF-kappa	B-protein	O
B	I-protein	O
inhibition	O	O
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
the	O	O
active	O	O
form	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
p65	I-protein	O
(	O	O
Rel	B-protein	O
A	I-protein	O
)	O	O
is	O	O
commonly	O	O
expressed	O	O
in	O	O
neoplastic	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
in	O	O
patients	O	O
with	O	O
MF	O	O
.	O	O

In	O	O
CTCL	O	O
cell	O	O
lines	O	O
,	O	O
the	O	O
significant	O	O
decrease	O	O
in	O	O
nuclear	O	O
NF-kappa	B-protein	O
B	I-protein	O
expression	O	O
and	O	O
the	O	O
marked	O	O
increase	O	O
in	O	O
spontaneous	O	O
apoptosis	O	O
caused	O	O
by	O	O
chemical	O	O
NF-kappa	B-protein	O
B	I-protein	O
inhibition	O	O
suggest	O	O
a	O	O
critical	O	O
role	O	O
for	O	O
NF-kappa	B-protein	O
B	I-protein	O
in	O	O
the	O	O
pathogenesis	O	O
and	O	O
tumor	O	O
cell	O	O
maintenance	O	O
of	O	O
CTCLs	O	O
.	O	O

HUM	O	O
PATHOL	O	O
31	O	O
:	O	O
1482-1490	O	O
.	O	O

Human	O	O
T-cell	O	O
leukemia	O	O
virus	O	O
type	O	O
1	O	O
tax	O	O
protein	O	O
activates	O	O
transcription	O	O
through	O	O
AP-1	O	O
site	O	O
by	O	O
inducing	O	O
DNA	O	O
binding	O	O
activity	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Human	O	O
T-cell	O	O
leukemia	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HTLV-1	O	O
)	O	O
Tax	O	O
protein	O	O
induces	O	O
the	O	O
expression	O	O
of	O	O
various	O	O
family	O	O
members	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
AP-1	I-protein	O
,	O	O
such	O	O
as	O	O
c-Jun	B-protein	O
,	O	O
JunD	O	O
,	O	O
c-Fos	O	O
,	O	O
and	O	O
Fra-1	B-protein	O
,	O	O
at	O	O
the	O	O
level	O	O
of	O	O
RNA	O	O
expression	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
examined	O	O
the	O	O
activity	O	O
of	O	O
Tax	O	O
in	O	O
transcription	O	O
through	O	O
AP-1-binding	O	O
sites	O	O
(	O	O
AP-1	B-DNA	O
site	I-DNA	O
)	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Transient	O	O
transfection	O	O
studies	O	O
showed	O	O
that	O	O
Tax	O	O
activated	O	O
the	O	O
expression	O	O
of	O	O
a	O	O
luciferase	B-DNA	O
gene	I-DNA	O
regulated	O	O
by	O	O
two	O	O
copies	O	O
of	O	O
an	O	O
AP-1	B-DNA	O
site	I-DNA	O
in	O	O
the	O	O
human	B-cell_line	O
Jurkat	I-cell_line	O
T-cell	I-cell_line	O
line	I-cell_line	O
.	O	O

Tax	O	O
activates	O	O
the	O	O
expression	O	O
of	O	O
viral	O	O
and	O	O
cellular	O	O
genes	O	O
through	O	O
two	O	O
different	O	O
enhancers	O	O
:	O	O
a	O	O
cAMP-responsive	O	O
(	O	O
CRE	O	O
)	O	O
-like	O	O
element	O	O
and	O	O
a	O	O
kappaB	B-DNA	O
element	I-DNA	O
.	O	O

Two	O	O
Tax	O	O
mutants	O	O
differentially	O	O
activated	O	O
expression	O	O
of	O	O
these	O	O
two	O	O
elements	B-DNA	O
.	O	O

Tax703	O	O
preferentially	O	O
activated	O	O
the	O	O
kappaB	B-DNA	O
element	I-DNA	O
but	O	O
not	O	O
the	O	O
CRE-like	O	O
one	O	O
,	O	O
whereas	O	O
TaxM22	O	O
showed	O	O
the	O	O
reverse	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
Tax703	O	O
and	O	O
Tax	O	O
,	O	O
but	O	O
not	O	O
TaxM22	O	O
,	O	O
converted	O	O
cell	O	O
growth	O	O
of	O	O
a	O	O
mouse	O	O
T-cell	O	O
line	O	O
from	O	O
being	O	O
interleukin	B-protein	O
(	O	O
IL	I-protein	O
)	O	O
-2-dependent	O	O
to	O	O
being	O	O
IL-2-independent	O	O
.	O	O

Unlike	O	O
the	O	O
wild-type	O	O
Tax	O	O
,	O	O
Tax703	O	O
and	O	O
TaxM22	O	O
only	O	O
weakly	O	O
activated	O	O
the	O	O
AP-1	B-DNA	O
site	I-DNA	O
in	O	O
the	O	O
T-cell	O	O
line	O	O
.	O	O

Thus	O	O
,	O	O
Tax	O	O
seems	O	O
to	O	O
activate	O	O
the	O	O
AP-1	B-DNA	O
site	I-DNA	O
via	O	O
mechanisms	O	O
distinct	O	O
from	O	O
those	O	O
of	O	O
kappaB	O	O
or	O	O
CRE-like	B-DNA	O
elements	I-DNA	O
,	O	O
and	O	O
the	O	O
activation	O	O
of	O	O
the	O	O
AP-1	B-DNA	O
site	I-DNA	O
is	O	O
dispensable	O	O
for	O	O
IL-2-independent	O	O
growth	O	O
of	O	O
CTLL-2	O	O
.	O	O

Electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
showed	O	O
that	O	O
Tax	O	O
induced	O	O
strong	O	O
binding	O	O
activity	O	O
to	O	O
an	O	O
AP-1	B-DNA	O
site	I-DNA	O
in	O	O
CTLL-2	O	O
,	O	O
whereas	O	O
Tax703	O	O
did	O	O
not	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
induction	O	O
of	O	O
binding	O	O
activity	O	O
to	O	O
the	O	O
AP-1	B-DNA	O
site	I-DNA	O
is	O	O
essential	O	O
for	O	O
the	O	O
transcriptional	O	O
activation	O	O
by	O	O
Tax	O	O
.	O	O

The	O	O
binding	B-protein	O
complex	I-protein	O
induced	O	O
by	O	O
Tax	O	O
in	O	O
CTLL-2	O	O
contained	O	O
JunD	O	O
and	O	O
Fra-2	O	O
.	O	O

Other	O	O
AP-1	B-protein	O
proteins	I-protein	O
were	O	O
undetectable	O	O
.	O	O

Activation	O	O
of	O	O
transcription	O	O
through	O	O
the	O	O
AP-1	B-DNA	O
site	I-DNA	O
in	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
by	O	O
JunD	O	O
and/or	O	O
Fra-2	O	O
was	O	O
weak	O	O
.	O	O

c-Jun	B-protein	O
,	O	O
JunB	O	O
,	O	O
and	O	O
c-Fos	O	O
activation	O	O
was	O	O
greater	O	O
,	O	O
although	O	O
the	O	O
level	O	O
was	O	O
still	O	O
less	O	O
than	O	O
that	O	O
with	O	O
Tax	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
induction	O	O
of	O	O
AP-1	B-RNA	O
mRNA	I-RNA	O
by	O	O
Tax	O	O
may	O	O
not	O	O
be	O	O
sufficient	O	O
for	O	O
a	O	O
complete	O	O
activation	O	O
of	O	O
AP-1	B-protein	O
site	I-DNA	O
by	O	O
Tax	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
Tax	O	O
activates	O	O
the	O	O
transcription	O	O
of	O	O
cellular	O	O
genes	O	O
with	O	O
AP-1	B-protein	O
sites	O	O
by	O	O
inducing	O	O
the	O	O
DNA-binding	O	O
activity	O	O
of	O	O
AP-1	B-protein	O
proteins	I-protein	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
a	O	O
mechanism	O	O
distinct	O	O
from	O	O
those	O	O
of	O	O
CRE-like	O	O
and	O	O
kappaB	O	O
elements	O	O
.	O	O

Copyright	O	O
2001	O	O
Academic	O	O
Press	O	O
.	O	O

Strict	O	O
control	O	O
of	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
replication	O	O
by	O	O
a	O	O
genetic	O	O
switch	O	O
:	O	O
Tet	O	O
for	O	O
Tat	O	O
.	O	O

Live-attenuated	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HIV-1	B-protein	O
)	O	O
variants	O	O
have	O	O
shown	O	O
great	O	O
promise	O	O
as	O	O
AIDS	O	O
vaccines	O	O
,	O	O
but	O	O
continued	O	O
replication	O	O
can	O	O
lead	O	O
to	O	O
the	O	O
selection	O	O
of	O	O
faster-replicating	O	O
variants	O	O
that	O	O
are	O	O
pathogenic	O	O
.	O	O

We	O	O
therefore	O	O
designed	O	O
HIV-1	O	O
genomes	O	O
that	O	O
replicate	O	O
exclusively	O	O
upon	O	O
addition	O	O
of	O	O
the	O	O
nontoxic	B-protein	O
effector	I-protein	O
doxycycline	I-protein	O
(	O	O
dox	B-protein	O
)	O	O
.	O	O

This	O	O
was	O	O
achieved	O	O
by	O	O
replacement	O	O
of	O	O
the	O	O
viral	O	O
TAR-Tat	O	O
system	O	O
for	O	O
transcriptional	O	O
activation	O	O
by	O	O
the	O	O
Escherichia	O	O
coli-derived	O	O
Tet	O	O
system	O	O
for	O	O
inducible	O	O
gene	O	O
expression	O	O
.	O	O

These	O	O
designer	O	O
``	O	O
HIV-rtTA	O	O
''	O	O
viruses	O	O
replicate	O	O
in	O	O
a	O	O
strictly	O	O
dox-dependent	O	O
manner	O	O
both	O	O
in	O	O
a	O	O
T-cell	O	O
line	O	O
and	O	O
in	O	O
primary	B-cell_line	O
blood	I-cell_line	O
cells	I-cell_line	O
,	O	O
and	O	O
the	O	O
rate	O	O
of	O	O
replication	O	O
can	O	O
be	O	O
fine-tuned	O	O
by	O	O
simple	O	O
variation	O	O
of	O	O
the	O	O
dox	O	O
concentration	I-protein	O
.	O	O

These	O	O
HIV-rtTA	O	O
viruses	O	O
provide	O	O
a	O	O
tool	O	O
to	O	O
perform	O	O
genetics	O	O
,	O	O
e.g.	O	O
,	O	O
selection	O	O
and	O	O
optimization	O	O
experiments	O	O
,	O	O
with	O	O
the	O	O
E.	O	O
coli-derived	O	O
Tet	O	O
reagents	O	O
in	O	O
a	O	O
eukaryotic	O	O
background	O	O
.	O	O

Furthermore	O	O
,	O	O
such	O	O
viruses	O	O
may	O	O
represent	O	O
improved	O	O
vaccine	O	O
candidates	O	O
because	O	O
their	O	O
replication	O	O
can	O	O
be	O	O
turned	O	O
on	O	O
and	O	O
off	O	O
at	O	O
will	O	O
.	O	O

Synovial	O	O
fluid	O	O
induced	O	O
nuclear	O	O
factor-kappaB	O	O
DNA	O	O
binding	O	O
in	O	O
a	O	O
monocytic	B-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
effects	O	O
of	O	O
synovial	O	O
fluids	O	O
(	O	O
SF	B-protein	O
)	O	O
on	O	O
DNA	O	O
binding	O	O
activity	O	O
of	O	O
transcription	B-protein	O
factor	I-protein	O
nuclear	B-protein	O
factor-kappaB	I-protein	O
(	O	O
NF-kappaB	B-protein	O
)	O	O
in	O	O
the	O	O
Mono	O	O
Mac	O	O
6	O	O
monocytic/macrophage	O	O
cell	O	O
line	O	O
as	O	O
a	O	O
model	O	O
for	O	O
the	O	O
interaction	O	O
between	O	O
SF	O	O
and	O	O
synovial	O	O
tissue	O	O
macrophages	O	O
in	O	O
arthritis	O	O
.	O	O

METHODS	O	O
:	O	O
Mono	O	O
Mac	O	O
6	O	O
cells	O	O
were	O	O
incubated	O	O
with	O	O
SF	O	O
from	O	O
the	O	O
knee	O	O
joints	O	O
of	O	O
human	O	O
subjects	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
(	O	O
RA	O	O
)	O	O
,	O	O
undifferentiated	O	O
seronegative	O	O
oligoarthritis	O	O
,	O	O
and	O	O
osteoarthritis	O	O
(	O	O
OA	O	O
)	O	O
.	O	O

Nuclear	O	O
extracts	O	O
prepared	O	O
from	O	O
the	O	O
Mono	O	O
Mac	O	O
6	O	O
cells	O	O
and	O	O
RA	O	O
synovial	O	O
tissue	O	O
were	O	O
analyzed	O	O
by	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
analysis	O	O
(	O	O
EMSA	O	O
)	O	O
for	O	O
NF-kappaB	O	O
DNA	B-protein	O
binding	I-protein	O
proteins	I-protein	O
.	O	O

RESULTS	O	O
:	O	O
Induction	O	O
of	O	O
NF-kappaB	O	O
DNA	O	O
binding	O	O
by	O	O
the	O	O
p65	B-protein	O
(	I-protein	O
RelA	I-protein	O
)	I-protein	O
/p50	I-protein	O
heterodimer	I-protein	O
was	O	O
observed	O	O
in	O	O
response	O	O
to	O	O
incubation	O	O
of	O	O
Mono	O	O
Mac	O	O
6	O	O
cells	O	O
with	O	O
SF	O	O
(	O	O
20	O	O
%	O	O
in	O	O
culture	O	O
medium	O	O
)	O	O
from	O	O
5	O	O
of	O	O
8	O	O
subjects	O	O
with	O	O
RA	O	O
,	O	O
4	O	O
of	O	O
5	O	O
with	O	O
OA	B-protein	O
,	O	O
and	O	O
none	O	O
of	O	O
3	O	O
with	O	O
undifferentiated	O	O
seronegative	O	O
oligoarthritis	O	O
.	O	O

Incubation	O	O
of	O	O
SF	O	O
with	O	O
neutralizing	B-protein	O
antibodies	I-protein	O
against	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor-alpha	O	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
,	O	O
but	O	O
not	O	O
antibodies	O	O
against	O	O
interleukin	B-protein	O
6	O	O
(	O	O
IL-6	O	O
)	O	O
,	O	O
significantly	O	O
reduced	O	O
the	O	O
induction	O	O
of	O	O
p65/p50	O	O
binding	O	O
activity	O	O
in	O	O
SF	O	O
from	O	O
subjects	O	O
with	O	O
RA	O	O
and	O	O
OA	O	O
.	O	O

Unexpectedly	O	O
,	O	O
a	O	O
slowly	O	O
migrating	O	O
SF	O	O
inducible	O	O
NF-kappaB	O	O
-binding	O	O
complex	O	O
was	O	O
observed	O	O
in	O	O
EMSA	O	O
of	O	O
Mono	O	O
Mac	O	O
6	O	O
cells	O	O
after	O	O
incubation	O	O
with	O	O
SF	O	O
from	O	O
5	O	O
of	O	O
8	O	O
RA	O	O
and	O	O
2	O	O
of	O	O
5	O	O
OA	O	O
subjects	O	O
.	O	O

The	O	O
induction	O	O
of	O	O
this	O	O
complex	O	O
by	O	O
SF	O	O
was	O	O
not	O	O
affected	O	O
by	O	O
neutralization	O	O
of	O	O
TNF-alpha	B-protein	O
or	O	O
IL-6	O	O
in	O	O
SF	O	O
,	O	O
and	O	O
the	O	O
complex	B-protein	O
was	O	O
not	O	O
inducible	O	O
by	O	O
TNF-alpha	O	O
,	O	O
IL-1beta	O	O
,	O	O
TNF-alpha	O	O
/	O	O
IL-1beta	O	O
,	O	O
IL-6	O	O
,	O	O
platelet	O	O
derived	O	O
growth	I-protein	O
factor	I-protein	O
,	O	O
lipopolysaccharide	O	O
,	O	O
or	O	O
tetradecanoyl	O	O
phorbol	O	O
acetate	O	O
.	O	O

The	O	O
slowly	B-protein	O
migrating	I-protein	O
complex	I-protein	O
could	O	O
not	O	O
be	O	O
supershifted	O	O
with	O	O
antibodies	O	O
against	O	O
NF-kappaB	O	O
,	O	O
Jun	O	O
,	O	O
or	O	O
the	O	O
transcriptional	O	O
coactivators	O	O
p300	O	O
or	O	O
CBP	O	O
.	O	O

A	O	O
NF-kappaB-binding	O	O
complex	O	O
with	O	O
similar	O	O
slow	O	O
mobility	O	O
was	O	O
observed	O	O
in	O	O
nuclear	O	O
extracts	O	O
prepared	O	O
from	O	O
fresh	O	O
human	O	O
RA	O	O
synovial	O	O
tissue	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Biological	O	O
activity	O	O
of	O	O
TNF-alpha	O	O
in	O	O
SF	O	O
from	O	O
RA	O	O
and	O	O
OA	O	O
subjects	O	O
is	O	O
capable	O	O
of	O	O
inducing	O	O
p65/p50	O	O
NF-kappaB	O	O
DNA	O	O
binding	O	O
activity	O	O
in	O	O
macrophages	O	O
.	O	O

A	O	O
property	O	O
of	O	O
SF	O	O
that	O	O
is	O	O
independent	O	O
of	O	O
TNF-alpha	B-protein	O
and	O	O
other	O	O
cytokines	B-protein	O
is	O	O
responsible	O	O
for	O	O
the	O	O
induction	O	O
of	O	O
a	O	O
novel	O	O
slowly	O	O
migrating	I-protein	O
NF-kappaB-binding	I-protein	O
complex	I-protein	O
.	O	O

Soluble	O	O
mediators	O	O
in	O	O
SF	O	O
of	O	O
subjects	O	O
with	O	O
RA	O	O
and	O	O
OA	O	O
can	O	O
therefore	O	O
modulate	O	O
binding	O	O
of	O	O
nuclear	B-protein	O
proteins	I-protein	O
to	O	O
the	O	O
NF-kappaB	B-DNA	O
binding	I-DNA	O
site	I-DNA	O
in	O	O
macrophages	O	O
and	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
inflammatory	O	O
gene	O	O
expression	O	O
in	O	O
arthritis	O	O
.	O	O

Peroxisome	O	O
proliferator	O	O
activator	O	O
receptor-gamma	O	O
agonists	O	O
and	O	O
15-deoxy-Delta	B-protein	O
(	O	O
12	B-protein	O
,	O	O
14	O	O
)	O	O
(	O	O
12	B-protein	O
,	O	O
14	O	O
)	O	O
-PGJ	O	O
(	O	O
2	O	O
)	O	O
induce	O	O
apoptosis	O	O
in	O	O
normal	O	O
and	O	O
malignant	O	O
B-lineage	O	O
cells	O	O
.	O	O

The	O	O
research	O	O
described	O	O
herein	O	O
evaluates	O	O
the	O	O
expression	O	O
and	O	O
functional	O	O
significance	O	O
of	O	O
peroxisome	O	O
proliferator	O	O
activator	I-protein	O
receptor-gamma	I-protein	O
(	O	O
PPAR-gamma	O	O
)	O	O
on	O	O
B-lineage	B-cell_type	O
cells	I-cell_type	O
.	O	O

Normal	B-cell_type	O
mouse	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
and	O	O
a	O	O
variety	O	O
of	O	O
B	B-cell_type	O
lymphoma	I-cell_type	O
cells	I-cell_type	O
reflective	O	O
of	O	O
stages	O	O
of	O	O
B	B-protein	O
cell	I-protein	O
differentiation	O	O
(	O	O
e.g.	B-protein	O
,	O	O
70Z/3	O	O
,	O	O
CH31	O	O
,	O	O
WEHI-231	O	O
,	O	O
CH12	O	O
,	O	O
and	O	O
J558	O	O
)	O	O
express	O	O
PPAR-gamma	O	O
mRNA	I-RNA	O
and	O	O
,	O	O
by	O	O
Western	O	O
blot	O	O
analysis	O	O
,	O	O
the	O	O
67-kDa	B-protein	O
PPAR-gamma	I-protein	O
protein	I-protein	O
.	O	O

15-Deoxy-Delta	O	O
(	O	O
12	B-protein	O
,	O	O
14	B-protein	O
)	O	O
-PGJ	O	O
(	O	O
2	O	O
)	O	O
(	O	O
15d-PGJ	O	O
(	O	O
2	O	O
)	O	O
)	O	O
,	O	O
a	O	O
PPAR-gamma	O	O
agonist	O	O
,	O	O
has	O	O
a	O	O
dose-dependent	O	O
antiproliferative	O	O
and	O	O
cytotoxic	O	O
effect	O	O
on	O	O
normal	O	O
and	O	O
malignant	O	O
B	I-cell_type	O
cells	I-cell_type	O
as	O	O
shown	O	O
by	O	O
[	O	O
(	O	O
3	B-protein	O
)	O	O
H	O	O
]	O	O
thymidine	O	O
and	O	O
3-	O	O
[	O	O
4	O	O
,	O	O
5-dimethylthiazol-2-yl	O	O
]	O	O
-2	O	O
,	O	O
5-diphenyltetrazolium	O	O
bromide	O	O
assays	O	O
.	O	O

Only	O	O
PPAR-gamma	O	O
agonists	O	O
(	O	O
thiazolidinediones	B-protein	O
)	O	O
,	O	O
and	O	O
not	O	O
PPAR-alpha	O	O
agonists	O	O
,	O	O
mimicked	O	O
the	O	O
effect	O	O
of	O	O
15d-PGJ	O	O
(	O	O
2	O	O
)	O	O
on	O	O
B-lineage	B-cell_type	O
cells	I-cell_type	O
,	O	O
indicating	O	O
that	O	O
the	O	O
mechanism	O	O
by	O	O
which	O	O
15d-PGJ	O	O
(	O	O
2	I-cell_line	O
)	O	O
negatively	O	O
affects	O	O
B-lineage	O	O
cells	O	O
involves	O	O
in	O	O
part	O	O
PPAR-gamma	O	O
.	O	O

The	O	O
mechanism	O	O
by	O	O
which	O	O
PPAR-gamma	O	O
agonists	O	O
induce	O	O
cytotoxicity	O	O
is	O	O
via	O	O
apoptosis	O	O
,	O	O
as	O	O
shown	O	O
by	O	O
annexin	O	O
V	O	O
staining	O	O
and	O	O
as	O	O
confirmed	O	O
by	O	O
DNA	O	O
fragmentation	O	O
detected	O	O
using	O	O
the	O	O
TUNEL	O	O
assay	O	O
.	O	O

Interestingly	O	O
,	O	O
addition	O	O
of	O	O
PGF	O	O
(	O	O
2alpha	B-protein	O
)	O	O
,	O	O
which	O	O
was	O	O
not	O	O
known	O	O
to	O	O
affect	O	O
lymphocytes	I-cell_type	O
,	O	O
dramatically	O	O
attenuated	O	O
the	O	O
deleterious	O	O
effects	O	O
of	O	O
PPAR-gamma	O	O
agonists	O	O
on	O	O
B	O	O
lymphomas	O	O
.	O	O

Surprisingly	O	O
,	O	O
15d-PGJ	O	O
(	O	O
2	O	O
)	O	O
induced	O	O
a	O	O
massive	O	O
increase	O	O
in	O	O
nuclear	B-protein	O
mitogen-activated	I-protein	O
protein	I-protein	O
kinase	I-protein	O
activation	O	O
,	O	O
and	O	O
pretreatment	O	O
with	O	O
PGF	O	O
(	O	O
2alpha	O	O
)	O	O
blunted	O	O
the	O	O
mitogen-activated	O	O
protein	I-protein	O
kinase	I-protein	O
activation	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
evaluating	O	O
PPAR-gamma	O	O
expression	O	O
and	O	O
its	O	O
significance	O	O
on	O	O
B	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

PPAR-gamma	O	O
agonists	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
counterbalance	O	O
to	O	O
the	O	O
stimulating	O	O
effects	O	O
of	O	O
other	O	O
PGs	O	O
,	O	O
namely	O	O
PGE	O	O
(	O	O
2	O	O
)	O	O
,	O	O
which	O	O
promotes	O	O
B	O	O
cell	O	O
differentiation	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
use	O	O
of	O	O
PGs	O	O
,	O	O
such	O	O
as	O	O
15d-PGJ	O	O
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
synthetic	O	O
PPAR-gamma	O	O
agonists	O	O
to	O	O
induce	O	O
apoptosis	O	O
in	O	O
B-lineage	B-cell_type	O
cells	I-cell_type	O
may	O	O
lead	O	O
to	O	O
the	O	O
development	O	O
of	O	O
novel	O	O
therapies	O	O
for	O	O
fatal	O	O
B	O	O
lymphomas	O	O

Inhibition	O	O
of	O	O
STAT3	B-protein	O
signaling	O	O
leads	O	O
to	O	O
apoptosis	O	O
of	O	O
leukemic	B-protein	O
large	I-cell_type	O
granular	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
decreased	O	O
Mcl-1	O	O
expression	O	O
.	O	O

Large	O	O
granular	I-cell_line	O
lymphocyte	I-cell_line	O
(	O	O
LGL	B-cell_type	O
)	O	O
leukemia	O	O
is	O	O
characterized	O	O
by	O	O
the	O	O
expansion	O	O
of	O	O
antigen-activated	O	O
cytotoxic	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

These	O	O
leukemic	B-cell_type	O
cells	I-cell_type	O
are	O	O
resistant	O	O
to	O	O
Fas-mediated	O	O
apoptosis	O	O
despite	O	O
expressing	O	O
high	O	O
levels	O	O
of	O	O
Fas	O	O
.	O	O

We	O	O
found	O	O
that	O	O
leukemic	B-protein	O
LGL	I-protein	O
from	O	O
19	O	O
patients	O	O
displayed	O	O
high	O	O
levels	O	O
of	O	O
activated	O	O
STAT3	B-protein	O
.	O	O

Treatment	O	O
of	O	O
leukemic	B-protein	O
LGL	I-protein	O
with	O	O
the	O	O
JAK-selective	B-protein	O
tyrosine	I-protein	O
kinase	I-protein	O
inhibitor	O	O
AG-490	O	O
induced	O	O
apoptosis	O	O
with	O	O
a	O	O
corresponding	O	O
decrease	O	O
in	O	O
STAT	O	O
-DNA	O	O
binding	O	O
activity	O	O
.	O	O

Moreover	O	O
,	O	O
using	O	O
an	O	O
antisense	O	O
oligonucleotide	O	O
approach	O	O
to	O	O
diminish	O	O
STAT3	O	O
expression	O	O
,	O	O
we	O	O
found	O	O
that	O	O
Fas	O	O
sensitivity	O	O
was	O	O
restored	O	O
in	O	O
leukemic	O	O
LGL	B-cell_type	O
.	O	O

AG-490-induced	O	O
apoptosis	O	O
in	O	O
leukemic	O	O
LGL	O	O
was	O	O
independent	O	O
of	O	O
Bcl-xL	O	O
or	O	O
Bcl-2	O	O
expression	O	O
.	O	O

However	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
Bcl-2-family	B-protein	O
protein	I-protein	O
Mcl-1	O	O
was	O	O
significantly	O	O
reduced	O	O
by	O	O
AG-490	O	O
treatment	O	O
.	O	O

Activated	O	O
STAT3	O	O
was	O	O
shown	O	O
to	O	O
bind	O	O
an	O	O
SIE-related	B-DNA	O
element	I-DNA	O
in	O	O
the	O	O
murine	B-DNA	O
mcl-1	I-DNA	O
promoter	I-DNA	O
.	O	O

Using	O	O
a	O	O
luciferase	B-DNA	O
reporter	I-DNA	O
assay	I-DNA	O
,	O	O
we	O	O
demonstrated	O	O
that	O	O
v-src	O	O
overexpression	O	O
in	O	O
NIH3T3	O	O
induced	O	O
STAT3	O	O
-dependent	O	O
transcriptional	O	O
activity	O	O
from	O	O
the	O	O
mcl-1	B-DNA	O
promoter	I-DNA	O
and	O	O
increased	O	O
endogenous	O	O
Mcl-1	O	O
protein	O	O
levels	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
STAT3	O	O
activation	O	O
contributed	O	O
to	O	O
accumulation	O	O
of	O	O
the	O	O
leukemic	B-protein	O
LGL	I-protein	O
clones	I-protein	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
investigation	O	O
should	O	O
focus	O	O
on	O	O
novel	O	O
strategies	O	O
targeting	O	O
STAT3	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
LGL	O	O
leukemia	O	O
.	O	O

Decreased	B-DNA	O
immediate	I-DNA	O
inflammatory	I-DNA	O
gene	I-DNA	O
induction	O	O
in	O	O
activating	O	O
transcription	O	O
factor-2	O	O
mutant	O	O
mice	O	O
.	O	O

Transcription	B-protein	O
factor	I-protein	O
activating	B-protein	O
transcription	I-protein	O
factor	I-protein	O
(	O	O
ATF	B-protein	O
)	O	O
-2	O	O
is	O	O
activated	O	O
by	O	O
inflammatory	O	O
signals	O	O
transduced	O	O
by	O	O
the	O	O
JNK	B-protein	O
and	O	O
p38	O	O
MAP	B-protein	O
kinase	I-protein	O
pathways	O	O
.	O	O

To	O	O
better	O	O
define	O	O
the	O	O
role	O	O
of	O	O
ATF-2	O	O
in	O	O
inflammation	O	O
,	O	O
adult	O	O
mice	O	O
expressing	O	O
small	O	O
amounts	O	O
of	O	O
a	O	O
mutant	O	O
ATF-2	O	O
protein	O	O
were	O	O
challenged	O	O
with	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
,	O	O
anti-CD3	O	O
antibody	O	O
or	O	O
virus	O	O
.	O	O

Within	O	O
3	O	O
h	O	O
of	O	O
challenge	O	O
by	O	O
LPS	O	O
,	O	O
ATF-2	O	O
mutant	O	O
mice	O	O
had	O	O
decreased	O	O
induction	O	O
of	O	O
the	O	O
adhesion	B-protein	O
molecules	I-protein	O
E-selectin	I-protein	O
,	O	O
P-selectin	O	O
and	O	O
VCAM-1	B-protein	O
as	O	O
well	O	O
as	O	O
the	O	O
cytokines	B-protein	O
tumor	I-protein	O
necrosis	I-protein	O
factor-alpha	I-protein	O
,	O	O
IL-1beta	O	O
and	O	O
IL-6	O	O
compared	O	O
with	O	O
control	O	O
mice	O	O
.	O	O

Stimulation	O	O
of	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
by	O	O
anti-CD3	O	O
antibody	O	O
also	O	O
showed	O	O
less	O	O
induction	O	O
of	O	O
IL-1	B-protein	O
and	O	O
IL-6	O	O
in	O	O
ATF-2	O	O
mutant	O	O
tissues	O	O
.	O	O

ATF-2	O	O
mutant	O	O
thymocytes	O	O
treated	O	O
with	O	O
anti-CD3	O	O
antibody	O	O
in	O	O
vitro	O	O
demonstrated	O	O
reduced	O	O
induction	O	O
of	O	O
c-Jun	O	O
,	O	O
JunB	O	O
,	O	O
JunD	O	O
and	O	O
Fra-2	O	O
.	O	O

However	O	O
,	O	O
similar	O	O
to	O	O
what	O	O
was	O	O
observed	O	O
after	O	O
p38	O	O
kinase	O	O
inhibition	O	O
in	O	O
normal	O	O
mice	O	O
,	O	O
relative	O	O
ATF-2	O	O
deficiency	O	O
did	O	O
not	O	O
prevent	O	O
the	O	O
development	O	O
of	O	O
a	O	O
mononuclear	O	O
cell	O	O
infiltrate	O	O
in	O	O
the	O	O
week	O	O
following	O	O
an	O	O
inflammatory	O	O
stimulus	O	O
.	O	O

ATF-2	O	O
mutant	O	O
mice	O	O
proved	O	O
more	O	O
susceptible	O	O
to	O	O
death	O	O
than	O	O
control	O	O
mice	O	O
from	O	O
LPS	O	O
plus	O	O
D-galactosamine	O	O
injection	O	O
or	O	O
Coxsackievirus	O	O
B3	O	O
infection	O	O
and	O	O
had	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
mononuclear	O	O
pulmonary	O	O
infiltrates	O	O
after	O	O
exposure	O	O
to	O	O
Herpes	O	O
simplex	O	O
virus-1	O	O
.	O	O

ATF-2	O	O
is	O	O
essential	O	O
for	O	O
maximal	O	O
immediate	O	O
induction	O	O
of	O	O
adhesion	B-protein	O
molecules	I-protein	O
and	O	O
cytokine	B-protein	O
genes	I-DNA	O
,	O	O
but	O	O
at	O	O
later	O	O
time	O	O
points	O	O
may	O	O
even	O	O
protect	O	O
against	O	O
overactive	O	O
immune	O	O
responses	O	O
.	O	O

LIGHT	O	O
,	O	O
a	O	O
TNF-like	O	O
molecule	O	O
,	O	O
costimulates	O	O
T	O	O
cell	O	O
proliferation	O	O
and	O	O
is	O	O
required	O	O
for	O	O
dendritic	O	O
cell	O	O
-mediated	O	O
allogeneic	O	O
T	O	O
cell	O	O
response	O	O
.	O	O

LIGHT	O	O
is	O	O
a	O	O
recently	O	O
identified	O	O
member	O	O
of	O	O
the	O	O
TNF	B-protein	O
superfamily	I-protein	O
and	O	O
its	O	O
receptors	B-protein	O
,	O	O
herpesvirus	O	O
entry	O	O
mediator	O	O
and	O	O
lymphotoxin	O	O
beta	B-protein	O
receptor	I-protein	O
,	O	O
are	O	O
found	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
stromal	B-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
LIGHT	O	O
is	O	O
selectively	O	O
expressed	O	O
on	O	O
immature	O	O
dendritic	O	O
cells	O	O
(	O	O
DCs	O	O
)	O	O
generated	O	O
from	O	O
human	O	O
PBMCs	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
LIGHT	O	O
is	O	O
not	O	O
detectable	O	O
in	O	O
DCs	O	O
either	O	O
freshly	O	O
isolated	O	O
from	O	O
PBMCs	O	O
or	O	O
rendered	O	O
mature	O	O
in	O	O
vitro	O	O
by	O	O
LPS	O	O
treatment	O	O
.	O	O

Blockade	O	O
of	O	O
LIGHT	O	O
by	O	O
its	O	O
soluble	B-protein	O
receptors	I-protein	O
,	O	O
lymphotoxin	O	O
beta	O	O
receptor-Ig	O	O
or	O	O
HVEM-Ig	O	O
,	O	O
inhibits	O	O
the	O	O
induction	O	O
of	O	O
DC	O	O
-mediated	O	O
primary	O	O
allogeneic	O	O
T	O	O
cell	O	O
response	O	O
.	O	O

Furthermore	O	O
,	O	O
engagement	O	O
of	O	O
LIGHT	O	O
costimulates	O	O
human	I-protein	O
T	I-protein	O
cell	O	O
proliferation	O	O
,	O	O
amplifies	O	O
the	O	O
NF-kappaB	O	O
signaling	O	O
pathway	O	O
,	O	O
and	O	O
preferentially	O	O
induces	O	O
the	O	O
production	O	O
of	O	O
IFN-gamma	B-protein	O
,	O	O
but	O	O
not	O	O
IL-4	B-protein	O
,	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
antigenic	O	O
signal	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
LIGHT	O	O
is	O	O
a	O	O
costimulatory	O	O
molecule	O	O
involved	O	O
in	O	O
DC	O	O
-mediated	O	O
cellular	O	O
immune	O	O
responses	O	O
.	O	O

Suppression	O	O
of	O	O
HIV	B-protein	O
type	I-protein	O
1	O	O
replication	O	O
by	O	O
a	O	O
dominant-negative	O	O
Ets-1	O	O
mutant	O	O
.	O	O

Activity	O	O
of	O	O
the	O	O
distal	B-DNA	O
region	I-DNA	O
of	O	O
the	O	O
human	B-DNA	O
immunodeficiency	I-DNA	O
virus	I-DNA	O
(	O	O
HIV-1	B-DNA	O
)	O	O
long	O	O
terminal	B-DNA	O
repeat	I-DNA	O
(	O	O
LTR	B-DNA	O
)	O	O
,	O	O
which	O	O
contains	O	O
binding	O	O
sites	O	O
for	O	O
the	O	O
Ets-1	B-protein	O
and	I-protein	O
USF-1	I-protein	O
proteins	I-protein	O
,	O	O
is	O	O
integral	O	O
for	O	O
HIV-1	O	O
replication	O	O
.	O	O

The	O	O
Ets-1	B-protein	O
and	O	O
USF-1	B-protein	O
proteins	I-protein	O
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
HIV-1	B-DNA	O
LTR	I-DNA	O
distal	I-DNA	O
enhancer	I-DNA	O
region	I-DNA	O
,	O	O
as	O	O
indicated	O	O
by	O	O
the	O	O
potent	O	O
dominant	O	O
negative	O	O
effect	O	O
of	O	O
a	O	O
mutant	O	O
Ets-1	O	O
lacking	O	O
trans-activation	O	O
domains	O	O
on	O	O
the	O	O
transcriptional	O	O
activity	O	O
of	O	O
the	O	O
LTR	B-DNA	O
.	O	O

To	O	O
determine	O	O
the	O	O
biological	O	O
relevance	O	O
of	O	O
the	O	O
Ets-1	B-protein	O
and	I-protein	O
USF-1	I-protein	O
proteins	I-protein	O
in	O	O
HIV-1	O	O
replication	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
expression	O	O
of	O	O
the	O	O
dominant-negative	O	O
mutant	O	O
of	O	O
Ets-1	O	O
(	O	O
dnEts-1	B-protein	O
)	O	O
on	O	O
HIV-1	O	O
infection	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
demonstrated	O	O
that	O	O
expression	O	O
of	O	O
dnEts	O	O
markedly	O	O
suppressed	O	O
HIV-1	O	O
infection	O	O
of	O	O
a	O	O
T	B-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
.	O	O

This	O	O
finding	O	O
indicates	O	O
that	O	O
formation	O	O
of	O	O
a	O	O
transcriptionaly	O	O
active	O	O
USF-1/Ets-1	I-protein	O
complex	I-protein	O
is	O	O
important	O	O
in	O	O
the	O	O
productive	O	O
infection	O	O
of	O	O
cells	I-cell_type	O
by	O	O
HIV-1	O	O
,	O	O
and	O	O
suggests	O	O
that	O	O
inhibition	O	O
of	O	O
the	O	O
interaction	O	O
between	O	O
USF-1	O	O
and	O	O
Ets-1	O	O
with	O	O
the	O	O
HIV-1	B-DNA	O
LTR	I-DNA	O
may	O	O
provide	O	O
a	O	O
new	O	O
target	O	O
for	O	O
anti-HIV-1	O	O
gene	O	O
therapy	O	O
.	O	O

Human	O	O
eosinophils	O	O
constitutively	O	O
express	O	O
nuclear	O	O
factor	O	O
of	O	O
activated	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
p	O	O
and	O	O
c	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Eosinophils	O	O
are	O	O
now	O	O
known	O	O
to	O	O
produce	O	O
a	O	O
variety	O	O
of	O	O
proinflammatory	O	O
cytokines	B-protein	O
,	O	O
although	O	O
the	O	O
molecular	O	O
factors	I-protein	O
that	O	O
regulate	O	O
their	O	O
production	O	O
are	O	O
poorly	O	O
understood	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
almost	O	O
all	O	O
of	O	O
the	O	O
cytokines	B-protein	O
produced	O	O
by	O	O
eosinophils	B-protein	O
,	O	O
including	O	O
the	O	O
proallergic	B-protein	O
cytokine	I-protein	O
IL-4	I-protein	O
,	O	O
is	O	O
now	O	O
known	O	O
to	O	O
be	O	O
regulated	O	O
at	O	O
the	O	O
level	O	O
of	O	O
transcription	O	O
by	O	O
members	O	O
of	O	O
the	O	O
nuclear	B-protein	O
factor	I-protein	O
of	I-protein	O
activated	I-protein	O
T	I-protein	O
cells	I-protein	O
(	O	O
NFAT	B-protein	O
)	O	O
family	O	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
sought	O	O
to	O	O
characterize	O	O
the	O	O
expression	O	O
of	O	O
different	O	O
NFAT	B-protein	O
proteins	I-protein	O
in	O	O
resting	O	O
and	O	O
activated	O	O
eosinophils	B-cell_type	O
.	O	O

METHODS	O	O
:	O	O
Nuclear	O	O
and	O	O
whole	O	O
cell	O	O
extracts	O	O
were	O	O
obtained	O	O
from	O	O
both	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
eosinophils	I-cell_type	O
and	O	O
those	O	O
obtained	O	O
from	O	O
bronchoalveolar	O	O
lavage	O	O
fluid	O	O
of	O	O
asthmatic	O	O
subjects	O	O
after	O	O
endobronchial	O	O
allergen	O	O
challenge	O	O
.	O	O

NFAT	B-protein	O
expression	O	O
was	O	O
determined	O	O
by	O	O
using	O	O
immunoprecipitation	O	O
and	O	O
Western	O	O
blot	O	O
analysis	O	O
,	O	O
DNA-binding	O	O
assays	O	O
,	O	O
and	O	O
RT-PCR	O	O
analysis	O	O
of	O	O
eosinophil	B-RNA	O
mRNA	I-RNA	O
.	O	O

RESULTS	O	O
:	O	O
Both	O	O
peripheral	O	O
blood	O	O
and	O	O
bronchoalveolar	O	O
lavage	O	O
fluid	O	O
eosinophils	O	O
expressed	O	O
NFATp	O	O
and	O	O
NFATc	O	O
protein	O	O
.	O	O

Unlike	O	O
activated	B-cell_type	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
which	O	O
express	O	O
multiple	O	O
NFATc	B-protein	O
isoforms	I-protein	O
,	O	O
eosinophils	I-DNA	O
preferentially	O	O
express	O	O
the	O	O
approximately	B-protein	O
85-kd	I-protein	O
isoform	I-protein	O
.	O	O

In	O	O
addition	O	O
,	O	O
eosinophils	O	O
were	O	O
found	O	O
to	O	O
constitutively	O	O
express	O	O
NFATc	B-RNA	O
mRNA	I-RNA	O
.	O	O

A	O	O
brief	O	O
incubation	O	O
with	O	O
the	O	O
T	O	O
(	O	O
H	B-protein	O
)	O	O
2	O	O
cytokines	B-protein	O
IL-4	O	O
and	O	O
IL-5	O	O
was	O	O
sufficient	O	O
to	O	O
induce	O	O
the	O	O
nuclear	O	O
translocation	O	O
of	O	O
NFATc	O	O
.	O	O

Eosinophil	O	O
nuclear	O	O
extracts	O	O
contain	O	O
multiple	O	O
factors	I-protein	O
that	O	O
can	O	O
specifically	O	O
recognize	O	O
the	O	O
IL-4	B-DNA	O
promoter	I-DNA	O
P1	O	O
NFAT	O	O
site	O	O
in	O	O
DNA-binding	O	O
assays	O	O
,	O	O
including	O	O
NFATp	O	O
.	O	O

CONCLUSION	O	O
:	O	O
NFATp	O	O
and	O	O
NFATc	O	O
can	O	O
regulate	O	O
the	O	O
expression	O	O
of	O	O
cytokines	B-protein	O
and	O	O
other	O	O
genes	B-DNA	O
in	O	O
eosinophils	B-cell_type	O
but	O	O
appear	O	O
to	O	O
be	O	O
regulated	O	O
by	O	O
a	O	O
novel	O	O
signal	O	O
transduction	O	O
mechanism	O	O
in	O	O
these	O	O
cells	O	O
.	O	O

BLyS	O	O
BINDS	O	O
TO	O	O
B	O	O
CELLS	O	O
WITH	O	O
HIGH	O	O
AFFINITY	O	O
AND	O	O
INDUCES	O	O
ACTIVATION	O	O
OF	O	O
THE	O	O
TRANSCRIPTION	O	O
FACTORS	O	O
NF-kappaB	O	O
AND	O	O
ELF-1	O	O
.	O	O

B	I-protein	O
lymphocyte	O	O
stimulator	O	O
(	O	O
BLyS	B-protein	O
)	O	O
is	O	O
a	O	O
novel	O	O
member	O	O
of	O	O
the	O	O
TNF	B-protein	O
family	I-protein	O
of	O	O
proteins	I-protein	O
expressed	O	O
by	O	O
myeloid	B-cell_type	O
cells	I-cell_type	O
as	O	O
membrane-bound	O	O
and	O	O
soluble	O	O
forms	O	O
.	O	O

BLyS	O	O
was	O	O
shown	O	O
to	O	O
act	O	O
specifically	O	O
on	O	O
B	B-cell_type	O
cells	I-cell_type	O
,	O	O
inducing	O	O
proliferation	O	O
and	O	O
immunoglobulin	O	O
production	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
characterize	O	O
binding	O	O
of	O	O
radiolabeled	O	O
BLyS	O	O
to	O	O
its	O	O
cognate	B-protein	O
receptor	I-protein	O
on	O	O
human	B-cell_type	O
B	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
examine	O	O
intracellular	O	O
events	O	O
initiated	O	O
by	O	O
BLyS	O	O
binding	O	O
.	O	O

Similar	O	O
to	O	O
other	O	O
TNF	B-protein	O
family	O	O
members	O	O
,	O	O
BLyS	O	O
is	O	O
present	O	O
in	O	O
solution	O	O
as	O	O
a	O	O
homotrimer	O	O
as	O	O
determined	O	O
by	O	O
gel	O	O
filtration	O	O
chromatography	O	O
and	O	O
light	O	O
scattering	O	O
analysis	O	O
.	O	O

BLyS	O	O
binding	O	O
to	O	O
B	B-cell_type	O
cells	I-cell_type	O
is	O	O
specific	O	O
as	O	O
other	O	O
TNF	B-protein	O
family	O	O
members	O	O
tested	O	O
did	O	O
not	O	O
compete	O	O
for	O	O
(	O	O
125	O	O
)	O	O
I-	O	O
BLyS	O	O
binding	O	O
.	O	O

Analysis	O	O
of	O	O
equilibrium	O	O
binding	O	O
of	O	O
(	O	O
125	B-protein	O
)	O	O
I-labeled	O	O
BLyS	O	O
to	O	O
purified	O	O
human	B-cell_type	O
tonsillar	I-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
demonstrated	O	O
saturable	O	O
binding	O	O
.	O	O

Scatchard	O	O
analysis	O	O
of	O	O
the	O	O
binding	O	O
data	O	O
revealed	O	O
a	O	O
single	O	O
class	O	O
of	O	O
high-affinity	O	O
binding	O	O
on	O	O
human	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
with	O	O
approximately	O	O
2600	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
per	O	O
cell	O	O
and	O	O
an	O	O
apparent	B-protein	O
dissociation	I-protein	O
constant	O	O
(	O	O
K	O	O
(	O	O
D	O	O
)	O	O
)	O	O
of	O	O
about	O	O
0.1	O	O
nM	O	O
.	O	O

In	O	O
addition	O	O
we	O	O
report	O	O
that	O	O
BLyS	O	O
binding	O	O
to	O	O
B	B-cell_type	O
cells	I-cell_type	O
results	O	O
in	O	O
the	O	O
activation	O	O
of	O	O
NF-kappaB	O	O
and	O	O
the	O	O
Ets	B-protein	O
family	I-protein	O
transcription	I-protein	O
factor	I-protein	O
,	O	O
ELF-1	O	O
,	O	O
and	O	O
in	O	O
the	O	O
induction	O	O
of	O	O
mRNA	B-RNA	O
for	O	O
Polo-like	B-protein	O
kinase	I-protein	O
(	O	O
PLK	O	O
)	O	O
.	O	O

Copyright	O	O
2001	O	O
Academic	O	O
Press	O	O
.	O	O

Design	O	O
and	O	O
use	O	O
of	O	O
an	O	O
inducibly	O	O
activated	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
Nef	O	O
to	O	O
study	O	O
immune	O	O
modulation	O	O
.	O	O

The	O	O
Nef	B-protein	O
protein	I-protein	O
of	O	O
the	O	O
human	B-protein	O
immunodeficiency	I-protein	O
virus	I-protein	O
type	I-protein	O
1	I-protein	O
(	O	O
HIV-1	B-DNA	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
enhance	O	O
the	O	O
infectivity	O	O
of	O	O
virus	O	O
particles	O	O
,	O	O
downmodulate	O	O
cell	O	O
surface	O	O
proteins	O	O
,	O	O
and	O	O
associate	O	O
with	O	O
many	O	O
intracellular	I-protein	O
proteins	I-protein	O
that	O	O
are	O	O
thought	O	O
to	O	O
facilitate	O	O
HIV	O	O
infection	O	O
.	O	O

One	O	O
of	O	O
the	O	O
challenges	O	O
in	O	O
defining	O	O
the	O	O
molecular	O	O
events	O	O
regulated	O	O
by	O	O
Nef	O	O
has	O	O
been	O	O
obtaining	O	O
good	O	O
expression	O	O
of	O	O
Nef	B-protein	O
protein	I-protein	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

This	O	O
has	O	O
been	O	O
attributed	O	O
to	O	O
effects	O	O
of	O	O
Nef	O	O
on	O	O
cell	O	O
proliferation	O	O
and	O	O
apoptosis	O	O
.	O	O

We	O	O
have	O	O
designed	O	O
a	O	O
Nef	B-protein	O
protein	I-protein	O
that	O	O
is	O	O
readily	O	O
expressed	O	O
in	O	O
T-cell	O	O
lines	O	O
and	O	O
whose	O	O
function	O	O
is	O	O
inducibly	O	O
activated	O	O
.	O	O

It	O	O
is	O	O
composed	O	O
of	O	O
a	O	O
fusion	O	O
between	O	O
full-length	O	O
Nef	O	O
and	O	O
the	O	O
estrogen	B-protein	O
receptor	I-protein	O
hormone-binding	I-protein	O
domain	I-protein	O
(	O	O
Nef-ER	B-protein	O
)	O	O
.	O	O

The	O	O
Nef-ER	O	O
is	O	O
kept	O	O
in	O	O
an	O	O
inactive	O	O
state	O	O
due	O	O
to	O	O
steric	O	O
hindrance	O	O
,	O	O
and	O	O
addition	O	O
of	O	O
the	O	O
membrane-permeable	B-protein	O
drug	I-protein	O
4-hydroxytamoxifen	O	O
(	O	O
4-HT	B-protein	O
)	O	O
,	O	O
which	O	O
binds	O	O
to	O	O
the	O	O
ER	B-protein	O
domain	I-protein	O
,	O	O
leads	O	O
to	O	O
inducible	O	O
activation	O	O
of	O	O
Nef-ER	O	O
within	O	O
cells	I-cell_type	O
.	O	O

We	O	O
demonstrate	O	O
that	O	O
Nef-ER	O	O
inducibly	O	O
associates	O	O
with	O	O
the	O	O
62-kDa	B-protein	O
Ser/Thr	I-protein	O
kinase	I-protein	O
and	O	O
is	O	O
localized	O	O
to	O	O
specific	O	O
membrane	O	O
microdomains	O	O
(	O	O
lipid	O	O
rafts	O	O
)	O	O
only	O	O
after	O	O
activation	O	O
.	O	O

Using	O	O
this	O	O
inducible	O	O
Nef	O	O
,	O	O
we	O	O
also	O	O
compared	O	O
the	O	O
specific	O	O
requirements	O	O
for	O	O
CD4	O	O
and	O	O
HLA-A2	O	O
downmodulation	O	O
in	O	O
a	O	O
SupT1	O	O
T-cell	O	O
line	O	O
.	O	O

Half-maximal	O	O
downmodulation	O	O
of	O	O
cell	B-protein	O
surface	I-protein	O
CD4	I-protein	O
required	O	O
very	O	O
little	O	O
active	O	O
Nef-ER	O	O
and	O	O
occurred	O	O
as	O	O
early	O	O
as	O	O
4	O	O
h	O	O
after	O	O
addition	O	O
of	O	O
4-HT	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
50	O	O
%	O	O
downmodulation	O	O
of	O	O
HLA-A2	O	O
by	O	O
Nef	O	O
required	O	O
16	O	O
to	O	O
24	O	O
h	O	O
and	O	O
about	O	O
50-	O	O
to	O	O
100-fold-greater	O	O
concentrations	O	O
of	O	O
4-HT	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
HLA-A2	O	O
downmodulation	O	O
may	O	O
require	O	O
certain	O	O
threshold	O	O
levels	O	O
of	O	O
active	O	O
Nef	O	O
.	O	O

The	O	O
differential	O	O
timing	O	O
of	O	O
CD4	B-protein	O
and	O	O
HLA-A2	O	O
downmodulation	O	O
may	O	O
have	O	O
implications	O	O
for	O	O
HIV	O	O
pathogenesis	O	O
and	O	O
immune	O	O
evasion	O	O
.	O	O

Regulation	O	O
of	O	O
chemokine	B-RNA	O
mRNA	I-RNA	O
expression	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
vanadium-induced	O	O
pulmonary	O	O
inflammation	O	O
.	O	O

Environmental	O	O
and	O	O
occupational	O	O
exposure	O	O
to	O	O
vanadium	O	O
dusts	O	O
results	O	O
in	O	O
toxic	O	O
effects	O	O
mainly	O	O
confined	O	O
to	O	O
the	O	O
respiratory	O	O
system	O	O
.	O	O

Using	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
acute	O	O
lung	O	O
inflammation	O	O
induced	O	O
by	O	O
intratracheal	O	O
instillation	O	O
of	O	O
sodium	B-protein	O
metavanadate	I-protein	O
(	O	O
NaVO3	B-protein	O
)	O	O
at	O	O
the	O	O
dose	O	O
of	O	O
200	O	O
microg	O	O
V/kg	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
cytologic	O	O
characterization	O	O
of	O	O
pulmonary	O	O
inflammation	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
chemokine	B-RNA	O
mRNA	I-RNA	O
.	O	O

Significant	O	O
polymorphonuclear	O	O
leukocyte	B-protein	O
(	O	O
PMN	B-protein	O
)	O	O
influx	O	O
(	O	O
P	O	O
<	O	O
0.01	O	O
)	O	O
into	O	O
the	O	O
lung	O	O
was	O	O
noted	O	O
4	O	O
h	O	O
after	O	O
NaVO3	O	O
instillation	O	O
,	O	O
whereas	O	O
alveolar	O	O
macrophages	O	O
(	O	O
AMs	O	O
)	O	O
in	O	O
bronchoalveolar	O	O
lavage	O	O
(	O	O
BAL	O	O
)	O	O
cells	O	O
appeared	O	O
to	O	O
decrease	O	O
significantly	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
neither	O	O
PMNs	O	O
nor	O	O
AMs	O	O
changed	O	O
substantially	O	O
1	O	O
h	O	O
after	O	O
NaVO3	O	O
instillation	O	O
.	O	O

By	O	O
Northern	O	O
analysis	O	O
,	O	O
macrophage	O	O
inflammatory	B-protein	O
protein	I-protein	O
(	O	O
MIP	O	O
)	O	O
-2	O	O
mRNA	O	O
in	O	O
BAL	O	O
cells	O	O
increased	O	O
markedly	O	O
1	O	O
h	O	O
after	O	O
NaVO3	O	O
instillation	O	O
and	O	O
reduced	O	O
a	O	O
little	O	O
bit	O	O
at	O	O
4	O	O
h	O	O
,	O	O
whereas	O	O
MIP-1alpha	O	O
mRNA	O	O
in	O	O
BAL	O	O
cells	O	O
was	O	O
expressed	O	O
relatively	O	O
high	O	O
1	O	O
h	O	O
after	O	O
NaVO3	O	O
instillation	O	O
,	O	O
although	O	O
a	O	O
basal	O	O
expression	O	O
was	O	O
detected	O	O
in	O	O
control	O	O
group	O	O
,	O	O
and	O	O
returned	O	O
rapidly	O	O
nearly	O	O
to	O	O
control	O	O
level	O	O
at	O	O
4	O	O
h	O	O
.	O	O

Since	O	O
MIP-2	O	O
is	O	O
a	O	O
potent	O	O
PMN	O	O
chemoattractant	O	O
and	O	O
MIP-1alpha	O	O
is	O	O
a	O	O
potent	O	O
macrophage/monocyte	O	O
chemoattractant	O	O
has	O	O
been	O	O
well	O	O
known	O	O
.	O	O

The	O	O
facts	O	O
that	O	O
PMN	O	O
influx	O	O
was	O	O
preceded	O	O
by	O	O
increased	O	O
MIP-2	O	O
mRNA	O	O
expression	O	O
,	O	O
suggesting	O	O
that	O	O
MIP-2	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
development	O	O
of	O	O
NaVO3-induced	O	O
pulmonary	O	O
inflammation	O	O
,	O	O
whereas	O	O
increased	O	O
MIP-1alpha	O	O
mRNA	O	O
expression	O	O
was	O	O
followed	O	O
by	O	O
decreased	O	O
AMs	O	O
in	O	O
BAL	B-cell_type	O
cells	I-cell_type	O
,	O	O
suggesting	O	O
AMs	O	O
might	O	O
be	O	O
activated	O	O
by	O	O
MIP-1alpha	O	O
,	O	O
adherent	O	O
to	O	O
the	O	O
lining	O	O
surface	O	O
of	O	O
the	O	O
airways	O	O
and	O	O
then	O	O
resistant	O	O
to	O	O
be	O	O
washed	O	O
out	O	O
.	O	O

To	O	O
delineate	O	O
the	O	O
mechanisms	O	O
of	O	O
transcriptional	O	O
activation	O	O
,	O	O
we	O	O
recently	O	O
cloned	O	O
the	O	O
5'-flanking	B-DNA	O
region	I-DNA	O
of	O	O
the	O	O
MIP-2	B-DNA	O
gene	I-DNA	O
.	O	O

The	O	O
promotor	B-DNA	O
region	I-DNA	O
contains	O	O
consensus	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
for	O	O
transcription	B-protein	O
factor	I-protein	O
nuclear	B-protein	O
factor	I-protein	O
kappaB	I-protein	O
(	O	O
NF-kappaB	B-protein	O
)	O	O
and	O	O
activator	B-protein	O
protein-1	I-protein	O
(	O	O
AP-1	B-protein	O
)	O	O
.	O	O

Using	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
,	O	O
increased	O	O
nuclear	O	O
NF-kappaB	O	O
,	O	O
not	O	O
AP-1	B-protein	O
,	O	O
binding	O	O
activity	O	O
was	O	O
detected	O	O
1	O	O
h	O	O
after	O	O
NaVO3	O	O
instillation	O	O
,	O	O
which	O	O
correlated	O	O
with	O	O
the	O	O
induction	O	O
of	O	O
MIP-2	B-RNA	O
mRNA	I-RNA	O
.	O	O

p65	B-protein	O
(	O	O
Rel	B-protein	O
A	I-protein	O
)	O	O
and	O	O
p50	B-protein	O
protein	I-protein	O
appears	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
MIP-2	O	O
NF-kappaB	O	O
binding	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
studies	O	O
suggest	O	O
that	O	O
MIP-2	O	O
is	O	O
an	O	O
important	O	O
mediator	O	O
of	O	O
NaVO3-induced	O	O
pulmonary	O	O
inflammation	O	O
in	O	O
the	O	O
rat	O	O
model	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
elevated	O	O
MIP-2	O	O
mRNA	O	O
levels	O	O
are	O	O
accompanied	O	O
by	O	O
increased	O	O
NF-kappaB	O	O
binding	O	O
activity	O	O
in	O	O
BAL	B-cell_type	O
cells	I-cell_type	O
,	O	O
suggesting	O	O
possible	O	O
MIP-2	O	O
transcriptional	O	O
regulation	O	O
through	O	O
NF-kappaB	O	O
.	O	O

Activation	O	O
of	O	O
signal	O	O
transduction	O	O
and	O	O
apoptosis	O	O
in	O	O
healthy	O	O
lymphomonocytes	O	O
exposed	O	O
to	O	O
bystander	B-cell_type	O
HIV-1-infected	I-cell_type	O
cells	I-cell_type	O
.	O	O

Persistent	O	O
activation	O	O
of	O	O
the	O	O
immune	O	O
system	O	O
is	O	O
one	O	O
of	O	O
the	O	O
hallmarks	O	O
of	O	O
HIV-1	O	O
infection	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
analysed	O	O
the	O	O
induction	O	O
of	O	O
factors	B-protein	O
involved	O	O
in	O	O
cytokine	B-protein	O
signal	O	O
transduction	O	O
,	O	O
such	O	O
as	O	O
STAT	B-protein	O
1	I-protein	O
proteins	I-protein	O
and	O	O
IRF-1	O	O
mRNA	I-RNA	O
,	O	O
in	O	O
normal	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
(	O	O
PBMC	O	O
)	O	O
exposed	O	O
to	O	O
HIV-infected	B-cell_type	O
cells	I-cell_type	O
,	O	O
and	O	O
the	O	O
induction	O	O
of	O	O
apoptosis	O	O
.	O	O

Western	O	O
blot	B-protein	O
analyses	O	O
and	O	O
reverse	O	O
transcriptase-polymerase	O	O
chain	O	O
reaction	O	O
results	O	O
indicate	O	O
that	O	O
both	O	O
cells	O	O
infected	O	O
with	O	O
a	O	O
X4	B-cell_type	O
strain	I-cell_type	O
and	I-cell_type	O
cells	I-cell_type	O
infected	O	O
with	O	O
a	O	O
R5	O	O
strain	O	O
are	O	O
able	O	O
to	O	O
increase	O	O
intracellular	O	O
levels	O	O
of	O	O
STAT	B-protein	O
1alpha	I-protein	O
and	I-protein	O
beta	I-protein	O
proteins	I-protein	O
as	O	O
well	O	O
as	O	O
IRF-1	B-RNA	O
mRNA	I-RNA	O
.	O	O

This	O	O
effect	O	O
was	O	O
prevented	O	O
by	O	O
neutralizing	O	O
antibodies	O	O
against	O	O
interferon-alpha	O	O
(	O	O
IFN-alpha	O	O
)	O	O
.	O	O

HIV-1-infected	B-cell_type	O
cells	I-cell_type	O
dose-dependently	O	O
induced	O	O
apoptotic	O	O
commitment	O	O
in	O	O
normal	O	O
PBMC	O	O
,	O	O
as	O	O
revealed	O	O
by	O	O
DNA	O	O
fragmentation	O	O
analysis	O	O
,	O	O
but	O	O
this	O	O
was	O	O
not	O	O
accompanied	O	O
by	O	O
an	O	O
increase	O	O
of	O	O
caspase-3	O	O
activity	O	O
,	O	O
even	O	O
if	O	O
a	O	O
slight	O	O
up-regulation	O	O
of	O	O
IL-1beta-converting	O	O
enzyme	O	O
mRNA	I-RNA	O
was	O	O
detected	O	O
.	O	O

Apoptosis	O	O
induction	O	O
could	O	O
be	O	O
abrogated	O	O
mainly	O	O
by	O	O
antibodies	O	O
against	O	O
tumour	O	O
necrosis	O	O
factor-alpha	O	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
and	O	O
,	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
,	O	O
by	O	O
antibodies	B-protein	O
against	O	O
IFN-gamma	B-protein	O
.	O	O

All	O	O
these	O	O
findings	O	O
suggest	O	O
that	O	O
uninfected	O	O
PBMC	O	O
can	O	O
undergo	O	O
activation	O	O
of	O	O
signal	O	O
transduction	O	O
and	O	O
apoptosis	O	O
after	O	O
exposure	O	O
to	O	O
bystander	O	O
HIV-infected	B-cell_type	O
cells	I-cell_type	O
,	O	O
subsequent	O	O
to	O	O
the	O	O
induction	O	O
of	O	O
cytokines	B-protein	O
such	O	O
as	O	O
IFNs	O	O
and	O	O
TNF-alpha	B-protein	O
.	O	O

The	O	O
physical	O	O
association	O	O
of	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
theta	O	O
with	O	O
a	O	O
lipid	O	O
raft-associated	O	O
inhibitor	O	O
of	O	O
kappa	B-protein	O
B	I-protein	O
factor	I-protein	O
kinase	I-protein	O
(	O	O
IKK	B-protein	O
)	O	O
complex	O	O
plays	O	O
a	O	O
role	O	O
in	O	O
the	O	O
activation	O	O
of	O	O
the	O	O
NF-kappa	B-protein	O
B	I-protein	O
cascade	O	O
by	O	O
TCR	B-protein	O
and	O	O
CD28	B-protein	O
.	O	O

We	O	O
investigated	O	O
the	O	O
role	O	O
of	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
theta	I-protein	O
(	O	O
PKCtheta	B-protein	O
)	O	O
in	O	O
the	O	O
activation	O	O
of	O	O
the	O	O
NF-kappaB	O	O
cascade	O	O
in	O	O
primary	B-cell_line	O
human	I-cell_line	O
CD4	I-cell_line	O
(	I-cell_line	O
+	I-cell_line	O
)	I-cell_line	O
lymphocytes	I-cell_type	O
.	O	O

Among	O	O
six	O	O
or	O	O
so	O	O
PKC	O	O
isoforms	O	O
expressed	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
only	O	O
PKCtheta	O	O
participates	O	O
in	O	O
the	O	O
assembly	O	O
of	O	O
the	O	O
supramolecular	O	O
activation	O	O
clusters	O	O
at	O	O
the	O	O
contact	O	O
site	O	O
of	O	O
the	O	O
TCR	B-protein	O
with	O	O
Ag	O	O
.	O	O

Signaling	O	O
via	O	O
both	O	O
the	O	O
TCR	B-protein	O
and	O	O
CD28	O	O
is	O	O
required	O	O
for	O	O
optimal	O	O
activation	O	O
of	O	O
the	O	O
multisubunit	B-protein	O
IkappaB	I-protein	O
kinase	I-protein	O
(	O	O
IKK	B-protein	O
)	O	O
complex	O	O
in	O	O
primary	B-cell_line	O
human	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
;	O	O
this	O	O
activation	O	O
could	O	O
be	O	O
inhibited	O	O
by	O	O
a	O	O
Ca	O	O
(	O	O
2+	O	O
)	O	O
-independent	O	O
PKC	O	O
isoform	O	O
inhibitor	O	O
,	O	O
rottlerin	O	O
.	O	O

Moreover	O	O
,	O	O
endogenous	O	O
PKCtheta	O	O
physically	O	O
associates	O	O
with	O	O
activated	O	O
IKK	O	O
complexes	O	O
in	O	O
CD3/CD28-costimulated	O	O
primary	O	O
CD4	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
same	O	O
set	O	O
of	O	O
stimuli	O	O
also	O	O
induced	O	O
relocation	O	O
of	O	O
endogenous	O	O
PKCtheta	O	O
and	O	O
IKKs	O	O
to	O	O
a	O	O
GM1	O	O
ganglioside-enriched	O	O
,	O	O
detergent-insoluble	O	O
membrane	O	O
compartment	O	O
in	O	O
primary	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

IKKs	O	O
recruited	O	O
to	O	O
these	O	O
lipid	O	O
rafts	O	O
were	O	O
capable	O	O
of	O	O
phosphorylating	O	O
a	O	O
recombinant	O	O
IkappaBalpha	O	O
sustrate	O	O
.	O	O

Confocal	O	O
microscopy	O	O
further	O	O
demonstrated	O	O
that	O	O
exogenously	O	O
expressed	O	O
PKCtheta	O	O
and	O	O
IKKss	O	O
colocalize	O	O
in	O	O
the	O	O
membrane	O	O
of	O	O
CD3/CD28-costimulated	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
.	O	O

Constitutively	O	O
active	O	O
but	O	O
not	O	O
kinase-inactive	O	O
PKCtheta	O	O
activated	O	O
IKKbeta	O	O
in	O	O
Jurkat	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
.	O	O

Expression	O	O
of	O	O
dominant-active	O	O
PKCtheta	O	O
also	O	O
had	O	O
stimulatory	O	O
effects	O	O
on	O	O
the	O	O
CD28	O	O
response	O	O
element	O	O
of	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
data	O	O
show	O	O
that	O	O
the	O	O
activation	O	O
of	O	O
PKCtheta	O	O
by	O	O
the	O	O
TCR	B-protein	O
and	O	O
CD28	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
assembly	O	O
and	O	O
activation	O	O
of	O	O
IKK	O	O
complexes	O	O
in	O	O
the	O	O
T	O	O
cell	O	O
membrane	O	O

T-cell	O	O
-mediated	O	O
regulation	O	O
of	O	O
osteoclastogenesis	O	O
by	O	O
signalling	O	O
cross-talk	O	O
between	O	O
RANKL	O	O
and	O	O
IFN-gamma	B-protein	O
.	O	O

Bone	O	O
resorption	O	O
is	O	O
regulated	O	O
by	O	O
the	O	O
immune	O	O
system	O	O
,	O	O
where	O	O
T-cell	O	O
expression	O	O
of	O	O
RANKL	B-protein	O
(	O	O
receptor	I-protein	O
activator	I-protein	O
of	I-protein	O
nuclear	I-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
-kappaB	O	O
ligand	O	O
)	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
tumour-necrosis	B-protein	O
factor	I-protein	O
family	I-protein	O
that	O	O
is	O	O
essential	O	O
for	O	O
osteoclastogenesis	O	O
,	O	O
may	O	O
contribute	O	O
to	O	O
pathological	O	O
conditions	O	O
,	O	O
such	O	O
as	O	O
autoimmune	O	O
arthritis	O	O
.	O	O

However	O	O
,	O	O
whether	O	O
activated	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
maintain	O	O
bone	O	O
homeostasis	O	O
by	O	O
counterbalancing	O	O
the	O	O
action	O	O
of	O	O
RANKL	O	O
remains	O	O
unknown	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
T-cell	O	O
production	O	O
of	O	O
interferon	B-protein	O
(	O	O
IFN	B-protein	O
)	O	O
-gamma	O	O
strongly	O	O
suppresses	O	O
osteoclastogenesis	O	O
by	O	O
interfering	O	O
with	O	O
the	O	O
RANKL	O	O
-RANK	I-protein	O
signalling	I-protein	O
pathway	O	O
.	O	O

IFN-gamma	B-protein	O
induces	O	O
rapid	O	O
degradation	O	O
of	O	O
the	O	O
RANK	B-protein	O
adapter	I-protein	O
protein	I-protein	O
,	O	O
TRAF6	O	O
(	O	O
tumour	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
receptor-associated	I-protein	O
factor	I-protein	O
6	O	O
)	O	O
,	O	O
which	O	O
results	O	O
in	O	O
strong	O	O
inhibition	O	O
of	O	O
the	O	O
RANKL	O	O
-induced	O	O
activation	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappaB	I-protein	O
and	O	O
JNK	O	O
.	O	O

This	O	O
inhibition	O	O
of	O	O
osteoclastogenesis	O	O
is	O	O
rescued	O	O
by	O	O
overexpressing	O	O
TRAF6	O	O
in	O	O
precursor	B-cell_type	O
cells	I-cell_type	O
,	O	O
which	O	O
indicates	O	O
that	O	O
TRAF6	O	O
is	O	O
the	O	O
target	O	O
critical	O	O
for	O	O
the	O	O
IFN-gamma	B-protein	O
action	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
provide	O	O
evidence	O	O
that	O	O
the	O	O
accelerated	O	O
degradation	O	O
of	O	O
TRAF6	O	O
requires	O	O
both	O	O
its	O	O
ubiquitination	O	O
,	O	O
which	O	O
is	O	O
initiated	O	O
by	O	O
RANKL	B-protein	O
,	O	O
and	O	O
IFN-gamma	B-protein	O
-induced	O	O
activation	O	O
of	O	O
the	O	O
ubiquitin-proteasome	O	O
system	O	O
.	O	O

Our	O	O
study	O	O
shows	O	O
that	O	O
there	O	O
is	O	O
cross-talk	O	O
between	O	O
the	O	O
tumour	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
and	O	O
IFN	O	O
families	O	O
of	O	O
cytokines	B-protein	O
,	O	O
through	O	O
which	O	O
IFN-gamma	B-protein	O
provides	O	O
a	O	O
negative	O	O
link	O	O
between	O	O
T-cell	O	O
activation	O	O
and	O	O
bone	O	O
resorption	O	O
.	O	O

Our	O	O
results	O	O
may	O	O
offer	O	O
a	O	O
therapeutic	O	O
approach	O	O
to	O	O
treat	O	O
the	O	O
inflammation-induced	O	O
tissue	O	O
breakdown	O	O
.	O	O

Stromal-derived	B-protein	O
factor	I-protein	O
1	O	O
and	O	O
thrombopoietin	O	O
regulate	O	O
distinct	O	O
aspects	O	O
of	O	O
human	O	O
megakaryopoiesis	O	O
.	O	O

The	O	O
role	O	O
of	O	O
the	O	O
chemokine	B-protein	O
binding	I-protein	O
stromal-derived	I-protein	O
factor	I-protein	O
1	O	O
(	O	O
SDF-1	B-protein	O
)	O	O
in	O	O
normal	O	O
human	O	O
megakaryopoiesis	O	O
at	O	O
the	O	O
cellular	O	O
and	O	O
molecular	O	O
levels	O	O
and	O	O
its	O	O
comparison	O	O
with	O	O
that	O	O
of	O	O
thrombopoietin	B-protein	O
(	O	O
TPO	B-protein	O
)	O	O
have	O	O
not	O	O
been	O	O
determined	O	O
.	O	O

In	O	O
this	O	O
study	O	O
it	O	O
was	O	O
found	O	O
that	O	O
SDF-1	O	O
,	O	O
unlike	O	O
TPO	O	O
,	O	O
does	O	O
not	O	O
stimulate	O	O
alpha	B-protein	O
(	O	O
IIb	B-protein	O
)	I-protein	O
beta	I-protein	O
(	O	O
3	B-protein	O
)	O	O
(	O	O
+	O	O
)	O	O
cell	O	O
proliferation	O	O
or	O	O
differentiation	O	O
or	O	O
have	O	O
an	O	O
antiapoptotic	O	O
effect	O	O
.	O	O

However	O	O
,	O	O
it	O	O
does	O	O
induce	O	O
chemotaxis	O	O
,	O	O
trans-Matrigel	O	O
migration	O	O
,	O	O
and	O	O
secretion	O	O
of	O	O
matrix	O	O
metalloproteinase	O	O
9	O	O
(	O	O
MMP-9	O	O
)	O	O
and	O	O
vascular	B-protein	O
endothelial	I-protein	O
growth	I-protein	O
factor	I-protein	O
(	O	O
VEGF	O	O
)	O	O
by	O	O
these	O	O
cells	O	O
,	O	O
and	O	O
both	O	O
SDF-1	O	O
and	O	O
TPO	O	O
increase	O	O
the	O	O
adhesion	O	O
of	O	O
alpha	B-protein	O
(	I-protein	O
IIb	I-protein	O
)	I-protein	O
beta	I-protein	O
(	O	O
3	B-protein	O
)	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
to	O	O
fibrinogen	O	O
and	O	O
vitronectin	O	O
.	O	O

Investigating	O	O
the	O	O
intracellular	O	O
signaling	O	O
pathways	O	O
induced	O	O
by	O	O
SDF-1	O	O
and	O	O
TPO	O	O
revealed	O	O
some	O	O
overlapping	O	O
patterns	O	O
of	O	O
protein	B-protein	O
phosphorylation/activation	I-protein	O
(	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
[	O	O
MAPK	O	O
]	O	O
p42/44	O	O
,	O	O
MAPK	O	O
p38	O	O
,	O	O
and	O	O
AKT	O	O
[	O	O
protein	B-protein	O
kinase	I-protein	O
B	I-protein	O
]	O	O
)	O	O
and	O	O
some	O	O
that	O	O
were	O	O
distinct	O	O
for	O	O
TPO	O	O
(	O	O
eg	O	O
,	O	O
JAK-STAT	O	O
)	O	O
and	O	O
for	O	O
SDF-1	O	O
(	O	O
eg	O	O
,	O	O
NF-kappa	B-protein	O
B	I-protein	O
)	O	O
.	O	O

It	O	O
was	O	O
also	O	O
found	O	O
that	O	O
though	O	O
inhibition	O	O
of	O	O
phosphatidyl-inositol	O	O
3-kinase	O	O
(	O	O
PI-3K	B-protein	O
)	O	O
by	O	O
LY294002	O	O
in	O	O
alpha	B-protein	O
(	O	O
IIb	B-protein	O
)	I-protein	O
beta	I-protein	O
(	O	O
3	O	O
)	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
induced	O	O
apoptosis	O	O
and	O	O
inhibited	O	O
chemotaxis	O	O
adhesion	O	O
and	O	O
the	O	O
secretion	O	O
of	O	O
MMP-9	O	O
and	O	O
VEGF	O	O
,	O	O
the	O	O
inhibition	O	O
of	O	O
MAPK	O	O
p42/44	O	O
(	O	O
by	O	O
the	O	O
MEK	O	O
inhibitor	O	O
U0126	O	O
)	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
survival	O	O
,	O	O
proliferation	O	O
,	O	O
and	O	O
migration	O	O
of	O	O
these	O	O
cells	O	O
.	O	O

Hence	O	O
,	O	O
it	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
proliferative	O	O
effect	O	O
of	O	O
TPO	O	O
is	O	O
more	O	O
related	O	O
to	O	O
activation	O	O
of	O	O
the	O	O
JAK-STAT	B-protein	O
pathway	I-protein	O
(	O	O
unique	O	O
to	O	O
TPO	I-protein	O
)	O	O
,	O	O
and	O	O
the	O	O
PI-3K-AKT	O	O
axis	O	O
is	O	O
differentially	O	O
involved	O	O
in	O	O
TPO-	O	O
and	O	O
SDF-1-dependent	O	O
signaling	O	O
.	O	O

Accordingly	O	O
,	O	O
PI-3K	O	O
is	O	O
involved	O	O
in	O	O
TPO	O	O
-mediated	O	O
inhibition	O	O
of	O	O
apoptosis	O	O
,	O	O
TPO-	O	O
and	O	O
SDF-1-regulated	O	O
adhesion	O	O
to	O	O
fibrinogen	O	O
and	O	O
vitronectin	O	O
,	O	O
and	O	O
SDF-1	O	O
-mediated	O	O
migration	O	O
.	O	O

This	O	O
study	O	O
expands	O	O
the	O	O
understanding	O	O
of	O	O
the	O	O
role	O	O
of	O	O
SDF-1	O	O
and	O	O
TPO	O	O
in	O	O
normal	O	O
human	O	O
megakaryopoiesis	O	O
and	O	O
indicates	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
the	O	O
observed	O	O
differences	O	O
in	O	O
cellular	O	O
responses	O	O
.	O	O

(	O	O
Blood.	O	O
2000	O	O
;	O	O
96	O	O
:	O	O
4142-4151	O	O
)	O	O

Adhesion	O	O
of	O	O
immature	O	O
and	O	O
mature	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
induces	O	O
in	O	O
human	B-cell_line	O
thymic	I-cell_line	O
epithelial	I-cell_line	O
cells	I-cell_line	O
(	O	O
TEC	O	O
)	O	O
activation	O	O
of	O	O
IL-6	O	O
gene	O	O
trascription	B-protein	O
factors	I-protein	O
(	O	O
NF-kappaB	B-protein	O
and	O	O
NF-IL6	B-protein	O
)	O	O
and	O	O
IL-6	O	O
gene	O	O
expression	O	O
:	O	O
role	O	O
of	O	O
alpha3beta1	O	O
and	O	O
alpha6beta4	O	O
integrins	O	O
.	O	O

T	O	O
cell	O	O
precursors	O	O
homed	O	O
to	O	O
thymus	O	O
develop	O	O
in	O	O
close	O	O
contact	O	O
with	O	O
stromal	B-cell_type	O
cells	I-cell_type	O
.	O	O

Among	O	O
them	B-cell_line	O
,	I-cell_line	O
thymic	I-cell_line	O
epithelial	I-cell_line	O
cells	I-cell_line	O
(	O	O
TEC	O	O
)	O	O
are	O	O
known	O	O
to	O	O
exert	O	O
dominant	O	O
roles	O	O
in	O	O
their	O	O
survival	O	O
and	O	O
functional	O	O
shaping	O	O
.	O	O

Key	O	O
molecules	O	O
mediating	O	O
TEC	O	O
/	O	O
thymocytes	O	O
interactions	O	O
include	O	O
cytokines	B-protein	O
and	O	O
growth	B-protein	O
factors	I-protein	O
secreted	O	O
by	O	O
the	O	O
two	O	O
cell	O	O
types	O	O
and	O	O
adhesion	O	O
receptors	O	O
mediating	O	O
cell	O	O
contact	O	O
.	O	O

Signaling	O	O
events	O	O
triggered	O	O
in	O	O
thymocytes	O	O
by	O	O
adhesion	O	O
to	O	O
epithelial	O	O
cells	O	O
have	O	O
been	O	O
extensively	O	O
investigated	O	O
,	O	O
whereas	O	O
little	O	O
is	O	O
known	O	O
on	O	O
the	O	O
opposite	O	O
phenomenon	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
investigated	O	O
this	O	O
issue	O	O
in	O	O
a	O	O
co-culture	O	O
system	O	O
composed	O	O
of	O	O
TEC	O	O
cultures	O	O
derived	O	O
from	O	O
human	B-cell_type	O
normal	I-cell_type	O
thymus	O	O
and	O	O
heterologous	O	O
thymocytes	B-cell_type	O
.	O	O

We	O	O
demonstrated	O	O
that	O	O
thymocytes	O	O
adhere	O	O
to	O	O
TEC	O	O
involving	O	O
beta1	O	O
and	O	O
beta4	O	O
integrins	O	O
and	O	O
induce	O	O
the	O	O
clustering	O	O
of	O	O
alpha3beta1	O	O
and	O	O
alpha6beta4	O	O
heterodimers	O	O
at	O	O
the	O	O
TEC	O	O
surface	O	O
.	O	O

In	O	O
addition	O	O
thymocyte	O	O
adhesion	O	O
was	O	O
followed	O	O
by	O	O
activation	O	O
of	O	O
NF-kappaB	B-protein	O
and	O	O
NF-IL6	B-protein	O
gene	I-protein	O
transcription	B-protein	O
factors	I-protein	O
and	O	O
enhanced	O	O
IL-6	O	O
production	O	O
.	O	O

The	O	O
two	O	O
latter	O	O
phenomena	O	O
were	O	O
reproduced	O	O
by	O	O
the	O	O
cross-linking	O	O
of	O	O
the	O	O
alpha3	B-protein	O
,	O	O
alpha6	O	O
,	O	O
beta1	O	O
and	O	O
beta4	O	O
integrins	O	O
,	O	O
thus	O	O
implying	O	O
that	O	O
the	O	O
alpha3beta1	O	O
and	O	O
alpha6beta4	B-protein	O
heterodimers	I-protein	O
can	O	O
signal	O	O
during	O	O
thymocyte	O	O
adhesion	O	O
.	O	O

We	O	O
have	O	O
extended	O	O
our	O	O
previous	O	O
work	O	O
investigating	O	O
in	O	O
the	O	O
same	O	O
experimental	O	O
setting	O	O
the	O	O
inducing	O	O
activity	O	O
of	O	O
non	O	O
stimulated	O	O
or	O	O
activated	O	O
policlonal	O	O
or	O	O
clonal	O	O
mature	O	O
T	B-cell_type	O
cells	I-cell_type	O
as	O	O
representative	O	O
of	O	O
the	O	O
more	O	O
mature	O	O
thymocyte	O	O
subset	O	O
.	O	O

We	O	O
found	O	O
that	O	O
adhesion	O	O
of	O	O
unstimulated	O	O
T	O	O
cell	O	O
i	O	O
)	O	O
involved	O	O
beta1	O	O
,	O	O
but	O	O
not	O	O
beta4	O	O
integrin	O	O
functions	O	O
at	O	O
the	O	O
surface	O	O
ii	O	O
)	O	O
induced	O	O
the	O	O
clustering	O	O
of	O	O
alpha3beta1	O	O
,	O	O
but	O	O
not	O	O
alpha2beta1	O	O
heterodimers	O	O
at	O	O
the	O	O
TEC	O	O
surface	O	O
and	O	O
iii	O	O
)	O	O
up-regulated	O	O
the	O	O
nuclear	O	O
binding	O	O
activity	O	O
of	O	O
NF-kappaB	B-protein	O
transcription	I-protein	O
factor	I-protein	O
and	O	O
the	O	O
IL-6	O	O
secretion	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
alpha3beta1	O	O
and	O	O
alpha6beta4	O	O
heterodimers	O	O
are	O	O
induced	O	O
to	O	O
cluster	O	O
at	O	O
the	O	O
TEC	O	O
surface	O	O
recognizing	O	O
yet	O	O
unknown	O	O
cellular	O	O
ligands	O	O
differentially	O	O
expressed	O	O
during	O	O
T	O	O
cell	O	O
development	O	O
.	O	O

Identification	O	O
and	O	O
characterization	O	O
of	O	O
SKAT-2	O	O
,	O	O
a	O	O
novel	O	O
Th2-specific	O	O
zinc	O	O
finger	O	O
gene	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
a	O	O
novel	O	O
Kruppel-type	B-DNA	O
zinc	I-DNA	O
finger	O	O
(	O	O
ZF	B-DNA	O
)	O	O
gene	O	O
,	O	O
SKAT-2	O	O
,	O	O
which	O	O
is	O	O
selectively	O	O
expressed	O	O
by	O	O
murine	B-cell_type	O
Th2	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
protein	O	O
encoded	O	O
by	O	O
this	O	O
gene	O	O
has	O	O
14	O	O
C2H2-type	O	O
ZF	O	O
tandemly	O	O
arrayed	O	O
at	O	O
its	O	O
C	O	O
terminus	O	O
and	O	O
N-terminal	O	O
SCAN	O	O
box	O	O
and	O	O
KRAB	O	O
domains	O	O
.	O	O

SKAT-2	O	O
is	O	O
tissue	O	O
restricted	O	O
in	O	O
expression	O	O
at	O	O
the	O	O
RNA	O	O
level	O	O
,	O	O
detectable	O	O
only	O	O
in	O	O
brain	O	O
and	O	O
at	O	O
low	O	O
levels	O	O
in	O	O
kidney	O	O
and	O	O
spleen	O	O
and	O	O
few	O	O
hematopoietic	O	O
cell	O	O
lines	O	O
.	O	O

By	O	O
in	O	O
situ	O	O
hybridization	O	O
,	O	O
SKAT-2	O	O
expression	O	O
was	O	O
found	O	O
to	O	O
peak	O	O
in	O	O
antigen-stimulated	O	O
CD4	O	O
(	O	O
+	I-cell_line	O
)	I-cell_line	O
T	B-cell_type	O
cells	I-cell_type	O
after	O	O
2-3	O	O
days	O	O
of	O	O
culture	O	O
under	O	O
Th2	O	O
but	O	O
not	O	O
Th1	O	O
biasing	O	O
conditions	O	O
.	O	O

This	O	O
pattern	O	O
of	O	O
expression	O	O
closely	O	O
mirrored	O	O
that	O	O
of	O	O
GATA-3	O	O
in	O	O
the	O	O
same	B-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
transient	O	O
transfection	O	O
experiments	O	O
in	O	O
phorbol	O	O
12-myristate	O	O
13-acetate/ionomycin-stimulated	O	O
EL4	O	O
cells	O	O
,	O	O
SKAT-2	O	O
was	O	O
found	O	O
to	O	O
up-regulate	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
IL-4	B-protein	O
but	O	O
not	O	O
the	O	O
IL-5	B-DNA	O
promoter	I-DNA	O
,	O	O
contrasting	O	O
with	O	O
the	O	O
ability	O	O
of	O	O
GATA-3	O	O
to	O	O
activate	O	O
both	O	O
promoters	O	O
.	O	O

This	O	O
result	O	O
was	O	O
confirmed	O	O
using	O	O
clones	O	O
of	O	O
EL4	B-cell_type	O
cells	I-cell_type	O
stably	O	O
expressing	O	O
an	O	O
inducible	O	O
form	O	O
of	O	O
SKAT-2	O	O
,	O	O
thus	O	O
SKAT-2	O	O
is	O	O
a	O	O
novel	O	O
Th2-specific	O	O
gene	O	O
that	O	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
selective	O	O
regulation	O	O
of	O	O
cytokine	B-protein	O
genes	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

hsp70	O	O
interacting	O	O
protein	O	O
Hip	O	O
does	O	O
not	O	O
affect	O	O
glucocorticoid	O	O
receptor	O	O
folding	O	O
by	O	O
the	O	O
hsp90-based	O	O
chaperone	O	O
machinery	O	O
except	O	O
to	O	O
oppose	O	O
the	O	O
effect	O	O
of	O	O
BAG-1	O	O
.	O	O

Reticulocyte	O	O
lysate	O	O
contains	O	O
a	O	O
chaperone	O	O
system	O	O
that	O	O
assembles	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
.hsp90	O	O
heterocomplexes	O	O
.	O	O

Using	O	O
purified	O	O
proteins	O	O
,	O	O
we	O	O
have	O	O
prepared	O	O
a	O	O
five-protein	O	O
heterocomplex	O	O
assembly	O	O
system	O	O
consisting	O	O
of	O	O
two	O	O
proteins	O	O
essential	O	O
for	O	O
heterocomplex	O	O
assembly-	O	O
hsp90	O	O
and	O	O
hsp70	O	O
-and	O	O
three	O	O
proteins	O	O
that	O	O
act	O	O
as	O	O
co-chaperones	O	O
to	O	O
enhance	O	O
assembly-	O	O
Hop	O	O
,	O	O
hsp40	O	O
,	O	O
p23	O	O
[	O	O
Morishima	O	O
,	O	O
Y.	O	O
,	O	O
Kanelakis	O	O
,	O	O
K.	O	O
C.	O	O
,	O	O
Silverstein	O	O
,	O	O
A.	O	O
M.	O	O
,	O	O
Dittmar	O	O
,	O	O
K.	O	O
D.	O	O
,	O	O
Estrada	O	O
,	O	O
L.	O	O
,	O	O
and	O	O
Pratt	O	O
,	O	O
W.	O	O
B.	O	O
(	O	O
2000	O	O
)	O	O
J.	O	O
Biol.	O	O
Chem.	O	O
275	O	O
,	O	O
6894-6900	O	O
]	O	O
.	O	O

The	O	O
hsp70	O	O
co-chaperone	O	O
Hip	O	O
has	O	O
been	O	O
recovered	O	O
in	O	O
receptor.hsp90	O	O
heterocomplexes	O	O
at	O	O
an	O	O
intermediate	O	O
stage	O	O
of	O	O
assembly	O	O
in	O	O
reticulocyte	O	O
lysate	O	O
,	O	O
and	O	O
Hip	O	O
is	O	O
also	O	O
thought	O	O
to	O	O
be	O	O
an	O	O
intrinsic	O	O
component	O	O
of	O	O
the	O	O
assembly	O	O
machinery	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
immunodepletion	O	O
of	O	O
Hip	O	O
from	O	O
reticulocyte	O	O
lysate	O	O
or	O	O
addition	O	O
of	O	O
high	O	O
levels	O	O
of	O	O
Hip	O	O
to	O	O
the	O	O
purified	O	O
five-protein	O	O
system	O	O
does	O	O
not	O	O
affect	O	O
GR.hsp90	O	O
heterocomplex	O	O
assembly	O	O
or	O	O
the	O	O
activation	O	O
of	O	O
steroid	O	O
binding	O	O
activity	O	O
that	O	O
occurs	O	O
with	O	O
assembly	O	O
.	O	O

Despite	O	O
the	O	O
fact	O	O
that	O	O
Hip	O	O
does	O	O
not	O	O
affect	O	O
assembly	O	O
,	O	O
it	O	O
is	O	O
recovered	O	O
in	O	O
GR.hsp90	O	O
heterocomplexes	O	O
assembled	O	O
by	O	O
both	O	O
systems	O	O
.	O	O

In	O	O
the	O	O
five-protein	O	O
system	O	O
,	O	O
Hip	O	O
prevents	O	O
inhibition	O	O
of	O	O
assembly	O	O
by	O	O
the	O	O
hsp70	O	O
co-chaperone	O	O
BAG-1	O	O
,	O	O
and	O	O
cotransfection	O	O
of	O	O
Hip	O	O
with	O	O
BAG-1	O	O
opposes	O	O
BAG-1	O	O
reduction	O	O
of	O	O
steroid	O	O
binding	O	O
activity	O	O
in	O	O
COS	B-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
conclude	O	O
that	O	O
Hip	O	O
is	O	O
not	O	O
a	O	O
component	O	O
of	O	O
the	O	O
assembly	O	O
machinery	O	O
but	O	O
that	O	O
it	O	O
could	O	O
play	O	O
a	O	O
regulatory	O	O
role	O	O
in	O	O
opposition	O	O
to	O	O
BAG-1	O	O
.	O	O

Cutting	O	O
edge	O	O
:	O	O
STAT6-deficient	O	O
mice	O	O
have	O	O
enhanced	O	O
tumor	O	O
immunity	O	O
to	O	O
primary	O	O
and	O	O
metastatic	O	O
mammary	O	O
carcinoma	O	O
.	O	O

STAT4	B-protein	O
and	O	O
STAT6	O	O
are	O	O
essential	O	O
for	O	O
the	O	O
development	O	O
of	O	O
CD4	B-protein	O
(	O	O
+	I-DNA	O
)	O	O
Th1	O	O
and	O	O
Th2	O	O
development	O	O
,	O	O
respectively	O	O
.	O	O

Tumor	O	O
immunologists	O	O
have	O	O
hypothesized	O	O
that	O	O
Th1	B-cell_type	O
cells	I-cell_type	O
are	O	O
critical	O	O
in	O	O
tumor	O	O
immunity	O	O
because	O	O
they	O	O
facilitate	O	O
differentiation	O	O
of	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
which	O	O
are	O	O
potent	O	O
anti-tumor	O	O
effectors	O	O
.	O	O

We	O	O
have	O	O
used	B-protein	O
STAT4	I-protein	O
(	O	O
-/-	B-protein	O
)	O	O
and	O	O
STAT6	O	O
(	O	O
-/-	O	O
)	O	O
mice	O	O
to	O	O
test	O	O
this	O	O
hypothesis	O	O
.	O	O

BALB/c	O	O
and	O	O
knockout	O	O
mice	O	O
were	O	O
challenged	O	O
in	O	O
the	O	O
mammary	O	O
gland	O	O
with	O	O
the	O	O
highly	O	O
malignant	O	O
and	O	O
spontaneously	O	O
metastatic	O	O
BALB/c-derived	O	O
4T1	O	O
mammary	O	O
carcinoma	O	O
.	O	O

Primary	O	O
tumor	O	O
growth	O	O
and	O	O
metastatic	O	O
disease	O	O
are	O	O
reduced	O	O
in	O	O
STAT6	O	O
(	O	O
-/-	O	O
)	O	O
mice	O	O
relative	O	O
to	O	O
BALB/c	O	O
and	O	O
STAT4	B-protein	O
(	O	O
-/-	O	O
)	O	O
mice	O	O
.	O	O

Ab	O	O
depletions	O	O
demonstrate	O	O
that	O	O
the	O	O
effect	O	O
is	O	O
mediated	O	O
by	O	O
CD8	O	O
(	O	O
+	O	O
)	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
and	O	O
immunized	O	O
STAT6	O	O
(	O	O
-/-	O	O
)	O	O
mice	O	O
have	O	O
higher	O	O
levels	O	O
of	O	O
4T1-specific	O	O
CTL	O	O
than	O	O
BALB/c	O	O
or	O	O
STAT4	B-protein	O
(	O	O
-/-	O	O
)	O	O
mice	O	O
.	O	O

Surprisingly	O	O
,	O	O
Th1	O	O
or	O	O
Th2	B-cell_type	O
cells	I-cell_type	O
are	O	O
not	O	O
involved	O	O
,	O	O
because	O	O
CD4	O	O
depletion	O	O
does	O	O
not	O	O
diminish	O	O
the	O	O
anti-tumor	O	O
effect	O	O
.	O	O

Therefore	O	O
,	O	O
deletion	O	O
of	O	O
the	O	O
STAT6	B-DNA	O
gene	I-DNA	O
facilitates	O	O
development	O	O
of	O	O
potent	O	O
anti-tumor	B-protein	O
immunity	I-protein	O
via	O	O
a	O	O
CD4	B-DNA	O
(	I-DNA	O
+	I-DNA	O
)	O	O
-independent	O	O
pathway	O	O
.	O	O

Activation	O	O
of	O	O
oncogenic	B-protein	O
transcription	I-protein	O
factor	I-protein	O
AP-1	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
infected	O	O
with	O	O
human	O	O
T	O	O
cell	O	O
leukemia	O	O
virus	O	O
type	O	O
1	O	O
.	O	O

Human	O	O
T	O	O
cell	O	O
leukemia	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HTLV-1	O	O
)	O	O
Tax	O	O
protein	O	O
transforms	O	O
primary	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
in	O	O
vitro	O	O
.	O	O

We	O	O
previously	O	O
showed	O	O
that	O	O
Tax	O	O
induces	O	O
the	O	O
expression	O	O
of	O	O
various	O	O
family	O	O
members	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
AP-1	I-protein	O
such	O	O
as	O	O
c-Jun	B-protein	O
,	O	O
JunD	O	O
,	O	O
c-Fos	O	O
,	O	O
and	O	O
Fra-1	O	O
at	O	O
the	O	O
mRNA	B-RNA	O
level	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
examined	O	O
the	O	O
ability	O	O
of	O	O
Tax	O	O
to	O	O
activate	O	O
transcription	O	O
through	O	O
the	O	O
AP-1-binding	B-DNA	O
site	I-DNA	O
(	I-DNA	O
AP-1	I-DNA	O
site	I-DNA	O
)	O	O
.	O	O

A	O	O
transient	O	O
transfection	O	O
study	O	O
showed	O	O
that	O	O
Tax	O	O
can	O	O
activate	O	O
transcription	O	O
through	O	O
the	O	O
AP-1-binding	O	O
site	O	O
in	O	O
a	O	O
human	B-cell_line	O
T	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
,	O	O
whereas	O	O
any	O	O
combination	O	O
of	O	O
AP-1	B-protein	O
proteins	O	O
did	O	O
so	O	O
much	O	O
less	O	O
than	O	O
Tax	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
activation	O	O
of	O	O
the	O	O
AP-1	B-DNA	O
site	I-DNA	O
by	O	O
Tax	O	O
may	O	O
require	O	O
a	O	O
mechanism	O	O
other	O	O
than	O	O
the	O	O
induction	O	O
of	O	O
AP-1	B-RNA	O
mRNA	I-RNA	O
.	O	O

Fresh	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
leukemia	I-cell_type	O
cells	I-cell_type	O
of	O	O
all	O	O
surveyed	O	O
ATL	O	O
patients	O	O
displayed	O	O
constitutive	O	O
AP-1	B-protein	O
DNA-binding	O	O
activity	O	O
,	O	O
whereas	O	O
no	O	O
normal	O	O
individuals	O	O
did	O	O
.	O	O

However	O	O
,	O	O
the	O	O
HTLV-1	O	O
genes	B-DNA	O
,	O	O
including	O	O
tax	B-protein	O
,	O	O
are	O	O
not	O	O
significantly	O	O
expressed	O	O
in	O	O
fresh	O	O
leukemia	B-cell_type	O
cells	I-cell_type	O
from	O	O
ATL	O	O
patients	O	O
.	O	O

Our	O	O
present	O	O
results	O	O
suggest	O	O
that	O	O
activation	O	O
of	O	O
AP-1	B-protein	O
occurs	O	O
through	O	O
Tax-dependent	O	O
and	O	O
-independent	O	O
mechanisms	O	O
in	O	O
HTLV-1-infected	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
which	O	O
may	O	O
play	O	O
some	O	O
roles	O	O
in	O	O
dysregulated	O	O
phenotypes	O	O
of	O	O
HTLV-1-infected	B-cell_type	O
cells	I-cell_type	O
.	O	O

2	O	O
,	O	O
2	O	O
'	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
6'-pentachlorobiphenyl	O	O
induces	O	O
apoptosis	O	O
in	O	O
human	B-cell_type	O
monocytic	I-cell_type	O
cells	I-cell_type	O
.	O	O

Polychlorinatedbiphenyls	O	O
(	O	O
PCBs	O	O
)	O	O
are	O	O
a	O	O
group	O	O
of	O	O
persistent	O	O
and	O	O
widely	O	O
dispersed	O	O
environmental	O	O
pollutants	O	O
,	O	O
some	O	O
of	O	O
which	O	O
may	O	O
be	O	O
immunotoxic	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
PCBs	O	O
on	O	O
immune	O	O
system	O	O
by	O	O
assessing	O	O
apoptotic	O	O
cell	O	O
death	O	O
in	O	O
human	B-cell_line	O
monocytic	I-cell_line	O
U937	I-cell_line	O
cells	I-cell_line	O
.	O	O

Among	O	O
the	O	O
various	O	O
congeners	O	O
tested	O	O
,	O	O
2	O	O
,	O	O
2	O	O
'	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
6'-pentachlorobiphenyl	O	O
(	O	O
PeCB	O	O
)	O	O
,	O	O
a	O	O
highly	O	O
ortho-substituted	O	O
congener	O	O
,	O	O
specifically	O	O
induced	O	O
DNA	O	O
fragmentation	O	O
,	O	O
a	O	O
hallmark	O	O
of	O	O
apoptosis	O	O
,	O	O
while	O	O
the	O	O
other	O	O
examined	O	O
di-	O	O
,	O	O
tri-	O	O
,	O	O
tetra-	O	O
,	O	O
and	O	O
pentachlorobiphenyls	O	O
did	O	O
not	O	O
.	O	O

To	O	O
further	O	O
study	O	O
the	O	O
2	O	O
,	O	O
2	O	O
'	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
6'-PeCB-induced	O	O
cell	O	O
death	O	O
,	O	O
various	O	O
features	O	O
of	O	O
apoptosis	O	O
were	O	O
examined	O	O
.	O	O

2	O	O
,	O	O
2	O	O
'	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
6'-PeCB	O	O
caused	O	O
a	O	O
decrease	O	O
in	O	O
cell	O	O
viability	O	O
and	O	O
induced	O	O
cellular	O	O
morphologic	O	O
features	O	O
characteristic	O	O
of	O	O
apoptosis	O	O
such	O	O
as	O	O
chromatin	O	O
aggregation	O	O
and	O	O
apoptotic	O	O
bodies	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
caspase-3	O	O
,	O	O
an	O	O
executioner	O	O
of	O	O
apoptosis	O	O
,	O	O
was	O	O
activated	O	O
and	O	O
its	O	O
substrate	O	O
,	O	O
poly	O	O
(	O	O
ADP-ribose	B-protein	O
)	O	O
polymerase	O	O
(	O	O
PARP	O	O
)	O	O
,	O	O
was	O	O
cleaved	O	O
during	O	O
2	O	O
,	O	O
2	O	O
'	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
6'-PeCB-induced	O	O
apoptosis	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
3	O	O
,	O	O
3	O	O
'	O	O
,	O	O
4	B-protein	O
,	O	O
4	O	O
'	O	O
,	O	O
5-PeCB	O	O
,	O	O
a	O	O
congener	O	O
of	O	O
coplanar	O	O
structure	O	O
,	O	O
as	O	O
well	O	O
as	O	O
2	O	O
,	O	O
3	O	O
,	O	O
7	O	O
,	O	O
8-TCDD	O	O
did	O	O
not	O	O
induce	O	O
apoptosis	O	O
in	O	O
these	O	O
human	B-cell_type	O
monocytic	I-cell_type	O
cells	I-cell_type	O
,	O	O
although	O	O
they	O	O
potently	O	O
induced	O	O
CYP	O	O
1A1	O	O
in	O	O
human	B-cell_line	O
hepatoma	I-cell_line	O
Hep	I-cell_line	O
G2	I-cell_line	O
cells	I-cell_line	O
.	O	O

Taken	O	O
together	O	O
,	O	O
the	O	O
data	O	O
indicate	O	O
that	O	O
2	O	O
,	O	O
2	O	O
'	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
6'-PeCB	O	O
induces	O	O
apoptosis	O	O
in	O	O
human	B-cell_type	O
monocytic	I-cell_type	O
cells	I-cell_type	O
through	O	O
a	O	O
mechanism	O	O
that	O	O
is	O	O
independent	O	O
of	O	O
the	O	O
arylhydrocarbon	B-protein	O
receptor	I-protein	O
.	O	O

This	O	O
suggests	O	O
a	O	O
possibly	O	O
separate	O	O
mechanism	O	O
by	O	O
which	O	O
PCBs	O	O
cause	O	O
immunosuppression	O	O
.	O	O

Effects	O	O
of	O	O
deregulated	O	O
Raf	B-protein	O
activation	O	O
on	O	O
integrin	B-protein	O
,	O	O
cytokine-receptor	O	O
expression	O	O
and	O	O
the	O	O
induction	O	O
of	O	O
apoptosis	O	O
in	O	O
hematopoietic	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
effects	O	O
of	O	O
deregulated	O	O
Raf	B-protein	O
activation	O	O
on	O	O
the	O	O
growth	O	O
and	O	O
differentiation	O	O
of	O	O
hematopoietic	B-cell_type	O
cells	I-cell_type	O
were	O	O
investigated	O	O
.	O	O

The	O	O
cytokine-dependent	B-protein	O
murine	I-protein	O
myeloid	I-protein	O
FDC-P1	I-protein	O
and	O	O
human	O	O
erythroleukemic	I-cell_line	O
TF-1	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
were	O	O
transformed	O	O
to	O	O
grow	O	O
in	O	O
response	O	O
to	O	O
deregulated	O	O
Raf	O	O
expression	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
exogenous	O	O
cytokines	B-protein	O
.	O	O

The	O	O
conditionally	B-protein	O
active	I-protein	O
Raf	I-protein	O
proteins	I-protein	O
were	O	O
regulated	O	O
by	O	O
beta-estradiol	O	O
as	O	O
cDNAs	O	O
containing	O	O
the	O	O
Raf	B-protein	O
catalytic	I-protein	O
,	O	O
but	O	O
lacking	O	O
negative-regulatory	O	O
domains	I-protein	O
,	O	O
were	O	O
ligated	O	O
to	O	O
the	O	O
hormone	B-protein	O
binding	I-protein	O
domain	I-protein	O
of	O	O
the	O	O
estrogen	B-protein	O
receptor	I-protein	O
(	O	O
deltaRaf	O	O
:	O	O
ER	B-protein	O
)	O	O
.	O	O

Continuous	O	O
deltaRaf	O	O
expression	O	O
prevented	O	O
apoptosis	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
exogenous	O	O
cytokines	B-protein	O
and	O	O
altered	O	O
the	O	O
morphology	O	O
of	O	O
the	O	O
FD/deltaRaf	B-cell_line	O
:	I-cell_line	O
ER	I-cell_line	O
cells	I-cell_type	O
as	O	O
they	O	O
grew	O	O
in	O	O
large	O	O
aggregated	O	O
masses	O	O
(	O	O
>	B-cell_line	O
100	I-cell_line	O
cells	I-cell_line	O
)	O	O
whereas	O	O
the	O	O
parental	O	O
cytokine-dependent	O	O
FDC-P1	O	O
cells	O	O
grew	O	O
in	O	O
smaller	O	O
grape-like	O	O
clusters	O	O
(	O	O
<	O	O
10	O	O
cells	O	O
)	O	O
.	O	O

FD/deltaRaf-1	O	O
:	O	O
ER	B-cell_type	O
cells	I-cell_type	O
growing	O	O
in	O	O
response	O	O
to	O	O
Raf	O	O
activation	O	O
displayed	O	O
decreased	O	O
levels	O	O
of	O	O
the	O	O
Mac-2	O	O
and	O	O
Mac-3	O	O
molecules	O	O
on	O	O
their	O	O
cell	O	O
surface	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
when	O	O
these	O	O
cells	O	O
were	O	O
cultured	O	O
in	O	O
IL-3	O	O
,	O	O
higher	O	O
levels	O	O
of	O	O
these	O	O
adhesion	O	O
molecules	O	O
were	O	O
detected	O	O
.	O	O

Expression	O	O
of	O	O
activated	B-protein	O
Raf	I-protein	O
oncoproteins	O	O
also	O	O
abrogated	O	O
cytokine	O	O
dependency	O	O
and	O	O
prevented	O	O
apoptosis	O	O
of	O	O
TF-1	B-cell_type	O
cells	I-cell_type	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
differentiation	O	O
status	O	O
of	O	O
these	O	O
Raf-responsive	B-cell_type	O
cells	I-cell_type	O
was	O	O
more	O	O
immature	O	O
upon	O	O
Raf	O	O
activation	O	O
as	O	O
culture	O	O
with	O	O
the	O	O
differentiation-inducing	O	O
agent	O	O
phorbol	O	O
12	O	O
myristate	O	O
13-acetate	O	O
(	O	O
PMA	O	O
)	O	O
and	O	O
beta-estradiol	O	O
resulted	O	O
in	O	O
decreased	O	O
levels	O	O
of	O	O
the	O	O
CD11b	O	O
and	O	O
CD18	O	O
integrin	B-protein	O
molecules	O	O
on	O	O
the	O	O
cell	O	O
surface	O	O
.	O	O

In	O	O
contrast	O	O
when	O	O
the	O	O
Raf-responsive	B-cell_type	O
cells	I-cell_type	O
were	O	O
induced	O	O
to	O	O
differentiate	O	O
with	O	O
PMA	O	O
and	O	O
GM-CSF	B-protein	O
,	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
deltaRaf	O	O
:	O	O
ER	O	O
activation	O	O
,	O	O
increased	O	O
levels	O	O
of	O	O
the	O	O
CD11b	B-protein	O
and	I-protein	O
CD18	I-protein	O
molecules	I-protein	O
were	O	O
detected	O	O
.	O	O

Retinoic	O	O
acid	O	O
(	O	O
RA	O	O
)	O	O
inhibited	O	O
3H-thymidine	O	O
incorporation	O	O
in	O	O
response	O	O
to	O	O
GM-CSF	O	O
.	O	O

Interestingly	O	O
,	O	O
Raf	B-protein	O
activation	O	O
counterbalanced	O	O
the	O	O
inhibition	O	O
of	O	O
DNA	O	O
synthesis	O	O
caused	O	O
by	O	O
RA	B-protein	O
but	O	O
not	O	O
PMA	O	O
.	O	O

Thus	O	O
deregulated	O	O
Raf	B-protein	O
expression	O	O
can	O	O
alter	O	O
cytokine	B-protein	O
dependency	O	O
,	O	O
integrin	B-protein	O
expression	O	O
and	O	O
the	O	O
stage	O	O
of	O	O
differentiation	O	O
.	O	O

These	O	O
Raf-responsive	O	O
cell	O	O
lines	O	O
will	O	O
be	O	O
useful	O	O
in	O	O
elucidating	O	O
the	O	O
roles	O	O
of	O	O
the	O	O
MAP	O	O
kinase	O	O
cascade	O	O
on	O	O
hematopoietic	O	O
cell	O	O
differentiation	O	O
and	O	O
malignant	O	O
transformation	O	O

Cyclic	O	O
AMP	O	O
activates	O	O
p38	O	O
mitogen-activated	O	O
protein	O	O
kinase	O	O
in	O	O
Th2	B-cell_type	O
cells	I-cell_type	O
:	O	O
phosphorylation	O	O
of	O	O
GATA-3	O	O
and	O	O
stimulation	O	O
of	O	O
Th2	O	O
cytokine	B-protein	O
gene	O	O
expression	O	O
.	O	O

cAMP	O	O
is	O	O
an	O	O
important	O	O
second	O	O
messenger	O	O
with	O	O
immunomodulatory	O	O
properties	O	O
.	O	O

Elevation	O	O
of	O	O
intracellular	O	O
cAMP	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
induced	O	O
by	O	O
agents	O	O
such	O	O
as	O	O
IL-1alpha	O	O
or	O	O
PGs	O	O
,	O	O
inhibits	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

In	O	O
effector	O	O
T	B-cell_type	O
cells	I-cell_type	O
,	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
level	O	O
of	O	O
intracellular	O	O
cAMP	O	O
inhibits	O	O
cytokine	O	O
production	O	O
in	O	O
Th1	B-cell_type	O
cells	I-cell_type	O
but	O	O
stimulates	O	O
cytokine	O	O
production	O	O
in	O	O
Th2	B-cell_type	O
cells	I-cell_type	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
cAMP-induced	O	O
effects	O	O
in	O	O
Th2	B-cell_type	O
cells	I-cell_type	O
occur	O	O
independently	O	O
of	O	O
the	O	O
protein	B-protein	O
kinase	I-protein	O
A	O	O
pathway	O	O
,	O	O
which	O	O
is	O	O
the	O	O
major	O	O
mediator	O	O
of	O	O
cAMP-induced	O	O
signaling	O	O
events	O	O
in	O	O
most	B-cell_type	O
cell	I-cell_type	O
types	I-cell_type	O
.	O	O

Instead	O	O
,	O	O
cAMP	O	O
stimulates	O	O
activation	O	O
of	O	O
p38	B-protein	O
mitogen-activated	I-protein	O
protein	I-protein	O
kinase	I-protein	O
in	O	O
Th2	B-cell_type	O
cells	I-cell_type	O
.	O	O

This	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
Th2	O	O
-selective	O	O
event	O	O
because	O	O
cAMP	O	O
barely	O	O
increased	O	O
p38	O	O
phosphorylation	O	O
in	O	O
Th1	B-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
show	O	O
that	O	O
in	O	O
Th2	B-cell_type	O
cells	I-cell_type	O
,	O	O
cAMP	O	O
promotes	O	O
the	O	O
production	O	O
of	O	O
both	O	O
IL-5	B-protein	O
and	O	O
IL-13	B-protein	O
,	O	O
which	O	O
play	O	O
distinct	O	O
but	O	O
critical	O	O
roles	O	O
in	O	O
asthma	O	O
pathogenesis	O	O
.	O	O

Our	O	O
data	O	O
also	O	O
show	O	O
that	O	O
cAMP	O	O
causes	O	O
increased	O	O
phosphorylation	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
GATA-3	I-protein	O
,	O	O
which	O	O
we	O	O
have	O	O
shown	O	O
is	O	O
a	O	O
critical	O	O
regulator	O	O
of	O	O
Th2	O	O
cytokine	B-protein	O
gene	O	O
expression	O	O
and	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
of	O	O
airway	O	O
inflammation	O	O
in	O	O
mice	O	O
.	O	O

Thus	O	O
,	O	O
Th2	O	O
-specific	O	O
GATA-3	O	O
expression	O	O
and	O	O
p38	B-protein	O
mitogen-activated	I-protein	O
protein	I-protein	O
kinase	I-protein	O
activation	O	O
together	O	O
provide	O	O
a	O	O
molecular	O	O
basis	O	O
for	O	O
the	O	O
differential	O	O
effects	O	O
of	O	O
cAMP	O	O
in	O	O
the	O	O
two	O	O
T	O	O
helper	O	O
cell	O	O
subsets	O	O
.	O	O

Characterization	O	O
of	O	O
IL-4	B-protein	O
and	O	O
IL-13	O	O
signals	O	O
dependent	O	O
on	O	O
the	O	O
human	B-DNA	O
IL-13	I-DNA	O
receptor	I-DNA	O
alpha	I-DNA	O
chain	O	O
1	O	O
:	O	O
redundancy	O	O
of	O	O
requirement	O	O
of	O	O
tyrosine	O	O
residue	O	O
for	O	O
STAT3	B-protein	O
activation	O	O
.	O	O

IL-4	O	O
and	O	O
IL-13	O	O
are	O	O
pleiotropic	O	O
cytokines	B-protein	O
whose	O	O
biological	O	O
activities	O	O
overlap	O	O
with	O	O
each	O	O
other	O	O
.	O	O

IL-13	B-protein	O
receptor	I-protein	O
alpha	I-protein	O
chain	I-protein	O
1	O	O
(	O	O
IL-13R	B-protein	O
alpha	I-protein	O
1	I-protein	O
)	O	O
is	O	O
necessary	O	O
for	O	O
binding	O	O
to	O	O
IL-13	B-protein	O
,	O	O
and	O	O
the	O	O
heterodimer	B-protein	O
composed	I-protein	O
of	O	O
IL-13R	B-protein	O
alpha	I-protein	O
1	I-protein	O
and	O	O
IL-4R	O	O
alpha	B-protein	O
chain	O	O
transduces	O	O
IL-13	O	O
and	O	O
IL-4	O	O
signals	O	O
;	O	O
however	O	O
,	O	O
the	O	O
functional	O	O
mapping	O	O
of	O	O
the	O	O
intracellular	B-protein	O
domain	I-protein	O
of	O	O
IL-13R	B-protein	O
alpha	I-protein	O
1	O	O
is	O	O
not	O	O
fully	O	O
understood	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
constructed	O	O
wild	O	O
and	O	O
mutated	O	O
types	O	O
of	O	O
human	B-protein	O
IL-13R	I-protein	O
alpha	I-protein	O
1	O	O
,	O	O
and	O	O
analyzed	O	O
IL-4	O	O
and	O	O
IL-13	O	O
signals	O	O
using	O	O
an	O	O
IL-13R	O	O
alpha	I-protein	O
1	O	O
-transfected	O	O
human	B-cell_line	O
B	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
.	O	O

Expression	O	O
of	O	O
IL-13R	B-protein	O
alpha	I-protein	O
1	O	O
evoked	O	O
STAT3	O	O
activation	O	O
by	O	O
IL-4	B-protein	O
and	O	O
IL-13	B-protein	O
,	O	O
and	O	O
in	O	O
stimulated	O	O
human	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
,	O	O
on	O	O
which	O	O
IL-13R	B-protein	O
alpha	I-protein	O
1	O	O
was	O	O
highly	O	O
expressed	O	O
,	O	O
IL-4	O	O
and	O	O
IL-13	B-protein	O
induced	O	O
STAT3	O	O
activation	O	O
.	O	O

Replacement	O	O
of	O	O
the	O	O
two	O	O
tyrosine	O	O
residues	O	O
completely	O	O
abolished	O	O
STAT3	O	O
activation	O	O
,	O	O
although	O	O
replacing	O	O
either	O	O
tyrosine	O	O
residue	O	O
alone	O	O
retained	O	O
it	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
Box1	B-DNA	O
region	I-DNA	O
and	O	O
the	O	O
C-terminal	O	O
tail	O	O
of	O	O
IL-13R	B-protein	O
alpha	I-protein	O
1	O	O
were	O	O
critical	O	O
for	O	O
binding	O	O
to	O	O
Tyk2	O	O
,	O	O
and	O	O
activation	O	O
of	O	O
Jak1	B-protein	O
,	O	O
Tyk2	O	O
,	O	O
the	O	O
insulin	B-protein	O
receptor	I-protein	O
substrate-1	O	O
and	O	O
STAT6	O	O
respectively	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
STAT3	B-protein	O
activation	O	O
is	O	O
involved	O	O
with	O	O
IL-4	O	O
and	O	O
IL-13	O	O
signals	O	O
in	O	O
human	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
along	O	O
with	O	O
the	O	O
activation	O	O
of	O	O
STAT6	B-protein	O
,	O	O
and	O	O
that	O	O
there	O	O
is	O	O
a	O	O
unique	O	O
sequence	O	O
in	O	O
IL-13R	O	O
alpha	O	O
1	O	O
to	O	O
activate	O	O
STAT3	O	O
.	O	O

Functional	O	O
uncoupling	O	O
of	O	O
the	O	O
Janus	B-protein	O
kinase	I-protein	O
3-Stat5	O	O
pathway	O	O
in	O	O
malignant	O	O
growth	O	O
of	O	O
human	O	O
T	O	O
cell	O	O
leukemia	O	O
virus	O	O
type	O	O
1-transformed	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

Human	O	O
T	O	O
cell	O	O
leukemia	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HTLV-1	O	O
)	O	O
transforms	O	O
cytokine	O	O
-dependent	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
causes	O	O
adult	O	O
T	O	O
cell	O	O
leukemia	O	O
.	O	O

Janus	B-protein	O
tyrosine	I-protein	O
kinase	I-protein	O
(	O	O
Jak	B-protein	O
)	O	O
3	O	O
and	O	O
transcription	B-protein	O
factors	I-protein	O
Stat5a	O	O
and	O	O
Stat5b	O	O
are	O	O
essential	O	O
for	O	O
the	O	O
proliferation	O	O
of	O	O
normal	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
and	O	O
are	O	O
constitutively	O	O
hyperactivated	O	O
in	O	O
both	O	O
HTLV-1-transformed	B-cell_line	O
human	I-cell_line	O
T	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
and	O	O
lymphocytes	I-cell_type	O
isolated	O	O
from	O	O
HTLV-1-infected	O	O
patients	O	O
;	O	O
therefore	O	O
,	O	O
a	O	O
critical	O	O
role	O	O
for	O	O
the	O	O
Jak3-Stat5	O	O
pathway	O	O
in	O	O
the	O	O
progression	O	O
of	O	O
this	O	O
disease	O	O
has	O	O
been	O	O
postulated	O	O
.	O	O

We	O	O
recently	O	O
reported	O	O
that	O	O
tyrphostin	O	O
AG-490	O	O
selectively	O	O
blocked	O	O
IL-2	O	O
activation	O	O
of	O	O
Jak3/Stat5	O	O
and	O	O
growth	O	O
of	O	O
murine	B-cell_line	O
T	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

Here	O	O
we	O	O
demonstrate	O	O
that	O	O
disruption	O	O
of	O	O
Jak3/Stat5a/b	O	O
signaling	O	O
with	O	O
AG-490	O	O
(	O	O
50	O	O
&	O	O
mgr	O	O
;	O	O
M	O	O
)	O	O
blocked	O	O
the	O	O
proliferation	O	O
of	O	O
primary	B-cell_line	O
human	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
but	O	O
paradoxically	O	O
failed	O	O
to	O	O
inhibit	O	O
the	O	O
proliferation	O	O
of	O	O
HTLV-1-transformed	B-cell_line	O
human	I-cell_line	O
T	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
,	O	O
HuT-102	O	O
and	O	O
MT-2	O	O
.	O	O

Structural	O	O
homologues	O	O
of	O	O
AG-490	O	O
also	O	O
inhibited	O	O
the	O	O
proliferation	O	O
of	O	O
primary	B-cell_line	O
human	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
,	O	O
but	O	O
not	O	O
HTLV-1-infected	B-cell_type	O
cells	I-cell_type	O
.	O	O

Disruption	O	O
of	O	O
constitutive	O	O
Jak3/Stat5	O	O
activation	O	O
by	O	O
AG-490	O	O
was	O	O
demonstrated	O	O
by	O	O
inhibition	O	O
of	O	O
1	O	O
)	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
Jak3	B-protein	O
,	O	O
Stat5a	O	O
(	O	O
Tyr	B-protein	O
(	O	O
694	B-protein	O
)	O	O
)	O	O
,	O	O
and	O	O
Stat5b	O	O
(	O	O
Tyr	O	O
(	O	O
699	O	O
)	O	O
)	O	O
;	O	O
2	O	O
)	O	O
serine	O	O
phosphorylation	O	O
of	O	O
Stat5a	O	O
(	O	O
Ser	B-protein	O
(	O	O
726	B-protein	O
)	O	O
)	O	O
as	O	O
determined	O	O
by	O	O
a	O	O
novel	O	O
phosphospecific	O	O
Ab	O	O
;	O	O
and	O	O
3	O	O
)	O	O
Stat5a/b	O	O
DNA	O	O
binding	O	O
to	O	O
the	O	O
Stat5-responsive	B-DNA	O
beta-casein	I-DNA	O
promoter	I-DNA	O
.	O	O

In	O	O
contrast	O	O
,	O	O
AG-490	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
DNA	O	O
binding	O	O
by	O	O
p50/p65	O	O
components	O	O
of	O	O
NF-kappaB	B-protein	O
,	O	O
a	O	O
transcription	B-protein	O
factor	I-protein	O
activated	O	O
by	O	O
the	O	O
HTLV-1-encoded	B-protein	O
phosphoprotein	I-protein	O
,	O	O
Tax	O	O
.	O	O

Collectively	O	O
,	O	O
these	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
Jak3-Stat5	O	O
pathway	O	O
in	O	O
HTLV-1-transformed	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
has	O	O
become	O	O
functionally	O	O
redundant	O	O
for	O	O
proliferation	O	O
.	O	O

Reversal	O	O
of	O	O
this	O	O
functional	O	O
uncoupling	O	O
may	O	O
be	O	O
required	O	O
before	O	O
Jak3/Stat5	O	O
inhibitors	O	O
will	O	O
be	O	O
useful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
this	O	O
malignancy	O	O
.	O	O

The	O	O
Epstein-Barr	B-DNA	O
virus	O	O
promoter	O	O
initiating	O	O
B-cell	O	O
transformation	O	O
is	O	O
activated	O	O
by	O	O
RFX	B-protein	O
proteins	I-protein	O
and	O	O
the	O	O
B-cell-specific	B-protein	O
activator	I-protein	O
protein	I-protein	O
BSAP/Pax5	I-protein	O
.	O	O

Epstein-Barr	O	O
virus	O	O
(	O	O
EBV	O	O
)	O	O
-induced	O	O
B-cell	O	O
growth	O	O
transformation	O	O
,	O	O
a	O	O
central	O	O
feature	O	O
of	O	O
the	O	O
virus	O	O
'	O	O
strategy	O	O
for	O	O
colonizing	O	O
the	O	O
human	O	O
B-cell	O	O
system	O	O
,	O	O
requires	O	O
full	O	O
virus	O	O
latent	O	O
gene	O	O
expression	O	O
and	O	O
is	O	O
initiated	O	O
by	O	O
transcription	O	O
from	O	O
the	O	O
viral	B-DNA	O
promoter	I-DNA	O
Wp	O	O
.	O	O

Interestingly	O	O
,	O	O
when	O	O
EBV	O	O
accesses	O	O
other	O	O
cell	O	O
types	O	O
,	O	O
this	O	O
growth-transforming	O	O
program	O	O
is	O	O
not	O	O
activated	O	O
.	O	O

The	O	O
present	O	O
work	O	O
focuses	O	O
on	O	O
a	O	O
region	O	O
of	O	O
Wp	O	O
which	O	O
in	O	O
reporter	O	O
assays	O	O
confers	O	O
B-cell	O	O
-specific	O	O
activity	O	O
.	O	O

Bandshift	O	O
studies	O	O
indicate	O	O
that	O	O
this	O	O
region	O	O
contains	O	O
three	O	O
factor	O	O
binding	O	O
sites	I-DNA	O
,	O	O
termed	O	O
sites	B-protein	O
B	I-protein	O
,	O	O
C	O	O
,	O	O
and	O	O
D	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
a	O	O
previously	O	O
characterized	O	O
CREB	O	O
site	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
site	B-protein	O
C	O	O
binds	O	O
members	O	O
of	O	O
the	O	O
ubiquitously	O	O
expressed	O	O
RFX	O	O
family	O	O
of	O	O
proteins	I-protein	O
,	O	O
notably	O	O
RFX1	O	O
,	O	O
RFX3	O	O
,	O	O
and	O	O
the	O	O
associated	O	O
factor	O	O
MIBP1	O	O
,	O	O
whereas	O	O
sites	O	O
B	O	O
and	O	O
D	O	O
both	O	O
bind	O	O
the	O	O
B-cell-specific	B-protein	O
activator	I-protein	O
protein	I-protein	O
BSAP/Pax5	O	O
.	O	O

In	O	O
reporter	O	O
assays	O	O
with	O	O
mutant	O	O
Wp	O	O
constructs	O	O
,	O	O
the	O	O
loss	O	O
of	O	O
factor	B-protein	O
binding	O	O
to	O	O
any	O	O
one	O	O
of	O	O
these	O	O
sites	O	O
severely	O	O
impaired	O	O
promoter	O	O
activity	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
,	O	O
while	O	O
the	O	O
wild-type	B-DNA	O
promoter	I-DNA	O
could	O	O
be	O	O
activated	O	O
in	O	O
non-B	B-cell_type	O
cells	I-cell_type	O
by	O	O
ectopic	O	O
BSAP	B-protein	O
expression	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
Wp	O	O
regulation	O	O
by	O	O
BSAP	B-protein	O
helps	O	O
to	O	O
ensure	O	O
the	O	O
B-cell	O	O
specificity	O	O
of	O	O
EBV	O	O
's	O	O
growth-transforming	O	O
function	O	O
.	O	O

Activation	O	O
of	O	O
the	O	O
Lck	B-protein	O
tyrosine	I-protein	O
protein	I-protein	O
kinase	I-protein	O
by	O	O
the	O	O
Herpesvirus	B-protein	O
saimiri	I-protein	O
tip	I-protein	O
protein	I-protein	O
involves	O	O
two	O	O
binding	O	O
interactions	O	O
.	O	O

The	O	O
Tip	O	O
protein	O	O
of	O	O
Herpesvirus	O	O
saimiri	O	O
strain	O	O
484C	O	O
binds	O	O
to	O	O
and	O	O
activates	O	O
the	O	O
Lck	B-protein	O
tyrosine	I-protein	O
protein	I-protein	O
kinase	I-protein	O
.	O	O

Two	O	O
sequences	O	O
in	O	O
the	O	O
Tip	O	O
protein	O	O
were	O	O
previously	O	O
shown	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
binding	O	O
to	O	O
Lck	O	O
.	O	O

A	O	O
proline-rich	O	O
region	O	O
,	O	O
residues	O	O
132-141	O	O
,	O	O
binds	O	O
to	O	O
the	O	O
SH3	O	O
domain	O	O
of	O	O
the	O	O
Lck	B-protein	O
protein	I-protein	O
.	O	O

We	O	O
show	O	O
here	O	O
that	O	O
the	O	O
other	O	O
Lck-binding	O	O
domain	I-protein	O
,	O	O
residues	O	O
104-113	O	O
,	O	O
binds	O	O
to	O	O
the	O	O
carboxyl-terminal	O	O
half	O	O
of	O	O
Lck	O	O
and	O	O
that	O	O
this	O	O
binding	O	O
does	O	O
not	O	O
require	O	O
the	O	O
Lck	O	O
SH3	I-protein	O
domain	I-protein	O
.	O	O

Mutated	O	O
Tip	O	O
containing	O	O
only	O	O
one	O	O
functional	O	O
Lck-binding	O	O
domain	B-protein	O
can	O	O
bind	O	O
stably	O	O
to	O	O
Lck	O	O
,	O	O
although	O	O
not	O	O
as	O	O
strongly	O	O
as	O	O
wild-type	O	O
Tip	O	O
.	O	O

Interaction	O	O
of	O	O
Tip	O	O
with	O	O
Lck	O	O
through	O	O
either	O	O
Lck-binding	O	O
domain	O	O
increases	O	O
the	O	O
activity	O	O
of	O	O
Lck	O	O
in	O	O
vivo	O	O
.	O	O

Simultaneous	O	O
binding	O	O
of	O	O
both	O	O
domains	O	O
is	O	O
required	O	O
for	O	O
maximal	O	O
activation	O	O
of	O	O
Lck	O	O
.	O	O

The	O	O
transient	O	O
expression	O	O
of	O	O
Tip	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
was	O	O
found	O	O
to	O	O
stimulate	O	O
both	O	O
Stat3	O	O
-dependent	O	O
and	O	O
NF-AT	B-protein	O
-dependent	O	O
transcription	O	O
.	O	O

Mutant	O	O
forms	O	O
of	O	O
Tip	O	O
lacking	O	O
one	O	O
or	O	O
the	O	O
other	O	O
of	O	O
the	O	O
two	O	O
Lck-binding	O	O
domains	O	O
retained	O	O
the	O	O
ability	O	O
to	O	O
stimulate	O	O
Stat3	O	O
-dependent	O	O
transcription	O	O
.	O	O

Tip	O	O
lacking	O	O
the	O	O
proline-rich	O	O
Lck-binding	I-protein	O
domain	I-protein	O
exhibited	O	O
almost	O	O
wild-type	O	O
activity	O	O
in	O	O
this	O	O
assay	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
ablation	O	O
of	O	O
either	O	O
Lck-binding	O	O
domain	O	O
abolished	O	O
the	O	O
ability	O	O
of	O	O
Tip	O	O
to	O	O
stimulate	O	O
NF-AT	B-protein	O
-dependent	O	O
transcription	O	O
.	O	O

Full	O	O
biological	O	O
activity	O	O
of	O	O
Tip	O	O
,	O	O
therefore	O	O
,	O	O
appears	O	O
to	O	O
require	O	O
both	O	O
Lck-binding	O	O
domains	O	O
.	O	O

Accumulation	O	O
of	O	O
RXR	O	O
alpha	I-protein	O
during	O	O
activation	O	O
of	O	O
cycling	O	O
human	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
:	O	O
modulation	O	O
of	O	O
RXRE	O	O
transactivation	O	O
function	O	O
by	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
pathways	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
reported	O	O
that	O	O
the	O	O
activation	O	O
of	O	O
resting	B-cell_line	O
human	I-cell_line	O
immature	I-cell_line	O
peripheral	I-cell_line	O
blood	I-cell_line	O
T	I-cell_line	O
(	I-cell_line	O
PBT	I-cell_line	O
)	I-cell_line	O
lymphocytes	I-cell_type	O
is	O	O
associated	O	O
with	O	O
the	O	O
loss	O	O
of	O	O
retinoid	B-protein	O
X	I-protein	O
receptor	I-protein	O
alpha	I-protein	O
(	O	O
RXRalpha	B-protein	O
)	O	O
expression	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
have	O	O
demonstrated	O	O
that	O	O
,	O	O
unlike	O	O
resting	B-cell_type	O
cells	I-cell_type	O
,	O	O
activation	O	O
of	O	O
cycling	B-cell_line	O
human	I-cell_line	O
mature	I-cell_line	O
PBT	I-cell_line	O
lymphocytes	I-cell_line	O
,	I-cell_line	O
and	I-cell_line	O
T	I-cell_line	O
lymphocyte	I-cell_line	O
leukemia	O	O
cell	O	O
lines	O	O
is	O	O
accompanied	O	O
by	O	O
the	O	O
accumulation	O	O
of	O	O
RXRalpha	O	O
mRNA	I-RNA	O
and	O	O
protein	O	O
.	O	O

Interestingly	O	O
,	O	O
cyclosporin	O	O
A	O	O
further	O	O
augmented	O	O
RXRalpha	O	O
expression	O	O
,	O	O
indicating	O	O
the	O	O
involvement	O	O
of	O	O
calcineurin	O	O
pathways	O	O
in	O	O
the	O	O
process	O	O
.	O	O

9-cis	O	O
retinoic	O	O
acid	O	O
inhibited	O	O
the	O	O
accumulation	O	O
,	O	O
suggesting	O	O
that	O	O
retinoids	O	O
can	O	O
regulate	O	O
the	O	O
synthesis	O	O
of	O	O
their	O	O
own	O	O
receptors	O	O
during	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

Transfection	O	O
analysis	O	O
in	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
,	O	O
using	O	O
RXRE-dependent	O	O
reporter	O	O
assays	O	O
,	O	O
showed	O	O
that	O	O
RXRalpha	O	O
accumulated	O	O
during	O	O
T	O	O
cell	O	O
activation	O	O
was	O	O
transcriptionally	O	O
inactive	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
mechanism	O	O
of	O	O
such	O	O
inhibition	O	O
,	O	O
the	O	O
role	O	O
of	O	O
two	O	O
mitogen-activated	B-protein	O
protein	I-protein	O
kinase	I-protein	O
pathways	O	O
,	O	O
c-Jun	B-protein	O
N-terminal	I-protein	O
kinase	I-protein	O
(	O	O
JNK	B-protein	O
)	O	O
and	O	O
extracellular	O	O
signal-regulated	O	O
kinase	O	O
(	O	O
ERK	O	O
)	O	O
,	O	O
in	O	O
modulating	O	O
RXRE-dependent	O	O
transcription	O	O
,	O	O
was	O	O
explored	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
constitutively	O	O
active	O	O
MAP/ERK	B-protein	O
kinase	I-protein	O
kinase	I-protein	O
1	I-protein	O
(	O	O
MEKK1	O	O
)	O	O
inhibited	O	O
RXRE-dependent	O	O
transcription	O	O
,	O	O
whereas	O	O
dominant	O	O
negative	O	O
MEKK1	O	O
increased	O	O
the	O	O
transcription	O	O
,	O	O
indicating	O	O
the	O	O
involvement	O	O
of	O	O
JNK	O	O
signaling	O	O
pathways	O	O
in	O	O
the	O	O
process	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
expression	O	O
of	O	O
constitutively	O	O
active	O	O
MEK1	O	O
,	O	O
which	O	O
activates	O	O
ERK	O	O
pathway	O	O
,	O	O
enhanced	O	O
RXRE-dependent	O	O
activation	O	O
.	O	O

When	O	O
both	O	O
were	O	O
activated	O	O
simultaneously	O	O
,	O	O
JNK	O	O
pathway	O	O
was	O	O
dominant	O	O
over	O	O
ERK	O	O
pathway	O	O
and	O	O
resulted	O	O
in	O	O
inhibition	O	O
of	O	O
RXRE-mediated	O	O
transcription	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
a	O	O
dual	O	O
regulatory	O	O
control	O	O
of	O	O
RXRalpha	O	O
expression	O	O
during	O	O
the	O	O
activation	O	O
of	O	O
resting	O	O
and	O	O
cycling	O	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
indicate	O	O
a	O	O
dynamic	O	O
balance	O	O
between	O	O
JNK	O	O
and	O	O
ERK	O	O
pathways	O	O
in	O	O
modulating	O	O
RXRE-mediated	O	O
transactivation	O	O
.	O	O

The	O	O
proteasome	O	O
regulates	O	O
receptor-mediated	O	O
endocytosis	O	O
of	O	O
interleukin-2	B-protein	O
.	O	O

Recent	O	O
studies	O	O
have	O	O
increasingly	O	O
implicated	O	O
the	O	O
proteasome	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
cell	O	O
surface	B-protein	O
receptors	I-protein	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
role	O	O
of	O	O
the	O	O
proteasome	B-DNA	O
for	O	O
ligand-dependent	O	O
endocytosis	O	O
and	O	O
degradation	O	O
of	O	O
the	O	O
interleukin-2	B-protein	O
(	O	O
IL-2	B-protein	O
)	O	O
-interleukin-2	B-protein	O
receptor	I-protein	O
(	O	O
IL-2R	B-protein	O
)	O	O
complex	I-protein	O
.	O	O

Proteasome	O	O
inhibitors	O	O
impaired	O	O
internalization	O	O
of	O	O
IL-2.IL-2R	O	O
and	O	O
prevented	O	O
the	O	O
lysosomal	O	O
degradation	O	O
of	O	O
this	O	O
cytokine	B-protein	O
.	O	O

Based	O	O
on	O	O
time-course	O	O
studies	O	O
,	O	O
proteasome	O	O
activity	O	O
is	O	O
primarily	O	O
required	O	O
after	O	O
initial	O	O
endocytosis	O	O
of	O	O
the	O	O
IL-2.IL-2R	O	O
.	O	O

Proteasome	O	O
function	O	O
was	O	O
also	O	O
necessary	O	O
for	O	O
the	O	O
lysosomal	O	O
degradation	O	O
of	O	O
IL-2	B-protein	O
internalized	O	O
by	O	O
IL-2R	O	O
that	O	O
were	O	O
comprised	O	O
of	O	O
cytoplasmic	O	O
tailless	O	O
beta-	O	O
or	O	O
gamma	O	O
c-subunits	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
target	O	O
protein	O	O
for	O	O
the	O	O
proteasome	B-DNA	O
is	O	O
independent	O	O
of	O	O
either	O	O
the	O	O
cytoplasmic	B-protein	O
tail	O	O
of	O	O
the	O	O
IL-2R	B-protein	O
beta-	I-protein	O
or	I-protein	O
gamma	I-protein	O
c-subunits	I-protein	O
and	O	O
their	O	O
associated	O	O
signaling	O	O
components	O	O
.	O	O

Therefore	O	O
,	O	O
a	O	O
functional	O	O
proteasome	B-DNA	O
is	O	O
required	O	O
for	O	O
optimal	O	O
endocytosis	O	O
of	O	O
the	O	O
IL-2R/ligand	B-protein	O
complex	I-protein	O
and	O	O
is	O	O
essential	O	O
for	O	O
the	O	O
subsequent	O	O
lysosomal	O	O
degradation	O	O
of	O	O
IL-2	B-protein	O
,	O	O
possibly	O	O
by	O	O
regulating	O	O
trafficking	O	O
to	O	O
the	O	O
lysosome	O	O
.	O	O

Functional	O	O
characterization	O	O
of	O	O
the	O	O
two	O	O
alternative	O	O
promoters	O	O
of	O	O
human	B-DNA	O
p45	I-DNA	O
NF-E2	I-DNA	O
gene	I-DNA	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
transcription	B-protein	O
factor	I-protein	O
NF-E2	O	O
,	O	O
a	O	O
heterodimeric	B-protein	O
protein	I-protein	O
complex	I-protein	O
composed	O	O
of	O	O
p45	O	O
and	O	O
small	B-protein	O
Maf	I-protein	O
family	I-protein	O
proteins	I-protein	O
,	O	O
is	O	O
considered	O	O
crucial	O	O
for	O	O
the	O	O
proper	O	O
differentiation	O	O
of	O	O
erythrocytes	O	O
and	O	O
megakaryocytes	O	O
in	O	O
vivo	O	O
.	O	O

We	O	O
report	O	O
the	O	O
results	O	O
of	O	O
studies	O	O
aimed	O	O
at	O	O
understanding	O	O
the	O	O
regulatory	O	O
mechanisms	O	O
controlling	O	O
p45	O	O
gene	O	O
expression	O	O
in	O	O
erythroid	B-cell_type	O
cells	I-cell_type	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Human	O	O
p45	O	O
mRNAs	O	O
have	O	O
two	O	O
alternative	O	O
isoforms	O	O
,	O	O
aNF-E2	O	O
and	O	O
fNF-E2	O	O
,	O	O
and	O	O
these	O	O
isoforms	O	O
are	O	O
transcribed	O	O
from	O	O
the	O	O
alternative	B-DNA	O
promoters	I-DNA	O
.	O	O

We	O	O
investigated	O	O
lineage-specific	O	O
expression	O	O
of	O	O
both	O	O
isomers	O	O
in	O	O
human	B-cell_type	O
erythroid	I-cell_type	O
and	I-cell_type	O
megakaryocytic	I-cell_type	O
cells	I-cell_type	O
by	O	O
reverse	O	O
transcriptase	O	O
polymerase	O	O
chain	O	O
reaction	O	O
or	O	O
Northern	O	O
blot	O	O
analysis	O	O
.	O	O

For	O	O
functional	O	O
characterization	O	O
of	O	O
both	O	O
promoters	B-DNA	O
,	O	O
plasmids	O	O
in	O	O
which	O	O
reporter	B-DNA	O
genes	I-DNA	O
were	O	O
placed	O	O
under	O	O
the	O	O
control	O	O
of	O	O
a	O	O
series	O	O
of	O	O
truncated	B-protein	O
or	O	O
mutated	O	O
promoter	O	O
fragments	O	O
were	O	O
transfected	O	O
to	O	O
human	B-cell_type	O
hematopoietic	I-cell_type	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

RESULTS	O	O
:	O	O
When	O	O
CD34	O	O
(	O	O
+	O	O
)	O	O
cells	O	O
isolated	O	O
from	O	O
human	O	O
cord	O	O
blood	O	O
were	O	O
induced	O	O
to	O	O
unilineage	O	O
erythroid	O	O
or	O	O
megakaryocytic	O	O
differentiation	O	O
in	O	O
liquid	O	O
suspension	O	O
culture	O	O
,	O	O
both	O	O
transcripts	O	O
,	O	O
although	O	O
barely	O	O
detected	O	O
at	O	O
day	O	O
0	O	O
,	O	O
were	O	O
induced	O	O
in	O	O
both	O	O
erythroid	O	O
and	O	O
megakaryocytic	O	O
cultures	O	O
.	O	O

fNF-E2	O	O
mRNA	I-RNA	O
was	O	O
found	O	O
to	O	O
be	O	O
more	O	O
abundant	O	O
in	O	O
erythroid	B-cell_type	O
cells	I-cell_type	O
than	O	O
megakaryocytic	B-cell_type	O
cells	I-cell_type	O
at	O	O
day	O	O
7	O	O
of	O	O
culture	O	O
.	O	O

Although	O	O
both	O	O
isomers	O	O
were	O	O
expressed	O	O
in	O	O
human	B-cell_line	O
erythroid-megakaryocytic	I-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
,	O	O
megakaryocytic	O	O
maturation	O	O
with	O	O
loss	O	O
of	O	O
erythroid	O	O
phenotype	O	O
induced	O	O
by	O	O
phorbol	O	O
12-myristate	O	O
13-acetate	O	O
(	O	O
PMA	O	O
)	O	O
resulted	O	O
in	O	O
exclusive	O	O
downregulation	O	O
of	O	O
fNF-E2	O	O
,	O	O
suggesting	O	O
that	O	O
fNF-E2	O	O
promoter	O	O
is	O	O
more	O	O
erythroid	O	O
specific	O	O
.	O	O

Functional	O	O
analysis	O	O
of	O	O
fNF-E2	O	O
promoter	O	O
showed	O	O
that	O	O
the	O	O
promoter	O	O
is	O	O
active	O	O
only	O	O
in	O	O
erythroid-megakaryocytic	B-cell_type	O
cells	I-cell_type	O
and	O	O
that	O	O
the	O	O
double	O	O
GATA	O	O
sit	O	O
e	O	O
in	O	O
the	O	O
proximal	B-DNA	O
region	I-DNA	O
is	O	O
necessary	O	O
for	O	O
its	O	O
efficient	O	O
activity	O	O
.	O	O

CONCLUSION	O	O
:	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
GATA	B-protein	O
proteins	I-protein	O
,	O	O
which	O	O
govern	O	O
the	O	O
differentiation	O	O
of	O	O
erythroid	B-cell_type	O
lineage	I-cell_type	O
cells	I-cell_type	O
,	O	O
are	O	O
required	O	O
for	O	O
full	O	O
promoter	O	O
activity	O	O
of	O	O
the	O	O
p45	B-DNA	O
gene	I-DNA	O
.	O	O

Transcriptional	O	O
activation	O	O
of	O	O
heme	O	O
oxygenase-1	O	O
and	O	O
its	O	O
functional	O	O
significance	O	O
in	O	O
acetaminophen-induced	O	O
hepatitis	O	O
and	O	O
hepatocellular	O	O
injury	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

BACKGROUND/AIM	O	O
:	O	O
Glutathione	O	O
depletion	O	O
contributes	O	O
to	O	O
acetaminophen	O	O
hepatotoxicity	O	O
and	O	O
is	O	O
known	O	O
to	O	O
induce	O	O
the	O	O
oxidative	O	O
stress	O	O
reactant	O	O
heme	O	O
oxygenase-1	O	O
.	O	O

The	O	O
metabolites	O	O
of	O	O
the	O	O
heme	B-protein	O
oxygenase	I-protein	O
pathway	I-protein	O
,	O	O
biliverdin	O	O
,	O	O
carbon	O	O
monoxide	O	O
,	O	O
and	O	O
iron	O	O
may	O	O
modulate	O	O
acetaminophen	O	O
toxicity	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
cell-type	O	O
specific	O	O
expression	O	O
of	O	O
heme	O	O
oxygenase-1	O	O
and	O	O
its	O	O
impact	O	O
on	O	O
liver	O	O
injury	O	O
and	O	O
microcirculatory	O	O
disturbances	O	O
in	O	O
a	O	O
model	O	O
of	O	O
acetaminophen-induced	O	O
hepatitis	O	O
.	O	O

METHODS	O	O
:	O	O
Gene	O	O
expression	O	O
of	O	O
heme	O	O
oxygenase-1	O	O
was	O	O
studied	O	O
by	O	O
Northern-	O	O
and	O	O
Western	O	O
analysis	O	O
as	O	O
well	O	O
as	O	O
immunohistochemistry	O	O
.	O	O

The	O	O
time	O	O
course	O	O
of	O	O
heme	O	O
oxygenase-1	O	O
and	O	O
-2	O	O
,	O	O
cytokine-induced	O	O
neutrophil	O	O
chemoattractant-1	O	O
,	O	O
and	O	O
intercellular	O	O
adhesion	O	O
molecule-1	O	O
was	O	O
studied	O	O
by	O	O
Northern	O	O
analysis	O	O
.	O	O

DNA-binding	O	O
activity	O	O
of	O	O
nuclear	O	O
factor-kappaB	O	O
was	O	O
determined	O	O
by	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
.	O	O

Sinusoidal	O	O
perfusion	O	O
and	O	O
leukocyte-endothelial	O	O
interactions	O	O
were	O	O
assessed	O	O
by	O	O
intravital	O	O
microscopy	O	O
.	O	O

RESULTS	O	O
:	O	O
Acetaminophen	O	O
caused	O	O
a	O	O
moderate	O	O
sinusoidal	O	O
perfusion	O	O
failure	O	O
(	O	O
-15	O	O
%	O	O
)	O	O
and	O	O
infiltration	O	O
of	O	O
neutrophils	O	O
along	O	O
with	O	O
activation	O	O
of	O	O
nuclear	B-protein	O
factor-kappaB	I-protein	O
and	O	O
intercellular	I-protein	O
adhesion	O	O
molecule-1	O	O
and	O	O
cytokine-induced	O	O
neutrophil	O	O
chemoattractant-1	O	O
mRNAs	O	O
.	O	O

Induction	O	O
of	O	O
heme	O	O
oxygenase-1	O	O
mRNA	I-RNA	O
and	O	O
protein	O	O
(	O	O
approximately	O	O
30-fold	O	O
)	O	O
in	O	O
hepatocytes	O	O
and	O	O
non-parenchymal	B-cell_type	O
cells	I-cell_type	O
paralleled	O	O
the	O	O
inflammatory	O	O
response	O	O
.	O	O

Blockade	O	O
of	O	O
heme	O	O
oxygenase	O	O
activity	O	O
with	O	O
tin-protoporphyrin-IX	O	O
abrogated	O	O
acetaminophen-induced	O	O
hepatic	O	O
neutrophil	O	O
accumulation	O	O
and	O	O
nuclear	O	O
factor-kappaB	O	O
activation	O	O
,	O	O
but	O	O
failed	O	O
to	O	O
affect	O	O
sinusoidal	O	O
perfusion	O	O
and	O	O
liver	O	O
injury	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
inflammatory	O	O
response	O	O
associated	O	O
with	O	O
acetaminophen	O	O
hepatotoxicity	O	O
is	O	O
modulated	O	O
by	O	O
the	O	O
parallel	O	O
induction	O	O
of	O	O
the	O	O
heme	B-DNA	O
oxygenase-1	I-DNA	O
gene	I-DNA	O
.	O	O

However	O	O
,	O	O
heme	O	O
oxygenase-1	O	O
has	O	O
no	O	O
permissive	O	O
effect	O	O
on	O	O
sinusoidal	O	O
perfusion	O	O
and	O	O
does	O	O
not	O	O
affect	O	O
liver	O	O
injury	O	O
in	O	O
this	O	O
model	O	O
.	O	O

These	O	O
data	O	O
argue	O	O
against	O	O
a	O	O
central	O	O
role	O	O
of	O	O
nuclear	O	O
factor-kappaB	O	O
activation	O	O
and	O	O
neutrophil	O	O
infiltration	O	O
as	O	O
perpetuating	O	O
factors	O	O
of	O	O
liver	O	O
injury	O	O
in	O	O
acetaminophen	O	O
toxicity	O	O
.	O	O

Tumor	O	O
necrosis	O	O
factor-alpha	O	O
-induced	O	O
proliferation	O	O
requires	O	O
synthesis	O	O
of	O	O
granulocyte-macrophage	B-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
.	O	O

OBJECTIVE	O	O
:	O	O
Tumor	O	O
necrosis	O	O
factor-	O	O
alpha	O	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
induces	O	O
a	O	O
variety	O	O
of	O	O
cellular	O	O
responses	O	O
,	O	O
some	O	O
of	O	O
them	O	O
being	O	O
at	O	O
least	O	O
seemingly	O	O
contradictory	O	O
.	O	O

Thus	O	O
,	O	O
we	O	O
set	O	O
out	O	O
to	O	O
find	O	O
differences	O	O
in	O	O
the	O	O
modes	O	O
of	O	O
proliferative	O	O
and	O	O
apoptotic	O	O
responses	O	O
to	O	O
TNF-	O	O
alpha	B-protein	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
screened	O	O
a	O	O
panel	O	O
of	O	O
acute	O	O
myeloid	O	O
leukemia-derived	I-cell_line	O
cell	I-cell_line	O
lines	O	O
for	O	O
TNF-	O	O
alpha	O	O
-responsiveness	O	O
.	O	O

In	O	O
two	O	O
lines	O	O
(	O	O
OCI-AML-1	O	O
,	O	O
OCI-AML-11	O	O
)	O	O
,	O	O
TNF-	O	O
alpha	O	O
acted	O	O
as	O	O
an	O	O
apoptotic	O	O
agent	O	O
;	O	O
in	O	O
others	O	O
(	O	O
HU-3	O	O
,	O	O
M-07e	O	O
,	O	O
TF-1	O	O
)	O	O
,	O	O
it	O	O
had	O	O
the	O	O
opposite	O	O
effect	O	O
,	O	O
preventing	O	O
apoptosis	O	O
and	O	O
inducing	O	O
proliferation	O	O
.	O	O

Direct	O	O
and	O	O
indirect	O	O
signaling	O	O
mechanisms	O	O
,	O	O
including	O	O
NF-kappaB	O	O
activation	O	O
and	O	O
cytokine	O	O
synthesis	O	O
,	O	O
were	O	O
analyzed	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
cell	O	O
lines	O	O
tested	O	O
expressed	O	O
TNF-	O	O
alpha	B-protein	O
receptors	O	O
I	O	O
and	O	O
II	O	O
and	O	O
responded	O	O
to	O	O
TNF-	O	O
alpha	O	O
by	O	O
upregulation	O	O
of	O	O
intercellular	B-protein	O
adhesion	I-protein	O
molecule-1	I-protein	O
.	O	O

In	O	O
contrast	O	O
to	O	O
granulocyte-macrophage	B-protein	O
colony-stimulating	I-protein	O
factor	I-protein	O
(	O	O
GM-CSF	B-protein	O
)	O	O
,	O	O
TNF-	O	O
alpha	O	O
did	O	O
not	O	O
activate	O	O
the	O	O
MAP	B-protein	O
kinase	I-protein	O
and	O	O
p70S6	O	O
kinase	O	O
pathways	O	O
.	O	O

Nevertheless	O	O
,	O	O
inhibitors	O	O
of	O	O
these	O	O
pathways	O	O
clearly	O	O
reduced	O	O
the	O	O
TNF-alpha	O	O
-induced	O	O
cell	O	O
growth	O	O
,	O	O
indicating	O	O
that	O	O
TNF-	O	O
alpha-proliferative	O	O
cells	O	O
produced	O	O
a	O	O
growth	O	O
factor	O	O
that	O	O
induced	O	O
proliferation	O	O
upon	O	O
stimulation	O	O
of	O	O
the	O	O
above	O	O
pathways	O	O
.	O	O

Anti-GM-CSF	O	O
antibodies	O	O
inhibited	O	O
the	O	O
TNF-alpha	O	O
-induced	O	O
growth	O	O
,	O	O
suggesting	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
autocrine	O	O
loop	O	O
for	O	O
cell	O	O
proliferation	O	O
mediated	O	O
by	O	O
GM-CSF	B-protein	O
.	O	O

Supporting	O	O
this	O	O
notion	O	O
,	O	O
TNF-alpha	O	O
-induced	O	O
upregulation	O	O
of	O	O
GM-CSF	B-RNA	O
mRNA	I-RNA	O
levels	O	O
and	O	O
protein	O	O
secretion	O	O
in	O	O
the	O	O
TNF-alpha	O	O
-proliferative	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
TNF-alpha-apoptotic	B-cell_line	O
cell	I-cell_line	O
lines	I-cell_line	O
.	O	O

CONCLUSION	O	O
:	O	O
These	O	O
data	O	O
identify	O	O
GM-CSF	O	O
synthesis	O	O
as	O	O
an	O	O
early	O	O
and	O	O
essential	O	O
step	O	O
in	O	O
TNF-	O	O
alpha-induced	O	O
proliferation	O	O
.	O	O

We	O	O
show	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
TNF-alpha-treated	O	O
cell	O	O
lines	O	O
producing	O	O
no	O	O
or	O	O
only	O	O
minimal	O	O
amounts	O	O
of	O	O
GM-CSF	O	O
demonstrate	O	O
an	O	O
apoptotic	O	O
phenotype	O	O
,	O	O
while	O	O
cell	O	O
lines	O	O
with	O	O
high	O	O
GM-CSF	O	O
expression	O	O
rates	O	O
can	O	O
escape	O	O
from	O	O
growth	O	O
arrest	O	O
or	O	O
even	O	O
apoptosis	O	O
.	O	O

In	O	O
this	O	O
context	O	O
,	O	O
we	O	O
discuss	O	O
arguments	O	O
pointing	O	O
at	O	O
NF-kappaB	O	O
as	O	O
regulator	O	O
of	O	O
GM-CSF	O	O
synthesis	O	O
and	O	O
thus	O	O
indirectly	O	O
as	O	O
regulator	O	O
for	O	O
the	O	O
escape	O	O
of	O	O
TNF-alpha	O	O
-induced	O	O
apoptosis	O	O

Glucocorticoid	O	O
receptor	I-protein	O
content	O	O
of	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
:	O	O
evidence	O	O
for	O	O
heterogeneity	O	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
were	O	O
measured	O	O
in	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
that	O	O
were	O	O
isolated	O	O
from	O	O
peripheral	O	O
blood	O	O
by	O	O
either	O	O
nylon	O	O
wool	O	O
filtration	O	O
or	O	O
E-rosette	O	O
sedimentation	O	O
.	O	O

T	B-cell_type	O
cells	I-cell_type	O
isolated	O	O
by	O	O
nylon	O	O
wool	O	O
filtration	O	O
specifically	O	O
bind	O	O
6.7	O	O
+/-	O	O
0.2	O	O
fmol	O	O
of	O	O
dexamethasone	O	O
per	O	O
million	O	O
cells	O	O
(	O	O
equivalent	O	O
to	O	O
4000	O	O
+/-	O	O
200	O	O
receptors	O	O
per	O	O
cell	O	O
)	O	O
,	O	O
whereas	O	O
T	O	O
cells	O	O
isolated	O	O
by	O	O
E-rosette	O	O
sedimentation	O	O
bind	O	O
12.0	O	O
+/-	O	O
0.7	O	O
fmol	O	O
of	O	O
dexamethasone	O	O
per	O	O
million	O	O
cells	O	O
(	O	O
equivalent	O	O
to	O	O
7200	O	O
+/-	O	O
400	O	O
receptors	O	O
per	O	O
cell	O	O
)	O	O
.	O	O

This	O	O
difference	O	O
in	O	O
the	O	O
amount	O	O
of	O	O
dexamethasone	O	O
bound	O	O
by	O	O
the	O	O
two	O	O
T	O	O
cell	O	O
preparations	O	O
was	O	O
significant	O	O
(	O	O
p	O	O
less	O	O
than	O	O
.001	O	O
)	O	O
and	O	O
was	O	O
present	O	O
immediately	O	O
after	O	O
cell	O	O
isolation	O	O
.	O	O

The	O	O
binding	O	O
affinities	O	O
of	O	O
the	O	O
different	B-DNA	O
T	I-DNA	O
cell	O	O
preparations	O	O
for	O	O
dexamethasone	O	O
were	O	O
similar	O	O
.	O	O

T	B-cell_type	O
cells	I-cell_type	O
that	O	O
are	O	O
isolated	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
nylon	O	O
wool	O	O
filtration	O	O
followed	O	O
by	O	O
E-rosette	O	O
sedimentation	O	O
bind	O	O
the	O	O
same	O	O
amount	O	O
of	O	O
dexamethasone	O	O
as	O	O
T	B-cell_type	O
cells	I-cell_type	O
isolated	O	O
by	O	O
nylon	O	O
wool	O	O
filtration	O	O
alone	O	O
.	O	O

T	B-cell_type	O
cells	I-cell_type	O
isolated	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
E-rosette	O	O
sedimentation	O	O
following	O	O
by	O	O
nylon	O	O
wool	O	O
filtration	O	O
bind	O	O
less	O	O
dexamethasone	O	O
than	O	O
do	O	O
T	B-cell_type	O
cells	I-cell_type	O
isolated	O	O
by	O	O
E-rosette	O	O
sedimentation	O	O
alone	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
T	B-cell_type	O
cells	I-cell_type	O
are	O	O
heterogeneous	O	O
with	O	O
respect	O	O
to	O	O
their	O	O
quantity	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
.	O	O

Isolation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
by	O	O
E-rosette	O	O
sedimentation	O	O
enriches	O	O
for	O	O
T	B-cell_type	O
cells	I-cell_type	O
that	O	O
have	O	O
a	O	O
greater	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
,	O	O
and	O	O
isolation	O	O
of	O	O
T	B-cell_type	O
cells	I-cell_type	O
by	O	O
nylon	O	O
wool	O	O
filtration	O	O
enriches	O	O
for	O	O
T	B-cell_type	O
cells	I-cell_type	O
that	O	O
have	O	O
a	O	O
lesser	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
and	O	O
glucocorticoid	O	O
sensitivity	O	O
of	O	O
human	B-cell_type	O
leukemic	I-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
have	O	O
established	O	O
optimal	O	O
conditions	O	O
for	O	O
the	O	O
measurement	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
in	O	O
human	B-cell_type	O
white	I-cell_type	O
cells	I-cell_type	O
using	O	O
a	O	O
whole-cell	O	O
binding	O	O
assay	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone	O	O
as	O	O
the	O	O
ligand	O	O
,	O	O
and	O	O
the	O	O
subsequent	O	O
determination	O	O
of	O	O
the	O	O
GR	B-protein	O
content	O	O
in	O	O
normal	B-cell_type	O
human	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
in	O	O
leukemic	B-cell_type	O
cells	I-cell_type	O
of	O	O
patients	O	O
with	O	O
various	O	O
forms	O	O
of	O	O
acute	O	O
and	O	O
chronic	O	O
leukemia	O	O
.	O	O

A	O	O
number	O	O
of	O	O
leukemia	O	O
cell	O	O
lines	O	O
in	O	O
continuous	O	O
culture	O	O
were	O	O
also	O	O
subjected	O	O
to	O	O
the	O	O
GR	O	O
assay	O	O
,	O	O
and	O	O
the	O	O
results	O	O
were	O	O
correlated	O	O
with	O	O
the	O	O
sensitivity	O	O
of	O	O
these	O	O
cell	O	O
lines	O	O
to	O	O
glucocorticoid	O	O
steroids	O	O
in	O	O
vitro	O	O
.	O	O

The	O	O
GR	O	O
content	O	O
of	O	O
normal	B-cell_type	O
human	I-cell_type	O
lymphocytes	I-cell_type	O
amounted	O	O
to	O	O
4	O	O
,	O	O
850	O	O
+/-	O	O
1	O	O
,	O	O
340	O	O
(	O	O
mean	O	O
+/-	O	O
SD	O	O
)	O	O
receptors/cell	O	O
.	O	O

The	O	O
mean	O	O
equilibrium	O	O
dissociation	O	O
constant	O	O
(	O	O
KD	O	O
)	O	O
of	O	O
the	O	O
interaction	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone	O	O
with	O	O
the	O	O
GR	B-protein	O
was	O	O
1.2	O	O
x	O	O
10	O	O
(	O	O
-8	O	O
)	O	O
M	O	O
.	O	O

Steroidal	O	O
compounds	O	O
with	O	O
a	O	O
known	O	O
glucocorticoid	O	O
potency	O	O
effectively	O	O
competed	O	O
for	O	O
the	O	O
binding	O	O
,	O	O
whereas	O	O
steroids	O	O
devoid	O	O
of	O	O
glucocorticoid	O	O
activity	O	O
(	O	O
e.g.	O	O
estradiol-17	O	O
beta	O	O
and	O	O
testosterone	O	O
)	O	O
were	O	O
ineffective	O	O
.	O	O

The	O	O
GR	O	O
content	O	O
of	O	O
the	O	O
blast	B-cell_type	O
cells	I-cell_type	O
obtained	O	O
from	O	O
eight	O	O
patients	O	O
suffering	O	O
from	O	O
acute	O	O
leukemia	O	O
and	O	O
four	O	O
patients	O	O
with	O	O
a	O	O
blast	O	O
crisis	O	O
of	O	O
chronic	O	O
myelocytic	O	O
leukemia	O	O
was	O	O
found	O	O
to	O	O
be	O	O
highly	O	O
variable	O	O
(	O	O
3	O	O
,	O	O
230-29	O	O
,	O	O
900	O	O
receptors/cell	O	O
)	O	O
,	O	O
while	O	O
the	O	O
lymphocytes	O	O
of	O	O
six	O	O
patients	O	O
with	O	O
chronic	O	O
lymphatic	O	O
leukemia	O	O
contained	O	O
a	O	O
rather	O	O
stable	O	O
GR	O	O
content	O	O
(	O	O
2	O	O
,	O	O
930-5	O	O
,	O	O
120	O	O
receptors/cell	O	O
)	O	O
,	O	O
which	O	O
was	O	O
comparable	O	O
with	O	O
that	O	O
of	O	O
normal	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

GR	O	O
was	O	O
identified	O	O
in	O	O
all	O	O
the	O	O
12	B-cell_line	O
malignant	I-cell_line	O
continuous	I-cell_line	O
white	I-cell_line	O
cell	I-cell_line	O
lines	O	O
studied	O	O
.	O	O

Large	B-cell_type	O
cells	I-cell_type	O
contained	O	O
more	O	O
GR	O	O
than	O	O
the	O	O
smaller	O	O
ones	O	O
.	O	O

There	O	O
was	O	O
no	O	O
apparent	O	O
correlation	O	O
between	O	O
the	O	O
GR	O	O
concentration	O	O
and	O	O
the	O	O
sensitivity	O	O
of	O	O
the	O	O
cells	O	O
in	O	O
vitro	O	O
to	O	O
glucocorticoids	O	O
as	O	O
judged	O	O
by	O	O
[	O	O
3H	O	O
]	O	O
thymidine	O	O
incorporation	O	O
studies	O	O
.	O	O

Distribution	O	O
of	O	O
the	O	O
surface	O	O
markers	O	O
in	O	O
the	O	O
leukemic	B-protein	O
cell	I-cell_line	O
lines	I-cell_line	O
did	O	O
not	O	O
relate	O	O
to	O	O
the	O	O
GR	O	O
concentration	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
presence	O	O
of	O	O
GR	B-protein	O
is	O	O
probably	O	O
a	O	O
universal	O	O
feature	O	O
of	O	O
the	O	O
leukemic	B-cell_type	O
cells	I-cell_type	O
,	O	O
and	O	O
,	O	O
from	O	O
a	O	O
clinical	O	O
standpoint	O	O
,	O	O
probably	O	O
does	O	O
not	O	O
alone	O	O
imply	O	O
steroid	O	O
responsiveness	O	O
.	O	O

Evidence	O	O
for	O	O
a	O	O
steroid	O	O
receptor	I-protein	O
in	O	O
rheumatoid	B-cell_line	O
synovial	I-cell_line	O
tissue	I-cell_line	O
cells	I-cell_line	O
.	O	O

One	O	O
mechanism	O	O
by	O	O
which	O	O
glucocorticoids	O	O
could	O	O
exert	O	O
their	O	O
anti-inflammatory	O	O
action	O	O
is	O	O
via	O	O
rapidly	O	O
saturable	O	O
,	O	O
stereo-specific	O	O
cytoplasmic	B-protein	O
protein	I-protein	O
receptors	I-protein	O
.	O	O

This	O	O
report	O	O
is	O	O
of	O	O
an	O	O
investigation	O	O
into	O	O
such	O	O
a	O	O
possibility	O	O
in	O	O
synovial	B-cell_line	O
cells	I-cell_line	O
.	O	O

Synovium	O	O
,	O	O
obtained	O	O
from	O	O
knee	O	O
joints	O	O
of	O	O
rheumatoid	O	O
patients	O	O
undergoing	O	O
surgery	O	O
,	O	O
was	O	O
incubated	O	O
with	O	O
clostridiopeptidase	O	O
A	O	O
and	O	O
trypsin-EDTA	O	O
to	O	O
obtain	O	O
cell	O	O
suspensions	O	O
.	O	O

These	O	O
,	O	O
together	O	O
with	O	O
cells	O	O
obtained	O	O
from	O	O
synovial	O	O
fluid	O	O
aspirated	O	O
from	O	O
patients	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
,	O	O
were	O	O
identified	O	O
by	O	O
electron	O	O
microscopy	O	O
.	O	O

Duplicate	O	O
samples	O	O
of	O	O
these	O	O
cell	O	O
suspensions	O	O
were	O	O
incubated	O	O
with	O	O
increasing	O	O
concentrations	O	O
of	O	O
H3Dexamethasone	O	O
(	O	O
1	O	O
x	I-protein	O
10	I-protein	O
(	O	O
-10	B-protein	O
)	O	O
M-1	O	O
x	O	O
10	O	O
(	O	O
-9	O	O
)	O	O
M	O	O
)	O	O
for	O	O
30	O	O
minutes	O	O
at	O	O
37	O	O
degrees	O	O
C	O	O
.	O	O

Analysis	O	O
of	O	O
the	O	O
proportion	O	O
of	O	O
steroid	O	O
bound	O	O
to	O	O
whole	B-cell_type	O
cells	I-cell_type	O
showed	O	O
evidence	O	O
for	O	O
specific	O	O
,	O	O
rapidly	O	O
saturable	O	O
,	O	O
receptors	O	O
in	O	O
the	O	O
cells	O	O
obtained	O	O
from	O	O
synovial	O	O
tissue	O	O
,	O	O
but	O	O
this	O	O
was	O	O
not	O	O
found	O	O
in	O	O
synovial	B-cell_line	O
fluid	I-cell_line	O
cells	I-cell_line	O
.	O	O

Electron	O	O
micrographs	O	O
showed	O	O
that	O	O
cells	O	O
obtained	O	O
from	O	O
synovial	O	O
tissue	O	O
consisted	O	O
of	O	O
synovial	O	O
fibroblast	O	O
-	O	O
and	O	O
macrophage-types	O	O
,	O	O
lymphocytes	I-cell_type	O
,	O	O
monocytes	B-cell_type	O
and	O	O
macrophages	O	O
.	O	O

Polymorphonuclear	O	O
leucocytes	O	O
appeared	O	O
to	O	O
be	O	O
absent	O	O
.	O	O

However	O	O
,	O	O
in	O	O
synovial	O	O
fluid	O	O
cell	O	O
type	O	O
polymorphonuclear	O	O
leucocytes	O	O
were	O	O
the	O	O
predominant	O	O
cell	O	O
type	O	O
.	O	O

We	O	O
concluded	O	O
from	O	O
this	O	O
,	O	O
that	O	O
one	O	O
or	O	O
more	O	O
of	O	O
the	O	O
cell	I-cell_type	O
types	I-cell_type	O
present	O	O
in	O	O
synovial	O	O
tissue	O	O
contain	O	O
a	O	O
specific	O	O
steroid	O	O
receptor	I-protein	O
,	O	O
but	O	O
that	O	O
this	O	O
is	O	O
lacking	O	O
in	O	O
synovial	O	O
fluid	O	O
polymorphonuclear	O	O
leucocytes	O	O
.	O	O

Clinical	O	O
implications	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
human	O	O
leukemia	O	O
.	O	O

Glucorticoid	O	O
receptors	O	O
were	O	O
studied	O	O
in	O	O
various	O	O
populations	O	O
of	O	O
normal	B-cell_type	O
human	I-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
leukemic	O	O
lymphoblasts	O	O
.	O	O

Normal	O	O
lymphocytes	O	O
contain	O	O
low	O	O
levels	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
(	O	O
approximately	O	O
2	O	O
,	O	O
500	O	O
sites/cell	O	O
)	O	O
which	O	O
are	O	O
identical	O	O
in	O	O
T-	O	O
and	O	O
non-T-fractions	O	O
.	O	O

Phytohemagglutinin	O	O
treatment	O	O
increases	O	O
levels	O	O
about	O	O
3-fold	O	O
.	O	O

Leukemic	O	O
lymphoblasts	O	O
contain	O	O
larger	O	O
numbers	O	O
of	O	O
receptor	O	O
sites	O	O
.	O	O

Presence	O	O
of	O	O
receptor	O	O
is	O	O
correlated	O	O
with	O	O
in	O	O
vitro	O	O
sensitivitiy	O	O
to	O	O
glucocorticoids	O	O
and	O	O
in	O	O
vivo	O	O
response	O	O
to	O	O
therapy	O	O
.	O	O

Quantity	O	O
of	O	O
receptor	O	O
is	O	O
also	O	O
correlated	O	O
with	O	O
complete	O	O
remission	O	O
duration	O	O
independently	O	O
of	O	O
leukemic	O	O
cell	O	O
type	O	O
(	O	O
T	O	O
or	O	O
null	O	O
)	O	O
,	O	O
initial	O	O
WBC	O	O
,	O	O
or	O	O
age	O	O
of	O	O
patient	O	O
.	O	O

Quantitative	O	O
determination	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
levels	O	O
in	O	O
acute	O	O
lymphoblastic	O	O
leukemia	O	O
may	O	O
be	O	O
of	O	O
value	O	O
both	O	O
as	O	O
an	O	O
independent	O	O
prognostic	O	O
variable	O	O
and	O	O
in	O	O
suggesting	O	O
which	O	O
patients	O	O
should	O	O
receive	O	O
glucocorticoid	O	O
therapy	O	O
.	O	O

Functional	O	O
and	O	O
physical	O	O
interaction	O	O
of	O	O
protein-tyrosine	B-protein	O
kinases	I-protein	O
Fyn	O	O
and	O	O
Csk	O	O
in	O	O
the	O	O
T-cell	O	O
signaling	O	O
system	O	O
.	O	O

The	O	O
Src-like	B-protein	O
protein-tyrosine	I-protein	O
kinase	I-protein	O
Fyn	O	O
is	O	O
associated	O	O
with	O	O
T-cell	O	O
antigen	O	O
receptor	O	O
.	O	O

Transient	O	O
expression	O	O
of	O	O
actively	O	O
mutated	O	O
Fyn	O	O
,	O	O
having	O	O
Phe-528	O	O
instead	O	O
of	O	O
Tyr-528	O	O
or	O	O
Thr-338	O	O
instead	O	O
of	O	O
Ile-338	O	O
,	O	O
in	O	O
Jurkat	O	O
T-cells	O	O
stimulated	O	O
the	O	O
serum	B-DNA	O
response	I-DNA	O
element	I-DNA	O
(	O	O
SRE	O	O
)	O	O
,	O	O
12-O-tetradecanoyl-phorbol-13-acetate	O	O
response	O	O
element	O	O
,	O	O
cyclic	O	O
AMP	O	O
response	O	O
element	O	O
,	O	O
and	O	O
c-fos	B-DNA	O
promoter	I-DNA	O
.	O	O

The	O	O
stimulation	O	O
of	O	O
SRE	O	O
was	O	O
particularly	O	O
prominent	O	O
not	O	O
only	O	O
with	O	O
active	O	O
Fyn	O	O
but	O	O
also	O	O
with	O	O
normal	O	O
(	O	O
wild-type	O	O
)	O	O
Fyn	O	O
.	O	O

SRE	O	O
was	O	O
also	O	O
stimulated	O	O
by	O	O
both	O	O
normal	O	O
and	O	O
active	O	O
Lck	O	O
.	O	O

Furthermore	O	O
,	O	O
normal	O	O
and	O	O
active	O	O
Fyn	O	O
stimulated	O	O
transcription	O	O
from	O	O
the	O	O
IL-2	B-DNA	O
gene	I-DNA	O
promoter	I-DNA	O
when	O	O
transfected	B-cell_line	O
cells	I-cell_line	O
were	O	O
stimulated	O	O
by	O	O
concanavalin	O	O
A	O	O
plus	O	O
12-O-tetradecanoylphorbol-13-acetate	O	O
.	O	O

Under	O	O
the	O	O
same	O	O
conditions	O	O
,	O	O
Lck	O	O
did	O	O
not	O	O
stimulate	O	O
IL-2	O	O
promoter	O	O
unless	O	O
it	O	O
was	O	O
activated	O	O
by	O	O
mutation	O	O
.	O	O

Interestingly	O	O
,	O	O
a	O	O
mutant	O	O
Fyn	O	O
,	O	O
which	O	O
has	O	O
deletions	O	O
within	O	O
the	O	O
SH2	O	O
region	O	O
and	O	O
so	O	O
is	O	O
able	O	O
to	O	O
transform	O	O
chicken	O	O
embryo	O	O
fibroblasts	O	O
,	O	O
did	O	O
not	O	O
stimulate	O	O
either	O	O
the	O	O
c-fos	B-DNA	O
or	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
,	O	O
suggesting	O	O
the	O	O
importance	O	O
of	O	O
this	O	O
region	O	O
in	O	O
T-cell	O	O
signaling	O	O
.	O	O

Csk	O	O
,	O	O
which	O	O
phosphorylates	O	O
tyrosine	O	O
residues	O	O
in	O	O
the	O	O
negative	O	O
regulatory	O	O
sites	O	O
of	O	O
Src	O	O
family	I-protein	O
kinases	I-protein	O
,	O	O
down-regulated	O	O
Fyn-	O	O
and	O	O
Lck-mediated	O	O
stimulation	O	O
of	O	O
the	O	O
serum	B-DNA	O
response	I-DNA	O
element	I-DNA	O
and	O	O
Fyn-mediated	O	O
enhancement	O	O
of	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
activity	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
Fyn	O	O
and	O	O
Lck	O	O
,	O	O
whose	O	O
activities	O	O
are	O	O
regulated	O	O
by	O	O
Csk	O	O
,	O	O
are	O	O
involved	O	O
in	O	O
different	O	O
phases	O	O
of	O	O
T-cell	O	O
activation	O	O
.	O	O

A	O	O
novel	O	O
NF-kappa	B-protein	O
B	I-protein	O
complex	I-protein	O
containing	O	O
p65	O	O
homodimers	O	O
:	O	O
implications	O	O
for	O	O
transcriptional	O	O
control	O	O
at	O	O
the	O	O
level	O	O
of	O	O
subunit	O	O
dimerization	O	O
.	O	O

The	O	O
predominant	O	O
inducible	O	O
form	O	O
of	O	O
the	O	O
NF-kappa	B-protein	O
B	I-protein	O
transcription	I-protein	O
factor	I-protein	O
is	O	O
a	O	O
heteromeric	O	O
complex	O	O
containing	O	O
two	O	O
Rel-related	O	O
DNA-binding	B-protein	O
subunits	I-protein	O
,	O	O
termed	O	O
p65	B-protein	O
and	O	O
p50	B-protein	O
.	O	O

Prior	O	O
transfection	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
when	O	O
these	O	O
p65	B-protein	O
and	O	O
p50	B-protein	O
subunits	I-protein	O
are	O	O
expressed	O	O
independently	O	O
as	O	O
stable	O	O
homodimers	O	O
,	O	O
p65	B-protein	O
stimulates	O	O
kappa	O	O
B-directed	O	O
transcription	O	O
,	O	O
whereas	O	O
p50	O	O
functions	O	O
as	O	O
a	O	O
kappa	O	O
B-specific	O	O
repressor	I-protein	O
.	O	O

While	O	O
authentic	O	O
p50	B-protein	O
homodimers	O	O
(	O	O
previously	O	O
termed	O	O
KBF1	O	O
)	O	O
have	O	O
been	O	O
detected	O	O
in	O	O
nuclear	O	O
extracts	O	O
from	O	O
nontransfected	O	O
cells	O	O
,	O	O
experimental	O	O
evidence	O	O
supporting	O	O
the	O	O
existence	O	O
of	O	O
p65	O	O
homodimers	O	O
in	O	O
vivo	O	O
was	O	O
lacking	O	O
.	O	O

We	O	O
now	O	O
provide	O	O
direct	O	O
biochemical	O	O
evidence	O	O
for	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
endogenous	O	O
pool	O	O
of	O	O
inducible	O	O
p65	O	O
homodimers	O	O
in	O	O
intact	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

As	O	O
with	O	O
the	O	O
prototypical	O	O
NF-kappa	B-protein	O
B	I-protein	O
p50-p65	I-protein	O
heterodimer	I-protein	O
,	O	O
this	O	O
novel	O	O
p65	O	O
homodimeric	O	O
form	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
is	O	O
functionally	O	O
sequestered	O	O
in	O	O
the	O	O
cytoplasm	O	O
but	O	O
rapidly	O	O
appears	O	O
in	O	O
the	O	O
nuclear	O	O
compartment	O	O
following	O	O
cellular	O	O
stimulation	O	O
.	O	O

Site-directed	O	O
mutagenesis	O	O
studies	O	O
indicate	O	O
that	O	O
the	O	O
homodimerization	O	O
function	O	O
of	O	O
p65	B-protein	O
is	O	O
dependent	O	O
upon	O	O
the	O	O
presence	O	O
of	O	O
cysteine	O	O
216	O	O
and	O	O
a	O	O
conserved	O	O
recognition	I-protein	O
motif	I-protein	O
for	O	O
protein	I-protein	O
kinase	I-protein	O
A	O	O
(	O	O
RRPS	O	O
;	O	O
amino	O	O
acids	O	O
273	O	O
to	O	O
276	O	O
)	O	O
,	O	O
both	O	O
of	O	O
which	O	O
reside	O	O
within	O	O
a	O	O
91-amino-acid	O	O
segment	O	O
of	O	O
the	O	O
Rel	B-protein	O
homology	I-protein	O
domain	I-protein	O
that	O	O
mediates	O	O
self-association	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
mutations	O	O
at	O	O
these	O	O
two	O	O
sites	O	O
do	O	O
not	O	O
affect	O	O
heterodimerization	O	O
of	O	O
p65	O	O
with	O	O
p50	B-protein	O
or	O	O
its	O	O
functional	O	O
interaction	O	O
with	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
.	O	O

These	O	O
later	O	O
findings	O	O
indicate	O	O
that	O	O
neither	O	O
homo-	O	O
nor	O	O
heterodimer	O	O
formation	O	O
is	O	O
an	O	O
absolute	O	O
prerequisite	O	O
for	O	O
I	O	O
kappa	O	O
B	O	O
alpha	O	O
recognition	O	O
of	O	O
p65	B-protein	O
.	O	O

Taken	O	O
together	O	O
with	O	O
prior	O	O
in	O	O
vivo	O	O
transcription	O	O
studies	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
biological	O	O
activities	O	O
of	O	O
p65	B-protein	O
and	I-protein	O
p50	I-protein	O
homodimers	O	O
are	O	O
independently	O	O
regulated	O	O
,	O	O
thereby	O	O
providing	O	O
an	O	O
integrated	O	O
and	O	O
flexible	O	O
control	O	O
mechanism	O	O
for	O	O
the	O	O
rapid	O	O
activation	O	O
and	O	O
repression	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
/	O	O
Rel	O	O
-directed	O	O
gene	O	O
expression	O	O
.	O	O

Carrier	O	O
determination	O	O
for	O	O
X-linked	O	O
agammaglobulinemia	O	O
using	O	O
X	O	O
inactivation	O	O
analysis	O	O
of	O	O
purified	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
report	O	O
the	O	O
development	O	O
of	O	O
a	O	O
relatively	B-protein	O
quick	I-protein	O
and	O	O
simple	O	O
method	O	O
for	O	O
the	O	O
assessment	O	O
of	O	O
X	B-protein	O
inactivation	O	O
status	O	O
for	O	O
carrier	O	O
determination	O	O
in	O	O
families	O	O
affected	O	O
by	O	O
X-linked	O	O
agammaglobulinemia	O	O
(	O	O
XLA	O	O
)	O	O
.	O	O

This	O	O
method	O	O
utilises	O	O
an	O	O
immunomagnetic	O	O
separation	O	O
technique	O	O
for	O	O
B	O	O
cell	O	O
purification	O	O
and	O	O
a	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
based	O	O
assay	O	O
for	O	O
the	O	O
determination	O	O
of	O	O
methylation	O	O
status	O	O
at	O	O
the	O	O
androgen	B-DNA	O
receptor	I-DNA	O
(	O	O
AR	B-DNA	O
)	O	O
gene	O	O
locus	O	O
to	O	O
assess	O	O
whether	O	O
X	O	O
inactivation	O	O
is	O	O
random	O	O
or	O	O
non-random	O	O
at	O	O
this	O	O
locus	O	O
.	O	O

We	O	O
report	O	O
the	O	O
results	O	O
we	O	O
have	O	O
obtained	O	O
using	O	O
this	O	O
assay	O	O
to	O	O
investigate	O	O
females	O	O
known	O	O
to	O	O
be	O	O
carriers	O	O
of	O	O
various	O	O
X-linked	O	O
immunodeficiency	O	O
disorders	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
investigated	O	O
four	O	O
females	O	O
from	O	O
different	O	O
families	O	O
affected	O	O
by	O	O
XLA	O	O
,	O	O
two	O	O
of	O	O
whom	O	O
were	O	O
of	O	O
unknown	O	O
carrier	O	O
status	O	O
,	O	O
and	O	O
we	O	O
discuss	O	O
the	O	O
results	O	O
obtained	O	O
with	O	O
this	O	O
and	O	O
other	O	O
X-inactivation	O	O
assays	O	O
.	O	O

A	O	O
similar	O	O
assay	O	O
has	O	O
recently	O	O
been	O	O
described	O	O
by	O	O
Allen	O	O
et	O	O
al.	O	O
(	O	O
1992	O	O
)	O	O
and	O	O
applied	O	O
to	O	O
members	O	O
of	O	O
one	O	O
family	O	O
affected	O	O
by	O	O
XLA	O	O
.	O	O

Effects	O	O
of	O	O
IL-4	B-protein	O
and	O	O
Fc	B-protein	O
gamma	I-protein	O
receptor	I-protein	O
II	O	O
engagement	O	O
on	O	O
Egr-1	O	O
expression	O	O
during	O	O
stimulation	O	O
of	O	O
B	B-cell_type	O
lymphocytes	I-cell_type	O
by	O	O
membrane	O	O
immunoglobulin	O	O
crosslinking	O	O
.	O	O

Egr-1	O	O
is	O	O
an	O	O
immediate	B-DNA	O
early	I-DNA	O
gene	I-DNA	O
that	O	O
is	O	O
rapidly	O	O
upregulated	O	O
in	O	O
response	O	O
to	O	O
mitogenic	O	O
signals	O	O
induced	O	O
by	O	O
antigen	O	O
receptor	I-protein	O
crosslinking	O	O
on	O	O
murine	B-cell_type	O
B	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
levels	O	O
of	O	O
Egr-1	O	O
expression	O	O
are	O	O
closely	O	O
correlated	O	O
with	O	O
B	O	O
cell	O	O
proliferation	O	O
in	O	O
several	O	O
models	O	O
of	O	O
B	B-protein	O
cell	O	O
activation	O	O
and	O	O
tolerance	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
expression	O	O
of	O	O
Egr-1	O	O
during	O	O
B	O	O
cell	O	O
stimulation	O	O
with	O	O
Fab'2	O	O
and	O	O
IgG	B-protein	O
anti-immunoglobulin	I-protein	O
(	O	O
anti-Ig	B-protein	O
)	O	O
,	O	O
since	O	O
it	O	O
is	O	O
known	O	O
that	O	O
Fab'2	O	O
anti-Ig	O	O
is	O	O
mitogenic	O	O
while	O	O
IgG	O	O
anti-Ig	O	O
is	O	O
not	O	O
,	O	O
owing	O	O
to	O	O
a	O	O
dominant	O	O
inhibitory	O	O
effect	O	O
of	O	O
crosslinking	O	O
the	O	O
B	B-protein	O
cell	I-protein	O
Fc	I-protein	O
gamma	I-protein	O
RII	O	O
to	O	O
membrane	O	O
Ig	O	O
.	O	O

While	O	O
mitogenic	O	O
doses	O	O
of	O	O
Fab'2	O	O
anti-Ig	O	O
induce	O	O
large	O	O
and	O	O
rapid	O	O
increases	O	O
in	O	O
Egr-1	O	O
expression	O	O
,	O	O
IgG	O	O
anti-Ig	O	O
results	O	O
in	O	O
smaller	O	O
increases	O	O
in	O	O
Egr-1	O	O
mRNA	I-RNA	O
,	O	O
comparable	O	O
to	O	O
that	O	O
seen	O	O
with	O	O
submitogenic	O	O
concentrations	O	O
of	O	O
Fab'2	O	O
anti-Ig	O	O
.	O	O

However	O	O
,	O	O
the	O	O
correlation	O	O
between	O	O
Egr-1	O	O
expression	O	O
and	O	O
B	B-protein	O
cell	O	O
proliferation	O	O
breaks	O	O
down	O	O
when	O	O
IL-4	O	O
is	O	O
added	O	O
as	O	O
a	O	O
co-mitogen	O	O
to	O	O
induce	O	O
B	O	O
cell	O	O
proliferation	O	O
with	O	O
IgG	O	O
anti-Ig	O	O
or	O	O
submitogenic	O	O
concentrations	O	O
of	O	O
Fab'2	O	O
anti-Ig	O	O
.	O	O

No	O	O
corresponding	O	O
increases	O	O
in	O	O
Egr-1	O	O
mRNA	I-RNA	O
levels	O	O
are	O	O
observed	O	O
when	O	O
IL-4	O	O
is	O	O
added	O	O
.	O	O

Therefore	O	O
,	O	O
IL-4	O	O
overcomes	O	O
Fc	O	O
receptor-mediated	O	O
inhibition	O	O
of	O	O
B	B-protein	O
cell	O	O
proliferation	O	O
without	O	O
affecting	O	O
inhibition	O	O
of	O	O
Egr-1	O	O
mRNA	I-RNA	O
induction	O	O
,	O	O
as	O	O
demonstrated	O	O
earlier	O	O
for	O	O
c-myc	O	O
mRNA	I-RNA	O
in	O	O
this	O	O
system	O	O
.	O	O

Identification	O	O
of	O	O
a	O	O
novel	O	O
cyclosporin-sensitive	O	O
element	I-DNA	O
in	O	O
the	O	O
human	B-DNA	O
tumor	I-DNA	O
necrosis	I-DNA	O
factor	I-DNA	O
alpha	I-DNA	O
gene	I-DNA	O
promoter	I-DNA	O
.	O	O

Tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
alpha	I-protein	O
(	O	O
TNF-alpha	B-protein	O
)	O	O
,	O	O
a	O	O
cytokine	O	O
with	O	O
pleiotropic	O	O
biological	O	O
effects	O	O
,	O	O
is	O	O
produced	O	O
by	O	O
a	O	O
variety	O	O
of	O	O
cell	O	O
types	O	O
in	O	O
response	O	O
to	O	O
induction	O	O
by	O	O
diverse	O	O
stimuli	O	O
.	O	O

In	O	O
this	O	O
paper	O	O
,	O	O
TNF-alpha	O	O
mRNA	O	O
is	O	O
shown	O	O
to	O	O
be	O	O
highly	O	O
induced	O	O
in	O	O
a	O	O
murine	O	O
T	O	O
cell	O	O
clone	O	O
by	O	O
stimulation	O	O
with	O	O
T	B-protein	O
cell	I-protein	O
receptor	I-protein	O
(	O	O
TCR	B-protein	O
)	O	O
ligands	O	O
or	O	O
by	O	O
calcium	O	O
ionophores	O	O
alone	O	O
.	O	O

Induction	O	O
is	O	O
rapid	O	O
,	O	O
does	O	O
not	O	O
require	O	O
de	O	O
novo	O	O
protein	O	O
synthesis	O	O
,	O	O
and	O	O
is	O	O
completely	O	O
blocked	O	O
by	O	O
the	O	O
immunosuppressant	O	O
cyclosporin	O	O
A	O	O
(	O	O
CsA	O	O
)	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
a	O	O
human	B-DNA	O
TNF-alpha	I-DNA	O
promoter	I-DNA	O
element	I-DNA	O
,	O	O
kappa	B-DNA	O
3	I-DNA	O
,	O	O
which	O	O
plays	O	O
a	O	O
key	O	O
role	O	O
in	O	O
the	O	O
calcium-mediated	O	O
inducibility	O	O
and	O	O
CsA	O	O
sensitivity	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

In	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
,	O	O
an	O	O
oligonucleotide	O	O
containing	O	O
kappa	B-DNA	O
3	I-protein	O
forms	I-protein	O
two	O	O
DNA	B-protein	O
protein	I-protein	O
complexes	I-protein	O
with	I-protein	O
proteins	I-protein	O
that	O	O
are	O	O
present	O	O
in	O	O
extracts	O	O
from	O	O
unstimulated	B-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
.	O	O

These	O	O
complexes	O	O
appear	O	O
in	O	O
nuclear	O	O
extracts	O	O
only	O	O
after	O	O
T	O	O
cell	O	O
stimulation	O	O
.	O	O

Induction	O	O
of	O	O
the	O	O
inducible	O	O
nuclear	B-protein	O
complexes	I-protein	O
is	O	O
rapid	O	O
,	O	O
independent	O	O
of	O	O
protein	O	O
synthesis	O	O
,	O	O
and	O	O
blocked	O	O
by	O	O
CsA	O	O
,	O	O
and	O	O
thus	O	O
,	O	O
exactly	O	O
parallels	O	O
the	O	O
induction	O	O
of	O	O
TNF-alpha	O	O
mRNA	I-RNA	O
by	O	O
TCR	B-protein	O
ligands	O	O
or	O	O
by	O	O
calcium	O	O
ionophore	O	O
.	O	O

Our	O	O
studies	O	O
indicate	O	O
that	O	O
the	O	O
kappa	B-protein	O
3	I-protein	O
binding	I-protein	O
factor	I-protein	O
resembles	O	O
the	O	O
preexisting	O	O
component	O	O
of	O	O
nuclear	B-protein	O
factor	I-protein	O
of	O	O
activated	I-protein	O
T	I-protein	O
cells	I-cell_type	O
.	O	O

Thus	O	O
,	O	O
the	O	O
TNF-alpha	B-DNA	O
gene	I-DNA	O
is	O	O
an	O	O
immediate	B-DNA	O
early	I-DNA	O
gene	I-DNA	O
in	O	O
activated	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
and	O	O
provides	O	O
a	O	O
new	O	O
model	O	O
system	O	O
in	O	O
which	O	O
to	O	O
study	O	O
CsA-sensitive	O	O
gene	O	O
induction	O	O
in	O	O
activated	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

Differences	O	O
in	O	O
expression	O	O
of	O	O
transcription	B-protein	O
factor	I-protein	O
AP-1	B-protein	O
in	O	O
human	B-cell_type	O
promyelocytic	I-cell_type	O
HL-60	I-cell_type	O
cells	I-cell_type	O
during	O	O
differentiation	O	O
towards	O	O
macrophages	O	O
versus	O	O
granulocytes	O	O
.	O	O

Commitment	O	O
of	O	O
HL-60	B-cell_type	O
cells	I-cell_type	O
to	O	O
macrophage	O	O
or	O	O
granulocytic	O	O
differentiation	O	O
was	O	O
achieved	O	O
by	O	O
incubation	O	O
with	O	O
4	O	O
beta-phorbol	O	O
12-myristate	O	O
13-acetate	O	O
(	O	O
PMA	O	O
)	O	O
for	O	O
30-60	O	O
min	O	O
or	O	O
with	O	O
dimethyl	O	O
sulphoxide	O	O
(	O	O
DMSO	O	O
)	O	O
for	O	O
24	O	O
h	O	O
respectively	O	O
.	O	O

The	O	O
commitment	O	O
stage	O	O
towards	O	O
PMA-induced	O	O
macrophage	O	O
differentiation	O	O
was	O	O
associated	O	O
with	O	O
increases	O	O
in	O	O
jun	O	O
B	O	O
and	O	O
c-fos	B-RNA	O
mRNA	I-RNA	O
levels	O	O
,	O	O
as	O	O
well	O	O
as	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
binding	O	O
activity	O	O
of	O	O
transcription	B-protein	O
factor	I-protein	O
AP-1	B-protein	O
.	O	O

Nevertheless	O	O
,	O	O
gel	O	O
retardation	O	O
analysis	O	O
indicated	O	O
that	O	O
the	O	O
AP-1	O	O
activity	O	O
detected	O	O
in	O	O
untreated	B-cell_type	O
cells	I-cell_type	O
was	O	O
drastically	O	O
reduced	O	O
during	O	O
the	O	O
commitment	O	O
stage	O	O
of	O	O
DMSO-induced	O	O
HL-60	O	O
differentiation	O	O
towards	O	O
granulocytes	O	O
.	O	O

When	O	O
HL-60	B-cell_line	O
cells	I-cell_line	O
were	O	O
treated	O	O
with	O	O
sodium	O	O
butyrate	O	O
,	O	O
which	O	O
induced	O	O
monocytic	O	O
differentiation	O	O
,	O	O
a	O	O
remarkable	O	O
increase	O	O
in	O	O
AP-1	O	O
binding	O	O
activity	O	O
was	O	O
detected	O	O
.	O	O

Treatment	O	O
of	O	O
HL-60	O	O
cells	I-cell_type	O
with	O	O
1	B-protein	O
alpha	I-protein	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
,	O	O
another	O	O
monocytic	O	O
differentiation	O	O
agent	B-protein	O
,	O	O
induced	O	O
a	O	O
weak	O	O
,	O	O
but	O	O
appreciable	O	O
,	O	O
increase	O	O
in	O	O
AP-1	O	O
activity	O	O
.	O	O

Furthermore	O	O
,	O	O
addition	O	O
of	O	O
sodium	O	O
butyrate	O	O
or	O	O
1	O	O
alpha	I-protein	O
,	O	O
25-dihydroxyvitamin	O	O
D3	O	O
to	O	O
HL-60	O	O
cells	I-cell_type	O
induced	O	O
the	O	O
expression	O	O
of	O	O
c-fos	B-DNA	O
,	O	O
c-jun	O	O
,	O	O
jun	O	O
B	I-protein	O
and	O	O
jun	O	O
D	O	O
proto-oncogenes	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
when	O	O
HL-60	O	O
cells	I-cell_line	O
were	O	O
treated	O	O
with	O	O
retinoic	O	O
acid	O	O
,	O	O
a	O	O
granulocytic	O	O
differentiation	O	O
inducer	O	O
,	O	O
no	O	O
enhanced	O	O
AP-1	B-protein	O
binding	O	O
activity	O	O
was	O	O
observed	O	O
,	O	O
and	O	O
only	O	O
a	O	O
weak	O	O
increase	O	O
in	O	O
jun	O	O
D	O	O
mRNA	I-RNA	O
level	O	O
was	O	O
detected	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
formation	O	O
of	O	O
AP-1	B-protein	O
is	O	O
not	O	O
required	O	O
for	O	O
the	O	O
induction	O	O
of	O	O
HL-60	O	O
differentiation	O	O
towards	O	O
granulocytes	O	O
,	O	O
whereas	O	O
induction	O	O
of	O	O
monocytic	O	O
differentiation	O	O
is	O	O
correlated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
AP-1	O	O
activity	O	O
.	O	O

The	O	O
differential	O	O
expression	O	O
of	O	O
AP-1	B-protein	O
activity	O	O
may	O	O
be	O	O
critical	O	O
in	O	O
the	O	O
differentiation	O	O
of	O	O
HL-60	B-cell_type	O
cells	I-cell_type	O
towards	O	O
monocytic	O	O
or	O	O
granulocytic	O	O
lineages	O	O

Glucocorticoid	O	O
receptors	O	O
and	O	O
sensitivity	O	O
in	O	O
leukemias	O	O
.	O	O

In	O	O
an	O	O
attempt	O	O
to	O	O
investigate	O	O
the	O	O
utility	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
determination	O	O
to	O	O
predict	O	O
clinical	O	O
responsiveness	O	O
in	O	O
human	O	O
leukemias	O	O
we	O	O
have	O	O
studied	O	O
glucocorticoid	O	O
receptors	O	O
in	O	O
the	O	O
leukemic	B-cell_type	O
cells	I-cell_type	O
from	O	O
46	O	O
patients	O	O
and	O	O
in	O	O
the	O	O
lymphocytes	I-cell_type	O
from	O	O
18	O	O
normal	O	O
donors	O	O
.	O	O

In	O	O
the	O	O
normal	O	O
lymphocytes	O	O
there	O	O
were	O	O
3	O	O
,	O	O
875	O	O
(	O	O
Median	O	O
)	O	O
specific	O	O
binding	O	O
sites	O	O
per	O	O
cell	O	O
.	O	O

The	O	O
blasts	O	O
from	O	O
17	O	O
patients	O	O
with	O	O
ANLL	O	O
had	O	O
on	O	O
average	O	O
higher	O	O
levels	O	O
of	O	O
binding	O	O
sites	O	O
per	O	O
cell	O	O
(	O	O
Median	O	O
=	O	O
7	O	O
,	O	O
250	O	O
,	O	O
range	O	O
:	O	O
0	O	O
to	O	O
15	O	O
,	O	O
295	O	O
)	O	O
than	O	O
the	O	O
other	O	O
leukemias	O	O
.	O	O

Of	O	O
the	O	O
15	O	O
patients	O	O
with	O	O
CLL	O	O
,	O	O
six	O	O
had	O	O
received	O	O
glucocorticoid	O	O
treatment	O	O
for	O	O
3	O	O
to	O	O
5	O	O
years	O	O
.	O	O

Their	O	O
lymphocytes	O	O
had	O	O
lower	O	O
number	O	O
of	O	O
receptors	B-protein	O
(	O	O
Median	O	O
=	O	O
2	O	O
,	O	O
000	O	O
)	O	O
than	O	O
the	O	O
other	O	O
cases	O	O
which	O	O
were	O	O
newly	O	O
diagnosed	O	O
(	O	O
Median	O	O
=	O	O
4	O	O
,	O	O
500	O	O
)	O	O
.	O	O

Four	O	O
patients	O	O
had	O	O
ALL/AUL	O	O
,	O	O
three	O	O
patients	O	O
had	O	O
blast	O	O
crisis	O	O
as	O	O
terminal	O	O
phase	O	O
of	O	O
CML	O	O
,	O	O
and	O	O
seven	O	O
had	O	O
leukemic	O	O
Non-Hodgkin	O	O
lymphomas	O	O
(	O	O
Median	O	O
=	O	O
3	O	O
,	O	O
500	O	O
sites/cell	O	O
)	O	O
.	O	O

In	O	O
24	O	O
patients	O	O
we	O	O
have	O	O
also	O	O
studied	O	O
the	O	O
in	O	O
vitro	O	O
sensitivity	O	O
of	O	O
the	O	O
leukemic	B-cell_type	O
cells	I-cell_type	O
to	O	O
dexamethasone	O	O
.	O	O

There	O	O
was	O	O
no	O	O
marked	O	O
correlation	O	O
between	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
levels	O	O
and	O	O
in	O	O
vitro	O	O
sensitivity	O	O
.	O	O

An	O	O
attempt	O	O
to	O	O
correlate	O	O
receptor	O	O
levels	O	O
with	O	O
clinical	O	O
responsiveness	O	O
demonstrated	O	O
that	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
determination	O	O
might	O	O
be	O	O
of	O	O
value	O	O
in	O	O
patients	O	O
with	O	O
lymphoid	O	O
malignancies	O	O
but	O	O
probably	O	O
not	O	O
in	O	O
patients	O	O
with	O	O
other	O	O
leukemias	O	O
.	O	O

'Activation-labile	O	O
'	O	O
glucocorticoid-receptor	O	O
complexes	O	O
of	O	O
a	O	O
steroid-resistant	O	O
variant	O	O
of	O	O
CEM-C7	B-cell_type	O
human	I-cell_type	O
lymphoid	I-cell_type	O
cells	I-cell_type	O
.	O	O

For	O	O
cytoplasmic	O	O
glucocorticoid-receptor	O	O
complexes	O	O
to	O	O
enter	O	O
and	O	O
accumulate	O	O
in	O	O
the	O	O
nucleus	O	O
a	O	O
temperature-dependent	O	O
event	O	O
,	O	O
'activation	O	O
'	O	O
is	O	O
required	O	O
.	O	O

Activation	O	O
can	O	O
be	O	O
achieved	O	O
in	O	O
vitro	O	O
by	O	O
increased	O	O
ionic	O	O
strength	O	O
,	O	O
dilution	O	O
or	O	O
gel	O	O
filtration	O	O
and	O	O
is	O	O
manifested	O	O
by	O	O
an	O	O
increased	O	O
affinity	O	O
of	O	O
steroid-receptor	B-protein	O
complex	I-protein	O
for	O	O
DNA	O	O
and	O	O
an	O	O
altered	O	O
elution	O	O
profile	O	O
from	O	O
ion-exchange	O	O
resins	O	O
.	O	O

Munck	O	O
and	O	O
Foley	O	O
have	O	O
shown	O	O
that	O	O
activated	O	O
complexes	O	O
isolated	O	O
from	O	O
thymocytes	B-cell_type	O
elute	O	O
from	O	O
DEAE-cellulose	O	O
in	O	O
a	O	O
manner	O	O
identical	O	O
to	O	O
complexes	O	O
activated	O	O
in	O	O
vitro	O	O
.	O	O

We	O	O
report	O	O
here	O	O
that	O	O
DEAE-cellulose	O	O
chromatography	O	O
of	O	O
steroid-receptor	O	O
complexes	O	O
from	O	O
CEM-C7	O	O
,	O	O
a	O	O
cloned	O	O
human	O	O
leukaemic	O	O
T-cell	O	O
line	O	O
sensitive	O	O
to	O	O
the	O	O
cytolytic	O	O
action	O	O
of	O	O
glucocorticoids	O	O
,	O	O
and	O	O
its	O	O
steroid-resistant	O	O
subclone	O	O
4R4	O	O
demonstrated	O	O
that	O	O
steroid	O	O
receptors	O	O
of	O	O
clone	O	O
4R4	O	O
can	O	O
not	O	O
form	O	O
stable	O	O
activated	O	O
complexes	O	O
.	O	O

This	O	O
defines	O	O
a	O	O
new	O	O
defect	O	O
in	O	O
receptor	O	O
action	O	O
,	O	O
activation	O	O
lability	O	O
(	O	O
r+act1	O	O
)	O	O
,	O	O
which	O	O
is	O	O
unlike	O	O
either	O	O
the	O	O
r-	O	O
,	O	O
r+nt-	O	O
,	O	O
or	O	O
r+nti	O	O
phenotypes	O	O
previously	O	O
described	O	O
for	O	O
mouse	O	O
lymphoid	O	O
variants	O	O
.	O	O

Granulocytes	O	O
in	O	O
the	O	O
endometrium	O	O
of	O	O
post-partum	O	O
women	O	O
.	O	O

Endometrial	O	O
samples	O	O
of	O	O
women	O	O
at	O	O
various	O	O
stages	O	O
of	O	O
gonadal	O	O
activity	O	O
after	O	O
parturition	O	O
were	O	O
examined	O	O
for	O	O
the	O	O
presence	O	O
and	O	O
numbers	O	O
of	O	O
endometrial	O	O
granulocytes	O	O
.	O	O

Although	O	O
samples	O	O
at	O	O
all	O	O
the	O	O
stages	O	O
contained	O	O
significant	O	O
numbers	O	O
of	O	O
the	O	O
granulocytes	O	O
(	O	O
i.e.	I-DNA	O
greater	I-DNA	O
than	O	O
7/high-power	O	O
field	O	O
)	O	O
,	O	O
the	O	O
100	O	O
%	O	O
values	O	O
for	O	O
late-proliferative	O	O
and	O	O
adaptation	O	O
hyperplasia	O	O
were	O	O
significantly	O	O
higher	O	O
than	O	O
the	O	O
values	O	O
for	O	O
the	O	O
resting	O	O
(	O	O
81.8	O	O
%	O	O
)	O	O
,	O	O
early	O	O
(	O	O
82.4	O	O
%	O	O
)	O	O
and	O	O
mid-	O	O
(	O	O
87.9	O	O
%	O	O
)	O	O
proliferative	O	O
and	O	O
secretory	O	O
(	O	O
83.3	O	O
%	O	O
)	O	O
phases	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
this	O	O
correlates	O	O
with	O	O
the	O	O
suggestion	O	O
that	O	O
the	O	O
granulocytes	O	O
constitute	O	O
a	O	O
receptor	O	O
system	O	O
for	O	O
oestrogens	O	O
.	O	O

Interaction	O	O
of	O	O
glucocorticoids	O	O
with	O	O
macrophages	B-protein	O
.	O	O

Identification	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
monocytes	B-cell_type	O
and	O	O
macrophages	O	O
.	O	O

Glucocorticoid	O	O
binding	O	O
was	O	O
measured	O	O
in	O	O
resident	O	O
and	O	O
thioglycollate-elicited	O	O
mouse	O	O
peritoneal	O	O
macrophages	O	O
,	O	O
rabbit	O	O
alveolar	O	O
macrophages	O	O
,	O	O
and	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
.	O	O

Two	O	O
assays	O	O
of	O	O
binding	O	O
were	O	O
used	O	O
--	O	O
an	O	O
assay	O	O
with	O	O
intact	I-cell_type	O
cells	I-cell_type	O
in	O	O
suspension	O	O
or	O	O
monolayers	O	O
,	O	O
and	O	O
an	O	O
assay	O	O
of	O	O
cytosol	O	O
and	O	O
nuclear	O	O
forms	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
.	O	O

The	O	O
mononuclear	O	O
phagocytes	O	O
contained	O	O
approximately	O	O
equal	O	O
to	O	O
4	B-protein	O
--	O	O
10	O	O
X	B-protein	O
10	I-protein	O
(	O	O
3	B-protein	O
)	O	O
high	O	O
affinity	O	O
receptor	O	O
sites	O	O
per	O	O
cell	O	O
,	O	O
with	O	O
dissociation	O	O
constants	O	O
of	O	O
approximately	O	O
equal	O	O
to	O	O
2	O	O
--	O	O
8	O	O
nM	O	O
dexamethasone	O	O
.	O	O

The	O	O
binding	O	O
to	O	O
the	O	O
saturable	B-DNA	O
sites	I-DNA	O
was	O	O
specific	O	O
for	O	O
steroids	O	O
with	O	O
glucocorticoid	B-protein	O
or	O	O
antiglucocorticoid	O	O
activity	O	O
.	O	O

Cortisol	O	O
,	O	O
corticosterone	O	O
,	O	O
and	O	O
progesterone	O	O
competed	O	O
with	O	O
dexamethasone	O	O
for	O	O
binding	O	O
,	O	O
whereas	O	O
estradiol	O	O
,	O	O
dihydrotestosterone	O	O
,	O	O
and	O	O
11-epicortisol	O	O
competed	O	O
very	O	O
little	O	O
.	O	O

Binding	O	O
of	O	O
dexamethasone	O	O
to	O	O
cytosol	O	O
and	O	O
nuclear	O	O
forms	O	O
of	O	O
the	O	O
receptor	B-protein	O
complex	I-protein	O
and	O	O
temperature-sensitive	O	O
translocation	O	O
of	O	O
cytosol	O	O
forms	O	O
to	O	O
nuclear	O	O
forms	O	O
were	O	O
shown	O	O
.	O	O

At	O	O
37	O	O
degrees	O	O
C	O	O
the	O	O
predominant	O	O
form	O	O
of	O	O
the	O	O
hormone-receptor	B-protein	O
complex	I-protein	O
was	O	O
nuclear	O	O
.	O	O

These	O	O
results	O	O
demonstrate	O	O
that	O	O
corticosteroids	O	O
interact	O	O
with	O	O
macrophages	O	O
at	O	O
physiological	O	O
concentrations	O	O
.	O	O

Nitric	O	O
oxide	O	O
signaling	O	O
:	O	O
a	O	O
possible	O	O
role	O	O
for	O	O
G	O	O
proteins	I-protein	O
.	O	O

We	O	O
have	O	O
previously	O	O
reported	O	O
various	O	O
inductive	O	O
effects	O	O
of	O	O
nitric	O	O
oxide	O	O
on	O	O
human	O	O
PBMC	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
novel	O	O
and	O	O
potentially	O	O
important	O	O
mechanism	O	O
of	O	O
nitric	O	O
oxide	O	O
signaling-through	O	O
direct	O	O
activation	O	O
of	O	O
guanine	B-protein	O
nucleotide-binding	I-protein	O
proteins	I-protein	O
(	O	O
G	B-protein	O
proteins	I-protein	O
)	O	O
.	O	O

We	O	O
have	O	O
found	O	O
that	O	O
nitric	O	O
oxide	O	O
treatment	O	O
of	O	O
membranes	O	O
isolated	O	O
from	O	O
fresh	O	O
human	O	O
PBMC	O	O
enhances	O	O
the	O	O
ability	O	O
of	O	O
these	O	O
membranes	O	O
to	O	O
hydrolyze	O	O
[	O	O
gamma-32P	O	O
]	O	O
GTP	O	O
and	O	O
bind	O	O
[	O	O
gamma-35S	O	O
]	O	O
GTP	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
treatment	O	O
of	O	O
whole	B-cell_type	O
cells	I-cell_type	O
with	O	O
nitric	O	O
oxide	O	O
yielded	O	O
membranes	O	O
with	O	O
enhanced	O	O
GTPase	O	O
activity	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
GTPase	O	O
activity	O	O
of	O	O
pure	B-protein	O
,	O	O
recombinant	B-protein	O
Gs	I-protein	O
alpha	I-protein	O
,	O	O
Gi	B-protein	O
alpha	I-protein	O
1	O	O
,	O	O
and	O	O
p21ras	O	O
was	O	O
greatly	O	O
enhanced	O	O
by	O	O
nitric	O	O
oxide	O	O
.	O	O

In	O	O
support	O	O
of	O	O
the	O	O
existence	O	O
of	O	O
this	O	O
pathway	O	O
in	O	O
whole	B-cell_type	O
cells	I-cell_type	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
G	B-DNA	O
protein	I-protein	O
inhibitor	O	O
,	O	O
GDP-beta-S	O	O
,	O	O
blocked	O	O
NF-kappa	B-protein	O
B	I-protein	O
translocation	O	O
induced	O	O
by	O	O
nitric	O	O
oxide	O	O
or	O	O
LPS	O	O
in	O	O
permeabilized	B-cell_type	O
cells	I-cell_type	O
.	O	O

In	O	O
addition	O	O
,	O	O
nitric	O	O
oxide	O	O
greatly	O	O
reduced	O	O
the	O	O
pertussis	O	O
toxin-mediated	O	O
ADP-ribosylation	O	O
of	O	O
45-	B-protein	O
and	O	O
41-kDa	B-protein	O
proteins	I-protein	O
in	O	O
membranes	O	O
of	O	O
these	O	O
cells	O	O
.	O	O

Because	O	O
G	O	O
proteins	I-protein	O
play	O	O
a	O	O
central	O	O
role	O	O
in	O	O
many	O	O
diverse	O	O
signaling	O	O
systems	O	O
,	O	O
activation	O	O
by	O	O
an	O	O
endogenous	O	O
and	O	O
inducible	O	O
oxidant	O	O
may	O	O
represent	O	O
a	O	O
novel	O	O
signaling	O	O
pathway	O	O
.	O	O

The	O	O
granulocyte-macrophage	B-DNA	O
colony-stimulating	I-DNA	O
factor	I-DNA	O
promoter	I-DNA	O
cis-acting	I-DNA	O
element	I-DNA	O
CLE0	O	O
mediates	O	O
induction	O	O
signals	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
is	O	O
recognized	O	O
by	O	O
factors	I-protein	O
related	O	O
to	O	O
AP1	B-protein	O
and	O	O
NFAT	B-protein	O
.	O	O

Expression	O	O
of	O	O
the	O	O
granulocyte-macrophage	B-DNA	O
colony-stimulating	I-DNA	O
factor	I-DNA	O
(	I-DNA	O
GM-CSF	I-DNA	O
)	I-DNA	O
gene	I-DNA	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
is	O	O
activated	O	O
by	O	O
the	O	O
combination	O	O
of	O	O
phorbol	O	O
ester	O	O
(	O	O
phorbol	O	O
myristate	I-protein	O
acetate	I-protein	O
)	O	O
and	O	O
calcium	O	O
ionophore	O	O
(	O	O
A23187	O	O
)	O	O
,	O	O
which	O	O
mimic	O	O
antigen	O	O
stimulation	O	O
through	O	O
the	O	O
T-cell	B-protein	O
receptor	I-protein	O
.	O	O

We	O	O
have	O	O
previously	O	O
shown	O	O
that	O	O
a	O	O
fragment	O	O
containing	B-DNA	O
bp	I-DNA	O
-95	O	O
to	O	O
+27	O	O
of	O	O
the	O	O
mouse	B-DNA	O
GM-CSF	I-DNA	O
promoter	I-DNA	O
can	O	O
confer	O	O
inducibility	O	O
to	O	O
reporter	B-DNA	O
genes	I-DNA	O
in	O	O
the	O	O
human	O	O
Jurkat	B-cell_line	O
T-cell	I-cell_line	O
line	I-cell_line	O
.	O	O

Here	O	O
we	O	O
use	O	O
an	O	O
in	O	O
vitro	O	O
transcription	O	O
system	O	O
to	O	O
demonstrate	O	O
that	O	O
a	O	O
cis-acting	B-DNA	O
element	I-DNA	O
(	O	O
positions	O	O
-54	O	O
to	O	O
-40	O	O
)	O	O
,	O	O
referred	O	O
to	O	O
as	O	O
CLE0	O	O
,	O	O
is	O	O
a	O	O
target	O	O
for	O	O
the	O	O
induction	O	O
signals	O	O
.	O	O

We	O	O
observed	O	O
induction	O	O
with	O	O
templates	O	O
containing	O	O
intact	O	O
CLE0	O	O
but	O	O
not	O	O
with	O	O
templates	O	O
with	O	O
deleted	B-protein	O
or	O	O
mutated	O	O
CLE0	O	O
.	O	O

We	O	O
also	O	O
observed	O	O
that	O	O
two	O	O
distinct	O	O
signals	O	O
were	O	O
required	O	O
for	O	O
the	O	O
stimulation	O	O
through	O	O
CLE0	O	O
,	O	O
since	O	O
only	O	O
extracts	O	O
from	O	O
cells	O	O
treated	O	O
with	O	O
both	O	O
phorbol	O	O
myristate	O	O
acetate	O	O
and	O	O
A23187	O	O
supported	O	O
optimal	O	O
induction	O	O
.	O	O

Stimulation	O	O
probably	O	O
was	O	O
mediated	O	O
by	O	O
CLE0-binding	B-protein	O
proteins	I-protein	O
because	O	O
depletion	O	O
of	O	O
these	O	O
proteins	O	O
specifically	B-DNA	O
reduced	I-DNA	O
GM-CSF	I-DNA	O
transcription	O	O
.	O	O

One	O	O
of	O	O
the	O	O
binding	B-protein	O
factors	I-protein	O
possessed	O	O
biochemical	O	O
and	O	O
immunological	O	O
features	O	O
identical	O	O
to	O	O
those	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
AP1	B-protein	O
.	O	O

Another	B-protein	O
factor	I-protein	O
resembled	O	O
the	O	O
T-cell-specific	B-protein	O
factor	I-protein	O
NFAT	B-protein	O
.	O	O

The	O	O
characteristics	O	O
of	O	O
these	O	O
two	O	O
factors	B-protein	O
are	O	O
consistent	O	O
with	O	O
their	O	O
involvement	O	O
in	O	O
GM-CSF	B-cell_type	O
induction	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
CLE0-like	B-DNA	O
elements	I-DNA	O
in	O	O
the	O	O
promoters	B-DNA	O
of	O	O
interleukin-3	O	O
(	O	O
IL-3	O	O
)	O	O
,	O	O
IL-4	O	O
,	O	O
IL-5	B-protein	O
,	O	O
GM-CSF	B-protein	O
,	O	O
and	O	O
NFAT	B-protein	O
sites	O	O
in	O	O
the	O	O
IL-2	B-DNA	O
promoter	I-DNA	O
suggests	O	O
that	O	O
the	O	O
factors	B-protein	O
we	O	O
detected	O	O
,	O	O
or	O	O
related	O	O
factors	I-protein	O
that	O	O
recognize	O	O
these	O	O
sites	O	O
,	O	O
may	O	O
account	O	O
for	O	O
the	O	O
coordinate	O	O
induction	O	O
of	O	O
these	O	O
genes	O	O
during	O	O
T-cell	O	O
activation	O	O
.	O	O

Identification	O	O
and	O	O
characterization	O	O
of	O	O
an	O	O
Alu-containing	O	O
,	O	O
T-cell-specific	O	O
enhancer	O	O
located	O	O
in	O	O
the	O	O
last	O	O
intron	O	O
of	O	O
the	O	O
human	B-DNA	O
CD8	I-DNA	O
alpha	I-DNA	O
gene	I-DNA	O
.	O	O

Expression	O	O
of	O	O
the	O	O
human	B-DNA	O
CD8	I-DNA	O
alpha	I-DNA	O
gene	I-DNA	O
is	O	O
restricted	O	O
to	O	O
cells	O	O
of	O	O
the	O	O
lymphoid	B-protein	O
lineage	I-protein	O
and	O	O
developmentally	O	O
regulated	O	O
during	O	O
thymopoiesis	O	O
.	O	O

As	O	O
an	O	O
initial	O	O
step	O	O
towards	O	O
understanding	O	O
the	O	O
molecular	O	O
basis	O	O
for	O	O
tissue-specific	O	O
expression	O	O
of	O	O
this	O	O
gene	O	O
,	O	O
we	O	O
surveyed	O	O
the	O	O
surrounding	O	O
chromatin	O	O
structure	O	O
for	O	O
potential	O	O
cis-acting	B-protein	O
regulatory	I-protein	O
regions	O	O
by	O	O
DNase	B-protein	O
I	I-protein	O
hypersensitivity	O	O
mapping	O	O
and	O	O
found	O	O
four	O	O
hypersensitive	B-protein	O
sites	O	O
,	O	O
three	O	O
of	O	O
which	O	O
were	O	O
T	O	O
cell	O	O
restricted	O	O
.	O	O

By	O	O
using	O	O
a	O	O
reporter-based	O	O
expression	O	O
approach	O	O
,	O	O
a	O	O
T-cell-specific	O	O
enhancer	O	O
was	O	O
identified	O	O
by	O	O
its	O	O
close	O	O
association	O	O
with	O	O
a	O	O
prominent	O	O
T-cell-restricted	O	O
hypersensitive	O	O
sites	O	O
in	O	O
the	O	O
last	O	O
intron	O	O
of	O	O
the	O	O
CD8	B-DNA	O
alpha	I-DNA	O
gene	I-DNA	O
.	O	O

Deletion	O	O
studies	O	O
demonstrated	O	O
that	O	O
the	O	O
minimal	B-DNA	O
enhancer	I-DNA	O
is	O	O
adjacent	O	O
to	O	O
a	O	O
negative	B-DNA	O
regulatory	I-DNA	O
element	I-DNA	O
.	O	O

DNA	O	O
sequence	O	O
analysis	O	O
of	O	O
the	O	O
minimal	B-DNA	O
enhancer	I-DNA	O
revealed	O	O
a	O	O
striking	O	O
cluster	O	O
of	O	O
consensus	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
for	O	O
Ets-1	O	O
,	O	O
TCF-1	O	O
,	O	O
CRE	O	O
,	O	O
GATA-3	O	O
,	O	O
LyF-1	O	O
,	O	O
and	O	O
bHLH	O	O
proteins	O	O
which	O	O
were	O	O
verified	O	O
by	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
5	O	O
'	O	O
end	O	O
of	O	O
the	O	O
enhancer	B-DNA	O
was	O	O
composed	O	O
of	O	O
an	O	O
Alu	B-DNA	O
repeat	I-DNA	O
which	O	O
contained	O	O
the	O	O
GATA-3	O	O
,	O	O
bHLH	O	O
,	O	O
and	O	O
LyF-1	B-protein	O
binding	I-protein	O
sites	I-protein	O
.	O	O

Site-directed	O	O
mutation	O	O
of	O	O
the	O	O
Ets-1	B-DNA	O
and	I-DNA	O
GATA-3	I-DNA	O
sites	I-DNA	O
dramatically	I-DNA	O
reduced	I-DNA	O
enhancer	I-DNA	O
activity	O	O
.	O	O

The	O	O
functional	O	O
importance	O	O
of	O	O
the	O	O
other	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
only	O	O
became	O	O
apparent	O	O
when	O	O
combinations	O	O
of	O	O
mutations	O	O
were	O	O
analyzed	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
human	B-DNA	O
CD8	I-DNA	O
alpha	I-DNA	O
gene	I-DNA	O
is	O	O
regulated	O	O
by	O	O
the	O	O
interaction	O	O
of	O	O
multiple	O	O
T-cell	B-protein	O
nuclear	I-protein	O
proteins	I-protein	O
with	O	O
a	O	O
transcriptional	B-DNA	O
enhancer	I-DNA	O
located	O	O
in	O	O
the	O	O
last	O	O
intron	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
CD8	B-DNA	O
alpha	I-DNA	O
enhancer	I-DNA	O
with	O	O
other	O	O
recently	O	O
identified	O	O
T-cell-specific	B-DNA	O
regulatory	I-DNA	O
elements	I-DNA	O
suggests	O	O
that	O	O
a	O	O
common	O	O
set	O	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
regulates	O	O
several	O	O
T-cell	O	O
genes	I-DNA	O
.	O	O

Molecular	O	O
regulation	O	O
of	O	O
the	O	O
human	B-DNA	O
IL-3	I-DNA	O
gene	I-DNA	O
:	O	O
inducible	O	O
T	O	O
cell-restricted	O	O
expression	O	O
requires	O	O
intact	O	O
AP-1	B-protein	O
and	O	O
Elf-1	O	O
nuclear	B-protein	O
protein	I-protein	O
binding	O	O
sites	O	O
.	O	O

Interleukin	B-protein	O
3	I-protein	O
(	O	O
IL-3	O	O
)	O	O
is	O	O
a	O	O
hematopoietic	O	O
stem-cell	O	O
growth	O	O
and	O	O
differentiation	B-protein	O
factor	I-protein	O
that	O	O
is	O	O
expressed	O	O
solely	O	O
in	O	O
activated	B-cell_type	O
T	I-cell_type	O
and	I-cell_type	O
NK	I-cell_type	O
cells	I-cell_type	O
.	O	O

Studies	O	O
to	O	O
date	O	O
have	O	O
identified	O	O
elements	B-DNA	O
5	I-DNA	O
'	O	O
to	O	O
the	O	O
IL-3	O	O
coding	O	O
sequences	O	O
that	O	O
regulate	O	O
its	O	O
transcription	O	O
,	O	O
but	O	O
the	O	O
sequences	O	O
that	O	O
confer	O	O
T	O	O
cell-specific	O	O
expression	O	O
remain	O	O
to	O	O
be	O	O
clearly	O	O
defined	O	O
.	O	O

We	O	O
have	O	O
now	O	O
identified	O	O
DNA	O	O
sequences	O	O
that	O	O
are	O	O
required	O	O
for	O	O
T	O	O
cell-restricted	O	O
IL-3	O	O
gene	O	O
transcription	O	O
.	O	O

A	O	O
series	O	O
of	O	O
transient	O	O
transfections	O	O
performed	O	O
with	O	O
human	B-DNA	O
IL-3-chloramphenicol	I-DNA	O
acetyltransferase	I-DNA	O
(	O	O
CAT	B-DNA	O
)	I-DNA	O
reporter	I-DNA	O
plasmids	O	O
in	O	O
T	B-cell_type	O
and	I-cell_type	O
non-T	I-cell_type	O
cells	I-cell_type	O
revealed	O	O
that	O	O
a	O	O
plasmid	O	O
containing	O	O
319	B-DNA	O
bp	I-DNA	O
of	O	O
5	B-DNA	O
'	I-DNA	O
flanking	I-DNA	O
sequences	O	O
was	O	O
active	O	O
exclusively	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

Deletion	O	O
analysis	O	O
revealed	O	O
that	O	O
T	O	O
cell	O	O
specificity	O	O
was	O	O
conferred	O	O
by	O	O
a	O	O
49-bp	B-protein	O
fragment	I-protein	O
(	O	O
bp	I-DNA	O
-319	O	O
to	O	O
-270	O	O
)	O	O
that	O	O
included	O	O
a	O	O
potential	O	O
binding	O	O
site	O	O
for	O	O
AP-1	B-protein	O
transcription	B-protein	O
factors	I-protein	O
6	O	O
bp	O	O
upstream	O	O
of	O	O
a	O	O
binding	B-DNA	O
site	I-DNA	O
for	O	O
Elf-1	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
Ets	B-protein	O
family	I-protein	O
of	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

DNaseI	O	O
footprint	O	O
and	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
analyses	O	O
performed	O	O
with	O	O
MLA-144	O	O
T	O	O
cell	O	O
nuclear	O	O
extracts	O	O
demonstrated	O	O
that	O	O
this	O	O
49-bp	O	O
region	O	O
contains	O	O
a	O	O
nuclear	O	O
protein	O	O
binding	O	O
region	O	O
that	O	O
includes	O	O
consensus	O	O
AP-1	O	O
and	O	O
Elf-1	O	O
binding	O	O
sites	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
extracts	O	O
prepared	O	O
from	O	O
purified	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
contained	O	O
proteins	O	O
that	O	O
bound	O	O
to	O	O
synthetic	O	O
oligonucleotides	O	O
corresponding	O	O
to	O	O
the	O	O
AP-1	B-protein	O
and	O	O
Elf-1	O	O
binding	O	O
sites	O	O
.	O	O

In	O	O
vitro-transcribed	O	O
and	O	O
-translated	O	O
Elf-1	O	O
protein	O	O
bound	O	O
specifically	O	O
to	O	O
the	O	O
Elf-1	B-DNA	O
site	I-DNA	O
,	O	O
and	O	O
Elf-1	O	O
antisera	O	O
competed	O	O
and	O	O
super	O	O
shifted	O	O
nuclear	O	O
protein	O	O
complexes	O	O
present	O	O
in	O	O
MLA-144	O	O
nuclear	O	O
extracts	O	O
.	O	O

Moreover	O	O
,	O	O
addition	O	O
of	O	O
anti-Jun	O	O
family	O	O
antiserum	O	O
in	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
reactions	O	O
completely	O	O
blocked	O	O
formation	O	O
of	O	O
the	O	O
AP-1-related	B-protein	O
complexes	I-protein	O
.	O	O

Transient	O	O
transfection	O	O
studies	O	O
in	O	O
MLA-144	O	O
T	B-cell_type	O
cells	I-cell_type	O
revealed	O	O
that	O	O
constructs	O	O
containing	O	O
mutations	O	O
in	O	O
the	O	O
AP-1	B-DNA	O
site	I-DNA	O
almost	O	O
completely	O	O
abolished	O	O
CAT	O	O
activity	O	O
while	O	O
mutation	O	O
of	O	O
the	O	O
Elf-1	B-DNA	O
site	I-DNA	O
or	O	O
the	O	O
NF-IL-3	B-DNA	O
site	I-DNA	O
,	O	O
a	O	O
previously	O	O
described	O	O
nuclear	B-protein	O
protein	I-protein	O
binding	I-DNA	O
site	I-DNA	O
(	O	O
bp.	O	O
-155	O	O
to	O	O
-148	O	O
)	O	O
in	O	O
the	O	O
IL-3	B-DNA	O
promoter	I-DNA	O
,	O	O
reduced	O	O
CAT	O	O
activity	O	O
to	O	O
<	O	O
25	O	O
%	O	O
of	O	O
the	O	O
activity	O	O
given	O	O
by	O	O
wild-type	O	O
constructs	I-DNA	O
.	O	O

We	O	O
conclude	O	O
that	O	O
expression	O	O
of	O	O
the	O	O
human	B-DNA	O
IL-3	I-DNA	O
gene	I-DNA	O
requires	O	O
the	O	O
AP-1	B-DNA	O
and	I-DNA	O
Elf-1	I-DNA	O
binding	I-DNA	O
sites	I-DNA	O
;	O	O
however	O	O
,	O	O
unlike	O	O
other	O	O
previously	O	O
characterized	O	O
cytokine	O	O
genes	O	O
such	O	O
as	O	O
IL-2	B-protein	O
,	O	O
the	O	O
AP-1	B-protein	O
and	O	O
Elf-1	B-protein	O
factors	I-protein	O
can	O	O
bind	O	O
independently	O	O
in	O	O
the	O	O
IL-3	O	O
gene	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O

Combination	O	O
IL-2	B-protein	O
and	O	O
IL-4	O	O
reduces	O	O
glucocorticoid	O	O
receptor-binding	O	O
affinity	O	O
and	O	O
T	O	O
cell	O	O
response	O	O
to	O	O
glucocorticoids	O	O
.	O	O

The	O	O
mechanisms	O	O
contributing	O	O
to	O	O
persistent	O	O
T	O	O
cell	O	O
activation	O	O
and	O	O
poor	O	O
response	O	O
to	O	O
glucocorticoids	O	O
in	O	O
chronic	O	O
inflammatory	O	O
illnesses	O	O
such	O	O
as	O	O
steroid	O	O
resistant	O	O
(	O	O
SR	O	O
)	O	O
asthma	O	O
are	O	O
poorly	O	O
defined	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
possibility	O	O
that	O	O
certain	O	O
cytokines	B-protein	O
,	O	O
specifically	O	O
IL-2	B-protein	O
and	O	O
IL-4	O	O
,	O	O
could	O	O
affect	O	O
T	O	O
cell	O	O
response	O	O
to	O	O
glucocorticoids	O	O
.	O	O

A	O	O
[	O	O
3H	O	O
]	O	O
dexamethasone	O	O
radioligand-binding	O	O
assay	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
the	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
and	O	O
dissociation	O	O
constant	O	O
(	O	O
Kd	O	O
)	O	O
in	O	O
PBMC	O	O
from	O	O
normal	O	O
donors	O	O
and	O	O
patients	O	O
with	O	O
SR	O	O
asthma	O	O
,	O	O
cultured	O	O
in	O	O
the	O	O
absence	O	O
and	O	O
presence	O	O
of	O	O
these	O	O
cytokines	B-protein	O
.	O	O

PBMC	O	O
from	O	O
normal	O	O
donors	O	O
incubated	O	O
for	O	O
48	O	O
h	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
combination	O	O
IL-2	B-protein	O
+	O	O
IL-4	O	O
had	O	O
nuclear	O	O
GR	O	O
with	O	O
significantly	O	O
reduced	O	O
binding	O	O
affinity	O	O
(	O	O
GR	B-protein	O
Kd	O	O
=	O	O
36.1	O	O
+/-	O	O
1.63	O	O
nM	O	O
,	O	O
mean	O	O
+/-	O	O
SEM	O	O
;	O	O
p	O	O
=	O	O
0.0001	O	O
)	O	O
as	O	O
compared	O	O
with	O	O
PBMC	O	O
incubated	O	O
with	O	O
medium	O	O
alone	O	O
(	O	O
GR	O	O
Kd	O	O
=	O	O
6.74	O	O
+/-	O	O
0.46	O	O
nM	O	O
)	O	O
.	O	O

The	O	O
cytosolic	O	O
GR	B-protein	O
Kd	I-protein	O
remained	O	O
unchanged	O	O
.	O	O

However	O	O
,	O	O
when	O	O
PBMC	O	O
were	O	O
incubated	O	O
with	O	O
IL-2	B-protein	O
alone	O	O
or	O	O
IL-4	O	O
alone	O	O
,	O	O
no	O	O
change	O	O
in	O	O
GR-binding	O	O
affinity	O	O
was	O	O
observed	O	O
.	O	O

Furthermore	O	O
,	O	O
when	O	O
T	B-cell_type	O
cells	I-cell_type	O
and	O	O
non-T	B-cell_type	O
cells	I-cell_type	O
were	O	O
individually	O	O
stimulated	O	O
with	O	O
combination	O	O
IL-2	B-protein	O
+	O	O
IL-4	O	O
,	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
GR-binding	O	O
affinity	O	O
was	O	O
observed	O	O
only	O	O
in	O	O
the	O	O
T	O	O
cell	O	O
population	O	O
(	O	O
p	O	O
=	O	O
0.0001	O	O
)	O	O
.	O	O

The	O	O
IL-2	B-protein	O
+	O	O
IL-4-induced	O	O
alteration	O	O
in	O	O
PBMC	O	O
GR	O	O
Kd	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
GR	B-protein	O
number	O	O
(	O	O
8348	O	O
+/-	O	O
964	O	O
vs	O	O
1710	O	O
+/-	O	O
228	O	O
sites/cell	O	O
;	O	O
p	O	O
=	O	O
0.0003	O	O
)	O	O
.	O	O

More	O	O
importantly	O	O
,	O	O
the	O	O
alteration	O	O
in	O	O
PBMC	O	O
GR-binding	O	O
affinity	O	O
with	O	O
IL-2	B-protein	O
+	O	O
IL-4	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
functional	O	O
change	O	O
in	O	O
T	O	O
cell	O	O
response	O	O
to	O	O
methylprednisolone	O	O
MPN	O	O
,	O	O
i.e.	O	O
,	O	O
a	O	O
reduced	O	O
inhibitory	O	O
effect	O	O
of	O	O
MPN	O	O
on	O	O
PMA/ionomycin-induced	O	O
T	B-cell_type	O
cell	I-cell_type	O
proliferation	O	O
.	O	O

These	O	O
effects	O	O
of	O	O
IL-2	B-protein	O
+	O	O
IL-4	O	O
on	O	O
PBMC	O	O
GR	O	O
affinity	O	O
and	O	O
response	O	O
to	O	O
MPN	O	O
were	O	O
blocked	O	O
by	O	O
co-incubation	O	O
with	O	O
IFN-gamma	B-protein	O
.	O	O

Freshly	O	O
isolated	O	O
PBMC	O	O
from	O	O
four	O	O
patients	O	O
with	O	O
SR	O	O
asthma	O	O
had	O	O
a	O	O
significantly	O	O
reduced	O	O
GR-binding	O	O
affinity	O	O
(	O	O
Kd	O	O
=	O	O
40.0	O	O
+/-	O	O
2.68	O	O
nM	O	O
;	O	O
p	O	O
=	O	O
0.0001	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
seven	O	O
normal	O	O
subjects	O	O
(	O	O
7.15	O	O
+/-	O	O
0.41	O	O
nM	O	O
)	O	O
.	O	O

The	O	O
altered	O	O
PBMC	O	O
GR	B-protein	O
binding	O	O
from	O	O
patients	O	O
with	O	O
SR	O	O
asthma	O	O
reversed	O	O
to	O	O
normal	O	O
when	O	O
incubated	O	O
with	O	O
medium	O	O
alone	O	O
,	O	O
but	O	O
was	O	O
sustained	O	O
with	O	O
IL-2	B-protein	O
+	O	O
IL-4	O	O
.	O	O

These	O	O
observations	O	O
suggest	O	O
that	O	O
with	O	O
persistent	O	O
inflammation	O	O
certain	O	O
cytokines	O	O
may	O	O
contribute	O	O
to	O	O
an	O	O
impaired	O	O
response	O	O
to	O	O
glucocorticoids	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
IL-2	B-protein	O
and	O	O
IL-4	O	O
were	O	O
blocked	O	O
by	O	O
IFN-gamma	B-protein	O
.	O	O

Characterization	O	O
of	O	O
the	O	O
human	B-DNA	O
CD4	I-DNA	O
gene	I-DNA	O
promoter	I-DNA	O
:	O	O
transcription	O	O
from	O	O
the	O	O
CD4	B-DNA	O
gene	I-DNA	O
core	I-DNA	O
promoter	I-DNA	O
is	O	O
tissue-specific	O	O
and	O	O
is	O	O
activated	O	O
by	O	O
Ets	B-protein	O
proteins	I-protein	O
.	O	O

We	O	O
analyzed	O	O
the	O	O
5	B-DNA	O
'	I-DNA	O
transcription	O	O
control	O	O
sequences	O	O
of	O	O
the	O	O
human	B-DNA	O
CD4	I-DNA	O
gene	I-DNA	O
.	O	O

We	O	O
located	O	O
the	O	O
transcription	B-DNA	O
initiation	I-DNA	O
site	I-DNA	O
and	O	O
showed	O	O
that	O	O
the	O	O
CD4	B-DNA	O
core	I-DNA	O
promoter	I-DNA	O
(	O	O
positions	O	O
-40	O	O
to	O	O
+16	O	O
)	O	O
lacks	O	O
a	O	O
classical	O	O
``	O	O
TATA	O	O
''	O	O
or	O	O
initiator	O	O
positioning	O	O
consensus	O	O
sequence	O	O
but	O	O
directs	O	O
precise	O	O
and	O	O
efficient	O	O
transcription	O	O
when	O	O
coupled	O	O
to	O	O
the	O	O
ubiquitously	O	O
active	O	O
simian	O	O
virus	O	O
40	O	O
enhancer	O	O
.	O	O

The	O	O
transcriptional	O	O
activity	O	O
of	O	O
the	O	O
CD4	B-DNA	O
gene	I-DNA	O
promoter	I-DNA	O
correlated	O	O
with	O	O
CD4	B-protein	O
expression	O	O
in	O	O
various	B-cell_type	O
cell	I-cell_type	O
types	I-cell_type	O
.	O	O

Interestingly	O	O
,	O	O
the	O	O
CD4	B-DNA	O
core	I-DNA	O
promoter	I-DNA	O
also	O	O
displayed	O	O
a	O	O
tissue-specific	O	O
transcriptional	O	O
activity	O	O
.	O	O

Within	O	O
this	O	O
fragment	O	O
,	O	O
three	O	O
nucleic	O	O
acid	O	O
sequences	O	O
are	O	O
completely	O	O
conserved	O	O
in	O	O
the	O	O
murine	B-DNA	O
CD4	I-DNA	O
gene	I-DNA	O
.	O	O

One	O	O
of	O	O
these	O	O
sequences	O	O
contains	O	O
a	O	O
perfect	O	O
ETS	O	O
consensus	B-DNA	O
sequence	I-DNA	O
.	O	O

Another	O	O
ETS	O	O
consensus	O	O
sequence	O	O
is	O	O
located	O	O
1060	O	O
nt	O	O
upstream	O	O
.	O	O

Electrophoretic-mobility-shift	O	O
assays	O	O
showed	O	O
that	O	O
the	O	O
core	B-DNA	O
promoter	I-DNA	O
ETS	O	O
motif	O	O
binds	O	O
an	O	O
Ets-related	B-protein	O
protein	I-protein	O
specifically	O	O
expressed	O	O
at	O	O
high	O	O
levels	O	O
in	O	O
CD4+	B-cell_line	O
cells	I-cell_line	O
.	O	O

Moreover	O	O
,	O	O
in	O	O
CD4-	B-cell_type	O
cells	I-cell_type	O
,	O	O
overexpression	O	O
of	O	O
Ets-1	O	O
or	O	O
Ets-2	O	O
efficiently	O	O
and	O	O
specifically	O	O
activated	O	O
transcription	O	O
from	O	O
the	O	O
CD4	B-DNA	O
promoter	I-DNA	O
and	O	O
core	B-DNA	O
promoter	I-DNA	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
Ets	O	O
transcription	B-protein	O
factors	I-protein	O
play	O	O
a	O	O
central	O	O
role	O	O
in	O	O
controlling	O	O
CD4	B-DNA	O
gene	I-DNA	O
expression	O	O
,	O	O
by	O	O
binding	O	O
to	O	O
both	O	O
a	O	O
classical	O	O
remote	I-DNA	O
site	I-DNA	O
and	O	O
an	O	O
unusual	B-DNA	O
proximal	I-DNA	O
activator	I-DNA	O
sequence	I-DNA	O

Glucocorticoid	B-protein	O
receptor	I-protein	O
activation	O	O
and	O	O
inactivation	O	O
in	O	O
c	O	O
ultured	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Although	O	O
glucocorticoids	O	O
are	O	O
not	O	O
cytolytic	O	O
for	O	O
and	O	O
do	O	O
not	O	O
inhibit	O	O
the	O	O
growth	O	O
of	O	O
the	O	O
IM-9	O	O
line	O	O
of	O	O
cultured	O	O
human	O	O
lymphoblasts	O	O
,	O	O
these	O	O
cells	O	O
have	O	O
a	O	O
high	O	O
steroid-binding	O	O
capacity	O	O
.	O	O

We	O	O
have	O	O
used	O	O
IM-9	O	O
cells	O	O
in	O	O
order	O	O
to	O	O
examine	O	O
whether	O	O
unoccupied	O	O
glucocorticoid	O	O
receptors	O	O
are	O	O
inactivated	O	O
and	O	O
activated	O	O
in	O	O
intact	B-cell_type	O
cells	I-cell_type	O
.	O	O

when	O	O
IM-9	B-cell_line	O
cells	I-cell_line	O
are	O	O
incubated	O	O
in	O	O
glucose-free	O	O
medium	O	O
in	O	O
a	O	O
nitrogen	O	O
atmosphere	O	O
,	O	O
both	O	O
their	O	O
ability	O	O
to	O	O
bind	O	O
triamcinolone	O	O
acetonide	O	O
and	O	O
their	O	O
ATP	O	O
levels	O	O
decline	O	O
and	O	O
,	O	O
when	O	O
glucose	O	O
and	O	O
oxygen	O	O
are	O	O
reintroduced	O	O
,	O	O
ATP	O	O
levels	O	O
and	O	O
receptor	O	O
activity	O	O
return	O	O
.	O	O

The	O	O
specific	O	O
glucocorticoid-binding	O	O
activity	O	O
of	O	O
cytosol	O	O
prepared	O	O
from	O	O
cells	O	O
exposed	O	O
to	O	O
various	O	O
degrees	O	O
of	O	O
energy	O	O
limitation	O	O
is	O	O
directly	O	O
correlated	O	O
with	O	O
the	O	O
ATP	O	O
content	O	O
.	O	O

Receptor	O	O
activation	O	O
in	O	O
intact	B-cell_type	O
cells	I-cell_type	O
is	O	O
rapid	O	O
and	O	O
independent	O	O
of	O	O
protein	O	O
synthesis	O	O
.	O	O

Cytosol	O	O
prepared	O	O
from	O	O
inactivated	B-cell_type	O
cells	I-cell_type	O
can	O	O
not	O	O
be	O	O
activated	O	O
by	O	O
addition	O	O
of	O	O
ATP	O	O
.	O	O

The	O	O
inactivation	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
that	O	O
occurs	O	O
when	O	O
cytosol	O	O
from	O	O
normal	O	O
IM-9	O	O
cells	O	O
is	O	O
incubated	O	O
at	O	O
25	O	O
degrees	O	O
C	O	O
is	O	O
inhibited	O	O
by	O	O
molybdate	O	O
,	O	O
vanadate	O	O
,	O	O
fluoride	O	O
,	O	O
ATP	O	O
,	O	O
and	O	O
several	O	O
other	O	O
nucleotides	O	O
.	O	O

The	O	O
experiments	O	O
with	O	O
intact	O	O
human	O	O
lymphoblasts	O	O
suggest	O	O
that	O	O
assays	O	O
of	O	O
specific	O	O
glucocorticoid-binding	O	O
capacity	O	O
do	O	O
not	O	O
necessarily	O	O
reflect	O	O
the	O	O
cellular	O	O
content	O	O
of	O	O
receptor	O	O
protein	O	O
.	O	O

Glucocorticoids	O	O
and	O	O
lymphocytes	I-cell_type	O
.	O	O

II	O	O
.	O	O

Cell	O	O
cycle-dependent	O	O
changes	O	O
in	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
content	O	O
.	O	O

To	O	O
study	O	O
variations	O	O
in	O	O
glucocorticoid	O	O
receptor	O	O
levels	O	O
during	O	O
the	O	O
cell	O	O
cycle	O	O
,	O	O
we	O	O
have	O	O
separated	O	O
mitogen-stimulated	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
rat	O	O
lymph	B-cell_type	O
node	I-cell_type	O
cells	I-cell_type	O
by	O	O
unit	O	O
gravity	O	O
sedimentation	O	O
and	O	O
measured	O	O
glucocorticoid	B-protein	O
binding	O	O
in	O	O
the	O	O
resultant	O	O
fractions	O	O
.	O	O

By	O	O
morphologic	O	O
criteria	O	O
and	O	O
thymidine	O	O
incorporation	O	O
,	O	O
the	O	O
fractions	O	O
were	O	O
separated	O	O
into	O	O
populations	O	O
of	O	O
G0	O	O
and	O	O
G1	O	O
phase	O	O
and	O	O
S	O	O
and	O	O
post-S	B-cell_type	O
phase	I-cell_type	O
cells	I-cell_type	O
.	O	O

A	O	O
2-	O	O
to	O	O
3-fold	O	O
increase	O	O
in	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
sites	O	O
per	O	O
cell	O	O
,	O	O
for	O	O
cells	O	O
in	O	O
the	O	O
S	O	O
and	O	O
post-S	O	O
phase	O	O
over	O	O
those	O	O
in	O	O
G0	O	O
and	O	O
G1	O	O
,	O	O
was	O	O
observed	O	O
with	O	O
both	O	O
nonstimulated	O	O
rat	O	O
lymph	O	O
node	O	O
cell	O	O
suspensions	O	O
and	O	O
concanavalin	O	O
A-stimulated	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

These	O	O
observations	O	O
together	O	O
with	O	O
those	O	O
from	O	O
other	O	O
studies	O	O
indicate	O	O
that	O	O
formation	O	O
of	O	O
new	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
near	O	O
the	O	O
S	O	O
phase	O	O
may	O	O
be	O	O
a	O	O
general	O	O
phenomenon	O	O
in	O	O
proliferating	B-cell_type	O
cells	I-cell_type	O
.	O	O

We	O	O
propose	O	O
that	O	O
this	O	O
increase	O	O
in	O	O
glucocorticoid	O	O
receptors	O	O
during	O	O
the	O	O
cell	O	O
cycle	O	O
may	O	O
explain	O	O
the	O	O
increase	O	O
in	O	O
glucocorticoid	O	O
receptors	O	O
in	O	O
mitogen-stimulated	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

The	O	O
leukocyte	O	O
migration	O	O
inhibition	O	O
response	O	O
to	O	O
certain	O	O
breast	O	O
cancer-related	O	O
antigens	O	O
(	O	O
MCF-7	O	O
and	O	O
MuMTV	O	O
)	O	O
:	O	O
their	O	O
potential	O	O
as	O	O
discriminants	O	O
.	O	O

Certain	O	O
oncogenic	O	O
viruses	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
human	O	O
breast	O	O
cancer	O	O
,	O	O
including	O	O
the	O	O
murine	B-protein	O
mammary	I-protein	O
tumor	I-protein	O
virus	I-protein	O
(	O	O
MuMTV	B-protein	O
)	O	O
and	O	O
the	O	O
Mason-Pfizer	O	O
monkey	O	O
virus	O	O
(	O	O
MPMV	O	O
)	O	O
.	O	O

We	O	O
have	O	O
used	O	O
the	O	O
leukocyte	O	O
migration	O	O
inhibition	O	O
(	O	O
LMI	O	O
)	O	O
response	O	O
to	O	O
assay	O	O
the	O	O
response	O	O
to	O	O
several	O	O
potential	O	O
breast	O	O
cancer-related	O	O
antigens	O	O
,	O	O
including	O	O
MuMTV	O	O
,	O	O
MPMV	O	O
,	O	O
and	O	O
a	O	O
breast	O	O
cancer	O	O
cultured	O	O
cell	O	O
line	O	O
,	O	O
MCF-7	O	O
,	O	O
in	O	O
96	O	O
breast	O	O
cancer	O	O
patients	O	O
,	O	O
in	O	O
32	O	O
women	O	O
with	O	O
benign	O	O
breast	O	O
disease	O	O
,	O	O
and	O	O
in	O	O
67	O	O
normal	O	O
women	O	O
.	O	O

The	O	O
lowest	O	O
tenth	O	O
percentile	O	O
of	O	O
control	O	O
(	O	O
LMI	B-protein	O
)	O	O
responses	O	O
was	O	O
used	O	O
as	O	O
the	O	O
cutoff	O	O
point	O	O
to	O	O
designate	O	O
responders	O	O
.	O	O

Breast	O	O
cancer	O	O
patients	O	O
showed	O	O
significant	O	O
responses	O	O
to	O	O
MuMTV	O	O
(	O	O
49	O	O
%	O	O
and	O	O
to	O	O
MCF-7	O	O
(	O	O
50	O	O
%	O	O
)	O	O
,	O	O
but	O	O
not	O	O
to	O	O
MPMV	O	O
(	O	O
29	O	O
%	O	O
)	O	O
.	O	O

In	O	O
a	O	O
paired-antigen	O	O
study	O	O
using	O	O
MuMTV	O	O
and	O	O
MCF-7	O	O
,	O	O
75	O	O
%	O	O
of	O	O
the	O	O
breast	O	O
cancer	O	O
patients	O	O
responded	O	O
,	O	O
versus	O	O
18	O	O
%	O	O
of	O	O
the	O	O
normal	B-protein	O
women	I-protein	O
(	O	O
P	O	O
less	O	O
than	O	O
0.0050	O	O
)	O	O
.	O	O

The	O	O
potential	O	O
for	O	O
this	O	O
assay	O	O
to	O	O
distinguish	O	O
``	O	O
normal	O	O
''	O	O
from	O	O
``	O	O
breast	O	O
cancer	O	O
''	O	O
was	O	O
analyzed	O	O
using	O	O
a	O	O
migration	O	O
index	O	O
derived	O	O
from	O	O
discriminant	O	O
analysis	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
the	O	O
assay	O	O
to	O	O
discriminate	O	O
``	O	O
normal	O	O
''	O	O
from	O	O
``	O	O
cancer	O	O
''	O	O
was	O	O
significant	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.001	O	O
)	O	O
and	O	O
showed	O	O
a	O	O
sensitivity	O	O
of	O	O
detecting	O	O
``	O	O
cancer	O	O
''	O	O
of	O	O
75	O	O
%	O	O
.	O	O

The	O	O
overall	O	O
responses	O	O
to	O	O
MuMTV	O	O
and	O	O
MCF-7	O	O
were	O	O
analyzed	O	O
with	O	O
reference	O	O
to	O	O
certain	O	O
prognostic	O	O
factors	I-protein	O
,	O	O
but	O	O
showed	O	O
no	O	O
relation	O	O
to	O	O
age	O	O
,	O	O
menstrual	O	O
status	O	O
,	O	O
estrogen	O	O
receptor	O	O
status	O	O
,	O	O
or	O	O
stage	O	O
of	O	O
disease	O	O
.	O	O

The	O	O
above	O	O
reactions	O	O
suggest	O	O
that	O	O
a	O	O
large	O	O
proportion	O	O
of	O	O
breast	O	O
cancer	O	O
patients	O	O
exhibit	O	O
presensitization	O	O
to	O	O
antigenfs	O	O
found	O	O
in	O	O
MuMTV	O	O
and	O	O
MCF-7	O	O
,	O	O
which	O	O
may	O	O
be	O	O
cross-reactive	O	O
with	O	O
antigens	O	O
in	O	O
the	O	O
primary	O	O
cancer	O	O
.	O	O

These	O	O
responses	O	O
appear	O	O
to	O	O
be	O	O
independent	O	O
of	O	O
major	O	O
prognostic	O	O
variables	O	O
.	O	O

Further	O	O
refinement	O	O
of	O	O
this	O	O
assay	O	O
may	O	O
yield	O	O
one	O	O
which	O	O
is	O	O
more	O	O
highly	O	O
discriminating	O	O
for	O	O
breast	O	O
cancer	O	O
.	O	O

Chronic	O	O
lymphatic	O	O
leukaemia	O	O
:	O	O
cellular	O	O
effects	O	O
of	O	O
glucocorticoids	O	O
in	O	O
vitro	O	O
.	O	O

Glucocorticoid	O	O
receptor	O	O
levels	O	O
and	O	O
steroid	O	O
induced	O	O
inhibition	O	O
of	O	O
nucleic	O	O
acid	O	O
precursors	O	O
have	O	O
been	O	O
examined	O	O
in	O	O
lymphocytes	O	O
from	O	O
27	O	O
patients	O	O
at	O	O
different	O	O
stages	O	O
of	O	O
chronic	O	O
lymphatic	O	O
leukaemia	O	O
.	O	O

No	O	O
correlation	O	O
can	O	O
be	O	O
found	O	O
between	O	O
the	O	O
level	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
and	O	O
the	O	O
stage	O	O
of	O	O
the	O	O
disease	B-DNA	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
a	O	O
significant	O	O
difference	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0.02	O	O
)	O	O
was	O	O
found	O	O
between	O	O
stage	O	O
O	O	O
and	O	O
stage	O	O
III/IV	O	O
patients	O	O
,	O	O
in	O	O
terms	O	O
of	O	O
the	O	O
in	O	O
vitro	O	O
effect	O	O
of	O	O
dexamethasone	O	O
on	O	O
[	O	O
3H	O	O
]	O	O
uridine	O	O
incorporation	O	O
.	O	O

Pyrrolidine	O	O
dithiocarbamate	O	O
inhibits	O	O
NF-kappa	B-protein	O
B	I-protein	O
mobilization	O	O
and	O	O
TNF	B-protein	O
production	O	O
in	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
.	O	O

The	O	O
human	B-DNA	O
TNF	B-DNA	O
promoter	I-DNA	O
contains	O	O
four	O	O
potential	O	O
nuclear	B-protein	O
factor-kappa	I-protein	O
B	I-protein	O
(	O	O
NF-kappa	B-DNA	O
B	I-DNA	O
)	O	O
-binding	O	O
sites	O	O
,	O	O
with	O	O
the	O	O
strongest	O	O
binding	O	O
seen	O	O
for	O	O
the	O	O
-605	B-DNA	O
motif	I-DNA	O
.	O	O

Nuclear	O	O
extracts	O	O
from	O	O
unstimulated	O	O
cells	O	O
of	O	O
the	O	O
human	B-cell_line	O
monocytic	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
,	O	O
Mono	O	O
Mac	O	O
6	O	O
,	O	O
contain	O	O
one	O	O
specific	O	O
binding	B-protein	O
protein	I-protein	O
(	I-protein	O
complex	I-protein	O
II	I-protein	O
)	O	O
,	O	O
consistent	O	O
with	O	O
a	O	O
constitutive	O	O
p50	B-protein	O
homodimer	I-protein	O
.	O	O

Stimulation	O	O
of	O	O
Mono	O	O
Mac	O	O
6	O	O
cells	O	O
with	O	O
LPS	O	O
will	O	O
increase	O	O
complex	B-protein	O
II	I-protein	O
and	O	O
will	O	O
strongly	O	O
induce	O	O
a	O	O
second	O	O
specific	O	O
complex	O	O
(	O	O
complex	O	O
I	O	O
)	O	O
,	O	O
which	O	O
represents	O	O
the	O	O
p50/65	O	O
heterodimer	O	O
.	O	O

Treatment	O	O
of	O	O
Mono	O	O
Mac	I-cell_line	O
6	I-cell_line	O
cells	I-cell_line	O
with	O	O
pyrrolidine-dithiocarbamate	O	O
(	O	O
PDTC	O	O
)	O	O
at	O	O
300	O	O
microM	O	O
will	O	O
block	O	O
the	O	O
LPS-induced	O	O
complex	O	O
I	O	O
almost	O	O
completely	O	O
and	O	O
will	O	O
reduce	O	O
complex	O	O
II	O	O
to	O	O
the	O	O
constitutive	O	O
level	O	O
.	O	O

Binding	O	O
activity	O	O
of	O	O
other	O	O
nuclear	B-protein	O
factors	I-protein	O
that	O	O
recognize	O	O
the	O	O
SP-1	O	O
and	O	O
c/EBP	B-protein	O
motifs	I-protein	O
of	O	O
the	O	O
human	B-DNA	O
TNF	I-DNA	O
promoter	I-DNA	O
is	O	O
not	O	O
affected	O	O
by	O	O
such	O	O
treatment	O	O
.	O	O

Northern	O	O
blot	O	O
analysis	O	O
demonstrates	O	O
that	O	O
PDTC	O	O
treatment	O	O
will	O	O
strongly	O	O
reduce	O	O
LPS-induced	O	O
TNF	B-protein	O
transcripts	O	O
.	O	O

Secreted	O	O
TNF	B-protein	O
protein	I-protein	O
as	O	O
detected	O	O
in	O	O
the	O	O
Wehi	O	O
164S/ActD	O	O
bioassay	O	O
and	O	O
in	O	O
a	O	O
sandwich	O	O
immunoassay	O	O
was	O	O
similarly	O	O
reduced	O	O
by	O	O
PDTC	O	O
.	O	O

Kinetic	O	O
analyses	O	O
show	O	O
that	O	O
after	O	O
LPS	O	O
stimulation	O	O
,	O	O
NF-kappa	B-protein	O
B	I-protein	O
will	O	O
peak	O	O
at	O	O
1	O	O
h	O	O
,	O	O
TNF	B-protein	O
transcript	O	O
prevalence	O	O
at	O	O
2	O	O
h	O	O
,	O	O
and	O	O
TNF	B-protein	O
protein	I-protein	O
at	O	O
4	O	O
h	O	O
.	O	O

PDTC	O	O
did	O	O
not	O	O
shift	O	O
this	O	O
response	O	O
to	O	O
LPS	O	O
to	O	O
a	O	O
later	O	O
time	O	O
,	O	O
but	O	O
suppressed	O	O
NF-kappa	B-protein	O
B	I-protein	O
mobilization	O	O
,	O	O
TNF	B-protein	O
transcripts	I-protein	O
,	O	O
and	O	O
TNF	B-protein	O
protein	I-protein	O
over	O	O
the	O	O
entire	O	O
8-h	O	O
observation	O	O
period	O	O
.	O	O

Analysis	O	O
of	O	O
freshly	O	O
isolated	O	O
,	O	O
LPS-stimulated	B-cell_type	O
blood	I-cell_type	O
monocytes	I-cell_type	O
showed	O	O
a	O	O
similar	O	O
blockade	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
.	O	O

Furthermore	O	O
,	O	O
in	O	O
these	O	O
primary	B-cell_type	O
cells	I-cell_type	O
,	O	O
induction	O	O
of	O	O
TNF	B-protein	O
transcripts	B-protein	O
,	O	O
as	O	O
determined	O	O
by	O	O
Northern	O	O
blot	O	O
analysis	O	O
and	O	O
by	O	O
quantitative	O	O
polymerase	O	O
chain	O	O
reaction	O	O
,	O	O
was	O	O
prevented	O	O
by	O	O
PDTC	O	O
as	O	O
was	O	O
TNF	B-protein	O
protein	I-protein	O
production	O	O
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
dithiocarbamates	O	O
can	O	O
profoundly	O	O
affect	O	O
cytokine	B-protein	O
expression	O	O
and	O	O
suggest	O	O
that	O	O
NF-kappa	B-protein	O
B	I-protein	O
is	O	O
involved	O	O
in	O	O
LPS-induced	O	O
TNF	B-protein	O
gene	O	O
expression	O	O
in	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
.	O	O

Comparing	O	O
regions	O	O
of	O	O
the	O	O
Epstein-Barr	B-DNA	O
virus	O	O
ZEBRA	O	O
protein	O	O
which	O	O
function	O	O
as	O	O
transcriptional	O	O
activating	O	O
sequences	O	O
in	O	O
Saccharomyces	O	O
cerevisiae	O	O
and	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
ZEBRA	B-protein	O
protein	I-protein	O
activates	O	O
expression	O	O
of	O	O
Epstein-Barr	O	O
virus	O	O
early-lytic-cycle	O	O
genes	O	O
in	O	O
human	B-cell_type	O
B	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Here	O	O
it	O	O
is	O	O
shown	O	O
that	O	O
ZEBRA	O	O
also	O	O
behaves	O	O
as	O	O
a	O	O
sequence-specific	O	O
transcriptional	O	O
activator	O	O
in	O	O
Saccharomyces	O	O
cerevisiae	O	O
.	O	O

Deletional	O	O
mutagenesis	O	O
defined	O	O
three	O	O
regions	O	O
of	O	O
ZEBRA	O	O
that	O	O
participate	O	O
in	O	O
activation	O	O
in	O	O
S.	O	O
cerevisiae	O	O
.	O	O

These	O	O
regions	O	O
are	O	O
designated	O	O
YI	B-protein	O
(	O	O
amino	B-protein	O
acids	I-protein	O
[	O	O
aa	O	O
]	O	O
1	O	O
to	O	O
25	O	O
)	O	O
,	O	O
YII	O	O
(	O	O
aa	O	O
51	O	O
to	O	O
102	O	O
)	O	O
,	O	O
and	O	O
YIII	O	O
(	O	O
aa	O	O
228	O	O
to	O	O
245	O	O
)	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
three	B-DNA	O
regions	I-DNA	O
of	O	O
the	O	O
native	B-protein	O
ZEBRA	I-protein	O
protein	I-protein	O
act	O	O
together	O	O
to	O	O
mediate	O	O
activation	O	O
when	O	O
assayed	O	O
on	O	O
ZEBRA	O	O
binding	B-DNA	O
sites	I-DNA	O
.	O	O

However	O	O
,	O	O
when	O	O
fused	O	O
to	O	O
the	O	O
DNA	B-protein	O
binding	I-protein	O
domain	I-protein	O
of	O	O
GAL	B-protein	O
4	I-protein	O
and	O	O
assayed	O	O
on	O	O
GAL4	B-DNA	O
binding	I-DNA	O
sites	I-DNA	O
,	O	O
regions	O	O
YII	O	O
and	O	O
YIII	O	O
were	O	O
each	O	O
sufficient	O	O
to	O	O
confer	O	O
activation	O	O
in	O	O
S.	O	O
cerevisiae	O	O
.	O	O

Regions	O	O
of	O	O
ZEBRA	O	O
which	O	O
affected	O	O
activation	O	O
in	O	O
S.	O	O
cerevisiae	O	O
were	O	O
also	O	O
required	O	O
in	O	O
human	B-cell_type	O
B	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

The	O	O
amino-terminal	B-DNA	O
region	I-DNA	O
of	O	O
ZEBRA	O	O
(	O	O
aa	O	O
1	O	O
to	O	O
98	O	O
)	O	O
was	O	O
required	O	O
for	O	O
activation	O	O
both	O	O
in	O	O
S.	O	O
cerevisiae	O	O
and	O	O
in	O	O
human	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
;	O	O
deletion	O	O
of	O	O
the	O	O
carboxy-terminal	O	O
18	O	O
aa	O	O
also	O	O
significantly	O	O
reduced	O	O
activation	O	O
in	O	O
both	O	O
cell	I-cell_type	O
types	I-cell_type	O
.	O	O

Thus	O	O
,	O	O
the	O	O
behavior	O	O
of	O	O
ZEBRA	O	O
in	O	O
human	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
and	O	O
S.	O	O
cerevisiae	O	O
suggests	O	O
that	O	O
the	O	O
protein	O	O
contains	O	O
universal	O	O
activation	O	O
motifs	O	O
that	O	O
interact	O	O
with	O	O
conserved	O	O
components	O	O
of	O	O
the	O	O
transcription	B-protein	O
machinery	I-protein	O
.	O	O

However	O	O
,	O	O
certain	O	O
deletion	O	O
mutants	O	O
of	O	O
ZEBRA	O	O
containing	O	O
mutations	O	O
in	O	O
the	O	O
N-terminal	B-DNA	O
region	I-DNA	O
exhibited	O	O
discordant	O	O
behaviors	O	O
in	O	O
S.	O	O
cerevisiae	O	O
and	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
.	O	O

For	O	O
example	O	O
,	O	O
deletion	O	O
of	O	O
ZEBRA	O	O
aa	O	O
26	O	O
to	O	O
51	O	O
impaired	O	O
activation	O	O
to	O	O
a	O	O
great	O	O
extent	O	O
in	O	O
B	B-cell_type	O
cells	I-cell_type	O
but	O	O
had	O	O
little	O	O
or	O	O
no	O	O
effect	O	O
in	O	O
S.	O	O
cerevisiae	O	O
.	O	O

The	O	O
discordant	O	O
mutants	O	O
may	O	O
reflect	O	O
interactions	O	O
with	O	O
a	O	O
variable	O	O
domain	O	O
of	O	O
a	O	O
conserved	O	O
component	I-protein	O
or	O	O
unique	O	O
interactions	O	O
with	O	O
specialized	O	O
components	O	O
of	O	O
the	O	O
basal	O	O
transcription	O	O
apparatus	O	O
in	O	O
different	B-cell_type	O
cells	I-cell_type	O
.	O	O

Functional	O	O
interaction	O	O
of	O	O
the	O	O
v-Rel	B-DNA	O
and	I-DNA	O
c-Rel	I-DNA	O
oncoproteins	O	O
with	O	O
the	O	O
TATA-binding	B-protein	O
protein	I-protein	O
and	O	O
association	O	O
with	O	O
transcription	B-protein	O
factor	I-protein	O
IIB	O	O
.	O	O

Rel	B-protein	O
family	I-protein	O
proteins	I-protein	O
regulate	O	O
the	O	O
expression	O	O
of	O	O
genes	O	O
linked	O	O
to	O	O
kappa	B-protein	O
B-binding	I-protein	O
motifs	I-protein	O
.	O	O

Little	O	O
is	O	O
known	O	O
,	O	O
however	O	O
,	O	O
of	O	O
the	O	O
mechanism	O	O
by	O	O
which	O	O
they	O	O
enhance	O	O
transcription	O	O
.	O	O

We	O	O
have	O	O
investigated	O	O
the	O	O
ability	O	O
of	O	O
the	O	O
v-Rel	O	O
and	O	O
c-Rel	O	O
oncoproteins	O	O
to	O	O
interact	O	O
with	O	O
components	O	O
of	O	O
the	O	O
basal	O	O
transcription	O	O
machinery	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
both	O	O
the	O	O
acidic	B-protein	O
transcription	O	O
activation	O	O
domain	O	O
mapping	O	O
to	O	O
the	O	O
unique	B-protein	O
C	I-protein	O
terminus	O	O
of	O	O
chicken	O	O
c-Rel	O	O
and	O	O
the	O	O
F9	B-DNA	O
cell-specific	I-DNA	O
activation	O	O
region	O	O
common	O	O
to	O	O
both	O	O
v-Rel	O	O
and	O	O
c-Rel	O	O
interact	O	O
with	O	O
the	O	O
TATA-binding	B-protein	O
protein	I-protein	O
(	O	O
TBP	O	O
)	O	O
and	O	O
transcription	B-protein	O
factor	I-protein	O
IIB	O	O
(	O	O
TFIIB	O	O
)	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

We	O	O
also	O	O
demonstrate	O	O
that	O	O
TPB	O	O
interaction	O	O
with	O	O
Rel	O	O
activation	O	O
regions	O	O
leads	O	O
to	O	O
synergistic	O	O
activation	O	O
of	O	O
transcription	O	O
of	O	O
a	O	O
kappa	B-DNA	O
B-linked	I-DNA	O
reporter	I-DNA	O
gene	I-DNA	O
.	O	O

Combined	O	O
with	O	O
the	O	O
observation	O	O
that	O	O
the	O	O
mouse	B-DNA	O
c-Rel	I-DNA	O
and	O	O
human	B-protein	O
RelA	I-protein	O
proteins	I-protein	O
also	O	O
interact	O	O
with	O	O
TBP	O	O
and	O	O
TFIIB	O	O
in	O	O
vitro	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
association	O	O
with	O	O
basal	O	O
transcription	B-protein	O
factors	I-protein	O
is	O	O
important	O	O
for	O	O
the	O	O
transcriptional	O	O
activities	O	O
of	O	O
Rel	B-protein	O
family	I-protein	O
proteins	I-protein	O
.	O	O

p21ras	O	O
and	O	O
calcineurin	O	O
synergize	O	O
to	O	O
regulate	O	O
the	O	O
nuclear	B-protein	O
factor	I-protein	O
of	O	O
activated	B-cell_type	O
T	I-protein	O
cells	I-cell_type	O
.	O	O

In	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
triggering	O	O
of	O	O
the	O	O
T	B-protein	O
cell	I-protein	O
receptor	I-protein	O
(	O	O
TCR	B-protein	O
)	O	O
induces	O	O
several	O	O
signaling	O	O
cascades	O	O
which	O	O
ultimately	O	O
synergize	O	O
to	O	O
induce	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
nuclear	B-protein	O
factor	I-protein	O
of	O	O
activated	I-protein	O
T	I-protein	O
cells	I-protein	O
(	O	O
NFAT	B-protein	O
)	O	O
,	O	O
a	O	O
DNA	B-protein	O
binding	I-protein	O
complex	I-protein	O
critical	O	O
to	O	O
the	O	O
inducibility	O	O
and	O	O
T	O	O
cell	O	O
specificity	O	O
of	O	O
the	O	O
T	B-protein	O
cell	I-protein	O
growth	I-protein	O
factor	I-protein	O
interleukin	I-protein	O
2	I-protein	O
.	O	O

One	O	O
immediate	O	O
consequence	O	O
of	O	O
T	O	O
cell	O	O
activation	O	O
via	O	O
the	O	O
TCR	B-protein	O
is	O	O
an	O	O
increase	O	O
in	O	O
cytosolic	O	O
calcium	O	O
.	O	O

Calcium	O	O
signals	O	O
are	O	O
important	O	O
for	O	O
NFAT	B-protein	O
induction	O	O
,	O	O
and	O	O
recent	O	O
studies	O	O
have	O	O
identified	O	O
calcineurin	O	O
,	O	O
a	O	O
calcium-calmodulin	O	O
dependent	O	O
serine-threonine	O	O
phosphatase	O	O
,	O	O
as	O	O
a	O	O
prominent	O	O
component	O	O
of	O	O
the	O	O
calcium	O	O
signaling	O	O
pathway	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

A	O	O
second	O	O
important	O	O
molecule	O	O
in	O	O
TCR	B-protein	O
signal	O	O
transduction	O	O
is	O	O
the	O	O
guanine	O	O
nucleotide	O	O
binding	O	O
protein	O	O
,	O	O
p21ras	O	O
,	O	O
which	O	O
is	O	O
coupled	O	O
to	O	O
the	O	O
TCR	B-protein	O
by	O	O
a	O	O
protein	O	O
tyrosine	O	O
kinase	O	O
dependent	O	O
mechanism	O	O
.	O	O

The	O	O
experiments	O	O
presented	O	O
here	O	O
show	O	O
that	O	O
expression	O	O
by	O	O
transfection	O	O
of	O	O
mutationally	O	O
activated	O	O
calcineurin	B-protein	O
or	O	O
activated	O	O
p21ras	O	O
alone	O	O
is	O	O
insufficient	O	O
for	O	O
NFAT	O	O
transactivation	O	O
.	O	O

However	O	O
,	O	O
coexpression	O	O
of	O	O
the	O	O
activated	O	O
calcineurin	O	O
with	O	O
activated	O	O
p21ras	B-protein	O
could	O	O
mimic	O	O
TCR	B-protein	O
signals	O	O
in	O	O
NFAT	O	O
induction	O	O
.	O	O

These	O	O
data	O	O
identify	O	O
calcineurin	O	O
and	O	O
p21ras	O	O
as	O	O
cooperative	O	O
partners	O	O
in	O	O
T	O	O
cell	O	O
activation	O	O
.	O	O

Expression	O	O
of	O	O
the	O	O
chicken	B-protein	O
GATA	I-protein	O
factor	I-protein	O
family	I-protein	O
during	O	O
early	O	O
erythroid	O	O
development	O	O
and	O	O
differentiation	O	O
.	O	O

The	O	O
DNA	B-DNA	O
motif	I-DNA	O
WGATAR	O	O
has	O	O
been	O	O
identified	O	O
within	O	O
transcriptional	O	O
regulatory	O	O
domains	O	O
of	O	O
globin	O	O
and	O	O
other	O	O
erythroid-specific	O	O
genes	O	O
and	O	O
the	O	O
activator	B-protein	O
proteins	I-protein	O
that	O	O
bind	O	O
to	O	O
this	O	O
regulatory	B-DNA	O
element	I-DNA	O
,	O	O
the	O	O
GATA	B-protein	O
factors	I-protein	O
,	O	O
belong	O	O
to	O	O
a	O	O
multi-gene	B-protein	O
family	I-protein	O
that	O	O
is	O	O
expressed	O	O
in	O	O
chicken	B-cell_type	O
erythroid	B-cell_type	O
cells	I-cell_type	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
,	O	O
as	O	O
in	O	O
chickens	O	O
,	O	O
multiple	O	O
members	O	O
of	O	O
the	O	O
GATA	B-protein	O
factor	I-protein	O
family	I-protein	O
are	O	O
expressed	O	O
in	O	O
human	B-cell_type	O
and	I-cell_type	O
murine	I-cell_line	O
erythroid	I-cell_line	O
cells	I-cell_line	O
.	O	O

During	O	O
the	O	O
early	O	O
stages	O	O
of	O	O
chicken	O	O
embryogenesis	O	O
(	O	O
well	O	O
before	O	O
blood	O	O
island	O	O
formation	O	O
)	O	O
,	O	O
each	O	O
of	O	O
the	O	O
GATA	B-protein	O
family	I-protein	O
members	O	O
is	O	O
transcribed	O	O
with	O	O
a	O	O
unique	O	O
temporal	O	O
and	O	O
spatial	O	O
pattern	O	O
.	O	O

In	O	O
the	O	O
primitive	B-protein	O
erythroid	I-protein	O
lineage	I-protein	O
,	O	O
transcription	O	O
of	O	O
the	O	O
embryonic	B-DNA	O
epsilon-globin	I-DNA	O
gene	I-DNA	O
parallels	O	O
GATA-1	B-protein	O
expression	O	O
while	O	O
the	O	O
switch	O	O
to	O	O
beta-globin	O	O
transcription	O	O
in	O	O
definitive	B-cell_type	O
erythroid	B-cell_type	O
cells	I-cell_type	O
is	O	O
directly	O	O
preceded	O	O
by	O	O
a	O	O
pronounced	O	O
increase	O	O
in	O	O
GATA-3	O	O
accumulation	O	O
.	O	O

The	O	O
timing	O	O
and	O	O
pattern	O	O
of	O	O
expression	O	O
of	O	O
these	O	O
different	O	O
mRNAs	O	O
during	O	O
avian	O	O
erythroid	O	O
development	O	O
and	O	O
differentiation	O	O
suggests	O	O
that	O	O
temporally	O	O
regulated	O	O
changes	O	O
in	O	O
GATA	O	O
factor	O	O
expression	O	O
are	O	O
required	O	O
for	O	O
vertebrate	O	O
hematopoiesis	O	O
.	O	O

Molecular	O	O
regulation	O	O
of	O	O
human	O	O
interleukin	B-protein	O
2	I-protein	O
and	O	O
T-cell	O	O
function	O	O
by	O	O
interleukin	B-protein	O
4	I-protein	O
.	O	O

Distinct	O	O
functional	O	O
T-cell	O	O
subsets	O	O
,	O	O
differing	O	O
in	O	O
the	O	O
patterns	O	O
of	O	O
lymphokines	O	O
produced	O	O
,	O	O
regulate	O	O
cell-mediated	O	O
and	O	O
humoral	O	O
immune	O	O
responses	O	O
.	O	O

The	O	O
two	O	O
major	O	O
types	O	O
and	O	O
their	O	O
principal	O	O
products	B-protein	O
,	O	O
interleukin	B-protein	O
4	I-protein	O
and	O	O
interferon	B-protein	O
gamma	I-protein	O
(	O	O
IL-4	B-protein	O
and	O	O
IFN-gamma	B-protein	O
)	O	O
,	O	O
are	O	O
reciprocally	O	O
negatively	O	O
interactive	O	O
.	O	O

To	O	O
analyze	O	O
the	O	O
molecular	O	O
mechanism	O	O
of	O	O
IL-4-mediated	O	O
suppression	O	O
of	O	O
cell-mediated	O	O
immunity	O	O
we	O	O
studied	O	O
its	O	O
effects	O	O
on	O	O
expression	O	O
of	O	O
interleukin	B-protein	O
2	I-protein	O
(	O	O
IL-2	B-protein	O
)	O	O
and	O	O
IFN-gamma	B-protein	O
.	O	O

IL-4	O	O
pretreatment	O	O
of	O	O
Jurkat	B-cell_line	O
cells	I-cell_line	O
prior	O	O
to	O	O
stimulation	O	O
resulted	O	O
in	O	O
a	O	O
decrease	O	O
in	O	O
transcription	O	O
of	O	O
the	O	O
IL2	B-DNA	O
gene	I-DNA	O
.	O	O

IL-4	O	O
suppressed	O	O
IL-2	B-protein	O
and	O	O
IFN-gamma	B-RNA	O
mRNA	I-RNA	O
levels	O	O
in	O	O
primary	B-cell_line	O
human	I-cell_line	O
T	I-cell_line	O
cells	I-cell_type	O
,	O	O
and	O	O
addition	O	O
of	O	O
anti-CD28	O	O
antibodies	O	O
relieved	O	O
this	O	O
suppression	O	O
.	O	O

Using	O	O
enhancer-reporter	O	O
constructs	O	O
,	O	O
IL-4	O	O
specifically	O	O
down-regulated	O	O
the	O	O
NFIL-2B	O	O
element	I-DNA	O
.	O	O

Electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
using	O	O
a	O	O
DNA	O	O
oligomer	O	O
containing	O	O
the	O	O
NFIL-2B	B-DNA	O
binding	I-DNA	O
site	I-DNA	O
indicated	O	O
that	O	O
IL-4	O	O
inhibited	O	O
the	O	O
NFIL-2B	B-protein	O
complex	I-protein	O
and	O	O
that	O	O
the	O	O
NFIL-2B	B-protein	O
DNA	I-protein	O
binding	I-protein	O
factor	I-protein	O
is	O	O
distinct	O	O
from	O	O
AP-	O	O
1	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
IL-4	O	O
may	O	O
regulate	O	O
development	O	O
and	O	O
function	O	O
of	O	O
T-cell	O	O
subsets	O	O
involved	O	O
in	O	O
cell-mediated	O	O
immunity	O	O
in	O	O
part	O	O
by	O	O
inhibiting	B-protein	O
factors	I-protein	O
required	O	O
for	O	O
transcription	O	O
of	O	O
the	O	O
IL2	B-DNA	O
gene	I-DNA	O

Immunochemical	O	O
differences	O	O
between	O	O
glucocorticoid	O	O
receptors	O	O
from	O	O
corticoid-sensitive	O	O
and	O	O
-resistant	O	O
malignant	O	O
lymphocytes	I-cell_type	O
.	O	O

We	O	O
have	O	O
explored	O	O
the	O	O
possibility	O	O
of	O	O
using	O	O
antibodies	I-protein	O
against	O	O
purified	O	O
rat	O	O
liver	O	O
glucocorticoid	O	O
receptors	O	O
to	O	O
study	O	O
the	O	O
immunochemical	O	O
properties	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
from	O	O
murine	O	O
and	O	O
human	B-cell_type	O
malignant	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

For	O	O
this	O	O
purpose	O	O
,	O	O
purified	O	O
immune	O	O
immunoglobulin	O	O
G	O	O
was	O	O
covalently	O	O
linked	O	O
to	O	O
Sepharose	O	O
CL-4B	O	O
.	O	O

We	O	O
then	O	O
examined	O	O
the	O	O
ability	O	O
of	O	O
the	O	O
affinity	O	O
gel	O	O
to	O	O
recognize	O	O
cytosolic	O	O
[	O	O
3H	O	O
]	O	O
triamcinolone	O	O
acetonide-receptor	O	O
complexes	O	O
from	O	O
the	O	O
corticoid-sensitive	O	O
(	O	O
CS	O	O
)	O	O
and	O	O
-resistant	O	O
strains	O	O
of	O	O
mouse	O	O
lymphoma	O	O
P1798	O	O
,	O	O
from	O	O
CS	O	O
lymphocytes	O	O
of	O	O
patients	O	O
with	O	O
chronic	O	O
lymphatic	O	O
leukemia	O	O
,	O	O
and	O	O
from	O	O
a	O	O
CS	O	O
clone	O	O
of	O	O
human	O	O
leukemic	O	O
lymphoblasts	O	O
in	O	O
tissue	O	O
culture	O	O
(	O	O
CH6	O	O
)	O	O
.	O	O

Mouse	O	O
thymus	O	O
was	O	O
used	O	O
as	O	O
a	O	O
source	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
from	O	O
normal	B-cell_type	O
CS	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Whereas	O	O
the	O	O
immunoaffinity	O	O
column	O	O
retained	O	O
70	O	O
to	O	O
84	O	O
%	O	O
of	O	O
the	O	O
58-	O	O
to	O	O
62-A	O	O
(	O	O
Stokes	O	O
radius	O	O
)	O	O
[	O	O
3H	O	O
]	O	O
triamcinolone	O	O
acetonide-receptor	O	O
complexes	O	O
characteristic	O	O
of	O	O
the	O	O
CS	B-protein	O
mouse	I-protein	O
and	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
it	O	O
failed	O	O
to	O	O
recognize	O	O
the	O	O
27-	O	O
to	O	O
28-A	O	O
(	O	O
Stokes	O	O
radius	O	O
)	O	O
glucocorticoid	O	O
receptor	O	O
present	O	O
in	O	O
corticoid-resistant	O	O
mouse	B-cell_line	O
lymphoma	I-cell_line	O
P1798	I-cell_line	O
cells	I-cell_line	O
.	O	O

Therefore	O	O
,	O	O
under	O	O
appropriate	O	O
experimental	O	O
conditions	O	O
,	O	O
it	O	O
was	O	O
possible	O	O
to	O	O
demonstrate	O	O
cross-reactivity	O	O
between	O	O
the	O	O
antiserum	O	O
against	O	O
rat	O	O
liver	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
and	O	O
the	O	O
58-	O	O
to	O	O
62-A	O	O
(	O	O
Stokes	O	O
radius	O	O
)	O	O
glucocorticoid	O	O
receptor	O	O
from	O	O
species	O	O
as	O	O
diverse	O	O
as	O	O
mouse	O	O
and	O	O
humans	O	O
.	O	O

Heterogeneity	O	O
of	O	O
the	O	O
in	O	O
vitro	O	O
responses	O	O
to	O	O
glucocorticoids	O	O
in	O	O
acute	O	O
leukemia	O	O
.	O	O

In	O	O
leukocyte	O	O
population	O	O
freshly	O	O
isolated	O	O
from	O	O
the	O	O
blood	O	O
of	O	O
26	O	O
patients	O	O
with	O	O
acute	O	O
leukemia	O	O
,	O	O
we	O	O
have	O	O
measured	O	O
several	O	O
parameters	O	O
including	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
,	O	O
nucleoside	O	O
incorporation	O	O
,	O	O
percentage	O	O
of	O	O
cells	O	O
in	O	O
S	O	O
phase	O	O
,	O	O
and	O	O
steroid-induced	O	O
cell	O	O
lysis	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
in	O	O
some	O	O
cases	O	O
,	O	O
the	O	O
short-term	O	O
response	O	O
to	O	O
steroid	O	O
therapy	O	O
was	O	O
determined	O	O
.	O	O

Although	O	O
,	O	O
in	O	O
all	O	O
the	O	O
patients	O	O
studied	O	O
,	O	O
leukocytes	O	O
were	O	O
found	O	O
to	O	O
contain	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
,	O	O
we	O	O
failed	O	O
to	O	O
demonstrate	O	O
any	O	O
correlation	O	O
between	O	O
the	O	O
level	O	O
of	O	O
binding	O	O
sites	O	O
and	O	O
the	O	O
in	O	O
vitro	O	O
or	O	O
in	O	O
vivo	O	O
response	O	O
to	O	O
glucocorticoids	O	O
.	O	O

This	O	O
absence	O	O
of	O	O
correlation	O	O
could	O	O
be	O	O
in	O	O
part	O	O
explained	O	O
by	O	O
the	O	O
marked	O	O
heterogeneity	O	O
of	O	O
the	O	O
steroid	O	O
response	O	O
demonstrated	O	O
in	O	O
leukocyte	O	O
subpopulations	O	O
.	O	O

It	O	O
appears	O	O
,	O	O
however	O	O
,	O	O
that	O	O
the	O	O
degree	O	O
of	O	O
steroid	O	O
action	O	O
in	O	O
vitro	O	O
as	O	O
well	O	O
as	O	O
the	O	O
extent	O	O
of	O	O
spontaneous	O	O
and	O	O
dexamethasone-induced	O	O
cell	O	O
death	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
number	O	O
of	O	O
cells	I-cell_type	O
in	O	O
the	O	O
S	O	O
phase	O	O
of	O	O
the	O	O
cell	O	O
cycle	O	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
in	O	O
cytosol	O	O
and	O	O
nuclear	O	O
extract	O	O
of	O	O
human	O	O
leukocytes	O	O
.	O	O

Cortisol	O	O
binding	O	O
by	O	O
cytosol	O	O
and	O	O
0.4	O	O
M	O	O
KCl	O	O
extract	O	O
of	O	O
the	O	O
nuclear	O	O
fraction	O	O
of	O	O
human	O	O
leukocytes	O	O
were	O	O
studied	O	O
by	O	O
gel	O	O
chromatography	O	O
and	O	O
ion	O	O
exchange	O	O
filtration	O	O
on	O	O
DEAE	O	O
cellulose	O	O
.	O	O

The	O	O
cytoplasmic	B-protein	O
cortisol	I-protein	O
binding	I-protein	O
protein	I-protein	O
has	O	O
a	O	O
molecular	O	O
weight	O	O
95	O	O
000	O	O
and	O	O
the	O	O
soluble	O	O
nuclear	B-protein	O
binding	I-protein	O
protein	I-protein	O
50	O	O
000	O	O
.	O	O

The	O	O
absence	O	O
of	O	O
the	O	O
uptake	O	O
of	O	O
radioactive	B-protein	O
cortisol	O	O
by	O	O
isolated	O	O
nuclei	O	O
and	O	O
the	O	O
apparent	B-protein	O
requirement	O	O
of	O	O
the	O	O
cytosol	O	O
for	O	O
glucocorticoid	O	O
specific	O	O
binding	O	O
in	O	O
nuclear	B-protein	O
receptor	I-protein	O
sites	O	O
was	O	O
observed	O	O
.	O	O

The	O	O
association	O	O
constant	O	O
characterising	O	O
the	O	O
binding	O	O
of	O	O
cortisol	O	O
to	O	O
cytosol	O	O
was	O	O
KA	O	O
=	O	O
3.5	O	O
.	O	O
10	O	O
(	O	O
9	O	O
)	O	O
l/mol	O	O
.	O	O

Corticosteroid-induced	O	O
lymphopenia	O	O
,	O	O
immunosuppression	O	O
,	O	O
and	O	O
body	O	O
defense	O	O
.	O	O

The	O	O
apparent	O	O
paradox	O	O
of	O	O
heightened	O	O
adrenal	O	O
corticosteroid	O	O
levels	O	O
associated	O	O
with	O	O
reduction	O	O
in	O	O
the	O	O
competence	O	O
of	O	O
the	O	O
body	O	O
's	O	O
defensive	O	O
apparatus	O	O
to	O	O
cope	O	O
with	O	O
exposure	O	O
to	O	O
new	O	O
microbial	O	O
antigens	O	O
is	O	O
considered	O	O
.	O	O

The	O	O
question	O	O
is	O	O
asked	O	O
how	O	O
this	O	O
lowered	O	O
defensive	O	O
capability	O	O
,	O	O
which	O	O
occurs	O	O
in	O	O
the	O	O
face	O	O
of	O	O
a	O	O
threat	O	O
to	O	O
body	O	O
integrity	O	O
,	O	O
is	O	O
consistent	O	O
with	O	O
Cannon	O	O
's	O	O
principals	O	O
of	O	O
the	O	O
``	O	O
wisdom	O	O
of	O	O
the	O	O
body.	O	O
''	O	O

The	O	O
suggestion	O	O
is	O	O
offered	O	O
that	O	O
the	O	O
immunologic	O	O
response	O	O
to	O	O
self-antigens	O	O
exposed	O	O
by	O	O
disease	O	O
or	O	O
trauma	O	O
may	O	O
be	O	O
suppressed	O	O
by	O	O
corticosteroid	O	O
to	O	O
offset	O	O
the	O	O
likelihood	O	O
of	O	O
autoimmune	O	O
attack	O	O
.	O	O

Protein	O	O
tyrosine	O	O
kinase	O	O
activation	O	O
is	O	O
required	O	O
for	O	O
lipopolysaccharide	O	O
induction	O	O
of	O	O
cytokines	B-protein	O
in	O	O
human	B-cell_type	O
blood	I-cell_type	O
monocytes	I-cell_type	O
.	O	O

Bacterial	O	O
LPS	O	O
induce	O	O
production	O	O
of	O	O
cytokines	B-protein	O
such	O	O
as	O	O
IL-1	B-protein	O
,	O	O
IL-6	O	O
,	O	O
and	O	O
TNF	B-protein	O
in	O	O
mononuclear	O	O
phagocytes	O	O
,	O	O
and	O	O
this	O	O
represents	O	O
a	O	O
central	O	O
component	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
septic	O	O
shock	O	O
syndrome	O	O
.	O	O

However	O	O
,	O	O
the	O	O
mechanisms	O	O
by	O	O
which	O	O
LPS	O	O
activates	O	O
these	O	O
cells	O	O
to	O	O
express	O	O
cytokines	B-protein	O
are	O	O
not	O	O
completely	O	O
characterized	O	O
.	O	O

The	O	O
present	O	O
study	O	O
addressed	O	O
the	O	O
role	O	O
of	O	O
different	B-protein	O
protein	I-protein	O
kinases	I-protein	O
in	O	O
the	O	O
LPS	O	O
induction	O	O
of	O	O
cytokines	B-protein	O
.	O	O

It	O	O
is	O	O
shown	O	O
that	O	O
LPS	O	O
induced	O	O
a	O	O
12-	O	O
to	O	O
16-fold	O	O
increase	O	O
in	O	O
IL-1	B-protein	O
beta	I-protein	O
,	O	O
IL-6	O	O
,	O	O
and	O	O
TNF-alpha	O	O
mRNA	I-RNA	O
levels	O	O
,	O	O
and	O	O
this	O	O
was	O	O
completely	O	O
or	O	O
more	O	O
than	O	O
80	O	O
%	O	O
blocked	O	O
by	O	O
the	O	O
protein	O	O
tyrosine	O	O
kinase	O	O
specific	O	O
inhibitors	O	O
herbimycin	O	O
A	O	O
and	O	O
genistein	O	O
at	O	O
the	O	O
concentrations	O	O
of	O	O
1.7	O	O
and	O	O
37	O	O
microM	O	O
,	O	O
respectively	O	O
.	O	O

Protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
inhibition	O	O
by	O	O
staurosporine	O	O
reduced	O	O
LPS	O	O
induction	O	O
of	O	O
TNF-alpha	B-protein	O
,	O	O
whereas	O	O
it	O	O
had	O	O
no	O	O
effects	O	O
on	O	O
IL-6	O	O
and	O	O
IL-1	B-protein	O
beta	I-protein	O
.	O	O

Inhibition	O	O
of	O	O
protein	B-protein	O
kinase	I-protein	O
A	O	O
by	O	O
H89	O	O
reduced	O	O
IL-6	O	O
mRNA	B-RNA	O
levels	O	O
but	O	O
did	O	O
not	O	O
detectably	O	O
change	O	O
IL-1	B-protein	O
beta	O	O
or	O	O
TNF-alpha	O	O
mRNA	O	O
levels	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
LPS	O	O
did	O	O
not	O	O
increase	O	O
leukemia	O	O
inhibitory	O	O
factor	O	O
mRNA	I-RNA	O
,	O	O
which	O	O
was	O	O
constitutively	O	O
expressed	O	O
and	O	O
not	O	O
significantly	O	O
reduced	O	O
by	O	O
these	O	O
inhibitors	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
cytokine	O	O
mRNA	B-RNA	O
levels	O	O
,	O	O
LPS-induced	O	O
IL-6	O	O
protein	O	O
synthesis	O	O
and	O	O
IL-6	O	O
bioactivity	O	O
were	O	O
also	O	O
reduced	O	O
to	O	O
baseline	O	O
levels	O	O
by	O	O
the	O	O
PTK	O	O
inhibitors	O	O
herbimycin	O	O
A	O	O
and	O	O
genistein	O	O
.	O	O

Both	O	O
PTK	O	O
inhibitors	O	O
also	O	O
reduced	O	O
the	O	O
LPS	O	O
activation	O	O
of	O	O
nuclear	B-protein	O
factor-kappa	I-protein	O
B	I-protein	O
(	O	O
NF-kappa	B-protein	O
B	I-protein	O
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
transcription	B-protein	O
factor	I-protein	O
involved	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
cytokine	B-protein	O
genes	O	O
such	O	O
as	O	O
IL-6	O	O
and	O	O
TNF-alpha	O	O
.	O	O

The	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
was	O	O
also	O	O
reduced	O	O
by	O	O
H89	O	O
,	O	O
whereas	O	O
staurosporine	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
this	O	O
response	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
these	O	O
findings	O	O
suggest	O	O
that	O	O
protein	B-protein	O
kinase	I-protein	O
C	I-protein	O
and	I-protein	O
protein	I-protein	O
kinase	I-protein	O
A	O	O
appear	O	O
to	O	O
have	O	O
selective	O	O
effects	O	O
in	O	O
the	O	O
LPS	O	O
induction	O	O
of	O	O
cytokines	B-protein	O
,	O	O
whereas	O	O
PTK	O	O
is	O	O
required	O	O
for	O	O
LPS	O	O
induction	O	O
of	O	O
a	O	O
broad	O	O
spectrum	O	O
of	O	O
cytokines	B-protein	O
and	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
in	O	O
monocytes	B-cell_type	O
.	O	O

In	O	O
vivo	O	O
control	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
by	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
.	O	O

The	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappa	B-protein	O
B	I-protein	O
is	O	O
stored	O	O
in	O	O
the	O	O
cytoplasm	O	O
in	O	O
complexes	O	O
with	O	O
the	O	O
inhibitor	O	O
protein	B-protein	O
I	I-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
in	O	O
vitro	O	O
that	O	O
dissociation	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
from	O	O
these	O	O
complexes	O	O
results	O	O
in	O	O
active	O	O
NF-kappa	B-protein	O
B	I-protein	O
.	O	O

In	O	O
this	O	O
report	O	O
we	O	O
show	O	O
that	O	O
lipopolysaccharide	O	O
(	O	O
LPS	O	O
)	O	O
-induced	O	O
activation	O	O
of	O	O
B	B-cell_type	O
or	O	O
pre-B	B-cell_type	O
cells	I-cell_type	O
results	O	O
in	O	O
loss	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
from	O	O
NF-kappa	B-protein	O
B	I-protein	O
complexes	O	O
in	O	O
vivo	O	O
.	O	O

Many	O	O
liberated	O	O
NF-kappa	B-protein	O
B	I-protein	O
dimers	O	O
reached	O	O
the	O	O
nucleus	O	O
,	O	O
where	O	O
increased	O	O
c-rel	O	O
,	O	O
p65	B-protein	O
and	O	O
p50	O	O
were	O	O
detected	O	O
by	O	O
immunoblotting	O	O
and	O	O
by	O	O
DNA	O	O
binding	O	O
assays	O	O
.	O	O

Some	O	O
liberated	O	O
dimers	O	O
were	O	O
retained	O	O
in	O	O
the	O	O
cytoplasm	O	O
,	O	O
however	O	O
,	O	O
through	O	O
binding	O	O
to	O	O
newly	O	O
synthesized	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
,	O	O
a	O	O
finding	O	O
which	O	O
strongly	O	O
suggests	O	O
(	O	O
i	O	O
)	O	O
that	O	O
the	O	O
LPS-induced	O	O
signal	O	O
causes	O	O
dissociation	O	O
of	O	O
complexes	O	O
rather	O	O
than	O	O
preventing	O	O
their	O	O
association	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
that	O	O
dissociation	O	O
results	O	O
from	O	O
modification	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
and	O	O
not	O	O
of	O	O
c-rel	B-protein	O
or	O	O
p65	B-protein	O
.	O	O

No	O	O
effect	O	O
of	O	O
LPS	O	O
treatment	O	O
was	O	O
detected	O	O
on	O	O
p105	O	O
or	O	O
p100	O	O
,	O	O
which	O	O
also	O	O
retain	O	O
rel	O	O
family	O	O
members	O	O
in	O	O
the	O	O
cytoplasm	O	O
.	O	O

Quite	O	O
unexpectedly	O	O
,	O	O
we	O	O
also	O	O
found	O	O
that	O	O
in	O	O
unstimulated	B-cell_type	O
cells	I-cell_type	O
there	O	O
is	O	O
a	O	O
constant	O	O
ongoing	O	O
process	O	O
of	O	O
degradation	O	O
and	O	O
replacement	O	O
of	O	O
complexed	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
.	O	O

We	O	O
propose	O	O
that	O	O
this	O	O
turnover	O	O
results	O	O
in	O	O
the	O	O
low	O	O
level	O	O
of	O	O
active	O	O
NF-kappa	B-protein	O
B	I-protein	O
presumably	O	O
necessary	O	O
even	O	O
in	O	O
the	O	O
unstimulated	O	O
cell	O	O
,	O	O
and	O	O
that	O	O
the	O	O
high	O	O
rate	O	O
of	O	O
synthesis	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
provides	O	O
the	O	O
ability	O	O
to	O	O
turn	O	O
off	O	O
NF-kappa	B-protein	O
B	I-protein	O
activity	O	O
rapidly	O	O
as	O	O
soon	O	O
as	O	O
the	O	O
activating	O	O
signal	O	O
ceases	O	O
.	O	O

Identification	O	O
of	O	O
a	O	O
killer	B-DNA	O
cell-specific	I-DNA	O
regulatory	I-DNA	O
element	I-DNA	O
of	O	O
the	O	O
mouse	B-DNA	O
perforin	I-DNA	O
gene	I-DNA	O
:	O	O
an	O	O
Ets-binding	O	O
site-homologous	O	O
motif	O	O
that	O	O
interacts	O	O
with	O	O
Ets-related	B-protein	O
proteins	I-protein	O
.	O	O

The	O	O
gene	O	O
encoding	O	O
the	O	O
cytolytic	O	O
protein	O	O
perforin	O	O
is	O	O
selectively	O	O
expressed	O	O
by	O	O
activated	B-cell_type	O
killer	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

To	O	O
understand	O	O
the	O	O
mechanisms	O	O
underlying	O	O
the	O	O
cell-type-specific	O	O
expression	O	O
of	O	O
this	O	O
gene	O	O
,	O	O
we	O	O
have	O	O
characterized	O	O
the	O	O
regulatory	O	O
functions	O	O
and	O	O
the	O	O
DNA-protein	O	O
interactions	O	O
of	O	O
the	O	O
5'-flanking	B-DNA	O
region	I-DNA	O
of	O	O
the	O	O
mouse	B-DNA	O
perforin	I-DNA	O
gene	I-DNA	O
(	O	O
Pfp	B-protein	O
)	O	O
.	O	O

A	O	O
region	O	O
extending	O	O
from	O	O
residues	O	O
+62	O	O
through	O	O
-141	O	O
,	O	O
which	O	O
possesses	O	O
the	O	O
essential	O	O
promoter	O	O
activity	O	O
,	O	O
and	O	O
regions	O	O
further	O	O
upstream	O	O
,	O	O
which	O	O
are	O	O
able	O	O
to	O	O
either	O	O
enhance	O	O
or	O	O
suppress	O	O
gene	O	O
expression	O	O
,	O	O
were	O	O
identified	O	O
.	O	O

The	O	O
region	O	O
between	O	O
residues	O	O
-411	O	O
and	O	O
-566	O	O
was	O	O
chosen	O	O
for	O	O
further	O	O
characterization	O	O
,	O	O
since	O	O
it	O	O
contains	O	O
an	O	O
enhancer-like	O	O
activity	O	O
.	O	O

We	O	O
have	O	O
identified	O	O
a	O	O
32-mer	B-DNA	O
sequence	I-DNA	O
(	O	O
residues	O	O
-491	O	O
to	O	O
-522	O	O
)	O	O
which	O	O
appeared	O	O
to	O	O
be	O	O
capable	O	O
of	O	O
enhancing	O	O
gene	O	O
expression	O	O
in	O	O
a	O	O
killer	O	O
cell-specific	O	O
manner	O	O
.	O	O

Within	O	O
this	O	O
segment	O	O
,	O	O
a	O	O
9-mer	O	O
motif	O	O
(	O	O
5'-ACAGGAAGT-3	B-DNA	O
'	I-DNA	O
,	O	O
residues	O	O
-505	O	O
to	O	O
-497	O	O
;	O	O
designated	O	O
NF-P	O	O
motif	O	O
)	O	O
,	O	O
which	O	O
is	O	O
highly	O	O
homologous	O	O
to	O	O
the	O	O
Ets	B-DNA	O
proto-oncoprotein-binding	I-DNA	O
site	I-DNA	O
,	O	O
was	O	O
found	O	O
to	O	O
interact	O	O
with	O	O
two	O	O
proteins	I-protein	O
,	O	O
NF-P1	O	O
and	O	O
NF-P2	O	O
.	O	O

NF-P2	O	O
appears	O	O
to	O	O
be	O	O
induced	O	O
by	O	O
reagents	O	O
known	O	O
to	O	O
up-regulate	O	O
the	O	O
perforin	O	O
message	O	O
level	O	O
and	O	O
is	O	O
present	O	O
exclusively	O	O
in	O	O
killer	B-cell_type	O
cells	I-cell_type	O
.	O	O

Electrophoretic	O	O
mobility	O	O
shift	O	O
assay	O	O
and	O	O
UV	O	O
cross-linking	O	O
experiments	O	O
revealed	O	O
that	O	O
NF-P1	O	O
and	O	O
NF-P2	O	O
may	O	O
possess	O	O
common	O	O
DNA-binding	O	O
subunits	O	O
.	O	O

However	O	O
,	O	O
the	O	O
larger	O	O
native	O	O
molecular	O	O
mass	O	O
of	O	O
NF-P1	O	O
suggests	O	O
that	O	O
NF-P1	O	O
contains	O	O
an	O	O
additional	O	O
non-DNA-binding	O	O
subunit	O	O
(	O	O
s	O	O
)	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
homology	O	O
between	O	O
the	O	O
NF-P	B-DNA	O
motif	I-DNA	O
and	O	O
other	O	O
Ets	O	O
proto-oncoprotein-binding	I-DNA	O
sites	I-DNA	O
,	O	O
it	O	O
is	O	O
postulated	O	O
that	O	O
NF-P1	O	O
and	O	O
NF-P2	O	O
belong	O	O
to	O	O
the	O	O
Ets	B-protein	O
protein	I-protein	O
family	I-protein	O
.	O	O

Results	O	O
obtained	O	O
from	O	O
the	O	O
binding	O	O
competition	O	O
assay	O	O
,	O	O
nevertheless	O	O
,	O	O
suggest	O	O
that	O	O
NF-P1	O	O
and	O	O
NF-P2	O	O
are	O	O
related	O	O
to	O	O
but	O	O
distinct	O	O
from	O	O
Ets	B-protein	O
proteins	I-protein	O
,	O	O
e.g.	O	O
,	O	O
Ets-1	O	O
,	O	O
Ets-2	O	O
,	O	O
and	O	O
NF-AT/Elf-1	O	O
,	O	O
known	O	O
to	O	O
be	O	O
expressed	O	O
in	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
role	O	O
of	O	O
NF-kappa	B-protein	O
B1	I-protein	O
(	O	O
p50/p105	B-protein	O
)	O	O
gene	O	O
expression	O	O
in	O	O
activation	O	O
of	O	O
human	O	O
blood	O	O
T-lymphocytes	O	O
via	O	O
CD2	O	O
and	O	O
CD28	B-protein	O
adhesion	I-protein	O
molecules	I-protein	O
.	O	O

Stimulation	O	O
of	O	O
primary	B-protein	O
human	O	O
T-lymphocytes	O	O
via	O	O
CD2	O	O
and	O	O
CD28	B-protein	O
adhesion	I-protein	O
molecules	I-protein	O
induces	O	O
a	O	O
long-lasting	O	O
proliferation	O	O
(	O	O
>	O	O
3	I-protein	O
weeks	I-protein	O
)	O	O
.	O	O

This	O	O
potent	O	O
activation	O	O
does	O	O
not	O	O
require	O	O
accessory	O	O
cells	O	O
,	O	O
such	O	O
as	O	O
monocytes	B-cell_type	O
,	O	O
but	O	O
depends	O	O
on	O	O
persistent	O	O
interleukin	B-protein	O
2	I-protein	O
(	O	O
IL-2	B-protein	O
)	O	O
secretion	O	O
and	O	O
receptivity	O	O
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
high	O	O
and	O	O
prolonged	O	O
expression	O	O
of	O	O
the	O	O
inducible	B-DNA	O
CD25/IL-2	I-DNA	O
receptor	I-DNA	O
alpha	I-DNA	O
(	I-DNA	O
IL-2R	I-DNA	O
alpha	I-DNA	O
)	I-DNA	O
chain	I-DNA	O
gene	I-DNA	O
.	O	O

The	O	O
transcription	B-protein	O
factor	I-protein	O
NF-kappa	B-protein	O
B	I-protein	O
participates	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
both	O	O
IL-2	B-protein	O
and	O	O
IL-2R	B-DNA	O
alpha	I-DNA	O
genes	I-DNA	O
,	O	O
as	O	O
well	O	O
as	O	O
multiple	O	O
cellular	B-DNA	O
genes	I-DNA	O
involved	O	O
in	O	O
T-cell	O	O
proliferation	O	O
.	O	O

To	O	O
evaluate	O	O
the	O	O
role	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
in	O	O
human	O	O
peripheral	B-protein	O
blood	I-protein	O
T-lymphocytes	O	O
,	O	O
we	O	O
previously	O	O
analyzed	O	O
the	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B-related	I-protein	O
complexes	I-protein	O
in	O	O
response	O	O
to	O	O
CD2+CD28	O	O
costimulation	O	O
.	O	O

We	O	O
demonstrated	O	O
a	O	O
long-term	O	O
induction	O	O
of	O	O
p50/p65	B-protein	O
heterodimer	I-protein	O
,	O	O
a	O	O
putative	B-protein	O
p65/c-Rel	I-protein	O
heterodimer	I-protein	O
,	O	O
and	O	O
a	O	O
constitutive	O	O
nuclear	O	O
expression	O	O
of	O	O
KBF1/p50	O	O
homodimers	O	O
.	O	O

As	O	O
the	O	O
role	O	O
of	O	O
p50	O	O
remains	O	O
unclear	O	O
,	O	O
we	O	O
focused	O	O
our	O	O
present	O	O
study	O	O
on	O	O
NF-kappa	B-protein	O
B1	I-protein	O
(	O	O
p50/p105	O	O
)	O	O
gene	O	O
regulation	O	O
.	O	O

Using	O	O
electrophoretic	O	O
mobility	O	O
shift	O	O
assays	O	O
and	O	O
Western	O	O
and	O	O
Northern	O	O
blot	O	O
analyses	O	O
,	O	O
we	O	O
studied	O	O
NF-kappa	B-protein	O
B1	I-protein	O
gene	O	O
expression	O	O
during	O	O
T-cell	O	O
stimulation	O	O
via	O	O
CD2+CD28	O	O
.	O	O

We	O	O
observed	O	O
a	O	O
transient	O	O
4-	O	O
to	O	O
5-fold	O	O
increase	O	O
of	O	O
NF-kappa	B-protein	O
B1	I-protein	O
gene	I-DNA	O
expression	O	O
at	O	O
both	O	O
the	O	O
mRNA	B-RNA	O
and	O	O
protein	O	O
levels	O	O
,	O	O
lasting	O	O
for	O	O
at	O	O
least	O	O
24	O	O
h	O	O
.	O	O

p50	O	O
DNA-binding	O	O
activity	O	O
apparently	O	O
stays	O	O
highly	O	O
controlled	O	O
when	O	O
p105	O	O
expression	O	O
is	O	O
enhanced	O	O
by	O	O
a	O	O
physiological	O	O
stimulus	O	O
of	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
T-cells	O	O
.	O	O

Partial	O	O
inhibition	O	O
of	O	O
p50	B-protein	O
and	O	O
p105	O	O
expression	O	O
by	O	O
NF-kappa	B-protein	O
B1	O	O
antisense	O	O
oligonucleotides	O	O
significantly	O	O
reduced	O	O
T-cell	O	O
proliferation	O	O
and	O	O
CD25/IL-2R	B-protein	O
alpha	I-protein	O
cell	O	O
surface	O	O
expression	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O

Vitamin	O	O
D	O	O
receptor	O	O
quantitation	O	O
in	O	O
human	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
in	O	O
health	O	O
and	O	O
disease	O	O
.	O	O

Vitamin	O	O
D	O	O
receptor	O	O
(	O	O
VDR	O	O
)	O	O
concentration	O	O
was	O	O
quantitated	O	O
in	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
(	O	O
PBMC	O	O
)	O	O
from	O	O
patients	O	O
with	O	O
absorptive	O	O
hypercalciuria	O	O
(	O	O
AH	O	O
)	O	O
and	O	O
patients	O	O
with	O	O
high	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
due	O	O
to	O	O
acquired	O	O
or	O	O
transient	O	O
disease	O	O
states	O	O
and	O	O
the	O	O
results	O	O
compared	O	O
to	O	O
those	O	O
in	O	O
normal	O	O
subjects	O	O
.	O	O

VDR	O	O
concentration	O	O
in	O	O
resting	B-cell_type	O
cells	I-cell_type	O
was	O	O
not	O	O
different	O	O
between	O	O
the	O	O
three	O	O
groups	O	O
and	O	O
represented	O	O
constitutive	O	O
receptor	I-protein	O
expression	O	O
of	O	O
monocytes	B-cell_type	O
.	O	O

Following	O	O
activation	O	O
with	O	O
phytohemagglutinin	O	O
,	O	O
patients	O	O
with	O	O
hypercalcitriolemia	O	O
demonstrated	O	O
significantly	O	O
greater	O	O
VDR	O	O
concentrations	O	O
.	O	O

Patients	O	O
with	O	O
AH	O	O
demonstrated	O	O
a	O	O
normal	O	O
value	O	O
for	O	O
the	O	O
group	O	O
,	O	O
but	O	O
6	O	O
patients	O	O
had	O	O
significantly	O	O
greater	O	O
concentrations	O	O
of	O	O
VDR	O	O
despite	O	O
normal	O	O
plasma	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
in	O	O
four	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

Proliferation	O	O
,	O	O
as	O	O
assessed	O	O
from	O	O
[	O	O
3H	O	O
]	O	O
thymidine	O	O
incorporation	O	O
was	O	O
inversely	O	O
correlated	O	O
with	O	O
serum	O	O
1	O	O
,	O	O
25	O	O
(	O	O
OH	O	O
)	O	O
2D3	O	O
and	O	O
was	O	O
significant	O	O
(	O	O
R	O	O
=	O	O
-0.299	O	O
,	O	O
p	O	O
=	O	O
0.048	O	O
)	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
the	O	O
results	O	O
suggest	O	O
that	O	O
PBMC	O	O
provide	O	O
a	O	O
useful	O	O
system	O	O
for	O	O
studying	O	O
VDR	O	O
status	O	O
in	O	O
transient	O	O
or	O	O
acquired	O	O
states	O	O
of	O	O
hypercalcitriolemia	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
studies	O	O
in	O	O
patients	O	O
with	O	O
absorptive	O	O
hypercalciuria	O	O
disclosed	O	O
it	O	O
to	O	O
be	O	O
a	O	O
heterogeneous	O	O
disorder	O	O
,	O	O
characterized	O	O
by	O	O
both	O	O
vitamin	O	O
D-dependent	O	O
and	O	O
D-independent	O	O
forms	O	O
of	O	O
receptor	O	O
up-regulation	O	O
.	O	O

Reactive	O	O
oxygen	O	O
intermediates	O	O
activate	O	O
NF-kappa	B-protein	O
B	I-protein	O
in	O	O
a	O	O
tyrosine	O	O
kinase-dependent	O	O
mechanism	O	O
and	O	O
in	O	O
combination	O	O
with	O	O
vanadate	O	O
activate	O	O
the	O	O
p56lck	O	O
and	O	O
p59fyn	O	O
tyrosine	O	O
kinases	O	O
in	O	O
human	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

We	O	O
have	O	O
previously	O	O
observed	O	O
that	O	O
ionizing	O	O
radiation	O	O
induces	O	O
tyrosine	O	O
phosphorylation	O	O
in	O	O
human	O	O
B-lymphocyte	O	O
precursors	O	O
by	O	O
stimulation	O	O
of	O	O
unidentified	O	O
tyrosine	O	O
kinases	I-protein	O
and	O	O
this	O	O
phosphorylation	O	O
is	O	O
substantially	O	O
augmented	O	O
by	O	O
vanadate	O	O
.	O	O

Ionizing	O	O
radiation	O	O
generates	O	O
reactive	O	O
oxygen	O	O
intermediates	O	O
(	O	O
ROI	B-protein	O
)	O	O
.	O	O

Because	O	O
H2O2	O	O
is	O	O
a	O	O
potent	O	O
ROI	O	O
generator	O	O
that	O	O
readily	O	O
crosses	O	O
the	O	O
plasma	O	O
membrane	O	O
,	O	O
we	O	O
used	O	O
H2O2	O	O
to	O	O
examine	O	O
the	O	O
effects	O	O
of	O	O
ROI	O	O
on	O	O
signal	O	O
transduction	O	O
.	O	O

We	O	O
now	O	O
provide	O	O
evidence	O	O
that	O	O
the	O	O
tyrosine	O	O
kinase	O	O
inhibitor	O	O
herbimycin	O	O
A	O	O
and	O	O
the	O	O
free	O	O
radical	O	O
scavenger	O	O
N-acetyl-cysteine	O	O
inhibit	O	O
both	O	O
radiation-induced	O	O
and	O	O
H2O2-induced	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
,	O	O
indicating	O	O
that	O	O
activation	O	O
triggered	O	O
by	O	O
ROI	O	O
is	O	O
dependent	O	O
on	O	O
tyrosine	B-protein	O
kinase	I-protein	O
activity	O	O
.	O	O

H2O2	O	O
was	O	O
found	O	O
to	O	O
stimulate	O	O
Ins-1	O	O
,	O	O
4	O	O
,	O	O
5-P3	O	O
production	O	O
in	O	O
a	O	O
tyrosine	O	O
kinase-dependent	O	O
manner	O	O
and	O	O
to	O	O
induce	O	O
calcium	O	O
signals	O	O
that	O	O
were	O	O
greatly	O	O
augmented	O	O
by	O	O
vanadate	O	O
.	O	O

The	O	O
synergistic	O	O
induction	O	O
of	O	O
tyrosine	O	O
phosphorylation	O	O
by	O	O
H2O2	O	O
plus	O	O
vanadate	O	O
included	O	O
physiologically	O	O
relevant	O	O
proteins	O	O
such	O	O
as	O	O
PLC	O	O
gamma	O	O
1	O	O
.	O	O

Although	O	O
treatment	O	O
of	O	O
cells	O	O
with	O	O
H2O2	O	O
alone	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
activity	O	O
of	O	O
src	B-protein	O
family	I-protein	O
kinases	I-protein	O
,	O	O
treatment	O	O
with	O	O
H2O2	O	O
plus	O	O
vanadate	O	O
led	O	O
to	O	O
activation	O	O
of	O	O
the	O	O
p56lck	B-protein	O
and	O	O
p59fyn	B-protein	O
tyrosine	I-protein	O
kinases	I-protein	O
.	O	O

The	O	O
combined	O	O
inhibition	O	O
of	O	O
phosphatases	B-protein	O
and	O	O
activation	O	O
of	O	O
kinases	B-protein	O
provides	O	O
a	O	O
potent	O	O
mechanism	O	O
for	O	O
the	O	O
synergistic	O	O
effects	O	O
of	O	O
H2O2	O	O
plus	O	O
vanadate	O	O
.	O	O

Induction	O	O
of	O	O
tyrosine	O	O
phosphorylation	O	O
by	O	O
ROI	O	O
may	O	O
thus	O	O
lead	O	O
to	O	O
many	O	O
of	O	O
the	O	O
pleiotropic	O	O
effects	O	O
of	O	O
ROI	O	O
in	O	O
lymphoid	B-cell_type	O
cells	I-cell_type	O
,	O	O
including	O	O
downstream	O	O
activation	O	O
of	O	O
PLC	O	O
gamma	O	O
1	O	O
and	O	O
NF-kappa	B-protein	O
B	I-protein	O

Influence	O	O
of	O	O
sex	B-protein	O
hormone	I-protein	O
binding	O	O
globulin	O	O
and	O	O
serum	O	O
albumin	O	O
on	O	O
the	O	O
conversion	O	O
of	O	O
androstenedione	O	O
to	O	O
testosterone	O	O
by	O	O
human	B-protein	O
erythrocytes	I-protein	O
.	O	O

The	O	O
influence	O	O
of	O	O
human	B-protein	O
serum	I-protein	O
albumin	I-protein	O
and	O	O
sex	B-protein	O
hormone	I-protein	O
binding	I-protein	O
globulin	I-protein	O
(	O	O
SHBG	B-protein	O
)	O	O
on	O	O
the	O	O
enzymic	O	O
conversion	O	O
of	O	O
androstenedione	O	O
to	O	O
testosterone	O	O
in	O	O
human	O	O
erythrocytes	O	O
was	O	O
investigated	O	O
in	O	O
vitro	O	O
.	O	O

Total	O	O
plasma	O	O
and	O	O
albumin	O	O
delayed	O	O
the	O	O
conversion	O	O
rate	O	O
of	O	O
androstenedione	O	O
,	O	O
while	O	O
SHBG	O	O
increased	O	O
it	O	O
markedly	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
SHBG	O	O
was	O	O
largely	O	O
abolished	O	O
by	O	O
heating	O	O
to	O	O
60	O	O
degrees	O	O
C	O	O
for	O	O
1	O	O
h	O	O
and	O	O
by	O	O
saturating	O	O
its	O	O
binding	O	O
sites	O	O
by	O	O
DHT	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
both	O	O
proteins	O	O
was	O	O
found	O	O
to	O	O
be	O	O
related	O	O
to	O	O
their	O	O
concentration	O	O
.	O	O

It	O	O
appears	O	O
that	O	O
the	O	O
binding	B-DNA	O
sites	I-DNA	O
of	O	O
albumin	O	O
provide	O	O
a	O	O
mechanism	O	O
for	O	O
retarding	O	O
androstenedione	O	O
uptake	O	O
by	O	O
the	O	O
erythrocytes	O	O
and	O	O
that	O	O
the	O	O
high	O	O
binding	O	O
affinity	O	O
of	O	O
SHBG	O	O
for	O	O
testosterone	O	O
facilitates	O	O
the	O	O
diffusion	O	O
of	O	O
this	O	O
steroid	O	O
out	O	O
of	O	O
the	O	O
cell	B-protein	O
and	O	O
thus	O	O
,	O	O
displaces	O	O
the	O	O
chemical	O	O
equilibrium	O	O
within	O	O
the	O	O
cell	O	O
.	O	O

Glucocorticoids	O	O
and	O	O
lymphocytes	I-cell_type	O
.	O	O

I	B-protein	O
.	O	O

Increased	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
levels	O	O
in	O	O
antigen-stimulated	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Recently	O	O
a	O	O
2-	O	O
to	O	O
3-fold	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
lymphocytes	I-cell_type	O
has	O	O
been	O	O
noted	O	O
after	O	O
in	O	O
vitro	O	O
mitogen	O	O
stimulation	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
extend	O	O
these	O	O
observations	O	O
to	O	O
in	O	O
vivo	O	O
immunization	O	O
.	O	O

After	O	O
unilateral	O	O
immunization	O	O
of	O	O
adrenalectomized	O	O
male	O	O
rats	O	O
,	O	O
a	O	O
50	O	O
%	O	O
increase	O	O
in	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
sites	O	O
per	O	O
cell	O	O
,	O	O
determined	O	O
by	O	O
binding	O	O
of	O	O
dexamethasone	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
cell	O	O
suspensions	O	O
of	O	O
homolateral	O	O
lymph	O	O
nodes	O	O
over	O	O
those	O	O
from	O	O
the	O	O
contralateral	O	O
nonimmunized	O	O
side	O	O
of	O	O
the	O	O
same	O	O
animal	O	O
.	O	O

The	O	O
association	O	O
constant	O	O
for	O	O
dexamethasone	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
as	O	O
was	O	O
the	O	O
stereospecificity	O	O
for	O	O
various	O	O
steroids	O	O
,	O	O
the	O	O
time	O	O
course	O	O
of	O	O
cytoplasmic	B-protein	O
and	O	O
nuclear	O	O
association	O	O
,	O	O
and	O	O
cytoplasmic-to-nuclear	O	O
translocation	O	O
.	O	O

Despite	O	O
a	O	O
50	O	O
%	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
sites	O	O
per	O	O
cell	O	O
,	O	O
the	O	O
cells	O	O
from	O	O
the	O	O
homolateral	O	O
and	O	O
controlateral	O	O
lymph	O	O
nodes	O	O
were	O	O
equally	O	O
sensitive	O	O
to	O	O
the	O	O
inhibitory	O	O
effects	O	O
of	O	O
dexamethasone	O	O
,	O	O
as	O	O
determined	O	O
by	O	O
measurements	O	O
of	O	O
the	O	O
incorporation	O	O
of	O	O
radiolabeled	B-protein	O
precursors	I-protein	O
of	O	O
protein	B-protein	O
,	O	O
RNA	B-protein	O
,	O	O
and	O	O
DNA	B-protein	O
,	O	O
or	O	O
measurements	O	O
of	O	O
in	O	O
vitro	O	O
cell	O	O
survival	O	O
.	O	O

Glucocorticoid	O	O
receptors	O	O
and	O	O
actions	O	O
in	O	O
rat	O	O
thymocytes	B-cell_type	O
and	O	O
immunologically	O	O
stimulated	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

After	O	O
reviewing	O	O
briefly	O	O
our	O	O
earlier	O	O
studies	O	O
on	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
and	O	O
mechanisms	O	O
in	O	O
thymus	B-cell_type	O
cells	I-cell_type	O
,	O	O
we	O	O
have	O	O
outlined	O	O
results	O	O
from	O	O
the	O	O
following	O	O
two	O	O
areas	O	O
of	O	O
current	O	O
interest	O	O
in	O	O
our	O	O
laboratories	O	O
:	O	O
the	O	O
``	O	O
life-cycle	O	O
''	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
and	O	O
complexes	O	O
in	O	O
thymus	B-cell_type	O
cells	I-cell_type	O
,	O	O
and	O	O
the	O	O
levels	O	O
of	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
and	O	O
sensitivity	O	O
in	O	O
immunologically	O	O
stimulated	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Several	O	O
of	O	O
our	O	O
results	O	O
on	O	O
energetics	O	O
and	O	O
kinetics	O	O
of	O	O
hormone	O	O
binding	O	O
to	O	O
glucocorticoid	B-protein	O
receptors	I-protein	O
in	O	O
rat	O	O
thymus	B-cell_type	O
cells	I-cell_type	O
seem	O	O
to	O	O
require	O	O
extension	O	O
of	O	O
the	O	O
simplest	O	O
model	O	O
of	O	O
hormone-receptor	O	O
transformations	O	O
in	O	O
intact	B-cell_type	O
cells	I-cell_type	O
.	O	O

ATP-depletion	O	O
experiments	O	O
suggest	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
nonbinding	O	O
form	O	O
of	O	O
the	O	O
receptor	B-DNA	O
;	I-DNA	O
``	O	O
chase	O	O
''	O	O
experiments	O	O
suggest	O	O
reaction	O	O
of	O	O
hormone	O	O
directly	O	O
with	O	O
nuclear-bound	B-protein	O
receptor	I-protein	O
;	O	O
experiments	O	O
on	O	O
depletion	O	O
and	O	O
replenishment	O	O
of	O	O
cytoplasmic	B-protein	O
receptor	I-protein	O
using	O	O
cortisol	O	O
and	O	O
dexamethasone	O	O
suggest	O	O
the	O	O
existence	O	O
of	O	O
at	O	O
least	O	O
two	O	O
subpopulations	O	O
of	O	O
nuclear-bound	O	O
hormone-receptor	O	O
complex	I-protein	O
.	O	O

We	O	O
have	O	O
found	O	O
that	O	O
mitogen	O	O
or	O	O
immunologic	O	O
stimulation	O	O
of	O	O
human	B-cell_type	O
peripheral	I-cell_type	O
lymphocytes	I-cell_type	O
in	O	O
culture	O	O
leads	O	O
within	O	O
24	O	O
h	O	O
or	O	O
so	O	O
to	O	O
a	O	O
striking	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
sites	O	O
per	O	O
cell	O	O
.	O	O

We	O	O
believe	O	O
this	O	O
increase	O	O
may	O	O
be	O	O
due	O	O
to	O	O
partial	O	O
synchronization	O	O
of	O	O
the	O	O
cell	O	O
population	O	O
in	O	O
a	O	O
phase	O	O
of	O	O
the	O	O
cell	O	O
cycle	O	O
in	O	O
which	O	O
receptor	O	O
content	O	O
is	O	O
high	O	O
.	O	O

Contrary	O	O
to	O	O
the	O	O
widely	O	O
held	O	O
view	O	O
that	O	O
mitogen-stimulated	O	O
cells	O	O
become	O	O
insensitive	O	O
to	O	O
glucocorticoids	O	O
,	O	O
our	O	O
experiments	O	O
show	O	O
that	O	O
with	O	O
respect	O	O
to	O	O
inhibition	O	O
of	O	O
thymidine	O	O
and	O	O
uridine	O	O
incorporation	O	O
and	O	O
glucose	O	O
uptake	O	O
,	O	O
the	O	O
cells	O	O
are	O	O
highly	O	O
sensitive	O	O
to	O	O
dexamethasone	O	O
at	O	O
24	O	O
,	O	O
48	O	O
,	O	O
and	O	O
72	O	O
h	O	O
after	O	O
stimulation	O	O
with	O	O
concanavalin	O	O
A	O	O
.	O	O

Nuclear	O	O
glucocorticoid	O	O
binding	O	O
in	O	O
chronic	O	O
lymphatic	O	O
leukemia	O	O
lymphocytes	I-cell_type	O
.	O	O

A	O	O
reliable	O	O
procedure	O	O
is	O	O
described	O	O
for	O	O
isolating	O	O
3H-triamcinolone	O	O
acetonide	O	O
(	O	O
3H-TA	O	O
)	O	O
receptor	O	O
complexes	O	O
from	O	O
purified	O	O
chronic	O	O
lymphatic	O	O
leukemia	O	O
(	O	O
CLL	O	O
)	O	O
lymphocyte	O	O
nuclei	O	O
,	O	O
based	O	O
on	O	O
the	O	O
use	O	O
of	O	O
carbobenzoxy-L-phenylalanine	O	O
(	O	O
CBZ-L-phe	O	O
)	O	O
to	O	O
prevent	O	O
breakdown	O	O
of	O	O
hormone-receptor	O	O
complexes	O	O
during	O	O
extraction	O	O
of	O	O
nuclei	O	O
with	O	O
0.6M	O	O
KCl	O	O
.	O	O

Using	O	O
this	O	O
method	O	O
,	O	O
specific	O	O
nuclear	O	O
glucocorticoid	O	O
binding	O	O
was	O	O
demonstrated	O	O
in	O	O
14/14	O	O
patients	O	O
with	O	O
untreated	O	O
CLL	O	O
.	O	O

No	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
levels	O	O
of	O	O
nuclear-associated	O	O
3H-TA	O	O
and	O	O
peripheral	O	O
white	B-protein	O
blood	I-protein	O
cell	O	O
count	O	O
or	O	O
rosetting	O	O
ability	O	O
of	O	O
circulating	O	O
lymphocytes	I-cell_type	O
.	O	O

Multiple	O	O
closely-linked	O	O
NFAT/octamer	O	O
and	O	O
HMG	B-protein	O
I	I-protein	O
(	O	O
Y	O	O
)	O	O
binding	O	O
sites	O	O
are	O	O
part	O	O
of	O	O
the	O	O
interleukin-4	B-DNA	O
promoter	I-DNA	O
.	O	O

We	O	O
show	O	O
here	O	O
that	O	O
the	O	O
immediate	B-DNA	O
upstream	I-DNA	O
region	I-DNA	O
(	O	O
from	O	O
position	O	O
-12	O	O
to	O	O
-270	O	O
)	O	O
of	O	O
the	O	O
murine	B-DNA	O
interleukin	I-DNA	O
4	I-DNA	O
(	I-DNA	O
Il-4	I-DNA	O
)	I-DNA	O
gene	I-DNA	O
harbors	O	O
a	O	O
strong	O	O
cell-type	O	O
specific	O	O
transcriptional	O	O
enhancer	I-DNA	O
.	O	O

In	O	O
T	B-cell_type	O
lymphoma	I-cell_type	O
cells	I-cell_type	O
,	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
Il-4	O	O
promoter/enhancer	O	O
is	O	O
stimulated	O	O
by	O	O
phorbol	O	O
esters	O	O
,	O	O
Ca++	O	O
ionophores	O	O
and	O	O
agonists	O	O
of	O	O
protein	B-protein	O
kinase	I-protein	O
A	O	O
and	O	O
inhibited	O	O
by	O	O
low	O	O
doses	O	O
of	O	O
the	O	O
immunosuppressant	O	O
cyclosporin	O	O
A	O	O
.	O	O

The	O	O
Il-4	O	O
promoter/enhancer	O	O
is	O	O
transcriptionally	O	O
inactive	O	O
in	O	O
B	B-cell_type	O
lymphoma	I-cell_type	O
cells	I-cell_type	O
and	O	O
HeLa	B-cell_type	O
cells	I-cell_type	O
.	O	O

DNase	B-protein	O
I	I-protein	O
footprint	O	O
protection	O	O
experiments	O	O
revealed	O	O
six	O	O
sites	O	O
of	O	O
the	O	O
Il-4	O	O
promoter/enhancer	O	O
to	O	O
be	O	O
bound	O	O
by	O	O
nuclear	B-protein	O
proteins	I-protein	O
from	O	O
lymphoid	B-cell_type	O
and	I-cell_type	O
myeloid	I-cell_type	O
cells	I-cell_type	O
.	O	O

Among	O	O
them	O	O
are	O	O
four	O	O
purine	O	O
boxes	O	O
which	O	O
have	O	O
been	O	O
described	O	O
to	O	O
be	O	O
important	O	O
sequence	O	O
motifs	O	O
of	O	O
the	O	O
Il-2	B-DNA	O
promoter	I-DNA	O
.	O	O

They	O	O
contain	O	O
the	O	O
motif	O	O
GGAAA	O	O
and	O	O
are	O	O
recognized	O	O
by	O	O
the	O	O
inducible	O	O
and	O	O
cyclosporin	B-protein	O
A-sensitive	I-protein	O
transcription	I-protein	O
factor	I-protein	O
NFAT-1	O	O
.	O	O

Three	O	O
of	O	O
the	O	O
Il-4	B-DNA	O
NFAT-1	I-DNA	O
sites	I-DNA	O
are	O	O
closely	O	O
linked	O	O
to	O	O
weak	O	O
binding	O	O
sites	O	O
of	O	O
Octamer	B-protein	O
factors	I-protein	O
.	O	O

Several	O	O
purine	O	O
boxes	O	O
and	O	O
an	O	O
AT-rich	O	O
protein-binding	O	O
site	O	O
of	O	O
the	O	O
Il-4	B-DNA	O
promoter	I-DNA	O
are	O	O
also	O	O
recognized	O	O
by	O	O
the	O	O
high	O	O
mobility	O	O
group	O	O
protein	O	O
HMG	O	O
I	O	O
(	O	O
Y	O	O
)	O	O
.	O	O

Whereas	O	O
the	O	O
binding	O	O
of	O	O
NFAT-1	B-protein	O
and	O	O
Octamer	B-protein	O
factors	I-protein	O
enhance	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
Il-4	B-DNA	O
promoter	I-DNA	O
,	O	O
the	O	O
binding	O	O
of	O	O
HMG	B-protein	O
I	I-protein	O
(	O	O
Y	B-protein	O
)	O	O
suppresses	O	O
its	O	O
activity	O	O
and	O	O
,	O	O
therefore	O	O
,	O	O
appears	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
suppression	O	O
of	O	O
Il-4	O	O
transcription	O	O
in	O	O
resting	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Reversibility	O	O
of	O	O
the	O	O
differentiated	O	O
state	O	O
in	O	O
somatic	B-cell_type	O
cells	I-cell_type	O
.	O	O

Analysis	O	O
of	O	O
de	O	O
novo	O	O
gene	O	O
activation	O	O
in	O	O
multinucleated	O	O
heterokaryons	O	O
has	O	O
shown	O	O
that	O	O
the	O	O
differentiated	O	O
state	O	O
,	O	O
although	O	O
stable	O	O
,	O	O
is	O	O
not	O	O
irreversible	O	O
,	O	O
and	O	O
can	O	O
be	O	O
reprogrammed	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
appropriate	O	O
combinations	O	O
of	O	O
trans-acting	B-protein	O
regulatory	I-protein	O
molecules	I-protein	O
.	O	O

These	O	O
properties	O	O
have	O	O
been	O	O
exploited	O	O
to	O	O
design	O	O
strategies	O	O
for	O	O
identifying	O	O
novel	O	O
regulators	O	O
of	O	O
cellular	O	O
differentiation	O	O
.	O	O

Phosphatidylcholine	O	O
hydrolysis	O	O
activates	O	O
NF-kappa	B-protein	O
B	I-protein	O
and	O	O
increases	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
replication	O	O
in	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
and	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

We	O	O
have	O	O
tested	O	O
whether	O	O
breakdown	O	O
of	O	O
phosphatidylcholine	O	O
(	O	O
PC	B-protein	O
)	O	O
initiated	O	O
by	O	O
exogenous	O	O
addition	O	O
of	O	O
a	O	O
PC-specific	B-protein	O
phospholipase	I-protein	O
C	I-protein	O
(	O	O
PC-PLC	B-protein	O
)	O	O
from	O	O
Bacillus	O	O
cereus	O	O
or	O	O
by	O	O
endogenous	O	O
overexpression	O	O
of	O	O
PC-PLC	O	O
induces	O	O
functional	O	O
activation	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
and	O	O
increases	O	O
human	B-protein	O
immunodeficiency	I-protein	O
virus	O	O
(	O	O
HIV	B-protein	O
)	O	O
enhancer	O	O
activity	O	O
.	O	O

PC-PLC-activated	O	O
hydrolysis	O	O
of	O	O
PC	O	O
was	O	O
found	O	O
to	O	O
induce	O	O
bona	O	O
fide	O	O
p50/p65	O	O
NF-kappa	B-protein	O
B	O	O
binding	O	O
activity	O	O
in	O	O
three	O	O
different	O	O
cell	O	O
lines	O	O
of	O	O
human	O	O
or	O	O
murine	O	O
origin	O	O
.	O	O

No	O	O
significant	O	O
changes	O	O
in	O	O
the	O	O
turnover	O	O
of	O	O
other	O	O
cellular	O	O
phospholipids	O	O
were	O	O
detected	O	O
in	O	O
PC-PLC-treated	B-cell_type	O
cells	I-cell_type	O
.	O	O

Induction	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
by	O	O
PC-PLC	O	O
did	O	O
not	O	O
depend	O	O
on	O	O
de	O	O
novo	O	O
synthesis	O	O
of	O	O
proteins	O	O
or	O	O
autocrine	O	O
secretion	O	O
of	O	O
either	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
or	O	O
interleukin	B-protein	O
1	I-protein	O
.	O	O

In	O	O
human	O	O
monocytic	O	O
and	O	O
lymphoblastoid	O	O
T-cell	O	O
lines	O	O
,	O	O
induction	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
by	O	O
PC-PLC	O	O
resulted	O	O
in	O	O
clear	O	O
induction	O	O
of	O	O
luciferase	O	O
expression	O	O
vectors	O	O
placed	O	O
under	O	O
the	O	O
control	O	O
of	O	O
synthetic	B-protein	O
kappa	I-protein	O
B	I-protein	O
enhancers	I-protein	O
or	O	O
wild	B-protein	O
type	I-protein	O
,	O	O
but	O	O
not	O	O
kappa	O	O
B-mutated	O	O
,	O	O
HIV	O	O
long	O	O
terminal	O	O
repeat	O	O
constructs	O	O
.	O	O

HIV	O	O
replication	O	O
was	O	O
increased	O	O
by	O	O
PC-PLC	O	O
in	O	O
chronically	B-cell_type	O
infected	I-cell_type	O
monocytes	B-cell_type	O
and	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
promoted	O	O
by	O	O
addition	O	O
of	O	O
exogenous	O	O
PC-PLC	O	O
correlated	O	O
with	O	O
an	O	O
intense	O	O
production	O	O
of	O	O
diacylglycerol	O	O
.	O	O

However	O	O
,	O	O
addition	O	O
of	O	O
a	O	O
phosphatidylinositol-specific	O	O
PLC	O	O
from	O	O
B.cereus	O	O
also	O	O
induced	O	O
diacylglycerol	O	O
but	O	O
did	O	O
not	O	O
activate	O	O
kappa	O	O
B	O	O
enhancer-directed	O	O
vectors	O	O
.	O	O

PC-PLC-induced	O	O
NF-kappa	B-protein	O
B	I-protein	O
activation	O	O
could	O	O
not	O	O
be	O	O
blocked	O	O
by	O	O
a	O	O
specific	O	O
inhibitor	O	O
of	O	O
phorbol	B-protein	O
ester-inducible	I-protein	O
protein	I-protein	O
kinases	I-protein	O
C	I-protein	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
a	O	O
cellular	O	O
transduction	O	O
pathway	O	O
,	O	O
dependent	O	O
on	O	O
specific	O	O
PC	O	O
breakdown	O	O
,	O	O
is	O	O
functional	O	O
in	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
and	O	O
monocytes	B-cell_type	O
and	O	O
may	O	O
be	O	O
used	O	O
by	O	O
various	O	O
transmembrane	O	O
receptors	O	O
to	O	O
activate	O	O
HIV	O	O
transcription	O	O
through	O	O
NF-kappa	B-protein	O
B-dependent	O	O
induction	O	O
of	O	O
the	O	O
HIV	B-DNA	O
enhancer	I-DNA	O
.	O	O

Novel	O	O
mechanism	O	O
for	O	O
inhibition	O	O
of	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
by	O	O
glucocorticoids	O	O
.	O	O

Glucocorticoids	O	O
inhibit	O	O
signal	O	O
transduction	O	O
through	O	O
IL-2	B-protein	O
receptor	I-protein	O
.	O	O

Interaction	O	O
of	O	O
IL-2	B-protein	O
with	O	O
its	O	O
high	O	O
affinity	O	O
membrane	B-protein	O
receptor	I-protein	O
complex	I-protein	O
(	O	O
IL-2R	B-protein	O
)	O	O
present	O	O
on	O	O
activated	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
induces	O	O
cell	O	O
proliferation	O	O
and	O	O
mediates	O	O
effector	O	O
functions	O	O
.	O	O

Glucocorticoids	O	O
inhibit	O	O
IL-2	B-protein	O
production	O	O
by	O	O
inhibiting	O	O
TCR-mediated	O	O
signal	O	O
transduction	O	O
.	O	O

We	O	O
asked	O	O
whether	O	O
they	O	O
also	O	O
inhibit	O	O
the	O	O
action	O	O
of	O	O
IL-2	B-protein	O
by	O	O
inhibiting	O	O
signal	O	O
transduction	O	O
through	O	O
IL-2R	B-protein	O
.	O	O

Human	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
,	O	O
stimulated	O	O
with	O	O
PMA	O	O
for	O	O
48	O	O
h	O	O
(	O	O
PMA	O	O
blasts	O	O
)	O	O
,	O	O
were	O	O
incubated	O	O
with	O	O
IL-2	B-protein	O
in	O	O
the	O	O
presence	O	O
of	O	O
incremental	O	O
dosages	O	O
of	O	O
dexamethasone	O	O
(	O	O
Dex	B-protein	O
;	I-protein	O
10	O	O
(	O	O
-5	O	O
)	O	O
-10	O	O
(	O	O
-9	O	O
)	O	O
M	O	O
)	O	O
.	O	O

Dex	O	O
inhibited	O	O
the	O	O
IL-2-dependent	O	O
proliferation	O	O
of	O	O
PMA	O	O
blasts	O	O
in	O	O
a	O	O
dose-dependent	O	O
fashion	O	O
(	O	O
IC50	O	O
,	O	O
5	O	O
x	O	O
10	O	O
(	O	O
-8	O	O
)	O	O
M	O	O
)	O	O
.	O	O

Cell	O	O
surface	O	O
expression	O	O
of	O	O
IL-2R	B-protein	O
alpha-	I-protein	O
and	O	O
beta-chains	O	O
as	O	O
determined	O	O
by	O	O
immunofluorescence	O	O
analysis	O	O
was	O	O
not	O	O
affected	O	O
by	O	O
Dex	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
Scatchard	O	O
plot	O	O
analysis	O	O
of	O	O
125I-labeled	O	O
IL-2	B-protein	O
showed	O	O
that	O	O
Dex	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
binding	O	O
of	O	O
IL-2	B-protein	O
,	O	O
thus	O	O
suggesting	O	O
that	O	O
inhibition	O	O
is	O	O
due	O	O
to	O	O
a	O	O
postreceptor	O	O
effect	O	O
.	O	O

Inhibition	O	O
of	O	O
T	B-cell_type	O
cell	I-cell_type	O
proliferation	O	O
by	O	O
Dex	O	O
was	O	O
associated	O	O
with	O	O
decreased	O	O
IL-2-dependent	O	O
tyrosine	O	O
phosphorylation	O	O
of	O	O
several	O	O
intracellular	B-protein	O
proteins	I-protein	O
and	O	O
decreased	O	O
phosphorylation	O	O
of	O	O
the	O	O
retinoblastoma	B-protein	O
gene	I-protein	O
product	I-protein	O
Rb	B-protein	O
,	O	O
a	O	O
protein	O	O
essential	O	O
for	O	O
controlling	O	O
the	O	O
progression	O	O
of	O	O
cells	O	O
through	O	O
the	O	O
cell	O	O
cycle	O	O
.	O	O

IL-2-dependent	O	O
IL-2R	B-protein	O
alpha	I-protein	O
expression	O	O
in	O	O
PMA	O	O
blasts	O	O
and	O	O
NF-kB	O	O
induction	O	O
in	O	O
resting	O	O
human	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
were	O	O
also	O	O
inhibited	O	O
by	O	O
Dex	O	O
.	O	O

These	O	O
results	O	O
demonstrate	O	O
that	O	O
glucocorticoids	O	O
inhibit	O	O
preactivated	O	O
T	B-cell_type	O
cells	I-cell_type	O
by	O	O
down-regulating	O	O
signal	O	O
transduction	O	O
through	O	O
IL-2R	B-protein	O
.	O	O

Chronic	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
infection	O	O
stimulates	O	O
distinct	O	O
NF-kappa	B-protein	O
B/rel	O	O
DNA	O	O
binding	O	O
activities	O	O
in	O	O
myelomonoblastic	B-cell_type	O
cells	I-cell_type	O
.	O	O

The	O	O
relationship	O	O
between	O	O
human	O	O
immunodeficiency	B-protein	O
virus	I-protein	O
type	I-protein	O
1	I-protein	O
(	O	O
HIV-1	B-DNA	O
)	O	O
infection	O	O
and	O	O
the	O	O
induction	O	O
of	O	O
NF-kappa	B-protein	O
B	I-protein	O
binding	O	O
activity	O	O
was	O	O
examined	O	O
in	O	O
a	O	O
myeloid	O	O
cell	O	O
model	O	O
of	O	O
HIV-1	O	O
infection	O	O
derived	O	O
from	O	O
the	O	O
PLB-985	B-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
.	O	O

Chronic	O	O
infection	O	O
of	O	O
PLB-985	B-cell_type	O
cells	I-cell_type	O
led	O	O
to	O	O
increased	O	O
monocyte-specific	O	O
surface	O	O
marker	O	O
expression	O	O
,	O	O
increased	O	O
c-fms	O	O
gene	O	O
transcription	O	O
,	O	O
and	O	O
morphological	O	O
alterations	O	O
consistent	O	O
with	O	O
differentiation	O	O
along	O	O
the	O	O
monocytic	B-cell_line	O
pathway	O	O
.	O	O

PLB-IIIB	B-cell_type	O
cells	I-cell_type	O
displayed	O	O
a	O	O
constitutive	O	O
NF-kappa	B-protein	O
B-like	I-protein	O
binding	O	O
activity	O	O
that	O	O
was	O	O
distinct	O	O
from	O	O
that	O	O
induced	O	O
by	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor	I-protein	O
alpha	I-protein	O
or	O	O
phorbol	O	O
12-myristate	O	O
13-acetate	O	O
treatment	O	O
of	O	O
the	O	O
parental	B-cell_line	O
PLB-985	I-cell_line	O
cell	I-cell_line	O
line	I-cell_line	O
.	O	O

This	O	O
unique	O	O
DNA	O	O
binding	O	O
activity	O	O
consisted	O	O
of	O	O
proteins	O	O
of	O	O
70	B-protein	O
,	O	O
90	B-protein	O
,	O	O
and	O	O
100	O	O
kDa	I-protein	O
with	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
binding	O	O
specificity	O	O
for	O	O
the	O	O
NF-kappa	B-DNA	O
B	I-DNA	O
site	I-DNA	O
within	O	O
the	O	O
PRDII	B-DNA	O
domain	I-DNA	O
of	O	O
beta	B-protein	O
interferon	I-protein	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
characterize	O	O
the	O	O
nature	O	O
of	O	O
these	O	O
proteins	O	O
and	O	O
demonstrate	O	O
that	O	O
binding	O	O
of	O	O
these	O	O
proteins	O	O
is	O	O
also	O	O
induced	O	O
following	O	O
Sendai	O	O
paramyxovirus	O	O
infection	O	O
.	O	O

The	O	O
70-kDa	B-protein	O
protein	I-protein	O
corresponds	O	O
to	O	O
the	O	O
NF-kappa	B-protein	O
B	I-protein	O
RelA	I-protein	O
(	O	O
p65	B-protein	O
)	O	O
subunit	O	O
,	O	O
which	O	O
is	O	O
activated	O	O
in	O	O
response	O	O
to	O	O
an	O	O
acute	O	O
paramyxovirus	O	O
infection	O	O
or	O	O
a	O	O
chronic	O	O
HIV-1	O	O
infection	O	O
.	O	O

Virus	O	O
infection	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
alter	O	O
the	O	O
amount	O	O
of	O	O
RelA	B-protein	O
(	O	O
p65	B-protein	O
)	I-protein	O
or	I-protein	O
NFKB1	I-protein	O
(	O	O
p50	B-protein	O
)	O	O
but	O	O
rather	O	O
affects	O	O
the	O	O
capacity	O	O
of	O	O
I	B-protein	O
kappa	I-protein	O
B	I-protein	O
alpha	I-protein	O
to	O	O
sequester	O	O
RelA	O	O
(	O	O
p65	B-protein	O
)	O	O
,	O	O
therefore	O	O
leading	O	O
to	O	O
constitutive	O	O
levels	O	O
of	O	O
RelA	O	O
DNA	B-protein	O
binding	I-protein	O
activity	O	O
and	O	O
to	O	O
increased	O	O
levels	O	O
of	O	O
NF-kappa	B-protein	O
B-dependent	I-protein	O
gene	I-DNA	O
activity	O	O
.	O	O

The	O	O
virally	O	O
induced	O	O
90-	O	O
to	O	O
100-kDa	B-protein	O
proteins	I-protein	O
have	O	O
a	O	O
distinct	O	O
binding	O	O
specificity	O	O
for	O	O
the	O	O
PRDII	B-DNA	O
domain	I-DNA	O
and	O	O
an	O	O
AT-rich	B-DNA	O
sequence	I-DNA	O
but	O	O
do	O	O
not	O	O
cross-react	O	O
with	O	O
NF-kappa	B-protein	O
B	I-protein	O
subunit-specific	O	O
antisera	O	O
directed	O	O
against	O	O
NFKB1	O	O
(	O	O
p105	O	O
or	O	O
p50	O	O
)	O	O
,	O	O
NFKB2	O	O
(	O	O
p100	O	O
or	O	O
p52	O	O
)	O	O
,	O	O
RelA	O	O
(	O	O
p65	O	O
)	O	O
,	O	O
or	O	O
c-rel	O	O
.	O	O

DNA	O	O
binding	O	O
of	O	O
the	O	O
90-	O	O
to	O	O
100-kDa	I-protein	O
proteins	I-protein	O
was	O	O
not	O	O
inhibited	O	O
by	O	O
recombinant	B-protein	O
I	I-protein	O
kappa	I-protein	O
B	I-protein	O
alpha/MAD-3	O	O
and	O	O
was	O	O
resistant	O	O
to	O	O
tryptic	O	O
digestion	O	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
proteins	O	O
may	O	O
not	O	O
be	O	O
NF-kappa	B-protein	O
B	I-protein	O
related	O	O
.	O	O

Transient	O	O
cotransfection	O	O
experiments	O	O
demonstrated	O	O
that	O	O
RelA	O	O
and	O	O
NFKB1	O	O
expression	O	O
maximally	O	O
stimulated	O	O
HIV-1	O	O
LTR-	O	O
and	O	O
NF-kappa	B-protein	O
B-dependent	I-DNA	O
reporter	I-DNA	O
genes	I-DNA	O
;	O	O
differences	O	O
in	O	O
NF-kappa	B-protein	O
B-like	O	O
binding	O	O
activity	O	O
were	O	O
also	O	O
reflected	O	O
in	O	O
higher	O	O
constitutive	O	O
levels	O	O
of	O	O
NF-kappa	B-protein	O
B-regulated	I-DNA	O
gene	I-DNA	O
expression	O	O
in	O	O
HIV-1-infected	B-cell_type	O
myeloid	I-cell_type	O
cells	I-cell_type	O
.	O	O

Presence	O	O
of	O	O
estrogen-binding	O	O
sites	O	O
on	O	O
macrophage-like	O	O
synoviocytes	O	O
and	O	O
CD8+	O	O
,	O	O
CD29+	O	O
,	O	O
CD45RO+	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
in	O	O
normal	O	O
and	O	O
rheumatoid	O	O
synovium	O	O
.	O	O

OBJECTIVE	O	O
.	O	O

To	O	O
study	O	O
the	O	O
presence	O	O
of	O	O
estrogen-binding	B-protein	O
sites	I-protein	O
(	O	O
EBS	B-protein	O
)	O	O
in	O	O
the	O	O
synovial	O	O
tissues	O	O
of	O	O
male	O	O
and	O	O
female	O	O
patients	O	O
with	O	O
rheumatoid	O	O
arthritis	O	O
(	O	O
RA	O	O
)	O	O
and	O	O
in	O	O
age-	O	O
and	O	O
sex-matched	O	O
healthy	O	O
controls	O	O
.	O	O

METHODS	O	O
.	O	O

Both	O	O
type	O	O
1	O	O
(	O	O
high	O	O
affinity	O	O
,	O	O
low	O	O
binding	O	O
capacity	O	O
)	O	O
and	O	O
type	O	O
2	O	O
(	O	O
reduced	O	O
affinity	O	O
,	O	O
higher	O	O
binding	O	O
capacity	O	O
)	O	O
EBS	O	O
were	O	O
investigated	O	O
in	O	O
both	O	O
soluble	O	O
and	O	O
nuclear	O	O
fractions	O	O
of	O	O
homogenized	O	O
synovial	O	O
tissue	O	O
samples	O	O
by	O	O
a	O	O
dextran-coated	O	O
charcoal	O	O
method	O	O
.	O	O

To	O	O
determine	O	O
what	O	O
type	O	O
of	O	O
synovial	O	O
cell	O	O
was	O	O
positive	O	O
for	O	O
EBS	O	O
,	O	O
cryosections	O	O
of	O	O
synovial	O	O
tissues	O	O
were	O	O
immunostained	O	O
with	O	O
a	O	O
specific	O	O
monoclonal	O	O
anti-estrogen	O	O
receptor	O	O
antibody	O	O
(	O	O
anti-ER	O	O
MAb	O	O
)	O	O
using	O	O
both	O	O
immunofluorescence	O	O
and	O	O
immunoperoxidase	O	O
techniques	O	O
.	O	O

Double	O	O
immunostaining	O	O
with	O	O
the	O	O
anti-ER	O	O
MAb	O	O
and	O	O
with	O	O
specific	O	O
MAb	O	O
to	O	O
detect	O	O
different	O	O
macrophage	O	O
antigens	O	O
(	O	O
Ber-MAC3	O	O
,	O	O
MAC387	O	O
,	O	O
CD68	O	O
)	O	O
and	O	O
CD8+	O	O
T	O	O
cell	O	O
subsets	O	O
(	O	O
CD29+	O	O
,	O	O
CD45RO+	O	O
and	O	O
CD29-	O	O
,	O	O
CD45RO-	O	O
)	O	O
was	O	O
performed	O	O
.	O	O

RESULTS	O	O
.	O	O

Higher	O	O
affinity	O	O
EBS	O	O
were	O	O
found	O	O
mostly	O	O
in	O	O
nuclear	O	O
cell	O	O
fractions	O	O
of	O	O
either	O	O
RA	O	O
or	O	O
control	O	O
synovial	O	O
tissues	O	O
(	O	O
28	O	O
of	O	O
the	O	O
33	B-protein	O
)	O	O
.	O	O

These	O	O
EBS	O	O
were	O	O
present	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
in	O	O
soluble	O	O
cell	O	O
fractions	O	O
(	O	O
11	O	O
of	O	O
the	O	O
33	B-protein	O
)	O	O
.	O	O

Immunostaining	O	O
showed	O	O
the	O	O
estrogen	B-cell_line	O
receptor-positive	I-cell_line	O
cells	I-cell_line	O
to	O	O
be	O	O
the	O	O
macrophage-like	O	O
synoviocytes	O	O
and	O	O
the	O	O
CD8+	O	O
,	O	O
CD29+	O	O
T	B-cell_type	O
cells	I-cell_type	O
both	O	O
in	O	O
RA	O	O
and	O	O
in	O	O
control	O	O
synovial	O	O
tissues	O	O
.	O	O

Higher	O	O
nuclear	O	O
content	O	O
of	O	O
EBS	O	O
was	O	O
consistent	O	O
with	O	O
more	O	O
intense	O	O
nuclear	O	O
staining	O	O
of	O	O
synoviocytes	O	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
.	O	O

CONCLUSION	O	O
.	O	O

It	O	O
is	O	O
conceivable	O	O
that	O	O
the	O	O
immunomodulatory	O	O
activity	O	O
exerted	O	O
by	O	O
estrogens	O	O
is	O	O
at	O	O
least	O	O
partly	O	O
mediated	O	O
through	O	O
their	O	O
interaction	O	O
with	O	O
EBS	O	O
that	O	O
are	O	O
present	O	O
on	O	O
macrophage-like	O	O
synoviocytes	O	O
,	O	O
functioning	O	O
as	O	O
antigen-processing	O	O
and	O	O
antigen-presenting	O	O
cells	O	O
,	O	O
and	O	O
on	O	O
antigen-experienced	O	O
(	O	O
memory	O	O
)	O	O
CD8+	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
(	O	O
CD29+	O	O
,	O	O
CD45RO+	O	O

